PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Kammerer, RA; Jaravine, VA; Frank, S; Schulthess, T; Landwehr, R; Lustig, A; Garcia-Echeverria, C; Alexandrescu, AT; Engel, J; Steinmetz, MO				Kammerer, RA; Jaravine, VA; Frank, S; Schulthess, T; Landwehr, R; Lustig, A; Garcia-Echeverria, C; Alexandrescu, AT; Engel, J; Steinmetz, MO			An intrahelical salt bridge within the trigger site stabilizes the GCN4 leucine zipper	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COILED-COIL FORMATION; X-RAY STRUCTURE; AMINO-ACIDS; HELIX PROPENSITY; CORTEXILLIN-I; ROD DOMAIN; PEPTIDES; PROTEINS; COMPLEX; REGION	We previously reported that a helical trigger segment within the GCN4 leucine zipper monomer is indispensable for the formation of its parallel two-stranded coiled coil. Here, we demonstrate that the intrinsic secondary structure of the trigger site is largely stabilized by an intrahelical salt bridge. Removal of this surface salt bridge by a single amino acid mutation induced only minor changes in the backbone structure of the GCN4 leucine zipper dimer as verified by nuclear magnetic resonance. The mutation, however, substantially destabilized the dimeric structure. These findings support the proposed hierarchic folding mechanism of the GCN4 coiled coil in which local helix formation within the trigger segment precedes dimerization.	Univ Basel, Biozentrum, Dept Biophys Chem, CH-4056 Basel, Switzerland; Univ Basel, Biozentrum, Dept Biol Struct, CH-4056 Basel, Switzerland; Novartis Pharma AG, Oncol Res, CH-4002 Basel, Switzerland; Novartis Pharma AG, Funct Genom Area, CH-4002 Basel, Switzerland	University of Basel; University of Basel; Novartis; Novartis	Kammerer, RA (corresponding author), Univ Manchester, Sch Biol Sci, Manchester M13 9PT, Lancs, England.		Steinmetz, Michel O/AAA-3349-2022; Jaravine, Victor/C-6957-2008	Steinmetz, Michel O/0000-0001-6157-3687; Kammerer, Richard/0000-0003-4570-5197				Baldwin RL, 1999, TRENDS BIOCHEM SCI, V24, P26, DOI 10.1016/S0968-0004(98)01346-2; BLABER M, 1993, SCIENCE, V260, P1637, DOI 10.1126/science.8503008; Burkhard P, 2000, STRUCTURE, V8, P223, DOI 10.1016/S0969-2126(00)00100-3; Cavanagh J., 1996, PROTEIN NMR SPECTROS; Dong HJ, 1996, J MOL BIOL, V260, P649, DOI 10.1006/jmbi.1996.0428; EDELHOCH H, 1967, BIOCHEMISTRY-US, V6, P1948, DOI 10.1021/bi00859a010; ELLENBERGER TE, 1992, CELL, V71, P1223, DOI 10.1016/S0092-8674(05)80070-4; Frank S, 2000, J BIOL CHEM, V275, P11672, DOI 10.1074/jbc.275.16.11672; GARCIAECHEVERRI.C, 1994, LETT PEPT SCI, V1, P255; Kammerer RA, 1998, P NATL ACAD SCI USA, V95, P13419, DOI 10.1073/pnas.95.23.13419; KONIG P, 1993, J MOL BIOL, V233, P139, DOI 10.1006/jmbi.1993.1490; LUMB KJ, 1994, BIOCHEMISTRY-US, V33, P7361, DOI 10.1021/bi00189a042; Moran LB, 1999, P NATL ACAD SCI USA, V96, P10699, DOI 10.1073/pnas.96.19.10699; Myers JK, 1999, J MOL BIOL, V289, P205, DOI 10.1006/jmbi.1999.2747; Myers JK, 1997, P NATL ACAD SCI USA, V94, P2833, DOI 10.1073/pnas.94.7.2833; ONEIL KT, 1990, SCIENCE, V250, P646, DOI 10.1126/science.2237415; OSHEA EK, 1991, SCIENCE, V254, P539, DOI 10.1126/science.1948029; OSHEA EK, 1992, CELL, V68, P699, DOI 10.1016/0092-8674(92)90145-3; Rohl CA, 1996, PROTEIN SCI, V5, P2623, DOI 10.1002/pro.5560051225; SAUDEK V, 1991, PROTEIN ENG, V4, P519, DOI 10.1093/protein/4.5.519; Smith JS, 1998, BIOCHEMISTRY-US, V37, P33, DOI 10.1021/bi972026h; Sosnick TR, 1996, PROTEINS, V24, P427; Spek EJ, 1998, PROTEIN SCI, V7, P2431, DOI 10.1002/pro.5560071121; Steinmetz MO, 1998, EMBO J, V17, P1883, DOI 10.1093/emboj/17.7.1883; THOMPSON KS, 1993, BIOCHEMISTRY-US, V32, P5491, DOI 10.1021/bi00072a001; VUISTER GW, 1993, J AM CHEM SOC, V115, P7772, DOI 10.1021/ja00070a024; WISHART DS, 1995, J BIOMOL NMR, V5, P67, DOI 10.1007/BF00227471; Wu KC, 2000, MOL BIOL CELL, V11, P3539, DOI 10.1091/mbc.11.10.3539; Yang JX, 1997, PROTEIN SCI, V6, P1264, DOI 10.1002/pro.5560060614; Yu YB, 2000, J CHROMATOGR A, V890, P81, DOI 10.1016/S0021-9673(00)00472-6; Zhu H, 2000, J MOL BIOL, V300, P1377, DOI 10.1006/jmbi.2000.3936; Zitzewitz JA, 2000, J MOL BIOL, V296, P1105, DOI 10.1006/jmbi.2000.3507	32	41	41	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 27	2001	276	17					13685	13688		10.1074/jbc.M010492200	http://dx.doi.org/10.1074/jbc.M010492200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	426PB	11134036	hybrid			2022-12-25	WOS:000168356600026
J	Romberg, L; Simon, M; Erickson, HP				Romberg, L; Simon, M; Erickson, HP			Polymerization of FtsZ, a bacterial homolog of tubulin - Is assembly cooperative?	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIVISION PROTEIN FTSZ; CELL-DIVISION; ESCHERICHIA-COLI; GTP HYDROLYSIS; DYNAMIC INSTABILITY; INDIVIDUAL MICROTUBULES; SELF-ASSOCIATION; BINDING-PROTEIN; ACTIN FILAMENT; RATE CONSTANTS	FtsZ is a bacterial homolog of tubulin that is essential for prokaryotic cytokinesis. In vitro, GTP induces FtsZ to assemble into straight, 6-nm-wide polymers. Here we show that the polymerization of these FtsZ filaments most closely resembles noncooperative (or "isodesmic") assembly; the polymers are single-stranded and assemble with no evidence of a nucleation phase and without a critical concentration. We have developed a model for the isodesmic polymerization that includes GTP hydrolysis in the scheme. The model can account for the lengths of the FtsZ polymers and their maximum steady state nucleotide hydrolysis rates. It predicts that unlike microtubules, FtsZ protofilaments consist of GTP bound FtsZ subunits that hydrolyze their nucleotide only slowly and are connected by high affinity longitudinal bonds with a nanomolar K-D.	Duke Univ, Med Ctr, Dept Cell Biol, Durham, NC 27710 USA; Brookhaven Natl Lab, Dept Biol, Upton, NY 11973 USA	Duke University; United States Department of Energy (DOE); Brookhaven National Laboratory	Romberg, L (corresponding author), Harvard Univ, Sch Med, Inst Chem & Cellular Biol, SGM 604, Boston, MA 02115 USA.				NIGMS NIH HHS [GM28553] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM028553] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMS ET, 1968, BIOCHEMISTRY-US, V7, P1044, DOI 10.1021/bi00843a025; Addinall SG, 1996, MOL MICROBIOL, V22, P231, DOI 10.1046/j.1365-2958.1996.00100.x; Addinall SG, 1997, MOL MICROBIOL, V25, P303, DOI 10.1046/j.1365-2958.1997.4641833.x; Addinall SG, 1996, J BACTERIOL, V178, P7167, DOI 10.1128/jb.178.24.7167-7172.1996; BAKER TS, 1978, J MOL BIOL, V123, P89, DOI 10.1016/0022-2836(78)90378-9; Boyle DS, 1997, MOL MICROBIOL, V24, P1263, DOI 10.1046/j.1365-2958.1997.4091773.x; BRAMHILL D, 1994, P NATL ACAD SCI USA, V91, P5813, DOI 10.1073/pnas.91.13.5813; Bramhill D, 1997, ANNU REV CELL DEV BI, V13, P395, DOI 10.1146/annurev.cellbio.13.1.395; DEBOER P, 1992, NATURE, V359, P254, DOI 10.1038/359254a0; Den Blaauwen T, 1999, J BACTERIOL, V181, P5167, DOI 10.1128/JB.181.17.5167-5175.1999; Desai A, 1997, ANNU REV CELL DEV BI, V13, P83, DOI 10.1146/annurev.cellbio.13.1.83; DRECHSEL DN, 1992, MOL BIOL CELL, V3, P1141, DOI 10.1091/mbc.3.10.1141; Erickson HP, 1996, P NATL ACAD SCI USA, V93, P519, DOI 10.1073/pnas.93.1.519; ERICKSON HP, 1989, J MOL BIOL, V206, P465, DOI 10.1016/0022-2836(89)90494-4; Erickson HP, 1998, TRENDS CELL BIOL, V8, P133, DOI 10.1016/S0962-8924(98)01237-9; ERICKSON HP, 1992, ANNU REV BIOPH BIOM, V21, P145, DOI 10.1146/annurev.bb.21.060192.001045; Erickson HP, 1996, J CELL BIOL, V135, P5, DOI 10.1083/jcb.135.1.5; ERICKSON HP, 1981, BIOPHYS J, V34, P293, DOI 10.1016/S0006-3495(81)84850-3; Erickson HP, 1997, TRENDS CELL BIOL, V7, P362, DOI 10.1016/S0962-8924(97)01108-2; Field CM, 1996, J CELL BIOL, V133, P605, DOI 10.1083/jcb.133.3.605; FRIEDEN C, 1983, BIOCHEMISTRY-US, V22, P5836, DOI 10.1021/bi00294a023; FRIGON RP, 1975, BIOCHEMISTRY-US, V14, P4559, DOI 10.1021/bi00692a001; GELADOPOULOS TP, 1991, ANAL BIOCHEM, V192, P112, DOI 10.1016/0003-2697(91)90194-X; Hale CA, 2000, J BACTERIOL, V182, P5153, DOI 10.1128/JB.182.18.5153-5166.2000; Hale CA, 1999, J BACTERIOL, V181, P167, DOI 10.1128/JB.181.1.167-176.1999; HIMES RH, 1977, J BIOL CHEM, V252, P6222; HYMAN AA, 1992, MOL BIOL CELL, V3, P1155, DOI 10.1091/mbc.3.10.1155; Khattar MM, 1997, J BACTERIOL, V179, P784, DOI 10.1128/jb.179.3.784-793.1997; KIRKWOOD JG, 1954, J POLYM SCI, V12, P1, DOI 10.1002/pol.1954.120120102; Liu Z, 1999, MOL MICROBIOL, V31, P1853, DOI 10.1046/j.1365-2958.1999.01322.x; Lowe J, 1999, EMBO J, V18, P2364, DOI 10.1093/emboj/18.9.2364; Lu CL, 1998, CELL MOTIL CYTOSKEL, V40, P71, DOI 10.1002/(SICI)1097-0169(1998)40:1<71::AID-CM7>3.3.CO;2-Z; Lu CL, 2000, J BACTERIOL, V182, P164, DOI 10.1128/JB.182.1.164-170.2000; Lutkenhaus J, 1997, ANNU REV BIOCHEM, V66, P93, DOI 10.1146/annurev.biochem.66.1.93; MITCHISON T, 1984, NATURE, V312, P232, DOI 10.1038/312232a0; MITCHISON T, 1984, NATURE, V312, P237, DOI 10.1038/312237a0; Mukherjee A, 1999, J BACTERIOL, V181, P823, DOI 10.1128/JB.181.3.823-832.1999; MUKHERJEE A, 1994, J BACTERIOL, V176, P2754, DOI 10.1128/JB.176.9.2754-2758.1994; MUKHERJEE A, 1993, P NATL ACAD SCI USA, V90, P1053, DOI 10.1073/pnas.90.3.1053; Mukherjee A, 1998, EMBO J, V17, P462, DOI 10.1093/emboj/17.2.462; Nogales E, 1998, NATURE, V391, P199, DOI 10.1038/34465; Nogales E, 1998, NAT STRUCT BIOL, V5, P451, DOI 10.1038/nsb0698-451; NORTHRUP SH, 1992, P NATL ACAD SCI USA, V89, P3338, DOI 10.1073/pnas.89.8.3338; OBRIEN ET, 1990, BIOCHEMISTRY-US, V29, P6648, DOI 10.1021/bi00480a014; OBRIEN ET, 1987, BIOCHEMISTRY-US, V26, P4148, DOI 10.1021/bi00387a061; OOSAWA F, 1962, J MOL BIOL, V4, P10, DOI 10.1016/S0022-2836(62)80112-0; Palacios P, 1996, MOL MICROBIOL, V20, P1093, DOI 10.1111/j.1365-2958.1996.tb02549.x; Pogliano J, 1997, P NATL ACAD SCI USA, V94, P559, DOI 10.1073/pnas.94.2.559; POLLARD TD, 1983, ANAL BIOCHEM, V134, P406, DOI 10.1016/0003-2697(83)90316-0; RayChaudhuri D, 1999, EMBO J, V18, P2372, DOI 10.1093/emboj/18.9.2372; RAYCHAUDHURI D, 1992, NATURE, V359, P251, DOI 10.1038/359251a0; REISLER E, 1970, BIOCHEMISTRY-US, V9, P3095, DOI 10.1021/bi00817a600; Rivas G, 2000, J BIOL CHEM, V275, P11740, DOI 10.1074/jbc.275.16.11740; Scheffers DJ, 2000, MOL MICROBIOL, V35, P1211, DOI 10.1046/j.1365-2958.2000.01791.x; Sept D, 1999, BIOPHYS J, V77, P2911, DOI 10.1016/S0006-3495(99)77124-9; Serio TR, 2000, SCIENCE, V289, P1317, DOI 10.1126/science.289.5483.1317; Sossong TM, 1999, BIOCHEMISTRY-US, V38, P14843, DOI 10.1021/bi990917e; Sun Q, 1998, J BACTERIOL, V180, P2050, DOI 10.1128/JB.180.8.2050-2056.1998; THUSIUS D, 1975, J MOL BIOL, V92, P413, DOI 10.1016/0022-2836(75)90289-2; TOBACMAN LS, 1982, J BIOL CHEM, V257, P4166; TRINCZEK B, 1993, MOL BIOL CELL, V4, P323, DOI 10.1091/mbc.4.3.323; VANHOLDE KE, 1985, PHYSICAL BIOCH, P220; VOTER WA, 1984, J BIOL CHEM, V259, P430; WALKER RA, 1988, J CELL BIOL, V107, P1437, DOI 10.1083/jcb.107.4.1437; WANG XD, 1993, MOL MICROBIOL, V9, P435, DOI 10.1111/j.1365-2958.1993.tb01705.x; White EL, 2000, J BACTERIOL, V182, P4028, DOI 10.1128/JB.182.14.4028-4034.2000; Yu XC, 1997, EMBO J, V16, P5455, DOI 10.1093/emboj/16.17.5455	67	178	179	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 13	2001	276	15					11743	11753		10.1074/jbc.M009033200	http://dx.doi.org/10.1074/jbc.M009033200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	421UK	11152458	hybrid			2022-12-25	WOS:000168081800044
J	van den Hurk, WH; Willems, HJJ; Bloemen, M; Martens, GJM				van den Hurk, WH; Willems, HJJ; Bloemen, M; Martens, GJM			Novel frameshift mutations near short simple repeats	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYLOID PRECURSOR PROTEIN; ALZHEIMERS-DISEASE; TRANSCRIPTS; SECRETION; MUTANTS; PEPTIDE	In patients with Alzheimer's disease or Down's syndrome, the cerebellar cortex exhibits protein deposits in neurofibrillary tangles and neuritic plaques. Recently, the deposits have been shown to contain protein fragments of ubiquitin-B and amyloid precursor protein (APP) with an aberrant carboxyl terminus resulting from frameshift mutations (dinucleotide deletions; Delta GU or Delta GA) in or adjacent to GAGAG motifs in their mRNAs, a process referred to as molecular misreading. We have now used a bacterial expression system with the green fluorescent protein as a reporter to screen gene transcripts from aged controls, Alzheimer's disease, and Down's syndrome for molecular misreading. Novel frameshift mutations at a number of locations in the transcripts of the ubiquitin-B and APP genes were discovered (Delta GA, DeltaG, Delta GU, Delta GG, Delta CA, Delta AU, DeltaA, Delta AA, DeltaC, DeltaU, and insertion of an A). Interestingly, most mutations were in close proximity of short simple repeats (GAGAG, GGUGGU, GAGACACACA, UCAUCAUCA, CAAACAAA, and GAAGAAGAA), demonstrating that the GAGAG motif does not constitute the only hot spot for transcriptional errors. Unlike the previously detected aberrant APP fragments, some of the novel ones have the potential to generate the neurotoxic peptide beta -amyloid, We conclude that during aging molecular misreading is a widespread phenomenon.	Univ Nijmegen, Dept Mol Anim Physiol, NL-6525 GA Nijmegen, Netherlands	Radboud University Nijmegen	Martens, GJM (corresponding author), Univ Nijmegen, Dept Mol Anim Physiol, Geert Grootepl 28, NL-6525 GA Nijmegen, Netherlands.	gmart@sci.kun.nl	Martens, Gerard JM/D-1925-2010; Bloemen, Marjon/W-9393-2018					BAKER RT, 1987, NUCLEIC ACIDS RES, V15, P443, DOI 10.1093/nar/15.2.443; CHEN WJ, 1990, J BIOL CHEM, V265, P3116; DESTROOPER B, 1993, J CELL BIOL, V121, P295, DOI 10.1083/jcb.121.2.295; EVANS DAP, 1994, P NATL ACAD SCI USA, V91, P6059, DOI 10.1073/pnas.91.13.6059; GLENNER GG, 1984, BIOCHEM BIOPH RES CO, V120, P885, DOI 10.1016/S0006-291X(84)80190-4; HAASS C, 1993, J BIOL CHEM, V268, P3021; HERSHKO A, 1985, BIOCHEM BIOPH RES CO, V128, P1079, DOI 10.1016/0006-291X(85)91050-2; Hol EM, 1998, PROG BRAIN RES, V117, P379; JACOBSEN JS, 1994, J BIOL CHEM, V269, P8376; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; LAI A, 1995, J BIOL CHEM, V270, P3565, DOI 10.1074/jbc.270.8.3565; Ono Y, 1997, J BIOCHEM-TOKYO, V121, P585; SELKOE DJ, 1994, ANNU REV CELL BIOL, V10, P373, DOI 10.1146/annurev.cb.10.110194.002105; van Leeuwen FW, 1998, SCIENCE, V279, P242, DOI 10.1126/science.279.5348.242; van Leeuwen FW, 1998, TRENDS NEUROSCI, V21, P331, DOI 10.1016/S0166-2236(98)01280-6; VANDENHURK WH, 1999, TEC BEHAV N, V13, P863	16	36	39	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 13	2001	276	15					11496	11498		10.1074/jbc.M011040200	http://dx.doi.org/10.1074/jbc.M011040200			3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	421UK	11139590	hybrid, Green Published			2022-12-25	WOS:000168081800011
J	Koroll, M; Rathjen, FG; Volkmer, H				Koroll, M; Rathjen, FG; Volkmer, H			The neural cell recognition molecule neurofascin interacts with syntenin-1 but not with syntenin-2, both of which reveal self-associating activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANKYRIN-BINDING-ACTIVITY; ADHESION MOLECULE; PDZ DOMAINS; L1 FAMILY; NERVOUS-SYSTEM; AXONAL SURFACE; PROTEIN; TYROSINE; SITE; F11	Neurofascin belongs to the L1 subgroup of the immunoglobulin superfamily of cell adhesion molecules and is implicated in axonal growth and fasciculation, We used yeast two-hybrid screening to identify proteins that interact with neurofascin intracellularly and therefore might link it to trafficking, spatial targeting, or signaling pathways, Here, we demonstrate that rat syntenin-1, previously published as syntenin, mda-9, or TACIP18 in human, is a neurofascin-binding protein that exhibits a wide-spread tissue expression pattern with a relative maximum in brain. Syntenin-1 was found not to interact with other vertebrate members of the L1 subgroup such as L1 itself or NrCAM, We confirmed the specificity of the neurofascin-syntenin-1 interaction by ligand-overlay assay, surface plasmon resonance analysis, and colocalization of both proteins in heterologous cells. The COOH terminus of neurofascin was mapped to interact with the second PDZ domain of syntenin-1. Furthermore, we isolated syntenin-2 that may be expressed in two isoforms, Despite their high sequence similarity to syntenin-1, syntenin-2 alpha, which interacts with neurexin I, and syntenin-2 beta do not bind to neurofascin or several other transmembrane proteins that are binding partners of syntenin-1, Finally, we report that syntenin-1 and -2 both form homodimers and can interact with each other.	Max Delbruck Ctr Mol Med, D-13092 Berlin, Germany	Helmholtz Association; Max Delbruck Center for Molecular Medicine	Rathjen, FG (corresponding author), Max Delbruck Ctr Mol Med, Robert Rossle Str 10, D-13092 Berlin, Germany.	Rathjen@mdc-berlin.de	Volkmer, Hansjuergen/AAU-9641-2021	Volkmer, Hansjuergen/0000-0002-3867-0603				Brummendorf T, 1998, CURR OPIN NEUROBIOL, V8, P87, DOI 10.1016/S0959-4388(98)80012-3; BRUMMENDORF T, 1989, NEURON, V2, P1351, DOI 10.1016/0896-6273(89)90073-1; Cohen NR, 1998, CURR BIOL, V8, P26, DOI 10.1016/S0960-9822(98)70017-X; Cowan CA, 2000, NEURON, V26, P417, DOI 10.1016/S0896-6273(00)81174-5; Dahme M, 1997, NAT GENET, V17, P346, DOI 10.1038/ng1197-346; Davis JQ, 1996, J CELL BIOL, V135, P1355, DOI 10.1083/jcb.135.5.1355; DAVIS JQ, 1994, J BIOL CHEM, V269, P27163; De Angelis E, 1999, EMBO J, V18, P4744, DOI 10.1093/emboj/18.17.4744; Demyanenko GP, 1999, J NEUROSCI, V19, P4907; Dubreuil RR, 1996, J CELL BIOL, V133, P647, DOI 10.1083/jcb.133.3.647; Fanning AS, 1999, J CLIN INVEST, V103, P767, DOI 10.1172/JCI6509; Fanning AS, 1999, CURR OPIN CELL BIOL, V11, P432, DOI 10.1016/S0955-0674(99)80062-3; Fernandez-Larrea J, 1999, MOL CELL, V3, P423, DOI 10.1016/S1097-2765(00)80470-0; Fialka I, 1999, J BIOL CHEM, V274, P26233, DOI 10.1074/jbc.274.37.26233; Garner CC, 2000, TRENDS CELL BIOL, V10, P274, DOI 10.1016/S0962-8924(00)01783-9; Garner CC, 2000, CURR OPIN NEUROBIOL, V10, P321, DOI 10.1016/S0959-4388(00)00093-3; Garver TD, 1997, J CELL BIOL, V137, P703, DOI 10.1083/jcb.137.3.703; Grootjans JJ, 2000, J BIOL CHEM, V275, P19933, DOI 10.1074/jbc.M002459200; Grootjans JJ, 1997, P NATL ACAD SCI USA, V94, P13683, DOI 10.1073/pnas.94.25.13683; Hassel B, 1997, J BIOL CHEM, V272, P28742, DOI 10.1074/jbc.272.45.28742; Hock B, 1998, P NATL ACAD SCI USA, V95, P9779, DOI 10.1073/pnas.95.17.9779; HORTSCH M, 1990, NEURON, V4, P697, DOI 10.1016/0896-6273(90)90196-M; Hortsch M, 2000, MOL CELL NEUROSCI, V15, P1, DOI 10.1006/mcne.1999.0809; Jefford G, 2000, J BIOL CHEM, V275, P27726; Kamiguchi H, 1998, J NEUROSCI, V18, P5311, DOI 10.1523/JNEUROSCI.18-14-05311.1998; Kamiguchi H, 1998, J NEUROSCI, V18, P3749, DOI 10.1523/jneurosci.18-10-03749.1998; Kamiguchi H, 2000, J NEUROSCI, V20, P3676, DOI 10.1523/JNEUROSCI.20-10-03676.2000; Kamiguchi H, 2000, CURR OPIN CELL BIOL, V12, P598, DOI 10.1016/S0955-0674(00)00138-1; Kiselyov VV, 1997, J BIOL CHEM, V272, P10125; Lambert S, 1997, J NEUROSCI, V17, P7025; Lin D, 1999, J BIOL CHEM, V274, P3726, DOI 10.1074/jbc.274.6.3726; Malhotra JD, 1998, J BIOL CHEM, V273, P33354, DOI 10.1074/jbc.273.50.33354; Moulding HD, 2000, J NEUROSCI, V20, P5696, DOI 10.1523/JNEUROSCI.20-15-05696.2000; Ponting CP, 1997, BIOESSAYS, V19, P469, DOI 10.1002/bies.950190606; RATHJEN FG, 1987, CELL, V51, P841, DOI 10.1016/0092-8674(87)90107-3; RATHJEN FG, 1987, J CELL BIOL, V104, P343, DOI 10.1083/jcb.104.2.343; Ren Q, 1998, J NEUROCHEM, V70, P1839; Schaefer AW, 1999, J BIOL CHEM, V274, P37965, DOI 10.1074/jbc.274.53.37965; Songyang Z, 1997, SCIENCE, V275, P73, DOI 10.1126/science.275.5296.73; Tait S, 2000, J CELL BIOL, V150, P657, DOI 10.1083/jcb.150.3.657; Torres R, 1998, NEURON, V21, P1453, DOI 10.1016/S0896-6273(00)80663-7; Tuvia S, 1997, P NATL ACAD SCI USA, V94, P12957, DOI 10.1073/pnas.94.24.12957; VOLKMER H, 1992, J CELL BIOL, V118, P149, DOI 10.1083/jcb.118.1.149; Volkmer H, 1996, J CELL BIOL, V135, P1059, DOI 10.1083/jcb.135.4.1059; Volkmer H, 1998, J CELL BIOL, V142, P1083, DOI 10.1083/jcb.142.4.1083; Zhang X, 1998, J BIOL CHEM, V273, P30785, DOI 10.1074/jbc.273.46.30785	46	99	106	0	9	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 6	2001	276	14					10646	10654		10.1074/jbc.M010647200	http://dx.doi.org/10.1074/jbc.M010647200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	420AC	11152476	hybrid			2022-12-25	WOS:000167980900013
J	Li, RA; Ennis, IL; French, RJ; Dudley, SC; Tomaselli, GF; Marban, E				Li, RA; Ennis, IL; French, RJ; Dudley, SC; Tomaselli, GF; Marban, E			Clockwise domain arrangement of the sodium channel revealed by mu-conotoxin (GIIIA) docking orientation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYSTEINE MUTAGENESIS; NA+ CHANNEL; BINDING-SITE; CONUS-GEOGRAPHUS; RAT SKELETAL; MUSCLE; PORE; RESIDUES; PEPTIDE; MUTANT	mu -Conotoxins (mu -CTXs) specifically inhibit Na+ flux by occluding the pore of voltage-gated Na+ channels. Although the three-dimensional structures of mu -CTXs are well defined, the molecular configuration of the channel receptor is much less certain; even the fundamental question of whether the four homologous Nat channel domains are arranged in a clockwise or counter-clockwise configuration remains unanswered. Residues Asp(762) and Glu(765) from domain II and Asp(1241) from domain III of rat skeletal muscle Naf channels are known to be critical for Ec-CTX binding. We probed toxin-channel interactions by determining the potency of block of wild-type, D762K, E765K, and D1241C channels by wildtype and point-mutated mu -CTXs (R1A, Q14D, K11A, K16A, and R19A). Individual interaction energies for different toxin-channel pairs were quantified from the half-blocking concentrations using mutant cycle analysis. We find that Asp(762) and Glu(765) interact strongly with Gln(14) and Arg(19) but not Arg(1) and that Asp(1241) is tightly coupled to Lys(16) but not Arg(1) or Lys(11). These newly identified toxin-channel interactions within adjacent domains, interpreted in light of the known asymmetric toxin structure, fix the orientation of the toxin with respect to the channel and reveal that the four internal domains of Na+ channels age arranged in a clockwise configuration as viewed from the extracellular surface.	Johns Hopkins Univ, Sch Med, Inst Mol Cardiobiol, Baltimore, MD 21205 USA; Univ Calgary, Dept Physiol & Biophys, Calgary, AB T2N 4N1, Canada; Emory Univ, Dept Med, Atlanta, GA 30322 USA; Emory Univ, Dept Physiol, Atlanta, GA 30322 USA	Johns Hopkins University; University of Calgary; Emory University; Emory University	Marban, E (corresponding author), Johns Hopkins Univ, Sch Med, Inst Mol Cardiobiol, 720 Rutland Ave,Ross 844, Baltimore, MD 21205 USA.		Marban, Eduardo/GWC-8514-2022; Li, Ronald/E-9833-2010; Dudley, Samuel C/A-7085-2009; Dudley, Samuel/AAR-7950-2021	Dudley, Samuel/0000-0001-5843-5961; Ennis, Irene/0000-0003-3510-7302	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL052768, R01HL064828, R01HL050411] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL-52768, R01 HL-50411, HL-64828] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BACKX PH, 1992, SCIENCE, V257, P248, DOI 10.1126/science.1321496; BECKER S, 1992, BIOCHEMISTRY-US, V31, P8229, DOI 10.1021/bi00150a016; Benitah JP, 1996, P NATL ACAD SCI USA, V93, P7392, DOI 10.1073/pnas.93.14.7392; CATTERALL WA, 1988, SCIENCE, V242, P50, DOI 10.1126/science.2459775; Chahine M, 1998, BIOPHYS J, V75, P236, DOI 10.1016/S0006-3495(98)77510-1; CHAHINE M, 1995, RECEPTOR CHANNEL, V3, P164; Chang NS, 1998, BIOCHEMISTRY-US, V37, P4407, DOI 10.1021/bi9724927; CHEN LQ, 1992, FEBS LETT, V309, P253, DOI 10.1016/0014-5793(92)80783-D; Chiamvimonvat N, 1996, NEURON, V16, P1037, DOI 10.1016/S0896-6273(00)80127-0; CRUZ LJ, 1985, J BIOL CHEM, V260, P9280; Dudley SC, 2000, J GEN PHYSIOL, V116, P679, DOI 10.1085/jgp.116.5.679; Dudley SC, 1995, BIOPHYS J, V69, P1657, DOI 10.1016/S0006-3495(95)80045-7; French R J, 1999, Methods Enzymol, V294, P575; GOLDSTEIN SAN, 1994, NEURON, V12, P1377, DOI 10.1016/0896-6273(94)90452-9; GRAY WR, 1988, ANNU REV BIOCHEM, V57, P665, DOI 10.1146/annurev.bi.57.070188.003313; Gross A, 1996, NEURON, V16, P399, DOI 10.1016/S0896-6273(00)80057-4; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HEINEMANN SH, 1992, PFLUG ARCH EUR J PHY, V422, P90, DOI 10.1007/BF00381519; HIDAKA Y, 1990, FEBS LETT, V264, P29, DOI 10.1016/0014-5793(90)80756-9; Hill JM, 1996, BIOCHEMISTRY-US, V35, P8824, DOI 10.1021/bi960073o; LANCELIN JM, 1991, BIOCHEMISTRY-US, V30, P6908, DOI 10.1021/bi00242a014; Li RA, 1997, BIOPHYS J, V73, P1874, DOI 10.1016/S0006-3495(97)78218-3; Li RA, 2000, J GEN PHYSIOL, V115, P81, DOI 10.1085/jgp.115.1.81; Li RK, 2000, J BIOL CHEM, V275, P27551; LIPKIND GM, 1994, BIOPHYS J, V66, P1, DOI 10.1016/S0006-3495(94)80746-5; MACKINNON R, 1989, SCIENCE, V245, P1382, DOI 10.1126/science.2476850; Marban E, 1998, J PHYSIOL-LONDON, V508, P647, DOI 10.1111/j.1469-7793.1998.647bp.x; MOCZYDLOWSKI E, 1986, P NATL ACAD SCI USA, V83, P5321, DOI 10.1073/pnas.83.14.5321; NAKAMURA H, 1983, EXPERIENTIA, V39, P590, DOI 10.1007/BF01971110; OLIVERA BM, 1990, SCIENCE, V249, P257, DOI 10.1126/science.2165278; PerezGarcia MT, 1996, P NATL ACAD SCI USA, V93, P300, DOI 10.1073/pnas.93.1.300; SATIN J, 1992, SCIENCE, V256, P1202, DOI 10.1126/science.256.5060.1202; SATO K, 1991, J BIOL CHEM, V266, P16989; SCHREIBER G, 1995, J MOL BIOL, V248, P478, DOI 10.1006/jmbi.1995.0235; STEPHAN MM, 1994, J MEMBRANE BIOL, V137, P1; TERLAU H, 1991, FEBS LETT, V293, P93, DOI 10.1016/0014-5793(91)81159-6; TRIMMER JS, 1989, NEURON, V3, P33, DOI 10.1016/0896-6273(89)90113-X; WAKAMATSU K, 1992, BIOCHEMISTRY-US, V31, P12577, DOI 10.1021/bi00165a006; Yamagishi T, 1997, BIOPHYS J, V73, P195, DOI 10.1016/S0006-3495(97)78060-3; YANAGAWA Y, 1986, NEUROSCI LETT, V64, P7, DOI 10.1016/0304-3940(86)90654-3	40	84	88	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 6	2001	276	14					11072	11077		10.1074/jbc.M010862200	http://dx.doi.org/10.1074/jbc.M010862200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	420AC	11154701	hybrid			2022-12-25	WOS:000167980900068
J	Anderson, JAM; Fredenburgh, JC; Stafford, AR; Guo, YS; Hirsh, J; Ghazarossian, V; Weitz, JI				Anderson, JAM; Fredenburgh, JC; Stafford, AR; Guo, YS; Hirsh, J; Ghazarossian, V; Weitz, JI			Hypersulfated low molecular weight heparin with reduced affinity for antithrombin acts as an anticoagulant by inhibiting intrinsic tenase and prothrombinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPOLYMERIZED HOLOTHURIAN GLYCOSAMINOGLYCAN; TISSUE FACTOR PATHWAY; COAGULATION-FACTOR XA; FACTOR VA BINDING; HUMAN FACTOR-IX; ACTIVE-SITE; FACTOR-VIIIA; CATALYTIC ACTIVITY; SUBSTRATE RECOGNITION; SELECTIVE-INHIBITION	In buffer systems, heparin and low molecular weight heparin (LMWH) directly inhibit the intrinsic factor X-activating complex (intrinsic tenase) but have no effect on the prothrombin-activating complex (prothrombinase). Although chemical modification of LMWH, to lower its affinity for antithrombin (LA-LMWH) has no effect on its ability to inhibit intrinsic tenase, N-desulfation of LMWH reduces its activity IS-fold, To further explore the role of sulfation, hypersulfated LA-LMWH was synthesized (sLA-LMWH), sLA-LMWH is not only a 32-fold more potent inhibitor of intrinsic tenase than LA-LMWH; it also acquires prothrombinase inhibitory activity, A direct correlation between the extent of sulfation of LA-LMWH and its inhibitory activity against intrinsic tenase and prothrombinase is observed. In plasma-based assays of tenase and prothrombinase, sLA-LMWH produces similar prolongation of clotting times in plasma depleted of antithrombin and/or heparin cofactor II as it does in control plasma. In contrast, heparin has no effect in antithrombin-depleted plasma. When the effect of sLA-LMWH on various components of tenase and prothrombinase was examined, its inhibitory activity was found to be cofactor-dependent (factors Va and VIIIa) and phospholipid-independent. These studies reveal that sLA-LMWH acts as a potent antithrombin-independent inhibitor of coagulation by attenuating intrinsic tenase and prothrombinase.	Hamilton Civ Hosp, Res Ctr, Hamilton, ON L8V 1C3, Canada; McMaster Univ, Dept Med, Hamilton, ON L8V 1C3, Canada; Vasc Therapeut Inc, Mt View, CA 94040 USA	McMaster University; McMaster University	Weitz, JI (corresponding author), Hamilton Civ Hosp, Res Ctr, Hamilton, ON L8V 1C3, Canada.		Weitz, Jeffrey/AAD-1929-2019	Weitz, Jeffrey/0000-0002-1092-7550				Ames B. N., 1966, METHOD ENZYMOL, P115, DOI DOI 10.1016/0076-6879(66)08014-5; BAJAJ SP, 1993, METHOD ENZYMOL, V222, P96; BARENHOLZ Y, 1977, BIOCHEMISTRY-US, V16, P2806, DOI 10.1021/bi00631a035; BARROW RT, 1994, J BIOL CHEM, V269, P26796; BARROW RT, 1994, J BIOL CHEM, V269, P593; BENEDICT CR, 1991, J CLIN INVEST, V88, P1760, DOI 10.1172/JCI115495; Betz A, 1997, BIOCHEMISTRY-US, V36, P181, DOI 10.1021/bi962060g; Betz A, 1998, J BIOL CHEM, V273, P10709, DOI 10.1074/jbc.273.17.10709; BLOOM JW, 1979, BIOCHEMISTRY-US, V18, P4419, DOI 10.1021/bi00587a023; Bode W, 1997, THROMB HAEMOSTASIS, V78, P501; BRANDSTETTER H, 1995, P NATL ACAD SCI USA, V92, P9796, DOI 10.1073/pnas.92.21.9796; Brandstetter H, 1996, J BIOL CHEM, V271, P29988, DOI 10.1074/jbc.271.47.29988; BROZE GJ, 1995, ANNU REV MED, V46, P103, DOI 10.1146/annurev.med.46.1.103; BROZE GJ, 1987, P NATL ACAD SCI USA, V84, P1886, DOI 10.1073/pnas.84.7.1886; CAPPELLO M, 1995, P NATL ACAD SCI USA, V92, P6152, DOI 10.1073/pnas.92.13.6152; Chang JL, 1998, J BIOL CHEM, V273, P12089, DOI 10.1074/jbc.273.20.12089; Desai UR, 1998, BIOCHEMISTRY-US, V37, P13033, DOI 10.1021/bi981426h; Esmon CT, 1996, J BIOL CHEM, V271, P13882, DOI 10.1074/jbc.271.23.13882; Fay PJ, 1998, J BIOL CHEM, V273, P19049, DOI 10.1074/jbc.273.30.19049; Fay PJ, 1999, J BIOL CHEM, V274, P15401, DOI 10.1074/jbc.274.22.15401; Feuerstein GZ, 1999, ARTERIOSCL THROM VAS, V19, P2554, DOI 10.1161/01.ATV.19.10.2554; Fredenburgh JC, 1997, J BIOL CHEM, V272, P25493, DOI 10.1074/jbc.272.41.25493; GAN ZR, 1994, J BIOL CHEM, V269, P1301; GROOTENHUIS PDJ, 1995, NAT STRUCT BIOL, V2, P736, DOI 10.1038/nsb0995-736; HASHIMOTO N, 1985, J BIOCHEM, V97, P1347, DOI 10.1093/oxfordjournals.jbchem.a135187; HIRSH J, 1992, BLOOD, V79, P1; INOUE Y, 1976, CARBOHYD RES, V46, P87, DOI 10.1016/S0008-6215(00)83533-8; JORDAN RE, 1980, J BIOL CHEM, V255, P73; Kolkman JA, 2000, BIOCHEMISTRY-US, V39, P7398, DOI 10.1021/bi992735q; Kolkman JA, 1999, BIOCHEM J, V339, P217, DOI 10.1042/0264-6021:3390217; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MANN KG, 1988, ANNU REV BIOCHEM, V57, P915, DOI 10.1146/annurev.bi.57.070188.004411; MANN KG, 1990, BLOOD, V76, P1; MANN KG, 1987, TRENDS BIOCHEM SCI, V12, P229, DOI 10.1016/0968-0004(87)90115-0; Mao SS, 1998, J BIOL CHEM, V273, P30086, DOI 10.1074/jbc.273.46.30086; Marder VJ., 1994, HEMOSTASIS THROMBOSI, P837; Mathus A, 1999, J BIOL CHEM, V274, P18477, DOI 10.1074/jbc.274.26.18477; NAGASAWA K, 1986, CARBOHYD RES, V158, P183, DOI 10.1016/0008-6215(86)84016-2; NAGASE H, 1995, BLOOD, V85, P1527, DOI 10.1182/blood.V85.6.1527.bloodjournal8561527; Nagase H, 1997, THROMB HAEMOSTASIS, V77, P399; Nagase H, 1997, THROMB HAEMOSTASIS, V78, P864; NESHEIM ME, 1984, SURV SYN PATHOL RES, V3, P219; OLSON ST, 1991, J BIOL CHEM, V266, P6342; PEPPER DS, 1977, THROMB RES, V11, P687, DOI 10.1016/0049-3848(77)90026-3; RAPAPORT SI, 1995, THROMB HAEMOSTASIS, V74, P7; Rezaie AR, 1998, J BIOL CHEM, V273, P16824, DOI 10.1074/jbc.273.27.16824; Rezaie AR, 2000, J BIOL CHEM, V275, P3320, DOI 10.1074/jbc.275.5.3320; Rudolph AE, 2000, BIOCHEMISTRY-US, V39, P2861, DOI 10.1021/bi992379b; SCHOEN P, 1990, THROMB RES, V57, P415, DOI 10.1016/0049-3848(90)90257-D; Sheehan JP, 1998, BLOOD, V92, P1617, DOI 10.1182/blood.V92.5.1617.417k13_1617_1625; Sturzebecher J, 1997, FEBS LETT, V412, P295, DOI 10.1016/S0014-5793(97)00811-9; Taniuchi Y, 1998, THROMB HAEMOSTASIS, V79, P543; TUSZYNSKI GP, 1987, J BIOL CHEM, V262, P9718; VLASUK GP, 1993, THROMB HAEMOSTASIS, V70, P212; Weitz JI, 1999, CIRCULATION, V99, P682, DOI 10.1161/01.CIR.99.5.682; Weitz JI, 1997, NEW ENGL J MED, V337, P688, DOI 10.1056/NEJM199709043371007; Wong AG, 1997, THROMB HAEMOSTASIS, V77, P1143	57	26	26	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 30	2001	276	13					9755	9761		10.1074/jbc.M010048200	http://dx.doi.org/10.1074/jbc.M010048200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	420GC	11134031	hybrid			2022-12-25	WOS:000167996400025
J	Jensen, AA; Sheppard, PO; Jensen, LB; O'Hara, PJ; Brauner-Osborne, H				Jensen, AA; Sheppard, PO; Jensen, LB; O'Hara, PJ; Brauner-Osborne, H			Construction of a high affinity zinc binding site in the metabotropic glutamate receptor mGluR1 - Noncompetitive antagonism originating from the amino-terminal domain of a family C G-protein-coupled receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-SENSING RECEPTOR; METAL-ION SITES; EXTRACELLULAR DOMAIN; LIGAND-BINDING; AGONIST-BINDING; MOLECULAR-CLONING; CA2+ RECEPTOR; EXPRESSION; SUBTYPE; REGION	The metabotropic glutamate receptors (mGluRs) belong to family C of the G-protein-coupled receptor (GPCR) superfamily. The receptors are characterized by having unusually long amino-terminal domains (ATDs), to which agonist binding has been shown to take place. Previously, we have constructed a molecular model of the ATD of mGluR1 based on a weak amino acid sequence similarity with a bacterial periplasmic binding protein. The ATD consists of two globular lobes, which are speculated to contract from an "open" to a "closed" conformation following agonist binding. In the present study, we have created a Zn2+ binding site in mGluR1b by mutating the residue Lys(260) to a histidine, Zinc acts as a noncompetitive antagonist of agonist-induced IP accumulation on the K260H mutant with an IC50 value of 2 muM, Alanine mutations of three potential "zinc coligands" in proximity to the introduced histidine in K260H knock out the ability of Zn2+ to antagonize the agonist-induced response. Zn2+ binding to K260H does not appear to affect the dimerization of the receptor, Instead, we propose that binding of zinc has introduced a structural constraint in the ATD lobe, preventing the formation of a "closed" conformation, and thus stabilizing a more or less inactive "open" form of the ATD, This study presents the first metal ion site constructed in a family C GPCR, Furthermore, it is the first time a metal ion site has been created in a region outside of the seven transmembrane regions of a GPCR and the loops connecting these. The findings offer valuable insight into the mechanism of ATD closure and family C receptor activation. Furthermore, the findings demonstrate that ATD regions other than those participating in agonist binding could be potential targets for new generations of ligands for this family of receptors.	Royal Danish Sch Pharm, Dept Med Chem, NeuroSci PharmaBiotec Res Ctr, DK-2100 Copenhagen, Denmark; Royal Danish Sch Pharm, Dept Pharmacol, NeuroSci PharmaBiotec Res Ctr, DK-2100 Copenhagen, Denmark; ZymoGenet Inc, Seattle, WA 98102 USA	Royal Danish School of Pharmacy; Royal Danish School of Pharmacy; Zymogenet Inc.	Brauner-Osborne, H (corresponding author), Royal Danish Sch Pharm, Dept Med Chem, NeuroSci PharmaBiotec Res Ctr, 2 Univ Pk, DK-2100 Copenhagen, Denmark.	hbo@dfh.dk	Bräuner-Osborne, Hans/D-7260-2011; Jensen, Anders/AAJ-3335-2020	Bräuner-Osborne, Hans/0000-0001-9495-7388; Jensen, Anders/0000-0002-7927-5052				Alberts IL, 1998, PROTEIN SCI, V7, P1700, DOI 10.1002/pro.5560070805; Annoura H, 1996, BIOORG MED CHEM LETT, V6, P763, DOI 10.1016/0960-894X(96)00104-7; Brauner-Osborne H, 2000, J MED CHEM, V43, P2609, DOI 10.1021/jm000007r; Brauner-Osborne H, 2000, GENOMICS, V65, P121, DOI 10.1006/geno.2000.6164; Brauner-Osborne H, 1999, J BIOL CHEM, V274, P18382, DOI 10.1074/jbc.274.26.18382; Brauner-Osborne H, 1999, NEUROREPORT, V10, P3923; Brown EM, 1999, AM J MED, V106, P238, DOI 10.1016/S0002-9343(98)00418-5; CHAHINE M, 1994, PFLUG ARCH EUR J PHY, V427, P136, DOI 10.1007/BF00585952; CHAKRABARTI P, 1990, PROTEIN ENG, V4, P57, DOI 10.1093/protein/4.1.57; Cheng YJ, 1998, J BIOL CHEM, V273, P35008, DOI 10.1074/jbc.273.52.35008; CHRISTIANSON DW, 1991, ADV PROTEIN CHEM, V42, P281; Doherty AJ, 1999, BIOCHEM J, V341, P415, DOI 10.1042/0264-6021:3410415; Elling CE, 1997, ANN NY ACAD SCI, V814, P142, DOI 10.1111/j.1749-6632.1997.tb46152.x; Elling CE, 1999, P NATL ACAD SCI USA, V96, P12322, DOI 10.1073/pnas.96.22.12322; Elling CE, 1997, FOLD DES, V2, pS76, DOI 10.1016/S1359-0278(97)00068-0; ELLING CE, 1995, NATURE, V374, P74, DOI 10.1038/374074a0; Galvez T, 2000, J BIOL CHEM, V275, P41166, DOI 10.1074/jbc.M007848200; Galvez T, 1999, J BIOL CHEM, V274, P13362, DOI 10.1074/jbc.274.19.13362; Gasparini F, 1999, NEUROPHARMACOLOGY, V38, P1493, DOI 10.1016/S0028-3908(99)00082-9; Hammerland LG, 1998, MOL PHARMACOL, V53, P1083; Hampson DR, 1999, J BIOL CHEM, V274, P33488, DOI 10.1074/jbc.274.47.33488; Han GM, 1999, J BIOL CHEM, V274, P10008, DOI 10.1074/jbc.274.15.10008; Holst B, 2000, MOL PHARMACOL, V58, P263, DOI 10.1124/mol.58.2.263; IPPOLITO JA, 1994, BIOCHEMISTRY-US, V33, P15241, DOI 10.1021/bi00255a004; Jensen AA, 2000, EUR J PHARMACOL, V397, P247, DOI 10.1016/S0014-2999(00)00283-1; Jensen AA, 2000, J BIOL CHEM, V275, P29547, DOI 10.1074/jbc.M910023199; KIEFER LL, 1994, BIOCHEMISTRY-US, V33, P15233, DOI 10.1021/bi00255a003; Kolczewski S, 1999, BIOORG MED CHEM LETT, V9, P2173, DOI 10.1016/S0960-894X(99)00346-7; Lesburg CA, 1997, BIOCHEMISTRY-US, V36, P15780, DOI 10.1021/bi971296x; Litschig S, 1999, MOL PHARMACOL, V55, P453; Loland CJ, 1999, J BIOL CHEM, V274, P36928, DOI 10.1074/jbc.274.52.36928; Lu ZL, 2000, J BIOL CHEM, V275, P5682, DOI 10.1074/jbc.275.8.5682; Malitschek B, 1999, MOL PHARMACOL, V56, P448, DOI 10.1124/mol.56.2.448; MCGRATH ME, 1993, BIOCHEMISTRY-US, V32, P1914, DOI 10.1021/bi00059a005; Mohler H, 1999, Trends Pharmacol Sci, V20, P87, DOI 10.1016/S0165-6147(99)01323-1; NAKANISHI S, 1994, NEURON, V13, P1031, DOI 10.1016/0896-6273(94)90043-4; Nanevicz T, 1996, J BIOL CHEM, V271, P702, DOI 10.1074/jbc.271.2.702; Nemeth EF, 1998, P NATL ACAD SCI USA, V95, P4040, DOI 10.1073/pnas.95.7.4040; OHARA PJ, 1993, NEURON, V11, P41, DOI 10.1016/0896-6273(93)90269-W; Okamoto T, 1998, J BIOL CHEM, V273, P13089, DOI 10.1074/jbc.273.21.13089; Pace AJ, 1999, J BIOL CHEM, V274, P11629, DOI 10.1074/jbc.274.17.11629; Pagano A, 2000, J BIOL CHEM, V275, P33750, DOI 10.1074/jbc.M006230200; Pin JP, 1999, EUR J PHARMACOL, V375, P277, DOI 10.1016/S0014-2999(99)00258-7; Quiocho FA, 1996, MOL MICROBIOL, V20, P17, DOI 10.1111/j.1365-2958.1996.tb02484.x; Ray K, 2000, J BIOL CHEM, V275, P34245, DOI 10.1074/jbc.M005581200; Ray K, 1999, J BIOL CHEM, V274, P27642, DOI 10.1074/jbc.274.39.27642; REGAN L, 1993, ANNU REV BIOPH BIOM, V22, P257, DOI 10.1146/annurev.bb.22.060193.001353; REGAN L, 1995, TRENDS BIOCHEM SCI, V20, P280, DOI 10.1016/S0968-0004(00)89044-1; REID SNM, 1995, J COMP NEUROL, V355, P470, DOI 10.1002/cne.903550311; Robbins MJ, 2000, GENOMICS, V67, P8, DOI 10.1006/geno.2000.6226; Romano C, 1999, NEUROPHARMACOLOGY, V38, pA37; Romano C, 1996, J BIOL CHEM, V271, P28612, DOI 10.1074/jbc.271.45.28612; Schoepp DD, 1999, NEUROPHARMACOLOGY, V38, P1431, DOI 10.1016/S0028-3908(99)00092-1; Sheikh SP, 1999, J BIOL CHEM, V274, P17033, DOI 10.1074/jbc.274.24.17033; Sheikh SP, 1996, NATURE, V383, P347, DOI 10.1038/383347a0; TAKAHASHI K, 1993, J BIOL CHEM, V268, P19341; Tirindelli R, 1998, TRENDS NEUROSCI, V21, P482, DOI 10.1016/S0166-2236(98)01274-0; Tones MA, 1995, NEUROREPORT, V7, P117, DOI 10.1097/00001756-199512290-00028; Tsuji Y, 2000, J BIOL CHEM, V275, P28144; Varney MA, 1999, J PHARMACOL EXP THER, V290, P170; Wichmann J, 1999, BIOORG MED CHEM LETT, V9, P1573, DOI 10.1016/S0960-894X(99)00227-9	61	12	12	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 30	2001	276	13					10110	10118		10.1074/jbc.M007220200	http://dx.doi.org/10.1074/jbc.M007220200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	420GC	11133983	hybrid			2022-12-25	WOS:000167996400071
J	Korolkova, YV; Kozlov, SA; Lipkin, AV; Pluzhnikov, KA; Hadley, JK; Filippov, AK; Brown, DA; Angelo, K; Strobaek, D; Jespersen, T; Olesen, SP; Jensen, BS; Grishin, EV				Korolkova, YV; Kozlov, SA; Lipkin, AV; Pluzhnikov, KA; Hadley, JK; Filippov, AK; Brown, DA; Angelo, K; Strobaek, D; Jespersen, T; Olesen, SP; Jensen, BS; Grishin, EV			An ERG channel inhibitor from the scorpion Buthus eupeus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							K+-CHANNEL; 3-DIMENSIONAL STRUCTURE; POTASSIUM CHANNELS; FUNCTIONAL EXPRESSION; CHARYBDOTOXIN; TOXIN; PEPTIDE; PURIFICATION; RECEPTOR; BLOCKER	The isolation of the peptide inhibitor of M-type K+ current, BeKm-1, from the venom of the Central Asian scorpion Buthus eupeus has been described previously (Fillipov A. K,, Kozlov, S, A, Pluzhnikov, K. A., Grishin, E. V., and Brown, D, A (1996) FEBS Lett, 384, 277-280). Here we report the cloning, expression, and selectivity of BeKm-1. A full-length cDNA of 365 nucleotides encoding the precursor of BeKm-1 was isolated using the rapid amplification of cDNA ends polymerase chain reaction technique from mRNA obtained from scorpion telsons, Sequence analysis of the cDNA revealed that the precursor contains a signal peptide of 21 amino acid residues. The mature toxin consists of 36 amino acid residues. BeKm-1 belongs to the family of scorpion venom potassium channel blockers and represents a new subgroup of these toxins. The recombinant BeKm-1 was produced as a Protein A fusion product in the periplasm of Escherichia coli. After cleavage and high performance liquid chromatography purification, recombinant BeKm-1 displayed the same properties as the native toxin, Three BeKm-1 mutants (R27K, F32K, and R27K/F32K) were generated, purified, and characterized. Recombinant wild-type BeKm-1 and the three mutants partly inhibited the native M-like current in NG108-15 at 100 nM. The effect of the recombinant BeKm-1 on different K+ channels was also studied. BeKm-1 inhibited hERG1 channels with an IC50 of 3.3 nM, but had no effect at 100 nM on hEAG, hSK1, rSK2, hIK, hBK, KCNQ1/KCNE1, KCNQ2/KCNQ3, KCNQ4 channels, and minimal effect on rELK1. Thus, BeKm-1 was shown to be a novel specific blocker of hERG1 potassium channels.	Russian Acad Sci, Shemyakin & Ovchinnikov Inst Bioorgan Chem, Moscow 117997, Russia; UCL, Dept Pharmacol, London WC1E 6BT, England; Univ Copenhagen, Panum Inst, Dept Med Physiol, DK-2200 Copenhagen N, Denmark; NeuroSearch AS, DK-2750 Ballerup, Denmark	Russian Academy of Sciences; Pushchino Scientific Center for Biological Research (PSCBI) of the Russian Academy of Sciences; Institute of Bioorganic Chemistry of the Russian Academy of Sciences; University of London; University College London; University of Copenhagen	Korolkova, YV (corresponding author), Russian Acad Sci, Shemyakin & Ovchinnikov Inst Bioorgan Chem, Ul Miklukho Maklaya 16-10,GSP-7, Moscow 117997, Russia.	july@ibch.ru	Kozlov, Sergey A/D-1548-2012; Olesen, Søren P/H-4206-2011; Jespersen, Thomas/G-4860-2011; Olesen, Søren-Peter/B-9621-2012; Lipkin, Alexey V/F-9028-2014; Brown, David A/J-9019-2012	Kozlov, Sergey A/0000-0002-0242-4240; Olesen, Søren P/0000-0002-4381-5192; Jespersen, Thomas/0000-0001-6575-360X; Lipkin, Alexey V/0000-0001-7624-8529; 				Abbott GW, 1999, CELL, V97, P175, DOI 10.1016/S0092-8674(00)80728-X; ADAMS PR, 1982, J PHYSIOL-LONDON, V332, P223, DOI 10.1113/jphysiol.1982.sp014411; Aiyar J, 1996, J BIOL CHEM, V271, P31013, DOI 10.1074/jbc.271.49.31013; AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; BONTEMS F, 1991, EUR J BIOCHEM, V196, P19, DOI 10.1111/j.1432-1033.1991.tb15780.x; BouhaoualaZahar B, 1996, EUR J BIOCHEM, V238, P653, DOI 10.1111/j.1432-1033.1996.0653w.x; BOYER HW, 1969, J MOL BIOL, V41, P459, DOI 10.1016/0022-2836(69)90288-5; BROWN DA, 1988, J PHYSIOL-LONDON, V397, P167, DOI 10.1113/jphysiol.1988.sp016994; BROWN DA, 1980, NATURE, V283, P673, DOI 10.1038/283673a0; Christie MJ, 1995, CLIN EXP PHARMACOL P, V22, P944, DOI 10.1111/j.1440-1681.1995.tb02331.x; Coetzee WA, 1999, ANN NY ACAD SCI, V868, P233, DOI 10.1111/j.1749-6632.1999.tb11293.x; Engeland B, 1998, J PHYSIOL-LONDON, V513, P647, DOI 10.1111/j.1469-7793.1998.647ba.x; FERNANDEZ I, 1994, BIOCHEMISTRY-US, V33, P14256, DOI 10.1021/bi00251a038; Filippov AK, 1996, FEBS LETT, V384, P277, DOI 10.1016/0014-5793(96)00333-X; GARCIACALVO M, 1993, J BIOL CHEM, V268, P18866; GOLDSTEIN SAN, 1994, NEURON, V12, P1377, DOI 10.1016/0896-6273(94)90452-9; Gurrola GB, 1999, FASEB J, V13, P953, DOI 10.1096/fasebj.13.8.953; HARVEY AL, 1995, TOXICON, V33, P425, DOI 10.1016/0041-0101(94)00181-7; HIDALGO P, 1995, SCIENCE, V268, P307, DOI 10.1126/science.7716527; Jensen BS, 1998, AM J PHYSIOL-CELL PH, V275, pC848, DOI 10.1152/ajpcell.1998.275.3.C848; JOHNSON BA, 1992, BIOCHEMISTRY-US, V31, P8151, DOI 10.1021/bi00150a006; JOHNSON BA, 1994, BIOCHEMISTRY-US, V33, P15061, DOI 10.1021/bi00254a015; KAWASAKI I, 1972, ANAL BIOCHEM, V48, P546, DOI 10.1016/0003-2697(72)90110-8; Kharrat R, 1996, EUR J BIOCHEM, V242, P491, DOI 10.1111/j.1432-1033.1996.0491r.x; KIYATKIN N, 1993, EUR J BIOCHEM, V213, P121, DOI 10.1111/j.1432-1033.1993.tb17741.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Legros C, 1997, FEBS LETT, V417, P123, DOI 10.1016/S0014-5793(97)01177-0; Legros C, 1996, FEBS LETT, V390, P81, DOI 10.1016/0014-5793(96)00616-3; Legros C, 1997, FEBS LETT, V402, P45, DOI 10.1016/S0014-5793(96)01492-5; LOH EY, 1989, SCIENCE, V243, P217, DOI 10.1126/science.2463672; Lu Z, 1997, BIOCHEMISTRY-US, V36, P6936, DOI 10.1021/bi9702849; MACKINNON R, 1989, SCIENCE, V245, P1382, DOI 10.1126/science.2476850; MACKINNON R, 1990, NEURON, V5, P767, DOI 10.1016/0896-6273(90)90335-D; MACKINNON R, 1991, NATURE, V350, P232, DOI 10.1038/350232a0; MACKINNON R, 1988, NEURON, V1, P997, DOI 10.1016/0896-6273(88)90156-0; Meves H, 1999, BRIT J PHARMACOL, V127, P1213, DOI 10.1038/sj.bjp.0702642; MIHAILOVA AG, 1999, FEBS LETT, V442, P226; MILLER C, 1995, NEURON, V15, P5, DOI 10.1016/0896-6273(95)90057-8; Naranjo D, 1996, NEURON, V16, P123, DOI 10.1016/S0896-6273(00)80029-X; Olamendi-Portugal T, 1998, TOXICON, V36, P759, DOI 10.1016/S0041-0101(97)00163-3; OlamendiPortugal T, 1996, BIOCHEM J, V315, P977, DOI 10.1042/bj3150977; PARK CS, 1991, P NATL ACAD SCI USA, V88, P2046, DOI 10.1073/pnas.88.6.2046; Ranganathan R, 1996, NEURON, V16, P131, DOI 10.1016/S0896-6273(00)80030-6; ROBBINS J, 1992, J PHYSIOL-LONDON, V451, P159, DOI 10.1113/jphysiol.1992.sp019159; Rowan EG, 1996, BRAZ J MED BIOL RES, V29, P1765; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Selyanko AA, 1999, J NEUROSCI, V19, P7742; SMITH C, 1986, J BIOL CHEM, V261, P4607; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; Stansfeld C, 1997, TRENDS NEUROSCI, V20, P13, DOI 10.1016/S0166-2236(96)20058-X; Stansfeld CE, 1996, P NATL ACAD SCI USA, V93, P9910, DOI 10.1073/pnas.93.18.9910; Strobaek D, 2000, BRIT J PHARMACOL, V129, P991, DOI 10.1038/sj.bjp.0703120; Strobaek D, 1996, NEUROPHARMACOLOGY, V35, P903, DOI 10.1016/0028-3908(96)00096-2; TREMEAU O, 1995, J BIOL CHEM, V270, P9362, DOI 10.1074/jbc.270.16.9362; Tytgat J, 1999, TRENDS PHARMACOL SCI, V20, P444, DOI 10.1016/S0165-6147(99)01398-X; Wang HS, 1998, SCIENCE, V282, P1890, DOI 10.1126/science.282.5395.1890	57	81	85	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 30	2001	276	13					9868	9876		10.1074/jbc.M005973200	http://dx.doi.org/10.1074/jbc.M005973200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	420GC	11136720	hybrid			2022-12-25	WOS:000167996400040
J	Kenny, MK; Mendez, F; Sandigursky, M; Kureekattil, RP; Goldman, JD; Franklin, WA; Bases, R				Kenny, MK; Mendez, F; Sandigursky, M; Kureekattil, RP; Goldman, JD; Franklin, WA; Bases, R			Heat shock protein 70 binds to human apurinic/apyrimidinic endonuclease and stimulates endonuclease activity at abasic sites	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN APURINIC ENDONUCLEASE; NUCLEOTIDE EXCISION-REPAIR; NITRIC-OXIDE; RESISTANCE; CELLS; SUBSTRATE	The interaction of human heat shock protein 70 (HSP70) with human apurinic/apyrimidinic endonuclease (HAP1) was demonstrated by coimmunoprecipitation. A combination of HSP70 and HAP1 also caused a shift in the electrophoretic mobility of a DNA fragment containing an apurinic/apyrimidinic site. The functional consequence of the HSP70/HAP1 interaction was a 10-100-fold enhancement of endonuclease activity at abasic sites. The physical and functional interaction between HSP70 and HAP1 did not require the addition of ATP. The association of HSP70 and a key base excision repair enzyme suggests a role for heat shock proteins in promoting base excision repair. These findings provide a possible mechanism by which HSP70 protects cells against oxidative stress.	Montefiore Med Ctr, Albert Einstein Coll Med, Dept Radiat Oncol, Bronx, NY 10467 USA; Montefiore Med Ctr, Albert Einstein Coll Med, Dept Radiol, Bronx, NY 10467 USA	Montefiore Medical Center; Yeshiva University; Albert Einstein College of Medicine; Montefiore Medical Center; Yeshiva University; Albert Einstein College of Medicine	Bases, R (corresponding author), Montefiore Med Ctr, Albert Einstein Coll Med, Dept Radiat Oncol, 111 E 210 St, Bronx, NY 10467 USA.				NCI NIH HHS [P30 CA 13330, CA 71612, CA 52025] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA052025, P30CA013330, R29CA052025, R29CA071612] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BELLMANN K, 1995, J CLIN INVEST, V95, P2840, DOI 10.1172/JCI117989; Burkart V, 2000, J BIOL CHEM, V275, P19521, DOI 10.1074/jbc.M002265200; Chow KC, 2000, FEBS LETT, V478, P133, DOI 10.1016/S0014-5793(00)01822-6; COVERLEY D, 1992, NUCLEIC ACIDS RES, V20, P3873, DOI 10.1093/nar/20.15.3873; FEIGE U, 1994, EXPERIENTIA, V50, P979, DOI 10.1007/BF01923452; Fujihara SM, 1999, EMBO J, V18, P411, DOI 10.1093/emboj/18.2.411; GEORGOPOULOS C, 1993, ANNU REV CELL BIOL, V9, P601, DOI 10.1146/annurev.cb.09.110193.003125; GUNTHER E, 1994, EXPERIENTIA, V50, P981; Masuda Y, 1998, J BIOL CHEM, V273, P30352, DOI 10.1074/jbc.273.46.30352; Mendez F, 2000, RADIAT RES, V153, P186, DOI 10.1667/0033-7587(2000)153[0186:HSPAWB]2.0.CO;2; Rothwell DG, 2000, NUCLEIC ACIDS RES, V28, P2207, DOI 10.1093/nar/28.11.2207; Wilson DM, 1997, NUCLEIC ACIDS RES, V25, P933, DOI 10.1093/nar/25.5.933; Zou Y, 1998, J BIOL CHEM, V273, P12887, DOI 10.1074/jbc.273.21.12887	13	54	58	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 23	2001	276	12					9532	9536		10.1074/jbc.M009297200	http://dx.doi.org/10.1074/jbc.M009297200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	413HV	11133992	hybrid			2022-12-25	WOS:000167607700120
J	Kawanaka, H; Tomikawa, M; Jones, MK; Pai, R; Szabo, IL; Sugimachi, K; Sarfeh, IJ; Tarnawski, AS				Kawanaka, H; Tomikawa, M; Jones, MK; Pai, R; Szabo, IL; Sugimachi, K; Sarfeh, IJ; Tarnawski, AS			Portal hypertensive gastric mucosa has reduced activation of MAP kinase (ERK2) in response to alcohol injury: A key to impaired healing?	FASEB JOURNAL			English	Article									Dept Vet Affairs Med Ctr, Dept Med, Long Beach, CA USA; Dept Vet Affairs Med Ctr, Dept Surg, Long Beach, CA USA; Univ Calif Irvine, Irvine, CA 90822 USA; Kyushu Univ, Dept Surg 2, Fukuoka 812, Japan	US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Long Beach Healthcare System; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Long Beach Healthcare System; University of California System; University of California Irvine; Kyushu University	Tarnawski, AS (corresponding author), DVA Med Ctr, Gastroenterol Sect 111G, 5901 E 7th St, Long Beach, CA 90822 USA.								0	18	19	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAR	2001	15	3					574	576						3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	410BE	11259371				2022-12-25	WOS:000167419500009
J	Weaver, BK; Ando, O; Kumar, KP; Reich, NC				Weaver, BK; Ando, O; Kumar, KP; Reich, NC			Apoptosis is promoted by the dsRNA-activated factor (DRAF1) during viral infection independent of the action of interferon or p53	FASEB JOURNAL			English	Article						IRF-3; transcription; defense; gene expression	DOUBLE-STRANDED-RNA; DEPENDENT PROTEIN-KINASE; DNA-DAMAGING AGENTS; VIRUS-INFECTION; SIGNAL-TRANSDUCTION; REGULATORY FACTOR-3; CELL-LINE; TRANSCRIPTION; GENE; BINDING	An apoptotic cellular defense mechanism is triggered in response to viral dsRNA generated during the course of infection by many DNA and RNA viruses. We demonstrate that apoptosis induced by dsRNA or a paramyxovirus is independent of the action of interferon as it can proceed in a variety of cell lines and primary cells deficient in an interferon response. Initiation of apoptosis appears to be triggered by activation of a cellular transcription factor, the dsRNA-activated factor (DRAF1), DRAF1 is composed of interferon regulatory factor 3 (IRF-3) and the transcriptional coactivators CREB binding protein (CBP) or p300. We find that activation of IRF-3 in the absence of viral infection stimulates apoptosis, In addition, a negative interfering mutant blocks both target gene induction and apoptosis, demonstrating a requirement for gene expression by IRF-3/DRAF1 to promote apoptosis. IRF-3/DRAF1 target gene expression is also induced in response to a distinct apoptotic stimulus, the DNA damaging agent: etoposide, The activity of the p53 tumor suppressor does not appear to be required for IRF-3/DRAF1-mediated apoptosis.	SUNY Stony Brook, Dept Pathol, Stony Brook, NY 11794 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Reich, NC (corresponding author), SUNY Stony Brook, Dept Pathol, Acad Tower B,Nicolls Rd, Stony Brook, NY 11794 USA.				NCI NIH HHS [R01CA50773, P01CA28146] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA028146, R01CA050773] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Arriola EL, 1999, ONCOGENE, V18, P1081, DOI 10.1038/sj.onc.1202391; Bitzer M, 1999, J VIROL, V73, P702, DOI 10.1128/JVI.73.1.702-708.1999; Chiou SK, 1998, VIROLOGY, V244, P108, DOI 10.1006/viro.1998.9077; DALY C, 1993, MOL CELL BIOL, V13, P3756, DOI 10.1128/MCB.13.6.3756; DALY C, 1995, J BIOL CHEM, V270, P23739, DOI 10.1074/jbc.270.40.23739; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Demaeyer E., 1988, INTERFERONS OTHER RE; Der SD, 1997, P NATL ACAD SCI USA, V94, P3279, DOI 10.1073/pnas.94.7.3279; FRITSCHE M, 1993, ONCOGENE, V8, P307; FUSE A, 1984, JPN J CANCER RES, V75, P379; Gabriele L, 1999, J EXP MED, V190, P411, DOI 10.1084/jem.190.3.411; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; GILMOUR KC, 1995, GENE EXPRESSION, V5, P1; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; HAINES DS, 1991, J CELL BIOCHEM, V46, P9, DOI 10.1002/jcb.240460104; Han JH, 1996, GENE DEV, V10, P461, DOI 10.1101/gad.10.4.461; Hande KR, 1998, BBA-GENE STRUCT EXPR, V1400, P173, DOI 10.1016/S0167-4781(98)00134-1; Harada H, 1998, BIOCHIMIE, V80, P641, DOI 10.1016/S0300-9084(99)80017-0; HWANG SY, 1995, P NATL ACAD SCI USA, V92, P11284, DOI 10.1073/pnas.92.24.11284; IHLE JN, 1995, ANNU REV IMMUNOL, V13, P369, DOI 10.1146/annurev.iy.13.040195.002101; Kibler KV, 1997, J VIROL, V71, P1992, DOI 10.1128/JVI.71.3.1992-2003.1997; Kim T, 1999, J BIOL CHEM, V274, P30686, DOI 10.1074/jbc.274.43.30686; KOROMILAS AE, 1992, SCIENCE, V257, P1685, DOI 10.1126/science.1382315; KUMAR KP, 2000, IN PRESS MOL CELL BI; LAM KM, 1995, MICROB PATHOGENESIS, V19, P169, DOI 10.1006/mpat.1995.0055; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LEVY D, 1986, P NATL ACAD SCI USA, V83, P8929, DOI 10.1073/pnas.83.23.8929; Lin RT, 1998, MOL CELL BIOL, V18, P2986, DOI 10.1128/MCB.18.5.2986; Mamane Y, 1999, GENE, V237, P1, DOI 10.1016/S0378-1119(99)00262-0; May P, 1999, ONCOGENE, V18, P7621, DOI 10.1038/sj.onc.1203285; MULLER M, 1993, EMBO J, V12, P4221, DOI 10.1002/j.1460-2075.1993.tb06106.x; Nguyen Hannah, 1997, Cytokine and Growth Factor Reviews, V8, P293, DOI 10.1016/S1359-6101(97)00019-1; Nozawa H, 1999, GENE DEV, V13, P1240, DOI 10.1101/gad.13.10.1240; Oren M, 1999, J BIOL CHEM, V274, P36031, DOI 10.1074/jbc.274.51.36031; Owczarek CM, 1997, J BIOL CHEM, V272, P23865, DOI 10.1074/jbc.272.38.23865; PINE R, 1994, EMBO J, V13, P158, DOI 10.1002/j.1460-2075.1994.tb06245.x; Prives C, 1999, J PATHOL, V187, P112; RAO L, 1992, P NATL ACAD SCI USA, V89, P7742, DOI 10.1073/pnas.89.16.7742; RAY CA, 1992, CELL, V69, P597, DOI 10.1016/0092-8674(92)90223-Y; REICH N, 1987, P NATL ACAD SCI USA, V84, P3694; Salvesen GS, 1997, CELL, V91, P443, DOI 10.1016/S0092-8674(00)80430-4; Sato M, 1998, FEBS LETT, V425, P112, DOI 10.1016/S0014-5793(98)00210-5; SCHINDLER C, 1995, ANNU REV BIOCHEM, V64, P621, DOI 10.1146/annurev.bi.64.070195.003201; SHAULIAN E, 1995, ONCOGENE, V10, P671; SHAULIAN E, 1992, MOL CELL BIOL, V12, P5581, DOI 10.1128/MCB.12.12.5581; SHAW P, 1992, P NATL ACAD SCI USA, V89, P4495, DOI 10.1073/pnas.89.10.4495; SHEN YQ, 1995, CURR OPIN GENET DEV, V5, P105, DOI 10.1016/S0959-437X(95)90061-6; Srivastava SP, 1998, J BIOL CHEM, V273, P2416, DOI 10.1074/jbc.273.4.2416; Stark GR, 1998, ANNU REV BIOCHEM, V67, P227, DOI 10.1146/annurev.biochem.67.1.227; Stommel JM, 1999, EMBO J, V18, P1660, DOI 10.1093/emboj/18.6.1660; Tanaka N, 1998, GENES CELLS, V3, P29, DOI 10.1046/j.1365-2443.1998.00164.x; van Engeland M, 1998, CYTOMETRY, V31, P1, DOI 10.1002/(SICI)1097-0320(19980101)31:1<1::AID-CYTO1>3.0.CO;2-R; Villa P, 1997, TRENDS BIOCHEM SCI, V22, P388, DOI 10.1016/S0968-0004(97)01107-9; WATHELET MG, 1992, EUR J BIOCHEM, V206, P901, DOI 10.1111/j.1432-1033.1992.tb16999.x; Wathelet MG, 1998, MOL CELL, V1, P507, DOI 10.1016/S1097-2765(00)80051-9; Weaver BK, 1998, MOL CELL BIOL, V18, P1359, DOI 10.1128/MCB.18.3.1359; WHITE E, 1990, MOL CELL BIOL, V10, P120, DOI 10.1128/MCB.10.1.120; Williams BRG, 1999, ONCOGENE, V18, P6112, DOI 10.1038/sj.onc.1203127; Yoneyama M, 1998, EMBO J, V17, P1087, DOI 10.1093/emboj/17.4.1087; Zhou AM, 1998, J INTERF CYTOK RES, V18, P953, DOI 10.1089/jir.1998.18.953	60	60	64	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	FEB	2001	15	2					501	514		10.1096/fj.00-0222com	http://dx.doi.org/10.1096/fj.00-0222com			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	400LK	11156966				2022-12-25	WOS:000166872900032
J	Raffo, AJ; Kim, AL; Fine, RL				Raffo, AJ; Kim, AL; Fine, RL			Formation of nuclear Bax/p53 complexes is associated with chemotherapy induced apoptosis	ONCOGENE			English	Article						p53; Bax; nuclear complexes; apoptosis; chemotherapy	PROGRAMMED CELL-DEATH; WILD-TYPE P53; BAX GENE; P53-DEPENDENT APOPTOSIS; 3'-TO-5' EXONUCLEASE; IN-VIVO; MELANOMA; INHIBITION; EXCLUSION; PROTEIN	Mechanisms by which chemotherapeutic agents induce apoptosis are not completely understood. Current knowledge of the actual pharmacologic effects of chemotherapy and their biochemical mechanisms are better understood than the downstream events, which initiate the apoptotic cascade. The chemotherapeutic agent cisplatin causes DNA damage and can induce apoptosis in several types of human cancers. We found the formation of previously unreported nuclear complexes between the tumor suppressor protein p53 and the pro-apoptotic protein Bax, in human melanoma cell lines induced into apoptosis following cisplatin exposure. These detergent resistant complexes were detected: after wild type (wt) p53 and Bax increased in the nucleus; at the same time when active cytoplasmic apoptosis related protease, caspase 3/CPP32 appeared; and prior to the detection of apoptotic DNA fragmentation. Three channel fluorescence laser scanning confocal image microscopy revealed that the nuclear Bax/p53 complexes remained in the nucleus and localized proximal to DNA fragmentation sites as assayed by TUNEL after cisplatin exposure. Two human melanoma cell lines, expressing wt p53, were induced into apoptosis after cisplatin exposure, however they differed in the timing of this induction. In both cell lines the formation of nuclear Bax/p53 co-immunoprecipitable complexes correlated with the timing of the induction of apoptosis, The degree of apoptosis induced by different concentrations of cisplatin correlated with the amount of nuclear Bax/p53 complexes. The coimmunoprecipitation of Bax and p53 was found regardless of the antibodies tested and was specific since Bcl-x(L)/p53 complexes were not detected. Additionally, the human prostate cancer cell line, LNCaP, also formed nuclear Bax/p53 complexes only after apoptosis was induced by paclitaxel.	Columbia Univ, Coll Phys & Surg, Div Med Oncol, Expt Therapeut Program, New York, NY 10032 USA	Columbia University	Fine, RL (corresponding author), Columbia Univ, Coll Phys & Surg, Div Med Oncol, Expt Therapeut Program, 650 W 168th St,Black Bldg,Room BB-20-25, New York, NY 10032 USA.				NATIONAL CANCER INSTITUTE [P30CA013696] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR010506] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P30AR044535] Funding Source: NIH RePORTER; NCI NIH HHS [P30-CA13696-27, 5 P30 CA13696] Funding Source: Medline; NCRR NIH HHS [1S10 RR10506] Funding Source: Medline; NIAMS NIH HHS [P30AR 44535] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ALBINO AP, 1994, MELANOMA RES, V4, P35, DOI 10.1097/00008390-199402000-00006; Barinaga M, 1998, SCIENCE, V280, P32, DOI 10.1126/science.280.5360.32; Bedner E, 1999, CYTOMETRY, V35, P181, DOI 10.1002/(SICI)1097-0320(19990301)35:3<181::AID-CYTO1>3.0.CO;2-5; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; Dennis LK, 1999, ARCH DERMATOL, V135, P275, DOI 10.1001/archderm.135.3.275; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; Gross A, 1998, EMBO J, V17, P3878, DOI 10.1093/emboj/17.14.3878; Hall HI, 1999, J AM ACAD DERMATOL, V40, P35, DOI 10.1016/S0190-9622(99)70562-1; HAUPT Y, 1995, GENE DEV, V9, P2170, DOI 10.1101/gad.9.17.2170; Ho YS, 1999, BIOCHEM PHARMACOL, V57, P143, DOI 10.1016/S0006-2952(98)00272-X; Janus F, 1999, MOL CELL BIOL, V19, P2155; Knippschild U, 1996, ONCOGENE, V12, P1755; Kobayashi T, 1998, ONCOGENE, V16, P1587, DOI 10.1038/sj.onc.1201681; Li G, 1998, MELANOMA RES, V8, P17, DOI 10.1097/00008390-199802000-00004; Mandal M, 1998, ONCOGENE, V17, P999, DOI 10.1038/sj.onc.1202020; Marchenko ND, 2000, J BIOL CHEM, V275, P16202, DOI 10.1074/jbc.275.21.16202; Martin DS, 1997, CANCER INVEST, V15, P372, DOI 10.3109/07357909709039742; MARTIN SJ, 1995, J EXP MED, V182, P1545, DOI 10.1084/jem.182.5.1545; MIYASHITA T, 1995, CELL, V80, P293; MOLL UM, 1992, P NATL ACAD SCI USA, V89, P7262, DOI 10.1073/pnas.89.15.7262; Muchmore SW, 1996, NATURE, V381, P335, DOI 10.1038/381335a0; Mummenbrauer T, 1996, CELL, V85, P1089, DOI 10.1016/S0092-8674(00)81309-4; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; Ouyang H, 1998, CLIN CANCER RES, V4, P1071; Pan GH, 1998, J BIOL CHEM, V273, P5841, DOI 10.1074/jbc.273.10.5841; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Sakao Y, 1998, JPN J CANCER RES, V89, P1020, DOI 10.1111/j.1349-7006.1998.tb00491.x; Schendel SL, 1997, P NATL ACAD SCI USA, V94, P5113, DOI 10.1073/pnas.94.10.5113; Schlamp CL, 1997, J NATL CANCER I, V89, P1530, DOI 10.1093/jnci/89.20.1530; Tremblais K, 1999, BIOCHEM BIOPH RES CO, V260, P582, DOI 10.1006/bbrc.1999.0904; Wolter KG, 1997, J CELL BIOL, V139, P1281, DOI 10.1083/jcb.139.5.1281; Yin CY, 1997, NATURE, V385, P637, DOI 10.1038/385637a0; Zerp SF, 1999, BRIT J CANCER, V79, P921, DOI 10.1038/sj.bjc.6690147; Zhivotovsky B, 1999, CELL DEATH DIFFER, V6, P644, DOI 10.1038/sj.cdd.4400536	36	51	61	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 14	2000	19	54					6216	6228		10.1038/sj.onc.1203995	http://dx.doi.org/10.1038/sj.onc.1203995			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	388YK	11175336				2022-12-25	WOS:000166210500005
J	Liu, D; Yang, XH; Yang, DL; Zhou, SY				Liu, D; Yang, XH; Yang, DL; Zhou, SY			Genetic screens in mammalian cells by enhanced retroviral mutagens	ONCOGENE			English	Article						genetic screen; retroviral mutagen; oncogene; epitope tagging	EMBRYONIC STEM-CELLS; SIGNAL-TRANSDUCTION PATHWAY; MURINE LEUKEMIA-VIRUS; HOMOLOGOUS RECOMBINATION; PROTEIN-KINASE; V-RAF; CLONING; EXPRESSION; ONCOGENE; ACTIVATION	Genetic approaches such as retrovirus-mediated mutagenesis and cDNA expression libraries have contributed greatly to our understanding of signal transduction in mammalian cells. However, previously described methods for retroviral insertional mutagenesis are hindered by low mutagenesis rates and difficulties in cloning mutated genes. cDNA expression library methods are usually cell-type dependent and bias towards abundant and short messages. With the near completion of the genome projects, alternative genetic methods are needed where large numbers of genes can be more easily isolated and biochemically studied. We have developed a novel retrovirus-mediated genetic screening method in cultured cells. To achieve efficient and regulated mutagenesis, we constructed Enhanced Retroviral Mutagen (ERR I) vectors that contained several engineered sequences (e.g., an ERM Tag and a splice donor) controlled by a tetracycline-responsive promoter. Endogenous genes can thus be randomly activated and tagged in a conditional system. NIH3T3 cells were used to screen for focus-forming genes using the ERM strategy. We showed that these added sequences increased the screening efficiency by >10-fold, and allowed more direct identification of the genes targeted. Sequence analysis of similar to 10% of the >600 focus clones recovered revealed both known oncogenes and novel factors such as protein kinases and GTP/GDP exchange proteins. The ERM strategy should help to facilitate large-scale gene identification in diverse pathways and integrate both genetic (with the completion of the genome projects) and functional information more readily.	Baylor Coll Med, Verna & Marrs Mclean Dept Biochem & Mol Biol, Houston, TX 77030 USA	Baylor College of Medicine	Zhou, SY (corresponding author), Baylor Coll Med, Verna & Marrs Mclean Dept Biochem & Mol Biol, 1 Baylor Plaza, Houston, TX 77030 USA.							AHMED NN, 1993, ONCOGENE, V8, P1957; BARBACID M, 1978, J BIOL CHEM, V253, P1408; BARBACID M, 1981, J VIROL, V37, P518, DOI 10.1128/JVI.37.1.518-523.1981; BERNS A, 1988, ARCH VIROL, V102, P1, DOI 10.1007/BF01315558; Brennan J, 1999, METH MOL B, V97, P123, DOI 10.1385/1-59259-270-8:123; BROWN DW, 1988, VIROLOGY, V162, P239, DOI 10.1016/0042-6822(88)90414-X; BUSS JE, 1989, SCIENCE, V243, P1600, DOI 10.1126/science.2648572; CAPECCHI MR, 1989, SCIENCE, V244, P1288, DOI 10.1126/science.2660260; Chiarle R, 1999, CLIN IMMUNOL, V90, P157, DOI 10.1006/clim.1998.4636; CLARK J, 1993, P NATL ACAD SCI USA, V90, P8952, DOI 10.1073/pnas.90.19.8952; COFFIN JM, 1990, RETROVIRIDAE THEIR R; Cuenda A, 1996, EMBO J, V15, P4156, DOI 10.1002/j.1460-2075.1996.tb00790.x; DANDREA A, 1990, INT J CELL CLONING, V8, P173, DOI 10.1002/stem.5530080716; Darnell RB, 1996, P NATL ACAD SCI USA, V93, P4529, DOI 10.1073/pnas.93.10.4529; DORIN JR, 1989, SCIENCE, V243, P1357; FRIEDRICH G, 1991, GENE DEV, V5, P1513, DOI 10.1101/gad.5.9.1513; GONDA MA, 1982, J VIROL, V44, P520, DOI 10.1128/JVI.44.2.520-529.1982; GOSSEN M, 1993, TRENDS BIOCHEM SCI, V18, P471, DOI 10.1016/0968-0004(93)90009-C; GOSSLER A, 1989, SCIENCE, V244, P463, DOI 10.1126/science.2497519; GUNTAKA RV, 1993, MICROBIOL REV, V57, P511, DOI 10.1128/MMBR.57.3.511-521.1993; HAYWARD WS, 1981, NATURE, V290, P475, DOI 10.1038/290475a0; HULEIHEL M, 1986, MOL CELL BIOL, V6, P2655, DOI 10.1128/MCB.6.7.2655; Jaenisch R, 1986, Symp Fundam Cancer Res, V39, P59; JAENISCH R, 1988, SCIENCE, V240, P1468, DOI 10.1126/science.3287623; JOHNSON RS, 1989, SCIENCE, V245, P1234, DOI 10.1126/science.2506639; Kawai T, 1999, GENE, V227, P249, DOI 10.1016/S0378-1119(98)00605-2; KHOSRAVIFAR R, 1994, CANCER METAST REV, V13, P67, DOI 10.1007/BF00690419; Kojima T, 1999, NAT BIOTECHNOL, V17, P487, DOI 10.1038/8666; Kung H J, 1991, Curr Top Microbiol Immunol, V171, P1; Kuwabara PE, 1997, TRENDS GENET, V13, P455, DOI 10.1016/S0168-9525(97)01253-5; Li JY, 1999, NAT GENET, V23, P348, DOI 10.1038/15531; Liu D, 2000, CURR BIOL, V10, P1233, DOI 10.1016/S0960-9822(00)00733-8; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; MUSHINSKI JF, 1983, SCIENCE, V220, P795, DOI 10.1126/science.6687762; NAHARRO G, 1984, SCIENCE, V223, P63, DOI 10.1126/science.6318314; Norman JC, 1998, J CELL BIOL, V143, P1981, DOI 10.1083/jcb.143.7.1981; Okano HJ, 1999, GENE DEV, V13, P2087, DOI 10.1101/gad.13.16.2087; Paulus W, 1996, J VIROL, V70, P62, DOI 10.1128/JVI.70.1.62-67.1996; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; RAPP UR, 1983, P NATL ACAD SCI-BIOL, V80, P4218, DOI 10.1073/pnas.80.14.4218; Robinson H L, 1983, Prog Clin Biol Res, V119, P37; Rorth P, 1998, DEVELOPMENT, V125, P1049; Rorth P, 1996, P NATL ACAD SCI USA, V93, P12418, DOI 10.1073/pnas.93.22.12418; SCHULTZ A, 1984, VIROLOGY, V133, P431, DOI 10.1016/0042-6822(84)90409-4; SIMON MA, 1992, COLD SPRING HARB SYM, V57, P375, DOI 10.1101/SQB.1992.057.01.042; SKARNES WC, 1995, P NATL ACAD SCI USA, V92, P6592, DOI 10.1073/pnas.92.14.6592; Sorensen AB, 1996, J VIROL, V70, P4063; SRINIVASAN A, 1981, P NATL ACAD SCI-BIOL, V78, P2077, DOI 10.1073/pnas.78.4.2077; Stein B, 1996, J BIOL CHEM, V271, P11427, DOI 10.1074/jbc.271.19.11427; STORM S M, 1990, Critical Reviews in Oncogenesis, V2, P1; Su B, 1996, CURR OPIN IMMUNOL, V8, P402, DOI 10.1016/S0952-7915(96)80131-2; Tate P, 1998, J CELL SCI, V111, P2575; THOMPSON S, 1989, CELL, V56, P313, DOI 10.1016/0092-8674(89)90905-7; TSICHLIS PN, 1987, ANTICANCER RES, V7, P171; VONMELCHNER H, 1989, J VIROL, V63, P3227, DOI 10.1128/JVI.63.8.3227-3233.1989; WHITEHEAD I, 1995, ONCOGENE, V10, P713; WHITEHEAD I, 1995, MOL CELL BIOL, V15, P704; Whitehead LP, 1999, MOL CELL BIOL, V19, P7759; Wiles MV, 2000, NAT GENET, V24, P13, DOI 10.1038/71622; WONG BY, 1994, J VIROL, V68, P5523, DOI 10.1128/JVI.68.9.5523-5531.1994; YOSHIDA M, 1995, TRANSGENIC RES, V4, P277, DOI 10.1007/BF01969122; Zambrowicz BP, 1998, NATURE, V392, P608, DOI 10.1038/33423	64	35	35	0	3	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 7	2000	19	52					5964	5972		10.1038/sj.onc.1203992	http://dx.doi.org/10.1038/sj.onc.1203992			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	382MY	11146547				2022-12-25	WOS:000165827900002
J	Rahman, KMW; Aranha, O; Glazyrin, A; Chinni, SR; Sarkar, FH				Rahman, KMW; Aranha, O; Glazyrin, A; Chinni, SR; Sarkar, FH			Translocation of Bax to mitochondria induces apoptotic cell death in Indole-3-carbinol (I3C) treated breast cancer cells	ONCOGENE			English	Article						cell growth inhibition; I3C; Bax; mitochondria; apoptosis	CYTOCHROME-C; BCL-2; INDUCTION; INHIBITION; CYCLE; OVEREXPRESSION; CARCINOGENESIS; ACTIVATION; RELEASE; CYTOSOL	Epidemiological studies have suggested that the consumption of fruits and vegetables that provide several classes of compounds, including Indole3-carbinol (I3C), may have chemopreventive activity against breast cancer. Several in vitro and in vivo animal studies also provide convincing evidence for the anti-tumor activity of I3C, however, the molecular mechanism(s) by which I3C exerts its biological effects on breast cancer cells has not been fully elucidated. In this study, we investigated the effects of I3C in Her-2/neu over-expressing MDA-MB-435 breast cancer cells and compared these results with parental cells transfected with control vector, We focused our investigation in elucidating the molecular mechanism(s) by which I3C induces apoptosis in breast cancer cells. Our data show that I3C inhibits breast cancer cell growth in a dose dependent manner in Her-2/neu overexpressing and in normal Her-2/neu expressing cells. Induction of apoptosis was also observed in these cell lines when treated with I3C, as measured by poly (ADP-ribose) polymerase (PARP) and caspase-3 activation. In addition, we found that I3C up-regulates Bas, downregulates Bcl-2 and, thereby, increased the ratio of Bax to Bcl-2 favoring apoptosis, These results suggest that the alteration in the expression of these genes may play an important role in mediating the biological effects of I3C. Moreover, we also show the cellular localization of Bax by confocal microscopy, which showed diffuse distribution of Bax throughout the cytoplasmic compartment in breast cancer cells in control culture. However, in 13C treated cells, Bax showed a punctate pattern of distribution that was localized in the mitochondria, From these results, we conclude that the over-expression and translocation of Bax to mitochondria causes mitochondrial depolarization and activation of caspases, which may be one of the mechanism(s) by which I3C induces apoptotic processes in I3C treated breast cancer cells. Overall, our present data provide a novel molecular mechanism(s) by which 13C elicits its biological effects on both Her-2/neu over-expressing and with normal Her-2/neu expressing breast cancer cells, suggesting that 13C could be an effective agent in inducing apoptosis in breast cancer cells.	Wayne State Univ, Sch Med, Dept Pathol, Karmanos Canc Inst, Detroit, MI 48201 USA	Barbara Ann Karmanos Cancer Institute; Wayne State University	Sarkar, FH (corresponding author), Wayne State Univ, Sch Med, Dept Pathol, Karmanos Canc Inst, 9374 Scott Hall,540 E Canfield Ave, Detroit, MI 48201 USA.				NCI NIH HHS [P30CA22453] Funding Source: Medline; NIEHS NIH HHS [P30ES06639, ES 06639] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA022453] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES006639] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		*AIFCR, 1997, FOOD NUTR PREV CANC, P436; BAILEY G, 1987, ENVIRON HEALTH PERSP, V71, P147, DOI 10.2307/3430422; Birt DF, 1996, PROG CLIN BIOL RES, V395, P223; Bradbury MH, 1997, J CONTAM HYDROL, V28, P11, DOI 10.1016/S0169-7722(97)00002-8; BRADFIELD CA, 1991, ADV EXP MED BIOL, V289, P153; Broadbent TA, 1998, CURR MED CHEM, V5, P337; Byrd JC, 1998, BLOOD, V92, P3804, DOI 10.1182/blood.V92.10.3804; CHIARUGI V, 1994, CELL MOL BIOL RES, V40, P603; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; Cover CM, 1998, J BIOL CHEM, V273, P3838, DOI 10.1074/jbc.273.7.3838; Cover CM, 1999, CANCER RES, V59, P1244; DARMON AJ, 1995, NATURE, V377, P446, DOI 10.1038/377446a0; Desagher S, 1999, J CELL BIOL, V144, P891, DOI 10.1083/jcb.144.5.891; Flagg EW, 2000, EPIDEMIOLOGY, V11, P462, DOI 10.1097/00001648-200007000-00017; Freudenheim JL, 1996, JNCI-J NATL CANCER I, V88, P340, DOI 10.1093/jnci/88.6.340; Ge XK, 1996, BIOCHEM BIOPH RES CO, V228, P153, DOI 10.1006/bbrc.1996.1631; Gross A, 1998, EMBO J, V17, P3878, DOI 10.1093/emboj/17.14.3878; GRUBBS CJ, 1995, ANTICANCER RES, V15, P709; Hsu YT, 1997, J BIOL CHEM, V272, P13829, DOI 10.1074/jbc.272.21.13829; Huber WW, 1997, MUTAT RES-FUND MOL M, V376, P115, DOI 10.1016/S0027-5107(97)00033-X; Katdare M, 1998, ONCOL REP, V5, P311; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; KOJIMA T, 1994, CANCER RES, V54, P1446; Kroemer G, 1997, NAT MED, V3, P614, DOI 10.1038/nm0697-614; Li YW, 1998, ONCOGENE, V17, P2915, DOI 10.1038/sj.onc.1202218; LOUB WD, 1975, J NATL CANCER I, V54, P985; MIYASHITA T, 1994, CANCER RES, V54, P3131; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; NIWA T, 1994, STEROIDS, V59, P523, DOI 10.1016/0039-128X(94)90070-1; Nomura M, 1999, CANCER RES, V59, P5542; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; Parker BW, 1998, BLOOD, V91, P458, DOI 10.1182/blood.V91.2.458.458_458_465; Philpott NJ, 1996, BLOOD, V87, P2244, DOI 10.1182/blood.V87.6.2244.bloodjournal8762244; RYAN JJ, 1993, MOL CELL BIOL, V13, P711, DOI 10.1128/MCB.13.1.711; SALET C, 1995, INT J RADIAT BIOL, V67, P477, DOI 10.1080/09553009514550551; Salomons GS, 1997, INT J CANCER, V71, P959, DOI 10.1002/(SICI)1097-0215(19970611)71:6<959::AID-IJC9>3.0.CO;2-X; SEDLAK ML, 1995, P NATL ACAD SCI USA, V92, P7943; SHERTZER HG, 1984, CHEM-BIOL INTERACT, V48, P81, DOI 10.1016/0009-2797(84)90008-5; Tan M, 1997, CANCER RES, V57, P1199; TIWARI RK, 1994, J NATL CANCER I, V86, P126, DOI 10.1093/jnci/86.2.126; WATTENBERG LW, 1978, CANCER RES, V38, P1410; Wolter KG, 1997, J CELL BIOL, V139, P1281, DOI 10.1083/jcb.139.5.1281; Yu DH, 1996, ONCOGENE, V13, P1359	43	76	76	1	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 23	2000	19	50					5764	5771		10.1038/sj.onc.1203959	http://dx.doi.org/10.1038/sj.onc.1203959			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	376VP	11126363				2022-12-25	WOS:000165477700008
J	Pettersson, PL; Mannervik, B				Pettersson, PL; Mannervik, B			The role of glutathione in the isomerization of Delta(5)-androstene-3,17-dione catalyzed by human glutathione transferase A1-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							S-TRANSFERASE; ACTIVE-SITE; BINDING-SITE; DELTA-5-3-KETOSTEROID ISOMERASE; HETEROLOGOUS EXPRESSION; CRYSTAL-STRUCTURES; DRUG-RESISTANCE; PHAGE DISPLAY; MU-CLASS; RAT	Human glutathione transferase (GS'P') A1-1 efficiently catalyzes the isomerization of Delta (5)-androstene-3,17-dione (AD) into Delta (4)-androstene-3,17-dione. High activity requires glutathione, but enzymatic catalysis occurs also in the absence of this cofactor. Glutathione alone shows a limited catalytic effect. S-Alkylglutathione derivatives do not promote the reaction, and the pH dependence of the isomerization indicates that the glutathione thiolate serves as a base in the catalytic mechanism. Mutation of the active-site Tyr(9) into Phe significantly decreases the steady-state kinetic parameters, alters their pH dependence, and increases the pK(a) value of the enzyme-bound glutathione thiol. Thus, Tyr(9) promotes the reaction via its phenolic hydroxyl group in protonated form. GST A2-2 has a catalytic efficiency with AD 100-fold lower than the homologous GST A1-1. Another Alpha class enzyme, GST A4-4, is 1000-fold less active than GST A1-1. The Y9F mutant of GST A1-1 is more efficient than GST A2-2 and GST A4-4, both having a glutathione cofactor and an active-site Tyr(9) residue. The active sites of GST A2-2 and GST A1-1 differ by only four amino acid residues, suggesting that proper orientation of AD in relation to the thiolate of glutathione is crucial for high catalytic efficiency in the isomerization reaction. The GST A1-1-catalyzed steroid isomerization provides a complement to the previously described isomerase activity of 3 beta -hydroxysteroid dehydrogenase.	Uppsala Univ, Biomed Ctr, Dept Biochem, SE-75123 Uppsala, Sweden	Uppsala University	Mannervik, B (corresponding author), Uppsala Univ, Biomed Ctr, Dept Biochem, Box 576, SE-75123 Uppsala, Sweden.							Armstrong RN, 1997, CHEM RES TOXICOL, V10, P2, DOI 10.1021/tx960072x; Baez S, 1997, BIOCHEM J, V324, P25, DOI 10.1042/bj3240025; BARDSLEY WG, 1995, COMPUT CHEM, V19, P75, DOI 10.1016/0097-8485(95)00007-F; Barycki JJ, 1997, ARCH BIOCHEM BIOPHYS, V345, P16, DOI 10.1006/abbi.1997.0244; BENSON AM, 1977, P NATL ACAD SCI USA, V74, P158, DOI 10.1073/pnas.74.1.158; BENSON AM, 1976, BIOCHEM BIOPH RES CO, V69, P1073, DOI 10.1016/0006-291X(76)90482-4; BJORNESTEDT R, 1995, J MOL BIOL, V247, P765; Board PG, 1997, BIOCHEM J, V328, P929; Board PG, 2000, J BIOL CHEM, V275, P24798, DOI 10.1074/jbc.M001706200; BROTHERS PN, 1995, BIOCHEMISTRY-US, V34, P15453, DOI 10.1021/bi00047a009; CLARKE TR, 1993, ENDOCRINOLOGY, V132, P1971, DOI 10.1210/en.132.5.1971; CLELAND WW, 1963, BIOCHIM BIOPHYS ACTA, V67, P104, DOI 10.1016/0926-6569(63)90211-6; DIRR H, 1994, EUR J BIOCHEM, V220, P645, DOI 10.1111/j.1432-1033.1994.tb18666.x; Dragani B, 1997, J BIOL CHEM, V272, P25518, DOI 10.1074/jbc.272.41.25518; Fersht A., 1999, STRUCTURE MECH PROTE, P114; FERSHT A, 1999, STRUCTURE MECH PROTE, P178; FORD HC, 1974, J BIOL CHEM, V249, P1363; Gustafsson A, 1999, J MOL BIOL, V288, P787, DOI 10.1006/jmbi.1999.2712; Gustafsson A, 1999, BIOCHEMISTRY-US, V38, P16268, DOI 10.1021/bi991482y; Hansson LO, 1997, BIOCHEMISTRY-US, V36, P11252, DOI 10.1021/bi9702952; Hansson LO, 1999, J MOL BIOL, V287, P265, DOI 10.1006/jmbi.1999.2607; Hayes JD, 1995, CRIT REV BIOCHEM MOL, V30, P445, DOI 10.3109/10409239509083491; Hubatsch I, 1998, BIOCHEM J, V330, P175, DOI 10.1042/bj3300175; Ji XH, 1996, P NATL ACAD SCI USA, V93, P8208, DOI 10.1073/pnas.93.16.8208; KULIOPULOS A, 1987, BIOCHEMISTRY-US, V26, P3927, DOI 10.1021/bi00387a028; LIU SX, 1992, J BIOL CHEM, V267, P4296; LUUTHE V, 1991, BIOCHEMISTRY-US, V30, P8861; MANNERVIK B, 1985, P NATL ACAD SCI USA, V82, P7202, DOI 10.1073/pnas.82.21.7202; MANNERVIK B, 1992, BIOCHEM J, V282, P305, DOI 10.1042/bj2820305; MANNERVIK B, 1988, CRC CR REV BIOCH MOL, V23, P283, DOI 10.3109/10409238809088226; Massiah MA, 1998, BIOCHEMISTRY-US, V37, P14701, DOI 10.1021/bi981447b; MCTIGUE MA, 1995, J MOL BIOL, V246, P21, DOI 10.1006/jmbi.1994.0061; MEYER DJ, 1995, BIOCHEM J, V311, P739, DOI 10.1042/bj3110739; MEYER DJ, 1991, BIOCHEM J, V274, P409, DOI 10.1042/bj2740409; Payne AH, 1997, STEROIDS, V62, P169, DOI 10.1016/S0039-128X(96)00177-8; Pemble SE, 1996, BIOCHEM J, V319, P749, DOI 10.1042/bj3190749; RHOADS DM, 1987, BIOCHEM BIOPH RES CO, V145, P474, DOI 10.1016/0006-291X(87)91345-3; Rowe JD, 1997, BIOCHEM J, V325, P481, DOI 10.1042/bj3250481; SAMUELS LT, 1951, SCIENCE, V113, P490, DOI 10.1126/science.113.2939.490; SeguraAguilar J, 1997, J BIOL CHEM, V272, P5727, DOI 10.1074/jbc.272.9.5727; SINNING I, 1993, J MOL BIOL, V232, P192, DOI 10.1006/jmbi.1993.1376; STENBERG G, 1992, BIOCHEM J, V284, P313, DOI 10.1042/bj2840313; STENBERG G, 1991, FEBS LETT, V293, P153, DOI 10.1016/0014-5793(91)81174-7; STENBERG G, 1992, PROTEIN EXPRES PURIF, V3, P80, DOI 10.1016/1046-5928(92)90060-A; TALALAY P, 1955, BIOCHIM BIOPHYS ACTA, V18, P300, DOI 10.1016/0006-3002(55)90079-2; TEW KD, 1994, CANCER RES, V54, P4313; Thomas JL, 1998, J STEROID BIOCHEM, V66, P327, DOI 10.1016/S0960-0760(98)00058-2; THOMAS JL, 1989, J STEROID BIOCHEM, V33, P209, DOI 10.1016/0022-4731(89)90296-3; Thornburg LD, 1998, BIOCHEMISTRY-US, V37, P10499, DOI 10.1021/bi980099a; TSUCHIDA S, 1992, CRIT REV BIOCHEM MOL, V27, P337, DOI 10.3109/10409239209082566; VANOMMEN B, 1990, BIOCHEM J, V269, P609, DOI 10.1042/bj2690609; Wang JB, 2000, J BIOL CHEM, V275, P5493, DOI 10.1074/jbc.275.8.5493; WIDERSTEN M, 1994, BIOCHEMISTRY-US, V33, P11717, DOI 10.1021/bi00205a007; WIDERSTEN M, 1995, J MOL BIOL, V250, P115, DOI 10.1006/jmbi.1995.0362; Widersten M, 1996, BIOCHEMISTRY-US, V35, P7731, DOI 10.1021/bi9601619; WILCE MCJ, 1994, BBA-PROTEIN STRUCT M, V1205, P1, DOI 10.1016/0167-4838(94)90086-8	56	43	43	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 13	2001	276	15					11698	11704		10.1074/jbc.M009146200	http://dx.doi.org/10.1074/jbc.M009146200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	421UK	11152686	hybrid			2022-12-25	WOS:000168081800038
J	Benjannet, S; Elagoz, A; Wickham, L; Mamarbachi, M; Munzer, JS; Basak, A; Lazure, C; Cromlish, JA; Sisodia, S; Checler, F; Chretien, M; Seidah, NG				Benjannet, S; Elagoz, A; Wickham, L; Mamarbachi, M; Munzer, JS; Basak, A; Lazure, C; Cromlish, JA; Sisodia, S; Checler, F; Chretien, M; Seidah, NG			Post-translational processing of beta-secretase (beta-amyloid-converting enzyme) and its ectodomain shedding - The pro- and transmembrane/cytosolic domains affect its cellular activity and amyloid-beta production	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRECURSOR PROTEIN; ALZHEIMERS-DISEASE; PROPROTEIN CONVERTASE; IN-VITRO; ASPARTYL PROTEASE; HUMAN BRAIN; CLEAVAGE; FURIN; BACE; IDENTIFICATION	Processing of the beta -amyloid precursor protein (beta APP) by beta- and gamma -secretases generates the amyloidogenic peptide A beta, a major factor in the etiology of Alzheimer's disease. Following the recent identification of the beta -secretase beta -amyloid-converting enzyme (BACE), we herein investigate its zymogen processing, molecular properties, and cellular trafficking. Our data show that among the proprotein convertase family members, furin is the major converting enzyme of pro-BACE into BACE within the trans-Golgi network of HK293 cells. While we demonstrate that; the 24-amino acid prosegment is required for the efficient exit of pro-BACE from the endoplasmic reticulum, it may not play a strong inhibitory role since we observe that pro-BACE can produce significant quantities of the Swedish mutant beta APP(sw) beta -secretase product C99, BACE is palmitoylated at three Cys residues within its transmembrane/cytosolic tail and is sulfated at mature N-glycosylated moieties, Data with three different antibodies show that a small fraction of membrane-bound BACE is shed into the medium and that the extent of ectodomain shedding is palmitoylation-dependent. Overexpression of full-length BACE causes a significant increase in the production of C99 and a decrease in the alpha -secretase product APPs alpha. Although there is little increase in the generation of A beta by full-length BACE, overexpression of either a soluble form of BACE (equivalent to the shed form) or one lacking the prosegment leads to enhanced A beta levels. These findings suggest that the shedding of BACE may play a role in the amyloidogenic processing of beta APP.	Clin Res Inst Montreal, Montreal, PQ H2W 1R7, Canada; Ottawa Hosp, Loeb Hlth Res Inst, Dis Aging Unit, Ottawa, ON K1Y 4K9, Canada; Clin Res Inst Montreal, Montreal, PQ H2W 1R7, Canada; Univ Chicago, Dept Pharmacol & Physiol Sci, Chicago, IL 60637 USA; CNRS, Inst Pharmacol Mol & Cellulaire, UPR 411, F-06560 Valbonne, France	Institut de Recherche Clinique de Montreal (IRCM); Universite de Montreal; University of Ottawa; Ottawa Hospital Research Institute; Institut de Recherche Clinique de Montreal (IRCM); Universite de Montreal; University of Chicago; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur	Seidah, NG (corresponding author), Clin Res Inst Montreal, 110 Pine Ave W, Montreal, PQ H2W 1R7, Canada.		Seidah, Nabil/I-3596-2013; Checler, Frederic/C-1241-2009	Seidah, Nabil/0000-0001-6503-9342; Checler, Frederic/0000-0003-2098-1750; CHRETIEN, Michel/0000-0002-8588-4460				ANDERSON ED, 1993, J BIOL CHEM, V268, P24887; Barelli HL, 1997, MOL MED, V3, P695, DOI 10.1007/BF03401708; Beisswanger R, 1998, P NATL ACAD SCI USA, V95, P11134, DOI 10.1073/pnas.95.19.11134; Benjannet S, 1997, J BIOL CHEM, V272, P26210, DOI 10.1074/jbc.272.42.26210; Bennett BD, 2000, J BIOL CHEM, V275, P37712, DOI 10.1074/jbc.M005339200; BOWMAN EJ, 1988, P NATL ACAD SCI USA, V85, P7972, DOI 10.1073/pnas.85.21.7972; Buxbaum JD, 1998, J BIOL CHEM, V273, P27765, DOI 10.1074/jbc.273.43.27765; Capell A, 2000, J BIOL CHEM, V275, P30849, DOI 10.1074/jbc.M003202200; CHECLER F, 1995, J NEUROCHEM, V65, P1431; Creemers JWM, 2001, J BIOL CHEM, V276, P4211, DOI 10.1074/jbc.M006947200; Decroly E, 1996, J BIOL CHEM, V271, P30442, DOI 10.1074/jbc.271.48.30442; Greenfield JP, 1999, P NATL ACAD SCI USA, V96, P742, DOI 10.1073/pnas.96.2.742; Haniu M, 2000, J BIOL CHEM, V275, P21099, DOI 10.1074/jbc.M002095200; Huse JT, 2000, J BIOL CHEM, V275, P33729, DOI 10.1074/jbc.M004175200; Hussain I, 1999, MOL CELL NEUROSCI, V14, P419, DOI 10.1006/mcne.1999.0811; Karaivanova VK, 1998, BIOCHEM J, V329, P511; Koike H, 1999, BIOCHEM J, V343, P371, DOI 10.1042/0264-6021:3430371; Lammich S, 1999, P NATL ACAD SCI USA, V96, P3922, DOI 10.1073/pnas.96.7.3922; Lin XL, 2000, P NATL ACAD SCI USA, V97, P1456, DOI 10.1073/pnas.97.4.1456; LIPPINCOTTSCHWARTZ J, 1991, CELL, V67, P601, DOI 10.1016/0092-8674(91)90534-6; Lopez-Perez E, 1999, J NEUROCHEM, V73, P2056; LUSSON J, 1993, P NATL ACAD SCI USA, V90, P6691, DOI 10.1073/pnas.90.14.6691; Marcinkiewicz M, 2000, J NEUROCHEM, V75, P2133, DOI 10.1046/j.1471-4159.2000.0752133.x; MATLIN KS, 1983, CELL, V34, P233, DOI 10.1016/0092-8674(83)90154-X; Mercure C, 1996, HYPERTENSION, V28, P840, DOI 10.1161/01.HYP.28.5.840; Munzer JS, 1997, J BIOL CHEM, V272, P19672, DOI 10.1074/jbc.272.32.19672; Naslund J, 2000, JAMA-J AM MED ASSOC, V283, P1571, DOI 10.1001/jama.283.12.1571; Resh MD, 1999, BBA-MOL CELL RES, V1451, P1, DOI 10.1016/S0167-4889(99)00075-0; Rigot V, 1999, EUR J BIOCHEM, V261, P659, DOI 10.1046/j.1432-1327.1999.00300.x; ROMPAEY LV, 1997, BIOCHEM J, V326, P507; Sauder JM, 2000, J MOL BIOL, V300, P241, DOI 10.1006/jmbi.2000.3860; Schweizer A, 1996, J CELL BIOL, V132, P577, DOI 10.1083/jcb.132.4.577; Seidah NG, 1999, BRAIN RES, V848, P45, DOI 10.1016/S0006-8993(99)01909-5; Seidah NG, 1999, P NATL ACAD SCI USA, V96, P1321, DOI 10.1073/pnas.96.4.1321; Selkoe DJ, 1997, SCIENCE, V275, P630, DOI 10.1126/science.275.5300.630; Sinha S, 1999, NATURE, V402, P537, DOI 10.1038/990114; SISODIA SS, 1990, SCIENCE, V248, P492, DOI 10.1126/science.1691865; Skovronsky DM, 2000, J BIOL CHEM, V275, P2568, DOI 10.1074/jbc.275.4.2568; TAKAHASHI S, 1995, J BIOL CHEM, V270, P26565, DOI 10.1074/jbc.270.44.26565; Toure BB, 2000, J BIOL CHEM, V275, P2349, DOI 10.1074/jbc.275.4.2349; Van Gassen G, 2000, NEUROBIOL DIS, V7, P135, DOI 10.1006/nbdi.2000.0306; vandeLoo JWHP, 1997, J BIOL CHEM, V272, P27116, DOI 10.1074/jbc.272.43.27116; Vassar R, 1999, SCIENCE, V286, P735, DOI 10.1126/science.286.5440.735; Wolfe MS, 1999, BIOCHEMISTRY-US, V38, P4720, DOI 10.1021/bi982562p; Xiang Y, 2000, MOL BIOL CELL, V11, P1257, DOI 10.1091/mbc.11.4.1257; Yan RQ, 1999, NATURE, V402, P533, DOI 10.1038/990107; Yu G, 1998, J BIOL CHEM, V273, P16470, DOI 10.1074/jbc.273.26.16470; Zhong M, 1999, J BIOL CHEM, V274, P33913, DOI 10.1074/jbc.274.48.33913	48	265	272	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 6	2001	276	14					10879	10887		10.1074/jbc.M009899200	http://dx.doi.org/10.1074/jbc.M009899200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	420AC	11152688	hybrid			2022-12-25	WOS:000167980900044
J	Otsuka, F; Yamamoto, S; Erickson, GF; Shimasaki, S				Otsuka, F; Yamamoto, S; Erickson, GF; Shimasaki, S			Bone morphogenetic protein-15 inhibits follicle-stimulating hormone (FSH) action by suppressing FSH receptor expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-DIFFERENTIATION FACTOR-9; RAT GRANULOSA-CELLS; MESSENGER-RIBONUCLEIC-ACID; CHAIN CLEAVAGE CYTOCHROME-P-450; MOUSE OOCYTES; INDEPENDENT REGULATION; MAMMALIAN OVARY; HOMOLOG GDF-9B; OVULATION RATE; CUMULUS CELLS	We have recently reported that oocyte-derived bone morphogenetic protein-15 (BMP-15) can directly modulate follicle-stimulating hormone (FSH) action in rat granulosa cells. Here, we investigate underlying mechanisms of this BMP-15 effect. Treatment with BMP-15 alone exerted no significant effect on the basal expression of mRNAs encoding steroidogenic acute regulatory protein, P450 side chain cleavage enzyme, P450 aromatase, 3 beta -hydroxysteroid dehydrogenase, luteinization hormone receptor, and inhibin/activin subunits. However, BMP-15 markedly inhibited the FSH-induced increases in these messages. In striking contrast, BMP-15 did not change the forskolin-induced levels of these transcripts, Thus, the inhibitory effect of BMP-15 on FSH action must be upstream of cAMP signaling. We next examined changes in FSH receptor mRNA expression. Interestingly, BMP-15 severely reduced the levels of FSH receptor mRNA in both basal and FSH-stimulated cells. To determine whether this effect was at the level of FSH function, we investigated the effect of BMP-15 on FSH bioactivity, Consistent with the mRNA data, BMP-15 inhibited the biological response of FSH, but not that of forskolin. Based on these results, we propose that BMP-15 is an important determinant of FSH action through its ability to inhibit FSH receptor expression. Because FSH plays an essential role in follicle growth and development, our findings could have new implications for understanding how oocyte growth factors contribute to folliculogenesis.	Univ Calif San Diego, Sch Med, Dept Reprod Med, La Jolla, CA 92093 USA	University of California System; University of California San Diego	Shimasaki, S (corresponding author), Univ Calif San Diego, Sch Med, Dept Reprod Med, 9500 Gilman Dr, La Jolla, CA 92093 USA.	sshimasaki@ucsd.edu			EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [U54HD012303] Funding Source: NIH RePORTER; NICHD NIH HHS [U54HD12303] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Aaltonen J, 1999, J CLIN ENDOCR METAB, V84, P2744, DOI 10.1210/jc.84.8.2744; Ariyoshi N, 1998, J BIOL CHEM, V273, P7610, DOI 10.1074/jbc.273.13.7610; BACICH DJ, 1994, ENDOCRINOLOGY, V135, P735, DOI 10.1210/en.135.2.735; BUCCIONE R, 1990, DEV BIOL, V138, P16, DOI 10.1016/0012-1606(90)90172-F; CANIPARI R, 1995, DEV BIOL, V167, P371, DOI 10.1006/dbio.1995.1031; CHAN YL, 1987, J BIOL CHEM, V262, P1111; DAVIS GH, 1992, BIOL REPROD, V46, P636, DOI 10.1095/biolreprod46.4.636; Dube JL, 1998, MOL ENDOCRINOL, V12, P1809, DOI 10.1210/me.12.12.1809; Elvin JA, 1999, MOL ENDOCRINOL, V13, P1035, DOI 10.1210/me.13.6.1035; Elvin JA, 1999, MOL ENDOCRINOL, V13, P1018, DOI 10.1210/me.13.6.1018; Elvin JA, 2000, P NATL ACAD SCI USA, V97, P10288, DOI 10.1073/pnas.180295197; Elvin JA, 2000, MOL CELL ENDOCRINOL, V159, P1, DOI 10.1016/S0303-7207(99)00185-9; Eppig JJ, 1997, BIOL REPROD, V56, P976, DOI 10.1095/biolreprod56.4.976; Eppig John J., 1997, Human Reproduction (Oxford), V12, P127; Erickson GF, 2000, TRENDS ENDOCRIN MET, V11, P193, DOI 10.1016/S1043-2760(00)00249-6; ERICKSON GF, 1978, ENDOCRINOLOGY, V102, P1275, DOI 10.1210/endo-102-4-1275; ERICKSON GF, 1983, MOL CELL ENDOCRINOL, V29, P21, DOI 10.1016/0303-7207(83)90003-5; ESCH FS, 1987, MOL ENDOCRINOL, V1, P388, DOI 10.1210/mend-1-5-388; Findlay JK, 1999, TRENDS ENDOCRIN MET, V10, P183, DOI 10.1016/S1043-2760(98)00144-1; FITZPATRICK SL, 1991, ENDOCRINOLOGY, V129, P1452, DOI 10.1210/endo-129-3-1452; Galloway SM, 2000, NAT GENET, V25, P279, DOI 10.1038/77033; GHERSEVICH S, 1994, ENDOCRINOLOGY, V135, P1963, DOI 10.1210/en.135.5.1963; GOLDSCHMIT D, 1989, ENDOCRINOLOGY, V124, P369, DOI 10.1210/endo-124-1-369; Hayashi M, 1999, ENDOCRINOLOGY, V140, P1236, DOI 10.1210/en.140.3.1236; HICKEY GJ, 1990, MOL ENDOCRINOL, V4, P3, DOI 10.1210/mend-4-1-3; HIRSHFIELD AN, 1991, INT REV CYTOL, V124, P43; HSUEH AJW, 1994, ENDOCR REV, V15, P707, DOI 10.1210/er.15.6.707; Jaatinen R, 1999, MOL CELL ENDOCRINOL, V156, P189, DOI 10.1016/S0303-7207(99)00100-8; Kumar TR, 1997, NAT GENET, V15, P201, DOI 10.1038/ng0297-201; Kumar TR, 1998, ENDOCRINOLOGY, V139, P3289, DOI 10.1210/en.139.7.3289; LACHANCE Y, 1990, J BIOL CHEM, V265, P20469; Laitinen M, 1998, MECH DEVELOP, V78, P135, DOI 10.1016/S0925-4773(98)00161-0; Matzuk MM, 2000, MOL CELL ENDOCRINOL, V163, P61, DOI 10.1016/S0303-7207(99)00241-5; Minegishi T, 2000, BIOL REPROD, V62, P325, DOI 10.1095/biolreprod62.2.325; MIURA R, 1994, BIOCHEM J, V299, P561, DOI 10.1042/bj2990561; OONK RB, 1989, J BIOL CHEM, V264, P21934; Otsuka F, 2000, J BIOL CHEM, V275, P39523, DOI 10.1074/jbc.M007428200; RICHARDS JS, 1995, RECENT PROG HORM RES, V50, P223; SALUSTRI A, 1990, J BIOL CHEM, V265, P19517; SHACKELL GH, 1993, BIOL REPROD, V48, P1150, DOI 10.1095/biolreprod48.5.1150; SIEBERT PD, 1992, NATURE, V359, P557, DOI 10.1038/359557a0; Simoni M, 1997, ENDOCR REV, V18, P739, DOI 10.1210/er.18.6.739; SPRENGEL R, 1990, MOL ENDOCRINOL, V4, P525, DOI 10.1210/mend-4-4-525; STEELE GL, 1993, OVARY, P113; Stocco DM, 1996, ENDOCR REV, V17, P221, DOI 10.1210/er.17.3.221; Tilly J L, 1996, Rev Reprod, V1, P162, DOI 10.1530/revreprod/1.3.162; TILLY JL, 1992, ENDOCRINOLOGY, V130, P1296, DOI 10.1210/en.130.3.1296; TSAIMORRIS CH, 1991, J BIOL CHEM, V266, P11355; VANDERHYDEN BC, 1995, BIOL REPROD, V53, P1243, DOI 10.1095/biolreprod53.6.1243; VANDERHYDEN BC, 1992, BIOL REPROD, V46, P1196, DOI 10.1095/biolreprod46.6.1196; VANDERHYDEN BC, 1990, DEV BIOL, V140, P307, DOI 10.1016/0012-1606(90)90081-S; Vitt UA, 2000, ENDOCRINOLOGY, V141, P3814, DOI 10.1210/en.141.10.3814; Vitt UA, 2000, BIOL REPROD, V62, P370, DOI 10.1095/biolreprod62.2.370	53	228	258	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 6	2001	276	14					11387	11392		10.1074/jbc.M010043200	http://dx.doi.org/10.1074/jbc.M010043200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	420AC	11154695	hybrid			2022-12-25	WOS:000167980900110
J	Yan, C; Luo, HL; Lee, JD; Abe, JI; Berk, BC				Yan, C; Luo, HL; Lee, JD; Abe, JI; Berk, BC			Molecular cloning of mouse ERK5/BMK1 splice variants and characterization of ERK5 functional domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE-1 BMK1; MAP KINASE KINASE; PROTEIN-KINASE; ENDOTHELIAL-CELLS; SHEAR-STRESS; NUCLEAR TRANSLOCATION; SENSITIVE KINASE; TYROSINE KINASES; GROWTH-FACTOR; SIGNAL	The mitogen-activated protein kinases (MAPKs) play important roles in regulation of cell growth and survival. Human MAPK 5 (ERK5) or Big MAP kinase 1 (BMK1) is a recently cloned member of the MAPK family. To identify ERK5-related kinases, we searched the GenBank(TM) expressed sequence tag (EST) data base for mouse cDNAs with homology to human ERK5. A full-length mouse cDNA that was highly homologous to the human ERK5 was identified. Further analysis of ERK5 polymerase chain reaction products generated from mouse embryo cDNA yielded three mouse ERK5 cDNAs (mERK5a, mERK5b, and mERK5c). Sequence analysis showed that these cDNAs are alternative splice products of the mouse ERK5 gene. Interestingly, expressed mERK5b and mERK5c act as dominant negative inhibitors based on inhibition of mERK5a kinase activity and mERK5a-mediated MEF2C transactivation. However, the physiological significance of mERK5b and mERK5c is not fully understood. Further investigation using these mouse ERK5 splice variants and other constructed mutants identified functional roles of several regions of mERK5, which-appear to be important for protein-protein interaction and intracellular localization. Specifically, we found that the long C-terminal tail, which contains a putative nuclear localization signal, is not required for activation and kinase activity but is responsible for the activation of nuclear transcription factor MEF2C due to nuclear targeting. In addition, the N-terminal domain spanning amino acids (aa) 1-77 is important for cytoplasmic targeting; the domain from aa 78 to 139 is required for association with the upstream kinase MEK5; and the domain from aa 140-406 is necessary for oligomerization. Taken together, these observations indicate that ERK5 is regulated by distinct mechanisms determined by its unique structure and presumably the presence of multiple splice variants.	Univ Rochester, Sch Med & Dent, Cardiovasc Res Ctr, Rochester, NY 14642 USA; Univ Washington, Sch Med, Dept Pathol, Seattle, WA 98195 USA; Scripps Res Inst, Dept Immunol, La Jolla, CA 92037 USA	University of Rochester; University of Washington; University of Washington Seattle; Scripps Research Institute	Berk, BC (corresponding author), Univ Rochester, Sch Med & Dent, Cardiovasc Res Ctr, Box 679,601 Elmwood Ave, Rochester, NY 14642 USA.			Berk, Bradford/0000-0002-2767-4115; Yan, Chen/0000-0002-1397-6358	NHLBI NIH HHS [HL49192, HL18645, T32HL07828] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL049192, T32HL007828, P01HL018645] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Abe J, 1996, J BIOL CHEM, V271, P16586, DOI 10.1074/jbc.271.28.16586; Abe MK, 1999, MOL CELL BIOL, V19, P1301; CATLING AD, 1995, MOL CELL BIOL, V15, P5214; COBB MH, 1994, SEMIN CANCER BIOL, V5, P261; Cuppen E, 1997, J BIOL CHEM, V272, P30215, DOI 10.1074/jbc.272.48.30215; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; Fukuda M, 1997, J BIOL CHEM, V272, P32642, DOI 10.1074/jbc.272.51.32642; Fukuda M, 1997, EMBO J, V16, P1901, DOI 10.1093/emboj/16.8.1901; GALLAGHER PJ, 1991, J BIOL CHEM, V266, P23945; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; HERSKOWITZ I, 1995, CELL, V80, P187, DOI 10.1016/0092-8674(95)90402-6; Kamakura S, 1999, J BIOL CHEM, V274, P26563, DOI 10.1074/jbc.274.37.26563; Kato Y, 1997, EMBO J, V16, P7054, DOI 10.1093/emboj/16.23.7054; Kato Y, 1998, NATURE, V395, P713, DOI 10.1038/27234; Khokhlatchev AV, 1998, CELL, V93, P605, DOI 10.1016/S0092-8674(00)81189-7; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; Lechner C, 1996, P NATL ACAD SCI USA, V93, P4355, DOI 10.1073/pnas.93.9.4355; LEE JD, 1995, BIOCHEM BIOPH RES CO, V213, P715, DOI 10.1006/bbrc.1995.2189; Lenormand P, 1998, J CELL BIOL, V142, P625, DOI 10.1083/jcb.142.3.625; LEVESQUE MJ, 1985, J BIOMECH ENG-T ASME, V107, P341, DOI 10.1115/1.3138567; Liao DF, 1997, J BIOL CHEM, V272, P6146, DOI 10.1074/jbc.272.10.6146; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; Mazaki Y, 1998, J BIOL CHEM, V273, P22435, DOI 10.1074/jbc.273.35.22435; MEANS AR, 1991, MOL CELL BIOL, V11, P3960, DOI 10.1128/MCB.11.8.3960; PLATH K, 1994, BIOCHEM BIOPH RES CO, V203, P1188, DOI 10.1006/bbrc.1994.2308; ROBBINS J, 1991, CELL, V64, P615, DOI 10.1016/0092-8674(91)90245-T; SCHALLER MD, 1993, MOL CELL BIOL, V13, P785, DOI 10.1128/MCB.13.2.785; Song HY, 1997, P NATL ACAD SCI USA, V94, P9792, DOI 10.1073/pnas.94.18.9792; Takahashi M, 1996, J CLIN INVEST, V98, P2623, DOI 10.1172/JCI119083; Yan C, 1999, J BIOL CHEM, V274, P143, DOI 10.1074/jbc.274.1.143; ZHOU GC, 1995, J BIOL CHEM, V270, P12665, DOI 10.1074/jbc.270.21.12665	32	126	131	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 6	2001	276	14					10870	10878		10.1074/jbc.M009286200	http://dx.doi.org/10.1074/jbc.M009286200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	420AC	11139578	hybrid			2022-12-25	WOS:000167980900043
J	Gupta, M; Kogut, P; Davis, FJ; Belaguli, NS; Schwartz, RJ; Gupta, MP				Gupta, M; Kogut, P; Davis, FJ; Belaguli, NS; Schwartz, RJ; Gupta, MP			Physical interaction between the MADS box of serum response factor and the TEA/ATTS DNA-binding domain of transcription enhancer factor-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-ACTIN GENE; MUSCLE-SPECIFIC TRANSCRIPTION; HEAVY-CHAIN GENE; M-CAT ELEMENTS; FACTOR-I; INDUCIBLE EXPRESSION; PROMOTER ELEMENTS; CARDIAC MYOCYTES; XENOPUS-EMBRYOS; FACTOR RTEF-1	Serum response factor is a MADS box transcription factor that binds to consensus sequences CC(A/T)(6)GG found in the promoter region of several serum-inducible and muscle-specific genes. In skeletal myocytes serum response factor (SRF) has been shown to heterodimerize with the myogenic basic helix-loop-helix family of factors, related to MyoD, for control of muscle gene regulation. Here we report that SRF binds to another myogenic factor, TEF-1, that has been implicated in the regulation of a variety of cardiac muscle genes. By using different biochemical assays such as affinity precipitation of protein, GST-pulldown assay, and coimmunoprecipitation of proteins, we show that SRF binds to TEF-1 both in in vitro and in vivo assay conditions. A strong interaction of SRF with TEF-1 was seen even when one protein was denatured and immobilized on nitrocellulose membrane, indicating a direct and stable interaction between SRF and TEF-1, which occurs without a cofactor. This interaction is mediated through the C-terminal subdomain of MADS box of SRF encompassing amino acids 204-244 and the putative 2nd and 3rd alpha -helix/beta -sheet configuration of the TEA/ATTS DNA-binding domain of TEF-1, In the transient transfection assay, a positive cooperative effect of SRF and TEF-1 was observed when DNA-binding sites for both factors, serum response element and M-CAT respectively, were intact; mutation of either site abolished their synergistic effect. Similarly, an SRF mutant, SRFpm-1, defective in DNA binding failed to collaborate with TEF-1 for gene regulation, indicating that the synergistic trans-activation function of SRF and TEF-1 occurs via their binding to cognate DNA-binding sites. Our results demonstrate a novel association between SRF and TEF-1 for cardiac muscle gene regulation and disclose a general mechanism by which these two super families of factors are likely to control diversified biological functions.	Univ Illinois, Heart Inst Children, Chicago, IL 60612 USA; Univ Illinois, Dept Physiol & Biophys, Chicago, IL 60612 USA; Univ Illinois, Dept Surg, Div Cardiac & Thorac, Chicago, IL 60637 USA; Baylor Coll Med, Dept Cell Biol, Houston, TX 77030 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; Baylor College of Medicine	Gupta, MP (corresponding author), Univ Chicago, Dept Surg Cardiac & Thorac, MC 834-4648, Chicago, IL 60637 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL068083] Funding Source: NIH RePORTER; NHLBI NIH HHS [R0-1 HL-68083] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Belaguli NS, 2000, MOL CELL BIOL, V20, P7550, DOI 10.1128/MCB.20.20.7550-7558.2000; Belaguli NS, 1999, MOL CELL BIOL, V19, P4582; Belaguli NS, 1997, J BIOL CHEM, V272, P18222, DOI 10.1074/jbc.272.29.18222; Berger LC, 1996, J VIROL, V70, P1203, DOI 10.1128/JVI.70.2.1203-1212.1996; BOXER LM, 1989, MOL CELL BIOL, V9, P515, DOI 10.1128/MCB.9.2.515; Butler AJ, 1999, MOL CELL BIOL, V19, P296; CAMPBELL S, 1992, GENE DEV, V6, P367, DOI 10.1101/gad.6.3.367; Carson JA, 1996, AM J PHYSIOL-CELL PH, V270, pC1624, DOI 10.1152/ajpcell.1996.270.6.C1624; CHAMBERS AE, 1994, GENE DEV, V8, P1324, DOI 10.1101/gad.8.11.1324; Chen CY, 1996, MOL CELL BIOL, V16, P6372; CHEN Z, 1994, GENE DEV, V8, P2293, DOI 10.1101/gad.8.19.2293; CHOW KL, 1990, MOL CELL BIOL, V10, P528, DOI 10.1128/MCB.10.2.528; Croissant JD, 1996, DEV BIOL, V177, P250, DOI 10.1006/dbio.1996.0160; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Eadara JK, 1996, VIROLOGY, V223, P120, DOI 10.1006/viro.1996.0461; Franzoso G, 1996, EMBO J, V15, P3403, DOI 10.1002/j.1460-2075.1996.tb00706.x; GILMAN MZ, 1986, MOL CELL BIOL, V6, P4305, DOI 10.1128/MCB.6.12.4305; GREENBERG ME, 1987, MOL CELL BIOL, V7, P1217, DOI 10.1128/MCB.7.3.1217; Groisman R, 1996, J BIOL CHEM, V271, P5258; GUALBERTO A, 1992, MOL CELL BIOL, V12, P4209, DOI 10.1128/MCB.12.9.4209; Gupta MP, 1997, MOL CELL BIOL, V17, P3924, DOI 10.1128/MCB.17.7.3924; GUPTA MP, 1994, J BIOL CHEM, V269, P29677; Gupta MP, 2000, NUCLEIC ACIDS RES, V28, P3168, DOI 10.1093/nar/28.16.3168; Hautmann MB, 1997, CIRC RES, V81, P600, DOI 10.1161/01.RES.81.4.600; Hines WA, 1999, MOL CELL BIOL, V19, P1841; HWANG JJ, 1993, EMBO J, V12, P2337, DOI 10.1002/j.1460-2075.1993.tb05888.x; Jacquemin P, 1997, TRENDS CARDIOVAS MED, V7, P192, DOI 10.1016/S1050-1738(97)00052-2; Jiang SW, 1996, J BIOL CHEM, V271, P9510, DOI 10.1074/jbc.271.16.9510; JOHANSEN FE, 1993, MOL CELL BIOL, V13, P4640, DOI 10.1128/MCB.13.8.4640; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; KARNS LR, 1995, J BIOL CHEM, V270, P410, DOI 10.1074/jbc.270.1.410; Koo HM, 1996, CIRCULATION, V94, P1322; Larkin SB, 1996, MOL CELL BIOL, V16, P3742; MACLELLAN WR, 1994, J BIOL CHEM, V269, P16754; Maira SM, 1996, EMBO J, V15, P5849, DOI 10.1002/j.1460-2075.1996.tb00972.x; MAR JH, 1990, MOL CELL BIOL, V10, P4271, DOI 10.1128/MCB.10.8.4271; MELIN F, 1993, EMBO J, V12, P4657, DOI 10.1002/j.1460-2075.1993.tb06154.x; METZLER DE, 1977, BIOCH CHEM REACTIONS, P75; MOLKENTIN JD, 1994, MOL CELL BIOL, V14, P5056, DOI 10.1128/MCB.14.8.5056; NATESAN S, 1995, MOL CELL BIOL, V15, P5979; PRYWES R, 1992, NUCLEIC ACIDS RES, V20, P513, DOI 10.1093/nar/20.3.513; SHAW PE, 1992, EMBO J, V11, P3011, DOI 10.1002/j.1460-2075.1992.tb05371.x; SHIMIZU N, 1993, NUCLEIC ACIDS RES, V21, P4103, DOI 10.1093/nar/21.17.4103; SHORE P, 1995, EUR J BIOCHEM, V229, P1, DOI 10.1111/j.1432-1033.1995.tb20430.x; SHORE P, 1994, MOL CELL BIOL, V14, P3283, DOI 10.1128/MCB.14.5.3283; Simmonds AJ, 1998, GENE DEV, V12, P3815, DOI 10.1101/gad.12.24.3815; Spencer JA, 1999, J BIOL CHEM, V274, P15686, DOI 10.1074/jbc.274.22.15686; STEWART AFR, 1994, J BIOL CHEM, V269, P3147; Stewart AFR, 1998, CIRC RES, V83, P43, DOI 10.1161/01.RES.83.1.43; TAYLOR M, 1989, DEVELOPMENT, V106, P67; TREISMAN R, 1994, CURR OPIN GENET DEV, V4, P96, DOI 10.1016/0959-437X(94)90097-3; Ueyama T, 2000, J BIOL CHEM, V275, P17476, DOI 10.1074/jbc.M001970200; VANDROMME M, 1992, J CELL BIOL, V118, P1489, DOI 10.1083/jcb.118.6.1489; VINCENT CK, 1993, MOL CELL BIOL, V13, P1264, DOI 10.1128/MCB.13.2.1264; XIAO JH, 1991, CELL, V65, P551, DOI 10.1016/0092-8674(91)90088-G; Zhu C, 1997, MOL CELL BIOL, V17, P4957, DOI 10.1128/MCB.17.9.4957; ZHU H, 1991, MOL CELL BIOL, V11, P2273, DOI 10.1128/MCB.11.4.2273	57	59	61	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 30	2001	276	13					10413	10422		10.1074/jbc.M008625200	http://dx.doi.org/10.1074/jbc.M008625200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	420GC	11136726	hybrid			2022-12-25	WOS:000167996400108
J	Li, BM; Comai, L				Li, BM; Comai, L			Requirements for the nucleolytic processing of DNA ends by the Werner syndrome protein-Ku70/80 complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; STRAND BREAK REPAIR; KU PROTEIN; CATALYTIC SUBUNIT; SYNDROME GENE; HELICASE; EXONUCLEASE; BINDING; CELLS; LOCALIZATION	Werner syndrome (WS) is an inherited disease characterized by premature onset of aging, increased cancer incidence, and genomic instability. The WS gene encodes a protein with helicase and exonuclease activities. Our previous studies indicated that the Werner syndrome protein (WRN) interacts with Ku, a heterodimeric factor of 70- and 80-kDa subunits implicated in the repair of double strand DNA breaks, Moreover, we demonstrated that Ku70/80 strongly stimulates and alters WRN exonuclease activity. In this report, we investigate further the association between WRN and Ku70/ 80. First, using various WRN deletion mutants we show that 50 amino acids at the amino terminus are required and sufficient to interact with Ku70/80. In addition, our data indicate that the region of Ku80 between amino acids 215 and 276 is necessary for binding to WRN, Then, we show that the amino-terminal region of WRN from amino acid 1 to 388, which comprise the exonuclease domain, can be efficiently stimulated by Ku to degrade DNA substrates, indicating that the helicase domain and the carboxyl-terminal tail are not required for the stimulatory process. Finally, using gel shift assays, we demonstrate that Ku recruits WRN to DNA, Taken together, these results suggest that Ku-mediated activation of WRN exonuclease activity may play an important role in a cellular pathway that requires processing of DNA ends.	Univ So Calif, Dept Mol Microbiol & Immunol, Keck Sch Med, Los Angeles, CA 90033 USA	University of Southern California	Comai, L (corresponding author), Univ So Calif, Dept Mol Microbiol & Immunol, Keck Sch Med, 2011 Zonal Ave,HMR-509, Los Angeles, CA 90033 USA.		Comai, Lucio/L-5905-2019; Comai, Lucio/H-9524-2019	Comai, Lucio/0000-0003-3109-1841; 				Bachant JB, 1999, NATURE, V398, P757, DOI 10.1038/19641; Bailey SM, 1999, P NATL ACAD SCI USA, V96, P14899, DOI 10.1073/pnas.96.26.14899; Baumann P, 1998, P NATL ACAD SCI USA, V95, P14066, DOI 10.1073/pnas.95.24.14066; Cooper MP, 2000, GENE DEV, V14, P907; Critchlow SE, 1998, TRENDS BIOCHEM SCI, V23, P394, DOI 10.1016/S0968-0004(98)01284-5; DEVRIES E, 1989, J MOL BIOL, V208, P65, DOI 10.1016/0022-2836(89)90088-0; Difilippantonio MJ, 2000, NATURE, V404, P510, DOI 10.1038/35006670; Dyer CAE, 1998, AGE AGEING, V27, P73, DOI 10.1093/ageing/27.1.73; Dynan WS, 1998, NUCLEIC ACIDS RES, V26, P1551, DOI 10.1093/nar/26.7.1551; ELLIS NA, 1995, CELL, V83, P655, DOI 10.1016/0092-8674(95)90105-1; EPSTEIN CJ, 1966, MEDICINE, V45, P177, DOI 10.1097/00005792-196605000-00001; FUJIWARA Y, 1977, J CELL PHYSIOL, V92, P365, DOI 10.1002/jcp.1040920305; FUKUCHI K, 1989, P NATL ACAD SCI USA, V86, P5893, DOI 10.1073/pnas.86.15.5893; GEBHART E, 1988, HUM GENET, V80, P135, DOI 10.1007/BF00702855; Gell D, 1999, NUCLEIC ACIDS RES, V27, P3494, DOI 10.1093/nar/27.17.3494; Goto M, 1996, CANCER EPIDEM BIOMAR, V5, P239; GOTTLIEB TM, 1993, CELL, V72, P131, DOI 10.1016/0092-8674(93)90057-W; Grawunder U, 1997, NATURE, V388, P492, DOI 10.1038/41358; Gray MD, 1998, EXP CELL RES, V242, P487, DOI 10.1006/excr.1998.4124; Gray MD, 1997, NAT GENET, V17, P100, DOI 10.1038/ng0997-100; Hammarsten O, 1998, P NATL ACAD SCI USA, V95, P525, DOI 10.1073/pnas.95.2.525; Huang SR, 1998, NAT GENET, V20, P114, DOI 10.1038/2410; Jin SF, 1997, EMBO J, V16, P6874, DOI 10.1093/emboj/16.22.6874; Kamath-Loeb AS, 1998, J BIOL CHEM, V273, P34145, DOI 10.1074/jbc.273.51.34145; Kanaar R, 1998, TRENDS CELL BIOL, V8, P483, DOI 10.1016/S0962-8924(98)01383-X; Karanjawala ZE, 1999, CURR BIOL, V9, P1501, DOI 10.1016/S0960-9822(00)80123-2; Li BM, 2000, J BIOL CHEM, V275, P28349, DOI 10.1074/jbc.C000289200; Marciniak RA, 1998, P NATL ACAD SCI USA, V95, P6887, DOI 10.1073/pnas.95.12.6887; Martin G M, 1978, Birth Defects Orig Artic Ser, V14, P5; Matsumoto T, 1997, NAT GENET, V16, P335, DOI 10.1038/ng0897-335; MIMORI T, 1986, J BIOL CHEM, V261, P375; Moser MJ, 1997, NUCLEIC ACIDS RES, V25, P5110, DOI 10.1093/nar/25.24.5110; Mushegian AR, 1997, P NATL ACAD SCI USA, V94, P5831, DOI 10.1073/pnas.94.11.5831; Ochem AE, 1997, J BIOL CHEM, V272, P29919, DOI 10.1074/jbc.272.47.29919; Orren DK, 1999, NUCLEIC ACIDS RES, V27, P3557, DOI 10.1093/nar/27.17.3557; PAILLARD S, 1991, NUCLEIC ACIDS RES, V19, P5619, DOI 10.1093/nar/19.20.5619; Paull TT, 1999, GENE DEV, V13, P1276, DOI 10.1101/gad.13.10.1276; Paull TT, 1998, MOL CELL, V1, P969, DOI 10.1016/S1097-2765(00)80097-0; Paull TT, 2000, P NATL ACAD SCI USA, V97, P6409, DOI 10.1073/pnas.110144297; PURANAM KL, 1994, J BIOL CHEM, V269, P29838; Ramsden DA, 1998, EMBO J, V17, P609, DOI 10.1093/emboj/17.2.609; RUNGER TM, 1994, J INVEST DERMATOL, V102, P45, DOI 10.1111/1523-1747.ep12371730; SALK D, 1985, ADV EXP MED BIOL, V190, P541; Shen JC, 2000, NUCLEIC ACIDS RES, V28, P3260, DOI 10.1093/nar/28.17.3260; Shen JC, 1998, J BIOL CHEM, V273, P34139, DOI 10.1074/jbc.273.51.34139; Shen JC, 1998, NUCLEIC ACIDS RES, V26, P2879, DOI 10.1093/nar/26.12.2879; Singleton BK, 1999, MOL CELL BIOL, V19, P3267; STEFANINI M, 1989, MUTAT RES, V219, P179, DOI 10.1016/0921-8734(89)90013-1; Vogel H, 1999, P NATL ACAD SCI USA, V96, P10770, DOI 10.1073/pnas.96.19.10770; Wu XT, 1996, MOL CELL BIOL, V16, P5186; Yu CE, 1996, SCIENCE, V272, P258, DOI 10.1126/science.272.5259.258	51	86	87	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 30	2001	276	13					9896	9902		10.1074/jbc.M008575200	http://dx.doi.org/10.1074/jbc.M008575200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	420GC	11152456	hybrid			2022-12-25	WOS:000167996400044
J	Peron, P; Rahmani, M; Zagar, Y; Durand-Schneider, AM; Lardeux, B; Bernuau, D				Peron, P; Rahmani, M; Zagar, Y; Durand-Schneider, AM; Lardeux, B; Bernuau, D			Potentiation of smad transactivation by jun proteins during a combined treatment with epidermal growth factor and transforming growth factor-beta in rat hepatocytes - Role of phosphatidylinositol 8-kinase-induced AP-1 activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-TRANSFORMATION; INDUCED APOPTOSIS; KINASE PATHWAY; DNA-SYNTHESIS; TRANSCRIPTION; 3-KINASE; BINDING; FAMILY; IDENTIFICATION; SUPERFAMILY	Cross-talk between Smad and mitogen-activated protein kinase pathways has been described recently, and evidence for Smad cooperation with AP-1 is emerging. Here we report that epidermal growth factor (EGF) potentializes transforming growth factor beta (TGF-beta)-induced Smad3 transactivation in rat hepatocytes, an effect abrogated by TAM-67, a dominant negative mutant of AP-1, Antisense transfection experiments indicated that c-Jun and JunB were involved in the synergistic effect, and endogenous c-Jun physically associated with Smad3 during a combined EGF/TGF-beta treatment, We next investigated which signaling pathway transduced by EGF was responsible for the jun-induced synergism. Whereas inhibition of JNK had no effect, inhibition of the phosphatidylinositol-3 ' kinase (PI3-kinase) pathway by LY294002 or by expression of a dominant negative mutant of PI3-kinase reduced EGF/TGF-beta -induced Smad3 transcriptional activity. Transfection of an activated Has with a mutation enabling the activation of the PI3-kinase pathway alone mimicked the EGF/TGF-beta potentiation of Smad3 transactivation, and TAM-67 abolished this effect, suggesting that the PI3 -kinase pathway stimulates Smad3 via AP-1 stimulation. The EGF/TGF-beta -induced activation of Smad3 correlated with PI3-kinase and p38-dependent but not JNK-dependent phosphorylation of c-Jun, Since potentiation of a Smad-binding element-driven gene was also induced by EGF/TGF-beta treatment, this novel mechanism of Jun/Smad cooperation might be crucial for diversifying TGF-P responses.	Univ Paris 07, Fac Med Xavier Bichat, INSERM Unite 327, Biol Cellulaire Lab, F-75018 Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bichat-Claude Bernard - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Bernuau, D (corresponding author), Univ Paris 07, Fac Med Xavier Bichat, INSERM Unite 327, Biol Cellulaire Lab, F-75018 Paris, France.	bernuau@bichat.inserm.fr		Rahmani, Mohamed/0000-0002-3992-8039				Adachi-Yamada T, 1999, MOL CELL BIOL, V19, P2322; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; Attisano L, 1998, CURR OPIN CELL BIOL, V10, P188, DOI 10.1016/S0955-0674(98)80141-5; BALAVOINE S, 1990, EUR J BIOCHEM, V189, P617, DOI 10.1111/j.1432-1033.1990.tb15530.x; Bondeva T, 1998, SCIENCE, V282, P293, DOI 10.1126/science.282.5387.293; BROWN PH, 1994, ONCOGENE, V9, P791; BROWN PH, 1993, ONCOGENE, V8, P877; CARR BI, 1986, CANCER RES, V46, P2330; Chen RH, 1999, J BIOL CHEM, V274, P23013, DOI 10.1074/jbc.274.33.23013; Chen RH, 1998, ONCOGENE, V17, P1959, DOI 10.1038/sj.onc.1202111; Chen YG, 1998, GENE DEV, V12, P2144, DOI 10.1101/gad.12.14.2144; de Caestecker MP, 1998, GENE DEV, V12, P1587, DOI 10.1101/gad.12.11.1587; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; Dennler S, 2000, J BIOL CHEM, V275, P28858, DOI 10.1074/jbc.M910358199; Garrington TP, 1999, CURR OPIN CELL BIOL, V11, P211, DOI 10.1016/S0955-0674(99)80028-3; Hackel PO, 1999, CURR OPIN CELL BIOL, V11, P184, DOI 10.1016/S0955-0674(99)80024-6; Hanafusa H, 1999, J BIOL CHEM, V274, P27161, DOI 10.1074/jbc.274.38.27161; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Hu PPC, 1998, ENDOCR REV, V19, P349, DOI 10.1210/er.19.3.349; Huang CS, 1997, J BIOL CHEM, V272, P4187, DOI 10.1074/jbc.272.7.4187; Huang CS, 1996, MOL CELL BIOL, V16, P6427; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; Kimura N, 2000, J BIOL CHEM, V275, P17647, DOI 10.1074/jbc.M908622199; KINGSLEY DM, 1994, GENE DEV, V8, P133, DOI 10.1101/gad.8.2.133; Kretzschmar M, 1999, GENE DEV, V13, P804, DOI 10.1101/gad.13.7.804; Kretzschmar M, 1997, NATURE, V389, P618, DOI 10.1038/39348; Krymskaya VP, 1997, AM J PHYSIOL-LUNG C, V273, pL1220, DOI 10.1152/ajplung.1997.273.6.L1220; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; Le Cam A, 1995, Methods Mol Biol, V48, P141; Liberati NT, 1999, P NATL ACAD SCI USA, V96, P4844, DOI 10.1073/pnas.96.9.4844; Logan SK, 1997, MOL CELL BIOL, V17, P5784, DOI 10.1128/MCB.17.10.5784; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; MCMAHON JB, 1986, CANCER RES, V46, P4665; Nadori F, 1997, HEPATOLOGY, V26, P1477; NAKAMURA T, 1985, BIOCHEM BIOPH RES CO, V133, P1042, DOI 10.1016/0006-291X(85)91241-0; Osborn MT, 1999, BIOTECHNIQUES, V27, P887, DOI 10.2144/99275bm02; Roberts RA, 2000, HEPATOLOGY, V31, P420, DOI 10.1002/hep.510310223; RodriguezViciana P, 1997, CELL, V89, P457, DOI 10.1016/S0092-8674(00)80226-3; Sano Y, 1999, J BIOL CHEM, V274, P8949, DOI 10.1074/jbc.274.13.8949; SEED B, 1988, GENE, V67, P271, DOI 10.1016/0378-1119(88)90403-9; Seglen P O, 1976, Methods Cell Biol, V13, P29, DOI 10.1016/S0091-679X(08)61797-5; Shibuya H, 1996, SCIENCE, V272, P1179, DOI 10.1126/science.272.5265.1179; Thelen M, 1995, BIOCHEM BIOPH RES CO, V217, P1255, DOI 10.1006/bbrc.1995.2903; Tibbles LA, 1999, CELL MOL LIFE SCI, V55, P1230, DOI 10.1007/s000180050369; Verrecchia F, 2000, J BIOL CHEM, V275, P30226, DOI 10.1074/jbc.M005310200; WANG SR, 1985, IN VITRO CELL DEV B, V21, P526; Wong C, 1999, MOL CELL BIOL, V19, P1821; YAMAGUCHI K, 1995, SCIENCE, V270, P2008, DOI 10.1126/science.270.5244.2008; Yingling JM, 1997, MOL CELL BIOL, V17, P7019, DOI 10.1128/MCB.17.12.7019; Zawel L, 1998, MOL CELL, V1, P611, DOI 10.1016/S1097-2765(00)80061-1; Zhang Y, 1998, NATURE, V394, P909, DOI 10.1038/29814	51	27	28	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 30	2001	276	13					10524	10531		10.1074/jbc.M005919200	http://dx.doi.org/10.1074/jbc.M005919200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	420GC	11134003	hybrid			2022-12-25	WOS:000167996400121
J	Liao, HJ; Ji, QS; Carpenter, G				Liao, HJ; Ji, QS; Carpenter, G			Phospholipase C-gamma 1 is required for the induction of immediate early genes by platelet-derived growth factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-GAMMA; FACTOR RECEPTOR; PHOSPHORYLATION SITES; BETA-RECEPTOR; SIGNAL; CELL; IDENTIFICATION; MESSENGER; PATHWAYS; TERMINUS	To explore the functional role of phospholipase C-gamma1 (PLC-gamma1) in the induction of immediate early genes (IEGs), we have examined the influence of PLcg1 gene disruption on the expression of 14 IEG mRNAs induced by platelet-derived growth factor (PDGF). Plcg1-null embryos were used to produce immortalized fibroblasts genetically deficient in PLC-gamma1 (Null cells), and retroviral infection of those cells was used to derive PLC-gamma1 re-expressing cells (Null+ cells). In terms of PDGF activation of PDGF receptor tyrosine phosphorylation as well as the mitogen-activated protein kinases Erk1 and Erk2, Null and Null+ cells responded equivalently. However, the PDGF-dependent expression of all IEG mRNAs was diminished in cells lacking PLC-gamma1. The expression of FIC, COX-2, KC, JE, and c-fos mRNAs were most strongly compromised, as the stimulation of these genes was reduced by more than 90% in cells lacking PLC-gamma1, The combination of PIMA and ionomycin, downstream analogs of PLC activation, did provoke expression of mRNAs for these IEGs in the Null cells. We conclude that PLC-gamma1 is necessary for the maximal expression of many PDGF-induced IEGs and is essential for significant induction of at least five IEGs.	Vanderbilt Univ, Sch Med, Dept Biochem, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Dept Med, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University	Carpenter, G (corresponding author), Vanderbilt Univ, Sch Med, Dept Biochem, 221 Kirkland Hall, Nashville, TN 37232 USA.	graham.carpenter@mcmail.vanderbilt.edu			NCI NIH HHS [CA75195] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA075195] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALMENDRAL JM, 1988, MOL CELL BIOL, V8, P2140, DOI 10.1128/MCB.8.5.2140; BERRIDGE MJ, 1984, NATURE, V312, P315, DOI 10.1038/312315a0; Carpenter G, 1999, EXP CELL RES, V253, P15, DOI 10.1006/excr.1999.4671; CRABTREE GR, 1994, ANNU REV BIOCHEM, V63, P1045, DOI 10.1146/annurev.biochem.63.1.1045; Fambrough D, 1999, CELL, V97, P727, DOI 10.1016/S0092-8674(00)80785-0; HERSCHMAN HR, 1991, ANNU REV BIOCHEM, V60, P281, DOI 10.1146/annurev.biochem.60.1.281; HOMMA Y, 1989, BIOCHEM BIOPH RES CO, V164, P406, DOI 10.1016/0006-291X(89)91734-8; Ji GS, 1998, MOL BIOL CELL, V9, P749, DOI 10.1091/mbc.9.4.749; Ji QS, 1999, MOL CELL BIOL, V19, P4961; Ji QS, 1997, P NATL ACAD SCI USA, V94, P2999, DOI 10.1073/pnas.94.7.2999; KASHISHIAN A, 1993, MOL BIOL CELL, V4, P49, DOI 10.1091/mbc.4.1.49; LAROSE L, 1993, ONCOGENE, V8, P2493; Montmayeur JP, 1997, J BIOL CHEM, V272, P32670, DOI 10.1074/jbc.272.51.32670; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; Rao A, 1997, ANNU REV IMMUNOL, V15, P707, DOI 10.1146/annurev.immunol.15.1.707; Rhee SG, 1997, J BIOL CHEM, V272, P15045, DOI 10.1074/jbc.272.24.15045; Roche S, 1996, EMBO J, V15, P4940, DOI 10.1002/j.1460-2075.1996.tb00874.x; ROLLINS BJ, 1989, ADV CANCER RES, V53, P1; RONNSTRAND L, 1992, EMBO J, V11, P3911, DOI 10.1002/j.1460-2075.1992.tb05484.x; Schlessinger J, 2000, CELL, V103, P211, DOI 10.1016/j.cell.2010.06.011; Thackeray JR, 1998, DEVELOPMENT, V125, P5033; VALIUS M, 1993, MOL CELL BIOL, V13, P133, DOI 10.1128/MCB.13.1.133; VALIUS M, 1993, CELL, V73, P321, DOI 10.1016/0092-8674(93)90232-F; Wang DM, 2000, IMMUNITY, V13, P25, DOI 10.1016/S1074-7613(00)00005-4; Wang ZX, 1998, MOL CELL BIOL, V18, P590, DOI 10.1128/MCB.18.1.590	25	18	21	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 23	2001	276	12					8627	8630		10.1074/jbc.C100030200	http://dx.doi.org/10.1074/jbc.C100030200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	413HV	11254653	hybrid			2022-12-25	WOS:000167607700002
J	Ren, XY; Kasir, J; Rahamimoff, H				Ren, XY; Kasir, J; Rahamimoff, H			The transport activity of the Na+-Ca2+ exchanger NCX1 expressed in HEK 293 cells is sensitive to covalent modification of intracellular cysteine residues by sulfhydryl reagents	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FUNCTIONAL EXPRESSION; SINGLE CYSTEINE; TOPOLOGY; MUTANTS; CLONING; REGION; RBE-1; MODEL; SITE	Membrane permeable N-ethylmaleimide (NEM) and (2-aminoethyl)methanethiosulfonatehydrobromide (MTSEA) inhibited the rat brain Na+-Ca2+ exchanger RBE-2 (NCX1.5) expressed in HEK 293 cells in a dose dependent manner. 50% inhibition was obtained at 1 mM MTSEA and 1.65 mM NEM, External application of membrane impermeable [2-(trimethylammonium)ethyl]methanethiosulfonatebromide (MTSET) and sodium(2-sulfonatoethyl)methanethiosulfonate (MTSES) did not inhibit the transport activity in whole cells, Following reconstitution, however, of RBE-2 transfected, cell proteins into proteoliposomes, external application of MTSET and MTSES led to decrease in transport activity to 42.7 (S.D. = 9.1) and 51% (S.D. = 10.14), respectively. Similar results were obtained also when the rat heart isoform RHE-1 (NCX1.1) or the rat brain isoform RBE-1 (NCX1.4) was expressed. NEM and MTSEA inhibited Na+ gradient-dependent Ca2+ uptake also in HEK 293 cells expressing RBE-2/C14A/C20S/C122S/C780S (numbering corresponds to RBE-2), a mutant in which all putative extracellular cysteines were exchanged. To study the accessibility of different cysteines to covalent modification, surface biotinylation of cells expressing the wild type exchanger and its mutants was carried out using 3-(N-maleimidylpropionyl)biocytin. Surface biotinylation revealed immunoreactive protein derived from the wild type Na+-Ca2+ exchanger only if the transfected cells were exposed to the reducing agent Tris(2-carboxyethyl)phosphine. No reduction was needed when the single cysteine mutants of RBE-2, C14A, C20S, and C780S, were expressed. Treatment of the cells expressing these mutants with MTSET before biotinylation, led to a decrease in the amount of exchanger protein that was revealed. No immunoreactive protein was detected when the quadruple mutant RBE-2, C14A/C20S/C122S/C780S, was biotinylated, suggesting that no additional cysteines are accessible directly from the extracellular face of the membrane. Permeabilizing the cells expressing RBE-2/C14A/C20S/C122S/C780S with streptolysin O resulted in biotinylation of the exchanger protein. Its amount decreased if exposure to NEM preceded streptolysin O treatment. Our results suggest that Na+-Ca2+ exchange activity is inhibited by covalent modification with sulfhydryl reagents of cysteine residues that are accessible from the cytoplasmic face of the membrane.	Hebrew Univ Jerusalem, Hadassah Med Sch, Dept Biochem, IL-91120 Jerusalem, Israel	Hebrew University of Jerusalem	Rahamimoff, H (corresponding author), Hebrew Univ Jerusalem, Hadassah Med Sch, Dept Biochem, IL-91120 Jerusalem, Israel.	Hannah@cc.huji.ac.il						BARZILAI A, 1987, BIOCHEMISTRY-US, V26, P6113, DOI 10.1021/bi00393a025; Cook O, 1998, BBA-BIOMEMBRANES, V1371, P40, DOI 10.1016/S0005-2736(97)00272-1; DIPOLO R, 1993, BIOCHIM BIOPHYS ACTA, V1145, P75, DOI 10.1016/0005-2736(93)90383-B; Doering AE, 1998, J BIOL CHEM, V273, P778, DOI 10.1074/jbc.273.2.778; FURMAN I, 1995, J BIOL CHEM, V270, P19120, DOI 10.1074/jbc.270.32.19120; Grunewald M, 1998, NEURON, V21, P623, DOI 10.1016/S0896-6273(00)80572-3; Harlow E., 1988, ANTIBODIES LAB MANUA; HAZAMA S, 1983, Hokkaido Journal of Medical Science, V58, P354; HRYSHKO LV, 1993, BIOCHIM BIOPHYS ACTA, V1151, P35, DOI 10.1016/0005-2736(93)90068-B; Iwamoto T, 1999, FEBS LETT, V446, P264, DOI 10.1016/S0014-5793(99)00218-5; Kasir J, 1999, J BIOL CHEM, V274, P24873, DOI 10.1074/jbc.274.35.24873; KIRLEY TL, 1989, J BIOL CHEM, V264, P7185; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LOO TW, 1995, J BIOL CHEM, V270, P22957, DOI 10.1074/jbc.270.39.22957; LOW W, 1993, FEBS LETT, V316, P63, DOI 10.1016/0014-5793(93)81737-K; Nicoll DA, 1999, J BIOL CHEM, V274, P910, DOI 10.1074/jbc.274.2.910; NICOLL DA, 1990, SCIENCE, V250, P562, DOI 10.1126/science.1700476; ORLICKY J, 1987, GEN PHYSIOL BIOPHYS, V6, P155; PIERCE GN, 1986, J MEMBRANE BIOL, V94, P217, DOI 10.1007/BF01869717; Ren X, 1999, NEUROSCI LETT, pS34; Ruegg U T, 1977, Methods Enzymol, V47, P111; Santacruz-Toloza L, 2000, J BIOL CHEM, V275, P182, DOI 10.1074/jbc.275.1.182; Shafer DE, 2000, ANAL BIOCHEM, V282, P161, DOI 10.1006/abio.2000.4609; Stephan MM, 1997, BIOCHEMISTRY-US, V36, P1322, DOI 10.1021/bi962150l; Wakabayashi S, 2000, J BIOL CHEM, V275, P7942, DOI 10.1074/jbc.275.11.7942	25	15	15	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 23	2001	276	12					9572	9579		10.1074/jbc.M007823200	http://dx.doi.org/10.1074/jbc.M007823200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	413HV	11134012	hybrid			2022-12-25	WOS:000167607700126
J	Mooren, FC; Turi, S; Gunzel, D; Schlue, WR; Domschke, W; Singh, J; Lerch, MM				Mooren, FC; Turi, S; Gunzel, D; Schlue, WR; Domschke, W; Singh, J; Lerch, MM			Calcium-magnesium interactions in pancreatic acinar cells	FASEB JOURNAL			English	Article						acetylcholine; cholecystokinin-octapeptide (CCK); fura-2 (AM); ion transport; magfura-2 (AM); pancreatic acinar cells	INTRACELLULAR FREE MAGNESIUM; EXTRACELLULAR MG2+ CONCENTRATION; SUBLINGUAL MUCOUS ACINI; CYTOSOLIC-FREE MG2+; SECRETORY RESPONSES; EPITHELIAL-CELLS; RAT PANCREAS; GLAND-CELLS; MG-2+; TRANSPORT	Although the role of calcium (Ca2+) in the signal transduction and pathobiology of the exocrine pancreas is firmly established, the role of magnesium (Mg2+) remains unclear. We have characterized the intracellular distribution of Mg2+ in response to hormone stimulation in isolated mouse pancreatic acinar cells and studied the role of Mg2+ in modulating Ca2+ signaling using microspectrofluorometry and digital imaging of Ca2+- or Mg2+-sensitive fluorescent dyes as well as Mg2+-sensitive intracellular microelectrodes. Our results indicate that an increase in intracellular Mg2+ concentrations reduced the cholecystokinin (CCK) -induced Ca2+ oscillations by inhibiting the capacitive Ca2+ influx. An intracellular Ca2+ mobilization, on the other hand, was paralleled by a decrease in [Mg2+](i), which was reversible upon hormone withdrawal independent of the electrochemical gradients for Mg2+, Ca2+, Na+, and K+, and not caused by Mg2+ efflux from acinar cells. In an attempt to characterize possible Mg2+ stores that would explain the reversible, hormone-induced intracellular Mg2+ movements, we ruled out mitochondria or ATP as potential Mg2+ buffers and found that the CCK-induced [Mg2+](i) decrease was initiated at the basolateral part of the acinar cells, where most of the endoplasmic reticulum (ER) is located, and progressed from there toward the apical pole of the acinar cells in an antiparallel fashion to Ca2+ waves. These experiments represent the first characterization of intracellular Mg2+ movements in the exocrine pancreas, provide evidence for possible Mg2+ stores in the ER, and indicate that the spatial and temporal distribution of intracellular Mg concentrations profoundly affects acinar cell Ca2+ siGnaling.-Mooren, F. C., Turi, S., Gunzel, D., Schlue, W.-R., Domschke, W., Singh, J., Lerch, M. M. Calcium-magnesium interactions in pancreatic acinar cells.	Univ Munster, Dept Med B, D-48129 Munster, Germany; Univ Dusseldorf, Inst Neurobiol, D-4000 Dusseldorf, Germany; Univ Cent Lancashire, Dept Biol Sci, Cell Commun Grp, Preston PR1 2HE, Lancs, England	University of Munster; Heinrich Heine University Dusseldorf; University of Central Lancashire	Lerch, MM (corresponding author), Univ Munster, Dept Med B, Albert Schweitzer Str 33, D-48129 Munster, Germany.		Lerch, Markus M./E-2206-2016	Lerch, Markus M./0000-0002-9643-8263; Gunzel, Dorothee/0000-0002-7998-7164				AGUS Z, 1989, AM J PHYSIOL, V256, P452; ALVAREZLEEFMANS FJ, 1984, J PHYSIOL-LONDON, V354, P303, DOI 10.1113/jphysiol.1984.sp015377; BAUMANN O, 1991, P NATL ACAD SCI USA, V88, P741, DOI 10.1073/pnas.88.3.741; Berridge M, 1999, CURR BIOL, V9, pR157, DOI 10.1016/S0960-9822(99)80101-8; Berridge MJ, 1997, J EXP BIOL, V200, P315; Birch NG, 1993, MAGNESIUM CELL; BOND M, 1987, J BIOL CHEM, V262, P15636; CARAFOLI E, 1987, ANNU REV BIOCHEM, V56, P395, DOI 10.1146/annurev.biochem.56.1.395; CORKEY BE, 1986, J BIOL CHEM, V261, P2567; DAI LJ, 1992, AM J PHYSIOL, V262, pF1100; DIWAN JJ, 1987, BIOCHIM BIOPHYS ACTA, V895, P155, DOI 10.1016/S0304-4173(87)80001-0; FLATMAN PW, 1984, J MEMBRANE BIOL, V80, P1, DOI 10.1007/BF01868686; FRANCIS LP, 1990, EXP PHYSIOL, V75, P669, DOI 10.1113/expphysiol.1990.sp003445; FREUDENRICH CC, 1992, AM J PHYSIOL, V262, pC1024, DOI 10.1152/ajpcell.1992.262.4.C1024; GRUBBS RD, 1991, AM J PHYSIOL, V260, pC1158, DOI 10.1152/ajpcell.1991.260.6.C1158; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; GUKOVSKAYA A, 1994, AM J PHYSIOL, V266, pG350, DOI 10.1152/ajpgi.1994.266.3.G350; GUNTHER T, 1985, BIOCHEM BIOPH RES CO, V130, P540, DOI 10.1016/0006-291X(85)90450-4; Gunzel D, 1997, PFLUG ARCH EUR J PHY, V435, P65, DOI 10.1007/s004240050484; GYLFE E, 1990, BIOCHIM BIOPHYS ACTA, V1055, P82, DOI 10.1016/0167-4889(90)90094-T; HAJNOCZKY G, 1994, J BIOL CHEM, V269, P10280; Hintz K, 1999, PFLUG ARCH EUR J PHY, V437, P354, DOI 10.1007/s004240050789; Hofer AM, 1998, EMBO J, V17, P1986, DOI 10.1093/emboj/17.7.1986; HOFER AM, 1994, AM J PHYSIOL, V267, pG442, DOI 10.1152/ajpgi.1994.267.3.G442; HURLEY TW, 1992, AM J PHYSIOL, V263, pC300, DOI 10.1152/ajpcell.1992.263.2.C300; ISHIJIMA S, 1991, AM J PHYSIOL, V261, pC1074, DOI 10.1152/ajpcell.1991.261.6.C1074; JUNG DW, 1994, J BIOENERG BIOMEMBR, V26, P527, DOI 10.1007/BF00762737; KASAHARA K, 1993, BIOCHEM BIOPH RES CO, V197, P92, DOI 10.1006/bbrc.1993.2445; KASAI H, 1993, CELL, V74, P669, DOI 10.1016/0092-8674(93)90514-Q; Kruger B, 2000, AM J PATHOL, V157, P43, DOI 10.1016/S0002-9440(10)64515-4; LANSMAN JB, 1986, J GEN PHYSIOL, V88, P321, DOI 10.1085/jgp.88.3.321; LENNARD R, 1992, GEN PHARMACOL, V23, P903, DOI 10.1016/0306-3623(92)90244-E; LENNARD R, 1991, J PHYSIOL-LONDON, V435, P483, DOI 10.1113/jphysiol.1991.sp018520; LERCH MM, 1993, GASTROENTEROLOGY, V104, P1768, DOI 10.1016/0016-5085(93)90658-Y; Mooren FC, 1997, BBA-MOL CELL RES, V1358, P279, DOI 10.1016/S0167-4889(97)00062-1; MUALLEM S, 1990, J BIOL CHEM, V265, P12806; NG LL, 1991, CLIN SCI, V80, P539, DOI 10.1042/cs0800539; Petersen OH, 1999, BIOESSAYS, V21, P851, DOI 10.1002/(SICI)1521-1878(199910)21:10<851::AID-BIES7>3.3.CO;2-6; PETERSEN OH, 1992, J PHYSIOL-LONDON, V448, P1; RAJU B, 1989, AM J PHYSIOL, V256, P540; ROMANI A, 1992, FEBS LETT, V296, P135, DOI 10.1016/0014-5793(92)80364-M; ROMANI A, 1990, NATURE, V346, P841, DOI 10.1038/346841a0; Sebille S, 1996, BIOCHEM BIOPH RES CO, V227, P743, DOI 10.1006/bbrc.1996.1579; Sebille S, 1998, BIOCHEM BIOPH RES CO, V246, P111, DOI 10.1006/bbrc.1998.8494; Sueta Carla A., 1995, Magnesium Research, V8, P389; TOESCU EC, 1992, EMBO J, V11, P1623, DOI 10.1002/j.1460-2075.1992.tb05208.x; TOESCU EC, 1993, BIOCHEM BIOPH RES CO, V192, P854, DOI 10.1006/bbrc.1993.1493; TSUNODA Y, 1990, AM J PHYSIOL, V259, pG792, DOI 10.1152/ajpgi.1990.259.5.G792; Turi S, 2000, GASTROENTEROLOGY, V118, pA430, DOI 10.1016/S0016-5085(00)83832-9; vandePut FHMM, 1996, J BIOL CHEM, V271, P4999; WILLIAMS DA, 1990, CELL CALCIUM, V11, P75, DOI 10.1016/0143-4160(90)90061-X; WILLIAMS JA, 1978, AM J PHYSIOL, V235, pE517, DOI 10.1152/ajpendo.1978.235.5.E517; Wisdom DM, 1996, MOL CELL BIOCHEM, V154, P123, DOI 10.1007/BF00226780; Wisdom DM, 1996, EXP PHYSIOL, V81, P367, DOI 10.1113/expphysiol.1996.sp003941; Yoshimura M, 1996, BBA-MOL CELL RES, V1312, P151, DOI 10.1016/0167-4889(96)00034-1; YU HJ, 1995, PHARMACOLOGY, V51, P186, DOI 10.1159/000139334; ZHANG GH, 1994, J BIOL CHEM, V269, P10352; ZHANG GH, 1992, J BIOL CHEM, V267, P20721; ZHU ZM, 1995, BBA-MOL CELL RES, V1265, P89, DOI 10.1016/0167-4889(94)00231-3	59	51	52	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAR	2001	15	3					659	672		10.1096/fj.00-0172com	http://dx.doi.org/10.1096/fj.00-0172com			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	410BE	11259384				2022-12-25	WOS:000167419500023
J	Zauli, G; Milani, D; Mirandola, P; Mazzoni, M; Secchiero, P; Miscia, S; Capitani, S				Zauli, G; Milani, D; Mirandola, P; Mazzoni, M; Secchiero, P; Miscia, S; Capitani, S			HIV-1 Tat protein down-regulates CREB transcription factor expression in PC12 neuronal cells through a phosphatidylinositol 3-kinase/AKT/cyclic nucleoside phosphodiesterase pathway	FASEB JOURNAL			English	Article						extracellular Tat; signal transduction; cAMP; PC12; HIV-1-associated dementia	IMMUNODEFICIENCY-VIRUS TYPE-1; INSULIN-INDUCED PHOSPHORYLATION; GENE-TRANSCRIPTION; FRONTAL-CORTEX; GROWTH-FACTOR; BASIC DOMAIN; KINASE AKT; ACTIVATION; AIDS; BINDING	The addition of low concentrations (0.1-1 nM) of extracellular HIV-1 Tat protein to PC12 neuronal cells stimulated a rapid (peak at 5 min) elevation of the cAMP intracellular levels, which in turn induced the phosphorylation of CREB transcription factor (peak at 15 min) on serine-133 (Ser-133). On the contrary, at later time points (60-120 min) Tat induced a significant decline of intracellular cAMP with respect to the basal levels observed in control cells treated with bovine serum albumin. In blocking experiments performed with pharmacological inhibitors, Tat decreased the intracellular levels of cAMP and CREB Ser-133 phosphorylation through a signal transduction pathway involving the sequential activation of phosphatidylinositol 3-kinase, AKT, and cyclic nucleoside phosphodiesterases. Moreover, in transient transfection experiments, Tat inhibited transcription of CREB promoter in a manner strictly dependent on the presence of the cAMP-responsive elements (CRE) in the CREB promoter. Consistently, the expression of endogenous CREB protein was significantly reduced in PC12 cells by prolonged (24-48 h) treatment with Tat. This decline in the expression of CREB, which plays an essential role in the survival and function of neuronal cells, anticipated a progressive increase of apoptosis in Tat-treated cells. Although obtained in a neuronal cell Line, our findings might help to explain some aspects of the pathogenesis of HIV-l-associated dementia.	Univ Chieti, Inst Normal Morphol G Dannunzio, I-66100 Chieti, Italy; Univ Ferrara, Dept Morphol & Embryol, Human Anat Sect, I-44100 Ferrara, Italy	G d'Annunzio University of Chieti-Pescara; University of Ferrara	Zauli, G (corresponding author), Univ Chieti, Inst Normal Morphol G Dannunzio, Via Vestini 6, I-66100 Chieti, Italy.		Zauli, Giorgio/ABE-8001-2020; Mirandola, Prisco/L-3137-2015; Milani, Daniela/G-5579-2015; secchiero, paola/G-9689-2015	Mirandola, Prisco/0000-0002-5058-3924; Milani, Daniela/0000-0002-9540-7801; secchiero, paola/0000-0003-4101-7987; CAPITANI, Silvano/0000-0003-2795-6814; Zauli, Giorgio/0000-0002-3750-8698				ADLEBIASSETTE H, 1995, NEUROPATH APPL NEURO, V21, P218, DOI 10.1111/j.1365-2990.1995.tb01053.x; Albini A, 1998, P NATL ACAD SCI USA, V95, P13153, DOI 10.1073/pnas.95.22.13153; Albini A, 1996, NAT MED, V2, P1371, DOI 10.1038/nm1296-1371; BARILLARI G, 1993, P NATL ACAD SCI USA, V90, P7941, DOI 10.1073/pnas.90.17.7941; BEAVO JA, 1995, PHYSIOL REV, V75, P725, DOI 10.1152/physrev.1995.75.4.725; Bonni A, 1999, SCIENCE, V286, P1358, DOI 10.1126/science.286.5443.1358; Cafaro A, 1999, NAT MED, V5, P643, DOI 10.1038/9488; Cheng J, 1998, NEUROSCIENCE, V82, P97, DOI 10.1016/S0306-4522(97)00174-7; DIEP A, 1991, GENOMICS, V11, P1161, DOI 10.1016/0888-7543(91)90047-I; Du KY, 1998, J BIOL CHEM, V273, P32377, DOI 10.1074/jbc.273.49.32377; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; ENSOLI B, 1990, NATURE, V345, P84, DOI 10.1038/345084a0; EVERALL IP, 1991, LANCET, V337, P1119, DOI 10.1016/0140-6736(91)92786-2; FAWELL S, 1994, P NATL ACAD SCI USA, V91, P664, DOI 10.1073/pnas.91.2.664; Filippi CG, 1998, RADIOLOGY, V206, P491, DOI 10.1148/radiology.206.2.9457204; FRANK DA, 1994, CELL, V79, P5, DOI 10.1016/0092-8674(94)90394-8; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; Gallo RC, 1999, P NATL ACAD SCI USA, V96, P8324, DOI 10.1073/pnas.96.15.8324; GARRIELI Y, 1992, J CELL BIOL, V119, P493; Gelbard Harris A., 1995, Current Opinion in Pediatrics, V7, P655; GINTY DD, 1994, CELL, V77, P713, DOI 10.1016/0092-8674(94)90055-8; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; Gringeri A, 1998, J Hum Virol, V1, P293; HOEFFLER JP, 1990, MOL ENDOCRINOL, V4, P920, DOI 10.1210/mend-4-6-920; JONES KA, 1994, ANNU REV BIOCHEM, V63, P717, DOI 10.1146/annurev.bi.63.070194.003441; KETZLER S, 1990, ACTA NEUROPATHOL, V80, P92, DOI 10.1007/BF00294228; Kitamura T, 1999, MOL CELL BIOL, V19, P6286; KOLSON DL, 1994, J GEN VIROL, V75, P1927, DOI 10.1099/0022-1317-75-8-1927; Kruman II, 1998, EXP NEUROL, V154, P276, DOI 10.1006/exnr.1998.6958; KURE K, 1990, ACTA NEUROPATHOL, V80, P393, DOI 10.1007/BF00307693; MacKenzie SJ, 1998, P NATL ACAD SCI USA, V95, P3549, DOI 10.1073/pnas.95.7.3549; Maggirwar SB, 1999, J NEUROCHEM, V73, P578, DOI 10.1046/j.1471-4159.1999.0730578.x; MAGNUSON DSK, 1995, ANN NEUROL, V37, P373, DOI 10.1002/ana.410370314; Menegon A, 1997, BIOCHEM BIOPH RES CO, V238, P800, DOI 10.1006/bbrc.1997.7393; MERRILL JE, 1991, FASEB J, V5, P23921; MEYER TE, 1993, ENDOCRINOLOGY, V132, P770, DOI 10.1210/en.132.2.770; Milani D, 1996, J BIOL CHEM, V271, P22961, DOI 10.1074/jbc.271.38.22961; Milani D, 1998, AIDS, V12, P1275, DOI 10.1097/00002030-199811000-00008; Nath A, 1996, J VIROL, V70, P1475, DOI 10.1128/JVI.70.3.1475-1480.1996; Nath A, 1999, J BIOL CHEM, V274, P17098, DOI 10.1074/jbc.274.24.17098; New DR, 1998, J BIOL CHEM, V273, P17852, DOI 10.1074/jbc.273.28.17852; Pauza CD, 2000, P NATL ACAD SCI USA, V97, P3515, DOI 10.1073/pnas.070049797; PETITO CK, 1995, AM J PATHOL, V146, P1121; PHILIPPON V, 1994, VIROLOGY, V205, P519, DOI 10.1006/viro.1994.1673; POWER C, 1993, ANN NEUROL, V34, P339, DOI 10.1002/ana.410340307; SassoneCorsi P, 1995, ANNU REV CELL DEV BI, V11, P355, DOI 10.1146/annurev.cellbio.11.1.355; Schwarze SR, 1999, SCIENCE, V285, P1569, DOI 10.1126/science.285.5433.1569; SHENG M, 1991, SCIENCE, V252, P1427, DOI 10.1126/science.1646483; Walker WH, 1998, MOL CELL ENDOCRINOL, V143, P167, DOI 10.1016/S0303-7207(98)00082-3; WEEKS BS, 1995, J NEUROSCI RES, V42, P34, DOI 10.1002/jnr.490420105; WESTENDORP MO, 1995, NATURE, V375, P497, DOI 10.1038/375497a0; Wijkander J, 1998, ENDOCRINOLOGY, V139, P219, DOI 10.1210/en.139.1.219; Xing J, 1996, SCIENCE, V273, P959, DOI 10.1126/science.273.5277.959; YAMAMOTO KK, 1988, NATURE, V334, P494, DOI 10.1038/334494a0; ZAULI G, 1995, J ACQ IMMUN DEF SYND, V10, P306; Zauli G, 2000, J BIOL CHEM, V275, P4159, DOI 10.1074/jbc.275.6.4159	56	33	35	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	FEB	2001	15	2					483	491		10.1096/fj.00-0354com	http://dx.doi.org/10.1096/fj.00-0354com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	400LK	11156964				2022-12-25	WOS:000166872900030
J	Kim, YC; Song, KS; Yoon, G; Nam, MJ; Ryu, WS				Kim, YC; Song, KS; Yoon, G; Nam, MJ; Ryu, WS			Activated ras oncogene collaborates with HBx gene of hepatitis B virus to transform cells by suppressing HBx-mediated apoptosis	ONCOGENE			English	Article						hepatitis B virus; X gene; apoptosis; H-ras oncogene	NF-KAPPA-B; X-PROTEIN; TRANSGENIC MICE; HEPATOCELLULAR-CARCINOMA; IN-VIVO; C-MYC; EMBRYO FIBROBLASTS; TRANSCRIPTION; DEATH; EXPRESSION	The hepatitis B virus HBx protein is a promiscuous transactivator implicated in the development of hepatocellular carcinoma. The ectopic expression of HBx fails to transform both primary and immortalized rodent cells, but rather induces apoptosis, Furthermore, most transgenic mice harboring HBx do not develop liver tumors. Thus, it remains unclear whether and how HBx contributes to oncogenesis, Here, we show that HBx collaborates with activated H-ras to transform immortalized rodent cells. Indeed, REF52 cells transfected by both HBx and activated H-uas were morphologically transformed and were able to grow in soft agar, Remarkably, nude mice injected with REF52 cells transfected by both HBx and activated H-ras developed tumors, whereas the mice injected with REF52 cells transfected by either gene alone did not. Thus, we concluded that HBx could contribute to neoplastic transformation of cells in collaboration with other oncogenes, such as H-ras, that renders cells to overcome the HBx-mediated apoptosis, Further, we found that HBx mediated apoptosis was suppressed by activated H-ras through activation of the phosphatidylinositol-3 kinase and Akt pathway. Data presented here firmly established the oncogenic potential of HBx during multistage carcinogenesis.	Yonsei Univ, Dept Biochem, Seoul 120749, South Korea; Natl Inst Hlth, Div Canc Res, Seoul 122701, South Korea	Yonsei University; Korea Centers for Disease Control & Prevention (KCDC); Korea National Institute of Health (KNIH)	Ryu, WS (corresponding author), Yonsei Univ, Dept Biochem, 134 Shinchondong, Seoul 120749, South Korea.			Kim, Young Chul/0000-0002-6782-2186; Ryu, Wang-Shick/0000-0002-0383-5666				BEASLEY RP, 1981, LANCET, V2, P1129; BENN J, 1994, P NATL ACAD SCI USA, V91, P10350, DOI 10.1073/pnas.91.22.10350; BENN J, 1995, P NATL ACAD SCI USA, V92, P11215, DOI 10.1073/pnas.92.24.11215; Benn J, 1996, J VIROL, V70, P4978, DOI 10.1128/JVI.70.8.4978-4985.1996; BILLET O, 1995, J VIROL, V69, P5912, DOI 10.1128/JVI.69.9.5912-5916.1995; BLUM HE, 1992, J VIROL, V66, P1223, DOI 10.1128/JVI.66.2.1223-1227.1992; BUENDIA MA, 1992, ADV CANCER RES, V59, P167, DOI 10.1016/S0065-230X(08)60306-1; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; CHEN HS, 1993, J VIROL, V67, P1218, DOI 10.1128/JVI.67.3.1218-1226.1993; CHEONG JH, 1995, EMBO J, V14, P143, DOI 10.1002/j.1460-2075.1995.tb06984.x; Chirillo P, 1997, P NATL ACAD SCI USA, V94, P8162, DOI 10.1073/pnas.94.15.8162; Chirillo P, 1996, J VIROL, V70, P641, DOI 10.1128/JVI.70.1.641-646.1996; Dandri M, 1996, J VIROL, V70, P5246, DOI 10.1128/JVI.70.8.5246-5254.1996; Datta K, 1996, J BIOL CHEM, V271, P30835, DOI 10.1074/jbc.271.48.30835; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; DORIA M, 1995, EMBO J, V14, P4747, DOI 10.1002/j.1460-2075.1995.tb00156.x; FRANZA BR, 1986, CELL, V44, P409, DOI 10.1016/0092-8674(86)90462-9; GANEM D, 1987, ANNU REV BIOCHEM, V56, P651, DOI 10.1146/annurev.biochem.56.1.651; GUIDOTTI LG, 1995, J VIROL, V69, P6158, DOI 10.1128/JVI.69.10.6158-6169.1995; Haviv I, 1998, MOL CELL BIOL, V18, P1562, DOI 10.1128/MCB.18.3.1562; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; HOHNE M, 1990, EMBO J, V9, P1137, DOI 10.1002/j.1460-2075.1990.tb08220.x; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; KIM CM, 1991, NATURE, V351, P317, DOI 10.1038/351317a0; Kim H, 1998, J BIOL CHEM, V273, P381, DOI 10.1074/jbc.273.1.381; Klein NP, 1997, MOL CELL BIOL, V17, P6427, DOI 10.1128/MCB.17.11.6427; KOHL NE, 1987, ONCOGENE, V2, P41; KOIKE K, 1994, HEPATOLOGY, V19, P810, DOI 10.1002/hep.1840190403; KOIKE K, 1994, J CLIN INVEST, V94, P44, DOI 10.1172/JCI117343; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LEE TH, 1990, J VIROL, V64, P5939, DOI 10.1128/JVI.64.12.5939-5947.1990; Lee YH, 1998, J BIOL CHEM, V273, P25510, DOI 10.1074/jbc.273.39.25510; LIN HJL, 1995, MOL CELL BIOL, V15, P4536; LUCITO R, 1992, J VIROL, V66, P983, DOI 10.1128/JVI.66.2.983-991.1992; MAGUIRE HF, 1991, SCIENCE, V252, P842, DOI 10.1126/science.1827531; MIURA M, 1993, CELL, V75, P653, DOI 10.1016/0092-8674(93)90486-A; NATOLI G, 1994, ONCOGENE, V9, P2837; Oguey D, 1996, HEPATOLOGY, V24, P1024, DOI 10.1002/hep.510240508; PATERLINI P, 1995, HEPATOLOGY, V21, P313, DOI 10.1002/hep.1840210208; Qadri I, 1996, P NATL ACAD SCI USA, V93, P10578, DOI 10.1073/pnas.93.20.10578; Schuster R, 2000, ONCOGENE, V19, P1173, DOI 10.1038/sj.onc.1203417; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; SHIRAKATA Y, 1989, JPN J CANCER RES, V80, P617, DOI 10.1111/j.1349-7006.1989.tb01686.x; SPANDAU DF, 1988, J VIROL, V62, P427, DOI 10.1128/JVI.62.2.427-434.1988; Su F, 1996, J VIROL, V70, P4558, DOI 10.1128/JVI.70.7.4558-4566.1996; Su F, 1997, P NATL ACAD SCI USA, V94, P8744, DOI 10.1073/pnas.94.16.8744; Su Q, 1998, HEPATOLOGY, V27, P1109, DOI 10.1002/hep.510270428; Tarn C, 1999, J BIOL CHEM, V274, P2327, DOI 10.1074/jbc.274.4.2327; Terradillos O, 1997, ONCOGENE, V14, P395, DOI 10.1038/sj.onc.1200850; Terradillos O, 1998, ONCOGENE, V17, P2115, DOI 10.1038/sj.onc.1202432; WILLIAMS JS, 1995, P NATL ACAD SCI USA, V92, P3819, DOI 10.1073/pnas.92.9.3819; Yen T. S. Benedict, 1996, Journal of Biomedical Science, V3, P20; ZOULIM F, 1994, J VIROL, V68, P2026, DOI 10.1128/JVI.68.3.2026-2030.1994	53	69	84	0	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 4	2001	20	1					16	23		10.1038/sj.onc.1203840	http://dx.doi.org/10.1038/sj.onc.1203840			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	391NE	11244501				2022-12-25	WOS:000166361400003
J	Maa, MC; Hsieh, CY; Leu, TH				Maa, MC; Hsieh, CY; Leu, TH			Overexpression of p97(Eps8) leads to cellular transformation: implication of pleckstrin homology domain in p97(Eps8)-mediated ERK activation	ONCOGENE			English	Article						p97(Eps8); pleckstrin homology domain; transformation; ERK	TYROSINE KINASE SUBSTRATE; BETA-GAMMA-SUBUNITS; PROTEIN-KINASE; HIGH-AFFINITY; PH DOMAIN; SH3 DOMAIN; EPS8; BINDING; PHOSPHORYLATION; GENE	Two isoforms of Eps8, p(97Eps8) and p68(Eps8), have been identified as the substrates for receptor tyrosine kinases, Our previous studies indicated that both tyrosyl phosphorylation and protein expression of Eps8 were elevated in v-Src transformed cells, In an attempt to examine the role played by p97(Eps8) in tumorigenesis, we have first obtained cells overexpressing p97(Eps8) and its pleckstrin homology (PH)-truncated variant. We then demonstrated that cells overexpressing p97(Eps8) not only exhibited the ability of focus formation in cell culture but also promoted the tumor formation in mice as compared to controls, Furthermore, elevated serum-induced extracellular responsive kinase (ERK) activation was observed in p97(Eps8) overexpressors, This enhanced ERK activation was sensitive to a MEK1 specific inhibitor PD98059 and was important for p97(Eps8)-mediated transformation, since transfection of vectors expressing dominant negative MEK1 and p97(Eps8) abrogated focus formation by p97(Eps8) In contrast, PH-truncated p97(Eps8) failed to localize at the plasma membrane and that the truncated variant also did not elevate ERK activation and cellular transformation in response to serum stimulation, Our results thus indicated that: (1) the gene encoding p97(Eps8) was an oncogene; (ii) p97(Eps8)-induced oncogenesis was partly mediated by ERK activation; and (iii) the PH domain of p97(Eps8) was critical for its cellular localization, ERK activation and its ability to transform cells.	Natl Cheng Kung Univ, Coll Med, Dept Pharmacol, Tainan 70101, Taiwan; Chung shan Med & Dent Coll, Inst Biochem, Taichung 402, Taiwan	National Cheng Kung University; Chung Shan Medical University	Leu, TH (corresponding author), Natl Cheng Kung Univ, Coll Med, Dept Pharmacol, Tainan 70101, Taiwan.				Animal center at NCKU; National Science Council Grant (NSC) [89-2320-B-006-007]; NHRI [DOH-87-HR-625, NHRIGT-EX89S932L]	Animal center at NCKU; National Science Council Grant (NSC); NHRI(National Health Research Institutes - Taiwan)	We thank Dr Sally Parsons and Dr Michael Weber for the pBabe (puro) expression vector and polyclonal ERK antibody (TR2) respectively, Dr Garry P Norlan and Dr Sue Lin-Chao for the virus-packaging cell line fNX-Eco and Dr Ching-Hsine Huang and Dr Hsin-Fang Yang-Yen for their critical comments on this manuscript. We appreciate the technical help provided by Ya-Chun Chuang, Hsaio-Hwai Chen and Hong-Ming Lin. We are also grateful to the animal center at NCKU for the care of animals. This work was supported by National Science Council Grant to M-C Maa (NSC 89-2320-B-006-007) and grants of NHRI to T-H Leu (DOH-87-HR-625, NHRIGT-EX89S932L).	Biesova Z, 1997, ONCOGENE, V14, P233, DOI 10.1038/sj.onc.1200822; CASTAGNINO P, 1995, ONCOGENE, V10, P723; Costa GL, 2000, J IMMUNOL, V164, P3581, DOI 10.4049/jimmunol.164.7.3581; Falasca M, 1998, EMBO J, V17, P414, DOI 10.1093/emboj/17.2.414; FAZIOLI F, 1993, EMBO J, V12, P3799, DOI 10.1002/j.1460-2075.1993.tb06058.x; FERGUSON KM, 1995, CELL, V83, P1037, DOI 10.1016/0092-8674(95)90219-8; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; Frech M, 1997, J BIOL CHEM, V272, P8474, DOI 10.1074/jbc.272.13.8474; Gallo R, 1997, ONCOGENE, V15, P1929, DOI 10.1038/sj.onc.1201344; HARLAN JE, 1994, NATURE, V371, P168, DOI 10.1038/371168a0; KARLSSON T, 1995, ONCOGENE, V10, P1475; Kavran JM, 1998, J BIOL CHEM, V273, P30497, DOI 10.1074/jbc.273.46.30497; Kishan KVR, 1997, NAT STRUCT BIOL, V4, P739; Klippel A, 1997, MOL CELL BIOL, V17, P338, DOI 10.1128/MCB.17.1.338; MAA MC, 1992, ONCOGENE, V7, P2429; Maa MC, 1999, BBA-MOL CELL RES, V1450, P341, DOI 10.1016/S0167-4889(99)00069-5; Matoskova B, 1996, ONCOGENE, V12, P2679; MATOSKOVA B, 1995, MOL CELL BIOL, V15, P3805; Mongiovi AM, 1999, EMBO J, V18, P5300, DOI 10.1093/emboj/18.19.5300; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; MUSACCHIO A, 1993, TRENDS BIOCHEM SCI, V18, P343, DOI 10.1016/0968-0004(93)90071-T; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; PAYNE DM, 1991, EMBO J, V10, P885, DOI 10.1002/j.1460-2075.1991.tb08021.x; Provenzano C, 1998, EXP CELL RES, V242, P186, DOI 10.1006/excr.1998.4095; REUTER CWM, 1995, METHOD ENZYMOL, V255, P245; Scita G, 1999, NATURE, V401, P290, DOI 10.1038/45822; STURGILL TW, 1988, NATURE, V334, P715, DOI 10.1038/334715a0; TOUHARA K, 1994, J BIOL CHEM, V269, P10217; TROPPMAIR J, 1994, J BIOL CHEM, V269, P7030; TSUKADA S, 1994, P NATL ACAD SCI USA, V91, P11256, DOI 10.1073/pnas.91.23.11256; WONG WT, 1994, ONCOGENE, V9, P3057	31	29	33	0	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 4	2001	20	1					106	112		10.1038/sj.onc.1204069	http://dx.doi.org/10.1038/sj.onc.1204069			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	391NE	11244499				2022-12-25	WOS:000166361400012
J	Pang, LH; Knox, AJ				Pang, LH; Knox, AJ			Regulation of TNF-alpha-induced eotaxin release from cultured human airway smooth muscle cells by beta(2)-agonists and corticosteroids	FASEB JOURNAL			English	Article						eosinophil; cyclic AMP; asthma; phosphodiesterase; cytokine	PROTEIN-KINASE-A; CYCLIC ADENOSINE-MONOPHOSPHATE; NITRIC-OXIDE SYNTHASE; EOSINOPHIL CHEMOATTRACTANT; BRONCHOALVEOLAR LAVAGE; MOLECULAR-CLONING; ENDOTHELIAL-CELLS; EXPRESSION; RECEPTOR; ASTHMA	Eotaxin is a potent eosinophil chemoattractant that contributes to the eosinophilia seen in asthma and other allergic disorders. Recent studies have identified human airway smooth muscle (HASM) as a rich source of eotaxin, but the factors regulating its production are poorly understood. Here we describe for the first time that beta (2)-agonists can inhibit cytokine-induced eotaxin release. We found that TNF-alpha stimulated eotaxin release (assayed by ELISA) from HASM cells and that the release was partially inhibited by salbutamol and salmeterol. The effect of beta (2)-agonists was mimicked by forskolin and 8-bromo-cAMP and potentiated by the cAMP-dependent phosphodiesterase inhibitor rolipram, suggesting that it is cAMP dependent. We also found that the cAMP inhibition was likely at the transcription stage, although experiments with the PKA. inhibitors H-89 and Rp-cAMP or the PKG inhibitor KT5823 suggested that none of these kinases was involved. Partial inhibition of eotaxin release was also seen with the corticosteroids dexamethasone and fluticasone, The combined use of beta (2)-agonists, rolipram, and steroids abolished TNF-alpha -induced eotaxin release. These results suggest that the combination of a beta (2)-agonist, PDE inhibitor, and a corticosteroid may have additive beneficial effects in the treatment of the eosinophilia associated with asthma and other allergic diseases.	Univ Nottingham, City Hosp, Div Resp Med, Nottingham NG5 1PB, England	Nottingham University Hospital NHS Trust; Nottingham City Hospital; University of Nottingham	Pang, LH (corresponding author), Univ Nottingham, City Hosp, Div Resp Med, Clin Sci Bldg,Hucknall Rd, Nottingham NG5 1PB, England.			Knox, Alan/0000-0002-5906-4143				BROIDE DH, 1992, J ALLERGY CLIN IMMUN, V89, P958, DOI 10.1016/0091-6749(92)90218-Q; Brown JR, 1998, CLIN EXP IMMUNOL, V114, P137; Cass LA, 1999, MOL CELL BIOL, V19, P5882; Chung KF, 1999, BRIT J PHARMACOL, V127, P1145, DOI 10.1038/sj.bjp.0702660; Eickelberg O, 1999, J BIOL CHEM, V274, P1005, DOI 10.1074/jbc.274.2.1005; GarciaZepeda EA, 1996, NAT MED, V2, P449, DOI 10.1038/nm0496-449; Ghaffar O, 1999, AM J RESP CRIT CARE, V159, P1933, DOI 10.1164/ajrccm.159.6.9805039; Hein H, 1997, BIOCHEM BIOPH RES CO, V237, P537, DOI 10.1006/bbrc.1997.7169; John M, 1998, AM J RESP CELL MOL, V18, P84, DOI 10.1165/ajrcmb.18.1.2813; John M, 1997, J IMMUNOL, V158, P1841; Johnson SR, 1997, TRENDS PHARMACOL SCI, V18, P288, DOI 10.1016/S0165-6147(97)01092-4; JOSE PJ, 1994, J EXP MED, V179, P881, DOI 10.1084/jem.179.3.881; KARPINSKI BA, 1992, P NATL ACAD SCI USA, V89, P4820, DOI 10.1073/pnas.89.11.4820; Kitaura M, 1996, J BIOL CHEM, V271, P7725, DOI 10.1074/jbc.271.13.7725; KNUDSEN PJ, 1986, J IMMUNOL, V137, P3189; Lamkhioued B, 1997, J IMMUNOL, V159, P4593; Lilly CM, 1997, J CLIN INVEST, V99, P1767, DOI 10.1172/JCI119341; MATTOLI S, 1991, J ALLERGY CLIN IMMUN, V87, P794, DOI 10.1016/0091-6749(91)90125-8; Mattoli S, 1997, BIOCHEM BIOPH RES CO, V236, P299, DOI 10.1006/bbrc.1997.6958; Minshall EM, 1997, AM J RESP CELL MOL, V17, P683, DOI 10.1165/ajrcmb.17.6.2865; Mustafa SB, 1998, J BIOL CHEM, V273, P5073, DOI 10.1074/jbc.273.9.5073; Nazareth LV, 1996, J BIOL CHEM, V271, P19900, DOI 10.1074/jbc.271.33.19900; NEUMANN M, 1995, EMBO J, V14, P1991, DOI 10.1002/j.1460-2075.1995.tb07191.x; Pang LH, 1998, J IMMUNOL, V161, P2509; Pang LH, 1998, BRIT J PHARMACOL, V125, P1320, DOI 10.1038/sj.bjp.0702193; Pang LH, 1997, BIOCHEM PHARMACOL, V53, P493, DOI 10.1016/S0006-2952(96)00737-X; Pang LH, 1997, BRIT J PHARMACOL, V121, P579, DOI 10.1038/sj.bjp.0701152; Pauwels RA, 1997, NEW ENGL J MED, V337, P1405, DOI 10.1056/NEJM199711133372001; Ponath PD, 1996, J CLIN INVEST, V97, P604, DOI 10.1172/JCI118456; ROTHENBERG ME, 1995, P NATL ACAD SCI USA, V92, P8960, DOI 10.1073/pnas.92.19.8960; Rothenberg ME, 1996, MOL MED, V2, P334, DOI 10.1007/BF03401631; Sallusto F, 1997, SCIENCE, V277, P2005, DOI 10.1126/science.277.5334.2005; Uguccioni M, 1997, J CLIN INVEST, V100, P1137, DOI 10.1172/JCI119624; WILLIS SA, 1995, J IMMUNOL, V154, P1399; Woolcock A, 1996, AM J RESP CRIT CARE, V153, P1481, DOI 10.1164/ajrccm.153.5.8630590; Yamada H, 1997, BIOCHEM BIOPH RES CO, V231, P365, DOI 10.1006/bbrc.1997.6100; Ying S, 1997, EUR J IMMUNOL, V27, P3507, DOI 10.1002/eji.1830271252	37	119	127	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JAN	2001	15	1					261	269		10.1096/fj.00-0103com	http://dx.doi.org/10.1096/fj.00-0103com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	390TH	11149914				2022-12-25	WOS:000166312400035
J	Benvenuto, G; Li, SW; Brown, SJ; Braverman, R; Vass, WC; Cheadle, JP; Halley, DJJ; Sampson, JR; Wienecke, R; DeClue, JE				Benvenuto, G; Li, SW; Brown, SJ; Braverman, R; Vass, WC; Cheadle, JP; Halley, DJJ; Sampson, JR; Wienecke, R; DeClue, JE			The tuberous sclerosis-1 (TSC1) gene product hamartin suppresses cell growth and augments the expression of the TSC2 product tuberin by inhibiting its ubiquitination	ONCOGENE			English	Article						tuberous sclerosis (TSC); tumor suppressor genes; growth inhibition; ubiquitination	EKER RAT; NEOPLASTIC PHENOTYPE; PROTEASOME PATHWAY; RENAL-CARCINOMA; TARGET RAP1; IN-VIVO; COMPLEX; PROTEIN; DEGRADATION; HETEROZYGOSITY	We report here that overexpression of the tuberous sclerosis-1 (TSC1) gene product hamartin results in the inhibition of growth, as well as changes in cell morphology, Growth inhibition was associated with an increase in the endogenous level of the product of the tuberous sclerosis-2 (TSC2) gene, tuberin. As over-expression of tuberin inhibits cell growth, and hamartin is known to bind tuberin, these results suggested that hamartin stabilizes tuberin and this contributes to the inhibition of cell growth. Indeed, transient transfection of TSC1 increased the endogenous level of tuberin, and transient co-transfection of TSC1 with TSC2 resulted in higher tuberin levels. The stabilization was explained by the finding that tuberin is highly ubiquitinated in cells, while the fraction of tuberin that is bound to hamartin is not ubiquitinated, Go-expression of tuberin stabilized hamartin, which is weakly ubiquitinated, in transiently transfected cells. The amino-terminal two-thirds of tuberin was responsible for its ubiquitination and for stabilization of hamartin, A mutant of tuberin from a patient missense mutation of TSC2 was also highly ubiquitinated, and was unable to stabilize hamartin, We conclude that hamartin is a growth inhibitory protein whose biological effect is likely dependent on its interaction with tuberin.	NCI, Cellular Oncol Lab, Bethesda, MD 20892 USA; Cardiff Univ, Inst Med Genet, Cardiff CF4 4XN, S Glam, Wales; Erasmus Univ, Dept Clin Genet, NL-3015 GE Rotterdam, Netherlands; Univ Munich, Dept Dermatol, Klinikum Innenstadt, D-80337 Munich, Germany	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Cardiff University; Erasmus University Rotterdam; University of Munich	DeClue, JE (corresponding author), NCI, Cellular Oncol Lab, Bethesda, MD 20892 USA.		Warfield, Simon/B-3352-2009	Warfield, Simon/0000-0002-7659-3880; BENVENUTO, Giovanna/0000-0001-7155-2935				Ciechanover A, 1998, EMBO J, V17, P7151, DOI 10.1093/emboj/17.24.7151; Ciechanover A, 2000, J CELL BIOCHEM, P40; GOMEZ MR, 1999, TUBEROUS SCLEROSIS; GREEN AJ, 1994, NAT GENET, V6, P193, DOI 10.1038/ng0294-193; GREEN S, 1988, NUCLEIC ACIDS RES, V16, P369, DOI 10.1093/nar/16.1.369; Gutmann DH, 2000, ACTA NEUROPATHOL, V99, P223, DOI 10.1007/PL00007431; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Henske EP, 1996, AM J HUM GENET, V59, P400; HENSKE EP, 1995, GENE CHROMOSOME CANC, V13, P295, DOI 10.1002/gcc.2870130411; HUANG HJS, 1988, SCIENCE, V242, P1563, DOI 10.1126/science.3201247; Ito N, 1999, CELL, V96, P529, DOI 10.1016/S0092-8674(00)80657-1; Jin F, 1996, P NATL ACAD SCI USA, V93, P9154, DOI 10.1073/pnas.93.17.9154; JOHNSON MR, 1994, MOL CELL BIOL, V14, P641, DOI 10.1128/MCB.14.1.641; KNUDSON AG, 1993, P NATL ACAD SCI USA, V90, P10914, DOI 10.1073/pnas.90.23.10914; KOBAYASHI T, 1995, NAT GENET, V9, P70, DOI 10.1038/ng0195-70; Koepp DM, 1999, CELL, V97, P431, DOI 10.1016/S0092-8674(00)80753-9; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Lamb RF, 2000, NAT CELL BIOL, V2, P281, DOI 10.1038/35010550; Maki CG, 1996, CANCER RES, V56, P2649; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; Mizuguchi M, 2000, ACTA NEUROPATHOL, V99, P503, DOI 10.1007/s004010051152; Nellist M, 1999, J BIOL CHEM, V274, P35647, DOI 10.1074/jbc.274.50.35647; NELLIST M, 1993, CELL, V75, P1305; Nielsen KH, 1997, MOL CELL BIOL, V17, P7132, DOI 10.1128/MCB.17.12.7132; Orimoto K, 1996, BIOCHEM BIOPH RES CO, V219, P70, DOI 10.1006/bbrc.1996.0183; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; Plank TL, 1999, MODERN PATHOL, V12, P539; Plank TL, 1998, CANCER RES, V58, P4766; Qian XL, 1998, MOL CELL BIOL, V18, P771, DOI 10.1128/MCB.18.2.771; Roach ES, 1998, J CHILD NEUROL, V13, P624, DOI 10.1177/088307389801301206; Soucek T, 1998, P NATL ACAD SCI USA, V95, P15653, DOI 10.1073/pnas.95.26.15653; Soucek T, 1997, J BIOL CHEM, V272, P29301, DOI 10.1074/jbc.272.46.29301; TREIER M, 1994, CELL, V78, P787, DOI 10.1016/S0092-8674(94)90502-9; van Slegtenhorst M, 1998, HUM MOL GENET, V7, P1053, DOI 10.1093/hmg/7.6.1053; vanSlegtenhorst M, 1997, SCIENCE, V277, P805, DOI 10.1126/science.277.5327.805; VELU TJ, 1989, J VIROL, V63, P1384, DOI 10.1128/JVI.63.3.1384-1392.1989; WIEDERHOLT WC, 1985, NEUROLOGY, V35, P600, DOI 10.1212/WNL.35.4.600; Wienecke R, 1996, ONCOGENE, V13, P913; Wienecke R, 1997, AM J PATHOL, V150, P43; WIENECKE R, 1995, J BIOL CHEM, V270, P16409, DOI 10.1074/jbc.270.27.16409; Xiao GH, 1997, J BIOL CHEM, V272, P6097, DOI 10.1074/jbc.272.10.6097; YEUNG RS, 1994, P NATL ACAD SCI USA, V91, P11413, DOI 10.1073/pnas.91.24.11413	42	186	190	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 14	2000	19	54					6306	6316		10.1038/sj.onc.1204009	http://dx.doi.org/10.1038/sj.onc.1204009			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	388YK	11175345				2022-12-25	WOS:000166210500014
J	Strom, A; Arai, N; Leers, J; Gustafsson, JA				Strom, A; Arai, N; Leers, J; Gustafsson, JA			The hairy and enhancer of split homologue-1 (HES-1) mediates the proliferative effect of 17 beta-estradiol on breast cancer cell lines	ONCOGENE			English	Article						proliferation; HES-1; PCNA; antiestrogen; 17 beta-estradiol	LOOP-HELIX FACTORS; NEURONAL DIFFERENTIATION; TRANSCRIPTION FACTORS; MAMMALIAN HAIRY; EXPRESSION; GENE; INHIBITION; PROTEINS	The mechanism behind hormone dependent growth of breast cancer is presently not well understood. We show that the HES-1 protein level in the breast cancer cell lines T47D and MCF-7 is down regulated by 17 beta -estradiol treatment. This regulation could be reversed by addition of the anti-estrogens 4OH tamoxifen, raloxifen and Imperial Chemical Industries (ICI) 182,780, In T47D cells with inducible exogenous HES-1 expression, induced expression of HES-1 protein presented the proliferative Effect of 17 beta -estradiol and subsequent up regulation of proliferating cell nuclear antigen (PCNA), An inverse correlation between the HES-1 and PCNA protein levels respectively,vas found in colon cancer cell lines. These findings point to a potential role of HES-l as a tumor suppressor in epithelial cells, and as a mediator of 17 beta -estradiols proliferative effect on breast cancer cells.	Karolinska Inst, Novum, Ctr Biotechnol, S-14157 Huddinge, Sweden; Tokyo Med & Dent Univ, Grad Sch, Dept Maxillofacial Surg, Bunkyo Ku, Tokyo 1138549, Japan; Karolinska Inst, Novum, Dept Med Nutr, S-14186 Huddinge, Sweden	Karolinska Institutet; Tokyo Medical & Dental University (TMDU); Karolinska Institutet	Strom, A (corresponding author), Karolinska Inst, Novum, Ctr Biotechnol, S-14157 Huddinge, Sweden.							Apelqvist A, 1999, NATURE, V400, P877, DOI 10.1038/23716; Artavanis-Tsakonas S, 1999, SCIENCE, V284, P770, DOI 10.1126/science.284.5415.770; Castella P, 2000, MOL CELL BIOL, V20, P6170, DOI 10.1128/MCB.20.16.6170-6183.2000; Castella P, 1999, J NEUROSCI RES, V56, P229, DOI 10.1002/(SICI)1097-4547(19990501)56:3<229::AID-JNR2>3.0.CO;2-Z; Chen H, 1997, P NATL ACAD SCI USA, V94, P5355, DOI 10.1073/pnas.94.10.5355; FEDER JN, 1993, MOL CELL BIOL, V13, P105, DOI 10.1128/MCB.13.1.105; Ferguson AT, 1997, CRIT REV ONCOGENESIS, V8, P29, DOI 10.1615/CritRevOncog.v8.i1.20; Fisher AL, 1998, GENE DEV, V12, P1931, DOI 10.1101/gad.12.13.1931; FRIEDL A, 1994, EUR J CANCER, V30A, P1559, DOI 10.1016/0959-8049(94)00293-E; Harlow E., 1988, ANTIBODIES LAB MANUA; Hong JT, 1998, ONCOL REP, V5, P1025; ISHIBASHI M, 1994, EMBO J, V13, P1799, DOI 10.1002/j.1460-2075.1994.tb06448.x; Ishibashi M, 1995, GENE DEV, V9, P3136, DOI 10.1101/gad.9.24.3136; Kyo S, 1999, CANCER RES, V59, P5917; Lundin A, 2000, METHOD ENZYMOL, V305, P346; SASAI Y, 1992, GENE DEV, V6, P2620, DOI 10.1101/gad.6.12b.2620; STIFANI S, 1992, NAT GENET, V2, P119, DOI 10.1038/ng1092-119; Strom A, 1997, GENE DEV, V11, P3168, DOI 10.1101/gad.11.23.3168; Tomita K, 1999, GENE DEV, V13, P1203, DOI 10.1101/gad.13.9.1203; Tomita K, 1996, NEURON, V16, P723, DOI 10.1016/S0896-6273(00)80093-8	20	37	41	0	3	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 30	2000	19	51					5951	5953		10.1038/sj.onc.1203990	http://dx.doi.org/10.1038/sj.onc.1203990			3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	378CA	11127827				2022-12-25	WOS:000165563100015
J	Park, K; Verchere, CB				Park, K; Verchere, CB			Identification of a heparin binding domain in the N-terminal cleavage site of pro-islet amyloid polypeptide - Implications for islet amyloid formation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYPE-2 DIABETES-MELLITUS; ALZHEIMERS-DISEASE; IN-VITRO; SECRETORY GRANULES; APOLIPOPROTEIN-E; BETA-CELLS; A-BETA; SULFATE PROTEOGLYCANS; PRECURSOR PROTEIN; PANCREATIC-ISLETS	Islet amyloid deposits are a characteristic pathologic lesion of the pancreas in type 2 diabetes and are composed primarily of the islet beta cell peptide islet amyloid polypeptide (IAPP or amylin) as well as the basement membrane heparan sulfate proteoglycan perlecan. Impaired processing of the IAPP precursor has been implicated in the mechanism of islet amyloid formation. The Nand C-terminal cleavage sites where pro-LAPP is processed by prohormone convertases contain a series of basic amino acid residues that we hypothesized may interact with heparan sulfate proteoglycans. This possibility was tested using affinity chromatography by applying synthetic fragments of pro-IAPP to heparin-agarose and heparan sulfate-Sepharose. An N-terminal human pro-IAPP fragment (residues 1-30) was retained by both heparin-agarose and heparan sulfate-Sepharose, eluting at 0.18 M NaCl at pH 7.5. Substitution of alanine residues for two basic residues in the N-terminal cleavage site abolished heparin and heparan sulfate binding activity. At pH 5.5, the affinity of the wild-type peptide for heparin/heparan sulfate was increased, implying a role far histidine residues at positions 6 and 28 of pro-IAPP. A C-terminal pro-IAPP fragment (residues 41-67) had no specific affinity for either heparin or heparan sulfate, and the N- or C-terminal fragments had only weak affinity for chondroitin sulfate. These data suggest that monomeric N-terminal human pro-IAPP contains a heparin binding domain that is lost during normal processing of pro-IAPP.	Univ British Columbia, British Columbia Res Inst Childrens & Womens Hlth, Dept Pathol & Lab Med, Vancouver, BC V5Z 4H4, Canada	University of British Columbia	Verchere, CB (corresponding author), Univ British Columbia, British Columbia Res Inst Childrens & Womens Hlth, Dept Pathol & Lab Med, 950 W 28th Ave, Vancouver, BC V5Z 4H4, Canada.							Ancsin JB, 1999, J BIOL CHEM, V274, P7172, DOI 10.1074/jbc.274.11.7172; ANCSIN JB, 2001, IN PRESS METHODS MOL; BAIRD A, 1988, P NATL ACAD SCI USA, V85, P2324, DOI 10.1073/pnas.85.7.2324; CARDIN AD, 1986, BIOCHEM BIOPH RES CO, V134, P783, DOI 10.1016/S0006-291X(86)80489-2; CARDIN AD, 1989, ARTERIOSCLEROSIS, V9, P21, DOI 10.1161/01.ATV.9.1.21; Castillo GM, 1998, DIABETES, V47, P612, DOI 10.2337/diabetes.47.4.612; Charge SBP, 1996, J PATHOL, V179, P443; CLARK A, 1990, DIABETOLOGIA, V33, P285, DOI 10.1007/BF00403322; CLARK A, 1989, CELL TISSUE RES, V257, P179; Clarris HJ, 1997, J NEUROCHEM, V68, P1164; COOPER GJS, 1987, P NATL ACAD SCI USA, V84, P8628, DOI 10.1073/pnas.84.23.8628; DEKONING EJP, 1994, P NATL ACAD SCI USA, V91, P8467, DOI 10.1073/pnas.91.18.8467; DEWITT DA, 1993, EXP NEUROL, V121, P149, DOI 10.1006/exnr.1993.1081; Gervais FG, 1999, CELL, V97, P395, DOI 10.1016/S0092-8674(00)80748-5; GLENNER GG, 1971, SCIENCE, V174, P712, DOI 10.1126/science.174.4010.712; HALBAN PA, 1994, BIOCHEM J, V299, P1; Higham CE, 2000, EUR J BIOCHEM, V267, P4998, DOI 10.1046/j.1432-1327.2000.01548.x; Hoppener JWM, 2000, NEW ENGL J MED, V343, P411; Hou X, 1999, DIABETOLOGIA, V42, P188, DOI 10.1007/s001250051138; Inoue S, 1996, LAB INVEST, V74, P670; JI ZS, 1993, J BIOL CHEM, V268, P10160; KAHN CR, 1994, DIABETES, V43, P1066, DOI 10.2337/diab.43.8.1066; KAHN SE, 1990, DIABETES, V39, P634, DOI 10.2337/diabetes.39.5.634; Kahn SE, 1999, DIABETES, V48, P241, DOI 10.2337/diabetes.48.2.241; Kahn SE, 1997, DIABETES, V46, P1725, DOI 10.2337/diabetes.46.11.1725; KANATSUKA A, 1989, FEBS LETT, V259, P199, DOI 10.1016/0014-5793(89)81527-3; Kim SH, 1999, NAT NEUROSCI, V2, P984, DOI 10.1038/14783; Kisilevsky R, 1997, CRIT REV BIOCHEM MOL, V32, P361, DOI 10.3109/10409239709082674; Kudva YC, 1998, BIOCHEM J, V331, P809, DOI 10.1042/bj3310809; Larson JL, 2000, PROTEIN SCI, V9, P427; LORENZO A, 1994, NATURE, V368, P756, DOI 10.1038/368756a0; LUKINIUS A, 1989, DIABETOLOGIA, V32, P240, DOI 10.1007/BF00285291; MARGALIT H, 1993, J BIOL CHEM, V268, P19228; McLaurin J, 1999, EUR J BIOCHEM, V266, P1101, DOI 10.1046/j.1432-1327.1999.00957.x; NAIKI H, 1989, ANAL BIOCHEM, V177, P244, DOI 10.1016/0003-2697(89)90046-8; Naiki H, 1996, LAB INVEST, V74, P374; NARINDRASORASAK S, 1991, J BIOL CHEM, V266, P12878; OGAWA A, 1990, J CLIN INVEST, V85, P973, DOI 10.1172/JCI114528; Passafaro M, 1996, J BIOL CHEM, V271, P30096, DOI 10.1074/jbc.271.47.30096; PORTE D, 1989, DIABETES, V38, P1333, DOI 10.2337/diabetes.38.11.1333; PORTE D, 1991, DIABETES, V40, P166, DOI 10.2337/diabetes.40.2.166; SAXENA U, 1991, J BIOL CHEM, V266, P17516; SISODIA SS, 1990, SCIENCE, V248, P492, DOI 10.1126/science.1691865; SNOW AD, 1989, NEUROBIOL AGING, V10, P481, DOI 10.1016/0197-4580(89)90108-5; Verchere CB, 1996, P NATL ACAD SCI USA, V93, P3492, DOI 10.1073/pnas.93.8.3492; Verchere CB, 2000, DIABETES, V49, P1477, DOI 10.2337/diabetes.49.9.1477; Wang J, 2001, DIABETES, V50, P534, DOI 10.2337/diabetes.50.3.534; WARD WK, 1987, DIABETOLOGIA, V30, P698, DOI 10.1007/BF00296991; Watson DJ, 1997, J BIOL CHEM, V272, P31617, DOI 10.1074/jbc.272.50.31617; WESTERMARK P, 1987, AM J PATHOL, V127, P414; WESTERMARK P, 1989, DIABETES RES CLIN PR, V7, P219, DOI 10.1016/0168-8227(89)90008-9; YOUNG ID, 1992, ARCH PATHOL LAB MED, V116, P951; Zhou A, 1999, J BIOL CHEM, V274, P20745, DOI 10.1074/jbc.274.30.20745	53	84	87	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 18	2001	276	20					16611	16616		10.1074/jbc.M008423200	http://dx.doi.org/10.1074/jbc.M008423200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	432ZG	11145957	hybrid			2022-12-25	WOS:000168730400004
J	van der Wal, J; Habets, R; Varnai, P; Balla, T; Jalink, K				van der Wal, J; Habets, R; Varnai, P; Balla, T; Jalink, K			Monitoring agonist-induced phospholipase C activation in live cells by fluorescence resonance energy transfer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLECKSTRIN HOMOLOGY DOMAINS; ADRENAL GLOMERULOSA CELLS; INOSITOL 1,4,5-TRISPHOSPHATE; LYSOPHOSPHATIDIC ACID; PHOSPHATIDYLINOSITOL 4,5-BISPHOSPHATE; NEUROKININ RECEPTORS; NEURITE RETRACTION; CA2+ OSCILLATIONS; PLASMA-MEMBRANE; LIVING CELLS	Agonist-induced intracellular Ca2+ signals following phospholipase C (PLC) activation display a variety of patterns, including transient, sustained, and oscillatory behavior. These Ca2+ changes have been well characterized, but detailed kinetic analyses of PLC activation in single living cells is lacking, due to the absence of suitable indicators for use in vivo. Recently, green fluorescent protein-tagged pleckstrin homology domains have been employed to monitor PLC activation in single cells, based on (confocal) imaging of their fluorescence translocation from the membrane to the cytosol that occurs upon hydrolysis of phosphatidylinositol bisphosphate, Here we describe fluorescence resonance energy transfer between pleckstrin homology domains of PLC delta1 tagged with cyan and yellow fluorescent proteins as a sensitive readout of phosphatidylinositol bisphosphate metabolism for use both in cell populations and in single cells. Fluorescence resonance energy transfer requires significantly less excitation intensity, enabling prolonged and fast data acquisition without the cell damage that limits confocal experiments. It also allows experiments on motile or extremely flat cells, and can be scaled to record from cell populations as well as single neurites, Characterization of responses to various agonists by this method reveals that stimuli that elicit very similar Ca2+ mobilization responses can exhibit widely different kinetics of PLC activation, and that the latter appears to follow receptor activation more faithfully than the cytosolic Ca2+ transient.	Netherlands Canc Inst, Div Cell Biol, NL-1066 CX Amsterdam, Netherlands; NIH, Endocrinol & Reprod Res Branch, Bethesda, MD 20892 USA	Netherlands Cancer Institute; National Institutes of Health (NIH) - USA	Jalink, K (corresponding author), Netherlands Canc Inst, Div Cell Biol, Plesmanlaan 121, NL-1066 CX Amsterdam, Netherlands.			Balla, Tamas/0000-0002-9077-3335; Jalink, Kees/0000-0001-7019-3440	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [ZIAHD000196] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD000196] Funding Source: NIH RePORTER	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ALBLAS J, 1995, J BIOL CHEM, V270, P8944, DOI 10.1074/jbc.270.15.8944; ALBLAS J, 1993, J BIOL CHEM, V268, P22235; Alblas J, 1996, EMBO J, V15, P3351, DOI 10.1002/j.1460-2075.1996.tb00700.x; BALLA T, 1994, J BIOL CHEM, V269, P16101; CHAU LY, 1993, J NEUROCHEM, V60, P454, DOI 10.1111/j.1471-4159.1993.tb03172.x; DIVECHA N, 1991, EMBO J, V10, P3207, DOI 10.1002/j.1460-2075.1991.tb04883.x; Dupont G, 1998, BIOESSAYS, V20, P607, DOI 10.1002/(SICI)1521-1878(199808)20:8<607::AID-BIES2>3.3.CO;2-2; Gray A, 1999, BIOCHEM J, V344, P929, DOI 10.1042/0264-6021:3440929; Hirose K, 1999, SCIENCE, V284, P1527, DOI 10.1126/science.284.5419.1527; HUNYADY L, 1991, J BIOL CHEM, V266, P2783; JALINK K, 1992, J CELL BIOL, V118, P411, DOI 10.1083/jcb.118.2.411; JALINK K, 1993, CELL GROWTH DIFFER, V4, P247; Kranenburg O, 1999, MOL BIOL CELL, V10, P1851, DOI 10.1091/mbc.10.6.1851; Lankiewicz L, 1997, ACTA BIOCHIM POL, V44, P477, DOI 10.18388/abp.1997_4398; LEMMON MA, 1995, P NATL ACAD SCI USA, V92, P10472, DOI 10.1073/pnas.92.23.10472; Miyawaki A, 1997, NATURE, V388, P882, DOI 10.1038/42264; MIYAWAKI A, 2000, IN PRESS CALCIUM SIG, P3; MYERS DE, 1989, CELL SIGNAL, V1, P335, DOI 10.1016/0898-6568(89)90052-1; Paltauf-Doburzynska J, 2000, J PHYSIOL-LONDON, V524, P701, DOI 10.1111/j.1469-7793.2000.00701.x; Patterson GH, 1997, BIOPHYS J, V73, P2782, DOI 10.1016/S0006-3495(97)78307-3; Pollok BA, 1999, TRENDS CELL BIOL, V9, P57, DOI 10.1016/S0962-8924(98)01434-2; Stauffer TP, 1998, CURR BIOL, V8, P343, DOI 10.1016/S0960-9822(98)70135-6; STEPHENS L, 1993, BIOCHEM J, V296, P481, DOI 10.1042/bj2960481; Tall EG, 2000, CURR BIOL, V10, P743, DOI 10.1016/S0960-9822(00)00541-8; Thomas AP, 1996, FASEB J, V10, P1505, DOI 10.1096/fasebj.10.13.8940296; TILLY BC, 1990, BIOCHEM J, V266, P235, DOI 10.1042/bj2660235; TILLY BC, 1988, BIOCHEM J, V252, P857, DOI 10.1042/bj2520857; Tsien RY, 1998, ANNU REV BIOCHEM, V67, P509, DOI 10.1146/annurev.biochem.67.1.509; van Leeuwen FN, 1999, NAT CELL BIOL, V1, P242, DOI 10.1038/12068; VANDERBEND RL, 1992, BIOCHEM J, V285, P235, DOI 10.1042/bj2850235; Varnai P, 1998, J CELL BIOL, V143, P501, DOI 10.1083/jcb.143.2.501; Varnai P, 1999, J BIOL CHEM, V274, P10983, DOI 10.1074/jbc.274.16.10983; Vollmer JY, 1999, J BIOL CHEM, V274, P37915, DOI 10.1074/jbc.274.53.37915; Wiedemann C, 1996, EMBO J, V15, P2094, DOI 10.1002/j.1460-2075.1996.tb00563.x; WIJELATH ES, 1988, BIOCHEM BIOPH RES CO, V152, P392, DOI 10.1016/S0006-291X(88)80726-5; Zhang CY, 1996, MOL PHARMACOL, V50, P864; Zhu DM, 2000, J BIOL CHEM, V275, P6063, DOI 10.1074/jbc.275.9.6063	37	203	211	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 4	2001	276	18					15337	15344		10.1074/jbc.M007194200	http://dx.doi.org/10.1074/jbc.M007194200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	429QQ	11152673	hybrid			2022-12-25	WOS:000168528800108
J	Low, WK; Lin, QS; Stathakis, C; Miao, M; Fletcher, GL; Hew, CL				Low, WK; Lin, QS; Stathakis, C; Miao, M; Fletcher, GL; Hew, CL			Isolation and characterization of skin-type, type I antifreeze polypeptides from the longhorn sculpin, Myoxocephalus octodecemspinosus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WINTER FLOUNDER; SHORTHORN SCULPIN; PROTEIN; ICE; OCTODECIMSPINOSIS; EXPRESSION; GLYCOPROTEINS; CONSERVATION; MECHANISMS; EVOLUTION	The antifreeze polypeptides (AFPs) are found in several marine fish and have been grouped into four distinct biochemical classes (type I-IV), Recently, the new subclass of skin-type, type I AFPs that are produced intracellularly as mature polypeptides have been identified in the winter flounder (Pleuronectes americanus) and the shorthorn sculpin (Myoxocephalus scorpius). This study demonstrates the presence of skin-type AFPs in the longhorn sculpin (Myoxocephalus octodecemspinosus), which produces type IV serum AFPs. Using polymerase chain reaction-based methods, a clone that encoded for a type I AFP was identified. The clone lacked a signal sequence, indicating that the mature polypeptide is produced in the cytosol, A recombinant protein was produced in Escherichia coli and antifreeze activity was characterized, Four individual Ala-rich polypeptides with antifreeze activity mere isolated from the skin tissue. One polypeptide was completely sequenced by tandem MS. This study provides the first evidence of a fish species that produces two different biochemical classes of antifreeze proteins (type I and type IV), and enforces the notion that skin-type AFPs are a widespread biological phenomenon in fish.	Natl Univ Singapore, Dept Biol Sci, Singapore 119260, Singapore; Hosp Sick Children, Div Struct Biol & Biochem, Toronto, ON M5G 1X8, Canada; Univ Toronto, Dept Biochem, Toronto, ON M5G 1L5, Canada; Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON M5G 1L5, Canada; Mem Univ Newfoundland, Ctr Ocean Sci, St Johns, NF A1C 5S7, Canada	National University of Singapore; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University of Toronto; Memorial University Newfoundland	Hew, CL (corresponding author), Natl Univ Singapore, Dept Biol Sci, Singapore 119260, Singapore.		Lin, Qingsong/H-9794-2012; Hew, Choy Leong/I-1501-2012	Lin, Qingsong/0000-0001-9117-8514; Hew, Choy Leong/0000-0002-9441-0064				Baardsnes J, 1999, FEBS LETT, V463, P87, DOI 10.1016/S0014-5793(99)01588-4; CHAKRABARTTY A, 1991, EUR J BIOCHEM, V202, P1057, DOI 10.1111/j.1432-1033.1991.tb16470.x; CHAKRABARTTY A, 1989, J BIOL CHEM, V264, P11313; CHAKRABARTTY A, 1988, CAN J ZOOL, V66, P403, DOI 10.1139/z88-057; Cheng AL, 1997, BIOPHYS J, V73, P2851, DOI 10.1016/S0006-3495(97)78315-2; Cheng CHC, 1998, CURR OPIN GENET DEV, V8, P715, DOI 10.1016/S0959-437X(98)80042-7; Davies PL, 1997, CURR OPIN STRUC BIOL, V7, P828, DOI 10.1016/S0959-440X(97)80154-6; DAVIES PL, 1992, GENE, V112, P171, DOI 10.1016/0378-1119(92)90373-W; DAVIES PL, 1990, FASEB J, V4, P2460, DOI 10.1096/fasebj.4.8.2185972; Deng GJ, 1998, BBA-PROTEIN STRUCT M, V1388, P305, DOI 10.1016/S0167-4838(98)00180-0; Deng GJ, 1997, FEBS LETT, V402, P17, DOI 10.1016/S0014-5793(96)01466-4; DEVRIES AL, 1983, ANNU REV PHYSIOL, V45, P245, DOI 10.1146/annurev.ph.45.030183.001333; DURET L, 1993, NUCLEIC ACIDS RES, V21, P2315, DOI 10.1093/nar/21.10.2315; FEENEY RE, 1986, ANNU REV BIOPHYS BIO, V15, P59; Gong ZY, 1996, J BIOL CHEM, V271, P4106, DOI 10.1074/jbc.271.8.4106; Harding MM, 1999, EUR J BIOCHEM, V264, P653, DOI 10.1046/j.1432-1327.1999.00617.x; Hays LM, 1996, P NATL ACAD SCI USA, V93, P6835, DOI 10.1073/pnas.93.13.6835; HEW CL, 1980, CAN J BIOCHEM CELL B, V58, P377, DOI 10.1139/o80-049; HEW CL, 1985, EUR J BIOCHEM, V151, P167, DOI 10.1111/j.1432-1033.1985.tb09081.x; HEW CL, 1992, EUR J BIOCHEM, V203, P33, DOI 10.1111/j.1432-1033.1992.tb19824.x; Lin GS, 1999, FEBS LETT, V453, P331, DOI 10.1016/S0014-5793(99)00752-8; Lin QS, 1999, EUR J BIOCHEM, V264, P49, DOI 10.1046/j.1432-1327.1999.00569.x; Lipman DJ, 1997, NUCLEIC ACIDS RES, V25, P3580, DOI 10.1093/nar/25.18.3580; Low WK, 1998, J BIOL CHEM, V273, P23098, DOI 10.1074/jbc.273.36.23098; SICHERI F, 1995, NATURE, V375, P427, DOI 10.1038/375427a0; WEN DY, 1992, J BIOL CHEM, V267, P14102; YANG DSC, 1988, NATURE, V333, P232, DOI 10.1038/333232a0; Yeh Y, 1996, CHEM REV, V96, P601, DOI 10.1021/cr950260c; Zhao ZH, 1998, BBA-PROTEIN STRUCT M, V1382, P177, DOI 10.1016/S0167-4838(97)00197-0	29	23	27	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 13	2001	276	15					11582	11589		10.1074/jbc.M009293200	http://dx.doi.org/10.1074/jbc.M009293200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	421UK	11136728	hybrid			2022-12-25	WOS:000168081800024
J	Surtees, JA; Funnell, BE				Surtees, JA; Funnell, BE			The DNA binding domains of P1 ParB and the architecture of the P1 plasmid partition complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTEGRATION HOST FACTOR; PROTEIN SECONDARY STRUCTURE; BACTERIAL PLASMIDS; CHROMOSOME; SPECIFICITY; SITE; ORGANIZATION; LOCALIZATION; RECOGNITION; SPORULATION	Stable maintenance of P1 plasmids in Escherichia coli is mediated by a high affinity nucleoprotein complex called the partition complex, which consists of ParB and the E. coli integration host factor (IHF) bound specifically to the P1 parS site. IHF strongly stimulates ParB binding to parS, and the minimal partition complex contains a single dimer of ParB, To examine the architecture of the partition complex, we have investigated the DNA binding activity of various ParB fragments. Gel mobility shift and DNase I protection assays showed that the first 141 residues of ParB are dispensable for the formation of the minimal, high affinity partition complex. A fragment missing only the last 16 amino acids of ParB bound specifically to parS, but binding was weak and was no longer stimulated by IHF. The ability of IHF to stimulate ParB binding to parS correlated with the ability of ParB to dimerize via its C terminus. Using full and partial parS sites, we show that two regions of ParB, one in the center and the other near the C terminus of the protein, interact with distinct sequences within parS. Based on these data, we have proposed a model of how the ParB dimer binds parS to form the minimal partition complex.	Univ Toronto, Dept Mol & Med Genet, Toronto, ON M5S 1A8, Canada	University of Toronto	Funnell, BE (corresponding author), Univ Toronto, Dept Mol & Med Genet, Toronto, ON M5S 1A8, Canada.			Funnell, Barbara/0000-0002-1828-6567				ABELES AL, 1985, J MOL BIOL, V185, P261, DOI 10.1016/0022-2836(85)90402-4; Bouet JY, 2000, J BIOL CHEM, V275, P8213, DOI 10.1074/jbc.275.11.8213; Bouet JY, 1999, EMBO J, V18, P1415, DOI 10.1093/emboj/18.5.1415; DAVIS MA, 1990, EMBO J, V9, P991, DOI 10.1002/j.1460-2075.1990.tb08201.x; DAVIS MA, 1992, MOL MICROBIOL, V6, P1141, DOI 10.1111/j.1365-2958.1992.tb01552.x; DAVIS MA, 1988, EMBO J, V7, P1881, DOI 10.1002/j.1460-2075.1988.tb03021.x; DODD IB, 1990, NUCLEIC ACIDS RES, V18, P5019, DOI 10.1093/nar/18.17.5019; Erdmann N, 1999, P NATL ACAD SCI USA, V96, P14905, DOI 10.1073/pnas.96.26.14905; FUNNELL BE, 1988, J BACTERIOL, V170, P954, DOI 10.1128/JB.170.2.954-960.1988; FUNNELL BE, 1993, J BIOL CHEM, V268, P3616; FUNNELL BE, 1991, J BIOL CHEM, V266, P14328; FUNNELL BE, 1988, P NATL ACAD SCI USA, V85, P6657, DOI 10.1073/pnas.85.18.6657; FUNNELL BE, 1994, BIOCHIMIE, V76, P924, DOI 10.1016/0300-9084(94)90017-5; Gal-Mor O, 1998, GENE, V217, P83, DOI 10.1016/S0378-1119(98)00357-6; Gerdes K, 2000, MOL MICROBIOL, V37, P455, DOI 10.1046/j.1365-2958.2000.01975.x; Hanai R, 1996, J BIOL CHEM, V271, P17469, DOI 10.1074/jbc.271.29.17469; HAYES F, 1993, P NATL ACAD SCI USA, V90, P9228, DOI 10.1073/pnas.90.19.9228; HAYES F, 1994, J MOL BIOL, V243, P190, DOI 10.1006/jmbi.1994.1646; IRETON K, 1994, J BACTERIOL, V176, P5320, DOI 10.1128/JB.176.17.5320-5329.1994; Kim HJ, 2000, J BACTERIOL, V182, P1313, DOI 10.1128/JB.182.5.1313-1320.2000; Lin DCH, 1998, CELL, V92, P675, DOI 10.1016/S0092-8674(00)81135-6; Lobocka M, 1996, J MOL BIOL, V259, P366, DOI 10.1006/jmbi.1996.0326; LUDTKE DN, 1989, J MOL BIOL, V209, P393, DOI 10.1016/0022-2836(89)90005-3; MARTIN KA, 1991, J BACTERIOL, V173, P3630, DOI 10.1128/JB.173.12.3630-3634.1991; Mohl DA, 1997, CELL, V88, P675, DOI 10.1016/S0092-8674(00)81910-8; MORI H, 1989, J BIOL CHEM, V264, P15535; MOTALLEBIVESHAREH M, 1990, MOL MICROBIOL, V4, P1455, DOI 10.1111/j.1365-2958.1990.tb02056.x; PABO CO, 1992, ANNU REV BIOCHEM, V61, P1053, DOI 10.1146/annurev.bi.61.070192.005201; Radnedge L, 1998, EMBO J, V17, P6076, DOI 10.1093/emboj/17.20.6076; Radnedge L, 1996, EMBO J, V15, P1155, DOI 10.1002/j.1460-2075.1996.tb00454.x; ROST B, 1994, PROTEINS, V19, P55, DOI 10.1002/prot.340190108; ROST B, 1993, J MOL BIOL, V232, P584, DOI 10.1006/jmbi.1993.1413; Sambrook J., 2002, MOL CLONING LAB MANU; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; Surtees JA, 1999, J BACTERIOL, V181, P5898, DOI 10.1128/JB.181.19.5898-5908.1999; WILLIAMS DR, 1992, J GEN MICROBIOL, V138, P1; Youngren B, 2000, J BACTERIOL, V182, P3924, DOI 10.1128/JB.182.14.3924-3928.2000	37	49	49	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 13	2001	276	15					12385	12394		10.1074/jbc.M009370200	http://dx.doi.org/10.1074/jbc.M009370200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	421UK	11150297	hybrid			2022-12-25	WOS:000168081800126
J	Verine, A; Le Petit-Thevenin, J; Panicot-Dubois, L; Valette, A; Lombardo, D				Verine, A; Le Petit-Thevenin, J; Panicot-Dubois, L; Valette, A; Lombardo, D			Phosphorylation of the oncofetal variant of the human bile salt-dependent lipase - Identification of phosphorylation site and relation with secretion process	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARBOXYL ESTER LIPASE; PANCREATIC CHOLESTEROL ESTERASE; MOLECULAR-CLONING; STIMULATED LIPASE; CDNA CLONING; CELLS; HYDROLASE; PURIFICATION; PROTEIN; LYSOPHOSPHOLIPASE	In this paper, we report, for the first time, the localization of the phosphorylation site of the fetoacinar pancreatic protein (FAPP), which is an oncofetal variant of the pancreatic bile salt-dependent lipase. Using Chinese hamster ovary (CHO) cells transfected with the cDNA encoding FAPP, we radiolabeled the enzyme with P-32, and then the protein was purified by affinity chromatography on cholate-immobilized Sepharose column and submitted to a CNBr hydrolysis. Analysis of peptides by high pressure liquid chromatography, associated with the radioactivity profile, revealed that the phosphorylation site is located at threonine 340, Site-specific mutagenesis experiments, in which the threonine was replaced by an alanine residue, were used to invalidate the phosphorylation of FAPP and to study the influence of the modification on the activity and secretion of the enzyme. These studies showed that CHO cells, transfected with the mutated cDNA of FAPP, kept all of their ability to synthesize the protein, but the loss of the phosphorylation motif prevented the release of the protein in the extracellular compartment, However, the mutated enzyme, which was sequestrated in the transfected CHO cells, remains active on bile salt-dependent lipase substrates.	Fac Med Marseille, INSERM, U260, F-13385 Marseille 5, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite	Verine, A (corresponding author), Fac Med Marseille, INSERM, U260, 27 Blvd Jean Moulin, F-13385 Marseille 5, France.		Panicot-Dubois, Laurence/E-3030-2016	Panicot-Dubois, Laurence/0000-0003-0848-5009				ABOUAKIL N, 1988, BIOCHIM BIOPHYS ACTA, V961, P299, DOI 10.1016/0005-2760(88)90077-X; Ansaldi M, 1996, ANAL BIOCHEM, V234, P110, DOI 10.1006/abio.1996.0060; BRUNEAU N, 1995, EUR J BIOCHEM, V233, P209, DOI 10.1111/j.1432-1033.1995.209_1.x; Bruneau N, 1997, J BIOL CHEM, V272, P27353, DOI 10.1074/jbc.272.43.27353; BRUNEAU N, 1995, J BIOL CHEM, V270, P13524, DOI 10.1074/jbc.270.22.13524; Caillol N, 2000, J CELL BIOCHEM, V79, P628, DOI 10.1002/1097-4644(20001215)79:4<628::AID-JCB120>3.0.CO;2-T; COLWELL NS, 1993, BIOCHIM BIOPHYS ACTA, V1172, P175, DOI 10.1016/0167-4781(93)90288-O; ESCRIBANO MJ, 1989, J BIOL CHEM, V264, P21865; GJELLESVIK DR, 1992, BIOCHIM BIOPHYS ACTA, V1124, P123, DOI 10.1016/0005-2760(92)90088-D; GOLDBERG E, 1972, J BIOL CHEM, V247, P2044; HAN JH, 1987, BIOCHEMISTRY-US, V26, P1617, DOI 10.1021/bi00380a020; Howles PN, 1996, J BIOL CHEM, V271, P7196, DOI 10.1074/jbc.271.12.7196; KYGER EM, 1989, BIOCHEM BIOPH RES CO, V164, P1302, DOI 10.1016/0006-291X(89)91811-1; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Le Petit-Thevenin J, 2001, BBA-MOL CELL BIOL L, V1530, P184, DOI 10.1016/S1388-1981(00)00181-5; LINDSTROM MB, 1988, BIOCHIM BIOPHYS ACTA, V959, P178, DOI 10.1016/0005-2760(88)90029-X; LOMBARDO D, 1978, BIOCHIM BIOPHYS ACTA, V527, P142, DOI 10.1016/0005-2744(78)90263-2; LOMBARDO D, 1980, BIOCHIM BIOPHYS ACTA, V611, P147, DOI 10.1016/0005-2744(80)90050-9; Madeyski K, 1999, GENE, V239, P273, DOI 10.1016/S0378-1119(99)00410-2; MAS E, 1993, BIOCHEM J, V289, P609, DOI 10.1042/bj2890609; MIRALLES F, 1993, EUR J CELL BIOL, V60, P115; Panicot L, 1999, GLYCOBIOLOGY, V9, P935, DOI 10.1093/glycob/9.9.935; Pasqualini E, 1997, BIOCHEM J, V327, P527, DOI 10.1042/bj3270527; Pasqualini E, 1998, J BIOL CHEM, V273, P28208, DOI 10.1074/jbc.273.43.28208; Pasqualini E, 2000, BIOCHEM J, V345, P121, DOI 10.1042/0264-6021:3450121; REICHSTEINER M, 1996, TRENDS BIOCHEM SCI, V21, P267; REUE K, 1991, J LIPID RES, V32, P267; Sbarra V, 1998, BBA-LIPID LIPID MET, V1393, P80, DOI 10.1016/S0005-2760(98)00067-8; SHAMIR R, 1995, BIOCHEMISTRY-US, V34, P6351, DOI 10.1021/bi00019a013; SUGO T, 1993, EUR J BIOCHEM, V216, P799, DOI 10.1111/j.1432-1033.1993.tb18200.x; Verine A, 1999, BIOCHEM J, V342, P179, DOI 10.1042/0264-6021:3420179; White J, 1999, J CELL BIOL, V147, P743, DOI 10.1083/jcb.147.4.743	32	9	9	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 13	2001	276	15					12356	12361		10.1074/jbc.M008658200	http://dx.doi.org/10.1074/jbc.M008658200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	421UK	11148205	hybrid			2022-12-25	WOS:000168081800122
J	Baumann, CT; Maruvada, P; Hager, GL; Yen, PM				Baumann, CT; Maruvada, P; Hager, GL; Yen, PM			Nuclear cytoplasmic shuttling by thyroid hormone receptors - Multiple protein interactions are required for nuclear retention	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEASOME-DEPENDENT DEGRADATION; HUMAN ESTROGEN-RECEPTOR; RETINOIC ACID RECEPTOR; GLUCOCORTICOID-RECEPTOR; PROGESTERONE-RECEPTOR; LIVING CELLS; HISTONE ACETYLTRANSFERASE; MEDIATED PROTEOLYSIS; ANDROGEN RECEPTOR; BINDING DOMAIN	In this report, we have studied the intracellular dynamics and distribution of the thyroid hormone receptor-beta (TR beta) in living cells, utilizing fusions to the green fluorescent protein. Wild-type TB beta was mostly nuclear in both the absence and presence of triiodothyronine; however, triiodothyronine induced a nuclear reorganization of TR beta. By mutating defined regions of TR beta, we found that both nuclear corepressor and retinoid X receptor are involved in maintaining the unliganded receptor within the nucleus. A TR beta mutant defective in DNA binding had only a slightly altered nuclear/cytoplasmic distribution compared with wild-type TR beta; thus, site-specific DNA binding is not essential for maintaining TR beta within the nucleus. Both AT beta depletion studies and heterokaryon analysis demonstrated that TR beta rapidly shuttles between the nuclear and the cytoplasmic compartments. Cotransfection of nuclear corepressor and retinoid X receptor markedly decreased the shuttling by maintaining unliganded TR beta within the nucleus. In summary, our findings demonstrate that TR beta rapidly shuttles between the nucleus and the cytoplasm and that protein-protein interactions of TR beta with various cofactors, rather than specific DNA interactions, play the predominant role in determining the intracellular distribution of the receptor.	NCI, Lab Recept Biol & Gene Express, Bethesda, MD 20892 USA; NIDDKD, Mol Regulat & Neuroendocrinol Sect, Clin Endocrinol Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Hager, GL (corresponding author), NCI, Lab Recept Biol & Gene Express, 41 Lib Dr,Bldg 41,Rm B602, Bethesda, MD 20892 USA.		Yen, Paul M/V-9857-2019	Yen, Paul/0000-0002-3790-8114	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK055101] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alarid ET, 1999, MOL ENDOCRINOL, V13, P1522, DOI 10.1210/me.13.9.1522; BANIAHMAD A, 1992, EMBO J, V11, P1015, DOI 10.1002/j.1460-2075.1992.tb05140.x; Baumann CT, 1999, CELL BIOCHEM BIOPHYS, V31, P119, DOI 10.1007/BF02738167; CAPCO DG, 1982, CELL, V29, P847, DOI 10.1016/0092-8674(82)90446-9; Chen HW, 1997, CELL, V90, P569, DOI 10.1016/S0092-8674(00)80516-4; DALMAN FC, 1990, J BIOL CHEM, V265, P3615; Davis PJ, 1996, THYROID, V6, P497, DOI 10.1089/thy.1996.6.497; El Khissiin A, 1999, FEBS LETT, V448, P160, DOI 10.1016/S0014-5793(99)00343-9; Fejes-Toth G, 1998, P NATL ACAD SCI USA, V95, P2973, DOI 10.1073/pnas.95.6.2973; GANNON F, 1976, STEROIDS, V28, P669, DOI 10.1016/0039-128X(76)90008-8; Georget V, 1997, MOL CELL ENDOCRINOL, V129, P17, DOI 10.1016/S0303-7207(97)04034-3; GOVINDAN MV, 1980, EXP CELL RES, V127, P293, DOI 10.1016/0014-4827(80)90435-8; GOVINDAN MV, 1985, NUCLEIC ACIDS RES, V13, P8293, DOI 10.1093/nar/13.23.8293; GUIOCHONMANTEL A, 1989, CELL, V57, P1147, DOI 10.1016/0092-8674(89)90052-4; GUIOCHONMANTEL A, 1991, EMBO J, V10, P3851, DOI 10.1002/j.1460-2075.1991.tb04954.x; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; HOUSLEY PR, 1990, J BIOL CHEM, V265, P12778; Htun H, 1999, MOL BIOL CELL, V10, P471, DOI 10.1091/mbc.10.2.471; Htun H, 1996, P NATL ACAD SCI USA, V93, P4845, DOI 10.1073/pnas.93.10.4845; HUTCHISON KA, 1994, J BIOL CHEM, V269, P5043; JOHNSON JL, 1995, MOL ENDOCRINOL, V9, P670, DOI 10.1210/me.9.6.670; Koenig RJ, 1998, THYROID, V8, P703, DOI 10.1089/thy.1998.8.703; LEFEBVRE P, 1988, BIOCHEMISTRY-US, V27, P9186, DOI 10.1021/bi00426a017; Lim CS, 1999, MOL ENDOCRINOL, V13, P366, DOI 10.1210/me.13.3.366; Liu Y, 1998, MOL ENDOCRINOL, V12, P34, DOI 10.1210/mend.12.1.0046; MANGELSDORF DJ, 1992, GENE DEV, V6, P329, DOI 10.1101/gad.6.3.329; McKenna NJ, 1999, ENDOCR REV, V20, P321, DOI 10.1210/er.20.3.321; McNally JG, 2000, SCIENCE, V287, P1262, DOI 10.1126/science.287.5456.1262; Nawaz Z, 1999, P NATL ACAD SCI USA, V96, P1858, DOI 10.1073/pnas.96.5.1858; Nickerson JA, 1995, INT REV CYTOL, V162A, P67; OPPENHEIMER JH, 1975, ENDOCR RES COMMUN, V2, P309, DOI 10.1080/07435807509089004; PAPAMICHAIL M, 1980, EXP CELL RES, V125, P490, DOI 10.1016/0014-4827(80)90144-5; Pratt WB, 1997, ENDOCR REV, V18, P306, DOI 10.1210/er.18.3.306; PRATT WB, 1990, MOL CELL ENDOCRINOL, V74, P69; RASTINEJAD F, 1995, NATURE, V375, P203, DOI 10.1038/375203a0; SAMUELS HH, 1973, SCIENCE, V181, P1253, DOI 10.1126/science.181.4106.1253; Shibata H, 1997, RECENT PROG HORM RES, V52, P141; Spencer TE, 1997, NATURE, V389, P194, DOI 10.1038/38304; SPINDLER BJ, 1975, J BIOL CHEM, V250, P4113; Stenoien DL, 2000, MOL ENDOCRINOL, V14, P518, DOI 10.1210/me.14.4.518; SUGAWARA A, 1994, J BIOL CHEM, V269, P433; Syvala H, 1998, LIFE SCI, V63, P1505, DOI 10.1016/S0024-3205(98)00417-2; Tang YT, 1996, MOL CELL BIOL, V16, P1989; Ting YT, 1997, J BIOL CHEM, V272, P4129, DOI 10.1074/jbc.272.7.4129; VANSTEENSEL B, 1995, J CELL SCI, V108, P3003; VANSTEENSEL B, 1995, J CELL BIOCHEM, V57, P465, DOI 10.1002/jcb.240570312; WELSHONS WV, 1984, NATURE, V307, P747, DOI 10.1038/307747a0; Wu J, 1999, J BIOL CHEM, V274, P29202, DOI 10.1074/jbc.274.41.29202; Xu L, 1999, CURR OPIN GENET DEV, V9, P140, DOI 10.1016/S0959-437X(99)80021-5; Yao TP, 1996, P NATL ACAD SCI USA, V93, P10626, DOI 10.1073/pnas.93.20.10626; YEN PM, 1995, ENDOCRINOLOGY, V136, P2845, DOI 10.1210/en.136.7.2845; Yoh SM, 1997, MOL ENDOCRINOL, V11, P470, DOI 10.1210/me.11.4.470; Zamir I, 1997, P NATL ACAD SCI USA, V94, P14400, DOI 10.1073/pnas.94.26.14400; Zamir I, 1996, MOL CELL BIOL, V16, P5458; Zhang JS, 1999, MOL CELL BIOL, V19, P6448; Zhu J, 1999, P NATL ACAD SCI USA, V96, P14807, DOI 10.1073/pnas.96.26.14807; Zhu XG, 1998, J BIOL CHEM, V273, P27058, DOI 10.1074/jbc.273.42.27058	57	113	116	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 6	2001	276	14					11237	11245		10.1074/jbc.M011112200	http://dx.doi.org/10.1074/jbc.M011112200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	420AC	11152480	hybrid			2022-12-25	WOS:000167980900089
J	Damia, G; Sanchez, Y; Erba, E; Broggini, M				Damia, G; Sanchez, Y; Erba, E; Broggini, M			DNA damage induces p53-dependent down-regulation of hCHK1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CYCLE; CHECKPOINT PATHWAY; PROTEIN-KINASE; FISSION YEAST; P53; CHK1; PHOSPHORYLATION; CDC25; CDS1; REPLICATION	The levels of the human checkpoint gene hCHK1 were measured in human cancer cells growing in vitro after treatment with the DNA damaging agent cis-dichlorodiammine platinum(II) (DDP), Treatment of human cancer cell lines with DDP induced a decrease in the hCHK1 protein levels starting 6 h after treatment, with a further decline at 24 and 48 h, A similar decrease in the levels of hCHK1 was found at the mRNA level by using Northern blot analysis. By using isogenic cell systems in which p53 was disrupted either by transfection with HPV-EG or by targeted homologous recombination, we found that the DNA damage-induced down-regulation of hCHK1 was only observable in wild type p53-expressing cells, with only a minor decline in the hCHK1 levels observable 48 h after treatment in cells with disrupted p53, Similarly, treatment of mutant p53-expressing human cancer cell lines with DDP did not result in changes in the levels of hCHK1. The p53-dependent down-regulation of hCHK1 is likely to be at transcriptional levels, as suggested by the lack of down-regulation of the hCHK1 when transfected under the control of a heterologous viral promoter. In addition, p53 is able to downregulate the luciferase activity under the control of the 5' flanking region of the hCHK1 gene. The data suggest a strict link between p53 and hCHK1 governing the activation and repression of the G(2) checkpoint in which both proteins participate.	Mario Negri Inst Pharmacol Res, Dept Oncol, Mol Pharmacol Unit, I-20157 Milan, Italy; Univ Cincinnati, Dept Mol Genet, Cincinnati, OH 45267 USA	Istituto di Ricerche Farmacologiche Mario Negri IRCCS; University System of Ohio; University of Cincinnati	Damia, G (corresponding author), Mario Negri Inst Pharmacol Res, Dept Oncol, Mol Pharmacol Unit, Via Eritrea 62, I-20157 Milan, Italy.		damia, giovanna/AAB-1428-2020; broggini, massimo/AAA-6460-2020	damia, giovanna/0000-0001-9749-434X; BROGGINI, MASSIMO/0000-0002-8138-9358				ALKHODAIRY F, 1994, MOL BIOL CELL, V5, P147, DOI 10.1091/mbc.5.2.147; BROGGINI M, 1991, CANCER RES, V51, P199; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Chan TA, 1999, NATURE, V401, P616, DOI 10.1038/44188; Chehab NH, 2000, GENE DEV, V14, P278; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; EL DW, 1993, CELL, V75, P817; FAN SJ, 1995, CANCER RES, V55, P1649; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; Hirao A, 2000, SCIENCE, V287, P1824, DOI 10.1126/science.287.5459.1824; Huang MX, 1998, CELL, V94, P595, DOI 10.1016/S0092-8674(00)81601-3; Jang YK, 1999, MOL CELL BIOL, V19, P7630; Kaneko Y, 1999, ONCOGENE, V18, P3673, DOI 10.1038/sj.onc.1202706; Ko LJ, 1996, GENE DEV, V56, P2649; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Lopez-Girona A, 1999, NATURE, V397, P172, DOI 10.1038/16488; Matsuoka S, 1998, SCIENCE, V282, P1893, DOI 10.1126/science.282.5395.1893; Meek DW, 1998, CELL SIGNAL, V10, P159, DOI 10.1016/S0898-6568(97)00119-8; Oren M, 1999, J BIOL CHEM, V274, P36031, DOI 10.1074/jbc.274.51.36031; Oren M., 1996, BIOCHIM BIOPHYS ACTA, V1288, P13, DOI DOI 10.1016/S0304-419X(96)00030-3; Peng CY, 1997, SCIENCE, V277, P1501, DOI 10.1126/science.277.5331.1501; Piwnica-Worms H, 1999, NATURE, V401, P535, DOI 10.1038/44029; Poon RYC, 1997, CANCER RES, V57, P5168; Prives C, 1998, CELL, V95, P5, DOI 10.1016/S0092-8674(00)81774-2; Richard GF, 1999, MOL GEN GENET, V261, P871, DOI 10.1007/s004380050031; Sambrook J., 2002, MOL CLONING LAB MANU; Sanchez Y, 1997, SCIENCE, V277, P1497, DOI 10.1126/science.277.5331.1497; Sanchez Y, 1999, SCIENCE, V286, P1166, DOI 10.1126/science.286.5442.1166; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Shieh SY, 2000, GENE DEV, V14, P289; Suganuma M, 1999, CANCER RES, V59, P5887; Tominaga K, 1999, J BIOL CHEM, V274, P31463, DOI 10.1074/jbc.274.44.31463; Vikhanskaya F, 1999, CLIN CANCER RES, V5, P937; WALWORTH N, 1993, NATURE, V363, P368, DOI 10.1038/363368a0; Walworth NC, 1996, SCIENCE, V271, P353, DOI 10.1126/science.271.5247.353; Wang QZ, 1996, J NATL CANCER I, V88, P956, DOI 10.1093/jnci/88.14.956; Weinert T, 1997, SCIENCE, V277, P1450, DOI 10.1126/science.277.5331.1450; Yao SL, 1996, NAT MED, V2, P1140, DOI 10.1038/nm1096-1140; Zeng Y, 1998, NATURE, V395, P507, DOI 10.1038/26766	39	19	19	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 6	2001	276	14					10641	10645		10.1074/jbc.M007178200	http://dx.doi.org/10.1074/jbc.M007178200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	420AC	11152453	hybrid			2022-12-25	WOS:000167980900012
J	Mills, KV; Paulus, H				Mills, KV; Paulus, H			Reversible inhibition of protein splicing by zinc ion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; SPLIT INTEIN; DNAE GENE; IN-VITRO; MECHANISM	Protein splicing involves the self-catalyzed excision of a protein-splicing element, the intein, from flanking polypeptides, the exteins, which are concomitantly joined by a peptide bond. Taking advantage of recently developed in vitro systems in which protein splicing occurs in trans to assay for protein-splicing inhibitors, we discovered that low concentrations of Zn2+ inhibited splicing mediated both by the RecA intein from Mycobacterium tuberculosis and by the naturally split DnaE intein from Synechocystis sp. PCC6803. Inhibition by Zn2+ was also observed with a cis-splicing system involving the RecA intein. In all experimental systems used, inhibition by Zn2+ could be completely reversed by the addition of EDTA. Zinc ion also inhibited hydroxylamine-dependent N-terminal cleavage of the RecA intein. All other divalent transition metal ions tested were less effective as inhibitors than Zn2+. The reversible inhibition by Zn2+ should be useful in studies of the mechanism of protein splicing and allow structural studies of unmodified protein-splicing precursors.	Boston Biomed Res Inst, Watertown, MA 02742 USA; Harvard Univ, Dept Chem & Chem Biol, Cambridge, MA 02138 USA; Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA	Boston Biomedical Research Institute; Harvard University; Harvard University; Harvard Medical School	Paulus, H (corresponding author), Boston Biomed Res Inst, 64 Grove St, Watertown, MA 02742 USA.	paulus@bbri.org	Wood, David W/B-2992-2012		NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR011301] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM055875] Funding Source: NIH RePORTER; NCRR NIH HHS [RR11301] Funding Source: Medline; NIGMS NIH HHS [R01 GM55875] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; COLEMAN JE, 1961, J BIOL CHEM, V236, P2244; DZELZKALNS VA, 1986, J BACTERIOL, V165, P964, DOI 10.1128/jb.165.3.964-971.1986; ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6; Evans TC, 2000, J BIOL CHEM, V275, P9091, DOI 10.1074/jbc.275.13.9091; KASAHARA M, 1974, J BIOCHEM, V76, P967; Lew BM, 1998, J BIOL CHEM, V273, P15887, DOI 10.1074/jbc.273.26.15887; Mills KV, 1998, P NATL ACAD SCI USA, V95, P3543, DOI 10.1073/pnas.95.7.3543; Paul-Soto R, 1999, BIOCHEMISTRY-US, V38, P16500, DOI 10.1021/bi9911381; Paulus H, 2000, ANNU REV BIOCHEM, V69, P447, DOI 10.1146/annurev.biochem.69.1.447; Poland BW, 2000, J BIOL CHEM, V275, P16408, DOI 10.1074/jbc.275.22.16408; Scott CP, 1999, P NATL ACAD SCI USA, V96, P13638, DOI 10.1073/pnas.96.24.13638; Shao Y, 1996, BIOCHEMISTRY-US, V35, P3810, DOI 10.1021/bi952592h; Shingledecker K, 2000, ARCH BIOCHEM BIOPHYS, V375, P138, DOI 10.1006/abbi.1999.1645; Shingledecker K, 1998, GENE, V207, P187, DOI 10.1016/S0378-1119(97)00624-0; Southworth MW, 1998, EMBO J, V17, P918, DOI 10.1093/emboj/17.4.918; SPENCER P, 1993, BIOCHEM J, V290, P279, DOI 10.1042/bj2900279; Wu H, 1998, BBA-PROTEIN STRUCT M, V1387, P422, DOI 10.1016/S0167-4838(98)00157-5; Wu H, 1998, P NATL ACAD SCI USA, V95, P9226, DOI 10.1073/pnas.95.16.9226; XU MQ, 1993, CELL, V75, P1371, DOI 10.1016/0092-8674(93)90623-X; Zhao SM, 2000, J BACTERIOL, V182, P1053, DOI 10.1128/JB.182.4.1053-1061.2000	21	54	59	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 6	2001	276	14					10832	10838		10.1074/jbc.M011149200	http://dx.doi.org/10.1074/jbc.M011149200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	420AC	11152694	hybrid			2022-12-25	WOS:000167980900038
J	White, WH; Gunyuzlu, PL; Toyn, JH				White, WH; Gunyuzlu, PL; Toyn, JH			Saccharomyces cerevisiae is capable of de novo pantothenic acid biosynthesis involving a novel pathway of beta-alanine production from spermine	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MONOAMINE-OXIDASE-B; ESCHERICHIA-COLI; CANDIDA-ALBICANS; BINDING SITE; YEAST; GENE; RESISTANCE; CLONING; ENCODES; IDENTIFICATION	Pantothenic acid and beta -alanine are metabolic intermediates in coenzyme A biosynthesis, Using a functional screen in the yeast Saccharomyces cerevisiae, a putative amine oxidase, encoded by FMS1, was found to be rate-limiting for beta -alanine and pantothenic acid biosynthesis. Overexpression of FMS1 caused excess pantothenic acid to be excreted into the medium, whereas deletion mutants required beta -alanine or pantothenic acid for growth. Furthermore, yeast genes ECM31 and YIL145c, which both have structural homology to genes of the bacterial pantothenic acid pathway, were also required for pantothenic acid biosynthesis. The homology of FMS1 to FAD-containing amine oxidases and its role in beta -alanine biosynthesis suggested that its substrates are polyamines. Indeed, we found that all the enzymes of the polyamine pathway in yeast are necessary for beta -alanine biosynthesis; spe1 Delta, spe2 Delta, spe3 Delta, and spe4 Delta are all beta -alanine auxotrophs, Thus, contrary to previous reports, yeast is naturally capable of pantothenic acid biosynthesis, and the beta -alanine is derived from methionine via a pathway involving spermine. These findings should facilitate the identification of further enzymes and biochemical pathways involved in polyamine degradation and pantothenic acid biosynthesis in S. cerevisiae and raise questions about these pathways in other organisms.	Dupont Pharmaceut Co, Expt Stn, Dept Appl Biotechnol, Wilmington, DE 19880 USA	DuPont	Toyn, JH (corresponding author), Dupont Pharmaceut Co, Expt Stn, Dept Appl Biotechnol, E336-239A,Rte 141 & Henry Clay Rd, Wilmington, DE 19880 USA.							BALASUNDARAM D, 1991, P NATL ACAD SCI USA, V88, P5872, DOI 10.1073/pnas.88.13.5872; BOEKE JD, 1984, MOL GEN GENET, V197, P345, DOI 10.1007/BF00330984; CARLSON M, 1982, CELL, V28, P145, DOI 10.1016/0092-8674(82)90384-1; CRONAN JE, 1980, J BACTERIOL, V141, P1291, DOI 10.1128/JB.141.3.1291-1297.1980; Genschel U, 1999, BIOCHEM J, V341, P669, DOI 10.1042/0264-6021:3410669; Gietz RD, 1995, METHOD MOL CELL BIOL, V5, P255; Glansdorff N, 1996, ESCHERICHIA COLI SAL, P408; Gunyuzlu PL, 2000, MOL BIOTECHNOL, V15, P29, DOI 10.1385/MB:15:1:29; Guthrie C, 1991, METHOD ENZYMOL, V194, P3; Hamasaki-Katagiri N, 1998, GENE, V210, P195, DOI 10.1016/S0378-1119(98)00027-4; Hodges PE, 1999, NUCLEIC ACIDS RES, V27, P69, DOI 10.1093/nar/27.1.69; HOLTTA E, 1977, BIOCHEMISTRY-US, V16, P91, DOI 10.1021/bi00620a015; Jackowski S., 1996, ESCHERICHIA COLI SAL, P687; Joets J, 1996, CURR GENET, V30, P115, DOI 10.1007/s002940050109; Kurtov D, 1999, MOL GEN GENET, V262, P115, DOI 10.1007/s004380051065; KWAN SW, 1995, ARCH BIOCHEM BIOPHYS, V316, P385, DOI 10.1006/abbi.1995.1051; LARGE PJ, 1992, FEMS MICROBIOL LETT, V88, P249, DOI 10.1111/j.1574-6968.1992.tb04991.x; Leonian LH, 1942, AM J BOT, V29, P459, DOI 10.2307/2437311; Lussier M, 1997, GENETICS, V147, P435; MALLOY PJ, 1993, P NATL ACAD SCI USA, V90, P1902, DOI 10.1073/pnas.90.5.1902; MANIVASAKAM P, 1995, NUCLEIC ACIDS RES, V23, P2799, DOI 10.1093/nar/23.14.2799; Marcireau C, 1996, YEAST, V12, P531, DOI 10.1002/(SICI)1097-0061(199605)12:6<531::AID-YEA934>3.3.CO;2-5; PADMANABHAN R, 1972, ARCH BIOCHEM BIOPHYS, V150, P531, DOI 10.1016/0003-9861(72)90071-9; Park MH, 1998, J BIOL CHEM, V273, P1677, DOI 10.1074/jbc.273.3.1677; Sambrook J., 2002, MOL CLONING LAB MANU; Sherman F., 1986, METHODS YEAST GENETI; SLOTNICK IJ, 1957, J BACTERIOL, V74, P122, DOI 10.1128/JB.74.2.122-125.1957; Stolz J, 1999, J BIOL CHEM, V274, P18747, DOI 10.1074/jbc.274.26.18747; TABOR CW, 1984, ANNU REV BIOCHEM, V53, P749, DOI 10.1146/annurev.bi.53.070184.003533; Toyn JH, 2000, YEAST, V16, P553, DOI 10.1002/(SICI)1097-0061(200004)16:6<553::AID-YEA554>3.0.CO;2-7; Wang XP, 1998, J BACTERIOL, V180, P822, DOI 10.1128/JB.180.4.822-830.1998; WILLIAMSON JM, 1979, J BIOL CHEM, V254, P8074; Winzeler EA, 1999, SCIENCE, V285, P901, DOI 10.1126/science.285.5429.901; ZHOU BP, 1995, J BIOL CHEM, V270, P23653, DOI 10.1074/jbc.270.40.23653; Zhou BP, 1998, J BIOL CHEM, V273, P14862, DOI 10.1074/jbc.273.24.14862	35	113	121	2	28	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 6	2001	276	14					10794	10800		10.1074/jbc.M009804200	http://dx.doi.org/10.1074/jbc.M009804200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	420AC	11154694	hybrid			2022-12-25	WOS:000167980900033
J	Bardwell, AJ; Flatauer, LJ; Matsukuma, K; Thorner, J; Bardwell, L				Bardwell, AJ; Flatauer, LJ; Matsukuma, K; Thorner, J; Bardwell, L			A conserved docking site in MEKs mediates high-affinity binding to MAP kinases and cooperates with a scaffold protein to enhance signal transmission	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHEROMONE RESPONSE PATHWAY; YEAST SACCHAROMYCES-CEREVISIAE; ANTHRAX LETHAL FACTOR; C-JUN; SUBSTRATE-SPECIFICITY; TRANSDUCTION PATHWAY; TRANSCRIPTION FACTOR; MUTATIONAL ANALYSIS; FILAMENTOUS-GROWTH; STRUCTURAL BASIS	The recognition of mitogen-activated protein kinases (MAPKs) by their upstream activators, MAPK/ERK kinases (MEKs), is crucial for the effective and accurate transmission of many signals. We demonstrated previously that the yeast MAPKs Kss1 and Fus3 bind with high affinity to the N terminus of the MEK Ste7, and proposed that a conserved motif in Ste7, the MAPK-docking site, mediates this interaction. Here we show that the corresponding sequences in human MEK1 and MEK2 are necessary and sufficient for the direct binding of the MAPKs ERK1 and ERK2, Mutations in MEK1, MEK2, or Ste7 that altered conserved residues in the docking site diminished binding of the cognate MAPKs, Furthermore, short peptides corresponding to the docking sites in these MEKs inhibited MEK1-mediated phosphorylation of ERK2 in vitro. In yeast cells, docking-defective alleles of Ste7 were modestly compromised in their ability to transmit the mating pheromone signal. This deficiency was dramatically enhanced when the ability of the Ste5 scaffold protein to associate with components of the MAPK cascade was also compromised. Thus, both the MEK-MAPK docking interaction and binding to the Ste5 scaffold make mutually reinforcing contributions to the efficiency of signaling by this MAPK cascade in vivo.	Univ Calif Irvine, Dept Dev & Cell Biol, Irvine, CA 92697 USA; Univ Calif Berkeley, Dept Cell & Mol Biol, Div Biochem & Mol Biol, Berkeley, CA 94720 USA	University of California System; University of California Irvine; University of California System; University of California Berkeley	Bardwell, L (corresponding author), Univ Calif Irvine, Dept Dev & Cell Biol, Irvine, CA 92697 USA.	bardwell@uci.edu	Bardwell, Lee/I-8284-2019; THORNER, Jeremy/O-6132-2019	Bardwell, Lee/0000-0002-2393-8363; THORNER, Jeremy/0000-0002-2583-500X	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM021841, R01GM021841, R01GM060366] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM060366-01, GM21841, R01 GM060366, GM60366, R01 GM021841] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adachi M, 2000, J CELL BIOL, V148, P849, DOI 10.1083/jcb.148.5.849; Atienza JM, 2000, J BIOL CHEM, V275, P20638, DOI 10.1074/jbc.M910024199; Bardwell L, 1998, P NATL ACAD SCI USA, V95, P15400, DOI 10.1073/pnas.95.26.15400; Bardwell L, 1998, GENE DEV, V12, P2887, DOI 10.1101/gad.12.18.2887; BARDWELL L, 1994, DEV BIOL, V166, P363, DOI 10.1006/dbio.1994.1323; Bardwell L, 1996, TRENDS BIOCHEM SCI, V21, P373, DOI 10.1016/S0968-0004(96)30032-7; Bardwell L, 1996, MOL CELL BIOL, V16, P3637; Brunet A, 1996, SCIENCE, V272, P1652, DOI 10.1126/science.272.5268.1652; Burack WR, 2000, CURR OPIN CELL BIOL, V12, P211, DOI 10.1016/S0955-0674(99)00078-2; Caffrey DR, 1999, J MOL EVOL, V49, P567, DOI 10.1007/PL00006578; CHAREST DL, 1993, MOL CELL BIOL, V13, P4679, DOI 10.1128/MCB.13.8.4679; CHOI KY, 1994, CELL, V78, P499; Cook JG, 1997, NATURE, V390, P85, DOI 10.1038/36355; Cook JG, 1996, GENE DEV, V10, P2831, DOI 10.1101/gad.10.22.2831; CREIGTON TE, 1993, PROTEIN STRUCTURES M; Duesbery NS, 1998, SCIENCE, V280, P734, DOI 10.1126/science.280.5364.734; Elion EA, 1998, SCIENCE, V281, P1625, DOI 10.1126/science.281.5383.1625; Enslen H, 2000, EMBO J, V19, P1301, DOI 10.1093/emboj/19.6.1301; Feng YY, 1998, CURR BIOL, V8, P267, DOI 10.1016/S0960-9822(98)70108-3; Ferrell JE, 1996, TRENDS BIOCHEM SCI, V21, P460, DOI 10.1016/S0968-0004(96)20026-X; Fukuda M, 1997, EMBO J, V16, P1901, DOI 10.1093/emboj/16.8.1901; GALCHEVAGARGOVA Z, 1994, SCIENCE, V265, P806, DOI 10.1126/science.8047888; Garrington TP, 1999, CURR OPIN CELL BIOL, V11, P211, DOI 10.1016/S0955-0674(99)80028-3; GIBBS JB, 1994, CELL, V79, P193, DOI 10.1016/0092-8674(94)90189-9; Graves JD, 1999, PHARMACOL THERAPEUT, V82, P111, DOI 10.1016/S0163-7258(98)00056-4; Gustin MC, 1998, MICROBIOL MOL BIOL R, V62, P1264, DOI 10.1128/MMBR.62.4.1264-1300.1998; HARTWELL LH, 1980, J CELL BIOL, V85, P811, DOI 10.1083/jcb.85.3.811; HASSON MS, 1994, MOL CELL BIOL, V14, P1054, DOI 10.1128/MCB.14.2.1054; Holland PM, 1999, CURR BIOL, V9, pR329, DOI 10.1016/S0960-9822(99)80205-X; Hunter T, 2000, CELL, V100, P113, DOI 10.1016/S0092-8674(00)81688-8; Inouye C, 1997, GENETICS, V147, P479; Inouye C, 1997, SCIENCE, V278, P103, DOI 10.1126/science.278.5335.103; Jacobs D, 1999, GENE DEV, V13, P163, DOI 10.1101/gad.13.2.163; Jiang Y, 1997, J BIOL CHEM, V272, P11096; Johnson LN, 1998, FEBS LETT, V430, P1, DOI 10.1016/S0014-5793(98)00606-1; Kallunki T, 1996, CELL, V87, P929, DOI 10.1016/S0092-8674(00)81999-6; KALLUNKI T, 1994, GENE DEV, V8, P2996, DOI 10.1101/gad.8.24.2996; Karandikar M, 1999, CELL CALCIUM, V26, P219, DOI 10.1054/ceca.1999.0074; Kelkar N, 2000, MOL CELL BIOL, V20, P1030, DOI 10.1128/MCB.20.3.1030-1043.2000; KEMP BE, 1994, TRENDS BIOCHEM SCI, V19, P440, DOI 10.1016/0968-0004(94)90126-0; Kieran MW, 1999, ONCOGENE, V18, P6647, DOI 10.1038/sj.onc.1203057; Kolman MF, 1997, J BIOL CHEM, V272, P16904, DOI 10.1074/jbc.272.27.16904; Lee JC, 2000, IMMUNOPHARMACOLOGY, V47, P185, DOI 10.1016/S0162-3109(00)00206-X; Leeuw T, 1998, NATURE, V391, P191, DOI 10.1038/34448; Levchenko A, 2000, P NATL ACAD SCI USA, V97, P5818, DOI 10.1073/pnas.97.11.5818; Lewis TS, 1998, ADV CANCER RES, V74, P49, DOI 10.1016/S0065-230X(08)60765-4; Lowman HB, 1997, ANNU REV BIOPH BIOM, V26, P401, DOI 10.1146/annurev.biophys.26.1.401; Mansour SJ, 1996, BIOCHEMISTRY-US, V35, P15529, DOI 10.1021/bi961854s; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; PEARSON RB, 1991, METHOD ENZYMOL, V200, P62; Posas F, 1997, SCIENCE, V276, P1702, DOI 10.1126/science.276.5319.1702; PRINTEN JA, 1994, GENETICS, V138, P609; Prowse CN, 2000, BIOCHEMISTRY-US, V39, P6258, DOI 10.1021/bi000277b; Pryciak PM, 1998, GENE DEV, V12, P2684, DOI 10.1101/gad.12.17.2684; Robinson MJ, 1996, J BIOL CHEM, V271, P29734, DOI 10.1074/jbc.271.47.29734; Rubinfeld H, 1999, J BIOL CHEM, V274, P30349, DOI 10.1074/jbc.274.43.30349; Schaeffer HJ, 1999, MOL CELL BIOL, V19, P2435; Schaeffer HJ, 1998, SCIENCE, V281, P1668, DOI 10.1126/science.281.5383.1668; Schulman BA, 1998, P NATL ACAD SCI USA, V95, P10453, DOI 10.1073/pnas.95.18.10453; Scott K, 1998, NATURE, V395, P805, DOI 10.1038/27448; SEGER R, 1992, J BIOL CHEM, V267, P14373; Sette C, 2000, MOL BIOL CELL, V11, P4033, DOI 10.1091/mbc.11.11.4033; Shapiro PS, 1999, MOL CELL BIOL, V19, P3551; SIKORSKI RS, 1989, GENETICS, V122, P19; Songyang Z, 1996, MOL CELL BIOL, V16, P6486; SONGYANG Z, 1995, NATURE, V373, P536, DOI 10.1038/373536a0; STEVENSON BJ, 1992, GENE DEV, V6, P1293, DOI 10.1101/gad.6.7.1293; Stewart S, 1999, MOL CELL BIOL, V19, P5523; Tanoue T, 2000, NAT CELL BIOL, V2, P110, DOI 10.1038/35000065; Therrien M, 1996, GENE DEV, V10, P2684, DOI 10.1101/gad.10.21.2684; Tournier C, 1999, MOL CELL BIOL, V19, P1569; Tsunoda S, 1998, CURR OPIN GENET DEV, V8, P419, DOI 10.1016/S0959-437X(98)80112-3; van Drogen F, 2000, CURR BIOL, V10, P630, DOI 10.1016/S0960-9822(00)00511-X; Vitale G, 1998, BIOCHEM BIOPH RES CO, V248, P706, DOI 10.1006/bbrc.1998.9040; WHITEWAY MS, 1995, SCIENCE, V269, P1572, DOI 10.1126/science.7667635; Whitmarsh AJ, 1998, TRENDS BIOCHEM SCI, V23, P481, DOI 10.1016/S0968-0004(98)01309-7; Whitmarsh AJ, 1998, SCIENCE, V281, P1671, DOI 10.1126/science.281.5383.1671; Wilsbacher JL, 1999, J BIOL CHEM, V274, P16988, DOI 10.1074/jbc.274.24.16988; Xia Y, 1998, GENE DEV, V12, P3369, DOI 10.1101/gad.12.21.3369; Xu BE, 1999, J BIOL CHEM, V274, P34029, DOI 10.1074/jbc.274.48.34029; Yang SH, 1998, EMBO J, V17, P1740, DOI 10.1093/emboj/17.6.1740; YASHAR B, 1995, MOL CELL BIOL, V15, P6545; Zanke BW, 1996, J BIOL CHEM, V271, P29876, DOI 10.1074/jbc.271.47.29876; ZHENG CF, 1993, J BIOL CHEM, V268, P23933; ZHENG CF, 1993, J BIOL CHEM, V268, P11435; ZHOU GC, 1995, J BIOL CHEM, V270, P12665, DOI 10.1074/jbc.270.21.12665; Zuniga A, 1999, J BIOL CHEM, V274, P21900, DOI 10.1074/jbc.274.31.21900	87	137	140	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 30	2001	276	13					10374	10386		10.1074/jbc.M010271200	http://dx.doi.org/10.1074/jbc.M010271200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	420GC	11134045	Green Accepted, hybrid			2022-12-25	WOS:000167996400104
J	Lee, YS; Han, JS; Jeon, Y; Hwang, DS				Lee, YS; Han, JS; Jeon, Y; Hwang, DS			The arc two-component signal transduction system inhibits in vitro Escherichia coli chromosomal initiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-LEVEL EXPRESSION; REPLICATION ORIGIN; DNA-REPLICATION; TRANSCRIPTIONAL ACTIVATION; ENZYMATIC REPLICATION; MEDIATING REPRESSION; REGULATORY SYSTEM; AEROBIC PATHWAYS; GENE-EXPRESSION; PROTEIN BINDS	Under anaerobic growth conditions, Escherichia coli operates a two-component signal transduction system, termed Are, that consists of ArcB protein, a transmembrane sensor kinase and ArcA protein, the cognate response regulator. In response to low oxygen levels, autophosphorylated ArcB phosphorylates ArcA, and the resulting phosphorylated ArcA (ArcA-P) functions as a transcriptional regulator of the genes necessary to maintain anaerobic growth. Under anaerobic conditions, cells maintain a slow growth rate, suggesting that the initiation of chromosomal replication is regulated to reduce the initiation frequency. DNase I footprinting experiments revealed that ArcA-P binds to the left region of the chromosomal origin, oriC, ArcA-P did not affect the in vitro replication of plasmid DNA containing the ColE1 origin nor the in vitro replication of viral DNAs; however, ArcA-P specifically inhibited in vitro E, coli chromosomal replication. This inhibition was caused by the prevention of open complex formation, a necessary step in the initiation of chromosomal replication. Our in vitro results suggest that the Are two-component system participates in regulating chromosomal initiation under anaerobic growth conditions.	Seoul Natl Univ, Inst Mol Biol & Genet, Sch Biol Sci, Seoul 151742, South Korea	Seoul National University (SNU)	Hwang, DS (corresponding author), Seoul Natl Univ, Inst Mol Biol & Genet, Sch Biol Sci, Seoul 151742, South Korea.	dshwang@plaza.snu.ac.kr						ASAI T, 1990, EMBO J, V9, P4065, DOI 10.1002/j.1460-2075.1990.tb07628.x; BACHMANN BJ, 1972, BACTERIOL REV, V36, P525, DOI 10.1128/MMBR.36.4.525-557.1972; BAKER TA, 1988, CELL, V55, P113, DOI 10.1016/0092-8674(88)90014-1; BEYERSMANN D, 1974, J BACTERIOL, V118, P783, DOI 10.1128/JB.118.3.783-789.1974; BRAMHILL D, 1988, CELL, V54, P915, DOI 10.1016/0092-8674(88)90102-X; BRAMHILL D, 1988, CELL, V52, P743, DOI 10.1016/0092-8674(88)90412-6; Carr KM, 1996, MOL MICROBIOL, V20, P1307, DOI 10.1111/j.1365-2958.1996.tb02649.x; CASSLER MR, 1995, EMBO J, V14, P5833, DOI 10.1002/j.1460-2075.1995.tb00271.x; Colloms SD, 1998, MOL MICROBIOL, V28, P521, DOI 10.1046/j.1365-2958.1998.00812.x; DRAPAL N, 1995, MOL MICROBIOL, V16, P597, DOI 10.1111/j.1365-2958.1995.tb02422.x; FULLER RS, 1983, P NATL ACAD SCI-BIOL, V80, P5817, DOI 10.1073/pnas.80.19.5817; FULLER RS, 1981, P NATL ACAD SCI-BIOL, V78, P7370, DOI 10.1073/pnas.78.12.7370; Georgellis D, 1997, J BACTERIOL, V179, P5429, DOI 10.1128/jb.179.17.5429-5435.1997; GUZMAN LM, 1995, J BACTERIOL, V177, P4121, DOI 10.1128/jb.177.14.4121-4130.1995; HWANG DS, 1992, J BIOL CHEM, V267, P23087; HWANG DS, 1990, CELL, V63, P325, DOI 10.1016/0092-8674(90)90165-B; HWANG DS, 1988, J BIOL CHEM, V263, P10625; HWANG DS, 1992, J BIOL CHEM, V267, P23083; IUCHI S, 1989, J BACTERIOL, V171, P868, DOI 10.1128/jb.171.2.868-873.1989; IUCHI S, 1989, J BACTERIOL, V171, P2889, DOI 10.1128/jb.171.5.2889-2893.1989; IUCHI S, 1990, J BACTERIOL, V172, P6020, DOI 10.1128/jb.172.10.6020-6025.1990; IUCHI S, 1994, J BACTERIOL, V176, P1695, DOI 10.1128/jb.176.6.1695-1701.1994; IUCHI S, 1988, P NATL ACAD SCI USA, V85, P1888, DOI 10.1073/pnas.85.6.1888; IUCHI S, 1992, J BACTERIOL, V174, P5617, DOI 10.1128/JB.174.17.5617-5623.1992; JOHNSTON S, 1985, GENE, V34, P137, DOI 10.1016/0378-1119(85)90121-0; KAGUNI JM, 1984, CELL, V38, P183, DOI 10.1016/0092-8674(84)90539-7; KAGUNI JM, 1982, NATURE, V296, P623, DOI 10.1038/296623a0; KORNBERG A, 1992, DNA REPLICATION, P521; Lee YS, 1996, MOL MICROBIOL, V19, P389, DOI 10.1046/j.1365-2958.1996.485902.x; Lynch AS, 1996, J BACTERIOL, V178, P6238, DOI 10.1128/JB.178.21.6238-6249.1996; LYNCH AS, 1996, ESCHERICHIA COLI SAL, V1, P1526; McGuire AM, 1999, MOL MICROBIOL, V32, P219, DOI 10.1046/j.1365-2958.1999.01347.x; MESSER W, 1996, ESCHERICHIA COLI SAL, V2, P1579; NINFA AJ, 1996, ESCHERICHIA COLI SAL, V1, P1246; Nystrom T, 1996, EMBO J, V15, P3219, DOI 10.1002/j.1460-2075.1996.tb00686.x; OKA A, 1980, MOL GEN GENET, V178, P9, DOI 10.1007/BF00267207; Parkinson J.S., 1995, 2 COMPONENT SIGNAL T, P9; Pellicer MT, 1999, J BIOL CHEM, V274, P1745, DOI 10.1074/jbc.274.3.1745; POLACZEK P, 1990, New Biologist, V2, P265; Sambrook J., 2002, MOL CLONING LAB MANU; SAWERS G, 1992, J BACTERIOL, V174, P3474, DOI 10.1128/JB.174.11.3474-3478.1992; SILVERMAN PM, 1991, J MOL BIOL, V218, P119, DOI 10.1016/0022-2836(91)90878-A; STAYTON MM, 1983, J BIOL CHEM, V258, P3205; STOCK JB, 1990, NATURE, V344, P395, DOI 10.1038/344395a0; Strohmaier H, 1998, J MOL BIOL, V277, P309, DOI 10.1006/jmbi.1997.1598; TARDAT B, 1993, MOL MICROBIOL, V9, P53, DOI 10.1111/j.1365-2958.1993.tb01668.x; TARDAT B, 1991, MOL MICROBIOL, V5, P455, DOI 10.1111/j.1365-2958.1991.tb02129.x; Torheim NK, 1999, EMBO J, V18, P4882, DOI 10.1093/emboj/18.17.4882; VERMA M, 1989, MOL GEN GENET, V216, P446, DOI 10.1007/BF00334389; VONMEYENBURG K, 1987, ESCHERICHIA COLI SAL, V2, P1555; YUNG BYM, 1989, J BIOL CHEM, V264, P6146; ZYSKIND JW, 1983, P NATL ACAD SCI-BIOL, V80, P1164, DOI 10.1073/pnas.80.5.1164	52	36	36	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 30	2001	276	13					9917	9923		10.1074/jbc.M008629200	http://dx.doi.org/10.1074/jbc.M008629200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	420GC	11133990	hybrid			2022-12-25	WOS:000167996400047
J	Prevot, D; Morel, AP; Voeltzel, T; Rostan, MC; Rimokh, R; Magaud, JP; Corbo, L				Prevot, D; Morel, AP; Voeltzel, T; Rostan, MC; Rimokh, R; Magaud, JP; Corbo, L			Relationships of the antiproliferative proteins BTG1 and BTG2 with CAF1, the human homolog of a component of the yeast CCR4 transcriptional complex - Involvement in estrogen receptor alpha signaling pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROGRAMMED CELL-DEATH; NEURONAL PC12 CELLS; NERVE GROWTH-FACTOR; NUCLEAR RECEPTOR; REGULATORY COMPLEX; TOB/BTG1 FAMILY; CYCLIN D1; GENE; EXPRESSION; PC3	We have reported previously the physical interaction of B-cell translocation gene proteins (BTG)1 and BTG2 with the mouse protein CAF1 (CCR4-associated factor 1) and suggested that these proteins may participate, through their association with CAF1, in transcription regulation. Here we describe the in vitro and in vivo association of these proteins with hPOP2, the human paralog of hCAF1, The physical and functional relationships between the BTG proteins and their partners hCAF1 and hPOP2 were investigated to find out how these interactions affect cellular processes, and in particular transcription regulation. We defined their interaction regions and examined their expression in various human tissues. We also show functional data indicating their involvement in estrogen receptor a (ER alpha)-mediated transcription regulation. We found that BTG1 and BTG2, probably through their interaction with CAF1 via a CCR4-like complex, can play both positive or negative roles in regulating the ER alpha function. In addition, our results indicate that two LXXLL motifs, referred to as nuclear receptor boxes, present in both BTG1 and BTG2, are involved in the regulation of ER alpha -mediated activation.	Ctr Leon Berard, INSERM, U453, F-69373 Lyon 08, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Centre Leon Berard	Corbo, L (corresponding author), Ctr Leon Berard, INSERM, U453, 28 Rue Laennec, F-69373 Lyon 08, France.		Rimokh, Ruth/G-7506-2014					Albert TK, 2000, NUCLEIC ACIDS RES, V28, P809, DOI 10.1093/nar/28.3.809; Bai YL, 1999, MOL CELL BIOL, V19, P6642; BEATO M, 1995, CELL, V83, P851, DOI 10.1016/0092-8674(95)90201-5; Bogdan JA, 1998, BIOCHEM J, V336, P471, DOI 10.1042/bj3360471; BRADBURY A, 1991, P NATL ACAD SCI USA, V88, P3353, DOI 10.1073/pnas.88.8.3353; Chen DG, 1999, SCIENCE, V284, P2174, DOI 10.1126/science.284.5423.2174; Fidler C, 1999, GENOMICS, V56, P134, DOI 10.1006/geno.1998.5687; FLETCHER BS, 1991, J BIOL CHEM, V266, P14511; GREEN S, 1988, NUCLEIC ACIDS RES, V16, P369, DOI 10.1093/nar/16.1.369; Gronemeyer H, 1995, PROTEIN PROFILE, V2, P1173; Guardavaccaro D, 2000, MOL CELL BIOL, V20, P1797, DOI 10.1128/MCB.20.5.1797-1815.2000; Guehenneux F, 1997, LEUKEMIA, V11, P370, DOI 10.1038/sj.leu.2400599; Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750; Horwitz KB, 1996, MOL ENDOCRINOL, V10, P1167, DOI 10.1210/me.10.10.1167; IACOPETTI P, 1994, MECH DEVELOP, V47, P127, DOI 10.1016/0925-4773(94)90085-X; Ikematsu N, 1999, ONCOGENE, V18, P7432, DOI 10.1038/sj.onc.1203193; Kalkhoven E, 1998, EMBO J, V17, P232, DOI 10.1093/emboj/17.1.232; Koh SS, 2001, J BIOL CHEM, V276, P1089, DOI 10.1074/jbc.M004228200; Levy A, 1999, GENE CHROMOSOME CANC, V24, P42, DOI 10.1002/(SICI)1098-2264(199901)24:1<42::AID-GCC6>3.0.CO;2-F; Lin WJ, 1996, J BIOL CHEM, V271, P15034, DOI 10.1074/jbc.271.25.15034; Liu HY, 1998, EMBO J, V17, P1096, DOI 10.1093/emboj/17.4.1096; Malatesta P, 2000, MECH DEVELOP, V90, P17, DOI 10.1016/S0925-4773(99)00224-5; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; Matsuda S, 1996, ONCOGENE, V12, P705; MESNER PW, 1995, J NEUROSCI, V15, P7357; Montagnoli A, 1996, CELL GROWTH DIFFER, V7, P1327; Pineau P, 1999, ONCOGENE, V18, P3127, DOI 10.1038/sj.onc.1202648; PlanasSilva MD, 1997, MOL CELL BIOL, V17, P4059, DOI 10.1128/MCB.17.7.4059; Prevot D, 2000, J BIOL CHEM, V275, P147, DOI 10.1074/jbc.275.1.147; RIMOKH R, 1991, GENE CHROMOSOME CANC, V3, P24, DOI 10.1002/gcc.2870030106; Rouault JP, 1998, J BIOL CHEM, V273, P22563, DOI 10.1074/jbc.273.35.22563; ROUAULT JP, 1992, EMBO J, V11, P1663, DOI 10.1002/j.1460-2075.1992.tb05213.x; Rouault JP, 1996, NAT GENET, V14, P482, DOI 10.1038/ng1296-482; TORA L, 1989, EMBO J, V8, P1981, DOI 10.1002/j.1460-2075.1989.tb03604.x; Treilleux I, 1997, MOL ENDOCRINOL, V11, P1319, DOI 10.1210/me.11.9.1319; Verma RS, 1999, CANCER INVEST, V17, P441, DOI 10.3109/07357909909021436; Wang SL, 1997, DEV BIOL, V188, P322, DOI 10.1006/dbio.1997.8655; Yoshida Y, 1998, ONCOGENE, V16, P2687, DOI 10.1038/sj.onc.1201805; Zwijsen RML, 1997, CELL, V88, P405, DOI 10.1016/S0092-8674(00)81879-6	39	109	114	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 30	2001	276	13					9640	9648		10.1074/jbc.M008201200	http://dx.doi.org/10.1074/jbc.M008201200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	420GC	11136725	hybrid			2022-12-25	WOS:000167996400010
J	Shieh, HL; Chen, Y; Brown, CR; Chiang, HL				Shieh, HL; Chen, Y; Brown, CR; Chiang, HL			Biochemical analysis of fructose-1,6-bisphosphatase import into vacuole import and degradation vesicles reveals a role for UBC1 in vesicle biogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UBIQUITIN-CONJUGATING ENZYMES; PLASMA-MEMBRANE PROTEINS; SACCHAROMYCES-CEREVISIAE; PEROXISOME DEGRADATION; PROTEASOME PATHWAY; YEAST VACUOLE; H+-ATPASE; CYTOPLASM; ENDOCYTOSIS; GLUCOSE	When Saccharomyces cerevisiae are shifted from medium containing poor carbon sources to medium containing fresh glucose, the key gluconeogenic enzyme fructose-1,6-bisphosphatase (FBPase) is imported into Vid (vacuole import and degradation) vesicles and then to the vacuole for degradation. Here, we show that FBPase import is independent of vacuole functions and proteasome degradation, However, FBPase import required the ubiquitin-conjugating enzyme Ubc1p, A strain containing a deletion of the UBC1 gene exhibited defective FBPase import. Furthermore, FBPase import was inhibited when cells overexpressed the K48R/K63R ubiquitin mutant that fails to form multiubiquitin chains. The defects in FBPase import seen for the Delta ubc1 and the K48R/K63R mutants were attributed to the Vid vesicle fraction. In the Delta ubc1 mutant, the level of the Vid vesicle-specific marker Vid24p was reduced in the vesicle fraction, suggesting that UBC1 is required for either Vid vesicle production or Vid24p binding to Vid vesicles. However, the K48R/K63R mutant did not prevent Vid24p binding to Vid vesicles, indicating that ubiquitin chain formation is dispensable for Vid24p binding to these structures. Our results support the findings that ubiquitin conjugation and ubiquitin chain formation play important roles in a number of cellular processes including organelle biogenesis.	Penn State Univ, Coll Med, Dept Cellular & Mol Physiol, Hershey, PA 17033 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health	Chiang, HL (corresponding author), Penn State Univ, Coll Med, Dept Cellular & Mol Physiol, 500 Univ Dr, Hershey, PA 17033 USA.				NIGMS NIH HHS [R01GM59480] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM059480] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMMERER G, 1986, MOL CELL BIOL, V6, P2490, DOI 10.1128/MCB.6.7.2490; Baba M, 1997, J CELL BIOL, V139, P1687, DOI 10.1083/jcb.139.7.1687; BACHMAIR A, 1986, SCIENCE, V234, P179, DOI 10.1126/science.3018930; Biederer T, 1996, EMBO J, V15, P2069, DOI 10.1002/j.1460-2075.1996.tb00560.x; Brown CR, 2000, J CELL BIOL, V150, P65, DOI 10.1083/jcb.150.1.65; CHIANG HL, 1991, NATURE, V350, P313, DOI 10.1038/350313a0; Chiang HL, 1996, J BIOL CHEM, V271, P9934, DOI 10.1074/jbc.271.17.9934; Chiang MC, 1998, J CELL BIOL, V140, P1347, DOI 10.1083/jcb.140.6.1347; Conibear E, 1998, BBA-MOL CELL RES, V1404, P211, DOI 10.1016/S0167-4889(98)00058-5; Drose S, 1997, J EXP BIOL, V200, P1; ELLISON MJ, 1991, J BIOL CHEM, V266, P21150; Fisk HA, 1999, J CELL BIOL, V145, P1199, DOI 10.1083/jcb.145.6.1199; Galan JM, 1996, J BIOL CHEM, V271, P10946, DOI 10.1074/jbc.271.18.10946; GANCEDO C, 1971, J BACTERIOL, V107, P401, DOI 10.1128/JB.107.2.401-405.1971; GRAHAM TR, 1993, EMBO J, V12, P869, DOI 10.1002/j.1460-2075.1993.tb05727.x; Haas A, 1996, EMBO J, V15, P3296, DOI 10.1002/j.1460-2075.1996.tb00694.x; HARDING TM, 1995, J CELL BIOL, V131, P591, DOI 10.1083/jcb.131.3.591; HEINEMEYER W, 1993, J BIOL CHEM, V268, P5115; Hicke L, 1996, CELL, V84, P277, DOI 10.1016/S0092-8674(00)80982-4; Hicke L, 1997, FASEB J, V11, P1215, DOI 10.1096/fasebj.11.14.9409540; Hiller MM, 1996, SCIENCE, V273, P1725, DOI 10.1126/science.273.5282.1725; Hilt W, 1996, TRENDS BIOCHEM SCI, V21, P96, DOI 10.1016/S0968-0004(96)10012-8; Hochstrasser M, 1996, ANNU REV GENET, V30, P405, DOI 10.1146/annurev.genet.30.1.405; Hoffman M, 1996, GENETICS, V143, P1555; Huang PH, 1997, J CELL BIOL, V136, P803, DOI 10.1083/jcb.136.4.803; Hutchins MU, 1999, J CELL SCI, V112, P4079; JENTSCH S, 1992, ANNU REV GENET, V26, P179, DOI 10.1146/annurev.ge.26.120192.001143; Jiang Y, 1998, EMBO J, V17, P6942, DOI 10.1093/emboj/17.23.6942; JONES EW, 1991, J BIOL CHEM, V266, P7963; JUNGMANN J, 1993, NATURE, V361, P369, DOI 10.1038/361369a0; KANE PM, 1992, J BIOL CHEM, V267, P447; Kim J, 1999, MOL BIOL CELL, V10, P1337, DOI 10.1091/mbc.10.5.1337; Klionsky DJ, 1998, J BIOL CHEM, V273, P10807, DOI 10.1074/jbc.273.18.10807; KLIONSKY DJ, 1990, MICROBIOL REV, V54, P266, DOI 10.1128/MMBR.54.3.266-292.1990; Klionsky DT, 1999, ANNU REV CELL DEV BI, V15, P1, DOI 10.1146/annurev.cellbio.15.1.1; KOLLING R, 1994, EMBO J, V13, P3261, DOI 10.1002/j.1460-2075.1994.tb06627.x; Lee DH, 1996, J BIOL CHEM, V271, P27280, DOI 10.1074/jbc.271.44.27280; Liang XH, 1999, NATURE, V402, P672, DOI 10.1038/45257; Mizushima N, 1998, NATURE, V395, P395, DOI 10.1038/26506; Nakamura N, 1997, J BIOCHEM, V121, P338; Parra KJ, 1998, MOL CELL BIOL, V18, P7064, DOI 10.1128/MCB.18.12.7064; RAYMOND CK, 1992, INT REV CYTOL, V139, P59, DOI 10.1016/S0074-7696(08)61410-2; Roth AF, 1996, J CELL BIOL, V134, P661, DOI 10.1083/jcb.134.3.661; SCHORK SM, 1995, J BIOL CHEM, V270, P26446, DOI 10.1074/jbc.270.44.26446; Schule T, 2000, EMBO J, V19, P2161, DOI 10.1093/emboj/19.10.2161; Scott SV, 1997, TRENDS CELL BIOL, V7, P225, DOI 10.1016/S0962-8924(97)01050-7; Scott SV, 1998, CURR OPIN CELL BIOL, V10, P523, DOI 10.1016/S0955-0674(98)80068-9; SEUFERT W, 1990, EMBO J, V9, P543, DOI 10.1002/j.1460-2075.1990.tb08141.x; SEUFERT W, 1990, EMBO J, V9, P4535, DOI 10.1002/j.1460-2075.1990.tb07905.x; Shieh HL, 1998, J BIOL CHEM, V273, P3381, DOI 10.1074/jbc.273.6.3381; WIEBEL FF, 1992, NATURE, V359, P73, DOI 10.1038/359073a0; YOSHIHISA T, 1990, J BIOL CHEM, V265, P22418; Yuan WP, 1999, MOL BIOL CELL, V10, P1353, DOI 10.1091/mbc.10.5.1353; Zoladek T, 1997, GENETICS, V145, P595	54	33	34	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 30	2001	276	13					10398	10406		10.1074/jbc.M001767200	http://dx.doi.org/10.1074/jbc.M001767200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	420GC	11134048	hybrid			2022-12-25	WOS:000167996400106
J	Leeb-Lundberg, LMF; Kang, DS; Lamb, DS; Lamb, ME; Fathy, DB				Leeb-Lundberg, LMF; Kang, DS; Lamb, DS; Lamb, ME; Fathy, DB			The human B1 bradykinin receptor exhibits high ligand-independent, constitutive activity - Roles of residues in the fourth intracellular and third transmembrane domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KININ B-1 RECEPTOR; PROTEIN-COUPLED RECEPTOR; HUMAN LUNG FIBROBLASTS; SMOOTH-MUSCLE CELLS; ALTERED FREQUENCY; INVERSE AGONISTS; HORMONE RECEPTOR; CARBOXYL TAIL; B2; ACTIVATION	The B1 bradykinin (BK) receptor (B1R) is a seven-transmembrane domain, G protein-coupled receptor that is induced by injury and important in inflammation and nociception. Here, we show that the human B1R exhibits a high level of ligand-independent, constitutive activity. Constitutive activity was identified by the increase in basal cellular phosphoinositide hydrolysis as a function of the density of the receptors in transiently transfected HEK293 cells. Several B1R peptide antagonists were neutral antagonists or very weakly efficacious inverse agonists, Constitutive B1R activity was further increased by alanine mutation of Asn(121) in the third transmembrane domain of the receptor (B1A(121)). This mutant resembled the agonist preferred receptor state since it also exhibited increased agonist affinity and decreased agonist responsiveness. A dramatic loss of constitutive activity occurred when the fourth intracellular C-terminal domain (IC-IV) of the human B2 BK receptor subtype (B2R), which exhibits minimal constitutive activity, was substituted in either B1R or B1A121 to make B1(B2ICIV) and B1(B2ICIV)A(121), respectively. Activity was partially recovered by subsequent alanine mutation of a cluster of two serines and two threonines in IC-IV of either B1(B2ICIV) or B1(B2ICIV)A121, a cluster that is important for B2R desensitization. The ligand-independent, constitutive activity of B1R therefore depends on epitopes in both transmembrane and intracellular domains. We propose that the activity is primarily due to the lack of critical epitopes in IC-IV that regulate such activity.	Univ Texas, Hlth Sci Ctr, Dept Biochem, San Antonio, TX 78229 USA	University of Texas System; University of Texas Health San Antonio	Leeb-Lundberg, LMF (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Biochem, Mail Code 7760,7703 Floyd Curl Dr, San Antonio, TX 78229 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM041659, R01GM041659] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM41659] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Arvanitakis L, 1997, NATURE, V385, P347, DOI 10.1038/385347a0; Austin CE, 1997, J BIOL CHEM, V272, P11420; Bachvarov DR, 1998, J AM SOC NEPHROL, V9, P598; Bachvarov DR, 1998, GASTROENTEROLOGY, V115, P1045, DOI 10.1016/S0016-5085(98)70071-X; BASCANDS JL, 1993, AM J PHYSIOL, V264, pF548, DOI 10.1152/ajprenal.1993.264.3.F548; BHOOLA KD, 1992, PHARMACOL REV, V44, P1; Blaukat A, 1999, BIOCHEMISTRY-US, V38, P1300, DOI 10.1021/bi981727r; Claeysen S, 1999, MOL PHARMACOL, V55, P910; COHEN GB, 1992, BIOCHEMISTRY-US, V31, P12592, DOI 10.1021/bi00165a008; COUGHLIN SR, 1994, CURR OPIN CELL BIOL, V6, P191, DOI 10.1016/0955-0674(94)90135-X; DAVIS AJ, 1994, BRIT J PHARMACOL, V113, P63, DOI 10.1111/j.1476-5381.1994.tb16174.x; deWeerd WFC, 1997, J BIOL CHEM, V272, P17858, DOI 10.1074/jbc.272.28.17858; Dray A, 1997, CAN J PHYSIOL PHARM, V75, P704, DOI 10.1139/cjpp-75-6-704; DRAY A, 1993, TRENDS NEUROSCI, V16, P99, DOI 10.1016/0166-2236(93)90133-7; FARMER SG, 1991, AGENTS ACTIONS, V34, P191, DOI 10.1007/BF01993275; Fathy DB, 1999, J BIOL CHEM, V274, P29603, DOI 10.1074/jbc.274.42.29603; Fathy DB, 1998, J BIOL CHEM, V273, P12210, DOI 10.1074/jbc.273.20.12210; Groblewski T, 1997, J BIOL CHEM, V272, P1822, DOI 10.1074/jbc.272.3.1822; Hasegawa H, 1996, J BIOL CHEM, V271, P1857, DOI 10.1074/jbc.271.4.1857; HESS JF, 1992, BIOCHEM BIOPH RES CO, V184, P260, DOI 10.1016/0006-291X(92)91187-U; Kenakin T, 1996, PHARMACOL REV, V48, P413; LAUE L, 1995, P NATL ACAD SCI USA, V92, P1906, DOI 10.1073/pnas.92.6.1906; LEEBLUNDBERG LMF, 1994, J BIOL CHEM, V269, P25970; Marceau F, 1998, PHARMACOL REV, V50, P357; Marie J, 1999, MOL PHARMACOL, V55, P92, DOI 10.1124/mol.55.1.92; Mary S, 1998, J BIOL CHEM, V273, P425, DOI 10.1074/jbc.273.1.425; Mathis SA, 1996, MOL PHARMACOL, V50, P128; MATUSLEIBOVITCH N, 1995, J BIOL CHEM, V270, P1041, DOI 10.1074/jbc.270.3.1041; MENKE JG, 1994, J BIOL CHEM, V269, P21588; PARMA J, 1993, NATURE, V365, P649, DOI 10.1038/365649a0; Perez DM, 1996, MOL PHARMACOL, V49, P112; Pesquero JB, 2000, P NATL ACAD SCI USA, V97, P8140, DOI 10.1073/pnas.120035997; Phagoo SB, 1999, MOL PHARMACOL, V56, P325, DOI 10.1124/mol.56.2.325; Pizard A, 1999, J BIOL CHEM, V274, P12738, DOI 10.1074/jbc.274.18.12738; PROUD D, 1988, ANNU REV IMMUNOL, V6, P49, DOI 10.1146/annurev.iy.06.040188.000405; Regoli D, 2000, P NATL ACAD SCI USA, V97, P7676, DOI 10.1073/pnas.150233397; REGOLI D, 1980, PHARMACOL REV, V32, P1; SAMAMA P, 1993, J BIOL CHEM, V268, P4625; Schanstra JP, 1998, J CLIN INVEST, V101, P2080, DOI 10.1172/JCI1359; Scheer A, 1997, J RECEPT SIGNAL TR R, V17, P57, DOI 10.3109/10799899709036594; STERANKA LR, 1988, P NATL ACAD SCI USA, V85, P3245, DOI 10.1073/pnas.85.9.3245; WARD PE, 1991, BRADYKININ ANTAGONIS, P147	42	58	60	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 23	2001	276	12					8785	8792		10.1074/jbc.M007396200	http://dx.doi.org/10.1074/jbc.M007396200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	413HV	11134011	hybrid			2022-12-25	WOS:000167607700024
J	Baumann, CA; Brady, MJ; Saltiel, AR				Baumann, CA; Brady, MJ; Saltiel, AR			Activation of glycogen synthase by insulin in 3T3-L1 adipocytes involves c-Cbl-associating protein (CAP)-dependent and CAP-independent signaling pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUCOSE-TRANSPORT; RAT ADIPOCYTES; PHOSPHATIDYLINOSITOL 3-KINASE; TYROSINE PHOSPHORYLATION; HORMONAL-STIMULATION; KINASE INHIBITION; POTENTIAL ROLE; TRANSLOCATION; CELLS; DEPHOSPHORYLATION	In adipose and muscle, insulin stimulates glucose uptake and glycogen synthase activity. Phosphatidylinositol 3-kinase (PI3K) activation is necessary but not sufficient for these metabolic actions of insulin. The insulin stimulated translocation of phospho c-Cbl to lipid rafts, via its association with CAP, comprises a second pathway regulating GLUT4 translocation. In 3T3-L1 adipocytes, overexpression of a dominant negative CAP mutant (CAP Delta SH3) completely blocked the insulin-stimulated glucose transport and glycogen synthesis but only partially inhibited glycogen synthase activation. In contrast, CAP Delta SH3 expression did not affect glycogen synthase activation by insulin in the absence of extracellular glucose. Moreover, CAP Delta SH3 has no effect on the PI3K dependent activation of protein phosphatase-l or phosphorylation of glycogen synthase kinase-3. These results indicate blockade of the c-Cbl/CAP pathway directly inhibits insulin-stimulated glucose uptake, which results in secondary inhibition of glycogen synthase activation and glycogen synthesis.	Univ Michigan, Med Ctr, Dept Med, Ann Arbor, MI 48109 USA; Univ Michigan, Med Ctr, Dept Physiol, Ann Arbor, MI 48109 USA; Pfizer Global Res & Dev, Dept Cell Biol, Ann Arbor, MI 48105 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; Pfizer	Saltiel, AR (corresponding author), Univ Michigan, Med Ctr, Dept Med, MSRB I,Rm 4520,1150 W Med Ctr Dr, Ann Arbor, MI 48109 USA.		Saltiel, Alan/L-3632-2019	Saltiel, Alan/0000-0002-9726-9828				Baumann CA, 2000, NATURE, V407, P202, DOI 10.1038/35025089; Brady MJ, 1999, J BIOL CHEM, V274, P27497, DOI 10.1074/jbc.274.39.27497; Brady MJ, 1999, TRENDS ENDOCRIN MET, V10, P408, DOI 10.1016/S1043-2760(99)00201-5; Brady MJ, 1997, J BIOL CHEM, V272, P29698, DOI 10.1074/jbc.272.47.29698; Brady MJ, 1998, J BIOL CHEM, V273, P14063, DOI 10.1074/jbc.273.23.14063; Cadefau J, 1997, BIOCHEM J, V322, P745, DOI 10.1042/bj3220745; Cohen P, 1997, FEBS LETT, V410, P3, DOI 10.1016/S0014-5793(97)00490-0; Cong LN, 1997, MOL ENDOCRINOL, V11, P1881, DOI 10.1210/me.11.13.1881; Czech MP, 1999, J BIOL CHEM, V274, P1865, DOI 10.1074/jbc.274.4.1865; FERNANDEZNOVELL JM, 1992, BIOCHEM J, V288, P497, DOI 10.1042/bj2880497; Guilherme A, 1998, J BIOL CHEM, V273, P33119, DOI 10.1074/jbc.273.50.33119; Hurel SJ, 1996, BIOCHEM J, V320, P871, DOI 10.1042/bj3200871; Jiang T, 1998, J BIOL CHEM, V273, P11017, DOI 10.1074/jbc.273.18.11017; LAWRENCE JC, 1978, J BIOL CHEM, V253, P2104; Lawrence JC, 1997, DIABETES, V46, P541, DOI 10.2337/diabetes.46.4.541; LAWRENCE JC, 1984, J BIOL CHEM, V259, P7975; LAZAR DF, 1995, J BIOL CHEM, V270, P20801, DOI 10.1074/jbc.270.35.20801; Mastick CC, 1997, J BIOL CHEM, V272, P20706, DOI 10.1074/jbc.272.33.20706; Min J, 1999, MOL CELL, V3, P751, DOI 10.1016/S1097-2765(01)80007-1; NIELSEN JN, 2001, IN PRESS J PHYSL; Ribon V, 1997, BIOCHEM J, V324, P839, DOI 10.1042/bj3240839; Ribon V, 1998, MOL CELL BIOL, V18, P872, DOI 10.1128/MCB.18.2.872; Ribon V, 1998, P NATL ACAD SCI USA, V95, P14751, DOI 10.1073/pnas.95.25.14751; SAKAUE H, 1995, J BIOL CHEM, V270, P11304, DOI 10.1074/jbc.270.19.11304; SHEPHERD PR, 1995, BIOCHEM J, V305, P25, DOI 10.1042/bj3050025; Standaert ML, 1997, J BIOL CHEM, V272, P30075, DOI 10.1074/jbc.272.48.30075; Tanti JF, 1996, J BIOL CHEM, V271, P25227, DOI 10.1074/jbc.271.41.25227; WELSH GI, 1993, BIOCHEM J, V294, P625, DOI 10.1042/bj2940625; WIESE RJ, 1995, J BIOL CHEM, V270, P3442, DOI 10.1074/jbc.270.7.3442	29	22	24	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 2	2001	276	9					6065	6068		10.1074/jbc.C000856200	http://dx.doi.org/10.1074/jbc.C000856200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	407FF	11222622	hybrid			2022-12-25	WOS:000167261000003
J	Barsyte, D; Lovejoy, DA; Lithgow, GJ				Barsyte, D; Lovejoy, DA; Lithgow, GJ			Longevity and heavy metal resistance in daf-2 and age-1 long-lived mutants of Caenorhabditis elegans	FASEB JOURNAL			English	Article						aging; nematode; metallothionein; insulin signaling; stress resistance; age genes	METALLOTHIONEIN-II GENES; LIFE-SPAN; OXIDATIVE STRESS; SUPEROXIDE-DISMUTASE; DIFFERENTIAL DISPLAY; RESPONSIVE GENES; DAUER FORMATION; MICE DEFICIENT; FAMILY MEMBER; RT-PCR	In the nematode Caenorhabditis elegans, dauer formation, stress resistance, and longevity are determined in part by DAF-2 (insulin receptor-like protein), AGE-1 (phosphatidylinositol-3-OH kinase catalytic subunit), and DAF-16 (forkhead transcription factor). Mutations in daf-2 and age-1 result in increased resistance to heat, oxidants, and UV. We have discovered that daf-2 and age-1 mutations result in increased Cd and Cu ion resistance in a 24 h toxicity assay. Lethal concentration (LC50) values for Cd and Cu ions in daf-2 and age-1 mutants were significantly (P<0.001) higher than in wild-type nematodes. However, LC50 values in daf-16;age-1 mutants were not significantly different, implying that metal resistance is influenced by a DAF-16-related function. As metallothionein (MT) proteins play a major role in metal detoxification, we examined the expression of MT genes both under noninducing conditions and after exposure to sublethal and acute heavy metal stress. MT1 mRNA levels were significantly (P<0.05) higher in daf-2 mutants compared to age-1 mutants and wild-type C. elegans under basal conditions. After 10 mM Cd treatment, induction of MT1 and MT2 mRNA was three- and twofold higher, respectively, in daf-2 mutant worms than in wild-type. However, a sublethal concentration of Cd (0.1 mM) resulted in even higher (three- to sevenfold) levels of both MT mRNAs in all strains, Cu did not induce MTI or MT2 mRNAs. These results are consistent with a model in which the insulin-signaling pathway determines life span through regulation of stress protein genes.-Barsyte, D., Lovejoy, D. A., Lithgow, G. J. Longevity and heavy metal resistance in daf-2 and age-1 long-lived mutants of Caenorhabditis elegans.	Univ Manchester, Sch Biol Sci, Manchester M13 9PT, Lancs, England	University of Manchester	Lithgow, GJ (corresponding author), Univ Manchester, Sch Biol Sci, 3-239 Stopford Bldg,Oxford Rd, Manchester M13 9PT, Lancs, England.							Barsyte D, 1999, COMP BIOCHEM PHYS C, V122, P287; Beckmann K. B., 1997, OXIDATIVE STRESS MOL, P201; BERNARD A, 1986, CADMIUM, P135; BRENNER S, 1974, GENETICS, V77, P71; Clemens S, 1999, EMBO J, V18, P3325, DOI 10.1093/emboj/18.12.3325; Cohen M., 1991, BIOL EFFECTS HEAVY M, P19; DORMAN JB, 1995, GENETICS, V141, P1399; FABIAN TJ, 1994, J GERONTOL, V49, pB145, DOI 10.1093/geronj/49.4.B145; Finney D J., 1952, PROBIT ANAL STAT TRE, P31; FREEDMAN JH, 1993, J BIOL CHEM, V268, P2554; FREEDMAN JH, 1989, J BIOL CHEM, V264, P5598; FRIEDMAN DB, 1988, J GERONTOL, V43, pB102, DOI 10.1093/geronj/43.4.B102; Ghoshal K, 1999, BIOCHEM BIOPH RES CO, V264, P735, DOI 10.1006/bbrc.1999.1563; Gil EB, 1999, P NATL ACAD SCI USA, V96, P2925, DOI 10.1073/pnas.96.6.2925; GOTTLIEB S, 1994, GENETICS, V137, P107; HALLIWELL B, 1990, METHOD ENZYMOL, V186, P1; HAMER DH, 1986, ANNU REV BIOCHEM, V55, P913, DOI 10.1146/annurev.biochem.55.1.913; HARMAN D, 1992, MUTAT RES, V275, P257, DOI 10.1016/0921-8734(92)90030-S; HARTWIG A, 1995, BIOMETALS, V8, P3; HATCHER EL, 1995, FREE RADICAL BIO MED, V19, P805, DOI 10.1016/0891-5849(95)00099-J; Ho YS, 1997, J BIOL CHEM, V272, P16644, DOI 10.1074/jbc.272.26.16644; Honda Y, 1999, FASEB J, V13, P1385, DOI 10.1096/fasebj.13.11.1385; KAGI JHR, 1988, BIOCHEMISTRY-US, V27, P8509, DOI 10.1021/bi00423a001; KENYON C, 1993, NATURE, V366, P461, DOI 10.1038/366461a0; Kimura KD, 1997, SCIENCE, V277, P942, DOI 10.1126/science.277.5328.942; Klaassen CD, 1999, ANNU REV PHARMACOL, V39, P267, DOI 10.1146/annurev.pharmtox.39.1.267; LARSEN PL, 1993, P NATL ACAD SCI USA, V90, P8905, DOI 10.1073/pnas.90.19.8905; LARSEN PL, 1995, GENETICS, V139, P1567; LAZO JS, 1995, J BIOL CHEM, V270, P5506, DOI 10.1074/jbc.270.10.5506; Lee KF, 1999, TOXICOL APPL PHARM, V154, P20, DOI 10.1006/taap.1998.8556; Liao VHC, 1998, J BIOL CHEM, V273, P31962, DOI 10.1074/jbc.273.48.31962; Lin K, 1997, SCIENCE, V278, P1319, DOI 10.1126/science.278.5341.1319; LITHGOW GJ, 1995, P NATL ACAD SCI USA, V92, P7540, DOI 10.1073/pnas.92.16.7540; Lithgow Gordon J., 1996, P55; Malone EA, 1996, GENETICS, V143, P1193; MASTERS BA, 1994, P NATL ACAD SCI USA, V91, P584, DOI 10.1073/pnas.91.2.584; Melov S, 2000, SCIENCE, V289, P1567, DOI 10.1126/science.289.5484.1567; MELOV S, 1994, NUCLEIC ACIDS RES, V22, P1075, DOI 10.1093/nar/22.6.1075; MICHALSKA AE, 1993, P NATL ACAD SCI USA, V90, P8088, DOI 10.1073/pnas.90.17.8088; MILLER BJ, 1990, SPORTS MED, V9, P1, DOI 10.2165/00007256-199009010-00001; Morris JZ, 1996, NATURE, V382, P536, DOI 10.1038/382536a0; Murakami S, 1996, GENETICS, V143, P1207; Muto N, 1999, COMP BIOCHEM PHYS C, V122, P75, DOI 10.1016/S0742-8413(98)10081-6; Ogg S, 1997, NATURE, V389, P994, DOI 10.1038/40194; Rouault JP, 1999, CURR BIOL, V9, P329, DOI 10.1016/S0960-9822(99)80143-2; SAMUNI A, 1981, J BIOL CHEM, V256, P2632; TAMAI KT, 1993, P NATL ACAD SCI USA, V90, P8013, DOI 10.1073/pnas.90.17.8013; Tawe WN, 1998, NUCLEIC ACIDS RES, V26, P1621, DOI 10.1093/nar/26.7.1621; THORNALLEY PJ, 1985, BIOCHIM BIOPHYS ACTA, V827, P36, DOI 10.1016/0167-4838(85)90098-6; Tissenbaum HA, 1998, GENETICS, V148, P703; Tsang SY, 1996, BIOCHEM J, V317, P13, DOI 10.1042/bj3170013; VANFLETEREN JR, 1995, FASEB J, V9, P1355, DOI 10.1096/fasebj.9.13.7557026; VANTLETEREN JR, 1993, BIOCHEM J, V292, P605; ZHOU JM, 1995, MOL GEN GENET, V248, P318, DOI 10.1007/BF02191599; Zimmermann K, 1996, BIOTECHNIQUES, V21, P268	55	203	221	2	46	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAR	2001	15	3					627	634		10.1096/fj.99-0966com	http://dx.doi.org/10.1096/fj.99-0966com			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	410BE	11259381				2022-12-25	WOS:000167419500020
J	Eickelberg, O; Pansky, A; Koehler, E; Bihl, M; Tamm, M; Hildebrand, P; Perruchoud, AP; Kashgarian, M; Roth, M				Eickelberg, O; Pansky, A; Koehler, E; Bihl, M; Tamm, M; Hildebrand, P; Perruchoud, AP; Kashgarian, M; Roth, M			Molecular mechanisms of TGF-beta antagonism by interferon gamma and cyclosporine A in lung fibroblasts	FASEB JOURNAL			English	Article						lung fibrosis; tumor growth factor beta; AP-1; IFN-gamma; Cs-A	GROWTH-FACTOR-BETA; IDIOPATHIC PULMONARY FIBROSIS; TRANSCRIPTIONAL ACTIVATION; COLLAGEN DEPOSITION; T-CELLS; EXPRESSION; GENE; ALVEOLITIS; DISEASE; COMPLEX	Lung fibrosis is a fatal condition of excess extracellular matrix (ECM) deposition associated with increased transforming growth factor beta (TGF-beta) activity. Although much is known about its pathological features, our understanding of the signal transduction pathways resulting in increased ECM and collagen deposition in response to TGF-beta is still incompletely defined. We have previously reported that a JunD homodimer of the transcription factor AP-1 is specifically activated by TGF-beta in lung fibroblasts. Here we demonstrate that JunD is also specifically required for TGF-beta -induced effects. Antisense against JunD, but not c-fos or c-jun, significantly inhibited collagen deposition in response to TGF-beta in primary human lung fibroblasts. We then investigated the ability of pharmacological agents to inhibit TGF-beta -induced signaling and collagen deposition. Cs-A and IFN-gamma, but not glucocorticoids, cyclophosphamide, or azathioprine, inhibited TGF-beta -induced signaling, as assessed by luciferase reporter gene assays, and collagen deposition. TGF-beta antagonism by Cs-A was associated with direct inhibition of JunD activation, as demonstrated by electrophoretic mobility shift analyses. In contrast, the effects of IFN-gamma required signal transducer and activator of transcription (STAT)-1. We thus identify the JunD isoform of AP-1 as an essential mediator of TGF-beta -induced effects in lung fibroblasts. TGF-beta -induced signaling and collagen deposition are efficiently antagonized by Cs-A and IFN-gamma treatment, both of which exhibit distinct molecular mechanisms of action. These observations therefore offer novel targets for future therapy of fibrotic lung disease.	Yale Univ, Sch Med, Dept Pathol, New Haven, CT 06520 USA; Univ Basel Hosp, Dept Res & Internal Med, CH-4031 Basel, Switzerland	Yale University; University of Basel	Eickelberg, O (corresponding author), Yale Univ, Sch Med, Dept Pathol, 310 Cedar St,LB20, New Haven, CT 06520 USA.	oliver.eickelberg@yale.edu	Roth, Michael/H-8657-2019; Köhler, Eleonore/D-2915-2012; Eickelberg, Oliver/A-5461-2013	Roth, Michael/0000-0002-8139-2821; Köhler, Eleonore/0000-0003-1977-9977; Eickelberg, Oliver/0000-0001-7170-0360				AGELLI M, 1988, METHOD ENZYMOL, V163, P642; ALTON EWFW, 1989, RESP MED, V83, P277, DOI 10.1016/S0954-6111(89)80196-9; Banerjee C, 1996, ENDOCRINOLOGY, V137, P1991, DOI 10.1210/en.137.5.1991; BIENKOWSKI RS, 1995, P SOC EXP BIOL MED, V209, P118; ChanYeung M, 1997, LANCET, V350, P651, DOI 10.1016/S0140-6736(97)06303-4; Coker RK, 1997, AM J PATHOL, V150, P981; CROUCH E, 1990, AM J PHYSIOL, V259, pL159, DOI 10.1152/ajplung.1990.259.4.L159; Egan JJ, 1999, LANCET, V354, P1839, DOI 10.1016/S0140-6736(99)00347-5; Eickelberg O, 1999, AM J PHYSIOL-LUNG C, V276, pL814, DOI 10.1152/ajplung.1999.276.5.L814; Eickelberg O, 1999, CIRCULATION, V99, P2276, DOI 10.1161/01.CIR.99.17.2276; Eickelberg O, 1999, J BIOL CHEM, V274, P12933, DOI 10.1074/jbc.274.18.12933; GAULDIE J, 1993, THORAX, V48, P931, DOI 10.1136/thx.48.9.931; Gay SE, 1998, AM J RESP CRIT CARE, V157, P1063, DOI 10.1164/ajrccm.157.4.9703022; Giordano A, 1999, J CELL PHYSIOL, V181, P218, DOI 10.1002/(SICI)1097-4652(199911)181:2<218::AID-JCP4>3.0.CO;2-5; GIRI SN, 1993, THORAX, V48, P959, DOI 10.1136/thx.48.10.959; Gorelik L, 2000, IMMUNITY, V12, P171, DOI 10.1016/S1074-7613(00)80170-3; GRUHN WB, 1987, J RHEUMATOL, V14, P1045; GURUJEYALAKSHMI G, 1995, EXP LUNG RES, V21, P791, DOI 10.3109/01902149509050842; Hagimoto N, 1997, AM J RESP CELL MOL, V17, P272, DOI 10.1165/ajrcmb.17.3.2893; HEIN R, 1992, BRIT J DERMATOL, V126, P496, DOI 10.1111/j.1365-2133.1992.tb15122.x; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Horvai AE, 1997, P NATL ACAD SCI USA, V94, P1074, DOI 10.1073/pnas.94.4.1074; Hubbard R, 1998, CHEST, V113, P396, DOI 10.1378/chest.113.2.396; JORDANA M, 1988, AM REV RESPIR DIS, V137, P579, DOI 10.1164/ajrccm/137.3.579; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; Katzenstein ALA, 1998, AM J RESP CRIT CARE, V157, P1301, DOI 10.1164/ajrccm.157.4.9707039; Kohler E, 1996, J VASC RES, V33, P315, DOI 10.1159/000159159; Korzus E, 1998, SCIENCE, V279, P703, DOI 10.1126/science.279.5351.703; LAURENT GJ, 1985, CIBA F SYMP, V114, P222; Letterio JJ, 1998, ANNU REV IMMUNOL, V16, P137, DOI 10.1146/annurev.immunol.16.1.137; Liberati NT, 1999, P NATL ACAD SCI USA, V96, P4844, DOI 10.1073/pnas.96.9.4844; Mapel DW, 1996, CHEST, V110, P1058, DOI 10.1378/chest.110.4.1058; Mason Robert J., 1999, American Journal of Respiratory and Critical Care Medicine, V160, P1771; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; MCANULTY RJ, 1995, EXP NEPHROL, V3, P96; McCormick LL, 1999, J IMMUNOL, V163, P5693; MOOLMAN JA, 1991, THORAX, V46, P592, DOI 10.1136/thx.46.8.592; OKADA T, 1993, LYMPHOKINE CYTOK RES, V12, P87; Pansky A, 2000, INT J CANCER, V85, P720, DOI 10.1002/(SICI)1097-0215(20000301)85:5<720::AID-IJC20>3.0.CO;2-O; Paulson M, 1999, J BIOL CHEM, V274, P25343, DOI 10.1074/jbc.274.36.25343; PFEUFFER I, 1994, J IMMUNOL, V153, P5572; RAGHU G, 1989, AM REV RESPIR DIS, V140, P95, DOI 10.1164/ajrccm/140.1.95; Raghu G, 1997, MAYO CLIN PROC, V72, P285, DOI 10.4065/72.3.285; ROBERTS AB, 1993, GROWTH FACTORS, V8, P1; Rogers DF, 1998, THORAX, V53, P200, DOI 10.1136/thx.53.3.200; SANTANA A, 1995, AM J RESP CELL MOL, V13, P34, DOI 10.1165/ajrcmb.13.1.7541221; Sauty A, 1997, EUR RESPIR J, V10, P2907, DOI 10.1183/09031936.97.10122907; SCHREIBER SL, 1992, IMMUNOL TODAY, V13, P136, DOI 10.1016/0167-5699(92)90111-J; Shozu M, 2000, MOL CELL ENDOCRINOL, V160, P123, DOI 10.1016/S0303-7207(99)00233-6; Sime PJ, 1997, J CLIN INVEST, V100, P768, DOI 10.1172/JCI119590; Song CZ, 1999, P NATL ACAD SCI USA, V96, P11776, DOI 10.1073/pnas.96.21.11776; Stark GR, 1998, ANNU REV BIOCHEM, V67, P227, DOI 10.1146/annurev.biochem.67.1.227; Tang WL, 1998, J BIOL CHEM, V273, P5506, DOI 10.1074/jbc.273.10.5506; TSUBOI A, 1994, BIOCHEM BIOPH RES CO, V199, P1064, DOI 10.1006/bbrc.1994.1337; Ulloa L, 1999, NATURE, V397, P710, DOI 10.1038/17826; Uria JA, 1998, J BIOL CHEM, V273, P9769, DOI 10.1074/jbc.273.16.9769; VENUTA F, 1993, J HEART LUNG TRANSPL, V12, P909; Virolle T, 1998, J BIOL CHEM, V273, P17318, DOI 10.1074/jbc.273.28.17318; Wang QJ, 1999, THORAX, V54, P805, DOI 10.1136/thx.54.9.805; Wang RQ, 2000, AM J PHYSIOL-LUNG C, V279, pL143, DOI 10.1152/ajplung.2000.279.1.L143; Wang TW, 1996, CELL, V86, P435, DOI 10.1016/S0092-8674(00)80116-6; Ward PA, 1998, AM J RESP CRIT CARE, V157, pS123, DOI 10.1164/ajrccm.157.4.nhlbi-10; WESTERGRENTHORSSON G, 1993, J CLIN INVEST, V92, P632, DOI 10.1172/JCI116631; Wong C, 1999, MOL CELL BIOL, V19, P1821; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S; YUE J, 2000, IN PRESS J BIOL CHEM; Zhang Y, 1998, NATURE, V394, P909, DOI 10.1038/29814; Ziesche R, 1999, NEW ENGL J MED, V341, P1264, DOI 10.1056/NEJM199910213411703	69	113	126	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2001	15	3					797	806		10.1096/fj.00-0233com	http://dx.doi.org/10.1096/fj.00-0233com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	410BE	11259398				2022-12-25	WOS:000167419500037
J	Walpen, S; Beck, KF; Schaefer, L; Raslik, I; Eberhardt, W; Schaefer, RM; Pfeilschifter, J				Walpen, S; Beck, KF; Schaefer, L; Raslik, I; Eberhardt, W; Schaefer, RM; Pfeilschifter, J			Nitric oxide induces MIP-2 transcription in rat renal mesangial cells and in a rat model of glomerulonephritis	FASEB JOURNAL			English	Article									Univ Frankfurt Klinikum, Zentrum Pharmakol, D-60590 Frankfurt, Germany; Univ Munster, Innere Med Abt, D-4400 Munster, Germany	Goethe University Frankfurt; Goethe University Frankfurt Hospital; University of Munster	Pfeilschifter, J (corresponding author), Univ Frankfurt Klinikum, Zentrum Pharmakol, Theodor Stern Kai 7, D-60590 Frankfurt, Germany.			Schaefer, Liliana/0000-0002-3318-3005					0	49	49	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAR	2001	15	3					571	573						3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	410BE	11259370				2022-12-25	WOS:000167419500008
J	Emami, S; Le Floch, N; Bruyneel, E; Thim, L; May, F; Westley, B; Rio, MC; Mareel, M; Gespach, C				Emami, S; Le Floch, N; Bruyneel, E; Thim, L; May, F; Westley, B; Rio, MC; Mareel, M; Gespach, C			Induction of scattering and cellular invasion by trefoil peptides in src- and RhoA-transformed kidney and colonic epithelial cells	FASEB JOURNAL			English	Article						inflammation; pS2; SP; ITF; PI3 '-kinase; phospholipase C; rapamycin	HUMAN SPASMOLYTIC POLYPEPTIDE; EPIDERMAL GROWTH-FACTOR; GTP-BINDING-PROTEIN; PS2 GENE; PHOSPHATIDYLINOSITOL 3-KINASE; COLORECTAL-CANCER; CARCINOMA CELLS; FACTOR RECEPTOR; BETA-CATENIN; MICE LACKING	Trefoil factors (TFFs) are protease-resistant peptides that promote epithelial cell migration and mucosal restitution during inflammatory conditions and wound healing in the gastrointestinal tract. To date, the molecular mechanism of TFFs action and their possible role in tumor progression are unclear. In the present study, we observed that premalignant human colonic PC/AA/C1 and canine kidney MDCK epithelial cells are not competent to invade collagen gels in response to exogenously added TFFs (pS2, spasmolytic polypeptide, and intestinal trefoil factor). In contrast, activated src and RhoA exert permissive induction of invasion by the TFFs that produce similar parallel dose-response curves in src-transformed MDCKts.src and PCmsrc cells (EC50=20-40 nM). Cell scattering is also induced by TFFs in MDCKts.src cells. Stable expression of the pS2 cDNA promotes constitutive invasiveness in MDCKts.src-pS2 cells and human colonic HCT8/S11-pS2 cells established from a sporadic tumor. Furthermore, we found that TEE-mediated cellular invasion is dependent of several signaling pathways implicated in cell transformation and survival, including phosphoinositide PI3'-kinase, phospholipase C, protein kinase C, and the rapamycin target TOR. Constitutive and intense expression of pS2 was revealed by Western blot analyses and immunohistochemistry in human colorectal tumors and their adjacent control mucosa during the neoplastic progression, from the adenoma to the liver metastases. Our studies indicated that TFFs can be involved in cell scattering and tumor invasion via autocrine loops and may serve as potential targets in the control of colon cancer progression.	Hop St Antoine, INSERM Unit U482, F-75571 Paris 12, France; State Univ Ghent Hosp, Expt Cancerol Lab, B-9000 Ghent, Belgium; Novo Nordisk AS, DK-2880 Bagsvaerd, Denmark; Univ Newcastle Upon Tyne, Dept Pathol, Newcastle Upon Tyne NE1 4LP, Tyne & Wear, England; Univ Strasbourg 1, INSERM U184, GBMC, F-67404 Illkirch, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Ghent University; Ghent University Hospital; Novo Nordisk; Newcastle University - UK; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Gespach, C (corresponding author), Hop St Antoine, INSERM Unit U482, F-75571 Paris 12, France.		LE FLOCH, Nathalie/I-3415-2015	LE FLOCH, Nathalie/0000-0002-6411-7975				Andre T, 2000, INT J CANCER, V86, P174, DOI 10.1002/(SICI)1097-0215(20000415)86:2<174::AID-IJC5>3.3.CO;2-5; Attoub S, 2000, FASEB J, V14, P2329, DOI 10.1096/fj.00-0162; Babyatsky MW, 1996, GASTROENTEROLOGY, V110, P489, DOI 10.1053/gast.1996.v110.pm8566596; BEHRENS J, 1993, J CELL BIOL, V120, P757, DOI 10.1083/jcb.120.3.757; BONKHOFF H, 1995, HUM PATHOL, V26, P824, DOI 10.1016/0046-8177(95)90002-0; BROWN AMC, 1984, P NATL ACAD SCI-BIOL, V81, P6344, DOI 10.1073/pnas.81.20.6344; Cantley LC, 1999, P NATL ACAD SCI USA, V96, P4240, DOI 10.1073/pnas.96.8.4240; Chadwick MP, 1997, BIOCHEM J, V327, P117, DOI 10.1042/bj3270117; CHINERY R, 1992, BIOCHEM J, V285, P5, DOI 10.1042/bj2850005; Chou MM, 1996, CELL, V85, P573, DOI 10.1016/S0092-8674(00)81257-X; Colombel M, 1999, J UROLOGY, V162, P927, DOI 10.1097/00005392-199909010-00092; DELAGE S, 1993, CANCER RES, V53, P2762; DIGNASS A, 1994, J CLIN INVEST, V94, P376, DOI 10.1172/JCI117332; DIRENZO MF, 1995, CLIN CANCER RES, V1, P147; Efstathiou JA, 1999, P NATL ACAD SCI USA, V96, P2316, DOI 10.1073/pnas.96.5.2316; Efstathiou JA, 1998, P NATL ACAD SCI USA, V95, P3122, DOI 10.1073/pnas.95.6.3122; Empereur S, 1997, BRIT J CANCER, V75, P241, DOI 10.1038/bjc.1997.40; Falasca M, 1998, EMBO J, V17, P414, DOI 10.1093/emboj/17.2.414; Gampel A, 1999, CURR BIOL, V9, P955, DOI 10.1016/S0960-9822(99)80422-9; GESPACH C, 1988, CANCER RES, V48, P5079; Hall CL, 1996, ONCOGENE, V13, P2213; HANBY AM, 1993, GASTROENTEROLOGY, V105, P1110, DOI 10.1016/0016-5085(93)90956-D; Irby RB, 1999, NAT GENET, V21, P187, DOI 10.1038/5971; Jockusch BM, 1995, ANNU REV CELL DEV BI, V11, P379, DOI 10.1146/annurev.cellbio.11.1.379; Jou TS, 1998, J CELL BIOL, V142, P85, DOI 10.1083/jcb.142.1.85; Kato K, 1999, AM J PHYSIOL-GASTR L, V276, pG1105, DOI 10.1152/ajpgi.1999.276.5.G1105; Keely PJ, 1997, NATURE, V390, P632, DOI 10.1038/37656; Kotelevets L, 1998, J BIOL CHEM, V273, P14138, DOI 10.1074/jbc.273.23.14138; Lalani EN, 1999, LAB INVEST, V79, P537; Lefebvre O, 1996, SCIENCE, V274, P259, DOI 10.1126/science.274.5285.259; Liu D, 1997, LAB INVEST, V77, P557; Machado JC, 2000, J PATHOL, V190, P437; Marchbank T, 1998, J PATHOL, V185, P153; Mashimo H, 1996, SCIENCE, V274, P262, DOI 10.1126/science.274.5285.262; MASIAKOWSKI P, 1982, NUCLEIC ACIDS RES, V10, P7895, DOI 10.1093/nar/10.24.7895; MICHIYUKI K, 1998, P NATL ACAD SCI USA, V95, P178; Newton JL, 2000, GUT, V46, P312, DOI 10.1136/gut.46.3.312; NUNEZ AM, 1989, EMBO J, V8, P823, DOI 10.1002/j.1460-2075.1989.tb03443.x; Playford RJ, 1996, P NATL ACAD SCI USA, V93, P2137, DOI 10.1073/pnas.93.5.2137; Raymond E, 1997, ANTI-CANCER DRUG, V8, P876, DOI 10.1097/00001813-199710000-00009; RIO MC, 1991, GASTROENTEROLOGY, V100, P375, DOI 10.1016/0016-5085(91)90205-Y; RIO MC, 1988, SCIENCE, V241, P705, DOI 10.1126/science.3041593; Ronnstrand L, 1999, J BIOL CHEM, V274, P22089, DOI 10.1074/jbc.274.31.22089; Sander EE, 1998, J CELL BIOL, V143, P1385, DOI 10.1083/jcb.143.5.1385; Sands BE, 1996, ANNU REV PHYSIOL, V58, P253, DOI 10.1146/annurev.ph.58.030196.001345; SUEMORI S, 1991, P NATL ACAD SCI USA, V88, P11017, DOI 10.1073/pnas.88.24.11017; TAKAISHI K, 1994, ONCOGENE, V9, P273; TALAMONTI MS, 1993, J CLIN INVEST, V91, P53, DOI 10.1172/JCI116200; Taupin DR, 2000, P NATL ACAD SCI USA, V97, P799, DOI 10.1073/pnas.97.2.799; TERMUHLEN PM, 1993, J SURG RES, V54, P293, DOI 10.1006/jsre.1993.1046; THIM L, 1993, FEBS LETT, V318, P345, DOI 10.1016/0014-5793(93)80543-4; THIM L, 1995, BIOCHEMISTRY-US, V34, P4757, DOI 10.1021/bi00014a033; THIM L, 1989, FEBS LETT, V250, P85, DOI 10.1016/0014-5793(89)80690-8; Tomasetto C, 2000, GASTROENTEROLOGY, V118, P70, DOI 10.1016/S0016-5085(00)70415-X; TOMINAGA T, 1993, J CELL BIOL, V120, P1529, DOI 10.1083/jcb.120.6.1529; Tran CP, 1999, GUT, V44, P636, DOI 10.1136/gut.44.5.636; VERMEULEN SJ, 1995, CANCER RES, V55, P4722; VLEMINCKX K, 1991, CELL, V66, P107, DOI 10.1016/0092-8674(91)90143-M; vonEichelStreiber C, 1996, TRENDS MICROBIOL, V4, P375, DOI 10.1016/0966-842X(96)10061-5; Wang DG, 1997, INT J CANCER, V74, P270, DOI 10.1002/(SICI)1097-0215(19970620)74:3<270::AID-IJC6>3.0.CO;2-W; WEIDNER KM, 1991, P NATL ACAD SCI USA, V88, P7001, DOI 10.1073/pnas.88.16.7001; Wojciak-Stothard B, 1999, J CELL BIOL, V145, P1293, DOI 10.1083/jcb.145.6.1293; WRIGHT NA, 1993, GASTROENTEROLOGY, V104, P12, DOI 10.1016/0016-5085(93)90830-6; Yoshiji H, 1999, CANCER RES, V59, P4413	64	102	109	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	FEB	2001	15	2					351	361		10.1096/fj.00-0355com	http://dx.doi.org/10.1096/fj.00-0355com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	400LK	11156951				2022-12-25	WOS:000166872900017
J	Shi, H; Dirienzo, D; Zemel, MB				Shi, H; Dirienzo, D; Zemel, MB			Effects of dietary calcium on adipocyte lipid metabolism and body weight regulation in energy-restricted aP2-agouti transgenic mice	FASEB JOURNAL			English	Article									Univ Tennessee, Knoxville, TN 37996 USA; Natl Dairy Council, Rosemont, IL 60018 USA	University of Tennessee System; University of Tennessee Knoxville	Zemel, MB (corresponding author), Univ Tennessee, 1215 W Cumberland Ave,229, Knoxville, TN 37996 USA.			Zemel, Michael/0000-0003-4104-5750					0	225	231	0	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	FEB	2001	15	2					291	293						3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	400LK	11156940				2022-12-25	WOS:000166872900006
J	DeMeester, SL; Buchman, TG; Cobb, JP				DeMeester, SL; Buchman, TG; Cobb, JP			The heat shock paradox: does NF-kappa B determine cell fate?	FASEB JOURNAL			English	Article; Proceedings Paper	20th Annual Conference on Shock	JUN 15-18, 1997	INDIAN WELLS, CA			injury; cell death; apoptosis; I kappa B alpha	ENDOTHELIAL-CELLS; INDUCED APOPTOSIS; STRESS-RESPONSE; ACTIVATION; INJURY; SEPSIS; DEATH; ALPHA; INHIBITION; EXPRESSION	Cellular injury induces an adaptive response whether the insult is physical (e.g., heat, radiation), chemical (e.g., reactive oxygen species), infectious (e.g., bacteria), or inflammatory (e.g., lipopolysaccharide), Recent data indicate that the interactions of these responses are not predictable and that sequence permutations can have opposite effects on outcome after injury. Our overarching hypothesis is that interactions among stress responses contribute to the fate of cells, tissues, and organisms and that modulation of these interactions can have important affects on both function and survival. For example, whereas it is well known that a prior heat shock stress can protect cells against inflammatory stress both in vitro and in vivo, we and others have shown that induction of a subsequent heat stress in cells 'primed' by inflammation can precipitate cell death by apoptosis. We call this seemingly paradoxical ability of heat shock to induce cytoprotection and cytotoxicity the heat shock paradox. The molecular mechanisms by which cells integrate responses to these and other stresses are poorly understood. We present data linking the heat shock paradox to the activity of the acute-phase transcription factor nuclear factor kappa B (identifying an 'NF-kappaB paradox') and hypothesize that the mechanism is linked to the downstream effects of induction of NF-kappaB's endogenous inhibitor, I kappaB alpha, a putative heat shock protein.	Washington Univ, Sch Med, Dept Surg, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Anesthesiol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Med, St Louis, MO 63110 USA; Washington Univ, Sch Med, Cellular Injury & Adaptat Lab, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL)	Cobb, JP (corresponding author), Washington Univ, Sch Med, Dept Surg, Campus Box 8109,660 S Euclid Ave, St Louis, MO 63110 USA.	cobb@msnotes.wustl.edu		Buchman, Timothy/0000-0001-7350-5921	NIGMS NIH HHS [GM 59960] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM059960] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Barinaga M, 1996, SCIENCE, V274, P724, DOI 10.1126/science.274.5288.724; BEG AA, 1995, NATURE, V376, P167, DOI 10.1038/376167a0; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; BUCHMAN TG, 1993, AM J PHYSIOL, V265, pH165, DOI 10.1152/ajpheart.1993.265.1.H165; Cobb JP, 1996, BRIT J ANAESTH, V77, P3, DOI 10.1093/bja/77.1.3; Cobb JP, 1999, CRIT CARE MED, V27, P1695, DOI 10.1097/00003246-199908000-00078; De Maio A, 1995, New Horiz, V3, P198; DeMeester SL, 1997, ARCH SURG-CHICAGO, V132, P1283; DeMeester SL, 1998, CRIT CARE MED, V26, P1500, DOI 10.1097/00003246-199809000-00016; DeMeester SL, 1998, SHOCK, V10, P1, DOI 10.1097/00024382-199807000-00001; DeMeester SL, 1998, SURGERY, V124, P362, DOI 10.1016/S0039-6060(98)70142-4; DEMEESTER SL, 1997, SHOCK S2, V7, P5; Ferran C, 1998, BLOOD, V91, P2249, DOI 10.1182/blood.V91.7.2249.2249_2249_2258; FERRAN C, 1995, BIOCHEM BIOPH RES CO, V214, P212, DOI 10.1006/bbrc.1995.2277; HOTCHKISS R, 1993, AM J PHYSIOL, V265, pR1447, DOI 10.1152/ajpregu.1993.265.6.R1447; Hotchkiss RS, 1999, CRIT CARE MED, V27, P1230, DOI 10.1097/00003246-199907000-00002; Hotchkiss RS, 1997, CRIT CARE MED, V25, P1298, DOI 10.1097/00003246-199708000-00015; MINOWADA G, 1995, J CLIN INVEST, V95, P3, DOI 10.1172/JCI117655; MOORE FA, 1995, SURG CLIN N AM, V75, P257, DOI 10.1016/S0039-6109(16)46587-4; Morishita R, 1997, NAT MED, V3, P894, DOI 10.1038/nm0897-894; Nasraway SA, 1999, CRIT CARE MED, V27, P427, DOI 10.1097/00003246-199902000-00054; PIPER RD, 1997, SEPSIS MULTIORGAN FA, P189; RABINDRAN SK, 1991, P NATL ACAD SCI USA, V88, P6906, DOI 10.1073/pnas.88.16.6906; SAAD S, 1995, SURGERY, V118, P510, DOI 10.1016/S0039-6060(05)80367-8; VAN AD, 1996, SCIENCE, V274, P787; VILLAR J, 1994, CRIT CARE MED, V22, P914; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Wang JH, 1997, AM J PHYSIOL-CELL PH, V272, pC1543, DOI 10.1152/ajpcell.1997.272.5.C1543; Wang YR, 1996, SHOCK, V6, P134, DOI 10.1097/00024382-199608000-00009; Wong HR, 1997, J CLIN INVEST, V99, P2423, DOI 10.1172/JCI119425; Wong HR, 1999, SHOCK, V12, P323, DOI 10.1097/00024382-199910000-00012; Wrighton CJ, 1996, J EXP MED, V183, P1013, DOI 10.1084/jem.183.3.1013; Xu DZ, 1996, ARCH SURG-CHICAGO, V131, P1222	34	93	96	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2001	15	1					270	274		10.1096/fj.00-0170hyp	http://dx.doi.org/10.1096/fj.00-0170hyp			5	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	390TH	11149915				2022-12-25	WOS:000166312400036
J	Shapiro, L; Pott, GB; Ralston, AH				Shapiro, L; Pott, GB; Ralston, AH			Alpha-1-antitrypsin inhibits human immunodeficiency virus type 1	FASEB JOURNAL			English	Article						alpha-1-proteinase inhibitor; serine proteinase inhibitors; HIV-1; NF-kappa B; interleukin 18	TUMOR-NECROSIS-FACTOR; LEUKOCYTE PROTEASE INHIBITOR; NF-KAPPA-B; FACTOR-ALPHA; CELL-LINE; HUMAN LYMPHOCYTES-T4+; CONVERTING-ENZYME; HIV-INFECTION; WHOLE-BLOOD; IN-VITRO	Several observations suggest the existence of potent endogenous suppressors of human immunodeficiency virus type 1 (HIV-l) production, and inhibitors of serine proteases may participate in this effect. Alpha-1-antitrypsin (AAT) is the most abundant circulating serine protease inhibitor. Physiological AAT concentrations inhibited HIV-1 production in chronically infected U1 monocytic cells, reduced virus replication in freshly infected peripheral blood mononuclear cells, and blocked infection of permissive HeLa cells, In U1 cells, AAT suppressed activation of the HIV-1-inducing transcription factor NF-kappaB. Similar results were obtained using CE-2072, a synthetic inhibitor of host serine proteases, HIV-1 did not replicate in blood obtained from healthy volunteers, but marked replication was observed in blood from individuals with hereditary AAT deficiency. These results identify AAT as a candidate circulating HIV-1 inhibitor in vivo. Two different mechanisms of AAT-induced HIV-1 inhibition were identified, including reduced HIV-1 infectivity and blockade of HIV-1 production. A novel host-pathogen interaction is suggested, and an alternative strategy to treat HIV-1-related disease may be possible.	Univ Colorado, Hlth Sci Ctr, Dept Med, Div Infect Dis, Denver, CO 80262 USA; Univ Colorado, Hlth Sci Ctr, Dept Cellular & Struct Biol, Denver, CO 80262 USA; Amer Red Cross, Plasma Derivat Dept, Holland Lab, Rockville, MD 20855 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; American Red Cross	Shapiro, L (corresponding author), Univ Colorado, Hlth Sci Ctr, Dept Med, Div Infect Dis, Denver, CO 80262 USA.	shapiro@uchsc.edu			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI015614, R01AI015614] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 15614] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AVRIL LE, 1994, FEBS LETT, V345, P81, DOI 10.1016/0014-5793(94)00410-2; AVRIL LE, 1993, FEBS LETT, V317, P167, DOI 10.1016/0014-5793(93)81515-2; BAYLISS GJ, 1990, J MED VIROL, V31, P161, DOI 10.1002/jmv.1890310215; BLANK CA, 1994, ANN ALLERGY, V72, P105; BRISTOW CL, 1995, INT IMMUNOL, V7, P239, DOI 10.1093/intimm/7.2.239; Bush CE, 1996, J ACQ IMMUN DEF SYND, V13, P23, DOI 10.1097/00042560-199609000-00004; Carpenter CCJ, 2000, JAMA-J AM MED ASSOC, V283, P381, DOI 10.1001/jama.283.3.381; CARRELL RW, 1986, J CLIN INVEST, V78, P1427, DOI 10.1172/JCI112731; COAN MH, 1985, VOX SANG, V48, P333, DOI 10.1111/j.1423-0410.1985.tb00193.x; Coeshott C, 1999, P NATL ACAD SCI USA, V96, P6261, DOI 10.1073/pnas.96.11.6261; CRYSTAL RG, 1990, J CLIN INVEST, V85, P1343, DOI 10.1172/JCI114578; DIMITROV DH, 1990, J CLIN MICROBIOL, V28, P734, DOI 10.1128/JCM.28.4.734-737.1990; Donovan RM, 1996, J INFECT DIS, V174, P401, DOI 10.1093/infdis/174.2.401; DUH EJ, 1989, P NATL ACAD SCI USA, V86, P5974, DOI 10.1073/pnas.86.15.5974; EMBRETSON J, 1993, NATURE, V362, P359, DOI 10.1038/362359a0; FIORE JR, 1990, MICROBIOLOGICA, V13, P311; FOLKS TM, 1987, SCIENCE, V238, P800, DOI 10.1126/science.3313729; FOX PC, 1988, J AM DENT ASSOC, V116, P635, DOI 10.14219/jada.archive.1988.0002; Gass RJA, 1998, ANTIVIR THER, V3, P97; Gu Y, 1997, SCIENCE, V275, P206, DOI 10.1126/science.275.5297.206; HATTORI T, 1989, FEBS LETT, V248, P48, DOI 10.1016/0014-5793(89)80429-6; HENDERSON DK, 1990, ANN INTERN MED, V113, P740, DOI 10.7326/0003-4819-113-10-740; JAPOUR AJ, 1994, J CLIN MICROBIOL, V32, P2291, DOI 10.1128/JCM.32.9.2291-2294.1994; JEPPSSON JO, 1976, FEBS LETT, V65, P195, DOI 10.1016/0014-5793(76)80478-4; KEET IPM, 1992, AIDS, V6, P223, DOI 10.1097/00002030-199202000-00014; KIDO H, 1990, J BIOL CHEM, V265, P21979; KIDO H, 1991, FEBS LETT, V286, P233, DOI 10.1016/0014-5793(91)80981-8; KIMPTON J, 1992, J VIROL, V66, P2232, DOI 10.1128/JVI.66.4.2232-2239.1992; KINGSLEY LA, 1987, LANCET, V1, P345; LARDER BA, 1989, SCIENCE, V243, P1731, DOI 10.1126/science.2467383; LENARDO MJ, 1989, CELL, V58, P227, DOI 10.1016/0092-8674(89)90833-7; LYMAN D, 1986, JAMA-J AM MED ASSOC, V255, P1703, DOI 10.1001/jama.1986.03370130059009; MASSI G, 1994, ACTA PAEDIATR, V83, P1, DOI 10.1111/j.1651-2227.1994.tb13197.x; MAYER KH, 1987, ANN INTERN MED, V107, P428, DOI 10.7326/0003-4819-107-2-428_2; MCNEELY TB, 1995, J CLIN INVEST, V96, P456, DOI 10.1172/JCI118056; McNeely TB, 1997, BLOOD, V90, P1141, DOI 10.1182/blood.V90.3.1141.1141_1141_1149; NARAYANAM VR, 1991, J BIOL CHEM, V266, P9540; OSBORN L, 1989, P NATL ACAD SCI USA, V86, P2336, DOI 10.1073/pnas.86.7.2336; PANTALEO G, 1993, NATURE, V362, P355, DOI 10.1038/362355a0; POLI G, 1990, J EXP MED, V172, P151, DOI 10.1084/jem.172.1.151; Shapiro GG, 1998, IMMUNOL ALLERGY CLIN, V18, P1, DOI 10.1016/S0889-8561(05)70343-X; Shapiro L, 1995, P NATL ACAD SCI USA, V92, P12230, DOI 10.1073/pnas.92.26.12230; Shapley R, 1998, NAT NEUROSCI, V1, P95, DOI 10.1038/342; STOLLER RS, 1997, CHEST S6, V111, pS123; TIFFANY TO, 1987, FUNDAMENTALS CLIN CH, P74; TOKARS JI, 1993, ANN INTERN MED, V118, P913, DOI 10.7326/0003-4819-118-12-199306150-00001; WERNER BG, 1982, ANN INTERN MED, V97, P367, DOI 10.7326/0003-4819-97-3-367; WEWERS MD, 1987, NEW ENGL J MED, V316, P1055, DOI 10.1056/NEJM198704233161704; WINKELSTEIN W, 1987, JAMA-J AM MED ASSOC, V257, P321, DOI 10.1001/jama.257.3.321	49	116	124	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2001	15	1					115	122		10.1096/fj.00-0311com	http://dx.doi.org/10.1096/fj.00-0311com			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	390TH	11149899				2022-12-25	WOS:000166312400020
J	Pizon, V; Baldacci, G				Pizon, V; Baldacci, G			Rap1A protein interferes with various MAP kinase activating pathways in skeletal myogenic cells	ONCOGENE			English	Article						Rap1A; Ras-like protein; MAP kinases; myogenic differentiation	FIBROBLAST GROWTH-FACTOR; RAS-DEPENDENT ACTIVATION; PHOSPHATIDYLINOSITOL 3-KINASE; MUSCLE DIFFERENTIATION; INDEPENDENT PATHWAYS; HUMAN-PLATELETS; IN-VITRO; C-ZETA; SPECIFICITY; RECEPTOR	Constitutive expression of the activated Rap1A protein inhibits differentiation of myogenic C2 cells whereas the inactivated Rap1A protein favours cell differentiation and induces late endocytic compartments clustering. Although the role of Rap1A in MAPK activation has been analysed in various cell;types, the signalling pathways activated by Rap1A have not been explored in myogenic cells. In this study, me investigated MAP kinase activity in control C2 myoblasts and in stable C2 cell lines expressing mutated Rap1A proteins. We provide evidence that Rap1A mutants promote ERK activation and that the active protein induces a more sustained activation than the inactive protein. In addition, we established that various pathways mediate transient ERK activation in control cells and in cells expressing the inactivated Rap1A protein. In these cells, ERK are activated by a Raf/MEK-dependent pathway, a PI3K/Raf-independent pathway and a third undetermined pathway. In cells expressing the activated Rap1A protein, a PI3K/Raf/MEK-dependent pathway mediates transient ERK activation. However, MAPK activation appears more complex since, according to the state of the myoblasts or the duration of MAPK stimulation, we observed that Rap1A protein could interfere or not with ERK activation.	Inst Andre Lwoff, UPR 1983, F-94801 Villejuif, France; Univ Paris Sud, Inst Curie, UMR 2027, F-91405 Orsay, France	UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Universite Paris Saclay	Pizon, V (corresponding author), Inst Andre Lwoff, UPR 1983, 7 Rue Guy Moquet,BP8, F-94801 Villejuif, France.		Pizon, Veronique/M-5590-2018	Pizon, Veronique/0000-0003-3596-8313				ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; ALTSCHULER DL, 1995, J BIOL CHEM, V270, P10373, DOI 10.1074/jbc.270.18.10373; Bennett AM, 1997, SCIENCE, V278, P1288, DOI 10.1126/science.278.5341.1288; Bos JL, 1998, EMBO J, V17, P6776, DOI 10.1093/emboj/17.23.6776; Boussiotis VA, 1997, SCIENCE, V278, P124, DOI 10.1126/science.278.5335.124; CAMPBELL JS, 1995, P NATL ACAD SCI USA, V92, P870, DOI 10.1073/pnas.92.3.870; Camps M, 2000, FASEB J, V14, P6, DOI 10.1096/fasebj.14.1.6; COOK SJ, 1993, EMBO J, V12, P3475, DOI 10.1002/j.1460-2075.1993.tb06022.x; COUGHLIN SR, 1985, CELL, V43, P243, DOI 10.1016/0092-8674(85)90029-7; CRESPO P, 1994, NATURE, V369, P418, DOI 10.1038/369418a0; DIAZMECO MT, 1994, J BIOL CHEM, V269, P31706; Dorman CM, 1999, ONCOGENE, V18, P5167, DOI 10.1038/sj.onc.1202907; Dremier S, 2000, BIOCHEM BIOPH RES CO, V267, P7, DOI 10.1006/bbrc.1999.1919; Franke B, 1997, EMBO J, V16, P252, DOI 10.1093/emboj/16.2.252; Grammer TC, 1997, ONCOGENE, V14, P1635, DOI 10.1038/sj.onc.1201000; Hu CD, 1999, J BIOL CHEM, V274, P48, DOI 10.1074/jbc.274.1.48; Kaliman P, 1996, J BIOL CHEM, V271, P19146, DOI 10.1074/jbc.271.32.19146; KUDLA AJ, 1995, MOL CELL BIOL, V15, P3238; Kundra A, 1998, J BIOL CHEM, V273, P3848, DOI 10.1074/jbc.273.7.3848; LAPETINA EG, 1989, P NATL ACAD SCI USA, V86, P3131, DOI 10.1073/pnas.86.9.3131; LEROSEY I, 1991, BIOCHEM BIOPH RES CO, V175, P430, DOI 10.1016/0006-291X(91)91582-W; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; McCawley LJ, 1999, J BIOL CHEM, V274, P4347, DOI 10.1074/jbc.274.7.4347; Mellor H, 1998, BIOCHEM J, V332, P281, DOI 10.1042/bj3320281; Milasincic DJ, 1996, MOL CELL BIOL, V16, P5964; Mourey RJ, 1996, J BIOL CHEM, V271, P3795; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; Okada S, 1998, EMBO J, V17, P2554, DOI 10.1093/emboj/17.9.2554; OLSON EN, 1987, MOL CELL BIOL, V7, P2104, DOI 10.1128/MCB.7.6.2104; Pinset C, 1997, CR ACAD SCI III-VIE, V320, P367, DOI 10.1016/S0764-4469(97)85024-X; PIZON V, 1994, J CELL SCI, V107, P1661; Pizon V, 1999, EXP CELL RES, V246, P56, DOI 10.1006/excr.1998.4284; Ramocki MB, 1998, J BIOL CHEM, V273, P17696, DOI 10.1074/jbc.273.28.17696; Reedquist KA, 2000, J CELL BIOL, V148, P1151, DOI 10.1083/jcb.148.6.1151; RodriguezViciana P, 1997, CELL, V89, P457, DOI 10.1016/S0092-8674(00)80226-3; RUSSELL M, 1995, J BIOL CHEM, V270, P11757, DOI 10.1074/jbc.270.20.11757; Schonwasser DC, 1998, MOL CELL BIOL, V18, P790, DOI 10.1128/MCB.18.2.790; Takano H, 1998, MOL CELL BIOL, V18, P1580, DOI 10.1128/MCB.18.3.1580; Takeda H, 1999, EMBO J, V18, P386, DOI 10.1093/emboj/18.2.386; TOKER A, 1994, J BIOL CHEM, V269, P32358; Tzivion G, 1998, NATURE, V394, P88, DOI 10.1038/27938; Vossler MR, 1997, CELL, V89, P73, DOI 10.1016/S0092-8674(00)80184-1; White MA, 1996, J BIOL CHEM, V271, P16439, DOI 10.1074/jbc.271.28.16439; Widmann C, 1999, PHYSIOL REV, V79, P143, DOI 10.1152/physrev.1999.79.1.143; YANO H, 1993, J BIOL CHEM, V268, P25846; York RD, 1998, NATURE, V392, P622, DOI 10.1038/33451; Zwartkruis FJT, 1998, EMBO J, V17, P5905, DOI 10.1093/emboj/17.20.5905	47	24	24	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 7	2000	19	52					6074	6081		10.1038/sj.onc.1203984	http://dx.doi.org/10.1038/sj.onc.1203984			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	382MY	11146560				2022-12-25	WOS:000165827900015
J	Milligan, L; Antoine, E; Bisbal, C; Weber, M; Brunel, C; Forne, T; Cathala, G				Milligan, L; Antoine, E; Bisbal, C; Weber, M; Brunel, C; Forne, T; Cathala, G			H19 gene expression is up-regulated exclusively by stabilization of the RNA during muscle cell differentiation	ONCOGENE			English	Article						H19; parental imprinting; post-transcriptional regulation; muscle cell differentiation	TUMOR-SUPPRESSOR GENE; MYC MESSENGER-RNA; FACTOR-II GENE; IMPRINTED GENES; ALPHA-FETOPROTEIN; IGF2 EXPRESSION; WILMS-TUMOR; METHYLATION; DELETION; TRANSCRIPTION	H19 is a paternally imprinted gene whose expression produces a 2.4 kb RNA in most tissues during development and in mammalian myoblastic cell lines upon differentiation. Deletion of the active maternal allele of H19 and its flanking regions in the mouse leads to biallelic methylation and loss of imprinting of the neighbouring Igf2 gene, The function of H19 RNA remains unknown and, although polysome-associated, the absence of a conserved open reading frame suggests that it does not encode a protein product. We describe a novel post-transcriptional regulation of H19 gene expression which,in spite of this lack of coding capacity, is dependent on translational activity. We show that stabilization of the RNA is solely responsible for its accumulation during in vitro muscle cell differentiation, This conclusion is based on the finding that inhibition of protein synthesis results in a dramatic destabilization of H19 RNA in proliferating mouse C2C12 myoblastic cells but not in differentiated cells, and on run-on experiments which showed that the rate of transcription of H19 RNA remains constant during muscle cell differentiation. This mechanism could also be involved in H19 gene expression during mouse development in addition to its transcriptional activation which we have shown to occur.	Univ Montpellier 2, Inst Genet Mol, UMR 5535 CNRS, F-34293 Montpellier 5, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Montpellier	Cathala, G (corresponding author), Univ Montpellier 2, Inst Genet Mol, UMR 5535 CNRS, IFR 24,1919 Route de Mende, F-34293 Montpellier 5, France.		Bisbal, Catherine/I-6984-2016; Weber, Michael/P-1914-2016; Forne, Thierry/D-3718-2013	Bisbal, Catherine/0000-0003-1086-020X; Weber, Michael/0000-0003-3484-5821; Forne, Thierry/0000-0002-9179-1551; Milligan, Laura/0000-0001-6985-3034				Ainscough JFX, 1997, DEVELOPMENT, V124, P3621; Barlow DP, 1997, EMBO J, V16, P6899, DOI 10.1093/emboj/16.23.6899; BARTOLOMEI MS, 1991, NATURE, V351, P153, DOI 10.1038/351153a0; BIRAN H, 1994, TUMOR BIOL, V15, P123, DOI 10.1159/000217882; BRANNAN CI, 1990, MOL CELL BIOL, V10, P28, DOI 10.1128/MCB.10.1.28; Cui HM, 1998, NAT MED, V4, P1276, DOI 10.1038/3260; Cui HM, 1997, CANCER RES, V57, P4469; DANI C, 1984, P NATL ACAD SCI-BIOL, V81, P7046, DOI 10.1073/pnas.81.22.7046; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; DECHIARA TM, 1991, CELL, V64, P849, DOI 10.1016/0092-8674(91)90513-X; DEPONTIZILLI L, 1988, P NATL ACAD SCI USA, V85, P1389, DOI 10.1073/pnas.85.5.1389; Dugimont T, 1998, ONCOGENE, V16, P2395, DOI 10.1038/sj.onc.1201742; EVERSOLECIRE P, 1995, CELL GROWTH DIFFER, V6, P337; Fan XHC, 1998, P NATL ACAD SCI USA, V95, P15293, DOI 10.1073/pnas.95.26.15293; Forne T, 1997, P NATL ACAD SCI USA, V94, P10243, DOI 10.1073/pnas.94.19.10243; HAO Y, 1993, NATURE, V365, P764, DOI 10.1038/365764a0; Hayashida T, 1997, J BIOCHEM-TOKYO, V122, P901; Hibi K, 1996, CANCER RES, V56, P480; Hurst LD, 1999, TRENDS GENET, V15, P134, DOI 10.1016/S0168-9525(99)01696-0; Jones BK, 1998, GENE DEV, V12, P2200, DOI 10.1101/gad.12.14.2200; Joubel A, 1996, CELL MOL BIOL, V42, P1159; Jouvenot Y, 1999, CURR BIOL, V9, P1199, DOI 10.1016/S0960-9822(00)80026-3; Juan V, 2000, NUCLEIC ACIDS RES, V28, P1221, DOI 10.1093/nar/28.5.1221; Junien C, 1992, CURR OPIN GENET DEV, V2, P431, DOI 10.1016/S0959-437X(05)80154-6; KIM DK, 1994, J CLIN INVEST, V93, P355, DOI 10.1172/JCI116967; Ladomery M, 1997, BIOESSAYS, V19, P903, DOI 10.1002/bies.950191010; LEIBOVITCH MP, 1991, BIOCHEM BIOPH RES CO, V180, P1241, DOI 10.1016/S0006-291X(05)81329-4; LEIGHTON PA, 1995, NATURE, V375, P34, DOI 10.1038/375034a0; LEIGHTON PA, 1995, GENE DEV, V9, P2079, DOI 10.1101/gad.9.17.2079; LI XR, 1995, ONCOGENE, V11, P221; Li YM, 1998, J BIOL CHEM, V273, P28247, DOI 10.1074/jbc.273.43.28247; LustigYariv O, 1997, ONCOGENE, V15, P169, DOI 10.1038/sj.onc.1201175; Mitchell P, 2000, CURR OPIN GENET DEV, V10, P193, DOI 10.1016/S0959-437X(00)00063-0; MOULTON T, 1994, NAT GENET, V7, P440, DOI 10.1038/ng0794-440; PACHNIS V, 1988, EMBO J, V7, P673, DOI 10.1002/j.1460-2075.1988.tb02862.x; PACHNIS V, 1984, P NATL ACAD SCI-BIOL, V81, P5523, DOI 10.1073/pnas.81.17.5523; RAYNAL F, 1984, FEBS LETT, V167, P263, DOI 10.1016/0014-5793(84)80139-8; Reik W, 1998, CURR OPIN GENET DEV, V8, P154, DOI 10.1016/S0959-437X(98)80136-6; REIK W, 1994, HUM MOL GENET, V3, P1297, DOI 10.1093/hmg/3.8.1297; Ripoche MA, 1997, GENE DEV, V11, P1596, DOI 10.1101/gad.11.12.1596; SINGER C, 1995, CANCER RES, V55, P2448; Smith CM, 1998, MOL CELL BIOL, V18, P6897, DOI 10.1128/MCB.18.12.6897; TANIGUCHI T, 1995, P NATL ACAD SCI USA, V92, P2159, DOI 10.1073/pnas.92.6.2159; Thorvaldsen JL, 1998, GENE DEV, V12, P3693, DOI 10.1101/gad.12.23.3693; Tilghman SM, 1999, CELL, V96, P185, DOI 10.1016/S0092-8674(00)80559-0; Tremblay KD, 1997, MOL CELL BIOL, V17, P4322, DOI 10.1128/MCB.17.8.4322; VACHER J, 1992, MOL CELL BIOL, V12, P856, DOI 10.1128/MCB.12.2.856; Verkerk AJMH, 1997, ONCOGENE, V14, P95, DOI 10.1038/sj.onc.1200802; WISDOM R, 1990, J BIOL CHEM, V265, P19015; Yeilding NM, 1998, J BIOL CHEM, V273, P15749, DOI 10.1074/jbc.273.25.15749; YOOWARREN H, 1988, MOL CELL BIOL, V8, P4707, DOI 10.1128/MCB.8.11.4707; Yun K, 1996, AM J PATHOL, V148, P1081	52	38	39	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 23	2000	19	50					5810	5816		10.1038/sj.onc.1203965	http://dx.doi.org/10.1038/sj.onc.1203965			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	376VP	11126368				2022-12-25	WOS:000165477700013
J	Melen, K; Kinnunen, L; Julkunen, I				Melen, K; Kinnunen, L; Julkunen, I			Arginine/lysine-rich structural element is involved in interferon-induced nuclear import of STATs	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE KINASE; HUMAN MXB PROTEIN; DNA-BINDING; TRANSCRIPTION FACTOR; SIGNAL-TRANSDUCTION; GENE-EXPRESSION; ALPHA; TRANSLOCATION; LOCALIZATION; ACTIVATOR	Signal transducers and activators of transcription (STATs) are latent cytoplasmic transcription factors, which mediate interferon (IFN), interleukin, and some growth factor and peptide hormone signaling in cells, IFN stimulation results in tyrosine phosphorylation, dimerization, and nuclear import of STATs. In response to IFN-gamma stimulation, STAT1 forms homodimers, whereas IFN-alpha induction results in the formation of STAT1.STAT2 heterodimers, which assemble with p48 protein in the nucleus. Phosphorylation as such is not sufficient to target STATs into the nucleus; rather, the dimerization triggered by phosphorylation is essential. Although IFN-induced nuclear import of STATs is mediated by the importin/Ran transport system, no classic nuclear localization signal (NLS) has been found in STATs. In the three-dimensional structure of STAT1, we observed a structural arginine/lysine-rich element within the DNA-binding domain of the molecule. We created a series of point mutations in these elements of STAT1 and STAT2 and showed by transient transfection/IFN stimulation assay that this site is essential for the nuclear import of both STAT1 and STAT2. The results suggest that two arginine/lysine-rich elements, one in each STAT monomer, are required for IFN-induced nuclear import of STAT dimers, import-defective STAT1 and STAT2 proteins were readily phosphorylated and dimerized, but they functioned as dominant negative molecules inhibiting the nuclear import of heterologous STAT protein.	Natl Publ Hlth Inst, Dept Microbiol, Lab Viral & Mol Immunol, FIN-00300 Helsinki, Finland; Natl Publ Hlth Inst, Dept Epidemiol & Hlth Promot, Diabet & Genet Epidemiol Unit, FIN-00300 Helsinki, Finland	Finland National Institute for Health & Welfare; Finland National Institute for Health & Welfare	Melen, K (corresponding author), Natl Publ Hlth Inst, Dept Microbiol, Lab Viral & Mol Immunol, Mannerheimintie 166, FIN-00300 Helsinki, Finland.	krister.melen@ktl.fi	Kinnunen, Leena/B-7059-2012	Kinnunen, Leena/0000-0001-8739-4812				ADAM EJH, 1994, J CELL BIOL, V125, P547, DOI 10.1083/jcb.125.3.547; Becker S, 1998, NATURE, V394, P145, DOI 10.1038/28101; CANTELL K, 1986, METHOD ENZYMOL, V119, P54; Cantell K, 1981, Methods Enzymol, V78, P29; Chatterjee-Kishore M, 2000, EMBO J, V19, P4111, DOI 10.1093/emboj/19.15.4111; Chen XM, 1998, CELL, V93, P827, DOI 10.1016/S0092-8674(00)81443-9; Conti E, 1998, CELL, V94, P193, DOI 10.1016/S0092-8674(00)81419-1; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; Farrar JD, 2000, J BIOL CHEM, V275, P2693, DOI 10.1074/jbc.275.4.2693; FU XY, 1992, P NATL ACAD SCI USA, V89, P7840, DOI 10.1073/pnas.89.16.7840; FU XY, 1990, P NATL ACAD SCI USA, V87, P8555, DOI 10.1073/pnas.87.21.8555; Gorlich D, 1996, SCIENCE, V271, P1513, DOI 10.1126/science.271.5255.1513; GORLICH D, 1994, CELL, V79, P767, DOI 10.1016/0092-8674(94)90067-1; Gorlich D, 1996, EMBO J, V15, P1810, DOI 10.1002/j.1460-2075.1996.tb00530.x; Ihle JN, 1996, CELL, V84, P331, DOI 10.1016/S0092-8674(00)81277-5; KESSLER DS, 1990, GENE DEV, V4, P1753, DOI 10.1101/gad.4.10.1753; Koster M, 1999, EUR J BIOCHEM, V260, P137, DOI 10.1046/j.1432-1327.1999.00149.x; LACASSE EC, 1995, NUCLEIC ACIDS RES, V23, P1647, DOI 10.1093/nar/23.10.1647; Lackmann M, 1998, GROWTH FACTORS, V16, P39, DOI 10.3109/08977199809017490; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lehtonen A, 1997, J IMMUNOL, V159, P794; Matikainen S, 1999, BLOOD, V93, P1980, DOI 10.1182/blood.V93.6.1980.406k20_1980_1991; McBride KM, 2000, EMBO J, V19, P6196, DOI 10.1093/emboj/19.22.6196; MELCHIOR F, 1993, J CELL BIOL, V123, P1649, DOI 10.1083/jcb.123.6.1649; Melen K, 1997, J BIOL CHEM, V272, P32353, DOI 10.1074/jbc.272.51.32353; Melen K, 1996, J BIOL CHEM, V271, P23478, DOI 10.1074/jbc.271.38.23478; Milocco LH, 1999, MOL CELL BIOL, V19, P2913; MOORE MS, 1993, NATURE, V365, P661, DOI 10.1038/365661a0; MORIN N, 1989, MOL CELL BIOL, V9, P4372, DOI 10.1128/MCB.9.10.4372; Mowen K, 1998, J BIOL CHEM, V273, P30073, DOI 10.1074/jbc.273.46.30073; MULLER M, 1993, NATURE, V366, P129, DOI 10.1038/366129a0; NAKABAYASHI H, 1982, CANCER RES, V42, P3858; Ndubuisi MI, 1999, J BIOL CHEM, V274, P25499, DOI 10.1074/jbc.274.36.25499; QUELLE FW, 1995, J BIOL CHEM, V270, P20775, DOI 10.1074/jbc.270.35.20775; SAYLE RA, 1995, TRENDS BIOCHEM SCI, V20, P374, DOI 10.1016/S0968-0004(00)89080-5; SCHINDLER C, 1992, P NATL ACAD SCI USA, V89, P7836, DOI 10.1073/pnas.89.16.7836; Sekimoto T, 1997, EMBO J, V16, P7067, DOI 10.1093/emboj/16.23.7067; Sekimoto T, 1996, J BIOL CHEM, V271, P31017, DOI 10.1074/jbc.271.49.31017; SILVENNOINEN O, 1993, P NATL ACAD SCI USA, V90, P8429, DOI 10.1073/pnas.90.18.8429; Stancato LF, 1996, J BIOL CHEM, V271, P4134; Strehlow I, 1998, J BIOL CHEM, V273, P28049, DOI 10.1074/jbc.273.43.28049; Subramaniam PS, 2000, J CELL SCI, V113, P2771; Summers M., 1986, TEX AGR EXP STN B, V1555, P1; Takaoka A, 2000, SCIENCE, V288, P2357, DOI 10.1126/science.288.5475.2357; VEALS SA, 1992, MOL CELL BIOL, V12, P3315, DOI 10.1128/MCB.12.8.3315; VELAZQUEZ L, 1992, CELL, V70, P313, DOI 10.1016/0092-8674(92)90105-L; Weis K, 1996, EMBO J, V15, P1818, DOI 10.1002/j.1460-2075.1996.tb00531.x	49	105	110	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 11	2001	276	19					16447	16455		10.1074/jbc.M008821200	http://dx.doi.org/10.1074/jbc.M008821200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	431GH	11150296	hybrid			2022-12-25	WOS:000168623100117
J	Ivanov, KI; Puustinen, P; Merits, A; Saarma, M; Makinen, K				Ivanov, KI; Puustinen, P; Merits, A; Saarma, M; Makinen, K			Phosphorylation down-regulates the RNA binding function of the coat protein of potato virus A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TOBACCO MOSAIC-VIRUS; CELL-TO-CELL; MOVEMENT PROTEIN; NONTOXIC CONCENTRATIONS; ETCH POTYVIRUS; NUCLEIC-ACIDS; VIRAL-RNA; TRANSPORT; PLANTS; TRAFFICKING	Plant viruses encode movement proteins (MPs) to facilitate transport of their genomes from infected into neighboring healthy cells through plasmodesmata, Growing evidence suggests that specific phosphorylation events can regulate MP functions. The coat protein (CP) of potato virus A (PVA; genus Potyvirus) is a multifunctional protein involved both in virion assembly and virus movement. Labeling of PVA-infected tobacco leaves with [P-33]orthophosphate demonstrated that PVA CP is phosphorylated in vivo. Competition assays established that PVA CP and the well characterized 30-kDa MP of tobacco mosaic virus (genus Tobamovirus) are phosphorylated in vitro by the same Ser/Thr kinase activity from tobacco leaves. This activity exhibits a strong preference for Mn2+ over Mg2+, can be inhibited by micromolar concentrations of Zn2+ and Cd2+, and is not Ca2+-dependent. Tryptic phosphopeptide mapping revealed that PVA CP was phosphorylated by this protein kinase activity on multiple sites. In contrast, PVA CP was not phosphorylated when packaged into virions, suggesting that the phosphorylation sites are located within the RNA binding domain and not exposed on the surface of the virion. Furthermore, two independent experimental approaches demonstrated that the RNA binding function of PVA CP is strongly inhibited by phosphorylation, From these findings, we suggest that protein phosphorylation represents a possible mechanism regulating formation and/or stability of viral ribonucleoproteins in planta.	Univ Helsinki, Viikki Bioctr, Inst Biotechnol, FIN-00014 Helsinki, Finland	University of Helsinki	Makinen, K (corresponding author), Univ Helsinki, Viikki Bioctr, Inst Biotechnol, POB 56, FIN-00014 Helsinki, Finland.		Mäkinen, Kristiina M/C-8650-2012; Ivanov, Konstantin/C-4644-2015; Merits, Andres/H-3125-2015	Mäkinen, Kristiina M/0000-0001-8233-8942; Ivanov, Konstantin/0000-0001-9198-5674; Merits, Andres/0000-0001-8193-0071				ATKINS D, 1991, J GEN VIROL, V72, P2831, DOI 10.1099/0022-1317-72-11-2831; Beeler T, 1997, BBA-BIOMEMBRANES, V1323, P310, DOI 10.1016/S0005-2736(96)00199-X; Carrington JC, 1996, PLANT CELL, V8, P1669, DOI 10.1105/tpc.8.10.1669; Chen MH, 2000, EMBO J, V19, P913, DOI 10.1093/emboj/19.5.913; Citovsky V, 1998, PLANT J, V16, P13, DOI 10.1046/j.1365-313x.1998.00263.x; CITOVSKY V, 1990, CELL, V60, P637, DOI 10.1016/0092-8674(90)90667-4; CITOVSKY V, 1992, PLANT CELL, V4, P397, DOI 10.1105/tpc.4.4.397; CITOVSKY V, 1991, BIOESSAYS, V13, P373, DOI 10.1002/bies.950130802; CITOVSKY V, 1993, GENE DEV, V7, P904, DOI 10.1101/gad.7.5.904; Cruz SS, 1999, TRENDS MICROBIOL, V7, P237, DOI 10.1016/S0966-842X(99)01508-5; Daros JA, 1997, VIROLOGY, V237, P327, DOI 10.1006/viro.1997.8802; DOLJA VV, 1994, EMBO J, V13, P1482, DOI 10.1002/j.1460-2075.1994.tb06403.x; Dorokhov YL, 1999, FEBS LETT, V461, P223, DOI 10.1016/S0014-5793(99)01447-7; Ghoshroy S, 1998, PLANT J, V13, P591, DOI 10.1046/j.1365-313X.1998.00061.x; HALEY A, 1995, PLANT J, V8, P715, DOI 10.1046/j.1365-313X.1995.08050715.x; HAMMOND J, 1988, J VIROL METHODS, V20, P203, DOI 10.1016/0166-0934(88)90124-3; HUGHES RK, 1995, MOL PLANT MICROBE IN, V8, P658, DOI 10.1094/MPMI-8-0658; IVANOV KI, 1994, FEBS LETT, V346, P217, DOI 10.1016/0014-5793(94)00477-3; Karpova OV, 1997, VIROLOGY, V230, P11, DOI 10.1006/viro.1997.8472; Karpova OV, 1999, VIROLOGY, V261, P20, DOI 10.1006/viro.1999.9842; Kawakami S, 1999, J VIROL, V73, P6831, DOI 10.1128/JVI.73.8.6831-6840.1999; Kragler F, 1998, PLANT J, V15, P367, DOI 10.1046/j.1365-313X.1998.00219.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lazarowitz SG, 1999, PLANT CELL, V11, P535, DOI 10.1105/tpc.11.4.535; Lee JY, 2000, PLANTA, V210, P177, DOI 10.1007/PL00008124; Mas P, 1999, J CELL BIOL, V147, P945, DOI 10.1083/jcb.147.5.945; MCDONALD JG, 1977, J GEN VIROL, V35, P251, DOI 10.1099/0022-1317-35-2-251; Merits A, 1998, J GEN VIROL, V79, P3123, DOI 10.1099/0022-1317-79-12-3123; Oparka KJ, 1999, CELL, V97, P743, DOI 10.1016/S0092-8674(00)80786-2; PUURAND U, 1992, VIRUS RES, V23, P99, DOI 10.1016/0168-1702(92)90070-P; Revers F, 1999, MOL PLANT MICROBE IN, V12, P367, DOI 10.1094/MPMI.1999.12.5.367; Seron K, 1996, VIROLOGY, V219, P274, DOI 10.1006/viro.1996.0246; SHUKLA DD, 1994, POTYVIRIDAE, P124; Sokolova M, 1997, FEBS LETT, V400, P201, DOI 10.1016/S0014-5793(96)01380-4; Sun GQ, 1997, BIOCHEMISTRY-US, V36, P2139, DOI 10.1021/bi962291n; Sun GQ, 1999, BIOCHEMISTRY-US, V38, P5659, DOI 10.1021/bi982793w; Vihinen H, 2000, J BIOL CHEM, V275, P27775; Waigmann E, 2000, EMBO J, V19, P4875, DOI 10.1093/emboj/19.18.4875; WATANABE Y, 1992, FEBS LETT, V313, P181, DOI 10.1016/0014-5793(92)81440-W; ZAWORSKI PG, 1988, ANAL BIOCHEM, V173, P440, DOI 10.1016/0003-2697(88)90211-4	40	70	72	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 27	2001	276	17					13530	13540		10.1074/jbc.M009551200	http://dx.doi.org/10.1074/jbc.M009551200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	426PB	11152464	hybrid			2022-12-25	WOS:000168356600006
J	Hagen, KD; Meeks, JC				Hagen, KD; Meeks, JC			The unique cyanobacterial protein OpcA is an allosteric effector of glucose-6-phosphate dehydrogenase in Nostoc punctiforme ATCC 29133	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SP STRAIN ATCC-29133; ANABAENA SP PCC-7120; ELECTRON DONATION; REDOX MODULATION; HETEROCYSTS; LIGHT; NITROGENASE; THIOREDOXIN; FERREDOXIN; EXPRESSION	Glucose-6-phosphate dehydrogenase (G6PD), encoded by zwf, is essential for nitrogen fixation and dark heterotrophic growth of the cyanobacterium Nostoc punctiforme ATCC 29133, In N. punctiforme, zwf is part of a four-gene operon transcribed in the order fbp-tal-zwf-opcA, Genetic analyses indicated that opcA is required for G6PD activity. To define the role of opcA, the synthesis, aggregation state, and activity of G6PD in N. punctiforme strains expressing different amounts of G6PD and/or OpcA were examined. A single tetrameric form of G6PD was consistently observed for all strains, as well as for recombinant N. punctiforme His-G6PD purified from Escherichia coli, regardless of the quantity of OpcA present. However, His-G6PD and the G6PD of strain UCD 351, which lacks OpcA, had low affinities for glucose 6-phosphate (G6P) substrate (K-m (app) = 65 and 85 mM, respectively) relative to wild-type N. punctiforme G6PD (K-m (app) = 0.5 mM). Near wild-type affinities for G6P were observed for these enzymes when saturating amounts of His-OpcA- or OpcA-containing extract were added. Kinetic studies were consistent with OpcA acting as an allosteric activator of G6PD. A role in redox modulation of G6PD activity was also indicated, because thioredoxin-mediated inactivation and reactivation of His-G6PD occurred only when His-OpcA was present.	Univ Calif Davis, Microbiol Sect, Div Biol Sci, Davis, CA 95616 USA	University of California System; University of California Davis	Meeks, JC (corresponding author), Univ Calif Davis, Microbiol Sect, Div Biol Sci, 1 Shields Ave, Davis, CA 95616 USA.	jcmeeks@ucdavis.edu		Hagen, Kari/0000-0001-9673-2481				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; APTE SK, 1978, PROC R SOC SER B-BIO, V200, P1, DOI 10.1098/rspb.1978.0001; Ausubel FM, 1994, CURRENT PROTOCOLS MO; BLACK TA, 1993, MOL MICROBIOL, V9, P77, DOI 10.1111/j.1365-2958.1993.tb01670.x; BOTHE H, 1988, METHOD ENZYMOL, V167, P496; BUCHANAN BB, 1980, ANNU REV PLANT PHYS, V31, P341, DOI 10.1146/annurev.pp.31.060180.002013; BUCHANAN BB, 1991, ARCH BIOCHEM BIOPHYS, V288, P1, DOI 10.1016/0003-9861(91)90157-E; CAMPBELL EL, 1992, J GEN MICROBIOL, V138, P473, DOI 10.1099/00221287-138-3-473; COHEN MF, 1994, MICROBIOL-SGM, V140, P3233, DOI 10.1099/13500872-140-12-3233; COSSAR JD, 1984, J GEN MICROBIOL, V130, P991; ELHAI J, 1988, GENE, V68, P119, DOI 10.1016/0378-1119(88)90605-1; Gleason FK, 1996, ARCH BIOCHEM BIOPHYS, V334, P277, DOI 10.1006/abbi.1996.0456; Hanson TE, 1998, MICROBIOL-SGM, V144, P1537, DOI 10.1099/00221287-144-6-1537; Harlow E., 1988, ANTIBODIES LAB MANUA; Levy H R, 1979, Adv Enzymol Relat Areas Mol Biol, V48, P97; NEWMAN J, 1995, FEMS MICROBIOL LETT, V133, P187, DOI 10.1111/j.1574-6968.1995.tb07882.x; RIPPKA R, 1992, PASTURE CULTURE COLL; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SCHAEFFER F, 1978, ARCH MICROBIOL, V116, P9, DOI 10.1007/BF00408728; SCHEIBE R, 1989, ARCH BIOCHEM BIOPHYS, V274, P290, DOI 10.1016/0003-9861(89)90441-4; SCHEIBE R, 1990, BOT ACTA, V103, P327, DOI 10.1111/j.1438-8677.1990.tb00170.x; SUMMERS ML, 1995, J BACTERIOL, V177, P6184, DOI 10.1128/jb.177.21.6184-6194.1995; Summers ML, 1996, MOL MICROBIOL, V22, P473, DOI 10.1046/j.1365-2958.1996.1371502.x; SUMMERS ML, 1995, THESIS U CALIFORNIA; Sundaram S, 1998, MICROBIOL-SGM, V144, P1549, DOI 10.1099/00221287-144-6-1549; UDVARDY J, 1984, J BACTERIOL, V157, P681, DOI 10.1128/JB.157.2.681-683.1984; UDVARDY J, 1983, FEBS LETT, V152, P97, DOI 10.1016/0014-5793(83)80490-6; Wenderoth I, 1997, J BIOL CHEM, V272, P26985, DOI 10.1074/jbc.272.43.26985; Wendt UK, 1999, PLANT MOL BIOL, V40, P487, DOI 10.1023/A:1006257230779; WINKENBACH F, 1973, PLANT PHYSIOL, V52, P480, DOI 10.1104/pp.52.5.480	30	39	42	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 13	2001	276	15					11477	11486		10.1074/jbc.M010472200	http://dx.doi.org/10.1074/jbc.M010472200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	421UK	11152472	hybrid			2022-12-25	WOS:000168081800009
J	Venhudova, G; Canals, F; Querol, E; Aviles, FX				Venhudova, G; Canals, F; Querol, E; Aviles, FX			Mutations in the N- and C-terminal tails of potato carboxypeptidase inhibitor influence its oxidative refolding process at the reshuffling stage	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DISULFIDE FOLDING PATHWAY; EPIDERMAL GROWTH-FACTOR; TRYPSIN-INHIBITOR; METALLOCARBOXYPEPTIDASE INHIBITOR; GENE-EXPRESSION; PROTEIN; STABILITY; MECHANISM; SEQUENCES; COMPLEX	A comparative study of the oxidative refolding for nine selected potato carboxypeptidase inhibitor (PCI) mutants was carried out using the disulfide quenching approach. The mutations were performed at the N- and C-terminal tails of PCI outside its disulfide stabilized central core. The differences between the refolding of wild type and mutant proteins were observed in the second phase of the refolding process, the reshuffling of disulfide bridges, although the first phase, nonspecific packing, was not greatly affected by the mutations. Point mutations at the C-tail or deletion of up to three C-terminal residues of PCI resulted in a lower efficiency of the reshuffling process. In the case of the mutants lacking five N-terminal or four or five C-terminal residues, no "native-like" form was observed after the refolding process. On the other hand, the double mutant G35P/P36G did not attain a native-like form either, al though one slightly more stable species was observed after being submitted to refolding, The disulfide pairing of this species is different from that of the wtPCI native form. The differences between the refolding process of wild type and mutant forms are interpreted in the light of the new view of protein folding. The results of the present study support the hypothesis that the refolding of this small disulfide-rich protein, and others, is driven by noncovalent interactions at the reshuffling stage. It is also shown that the interactions established between the N- and C-tail residues and the core of PCI are important for the proper refolding of the protein.	Univ Autonoma Barcelona, Inst Biol Fonamental, E-08193 Barcelona, Spain; Univ Autonoma Barcelona, Dept Bioquim & Biol Mol, E-08193 Barcelona, Spain	Autonomous University of Barcelona; Autonomous University of Barcelona	Aviles, FX (corresponding author), Univ Autonoma Barcelona, Inst Biol Fonamental, E-08193 Barcelona, Spain.		Avilés, Francesc Xavier/A-2664-2015; Aviles, Francesc Xavier/F-3482-2019	Avilés, Francesc Xavier/0000-0002-1399-6789; Aviles, Francesc Xavier/0000-0002-1399-6789				Adler A J, 1973, Methods Enzymol, V27, P675; BALDWIN RL, 1994, NATURE, V369, P183, DOI 10.1038/369183a0; Blanco-Aparicio C, 1998, J BIOL CHEM, V273, P12370, DOI 10.1074/jbc.273.20.12370; CHANG JY, 1995, J BIOL CHEM, V270, P9207, DOI 10.1074/jbc.270.16.9207; Chang JY, 2000, J BIOL CHEM, V275, P8287, DOI 10.1074/jbc.275.12.8287; CHANG JY, 1994, J BIOL CHEM, V269, P22087; Chang JY, 1997, J BIOL CHEM, V272, P69; Chang JY, 1996, BIOCHEMISTRY-US, V35, P11702, DOI 10.1021/bi9606915; Chang JY, 2000, J BIOL CHEM, V275, P14205, DOI 10.1074/jbc.275.19.14205; CHATRENET B, 1993, J BIOL CHEM, V268, P20988; CLORE GM, 1987, BIOCHEMISTRY-US, V26, P8012, DOI 10.1021/bi00398a069; Creighton T E, 1986, Methods Enzymol, V131, P83; CREIGHTON TE, 1984, J MOL BIOL, V179, P497, DOI 10.1016/0022-2836(84)90077-9; Creighton Thomas E., 1992, P301; Dill KA, 1997, NAT STRUCT BIOL, V4, P10, DOI 10.1038/nsb0197-10; GAY GD, 1995, J MOL BIOL, V254, P968, DOI 10.1006/jmbi.1995.0669; GHRAYEB J, 1984, EMBO J, V3, P2437, DOI 10.1002/j.1460-2075.1984.tb02151.x; HASS GM, 1980, BIOCHEM BIOPH RES CO, V97, P1481, DOI 10.1016/S0006-291X(80)80032-5; HASS GM, 1976, BIOCHEMISTRY-US, V15, P93, DOI 10.1021/bi00646a015; HASS GM, 1981, METHOD ENZYMOL, V80, P778; Klement P, 1999, BLOOD, V94, P2735, DOI 10.1182/blood.V94.8.2735.420k30_2735_2743; LIN SL, 1995, NAT STRUCT BIOL, V2, P835, DOI 10.1038/nsb1095-835; LING MH, 1993, J BIOL CHEM, V268, P810; Marino-Buslje C, 2000, EUR J BIOCHEM, V267, P1502, DOI 10.1046/j.1432-1327.2000.01150.x; MARTINEAU B, 1991, MOL GEN GENET, V228, P281, DOI 10.1007/BF00282477; Mas JM, 1998, J MOL BIOL, V284, P541, DOI 10.1006/jmbi.1998.2194; MOLINA MA, 1992, GENE, V116, P129, DOI 10.1016/0378-1119(92)90508-M; MOLINA MA, 1994, J BIOL CHEM, V269, P21467; Otlewski J, 1996, ACTA BIOCHIM POL, V43, P431; PriceCarter M, 1996, BIOCHEMISTRY-US, V35, P15547, DOI 10.1021/bi9615755; REES DC, 1982, J MOL BIOL, V160, P475, DOI 10.1016/0022-2836(82)90309-6; ROLKA K, 1992, BIOL CHEM H-S, V373, P1055, DOI 10.1515/bchm3.1992.373.2.1055; SHINDE U, 1993, TRENDS BIOCHEM SCI, V18, P442, DOI 10.1016/0968-0004(93)90146-E; Villanueva J, 1998, FEBS LETT, V440, P175, DOI 10.1016/S0014-5793(98)01447-1; WEISSMAN JS, 1991, SCIENCE, V253, P1386, DOI 10.1126/science.1716783; Wu J, 1997, PROTEIN SCI, V6, P391	36	16	17	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 13	2001	276	15					11683	11690		10.1074/jbc.M007927200	http://dx.doi.org/10.1074/jbc.M007927200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	421UK	11152676	hybrid			2022-12-25	WOS:000168081800036
J	Zanassi, P; Paolillo, M; Feliciello, A; Avvedimento, EV; Gallo, V; Schinelli, S				Zanassi, P; Paolillo, M; Feliciello, A; Avvedimento, EV; Gallo, V; Schinelli, S			cAMP-dependent protein kinase induces cAMP-response element-binding protein phosphorylation via an intracellular calcium release/ERK-dependent pathway in striatal neurons	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NERVE GROWTH-FACTOR; C-FOS TRANSCRIPTION; MAP KINASE; CYCLIC-AMP; B-RAF; MEMBRANE DEPOLARIZATION; CREB PHOSPHORYLATION; RYANODINE RECEPTOR; GENE-EXPRESSION; ACTIVATION	Activation of the cAMP dependent protein kinase A (PKA) pathway may induce cAMP-response element-binding protein (CREB) phosphorylation either directly or via cross-talk mechanisms with other signal transduction pathways. In this study, we have investigated in striatal primary cultures the mechanism by which activation of the cAMP/PKA-dependent pathway leads to CREB phosphorylation via the extracellular signal-regulated kinase (ERK) dependent pathway. We have found that PKA-induced CREB phosphorylation and CREB-dependent transcription are mediated by calcium (Ca2+) release from intracellular stores and are blocked by inhibitors of the protein kinase C and ERK pathways. This mechanism appears to be mediated by the small G-protein Rap1, whose activation appears to be primed by PKA-induced Ca2+ release but not further induced by direct or indirect PKA- or protein kinase C-dependent phosphorylation. These results suggest that, in striatal neurons, intracellular Ca2+ release, Rap1, and ERK pathway play a crucial role in the PKA induced CREB phosphorylation and CREB-dependent transcription.	Univ Pavia, Fac Farm, Dipartimento Farmacol Sperimentale & Applicata, I-27100 Pavia, Italy; CNR, Dipartimento Biol & Patol Cellulare & Mol, I-80131 Naples, Italy; Univ Catanzaro, Fac Med Catanzaro, Dipartimento Med Sperimentale, I-88100 Catanzaro, Italy; NICHD, Lab Cellular & Mol Neurophysiol, NIH, Bethesda, MD 20892 USA	University of Pavia; Consiglio Nazionale delle Ricerche (CNR); Magna Graecia University of Catanzaro; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Schinelli, S (corresponding author), Univ Pavia, Fac Farm, Dipartimento Farmacol Sperimentale & Applicata, 14 Viale Taramelli, I-27100 Pavia, Italy.	schnll@unipv.it	Paolillo, Mayra/N-2615-2015	Paolillo, Mayra/0000-0002-7751-3336; Feliciello, Antonio/0000-0002-7932-2170				Bito H, 1996, CELL, V87, P1203, DOI 10.1016/S0092-8674(00)81816-4; Blaukat A, 1999, J BIOL CHEM, V274, P14893, DOI 10.1074/jbc.274.21.14893; BURGERING BMT, 1995, TRENDS BIOCHEM SCI, V20, P18, DOI 10.1016/S0968-0004(00)88944-6; BURT DR, 1977, SCIENCE, V196, P327, DOI 10.1126/science.847477; Das S, 1997, SYNAPSE, V25, P227; de Rooij J, 1998, NATURE, V396, P474, DOI 10.1038/24884; Deisseroth K, 1998, NATURE, V392, P198, DOI 10.1038/32448; Finkbeiner S, 1997, NEURON, V19, P1031, DOI 10.1016/S0896-6273(00)80395-5; Franke B, 1997, EMBO J, V16, P252, DOI 10.1093/emboj/16.2.252; GINTY DD, 1994, CELL, V77, P713, DOI 10.1016/0092-8674(94)90055-8; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; Grewal SS, 2000, J BIOL CHEM, V275, P3722, DOI 10.1074/jbc.275.5.3722; Haug LS, 1999, J BIOL CHEM, V274, P7467, DOI 10.1074/jbc.274.11.7467; Impey S, 1998, NEURON, V21, P869, DOI 10.1016/S0896-6273(00)80602-9; Kawasaki H, 1998, SCIENCE, V282, P2275, DOI 10.1126/science.282.5397.2275; Kawasaki H, 1998, P NATL ACAD SCI USA, V95, P13278, DOI 10.1073/pnas.95.22.13278; Kornhauser JM, 1997, NEURON, V18, P839, DOI 10.1016/S0896-6273(00)80322-0; LEV S, 1995, NATURE, V376, P737, DOI 10.1038/376737a0; Martin KC, 1997, NEURON, V18, P899, DOI 10.1016/S0896-6273(00)80330-X; Marx SO, 2000, CELL, V101, P365, DOI 10.1016/S0092-8674(00)80847-8; NESTLER EJ, 1993, NEURON, V11, P995, DOI 10.1016/0896-6273(93)90213-B; Paolillo M, 1999, J BIOL CHEM, V274, P6546, DOI 10.1074/jbc.274.10.6546; Paolillo M, 1998, EUR J NEUROSCI, V10, P1937, DOI 10.1046/j.1460-9568.1998.00203.x; Perkinton MS, 1999, J NEUROSCI, V19, P5861, DOI 10.1523/JNEUROSCI.19-14-05861.1999; Roberson ED, 1999, J NEUROSCI, V19, P4337; ROSEN LB, 1994, NEURON, V12, P1207, DOI 10.1016/0896-6273(94)90438-3; SCHINELLI S, 1994, MOL BRAIN RES, V21, P162, DOI 10.1016/0169-328X(94)90389-1; Schmitt JM, 2000, J BIOL CHEM, V275, P25342, DOI 10.1074/jbc.M003213200; Seidel MG, 1999, J BIOL CHEM, V274, P25833, DOI 10.1074/jbc.274.36.25833; SHENG M, 1990, NEURON, V4, P571, DOI 10.1016/0896-6273(90)90115-V; SURMEIER DJ, 1995, NEURON, V14, P385, DOI 10.1016/0896-6273(95)90294-5; Vanhoutte P, 1999, MOL CELL BIOL, V19, P136; Vossler MR, 1997, CELL, V89, P73, DOI 10.1016/S0092-8674(00)80184-1; Wojcikiewicz RJH, 1998, J BIOL CHEM, V273, P5670, DOI 10.1074/jbc.273.10.5670; Yan Z, 1999, P NATL ACAD SCI USA, V96, P11607, DOI 10.1073/pnas.96.20.11607; Yao H, 1998, J BIOL CHEM, V273, P8240, DOI 10.1074/jbc.273.14.8240; York RD, 1998, NATURE, V392, P622, DOI 10.1038/33451; YOSHIDA A, 1992, J NEUROSCI, V12, P1094	38	137	138	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 13	2001	276	15					11487	11495		10.1074/jbc.M007631200	http://dx.doi.org/10.1074/jbc.M007631200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	421UK	11139572	hybrid			2022-12-25	WOS:000168081800010
J	Cessna, SG; Low, PS				Cessna, SG; Low, PS			An apoplastic Ca2+ sensor regulates internal Ca2+ release in aequorin-transformed tobacco cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYPOOSMOTIC SHOCK; CALCIUM; RECEPTOR; FLUXES; STORES; KINASE; SIGNAL	Removal of Ca2+ from tobacco suspension cell medium has two immediate effects on cytosolic Ca2+ fluxes: (i) externally derived Ca2+ influx (occurring in response to cold shock or hypo osmotic shock) is inhibited, and (ii) organellar Ca2+ release (induced by a fungally derived defense elicitor, caffeine, or hypo-osmotic shock) is elevated. We show here that the enhanced release of internal Ca2+ is Likely due to increased discharge from a caffeine-sensitive store in response to a signal transduced from an extracellular Ca2+ sensor. Thus, chelation of extracellular Ca2+ in the absence of any other stimulus directly activates release of intracellular Ca2+ into the cytosol, Evidence that this chelator-activated Ca2+ flux is dependent on a signaling pathway includes its abrogation by prior treatment with caffeine, and its inhibition by protein kinase inhibitors (K252a and staurosporine) and anion channel blockers (niflumate and anthracene-9-carboxylate). An unexpected characteristic of tobacco cell adaptation to low external Ca2+ was the emergence of a new Ca2+ compartment that was inaccessible to external EGTA, yet responsive to the usual stimulants of extracellular Ca2+ entry. Thus, cells that are exposed to EGTA for 20 min lose sensitivity to caffeine and defense elicitors, indicating that their intracellular Ca2+ pools have been depleted, Surprisingly, these same cells simultaneously regain their ability to respond to stimuli that usually activate extracellular Ca2+ influx even though all external Ca2+ is chelated, Because this gradual restoration of Ca2+ influx can be inhibited by the same kinase inhibitors that block EGTA-activated Ca2+ release, we propose that chelator-activated Ca2+ release from internal stores leads to deposition of this Ca2+ into a novel EGTA- and caffeine-insensitive compartment that can subsequently be activated by stimulants of extracellular Ca2+ entry.	Purdue Univ, Dept Chem, W Lafayette, IN 47904 USA; Purdue Univ, Biochem & Mol Biol Program, W Lafayette, IN 47904 USA	Purdue University System; Purdue University; Purdue University West Lafayette Campus; Purdue University System; Purdue University; Purdue University West Lafayette Campus	Low, PS (corresponding author), Purdue Univ, Dept Chem, 1393 Brown Bldg, W Lafayette, IN 47904 USA.			Cessna, Stephen/0000-0001-7233-8711; Low, Philip/0000-0001-9042-5528				ALLEN DG, 1977, SCIENCE, V195, P996, DOI 10.1126/science.841325; ALLISON JD, 1995, SSSA SPEC PUBL, V42, P241; BROWN EM, 1993, NATURE, V366, P575, DOI 10.1038/366575a0; Cessna SG, 1998, J BIOL CHEM, V273, P27286, DOI 10.1074/jbc.273.42.27286; CESSNA SG, 2001, IN PRESS PLANTA; Chandra S, 1997, J BIOL CHEM, V272, P28274, DOI 10.1074/jbc.272.45.28274; CLAPHAM DE, 1995, CELL, V80, P259, DOI 10.1016/0092-8674(95)90408-5; Fleischer A, 1999, PLANT PHYSIOL, V121, P829, DOI 10.1104/pp.121.3.829; Harmon AC, 2000, TRENDS PLANT SCI, V5, P154, DOI 10.1016/S1360-1385(00)01577-6; He ZH, 1996, J BIOL CHEM, V271, P19789, DOI 10.1074/jbc.271.33.19789; HOTH M, 1992, NATURE, V355, P353, DOI 10.1038/355353a0; Knight H, 1996, PLANT CELL, V8, P489, DOI 10.1105/tpc.8.3.489; KNIGHT MR, 1991, NATURE, V352, P524, DOI 10.1038/352524a0; Lewis RS, 1999, ADV SEC MESS PHOSPH, V33, P279; LIU D, 1994, P NATL ACAD SCI USA, V91, P1888, DOI 10.1073/pnas.91.5.1888; McGehee DS, 1997, J PHYSIOL-LONDON, V502, P31, DOI 10.1111/j.1469-7793.1997.031bl.x; MURASHIGE T, 1962, PHYSIOL PLANTARUM, V15, P473, DOI 10.1111/j.1399-3054.1962.tb08052.x; Riccardi D, 1999, CELL CALCIUM, V26, P77, DOI 10.1054/ceca.1999.0066; Sanders D, 1999, PLANT CELL, V11, P691, DOI 10.1105/tpc.11.4.691; Takahashi K, 1997, PLANT PHYSIOL, V113, P587, DOI 10.1104/pp.113.2.587; TAKEMURA H, 1989, J BIOL CHEM, V264, P12266; Tibbits CW, 1998, CARBOHYD RES, V310, P101, DOI 10.1016/S0008-6215(98)00172-4; Xu HX, 1998, PLANT CELL, V10, P585, DOI 10.1105/tpc.10.4.585; Yamaguchi T, 2000, ADV PHARMACOL, V47, P209	24	21	23	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 6	2001	276	14					10655	10662		10.1074/jbc.M006989200	http://dx.doi.org/10.1074/jbc.M006989200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	420AC	11139570	hybrid			2022-12-25	WOS:000167980900014
J	Verde, I; Pahlke, G; Salanova, M; Zhang, G; Wang, S; Coletti, D; Onuffer, J; Jin, SLC; Conti, M				Verde, I; Pahlke, G; Salanova, M; Zhang, G; Wang, S; Coletti, D; Onuffer, J; Jin, SLC; Conti, M			Myomegalin is a novel protein of the Golgi/centrosome that interacts with a cyclic nucleotide phosphodiesterase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KINASE-A; SUBCELLULAR-LOCALIZATION; CENTROSOMAL PROTEIN; SKELETAL-MUSCLE; GENE; IDENTIFICATION; ACTIVATION; VESICLES; DOMAIN; AMP	Subcellular targeting of the components of the cAMP-dependent pathway is thought to be essential for intracellular signaling. Here we have identified a novel protein, named myomegalin, that interacts with the cyclic nucleotide phosphodiesterase PDE4D, thereby targeting it to particulate structures. Myomegalin is a large 2,324-amino acid protein mostly composed of alpha -helical and coiled coil structures, with domains shared with microtubule-associated proteins, and a leucine zipper identical to that found in the Drosophila centrosomin. Transcripts of 7.5-8 kilobases were present in most tissues, whereas a short mRNA of 2.4 kilobases was detected only in rat testis. A third splicing variant was expressed predominantly in rat heart. Antibodies against the deduced sequence recognized particulate myomegalin proteins of 62 kDa in testis and 230-250 kDa in heart and skeletal muscle. Immunocytochemistry and transfection studies demonstrate colocalization of PDE4D and myomegalin in the Golgi/centrosomal area of cultured cells, and in sarcomeric structures of skeletal muscle. Myomegalin expressed in COS-7 cells coimmunoprecipitated with PDE4D3 and sequestered it to particulate structures. These findings indicate that myomegalin is a novel protein that functions as an anchor to localize components of the cAMP-dependent pathway to the Golgi/centrosomal region of the cell.	Stanford Univ, Sch Med, Div Reprod Biol, Dept Gynecol & Obstet, Stanford, CA 94305 USA; Berlex Biosci, Dept Immunol, Richmond, CA 94804 USA	Stanford University	Conti, M (corresponding author), Stanford Univ, Sch Med, Div Reprod Biol, Dept Gynecol & Obstet, Stanford, CA 94305 USA.	marco.conti@stanford.edu	Pinheiro, Maísa/E-7424-2012; Coletti, Dario/CAG-9308-2022; Coletti, Dario/U-2219-2018; Verde, Ignacio/M-3991-2013	Verde, Ignacio/0000-0003-3492-5725; Wang, Sonya/0000-0003-4429-0508; Coletti, Dario/0000-0001-7373-1953	NICHD NIH HHS [R01-HD20788] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD020788] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BAILLY E, 1989, EMBO J, V8, P3985, DOI 10.1002/j.1460-2075.1989.tb08581.x; Barr FA, 1999, CURR BIOL, V9, P381, DOI 10.1016/S0960-9822(99)80167-5; BEAVO JA, 1995, PHYSIOL REV, V75, P725, DOI 10.1152/physrev.1995.75.4.725; BLOODGOOD RA, 1992, BIOL CELL, V76, P291, DOI 10.1016/0248-4900(92)90431-Y; Bolger GB, 1997, BIOCHEM J, V328, P539; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRANDT PW, 1987, J MOL BIOL, V195, P885, DOI 10.1016/0022-2836(87)90492-X; Burkhardt JK, 1998, BBA-MOL CELL RES, V1404, P113, DOI 10.1016/S0167-4889(98)00052-4; COGHLAN VM, 1995, SCIENCE, V267, P108, DOI 10.1126/science.7528941; COHEN GB, 1995, CELL, V80, P237, DOI 10.1016/0092-8674(95)90406-9; Colledge M, 1999, TRENDS CELL BIOL, V9, P216, DOI 10.1016/S0962-8924(99)01558-5; CONTI M, 1995, ENDOCR REV, V16, P370, DOI 10.1210/er.16.3.370; Conti M, 2000, PROG NUCLEIC ACID RE, V63, P1; DECAMILLI P, 1986, J CELL BIOL, V103, P189, DOI 10.1083/jcb.103.1.189; Gao TY, 1997, J BIOL CHEM, V272, P19401, DOI 10.1074/jbc.272.31.19401; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HEUER JG, 1995, DEVELOPMENT, V121, P3861; HOLZBAUR ELF, 1991, NATURE, V351, P579, DOI 10.1038/351579a0; Houslay MD, 1998, ADV PHARMACOL, V44, P225, DOI 10.1016/S1054-3589(08)60128-3; Iona S, 1998, MOL PHARMACOL, V53, P23, DOI 10.1124/mol.53.1.23; JASMIN BJ, 1989, P NATL ACAD SCI USA, V86, P7218, DOI 10.1073/pnas.86.18.7218; Jilling T, 1996, J BIOL CHEM, V271, P4381; Jin SLC, 1998, J BIOL CHEM, V273, P19672, DOI 10.1074/jbc.273.31.19672; JOHNSON BD, 1994, P NATL ACAD SCI USA, V91, P11492, DOI 10.1073/pnas.91.24.11492; JOSWIG G, 1991, J CELL SCI, V98, P37; KERYER G, 1993, EXP CELL RES, V204, P230, DOI 10.1006/excr.1993.1029; Kjer-Nielsen L, 1999, CURR BIOL, V9, P385, DOI 10.1016/S0960-9822(99)80168-7; Li KJ, 1998, J CELL BIOL, V141, P455, DOI 10.1083/jcb.141.2.455; Lim J, 1999, J BIOL CHEM, V274, P19677, DOI 10.1074/jbc.274.28.19677; Liu HG, 1999, J BIOL CHEM, V274, P10557, DOI 10.1074/jbc.274.15.10557; Megraw TL, 1999, DEVELOPMENT, V126, P2829; MOCHLYROSEN D, 1995, SCIENCE, V268, P247, DOI 10.1126/science.7716516; Muniz M, 1997, P NATL ACAD SCI USA, V94, P14461, DOI 10.1073/pnas.94.26.14461; Munro S, 1999, CURR BIOL, V9, P377, DOI 10.1016/S0960-9822(99)80166-3; NIGG EA, 1985, EMBO J, V4, P2801, DOI 10.1002/j.1460-2075.1985.tb04006.x; Petzelt C, 1997, J CELL SCI, V110, P2573; PIERRE P, 1992, CELL, V70, P887, DOI 10.1016/0092-8674(92)90240-D; Pryzwansky Katherine B., 1998, Cell Biochemistry and Biophysics, V28, P251, DOI 10.1007/BF02737813; Reilein AR, 1998, J CELL BIOL, V142, P803, DOI 10.1083/jcb.142.3.803; ROSENMUND C, 1994, NATURE, V368, P853, DOI 10.1038/368853a0; RUBIN CS, 1994, BBA-MOL CELL RES, V1224, P467; Salanova M, 1999, ENDOCRINOLOGY, V140, P2297, DOI 10.1210/en.140.5.2297; Scholler JK, 1997, DNA CELL BIOL, V16, P515, DOI 10.1089/dna.1997.16.515; THOMPSON WJ, 1971, BIOCHEMISTRY-US, V10, P311; Witczak O, 1999, EMBO J, V18, P1858, DOI 10.1093/emboj/18.7.1858; Yang JC, 1998, J CELL BIOL, V142, P511, DOI 10.1083/jcb.142.2.511	47	156	161	2	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 6	2001	276	14					11189	11198		10.1074/jbc.M006546200	http://dx.doi.org/10.1074/jbc.M006546200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	420AC	11134006	hybrid, Green Published			2022-12-25	WOS:000167980900082
J	Yokoyama, T; Kimura, KM; Ushiki, Y; Yamada, S; Morooka, A; Nakashiba, T; Sassa, T; Itohara, S				Yokoyama, T; Kimura, KM; Ushiki, Y; Yamada, S; Morooka, A; Nakashiba, T; Sassa, T; Itohara, S			In vivo conversion of cellular prion protein to pathogenic isoforms, as monitored by conformation-specific antibodies	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MONOCLONAL-ANTIBODIES; PRP 27-30; SCRAPIE; MICE; EXPRESSION; CELLS; GENE; BINDING; COPPER	The central event in prion disease is thought to be conformational conversion of the cellular isoform of prion protein (PrPC) to the insoluble isoform PrPSc. We generated polyclonal and monoclonal antibodies by immunizing PrPC-null mice with native PrPC. All seven monoclonal antibodies (mAbs) immunoprecipitated PrPC, but they immunoprecipitated PrPSc weakly or not at all, thereby indicating preferential reactivities to PrPC in solution. Immunoprecipitation using these mAbs revealed a marked loss of PrPC in brains at the terminal stage of illness. Histoblot analyses using these polyclonal antibodies in combination of pretreatment of blots dissociated PrPC and PrPSc in situ and consistently demonstrated the decrease of PrPC at regions where PrPSc accumulated. interestingly, same mAbs showed immunohistochemical reactivities to abnormal isoforms. One group of mAbs showed reactivity to materials that accumulated in astrocytes, while the other group did so to amorphous plaques in neuropil. Epitope mapping indicated that single mAbs have reactivities to multiple epitopes, thus implying dual specificities. This suggests the importance of octarepeats as a part of PrPC-specific conformation. Our observations support the notion that loss of function of PrPC may partly underlie the pathogenesis of prion diseases. The conversion of PrPC to PrPSc may involve multiple steps at different sites.	Natl Inst Anim Hlth, Tsukuba, Ibaraki 3050856, Japan; Nippi Res Inst Biomatrix, Tokyo 1208601, Japan; RIKEN, Brain Sci Inst, Wako, Saitama 3510198, Japan; Kyoto Univ, Inst Virus Res, Sakyo Ku, Kyoto 6068507, Japan	National Agriculture & Food Research Organization - Japan; National Institute of Animal Health - Japan; RIKEN; Kyoto University	Itohara, S (corresponding author), Natl Inst Anim Hlth, Tsukuba, Ibaraki 3050856, Japan.		SASSA, Takayuki/B-2519-2012; Itohara, Shigeyoshi/I-8769-2012	SASSA, Takayuki/0000-0003-3145-9829; Itohara, Shigeyoshi/0000-0002-2410-9989				CASHMAN NR, 1990, CELL, V61, P185, DOI 10.1016/0092-8674(90)90225-4; CAUGHEY BW, 1991, BIOCHEMISTRY-US, V30, P7672, DOI 10.1021/bi00245a003; COLLINGE J, 1994, NATURE, V370, P295, DOI 10.1038/370295a0; Demart S, 1999, BIOCHEM BIOPH RES CO, V265, P652, DOI 10.1006/bbrc.1999.1730; DIEDRICH JF, 1991, P NATL ACAD SCI USA, V88, P375, DOI 10.1073/pnas.88.2.375; Fischer MB, 2000, NATURE, V408, P479, DOI 10.1038/35044100; GOMI H, 1995, NEURON, V14, P29, DOI 10.1016/0896-6273(95)90238-4; HORIUCHI M, 1995, J GEN VIROL, V76, P2583, DOI 10.1099/0022-1317-76-10-2583; INUMARU S, 1991, VIRUS RES, V21, P123; Korth C, 1997, NATURE, V390, P74, DOI 10.1038/36337; Krasemann S, 1996, MOL MED, V2, P725, DOI 10.1007/BF03401656; Kuwahara C, 1999, NATURE, V400, P225, DOI 10.1038/22241; McKenzie D, 1998, J BIOL CHEM, V273, P25545, DOI 10.1074/jbc.273.40.25545; Nishida N, 1999, LAB INVEST, V79, P689; OESCH B, 1985, CELL, V40, P735, DOI 10.1016/0092-8674(85)90333-2; PAN KM, 1993, P NATL ACAD SCI USA, V90, P10962, DOI 10.1073/pnas.90.23.10962; PRUSINER SB, 1991, SCIENCE, V252, P1515, DOI 10.1126/science.1675487; Raeber AJ, 1997, EMBO J, V16, P6057, DOI 10.1093/emboj/16.20.6057; SAFAR J, 1993, J BIOL CHEM, V268, P20276; Sakaguchi S, 1996, NATURE, V380, P528, DOI 10.1038/380528a0; TARABOULOS A, 1990, J CELL BIOL, V110, P2117, DOI 10.1083/jcb.110.6.2117; TARABOULOS A, 1992, P NATL ACAD SCI USA, V89, P7620, DOI 10.1073/pnas.89.16.7620; VAUGHN JL, 1977, IN VITRO CELL DEV B, V13, P213; Viles JH, 1999, P NATL ACAD SCI USA, V96, P2042, DOI 10.1073/pnas.96.5.2042; Weissmann C, 1999, SCIENCE, V286, P914, DOI 10.1126/science.286.5441.914; WESTAWAY D, 1987, CELL, V51, P651, DOI 10.1016/0092-8674(87)90134-6; WHITTINGTON MA, 1995, NAT GENET, V9, P197, DOI 10.1038/ng0295-197; Williamson RA, 1996, P NATL ACAD SCI USA, V93, P7279, DOI 10.1073/pnas.93.14.7279; Williamson RA, 1998, J VIROL, V72, P9413, DOI 10.1128/JVI.72.11.9413-9418.1998; YOKOYAMA T, 1995, CLIN DIAGN LAB IMMUN, V2, P172, DOI 10.1128/CDLI.2.2.172-176.1995; YOKOYAMA WM, 1991, CURRENT PROTOCOLS IM, V1; Zanusso G, 1998, P NATL ACAD SCI USA, V95, P8812, DOI 10.1073/pnas.95.15.8812	32	101	103	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 6	2001	276	14					11265	11271		10.1074/jbc.M008734200	http://dx.doi.org/10.1074/jbc.M008734200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	420AC	11152682	hybrid			2022-12-25	WOS:000167980900093
J	Gowri, PM; Ganguly, TC; Cao, JS; Devalaraja, MN; Groner, B; Vore, M				Gowri, PM; Ganguly, TC; Cao, JS; Devalaraja, MN; Groner, B; Vore, M			Conversion of threonine 757 to valine enhances stat5a transactivation potential	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-HORMONE STIMULATION; MAMMARY EPITHELIAL-CELLS; DNA-BINDING; RAT-LIVER; TYROSINE PHOSPHORYLATION; SERINE PHOSPHORYLATION; SIGNAL TRANSDUCER; PROTEIN-KINASE; GENE PROMOTER; FACTOR-I	The growth hormone family of cytokines transduces intracellular signals through the Jak2-Stat5 pathway to activate the transcription of target genes. Amino acids within the C termini of Stats constitute the transactivation domain but also regulate the time course of tyrosine phosphorylation and extent of DNA binding. We mutated Thr(757) in the C-terminal of Stat5a (Thr-Stat5) to Val (Val-Stat5) and Asp (Asp-Stat5) and examined the effect on nuclear translocation, DNA binding. and prolactin-induced transcriptional activation of a Stat5-responsive luciferase reporter gene. Val-Stat5 produced a 5-fold higher increase in transcriptional activity relative to Thr-Stat5; Asp-Stat5 produced a similar response to Thr-Stat5. The increased transactivation was ligand induced and was not due to differences in basal expression of Val-Stat5 or to a constitutively activated Stat5 protein. Similar rates of loss of DNA binding ability and phosphorylation of Val- and Thr-Stat5 were observed following a single pulse of prolactin, indicating that the dephosphorylation pathways were unaltered. The serine-threonine kinase inhibitor H7 inhibited the transactivation potential of Thr-, Val-, and Asp-Stat5 to a similar extent, eliminating phosphorylation of Thr757 as a regulatory mechanism. The results suggest that Thr757 modulates the transactivation potential of Stat5 by a mechanism(s) that is dependent on the formation of Stat5 dimers and/or their nuclear translocation.	Univ Kentucky, Grad Ctr Toxicol, Lexington, KY 40536 USA; Georg Speyer Haus, D-60596 Frankfurt, Germany	University of Kentucky	Vore, M (corresponding author), Univ Kentucky, Grad Ctr Toxicol, 306 Hlth Sci Res Bldg, Lexington, KY 40536 USA.		Vore, Mary/E-2177-2012					AZAM M, 1995, EMBO J, V14, P1402, DOI 10.1002/j.1460-2075.1995.tb07126.x; Beuvink I, 2000, J BIOL CHEM, V275, P10247, DOI 10.1074/jbc.275.14.10247; Briscoe J, 1996, TRENDS CELL BIOL, V6, P336, DOI 10.1016/0962-8924(96)10028-3; BURDON TG, 1994, MOL ENDOCRINOL, V8, P1528, DOI 10.1210/me.8.11.1528; Callus BA, 2000, J BIOL CHEM, V275, P16954, DOI 10.1074/jbc.M909976199; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; Engh RA, 1996, J BIOL CHEM, V271, P26157, DOI 10.1074/jbc.271.42.26157; Galsgaard ED, 1996, MOL ENDOCRINOL, V10, P652, DOI 10.1210/me.10.6.652; Ganguly TC, 1997, J CLIN INVEST, V99, P2906, DOI 10.1172/JCI119485; Gebert CA, 1997, MOL ENDOCRINOL, V11, P400, DOI 10.1210/me.11.4.400; GOUILLEUX F, 1994, EMBO J, V13, P4361, DOI 10.1002/j.1460-2075.1994.tb06756.x; GRONER B, 1995, CURR OPIN GENET DEV, V5, P587, DOI 10.1016/0959-437X(95)80027-1; Ihle JN, 1996, CELL, V84, P331, DOI 10.1016/S0092-8674(00)81277-5; KAZANSKY AV, 1995, MOL ENDOCRINOL, V9, P1598, DOI 10.1210/me.9.11.1598; Kirken RA, 1997, J BIOL CHEM, V272, P15459, DOI 10.1074/jbc.272.24.15459; Kirken RA, 1997, J BIOL CHEM, V272, P14098, DOI 10.1074/jbc.272.22.14098; Kordula T, 1996, J BIOL CHEM, V271, P6752, DOI 10.1074/jbc.271.12.6752; LI S, 1995, MOL CELL BIOL, V15, P2063; LIU XW, 1995, P NATL ACAD SCI USA, V92, P8831, DOI 10.1073/pnas.92.19.8831; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MARINI F, 1993, NUCLEIC ACIDS RES, V21, P2277, DOI 10.1093/nar/21.9.2277; Milocco LH, 1999, MOL CELL BIOL, V19, P2913; MORRIGL R, 1997, MOL CELL BIOL, V17, P3663; MORRIGL R, 1996, MOL CELL BIOL, V16, P5691; OBrien ML, 1996, CARCINOGENESIS, V17, P185, DOI 10.1093/carcin/17.2.185; Pfitzner E, 1998, MOL ENDOCRINOL, V12, P1582, DOI 10.1210/mend.12.10.0180; Ram PA, 1996, J BIOL CHEM, V271, P5929, DOI 10.1074/jbc.271.10.5929; Ram PA, 1997, J BIOL CHEM, V272, P17694, DOI 10.1074/jbc.272.28.17694; RIPPERGER JA, 1995, J BIOL CHEM, V270, P29998, DOI 10.1074/jbc.270.50.29998; SCHINDLER C, 1995, ANNU REV BIOCHEM, V64, P621, DOI 10.1146/annurev.bi.64.070195.003201; SIMS SH, 1993, MOL CELL BIOL, V13, P690, DOI 10.1128/MCB.13.1.690; Starr R, 1999, BIOESSAYS, V21, P47, DOI 10.1002/(SICI)1521-1878(199901)21:1<47::AID-BIES6>3.0.CO;2-N; Verdier F, 1998, MOL CELL BIOL, V18, P5852, DOI 10.1128/MCB.18.10.5852; Wang DM, 1996, MOL CELL BIOL, V16, P6141; Wartmann M, 1996, J BIOL CHEM, V271, P31863, DOI 10.1074/jbc.271.50.31863; WAXMAN DJ, 1995, J BIOL CHEM, V270, P13262, DOI 10.1074/jbc.270.22.13262; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; Xu XA, 1996, SCIENCE, V273, P794, DOI 10.1126/science.273.5276.794	38	5	5	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 30	2001	276	13					10485	10491		10.1074/jbc.M007156200	http://dx.doi.org/10.1074/jbc.M007156200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	420GC	11133982	hybrid			2022-12-25	WOS:000167996400116
J	Sayeski, PP; Ali, MS; Frank, SJ; Bernstein, KE				Sayeski, PP; Ali, MS; Frank, SJ; Bernstein, KE			The angotensin II-dependent nuclear translocation of Stat1 is mediated by the Jak2 protein motif (YRFRR)-Y-231	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANGIOTENSIN-II; AT(1) RECEPTOR; TYROSINE KINASE; CARDIAC MYOCYTES; RNA-POLYMERASE; N-TERMINUS; CELLS; DOMAIN; PATHWAY; PHOSPHORYLATION	In response to angiotensin II, Jak2 autophosphorylates and binds the angiotensin II AT(1) receptor. By studying a variety of Jak2 deletion proteins, we now show that the Jak2 protein motif (YRFRR)-Y-231 is required for the co-association of this kinase with the AT(1) receptor. We also used a full-length Jak2 protein containing a (231)FAAAA amino acid substitution. Although this protein still autophosphorylated in response to angiotensin II, it did not co-associate with the AT(1) receptor. This uncoupling indicates that AT(1)/Jak2 co-association is not necessary for angiotensin II-induced Jak2 autophosphorylation and that Jak2 autophosphorylation per se is insufficient for AT, receptor co-association, In response to angiotensin II, the Jak2-(231)FAAAA mutant will tyrosine phosphorylate Stat1. However, in the absence of AT(1)/Jak2 co-association, Stat1 did not translocate into the cell nucleus and failed to mediate gene transcription. This notable result indicates that Stat1 tyrosine phosphorylation alone is insufficient for Stat1 nuclear translocation. In summary, we now show that, although Jak2-mediated tyrosine phosphorylation of Stat1 is independent of receptor co-association, Jak2-mediated recruitment of Stat1 to the AT, receptor is critical for Stat1 nuclear translocation and subsequent gene transcription.	Emory Univ, Sch Med, Dept Pathol & Lab Med, Atlanta, GA 30322 USA; Univ Alabama, Div Endocrinol & Metab, Dept Med, Birmingham, AL 35294 USA	Emory University; University of Alabama System; University of Alabama Birmingham	Bernstein, KE (corresponding author), Emory Univ, Sch Med, Dept Pathol & Lab Med, 1639 Pierce Dr,7107 WWB, Atlanta, GA 30322 USA.			Bernstein, Kenneth/0000-0001-8097-3272	NHLBI NIH HHS [HL47035, F32-HL09678, HL61710] Funding Source: Medline; NIDDK NIH HHS [DK44280, DK39777, T32-DK07298, DK45215, DK51445] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL047035, R01HL061710, F32HL009678] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK039777, R01DK039777, R01DK051445, P50DK045215, R01DK044280] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ali MS, 2000, J BIOL CHEM, V275, P15586, DOI 10.1074/jbc.M908931199; Ali MS, 1998, BIOCHEM BIOPH RES CO, V249, P672, DOI 10.1006/bbrc.1998.9054; Ali MS, 1997, J BIOL CHEM, V272, P23382, DOI 10.1074/jbc.272.37.23382; Ausubel F.A., 1997, CURRENT PROTOCOLS MO, DOI DOI 10.1.4; BHAT GJ, 1995, J BIOL CHEM, V270, P19059, DOI 10.1074/jbc.270.32.19059; Briscoe J, 1996, TRENDS CELL BIOL, V6, P336, DOI 10.1016/0962-8924(96)10028-3; Cacalano NA, 1999, EMBO J, V18, P1549, DOI 10.1093/emboj/18.6.1549; CHEN WS, 1987, NATURE, V328, P820, DOI 10.1038/328820a0; DAMELL JE, 1997, SCIENCE, V277, P1630; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FAZIOLI F, 1993, MOL CELL BIOL, V13, P5814, DOI 10.1128/MCB.13.9.5814; FRANK SJ, 1995, J BIOL CHEM, V270, P14766; FUERST TR, 1989, J MOL BIOL, V206, P333, DOI 10.1016/0022-2836(89)90483-X; Herrington J, 1999, J BIOL CHEM, V274, P5138, DOI 10.1074/jbc.274.8.5138; ISHIDA M, 1995, CIRC RES, V77, P1053, DOI 10.1161/01.RES.77.6.1053; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; Li X, 1997, J BIOL CHEM, V272, P14341, DOI 10.1074/jbc.272.22.14341; MARRERO MB, 1995, NATURE, V375, P247, DOI 10.1038/375247a0; McWhinney CD, 1997, J MOL CELL CARDIOL, V29, P2513, DOI 10.1006/jmcc.1997.0489; Oppermann M, 1996, J BIOL CHEM, V271, P13266, DOI 10.1074/jbc.271.22.13266; Sadoshima J, 1996, EMBO J, V15, P775, DOI 10.1002/j.1460-2075.1996.tb00413.x; Sakai I, 1997, J BIOL CHEM, V272, P12350, DOI 10.1074/jbc.272.19.12350; Sayeski PP, 1999, J BIOL CHEM, V274, P33131, DOI 10.1074/jbc.274.46.33131; Sayeski PP, 1997, NUCLEIC ACIDS RES, V25, P1458, DOI 10.1093/nar/25.7.1458; Sayeski PP, 1998, REGUL PEPTIDES, V78, P19, DOI 10.1016/S0167-0115(98)00137-2; Sayeski PP, 1999, CIRC RES, V84, P1332, DOI 10.1161/01.RES.84.11.1332; Sayeski PP, 1998, CIRC RES, V82, P1279, DOI 10.1161/01.RES.82.12.1279; SCHINDLER C, 1995, ANNU REV BIOCHEM, V64, P621, DOI 10.1146/annurev.bi.64.070195.003201; SHIN TH, 1994, MOL ENDOCRINOL, V8, P704, DOI 10.1210/me.8.6.704; Strehlow I, 1998, J BIOL CHEM, V273, P28049, DOI 10.1074/jbc.273.43.28049; Yi WS, 1996, MOL ENDOCRINOL, V10, P1425, DOI 10.1210/me.10.11.1425; Yu CL, 2000, J BIOL CHEM, V275, P599, DOI 10.1074/jbc.275.1.599; ZHAO YM, 1995, J BIOL CHEM, V270, P13814, DOI 10.1074/jbc.270.23.13814	34	28	30	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 30	2001	276	13					10556	10563		10.1074/jbc.M008856200	http://dx.doi.org/10.1074/jbc.M008856200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	420GC	11152457	hybrid			2022-12-25	WOS:000167996400125
J	Inagaki, S; Ohoka, Y; Sugimoto, H; Fujioka, S; Amazaki, M; Kurinami, H; Miyazaki, N; Tohyama, M; Furuyama, T				Inagaki, S; Ohoka, Y; Sugimoto, H; Fujioka, S; Amazaki, M; Kurinami, H; Miyazaki, N; Tohyama, M; Furuyama, T			Sema4C, a transmembrane semaphorin, interacts with a post-synaptic density protein, PSD-95	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOMAIN-CONTAINING PROTEIN; PDZ-DOMAIN; AXON GUIDANCE; SIGNALING COMPLEXES; NEURITE OUTGROWTH; FAMILY; RECEPTOR; IDENTIFICATION; GENES; BRAIN	Semaphorins are known to act as chemorepulsive molecules that guide axons during neural development. Sema4C, a group 4 semaphorin, is a transmembrane semaphorin of unknown function. The cytoplasmic domain of Sema4C contains a proline-rich region that may interact with some signaling proteins. In this study, we demonstrate that Sema4C is enriched in the adult mouse brain and associated with PSD-95 isoforms containing PDZ (PSD-95/DLG/ZO-1) domains, such as PSD-95/SAP90, PSD-93/chapsin110, and SAP97/DLG-1, which are concentrated in the post-synaptic density of the brain. In the neocortex, S4C is enriched in the synaptic vesicle fraction and Triton X-100 insoluble post-synaptic density fraction. Immunostaining for Sema4C overlaps that for PSD-95 in superficial layers I-IV of the neocortex. In neocortical culture, S4C is colocalized with PSD-95 in neurons, with a dot-like pattern along the neurites. Sema4C thus may function in the cortical neurons as a hi-directional transmembrane ligand through interacting with PSD-95.	Osaka Univ, Fac Med, Sch Allied Hlth Sci, Neurobiol Grp, Suita, Osaka 5650871, Japan; Osaka Univ, Grad Sch Med, Dept Anat & Neurosci, Suita, Osaka 5650871, Japan; Osaka Univ, Grad Sch Med, Dept Otorhinolaryngol, Suita, Osaka 5650871, Japan	Osaka University; Osaka University; Osaka University	Inagaki, S (corresponding author), Osaka Univ, Fac Med, Sch Allied Hlth Sci, Neurobiol Grp, Yamadaoka 1-7, Suita, Osaka 5650871, Japan.			Furuyama, Tatsuo/0000-0001-7349-103X				Adams RH, 1997, EMBO J, V16, P6077, DOI 10.1093/emboj/16.20.6077; Bredt DS, 1998, CELL, V94, P691, DOI 10.1016/S0092-8674(00)81727-4; Brenman JE, 1996, CELL, V84, P757, DOI 10.1016/S0092-8674(00)81053-3; Cai HB, 1999, J NEUROSCI, V19, P6519; CARLIN RK, 1980, J CELL BIOL, V86, P831, DOI 10.1083/jcb.86.3.831; CHO KO, 1992, NEURON, V9, P929, DOI 10.1016/0896-6273(92)90245-9; Comeau MR, 1998, IMMUNITY, V8, P473, DOI 10.1016/S1074-7613(00)80552-X; De Vries L, 1998, P NATL ACAD SCI USA, V95, P12340, DOI 10.1073/pnas.95.21.12340; Eckhardt F, 1997, MOL CELL NEUROSCI, V9, P409, DOI 10.1006/mcne.1997.0644; Elhabazi A, 1997, J BIOL CHEM, V272, P23515, DOI 10.1074/jbc.272.38.23515; Fanning AS, 1999, CURR OPIN CELL BIOL, V11, P432, DOI 10.1016/S0955-0674(99)80062-3; Furuyama T, 1996, J BIOL CHEM, V271, P33376, DOI 10.1074/jbc.271.52.33376; Goodman CS, 1999, CELL, V97, P551, DOI 10.1016/S0092-8674(00)80766-7; Goslin  K., 1991, CULTURING NERVE CELL, P339; Hata Y, 1996, J NEUROSCI, V16, P2488; ICHTCHENKO K, 1995, CELL, V81, P435, DOI 10.1016/0092-8674(95)90396-8; INAGAKI S, 1995, FEBS LETT, V370, P269, DOI 10.1016/0014-5793(95)00850-9; INAGAKI S, 1991, BRAIN RES, V541, P354, DOI 10.1016/0006-8993(91)91038-3; Irie M, 1997, SCIENCE, V277, P1511, DOI 10.1126/science.277.5331.1511; Kameyama T, 1996, BIOCHEM BIOPH RES CO, V226, P396, DOI 10.1006/bbrc.1996.1367; Kim E, 1996, NEURON, V17, P103, DOI 10.1016/S0896-6273(00)80284-6; Kim JH, 1998, NEURON, V20, P683, DOI 10.1016/S0896-6273(00)81008-9; Kim SK, 1997, CURR OPIN CELL BIOL, V9, P853, DOI 10.1016/S0955-0674(97)80088-9; KISTNER U, 1993, J BIOL CHEM, V268, P4580; Kobayashi H, 1997, J NEUROSCI, V17, P8339; KOLODKIN AL, 1993, CELL, V75, P1389, DOI 10.1016/0092-8674(93)90625-Z; Kornau HC, 1997, CURR OPIN NEUROBIOL, V7, P368, DOI 10.1016/S0959-4388(97)80064-5; LUE RA, 1994, P NATL ACAD SCI USA, V91, P9818, DOI 10.1073/pnas.91.21.9818; LUO YL, 1993, CELL, V75, P217, DOI 10.1016/0092-8674(93)80064-L; Maestrini E, 1996, P NATL ACAD SCI USA, V93, P674, DOI 10.1073/pnas.93.2.674; Migaud M, 1998, NATURE, V396, P433, DOI 10.1038/24790; Miyazaki N, 1999, NEUROSCI RES, V33, P269, DOI 10.1016/S0168-0102(99)00015-2; Miyazaki N, 1999, NEUROSCIENCE, V93, P401, DOI 10.1016/S0306-4522(99)00134-7; MULLER BM, 1995, J NEUROSCI, V15, P2354, DOI 10.1523/JNEUROSCI.15-03-02354.1995; Niethammer M, 1998, NEURON, V20, P693, DOI 10.1016/S0896-6273(00)81009-0; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; PONGTING CP, 1997, BIOESSAYS, V19, P469; Ranganathan R, 1997, CURR BIOL, V7, pR770, DOI 10.1016/S0960-9822(06)00401-5; Sakai T, 1999, J BIOL CHEM, V274, P29666, DOI 10.1074/jbc.274.42.29666; Sambrook J., 2002, MOL CLONING LAB MANU; Scheiffele P, 2000, CELL, V101, P657, DOI 10.1016/S0092-8674(00)80877-6; Sheng M, 1996, NEURON, V17, P575, DOI 10.1016/S0896-6273(00)80190-7; Songyang Z, 1997, SCIENCE, V275, P73, DOI 10.1126/science.275.5296.73; Tamagnone L, 1999, CELL, V99, P71, DOI 10.1016/S0092-8674(00)80063-X; TessierLavigne M, 1996, SCIENCE, V274, P1123, DOI 10.1126/science.274.5290.1123; Tezuka T, 1999, P NATL ACAD SCI USA, V96, P435, DOI 10.1073/pnas.96.2.435; Tsunoda S, 1997, NATURE, V388, P243, DOI 10.1038/40805; Wang LH, 1999, J BIOL CHEM, V274, P14137, DOI 10.1074/jbc.274.20.14137; Winberg ML, 1998, CELL, V95, P903, DOI 10.1016/S0092-8674(00)81715-8; WOODS DF, 1993, MECH DEVELOP, V44, P85, DOI 10.1016/0925-4773(93)90059-7; Yagi T, 2000, GENE DEV, V14, P1169; Zhang WD, 1999, J NEUROSCI, V19, P96, DOI 10.1523/JNEUROSCI.19-01-00096.1999	52	55	60	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 23	2001	276	12					9174	9181		10.1074/jbc.M009051200	http://dx.doi.org/10.1074/jbc.M009051200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	413HV	11134026	hybrid			2022-12-25	WOS:000167607700075
J	Dashti, SR; Efimova, T; Eckert, RL				Dashti, SR; Efimova, T; Eckert, RL			MEK7-dependent activation of p38 MAP kinase in keratinocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN INVOLUCRIN PROMOTER; SIGNAL-TRANSDUCTION PATHWAY; DISTAL REGULATORY REGION; JUN NH2-TERMINAL KINASE; PROTEIN-KINASE; CELL-DIFFERENTIATION; CROSS-LINKING; DNA-BINDING; IN-VITRO; TRANSCRIPTION	Previous studies suggest that a PKC/Ras/MEKK1 cascade regulates involucrin (hINV) gene expression in human epidermal keratinocytes. MEK7, which is expressed in epidermis, has been identified as a member of this cascade (Efimova, T., LaCelle, P., Welter, J. F., and Eckert, R. L. (1998) J. Biol. Chem. 273, 24387-24395 and Efimova, T., and Eckert, R. L. (2000) J. Biol. Chem. 275, 1601-1607). However, the kinase that functions downstream of MEK7 has not been identified. Our present studies show that MEK7 expression in keratinocytes markedly activates p38 alpha and modestly activates JNK. Activation of p38 MAPK by MEK7 is a novel finding, as previous reports have assigned MEK7 as a JNK regulator. We also demonstrate that this regulation is physiologically important, as the p38 alpha- and JNK-dependent activities regulate hINV promoter activity and expression of the endogenous hINV gene.	Case Western Reserve Univ, Sch Med, Dept Physiol & Biophys, Cleveland, OH 44106 USA; Case Western Reserve Univ, Sch Med, Dept Biochem Reprod Biol Dermatol & Oncol, Cleveland, OH 44106 USA	Case Western Reserve University; Case Western Reserve University	Eckert, RL (corresponding author), Case Western Reserve Univ, Sch Med, Dept Physiol & Biophys, Rm E532,2109 Adelbert Rd, Cleveland, OH 44106 USA.			Dashti, Shervin/0000-0002-1552-9738; Efimova, Tatiana/0000-0002-9869-1545				Alonso G, 2000, J BIOL CHEM, V275, P40641, DOI 10.1074/jbc.M007835200; Balasubramanian S, 2000, BIOCHEM J, V350, P791, DOI 10.1042/0264-6021:3500791; Banks EB, 1999, BIOCHEM J, V337, P507, DOI 10.1042/0264-6021:3370507; Banks EB, 1998, BIOCHEM J, V331, P61, DOI 10.1042/bj3310061; CANO E, 1995, TRENDS BIOCHEM SCI, V20, P117, DOI 10.1016/S0968-0004(00)88978-1; Crish JF, 1998, J BIOL CHEM, V273, P30460, DOI 10.1074/jbc.273.46.30460; Cuenda A, 1997, EMBO J, V16, P295, DOI 10.1093/emboj/16.2.295; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; Eckert RL, 1997, PHYSIOL REV, V77, P397, DOI 10.1152/physrev.1997.77.2.397; Efimova T, 1998, J BIOL CHEM, V273, P24387, DOI 10.1074/jbc.273.38.24387; Efimova T, 2000, J BIOL CHEM, V275, P1601, DOI 10.1074/jbc.275.3.1601; Enslen H, 1998, J BIOL CHEM, V273, P1741, DOI 10.1074/jbc.273.3.1741; Green H, 1980, Harvey Lect, V74, P101; GRUDA MC, 1994, ONCOGENE, V9, P2537; Hale KK, 1999, J IMMUNOL, V162, P4246; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; Hu MCT, 1999, J BIOL CHEM, V274, P7095, DOI 10.1074/jbc.274.11.7095; Jiang Y, 1996, J BIOL CHEM, V271, P17920, DOI 10.1074/jbc.271.30.17920; Kato Y, 1997, EMBO J, V16, P7054, DOI 10.1093/emboj/16.23.7054; Kumar S, 1997, BIOCHEM BIOPH RES CO, V235, P533, DOI 10.1006/bbrc.1997.6849; LaCelle PT, 1998, SKIN PHARMACOL APPL, V11, P214, DOI 10.1159/000029830; Lechner C, 1996, P NATL ACAD SCI USA, V93, P4355, DOI 10.1073/pnas.93.9.4355; Li ZJ, 1996, BIOCHEM BIOPH RES CO, V228, P334, DOI 10.1006/bbrc.1996.1662; Ono K, 2000, CELL SIGNAL, V12, P1, DOI 10.1016/S0898-6568(99)00071-6; RICE RH, 1979, CELL, V18, P681, DOI 10.1016/0092-8674(79)90123-5; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; Ross SE, 1999, MOL CELL BIOL, V19, P8433; Tibbles LA, 1999, CELL MOL LIFE SCI, V55, P1230, DOI 10.1007/s000180050369; Tournier C, 1999, MOL CELL BIOL, V19, P1569; Vuong H, 2000, J BIOL CHEM, V275, P32250, DOI 10.1074/jbc.M005227200; Wang YB, 1998, J BIOL CHEM, V273, P2161, DOI 10.1074/jbc.273.4.2161; Wang YB, 1998, J BIOL CHEM, V273, P5423, DOI 10.1074/jbc.273.10.5423; WELTER JF, 1995, J BIOL CHEM, V270, P12614, DOI 10.1074/jbc.270.21.12614; Whitmarsh AJ, 2000, CELL MOL LIFE SCI, V57, P1172, DOI 10.1007/PL00000757; Whitmarsh AJ, 1998, TRENDS BIOCHEM SCI, V23, P481, DOI 10.1016/S0968-0004(98)01309-7; Yao ZB, 1997, J BIOL CHEM, V272, P32378, DOI 10.1074/jbc.272.51.32378	37	49	51	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 16	2001	276	11					8059	8063		10.1074/jbc.C000862200	http://dx.doi.org/10.1074/jbc.C000862200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	411AA	11244091	hybrid			2022-12-25	WOS:000167474900055
J	Vijaykumar, M; Naik, RS; Gowda, DC				Vijaykumar, M; Naik, RS; Gowda, DC			Plasmodium falciparum glycosylphosphatidylinositol-induced TNF-alpha secretion by macrophages is mediated without membrane insertion or endocytosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VASCULAR ENDOTHELIAL-CELLS; PROTEIN-KINASE-C; MANNOSE RECEPTOR; SIGNAL-TRANSDUCTION; TRYPANOSOMA-CRUZI; ANCHORS; BIOSYNTHESIS; EXPRESSION; PHAGOCYTOSIS; ACTIVATION	The glycosylphosphatidylinositols (GPIs) of Plasmodium falciparum are believed to contribute to the pathogenesis of malaria by inducing the secretion of proinflammatory cytokines by macrophages, Previous studies have shown that P, falciparum GPIs elicit toxic immune responses by protein tyrosine kinase (PTK)- and protein kinase C (PKC)-mediated cell signaling pathways, which are activated by the carbohydrate and acyl moieties of the intact GPIs, respectively. In this study, we show that induction of TNF-alpha by P, falciparum GPIs in macrophages is mediated by the recognition of the distal fourth mannose residue. This event is critical but not sufficient for the productive cell signaling; interaction by the acylglycerol moisty of GPIs is also required. These novel interactions are coupled to previously demonstrated PTK and PKC pathways, since the specific inhibitors of these kinases effectively blocked the GPI-induced TMF-alpha: production. Surprisingly, sn-2 lyso-GPIs were also able to elicit TNF-alpha secretion. Contrary to the prevailing notion, GPIs are neither inserted to the plasma membranes nor endocytosized, Thus, this study defines the GPI structural requirements and reveals a novel mechanism for the outside-in activation of cell signaling by P, falciparum GPIs in inducing proinflammatory responses.	Georgetown Univ, Med Ctr, Dept Biochem & Mol Biol, Washington, DC 20007 USA	Georgetown University	Gowda, DC (corresponding author), Georgetown Univ, Med Ctr, Dept Biochem & Mol Biol, 3900 Reservoir Rd NW, Washington, DC 20007 USA.		Vijay-Kumar, Matam/Q-8988-2019		NIAID NIH HHS [AI41139] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI041139] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Almeida IC, 2000, EMBO J, V19, P1476, DOI 10.1093/emboj/19.7.1476; Camargo MM, 1997, J IMMUNOL, V158, P5890; DRICKAMER K, 1994, MOL GLYCOBIOLOGY, P51; ENGLUND PT, 1993, ANNU REV BIOCHEM, V62, P121, DOI 10.1146/annurev.bi.62.070193.001005; Ferguson M. A. J., 1992, LIPID MODIFICATION P, P191; Ferguson MAJ, 1999, BBA-MOL BASIS DIS, V1455, P327, DOI 10.1016/S0925-4439(99)00058-7; Field MC, 1997, GLYCOBIOLOGY, V7, P161, DOI 10.1093/glycob/7.2.161-d; Gowda DC, 1997, J BIOL CHEM, V272, P6428, DOI 10.1074/jbc.272.10.6428; HERBERT E, 2000, BIOSCIENCE REP, V20, P213; Ilangumaran S, 1996, TRENDS CELL BIOL, V6, P163, DOI 10.1016/0962-8924(96)20012-1; JENSEN JB, 1978, AM J TROP MED HYG, V27, P1274, DOI 10.4269/ajtmh.1978.27.1274; LAMBROS C, 1979, J PARASITOL, V65, P418, DOI 10.2307/3280287; Linehan SA, 1999, J EXP MED, V189, P1961, DOI 10.1084/jem.189.12.1961; MCCONVILLE MJ, 1993, BIOCHEM J, V294, P305, DOI 10.1042/bj2940305; MENON AK, 1994, METHOD ENZYMOL, V230, P418; MILLER LH, 1993, MOL BIOCHEM PARASIT, V59, P1, DOI 10.1016/0166-6851(93)90002-F; Milne KG, 1999, J BIOL CHEM, V274, P1465, DOI 10.1074/jbc.274.3.1465; Murai M, 1996, IMMUNOLOGY, V89, P436, DOI 10.1046/j.1365-2567.1996.d01-765.x; MURAI M, 1995, J LEUKOCYTE BIOL, V57, P687, DOI 10.1002/jlb.57.4.687; Naik RS, 2000, J BIOL CHEM, V275, P24506, DOI 10.1074/jbc.M002151200; Naik RS, 2000, J EXP MED, V192, P1563, DOI 10.1084/jem.192.11.1563; Pays E, 1998, MOL BIOCHEM PARASIT, V91, P3, DOI 10.1016/S0166-6851(97)00183-7; Pereira-Chioccola VL, 1999, BIOCHEM SOC T, V27, P516, DOI 10.1042/bst0270516; RALTON JE, 1993, J BIOL CHEM, V268, P24183; Rowe JA, 1998, MOL BIOCHEM PARASIT, V92, P177, DOI 10.1016/S0166-6851(97)00237-5; Schofield L, 1996, J IMMUNOL, V156, P1886; Stahl PD, 1998, CURR OPIN IMMUNOL, V10, P50, DOI 10.1016/S0952-7915(98)80031-9; Tachado SD, 1996, J IMMUNOL, V156, P1897; Tachado SD, 1997, P NATL ACAD SCI USA, V94, P4022, DOI 10.1073/pnas.94.8.4022; Voth BR, 1998, MOL BIOCHEM PARASIT, V93, P31, DOI 10.1016/S0166-6851(98)00013-9; ZHANG F, 1992, P NATL ACAD SCI USA, V89, P5231, DOI 10.1073/pnas.89.12.5231	31	41	44	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 9	2001	276	10					6909	6912		10.1074/jbc.C100007200	http://dx.doi.org/10.1074/jbc.C100007200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	410MC	11152670	hybrid			2022-12-25	WOS:000167442900008
J	Copin, JC; Gasche, Y; Li, YB; Chan, PH				Copin, JC; Gasche, Y; Li, YB; Chan, PH			Prolonged hypoxia during cell development protects mature manganese superoxide dismutase-deficient astrocytes from damage by oxidative stress	FASEB JOURNAL			English	Article						paraquat; 8-oxo-7.8-dihydro-2 '-deoxyguanosine; mitochondria; adaptation; preconditioning	FREE-RADICAL THEORY; MAMMALIAN-CELLS; OXYGEN-TOXICITY; MUTANT MICE; SACCHAROMYCES-CEREVISIAE; KNOCKOUT MICE; SUSCEPTIBILITY; EXPRESSION; GENERATION; PHENOTYPE	Mouse astrocytes deficient in the mitochondrial form of superoxide dismutase do not grow in culture under 20% atmospheric O-2 levels, By flaw cytometry, immunocytochemistry, and enzymatic analysis we have shown that the oxygen block of cell division is due to a decrease in the number of cells entering the S phase of the cell cycle and is concomitant with higher DNA oxidation and impairment of mitochondrial functions. Seeding the cells under 5% O-2 until the cultures become confluent can circumvent this problem. An initial hypoxic environment increases the resistance of manganese superoxide dismutase-deficient astrocytes to superoxide radicals artificially produced by paraquat treatment, preserves respiratory activity, and allows normoxic division during a subsequent passage. DNA oxidation is then not higher than ill wild-type control cells. However, the adaptation of the cells is not due to compensation by other enzymes of the antioxidant defense system and is specific to cells totally lacking manganese superoxide dismutase, Alteration of the phenotype by prior hypoxia exposure in the SOD2-deficient mutant provide a unique model to study adaptative mechanisms of cellular resistance to oxygen toxicity.	Stanford Univ, Sch Med, Dept Neurosurg, Stanford, CA 94305 USA; Stanford Univ, Sch Med, Dept Neurol & Neurol Sci, Stanford, CA 94305 USA; Stanford Univ, Sch Med, Program Neurosci, Stanford, CA 94305 USA; Univ Calif San Francisco, Sch Med, Dept Neurol Surg, San Francisco, CA 94143 USA	Stanford University; Stanford University; Stanford University; University of California System; University of California San Francisco	Chan, PH (corresponding author), Stanford Univ, Neurosurg Labs, 1201 Welch Rd,MSLS P304, Stanford, CA 94305 USA.	phchan@leland.stanford.edu	Copin, Jean-Christophe/K-6890-2012		NINDS NIH HHS [NS36147, NS25372, NS14543] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS036147, P01NS014543, P50NS014543, R01NS025372] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALLEN RG, 1989, FREE RADICAL BIO MED, V6, P631, DOI 10.1016/0891-5849(89)90071-3; AMMENDOLA R, 1995, FEBS LETT, V371, P209, DOI 10.1016/0014-5793(95)00871-6; Barrientos A, 1999, J BIOL CHEM, V274, P16188, DOI 10.1074/jbc.274.23.16188; Beckman KB, 1998, PHYSIOL REV, V78, P547, DOI 10.1152/physrev.1998.78.2.547; Bohus B, 1998, PROG BRAIN RES, V119, P555; Brosche T, 1998, EXP GERONTOL, V33, P363, DOI 10.1016/S0531-5565(98)00014-X; BURDON RH, 1995, FREE RADICAL BIO MED, V18, P775, DOI 10.1016/0891-5849(94)00198-S; Cadet J, 1999, MUTAT RES-FUND MOL M, V424, P9, DOI 10.1016/S0027-5107(99)00004-4; Carden DL, 2000, J PATHOL, V190, P255, DOI 10.1002/(SICI)1096-9896(200002)190:3<255::AID-PATH526>3.0.CO;2-6; CHANCE B, 1979, PHYSIOL REV, V59, P527, DOI 10.1152/physrev.1979.59.3.527; CHURCH SL, 1993, P NATL ACAD SCI USA, V90, P3113, DOI 10.1073/pnas.90.7.3113; Crapo J D, 1978, Methods Enzymol, V53, P382; EGNER PA, 1985, CARCINOGENESIS, V6, P1167, DOI 10.1093/carcin/6.8.1167; FERNANDEZPOL JA, 1982, CANCER RES, V42, P609; Gerhold D, 1999, TRENDS BIOCHEM SCI, V24, P168, DOI 10.1016/S0968-0004(99)01382-1; Gingrich JR, 1998, ANNU REV NEUROSCI, V21, P377, DOI 10.1146/annurev.neuro.21.1.377; GOTO Y, 1992, FREE RADICAL BIO MED, V13, P47, DOI 10.1016/0891-5849(92)90165-D; Grisham MB, 1999, AM J PHYSIOL-GASTR L, V276, pG315, DOI 10.1152/ajpgi.1999.276.2.G315; GUIDOT DM, 1993, J BIOL CHEM, V268, P26699; HALLIWELL B, 1984, BIOCHEM J, V219, P1, DOI 10.1042/bj2190001; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; Huang TT, 1999, ANN NY ACAD SCI, V893, P95, DOI 10.1111/j.1749-6632.1999.tb07820.x; Huang TT, 1997, ARCH BIOCHEM BIOPHYS, V344, P424, DOI 10.1006/abbi.1997.0237; JOHNSON MH, 1994, BIOESSAYS, V16, P31, DOI 10.1002/bies.950160105; JUURLINK BHJ, 1992, NEUROMETHODS, V23, P269; KANE DJ, 1993, SCIENCE, V262, P1274, DOI 10.1126/science.8235659; KONG XJ, 1993, AM J PHYSIOL, V264, pL365, DOI 10.1152/ajplung.1993.264.4.L365; Kowaltowski AJ, 1999, FREE RADICAL BIO MED, V26, P463, DOI 10.1016/S0891-5849(98)00216-0; LAPINSKAS PJ, 1995, MOL CELL BIOL, V15, P1382; Lebovitz RM, 1996, P NATL ACAD SCI USA, V93, P9782, DOI 10.1073/pnas.93.18.9782; Lee JW, 1996, J BIOL CHEM, V271, P24885, DOI 10.1074/jbc.271.40.24885; LI YB, 1995, NAT GENET, V11, P376, DOI 10.1038/ng1295-376; Li YB, 1998, BRAIN RES, V814, P164, DOI 10.1016/S0006-8993(98)01082-8; Luck H., 1974, ESTIMATION CATALASE, V885; MANTHORPE M, 1986, DEV BRAIN RES, V25, P191, DOI 10.1016/0165-3806(86)90208-7; Melov S, 1999, P NATL ACAD SCI USA, V96, P846, DOI 10.1073/pnas.96.3.846; Murakami K, 1998, J NEUROSCI, V18, P205; MURRY CE, 1986, CIRCULATION, V74, P1124, DOI 10.1161/01.CIR.74.5.1124; ODONNELLTORMEY J, 1987, J EXP MED, V165, P500, DOI 10.1084/jem.165.2.500; PAGLIA DE, 1967, J LAB CLIN MED, V70, P158; STADTMAN ER, 1993, ANNU REV BIOCHEM, V62, P797, DOI 10.1146/annurev.bi.62.070193.004053; Stagliano NE, 1999, J CEREBR BLOOD F MET, V19, P757, DOI 10.1097/00004647-199907000-00005; Sun Y, 1996, FREE RADICAL BIO MED, V21, P335, DOI 10.1016/0891-5849(96)00109-8; Tomai F, 1999, CIRCULATION, V100, P559, DOI 10.1161/01.CIR.100.5.559; Tsan MF, 1998, AM J RESP CELL MOL, V19, P114, DOI 10.1165/ajrcmb.19.1.3066; UMAOKA Y, 1992, MOL REPROD DEV, V31, P28, DOI 10.1002/mrd.1080310106; VANLOON APGM, 1986, P NATL ACAD SCI USA, V83, P3820; Wiegand F, 1999, J CEREBR BLOOD F MET, V19, P1229, DOI 10.1097/00004647-199911000-00007; WIESE AG, 1995, ARCH BIOCHEM BIOPHYS, V318, P231, DOI 10.1006/abbi.1995.1225; Williams MD, 1998, J BIOL CHEM, V273, P28510, DOI 10.1074/jbc.273.43.28510; Woychik RP, 1998, MUTAT RES-FUND MOL M, V400, P3, DOI 10.1016/S0027-5107(98)00023-2; Yakes FM, 1997, P NATL ACAD SCI USA, V94, P514, DOI 10.1073/pnas.94.2.514; YU BP, 1994, PHYSIOL REV, V74, P139, DOI 10.1152/physrev.1994.74.1.139	53	16	16	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2001	15	2					525	534		10.1096/fj.00-0330com	http://dx.doi.org/10.1096/fj.00-0330com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	400LK	11156968				2022-12-25	WOS:000166872900034
J	Korff, T; Kimmina, S; Martiny-Baron, G; Augustin, HG				Korff, T; Kimmina, S; Martiny-Baron, G; Augustin, HG			Blood vessel maturation in a 3-dimensional spheroidal coculture model: direct contact with smooth muscle cells regulates endothelial cell quiescence and abrogates VEGF responsiveness	FASEB JOURNAL			English	Article						EC; SMC; spheroid; vascular; endothelial growth factor	PDGF-B; EXPRESSION; ANGIOGENESIS; DIFFERENTIATION; ANGIOPOIETIN-2; PERICYTES; BETA; CD34; RECRUITMENT; RECEPTOR	Paracrine interactions between endothelial cells (EC) and mural cells act as critical regulators of vessel wall assembly, vessel maturation and define a plasticity window for vascular remodeling. The present study was aimed at studying blood vessel maturation processes in a novel 3-dimensional spheroidal coculture system of EC and smooth muscle cells (SMC). Coculture spheroids differentiate spontaneously in a calcium-dependent manner to organize into a core of SMC and a surface layer of EC, thus mimicking the physiological assembly of blood vessels with surface lining EC and underlying mural cells. Coculture of EC with SMC induces a mature, quiescent EC phenotype as evidenced by 1) a significant increase in the number of junctional complexes of the EC surface layer, 2) a down-regulation of PDGF-B expression by cocultured EC, and 3) an increased resistance of EC to undergo apoptosis. Furthermore, EC cocultured with SMC become refractory to stimulation with VEGF (lack of CD34 expression on VEGF stimulation; inability to form capillary-like sprouts in a VEGF-dependent manner in a S-dimensional in gel angiogenesis assay). In contrast, costimulation with VEGF and Ang-2 induced sprouting angiogenesis originating from coculture spheroids consistent with a model of Ang-2-mediated vessel destabilization resulting in VEGF responsiveness. Ang-2 on its own was able to stimulate endothelial cells in the absence of Ang-l producing SMC, inducing lateral sheet migration as well as in gel sprouting angiogenesis. Taken together, the data establish the spheroidal EC/SMC system as a powerful cell. culture model to study paracrine interactions in the vessel wall and provide functional evidence for smooth muscle cell-mediated quiescence effects on endothelial cells.	Inst Mol Med, Tumor Biol Ctr, D-79106 Freiburg, Germany; Univ Gottingen, Sch Med, Dept Gynecol & Obstet, Cell Biol Lab, D-37075 Gottingen, Germany	University of Gottingen	Augustin, HG (corresponding author), Inst Mol Med, Tumor Biol Ctr, D-79106 Freiburg, Germany.		Augustin, Hellmut/AAA-5246-2020	Augustin, Hellmut/0000-0002-7173-4242				ALON T, 1995, NAT MED, V1, P1024, DOI 10.1038/nm1095-1024; ANTONELLIORLIDGE A, 1989, P NATL ACAD SCI USA, V86, P4544, DOI 10.1073/pnas.86.12.4544; AUGUSTIN HG, 1994, BIOESSAYS, V16, P901, DOI 10.1002/bies.950161208; Axel DI, 1997, J MOL CELL CARDIOL, V29, P2967, DOI 10.1006/jmcc.1997.0541; BAUMHUETER S, 1994, BLOOD, V84, P2554; Benjamin LE, 1997, P NATL ACAD SCI USA, V94, P8761, DOI 10.1073/pnas.94.16.8761; Benjamin LE, 1998, DEVELOPMENT, V125, P1591; BONIN LR, 1994, AM J PHYSIOL-HEART C, V267, pH1698, DOI 10.1152/ajpheart.1994.267.5.H1698; Carmeliet P, 2000, NAT MED, V6, P389, DOI 10.1038/74651; CARMELIET P, 2000, EXP CLIN REGULATION, P34; Cines DB, 1998, BLOOD, V91, P3527; DELIA D, 1993, BLOOD, V81, P1001; Fillinger MF, 1997, J SURG RES, V67, P169, DOI 10.1006/jsre.1996.4978; FINA L, 1990, BLOOD, V75, P2417; Gale NW, 1999, GENE DEV, V13, P1055, DOI 10.1101/gad.13.9.1055; Goede V, 1998, LAB INVEST, V78, P1385; Hanahan D, 1997, SCIENCE, V277, P48, DOI 10.1126/science.277.5322.48; Hellstrom M, 1999, DEVELOPMENT, V126, P3047; Hirschi KK, 1998, J CELL BIOL, V141, P805, DOI 10.1083/jcb.141.3.805; Kim I, 2000, CIRC RES, V86, P24, DOI 10.1161/01.RES.86.1.24; Korff T, 1998, J CELL BIOL, V143, P1341, DOI 10.1083/jcb.143.5.1341; Korff T, 1999, J CELL SCI, V112, P3249; Lindahl P, 1997, SCIENCE, V277, P242, DOI 10.1126/science.277.5323.242; Maisonpierre PC, 1997, SCIENCE, V277, P55, DOI 10.1126/science.277.5322.55; Mandriota SJ, 1998, CIRC RES, V83, P852, DOI 10.1161/01.RES.83.8.852; POWELL RJ, 1998, AM J PHYSIOL, V274, pH649; RISAU W, 1995, FASEB J, V9, P926, DOI 10.1096/fasebj.9.10.7615161; Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0; SATO Y, 1989, J CELL BIOL, V109, P309, DOI 10.1083/jcb.109.1.309; Stratmann A, 1998, AM J PATHOL, V153, P1459, DOI 10.1016/S0002-9440(10)65733-1; Suri C, 1996, CELL, V87, P1171, DOI 10.1016/S0092-8674(00)81813-9; Suri C, 1998, SCIENCE, V282, P468, DOI 10.1126/science.282.5388.468; Thurston G, 2000, NAT MED, V6, P460, DOI 10.1038/74725	33	286	316	5	49	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	FEB	2001	15	2					447	457		10.1096/fj.00-0139com	http://dx.doi.org/10.1096/fj.00-0139com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	400LK	11156960				2022-12-25	WOS:000166872900026
J	Vasile, E; Tomita, Y; Brown, LF; Kocher, O; Dvorak, HF				Vasile, E; Tomita, Y; Brown, LF; Kocher, O; Dvorak, HF			Differential expression of thymosin beta-10 by early passage and senescent vascular endothelium is modulated by VPF/VEGF: evidence for senescent endothelial cells in vivo at sites of atherosclerosis	FASEB JOURNAL			English	Article						cDNA arrays; lipoproteins; human aorta	LOW-DENSITY-LIPOPROTEIN; MACROPHAGE SCAVENGER RECEPTORS; GROWTH-FACTOR; IN-VIVO; REPLICATIVE SENESCENCE; MICROVASCULAR HYPERPERMEABILITY; TELOMERASE EXPRESSION; GENE OVEREXPRESSION; OXIDIZED LDL; ANGIOGENESIS	VPF/VEGF acts selectively on the vascular endothelium to enhance permeability, induce cell migration and division, and delay replicative senescence. To understand the changes in gene expression during endothelial senescence, we investigated genes that were differentially expressed in early vs, late passage (senescent) human dermal endothelial cells (HDMEC) using cDNA array hybridization, Early passage HDMEC cultured with or without VPF/VEGF overexpressed 9 and underexpressed 6 genes in comparison with their senescent counterparts. Thymosin beta -10 expression was modulated by VPF/VEGF and was strikingly down-regulated in senescent EC, The beta -thymosins are actin G-sequestering peptides that regulate actin dynamics and are overexpressed in neoplastic transformation. We have also identified senescent EC in the human aorta at sites overlying atherosclerotic plaques. These EC expressed senescence-associated neutral beta -galactosidase and, in contrast to adventitial microvessel endothelium, exhibited weak staining for thymosin beta -10. ISH performed on human malignant tumors revealed strong thymosin beta -10 expression in tumor blood vessels. This is the first report that T beta -10 expression is significantly reduced in senescent EC, that VPF/VEGF modulates thymosin beta -10 expression, and that EC can become senescent in vivo, The reduced expression of thymosin beta -10 may contribute to the senescent phenotype by reducing EC plasticity and thus impairing their response to migratory stimuli.	Beth Israel Deaconess Med Ctr, Dept Pathol, Boston, MA 02215 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School	Vasile, E (corresponding author), Beth Israel Deaconess Med Ctr, Dept Pathol, RN 280 D,330 Brookline Ave, Boston, MA 02215 USA.	evasile@caregroup.harvard.edu			NCI NIH HHS [CA-50453] Funding Source: Medline; NHLBI NIH HHS [HL-54465] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA050453] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL054465] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADES EW, 1992, J INVEST DERMATOL, V99, P683, DOI 10.1111/1523-1747.ep12613748; Arthur WT, 1998, MICROVASC RES, V55, P260, DOI 10.1006/mvre.1998.2078; ASHKENAS J, 1993, J LIPID RES, V34, P983; BILHEIMER DW, 1972, BIOCHIM BIOPHYS ACTA, V260, P212, DOI 10.1016/0005-2760(72)90034-3; BOND JA, 1995, CANCER RES, V55, P2404; BROWN LF, 1992, J EXP MED, V176, P1375, DOI 10.1084/jem.176.5.1375; BURRIG KF, 1991, ARTERIOSCLER THROMB, V11, P1678, DOI 10.1161/01.ATV.11.6.1678; Califano D, 1998, CANCER RES, V58, P823; Campisi J, 1996, EXP GERONTOL, V31, P7, DOI 10.1016/0531-5565(95)02024-1; Carpintero P, 1996, FEBS LETT, V394, P103, DOI 10.1016/0014-5793(96)00888-5; Chang BD, 1999, CANCER RES, V59, P3761; de Boer OJ, 1999, CARDIOVASC RES, V41, P443, DOI 10.1016/S0008-6363(98)00255-7; DENEKAMP J, 1990, CANCER METAST REV, V9, P267, DOI 10.1007/BF00046365; DETMAR M, 1990, J INVEST DERMATOL, V95, pS219, DOI 10.1111/1523-1747.ep12875807; DIMRI GP, 1994, COLD SPRING HARB SYM, V59, P67, DOI 10.1101/SQB.1994.059.01.010; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; Dvorak HF, 1999, CURR TOP MICROBIOL, V237, P97; DVORAK HF, 1995, AM J PATHOL, V146, P1029; GOLDSTEIN JL, 1983, METHOD ENZYMOL, V98, P241; HALL AK, 1995, CELL MOL BIOL RES, V41, P167; HALL AK, 1990, BRAIN RES MOL BRAIN, V8, P1291; Jiang XR, 1999, NAT GENET, V21, P111, DOI 10.1038/5056; Kraling BM, 1998, IN VITRO CELL DEV-AN, V34, P308; KRIEGER M, 1994, ANNU REV BIOCHEM, V63, P601, DOI 10.1146/annurev.bi.63.070194.003125; Levine E M, 1979, Int Rev Cytol Suppl, P67; Maier JAM, 1996, ATHEROSCLEROSIS, V123, P115, DOI 10.1016/0021-9150(95)05793-5; MAIER JAM, 1990, SCIENCE, V249, P1570, DOI 10.1126/science.2218499; MARKWELL MAK, 1978, ANAL BIOCHEM, V87, P206, DOI 10.1016/0003-2697(78)90586-9; Muruganandam A, 1997, FASEB J, V11, P1187, DOI 10.1096/fasebj.11.13.9367354; NEGRESALVAYRE A, 1992, FEBS LETT, V299, P60, DOI 10.1016/0014-5793(92)80101-L; PILI R, 1994, JNCI-J NATL CANCER I, V86, P1303, DOI 10.1093/jnci/86.17.1303; PITAS RE, 1990, J BIOL CHEM, V265, P12722; RAJAVASHISTH TB, 1990, NATURE, V344, P254, DOI 10.1038/344254a0; REDGRAVE TG, 1975, ANAL BIOCHEM, V65, P42, DOI 10.1016/0003-2697(75)90488-1; Rivard A, 1999, CIRCULATION, V99, P111, DOI 10.1161/01.CIR.99.1.111; Roth LWA, 1999, EUR J NEUROSCI, V11, P3488, DOI 10.1046/j.1460-9568.1999.00715.x; Santelli G, 1999, AM J PATHOL, V155, P799, DOI 10.1016/S0002-9440(10)65178-4; SENGER DR, 1993, CANCER METAST REV, V12, P303, DOI 10.1007/BF00665960; Shelton DN, 1999, CURR BIOL, V9, P939, DOI 10.1016/S0960-9822(99)80420-5; SHOLLEY MM, 1976, AM J ANAT, V147, P243, DOI 10.1002/aja.1001470208; Smith JR, 1996, SCIENCE, V273, P63, DOI 10.1126/science.273.5271.63; Steinberg D, 1997, J BIOL CHEM, V272, P20963, DOI 10.1074/jbc.272.34.20963; Sun HQ, 1996, J BIOL CHEM, V271, P9223, DOI 10.1074/jbc.271.16.9223; Vasile E, 1999, J HISTOCHEM CYTOCHEM, V47, P159, DOI 10.1177/002215549904700205; VASILE E, 1991, J SUBMICR CYTOL PATH, V23, P279; VASILE E, 1989, ATHEROSCLEROSIS, V75, P195, DOI 10.1016/0021-9150(89)90177-9; VASILE E, 1983, J CELL BIOL, V96, P1677, DOI 10.1083/jcb.96.6.1677; WANG E, 1995, CANCER RES, V55, P2284; Watanabe Y, 1997, ONCOGENE, V14, P2025, DOI 10.1038/sj.onc.1201033; Yang JW, 1999, J BIOL CHEM, V274, P26141, DOI 10.1074/jbc.274.37.26141; YU FX, 1994, CELL MOTIL CYTOSKEL, V27, P13, DOI 10.1002/cm.970270103; YU FX, 1993, J BIOL CHEM, V268, P502; Zhu WM, 1996, ARTERIOSCL THROM VAS, V16, P1104, DOI 10.1161/01.ATV.16.9.1104	53	177	190	0	10	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2001	15	2					458	466		10.1096/fj.00-0051com	http://dx.doi.org/10.1096/fj.00-0051com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	400LK	11156961				2022-12-25	WOS:000166872900027
J	Mashour, GA; Ratner, N; Khan, GA; Wang, HL; Martuza, RL; Kurtz, A				Mashour, GA; Ratner, N; Khan, GA; Wang, HL; Martuza, RL; Kurtz, A			The angiogenic factor midkine is aberrantly expressed in NF1-deficient Schwann cells and is a mitogen for neurofibroma-derived cells	ONCOGENE			English	Article						neurofibromatosis; midkine; pleiotrophin; schwann cells	FIBROBLAST GROWTH-FACTORS; TYPE-1 GENE-PRODUCT; DIFFERENTIAL EXPRESSION; ADULT-RAT; PLEIOTROPHIN; SURVIVAL; TUMORS; BRAIN; MOUSE; MK	Loss of the tumor suppressor gene NF1 in neurofibromatosis type 1 (NF1) contributes to the development of a variety of tumors, including malignant peripheral nerve sheath tumors (MPNST) and benign neurofibromas, Of the different cell types found in neurofibromas, Schwann cells usually provide between 40 and 80%, and are thought to be critical for tumor growth. Here we describe the identification of growth factors that are upregulated in NF1-/- mouse Schwann cells and are potential regulators of angiogenesis and cell growth. Basic fibroblast growth factor (FGF-2), platelet-derived growth factor (PDGF) and midkine (MK) were found to be induced by loss of neurofibromin and MK was further characterized. MK was induced in human neurofibromas, schwannomas, and various nervous system tumors associated with NF1 or NF2; midkine showed an expression pattern overlapping but distinct from its homolog pleiotrophin (PTN), Immunohistochemistry revealed expression of MK in S-100 positive Schwann cells of dermal and plexiform neurofibromas, and in endothelial cells of tumor blood vessels, but not in normal blood vessels, Furthermore, MK demonstrated potent mitogenic activity for human systemic and brain endothelial cells in vitro and stimulated proliferation and soft agar colony formation of human MPNST derived S100 positive cells and fibroblastoid cells derived from an NF1 neurofibroma, The data support a possible central role for MK as a mediator of angiogenesis and neurofibroma growth in NF1.	Harvard Univ, Sch Med, MGH, Charlestown, MA 02129 USA; Univ Cincinnati, Coll Med, Dept Cell Biol Neurobiol & Anat, Cincinnati, OH 45267 USA; Georgetown Univ, Sch Med, Dept Neurosurg, Vincent T Lombardi Canc Ctr, Washington, DC 20007 USA	Harvard University; University System of Ohio; University of Cincinnati; Georgetown University	Kurtz, A (corresponding author), Harvard Univ, Sch Med, MGH, Bldg 149,13th St, Charlestown, MA 02129 USA.			Kurtz, Andreas/0000-0003-3301-6546; RATNER, NANCY/0000-0001-5030-9354	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R29NS037895, R01NS028840] Funding Source: NIH RePORTER; NINDS NIH HHS [R01-NS28840, R29-NS37895] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Badache A, 1998, J CELL PHYSIOL, V177, P334, DOI 10.1002/(SICI)1097-4652(199811)177:2<334::AID-JCP15>3.0.CO;2-9; BERNARDS A, 1995, BBA-REV CANCER, V1242, P43, DOI 10.1016/0304-419X(95)00003-X; BLOCH B, 1992, DEV BRAIN RES, V70, P267, DOI 10.1016/0165-3806(92)90206-C; Carmeliet P, 2000, NATURE, V407, P249, DOI 10.1038/35025220; CHEN JK, 1991, J NEUROSCI RES, V30, P321, DOI 10.1002/jnr.490300207; Choudhuri R, 1997, CANCER RES, V57, P1814; COSTELLO P, 1990, J NEURO-ONCOL, V8, P231, DOI 10.1007/BF00177356; DECLUE JE, 1992, CELL, V69, P265, DOI 10.1016/0092-8674(92)90407-4; DECLUE JE, 1991, P NATL ACAD SCI USA, V88, P9914, DOI 10.1073/pnas.88.22.9914; Dugoff L, 1996, AM J MED GENET, V66, P7, DOI 10.1002/(SICI)1096-8628(19961202)66:1<7::AID-AJMG2>3.0.CO;2-R; Ferrara N, 1996, NATURE, V380, P439, DOI 10.1038/380439a0; Folkman J, 1995, NEW ENGL J MED, V333, P1757, DOI 10.1056/NEJM199512283332608; FRIESEL RE, 1995, FASEB J, V9, P919, DOI 10.1096/fasebj.9.10.7542215; GARVER RI, 1994, CANCER, V74, P1584, DOI 10.1002/1097-0142(19940901)74:5<1584::AID-CNCR2820740514>3.0.CO;2-V; GAVRILOVIC J, 1995, EUR J NEUROSCI, V7, P77, DOI 10.1111/j.1460-9568.1995.tb01022.x; GUTMANN DH, 1991, P NATL ACAD SCI USA, V88, P9658, DOI 10.1073/pnas.88.21.9658; GUTMANN DH, 1995, METABOLIC MOL BASES, P667; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; Ikematsu S, 2000, BRIT J CANCER, V83, P701, DOI 10.1054/bjoc.2000.1339; Iwasaki W, 1997, EMBO J, V16, P6936, DOI 10.1093/emboj/16.23.6936; Kadomatsu K, 1997, BRIT J CANCER, V75, P354, DOI 10.1038/bjc.1997.58; Kaname T, 1996, BIOCHEM BIOPH RES CO, V219, P256, DOI 10.1006/bbrc.1996.0214; Kaneda N, 1996, J BIOCHEM-TOKYO, V119, P1150; Kato S, 1999, J NEUROPATH EXP NEUR, V58, P430, DOI 10.1097/00005072-199905000-00002; KIKUCHI S, 1993, NEUROSCI LETT, V160, P9, DOI 10.1016/0304-3940(93)90904-Y; KIM HA, 1995, ONCOGENE, V11, P325; Kim HA, 1997, MOL CELL BIOL, V17, P862, DOI 10.1128/MCB.17.2.862; Kretschmer P J, 1991, Growth Factors, V5, P99, DOI 10.3109/08977199109000275; KURTZ A, 1994, DEVELOPMENT, V120, P2637; Kurtz A, 1995, CRIT REV ONCOGENESIS, V6, P151; Mashour GA, 1999, J INVEST DERMATOL, V113, P398, DOI 10.1046/j.1523-1747.1999.00699.x; MATSUMOTO K, 1994, NEUROSCI LETT, V178, P216, DOI 10.1016/0304-3940(94)90762-5; Milhiet PE, 1998, J ENDOCRINOL, V158, P389, DOI 10.1677/joe.0.1580389; Mishima K, 1997, NEUROSCI LETT, V233, P29, DOI 10.1016/S0304-3940(97)00619-8; NAKAGAWARA A, 1995, CANCER RES, V55, P1792; NAKAMOTO M, 1992, J BIOCHEM-TOKYO, V112, P346, DOI 10.1093/oxfordjournals.jbchem.a123903; OBrien T, 1996, CANCER RES, V56, P2515; Ohtani Y, 1999, INT J ONCOL, V15, P453; PANOSKALTSISMORTARI A, 1995, BIOTECHNIQUES, V18, P300; RATNER N, 1990, ANN NEUROL, V27, P298, DOI 10.1002/ana.410270312; Salvesen HB, 1999, INT J CANCER, V84, P539; SCHUBERT D, 1992, J NEUROBIOL, V23, P143, DOI 10.1002/neu.480230205; Schulte AM, 1996, P NATL ACAD SCI USA, V93, P14759, DOI 10.1073/pnas.93.25.14759; SHEELA S, 1990, J CELL BIOL, V111, P645, DOI 10.1083/jcb.111.2.645; TSUTSUI J, 1991, BIOCHEM BIOPH RES CO, V176, P792, DOI 10.1016/S0006-291X(05)80255-4; Tuszynski GP, 1996, BIOESSAYS, V18, P71, DOI 10.1002/bies.950180113; VANDERWINDEN JM, 1992, ANAT EMBRYOL, V186, P387; VOGEL KS, 1995, CELL, V82, P733, DOI 10.1016/0092-8674(95)90470-0; XU GF, 1990, CELL, V63, P835, DOI 10.1016/0092-8674(90)90149-9; Zhang N, 1999, Curr Opin Hematol, V6, P44, DOI 10.1097/00062752-199901000-00008; Zoller MET, 1997, CANCER-AM CANCER SOC, V79, P2125	51	99	106	0	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 4	2001	20	1					97	105		10.1038/sj.onc.1204026	http://dx.doi.org/10.1038/sj.onc.1204026			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	391NE	11244508				2022-12-25	WOS:000166361400011
J	McDonald, MC; Mota-Filipe, M; Paul, A; Cuzzocrea, S; Abdelrahman, M; Harwood, S; Plevin, R; Chatterjee, PK; Yaqoob, MM; Thiemermann, C				McDonald, MC; Mota-Filipe, M; Paul, A; Cuzzocrea, S; Abdelrahman, M; Harwood, S; Plevin, R; Chatterjee, PK; Yaqoob, MM; Thiemermann, C			Calpain inhibitor I reduces the activation of nuclear factor-kappa B and organ injury/dysfunction in hemorrhagic shock	FASEB JOURNAL			English	Article						calpain; cyclo-oxygenase; endotoxin; hemorrhage; multiple organ failure; nitric oxide; reperfusion injury	NITRIC-OXIDE SYNTHASE; NECROSIS-FACTOR-ALPHA; TRANSCRIPTION FACTOR; NEUTRAL PROTEASE; CYCLOOXYGENASE-2 EXPRESSION; CIRCULATORY FAILURE; BRIEF ISCHEMIA; RAT-HEART; PROTEOLYSIS; INDUCTION	There is limited evidence that inhibition of the activity of the cytosolic cysteine protease calpain reduces ischemia/reperfusion injury. The multiple organ injury associated with hemorrhagic shock is due at least in part to ischemia (during hemorrhage) and reperfusion (during resuscitation) of target organs. Here we investigate the effects of calpain inhibitor I on the organ injury (kidney, liver, pancreas, lung, intestine) and dysfunction (kidney) associated with hemorrhagic shock in the anesthetized rat. Hemorrhage and resuscitation with shed blood resulted in an increase in calpain activity (heart), activation of NF-kappaB (kidney), expression of iNOS and COX-2 (kidney), and the development of multiple organ injury and dysfunction, all of which were attenuated by calpain inhibitor I (10 mg/kg i.p.), administered 30 min prior to hemorrhage. Chymostatin, a serine protease inhibitor that does not prevent the activation of NF-kappaB, had no effect on the organ injury/failure caused by hemorrhagic shock. Pretreatment (for 1 h) of murine macrophages or rat aortic smooth muscle cells (activated with endotoxin) with calpain inhibitor I attenuated the binding of activated NF-kappaB to DNA and the degradation of I kappaB alpha, I kappaB alpha, and I kappaB epsilon. Selective inhibition of iNOS activity with L-NIL reduced the circulatory failure and liver injury, while selective inhibition of COX-2 activity with SC58635 reduced the renal dysfunction and liver injury caused by hemorrhagic shock. Thus, we provide evidence that the mechanisms by which calpain inhibitor I reduces the circulatory failure as well as the organ injury and dysfunction in hemorrhagic shock include I) inhibition of calpain activity, 2) inhibition of the activation of NF-kappaB and thus prevention of the expression of NF kappaB-dependent genes, 3) prevention of the expression of iNOS, and 4) prevention of the expression of COX-2. Inhibition of calpain activity may represent a novel therapeutic approach for the therapy of hemorrhagic shock.	St Bartholomews & Royal London Sch Med & Dent, William Harvey Res Inst, Dept Expt Med & Nephrol, London EC1M 6BQ, England; Univ Strathclyde, Dept Physiol & Pharmacol, SIBS, Glasgow G4 0NR, Lanark, Scotland; Univ Messina, Sch Med, Inst Pharmacol, I-98123 Messina, Italy	University of London; Queen Mary University London; University of Strathclyde; University of Messina	Thiemermann, C (corresponding author), St Bartholomews & Royal London Sch Med & Dent, William Harvey Res Inst, Dept Expt Med & Nephrol, Charterhouse Sq, London EC1M 6BQ, England.	c.thiemermann@mds.qmw.ac.uk	Mota-Filipe, Helder/M-6298-2013	Mota-Filipe, Helder/0000-0003-3045-2553; Paul, Andrew/0000-0001-5775-2332; Thiemermann, Christoph/0000-0003-4228-9722; Plevin, Robin/0000-0002-7849-1220				APPLEBY SB, 1994, BIOCHEM J, V302, P723, DOI 10.1042/bj3020723; ATSMA DE, 1995, CIRC RES, V76, P1071, DOI 10.1161/01.RES.76.6.1071; BAEUERLE PA, 1988, CELL, V53, P211, DOI 10.1016/0092-8674(88)90382-0; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; BARTUS RT, 1995, NEUROL RES, V17, P249, DOI 10.1080/01616412.1995.11740322; BAUE AE, 1993, PATHOPHYSIOLOGY SHOC, P1004; BROWN K, 1993, P NATL ACAD SCI USA, V90, P2532, DOI 10.1073/pnas.90.6.2532; Crofford LJ, 1997, ARTHRITIS RHEUM-US, V40, P226, DOI 10.1002/art.1780400207; Cryer HG, 1997, SHOCK, V8, P26, DOI 10.1097/00024382-199707000-00005; Cuzzocrea S, 1998, FREE RADICAL BIO MED, V24, P450, DOI 10.1016/S0891-5849(97)00280-3; Demetriades D, 1999, J TRAUMA, V46, P667, DOI 10.1097/00005373-199904000-00018; EDELSTEIN CL, 1995, P NATL ACAD SCI USA, V92, P7662, DOI 10.1073/pnas.92.17.7662; ERTEL W, 1992, ARCH SURG-CHICAGO, V127, P70; FENG L, 1995, J CLIN INVEST, V95, P1669, DOI 10.1172/JCI117842; GRISCAVAGE JM, 1995, BIOCHEM BIOPH RES CO, V215, P721, DOI 10.1006/bbrc.1995.2523; Griscavage JM, 1996, P NATL ACAD SCI USA, V93, P3308, DOI 10.1073/pnas.93.8.3308; HENKEL T, 1993, NATURE, V365, P182, DOI 10.1038/365182a0; HEWETT JA, 1993, AM J PHYSIOL, V265, pG1011, DOI 10.1152/ajpgi.1993.265.6.G1011; IIZUKA K, 1991, BIOCHEM MED METAB B, V46, P427, DOI 10.1016/0885-4505(91)90091-X; IIZUKA K, 1992, JPN HEART J, V33, P707; Iwamoto H, 1999, J CARDIOVASC PHARM, V33, P580, DOI 10.1097/00005344-199904000-00010; Kampfl A, 1997, J NEUROTRAUM, V14, P121, DOI 10.1089/neu.1997.14.121; Kengatharan M, 1996, BRIT J PHARMACOL, V117, P1163, DOI 10.1111/j.1476-5381.1996.tb16711.x; Kohli V, 1999, GASTROENTEROLOGY, V116, P168, DOI 10.1016/S0016-5085(99)70241-6; Kohli V, 1997, P NATL ACAD SCI USA, V94, P9354, DOI 10.1073/pnas.94.17.9354; Leach M, 1998, BRIT J PHARMACOL, V124, P586, DOI 10.1038/sj.bjp.0701869; LEE KS, 1991, P NATL ACAD SCI USA, V88, P7233, DOI 10.1073/pnas.88.16.7233; LIN YC, 1995, P NATL ACAD SCI USA, V92, P552, DOI 10.1073/pnas.92.2.552; Liu ZQ, 1996, FEBS LETT, V385, P109, DOI 10.1016/0014-5793(96)00360-2; Markgraf CG, 1998, STROKE, V29, P152, DOI 10.1161/01.STR.29.1.152; MATSUMURA Y, 1993, J CARDIOVASC PHARM, V22, P135, DOI 10.1097/00005344-199307000-00021; MELLONI E, 1989, TRENDS NEUROSCI, V12, P438, DOI 10.1016/0166-2236(89)90093-3; Milligan SA, 1996, ARCH BIOCHEM BIOPHYS, V335, P388, DOI 10.1006/abbi.1996.9998; Morgan WM, 1998, NEW HORIZ-SCI PRACT, V6, P150; Mota-Filipe H, 1999, SHOCK, V12, P255, DOI 10.1097/00024382-199910000-00002; Paul A, 1997, BRIT J PHARMACOL, V120, P1439, DOI 10.1038/sj.bjp.0701070; Plevin R, 1996, BIOCHEM J, V318, P657, DOI 10.1042/bj3180657; PONTREMOLI S, 1988, P NATL ACAD SCI USA, V85, P1740, DOI 10.1073/pnas.85.6.1740; RAMI A, 1993, BRAIN RES, V609, P67, DOI 10.1016/0006-8993(93)90856-I; Regel G, 1996, WORLD J SURG, V20, P422, DOI 10.1007/s002689900067; Ruetten H, 1997, BRIT J PHARMACOL, V121, P695, DOI 10.1038/sj.bjp.0701180; SAIDO TC, 1994, FASEB J, V8, P814, DOI 10.1096/fasebj.8.11.8070630; SASAKI T, 1984, J BIOL CHEM, V259, P2489; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; SEUBERT P, 1989, BRAIN RES, V492, P366, DOI 10.1016/0006-8993(89)90921-9; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; SIROIS J, 1993, J BIOL CHEM, V268, P12199; Sorimachi Y, 1997, J BIOCHEM-TOKYO, V122, P743; SZABO C, 1994, SHOCK, V2, P145, DOI 10.1097/00024382-199408000-00011; THIEMERMANN C, 1993, P NATL ACAD SCI USA, V90, P267, DOI 10.1073/pnas.90.1.267; THIEMERMANN C, 1995, BRIT J PHARMACOL, V116, P2845, DOI 10.1111/j.1476-5381.1995.tb15935.x; TODA G, 1989, JPN HEART J, V30, P375; Wang KKW, 1996, P NATL ACAD SCI USA, V93, P6687, DOI 10.1073/pnas.93.13.6687; WANG KKW, 1994, TRENDS PHARMACOL SCI, V15, P412, DOI 10.1016/0165-6147(94)90090-6; Wray GM, 1998, SHOCK, V9, P329, DOI 10.1097/00024382-199805000-00003; XIE QW, 1994, J BIOL CHEM, V269, P4705; Yamamoto K, 1995, J BIOL CHEM, V270, P31315, DOI 10.1074/jbc.270.52.31315; YOSHIDA K, 1993, BIOCHIM BIOPHYS ACTA, V1182, P215, DOI 10.1016/0925-4439(93)90143-O; YOSHIDA K, 1995, CIRC RES, V77, P603, DOI 10.1161/01.RES.77.3.603	59	100	117	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2001	15	1					171	186		10.1096/fj.99-0645com	http://dx.doi.org/10.1096/fj.99-0645com			16	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	390TH	11149905				2022-12-25	WOS:000166312400026
J	Rosenberg, C; Van Gurp, RJHLM; Geelen, E; Oosterhuis, JW; Looijenga, LHJ				Rosenberg, C; Van Gurp, RJHLM; Geelen, E; Oosterhuis, JW; Looijenga, LHJ			Overrepresentation of the short arm of chromosome 12 is related to invasive growth of human testicular seminomas and nonseminomas	ONCOGENE			English	Article						seminomas; nonseminomas; carcinoma in situ; 12p; gain	GERM-CELL TUMORS; COMPARATIVE GENOMIC HYBRIDIZATION; MOLECULAR CYTOGENETIC ANALYSIS; IN-SITU HYBRIDIZATION; CARCINOMA-INSITU; TESTIS; IDENTIFICATION; AMPLIFICATION; CANCER; PLOIDY	Overrepresentation of 12p-sequences, mostly due to isochromosome formation, is the only consistent chromosomal alteration found in invasive testicular germ cell tumors of adolescents and young adults (TGCTs), both seminomas and the various histological elenlents of nonseminomas, The biological role of extra 12p in the pathogenesis of this cancer is unclear, and it is also unknown so far, whether it is an early event, i,e,, already present in carcinoma ill situ, or related to invasive growth. Using comparative genomic hybridization (CGH) with DOP-PCR amplified DNA isolated from micro-dissected tumor cells, and double fluorescent in situ hybridization (FISH) on frozen tissue sections, we investigated the presence of overrepresentation of 12p sequences in different development stages of four seminomas and seven nonseminomas, in total 17 invasive components, in addition to the carcinoma in situ of each. CGH demonstrated relative gain of 12p-sequences in all invasive components except one, confirmed by FISH in most samples. In contrast, no gain was found in the carcinoma in situ samples by any of the methods. These findings show that overrepresentation of 12p is not an early event in the development of TGCTs, but relates to invasive growth.	Univ Rotterdam Hosp Daniel, Pathol Lab Expt Patho Oncol, Josephine Nefkens Inst, NL-3000 DR Rotterdam, Netherlands; Leiden Univ, Med Ctr, Dept Cytochem & Cytometry, Leiden, Netherlands	Erasmus University Rotterdam; Erasmus MC; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC	Looijenga, LHJ (corresponding author), Univ Rotterdam Hosp Daniel, Pathol Lab Expt Patho Oncol, Josephine Nefkens Inst, FGG EUR Bldg Be,Room 430B,POB 1738, NL-3000 DR Rotterdam, Netherlands.		Looijenga, Leendert/B-8145-2019; rosenberg, carla/N-4148-2015	Looijenga, Leendert/0000-0002-8146-1911; rosenberg, carla/0000-0003-3253-4448				ADAMI HO, 1994, INT J CANCER, V59, P33, DOI 10.1002/ijc.2910590108; ATKIN NB, 1982, LANCET, V2, P1349; DEGRAAFF WE, 1992, LAB INVEST, V66, P166; GONDOS B, 1993, EUR UROL, V23, P68; JORGENSEN N, 1995, LAB INVEST, V72, P223; KORN MW, 1996, GENE CHROMOSOME CANC, V17, P8; LOOIJENGA LHJ, 1990, CYTOGENET CELL GENET, V53, P216, DOI 10.1159/000132934; Looijenga LHJ, 1999, REV REPROD, V4, P90, DOI 10.1530/ror.0.0040090; Looijenga LHJ, 2000, J PATHOL, V191, P187, DOI 10.1002/(SICI)1096-9896(200006)191:2<187::AID-PATH584>3.0.CO;2-T; MOLLER H, 1989, J NATL CANCER I, V81, P1668, DOI 10.1093/jnci/81.21.1668-a; Mosselman S, 1996, P NATL ACAD SCI USA, V93, P2884, DOI 10.1073/pnas.93.7.2884; Mostert MC, 1998, ONCOGENE, V16, P2617, DOI 10.1038/sj.onc.1201787; Mostert MMC, 1996, CANCER GENET CYTOGEN, V87, P95, DOI 10.1016/0165-4608(95)00233-2; OOSTERHUIS JW, 1989, LAB INVEST, V60, P14; Ottesen AM, 1997, GENE CHROMOSOME CANC, V20, P412; RODRIGUEZ E, 1993, GENE CHROMOSOME CANC, V8, P230, DOI 10.1002/gcc.2870080405; Roelofs H, 2000, AM J PATHOL, V157, P1155, DOI 10.1016/S0002-9440(10)64631-7; Rosenberg C, 1999, LAB INVEST, V79, P1447; Rosenberg C, 1998, CYTOMETRY, V32, P337, DOI 10.1002/(SICI)1097-0320(19980801)32:4<337::AID-CYTO11>3.3.CO;2-9; Sandberg AA, 1996, J UROLOGY, V155, P1531, DOI 10.1016/S0022-5347(01)66124-X; SKAKKEBAEK NE, 1987, INT J ANDROL, V10, P19, DOI 10.1111/j.1365-2605.1987.tb00161.x; SUIJKERBUIJK RF, 1993, CANCER GENET CYTOGEN, V70, P85, DOI 10.1016/0165-4608(93)90173-J; SUIJKERBUIJK RF, 1994, CANCER GENET CYTOGEN, V78, P145, DOI 10.1016/0165-4608(94)90082-5; Summersgill B, 1998, BRIT J CANCER, V77, P305, DOI 10.1038/bjc.1998.47; TELENIUS H, 1992, GENOMICS, V13, P718, DOI 10.1016/0888-7543(92)90147-K; vanEchten J, 1997, CANCER GENET CYTOGEN, V96, P1; VANECHTENARENDS J, 1994, CANCER GENET CYTOGEN, V77, P194; VANKESSEL AG, 1989, CANCER GENET CYTOGEN, V40, P129, DOI 10.1016/0165-4608(89)90154-4; VORECHOVSKY I, 1989, NEOPLASMA, V36, P697; VOS A, 1990, CANCER GENET CYTOGEN, V46, P75, DOI 10.1016/0165-4608(90)90011-X; [No title captured]	31	105	109	0	3	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 30	2000	19	51					5858	5862		10.1038/sj.onc.1203950	http://dx.doi.org/10.1038/sj.onc.1203950			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	378CA	11127816				2022-12-25	WOS:000165563100004
J	Yu, ZK; Geyer, RK; Maki, CG				Yu, ZK; Geyer, RK; Maki, CG			MDM2-dependent ubiquitination of nuclear and cytoplasmic P53	ONCOGENE			English	Article						p53; MDM2; ubiquitination; nuclear export	PROTEIN; DEGRADATION; LOCALIZATION; DOMAIN; COMPLEX; FORMS; HDM2; SITE	Wild-type p53 is stabilized and accumulates in the nucleus of DNA damaged cells. The effect of stabilizing p53 is to inhibit cell growth, either through a G1 cell cycle arrest or apoptotic cell death. MDM2 can inhibit p53 activity, in part, by promoting its rapid degradation through the ubiquitin proteolysis pathway, In the current study, MDM2-mediated degradation of p53 was partially inhibited in cells treated with leptomycin B (LMB), a specific inhibitor of nuclear export. In contrast, levels of ubiquitinated p53 increased in LMB-treated cells, indicating that nuclear export is not required for p53 ubiquitination, To investigate this further, p53 mutants were generated which localize to either the nucleus or cytoplasm, and their susceptibility to MDM2-mediated ubiquitination was assessed. p53 mutants that localized to either the nucleus or the cytoplasm were efficiently ubiquitinated, and their steady-state levels decreased, when coexpressed with MDM2, In addition, an MDM2-mutant that localized to the cytoplasm was able to ubiquitinate and degrade a p53 mutant which was similarly localized in the cytoplasm, Our results indicate that nuclear export is not required for p53 ubiquitination, and that p53 proteins that localize to either the nucleus or cytoplasm can be ubiquitinated and degraded by MDM2.	Harvard Univ, Sch Publ Hlth, Dept Canc Cell Biol, Boston, MA 02115 USA	Harvard University; Harvard T.H. Chan School of Public Health	Maki, CG (corresponding author), Harvard Univ, Sch Publ Hlth, Dept Canc Cell Biol, Boston, MA 02115 USA.							AbouElela S, 1997, CANCER LETT, V117, P23, DOI 10.1016/S0304-3835(97)00196-1; Boyd SD, 2000, NAT CELL BIOL, V2, P563, DOI 10.1038/35023500; DavidPfeuty T, 1996, CELL GROWTH DIFFER, V7, P1211; Dobbelstein M, 1999, ONCOGENE, V18, P2101, DOI 10.1038/sj.onc.1202512; Fontoura BMA, 1997, MOL CELL BIOL, V17, P3146, DOI 10.1128/MCB.17.6.3146; Freedman DA, 1998, MOL CELL BIOL, V18, P7288, DOI 10.1128/MCB.18.12.7288; Fuchs SY, 1998, ONCOGENE, V17, P2543, DOI 10.1038/sj.onc.1202200; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; Geyer RK, 2000, NAT CELL BIOL, V2, P569, DOI 10.1038/35023507; Guerra B, 1998, FEBS LETT, V434, P115, DOI 10.1016/S0014-5793(98)00962-4; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; HUBBERT NL, 1992, J VIROL, V66, P6237, DOI 10.1128/JVI.66.10.6237-6241.1992; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Liang SH, 1998, J BIOL CHEM, V273, P19817, DOI 10.1074/jbc.273.31.19817; Liang SH, 1999, ONCOGENE, V18, P2163, DOI 10.1038/sj.onc.1202350; Maki CG, 1996, CANCER RES, V56, P2649; Maki CG, 1999, J BIOL CHEM, V274, P16531, DOI 10.1074/jbc.274.23.16531; Maki CG, 1997, MOL CELL BIOL, V17, P355, DOI 10.1128/MCB.17.1.355; MALTZMAN W, 1984, MOL CELL BIOL, V4, P1689, DOI 10.1128/MCB.4.9.1689; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; PIETENPOL JA, 1994, P NATL ACAD SCI USA, V91, P1998, DOI 10.1073/pnas.91.6.1998; Roth J, 1998, EMBO J, V17, P554, DOI 10.1093/emboj/17.2.554; SHAULSKY G, 1990, MOL CELL BIOL, V10, P6565, DOI 10.1128/MCB.10.12.6565; Stommel JM, 1999, EMBO J, V18, P1660, DOI 10.1093/emboj/18.6.1660; Tao WK, 1999, P NATL ACAD SCI USA, V96, P3077, DOI 10.1073/pnas.96.6.3077	29	87	88	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 30	2000	19	51					5892	5897		10.1038/sj.onc.1203980	http://dx.doi.org/10.1038/sj.onc.1203980			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	378CA	11127820				2022-12-25	WOS:000165563100008
J	Sheng, YH; Reddel, SW; Herzog, H; Wang, YX; Brighton, T; France, MP; Robertson, SA; Krilis, SA				Sheng, YH; Reddel, SW; Herzog, H; Wang, YX; Brighton, T; France, MP; Robertson, SA; Krilis, SA			Impaired thrombin generation in beta(2)-glycoprotein I null mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOTHELIAL-CELLS; BETA-2-GLYCOPROTEIN-I; ANTICOAGULANT; INHIBITOR; BINDING	Autoimmune antibodies to beta (2)-glycoprotein I (beta 2GPI) have been proposed to be clinically relevant because of their strong association with thrombosis, miscarriage, and thrombocytopenia, By using a homologous recombination approach, beta 2GPI-null mice were generated to begin to understand the physiologic and pathologic role of this prominent plasma protein in mammals. When beta 2GPI heterozygotes on a 129/Sv/C57BL/6 mixed genetic background were intercrossed, only 8.9% of the resulting 336 offspring possessed both disrupted alleles, These data suggest that beta 2GPI plays a beneficial role in implantation and/or fetal development in at least some mouse strains. Although those beta 2GPI-null mice that were born appeared to be relatively normal anatomically and histologically, subsequent analysis revealed that they possessed an impaired in vitro ability to generate thrombin relative to wild type mice. Thus, beta 2GPI also appears to play an important role in thrombin-mediated coagulation.	Univ New S Wales, Dept Immunol Allergy & Infect Dis, St George Hosp, Kogarah, NSW 2217, Australia; Univ New S Wales, Dept Med, St George Hosp, Kogarah, NSW 2217, Australia; Univ New S Wales, Dept Haematol, St George Hosp, Kogarah, NSW 2217, Australia; St Vincents Hosp, Garvan Inst Med Res, Darlinghurst, NSW 2010, Australia; Univ Sydney, Dept Vet Anat & Pathol, Sydney, NSW 2006, Australia; Univ Adelaide, Dept Obstet & Gynaecol, Adelaide, SA 5005, Australia; Univ Adelaide, Reprod Med Unit, Adelaide, SA 5005, Australia	St George Hospital; University of New South Wales Sydney; St George Hospital; University of New South Wales Sydney; St George Hospital; University of New South Wales Sydney; Garvan Institute of Medical Research; St Vincents Hospital Sydney; University of Sydney; University of Adelaide; University of Adelaide	Krilis, SA (corresponding author), Univ New S Wales, Dept Immunol Allergy & Infect Dis, St George Hosp, South St, Kogarah, NSW 2217, Australia.	s.krilis@unsw.edu.au	Robertson, Sarah A/C-8182-2009; sheng, yong H/C-5052-2013; Herzog, Herbert/B-8294-2008	Robertson, Sarah A/0000-0002-9967-0084; sheng, yong H/0000-0002-4623-9098; Reddel, Stephen/0000-0002-0169-3350				Balasubramanian K, 1998, J BIOL CHEM, V273, P29272, DOI 10.1074/jbc.273.44.29272; BANCSI LFJMM, 1992, THROMB HAEMOSTASIS, V67, P649; Del Papa N, 1998, J IMMUNOL, V160, P5572; EXNER T, 1978, BRIT J HAEMATOL, V40, P143, DOI 10.1111/j.1365-2141.1978.tb03648.x; GINSBERG JS, 1993, BLOOD, V81, P2958; HANLY JG, 1998, LUPUS, V7, P219; HOEG JM, 1985, ATHEROSCLEROSIS, V55, P25, DOI 10.1016/0021-9150(85)90163-7; Kandiah DA, 1998, ADV IMMUNOL, V70, P507, DOI 10.1016/S0065-2776(08)60393-4; KONTGEN F, 1993, METHOD ENZYMOL, V225, P878; Ma KY, 2000, J BIOL CHEM, V275, P15541, DOI 10.1074/jbc.275.20.15541; Matsuura E, 1998, LUPUS, V7, pS135, DOI 10.1177/096120339800700230; Mori T, 1996, THROMB HAEMOSTASIS, V75, P49; NIMPF J, 1987, ATHEROSCLEROSIS, V63, P109, DOI 10.1016/0021-9150(87)90110-9; POLTZ E, 1979, FEBS LETT, V102, P183; Rand MD, 1996, BLOOD, V88, P3432, DOI 10.1182/blood.V88.9.3432.bloodjournal8893432; Rosen ED, 1997, NATURE, V390, P290, DOI 10.1038/36862; SCHOUSBOE I, 1985, BLOOD, V66, P1086; Sheng YH, 1997, GENOMICS, V41, P128, DOI 10.1006/geno.1997.4610; THIAGARAJAN P, 1980, J CLIN INVEST, V66, P397, DOI 10.1172/JCI109869; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M	20	67	68	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 27	2001	276	17					13817	13821		10.1074/jbc.M010990200	http://dx.doi.org/10.1074/jbc.M010990200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	426PB	11145969	hybrid			2022-12-25	WOS:000168356600045
J	Innamorati, G; Le Gouill, C; Balamotis, M; Birnbaumer, M				Innamorati, G; Le Gouill, C; Balamotis, M; Birnbaumer, M			The long and the short cycle - Alternative intracellular routes for trafficking of G-protein-coupled receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							V2 VASOPRESSIN RECEPTOR; INDUCED INTERNALIZATION; TRANSFERRIN RECEPTOR; MEDIATED ENDOCYTOSIS; PHOSPHORYLATION; CELLS; RESENSITIZATION; COMPLEXES; ENDOSOMES; PATHWAYS	The C terminus of the human V2 vasopressin receptor contains multiple phosphorylation sites including a cluster of amino acids that when phosphorylated prevents the return of the internalized receptor to the cell surface. To identify the step where the recycling process was interrupted, the trafficking of the V2 receptor was compared with that of the recycling Via receptor after exposure to ligand, Initially, both receptors internalized in small peripheral endosomes, but a physical separation of their endocytic pathways was subsequently detected. The Via receptor remained evenly distributed throughout the cytosol, whereas the V2 receptor accumulated in a large aggregation of vesicles in the proximity of the nucleus where it colocalized with the transferrin receptor and Rab11, a small GTP-binding protein that is concentrated in the perinuclear recycling compartment; only marginal colocalization of Rab11 with the Via receptor was observed. Thus, the V2 receptor was sequestered in the perinuclear recycling compartment, Targeting to the perinuclear recycling compartment was determined by the receptor subtype and not by the inability to recycle, since the mutation S363A in the phosphorylation-dependent retention signal generated a Va receptor that was recycled via the same compartment, The perinuclear recycling compartment was enriched in p-arrestin after internalization of either wild type V2 receptor or its recycling mutant, indicating that long term interaction between the receptors and arrestin was not responsible for the intracellular retention. Thus, the fully phosphorylated retention domain overrides the natural tendency of the V2 receptor to recycle and, by preventing its exit from the perinuclear recycling compartment, interrupts its transit via the "long cycle." The data suggest that the inactivation of the domain, possibly by dephosphorylation, triggers the return of the receptor from the perinuclear compartment to the plasma membrane.	Univ Calif Los Angeles, Sch Med, Dept Anesthesiol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Sch Med, Dept Physiol, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Birnbaumer, M (corresponding author), Univ Calif Los Angeles, Sch Med, Dept Anesthesiol, Los Angeles, CA 90095 USA.		Innamorati, Giulio/GVU-1941-2022; Innamorati, Giulio/AAR-6314-2020	Innamorati, Giulio/0000-0003-0123-8777	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK041244] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-41-244] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bremnes T, 2000, J BIOL CHEM, V275, P17596, DOI 10.1074/jbc.M000142200; Cao TT, 1998, J BIOL CHEM, V273, P24592, DOI 10.1074/jbc.273.38.24592; CHUN MY, 1994, P NATL ACAD SCI USA, V91, P11728, DOI 10.1073/pnas.91.24.11728; Claing A, 2000, P NATL ACAD SCI USA, V97, P1119, DOI 10.1073/pnas.97.3.1119; Daro E, 1996, P NATL ACAD SCI USA, V93, P9559, DOI 10.1073/pnas.93.18.9559; Gaudriault G, 1997, J BIOL CHEM, V272, P2880, DOI 10.1074/jbc.272.5.2880; GORBULEV V, 1993, EUR J BIOCHEM, V215, P1, DOI 10.1111/j.1432-1033.1993.tb18000.x; Hasbi A, 2000, J PHARMACOL EXP THER, V293, P237; HOPKINS CR, 1990, NATURE, V346, P335, DOI 10.1038/346335a0; Innamorati G, 1998, J BIOL CHEM, V273, P7155, DOI 10.1074/jbc.273.12.7155; Innamorati G, 1996, MOL PHARMACOL, V50, P467; Innamorati G, 1997, J BIOL CHEM, V272, P2486; Innamorati G, 1999, J RECEPT SIGNAL TR R, V19, P315, DOI 10.3109/10799899909036654; Innamorati G, 1998, P NATL ACAD SCI USA, V95, P2222, DOI 10.1073/pnas.95.5.2222; Krisch B, 1998, J HISTOCHEM CYTOCHEM, V46, P1233, DOI 10.1177/002215549804601103; Krueger KM, 1997, J BIOL CHEM, V272, P5; Lin FB, 2000, J BIOL CHEM, V275, P19025, DOI 10.1074/jbc.275.25.19025; Liu J, 1996, J BIOL CHEM, V271, P8772, DOI 10.1074/jbc.271.15.8772; LUTZ W, 1990, P NATL ACAD SCI USA, V87, P6507, DOI 10.1073/pnas.87.17.6507; MCGRAW TE, 1987, J CELL BIOL, V105, P207, DOI 10.1083/jcb.105.1.207; Morrison KJ, 1996, MOL PHARMACOL, V50, P692; Oakley RH, 1999, J BIOL CHEM, V274, P32248, DOI 10.1074/jbc.274.45.32248; Oakley RH, 2000, J BIOL CHEM, V275, P17201, DOI 10.1074/jbc.M910348199; OHGURO H, 1993, BIOCHEMISTRY-US, V32, P5718, DOI 10.1021/bi00072a030; Pfeiffer R, 1998, EXP CELL RES, V244, P327, DOI 10.1006/excr.1998.4159; PROSSNITZ ER, 1995, J BIOL CHEM, V270, P1130, DOI 10.1074/jbc.270.3.1130; RAPOSO G, 1989, EUR J CELL BIOL, V50, P340; Ren MD, 1998, P NATL ACAD SCI USA, V95, P6187, DOI 10.1073/pnas.95.11.6187; ROETTGER BF, 1995, J CELL BIOL, V128, P1029, DOI 10.1083/jcb.128.6.1029; Shih ML, 1999, J BIOL CHEM, V274, P1588, DOI 10.1074/jbc.274.3.1588; TOOZE J, 1992, J CELL BIOL, V118, P813, DOI 10.1083/jcb.118.4.813; Trejo J, 1999, J BIOL CHEM, V274, P2216, DOI 10.1074/jbc.274.4.2216; Trischler M, 1999, J CELL SCI, V112, P4773; Tsao PI, 2000, J BIOL CHEM, V275, P11130, DOI 10.1074/jbc.275.15.11130; Ullrich O, 1996, J CELL BIOL, V135, P913, DOI 10.1083/jcb.135.4.913; YAMASHIRO DJ, 1984, CELL, V37, P789, DOI 10.1016/0092-8674(84)90414-8; Zhang J, 1997, RECEPTOR CHANNEL, V5, P193	37	133	133	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 20	2001	276	16					13096	13103		10.1074/jbc.M009780200	http://dx.doi.org/10.1074/jbc.M009780200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	423VN	11150299	hybrid			2022-12-25	WOS:000168198600089
J	Kresse, H; Seidler, DG; Muller, M; Breuer, E; Hausser, H; Roughley, PJ; Schonherr, E				Kresse, H; Seidler, DG; Muller, M; Breuer, E; Hausser, H; Roughley, PJ; Schonherr, E			Different usage of the glycosaminoglycan attachment sites of biglycan	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEUCINE-RICH REPEAT; DERMATAN SULFATE PROTEOGLYCAN; CORE PROTEIN; DECORIN; IDENTIFICATION; SEQUENCE; THROMBOMODULIN; GLYCOSYLATION; PURIFICATION; RECOGNITION	Biglycan is a member of the small leucine-rich proteoglycan family. Its core protein comprises two chondroitin/dermatan sulfate attachment sites on serine 42 and serine 47, respectively, which are the fifth and tenth amino add residues, respectively, after removal of the prepro peptide. Because the regulation of glycosaminoglycan chain assembly is not fully understood and because of the in vivo existence of monoglycanated biglycan, mutant core proteins were stably expressed in human 293 and Chinese hamster ovary cells in which i) either one or both serine residues were converted into alanine or threonine residues, ii) the number of acidic amino acids N-terminal of the respective serine residues was altered, and iii) a hexapeptide was inserted between the mutated site 1 and the unaltered site 2, Labeling experiments with [S-35]sulfate and [S-35]methionine indicated that serine 42 was almost fully used as the glycosaminoglycan attachment site regardless of whether site 2 was available or not for chain assembly. In contrast, substitution of site 2 was greatly influenced by the presence or absence of serine 42, although additional mutations demonstrated a direct influence of the amino acid sequence between the two sites. When site 2 was not substituted with a glycosaminoglycan chain, there was also no assembly of the linkage region. These results indicate that xylosyltransferase is the rate-limiting enzyme in glycosaminoglycan chain assembly and implicate a cooperative effect on the xylosyl transfer to site 2 by xylosylation of site 1, which probably becomes manifest before the removal of the propeptide. It is shown additionally that biglycan expressed in 293 cells may still contain the propeptide sequence and may carry heparan sulfate chains as well as sulfated N-linked oligosaccharides.	Univ Munster, Inst Physiol Chem & Pathobiochem, D-48149 Munster, Germany; McGill Univ, Shriners Hosp Children, Montreal, PQ H3G 1A6, Canada	University of Munster; McGill University	Kresse, H (corresponding author), Univ Munster, Inst Physiol Chem & Pathobiochem, Waldeyerstr 15, D-48149 Munster, Germany.	kresse@uni-muenster.de						ANTONSSON P, 1991, J BIOL CHEM, V266, P16859; Blaschke UK, 1996, J BIOL CHEM, V271, P30347, DOI 10.1074/jbc.271.48.30347; BOURDON MA, 1987, P NATL ACAD SCI USA, V84, P3194, DOI 10.1073/pnas.84.10.3194; Brinkmann T, 1997, J BIOL CHEM, V272, P11171; Dolan M, 1997, J BIOL CHEM, V272, P4316, DOI 10.1074/jbc.272.7.4316; Esko JD, 1996, CURR OPIN STRUC BIOL, V6, P663, DOI 10.1016/S0959-440X(96)80034-0; FISHER LW, 1987, J BIOL CHEM, V262, P9702; FISHER LW, 1989, J BIOL CHEM, V264, P4571; GERLITZ B, 1993, BIOCHEM J, V295, P131, DOI 10.1042/bj2950131; HAUSSER H, 1989, BIOCHEM J, V263, P137, DOI 10.1042/bj2630137; HAUSSER H, 1992, J BIOL CHEM, V267, P11559; Hausser H, 1999, BIOCHEM J, V344, P827, DOI 10.1042/0264-6021:3440827; Hocking AM, 1998, MATRIX BIOL, V17, P1; Hocking AM, 1996, J BIOL CHEM, V271, P19571, DOI 10.1074/jbc.271.32.19571; HUBER S, 1988, J BIOL CHEM, V263, P752; Iozzo RV, 1999, J BIOL CHEM, V274, P18843, DOI 10.1074/jbc.274.27.18843; Iozzo RV, 1998, ANNU REV BIOCHEM, V67, P609, DOI 10.1146/annurev.biochem.67.1.609; JOHNSTONE B, 1993, BIOCHEM J, V292, P661, DOI 10.1042/bj2920661; KEARNS AE, 1991, BIOCHEMISTRY-US, V30, P7477, DOI 10.1021/bi00244a016; KEARNS AE, 1993, J BIOL CHEM, V268, P11097; Kresse H, 1997, J BIOL CHEM, V272, P18404, DOI 10.1074/jbc.272.29.18404; Krishnan P, 1999, J BIOL CHEM, V274, P10945, DOI 10.1074/jbc.274.16.10945; LIN JH, 1994, J BIOL CHEM, V269, P25021; LOHMANDER LS, 1989, J BIOL CHEM, V264, P18775; MANN DM, 1990, J BIOL CHEM, V265, P5317; MARCUM JA, 1991, BIOCHEM BIOPH RES CO, V175, P706, DOI 10.1016/0006-291X(91)91623-K; MINTZ KP, 1994, J BIOL CHEM, V269, P4845; Nadanaka S, 1998, J BIOL CHEM, V273, P33728, DOI 10.1074/jbc.273.50.33728; NEAME PJ, 1989, J BIOL CHEM, V264, P8653; Pfeil U, 2000, GLYCOBIOLOGY, V10, P803, DOI 10.1093/glycob/10.8.803; RAUCH U, 1988, BIOL CHEM H-S, V369, P595, DOI 10.1515/bchm3.1988.369.2.595; ROUGHLEY PJ, 1993, BIOCHEM J, V295, P421, DOI 10.1042/bj2950421; ROUGHLEY PJ, 1996, BIOCHEM J, V318, P979; SCHONHERR E, 1993, BIOCHEM J, V290, P893, DOI 10.1042/bj2900893; Scott IC, 2000, J BIOL CHEM, V275, P30504, DOI 10.1074/jbc.M004846200; Torii T, 2000, GLYCOBIOLOGY, V10, P203, DOI 10.1093/glycob/10.2.203; VERTEL BM, 1993, J BIOL CHEM, V268, P11105; VONHEIJNE G, 1985, J MOL BIOL, V184, P99, DOI 10.1016/0022-2836(85)90046-4; Voshol H, 1996, J BIOL CHEM, V271, P22957, DOI 10.1074/jbc.271.38.22957; Weber IT, 1996, J BIOL CHEM, V271, P31767, DOI 10.1074/jbc.271.50.31767; WONGPALMS S, 1995, ARCH BIOCHEM BIOPHYS, V319, P383, DOI 10.1006/abbi.1995.1308	41	30	34	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 20	2001	276	16					13411	13416		10.1074/jbc.M009321200	http://dx.doi.org/10.1074/jbc.M009321200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	423VN	11145959	hybrid			2022-12-25	WOS:000168198600129
J	Bernard-Pierrot, I; Delbe, J; Caruelle, D; Barritault, D; Courty, J; Milhiet, PE				Bernard-Pierrot, I; Delbe, J; Caruelle, D; Barritault, D; Courty, J; Milhiet, PE			The lysine-rich C-terminal tail of heparin affin regulatory peptide is required for mitogenic and tumor formation activities	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULE HB-GAM; NIH 3T3 CELLS; NEURITE OUTGROWTH; BINDING-PROTEIN; PLEIOTROPHIN; PURIFICATION; EXPRESSION; RECEPTOR; MIDKINE; HARP	Heparin affin regulatory peptide (HARP) is a 18-kDa heparin-binding polypeptide that is highly expressed in developing tissues and in several primary human tumors. It seems to play a key role in cellular growth and differentiation. In vitro, HARP displays mitogenic, angiogenic, and neurite outgrowth activities. It is a secreted protein that is organized in two beta -sheet domains, each domain containing a cluster of basic residues. To assess determinants involved in the biological activities of HARP, C-terminally truncated proteins were produced in Chinese hamster ovary-K1 cells and tested for their mitogenic, tumor formation in nude mice and neurite outgrowth activities. Our data clearly indicate that the residues 111-136 of the lysine-rich C-terminal domain are involved in the mitogenic and tumor formation activities of HARP. Correlatively, no signal transduction was detected using the corresponding mutant, suggesting the absence of HARP binding to its high affinity receptor. However, this C-terminal domain of HARP is not involved in the neurite outgrowth activity. We also demonstrate that HARP signal peptide cleavage could led to two maturated forms that are both but differentially mitogenic.	Univ Paris 12, Lab Rech Croissance Cellulaire Reparat & Regener, CNRS, UPRESA 7053, F-94010 Creteil, France	Centre National de la Recherche Scientifique (CNRS); Universite Gustave-Eiffel; Universite Paris-Est-Creteil-Val-de-Marne (UPEC)	Courty, J (corresponding author), Univ Paris 12, Lab Rech Croissance Cellulaire Reparat & Regener, CNRS, UPRESA 7053, Ave Gen de Gaulle, F-94010 Creteil, France.	Courty@univ-paris12.fr	Courty, Jose/Q-3702-2018; Delbe, Jean/R-3680-2018					Bernard-Pierrot I, 1999, BIOCHEM BIOPH RES CO, V266, P437, DOI 10.1006/bbrc.1999.1835; CHAUHAN AK, 1993, P NATL ACAD SCI USA, V90, P679, DOI 10.1073/pnas.90.2.679; Choudhuri R, 1997, CANCER RES, V57, P1814; COURTY J, 1991, BIOCHEM BIOPH RES CO, V180, P145, DOI 10.1016/S0006-291X(05)81267-7; COURTY J, 2000, HEPARIN AFIN REGULAT, P145; Czubayko F, 1996, P NATL ACAD SCI USA, V93, P14753, DOI 10.1073/pnas.93.25.14753; DELBE J, 1995, J CELL PHYSIOL, V164, P47, DOI 10.1002/jcp.1041640107; Delbe J, 1999, PATHOL BIOL, V47, P352; FABRI L, 1992, BIOCHEM INT, V28, P1; FANG WJ, 1992, J BIOL CHEM, V267, P25889; Imai S, 1998, J CELL BIOL, V143, P1113, DOI 10.1083/jcb.143.4.1113; Kilpelainen I, 2000, J BIOL CHEM, V275, P13564, DOI 10.1074/jbc.275.18.13564; KOJIMA S, 1995, BIOCHEM BIOPH RES CO, V206, P468, DOI 10.1006/bbrc.1995.1066; KUO MD, 1992, BIOCHEM BIOPH RES CO, V182, P188, DOI 10.1016/S0006-291X(05)80129-9; LAAROUBI K, 1994, GROWTH FACTORS, V10, P89, DOI 10.3109/08977199409010982; Laaroubi Khalid, 1995, Progress in Growth Factor Research, V6, P25; LI YS, 1990, SCIENCE, V250, P1690, DOI 10.1126/science.2270483; LI YS, 1993, BIOCHEM BIOPH RES CO, V195, P1089, DOI 10.1006/bbrc.1993.2156; Maeda N, 1998, J CELL BIOL, V142, P203, DOI 10.1083/jcb.142.1.203; MILNER PG, 1989, BIOCHEM BIOPH RES CO, V165, P1096, DOI 10.1016/0006-291X(89)92715-0; MURAMATSU H, 1991, BIOCHEM BIOPH RES CO, V177, P652, DOI 10.1016/0006-291X(91)91838-4; PALERMO DP, 1991, J BIOTECHNOL, V19, P35, DOI 10.1016/0168-1656(91)90073-5; Papadimitriou E, 2000, BIOCHEM BIOPH RES CO, V274, P242, DOI 10.1006/bbrc.2000.3126; RAULAIS D, 1991, BIOCHEM BIOPH RES CO, V174, P708, DOI 10.1016/0006-291X(91)91475-R; RAULO E, 1994, J BIOL CHEM, V269, P12999; RAUVALA H, 1989, EMBO J, V8, P2933, DOI 10.1002/j.1460-2075.1989.tb08443.x; RAUVALA H, 1987, J BIOL CHEM, V262, P16625; Sato H, 1999, EXP CELL RES, V246, P152, DOI 10.1006/excr.1998.4304; Souttou B, 1997, J BIOL CHEM, V272, P19588, DOI 10.1074/jbc.272.31.19588; TAKAMATSU H, 1992, BIOCHEM BIOPH RES CO, V185, P224, DOI 10.1016/S0006-291X(05)80979-9; Vacherot F, 1999, J BIOL CHEM, V274, P7741, DOI 10.1074/jbc.274.12.7741; WELLSTEIN A, 1992, J BIOL CHEM, V267, P2582; Zhang N, 1999, P NATL ACAD SCI USA, V96, P6734, DOI 10.1073/pnas.96.12.6734; Zhang N, 1999, J BIOL CHEM, V274, P12959, DOI 10.1074/jbc.274.19.12959	34	38	40	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 13	2001	276	15					12228	12234		10.1074/jbc.M010913200	http://dx.doi.org/10.1074/jbc.M010913200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	421UK	11150308	hybrid			2022-12-25	WOS:000168081800106
J	Hanson, MN; Schoenberg, DR				Hanson, MN; Schoenberg, DR			Identification of in vivo mRNA decay intermediates corresponding to sites of in vitro cleavage by polysomal ribonuclease 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MYC MESSENGER-RNA; BINDING PROTEIN; CODING REGION; ENDONUCLEOLYTIC CLEAVAGE; 3'-UNTRANSLATED REGION; XENOPUS LIVER; IN-VITRO; DESTABILIZATION; PURIFICATION; TRANSLATION	Previous work from this laboratory identified a polysome-associated endonuclease whose activation by estrogen correlates with the coordinate destabilization of serum protein mRNAs. This enzyme, named polysomal ribonuclease 1, or PMR-1, is a novel member of the peroxidase gene family. A characteristic feature of PMR-1 is its ability to generate in vitro degradation intermediates by cleaving within overlapping APyrUGA elements in the 5'-coding region of albumin mRNA. The current study sought to determine whether the in vivo destabilization of albumin mRNA following estrogen administration involves the generation of decay intermediates that could be identified as products of PMR-1 cleavage. A sensitive ligation-mediated polymerase chain reaction technique was developed to identify labile decay intermediates, and its validity in identifying PMR-1-generated decay intermediates of albumin mRNA was confirmed by primer extension experiments performed with liver RNA that was isolated from estrogen-treated frogs or digested in vitro with the purified endonuclease. Ligation-mediated polymerase chain reaction was also used to identify decay intermediates from the 3'-end of albumin mRNA, and as a final proof of principle it was employed to identify in vivo decay intermediates of the c-myc coding region instability determinant corresponding to sites of in vitro cleavage by a polysome-associated endonuclease.	Ohio State Univ, Dept Mol & Cellular Biochem, Columbus, OH 43210 USA; Ohio State Univ, Ctr Comprehens Canc, Columbus, OH 43210 USA; Ohio State Univ, Mol Cellular & Dev Biol Grad Program, Columbus, OH 43210 USA	Ohio State University; James Cancer Hospital & Solove Research Institute; Ohio State University; Ohio State University	Hanson, MN (corresponding author), Ohio State Univ, Dept Mol & Cellular Biochem, 1645 Neil Ave, Columbus, OH 43210 USA.		Schoenberg, Daniel/J-3423-2019	Schoenberg, Daniel/0000-0003-4570-1946	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038277] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM038277, R01 GM038277-14, GM38277] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BERNSTEIN PL, 1992, GENE DEV, V6, P642, DOI 10.1101/gad.6.4.642; BINDER R, 1989, J BIOL CHEM, V264, P16910; BINDER R, 1994, EMBO J, V13, P1969, DOI 10.1002/j.1460-2075.1994.tb06466.x; Chernokalskaya E, 1997, NUCLEIC ACIDS RES, V25, P735, DOI 10.1093/nar/25.4.735; Chernokalskaya E, 1998, RNA, V4, P1537, DOI 10.1017/S1355838298980451; Cunningham KS, 2000, P NATL ACAD SCI USA, V97, P12498, DOI 10.1073/pnas.220425497; CUNNINGHAM KS, 2001, RIBONUCLEASE; DECKER CJ, 1993, GENE DEV, V7, P1632, DOI 10.1101/gad.7.8.1632; Dodson RE, 1997, J BIOL CHEM, V272, P12249, DOI 10.1074/jbc.272.19.12249; DOMPENCIEL RE, 1995, J BIOL CHEM, V270, P6108, DOI 10.1074/jbc.270.11.6108; Doyle GAR, 1998, NUCLEIC ACIDS RES, V26, P5036, DOI 10.1093/nar/26.22.5036; Gingras AC, 1999, ANNU REV BIOCHEM, V68, P913, DOI 10.1146/annurev.biochem.68.1.913; Imataka H, 1998, EMBO J, V17, P7480, DOI 10.1093/emboj/17.24.7480; Jacobson A, 1996, ANNU REV BIOCHEM, V65, P693, DOI 10.1146/annurev.bi.65.070196.003401; Jo H, 1998, METHODS, V16, P365, DOI 10.1006/meth.1998.0691; Lee CH, 1998, J BIOL CHEM, V273, P25261, DOI 10.1074/jbc.273.39.25261; Leeds P, 1997, ONCOGENE, V14, P1279, DOI 10.1038/sj.onc.1201093; Mathews DH, 1999, J MOL BIOL, V288, P911, DOI 10.1006/jmbi.1999.2700; NIELSEN DA, 1990, MOL CELL BIOL, V10, P371, DOI 10.1128/MCB.10.1.371; PASTORI RL, 1991, BIOCHEMISTRY-US, V30, P10490, DOI 10.1021/bi00107a018; PASTORI RL, 1991, MOL ENDOCRINOL, V5, P461, DOI 10.1210/mend-5-4-461; PROKIPCAK RD, 1994, J BIOL CHEM, V269, P9261; Rao MN, 1996, NUCLEIC ACIDS RES, V24, P4078, DOI 10.1093/nar/24.20.4078; ROSS J, 1995, MICROBIOL REV, V59, P423, DOI 10.1128/MMBR.59.3.423-450.1995; Schoenberg DR, 1999, METHODS, V17, P60, DOI 10.1006/meth.1998.0708; SCHOENBERG DR, 1997, MRNA METABOLISM POST, P217; THARUN S, 1997, MRNA METABOLISM POST, P181; van Dijk EL, 2000, J MOL BIOL, V300, P449, DOI 10.1006/jmbi.2000.3856; VANDIJK EL, 1998, RNA, V4, P1632; Wang ZR, 2000, EMBO J, V19, P295, DOI 10.1093/emboj/19.2.295	30	21	21	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 13	2001	276	15					12331	12337		10.1074/jbc.M010483200	http://dx.doi.org/10.1074/jbc.M010483200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	421UK	11152474	hybrid, Green Accepted			2022-12-25	WOS:000168081800119
J	James, IE; Marquis, RW; Blake, SM; Hwang, SM; Gress, CJ; Ru, Y; Zembryki, D; Yamashita, DS; McQueney, MS; Tomaszek, TA; Oh, HJ; Gowen, M; Veber, DF; Lark, MW				James, IE; Marquis, RW; Blake, SM; Hwang, SM; Gress, CJ; Ru, Y; Zembryki, D; Yamashita, DS; McQueney, MS; Tomaszek, TA; Oh, HJ; Gowen, M; Veber, DF; Lark, MW			Potent and selective cathepsin L inhibitors do not inhibit human osteoclast resorption in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BONE-RESORPTION; IN-VITRO; MOLECULAR-CLONING; OSTEOPETROSIS; TISSUE; ASSAY; MICE; VIVO	Cathepsins K and L are related cysteine proteases that have been proposed to play important roles in osteoclast-mediated bone resorption, To further examine the putative role of cathepsin L in bone resorption, we have evaluated selective and potent inhibitors of human cathepsin L and cathepsin K in an in vitro assay of human osteoclastic resorption and an in situ assay of osteoclast cathepsin activity, The potent selective cathepsin L inhibitors (K-i = 0.0099, 0.034, and 0.27 nM) were inactive in both the in situ cytochemical assay (IC50 > 1 muM) and the osteoclast-mediated bone resorption assay (IC50 > 300 nM). Conversely, the cathepsin K selective inhibitor was potently active in both the cytochemical (IC50 = 63 nM) and resorption (IC50 = 71 nM) assays. A recently reported dipeptide aldehyde with activity against cathepsins L (K-i = 0.052 mM) and K (K-i = 1.57 nM) was also active in both assays (IC50 = 110 and 115 nM, respectively) These data confirm that cathepsin K and not cathepsin L is the major protease responsible for human osteoclastic bone resorption.	SmithKline Beecham Pharmaceut, Dept Bone & Cartilage Biol, King Of Prussia, PA 19406 USA; SmithKline Beecham Pharmaceut, Dept Med Chem, King Of Prussia, PA 19406 USA; SmithKline Beecham Pharmaceut, Dept Prot Biochem, King Of Prussia, PA 19406 USA; SmithKline Beecham Pharmaceut, Dept Mech Enzymol, King Of Prussia, PA 19406 USA	GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline	James, IE (corresponding author), SmithKline Beecham Pharmaceut, Dept Bone & Cartilage Biol, 709 Swedeland Rd,POB 1539, King Of Prussia, PA 19406 USA.							BARON R, 1985, J CELL BIOL, V101, P2210, DOI 10.1083/jcb.101.6.2210; BROMME D, 1995, BIOL CHEM H-S, V376, P379, DOI 10.1515/bchm3.1995.376.6.379; DODDS RA, 1998, METHODS BONE BIOL, P198; Drake FH, 1996, J BIOL CHEM, V271, P12511, DOI 10.1074/jbc.271.21.12511; ELMORE SM, 1966, AM J MED, V40, P273, DOI 10.1016/0002-9343(66)90108-2; Foged NT, 1996, J BONE MINER RES, V11, P226; Gelb BD, 1996, SCIENCE, V273, P1236, DOI 10.1126/science.273.5279.1236; Gowen M, 1999, J BONE MINER RES, V14, P1654, DOI 10.1359/jbmr.1999.14.10.1654; HART KA, 1996, J BONE MINER RES, V11, pS181; INAOKA T, 1995, BIOCHEM BIOPH RES CO, V206, P89, DOI 10.1006/bbrc.1995.1013; James IE, 1999, J BONE MINER RES, V14, P1562, DOI 10.1359/jbmr.1999.14.9.1562; James IE, 1996, J BONE MINER RES, V11, P1608; KAHN AJ, 1975, NATURE, V258, P325, DOI 10.1038/258325a0; MEREDITH SC, 1978, J BONE JOINT SURG AM, V60, P1122, DOI 10.2106/00004623-197860080-00023; Saftig P, 1998, P NATL ACAD SCI USA, V95, P13453, DOI 10.1073/pnas.95.23.13453; Thompson SK, 1997, P NATL ACAD SCI USA, V94, P14249, DOI 10.1073/pnas.94.26.14249; VERBER DF, 2000, PEPTIDES NEW MILLENI, P453; Votta BJ, 1997, J BONE MINER RES, V12, P1396, DOI 10.1359/jbmr.1997.12.9.1396; WALKER DG, 1973, SCIENCE, V180, P275; Woo JT, 1996, EUR J PHARMACOL, V300, P131, DOI 10.1016/0014-2999(95)00858-6; Yasuma T, 1998, J MED CHEM, V41, P4301, DOI 10.1021/jm9803065	21	37	37	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 13	2001	276	15					11507	11511		10.1074/jbc.M010684200	http://dx.doi.org/10.1074/jbc.M010684200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	421UK	11148212	hybrid			2022-12-25	WOS:000168081800013
J	Schillace, RV; Voltz, JW; Sim, ATR; Shenolikar, S; Scott, JD				Schillace, RV; Voltz, JW; Sim, ATR; Shenolikar, S; Scott, JD			Multiple interactions within the AKAP220 signaling complex contribute to protein phosphatase 1 regulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KINASE-ANCHORING PROTEIN; RABBIT SKELETAL-MUSCLE; CATALYTIC SUBUNIT; MOLECULAR-CLONING; PHOSPHOPROTEIN PHOSPHATASE; TARGETING SUBUNITS; MYOSIN PHOSPHATASE; SCAFFOLD PROTEIN; SMOOTH-MUSCLE; BINDING MOTIF	The phosphorylation status of cellular proteins is controlled by the opposing actions of protein kinases and phosphatases. Compartmentalization of these enzymes is critical for spatial and temporal control of these phosphorylation/dephosphorylation events. We previously reported that a 220-kDa A-kinase anchoring protein (AKAP220) coordinates the location of the cAMP-dependent protein kinase (PKA) and the type 1 protein phosphatase catalytic subunit (PP1c) (Schillace, R. V., and Scott, J. D. (1999) Curr. Biol. 9, 321-324). We now demonstrate that an AKAP220 fragment is a competitive inhibitor of PP1c activity (K-i = 2.9 +/- 0.7 muM). Mapping studies and activity measurements indicate that several protein-protein interactions act synergistically to inhibit PP1. A consensus targeting motif, between residues 1195 and 1198 (Lys-Val-Gln-Phe), binds but does not affect enzyme activity, whereas determinants between residues 1711 and 1901 inhibit the phosphatase. Analysis of truncated PP1c and chimeric PP1/2A catalytic subunits suggests that AKAP220 inhibits the phosphatase in a manner distinct from all known PP1 inhibitors and toxins. Intermolecular interactions within the AKAP220 signaling complex further contribute to PP1 inhibition as addition of the PKA regulatory subunit (RII) enhances phosphatase inhibition. These experiments indicate that regulation of PP1 activity by AKAP220 involves a complex network of intra- and intermolecular interactions.	Oregon Hlth Sci Univ, Howard Hughes Med Inst, Vollum Inst, Portland, OR 97201 USA; Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, Durham, NC 27710 USA; Univ Newcastle, Fac Med & Hlth Sci, Sch Biomed Sci, Discipline Med Biochem, Newcastle, NSW 2308, Australia	Howard Hughes Medical Institute; Oregon Health & Science University; Duke University; University of Newcastle	Scott, JD (corresponding author), Oregon Hlth Sci Univ, Howard Hughes Med Inst, Vollum Inst, MRB 322,3181 SW Sam Jackson Pk Rd, Portland, OR 97201 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK052054, P01DK044239] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK52054, DK44239] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALESSI D, 1992, EUR J BIOCHEM, V210, P1023, DOI 10.1111/j.1432-1033.1992.tb17508.x; ALESSI DR, 1993, EUR J BIOCHEM, V213, P1055, DOI 10.1111/j.1432-1033.1993.tb17853.x; Allen PB, 1997, P NATL ACAD SCI USA, V94, P9956, DOI 10.1073/pnas.94.18.9956; Allen PB, 1998, J BIOL CHEM, V273, P4089, DOI 10.1074/jbc.273.7.4089; Beullens M, 1999, J BIOL CHEM, V274, P14053, DOI 10.1074/jbc.274.20.14053; BOLLEN M, 1994, FEBS LETT, V344, P196, DOI 10.1016/0014-5793(94)00391-2; Campos M, 1996, J BIOL CHEM, V271, P28478, DOI 10.1074/jbc.271.45.28478; CARR DW, 1991, J BIOL CHEM, V266, P14188; CAUDWELL FB, 1986, FEBS LETT, V194, P85, DOI 10.1016/0014-5793(86)80056-4; CHEN YH, 1994, FEBS LETT, V356, P51, DOI 10.1016/0014-5793(94)01231-8; Chin D, 2000, TRENDS CELL BIOL, V10, P322, DOI 10.1016/S0962-8924(00)01800-6; COGHLAN VM, 1995, BIOCHEM SOC T, V23, P591; COHEN P, 1989, J BIOL CHEM, V264, P21435; Colbran RJ, 1997, J NEUROCHEM, V69, P920; Colledge M, 2000, NEURON, V27, P107, DOI 10.1016/S0896-6273(00)00013-1; Colledge M, 1999, TRENDS CELL BIOL, V9, P216, DOI 10.1016/S0962-8924(99)01558-5; Connor JH, 1999, J BIOL CHEM, V274, P22366, DOI 10.1074/jbc.274.32.22366; Connor JH, 2000, J BIOL CHEM, V275, P18670, DOI 10.1074/jbc.M909312199; DENT P, 1992, EUR J BIOCHEM, V210, P1037, DOI 10.1111/j.1432-1033.1992.tb17509.x; Edwards AS, 2000, CURR OPIN CELL BIOL, V12, P217, DOI 10.1016/S0955-0674(99)00085-X; Egloff MP, 1997, EMBO J, V16, P1876, DOI 10.1093/emboj/16.8.1876; Faux MC, 1999, BIOCHEM J, V343, P443, DOI 10.1042/0264-6021:3430443; Faux MC, 1997, J BIOL CHEM, V272, P17038, DOI 10.1074/jbc.272.27.17038; Faux MC, 1996, TRENDS BIOCHEM SCI, V21, P312, DOI 10.1016/0968-0004(96)10040-2; FAUX MC, 1996, CELL, V70, P8; Fraser IDC, 2000, CURR BIOL, V10, P409, DOI 10.1016/S0960-9822(00)00419-X; Fraser IDC, 1998, EMBO J, V17, P2261, DOI 10.1093/emboj/17.8.2261; Fraser IDC, 1999, NEURON, V23, P423, DOI 10.1016/S0896-6273(00)80795-3; Greengard P, 1999, NEURON, V23, P435, DOI 10.1016/S0896-6273(00)80798-9; Harada H, 1999, MOL CELL, V3, P413, DOI 10.1016/S1097-2765(00)80469-4; HELPS NR, 1995, FEBS LETT, V377, P395; Hsieh-Wilson LC, 1999, BIOCHEMISTRY-US, V38, P4365, DOI 10.1021/bi982900m; Huang HB, 1999, J BIOL CHEM, V274, P7870, DOI 10.1074/jbc.274.12.7870; Huang LJS, 1999, J CELL BIOL, V145, P951, DOI 10.1083/jcb.145.5.951; HUBBARD MJ, 1990, EUR J BIOCHEM, V189, P243, DOI 10.1111/j.1432-1033.1990.tb15483.x; HUBBARD MJ, 1993, TRENDS BIOCHEM SCI, V18, P172, DOI 10.1016/0968-0004(93)90109-Z; Johnson DF, 1996, EUR J BIOCHEM, V239, P317, DOI 10.1111/j.1432-1033.1996.0317u.x; JURGENSEN SR, 1985, P NATL ACAD SCI USA, V82, P7565, DOI 10.1073/pnas.82.22.7565; Katayose Y, 2000, J BIOL CHEM, V275, P9209, DOI 10.1074/jbc.275.13.9209; KHATRA BS, 1985, BIOCHEM BIOPH RES CO, V130, P567, DOI 10.1016/0006-291X(85)90454-1; Klauck TM, 1996, SCIENCE, V271, P1589, DOI 10.1126/science.271.5255.1589; KREBS EG, 1985, BIOCHEM SOC T, V13, P813, DOI 10.1042/bst0130813; Lester LB, 1996, J BIOL CHEM, V271, P9460, DOI 10.1074/jbc.271.16.9460; Lin JW, 1998, J NEUROSCI, V18, P2017; Liu J, 2000, BIOCHEM J, V346, P77, DOI 10.1042/0264-6021:3460077; MacMillan LB, 1999, J BIOL CHEM, V274, P35845, DOI 10.1074/jbc.274.50.35845; Nauert JB, 1997, CURR BIOL, V7, P52, DOI 10.1016/S0960-9822(06)00027-3; Newlon MG, 1999, NAT STRUCT BIOL, V6, P222; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; PARK IK, 1994, J BIOL CHEM, V269, P28919; PARK IK, 1994, J BIOL CHEM, V269, P944; Printen JA, 1997, SCIENCE, V275, P1475, DOI 10.1126/science.275.5305.1475; Reinton N, 2000, DEV BIOL, V223, P194, DOI 10.1006/dbio.2000.9725; RENOUF S, 1995, FEBS LETT, V375, P75, DOI 10.1016/0014-5793(95)01180-M; Schillace RV, 1999, J CLIN INVEST, V103, P761, DOI 10.1172/JCI6491; Schillace RV, 1999, CURR BIOL, V9, P321, DOI 10.1016/S0960-9822(99)80141-9; Snyder GL, 1998, J NEUROSCI, V18, P10297; Steen RL, 2000, J CELL BIOL, V150, P1251, DOI 10.1083/jcb.150.6.1251; Surks HK, 1999, SCIENCE, V286, P1583, DOI 10.1126/science.286.5444.1583; SUTHERLAND EW, 1972, SCIENCE, V177, P401, DOI 10.1126/science.177.4047.401; TAYLOR SS, 1990, ANNU REV BIOCHEM, V59, P971, DOI 10.1146/annurev.bi.59.070190.004543; Van Eynde A, 1995, J BIOL CHEM, V270, P28068, DOI 10.1074/jbc.270.47.28068; Westphal RS, 2000, EMBO J, V19, P4589, DOI 10.1093/emboj/19.17.4589; Westphal RS, 1999, SCIENCE, V285, P93, DOI 10.1126/science.285.5424.93; Yan Z, 1999, NAT NEUROSCI, V2, P13, DOI 10.1038/4516; Yang J, 2000, J BIOL CHEM, V275, P22635, DOI 10.1074/jbc.M003082200; Zolnierowicz Stanislaw, 2000, EMBO (European Molecular Biology Organization) Journal, V19, P483, DOI 10.1093/emboj/19.4.483	67	50	52	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 13	2001	276	15					12128	12134		10.1074/jbc.M010398200	http://dx.doi.org/10.1074/jbc.M010398200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	421UK	11152471	hybrid			2022-12-25	WOS:000168081800093
J	Scorrano, L; Penzo, D; Petronilli, V; Pagano, F; Bernardi, P				Scorrano, L; Penzo, D; Petronilli, V; Pagano, F; Bernardi, P			Arachidonic acid causes cell death through the mitochondrial permeability transition - Implications for tumor necrosis factor-alpha apoptotic signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER MITOCHONDRIA; CYTOCHROME-C RELEASE; 2 SEPARATE SITES; CYCLOSPORINE-A; FATTY-ACIDS; GD3 GANGLIOSIDE; OXIDATIVE-PHOSPHORYLATION; MEMBRANE DEPOLARIZATION; PYRIDINE-NUCLEOTIDES; DEPENDENT ACTIVATION	We have investigated the effects of arachidonic and palmitic acids in isolated rat liver mitochondria and in rat hepatoma MH1C1 cells. We show that both compounds induce the mitochondrial permeability transition (PT). At variance from palmitic acid, however, arachidonic acid causes a PT at concentrations that do not cause PT-independent depolarization or respiratory inhibition, suggesting a specific effect on the PT pore. When added to intact MH1C1 cells, arachidonic acid but not palmitic acid caused a mitochondrial PT in situ that was accompanied by cytochrome c release and rapidly followed by cell death. All these effects of arachidonic acid could be prevented by cyclosporin A but not by the phospholipase A(2) inhibitor aristolochic acid. In contrast, tumor necrosis factor alpha caused phospholipid hydrolysis, induction of the PT, cytochrome c release, and cell death that could be inhibited by both cyclosporin A and aristolochic acid. These findings suggest that arachidonic acid produced by cytosolic phospholipase A(2) may be a mediator of tumor necrosis factor alpha cytotoxicity in situ through induction of the mitochondrial PT.	Dept Biomed Sci, CNR, Unit Study Biomembranes, Padua, Italy; Univ Padua, Dept Urol, I-35121 Padua, Italy	Consiglio Nazionale delle Ricerche (CNR); University of Padua	Bernardi, P (corresponding author), Dipartimento Sci Biomed Sperimentali, Viale Giuseppe Colombo 3, I-35121 Padua, Italy.	bernardi@civ.bio.unipd.it	Scorrano, Luca/A-6652-2008; Petronilli, Valeria/C-3558-2015; Scorrano, Luca/K-3967-2019; Bernardi, Paolo/C-3656-2008	Scorrano, Luca/0000-0002-8515-8928; Petronilli, Valeria/0000-0003-4026-6404; Scorrano, Luca/0000-0002-8515-8928; Bernardi, Paolo/0000-0001-9187-3736	Telethon [1141] Funding Source: Medline	Telethon(Fondazione Telethon)		ANDREYEV AY, 1989, EUR J BIOCHEM, V182, P585, DOI 10.1111/j.1432-1033.1989.tb14867.x; Arora AS, 1997, HEPATOLOGY, V25, P958, DOI 10.1002/hep.510250428; Baron JA, 2000, ANNU REV MED, V51, P511, DOI 10.1146/annurev.med.51.1.511; Bernardi P, 1999, EUR J BIOCHEM, V264, P687, DOI 10.1046/j.1432-1327.1999.00725.x; Bernardi P, 1999, PHYSIOL REV, V79, P1127, DOI 10.1152/physrev.1999.79.4.1127; BERNARDI P, 1992, J BIOL CHEM, V267, P8834; Bradham CA, 1998, MOL CELL BIOL, V18, P6353, DOI 10.1128/MCB.18.11.6353; Broekemeier KM, 1995, BIOCHEMISTRY-US, V34, P16440, DOI 10.1021/bi00050a027; Cao Y, 2000, P NATL ACAD SCI USA, V97, P11280, DOI 10.1073/pnas.200367597; Chan TA, 1998, P NATL ACAD SCI USA, V95, P681, DOI 10.1073/pnas.95.2.681; Chernyak BV, 1996, EUR J BIOCHEM, V238, P623, DOI 10.1111/j.1432-1033.1996.0623w.x; COSTANTINI P, 1995, TOXICOLOGY, V99, P77, DOI 10.1016/0300-483X(94)02997-9; Costantini P, 1996, J BIOL CHEM, V271, P6746, DOI 10.1074/jbc.271.12.6746; DeMaria R, 1997, SCIENCE, V277, P1652, DOI 10.1126/science.277.5332.1652; Di Paola M, 2000, BIOCHEMISTRY-US, V39, P6660, DOI 10.1021/bi9924415; Du CY, 2000, CELL, V102, P33, DOI 10.1016/S0092-8674(00)00008-8; DUCHEN MR, 1993, CARDIOVASC RES, V27, P1790, DOI 10.1093/cvr/27.10.1790; EMAUS RK, 1986, BIOCHIM BIOPHYS ACTA, V850, P436, DOI 10.1016/0005-2728(86)90112-X; Eriksson O, 1998, J BIOL CHEM, V273, P12669, DOI 10.1074/jbc.273.20.12669; Friberg H, 1998, J NEUROSCI, V18, P5151, DOI 10.1523/JNEUROSCI.18-14-05151.1998; Garcia-Ruiz C, 2000, FASEB J, V14, P847, DOI 10.1096/fasebj.14.7.847; GarciaRuiz C, 1997, J BIOL CHEM, V272, P11369; GUNTER TE, 1990, AM J PHYSIOL, V258, pC755, DOI 10.1152/ajpcell.1990.258.5.C755; GUTKNECHT J, 1988, J MEMBRANE BIOL, V106, P83, DOI 10.1007/BF01871769; HILLERED L, 1988, J NEUROSCI RES, V19, P94, DOI 10.1002/jnr.490190113; IGBAVBOA U, 1988, J BIOL CHEM, V263, P1405; IMBERTI R, 1993, J PHARMACOL EXP THER, V265, P392; Jayadev S, 1997, J BIOL CHEM, V272, P17196, DOI 10.1074/jbc.272.27.17196; JAYADEV S, 1994, J BIOL CHEM, V269, P5757; Li PA, 1997, BRAIN RES, V753, P133, DOI 10.1016/S0006-8993(97)00005-X; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Lorenzo HK, 1999, CELL DEATH DIFFER, V6, P516, DOI 10.1038/sj.cdd.4400527; LUVISETTO S, 1990, J BIOENERG BIOMEMBR, V22, P635, DOI 10.1007/BF00809068; MCGEERUSSELL SM, 1970, BRAIN RES, V20, P193, DOI 10.1016/0006-8993(70)90288-X; MUTCH DG, 1992, CANCER RES, V52, P866; NEALE ML, 1988, IMMUNOLOGY, V64, P81; PASTORINO JG, 1993, J BIOL CHEM, V268, P13791; Pastorino JG, 1996, J BIOL CHEM, V271, P29792, DOI 10.1074/jbc.271.47.29792; PETRONILLI V, 1994, BBA-BIOENERGETICS, V1187, P255, DOI 10.1016/0005-2728(94)90122-8; PETRONILLI V, 1993, J BIOL CHEM, V268, P21939; Petronilli V, 2001, J BIOL CHEM, V276, P12030, DOI 10.1074/jbc.M010604200; PETRONILLI V, 1994, J BIOL CHEM, V269, P16638; Rial E, 2001, BBA-BIOENERGETICS, V1504, P70, DOI 10.1016/S0005-2728(00)00240-1; ROSENTHAL MD, 1989, BIOCHIM BIOPHYS ACTA, V1001, P1, DOI 10.1016/0005-2760(89)90299-3; ROTTENBERG H, 1986, BIOCHEMISTRY-US, V25, P1747, DOI 10.1021/bi00355a045; SCHOLEFIELD PG, 1956, CAN J BIOCHEM PHYS, V34, P1227; Schonfeld P, 1997, FEBS LETT, V420, P167, DOI 10.1016/S0014-5793(97)01511-1; SCHULZEOSTHOFF K, 1992, J BIOL CHEM, V267, P5317; Scorrano L, 1999, J BIOL CHEM, V274, P22581, DOI 10.1074/jbc.274.32.22581; Susin SA, 1996, J EXP MED, V184, P1331, DOI 10.1084/jem.184.4.1331; Szalai G, 1999, EMBO J, V18, P6349, DOI 10.1093/emboj/18.22.6349; Tafani M, 2000, AM J PATHOL, V156, P2111, DOI 10.1016/S0002-9440(10)65082-1; Tepper AD, 1999, J CLIN INVEST, V103, P971, DOI 10.1172/JCI5457; Wallach D, 1999, ANNU REV IMMUNOL, V17, P331, DOI 10.1146/annurev.immunol.17.1.331; Wieckowski MR, 1998, FEBS LETT, V423, P339, DOI 10.1016/S0014-5793(98)00118-5; Wissing D, 1997, P NATL ACAD SCI USA, V94, P5073, DOI 10.1073/pnas.94.10.5073; WOITCZAK L, 1993, BIOCHIM BIOPHYS ACTA, V1183, P41, DOI 10.1016/0005-2728(93)90004-Y; YOSHIDA S, 1983, J NEUROCHEM, V40, P1278, DOI 10.1111/j.1471-4159.1983.tb13567.x	58	253	258	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 13	2001	276	15					12035	12040		10.1074/jbc.M010603200	http://dx.doi.org/10.1074/jbc.M010603200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	421UK	11134037	hybrid			2022-12-25	WOS:000168081800081
J	Churchill, GC; Galione, A				Churchill, GC; Galione, A			Prolonged inactivation of nicotinic acid adenine dinucleotide phosphate-induced Ca2+ release mediates a spatiotemporal Ca2+ memory	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIC ADP-RIBOSE; SEA-URCHIN EGGS; INOSITOL TRISPHOSPHATE; CALCIUM-RELEASE; PYRIDINE-NUCLEOTIDE; NAADP; MICROSOMES	Although numerous extracellular stimuli are coupled to increases in intracellular Ca2+, different stimuli are thought to achieve specificity by eliciting different spatiotemporal Ca2+ increases. We investigated the effect of nicotinic acid adenine dinucleotide phosphate (NAADP) inactivation on spatiotemporal Ca2+ signals in intact sea urchin eggs. The photorelease of NAADP but not inositol 1,4,5-trisphosphate or cyclic ADP-ribose resulted in self-inactivation. When NAADP was released first locally and subsequently globally, the spatial pattern of the first response shaped that of the second. Specifically, the local release of NAADP created a Ca2+ gradient that was reversed during the subsequent global release of NAADP. Neither cyclic ADP-ribose nor inositol 1,4,5-trisphosphate showed a similar effect. In contrast to homogenates, NAADP inactivation was reversible in intact eggs with resensitization occurring in similar to 20 min. Because initial NAADP responses affect later responses, NAADP can serve as a mechanism for a Ca2+ memory that has both spatial and temporal components. This NAADP-mediated Ca2+ memory provides a novel mechanism for cells to control spatiotemporal Ca2+ increases.	Univ Oxford, Dept Pharmacol, Oxford OX1 3QT, England	University of Oxford	Churchill, GC (corresponding author), Univ Oxford, Dept Pharmacol, Mansfield Rd, Oxford OX1 3QT, England.		Galione, Antony/E-5884-2011	Galione, Antony/0000-0002-4132-7646				Aarhus R, 1996, J BIOL CHEM, V271, P8513, DOI 10.1074/jbc.271.15.8513; Bak J, 1999, CURR BIOL, V9, P751, DOI 10.1016/S0960-9822(99)80335-2; Berg I, 2000, J CELL BIOL, V150, P581, DOI 10.1083/jcb.150.3.581; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; Billington RA, 2000, BIOCHEM BIOPH RES CO, V276, P112, DOI 10.1006/bbrc.2000.3444; Cancela JM, 1999, NATURE, V398, P74, DOI 10.1038/18032; Chini EN, 1996, BIOCHEM J, V316, P709, DOI 10.1042/bj3160709; Churchill GC, 2000, J BIOL CHEM, V275, P38687, DOI 10.1074/jbc.M005827200; CLAPPER DL, 1987, J BIOL CHEM, V262, P9561; Galione A, 2000, BIOL CELL, V92, P197, DOI 10.1016/S0248-4900(00)01070-4; Genazzani AA, 1997, TRENDS PHARMACOL SCI, V18, P108, DOI 10.1016/S0165-6147(96)01036-X; Genazzani AA, 1996, BIOCHEM J, V315, P721, DOI 10.1042/bj3150721; Genazzani AA, 1996, J BIOL CHEM, V271, P11599, DOI 10.1074/jbc.271.20.11599; LEE HC, 1995, J BIOL CHEM, V270, P2152, DOI 10.1074/jbc.270.5.2152; Lee HC, 1997, PHYSIOL REV, V77, P1133, DOI 10.1152/physrev.1997.77.4.1133; Lee HC, 1997, J BIOL CHEM, V272, P4172, DOI 10.1074/jbc.272.7.4172; Navazio L, 2000, P NATL ACAD SCI USA, V97, P8693, DOI 10.1073/pnas.140217897; Patel S, 2000, BIOCHEM J, V352, P725, DOI 10.1042/0264-6021:3520725	18	32	33	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 6	2001	276	14					11223	11225		10.1074/jbc.M009335200	http://dx.doi.org/10.1074/jbc.M009335200			3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	420AC	11139579	hybrid			2022-12-25	WOS:000167980900086
J	Gu, BJ; Zhang, WY; Worthington, RA; Sluyter, R; Dao-Ung, P; Petrou, S; Barden, JA; Wiley, JS				Gu, BJ; Zhang, WY; Worthington, RA; Sluyter, R; Dao-Ung, P; Petrou, S; Barden, JA; Wiley, JS			A Glu-496 to Ala polymorphism leads to loss of function of the human P2X(7) receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOLIPASE-D ACTIVITY; NUCLEOTIDE RECEPTOR; EXTRACELLULAR ATP; HUMAN-LYMPHOCYTES; XENOPUS-OOCYTES; PURINERGIC RECEPTORS; HUMAN MACROPHAGES; DENDRITIC CELLS; ION CHANNELS; ACTIVATION	P2X(7) receptor is a ligand-gated cation-selective channel that mediates ATP-induced apoptosis of cells of the immune system. We and others have shown that P2X(7) is nonfunctional both in lymphocytes and monocytes from some subjects. To study a possible genetic basis we sequenced DNA coding for the carboxyl-terminal tail of P2X(7). In 9 of 45 normal subjects a heterozygous nucleotide substitution (1513A-->C) was found, whereas 1 subject carried the homozygous substitution that codes for glutamic acid to alanine at amino acid position 496. Surface expression of P2X(7) on lymphocytes was not affected by this E496A polymorphism, demonstrated both by confocal microscopy and immunofluorescent staining. Monocytes and lymphocytes from the E496A homozygote subject expressed nonfunctional receptor, whereas heterozygotes showed P2X(7) function that was half that of germline P2X(7). Results of transfection experiments showed that the mutant P2X(7) receptor was nonfunctional when expressed at low receptor density but regained function at a high receptor density. This density dependence of mutant P2X(7) function was also seen on differentiation of fresh monocytes to macrophages with interferon-gamma, which up-regulated mutant P2X(7) and partially restored its function. P2X(7)-mediated apoptosis of lymphocytes was impaired in homozygous mutant P2X(7) compared with germline (8.6 versus 35.2%). The data suggest that the glutamic acid at position 496 is required for optimal assembly of the P2X(7) receptor.	Univ Sydney, Dept Med, Sydney, NSW 2006, Australia; Univ Sydney, Dept Anat & Histol, Sydney, NSW 2006, Australia; Univ Melbourne, Dept Physiol, Melbourne, Vic 3050, Australia	University of Sydney; University of Sydney; University of Melbourne	Wiley, JS (corresponding author), Nepean Hosp, Clin Sci Bldg, Penrith, NSW 2750, Australia.		Sluyter, Ronald/B-5798-2009; Petrou, Steven/M-8332-2013	Sluyter, Ronald/0000-0003-4909-686X; Petrou, Steven/0000-0002-4960-6375; Wiley, James/0000-0001-9421-4154; Gu, Ben/0000-0001-5500-4453				Biti R, 1997, NAT MED, V3, P252, DOI 10.1038/nm0397-252; Buell G, 1998, BLOOD, V92, P3521, DOI 10.1182/blood.V92.10.3521.422k50_3521_3528; Chessell IP, 1998, BRIT J PHARMACOL, V124, P1314, DOI 10.1038/sj.bjp.0701958; Chused TM, 1996, J IMMUNOL, V157, P1371; Collins A, 1999, P NATL ACAD SCI USA, V96, P15173, DOI 10.1073/pnas.96.26.15173; Coutinho-Silva R, 1999, AM J PHYSIOL-CELL PH, V276, pC1139, DOI 10.1152/ajpcell.1999.276.5.C1139; ELMOATASSIM C, 1992, J BIOL CHEM, V267, P23664; Fernando KC, 1999, ARCH BIOCHEM BIOPHYS, V362, P197, DOI 10.1006/abbi.1998.1045; Ferrari D, 1999, FEBS LETT, V447, P71, DOI 10.1016/S0014-5793(99)00270-7; Gargett CE, 1996, BIOCHEM J, V313, P529, DOI 10.1042/bj3130529; Grahames CBA, 1999, BRIT J PHARMACOL, V127, P1915, DOI 10.1038/sj.bjp.0702732; Gu B, 1998, BLOOD, V92, P946; Gu BJ, 2000, AM J PHYSIOL-CELL PH, V279, pC1189, DOI 10.1152/ajpcell.2000.279.4.C1189; HICKMAN SE, 1994, BLOOD, V84, P2452; Humphreys BD, 1998, J LEUKOCYTE BIOL, V64, P265, DOI 10.1002/jlb.64.2.265; Humphreys BD, 1996, J IMMUNOL, V157, P5627; Humphreys BD, 2000, J BIOL CHEM, V275, P26792; Klapperstuck M, 2000, BBA-BIOMEMBRANES, V1467, P444, DOI 10.1016/S0005-2736(00)00245-5; KUSNER DJ, 1994, BIOCHEM J, V304, P485, DOI 10.1042/bj3040485; Kusner DJ, 2000, J IMMUNOL, V164, P379, DOI 10.4049/jimmunol.164.1.379; Lammas DA, 1997, IMMUNITY, V7, P433, DOI 10.1016/S1074-7613(00)80364-7; Lester HA, 2000, ANNU REV NEUROSCI, V23, P89, DOI 10.1146/annurev.neuro.23.1.89; Li GH, 2000, J BIOL CHEM, V275, P29107, DOI 10.1074/jbc.M910277199; Nagy PV, 2000, IMMUNOL LETT, V72, P23, DOI 10.1016/S0165-2478(00)00168-1; Nicke A, 1998, EMBO J, V17, P3016, DOI 10.1093/emboj/17.11.3016; Nihei OK, 2000, BLOOD, V96, P996, DOI 10.1182/blood.V96.3.996.015k02_996_1005; NUTTLE LC, 1994, J BIOL CHEM, V269, P13988; PENG L, 1998, CHIN MED J, V78, P508; Petrou S, 1997, FEBS LETT, V411, P339, DOI 10.1016/S0014-5793(97)00700-X; Philpott NJ, 1996, BLOOD, V87, P2244, DOI 10.1182/blood.V87.6.2244.bloodjournal8762244; Rassendren F, 1997, J BIOL CHEM, V272, P5482, DOI 10.1074/jbc.272.9.5482; Sharma N, 2000, KIDNEY INT, V57, P803, DOI 10.1046/j.1523-1755.2000.00918.x; Sikora A, 1999, J IMMUNOL, V163, P558; Small KM, 2000, J BIOL CHEM, V275, P38518, DOI 10.1074/jbc.M004550200; Solle M, 2001, J BIOL CHEM, V276, P125, DOI 10.1074/jbc.M006781200; Surprenant A, 1996, SCIENCE, V272, P735, DOI 10.1126/science.272.5262.735; TATHAM PER, 1990, J GEN PHYSIOL, V95, P459, DOI 10.1085/jgp.95.3.459; Torres GE, 1999, J BIOL CHEM, V274, P6653, DOI 10.1074/jbc.274.10.6653; Walker RG, 2000, SCIENCE, V287, P2229, DOI 10.1126/science.287.5461.2229; Wiley JS, 1998, AM J PHYSIOL-CELL PH, V275, pC1224, DOI 10.1152/ajpcell.1998.275.5.C1224; ZHENG LM, 1991, J CELL BIOL, V112, P279, DOI 10.1083/jcb.112.2.279	41	260	279	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 6	2001	276	14					11135	11142		10.1074/jbc.M010353200	http://dx.doi.org/10.1074/jbc.M010353200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	420AC	11150303	Green Published			2022-12-25	WOS:000167980900075
J	Hansen, CH; Wittstock, U; Olsen, CE; Hick, AJ; Pickett, JA; Halkier, BA				Hansen, CH; Wittstock, U; Olsen, CE; Hick, AJ; Pickett, JA; Halkier, BA			Cytochrome P450CYP79F1 from Arabidopsis catalyzes the conversion of dihomomethionine and trihomomethionine to the corresponding aldoximes in the biosynthesis of aliphatic glucosinolates	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAPE BRASSICA-NAPUS; ESCHERICHIA-COLI; CYANOGENIC GLUCOSIDES; SORGHUM-BICOLOR; ENZYMES; EXPRESSION; THALIANA; PLANTS; TRANSFORMATION; METABOLISM	Glucosinolates are natural plant products that have received rising attention due to their role in interactions between pests and crop plants and as chemical protectors against cancer. Glucosinolates are derived from amino acids and have aldoximes as intermediates. We report that cytochrome P450 CYP79F1 catalyzes aldoxime:formation in the biosynthesis of aliphatic glucosinolates in Arabidopsis thaliana. Using recombinant CYP79F1 functionally expressed in Escherichia coli, we show that both dihomomethionine and trihomomethionine are metabolized by CYP79F1 resulting in the formation of 5-methylthiopentanaldoxime and 6-methylthiohexanaldoxime, respectively. 5-methylthiopentanaldoxime is the precursor of the major glucosinolates in leaves of A. thaliana, i.e. 4-methylthiobutylglucosinolate and 4-methylsulfinylbutylglucosinolate, and a variety of other glucosinolates in Brassica sp, Transgenic A. thaliana with cosuppression of CYP79F1 have a reduced content of aliphatic glucosinolates and a highly increased level of dihomomethionine and trihomomethionine. The transgenic plants have a morphological phenotype showing loss of apical dominance and formation of multiple axillary shoots. Our data provide the first evidence that a cytochrome P450 catalyzes the N-hydroxylation of chain-elongated methionine homologues to the corresponding aldoximes in the biosynthesis of aliphatic glucosinolates.	Royal Vet & Agr Univ, Plant Biochem Lab, Dept Plant Biol, DK-1871 Frederiksberg C, Denmark; Royal Vet & Agr Univ, Dept Chem, DK-1871 Frederiksberg C, Denmark; Royal Vet & Agr Univ, Ctr Mol Plant Physiol, DK-1871 Frederiksberg C, Denmark; Rothamsted Expt Stn, Harpenden AL5 2JQ, Herts, England	University of Copenhagen; University of Copenhagen; University of Copenhagen; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Rothamsted Research	Halkier, BA (corresponding author), Royal Vet & Agr Univ, Plant Biochem Lab, Dept Plant Biol, Thorvaldsensvej 40, DK-1871 Frederiksberg C, Denmark.	halkier@biobase.dk	Olsen, Carl E/H-3031-2014; Halkier, Barbara A/H-3196-2014	Olsen, Carl E/0000-0002-2275-0596; Halkier, Barbara A/0000-0002-3742-702X; Wittstock, Ute/0000-0002-0914-8453				Andersen MD, 2000, J BIOL CHEM, V275, P1966, DOI 10.1074/jbc.275.3.1966; [Anonymous], 1988, ACS SYM SER; Ausubel F., 1999, CURRENT PROTOCOLS MO; Bak S, 1999, PLANT J, V20, P663, DOI 10.1046/j.1365-313X.1999.00642.x; Bak S, 1998, PLANT MOL BIOL, V38, P725, DOI 10.1023/A:1006064202774; BARNES HJ, 1991, P NATL ACAD SCI USA, V88, P5597, DOI 10.1073/pnas.88.13.5597; BENNETT R, 1993, PLANT PHYSIOL, V102, P1307, DOI 10.1104/pp.102.4.1307; BENNETT R, 1995, PLANTA, V196, P239, DOI 10.1007/BF00201380; Bennett RN, 1997, PLANT PHYSIOL, V114, P1283, DOI 10.1104/pp.114.4.1283; BUCHNER R, 1987, GLUCOSINOLATES RAPES, P155; Clough SJ, 1998, PLANT J, V16, P735, DOI 10.1046/j.1365-313x.1998.00343.x; DAWSON GW, 1993, J BIOL CHEM, V268, P27154; Fahey JW, 1997, P NATL ACAD SCI USA, V94, P10367, DOI 10.1073/pnas.94.19.10367; FENWICK GR, 1983, CRC CR REV FOOD SCI, V18, P123, DOI 10.1080/10408398209527361; GIOVANELLI J, 1985, PLANT PHYSIOL, V78, P555, DOI 10.1104/pp.78.3.555; Graser G, 2000, ARCH BIOCHEM BIOPHYS, V378, P411, DOI 10.1006/abbi.2000.1812; HAJDUKIEWICZ P, 1994, PLANT MOL BIOL, V25, P989, DOI 10.1007/BF00014672; Halkier BA, 1999, NATURALLY OCCURRING GLYCOSIDES, P193; HALKIER BA, 1995, ARCH BIOCHEM BIOPHYS, V322, P369, DOI 10.1006/abbi.1995.1477; Halkier BA, 1997, TRENDS PLANT SCI, V2, P425, DOI 10.1016/S1360-1385(97)01128-X; HAUGHN GW, 1991, PLANT PHYSIOL, V97, P217, DOI 10.1104/pp.97.1.217; HOGGE LR, 1988, J CHROMATOGR SCI, V26, P551, DOI 10.1093/chromsci/26.11.551; Hull AK, 2000, P NATL ACAD SCI USA, V97, P2379, DOI 10.1073/pnas.040569997; Kim J, 2000, PLANT SCI, V151, P9, DOI 10.1016/S0168-9452(99)00188-0; Mikkelsen MD, 2000, J BIOL CHEM, V275, P33712, DOI 10.1074/jbc.M001667200; Miroux B, 1996, J MOL BIOL, V260, P289, DOI 10.1006/jmbi.1996.0399; Nielsen JS, 2000, PLANT PHYSIOL, V122, P1311, DOI 10.1104/pp.122.4.1311; OMURA T, 1964, J BIOL CHEM, V239, P2370; PORTER TD, 1991, METHOD ENZYMOL, V206, P108; Ravanel S, 1998, P NATL ACAD SCI USA, V95, P7805, DOI 10.1073/pnas.95.13.7805; Rodman JE, 1998, AM J BOT, V85, P997, DOI 10.2307/2446366; Ronemus MJ, 1996, SCIENCE, V273, P654, DOI 10.1126/science.273.5275.654; ROSSITER JT, 1990, PHYTOCHEMISTRY, V29, P2509, DOI 10.1016/0031-9422(90)85177-H; SIBBESEN O, 1995, J BIOL CHEM, V270, P3506, DOI 10.1074/jbc.270.8.3506; Wittstock U, 2000, J BIOL CHEM, V275, P14659, DOI 10.1074/jbc.275.19.14659; ZAMBRYSKI P, 1983, EMBO J, V2, P2143, DOI 10.1002/j.1460-2075.1983.tb01715.x; ZHANG YS, 1992, P NATL ACAD SCI USA, V89, P2399, DOI 10.1073/pnas.89.6.2399	37	118	131	0	29	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 6	2001	276	14					11078	11085		10.1074/jbc.M010123200	http://dx.doi.org/10.1074/jbc.M010123200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	420AC	11133994	hybrid			2022-12-25	WOS:000167980900069
J	Holmes, A; Abraham, DJ; Sa, S; Xu, SW; Black, CM; Leask, A				Holmes, A; Abraham, DJ; Sa, S; Xu, SW; Black, CM; Leask, A			CTGF and SMADs, maintenance of scleroderma phenotype is independent of SMAD signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-BETA; FACTOR GENE-EXPRESSION; NECROSIS-FACTOR-ALPHA; TGF-BETA; SYSTEMIC-SCLEROSIS; INDUCED PHOSPHORYLATION; COLLAGEN-SYNTHESIS; SKIN FIBROBLASTS; TISSUE-SECTIONS; MESSENGER-RNA	In normal adult fibroblasts, transforming growth factor-beta (TGF beta) induces the expression of connective tissue growth:factor (CTGF). CTGF independently promotes fibroblast proliferation and matrix deposition, and in acute models of fibrosis promotes cell proliferation and collagen deposition acting synergistically with TGF-beta, In contrast to normal fibroblasts, fibroblasts cultured from fibrotic tissues express high basal levels of CTGF, even in the absence of added TGF beta, Induction of transcription by TGF beta requires the action of SMAD proteins. In this report we have investigated the role of SMADs in the TGF beta -induction of CTGF in normal fibroblasts and in the elevated levels of CTGF expression found in dermal fibroblasts cultured from lesional areas of patients with scleroderma, a progressive fibrotic disorder that can affect all organs of the body. We have identified a functional SMAD binding site in the CTGF promoter. TGF beta -induction of CTGF is dependent on SMAD3 and SMAD4:but not SMAD2 and is p300-independent, However, mutation of the SMAD binding site does not reduce the high level of CTGF promoter activity observed in dermal fibroblasts cultured from lesional areas of scleroderma patients, Conversely, the previously termed TGF beta RE in the CTGF promoter is required for basal CTGF promoter activity in normal fibroblasts and for the:elevated level of CTGF promoter activity in scleroderma fibroblasts, Thus, the maintenance of the fibrotic phenotype in scleroderma fibroblasts, as visualized by: excess CTGF expression, appears to be independent of SMAD-dependent TGF beta signaling. Furthermore, given CTGF's activities, the high level of CTGF expression observed in scleroderma lesions may contribute to the excessive scarring observed in this disorder.	FibroGen Inc, San Francisco, CA 94080 USA; UCL Royal Free & Univ Coll Med Sch, Ctr Rheumatol, London NW3 2PF, England	FibroGen; University of London; University College London; UCL Medical School	Leask, A (corresponding author), FibroGen Inc, 225 Gateway Blvd, San Francisco, CA 94080 USA.	aleask@fibrogen.com	Leask, Andy/ABH-9433-2020; Leask, Andrew/G-5217-2015		NIAMS NIH HHS [AR45879] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR045879] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ABE M, 1994, ANAL BIOCHEM, V216, P276, DOI 10.1006/abio.1994.1042; Abraham DJ, 2000, J BIOL CHEM, V275, P15220, DOI 10.1074/jbc.275.20.15220; Afrakhte M, 1998, BIOCHEM BIOPH RES CO, V249, P505, DOI 10.1006/bbrc.1998.9170; Ashcroft GS, 1999, NAT CELL BIOL, V1, P260, DOI 10.1038/12971; Bitzer M, 2000, GENE DEV, V14, P187; BLACK CM, 1998, OXFORD TXB RHEUMATOL, P771; Blobe GC, 2000, NEW ENGL J MED, V342, P1350, DOI 10.1056/NEJM200005043421807; BRADHAM DM, 1991, J CELL BIOL, V114, P1285, DOI 10.1083/jcb.114.6.1285; Brigstock DR, 1997, J BIOL CHEM, V272, P20275, DOI 10.1074/jbc.272.32.20275; Chen SJ, 1999, J INVEST DERMATOL, V112, P49, DOI 10.1046/j.1523-1747.1999.00477.x; Dammeier J, 1998, INT J BIOCHEM CELL B, V30, P909, DOI 10.1016/S1357-2725(98)00046-6; DEGUCHI Y, 1992, ANN RHEUM DIS, V51, P362, DOI 10.1136/ard.51.3.362; di Mola FF, 1999, ANN SURG, V230, P63, DOI 10.1097/00000658-199907000-00010; Duncan MR, 1999, FASEB J, V13, P1774, DOI 10.1096/fasebj.13.13.1774; Feng XH, 1998, GENE DEV, V12, P2153, DOI 10.1101/gad.12.14.2153; Grotendorst Gary R., 1997, Cytokine and Growth Factor Reviews, V8, P171, DOI 10.1016/S1359-6101(97)00010-5; Grotendorst GR, 1996, CELL GROWTH DIFFER, V7, P469; GRUSCHWITZ M, 1990, J INVEST DERMATOL, V94, P197, DOI 10.1111/1523-1747.ep12874503; HAYASAKA A, 1991, J HEPATOL, V13, P328, DOI 10.1016/0168-8278(91)90077-O; HIGLEY H, 1994, ARTHRITIS RHEUM, V37, P278, DOI 10.1002/art.1780370218; Hua XX, 1998, GENE DEV, V12, P3084, DOI 10.1101/gad.12.19.3084; IGARASHI A, 1995, J INVEST DERMATOL, V105, P280, DOI 10.1111/1523-1747.ep12318465; Igarashi A, 1996, J INVEST DERMATOL, V106, P729, DOI 10.1111/1523-1747.ep12345771; INAGAKI Y, 1995, J BIOL CHEM, V270, P3353, DOI 10.1074/jbc.270.7.3353; Ito Y, 1998, KIDNEY INT, V53, P853, DOI 10.1046/j.1523-1755.1998.00820.x; Janknecht R, 1998, GENE DEV, V12, P2114, DOI 10.1101/gad.12.14.2114; Jonk LJC, 1998, J BIOL CHEM, V273, P21145, DOI 10.1074/jbc.273.33.21145; Kretzschmar M, 1998, CURR OPIN GENET DEV, V8, P103, DOI 10.1016/S0959-437X(98)80069-5; Lagna G, 1996, NATURE, V383, P832, DOI 10.1038/383832a0; LEASK A, 1991, P NATL ACAD SCI USA, V88, P7948, DOI 10.1073/pnas.88.18.7948; LEROY EC, 1974, J CLIN INVEST, V54, P880, DOI 10.1172/JCI107827; Liu XD, 1997, P NATL ACAD SCI USA, V94, P10669, DOI 10.1073/pnas.94.20.10669; Luo KX, 1999, GENE DEV, V13, P2196, DOI 10.1101/gad.13.17.2196; MaciasSilva M, 1996, CELL, V87, P1215, DOI 10.1016/S0092-8674(00)81817-6; McCartney-Francis N L, 1998, Int Rev Immunol, V16, P553, DOI 10.3109/08830189809043009; MCWHIRTER A, 1994, LAB INVEST, V71, P885; MORELAND LW, 1992, AM J MED, V93, P628, DOI 10.1016/0002-9343(92)90195-H; Mori T, 1999, J CELL PHYSIOL, V181, P153, DOI 10.1002/(SICI)1097-4652(199910)181:1<153::AID-JCP16>3.0.CO;2-K; Moussad EEDA, 2000, MOL GENET METAB, V71, P276, DOI 10.1006/mgme.2000.3059; Nakao A, 1999, J CLIN INVEST, V104, P5, DOI 10.1172/JCI6094; Nakao A, 1997, EMBO J, V16, P5353, DOI 10.1093/emboj/16.17.5353; NEEDLEMAN BW, 1990, ARTHRITIS RHEUM, V33, P650, DOI 10.1002/art.1780330507; PELTONEN J, 1990, ARTHRITIS RHEUM-US, V33, P1829, DOI 10.1002/art.1780331211; Querfeld C, 1999, J DERMATOL SCI, V21, P13, DOI 10.1016/S0923-1811(99)00008-0; Roberts AB, 1999, MICROBES INFECT, V1, P1265, DOI 10.1016/S1286-4579(99)00258-0; Sato S, 2000, J RHEUMATOL, V27, P149; Shen X, 1998, MOL BIOL CELL, V9, P3309, DOI 10.1091/mbc.9.12.3309; Shi-Wen X, 2000, EXP CELL RES, V259, P213, DOI 10.1006/excr.2000.4972; Shimo T, 1998, J BIOCHEM-TOKYO, V124, P130, DOI 10.1093/oxfordjournals.jbchem.a022071; SMITH EA, 1990, J INVEST DERMATOL, V95, pS125, DOI 10.1111/1523-1747.ep12874998; Stroschein SL, 1999, SCIENCE, V286, P771, DOI 10.1126/science.286.5440.771; Sun Y, 1999, P NATL ACAD SCI USA, V96, P12442, DOI 10.1073/pnas.96.22.12442; Verrecchia F, 2000, J BIOL CHEM, V275, P30226, DOI 10.1074/jbc.M005310200; Vindevoghel L, 1998, J BIOL CHEM, V273, P13053, DOI 10.1074/jbc.273.21.13053; Yamamura Y, 2000, J BIOL CHEM, V275, P36295, DOI 10.1074/jbc.M006023200; Zawel L, 1998, MOL CELL, V1, P611, DOI 10.1016/S1097-2765(00)80061-1; Zhang Y, 1998, NATURE, V394, P909, DOI 10.1038/29814	57	353	382	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 6	2001	276	14					10594	10601		10.1074/jbc.M010149200	http://dx.doi.org/10.1074/jbc.M010149200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	420AC	11152469	hybrid			2022-12-25	WOS:000167980900005
J	Nishimori, S; Tanaka, Y; Chiba, T; Fujii, M; Imamura, T; Miyazono, K; Ogasawara, T; Kawaguchi, H; Igarashi, T; Fujita, T; Tanaka, K; Toyoshima, H				Nishimori, S; Tanaka, Y; Chiba, T; Fujii, M; Imamura, T; Miyazono, K; Ogasawara, T; Kawaguchi, H; Igarashi, T; Fujita, T; Tanaka, K; Toyoshima, H			Smad-mediated transcription is required for transforming growth factor-beta 1-induced p57(Kip2) proteolysis in osteoblastic cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UBIQUITIN LIGASE COMPLEX; FACTOR-BETA; I RECEPTORS; DIFFERENTIATION; PROTEINS; DEGRADATION; KINASE; PROLIFERATION; INHIBITORS; PATHWAY	Cyclin-dependent kinase inhibitory proteins (CKIs) are negative regulators of the cell cycle. Of all CKls, only p57(Kip2) plays an essential role(s) that other CKIs cannot compensate for in embryonic development. Recently, we found that p57(Kip2) is degraded through the ubiquitin-proteasome pathway in osteoblastic cells stimulated to proliferation by transforming growth factor (TGF)-beta1 (Urano, T., Yashiroda, H., Muraoka, RI., Tanaka, K., Hosoi, T.:, Inoue, S., Ouchi, Y., and Toyoshima, H. (1999) J. Biol, Chem. 274, 12197-12200). We report here that TGF-beta1-induced p57(Kip2) proteolysis is mediated through transcription by the Smad pathway. When the constitutively active form of the TGF-beta type I receptor ALK-5(TD) was ectopically expressed in osteoblastic cells, p57(Kip2) that had been accumulated by serum starvation causing the cell-cycle arrest was rapidly degraded in a manner analogous to TGF-beta1 stimulation. Moreover, Smad2 or Smad3 with Smad4 enhanced the proteolytic pathway of p57(Kip2). Th, degradation of p57(Kip2) evoked by TGF-beta1 was blocked by forced expression of an inhibitory Smad called Smad7 or by the addition of actinomycin D or alpha -amanitin. These results indicate that accelerated degradation of p57(Kip2) by TGF-beta1/Smad signaling is mediated through a newly synthesized factor(s) that modifies p57(Kip2) or the ubiquitin-proteasome pathway.	Tokyo Metropolitan Inst Med Sci, Dept Mol Oncol, Bunkyo Ku, Tokyo 1138613, Japan; Tokyo Metropolitan Inst Med Sci, Dept Tumor Biochem, Bunkyo Ku, Tokyo 1138613, Japan; Univ Tokyo, Branch Hosp, Dept Internal Med, Bunkyo Ku, Tokyo 1128688, Japan; Univ Tokyo, Grad Sch Med, Dept Oral & Maxillofacial Surg, Bunkyo Ku, Tokyo 1138655, Japan; Japanese Fdn Canc Res, Inst Canc, Dept Biochem, Toshima Ku, Tokyo 1708455, Japan	Tokyo Metropolitan Institute of Medical Science; Tokyo Metropolitan Institute of Medical Science; University of Tokyo; University of Tokyo; Japanese Foundation for Cancer Research	Tanaka, K (corresponding author), Tokyo Metropolitan Inst Med Sci, Dept Mol Oncol, Bunkyo Ku, 3-18-22 Honkomagome, Tokyo 1138613, Japan.		Ogasawara, Toru/I-1629-2014	Ogasawara, Toru/0000-0002-2996-081X				Atfi A, 1997, J BIOL CHEM, V272, P1429, DOI 10.1074/jbc.272.3.1429; Carrano AC, 1999, NAT CELL BIOL, V1, P193, DOI 10.1038/12013; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; Derynck R, 1998, CELL, V95, P737, DOI 10.1016/S0092-8674(00)81696-7; Deshaies RJ, 1999, ANNU REV CELL DEV BI, V15, P435, DOI 10.1146/annurev.cellbio.15.1.435; FRANZEN P, 1993, CELL, V75, P681, DOI 10.1016/0092-8674(93)90489-D; Fujii M, 1999, MOL BIOL CELL, V10, P3801, DOI 10.1091/mbc.10.11.3801; Galan JM, 1999, P NATL ACAD SCI USA, V96, P9124, DOI 10.1073/pnas.96.16.9124; Hannigan M, 1998, BIOCHEM BIOPH RES CO, V246, P55, DOI 10.1006/bbrc.1998.8570; Harper JW, 1999, NAT CELL BIOL, V1, pE5, DOI 10.1038/8952; HARTSOUGH MT, 1995, J BIOL CHEM, V270, P7117, DOI 10.1074/jbc.270.13.7117; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Hocevar BA, 1999, EMBO J, V18, P1345, DOI 10.1093/emboj/18.5.1345; Ishizuya T, 1997, J CLIN INVEST, V99, P2961, DOI 10.1172/JCI119491; Liberati NT, 1999, P NATL ACAD SCI USA, V96, P4844, DOI 10.1073/pnas.96.9.4844; Maniatis T, 1999, GENE DEV, V13, P505, DOI 10.1101/gad.13.5.505; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Massague J, 2000, GENE DEV, V14, P627; Miyazono K, 2000, ADV IMMUNOL, V75, P115, DOI 10.1016/S0065-2776(00)75003-6; ROBEY PG, 1987, J CELL BIOL, V105, P457, DOI 10.1083/jcb.105.1.457; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; TENDIJKE P, 1994, SCIENCE, V264, P101, DOI 10.1126/science.8140412; Urano T, 1999, J BIOL CHEM, V274, P12197, DOI 10.1074/jbc.274.18.12197; Vidal A, 2000, GENE, V247, P1, DOI 10.1016/S0378-1119(00)00092-5; WIESER R, 1995, EMBO J, V14, P2199, DOI 10.1002/j.1460-2075.1995.tb07214.x; Wirbelauer C, 2000, EMBO J, V19, P5362, DOI 10.1093/emboj/19.20.5362; WONG GL, 1975, P NATL ACAD SCI USA, V72, P3167, DOI 10.1073/pnas.72.8.3167; Wrana JL, 2000, CELL, V100, P189, DOI 10.1016/S0092-8674(00)81556-1; Yan Y, 1997, GENE DEV, V11, P973, DOI 10.1101/gad.11.8.973; Zachariae W, 1999, GENE DEV, V13, P2039, DOI 10.1101/gad.13.16.2039; Zhang PM, 1997, NATURE, V387, P151, DOI 10.1038/387151a0; Zhou PB, 1998, MOL CELL, V2, P571, DOI 10.1016/S1097-2765(00)80156-2	33	51	58	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 6	2001	276	14					10700	10705		10.1074/jbc.M007499200	http://dx.doi.org/10.1074/jbc.M007499200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	420AC	11152674	hybrid			2022-12-25	WOS:000167980900020
J	Ahn, C; Morris, NR				Ahn, C; Morris, NR			NUDF, a fungal homolog of the human LIS1 protein, functions as a dimer in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LISSENCEPHALY GENE-PRODUCT; ASPERGILLUS-NIDULANS; CYTOPLASMIC DYNEIN; NUCLEAR MIGRATION; NEURONAL MIGRATION; DYNACTIN COMPLEX; HEAVY-CHAIN; NEUROSPORA; INTERACTS; MOVEMENT	The NUDF protein is required for nuclear migration through the mycelium of the filamentous fungus Aspergillus nidulans, It is of particular interest, because it closely resembles a human protein, LIS1, that is required for development of the cerebral cortex. Both are similar to 50-kDa proteins with a short N-terminal predicted coiled coil and seven WD-40 domains in the C-terminal half of the molecule. They also interact with homologous proteins, suggesting that they may have similar biochemical functions. Here we describe the purification to homogeneity of NUDF protein in a single step from a cell-free extract of A. nidulans. We demonstrate that NUDF is a homodimer, that its dimerization occurs via the N-terminal coiled coil region of the molecule, and that it must be a dimer to support the growth of A. nidulans.	Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Pharmacol, Piscataway, NJ 08854 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center	Morris, NR (corresponding author), Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Pharmacol, 675 Hoes Lane, Piscataway, NJ 08854 USA.				NIGMS NIH HHS [GM52309] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052309] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Beckwith SM, 1998, J CELL BIOL, V143, P1239, DOI 10.1083/jcb.143.5.1239; Efimov VP, 2000, J CELL BIOL, V150, P681, DOI 10.1083/jcb.150.3.681; Faulkner NE, 2000, NAT CELL BIOL, V2, P784, DOI 10.1038/35041020; GarciaHiguera I, 1996, BIOCHEMISTRY-US, V35, P13985, DOI 10.1021/bi9612879; Hirotsune S, 1998, NAT GENET, V19, P333, DOI 10.1038/1221; KIM JS, 1993, PROTEIN SCI, V2, P348; Kitagawa M, 2000, FEBS LETT, V479, P57, DOI 10.1016/S0014-5793(00)01856-1; Lei YD, 2000, DEV BIOL, V226, P57, DOI 10.1006/dbio.2000.9848; Liu Z, 2000, NAT CELL BIOL, V2, P776, DOI 10.1038/35041011; Liu Z, 1999, DEVELOPMENT, V126, P4477; Minke PF, 1999, MOL MICROBIOL, V32, P1065, DOI 10.1046/j.1365-2958.1999.01421.x; Morris NR, 2000, J CELL BIOL, V148, P1097, DOI 10.1083/jcb.148.6.1097; Morris SM, 1998, CURR BIOL, V8, P603, DOI 10.1016/S0960-9822(98)70232-5; OSMANI AH, 1990, J CELL BIOL, V111, P543, DOI 10.1083/jcb.111.2.543; PLAMANN M, 1994, J CELL BIOL, V127, P139, DOI 10.1083/jcb.127.1.139; Smith DS, 2000, NAT CELL BIOL, V2, P767, DOI 10.1038/35041000; Swan A, 1999, NAT CELL BIOL, V1, P444, DOI 10.1038/15680; Tinsley JH, 1996, MOL BIOL CELL, V7, P731, DOI 10.1091/mbc.7.5.731; VALLEE R, 1993, P NATL ACAD SCI USA, V90, P8769, DOI 10.1073/pnas.90.19.8769; Vallee RB, 2000, BBA-MOL CELL RES, V1496, P89, DOI 10.1016/S0167-4889(00)00011-2; WARING RB, 1989, GENE, V79, P119, DOI 10.1016/0378-1119(89)90097-8; Willins DA, 1997, MOL GEN GENET, V255, P194, DOI 10.1007/s004380050489; Xiang X, 2000, CURR BIOL, V10, P603, DOI 10.1016/S0960-9822(00)00488-7; Xiang X, 1999, CURR OPIN MICROBIOL, V2, P636, DOI 10.1016/S1369-5274(99)00034-X; XIANG X, 1995, MOL BIOL CELL, V6, P297, DOI 10.1091/mbc.6.3.297; XIANG X, 1994, P NATL ACAD SCI USA, V91, P2100, DOI 10.1073/pnas.91.6.2100	26	25	28	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 30	2001	276	13					9903	9909		10.1074/jbc.M010233200	http://dx.doi.org/10.1074/jbc.M010233200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	420GC	11134054	hybrid			2022-12-25	WOS:000167996400045
J	Haynes, LP; Evans, GJO; Morgan, A; Burgoyne, RD				Haynes, LP; Evans, GJO; Morgan, A; Burgoyne, RD			A direct inhibitory role for the Rab3-specific effector, Noc2, in Ca2+-regulated exocytosis in neuroendocrine cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADRENAL CHROMAFFIN CELLS; REGULATED EXOCYTOSIS; PC12 CELLS; NSEC-1 MUNC-18; RAB PROTEINS; GTPASE RAB3A; ALPHA-SNAP; BINDING; RABPHILIN-3A; SECRETION	Rab proteins comprise a family of GTPases, conserved from yeast to mammals, which are integral components of membrane trafficking pathways. Rab3A is a neural/neuroendocrine-specific member of the Rab family involved in Ca2+-regulated exocytosis, where it functions in an inhibitory capacity controlling recruitment of secretory vesicles into a releasable pool at the plasma membrane. The effector by which Rab3A exerts its inhibitory effect is unclear as the Rab3A effecters Rabphilin and RIM have been excluded from for this role. One putative Rab3A effector in dense-core granule exocytosis is the cytosolic zinc finger protein, Noc2, We have established that overexpression of Noc2 in PC12 cells has a direct inhibitory effect upon Ca2+-triggered exocytosis in permeabilized cells. We demonstrate specific nucleotide-dependent binding of Noc2 to Rab3A and show that the inhibition of exocytosis is dependent upon this interaction since Rab3A binding-deficient mutants of Noc2 do not inhibit exocytosis, We propose that Noc2 may be a negative effector for Rab3A in regulated exocytosis of dense-core granules from endocrine eels.	Univ Liverpool, Physiol Lab, Liverpool L69 3BX, Merseyside, England	University of Liverpool	Burgoyne, RD (corresponding author), Univ Liverpool, Physiol Lab, Crown St, Liverpool L69 3BX, Merseyside, England.	burgoyne@liverpool.ac.uk	Burgoyne, Robert/C-6706-2008; Morgan, Alan/AAI-8875-2020; Burgoyne, Robert D/P-6641-2019	Burgoyne, Robert/0000-0002-9219-0387; Burgoyne, Robert D/0000-0002-9219-0387; Evans, Gareth John Owen/0000-0003-2573-7001; Morgan, Alan/0000-0002-0346-1289				Arribas M, 1997, EUR J CELL BIOL, V74, P209; Burgoyne RD, 1998, BIOESSAYS, V20, P328, DOI 10.1002/(SICI)1521-1878(199804)20:4<328::AID-BIES9>3.0.CO;2-L; Calakos N, 1996, PHYSIOL REV, V76, P1; CHAMBERLAIN LH, 1995, J CELL BIOL, V130, P1063, DOI 10.1083/jcb.130.5.1063; Christoforidis S, 1999, NATURE, V397, P621, DOI 10.1038/17618; Chung SH, 1998, J BIOL CHEM, V273, P10240, DOI 10.1074/jbc.273.17.10240; Chung SH, 1999, J BIOL CHEM, V274, P18113, DOI 10.1074/jbc.274.25.18113; Chung SH, 1997, J NEUROCHEM, V69, P164; CHUNG SH, 1995, J BIOL CHEM, V270, P16714, DOI 10.1074/jbc.270.28.16714; Coppola T, 1999, EMBO J, V18, P5885, DOI 10.1093/emboj/18.21.5885; Darchen F, 2000, BIOCHIMIE, V82, P375, DOI 10.1016/S0300-9084(00)00219-4; DARCHEN F, 1990, P NATL ACAD SCI USA, V87, P5692, DOI 10.1073/pnas.87.15.5692; DARCHEN F, 1995, J CELL SCI, V108, P1639; Doussau F, 1998, J NEUROSCI, V18, P3147; Dulubova I, 1999, EMBO J, V18, P4372, DOI 10.1093/emboj/18.16.4372; Fisher RJ, 1999, PFLUG ARCH EUR J PHY, V437, P754, DOI 10.1007/s004240050842; GEPPERT M, 1994, NATURE, V369, P493, DOI 10.1038/369493a0; Geppert M, 1997, NATURE, V387, P810, DOI 10.1038/42954; Graham ME, 1997, MOL BIOL CELL, V8, P431, DOI 10.1091/mbc.8.3.431; Graham ME, 2000, BIOCHIMIE, V82, P469, DOI 10.1016/S0300-9084(00)00196-6; Graham ME, 1997, J NEUROCHEM, V69, P2369; Haynes LP, 1999, BIOCHEM J, V342, P707, DOI 10.1042/0264-6021:3420707; HOLZ RW, 1994, J BIOL CHEM, V269, P10229; Iezzi M, 1999, MOL ENDOCRINOL, V13, P202, DOI 10.1210/me.13.2.202; Joberty G, 1999, J CELL SCI, V112, P3579; Johannes L, 1998, J NEUROCHEM, V71, P1127; JOHANNES L, 1994, EMBO J, V13, P2029, DOI 10.1002/j.1460-2075.1994.tb06476.x; Kato M, 1996, J BIOL CHEM, V271, P31775, DOI 10.1074/jbc.271.50.31775; Kotake K, 1997, J BIOL CHEM, V272, P29407, DOI 10.1074/jbc.272.47.29407; LIAN JP, 1994, NATURE, V372, P698, DOI 10.1038/372698a0; Lupashin VV, 1997, SCIENCE, V276, P1255, DOI 10.1126/science.276.5316.1255; McFerran BW, 1998, J BIOL CHEM, V273, P22768, DOI 10.1074/jbc.273.35.22768; MCKIERNAN CJ, 1993, J BIOL CHEM, V268, P24449; Nonet ML, 1997, J NEUROSCI, V17, P8061; Novick P, 1997, CURR OPIN CELL BIOL, V9, P496, DOI 10.1016/S0955-0674(97)80025-7; Ostermeier C, 1999, CELL, V96, P363, DOI 10.1016/S0092-8674(00)80549-8; Park JB, 1997, J BIOL CHEM, V272, P20857, DOI 10.1074/jbc.272.33.20857; Peterson MR, 1999, CURR BIOL, V9, P159, DOI 10.1016/S0960-9822(99)80071-2; Pfeffer SR, 1999, NAT CELL BIOL, V1, pE17, DOI 10.1038/8967; Regazzi R, 1996, J CELL SCI, V109, P2265; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; Schluter OM, 1999, J NEUROSCI, V19, P5834, DOI 10.1523/JNEUROSCI.19-14-05834.1999; SHIRATAKI H, 1993, MOL CELL BIOL, V13, P2061, DOI 10.1128/MCB.13.4.2061; SIMONS K, 1993, NEURON, V11, P789, DOI 10.1016/0896-6273(93)90109-5; SOGAARD M, 1994, CELL, V78, P937, DOI 10.1016/0092-8674(94)90270-4; Steel GJ, 1997, BIOCHEM J, V325, P511, DOI 10.1042/bj3250511; SUDHOF TC, 1995, NATURE, V375, P645, DOI 10.1038/375645a0; VONMOLLARD GF, 1990, P NATL ACAD SCI USA, V87, P1988, DOI 10.1073/pnas.87.5.1988; Wang Y, 1997, NATURE, V388, P593, DOI 10.1038/41580; WICK PF, 1993, J BIOL CHEM, V268, P10983; YAMAGUCHI T, 1993, J BIOL CHEM, V268, P27164	51	45	51	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 30	2001	276	13					9726	9732		10.1074/jbc.M006959200	http://dx.doi.org/10.1074/jbc.M006959200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	420GC	11134008	hybrid			2022-12-25	WOS:000167996400021
J	Kakizawa, T; Miyamoto, T; Ichikawa, K; Takeda, T; Suzuki, S; Mori, J; Kumagai, M; Yamashita, K; Hashizume, K				Kakizawa, T; Miyamoto, T; Ichikawa, K; Takeda, T; Suzuki, S; Mori, J; Kumagai, M; Yamashita, K; Hashizume, K			Silencing mediator for retinoid and thyroid hormone receptors interacts with octamer transcription factor-1 and acts as a transcriptional repressor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HISTONE DEACETYLASE COMPLEX; ACUTE MYELOID-LEUKEMIA; POU DOMAIN; GLUCOCORTICOID-RECEPTOR; FUSION PARTNER; N-COR; OCT-1; COACTIVATOR; BINDING; SMRT	Octamer transcription factor-1 (Oct-l) is a member of the POU (Pit-l, Oct-1, unc-86) family of transcription factors and is involved in the transcriptional regulation of a variety of gene expressions related to cell cycle regulation, development, and hormonal signals. It has been shown that Oct-1 acts not only as a transcriptional activator but also as a transcriptional repressor for certain genes. The mechanism of the repressive function of Oct-1 has not been well understood. Here we demonstrate by using the glutathione S-transferase pull-down assays and coimmunoprecipitation assays that the POU domain of Oct-1 directly interacts with a silencing mediator for retinoid and thyroid hormone receptors (SMRT). The interaction surfaces are located in the C-terminal region of SMRT, which are different from previously described silencing domains I and II or receptor interacting domains I and II. In transient transfection assays in COS1 cells, overexpression of SMRT attenuated the augmentation of Oct-1 transcriptional activity by OBF-1/OCA-B, activator for Oct-1. In pull-down assays, increasing amounts of SMRT could compete the binding of OCA-B to Oct-1 POU domain. The activity of Oct-1 could be determined by a regulated balance between SMRT and OCA-B, Furthermore, cotransfected unliganded thyroid hormone receptor enhanced the transactivation by Oct-1, and addition of 3,3',5-tri-iodo-L-thyronine obliterated the stimulatory effects. Consequently, in the presence of cotransfected thyroid hormone receptor, the octamer response element acts as an element negatively regulated by 3,3',5-tri-iodo-L-thyronine. The results suggest that the transcriptional activity of Oct-1 can be modulated by interaction through its POU domain by a silencing mediator SMRT resulting in the cross-talk between Oct-1 and nuclear receptors.	Shinshu Univ, Sch Med, Dept Agingn Med & Geriatr, Matsumoto, Nagano 3908621, Japan	Shinshu University	Miyamoto, T (corresponding author), Shinshu Univ, Sch Med, Dept Agingn Med & Geriatr, 3-1-1 Asahi, Matsumoto, Nagano 3908621, Japan.	miyamoto@hsp.md.shinshu-u.ac.jp						Asahara H, 1999, MOL CELL BIOL, V19, P8219; Chandran UR, 1999, J BIOL CHEM, V274, P2372, DOI 10.1074/jbc.274.4.2372; CHEN JD, 1995, NATURE, V377, P454, DOI 10.1038/377454a0; COENJAERTS FEJ, 1994, EMBO J, V13, P5401, DOI 10.1002/j.1460-2075.1994.tb06875.x; FLETCHER C, 1987, CELL, V51, P773, DOI 10.1016/0092-8674(87)90100-0; Gelmetti V, 1998, MOL CELL BIOL, V18, P7185, DOI 10.1128/MCB.18.12.7185; Gstaiger M, 1996, EMBO J, V15, P2781, DOI 10.1002/j.1460-2075.1996.tb00638.x; Guenther MG, 2000, GENE DEV, V14, P1048; Heinzel T, 1997, NATURE, V387, P43, DOI 10.1038/387043a0; HERR W, 1988, GENE DEV, V2, P1513, DOI 10.1101/gad.2.12a.1513; Hong SH, 1997, P NATL ACAD SCI USA, V94, P9028, DOI 10.1073/pnas.94.17.9028; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; Inamoto S, 1997, J BIOL CHEM, V272, P29852, DOI 10.1074/jbc.272.47.29852; Kakizawa T, 1999, J BIOL CHEM, V274, P19103, DOI 10.1074/jbc.274.27.19103; KUTOH E, 1992, MOL CELL BIOL, V12, P4960, DOI 10.1128/MCB.12.11.4960; Lee SK, 2000, J BIOL CHEM, V275, P12470, DOI 10.1074/jbc.275.17.12470; Lin RJ, 1998, NATURE, V391, P811, DOI 10.1038/35895; Luo Y, 1998, MOL CELL BIOL, V18, P3803, DOI 10.1128/MCB.18.7.3803; LUO Y, 1995, MOL CELL BIOL, V15, P4115; Lutterbach B, 1998, MOL CELL BIOL, V18, P7176, DOI 10.1128/MCB.18.12.7176; MIYAMOTO T, 1991, ENDOCRINOLOGY, V129, P907, DOI 10.1210/endo-129-2-907; MURPHY S, 1992, MOL CELL BIOL, V12, P3247, DOI 10.1128/MCB.12.7.3247; Nagy L, 1997, CELL, V89, P373, DOI 10.1016/S0092-8674(00)80218-4; NAKAI A, 1988, MOL ENDOCRINOL, V2, P1087, DOI 10.1210/mend-2-11-1087; NAKSHATRI H, 1995, J BIOL CHEM, V270, P19613, DOI 10.1074/jbc.270.33.19613; Prefontaine GG, 1999, J BIOL CHEM, V274, P26713, DOI 10.1074/jbc.274.38.26713; Sauter P, 1998, MOL CELL BIOL, V18, P7397, DOI 10.1128/MCB.18.12.7397; Schwachtgen JL, 1998, BLOOD, V92, P1247, DOI 10.1182/blood.V92.4.1247.416k08_1247_1258; Shah PC, 1997, EMBO J, V16, P7105, DOI 10.1093/emboj/16.23.7105; STRUBIN M, 1995, CELL, V80, P497, DOI 10.1016/0092-8674(95)90500-6; STURM RA, 1988, NATURE, V336, P601, DOI 10.1038/336601a0; STURM RA, 1988, GENE DEV, V2, P1582, DOI 10.1101/gad.2.12a.1582; Subramaniam N, 1998, J BIOL CHEM, V273, P23567, DOI 10.1074/jbc.273.36.23567; Wang JX, 1998, P NATL ACAD SCI USA, V95, P10860, DOI 10.1073/pnas.95.18.10860; Xu L, 1998, NATURE, V395, P301, DOI 10.1038/26270; YOSHIDA M, 1990, J BIOL CHEM, V265, P17174; ZWILLING S, 1995, EMBO J, V14, P1198, DOI 10.1002/j.1460-2075.1995.tb07103.x; ZWILLING S, 1994, NUCLEIC ACIDS RES, V22, P1655, DOI 10.1093/nar/22.9.1655	38	26	27	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 30	2001	276	13					9720	9725		10.1074/jbc.M008531200	http://dx.doi.org/10.1074/jbc.M008531200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	420GC	11134019	hybrid			2022-12-25	WOS:000167996400020
J	Kasahara, M; Unno, T; Yashiro, K; Ohmori, M				Kasahara, M; Unno, T; Yashiro, K; Ohmori, M			CyaG, a novel cyanobacterial adenylyl cyclase and a possible ancestor of mammalian guanylyl cyclases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONE-ROD DYSTROPHY; SPIRULINA-PLATENSIS; RETGC-1; GENE; PROTEINS; DIMERIZATION; ACTIVATION; SEQUENCES; MUTATION; ENCODES	A novel gene encoding an adenylyl cyclase, designated cyaG, was identified in the filamentous cyanobacterium Spirulina platensis, The predicted amino acid sequence of the C-terminal region of cyaG was similar to the catalytic domains of Class III adenylyl and guanylyl cyclases, The N-terminal region next to the catalytic domain of CyaG was similar to the dimerization domain, which is highly conserved among guanylyl cyclases. As a whole, CyaG is more closely related to guanylyl cyclases than to adenylyl cyclases in its primary structure. The catalytic domain of CyaG was expressed in Escherichia coli and partially purified. CyaG showed adenylyl cyclase (but not guanylyl cyclase) activity. By site-directed mutagenesis of three amino acid residues (Lys(533), Ile(603), and Asp(605)) within the purine ring recognition site of CyaG to Glu, Arg, and Cys, respectively, CyaG was transformed to a guanylyl cyclase that produced cGMP instead of cAMP. Thus having properties of both cyclases, CyaG may therefore represent a critical position in the evolution of Class III adenylyl and guanylyl cyclases.	Univ Tokyo, Grad Sch Arts & Sci, Dept Life Sci, Tokyo 153, Japan	University of Tokyo	Ohmori, M (corresponding author), Univ Tokyo, Grad Sch Arts & Sci, Dept Life Sci, 4-6-1 Komaba, Tokyo 153, Japan.	cohmori@mail.ecc.u-tokyo.ac.jp						BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Buck J, 1999, P NATL ACAD SCI USA, V96, P79, DOI 10.1073/pnas.96.1.79; DANCHIN A, 1993, ADV SEC MESS PHOSPH, V27, P109; de Alda JAGO, 2000, J BACTERIOL, V182, P3839, DOI 10.1128/JB.182.13.3839-3842.2000; DE RE, 1973, BIOCHEM BIOPH RES CO, V55, P758; DEV IK, 1990, J BIOENERG BIOMEMBR, V22, P271, DOI 10.1007/BF00763168; FIELD J, 1988, MOL CELL BIOL, V8, P2159, DOI 10.1128/MCB.8.5.2159; Kasahara M, 1999, J BIOL CHEM, V274, P15167, DOI 10.1074/jbc.274.21.15167; Kasahara M, 1997, PLANT CELL PHYSIOL, V38, P828, DOI 10.1093/oxfordjournals.pcp.a029241; Kelsell RE, 1998, HUM MOL GENET, V7, P1179, DOI 10.1093/hmg/7.7.1179; KRUPINSKI J, 1989, SCIENCE, V244, P1558, DOI 10.1126/science.2472670; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEPPLA SH, 1984, ADV CYCLIC NUCL PROT, V17, P189; Linder JU, 1999, EMBO J, V18, P4222, DOI 10.1093/emboj/18.15.4222; Liu Y, 1997, P NATL ACAD SCI USA, V94, P13414, DOI 10.1073/pnas.94.25.13414; LONDOS C, 1977, J BIOL CHEM, V252, P5957; MACKLE MM, 1994, J BACTERIOL, V176, P1857, DOI 10.1128/jb.176.7.1857-1864.1994; Perrault I, 1998, AM J HUM GENET, V63, P651, DOI 10.1086/301985; Sambrook J., 1989, MOL CLONING LAB MANU, V2nd, ed.; Sismeiro O, 1998, J BACTERIOL, V180, P3339, DOI 10.1128/JB.180.13.3339-3344.1998; Sunahara RK, 1998, J BIOL CHEM, V273, P16332, DOI 10.1074/jbc.273.26.16332; Tesmer JJG, 1997, SCIENCE, V278, P1907, DOI 10.1126/science.278.5345.1907; Tucker CL, 1999, P NATL ACAD SCI USA, V96, P9039, DOI 10.1073/pnas.96.16.9039; Tucker CL, 1998, P NATL ACAD SCI USA, V95, P5993, DOI 10.1073/pnas.95.11.5993; VONHEIJNE G, 1985, J MOL BIOL, V184, P99, DOI 10.1016/0022-2836(85)90046-4; WILSON EM, 1995, BIOCHEMISTRY-US, V34, P4696, DOI 10.1021/bi00014a025; WOLFF J, 1980, P NATL ACAD SCI-BIOL, V77, P3841, DOI 10.1073/pnas.77.7.3841; Yahr TL, 1998, P NATL ACAD SCI USA, V95, P13899, DOI 10.1073/pnas.95.23.13899; Yashiro K, 1996, PLANT MOL BIOL, V31, P175, DOI 10.1007/BF00020618; Zhang GY, 1997, NATURE, V386, P247, DOI 10.1038/386247a0	30	30	32	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 30	2001	276	13					10564	10569		10.1074/jbc.M008006200	http://dx.doi.org/10.1074/jbc.M008006200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	420GC	11134014	hybrid			2022-12-25	WOS:000167996400126
J	Matsuo, Y; Akiyama, N; Nakamura, H; Yodoi, J; Noda, M; Kizaka-Kondoh, S				Matsuo, Y; Akiyama, N; Nakamura, H; Yodoi, J; Noda, M; Kizaka-Kondoh, S			Identification of a novel thioredoxin-related transmembrane protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM STRESS; BREFELDIN-A; DISULFIDE-ISOMERASE; REDOX REGULATION; QUALITY-CONTROL; GROWTH-FACTOR; CLONING; ER; REDUCTION; APOPTOSIS	We recently identified a series of transforming growth factor-beta -responsive genes in A549 human adenocarcinoma cell line by a gene trap screening method. Here we report the molecular cloning and characterization of one of these genes, designated TMX, that encodes a novel protein of 280 amino acid residues. The TMX protein possesses an N-terminal signal peptide followed by one thioredoxin (Trx)-like domain with a unique active site sequence, Cys-Pro-Ala-Cys, and a potential transmembrane domain. There are putative TMX homologs with identical active site sequences in the Caenorhabditis elegans and Drosophila genomes, Using recombinant proteins expressed in Escherichia coli, we demonstrated the activity of the Trx domain of TMX to cleave the interchain disulfide bridges in insulin in vitro, The TMX transcript is widely expressed in normal human tissues, and subcellular fractionation and immunostaining for an epitope-tagged TMX protein suggest that TMX is predominantly localized in the endoplasmic reticulum (ER), When TMX was expressed in HEK293 cells, it significantly suppressed the apoptosis induced by brefeldin A, an inhibitor of ER-Golgi transport. This activity was abolished when two Cys residues in the active site sequence were mutated to Ser, suggesting that the Trx-like activity of TMX may help relieve ER stress caused by brefeldin A.	Kyoto Univ, Grad Sch Med, Dept Mol Oncol, Sakyo Ku, Kyoto 6068501, Japan; Kyoto Univ, Inst Virus Res, Dept Biol Responses, Sakyo Ku, Kyoto 6068507, Japan	Kyoto University; Kyoto University	Noda, M (corresponding author), Kyoto Univ, Grad Sch Med, Dept Mol Oncol, Sakyo Ku, Kyoto 6068501, Japan.	mnoda@virus.kyoto-u.ac.jp	Kondoh, Shinae/C-6937-2015; Kondoh, Shinae/AAF-8745-2020	Kondoh, Shinae/0000-0003-3085-5782; Kondoh, Shinae/0000-0003-3085-5782; Matsuo, Yoshiyuki/0000-0002-3183-4871				Adams MD, 2000, SCIENCE, V287, P2185, DOI 10.1126/science.287.5461.2185; Akiyama N, 2000, MOL CELL BIOL, V20, P3266, DOI 10.1128/MCB.20.9.3266-3273.2000; Chardin P, 1999, CELL, V97, P153, DOI 10.1016/S0092-8674(00)80724-2; FREEDMAN RB, 1994, TRENDS BIOCHEM SCI, V19, P331, DOI 10.1016/0968-0004(94)90072-8; Guo H, 1998, EXP CELL RES, V245, P57, DOI 10.1006/excr.1998.4235; HAMMOND C, 1994, J CELL BIOL, V126, P41, DOI 10.1083/jcb.126.1.41; Harding HP, 1999, NATURE, V397, P271, DOI 10.1038/16729; Hayashi S, 1997, NUCLEIC ACIDS RES, V25, P4035, DOI 10.1093/nar/25.20.4035; Haze K, 1999, MOL BIOL CELL, V10, P3787, DOI 10.1091/mbc.10.11.3787; Hirota K, 1997, P NATL ACAD SCI USA, V94, P3633, DOI 10.1073/pnas.94.8.3633; HOGEBOOM GH, 1948, J BIOL CHEM, V172, P619; HOLMGREN A, 1985, ANNU REV BIOCHEM, V54, P237, DOI 10.1146/annurev.bi.54.070185.001321; HOLMGREN A, 1979, J BIOL CHEM, V254, P9627; HOLMGREN A, 1989, J BIOL CHEM, V264, P13963; JACKSON MR, 1990, EMBO J, V9, P3153, DOI 10.1002/j.1460-2075.1990.tb07513.x; KLAUSNER RD, 1992, J CELL BIOL, V116, P1071, DOI 10.1083/jcb.116.5.1071; KOIZUMI K, 1976, J BIOCHEM-TOKYO, V79, P739, DOI 10.1093/oxfordjournals.jbchem.a131126; Kondoh G, 1999, FEBS LETT, V458, P299, DOI 10.1016/S0014-5793(99)01172-2; Kopito RR, 1997, CELL, V88, P427, DOI 10.1016/S0092-8674(00)81881-4; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; Kurooka H, 1997, GENOMICS, V39, P331, DOI 10.1006/geno.1996.4493; LAURENT TC, 1964, J BIOL CHEM, V239, P3436; Lee KK, 1998, J BIOL CHEM, V273, P19160, DOI 10.1074/jbc.273.30.19160; Li Q, 1998, VIROLOGY, V252, P28, DOI 10.1006/viro.1998.9417; Makino Y, 1996, J CLIN INVEST, V98, P2469, DOI 10.1172/JCI119065; MATTHEWS JR, 1992, NUCLEIC ACIDS RES, V20, P3821, DOI 10.1093/nar/20.15.3821; MITSUI A, 1992, BIOCHEM BIOPH RES CO, V186, P1220, DOI 10.1016/S0006-291X(05)81536-0; MUNRO S, 1987, CELL, V48, P899, DOI 10.1016/0092-8674(87)90086-9; Nakagawa T, 2000, NATURE, V403, P98, DOI 10.1038/47513; Nakamura H, 1997, ANNU REV IMMUNOL, V15, P351, DOI 10.1146/annurev.immunol.15.1.351; NAKAMURA H, 1998, CURR TREND IMMUNOL, V1, P133; NOIVA R, 1992, J BIOL CHEM, V267, P3553; OBLONG JE, 1994, J BIOL CHEM, V269, P11714; POZZAN T, 1994, PHYSIOL REV, V74, P595, DOI 10.1152/physrev.1994.74.3.595; Schultz J, 2000, NUCLEIC ACIDS RES, V28, P231, DOI 10.1093/nar/28.1.231; Schultz J, 1998, P NATL ACAD SCI USA, V95, P5857, DOI 10.1073/pnas.95.11.5857; Shao RG, 1996, EXP CELL RES, V227, P190, DOI 10.1006/excr.1996.0266; Sidrauski C, 1998, TRENDS CELL BIOL, V8, P245, DOI 10.1016/S0962-8924(98)01267-7; Spyrou G, 1997, J BIOL CHEM, V272, P2936, DOI 10.1074/jbc.272.5.2936; TAGAYA Y, 1989, EMBO J, V8, P757, DOI 10.1002/j.1460-2075.1989.tb03436.x; Tirasophon W, 1998, GENE DEV, V12, P1812, DOI 10.1101/gad.12.12.1812; WAKASUGI N, 1990, P NATL ACAD SCI USA, V87, P8282, DOI 10.1073/pnas.87.21.8282; Wang XZ, 1998, EMBO J, V17, P5708, DOI 10.1093/emboj/17.19.5708; Welihinda AA, 1999, GENE EXPRESSION, V7, P293; WILSON R, 1994, NATURE, V368, P32, DOI 10.1038/368032a0; WOLLMAN EE, 1988, J BIOL CHEM, V263, P15506; Yoshida H, 1998, J BIOL CHEM, V273, P33741, DOI 10.1074/jbc.273.50.33741; Zhou MY, 1999, MOL CELL, V4, P925, DOI 10.1016/S1097-2765(00)80222-1	48	90	99	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 30	2001	276	13					10032	10038		10.1074/jbc.M011037200	http://dx.doi.org/10.1074/jbc.M011037200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	420GC	11152479	Green Submitted, hybrid			2022-12-25	WOS:000167996400062
J	Mongiat, M; Otto, J; Oldershaw, R; Ferrer, F; Sato, JD; Iozzo, RV				Mongiat, M; Otto, J; Oldershaw, R; Ferrer, F; Sato, JD; Iozzo, RV			Fibroblast growth factor-binding protein is a novel partner for perlecan protein core	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPARAN-SULFATE PROTEOGLYCAN; DENSITY-LIPOPROTEIN-RECEPTOR; CELL-ADHESION MOLECULES; COLLAGEN TYPE-IV; BASEMENT-MEMBRANES; DOMAIN-III; STRUCTURAL CHARACTERIZATION; 2-HYBRID SYSTEM; GLOBULAR DOMAIN; TUMOR-GROWTH	Perlecan, a widespread heparan sulfate proteoglycan, functions as a bioactive reservoir for growth factors by stabilizing them against misfolding or proteolysis. These factors, chiefly members of the fibroblast growth factor (FGF) gene family, are coupled to the N-terminal heparan sulfate chains, which augment high affinity binding and receptor activation. However, rather little is known about biological partners of the protein core. The major goal of this study was to identify novel proteins that interact with the protein core of perlecan. Using the yeast two-hybrid system and domain III of perlecan as bait, we screened similar to0.5 10(6) cDNA clones from a keratinocyte library and identified a strongly interactive clone. This cDNA corresponded to FGF-binding protein (FGF-BP), a secreted protein previously shown to bind acidic and basic FGF and to modulate their activities. Using a panel of deletion mutants, FGF-BP binding was localized to the second EGF repeat of domain III, a region very close to the binding site for FGF7. FGF-BP could be coimmunoprecipitated with an antibody against perlecan and bound in solution to recombinant domain III-alkaline phosphatase fusion protein. Immunohistochemical analyses revealed colocalization of FGF-BP and perlecan in the pericellular stroma of various squamous cell carcinomas suggesting a potential in vivo interaction. Thus, FGF-BP should be considered a novel biological ligand for perlecan, an interaction that could influence cancer growth and tissue remodeling.	Thomas Jefferson Univ, Dept Pathol Anat & Cell Biol, Philadelphia, PA 19107 USA; Amer Type Culture Collect, Div Cell Mol & Dev Biol, Manassas, VA 20110 USA; Thomas Jefferson Univ, Kimmel Canc Ctr, Cellular Biol & Signaling Program, Philadelphia, PA 19107 USA	Jefferson University; Jefferson University	Iozzo, RV (corresponding author), Thomas Jefferson Univ, Dept Pathol Anat & Cell Biol, 1020 Locust St,Rm 249,Jefferson Alumni Hall, Philadelphia, PA 19107 USA.		Mongiat, Maurizio/H-8297-2018; Iozzo, Renato/AAS-1980-2020	Mongiat, Maurizio/0000-0001-6509-0068; Iozzo, Renato/0000-0002-5908-5112	NCI NIH HHS [R01 CA47282, R01 CA39481] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA039481, R01CA047282] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adatia R, 1997, ANN ONCOL, V8, P1257, DOI 10.1023/A:1008243115385; Aho S, 1998, MATRIX BIOL, V17, P401, DOI 10.1016/S0945-053X(98)90100-7; Aigner A, 2000, GROWTH FACTORS, V18, P51, DOI 10.3109/08977190009003233; Arikawa-Hirasawa E, 1999, NAT GENET, V23, P354, DOI 10.1038/15537; Aviezer D, 1997, MOL CELL BIOL, V17, P1938, DOI 10.1128/MCB.17.4.1938; AVIEZER D, 1994, CELL, V79, P1005, DOI 10.1016/0092-8674(94)90031-0; BATTAGLIA C, 1992, EUR J BIOCHEM, V208, P359, DOI 10.1111/j.1432-1033.1992.tb17195.x; BATTAGLIA C, 1993, EUR J CELL BIOL, V61, P92; Bein K, 2000, J BIOL CHEM, V275, P32167, DOI 10.1074/jbc.M003834200; Bernfield M, 1999, ANNU REV BIOCHEM, V68, P729, DOI 10.1146/annurev.biochem.68.1.729; Brown JC, 1997, EUR J BIOCHEM, V250, P39, DOI 10.1111/j.1432-1033.1997.t01-1-00039.x; CARDIN AD, 1989, ARTERIOSCLEROSIS, V9, P21, DOI 10.1161/01.ATV.9.1.21; CHAKRAVARTI S, 1995, J BIOL CHEM, V270, P404, DOI 10.1074/jbc.270.1.404; CHIEN CT, 1991, P NATL ACAD SCI USA, V88, P9578, DOI 10.1073/pnas.88.21.9578; COHEN IR, 1993, P NATL ACAD SCI USA, V90, P10404, DOI 10.1073/pnas.90.21.10404; COHEN IR, 1994, CANCER RES, V54, P5771; Costell M, 1999, J CELL BIOL, V147, P1109, DOI 10.1083/jcb.147.5.1109; Couchman JR, 1996, J BIOL CHEM, V271, P9595, DOI 10.1074/jbc.271.16.9595; COUCHMAN JR, 1995, J HISTOCHEM CYTOCHEM, V43, P955, DOI 10.1177/43.9.7543915; Czubayko F, 1997, NAT MED, V3, P1137, DOI 10.1038/nm1097-1137; CZUBAYKO F, 1994, J BIOL CHEM, V269, P28243; DUNLEVY JR, 2000, PROTEOGLYCANS STRUCT, P275; Ettner N, 1998, FEBS LETT, V430, P217, DOI 10.1016/S0014-5793(98)00601-2; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FIELDS S, 1994, TRENDS GENET, V10, P286, DOI 10.1016/0168-9525(90)90012-U; Fuki IV, 2000, J BIOL CHEM, V275, P25742, DOI 10.1074/jbc.M909173199; Gohring W, 1998, EUR J BIOCHEM, V255, P60, DOI 10.1046/j.1432-1327.1998.2550060.x; Handler M, 1997, DEV DYNAM, V210, P130, DOI 10.1002/(SICI)1097-0177(199710)210:2<130::AID-AJA6>3.0.CO;2-H; Harris VK, 2000, J BIOL CHEM, V275, P10802, DOI 10.1074/jbc.275.15.10802; HAYASHI K, 1992, J CELL BIOL, V119, P945, DOI 10.1083/jcb.119.4.945; HEREMANS A, 1990, J BIOL CHEM, V265, P8716; Hopf M, 1999, EUR J BIOCHEM, V259, P917, DOI 10.1046/j.1432-1327.1999.00127.x; IOZZO RV, 1994, BIOCHEM J, V302, P625, DOI 10.1042/bj3020625; Iozzo RV, 1998, ANNU REV BIOCHEM, V67, P609, DOI 10.1146/annurev.biochem.67.1.609; IOZZO RV, 1984, J CELL BIOL, V99, P403, DOI 10.1083/jcb.99.2.403; ISEMURA M, 1987, J BIOL CHEM, V262, P8926; IWABUCHI K, 1993, ONCOGENE, V8, P1693; Joseph SJ, 1996, DEVELOPMENT, V122, P3443; KALLUNKI P, 1992, J CELL BIOL, V116, P559, DOI 10.1083/jcb.116.2.559; Kuo HJ, 1997, J BIOL CHEM, V272, P26522, DOI 10.1074/jbc.272.42.26522; Kurtz A, 1997, ONCOGENE, V14, P2671, DOI 10.1038/sj.onc.1201117; Lametsch R, 2000, J BIOL CHEM, V275, P19469, DOI 10.1074/jbc.M002550200; Lander AD, 2000, J CELL BIOL, V148, P227, DOI 10.1083/jcb.148.2.227; LiaudetCoopman EDE, 1996, J BIOL CHEM, V271, P21303, DOI 10.1074/jbc.271.35.21303; Lindahl U, 1998, J BIOL CHEM, V273, P24979, DOI 10.1074/jbc.273.39.24979; Mathiak M, 1997, CANCER RES, V57, P2130; Mongiat M, 2000, J BIOL CHEM, V275, P25471, DOI 10.1074/jbc.M001426200; Mongiat M, 2000, J BIOL CHEM, V275, P7095, DOI 10.1074/jbc.275.10.7095; MURDOCH AD, 1994, J HISTOCHEM CYTOCHEM, V42, P239, DOI 10.1177/42.2.7507142; MURDOCH AD, 1992, J BIOL CHEM, V267, P8544; NOONAN DM, 1993, KIDNEY INT, V43, P53, DOI 10.1038/ki.1993.10; NOONAN DM, 1991, J BIOL CHEM, V266, P22939; Nugent MA, 2000, P NATL ACAD SCI USA, V97, P6722, DOI 10.1073/pnas.97.12.6722; Okamoto T, 1996, IN VITRO CELL DEV-AN, V32, P69; Olsen BR, 1999, J CELL BIOL, V147, P909, DOI 10.1083/jcb.147.5.909; Peng HB, 1999, J CELL BIOL, V145, P911, DOI 10.1083/jcb.145.4.911; Perrimon N, 2000, NATURE, V404, P725, DOI 10.1038/35008000; Rak J, 1997, NAT MED, V3, P1083, DOI 10.1038/nm1097-1083; REINHARDT D, 1993, J BIOL CHEM, V268, P10881; ROGALSKI TM, 1993, GENE DEV, V7, P1471, DOI 10.1101/gad.7.8.1471; SAKSELA O, 1988, J CELL BIOL, V107, P743, DOI 10.1083/jcb.107.2.743; SCHULZE B, 1995, EUR J BIOCHEM, V231, P551, DOI 10.1111/j.1432-1033.1995.tb20731.x; Schulze B, 1996, MATRIX BIOL, V15, P349, DOI 10.1016/S0945-053X(96)90138-9; Selleck SB, 2000, TRENDS GENET, V16, P206, DOI 10.1016/S0168-9525(00)01997-1; Sharma B, 1998, J CLIN INVEST, V102, P1599, DOI 10.1172/JCI3793; SUNDARRAJ N, 1995, J CELL SCI, V108, P2663; TIMAR J, 1992, AM J PATHOL, V141, P467; VIGNY M, 1988, J CELL PHYSIOL, V137, P321, DOI 10.1002/jcp.1041370216; Villar MJ, 1999, J CELL BIOCHEM, V75, P665, DOI 10.1002/(SICI)1097-4644(19991215)75:4<665::AID-JCB12>3.0.CO;2-S; Wang XC, 1998, BIOCHEM MOL BIOL INT, V46, P81; Whitelock JM, 1996, J BIOL CHEM, V271, P10079, DOI 10.1074/jbc.271.17.10079; Whitelock JM, 1999, MATRIX BIOL, V18, P163, DOI 10.1016/S0945-053X(99)00014-1; WU DQ, 1991, J BIOL CHEM, V266, P16778; YURCHENCO PD, 1990, FASEB J, V4, P1577, DOI 10.1096/fasebj.4.6.2180767; YURCHENCO PD, 1987, J BIOL CHEM, V262, P17668	75	113	122	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 30	2001	276	13					10263	10271		10.1074/jbc.M011493200	http://dx.doi.org/10.1074/jbc.M011493200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	420GC	11148217	hybrid			2022-12-25	WOS:000167996400091
J	Scheiner, S; Kar, T; Gu, YL				Scheiner, S; Kar, T; Gu, YL			Strength of the (CH)-H-alpha center dot center dot O hydrogen bond of amino acid residues	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOT-O INTERACTIONS; NUCLEAR-MAGNETIC-RESONANCE; AB-INITIO CALCULATIONS; C-H...N INTERACTIONS; NMR CHEMICAL-SHIFT; CRYSTAL-STRUCTURE; CRYSTALLOGRAPHIC EVIDENCE; INTERACTION ENERGIES; BASIS-SETS; H-BOND	Although the peptide (CH)-H-alpha group has historically not been thought to form hydrogen bonds within proteins, ab initio quantum calculations show it to be a potent proton donor. Its binding energy to a water molecule lies in the range between 1.9 and 2.5 kcal/mol for nonpolar and polar amino acids; the hydrogen bond (H-bond) involving the charged lysine residue is even stronger than a conventional OH . .O interaction. The preferred H-bond lengths are quite uniform, about 3.32 Angstrom. Formation of each interaction results in a downfield shift of the bridging hydrogen's chemical shift and a blue shift in the (CH)-H-alpha stretching frequency, potential diagnostics of the presence of such an H-bond within a protein.	Utah State Univ, Dept Chem & Biochem, Logan, UT 84322 USA	Utah System of Higher Education; Utah State University	Scheiner, S (corresponding author), Utah State Univ, Dept Chem & Biochem, Logan, UT 84322 USA.	scheiner@cc.usu.edu	Scheiner, Steve/AAY-8761-2020		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM057936] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM57936] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADCOCK JL, 1995, J ORG CHEM, V60, P1999, DOI 10.1021/jo00112a021; Afonin AV, 1999, CAN J CHEM, V77, P416, DOI 10.1139/cjc-77-4-416; ALKORTA I, 1995, J PHYS CHEM-US, V99, P6457, DOI 10.1021/j100017a026; Alkorta I, 2000, J FLUORINE CHEM, V101, P233, DOI 10.1016/S0022-1139(99)00164-5; Ash EL, 2000, P NATL ACAD SCI USA, V97, P10371, DOI 10.1073/pnas.97.19.10371; Auffinger P, 1997, J MOL BIOL, V274, P54, DOI 10.1006/jmbi.1997.1370; Bedell BL, 1999, J PHYS CHEM A, V103, P4572, DOI 10.1021/jp990493y; Bella J, 1996, J MOL BIOL, V264, P734, DOI 10.1006/jmbi.1996.0673; Berger I, 1996, P NATL ACAD SCI USA, V93, P12116, DOI 10.1073/pnas.93.22.12116; BERKOVITCHYELLIN Z, 1984, ACTA CRYSTALLOGR B, V40, P159, DOI 10.1107/S0108768184001919; Biswas R, 1997, J MOL BIOL, V270, P511, DOI 10.1006/jmbi.1997.1118; BOYS SF, 1970, MOL PHYS, V19, P553, DOI 10.1080/00268977000101561; Brandl M, 1999, THEOR CHEM ACC, V101, P103, DOI 10.1007/s002140050415; Chakrabarti P, 1998, J MOL BIOL, V284, P867, DOI 10.1006/jmbi.1998.2199; Cubero E, 1999, CHEM PHYS LETT, V310, P445, DOI 10.1016/S0009-2614(99)00831-3; Cubero E, 1999, J PHYS CHEM A, V103, P6394, DOI 10.1021/jp990258f; DEREWENDA ZS, 1995, J MOL BIOL, V252, P248, DOI 10.1006/jmbi.1995.0492; DEREWENDA ZS, 1994, J MOL BIOL, V241, P83, DOI 10.1006/jmbi.1994.1475; Desiraju G.R., 1999, WEAK HYDROGEN BOND S, p[29, 293]; Desiraju GR, 1997, SCIENCE, V278, P404, DOI 10.1126/science.278.5337.404; Desiraju GR, 1996, ACCOUNTS CHEM RES, V29, P441, DOI 10.1021/ar950135n; Fabiola GF, 1997, ACTA CRYSTALLOGR D, V53, P316, DOI 10.1107/S0907444997000383; Frisch M. J., 1998, GAUSSIAN 98; Giribet CG, 1996, J CHEM SOC FARADAY T, V92, P3029, DOI 10.1039/ft9969203029; GLUSKER JP, 1995, ACTA CRYSTALLOGR D, V51, P418, DOI 10.1107/S0907444995003313; Gray NS, 1998, SCIENCE, V281, P533, DOI 10.1126/science.281.5376.533; Gu YL, 1999, J AM CHEM SOC, V121, P9411, DOI 10.1021/ja991795g; Harakas G, 1998, J AM CHEM SOC, V120, P6405, DOI 10.1021/ja9803411; Hartmann M, 2000, J PHYS CHEM A, V104, P968, DOI 10.1021/jp992234e; Hobza P, 1999, CHEM PHYS LETT, V303, P447, DOI 10.1016/S0009-2614(99)00217-1; Hobza P, 1999, CHEM PHYS LETT, V299, P180, DOI 10.1016/S0009-2614(98)01264-0; Hobza P, 1998, J PHYS CHEM A, V102, P2501, DOI 10.1021/jp973374w; Jeffrey G.A., 2012, HYDROGEN BONDING BIO; JEFFREY GA, 1982, INT J BIOL MACROMOL, V4, P173, DOI 10.1016/0141-8130(82)90048-4; Karger N, 1999, J PHYS CHEM A, V103, P8672, DOI 10.1021/jp990908f; Kim KS, 1997, J AM CHEM SOC, V119, P12952, DOI 10.1021/ja971836d; Kuduva SS, 1999, J AM CHEM SOC, V121, P1936, DOI 10.1021/ja981967u; LEONARD GA, 1995, ACTA CRYSTALLOGR D, V51, P136, DOI 10.1107/S0907444994004713; LI C, 1983, J CHEM SOC PERK T 1, P2193, DOI 10.1039/p19830002193; Mandel-Gutfreund Y, 1998, J MOL BIOL, V277, P1129, DOI 10.1006/jmbi.1998.1660; Meadows ES, 2000, J AM CHEM SOC, V122, P3325, DOI 10.1021/ja9940672; Mizuno K, 1998, J CHEM PHYS, V109, P9502, DOI 10.1063/1.477612; Musah RA, 1997, J AM CHEM SOC, V119, P9083, DOI 10.1021/ja9716766; NEUHEUSER T, 1994, J PHYS CHEM-US, V98, P6459, DOI 10.1021/j100077a007; Novoa JJ, 1997, CHEM PHYS LETT, V266, P23, DOI 10.1016/S0009-2614(96)01514-X; Novoa JJ, 1996, CHEM PHYS LETT, V251, P33, DOI 10.1016/0009-2614(96)00036-X; NOVOA JJ, 1991, J CHEM PHYS, V95, P5179, DOI 10.1063/1.461686; PASCARD C, 1995, ACTA CRYSTALLOGR D, V51, P407, DOI 10.1107/S0907444994014526; Peralta JE, 1999, J MOL STRUC-THEOCHEM, V491, P23, DOI 10.1016/S0166-1280(99)00027-5; PINCHAS S, 1963, J PHYS CHEM-US, V67, P1862, DOI 10.1021/j100803a030; PINCHAS S, 1955, ANAL CHEM, V27, P2, DOI 10.1021/ac60097a002; Rivelino R, 2000, CHEM PHYS LETT, V322, P207, DOI 10.1016/S0009-2614(00)00412-7; ROVIRA MC, 1995, CHEM PHYS, V200, P319, DOI 10.1016/0301-0104(95)00210-3; RUBIN J, 1972, BIOCHEMISTRY-US, V11, P3112, DOI 10.1021/bi00766a027; SAENGER W, 1973, ANGEW CHEM INT EDIT, V12, P591, DOI 10.1002/anie.197305911; SAMMES MP, 1976, J CHEM SOC PERK T 2, P1130, DOI 10.1039/p29760001130; SATONAKA H, 1988, B CHEM SOC JPN, V61, P2031, DOI 10.1246/bcsj.61.2031; Scheiner S, 2000, ADV MOL STRUCT RES, V6, P159; Scheiner S, 2000, J MOL STRUC-THEOCHEM, V500, P441, DOI 10.1016/S0166-1280(00)00375-4; SCHEINER S, 1994, ANNU REV PHYS CHEM, V45, P23; Scheiner S, 1997, T PHYS CHEM SER; SLASINSKI FM, 1976, J ORG CHEM, V41, P2693, DOI 10.1021/jo00878a007; SMITH DA, 1994, ACS SYM SER, V569, P82; Sponer J, 2000, J PHYS CHEM A, V104, P4592, DOI 10.1021/jp9943880; STEINER T, 1992, J AM CHEM SOC, V114, P10146, DOI 10.1021/ja00052a009; STEINER T, 1993, J AM CHEM SOC, V115, P4540, DOI 10.1021/ja00064a016; STEINER T, 1995, J CHEM SOC PERK T 2, P1315, DOI 10.1039/p29950001315; Steiner T, 2000, J PHYS CHEM A, V104, P433, DOI 10.1021/jp993179c; SUSSMAN JL, 1972, J MOL BIOL, V66, P403, DOI 10.1016/0022-2836(72)90423-8; SZCZESNIAK MM, 1993, J CHEM PHYS, V98, P3078, DOI 10.1063/1.465050; Takahara PM, 1996, J AM CHEM SOC, V118, P12309, DOI 10.1021/ja9625079; TAYLOR R, 1982, J AM CHEM SOC, V104, P5063, DOI 10.1021/ja00383a012; THOMAS KA, 1982, P NATL ACAD SCI-BIOL, V79, P4843, DOI 10.1073/pnas.79.16.4843; TURI L, 1993, J PHYS CHEM-US, V97, P12197, DOI 10.1021/j100149a017; Vargas R, 2000, J AM CHEM SOC, V122, P4750, DOI 10.1021/ja993600a; Wahl MC, 1997, TRENDS BIOCHEM SCI, V22, P97, DOI 10.1016/S0968-0004(97)01004-9; Wahl MC, 1996, NAT STRUCT BIOL, V3, P24, DOI 10.1038/nsb0196-24; WISHART DS, 1991, J MOL BIOL, V222, P311, DOI 10.1016/0022-2836(91)90214-Q; WOLINSKI K, 1990, J AM CHEM SOC, V112, P8251, DOI 10.1021/ja00179a005; Wu DY, 1999, J MOL STRUC-THEOCHEM, V459, P171, DOI 10.1016/S0166-1280(98)00273-5; Yoshida H, 1997, J PHYS CHEM A, V101, P1731, DOI 10.1021/jp9624010; ZHOU NE, 1992, J AM CHEM SOC, V114, P4320, DOI 10.1021/ja00037a042	82	260	265	0	25	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 30	2001	276	13					9832	9837		10.1074/jbc.M010770200	http://dx.doi.org/10.1074/jbc.M010770200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	420GC	11152477	hybrid			2022-12-25	WOS:000167996400035
J	Tian, B; Mathews, MB				Tian, B; Mathews, MB			Functional characterization of and cooperation between the double-stranded RNA-binding motifs of the protein kinase PKR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERFERON ACTION; MUTATIONAL ANALYSIS; MOLECULAR-BASIS; MESSENGER-RNA; IN-VIVO; DOMAIN; ACTIVATION; DIMERIZATION; MECHANISM; LOCALIZATION	The interferon-inducible double-stranded RNA (dsRNA)-activated protein kinase PKR is regulated by dsRNAs that interact with the two dsRNA-binding motifs (dsRBMs) in its N terminus. The dsRBM is a conserved protein motif found in many proteins from most organisms. In this study, we investigated the biochemical functions and cytological activities of the two PKR dsRBMs (dsRBM1 and dsRBM2) and the cooperation between them. We found that dsRBM1 has a higher affinity for binding to dsRNA than dsRBM2, In addition, dsRBM1 has RNA-annealing activity that is not displayed by dsRBM2, Both dsRBMs have an intrinsic ability to dimerize (dsRBM2) or multimerize (dsRBM1), Binding to dsRNA inhibits oligomerization of dsRBM1 but not dsRBM2 and strongly inhibits the dimerization of the intact PKR N terminus (p20) containing both dsRBMs, dsRBM1, like p20, activates reporter gene expression in transfection assays, and it plays a determinative role in localizing PKR to the nucleolus and cytoplasm of the cell. Thus, dsRBM2 has weak or no activity in dsRNA binding, stimulation of gene expression, and PKR localization, but it strongly enhances these functions of dsRBM1 when contained in p20. However, dsRBM2 does not enhance the annealing activity of dsRBM1, This study shows that the dsRBMs of PKR possess distinct properties and that some, but not all, of the functions of the enzyme depend on cooperation between the two motifs.	Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Biochem & Mol Biol, Newark, NJ 07103 USA; Univ Med & Dent New Jersey, New Jersey Med Sch, Grad Sch Biomed Sci, Newark, NJ 07103 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick; Rutgers State University Medical Center	Mathews, MB (corresponding author), Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Biochem & Mol Biol, Newark, NJ 07103 USA.	mathews@umdnj.edu		Tian, Bin/0000-0001-8903-8256	NIAID NIH HHS [AI34552] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI034552] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Besse S, 1998, EXP CELL RES, V239, P379, DOI 10.1006/excr.1997.3908; Bevilacqua PC, 1998, BIOCHEMISTRY-US, V37, P6303, DOI 10.1021/bi980113j; Bevilacqua PC, 1996, BIOCHEMISTRY-US, V35, P9983, DOI 10.1021/bi9607259; BISCHOFF JR, 1989, VIROLOGY, V172, P106, DOI 10.1016/0042-6822(89)90112-8; Brooks R, 1998, FEBS LETT, V434, P121, DOI 10.1016/S0014-5793(98)00963-6; BYCROFT M, 1995, EMBO J, V14, P3563, DOI 10.1002/j.1460-2075.1995.tb07362.x; Carpick BW, 1997, J BIOL CHEM, V272, P9510, DOI 10.1074/jbc.272.14.9510; Chu WM, 1998, MOL CELL BIOL, V18, P58, DOI 10.1128/MCB.18.1.58; Circle DA, 1997, RNA, V3, P438; CLEMENS MJ, 1994, BIOCHIMIE, V76, P770, DOI 10.1016/0300-9084(94)90081-7; Clemens MJ, 1997, J INTERF CYTOK RES, V17, P503, DOI 10.1089/jir.1997.17.503; COSENTINO GP, 1995, P NATL ACAD SCI USA, V92, P9445, DOI 10.1073/pnas.92.21.9445; Fierro-Monti I, 2000, TRENDS BIOCHEM SCI, V25, P241, DOI 10.1016/S0968-0004(00)01580-2; GREEN SR, 1992, GENE DEV, V6, P2478, DOI 10.1101/gad.6.12b.2478; GREEN SR, 1995, MOL CELL BIOL, V15, P358, DOI 10.1128/MCB.15.1.358; Gunnery S, 1998, METHODS, V15, P189, DOI 10.1006/meth.1998.0623; Hitti E, 1998, NUCLEIC ACIDS RES, V26, P4382, DOI 10.1093/nar/26.19.4382; JEFFREY IW, 1995, EXP CELL RES, V218, P17, DOI 10.1006/excr.1995.1126; JIMENEZGARCIA LF, 1993, J CELL SCI, V106, P11; Kaufman RJ, 2000, COLD SPRING HARBOR M, V39, P503; KOSTURA M, 1989, MOL CELL BIOL, V9, P1576, DOI 10.1128/MCB.9.4.1576; Krovat BC, 1996, J BIOL CHEM, V271, P28112, DOI 10.1074/jbc.271.45.28112; Kumar KU, 1999, MOL CELL BIOL, V19, P1116; Lamond AI, 1998, SCIENCE, V280, P547, DOI 10.1126/science.280.5363.547; LANGLAND JO, 1992, J BIOL CHEM, V267, P10729; Lewis JD, 2000, SCIENCE, V288, P1385, DOI 10.1126/science.288.5470.1385; MANCHE L, 1992, MOL CELL BIOL, V12, P5238, DOI 10.1128/MCB.12.11.5238; MATHEWS MB, 1991, J VIROL, V65, P5657, DOI 10.1128/JVI.65.11.5657-5662.1991; MCCORMACK SJ, 1994, VIROLOGY, V198, P92, DOI 10.1006/viro.1994.1011; MCCORMACK SJ, 1995, VIROLOGY, V206, P511, DOI 10.1016/S0042-6822(95)80067-0; MCMILLAN NAJ, 1995, J BIOL CHEM, V270, P2601, DOI 10.1074/jbc.270.6.2601; Melville MW, 2000, CELL MOL LIFE SCI, V57, P311, DOI 10.1007/PL00000692; Nanduri S, 1998, EMBO J, V17, P5458, DOI 10.1093/emboj/17.18.5458; Ortega LG, 1996, VIROLOGY, V215, P31, DOI 10.1006/viro.1996.0004; Osman F, 1999, GENE DEV, V13, P3280, DOI 10.1101/gad.13.24.3280; PATEL RC, 1995, P NATL ACAD SCI USA, V92, P8283, DOI 10.1073/pnas.92.18.8283; Patel RC, 1998, MOL CELL BIOL, V18, P7009, DOI 10.1128/MCB.18.12.7009; Patel RC, 1996, J BIOL CHEM, V271, P25657, DOI 10.1074/jbc.271.41.25657; Patel RC, 1999, J BIOL CHEM, V274, P20432, DOI 10.1074/jbc.274.29.20432; Patel RC, 1998, EMBO J, V17, P4379, DOI 10.1093/emboj/17.15.4379; Pe'ery T, 2000, COLD SPRING HARBOR M, V39, P371; Raine DA, 1998, FEBS LETT, V436, P343, DOI 10.1016/S0014-5793(98)01163-6; RendeFournier R, 1997, VIROLOGY, V238, P410, DOI 10.1006/viro.1997.8824; Robertson HD, 1996, BIOCHIMIE, V78, P909, DOI 10.1016/S0300-9084(97)86712-0; ROMANO PR, 1995, MOL CELL BIOL, V15, P365, DOI 10.1128/MCB.15.1.365; Romano PR, 1998, MOL CELL BIOL, V18, P2282, DOI 10.1128/MCB.18.4.2282; Rubin GM, 2000, SCIENCE, V287, P2204, DOI 10.1126/science.287.5461.2204; Ryter JM, 1998, EMBO J, V17, P7505, DOI 10.1093/emboj/17.24.7505; SCHMEDT C, 1995, J MOL BIOL, V249, P29, DOI 10.1006/jmbi.1995.0278; SCHWEMMLE M, 1992, P NATL ACAD SCI USA, V89, P10292, DOI 10.1073/pnas.89.21.10292; STJOHNSTON D, 1992, P NATL ACAD SCI USA, V89, P10979, DOI 10.1073/pnas.89.22.10979; Tan SL, 1998, MOL CELL BIOL, V18, P2431, DOI 10.1128/MCB.18.5.2431; THOMIS DC, 1993, J VIROL, V67, P7695, DOI 10.1128/JVI.67.12.7695-7700.1993; Tian B, 2000, RNA, V6, P79, DOI 10.1017/S1355838200991544; Williams BRG, 1997, BIOCHEM SOC T, V25, P509, DOI 10.1042/bst0250509; Wu SY, 1997, J BIOL CHEM, V272, P1291, DOI 10.1074/jbc.272.2.1291; Wu SY, 1996, J BIOL CHEM, V271, P1756, DOI 10.1074/jbc.271.3.1756; Zhang SS, 1999, J CELL SCI, V112, P2693; Zhu SH, 1997, J BIOL CHEM, V272, P14434, DOI 10.1074/jbc.272.22.14434	59	75	77	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 30	2001	276	13					9936	9944		10.1074/jbc.M007328200	http://dx.doi.org/10.1074/jbc.M007328200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	420GC	11134010	hybrid			2022-12-25	WOS:000167996400050
J	Yoshikawa, M; Iwasaki, H; Shinagawa, H				Yoshikawa, M; Iwasaki, H; Shinagawa, H			Evidence that phenylalanine 69 in Escherichia coli RuvC resolvase forms a stacking interaction during binding and destabilization of a holliday junction DNA substrate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REPAIR PROTEIN MUTS; HOMOLOGOUS RECOMBINATION; RNA-POLYMERASE; RESOLUTION; ENDONUCLEASE; CLEAVAGE; IDENTIFICATION; SPECIFICITY; MUTATIONS; MISMATCH	Escherichia coli RuvC resolvase is a specific endonuclease that recognizes and cleaves Holliday junctions formed during homologous recombination and recombinational repair. This study examines the phenotype of RuvC mutants with amino acid substitutions at phenylalanine 69 (F69L, F69Y, F69W, and F69A), a catalytically important residue that faces the catalytic center of the enzyme, F69Y, but not the other three mutants, almost fully complements the UV sensitivity of a Delta ruvC strain and substantially resolves synthetic Holliday junctions in vitro, In the presence of 100 mM NaCl, RuvC F69A and F69L are defective in junction binding, but F69Y and F69W retain near wild-type binding activity during a gel shift binding assay. KMnO4 was used to probe synthetic Holliday junction DNA in a complex with wild-type and mutant RuvC; F69A and F69L did not induce disruption of base pairing at the crossover to the same extent as wild-type RuvC, Thus, the aromatic ring of Phe-69 is involved in DNA binding, probably via a stacking interaction with a nucleotide base, and this interaction may induce a structural change in junction DNA that is required to form a catalytically competent complex.	Osaka Univ, Res Inst Microbial Dis, Dept Mol Microbiol, Suita, Osaka 565, Japan; Japan Sci & Technol Corp, PRESTO, Suita, Osaka 5650871, Japan	Osaka University; Japan Science & Technology Agency (JST)	Iwasaki, H (corresponding author), Osaka Univ, Res Inst Microbial Dis, Dept Mol Microbiol, Suita, Osaka 565, Japan.	iwasaki@biken.osaka-u.ac.jp	Iwasaki, Hiroshi/Y-7946-2018	Iwasaki, Hiroshi/0000-0002-0153-6873				ARIYOSHI M, 1994, CELL, V78, P1063, DOI 10.1016/0092-8674(94)90280-1; BENNETT RJ, 1993, CELL, V74, P1021, DOI 10.1016/0092-8674(93)90724-5; BENNETT RJ, 1995, P NATL ACAD SCI USA, V92, P5635, DOI 10.1073/pnas.92.12.5635; BENNETT RJ, 1995, J MOL BIOL, V252, P213, DOI 10.1006/jmbi.1995.0489; BENSON F, 1991, MOL GEN GENET, V225, P266, DOI 10.1007/BF00269858; BUCKLE M, 1991, METHOD ENZYMOL, V208, P236; CHURCHILL MEA, 1988, P NATL ACAD SCI USA, V85, P4653, DOI 10.1073/pnas.85.13.4653; DUCKETT DR, 1990, EMBO J, V9, P583, DOI 10.1002/j.1460-2075.1990.tb08146.x; DUNDERDALE HJ, 1991, NATURE, V354, P506, DOI 10.1038/354506a0; Hagan NFP, 1998, J MOL BIOL, V281, P17, DOI 10.1006/jmbi.1998.1934; HOLLIDAY R, 1964, GENET RES, V5, P282, DOI 10.1017/S0016672300001233; Ichiyanagi K, 1998, GENES CELLS, V3, P575, DOI 10.1046/j.1365-2443.1998.00213.x; IWASAKI H, 1991, EMBO J, V10, P4381, DOI 10.1002/j.1460-2075.1991.tb05016.x; KOWALCZYKOWSKI SC, 1994, MICROBIOL REV, V58, P401, DOI 10.1128/MMBR.58.3.401-465.1994; Lamers MH, 2000, NATURE, V407, P711, DOI 10.1038/35037523; LLOYD RG, 1984, MOL GEN GENET, V194, P303, DOI 10.1007/BF00383532; MANDAL TN, 1993, J BACTERIOL, V175, P4325, DOI 10.1128/JB.175.14.4325-4334.1993; Mizuuchi K, 1997, GENES CELLS, V2, P1, DOI 10.1046/j.1365-2443.1997.970297.x; Obmolova G, 2000, NATURE, V407, P703, DOI 10.1038/35037509; OTSUJI N, 1974, J BACTERIOL, V117, P337, DOI 10.1128/JB.117.2.337-344.1974; Roca AI, 1997, PROG NUCLEIC ACID RE, V56, P129, DOI 10.1016/S0079-6603(08)61005-3; SAITO A, 1995, P NATL ACAD SCI USA, V92, P7470, DOI 10.1073/pnas.92.16.7470; Sha RJ, 2000, BIOCHEMISTRY-US, V39, P11982, DOI 10.1021/bi001037z; SHAH R, 1994, CELL, V79, P853, DOI 10.1016/0092-8674(94)90074-4; SHIDA T, 1996, J BIOL CHEM, V42, P26105; Shinagawa H, 1996, TRENDS BIOCHEM SCI, V21, P107, DOI 10.1016/0968-0004(96)10014-1; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TAKAHAGI M, 1994, J BIOL CHEM, V269, P15132; TAKAHAGI M, 1991, J BACTERIOL, V173, P5747, DOI 10.1128/jb.173.18.5747-5753.1991; van Gool AJ, 1998, EMBO J, V17, P1838, DOI 10.1093/emboj/17.6.1838; van Gool AJ, 1999, GENE DEV, V13, P1861, DOI 10.1101/gad.13.14.1861; West SC, 1997, ANNU REV GENET, V31, P213, DOI 10.1146/annurev.genet.31.1.213; Yoshikawa M, 2000, GENES CELLS, V5, P803, DOI 10.1046/j.1365-2443.2000.00371.x	33	24	24	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 30	2001	276	13					10432	10436		10.1074/jbc.M010138200	http://dx.doi.org/10.1074/jbc.M010138200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	420GC	11152689	hybrid			2022-12-25	WOS:000167996400110
J	Zhang, XT; Cui, ZF; Miyakawa, T; Moye-Rowley, WS				Zhang, XT; Cui, ZF; Miyakawa, T; Moye-Rowley, WS			Cross-talk between transcriptional regulators of multidrug resistance in Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLEIOTROPIC DRUG-RESISTANCE; TRANSPORTER-ENCODING GENE; 4-NITROQUINOLINE N-OXIDE; YEAST; EXPRESSION; PDR1; ACTIVATION; PRODUCT; MUTANTS; DOMAIN	Multiple or pleiotropic drug resistance often arises in the yeast Saccharomyces cerevisiae due to genetic alterations of the functional state of the Cys(6)-Zn(II)(2) transcription factors Pdr1p and Pdr3p, Single amino acid substitutions give rise to hyperactive forms of these regulatory proteins, which in turn cause overproduction of downstream target genes that directly mediate multidrug resistance. Previous work has identified a novel Cys(6)-Zn(II)(2) transcription factor designated Yrr1p as mutant forms of this protein confer high level resistance to the cell cycle inhibitor reveromycin A and DNA damaging agent 4-nitroquinoline-N-oxide. In the present study, we demonstrate that Yrr1p also mediates oligomycin resistance through activation of the ATP-binding cassette transporter-encoding gene YOR1, Additionally, insertion of triplicated copies of the hemagglutinin epitope in the C-terminal region of Yrr1p causes the protein to behave as a hyperactive regulator of transcription. We have found that YRR1 expression is both controlled in a. Pdr1p/Pdr3p-dependent- manner and autoregulated. Chromatin immunoprecipitation experiments also show that Yrr1p associates with target prometers in vivo, Together these data argue that the signal generated by activation of Pdr1p and/or Pdr3p can be amplified through the action of these transcriptional regulatory proteins on downstream target genes, like YRR1, that also encode transcription factors.	Univ Iowa, Dept Physiol & Biophys, Iowa City, IA 52242 USA; Univ Iowa, Program Mol Biol, Iowa City, IA 52242 USA; Hiroshima Univ, Grad Sch Adv Sci Matter, Dept Mol Biotechnol, Higashihiroshima 7398526, Japan	University of Iowa; University of Iowa; Hiroshima University	Moye-Rowley, WS (corresponding author), Univ Iowa, Dept Physiol & Biophys, 5-612 Bowen Sci Bldg, Iowa City, IA 52242 USA.		Moye-Rowley, Scott/AFL-7135-2022	Moye-Rowley, Scott/0000-0002-7163-1120	NIGMS NIH HHS [GM49825] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BALZI E, 1987, J BIOL CHEM, V262, P16871; BALZI E, 1995, J BIOENERG BIOMEMBR, V27, P71, DOI 10.1007/BF02110333; BALZI E, 1994, J BIOL CHEM, V269, P2206; BISSINGER PH, 1994, J BIOL CHEM, V269, P4180; BURNS N, 1994, GENE DEV, V8, P1087, DOI 10.1101/gad.8.9.1087; Carvajal E, 1997, MOL GEN GENET, V256, P406, DOI 10.1007/s004380050584; Coleman ST, 1999, MOL CELL BIOL, V19, P8302; Coleman ST, 1997, J BIOL CHEM, V272, P23224, DOI 10.1074/jbc.272.37.23224; Cui Z, 1998, MOL MICROBIOL, V29, P1307, DOI 10.1046/j.1365-2958.1998.01027.x; Cui ZF, 1996, J BIOL CHEM, V271, P14712, DOI 10.1074/jbc.271.25.14712; Cui ZF, 1999, BIOSCI BIOTECH BIOCH, V63, P162, DOI 10.1271/bbb.63.162; DELAHODDE A, 1995, MOL CELL BIOL, V15, P4043; DELAVEAU T, 1994, MOL GEN GENET, V244, P501, DOI 10.1007/BF00583901; DeRisi J, 2000, FEBS LETT, V470, P156, DOI 10.1016/S0014-5793(00)01294-1; DEXTER D, 1994, GENETICS, V136, P505; EMR SD, 1986, J CELL BIOL, V102, P523, DOI 10.1083/jcb.102.2.523; Gottesman MM, 1995, ANNU REV GENET, V29, P607, DOI 10.1146/annurev.ge.29.120195.003135; GUARENTE L, 1983, METHOD ENZYMOL, V101, P181; Hach A, 1999, MOL CELL BIOL, V19, P4324; Hallstrom TC, 2000, MOL MICROBIOL, V36, P402, DOI 10.1046/j.1365-2958.2000.01858.x; Hallstrom TC, 2000, J BIOL CHEM, V275, P37347, DOI 10.1074/jbc.M007338200; Hallstrom TC, 1998, J BIOL CHEM, V273, P2098, DOI 10.1074/jbc.273.4.2098; HIRATA D, 1994, CURR GENET, V26, P285, DOI 10.1007/BF00310491; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; KATZMANN DJ, 1995, MOL CELL BIOL, V15, P6875; KATZMANN DJ, 1994, MOL CELL BIOL, V14, P4653, DOI 10.1128/MCB.14.7.4653; Katzmann DJ, 1996, J BIOL CHEM, V271, P23049, DOI 10.1074/jbc.271.38.23049; MEYERS S, 1992, CURR GENET, V21, P431, DOI 10.1007/BF00351651; Nourani A, 1997, MOL GEN GENET, V256, P397, DOI 10.1007/s004380050583; ONeill LP, 1996, METHOD ENZYMOL, V274, P189; RANK GH, 1976, MOL GEN GENET, V144, P281, DOI 10.1007/BF00341726; Sherman F, 1979, METHODS YEAST GENETI; SIKORSKI RS, 1989, GENETICS, V122, P19; STONE G, 1993, EMBO J, V12, P1375, DOI 10.1002/j.1460-2075.1993.tb05782.x; Wang D, 1999, J BIOL CHEM, V274, P19017, DOI 10.1074/jbc.274.27.19017	35	39	42	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 23	2001	276	12					8812	8819		10.1074/jbc.M010686200	http://dx.doi.org/10.1074/jbc.M010686200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	413HV	11134057	hybrid			2022-12-25	WOS:000167607700028
J	Rieske, P; Pongubala, JMR				Rieske, P; Pongubala, JMR			AKT induces transcriptional activity of PU.1 through phosphorylation-mediated modifications within its transactivation domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							B-CELL DEVELOPMENT; NF-KAPPA-B; STIMULATING FACTOR-RECEPTOR; NORMAL MYELOID DEVELOPMENT; ACTIVATED PROTEIN-KINASES; REGULATORY FACTOR FAMILY; IMMUNOGLOBULIN-KAPPA; GENE-EXPRESSION; PHOSPHATIDYLINOSITOL 3-KINASE; SOMATIC HYPERMUTATION	Signal transduction by the antigen receptor complexes is critical for developmental progression of B-lymphocytes, which are defined by assembly and sequential expression of immunoglobulin genes, which in turn are regulated by the enhancer elements. Although proximal antigen-receptor signal transduction pathways are well defined, the precise nuclear factors targeted by these signals remained unknown. Previous studies have demonstrated that tissue-restricted transcription factors including PU.1 and PU.1 interaction partner (PIP) function synergistically with c-Fos plus c-Jun to stimulate the kappa E3'-enhancer in 3T3 cells. In this study, we demonstrate that the functional synergy between these factors is enhanced in response to mitogen-activated protein kinase kinase kinase, in 3T3 cells, where the enhancer is inactive. However in S194 plasmacytoma cells, mitogen-activated protein kinase kinase kinase was able to stimulate the activity of PU.1 but unable to induce the kappa E3'-enhancer activity. We have found that Ras-phosphoinositide 3-kinase-dependent externally regulated kinase, AKT, induces kappa E3'-enhancer activity in both pre-B and plasmacytoma cells. AKT stimulation of the kappa E3'-enhancer is primarily due to PU.1 induction and is independent of PU.1 interaction with PIP. Activation of AKT had no effect on the expression levels of PU.1 or its protein-protein interaction with PIP. Using a series of deletion constructs, we have determined that the PU.1 acid-rich (amino acids 33-74) transactivation domain is necessary for AKT-mediated induction. Substitution analyses within this region indicate that phosphorylation of Ser(41) is necessary to respond to AKT. Consistent with these studies, ligation of antigen receptors in A20 B cells mimics AKT activation of PU.1. Taken together, these results provide evidence that PU.1 is induced by AKT signal in a phosphoinositide 3-kinase-dependent manner, leading to inducible or constitutive activation of its target genes.	MCP Hahnemann Univ, Sch Med, Dept Biochem, Philadelphia, PA 19102 USA	Drexel University	Pongubala, JMR (corresponding author), MCP Hahnemann Univ, Sch Med, Dept Biochem, 245 N 15th St, Philadelphia, PA 19102 USA.		Rieske, Piotr/M-4821-2015	Rieske, Piotr/0000-0002-2970-0970	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI046308] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 46308] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Aman MJ, 1998, J BIOL CHEM, V273, P33922, DOI 10.1074/jbc.273.51.33922; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; BAIN G, 1994, CELL, V79, P885, DOI 10.1016/0092-8674(94)90077-9; Brass AL, 1999, EMBO J, V18, P977, DOI 10.1093/emboj/18.4.977; Brass AL, 1996, GENE DEV, V10, P2335, DOI 10.1101/gad.10.18.2335; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; BURAS JA, 1995, MOL IMMUNOL, V32, P541, DOI 10.1016/0161-5890(95)00018-A; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; Celada A, 1996, J EXP MED, V184, P61, DOI 10.1084/jem.184.1.61; Chan TO, 1999, ANNU REV BIOCHEM, V68, P965, DOI 10.1146/annurev.biochem.68.1.965; CHEN HM, 1993, J BIOL CHEM, V268, P8230; CHENG AM, 1995, NATURE, V378, P303, DOI 10.1038/378303a0; DeFranco AL, 1998, SEMIN IMMUNOL, V10, P299, DOI 10.1006/smim.1998.0122; DeFranco AL, 1997, CURR OPIN IMMUNOL, V9, P296, DOI 10.1016/S0952-7915(97)80074-X; DeKoter RP, 2000, SCIENCE, V288, P1439, DOI 10.1126/science.288.5470.1439; DEL PL, 1997, SCIENCE, V278, P687; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DEVARY Y, 1991, MOL CELL BIOL, V11, P2804, DOI 10.1128/MCB.11.5.2804; EICHBAUM QG, 1994, J EXP MED, V179, P1985, DOI 10.1084/jem.179.6.1985; EISENBEIS CF, 1993, MOL CELL BIOL, V13, P6452, DOI 10.1128/MCB.13.10.6452; EISENBEIS CF, 1995, GENE DEV, V9, P1377, DOI 10.1101/gad.9.11.1377; FEINMAN R, 1994, EMBO J, V13, P3852, DOI 10.1002/j.1460-2075.1994.tb06696.x; Fisher RC, 1998, MOL CELL BIOL, V18, P4347, DOI 10.1128/MCB.18.7.4347; Fruman DA, 1999, SCIENCE, V283, P393, DOI 10.1126/science.283.5400.393; Gold MR, 2000, IMMUNOL REV, V176, P47; Gong SC, 1996, J EXP MED, V184, P2079, DOI 10.1084/jem.184.6.2079; Gong SC, 1996, SCIENCE, V272, P411, DOI 10.1126/science.272.5260.411; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GROSSCHEDL R, 1985, CELL, V41, P885, DOI 10.1016/S0092-8674(85)80069-6; Grossman A, 1996, GENOMICS, V37, P229, DOI 10.1006/geno.1996.0547; HAGMAN J, 1992, P NATL ACAD SCI USA, V89, P8889, DOI 10.1073/pnas.89.19.8889; HALL C V, 1983, Journal of Molecular and Applied Genetics, V2, P101; Heydemann A, 1996, MOL CELL BIOL, V16, P1676; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; HILL CS, 1995, CELL, V80, P199, DOI 10.1016/0092-8674(95)90403-4; Himmelmann A, 1997, BLOOD, V90, P3984, DOI 10.1182/blood.V90.10.3984; Hiramatsu R, 1995, CELL, V83, P1113, DOI 10.1016/0092-8674(95)90138-8; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HOHAUS S, 1995, MOL CELL BIOL, V15, P5830; Inaba T, 1996, MOL CELL BIOL, V16, P2264; Kim BC, 1999, J BIOL CHEM, V274, P24372, DOI 10.1074/jbc.274.34.24372; Kim YM, 1999, J IMMUNOL, V163, P2000; KITAMURA D, 1992, NATURE, V356, P154, DOI 10.1038/356154a0; KITAMURA D, 1992, CELL, V69, P823, DOI 10.1016/0092-8674(92)90293-L; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; Kops GJPL, 1999, NATURE, V398, P630, DOI 10.1038/19328; Kurosaki T, 2000, CURR OPIN IMMUNOL, V12, P276, DOI 10.1016/S0952-7915(00)00087-X; Kurosaki T, 1997, CURR OPIN IMMUNOL, V9, P309, DOI 10.1016/S0952-7915(97)80075-1; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; LIN HH, 1995, NATURE, V376, P263, DOI 10.1038/376263a0; Madrid LV, 2000, MOL CELL BIOL, V20, P1626, DOI 10.1128/MCB.20.5.1626-1638.2000; MAIZELS N, 1995, CELL, V83, P9, DOI 10.1016/0092-8674(95)90227-9; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MATSUYAMA T, 1995, NUCLEIC ACIDS RES, V23, P2127, DOI 10.1093/nar/23.12.2127; McKercher SR, 1996, EMBO J, V15, P5647, DOI 10.1002/j.1460-2075.1996.tb00949.x; MINDEN A, 1994, MOL CELL BIOL, V14, P6683, DOI 10.1128/MCB.14.10.6683; Mittrucker HW, 1997, SCIENCE, V275, P540, DOI 10.1126/science.275.5299.540; MOULTON KS, 1994, MOL CELL BIOL, V14, P4408, DOI 10.1128/MCB.14.7.4408; Ozes ON, 1999, NATURE, V401, P82; PAHL HL, 1993, J BIOL CHEM, V268, P5014; Perkel JM, 1998, J IMMUNOL, V160, P241; PONGUBALA JMR, 1995, J BIOL CHEM, V270, P10304, DOI 10.1074/jbc.270.17.10304; PONGUBALA JMR, 1991, MOL CELL BIOL, V11, P1040, DOI 10.1128/MCB.11.2.1040; PONGUBALA JMR, 1992, MOL CELL BIOL, V12, P368, DOI 10.1128/MCB.12.1.368; Pongubala JMR, 1997, P NATL ACAD SCI USA, V94, P127, DOI 10.1073/pnas.94.1.127; PONGUBALA JMR, 1993, SCIENCE, V259, P1622, DOI 10.1126/science.8456286; RAYGALLET D, 1995, ONCOGENE, V11, P303; ROSMARIN AG, 1995, P NATL ACAD SCI USA, V92, P801, DOI 10.1073/pnas.92.3.801; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SCOTT EW, 1994, SCIENCE, V265, P1573, DOI 10.1126/science.8079170; SHARPE MJ, 1991, EMBO J, V10, P2139, DOI 10.1002/j.1460-2075.1991.tb07748.x; Shaw AC, 1999, J EXP MED, V189, P123, DOI 10.1084/jem.189.1.123; SHIN MK, 1993, GENE DEV, V7, P2006, DOI 10.1101/gad.7.10.2006; Sizemore N, 1999, MOL CELL BIOL, V19, P4798; Tenen DG, 1997, BLOOD, V90, P489, DOI 10.1182/blood.V90.2.489.489_489_519; Torres RM, 1996, SCIENCE, V272, P1804, DOI 10.1126/science.272.5269.1804; TURNER M, 1995, NATURE, V378, P298, DOI 10.1038/378298a0; URBANEK P, 1994, CELL, V79, P901, DOI 10.1016/0092-8674(94)90079-5; WESTWICK JK, 1995, J BIOL CHEM, V270, P22689, DOI 10.1074/jbc.270.39.22689; WU H, 1994, MOL CELL BIOL, V14, P2129, DOI 10.1128/MCB.14.3.2129; Xia Y, 2000, P NATL ACAD SCI USA, V97, P5243, DOI 10.1073/pnas.97.10.5243; Yamagata T, 1996, MOL CELL BIOL, V16, P1283; Ying H, 1998, J IMMUNOL, V160, P2287; ZHANG DE, 1994, MOL CELL BIOL, V14, P373, DOI 10.1128/MCB.14.1.373; ZHUANG Y, 1994, CELL, V79, P875, DOI 10.1016/0092-8674(94)90076-0	87	40	41	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 16	2001	276	11					8460	8468		10.1074/jbc.M007482200	http://dx.doi.org/10.1074/jbc.M007482200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	411AA	11133986	hybrid			2022-12-25	WOS:000167474900106
J	De Wit, R; Makkinje, M; Boonstra, J; Verkleij, AJ; Post, JA				De Wit, R; Makkinje, M; Boonstra, J; Verkleij, AJ; Post, JA			Hydrogen peroxide reversibly inhibits epidermal growth factor (EGF) receptor internalization and coincident ubiquitination of the EGF receptor and Eps15	FASEB JOURNAL			English	Article									Univ Utrecht, Dept Mol Cell Biol, Inst Biomembranes, NL-3584 CH Utrecht, Netherlands	Utrecht University	De Wit, R (corresponding author), Univ Utrecht, Dept Mol Cell Biol, Inst Biomembranes, Padualaan 8, NL-3584 CH Utrecht, Netherlands.		Post, Jan A/B-7547-2011	Post, Jan A/0000-0003-3048-335X					0	26	27	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	FEB	2001	15	2					306	308						3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	400LK	11156945				2022-12-25	WOS:000166872900011
J	Taraseviciene-Stewart, L; Kasahara, Y; Alger, L; Hirth, P; McMahon, G; Waltenberger, J; Voelkel, NF; Tuder, RM				Taraseviciene-Stewart, L; Kasahara, Y; Alger, L; Hirth, P; McMahon, G; Waltenberger, J; Voelkel, NF; Tuder, RM			Inhibition of the VEGF receptor 2 combined with chronic hypoxia causes cell death-dependent pulmonary endothelial cell proliferation and severe pulmonary hypertension	FASEB JOURNAL			English	Article						apoptosis; survival; selection; pulmonary vascular remodeling; angiogenesis	NITRIC-OXIDE; FLK-1/KDR ACTIVATION; SURVIVAL FACTOR; GROWTH; PROSTACYCLIN; INFLAMMATION; EXPRESSION; APOPTOSIS; VESSELS; THERAPY	Our understanding of the pathobiology of severe pulmonary hypertension, usually a fatal disease, has been hampered by the lack of information of its natural history. We have demonstrated that, in human severe pulmonary hypertension, the precapillary pulmonary arteries show occlusion by proliferated endothelial cells. Vascular endothelial growth factor (VEGF) and its receptor 2 (VEGFR-2) are involved in proper maintenance, differentiation, and function of endothelial cells. We demonstrate here that VEGFR-2 blockade with SU5416 in combination with chronic hypobaric hypoxia causes severe pulmonary hypertension associated with precapillary arterial occlusion by proliferating endothelial cells. Prior to and concomitant with the development of severe pulmonary hypertension, lungs of chronically hypoxic SU5416-treated rats show significant pulmonary endothelial cell death, as demonstrated by activated caspase 3 immunostaining and TUNEL. The broad caspase inhibitor Z-Asp-CH2-DCB prevents the development of intravascular pulmonary endothelial cell growth and severe pulmonary hypertension caused by the combination of SU5416 and chronic hypoxia.	Univ Colorado, Hlth Sci Ctr, Dept Pathol, Denver, CO 80262 USA; Univ Colorado, Hlth Sci Ctr, Dept Med, Div Pulm Sci & Crit Care Med, Denver, CO 80262 USA; SUGEN Inc, S San Francisco, CA 94080 USA; Univ Ulm, Med Ctr, Dept Internal Med 2, D-89081 Ulm, Germany; Univ Colorado, Hlth Sci Ctr, Pulm Hypertens Ctr, Denver, CO 80262 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; Pfizer; Ulm University; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Tuder, RM (corresponding author), Univ Colorado, Hlth Sci Ctr, Dept Pathol, Campus Box B216,4200 E 9th Ave, Denver, CO 80262 USA.		Waltenberger, Johannes/I-1813-2013	Waltenberger, Johannes/0000-0002-2417-9880	NHLBI NIH HHS [R01 HL60195-01, 1RO1 HL60913-01] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL060195, R01HL060913] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALON T, 1995, NAT MED, V1, P1024, DOI 10.1038/nm1095-1024; Barst RJ, 1996, NEW ENGL J MED, V334, P296, DOI 10.1056/NEJM199602013340504; Cool CD, 1999, AM J PATHOL, V155, P411, DOI 10.1016/S0002-9440(10)65137-1; Daemen MARC, 1999, J CLIN INVEST, V104, P541, DOI 10.1172/JCI6974; Dimmeler S, 1999, CELL DEATH DIFFER, V6, P964, DOI 10.1038/sj.cdd.4400581; Feng YY, 1999, BIOCHEM BIOPH RES CO, V256, P192, DOI 10.1006/bbrc.1998.9790; Fong TAT, 1999, CANCER RES, V59, P99; Gerber HP, 1998, J BIOL CHEM, V273, P13313, DOI 10.1074/jbc.273.21.13313; Gerber HP, 1999, DEVELOPMENT, V126, P1149; Gerber HP, 1998, J BIOL CHEM, V273, P30336, DOI 10.1074/jbc.273.46.30336; HALBOWER AC, 1994, LAB INVEST, V71, P149; He H, 1999, J BIOL CHEM, V274, P25130, DOI 10.1074/jbc.274.35.25130; Jones PL, 1997, AM J PATHOL, V150, P1349; Kroll J, 1997, J BIOL CHEM, V272, P32521, DOI 10.1074/jbc.272.51.32521; Kroll J, 1998, BIOCHEM BIOPH RES CO, V252, P743, DOI 10.1006/bbrc.1998.9719; Lee SD, 1998, J CLIN INVEST, V101, P927, DOI 10.1172/JCI1910; MEYRICK B, 1980, AM J PATHOL, V100, P151; Morbidelli L, 1996, AM J PHYSIOL-HEART C, V270, pH411, DOI 10.1152/ajpheart.1996.270.1.H411; Murohara T, 1998, CIRCULATION, V97, P99, DOI 10.1161/01.CIR.97.1.99; Rabinovitch M, 1999, AM J PHYSIOL-LUNG C, V277, pL5, DOI 10.1152/ajplung.1999.277.1.L5; REID LM, 1989, PULMONARY PHYSL PATH; Scalia R, 1999, FASEB J, V13, P1039, DOI 10.1096/fasebj.13.9.1039; Shaheen RM, 1999, CANCER RES, V59, P5412; SHALABY F, 1995, NATURE, V376, P62, DOI 10.1038/376062a0; Srinivasan A, 1998, CELL DEATH DIFFER, V5, P1004, DOI 10.1038/sj.cdd.4400449; Tuder RM, 1999, CIRCULATION, V100, P241; TUDER RM, 1994, AM J PATHOL, V144, P275; TUDER RM, 1996, CIRCULATION, V94, P64; VOELKEL NF, 1994, AM J RESP CELL MOL, V11, P664, DOI 10.1165/ajrcmb.11.6.7946395; Voelkel NF, 1999, EUR RESPIR J, V14, P1246, DOI 10.1183/09031936.99.14612469; WAGENVOORT CA, 1970, CIRCULATION, V42, P1163, DOI 10.1161/01.CIR.42.6.1163; Yeager ME, 1999, CIRCULATION, V100, P587	32	581	600	0	30	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	FEB	2001	15	2					427	438		10.1096/fj.00-0343com	http://dx.doi.org/10.1096/fj.00-0343com			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	400LK	11156958				2022-12-25	WOS:000166872900024
J	Von Knethen, A; Brune, B				Von Knethen, A; Brune, B			Delayed activation of PPAR gamma by LPS and IFN-gamma attenuates the oxidative burst in macrophages	FASEB JOURNAL			English	Article						anti-inflammatory; sepsis; desensitization; respiratory burst	RECEPTOR-GAMMA; SEPTIC SHOCK; IN-VITRO; EXPRESSION; MECHANISMS; MONOCYTES; APOPTOSIS; ENDOTOXIN; ALPHA; CELLS	Desensitization of macrophages is important during the development of sepsis. It was our intention to identify mechanisms that promote macrophage deactivation upon contact with endotoxin (LPS) and interferon-gamma (IFN-gamma) in vitro. Macrophage activation was achieved with 12-O-tetradecanoylphorbol 13-acetate (TPA), and the oxidative burst (i.e., oxygen radical formation) was followed by oxidation of the redox-sensitive dyes hydroethidine and dichlorodihy-drofluorescein diacetate, Prestimulation of macrophages for 15 h with a combination of LPS/IFN-gamma attenuated oxygen radical formation in response to TPA, Taking the anti-inflammatory properties of the peroxisome proliferator-activating receptory (PPAR gamma) into consideration, we established activation of PPAR gamma in response to LPS/IFN-gamma by an electrophoretic mobility shift, supershift, and a reporter gene assay. The reporter contains a triple PPAR-responsive element (PPRE) in front of a thymidine kinase minimal promoter driving the luciferase gene, We demonstrated that PPRE decoy oligonucleotides, supplied in front of LPS/IFN-gamma, allowed a full oxidative burst to recover upon TPA addition, Furthermore, we suppressed the oxidative burst by using the PPAR gamma agonists 15-deoxy-Delta (12,14)-prostaglandin J(2), BRL. 49653, or ciglitazone. No effect was observed with WY 14643, a PPAR alpha agonist, We conclude that activation of PPARs, most likely PPAR gamma, promotes macrophage desensitization, thus attenuating the oxidative burst, This process appears important during development of sepsis.	Univ Erlangen Nurnberg, Fac Med, Dept Med 4, Expt Div, D-91054 Erlangen, Germany	University of Erlangen Nuremberg	Brune, B (corresponding author), Univ Erlangen Nurnberg, Fac Med, Dept Med 4, Expt Div, Loschgestrasse 8, D-91054 Erlangen, Germany.	mfm423@rzmail.uni-erlangen.de						Aderem A, 1999, ANNU REV IMMUNOL, V17, P593, DOI 10.1146/annurev.immunol.17.1.593; ALBINA JE, 1993, J IMMUNOL, V150, P5080; Arakawa T, 1996, J BIOL CHEM, V271, P29569, DOI 10.1074/jbc.271.47.29569; Beutler B, 2000, CURR OPIN IMMUNOL, V12, P20, DOI 10.1016/S0952-7915(99)00046-1; BOGDAN C, 1991, J EXP MED, V174, P1549, DOI 10.1084/jem.174.6.1549; Camandola S, 1996, BIOCHEM BIOPH RES CO, V229, P643, DOI 10.1006/bbrc.1996.1857; CAVAILLON JM, 1995, TRENDS MICROBIOL, V3, P320, DOI 10.1016/S0966-842X(00)88963-5; Chinetti G, 1998, J BIOL CHEM, V273, P25573, DOI 10.1074/jbc.273.40.25573; COHEN J, 1991, LANCET, V338, P736, DOI 10.1016/0140-6736(91)91453-2; Colville-Nash PR, 1998, J IMMUNOL, V161, P978; FORMAN BM, 1995, CELL, V83, P803, DOI 10.1016/0092-8674(95)90193-0; Gantner F, 1997, BRIT J PHARMACOL, V121, P221, DOI 10.1038/sj.bjp.0701124; Gilroy DW, 1999, NAT MED, V5, P698, DOI 10.1038/9550; GLAUSER MP, 1991, LANCET, V338, P732, DOI 10.1016/0140-6736(91)91452-Z; Herschman HR, 1997, ADV EXP MED BIOL, V407, P61; Hoshino K, 1999, J IMMUNOL, V162, P3749; Huang JT, 1999, NATURE, V400, P378, DOI 10.1038/22572; Imrich A, 1999, J LEUKOCYTE BIOL, V65, P499, DOI 10.1002/jlb.65.4.499; Jiang CY, 1998, NATURE, V391, P82, DOI 10.1038/34184; Karp CL, 1998, EUR J IMMUNOL, V28, P3128, DOI 10.1002/(SICI)1521-4141(199810)28:10<3128::AID-IMMU3128>3.0.CO;2-T; Kirschning CJ, 1998, J EXP MED, V188, P2091, DOI 10.1084/jem.188.11.2091; KLIEWER SA, 1995, CELL, V83, P813, DOI 10.1016/0092-8674(95)90194-9; Kwon G, 1999, J BIOL CHEM, V274, P18702, DOI 10.1074/jbc.274.26.18702; Leininger MT, 1999, BIOCHEM BIOPH RES CO, V263, P749, DOI 10.1006/bbrc.1999.1467; Michalik L, 1999, CURR OPIN BIOTECH, V10, P564, DOI 10.1016/S0958-1669(99)00030-0; Nagy L, 1998, CELL, V93, P229, DOI 10.1016/S0092-8674(00)81574-3; O'Farrell AM, 1998, EMBO J, V17, P1006, DOI 10.1093/emboj/17.4.1006; Paludan SR, 2000, J LEUKOCYTE BIOL, V67, P18, DOI 10.1002/jlb.67.1.18; RAETZ CRH, 1991, FASEB J, V5, P2652, DOI 10.1096/fasebj.5.12.1916089; Ricote M, 1998, NATURE, V391, P79, DOI 10.1038/34178; Rossi A, 2000, NATURE, V403, P103, DOI 10.1038/47520; Schoonbroodt S, 1997, BIOCHEM J, V321, P777, DOI 10.1042/bj3210777; Schulman IG, 1998, MOL CELL BIOL, V18, P3483, DOI 10.1128/MCB.18.6.3483; Spiegelman BM, 1998, CELL, V93, P153, DOI 10.1016/S0092-8674(00)81567-6; Takeuchi O, 1999, IMMUNITY, V11, P443, DOI 10.1016/S1074-7613(00)80119-3; Thieringer R, 2000, J IMMUNOL, V164, P1046, DOI 10.4049/jimmunol.164.2.1046; ULEVITCH RJ, 1995, ANNU REV IMMUNOL, V13, P437, DOI 10.1146/annurev.iy.13.040195.002253; Vadiveloo PK, 1999, J LEUKOCYTE BIOL, V66, P579, DOI 10.1002/jlb.66.4.579; Vamecq J, 1999, LANCET, V354, P141, DOI 10.1016/S0140-6736(98)10364-1; von Knethen A, 1998, ONCOGENE, V17, P387, DOI 10.1038/sj.onc.1201926; VUDAC N, 1995, J CLIN INVEST, V96, P741, DOI 10.1172/JCI118118; Wang LH, 2000, BLOOD, V95, P1249, DOI 10.1182/blood.V95.4.1249.004k39_1249_1257; ZIEGLERHEITBROCK HWL, 1995, J INFLAMM, V45, P13	43	70	70	0	6	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2001	15	2					535	544		10.1096/fj.00-0187com	http://dx.doi.org/10.1096/fj.00-0187com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	400LK	11156969				2022-12-25	WOS:000166872900035
J	Guittaut, M; Charpentier, S; Normand, T; Dubois, M; Raimond, J; Legrand, A				Guittaut, M; Charpentier, S; Normand, T; Dubois, M; Raimond, J; Legrand, A			Identification of an internal gene to the human galectin-3 gene with two different overlapping reading frames that do not encode galectin-3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALTERNATIVE TRANSLATION INITIATION; CARBOHYDRATE-BINDING PROTEIN-35; HUMAN MOLYBDOPTERIN SYNTHASE; III COLLAGEN GENE; MESSENGER-RNA; BICISTRONIC TRANSCRIPT; DISTINCT FORMS; EXPRESSION; CELLS; GROWTH	We previously reported that alternative transcripts were initiated within the second intron of the human Galectin-3 gene (LGALS3), We now demonstrate that these transcripts arise from an internal gene embedded within LGALS3 and named galig (Galectin-3 internal gene). Tissue-specific expression of galig was assayed by screening of several human tissues. Contrary to LGALS3, galig appears to be tightly regulated and principally activated in leukocytes from peripheral blood. Cloning and characterization of galig transcripts revealed that they contain two out-of-frame overlapping open-reading frames (ORFs). Transfection of expression vectors encoding enhanced green fluorescent protein (EGFP) chimeras indicated that both ORFs could be translated in proteins unrelated to Galectin-3. The ORF1 polypeptide targets EGFP to cytosol and nucleus whereas ORF2 targets EGFP to mitochondria. These results revealed the exceptional genetic organization of the LGALS3 locus.	Univ Orleans, CNRS, UPR4301, Ctr Biophys Mol, F-45071 Orleans 02, France	Centre National de la Recherche Scientifique (CNRS); CNRS - Institute of Chemistry (INC); Universite de Orleans	Legrand, A (corresponding author), Univ Orleans, CNRS, UPR4301, Ctr Biophys Mol, Rue Charles Sadron, F-45071 Orleans 02, France.		Guittaut, Michael/ABE-4274-2021	Guittaut, Michael/0000-0001-9540-5593				AGRWAL N, 1993, J BIOL CHEM, V268, P14932; Akiri G, 1998, ONCOGENE, V17, P227, DOI 10.1038/sj.onc.1202019; AOKI M, 1993, J BIOL CHEM, V268, P22723; Ayoubi TAY, 1996, FASEB J, V10, P453, DOI 10.1096/fasebj.10.4.8647344; Bao Q, 1999, GLYCOBIOLOGY, V9, P489, DOI 10.1093/glycob/9.5.489; BAO Q, 1995, J CELL SCI, V108, P2791; BARONDES SH, 1994, J BIOL CHEM, V269, P20807; BENNETT VD, 1990, J BIOL CHEM, V265, P2223; BOUSSIF O, 1995, P NATL ACAD SCI USA, V92, P7297, DOI 10.1073/pnas.92.16.7297; CALLIGARIS R, 1995, P NATL ACAD SCI USA, V92, P11598, DOI 10.1073/pnas.92.25.11598; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; FOWLIS D, 1995, DEV DYNAM, V203, P241, DOI 10.1002/aja.1002030211; Gray NK, 1998, ANNU REV CELL DEV BI, V14, P399, DOI 10.1146/annurev.cellbio.14.1.399; HAMANN KK, 1991, EXP CELL RES, V196, P82, DOI 10.1016/0014-4827(91)90458-7; Horwich A, 1990, CURR OPIN CELL BIOL, V2, P625, DOI 10.1016/0955-0674(90)90103-L; HSU DK, 1992, J BIOL CHEM, V267, P14167; Kadrofske MM, 1998, ARCH BIOCHEM BIOPHYS, V349, P7, DOI 10.1006/abbi.1997.0447; KOZAK M, 1992, ANNU REV CELL BIOL, V8, P197, DOI 10.1146/annurev.cb.08.110192.001213; LABARRIERE N, 1995, J BIOL CHEM, V270, P19205, DOI 10.1074/jbc.270.33.19205; LEE SJ, 1991, P NATL ACAD SCI USA, V88, P4250, DOI 10.1073/pnas.88.10.4250; LEGRAND A, 1991, AM J PATHOL, V139, P629; NAH HD, 1994, J BIOL CHEM, V269, P16443; NANGIAMAKKER P, 1993, CANCER RES, V53, P5033; Okazaki S, 1998, BIOCHEM BIOPH RES CO, V250, P347, DOI 10.1006/bbrc.1998.9331; Packham G, 1997, BIOCHEM J, V328, P807, DOI 10.1042/bj3280807; Perillo NL, 1998, J MOL MED, V76, P402, DOI 10.1007/s001090050232; QUELLE DE, 1995, CELL, V83, P993; RAIMOND J, 1995, FEBS LETT, V363, P165, DOI 10.1016/0014-5793(95)00310-6; Ritchie H, 1997, BIOCHEM BIOPH RES CO, V231, P425, DOI 10.1006/bbrc.1997.6126; Sloan J, 1999, NUCLEIC ACIDS RES, V27, P854, DOI 10.1093/nar/27.3.854; Stallmeyer B, 1999, AM J HUM GENET, V64, P698, DOI 10.1086/302295; SZABO G, 1994, MOL CELL BIOL, V14, P7535, DOI 10.1128/MCB.14.11.7535; VAGNER S, 1995, MOL CELL BIOL, V15, P35, DOI 10.1128/MCB.15.1.35; VOSS JW, 1991, J BIOL CHEM, V266, P12832; Yang RY, 1996, P NATL ACAD SCI USA, V93, P6737, DOI 10.1073/pnas.93.13.6737; Yang XL, 1998, ONCOGENE, V17, P981, DOI 10.1038/sj.onc.1202032; Zhang YJ, 1997, NUCLEIC ACIDS RES, V25, P2470, DOI 10.1093/nar/25.12.2470	37	31	31	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 26	2001	276	4					2652	2657		10.1074/jbc.M002523200	http://dx.doi.org/10.1074/jbc.M002523200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	398YV	11160123	hybrid			2022-12-25	WOS:000166784800050
J	Wang, ZW; Pan, WT; Lee, Y; Kakuma, T; Zhou, YT; Unger, RH				Wang, ZW; Pan, WT; Lee, Y; Kakuma, T; Zhou, YT; Unger, RH			The role of leptin resistance in the lipid abnormalities of aging	FASEB JOURNAL			English	Article						high-fat diet; hyperleptinemia; SOCS-3; fatty acids; hypothalamus; lipotoxicity	OBESE RATS; EXERCISE; DISEASE; SOCS-3; CELLS	Leptin resistance has been implicated in the pathogenesis of obesity-related complications involving abnormalities of lipid metabolism that resemble those of old age. To determine whether development of leptin resistance in advancing age might account for such abnormalities, we compared the effects of hyperleptinemia (>40 ng/ml) induced in 2-month-old and 18-month-old lean wild-type (+/+) Zucker diabetic fatty rats by adenovirus gene transfer. The decline in food intake, body weight, and body fat in old rats was only 25%, 50%, and 16%, respectively, of the young rats. Whereas in young rats plasma free fatty acids fell 44% and triacylglycerol (TG) 94%, neither changed in the rats. In hyperleptinemic young rats, adipocyte expression of preadipocyte factor 1 increased dramatically and leptin mRNA virtually disappeared; there was increased expression of acyl CoA oxidase, carnitine palmitoyl transferase 1, and their transcription factor peroxisome proliferator-activated receptor alpha, accounting for the reduction in body fat. These hyperleptinemia-induced changes were profoundly reduced in the old rats. On a high-fat diet, old rats consumed 28% more calories than the young and gained 1.5x as much fat, despite greater endogenous hyperleptinemia. Expression of a candidate leptin resistance factor, suppressor of cytokine signaling 3 (SOCS-3), was compared in the hypothalamus and white adipocytes of young and old rats before and after induction of hyperleptinemia; hypothalamic SOCS-3 mRNA was similar to 3x higher in old rats before, whereas it was 3x higher in WAT after, hyperleptinemia. We conclude that the anorexic and antilipopenic actions of leptin decline with age, possibly through increased SOCS-3 expression, and that this could account for the associated abnormalities in lipid metabolism of the elderly.	Univ Texas, SW Med Ctr, Ctr Diabet Res, Gifford Labs,Dept Internal Med, Dallas, TX 75290 USA; VA N Texas Hlth Care Syst, Dallas, TX 75216 USA	Diabetes & Endocrine Center; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA North Texas Health Care System	Unger, RH (corresponding author), Univ Texas, SW Med Ctr, Touchstone Ctr Diabet Res, 5323 Harry Hines Blvd, Dallas, TX 75235 USA.	Runger@mednet.Swmed.edu			NIDDK NIH HHS [DK02700-37] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK002700, R01DK002700] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alessio HM, 1997, RES Q EXERCISE SPORT, V68, P292, DOI 10.1080/02701367.1997.10608010; Barzilai N, 1999, J GERONTOL A-BIOL, V54, pB89, DOI 10.1093/gerona/54.3.B89; Bjorbaek C, 1999, J BIOL CHEM, V274, P30059, DOI 10.1074/jbc.274.42.30059; Bjorbaek C, 1998, MOL CELL, V1, P619, DOI 10.1016/S1097-2765(00)80062-3; Chen GX, 1996, P NATL ACAD SCI USA, V93, P14795, DOI 10.1073/pnas.93.25.14795; Das UN, 1999, PROSTAG LEUKOTR ESS, V61, P157, DOI 10.1054/plef.1999.0085; EVANS WJ, 1995, J GERONTOL A-BIOL, V50, P5, DOI 10.1093/gerona/50A.Special_Issue.5; HERZ J, 1993, P NATL ACAD SCI USA, V90, P2812, DOI 10.1073/pnas.90.7.2812; Higa M, 1999, P NATL ACAD SCI USA, V96, P11513, DOI 10.1073/pnas.96.20.11513; Koyama K, 1997, AM J PHYSIOL-ENDOC M, V273, pE708, DOI 10.1152/ajpendo.1997.273.4.E708; Lakowski B, 1996, SCIENCE, V272, P1010, DOI 10.1126/science.272.5264.1010; Lee CK, 1999, SCIENCE, V285, P1390, DOI 10.1126/science.285.5432.1390; LEE Y, 1994, P NATL ACAD SCI USA, V91, P10878, DOI 10.1073/pnas.91.23.10878; MCGARRY JD, 1992, SCIENCE, V258, P766, DOI 10.1126/science.1439783; POEHLMAN ET, 1995, INT J OBESITY, V19, pS93; Qian H, 1998, P SOC EXP BIOL MED, V219, P160, DOI 10.3181/00379727-219-44330; Shimabukuro M, 1998, J BIOL CHEM, V273, P32487, DOI 10.1074/jbc.273.49.32487; Shimabukuro M, 1998, P NATL ACAD SCI USA, V95, P2498, DOI 10.1073/pnas.95.5.2498; Shimabukuro M, 1997, P NATL ACAD SCI USA, V94, P4637, DOI 10.1073/pnas.94.9.4637; Shimizu M, 1996, DIABETES CARE, V19, P8, DOI 10.2337/diacare.19.1.8; SMAS CM, 1993, CELL, V73, P725, DOI 10.1016/0092-8674(93)90252-L; STEIN DT, 1995, INT J OBESITY, V19, P804; STRATTON JR, 1994, CIRCULATION, V89, P1648, DOI 10.1161/01.CIR.89.4.1648; Unger RH, 1997, TRENDS ENDOCRIN MET, V8, P276, DOI 10.1016/S1043-2760(97)00094-5; Unger RH, 1999, P NATL ACAD SCI USA, V96, P2327, DOI 10.1073/pnas.96.5.2327; Zhou YT, 2000, P NATL ACAD SCI USA, V97, P1784, DOI 10.1073/pnas.97.4.1784; Zhou YT, 1998, P NATL ACAD SCI USA, V95, P8898, DOI 10.1073/pnas.95.15.8898; Zhou YT, 1999, P NATL ACAD SCI USA, V96, P2391, DOI 10.1073/pnas.96.5.2391	28	113	126	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2001	15	1					108	114		10.1096/fj.00-0310com	http://dx.doi.org/10.1096/fj.00-0310com			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	390TH	11149898				2022-12-25	WOS:000166312400019
J	Kim, JS; Pirnia, F; Choi, YH; Nguyen, P; Knepper, B; Tsokos, M; Schulte, TW; Birrer, MJ; Blagosklonny, MV; Schaefer, O; Mushinski, JF; Trepel, JB				Kim, JS; Pirnia, F; Choi, YH; Nguyen, P; Knepper, B; Tsokos, M; Schulte, TW; Birrer, MJ; Blagosklonny, MV; Schaefer, O; Mushinski, JF; Trepel, JB			Lovastatin induces apoptosis in a primitive neuroectodermal tumor cell line in association with RB down-regulation and loss of the G-1 checkpoint	ONCOGENE			English	Article						lovastatin; differentiation; apoptosis; ESFT	PROSTATE CARCINOMA-CELLS; CYCLIN-DEPENDENT KINASES; EWINGS-SARCOMA; THYMOCYTE APOPTOSIS; DNA-BINDING; PHASE-I; CANCER; E2F-1; INHIBITION; INDUCTION	To develop a new approach to the treatment of primitive neuroectodermal tumors we evaluated the effect of the HMG-CoA reductase inhibitor lovastatin on the Ewing's sarcoma cell line CHP-100, Lovastatin induced neural morphology and markers including neuron-specific enolase and neurofilament protein. The acquisition of neural morphology required nem mRNA synthesis, and cDNA microarray analysis confirmed that lovastatin altered the program of gene expression. After morphologic differentiation the cells underwent rapidly progressive apoptosis. In normal development of neuronal progenitors, differentiation signals trigger p21(WAF1) accumulation, RB hypophosphorylation, enhanced RB-E2F-1 association, and G1 arrest, and these events have been shown to protect from apoptosis. In contrast, in the Ewing's sarcoma cells lovastatin triggered differentiation without causing cell cycle arrest: p21(WAF1) was not induced, RE remained hyperphosphorylated, and RE protein expression and RE-E2F-1 association were markedly downregulated, suggesting that loss of an RE-regulated G1 checkpoint promoted apoptosis. Consistent with this hypothesis, adenoviral p21(WAF1) decreased DNA synthesis and partially protected from lovastatin-induced cytotoxicity. The data demonstrate a new model for examining the genetic regulation of cell fate in a neural progenitor tumor and suggest a new approach to the treatment of this neoplasm.	NCI, Med Branch, NIH, Bethesda, MD 20892 USA; NCI, Pathol Lab, Div Clin Sci, NIH, Bethesda, MD 20892 USA; NCI, Genet Lab, Div Basic Sci, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Trepel, JB (corresponding author), NCI, Med Branch, NIH, Bldg 10,Room 12N230, Bethesda, MD 20892 USA.				NATIONAL CANCER INSTITUTE [Z01BC008727, ZIABC008727] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAILLY RA, 1994, MOL CELL BIOL, V14, P3230, DOI 10.1128/MCB.14.5.3230; BANG YJ, 1994, P NATL ACAD SCI USA, V91, P5330, DOI 10.1073/pnas.91.12.5330; BERNAL S, 1983, CANCER RES, V43, P1256; Blagosklonny MV, 2000, J CLIN INVEST, V105, P533, DOI 10.1172/JCI8625; Blagosklonny MV, 1997, INT J ONCOL, V11, P1165; CAVAZZANA AO, 1987, AM J PATHOL, V127, P507; Chen YNP, 1999, P NATL ACAD SCI USA, V96, P4325, DOI 10.1073/pnas.96.8.4325; DeGregori J, 1997, P NATL ACAD SCI USA, V94, P7245, DOI 10.1073/pnas.94.14.7245; Denny CT, 1996, CANCER INVEST, V14, P83, DOI 10.3109/07357909609018438; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Field SJ, 1996, CELL, V85, P549, DOI 10.1016/S0092-8674(00)81255-6; Fontaine C, 1997, ANN ONCOL, V8, P691, DOI 10.1023/A:1008271903643; GrayBablin J, 1997, CANCER RES, V57, P604; GUDAS JM, 1993, CELL GROWTH DIFFER, V4, P421; Hall M, 1996, ADV CANCER RES, V68, P67, DOI 10.1016/S0065-230X(08)60352-8; HENGST L, 1994, P NATL ACAD SCI USA, V91, P5291, DOI 10.1073/pnas.91.12.5291; Hense HW, 1999, ANN ONCOL, V10, P1073, DOI 10.1023/A:1008357018737; Horowitz ME, 1993, PRINCIPLES PRACTICE, P795; ISHIZAWA M, 1991, NUCLEIC ACIDS RES, V19, P5792, DOI 10.1093/nar/19.20.5792; JAKOBISIAK M, 1991, P NATL ACAD SCI USA, V88, P3628, DOI 10.1073/pnas.88.9.3628; Jang JS, 1999, ONCOGENE, V18, P1789, DOI 10.1038/sj.onc.1202497; Jurgens H F, 1994, Curr Opin Oncol, V6, P391; Kaelin WG, 1999, J CLIN INVEST, V104, P1503, DOI 10.1172/JCI8888; KAELIN WG, 1991, CELL, V64, P521, DOI 10.1016/0092-8674(91)90236-R; KASTAN MB, 1995, CANCER METAST REV, V14, P3, DOI 10.1007/BF00690207; KEYOMARSI K, 1991, CANCER RES, V51, P3602; Kogan SC, 1999, ONCOGENE, V18, P5261, DOI 10.1038/sj.onc.1202996; Kovar H, 1998, Sarcoma, V2, P3, DOI 10.1080/13577149878109; LADENSTEIN R, 1995, BONE MARROW TRANSPL, V15, P697; Larner J, 1998, AM J CLIN ONCOL-CANC, V21, P579, DOI 10.1097/00000421-199812000-00010; Lee SJ, 1998, J BIOL CHEM, V273, P10618, DOI 10.1074/jbc.273.17.10618; Lees JA, 1999, P NATL ACAD SCI USA, V96, P4221, DOI 10.1073/pnas.96.8.4221; LIPINSKI M, 1987, CANCER RES, V47, P183; Lipinski MM, 1999, ONCOGENE, V18, P7873, DOI 10.1038/sj.onc.1203244; Macaulay RJB, 1999, J NEURO-ONCOL, V42, P1, DOI 10.1023/A:1006164406202; MALTESE WA, 1985, J CLIN INVEST, V76, P1748, DOI 10.1172/JCI112165; MAY WA, 1993, MOL CELL BIOL, V13, P7393, DOI 10.1128/MCB.13.12.7393; MAY WA, 1993, P NATL ACAD SCI USA, V90, P5752, DOI 10.1073/pnas.90.12.5752; Muller C, 1999, INT J MOL MED, V3, P63; MUNRO E, 1994, EUR J CLIN INVEST, V24, P766, DOI 10.1111/j.1365-2362.1994.tb01074.x; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; PACHTER JS, 1984, DEV BIOL, V103, P200, DOI 10.1016/0012-1606(84)90021-6; Phillips AC, 1999, MOL CELL, V4, P771, DOI 10.1016/S1097-2765(00)80387-1; Phillips AC, 1997, GENE DEV, V11, P1853, DOI 10.1101/gad.11.14.1853; Polyak K, 1996, GENE DEV, V10, P1945, DOI 10.1101/gad.10.15.1945; Richon VM, 1998, P NATL ACAD SCI USA, V95, P3003, DOI 10.1073/pnas.95.6.3003; Ross SD, 1999, ARCH INTERN MED, V159, P1793, DOI 10.1001/archinte.159.15.1793; SCHLESINGER HR, 1976, CANCER RES, V36, P3094; Shan B, 1996, P NATL ACAD SCI USA, V93, P679, DOI 10.1073/pnas.93.2.679; Shapiro GI, 1999, J CLIN INVEST, V104, P1645, DOI 10.1172/JCI9054; Stewart ZA, 1999, CANCER RES, V59, P3831; Thibault A, 1996, CLIN CANCER RES, V2, P483; Thompson AD, 1999, ONCOGENE, V18, P5506, DOI 10.1038/sj.onc.1202928; Tsokos M, 1992, Perspect Pediatr Pathol, V16, P27; WHITESELL L, 1991, MOL CELL BIOL, V11, P1360, DOI 10.1128/MCB.11.3.1360; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0; Yamasaki L, 1996, CELL, V85, P537, DOI 10.1016/S0092-8674(00)81254-4	58	29	31	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 7	2000	19	52					6082	6090		10.1038/sj.onc.1204008	http://dx.doi.org/10.1038/sj.onc.1204008			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	382MY	11146561				2022-12-25	WOS:000165827900016
J	Lamorte, L; Kamikura, DM; Park, M				Lamorte, L; Kamikura, DM; Park, M			A switch from p130Cas/Crk to Gab1/Crk signaling correlates with anchorage independent growth and JNK activation in cells transformed by the Met receptor oncoprotein	ONCOGENE			English	Article						Crk; cytoskeleton; Gab1; JNK; Met tyrosine kinase; transformation	FOCAL ADHESION KINASE; ADAPTER PROTEIN CRK; TYROSINE PHOSPHORYLATION; SCATTER FACTOR; PROTOONCOGENE PRODUCT; COMPLEX-FORMATION; CARBOXY-TERMINUS; GRB2 BINDING; V-CRK; MIGRATION	Cell transformation is associated with anchorage independent growth and morphological changes characterized by reduced adhesion and spreading, The molecular signals that control these events are poorly understood. The Met receptor tyrosine kinase is deregulated in human tumors and an oncogenic derivative of this receptor transforms cells. In this paper we demonstrate that fibroblasts transformed by the Met oncoprotein display decreased cell spreading consistent with the loss of actin stress fibers and vinculin staining focal adhesions. In contrast to control cells, focal adhesion kinase, p130Cas and paxillin are weakly or not detectably tyrosine phosphorylated in Met transformed cells. Moreover, although paxillin and p130Cas associate with the Crk adapter protein in control cells, they fail to associate with Crk in Met transformed cells, yet these cells are motile and capable of wound closure to the same extent as control cells. In Met transformed cells, Crk predominantly associates with the CM and Gab1 docking proteins in a tyrosine phosphorylation dependent manner. The coupling of Gab1, but not Cbl, with Crk is retained in cells grown in suspension and enhances JNK activation. We propose that the loss of adhesion dependent signals required for cell cycle progression is compensated through Met induced Gab1/Crk signals.	McGill Univ, Ctr Hosp, Mol Oncol Grp, Montreal, PQ H3A 1A1, Canada; McGill Univ, Ctr Hosp, Mol Oncol Grp, Dept Med, Montreal, PQ H3A 1A1, Canada; McGill Univ, Ctr Hosp, Mol Oncol Grp, Dept Oncol, Montreal, PQ H3A 1A1, Canada	McGill University; McGill University; McGill University	Park, M (corresponding author), McGill Univ, Ctr Hosp, Mol Oncol Grp, 687 Pine Ave W,Room H5-10, Montreal, PQ H3A 1A1, Canada.							Andoniou CE, 1996, ONCOGENE, V12, P1981; Angers-Loustau A, 1999, J CELL BIOL, V144, P1019, DOI 10.1083/jcb.144.5.1019; Assoian RK, 1997, J CELL BIOL, V136, P1, DOI 10.1083/jcb.136.1.1; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; Cary LA, 1996, J CELL SCI, V109, P1787; DIRENZO MF, 1992, ONCOGENE, V7, P2549; Dolfi F, 1998, P NATL ACAD SCI USA, V95, P15394, DOI 10.1073/pnas.95.26.15394; FERRACINI R, 1995, ONCOGENE, V10, P739; FIXMAN ED, 1995, ONCOGENE, V10, P237; Fixman ED, 1996, J BIOL CHEM, V271, P13116, DOI 10.1074/jbc.271.22.13116; Fixman ED, 1997, J BIOL CHEM, V272, P20167, DOI 10.1074/jbc.272.32.20167; Garcia-Guzman M, 1999, ONCOGENE, V18, P7775, DOI 10.1038/sj.onc.1203198; Garrington TP, 1999, CURR OPIN CELL BIOL, V11, P211, DOI 10.1016/S0955-0674(99)80028-3; Giordano S, 1997, P NATL ACAD SCI USA, V94, P13868, DOI 10.1073/pnas.94.25.13868; Gu HH, 1998, MOL CELL, V2, P729, DOI 10.1016/S1097-2765(00)80288-9; Gual P, 2000, ONCOGENE, V19, P1509, DOI 10.1038/sj.onc.1203514; GUAN JL, 1992, NATURE, V358, P690, DOI 10.1038/358690a0; Guvakova MA, 1999, EXP CELL RES, V251, P244, DOI 10.1006/excr.1999.4566; Hanks SK, 1997, BIOESSAYS, V19, P137, DOI 10.1002/bies.950190208; HolgadoMadruga M, 1996, NATURE, V379, P560, DOI 10.1038/379560a0; Honda H, 1998, NAT GENET, V19, P361, DOI 10.1038/1246; Kamikura DM, 1996, BIOCHEMISTRY-US, V35, P1010, DOI 10.1021/bi9514065; Kamikura DM, 2000, MOL CELL BIOL, V20, P3482, DOI 10.1128/MCB.20.10.3482-3496.2000; Klemke RL, 1998, J CELL BIOL, V140, P961, DOI 10.1083/jcb.140.4.961; Kolibaba KS, 1997, BIOCHIM BIOPHYS ACTA, V1333, P217; Koochekpour S, 1997, CANCER RES, V57, P5391; Lo SS, 1999, MOL CARCINOGEN, V25, P150; Maroun CR, 1999, MOL CELL BIOL, V19, P1784; Matsuda M, 1996, CELL SIGNAL, V8, P335, DOI 10.1016/0898-6568(96)00067-8; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; Miyake S, 1997, CRIT REV ONCOGENESIS, V8, P189, DOI 10.1615/CritRevOncog.v8.i2-3.30; Oktay M, 1999, J CELL BIOL, V145, P1461, DOI 10.1083/jcb.145.7.1461; Owen JD, 1999, MOL CELL BIOL, V19, P4806; PARK M, 1986, CELL, V45, P895, DOI 10.1016/0092-8674(86)90564-7; Petit V, 2000, J CELL BIOL, V148, P957, DOI 10.1083/jcb.148.5.957; PONZETTO C, 1994, CELL, V77, P261, DOI 10.1016/0092-8674(94)90318-2; Raabe T, 1996, CELL, V85, P911, DOI 10.1016/S0092-8674(00)81274-X; RODRIGUES GA, 1993, MOL CELL BIOL, V13, P6711, DOI 10.1128/MCB.13.11.6711; Rodrigues GA, 1997, EMBO J, V16, P2634, DOI 10.1093/emboj/16.10.2634; ROSEN EM, 1994, J CELL BIOL, V127, P1783, DOI 10.1083/jcb.127.6.1783; Ruoslahti E, 1999, ADV CANCER RES, V76, P1, DOI 10.1016/S0065-230X(08)60772-1; SAKAI R, 1994, EMBO J, V13, P3748, DOI 10.1002/j.1460-2075.1994.tb06684.x; Sakkab D, 2000, J BIOL CHEM, V275, P10772, DOI 10.1074/jbc.275.15.10772; SAWASDIKOSOLA S, 2000, BIOCHIM BIOPHYS ACTA, V1471, P1; Schlaepfer DD, 1998, TRENDS CELL BIOL, V8, P151, DOI 10.1016/S0962-8924(97)01172-0; SCHLAEPFER DD, 1994, NATURE, V372, P786; Schmidt L, 1997, NAT GENET, V16, P68, DOI 10.1038/ng0597-68; Schoenwaelder SM, 1999, CURR OPIN CELL BIOL, V11, P274, DOI 10.1016/S0955-0674(99)80037-4; Schwartz MA, 1997, J CELL BIOL, V139, P575, DOI 10.1083/jcb.139.3.575; Sieg DJ, 1999, J CELL SCI, V112, P2677; Tanaka S, 1997, P NATL ACAD SCI USA, V94, P2356, DOI 10.1073/pnas.94.6.2356; Tibbles LA, 1999, CELL MOL LIFE SCI, V55, P1230, DOI 10.1007/s000180050369; Vuori K, 1996, MOL CELL BIOL, V16, P2606; VUORI K, 1995, J BIOL CHEM, V270, P22259, DOI 10.1074/jbc.270.38.22259; Yu DH, 1998, J BIOL CHEM, V273, P21125, DOI 10.1074/jbc.273.33.21125	55	50	50	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 7	2000	19	52					5973	5981		10.1038/sj.onc.1203977	http://dx.doi.org/10.1038/sj.onc.1203977			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	382MY	11146548				2022-12-25	WOS:000165827900003
J	Mukherjee, S; Louie, SG; Campbell, M; Esserman, L; Shyamala, G				Mukherjee, S; Louie, SG; Campbell, M; Esserman, L; Shyamala, G			Ductal growth is impeded in mammary glands of C-neu transgenic mice	ONCOGENE			English	Article						estrogen; estrogen receptor; C-neu; mammary gland; ductal growth	HUMAN-BREAST-CANCER; PROGESTERONE RECEPTORS; ESTROGEN-RECEPTOR; ERBB RECEPTORS; A-FORM; EXPRESSION; MORPHOGENESIS; PROTOONCOGENE; ABNORMALITIES; SUPERFAMILY	The steroid hormone, estradiol, is essential for both the growth of normal breast and induction of mammary carcinomas, The growth promoting effects of estrogen are presumed to be mediated by growth factors, in particular, epidermal growth factor, which mediates its effects through erbB receptors, erbB1 and erbB2/C-neu. C-neu is amplified and over-expressed in a large number of human cancers and transgenic mice over-expressing C-neu also develop mammary tumors, However, as set, the impact of C-neu over-expression on estrogen action during normal mammary development and hence, its precise role in carcinogenesis, remains unclear, In the present studies, we demonstrate that estradiol-dependent mammary ductal growth accompanying puberty is impaired in transgenic mice expressing wild type C-neu, and is intrinsic to the tissue. The impairment is not due to an overall impairment in estrogen action, since progesterone receptor expression is unaffected in C-neu mice. It is also not due to an intrinsic inability of the epithelial cells to proliferate, since impeded ductal growth co-exists,vith alveolar growth during pregnancy. Therefore, we propose that, depending on the physiological state, C-neu may either promote or inhibit the growth of mammary epithelial cells, and discuss its potential significance to carcinogenesis.	Univ Calif Berkeley, Lawrence Berkeley Lab, Div Life Sci, Berkeley, CA 94720 USA; Univ Calif San Francisco, Dept Surg, San Francisco, CA 94143 USA	United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley; University of California System; University of California San Francisco	Shyamala, G (corresponding author), Univ Calif Berkeley, Lawrence Berkeley Lab, Div Life Sci, 1 Cyclotron Rd,Bldg 74, Berkeley, CA 94720 USA.				NATIONAL CANCER INSTITUTE [R01CA066541] Funding Source: NIH RePORTER; NCI NIH HHS [CA 66541] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANTONIOTTI S, 1992, EUR J CANCER, V28A, P318, DOI 10.1016/S0959-8049(05)80045-0; Bocchinfuso WP, 1997, J MAMMARY GLAND BIOL, V2, P323, DOI 10.1023/A:1026339111278; BRESCIANI FRANCESCO, 1968, CELL TISSUE KINET, V1, P51, DOI 10.1111/j.1365-2184.1968.tb00193.x; COLEMAN S, 1990, DEV BIOL, V137, P425, DOI 10.1016/0012-1606(90)90267-M; COLEMAN S, 1988, DEV BIOL, V127, P304, DOI 10.1016/0012-1606(88)90317-X; Daniel C. W., 1987, The mammary gland. Development, regulation, and function., P3; DeckardJanatpour K, 1997, INT J ONCOL, V11, P235; DEOME KB, 1959, CANCER RES, V78, P515; GrausPorta D, 1997, EMBO J, V16, P1647, DOI 10.1093/emboj/16.7.1647; GUY CT, 1992, P NATL ACAD SCI USA, V89, P10578, DOI 10.1073/pnas.89.22.10578; Guy CT, 1996, J BIOL CHEM, V271, P7673, DOI 10.1074/jbc.271.13.7673; HAM J, 1988, NUCLEIC ACIDS RES, V16, P5263, DOI 10.1093/nar/16.12.5263; HASLAM SZ, 1988, ENDOCRINOLOGY, V122, P464, DOI 10.1210/endo-122-2-464; LYDON JP, 1995, GENE DEV, V9, P2266, DOI 10.1101/gad.9.18.2266; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; Muller WJ, 1996, MOL CELL BIOL, V16, P5726; MUTHUSWAMY SK, 1994, MOL CELL BIOL, V14, P735, DOI 10.1128/MCB.14.1.735; Raafat AM, 1999, ENDOCRINOLOGY, V140, P2570, DOI 10.1210/en.140.6.2570; READ LD, 1990, CANCER RES, V50, P3947; RUSSELL KS, 1992, CANCER RES, V52, P6624; Schroeder JA, 1998, CELL GROWTH DIFFER, V9, P451; Sebastian J, 1998, CELL GROWTH DIFFER, V9, P777; Shyamala G, 2000, P NATL ACAD SCI USA, V97, P3044, DOI 10.1073/pnas.97.7.3044; Shyamala G, 1997, J STEROID BIOCHEM, V63, P251, DOI 10.1016/S0960-0760(97)00128-3; SHYAMALA G, 1992, RECEPTOR, V2, P121; Shyamala G, 1998, P NATL ACAD SCI USA, V95, P696, DOI 10.1073/pnas.95.2.696; Shyamala G., 1980, Perspectives in steroid receptor research, P193; SHYAMALA G, 1987, ENDOCRINOLOGY, P127; Siegel PM, 1999, EMBO J, V18, P2149, DOI 10.1093/emboj/18.8.2149; SILBERSTEIN GB, 1994, ENDOCRINOLOGY, V134, P84, DOI 10.1210/en.134.1.84; Silberstein GB, 1996, CELL GROWTH DIFFER, V7, P945; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; SNEDEKER SM, 1991, P NATL ACAD SCI USA, V88, P276, DOI 10.1073/pnas.88.1.276; TSAI MJ, 1994, ANNU REV BIOCHEM, V63, P451, DOI 10.1146/annurev.biochem.63.1.451; VEGETO E, 1993, MOL ENDOCRINOL, V7, P1244, DOI 10.1210/me.7.10.1244	36	19	19	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 7	2000	19	52					5982	5987		10.1038/sj.onc.1203964	http://dx.doi.org/10.1038/sj.onc.1203964			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	382MY	11146549				2022-12-25	WOS:000165827900004
J	Liu, XD; Sun, Y; Ehrlich, M; Lu, T; Kloog, Y; Weinberg, RA; Lodish, HF; Henis, YI				Liu, XD; Sun, Y; Ehrlich, M; Lu, T; Kloog, Y; Weinberg, RA; Lodish, HF; Henis, YI			Disruption of TGF-beta growth inhibition hy oncogenic ras is linked to p27(Kip1) mislocalization	ONCOGENE			English	Article						mislocalization of p27(Kip1); oncogenic Ras; p27(Kip1) partner switching; TGF-beta growth inhibition	CELL-CYCLE ARREST; EPITHELIAL-CELLS; SKI ONCOPROTEIN; CDK INHIBITORS; SMAD PROTEINS; CANCER CELLS; TUMOR-CELLS; C-MYC; RECEPTOR; GENE	Expression of oncogenic Ras in epithelial tumor cells is linked to the loss of transforming growth factor-beta (TGF-beta) anti-proliferative activity, and was proposed to involve inhibition of Smad2/3 nuclear translocation, Here we studied several epithelial cell lines expressing oncogenic N-Ras(K61) and show that TGF-beta -induced nuclear translocation of and transcriptional activation by Smad2/3,were unaffected. In contrast, oncogenic Ras mediated nuclear-to-cytoplasmic mislocalization of p27(Kip1) (p27) and of the cyclin-dependent kinase (CDK) CDK6, but not CDK2, Concomitantly, oncogenic Ras abrogated the ability of p27 and from to CDK6, to enhance its inhibit CDK2 activity. TGF-beta to binding to Inactivation of Ras by a specific antagonist restored the growth inhibitory response to TGF-beta with concurrent normalization of p27 and CDK6 localization. Therefore, the disruption of TGF-beta -mediated growth inhibition by oncogenic Ras appears to be due to lack of inhibition of CDK2, caused by the sequestration of p27 and CDK2 in different subcellular compartments and by the loss of TGF-beta -induced partner switching of p27 from CDK6 to CDK2.	Nine Cambridge Ctr, Whitehead Inst Biomed Res, Cambridge, MA 02142 USA; Tel Aviv Univ, George S Wise Fac Life Sci, Dept Neurobiochem, IL-69978 Tel Aviv, Israel; MIT, Dept Biol, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT); Whitehead Institute; Tel Aviv University; Massachusetts Institute of Technology (MIT)	Henis, YI (corresponding author), Nine Cambridge Ctr, Whitehead Inst Biomed Res, Cambridge, MA 02142 USA.			Ehrlich, Marcelo/0000-0002-2352-1808; Henis, Yoav/0000-0002-1408-3877; LIU, XUEDONG/0000-0001-7209-4964				ALEXANDROW MG, 1995, CANCER RES, V55, P1452; Baldassarre G, 1999, J CLIN INVEST, V104, P865, DOI 10.1172/JCI6443; BOS JL, 1989, CANCER RES, V49, P4682; Catzavelos C, 1999, CANCER RES, V59, P684; Constantinescu SN, 1999, EMBO J, V18, P3334, DOI 10.1093/emboj/18.12.3334; DeCoteau JF, 1997, P NATL ACAD SCI USA, V94, P5877, DOI 10.1073/pnas.94.11.5877; Depoortere F, 2000, MOL BIOL CELL, V11, P1061, DOI 10.1091/mbc.11.3.1061; EWEN ME, 1993, CELL, V74, P1009, DOI 10.1016/0092-8674(93)90723-4; FILMUS J, 1992, ONCOGENE, V7, P521; FYNAN TM, 1993, CRIT REV ONCOGENESIS, V4, P493; Haklai R, 1998, BIOCHEMISTRY-US, V37, P1306, DOI 10.1021/bi972032d; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; Harbour JW, 1999, CELL, V98, P859, DOI 10.1016/S0092-8674(00)81519-6; HELIN K, 1992, CELL, V70, P337, DOI 10.1016/0092-8674(92)90107-N; HERRMANN C, 1995, J BIOL CHEM, V270, P2901, DOI 10.1074/jbc.270.7.2901; HOUCK KA, 1989, ONCOGENE, V4, P19; HSU IC, 1993, CARCINOGENESIS, V14, P987, DOI 10.1093/carcin/14.5.987; Hua XX, 1998, GENE DEV, V12, P3084, DOI 10.1101/gad.12.19.3084; INAGAKI M, 1993, P NATL ACAD SCI USA, V90, P5359, DOI 10.1073/pnas.90.11.5359; Kapus A, 1999, J BIOL CHEM, V274, P8093, DOI 10.1074/jbc.274.12.8093; KEETON MR, 1991, J BIOL CHEM, V266, P23048; KIMCHI A, 1988, SCIENCE, V240, P196, DOI 10.1126/science.2895499; Kretzschmar M, 1999, GENE DEV, V13, P804, DOI 10.1101/gad.13.7.804; Kurokawa M, 1998, NATURE, V394, P92, DOI 10.1038/27945; Liu XD, 1997, P NATL ACAD SCI USA, V94, P10669, DOI 10.1073/pnas.94.20.10669; Loda M, 1997, NAT MED, V3, P231, DOI 10.1038/nm0297-231; LONGSTREET M, 1992, ONCOGENE, V7, P1549; Luo KX, 1999, GENE DEV, V13, P2196, DOI 10.1101/gad.13.17.2196; Mal A, 1996, NATURE, V380, P262, DOI 10.1038/380262a0; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Niv H, 1999, J BIOL CHEM, V274, P1606, DOI 10.1074/jbc.274.3.1606; Oft M, 1996, GENE DEV, V10, P2462, DOI 10.1101/gad.10.19.2462; Oft M, 1998, CURR BIOL, V8, P1243, DOI 10.1016/S0960-9822(07)00533-7; Orend G, 1998, ONCOGENE, V16, P2575, DOI 10.1038/sj.onc.1201791; Piek E, 1999, FASEB J, V13, P2105, DOI 10.1096/fasebj.13.15.2105; PIETENPOL JA, 1990, P NATL ACAD SCI USA, V87, P3758, DOI 10.1073/pnas.87.10.3758; PlanasSilva MD, 1997, MOL CELL BIOL, V17, P4059, DOI 10.1128/MCB.17.7.4059; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; REYNISDOTTIR I, 1995, GENE DEV, V9, P1831, DOI 10.1101/gad.9.15.1831; Reynisdottir I, 1997, GENE DEV, V11, P492, DOI 10.1101/gad.11.4.492; ROBERTS AB, 1993, GROWTH FACTORS, V8, P1; Schiemann WP, 1999, BLOOD, V94, P2854, DOI 10.1182/blood.V94.8.2854.420k07_2854_2861; SCHWARZ LC, 1988, CANCER RES, V48, P6999; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Singh SP, 1998, CANCER RES, V58, P1730; Sun Y, 1999, MOL CELL, V4, P499, DOI 10.1016/S1097-2765(00)80201-4; Tomoda K, 1999, NATURE, V398, P160, DOI 10.1038/18230; Tsubari M, 1999, MOL CELL BIOL, V19, P3654; VALVERIUS EM, 1989, CANCER RES, V49, P6269; VANDENHEUVEL S, 1993, SCIENCE, V262, P2050, DOI 10.1126/science.8266103; Vlach J, 1996, EMBO J, V15, P6595, DOI 10.1002/j.1460-2075.1996.tb01050.x; Warner BJ, 1999, MOL CELL BIOL, V19, P5913; Weis B, 1999, ONCOGENE, V18, P2579, DOI 10.1038/sj.onc.1202602; WIESER R, 1993, MOL CELL BIOL, V13, P7239, DOI 10.1128/MCB.13.12.7239; YAMAGUCHI K, 1995, SCIENCE, V270, P2008, DOI 10.1126/science.270.5244.2008; Yang HY, 2000, J BIOL CHEM, V275, P24735, DOI 10.1074/jbc.C000147200; Yin JJ, 1999, J CLIN INVEST, V103, P197, DOI 10.1172/JCI3523	58	54	59	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 30	2000	19	51					5926	5935		10.1038/sj.onc.1203991	http://dx.doi.org/10.1038/sj.onc.1203991			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	378CA	11127824				2022-12-25	WOS:000165563100012
J	Alexandrova, A; Ivanov, A; Chumakov, P; Kopnin, B; Vasiliev, J				Alexandrova, A; Ivanov, A; Chumakov, P; Kopnin, B; Vasiliev, J			Changes in p53 expression in mouse fibroblasts can modify motility and extracellular matrix organization	ONCOGENE			English	Article						p53; cell shape; motility; fibronectin; focal contacts	TUMOR-SUPPRESSOR P53; WILD-TYPE P53; TRANSCRIPTIONAL REPRESSION; GENE-EXPRESSION; BINDING PROTEIN; BAX GENE; APOPTOSIS; PATHWAY; ARREST; MUTANT	Effects of p53 expression on cell morphology and motility were studied using the derivatives of p53-null 10(1) mouse fibroblasts with tetracycline-regulated expression of exogenous human p53, Induction of p53 expression was accompanied by significant decrease in extracellular matrix (fibronectin) and reduction of matrix fibrils, diminution of the number and size of focal contacts, decrease of cell areas, establishment of more elongated cell shape and alterations of actin cytoskeleton (actin bundles became thinner, their number and size decreased). Expression of His175 and Gln22/Ser23 p53 mutants caused no such effects. To study the influence of p53 expression on cell motility we used wound technique and videomicroscopy observation of single living cells. It was found that induction of p53 expression led to increase of lamellar activity of cell edge, However, in spite of enhanced lamellar activity p53-expressing cells migrated to shorter distance and filled the narrow wound in longer time as compared with their p53-null counterparts. Possible mechanisms of the influence of p53 expression on cell morphology and motility are discussed.	Russian Acad Sci, Engelgart Inst Mol Biol, Moscow, Russia; Moscow State Univ, Belozersky Inst Physicochem Biol, Moscow, Russia; Russian Canc Res Ctr, Inst Cancerogenesis, Moscow, Russia	Russian Academy of Sciences; Lomonosov Moscow State University	Chumakov, P (corresponding author), Russian Acad Sci, Engelgart Inst Mol Biol, Moscow, Russia.		Kopnin, Boris/R-8240-2019; Chumakov, Peter M/E-7731-2014	Kopnin, Boris/0000-0003-3100-2212; Ivanov, Alexey/0000-0002-8617-4604; Chumakov, Peter/0000-0002-8078-2908				Agapova LS, 1999, ONCOGENE, V18, P3135, DOI 10.1038/sj.onc.1202386; Amundson SA, 1998, ONCOGENE, V17, P3287, DOI 10.1038/sj.onc.1202576; Ashcroft M, 1999, ONCOGENE, V18, P7637, DOI 10.1038/sj.onc.1203012; BERSHADSKY AD, 1991, CELL MOTIL CYTOSKEL, V19, P152, DOI 10.1002/cm.970190303; BERSHADSKY AD, 1988, CYTOSKELETON, P268; Comer KA, 1998, ONCOGENE, V16, P1299, DOI 10.1038/sj.onc.1201645; Dunn G. A., 1986, J CELL SCI, V108, P1659; El-Deiry WS, 1998, SEMIN CANCER BIOL, V8, P345, DOI 10.1006/scbi.1998.0097; Farmer G, 1996, NUCLEIC ACIDS RES, V24, P4281, DOI 10.1093/nar/24.21.4281; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; Gloushankova N, 1997, ONCOGENE, V15, P2985, DOI 10.1038/sj.onc.1201483; Gottlieb TM, 1996, BBA-REV CANCER, V1287, P77, DOI 10.1016/0304-419X(95)00019-C; HARVEY DM, 1991, GENE DEV, V5, P2375, DOI 10.1101/gad.5.12b.2375; HORIKOSHI N, 1995, MOL CELL BIOL, V15, P227, DOI 10.1128/MCB.15.1.227; Iotsova V, 1996, CELL GROWTH DIFFER, V7, P629; Jimenez GS, 1999, ONCOGENE, V18, P7656, DOI 10.1038/sj.onc.1203013; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; LIN JY, 1994, GENE DEV, V8, P1235, DOI 10.1101/gad.8.10.1235; Metcalfe AMJ, 1997, NUCLEIC ACIDS RES, V25, P983, DOI 10.1093/nar/25.5.983; MIYASHITA T, 1995, CELL, V80, P293; MIYASHITA T, 1994, ONCOGENE, V9, P1799; MUKHOPADHYAY D, 1995, CANCER RES, V55, P6161; Murphy M, 1999, GENE DEV, V13, P2490, DOI 10.1101/gad.13.19.2490; Prives C, 1999, J PATHOL, V187, P112; Ryan KM, 1998, MOL CELL BIOL, V18, P3692, DOI 10.1128/MCB.18.7.3692; Sherr CJ, 1998, GENE DEV, V12, P2984, DOI 10.1101/gad.12.19.2984; Sionov RV, 1999, ONCOGENE, V18, P6145, DOI 10.1038/sj.onc.1203130; Sun YB, 1999, J BIOL CHEM, V274, P11535, DOI 10.1074/jbc.274.17.11535; Tan MJ, 2000, P NATL ACAD SCI USA, V97, P109, DOI 10.1073/pnas.97.1.109; Venot C, 1999, ONCOGENE, V18, P2405, DOI 10.1038/sj.onc.1202539; Yun J, 1999, J BIOL CHEM, V274, P29677, DOI 10.1074/jbc.274.42.29677; Zhao RB, 2000, GENE DEV, V14, P981	32	37	37	0	4	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 23	2000	19	50					5826	5830		10.1038/sj.onc.1203944	http://dx.doi.org/10.1038/sj.onc.1203944			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	376VP	11126371				2022-12-25	WOS:000165477700016
J	Wehrle-Haller, B; Imhof, BA				Wehrle-Haller, B; Imhof, BA			Stem cell factor presentation to c-kit - Identification of a basolateral targeting domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYMERIC IMMUNOGLOBULIN RECEPTOR; POLARIZED EPITHELIAL-CELLS; TRANS-GOLGI NETWORK; LEUCINE-BASED MOTIF; MDCK CELLS; DI-LEUCINE; CYTOPLASMIC DOMAIN; MONOCLONAL-ANTIBODY; STEEL(17H) MICE; SORTING SIGNAL	Stem cell factor (also known as mast cell growth factor and kit-ligand) is a transmembrane growth factor with a highly conserved cytoplasmic domain. Basolateral membrane expression in epithelia and persistent cell surface exposure of stem cell factor are required for complete biological activity in pigmentation, fertility, learning, and hematopoiesis. Here we show by site-directed mutagenesis that the cytoplasmic domain of stem cell factor contains a monomeric leucine-dependent basolateral targeting signal. N-terminal to this motif, a cluster of acidic amino acids serves to increase the efficiency of basolateral sorting mediated by the leucine residue. Hence, basolateral targeting of stem cell factor requires a mono-leucine determinant assisted by a cluster of acidic amino acids. This mono-leucine determinant is functionally conserved in colony-stimulating factor-1, a transmembrane growth factor related to stem cell factor. Furthermore, this leucine motif is not capable of inducing endocytosis, allowing for persistent cell surface expression of stem cell factor. In contrast, the mutated cytoplasmic tail found in the stem cell factor mutant Mgf(SI17H) induces constitutive endocytosis by a motif that is related to signals for endocytosis and lysosomal targeting. Our findings therefore present monoleucines as a novel type of protein sorting motif for transmembrane growth factors.	Ctr Med Univ Geneva, Dept Pathol, CH-1211 Geneva 4, Switzerland	University of Geneva	Wehrle-Haller, B (corresponding author), Ctr Med Univ Geneva, Dept Pathol, 1 Rue Michel Servet, CH-1211 Geneva 4, Switzerland.	Bernhard.Wehrle-Haller@medecine.unige.ch						AROETI B, 1993, J CELL BIOL, V123, P1149, DOI 10.1083/jcb.123.5.1149; Benting JH, 1999, J CELL BIOL, V146, P313, DOI 10.1083/jcb.146.2.313; BRANNAN CI, 1991, P NATL ACAD SCI USA, V88, P4671, DOI 10.1073/pnas.88.11.4671; BRANNAN CI, 1992, GENE DEV, V6, P1832, DOI 10.1101/gad.6.10.1832; Briley GP, 1997, MOL BIOL CELL, V8, P1619, DOI 10.1091/mbc.8.8.1619; CECCHINI MG, 1994, DEVELOPMENT, V120, P1357; CHENG HJ, 1994, MOL BIOL CELL, V5, P943, DOI 10.1091/mbc.5.9.943; Darsow T, 1998, J CELL BIOL, V142, P913, DOI 10.1083/jcb.142.4.913; Dietrich J, 1997, J CELL BIOL, V138, P271, DOI 10.1083/jcb.138.2.271; DOVER GA, 1991, CELL, V65, P9, DOI 10.1016/0092-8674(91)90401-J; FLANAGAN JG, 1991, CELL, V64, P1025, DOI 10.1016/0092-8674(91)90326-T; Folsch H, 1999, CELL, V99, P189, DOI 10.1016/S0092-8674(00)81650-5; Gut A, 1998, EMBO J, V17, P1919, DOI 10.1093/emboj/17.7.1919; Heilker R, 1999, BIOESSAYS, V21, P558, DOI 10.1002/(SICI)1521-1878(199907)21:7<558::AID-BIES4>3.0.CO;2-R; Hirst J, 1998, BBA-MOL CELL RES, V1404, P173, DOI 10.1016/S0167-4889(98)00056-1; Honing S, 1998, EMBO J, V17, P1304, DOI 10.1093/emboj/17.5.1304; HUANG EJ, 1992, MOL BIOL CELL, V3, P349, DOI 10.1091/mbc.3.3.349; IMHOF BA, 1983, CELL, V35, P667, DOI 10.1016/0092-8674(83)90099-5; Kapur R, 1999, BLOOD, V94, P1915; MASSAGUE J, 1993, ANNU REV BIOCHEM, V62, P515, DOI 10.1146/annurev.bi.62.070193.002503; MATTER K, 1994, J CELL BIOL, V126, P991, DOI 10.1083/jcb.126.4.991; MATTER K, 1992, CELL, V71, P741, DOI 10.1016/0092-8674(92)90551-M; Michaelson MD, 1996, DEVELOPMENT, V122, P2661; Molloy SS, 1998, J CELL BIOL, V142, P1399, DOI 10.1083/jcb.142.6.1399; Motro B, 1996, P NATL ACAD SCI USA, V93, P1808, DOI 10.1073/pnas.93.5.1808; Parichy DM, 1999, DEV GENES EVOL, V209, P349, DOI 10.1007/s004270050263; PAWSON T, 1990, TRENDS GENET, V6, P350, DOI 10.1016/0168-9525(90)90276-C; POND L, 1995, J BIOL CHEM, V270, P19989, DOI 10.1074/jbc.270.34.19989; Reich V, 1996, J CELL SCI, V109, P2133; RUBIN LA, 1985, HYBRIDOMA, V4, P91, DOI 10.1089/hyb.1985.4.91; Simmen T, 1999, MOL CELL BIOL, V19, P3136; Simmen T, 1999, J CELL SCI, V112, P45; Simonsen A, 1997, J CELL SCI, V110, P597; Simonsen A, 1998, EUR J CELL BIOL, V76, P25, DOI 10.1016/S0171-9335(98)80014-9; Tajima Y, 1998, J EXP MED, V187, P1451, DOI 10.1084/jem.187.9.1451; Traub LM, 1997, CURR OPIN CELL BIOL, V9, P527, DOI 10.1016/S0955-0674(97)80029-4; Wan L, 1998, CELL, V94, P205, DOI 10.1016/S0092-8674(00)81420-8; Wehrle-Haller B, 1999, DEV BIOL, V210, P71, DOI 10.1006/dbio.1999.9260; Weimbs T, 1997, TRENDS CELL BIOL, V7, P393, DOI 10.1016/S0962-8924(97)01130-6; Yan SD, 1997, P NATL ACAD SCI USA, V94, P5296, DOI 10.1073/pnas.94.10.5296	40	38	40	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 20	2001	276	16					12667	12674		10.1074/jbc.M008357200	http://dx.doi.org/10.1074/jbc.M008357200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	423VN	11152680	hybrid			2022-12-25	WOS:000168198600028
J	Craig, JC; Schumacher, MA; Mansoor, SE; Farrens, DL; Brennan, RG; Goodman, RH				Craig, JC; Schumacher, MA; Mansoor, SE; Farrens, DL; Brennan, RG; Goodman, RH			Consensus and variant cAMP-regulated enhancers have distinct CREB-binding properties	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REGION LEUCINE-ZIPPER; C-FOS TRANSCRIPTION; DNA-BINDING; RESPONSIVE ELEMENT; CRYSTAL-STRUCTURE; PROTEIN CREB; BASIC REGION; PHOSPHORYLATION; GCN4; DIMERIZATION	Recent determination of the cAMP response element-binding protein (CREB) basic leucine zipper (bZIP) consensus CRE crystal structure revealed key dimerization and DNA binding features that are conserved among members of the CREB/CREM/ATF-1 family of transcription factors. Dimerization appeared to be mediated by a Tyr(307)-Glu(312) interhelical hydrogen bond and a Glu(319)- Arg(314) electrostatic interaction. An unexpected hexahydrated Mg2+ ion was centered above the CRE in the dimer cavity. In the present study, we related these features to CREB dimerization and DNA binding. A Y307F substitution reduced dimer stability and DNA binding affinity, whereas a Y307R mutation produced a stabilizing effect. Mutation of Glu(319) to Ala or Lys attenuated dimerization and DNA binding. Mg2+ ions enhanced the binding affinity of wild-type CREB to the palindromic CRE by similar to 20-fold but did not do so for divergent CREs, Similarly, mutation of Lys(304), which mediates the CREB interaction with the hydrated Mg2+, blocked CREB binding to the palindromic but not the variant CRE sequences. The distinct binding characteristics of the K304A mutants to the consensus and variant CRE sequences indicate that CREB binding to these elements is differentially regulated by Mg2+ ions, We suggest that CREB binds the consensus and variant CRE sequences through fundamentally distinct mechanisms.	Oregon Hlth & Sci Univ, Vollum Inst, Portland, OR 97201 USA; Oregon Hlth & Sci Univ, Dept Biochem & Mol Biol, Portland, OR 97201 USA	Oregon Health & Science University; Oregon Health & Science University	Goodman, RH (corresponding author), Oregon Hlth & Sci Univ, Vollum Inst, 3181 SW Sam Jackson Pk Rd, Portland, OR 97201 USA.	goodmanr@ohsu.edu		Brennan, Richard/0000-0001-7647-485X				BENBROOK DM, 1990, ONCOGENE, V5, P295; BROCARD JB, 1993, NEURON, V11, P751, DOI 10.1016/0896-6273(93)90084-5; De Cesare D, 2000, PROG NUCLEIC ACID RE, V64, P343, DOI 10.1016/S0079-6603(00)64009-6; DWARKI VJ, 1990, EMBO J, V9, P225, DOI 10.1002/j.1460-2075.1990.tb08099.x; EFTINK MR, 1994, BIOPHYS J, V66, P482, DOI 10.1016/S0006-3495(94)80799-4; ELLENBERGER T, 1994, CURR OPIN STRUC BIOL, V4, P12, DOI 10.1016/S0959-440X(94)90054-X; ELLENBERGER TE, 1992, CELL, V71, P1223, DOI 10.1016/S0092-8674(05)80070-4; ENSLEN H, 1994, J BIOL CHEM, V269, P15520; Fass DM, 2001, J BIOL CHEM, V276, P2992, DOI 10.1074/jbc.M008274200; GINTY DD, 1994, CELL, V77, P713, DOI 10.1016/0092-8674(94)90055-8; GLOVER JNM, 1995, NATURE, V373, P257, DOI 10.1038/373257a0; HAI TW, 1989, GENE DEV, V3, P2083, DOI 10.1101/gad.3.12b.2083; Kato H, 1998, BRAIN RES, V779, P329, DOI 10.1016/S0006-8993(97)01232-8; KELLER W, 1995, J MOL BIOL, V254, P657, DOI 10.1006/jmbi.1995.0645; KERPPOLA T, 1995, NATURE, V373, P199, DOI 10.1038/373199a0; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LAOIDE BM, 1993, EMBO J, V12, P1179, DOI 10.1002/j.1460-2075.1993.tb05759.x; LORIAUX MM, 1994, J BIOL CHEM, V269, P28839; Lundblad JR, 1998, J BIOL CHEM, V273, P19251, DOI 10.1074/jbc.273.30.19251; Mansoor SE, 1999, BIOCHEMISTRY-US, V38, P16383, DOI 10.1021/bi991331v; MONTMINY MR, 1986, P NATL ACAD SCI USA, V83, P6682, DOI 10.1073/pnas.83.18.6682; Moreno CS, 1999, IMMUNITY, V10, P143, DOI 10.1016/S1074-7613(00)80015-1; NICHOLS M, 1992, EMBO J, V11, P3337, DOI 10.1002/j.1460-2075.1992.tb05412.x; Pace C. N., 1997, PROTEIN STRUCTURE PR, V2, P299; Richards JP, 1996, J BIOL CHEM, V271, P13716, DOI 10.1074/jbc.271.23.13716; ROSS JBA, 1999, TOPICS FLUORESCENCE, P1; SANTIAGORIVERA ZI, 1993, PROTEIN SCI, V2, P1461, DOI 10.1002/pro.5560020910; Schumacher MA, 2000, J BIOL CHEM, V275, P35242, DOI 10.1074/jbc.M007293200; SELLERS JW, 1990, MOL CELL BIOL, V10, P5077, DOI 10.1128/MCB.10.10.5077; Shaywitz AJ, 1999, ANNU REV BIOCHEM, V68, P821, DOI 10.1146/annurev.biochem.68.1.821; SHENG M, 1990, NEURON, V4, P571, DOI 10.1016/0896-6273(90)90115-V; SHORT ML, 1991, NUCLEIC ACIDS RES, V19, P4290, DOI 10.1093/nar/19.15.4290; WEISS MA, 1990, NATURE, V347, P575, DOI 10.1038/347575a0; Wu XL, 1998, J BIOL CHEM, V273, P20820, DOI 10.1074/jbc.273.33.20820; YUN Y, 1990, MOL ENDOCRINOL, V4, P931, DOI 10.1210/mend-4-6-931	35	58	61	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 13	2001	276	15					11719	11728		10.1074/jbc.M010263200	http://dx.doi.org/10.1074/jbc.M010263200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	421UK	11134034	hybrid			2022-12-25	WOS:000168081800041
J	Heimpel, S; Basset, G; Odoy, S; Klingenberg, M				Heimpel, S; Basset, G; Odoy, S; Klingenberg, M			Expression of the mitochondrial ADP/ATP carrier in Escherichia coli - Renaturation, reconstitution, and the effect of mutations on 10 positive residues	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADP ATP CARRIER; ADENINE-NUCLEOTIDE CARRIER; 6 ARGININE MUTATIONS; SACCHAROMYCES-CEREVISIAE; TRANSPORT PROTEIN; BACTERIAL EXPRESSION; UNCOUPLING PROTEIN; YEAST; TRANSLOCATOR; SEQUENCE	Previously, the role of residues in the ADP/ATP carrier (AAC) from Saccharomyces cerevisiae has been studied by mutagenesis, but the dependence of mitochondrial biogenesis on functional AAC impedes segregation of the mutational effects on transport and biogenesis. Unlike other mitochondrial carriers, expression of the AAC from yeast or mammalians in Escherichia coli encountered difficulties because of disparate codon usage. Here we introduce the AAC from Neurospora crassa in E. coli, where it is accumulated in inclusion bodies and establish the reconstitution conditions. AAC expressed with heat shock vector gave higher activity than with pET-3a, Transport activity was absolutely dependent on cardiolipin. The 10 single mutations of intrahelical positive residues and of the matrix repeat (+X+) motif resulted in lower activity, except of R245A. R143A had decreased sensitivity toward carboxyatractylate. The ATP-linked exchange is generally more affected than ADP exchange. This reflects a charge network that propagates positive charge defects to ATP(4-) more strongly than to ADP(3-) transport. Comparison to the homologous mutants of yeast AAC2 permits attribution of the roles of these residues more to ADP/ATP transport or to AAC import into mitochondria.	Univ Munich, Inst Phys Biochem, D-80336 Munich, Germany	University of Munich	Klingenberg, M (corresponding author), Univ Munich, Inst Phys Biochem, Schillerstr 44, D-80336 Munich, Germany.							AQUILA H, 1978, EUR J BIOCHEM, V85, P549, DOI 10.1111/j.1432-1033.1978.tb12270.x; ARENDS H, 1984, EMBO J, V3, P377, DOI 10.1002/j.1460-2075.1984.tb01815.x; BEYER K, 1985, BIOCHEMISTRY-US, V24, P3826; BOGNER W, 1986, EUR J BIOCHEM, V161, P611, DOI 10.1111/j.1432-1033.1986.tb10485.x; BRANDOLIN G, 1980, BIOCHIM BIOPHYS ACTA, V592, P592, DOI 10.1016/0005-2728(80)90103-6; CLELAND JL, 1992, BIO-TECHNOL, V10, P1013, DOI 10.1038/nbt0992-1013; DREES M, 1988, BIOCHEMISTRY-US, V27, P8584, DOI 10.1021/bi00423a012; EMR SD, 1986, J CELL BIOL, V102, P523, DOI 10.1083/jcb.102.2.523; ERDELT H, 1972, EUR J BIOCHEM, V30, P107, DOI 10.1111/j.1432-1033.1972.tb02077.x; FIERMONTE G, 1993, BIOCHEM J, V294, P293, DOI 10.1042/bj2940293; FRANKEL S, 1991, P NATL ACAD SCI USA, V88, P1192, DOI 10.1073/pnas.88.4.1192; Heidkamper D, 1996, BIOCHEMISTRY-US, V35, P16144, DOI 10.1021/bi960668j; HOFFMANN B, 1994, J BIOL CHEM, V269, P1940; Jiang F, 2000, J BIOL CHEM, V275, P22387, DOI 10.1074/jbc.M909868199; KAPLAN RS, 1985, ANAL BIOCHEM, V150, P97, DOI 10.1016/0003-2697(85)90445-2; KAPLAN RS, 1995, J BIOL CHEM, V270, P4108, DOI 10.1074/jbc.270.8.4108; KLINGENBERG M, 1973, EUR J BIOCHEM, V38, P346, DOI 10.1111/j.1432-1033.1973.tb03067.x; Klingenberg M, 1995, METHOD ENZYMOL, V260, P369, DOI 10.1016/0076-6879(95)60151-1; KLINGENBERG M, 1985, ENZYMES BIOL MEMBR, V4, P511; Klingenberg M, 1976, ENZYMES BIOLOGICAL M, V3, P383; KLINGENBERG M, 1991, STUDY ENZYMES, V2, P367; KLINGENBERG M, 1987, ADV MEMBRANE BIOCH B, P389; KNIRSCH M, 1989, FEBS LETT, V244, P427, DOI 10.1016/0014-5793(89)80577-0; KRAMER R, 1977, FEBS LETT, V82, P363, DOI 10.1016/0014-5793(77)80622-4; KRAMER R, 1984, BIOCHIM BIOPHYS ACTA, V765, P353, DOI 10.1016/0005-2728(84)90176-2; KRAMER R, 1980, BIOCHEMISTRY-US, V19, P556; LASVARENNE JB, 1984, J MOL BIOL, V180, P549; LAWSON JE, 1988, J BIOL CHEM, V263, P14812; MAHLKE K, 1991, THESIS U MUNICH MUNI; Muller V, 1997, BIOCHEMISTRY-US, V36, P16008, DOI 10.1021/bi971867l; Muller V, 1996, BIOCHEMISTRY-US, V35, P16132, DOI 10.1021/bi960667r; NECKELMANN N, 1987, P NATL ACAD SCI USA, V84, P7580, DOI 10.1073/pnas.84.21.7580; NELSON DR, 1993, J MOL BIOL, V230, P1171, DOI 10.1006/jmbi.1993.1234; Nelson DR, 1998, J MOL BIOL, V277, P285, DOI 10.1006/jmbi.1997.1594; Nelson DR, 1996, BBA-BIOENERGETICS, V1275, P133, DOI 10.1016/0005-2728(96)00063-1; POWELL SJ, 1989, BIOCHEMISTRY-US, V28, P866, DOI 10.1021/bi00428a069; RUNSWICK MJ, 1990, BIOCHEMISTRY-US, V29, P11033, DOI 10.1021/bi00502a004; Sambrook J., 2002, MOL CLONING LAB MANU; SCHAFFNE.W, 1973, ANAL BIOCHEM, V56, P502, DOI 10.1016/0003-2697(73)90217-0; SCHAUDER B, 1987, GENE, V52, P279, DOI 10.1016/0378-1119(87)90054-0; WEIDEMAN.MJ, 1970, EUR J BIOCHEM, V16, P313, DOI 10.1111/j.1432-1033.1970.tb01086.x; WELLS MA, 1969, METHOD ENZYMOL, V14, P178; WINKLER E, 1992, EUR J BIOCHEM, V207, P135, DOI 10.1111/j.1432-1033.1992.tb17030.x; WOHLRAB H, 1994, BIOCHEMISTRY-US, V33, P9371, DOI 10.1021/bi00198a001	44	44	46	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 13	2001	276	15					11499	11506		10.1074/jbc.M010586200	http://dx.doi.org/10.1074/jbc.M010586200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	421UK	11136735	hybrid			2022-12-25	WOS:000168081800012
J	Petronilli, V; Penzo, D; Scorrano, L; Bernardi, P; Di Lisa, F				Petronilli, V; Penzo, D; Scorrano, L; Bernardi, P; Di Lisa, F			The mitochondrial permeability transition, release of cytochrome c and cell death - Correlation with the duration of pore openings in situ	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CA-2+-INDUCED MEMBRANE TRANSITION; CYCLOSPORINE-A; MEDIATED APOPTOSIS; INTACT-CELLS; ACTIVATION; CHANNEL; BAX; HEPATOCYTES; MODULATION; INDUCTION	We investigated the relationship between opening of the permeability transition pore (PTP), mitochondrial depolarization, cytochrome c release, and occurrence of cell death in rat hepatoma MH1C1 cells. Treatment with arachidonic acid or A23187 induces PTP opening in situ with similar kinetics, as assessed by the calcein loading-Co2+ quenching technique (Petronilli, V., Miotto, G., Canton, M., Colonna, R., Bernardi, P., and Di Lisa, F. (1999) Biophys, J. 76, 725-734), Yet depolarization, as assessed from the changes of mitochondrial tetramethylrhodamine methyl ester (TMRM) fluorescence, is rapid and extensive with arachidonic acid and slow and partial with A23187. Cyclosporin A-inhibitable release of cytochrome c and cell death correlate with the changes of TMRM fluorescence but not with those of calcein fluorescence. Since pore opening must be accompanied by depolarization, we conclude that short PTP openings are detected only by trapped calcein and may have little impact on cell viability, while changes of TMRM distribution require longer PTP openings, which cause release of cytochrome c and may result in cell death. Modulation of the open time appears to be the key element in determining the outcome of stimuli that converge on the PTP.	Univ Padua, Dept Biomed Sci, CNR, Unit Study Biomembranes, I-35100 Padua, Italy; Univ Padua, Dept Biol Chem, I-35100 Padua, Italy	Consiglio Nazionale delle Ricerche (CNR); University of Padua; University of Padua	Petronilli, V (corresponding author), Univ Padua, Dept Biomed Sci, CNR, Unit Study Biomembranes, Viale Giuseppe Colombo 3, I-35100 Padua, Italy.		Scorrano, Luca/A-6652-2008; Bernardi, Paolo/C-3656-2008; Scorrano, Luca/K-3967-2019; Petronilli, Valeria/C-3558-2015	Scorrano, Luca/0000-0002-8515-8928; Bernardi, Paolo/0000-0001-9187-3736; Scorrano, Luca/0000-0002-8515-8928; Petronilli, Valeria/0000-0003-4026-6404; Di Lisa, Fabio/0000-0001-9757-8818	Telethon [1141] Funding Source: Medline	Telethon(Fondazione Telethon)		Adachi S, 1998, J BIOL CHEM, V273, P19892, DOI 10.1074/jbc.273.31.19892; Bernardi P, 1999, EUR J BIOCHEM, V264, P687, DOI 10.1046/j.1432-1327.1999.00725.x; BERNARDI P, 1992, J BIOL CHEM, V267, P2934; BERNARDI P, 1981, J BIOL CHEM, V256, P7187; Bernardi P, 1999, PHYSIOL REV, V79, P1127, DOI 10.1152/physrev.1999.79.4.1127; BERNARDI P, 1992, J BIOL CHEM, V267, P8834; Bradham CA, 1998, MOL CELL BIOL, V18, P6353, DOI 10.1128/MCB.18.11.6353; Budihardjo I, 1999, ANNU REV CELL DEV BI, V15, P269, DOI 10.1146/annurev.cellbio.15.1.269; Chai JJ, 2000, NATURE, V406, P855, DOI 10.1038/35022514; Du CY, 2000, CELL, V102, P33, DOI 10.1016/S0092-8674(00)00008-8; DUCHEN MR, 1993, CARDIOVASC RES, V27, P1790, DOI 10.1093/cvr/27.10.1790; Eskes R, 2000, MOL CELL BIOL, V20, P929, DOI 10.1128/MCB.20.3.929-935.2000; Fontaine E, 1999, J BIOENERG BIOMEMBR, V31, P335, DOI 10.1023/A:1005475802350; Frey TG, 2000, TRENDS BIOCHEM SCI, V25, P319, DOI 10.1016/S0968-0004(00)01609-1; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; Gross A, 1999, J BIOL CHEM, V274, P1156, DOI 10.1074/jbc.274.2.1156; HAWORTH RA, 1979, ARCH BIOCHEM BIOPHYS, V195, P460, DOI 10.1016/0003-9861(79)90372-2; HUNTER DR, 1979, ARCH BIOCHEM BIOPHYS, V195, P453, DOI 10.1016/0003-9861(79)90371-0; HUNTER DR, 1979, ARCH BIOCHEM BIOPHYS, V195, P468, DOI 10.1016/0003-9861(79)90373-4; Huser J, 1998, BIOPHYS J, V74, P2129, DOI 10.1016/S0006-3495(98)77920-2; IMBERTI R, 1993, J PHARMACOL EXP THER, V265, P392; Kroemer G, 2000, NAT MED, V6, P513, DOI 10.1038/74994; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; LOEW LM, 1993, BIOPHYS J, V65, P2396, DOI 10.1016/S0006-3495(93)81318-3; Nicholls DG, 2000, TRENDS NEUROSCI, V23, P166, DOI 10.1016/S0166-2236(99)01534-9; Nicolli A, 1996, J BIOL CHEM, V271, P2185, DOI 10.1074/jbc.271.4.2185; Pastorino JG, 1998, J BIOL CHEM, V273, P7770, DOI 10.1074/jbc.273.13.7770; PASTORINO JG, 1993, J BIOL CHEM, V268, P13791; Pastorino JG, 1999, J BIOL CHEM, V274, P31734, DOI 10.1074/jbc.274.44.31734; PETRONILLI V, 1994, BBA-BIOENERGETICS, V1187, P255, DOI 10.1016/0005-2728(94)90122-8; Petronilli V, 1999, BIOPHYS J, V76, P725, DOI 10.1016/S0006-3495(99)77239-5; Rottenberg H, 1998, BBA-MOL CELL RES, V1404, P393, DOI 10.1016/S0167-4889(98)00088-3; Scorrano L, 2001, J BIOL CHEM, V276, P12035, DOI 10.1074/jbc.M010603200; Scorrano L, 1999, J BIOL CHEM, V274, P22581, DOI 10.1074/jbc.274.32.22581; Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135; Susin SA, 1996, J EXP MED, V184, P1331, DOI 10.1084/jem.184.4.1331; SZABO I, 1991, J BIOL CHEM, V266, P3376; SZABO I, 1992, J BIOENERG BIOMEMBR, V24, P111, DOI 10.1007/BF00769537; Vande Velde C, 2000, MOL CELL BIOL, V20, P5454, DOI 10.1128/MCB.20.15.5454-5468.2000; Verhagen AM, 2000, CELL, V102, P43, DOI 10.1016/S0092-8674(00)00009-X; Wei MC, 2000, GENE DEV, V14, P2060; Zou H, 1999, J BIOL CHEM, V274, P11549, DOI 10.1074/jbc.274.17.11549	43	403	421	0	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 13	2001	276	15					12030	12034		10.1074/jbc.M010604200	http://dx.doi.org/10.1074/jbc.M010604200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	421UK	11134038	hybrid			2022-12-25	WOS:000168081800080
J	Quijano, C; Hernandez-Saavedra, D; Castro, L; McCord, JM; Freeman, BA; Radi, R				Quijano, C; Hernandez-Saavedra, D; Castro, L; McCord, JM; Freeman, BA; Radi, R			Reaction of peroxynitrite with Mn-superoxide dismutase - Role of the metal center in decomposition kinetics and nitration	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE; ESCHERICHIA-COLI; PROSTACYCLIN SYNTHASE; TYROSINE NITRATION; MANGANESE; INACTIVATION; OXIDATION; PURIFICATION; EXPRESSION; RADICALS	Manganese superoxide dismutase (Mn-SOD), a critical mitochondrial antioxidant enzyme, becomes inactivated and nitrated in vitro and potentially in vivo by peroxynitrite. Since peroxynitrite readily reacts with transition metal centers, we assessed the role of the manganese ion in the reaction between peroxynitrite and Mn-SOD. Peroxynitrite reacts with human recombinant and Escherichia coli Mn-SOD with a second order rate constant of 1.0 +/- 0.2 x 10(5) and 1.4 +/- 0.2 x 105 M-1 s(-1) at pH 7.47 and 37 degreesC, respectively. The E. coli apoenzyme, obtained by removing the manganese ion from the active site, presents a rate constant < 10(4) M-1 s(-1) for the reaction with peroxynitrite, whereas that of the manganese-reconstituted apoenzyme (apo/Mn) was comparable to that of the holoenzyme. Peroxynitrite-dependent nitration of 4-hydroxyphenylacetic acid was increased 21% by Mn-SOD. The apo/Mn also promoted nitration, but the ape and the zinc-substituted apoenzyme (apo/Zn) enzymes did not. The extent of tyrosine nitration in the enzyme was also affected by the presence and nature (i.e. manganese or zinc) of the metal center in the active site. For comparative purposes, we also studied the reaction of peroxynitrite with low molecular weight complexes of manganese and zinc with tetrakis-(4-benzoic acid) porphyrin (tbap). Mn(tbap) reacts with peroxynitrite with a rate constant of 6.8 +/- 0.1 x 10(4) M-1 s(-1) and maximally increases nitration yields by 350%. Zn(tbap), on the other hand, affords protection against nitration. Our results indicate that the manganese ion in Mn-SOD plays an important role in the decomposition kinetics of peroxynitrite and in peroxynitrite-dependent nitration of self and remote tyrosine residues.	Univ Republica, Fac Med, Dept Bioquim, Montevideo 11800, Uruguay; Univ Colorado, Webb Waring Lung Inst, Denver, CO 80262 USA; Univ Alabama Birmingham, Dept Anesthesiol, Birmingham, AL 35233 USA; Univ Alabama Birmingham, Ctr Free Rad Res, Birmingham, AL 35233 USA	Universidad de la Republica, Uruguay; University of Colorado System; University of Colorado Denver; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham	Radi, R (corresponding author), Univ Republica, Fac Med, Dept Bioquim, Av Gen Flores 2125, Montevideo 11800, Uruguay.	rradi@fmed.edu.uy	McCord, Joe/GWU-8607-2022; Hernandez-Saavedra, Daniel/AGO-1286-2022; Freeman, Bruce A/H-9342-2012	Hernandez-Saavedra, Daniel/0000-0003-1449-944X	FIC NIH HHS [R03-TW0099] Funding Source: Medline	FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC))		Alvarez B, 1999, J BIOL CHEM, V274, P842, DOI 10.1074/jbc.274.2.842; BECK Y, 1987, NUCLEIC ACIDS RES, V15, P9076, DOI 10.1093/nar/15.21.9076; BECKMAN JS, 1990, P NATL ACAD SCI USA, V87, P1620, DOI 10.1073/pnas.87.4.1620; BECKMAN JS, 1992, ARCH BIOCHEM BIOPHYS, V298, P438, DOI 10.1016/0003-9861(92)90432-V; BEYER W, 1991, PROG NUCLEIC ACID RE, V40, P221; BEYER WF, 1989, BIOCHEMISTRY-US, V28, P4403, DOI 10.1021/bi00436a042; BOVERIS A, 1984, METHOD ENZYMOL, V105, P429; Brito C, 1999, J IMMUNOL, V162, P3356; CASTRO L, 1994, J BIOL CHEM, V269, P29409; Christianson DW, 1999, ANNU REV BIOCHEM, V68, P33, DOI 10.1146/annurev.biochem.68.1.33; COTTON FA, 1988, QUIMIKCA INORGANIC A; Crapo J D, 1978, Methods Enzymol, V53, P382; Crow JP, 1999, ARCH BIOCHEM BIOPHYS, V371, P41, DOI 10.1006/abbi.1999.1414; CROW JP, 1995, BIOCHEMISTRY-US, V34, P3544, DOI 10.1021/bi00011a008; Denicola A, 1996, ARCH BIOCHEM BIOPHYS, V328, P208, DOI 10.1006/abbi.1996.0162; Denicola A, 1996, ARCH BIOCHEM BIOPHYS, V333, P49, DOI 10.1006/abbi.1996.0363; Eliasson MJL, 1999, J NEUROSCI, V19, P5910, DOI 10.1523/JNEUROSCI.19-14-05910.1999; Ferrer-Sueta G, 1997, CHEM RES TOXICOL, V10, P1338, DOI 10.1021/tx970116h; Ferrer-Sueta G, 1999, CHEM RES TOXICOL, V12, P442, DOI 10.1021/tx980245d; FLORE L, 1987, METHOD ENZYMOL, V105, P93; FLORIS R, 1993, EUR J BIOCHEM, V215, P767, DOI 10.1111/j.1432-1033.1993.tb18091.x; Gao BF, 1996, GENE, V176, P269, DOI 10.1016/0378-1119(96)00246-6; Ghafourifar P, 1999, J BIOL CHEM, V274, P31185, DOI 10.1074/jbc.274.44.31185; Ghafourifar P, 1997, FEBS LETT, V418, P291, DOI 10.1016/S0014-5793(97)01397-5; Giulivi C, 1998, J BIOL CHEM, V273, P11038, DOI 10.1074/jbc.273.18.11038; GOLDSTEIN S, 1995, FREE RADICAL BIO MED, V19, P505, DOI 10.1016/0891-5849(95)00034-U; GROSS SS, 1995, ANNU REV PHYSIOL, V57, P737, DOI 10.1146/annurev.ph.57.030195.003513; GROVES JT, 1995, J AM CHEM SOC, V117, P9578, DOI 10.1021/ja00142a032; HO YS, 1988, FEBS LETT, V229, P256, DOI 10.1016/0014-5793(88)81136-0; HUGH, 1968, J CHEM SOC, P450; HUIE RE, 1993, FREE RADICAL RES COM, V18, P195, DOI 10.3109/10715769309145868; ISCHIROPOULOS H, 1992, ARCH BIOCHEM BIOPHYS, V298, P431, DOI 10.1016/0003-9861(92)90431-U; KEELE BB, 1970, J BIOL CHEM, V245, P6176; Kissner R, 1997, CHEM RES TOXICOL, V10, P1285, DOI 10.1021/tx970160x; KRALL J, 1988, J BIOL CHEM, V263, P1910; Lebovitz RM, 1996, P NATL ACAD SCI USA, V93, P9782, DOI 10.1073/pnas.93.18.9782; LI YB, 1995, NAT GENET, V11, P376, DOI 10.1038/ng1295-376; Liu RG, 2000, FREE RADICAL BIO MED, V28, P1197, DOI 10.1016/S0891-5849(00)00237-9; MacMillan-Crow LA, 1998, BIOCHEMISTRY-US, V37, P1613, DOI 10.1021/bi971894b; MacMillanCrow LA, 1996, P NATL ACAD SCI USA, V93, P11853, DOI 10.1073/pnas.93.21.11853; MARKLUND S, 1978, INT J BIOCHEM, V9, P299, DOI 10.1016/0020-711X(78)90101-5; MARRES CAM, 1985, EUR J BIOCHEM, V147, P153, DOI 10.1111/j.1432-1033.1985.tb08731.x; MATSUDA Y, 1990, EUR J BIOCHEM, V194, P713, DOI 10.1111/j.1432-1033.1990.tb19461.x; Melov S, 1999, P NATL ACAD SCI USA, V96, P846, DOI 10.1073/pnas.96.3.846; Omar B, 1991, OXIDATIVE STRESS OXI, P493; OSE DE, 1976, J BIOL CHEM, V251, P1217; OSE DE, 1979, ARCH BIOCHEM BIOPHYS, V194, P360, DOI 10.1016/0003-9861(79)90628-3; RADI R, 1991, J BIOL CHEM, V266, P4244; RADI R, 1994, ARCH BIOCHEM BIOPHYS, V308, P89, DOI 10.1006/abbi.1994.1013; Radi R., 2000, BIOL CHEM PEROXYNITR, P57; Ramezanian MS, 1996, CHEM RES TOXICOL, V9, P232, DOI 10.1021/tx950135w; Tatoyan A, 1998, J BIOL CHEM, V273, P11044, DOI 10.1074/jbc.273.18.11044; THOMSON L, 1995, ARCH BIOCHEM BIOPHYS, V319, P491, DOI 10.1006/abbi.1995.1321; TURRENS JF, 1982, ARCH BIOCHEM BIOPHYS, V217, P401, DOI 10.1016/0003-9861(82)90518-5; WEISIGER RA, 1973, J BIOL CHEM, V248, P3582; WENDEL A, 1991, OXIDATIVE STRESS OXI, P585; Yamakura F, 1998, J BIOL CHEM, V273, P14085, DOI 10.1074/jbc.273.23.14085; Zou MH, 1996, FEBS LETT, V382, P101, DOI 10.1016/0014-5793(96)00160-3; Zou MH, 2000, ARCH BIOCHEM BIOPHYS, V376, P149, DOI 10.1006/abbi.2000.1699; Zou MH, 1997, BIOL CHEM, V378, P707, DOI 10.1515/bchm.1997.378.7.707	60	165	176	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 13	2001	276	15					11631	11638		10.1074/jbc.M009429200	http://dx.doi.org/10.1074/jbc.M009429200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	421UK	11152462	hybrid			2022-12-25	WOS:000168081800030
J	Zoraghi, R; Kunz, S; Gong, KW; Seebeck, T				Zoraghi, R; Kunz, S; Gong, KW; Seebeck, T			Characterization of TbPDE2A, a novel cyclic nucleotide-specific phosphodiesterase from the protozoan parasite Trypanosoma brucei	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CGMP-SPECIFIC PHOSPHODIESTERASE; SACCHAROMYCES-CEREVISIAE; AMP PHOSPHODIESTERASE; AFRICAN TRYPANOSOMES; ADENYLATE-CYCLASE; MOLECULAR-CLONING; GENE FAMILY; EXPRESSION; BINDING; DIFFERENTIATION	This study reports the identification and characterization of a cAMP-specific phosphodiesterase from the parasitic hemoflagellate Trypanosoma brucei, TbPDE2A is a class I phosphodiesterase, Its catalytic domain exhibits 30-40% sequence identity with those of all 11 mammalian phosphodiesterase (PDE) families, as well as with PDE2 from Saccharomyces cerevisiae, dunce from Drosophila melanogaster, and regA from Dictyostelium discoideum. The overall structure of TbPDE2A resembles that of human PDE11A in that its N-terminal region contains a single GAF domain. This domain is very similar to those of the mammalian PDE2, -5, -6, -10, and -11, where it constitutes a potential cGMP binding site. TbPDE2A can be expressed in S. cerevisiae, and it complements an S, cerevisiae PDE deletion strain. Recombinant TbPDE2A is specific for cAMP, with a K-m of similar to2 muM. It is entirely resistant to the nonselective PDE inhibitor 3-isobutyl-1-methylxanthine, but it is sensitive to trequinsin, dipyridamole, sildenafil, and ethaverine with IC50 values of 5.4, 5.9, 9.4, and 14.2 muM, respectively. All four compounds inhibit proliferation of bloodstream form trypanosomes in culture, indicating that TbPDE2A is an essential enzyme.	Univ Bern, Inst Cell Biol, CH-3012 Bern, Switzerland	University of Bern	Seebeck, T (corresponding author), Univ Bern, Inst Cell Biol, Baltzerstr 4, CH-3012 Bern, Switzerland.	thomas.seebeck@izb.unibe.ch						Alexandre S, 1996, MOL BIOCHEM PARASIT, V77, P173, DOI 10.1016/0166-6851(96)02591-1; ALEXANDRE S, 1990, MOL BIOCHEM PARASIT, V43, P279, DOI 10.1016/0166-6851(90)90152-C; Aravind L, 1997, TRENDS BIOCHEM SCI, V22, P458, DOI 10.1016/S0968-0004(97)01148-1; Atienza JM, 1998, METHODS, V14, P35, DOI 10.1006/meth.1997.0563; Barnette M S, 1999, Prog Drug Res, V53, P193; Bastin P, 1996, MOL BIOCHEM PARASIT, V77, P235, DOI 10.1016/0166-6851(96)02598-4; BEAVO JA, 1990, TRENDS PHARMACOL SCI, V11, P150, DOI 10.1016/0165-6147(90)90066-H; BEAVO JA, 1995, PHYSIOL REV, V75, P725, DOI 10.1152/physrev.1995.75.4.725; Bielekova B, 2000, J IMMUNOL, V164, P1117, DOI 10.4049/jimmunol.164.2.1117; BODLEY AL, 1995, J INFECT DIS, V172, P1157, DOI 10.1093/infdis/172.4.1157; BRUN R, 1979, ACTA TROP, V36, P289; CHARBONNEAU H, 1986, P NATL ACAD SCI USA, V83, P9308, DOI 10.1073/pnas.83.24.9308; Clayton C, 1998, MOL BIOCHEM PARASIT, V97, P221, DOI 10.1016/S0166-6851(98)00115-7; DANCIGER M, 1995, GENOMICS, V30, P1, DOI 10.1006/geno.1995.0001; Doherty AM, 1999, CURR OPIN CHEM BIOL, V3, P466, DOI 10.1016/S1367-5931(99)80068-4; DRYIA TP, 1996, NAT GENET, V13, P358; Fawcett L, 2000, P NATL ACAD SCI USA, V97, P3702, DOI 10.1073/pnas.050585197; FRANCIS SH, 1994, J BIOL CHEM, V269, P22477; Fujishige K, 1999, J BIOL CHEM, V274, P18438, DOI 10.1074/jbc.274.26.18438; Henras A, 1998, EMBO J, V17, P7078, DOI 10.1093/emboj/17.23.7078; HESSE F, 1995, MOL BIOCHEM PARASIT, V70, P157, DOI 10.1016/0166-6851(95)00027-X; HOYER LL, 1994, MICROBIOL-UK, V140, P1533, DOI 10.1099/13500872-140-7-1533; Jacobitz S, 1997, MOL PHARMACOL, V51, P999, DOI 10.1124/mol.51.6.999; KIELY PDW, 1995, EUR J IMMUNOL, V25, P2899, DOI 10.1002/eji.1830251029; LACOMBE ML, 1986, J BIOL CHEM, V261, P6811; Langtry HD, 1999, DRUGS, V57, P967, DOI 10.2165/00003495-199957060-00015; McAllisterLucas LM, 1995, J BIOL CHEM, V270, P30671, DOI 10.1074/jbc.270.51.30671; Moreland RB, 1998, LIFE SCI, V62, pPL309, DOI 10.1016/S0024-3205(98)00158-1; MUMBERG D, 1995, GENE, V156, P119, DOI 10.1016/0378-1119(95)00037-7; MURPHY NB, 1987, J MOL BIOL, V195, P855, DOI 10.1016/0022-2836(87)90490-6; Naula C, 2000, PARASITOL TODAY, V16, P35, DOI 10.1016/S0169-4758(99)01582-3; NIKAWA JI, 1987, MOL CELL BIOL, V7, P3629, DOI 10.1128/MCB.7.10.3629; PAVETO C, 1995, J BIOL CHEM, V270, P16576, DOI 10.1074/jbc.270.28.16576; Pays Etienne, 1997, P199; Petersen-Jones SM, 1999, INVEST OPHTH VIS SCI, V40, P1637; PILLAI R, 1993, P NATL ACAD SCI USA, V90, P11970, DOI 10.1073/pnas.90.24.11970; Rascon A, 2000, MOL BIOCHEM PARASIT, V106, P283, DOI 10.1016/S0166-6851(99)00224-8; REED SL, 1985, INFECT IMMUN, V49, P844, DOI 10.1128/IAI.49.3.844-847.1985; Rieckmann P, 1996, J NEUROIMMUNOL, V64, P193, DOI 10.1016/0165-5728(95)00176-X; SASS P, 1986, P NATL ACAD SCI USA, V83, P9303, DOI 10.1073/pnas.83.24.9303; Sbicego S, 1999, MOL BIOCHEM PARASIT, V104, P311, DOI 10.1016/S0166-6851(99)00157-7; SCHILLING RJ, 1994, ANAL BIOCHEM, V216, P154, DOI 10.1006/abio.1994.1019; SCHLAEPPI K, 1989, J CELL BIOL, V109, P1695, DOI 10.1083/jcb.109.4.1695; SEEBECK T, 1999, NOVA ACT LEOPOLD, V78, P227; Soderling SH, 1999, P NATL ACAD SCI USA, V96, P7071, DOI 10.1073/pnas.96.12.7071; Soderling SH, 1998, J BIOL CHEM, V273, P15553, DOI 10.1074/jbc.273.25.15553; Spina D, 1998, ADV PHARMACOL, V44, P33, DOI 10.1016/S1054-3589(08)60125-8; Turko IV, 1996, J BIOL CHEM, V271, P22240, DOI 10.1074/jbc.271.36.22240; Valverde D, 1996, HUM GENET, V97, P35; Vassella E, 1997, J CELL SCI, V110, P2661; VICKERMAN K, 1985, BRIT MED BULL, V41, P105, DOI 10.1093/oxfordjournals.bmb.a072036; WALTER RD, 1982, MOL BIOCHEM PARASIT, V6, P287, DOI 10.1016/0166-6851(82)90061-5; WANG Y, 1991, MOL PHARMACOL, V40, P750; Xu RX, 2000, SCIENCE, V288, P1822, DOI 10.1126/science.288.5472.1822	54	31	31	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 13	2001	276	15					11559	11566		10.1074/jbc.M005419200	http://dx.doi.org/10.1074/jbc.M005419200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	421UK	11134002	hybrid			2022-12-25	WOS:000168081800021
J	Ghosh, AK; Yuan, WH; Mori, Y; Chen, SJ; Varga, J				Ghosh, AK; Yuan, WH; Mori, Y; Chen, SJ; Varga, J			Antagonistic regulation of type I collagen gene expression by interferon-gamma and transforming growth factor-beta - Integration at the level of p300/CBP transcriptional coactivators	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN SKIN FIBROBLASTS; NECROSIS-FACTOR-ALPHA; ACTIVATOR INHIBITOR-1 GENE; HUMAN DERMAL FIBROBLASTS; CBP-INDUCED STIMULATION; TGF-BETA; SMAD PROTEINS; MESSENGER-RNA; SIGNALING PATHWAYS; COL1A2 PROMOTER	Among the extracellular signals that modulate the synthesis of collagen, transforming growth factor-beta (TGF-beta) and interferon-gamma (IFN-gamma) are preeminent. These two cytokines exert antagonistic effects on fibroblasts, and play important roles in the physiologic regulation of extracellular matrix turnover. We have shown previously that in normal skin fibroblasts, TGF-beta positively regulates alpha2(I) procollagen gene (COL1A2) promoter activity through the cellular Smad signal transduction pathway. In contrast, IFN-gamma activates Stat1 alpha, down-regulates COL1A2 transcription, and abrogates its stimulation induced by TGF-beta, The level of integration of the two pathways mediating antagonistic collagen regulation is unknown. We now report that IFN-gamma abrogates TGF-beta -stimulated COL1A2 transcription in fibroblasts by inhibiting Smad activities. IFN-gamma appears to induce competition between activated Stat1 alpha and Smad3 for interaction with limiting amounts of cellular p300/CBP, Overexpression of p300 restored COL1A2 stimulation by TGF-beta in the presence of IFN-gamma, and potentiated IFN-beta -dependent positive transcriptional responses. In contrast to fibroblasts, in U4A cells lacking Jak1 and consequently unable to activate Stat1 alpha -mediated responses, IFN-gamma failed to repress TGF-beta -induced transcription. These results indicate that as essential coactivators for both Smad3 and Stat1 alpha, nuclear p300/CBP integrate signals that positively or negatively regulate COL1A2 transcription. The findings implicate a novel mechanism to account for antagonistic interaction of Smad and Jak-Stat pathways in regulation of target genes. In fibroblasts responding to cytokines with opposing effects on collagen transcription, the relative levels of cellular coactivators, and their interaction with regulated transcription factors, may govern the net effect.	Univ Illinois, Coll Med, Rheumatol Sect, Chicago, IL 60607 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Varga, J (corresponding author), Univ Illinois, Coll Med, Rheumatol Sect, M-C 733,1158 Mol Biol Res Bldg,900 S Ashland Ave, Chicago, IL 60607 USA.				NIAMS NIH HHS [AR42309, AR46390] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R03AR046390, R01AR042309] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Afrakhte M, 1998, BIOCHEM BIOPH RES CO, V249, P505, DOI 10.1006/bbrc.1998.9170; Ala-aho R, 2000, ONCOGENE, V19, P248, DOI 10.1038/sj.onc.1203306; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; BANNISTER AJ, 1995, EMBO J, V14, P4758, DOI 10.1002/j.1460-2075.1995.tb00157.x; Bannister AJ, 1995, ONCOGENE, V11, P2509; BAUVOIS B, 1992, J IMMUNOL, V148, P3912; Bhattacharya S, 1996, NATURE, V383, P344, DOI 10.1038/383344a0; Bitzer M, 2000, GENE DEV, V14, P187; Boehm U, 1997, ANNU REV IMMUNOL, V15, P749, DOI 10.1146/annurev.immunol.15.1.749; BORDER WA, 1994, NEW ENGL J MED, V331, P1286; Boyes J, 1998, NATURE, V396, P594, DOI 10.1038/25166; Chen SJ, 1999, J INVEST DERMATOL, V112, P49, DOI 10.1046/j.1523-1747.1999.00477.x; Chen SJ, 2000, J CELL PHYSIOL, V183, P381, DOI 10.1002/(SICI)1097-4652(200006)183:3<381::AID-JCP11>3.0.CO;2-O; Chen X, 1997, NATURE, V389, P85, DOI 10.1038/38008; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; Chung KY, 1996, J BIOL CHEM, V271, P3272, DOI 10.1074/jbc.271.6.3272; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; Derynck R, 1998, CELL, V95, P737, DOI 10.1016/S0092-8674(00)81696-7; Dickensheets HL, 1999, P NATL ACAD SCI USA, V96, P10800, DOI 10.1073/pnas.96.19.10800; Feng XH, 1998, GENE DEV, V12, P2153, DOI 10.1101/gad.12.14.2153; Ghosh AK, 2000, ONCOGENE, V19, P3546, DOI 10.1038/sj.onc.1203693; Hayashi H, 1997, CELL, V89, P1165, DOI 10.1016/S0092-8674(00)80303-7; Higashi K, 1998, MATRIX BIOL, V16, P447, DOI 10.1016/S0945-053X(98)90016-6; Horvai AE, 1997, P NATL ACAD SCI USA, V94, P1074, DOI 10.1073/pnas.94.4.1074; Hua XX, 1999, P NATL ACAD SCI USA, V96, P13130, DOI 10.1073/pnas.96.23.13130; Hua XX, 1998, GENE DEV, V12, P3084, DOI 10.1101/gad.12.19.3084; IGNOTZ RA, 1987, J BIOL CHEM, V262, P6443; Ihn H, 1997, J BIOL CHEM, V272, P24666, DOI 10.1074/jbc.272.39.24666; INAGAKI Y, 1994, J BIOL CHEM, V269, P14828; Janknecht R, 1998, GENE DEV, V12, P2114, DOI 10.1101/gad.12.14.2114; JIMENEZ SA, 1994, J BIOL CHEM, V269, P12684; Jonk LJC, 1998, J BIOL CHEM, V273, P21145, DOI 10.1074/jbc.273.33.21145; KAHARI VM, 1990, J CLIN INVEST, V86, P1489, DOI 10.1172/JCI114866; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; KINGSLEY DM, 1994, GENE DEV, V8, P133, DOI 10.1101/gad.8.2.133; Lagna G, 1996, NATURE, V383, P832, DOI 10.1038/383832a0; Liberati NT, 1999, P NATL ACAD SCI USA, V96, P4844, DOI 10.1073/pnas.96.9.4844; Liu XD, 1997, P NATL ACAD SCI USA, V94, P10669, DOI 10.1073/pnas.94.20.10669; MaciasSilva M, 1996, CELL, V87, P1215, DOI 10.1016/S0092-8674(00)81817-6; MOSES H, 1992, J IMMUNOL, V148, P3642; Moustakas A, 1998, P NATL ACAD SCI USA, V95, P6733, DOI 10.1073/pnas.95.12.6733; MULLER M, 1993, NATURE, V366, P129, DOI 10.1038/366129a0; Nagarajan RP, 2000, BIOCHEM J, V348, P591, DOI 10.1042/0264-6021:3480591; Nakao A, 1997, NATURE, V389, P631, DOI 10.1038/39369; Nakashima K, 1999, SCIENCE, V284, P479, DOI 10.1126/science.284.5413.479; Nishihara A, 1998, GENES CELLS, V3, P613, DOI 10.1046/j.1365-2443.1998.00217.x; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; Perkins ND, 1997, SCIENCE, V275, P523, DOI 10.1126/science.275.5299.523; Pouponnot C, 1998, J BIOL CHEM, V273, P22865, DOI 10.1074/jbc.273.36.22865; Sharma B, 1998, J BIOL CHEM, V273, P4642, DOI 10.1074/jbc.273.8.4642; Shen X, 1998, MOL BIOL CELL, V9, P3309, DOI 10.1091/mbc.9.12.3309; Shi YG, 1998, CELL, V94, P585, DOI 10.1016/S0092-8674(00)81600-1; Topper JN, 1998, P NATL ACAD SCI USA, V95, P9506, DOI 10.1073/pnas.95.16.9506; Turner BM, 1998, CELL MOL LIFE SCI, V54, P21, DOI 10.1007/s000180050122; Ulloa L, 1999, NATURE, V397, P710, DOI 10.1038/17826; VARGA J, 1990, EUR J CLIN INVEST, V20, P487, DOI 10.1111/j.1365-2362.1990.tb01915.x; Venkataraman C, 1999, J IMMUNOL, V162, P4053; Verrecchia F, 2000, J BIOL CHEM, V275, P30226, DOI 10.1074/jbc.M005310200; Wu RY, 1997, MOL CELL BIOL, V17, P2521, DOI 10.1128/MCB.17.5.2521; Yanagisawa J, 1999, SCIENCE, V283, P1317, DOI 10.1126/science.283.5406.1317; Yuan WH, 1999, J CELL PHYSIOL, V179, P97, DOI 10.1002/(SICI)1097-4652(199904)179:1<97::AID-JCP12>3.3.CO;2-5; Yuan WH, 1998, J CELL PHYSIOL, V177, P174, DOI 10.1002/(SICI)1097-4652(199810)177:1<174::AID-JCP18>3.0.CO;2-D; YUFIT T, 1995, J INVEST DERMATOL, V105, P388, DOI 10.1111/1523-1747.ep12320990; Zawel L, 1998, MOL CELL, V1, P611, DOI 10.1016/S1097-2765(00)80061-1; Zhang JJ, 1996, P NATL ACAD SCI USA, V93, P15092, DOI 10.1073/pnas.93.26.15092; Zhang Y, 1998, NATURE, V394, P909, DOI 10.1038/29814; Zhang Y, 1996, NATURE, V383, P168, DOI 10.1038/383168a0	69	199	217	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 6	2001	276	14					11041	11048		10.1074/jbc.M004709200	http://dx.doi.org/10.1074/jbc.M004709200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	420AC	11134049	hybrid, Green Submitted			2022-12-25	WOS:000167980900064
J	Hung, HL; Kim, AY; Hong, W; Rakowski, C; Blobel, GA				Hung, HL; Kim, AY; Hong, W; Rakowski, C; Blobel, GA			Stimulation of NF-E2 DNA binding by CREB-binding protein (CBP)-mediated acetylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOCUS-CONTROL REGION; BETA-GLOBIN LOCUS; TRANSCRIPTION FACTOR GATA-1; PORPHOBILINOGEN DEAMINASE GENE; HEMATOPOIETIC TRANSCRIPTION; IN-VITRO; HISTONE ACETYLTRANSFERASES; CHROMATIN STRUCTURE; ERYTHROID-CELLS; WW DOMAINS	The hematopoietic transcription factor NF-E2 is an important regulator of erythroid and megakaryocytic gene expression, The transcription cofactor cAMP-response element-binding protein (CREB)-binding protein (CEP) has previously been implicated in mediating NF-E2 function. In this report, we examined the role of CBP, a coactivator with intrinsic acetyltransferase activity, in the regulation of NF-E2, We found that both the hematopoietic-specific subunit of NF-E2, p45, and the widely expressed small subunit, MafG, interact with CBP in vitro and in vivo. CBP acetylates MafG;, but not p45, predominantly in the basic region of MafG. Immunoprecipitation experiments with anti acetyl lysine antibodies demonstrate that MafG is acetylated in vivo in erythroid cells. Transfection experiments further show that CBP stimulates MafG acetylation in intact cells in an E1A sensitive manner. Acetylation of MafG augments DNA binding activity of NF-E2, and mutations at the major acetylation sites markedly reduce DNA binding and transcriptional activation by NF-E2. Together, these results suggest that recruitment of CBP by NF-E2 to specific erythroid/megakaryocytic promoters might regulate transcription by at least two mechanisms involving both modification of chromatin structure and modulation of transcription factor activity.	Childrens Hosp Philadelphia, Abramson Pediat Res Ctr 316A, Div Hematol, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania	Blobel, GA (corresponding author), Childrens Hosp Philadelphia, Abramson Pediat Res Ctr 316A, Div Hematol, 34th St & Civ Ctr Blvd, Philadelphia, PA 19104 USA.				NIDDK NIH HHS [1RO1DK54937, 1F32DK10027] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK054937, F32DK010027] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Amrolia PJ, 1997, P NATL ACAD SCI USA, V94, P10051, DOI 10.1073/pnas.94.19.10051; ANDREWS NC, 1993, NATURE, V362, P722, DOI 10.1038/362722a0; Andrews NC, 1998, INT J BIOCHEM CELL B, V30, P429, DOI 10.1016/S1357-2725(97)00135-0; Armstrong JA, 1996, MOL CELL BIOL, V16, P5634; Armstrong JA, 1998, CELL, V95, P93, DOI 10.1016/S0092-8674(00)81785-7; Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; Bean TL, 1997, NUCLEIC ACIDS RES, V25, P2509, DOI 10.1093/nar/25.12.2509; Blank V, 1997, BLOOD, V89, P3925, DOI 10.1182/blood.V89.11.3925; Blank V, 1997, TRENDS BIOCHEM SCI, V22, P437, DOI 10.1016/S0968-0004(97)01105-5; Blobel GA, 2000, BLOOD, V95, P745, DOI 10.1182/blood.V95.3.745.003k05_745_755; Blobel GA, 1998, P NATL ACAD SCI USA, V95, P2061, DOI 10.1073/pnas.95.5.2061; Boyes J, 1998, NATURE, V396, P594, DOI 10.1038/25166; CHAN JY, 1993, P NATL ACAD SCI USA, V90, P11371, DOI 10.1073/pnas.90.23.11371; Cheng XB, 1997, MOL CELL BIOL, V17, P1407, DOI 10.1128/MCB.17.3.1407; CHRETIEN S, 1988, P NATL ACAD SCI USA, V85, P6, DOI 10.1073/pnas.85.1.6; Cosma MP, 1999, CELL, V97, P299, DOI 10.1016/S0092-8674(00)80740-0; ELLENBERGER TE, 1992, CELL, V71, P1223, DOI 10.1016/S0092-8674(05)80070-4; Elnitski L, 1997, J BIOL CHEM, V272, P369; Forsberg EC, 2000, P NATL ACAD SCI USA, V97, P14494, DOI 10.1073/pnas.97.26.14494; Forsberg EC, 1999, J BIOL CHEM, V274, P26850, DOI 10.1074/jbc.274.38.26850; Gavva NR, 1997, J BIOL CHEM, V272, P24105, DOI 10.1074/jbc.272.39.24105; Gong QH, 1996, MOL CELL BIOL, V16, P6055; Goodman RH, 2000, GENE DEV, V14, P1553; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; HEBBES TR, 1994, EMBO J, V13, P1823, DOI 10.1002/j.1460-2075.1994.tb06451.x; Hung HL, 1999, MOL CELL BIOL, V19, P3496; IGARASHI K, 1995, J BIOL CHEM, V270, P7615, DOI 10.1074/jbc.270.13.7615; IGARASHI K, 1995, P NATL ACAD SCI USA, V92, P7445, DOI 10.1073/pnas.92.16.7445; IGARASHI K, 1994, NATURE, V367, P568, DOI 10.1038/367568a0; Kobayashi A, 1999, J BIOL CHEM, V274, P6443, DOI 10.1074/jbc.274.10.6443; KOTKOW KJ, 1995, MOL CELL BIOL, V15, P4640; Krebs JE, 1999, GENE DEV, V13, P1412, DOI 10.1101/gad.13.11.1412; Liu L, 1999, MOL CELL BIOL, V19, P1202; MIGNOTTE V, 1989, P NATL ACAD SCI USA, V86, P6548, DOI 10.1073/pnas.86.17.6548; MOI P, 1994, P NATL ACAD SCI USA, V91, P9926, DOI 10.1073/pnas.91.21.9926; Mosser EA, 1998, BIOCHEMISTRY-US, V37, P13686, DOI 10.1021/bi981310l; NEY PA, 1993, MOL CELL BIOL, V13, P5604, DOI 10.1128/MCB.13.9.5604; NEY PA, 1990, GENE DEV, V4, P993, DOI 10.1101/gad.4.6.993; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; Onodera K, 1999, J BIOL CHEM, V274, P21162, DOI 10.1074/jbc.274.30.21162; Oyake T, 1996, MOL CELL BIOL, V16, P6083; Sakaguchi K, 1998, GENE DEV, V12, P2831, DOI 10.1101/gad.12.18.2831; Schubeler D, 2000, GENE DEV, V14, P940; Shavit JA, 1998, GENE DEV, V12, P2164, DOI 10.1101/gad.12.14.2164; Shikama N, 1997, TRENDS CELL BIOL, V7, P230, DOI 10.1016/S0962-8924(97)01048-9; SHIVDASANI RA, 1995, P NATL ACAD SCI USA, V92, P8690, DOI 10.1073/pnas.92.19.8690; TALBOT D, 1991, EMBO J, V10, P1391, DOI 10.1002/j.1460-2075.1991.tb07659.x; Zhang WJ, 1998, P NATL ACAD SCI USA, V95, P9855, DOI 10.1073/pnas.95.17.9855	48	71	75	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 6	2001	276	14					10715	10721		10.1074/jbc.M007846200	http://dx.doi.org/10.1074/jbc.M007846200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	420AC	11154691	hybrid			2022-12-25	WOS:000167980900022
J	Mirnikjoo, B; Brown, SE; Kim, HFS; Marangell, LB; Sweatt, JD; Weeber, EJ				Mirnikjoo, B; Brown, SE; Kim, HFS; Marangell, LB; Sweatt, JD; Weeber, EJ			Protein kinase inhibition by omega-3 fatty acids	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LONG-TERM POTENTIATION; AGE-RELATED-CHANGES; DOCOSAHEXAENOIC ACID; ELECTROCONVULSIVE SHOCK; EICOSAPENTAENOIC ACID; LEARNING-ABILITY; BIPOLAR DISORDER; RAT HIPPOCAMPUS; CYCLIC-AMP; BRAIN	Recent data suggest that omega -3 fatty acids may be effective in epilepsy, cardiovascular disorders, arthritis, and as mood stabilizers for bipolar disorder; however, the mechanism of action of these compounds is unknown. Based oh earlier studies implicating omega -3 fatty acids as inhibitors of protein kinase C activity in intact cells, we hypothesized that omega -3 fatty acids may act through direct inhibition of second messenger-regulated kinases and sought to determine whether the omega -3 double bond might uniquely confer pharmacologic efficacy and potency for fatty acids of this type. In our studies we observed that omega -3 fatty acids inhibited the in vitro activities of cAMP-dependent protein kinase, protein kinase C, Ca2+/calmodulin-dependent protein kinase II, and the mitogen-activated protein kinase (MAPK), Our results with a series of long-chain fatty acid structural homologs suggest an important role for the omega -3 double bond in conferring inhibitory efficacy. To assess whether omega -3 fatty acids were capable of inhibiting protein kinases in living neurons, we evaluated their effect on signal transduction pathways in the hippocampus. We found that omega -3 fatty acids could prevent serotonin receptor-induced MAPK activation in hippocampal slice preparations, In addition, we evaluated the effect of omega -3 fatty acids on hippocampal long-term potentiation, a form of synaptic plasticity known to be dependent on protein kinase activation. We observed that omega -3 fatty acids blocked long-term potentiation induction without inhibiting basal synaptic transmission. Overall, our results from both in vitro and live cell preparations suggest that inhibition of second messenger-regulated protein kinases is one locus of action of omega -3 fatty acids.	Baylor Coll Med, Div Neurosci, Houston, TX 77030 USA; Baylor Coll Med, Dept Psychiat & Behav Sci, Houston, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine	Weeber, EJ (corresponding author), Baylor Coll Med, Div Neurosci, Houston, TX 77030 USA.	eweeber@cns.bcm.tmc.edu	Weeber, Edwin J/A-5396-2012	Sweatt, J. David/0000-0003-3567-485X				ANDERSON GJ, 1990, PEDIATR RES, V27, P89, DOI 10.1203/00006450-199001000-00023; Bazan N G, 1989, Prog Clin Biol Res, V312, P95; BAZAN NG, 1970, BIOCHIM BIOPHYS ACTA, V218, P1, DOI 10.1016/0005-2760(70)90086-X; BAZAN NG, 1970, LIFE SCI, V9, P501, DOI 10.1016/0024-3205(70)90205-5; BAZAN NG, 1990, UPSALA J MED SCI, P97; BOURRE JM, 1990, BIOCHIM BIOPHYS ACTA, V1043, P149, DOI 10.1016/0005-2760(90)90288-9; Chen HM, 1999, INVEST OPHTH VIS SCI, V40, P2418; CHENG G, 1994, BRAIN RES, V646, P230, DOI 10.1016/0006-8993(94)90083-3; Delion S, 1997, J LIPID RES, V38, P680; Engler MB, 1999, AM J HYPERTENS, V12, P1225, DOI 10.1016/S0895-7061(99)90060-2; English JD, 1997, J BIOL CHEM, V272, P19103, DOI 10.1074/jbc.272.31.19103; Gamoh S, 1999, NEUROSCIENCE, V93, P237, DOI 10.1016/S0306-4522(99)00107-4; HARDY SJ, 1994, J NEUROCHEM, V62, P1546; HIDAKA H, 1984, BIOCHEMISTRY-US, V23, P5036, DOI 10.1021/bi00316a032; Hilty DM, 2000, J NEUROPSYCH CLIN N, V12, P283, DOI 10.1176/appi.neuropsych.12.2.283-a; HOLIAN O, 1992, ANTICANCER RES, V12, P975; Homayoun P, 2000, NEUROCHEM RES, V25, P269, DOI 10.1023/A:1007583806138; HVALBY O, 1994, P NATL ACAD SCI USA, V91, P4761, DOI 10.1073/pnas.91.11.4761; INAGAKI M, 1986, MOL PHARMACOL, V29, P577; Itokazu N, 2000, BRAIN RES, V862, P211, DOI 10.1016/S0006-8993(00)02129-6; Johannessen CU, 2000, NEUROCHEM INT, V37, P103, DOI 10.1016/S0197-0186(00)00013-9; Martin KC, 1997, CELL, V91, P927, DOI 10.1016/S0092-8674(00)80484-5; McGahon B, 1997, NEUROSCIENCE, V81, P9, DOI 10.1016/S0306-4522(97)00116-4; McGahon BM, 1999, NEUROSCIENCE, V94, P305, DOI 10.1016/S0306-4522(99)00219-5; MCPHAIL LC, 1984, SCIENCE, V224, P622, DOI 10.1126/science.6231726; MURAKAMI K, 1986, J BIOL CHEM, V261, P5424; Nanjo A, 1999, J NUTR SCI VITAMINOL, V45, P633, DOI 10.3177/jnsv.45.633; NISHIKAWA M, 1994, J PHYSIOL-LONDON, V475, P83, DOI 10.1113/jphysiol.1994.sp020051; PEPE S, 1994, P NATL ACAD SCI USA, V91, P8832, DOI 10.1073/pnas.91.19.8832; POLING JS, 1995, MOL PHARMACOL, V47, P381; Radominska-Pandya A, 2000, J BIOL CHEM, V275, P22324, DOI 10.1074/jbc.M907722199; Richardson AJ, 1999, INT J PSYCHOPHYSIOL, V34, P333, DOI 10.1016/S0167-8760(99)00090-2; Roberson ED, 1996, J BIOL CHEM, V271, P30436, DOI 10.1074/jbc.271.48.30436; SPEIZER LA, 1991, AM J PHYSIOL, V261, pE109, DOI 10.1152/ajpendo.1991.261.1.E109; Stoll AL, 1999, ARCH GEN PSYCHIAT, V56, P407, DOI 10.1001/archpsyc.56.5.407; Suzuki H, 1998, MECH AGEING DEV, V101, P119, DOI 10.1016/S0047-6374(97)00169-3; TAYLOR SS, 1994, STRUCTURE, V2, P345, DOI 10.1016/S0969-2126(00)00036-8; TAYLOR SS, 1993, RECEPTOR, V3, P165; Xiao YF, 1999, BRAIN RES, V846, P112, DOI 10.1016/S0006-8993(99)01997-6; Young C, 1998, NEUROSCI LETT, V247, P198, DOI 10.1016/S0304-3940(98)00272-9; Young G, 1998, MED PEDIATR ONCOL, V30, P117, DOI 10.1002/(SICI)1096-911X(199802)30:2<117::AID-MPO9>3.0.CO;2-L; Zimmer L, 2000, J LIPID RES, V41, P32	42	136	143	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 6	2001	276	14					10888	10896		10.1074/jbc.M008150200	http://dx.doi.org/10.1074/jbc.M008150200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	420AC	11152679	hybrid			2022-12-25	WOS:000167980900045
J	Hunsucker, SA; Spychala, J; Mitchell, BS				Hunsucker, SA; Spychala, J; Mitchell, BS			Human cytosolic 5 '-nucleotidase I - Characterization and role in nucleoside analog resistance	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENOSINE FORMATION; CELL-LINES; SOLUBLE 5'-NUCLEOTIDASE; PIGEON HEART; CANCER CELL; RAT-HEART; NUCLEOTIDE; AMP; PURIFICATION; GEMCITABINE	Nucleoside analogs are important in the treatment of hematologic malignancies, solid tumors, and viral infections. Their metabolism to the triphosphate form is central to their chemotherapeutic efficacy. Although the nucleoside kinases responsible for the phosphorylation of these compounds have been well described, the nucleotidases that may mediate drug resistance through dephosphorylation remain obscure, We have cloned and characterized a novel human cytosolic 5 ' -nucleotidase (cN-I) that potentially may have an important role in nucleoside analog metabolism. It is expressed at a high level in skeletal and heart muscle, at an intermediate level in pancreas and brain, and at a low level in kidney, testis, and uterus, The recombinant cN-I showed high affinity toward dCMP and lower affinity toward AMP and IMP, ADP was necessary for maximal catalytic activity. Expression of cN-I in Jurkat and HEK 293 cells conferred resistance to 2-chloro-2 ' -deoxyadenosine, with a 49-fold increase in the IC50 in HEK 293 and a greater than 400-fold increase in the IC50 in Jurkat cells. Expression of cN-I also conferred a 22-fold increase in the IC50 to 2 ' ,3 ' -difluorodeoxycytidine in HEK 293 cells and an 82-fold increase in the IC50 to 2 ' ,3 ' -dideoxycytidine in Jurkat cells. These data indicate that cN-I may play an important role in the regulation of physiological pyrimidine nucleotide pools and may also alter the therapeutic efficacy of certain nucleoside analogs.	Univ N Carolina, Lineberger Comprehens Canc Ctr, Dept Pharmacol, Chapel Hill, NC 27599 USA; Univ N Carolina, Lineberger Comprehens Canc Ctr, Dept Med, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Spychala, J (corresponding author), Univ N Carolina, Lineberger Comprehens Canc Ctr, Dept Pharmacol, Chapel Hill, NC 27599 USA.			Hunsucker, Sally/0000-0002-7034-7355	NATIONAL CANCER INSTITUTE [R01CA034085] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007040] Funding Source: NIH RePORTER; NCI NIH HHS [2R01CA034085-18] Funding Source: Medline; NIGMS NIH HHS [5T32GM07040-26] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARNER ESJ, 1995, PHARMACOL THERAPEUT, V67, P155, DOI 10.1016/0163-7258(95)00015-9; Brito RA, 1999, ONCOLOGY-BASEL, V57, P2, DOI 10.1159/000055262; Brown JM, 2000, MOL MED TODAY, V6, P157, DOI 10.1016/S1357-4310(00)01677-4; CARSON DA, 1991, BIOCHIM BIOPHYS ACTA, V1091, P22, DOI 10.1016/0167-4889(91)90216-K; CASS CE, 1995, DRUG TRANSPORT ANTIM, P403; CHEN PS, 1956, ANAL CHEM, V28, P1756, DOI 10.1021/ac60119a033; DARVISH A, 1993, AM J PHYSIOL, V264, pH1528; Garvey EP, 1998, BIOCHEMISTRY-US, V37, P9043, DOI 10.1021/bi980209d; Genini D, 2000, J BIOL CHEM, V275, P29, DOI 10.1074/jbc.275.1.29; Grant S, 1998, ADV CANCER RES, V72, P197; Hapke DM, 1996, CANCER RES, V56, P2343; HE MX, 1992, J MOL CELL CARDIOL, V24, P79, DOI 10.1016/0022-2828(92)91161-W; HEADRICK JP, 1989, BIOCHEM J, V261, P541, DOI 10.1042/bj2610541; JENNINGS RB, 1985, ANNU REV PHYSIOL, V47, P727, DOI 10.1146/annurev.ph.47.030185.003455; Leoni LM, 1998, P NATL ACAD SCI USA, V95, P9567, DOI 10.1073/pnas.95.16.9567; LEWIS W, 1995, NAT MED, V1, P417, DOI 10.1038/nm0595-417; MARSZALEK J, 1989, COMPUT APPL BIOSCI, V5, P239; MULLANE K, 1995, J MOL CELL CARDIOL, V27, P1041, DOI 10.1016/0022-2828(95)90073-X; NEWBY AC, 1988, BIOCHEM J, V253, P123, DOI 10.1042/bj2530123; NEWBY AC, 1984, TRENDS BIOCHEM SCI, V9, P42, DOI 10.1016/0968-0004(84)90176-2; OKA J, 1994, BIOCHEM BIOPH RES CO, V205, P917, DOI 10.1006/bbrc.1994.2752; PLAGEMANN PGW, 1989, MOL PHARMACOL, V36, P185; PLAGEMANN PGW, 1988, BIOCHIM BIOPHYS ACTA, V947, P405, DOI 10.1016/0304-4157(88)90002-0; Rofstad EK, 2000, INT J RADIAT BIOL, V76, P589, DOI 10.1080/095530000138259; Sala-Newby GB, 1999, J BIOL CHEM, V274, P17789, DOI 10.1074/jbc.274.25.17789; Sala-Newby GB, 2000, J BIOL CHEM, V275, P11666, DOI 10.1074/jbc.275.16.11666; Schirmer M, 1998, EXP HEMATOL, V26, P1223; Simpson AJG, 2000, NATURE, V406, P151, DOI 10.1038/35018003; Skladanowski AC, 1996, AM J PHYSIOL-HEART C, V270, pH1493, DOI 10.1152/ajpheart.1996.270.4.H1493; SKLADANOWSKI AC, 1990, BIOCHEM J, V268, P117, DOI 10.1042/bj2680117; Spychala J, 1999, EUR J BIOCHEM, V259, P851, DOI 10.1046/j.1432-1327.1999.00099.x; SPYCHALA J, 1988, J BIOL CHEM, V263, P18759; TRAUT TW, 1994, EUR J BIOCHEM, V222, P9, DOI 10.1111/j.1432-1033.1994.tb18835.x; TRUONG VL, 1988, BIOCHEM J, V253, P117, DOI 10.1042/bj2530117; van Moorsel CJA, 1999, BRIT J CANCER, V80, P981, DOI 10.1038/sj.bjc.6690452; YAMAZAKI Y, 1991, BIOCHEMISTRY-US, V30, P1503, DOI 10.1021/bi00220a009	36	95	100	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 30	2001	276	13					10498	10504		10.1074/jbc.M011218200	http://dx.doi.org/10.1074/jbc.M011218200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	420GC	11133996	hybrid			2022-12-25	WOS:000167996400118
J	Xiong, GM; Maser, E				Xiong, GM; Maser, E			Regulation of the steroid-inducible 3 alpha-hydroxysteroid dehydrogenase/carbonyl reductase gene in Comamonas testosteroni	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; PSEUDOMONAS-TESTOSTERONI; MOLECULAR-CLONING; DELTA-5-3-KETOSTEROID ISOMERASE; ANTIBIOTIC-RESISTANCE; TYROSINE RESIDUES; EXPRESSION; PROTEIN; OVEREXPRESSION; SUPERFAMILY	The Comamonas testosteroni 3 alpha -hydroxysteroid dehydrogenase/carbonyl reductase gene (hsdA) codes for an adaptive enzyme in the degradation of steroid compounds. However, no information was available on the molecular regulation of steroid-inducible genes nor on the mechanism of steroid signaling in procaryotes. We, therefore, investigated the cis- and trans-acting elements of hsdA expression to infer the mechanism of its molecular regulation by steroids. The gene was localized on a 5.257-kilobase EcoRI fragment of C, testosteroni chromosomal DNA. The promoter was characterized, and the transcriptional start site was identified. Two palindromic operator domains were found upstream of hsdA, A new gene coding for a trans-acting negative regulator (repressor A, RepA) of hsdA expression was characterized. The specific interaction between RepA, testosterone, and the operator domain is demonstrated. From our results we conclude that hsdA is under negative transcriptional control by an adjacent gene product (RepA), Accordingly, induction of hsdA by steroids in fact is a derepression, where steroidal inducers bind to the repressor, thereby preventing its binding to the hsdA operator.	Univ Marburg, Sch Med, Dept Pharmacol & Toxicol, D-35033 Marburg, Germany	Philipps University Marburg	Maser, E (corresponding author), Univ Marburg, Sch Med, Dept Pharmacol & Toxicol, Karl von Frisch Str 1, D-35033 Marburg, Germany.							Arai H, 1999, MOL MICROBIOL, V33, P1132, DOI 10.1046/j.1365-2958.1999.01554.x; BAKER ME, 1995, P SOC EXP BIOL MED, V208, P131; BAKER ME, 1992, CAN J MICROBIOL, V38, P541, DOI 10.1139/m92-089; BARBARO DJ, 1987, REV INFECT DIS, V9, P124; CHENG KC, 1991, MOL ENDOCRINOL, V5, P823, DOI 10.1210/mend-5-6-823; COULTER AW, 1968, J BIOL CHEM, V243, P3238; Florin C, 1996, J BACTERIOL, V178, P3322, DOI 10.1128/jb.178.11.3322-3330.1996; FUJITA Y, 1987, P NATL ACAD SCI USA, V84, P4524, DOI 10.1073/pnas.84.13.4524; GARCIAVALDES E, 1988, APPL ENVIRON MICROB, V54, P2478; GENTIRAIMONDI S, 1991, GENE, V105, P43, DOI 10.1016/0378-1119(91)90512-A; GENUS JMC, 1977, PHYTOCHEMISTRY, V17, P1; Grimm C, 2000, J BIOL CHEM, V275, P41333, DOI 10.1074/jbc.M007559200; Jez JM, 1997, BIOCHEM J, V326, P625, DOI 10.1042/bj3260625; JORNVALL H, 1995, BIOCHEMISTRY-US, V34, P6003, DOI 10.1021/bi00018a001; KOVACH ME, 1995, GENE, V166, P175, DOI 10.1016/0378-1119(95)00584-1; KULIOPULOS A, 1987, P NATL ACAD SCI USA, V84, P8893, DOI 10.1073/pnas.84.24.8893; LENARD J, 1992, TRENDS BIOCHEM SCI, V17, P147, DOI 10.1016/0968-0004(92)90323-2; LEPPIK RA, 1987, BIOCHEM J, V423, P15; LI YK, 1993, BIOCHEMISTRY-US, V32, P1816, DOI 10.1021/bi00058a016; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MACDONALD IA, 1976, BIOCHIM BIOPHYS ACTA, V450, P142, DOI 10.1016/0005-2760(76)90086-2; MACDONALD IA, 1979, APPL ENVIRON MICROB, V37, P992, DOI 10.1128/AEM.37.5.992-1000.1979; MALLONEE DH, 1990, J BACTERIOL, V172, P7011, DOI 10.1128/jb.172.12.7011-7019.1990; MARCUS PI, 1956, J BIOL CHEM, V218, P661; MASER E, 1992, FEBS LETT, V297, P196, DOI 10.1016/0014-5793(92)80359-O; Mobus E, 1998, J BIOL CHEM, V273, P30888, DOI 10.1074/jbc.273.47.30888; Mobus E, 1997, J BACTERIOL, V179, P5951; Mobus E, 1999, ADV EXP MED BIOL, V463, P395; MOLNAR I, 1995, MOL MICROBIOL, V15, P895, DOI 10.1111/j.1365-2958.1995.tb02359.x; OPPERMANN UCT, 1993, ADV EXP MED BIOL, V328, P379; Oppermann UCT, 1996, J STEROID BIOCHEM, V58, P217, DOI 10.1016/0960-0760(96)00021-0; Oppermann UCT, 1996, EUR J BIOCHEM, V241, P744, DOI 10.1111/j.1432-1033.1996.00744.x; Oppermann UCT, 1997, BIOCHEMISTRY-US, V36, P34, DOI 10.1021/bi961803v; PERSSON B, 1991, EUR J BIOCHEM, V200, P537, DOI 10.1111/j.1432-1033.1991.tb16215.x; PLESIAT P, 1991, J BACTERIOL, V173, P7219, DOI 10.1128/jb.173.22.7219-7227.1991; Sambrook J., 2002, MOL CLONING LAB MANU; SUZUKI K, 1993, GENE, V130, P137, DOI 10.1016/0378-1119(93)90357-9; TALALAY P, 1952, NATURE, V170, P620, DOI 10.1038/170620a0; THOMAS JE, 1989, J STEROID BIOCHEM, V32, P27, DOI 10.1016/0022-4731(89)90009-5; TOMKINS GM, 1956, J BIOL CHEM, V218, P437; UWAJIMA T, 1978, AGR BIOL CHEM TOKYO, V42, P1577, DOI 10.1080/00021369.1978.10863207; WATANABE M, 1979, J STEROID BIOCHEM, V10, P207, DOI 10.1016/0022-4731(79)90237-1; WU PG, 1994, BIOCHEMISTRY-US, V33, P7415, DOI 10.1021/bi00189a048; XIONG GM, 1992, EUR J BIOCHEM, V204, P789, DOI 10.1111/j.1432-1033.1992.tb16696.x	44	54	60	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 30	2001	276	13					9961	9970		10.1074/jbc.M010962200	http://dx.doi.org/10.1074/jbc.M010962200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	420GC	11139589	hybrid			2022-12-25	WOS:000167996400053
J	Tsuji, T; Usui, S; Aida, T; Tachikawa, T; Hu, GF; Sasaki, A; Matsumura, T; Todd, R; Wong, DTW				Tsuji, T; Usui, S; Aida, T; Tachikawa, T; Hu, GF; Sasaki, A; Matsumura, T; Todd, R; Wong, DTW			Induction of epithelial differentiation and DNA demethylation in hamster malignant oral keratinocyte by ornithine decarboxylase antizyme	ONCOGENE			English	Article						oral cancer; hamster; ornithine decarboxylase antizyme; differentiation; DNA demethylation	MOUSE-TISSUE INHIBITOR; POUCH CARCINOGENESIS MODEL; ALPHA-DIFLUOROMETHYLORNITHINE; METHYLTRANSFERASE ACTIVITY; POLYAMINE LEVELS; GENE-EXPRESSION; RETINOIC ACID; COLON-CANCER; ANTITUMOR-ACTIVITY; METHYLATION STATUS	The hamster ornithine decarboxylase antizyme (ODC-Az) cDNA was transfected into the hamster malignant oral keratinocyte cell line, HCPC-1, Ectopic expression of ODC-Az resulted in the reversion of malignant phenotypes and alteration of DNA methylation status of CCGG sites. The phenotypes examined include ODC enzymatic activity, doubling time, morphological change, anchorage dependent growth, tumorigenicity in nude mice, induction of epithelial differentiation marker protein (involucrin), and change of cell cycle position. Comparison of CCGG DNA methylation status of the ODC-Az and control vector transfectants revealed a significant increase in demethylation of 5-methyl cytosines (m(5)C) of CCGG sites in the ODC-Az transfectants. Ectopic expression of ODC-Az gene in hamster malignant oral keratinocytes led to reduce ODC activity and the subsequent demethylation of 5-methyl cytosines, presumably via the ODC/ polyamines/ decarboxylated S-adenosylmethionine (dc-AdoMet) pathways. Our data suggest that ODC-Az shared the same pathway of polyamines/ dc-AdoMet/DNA methyltransferase (DNA MTase), We propose that ODC-Az mediates a novel mechanism in tumor suppression by DNA demethylation and presumably re-activation of key cellular genes silenced by DNA hypermethylation during cancer development.	Showa Univ, Sch Dent, Dept Oral Pathol, Tokyo 1428555, Japan; Harvard Univ, Sch Med, Dept Radiol, Ctr Biochem & Biophys Sci & Med, Boston, MA 02115 USA; Okayama Univ, Sch Dent, Dept Oral & Maxillofacial Surg 2, Okayama 7008525, Japan; Massachusetts Gen Hosp, Dept Oral & Maxillofacial Surg, Boston, MA 02114 USA	Showa University; Harvard University; Harvard Medical School; Okayama University; Harvard University; Massachusetts General Hospital	Wong, DTW (corresponding author), Harvard Univ, Sch Dent Med, Dept Oral Med & Diagnost Sci, Div Oral Pathol, Boston, MA 02115 USA.				NIDCR NIH HHS [DE-12529, DE-11983, DE-12467] Funding Source: Medline; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R29DE011983, R03DE012529, P01DE012467] Funding Source: NIH RePORTER	NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Alani RM, 1999, P NATL ACAD SCI USA, V96, P9637, DOI 10.1073/pnas.96.17.9637; Aringer M, 1999, LIFE SCI, V64, P2173, DOI 10.1016/S0024-3205(98)00538-4; AUVINEN M, 1992, NATURE, V360, P355, DOI 10.1038/360355a0; Bachman KE, 1999, CANCER RES, V59, P798; BAYLIN SB, 1991, CANCER CELL-MON REV, V3, P383; Baylin SB, 1998, ADV CANCER RES, V72, P141; Belinsky SA, 1996, P NATL ACAD SCI USA, V93, P4045, DOI 10.1073/pnas.93.9.4045; BESTOR TH, 1984, MOL CELL BIOL, V4, P1800, DOI 10.1128/MCB.4.9.1800; Bruey JM, 2000, NAT CELL BIOL, V2, P645, DOI 10.1038/35023595; Chao C, 1996, CANCER RES, V56, P4811; Chuang LSH, 1997, SCIENCE, V277, P1996, DOI 10.1126/science.277.5334.1996; CLIFFORD A, 1995, CANCER RES, V55, P1680; Domann FE, 2000, INT J CANCER, V85, P805, DOI 10.1002/(SICI)1097-0215(20000315)85:6<805::AID-IJC12>3.0.CO;2-5; Duranton B, 1998, EXP CELL RES, V243, P319, DOI 10.1006/excr.1998.4148; ELDEIRY WS, 1991, P NATL ACAD SCI USA, V88, P3470, DOI 10.1073/pnas.88.8.3470; FEUERSTEIN BG, 1991, J CELL BIOCHEM, V46, P37, DOI 10.1002/jcb.240460107; Freshney RI, 1994, CULTURE ANIMAL CELLS; Frostesjo L, 1997, J BIOL CHEM, V272, P4359, DOI 10.1074/jbc.272.7.4359; GAINES DW, 1988, ANAL BIOCHEM, V174, P88, DOI 10.1016/0003-2697(88)90522-2; GIMENEZCONTI IB, 1993, J CELL BIOCHEM, P83; GIMENEZCONTI IB, 1992, ADV EXP MED BIOL, V320, P63; GOSULE LC, 1978, J MOL BIOL, V121, P311, DOI 10.1016/0022-2836(78)90366-2; Harper JW, 1997, CANCER SURV, V29, P91; HAWTREY AO, 1984, MED HYPOTHESES, V15, P125, DOI 10.1016/0306-9877(84)90117-8; Hayashi S, 1996, TRENDS BIOCHEM SCI, V21, P27, DOI 10.1016/0968-0004(96)80882-6; HAYASHI S, 1989, ORNITHINE DECARBOXYL, P47; Heby O, 1995, INT J DEV BIOL, V39, P737; Heby O, 1988, Adv Exp Med Biol, V250, P291; Henkel AW, 1999, CELL TISSUE RES, V296, P229, DOI 10.1007/s004410051284; HICKOK NJ, 1992, J INVEST DERMATOL, V98, P327, DOI 10.1111/1523-1747.ep12499799; Iismaa T P, 1999, Results Probl Cell Differ, V26, P257; ISSA JPJ, 1993, J NATL CANCER I, V85, P1235, DOI 10.1093/jnci/85.15.1235; Ito T, 1999, HISTOL HISTOPATHOL, V14, P895, DOI 10.14670/HH-14.895; Iwata S, 1999, ONCOGENE, V18, P165, DOI 10.1038/sj.onc.1202275; Janssen BLM, 1999, MELANOMA RES, V9, P213, DOI 10.1097/00008390-199906000-00002; Kim HT, 1997, BIOCHEM J, V324, P547, DOI 10.1042/bj3240547; Kim SY, 1997, CANCER RES, V57, P38; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAIRD PW, 1995, CELL, V81, P197, DOI 10.1016/0092-8674(95)90329-1; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; LI XQ, 1994, MOL CELL BIOL, V14, P87, DOI 10.1128/MCB.14.1.87; LINDEN M, 1985, J CELL PHYSIOL, V125, P273, DOI 10.1002/jcp.1041250215; LUNDELL L, 1986, SCAND J GASTROENTERO, V21, P829, DOI 10.3109/00365528609011126; MAKOS M, 1992, P NATL ACAD SCI USA, V89, P1929, DOI 10.1073/pnas.89.5.1929; MAO Y, 1993, BIOCHEM J, V295, P641, DOI 10.1042/bj2950641; MARTON LJ, 1995, ANNU REV PHARMACOL, V35, P55, DOI 10.1146/annurev.pa.35.040195.000415; MATSUFUJI S, 1995, CELL, V80, P51, DOI 10.1016/0092-8674(95)90450-6; McCarty MF, 1997, MED HYPOTHESES, V48, P297, DOI 10.1016/S0306-9877(97)90098-0; MEGOSH L, 1995, CANCER RES, V55, P4205; Mehlen P, 1997, J BIOL CHEM, V272, P31657, DOI 10.1074/jbc.272.50.31657; Missero C, 1996, GENE DEV, V10, P3065, DOI 10.1101/gad.10.23.3065; Mitchell JLA, 1996, BIOCHEM J, V317, P811, DOI 10.1042/bj3170811; Monzon RI, 1996, CELL GROWTH DIFFER, V7, P1751; ODUKOYA O, 1983, JNCI-J NATL CANCER I, V71, P1252; PAWELCZYK T, 1993, BIOCHEM PHARMACOL, V45, P493, DOI 10.1016/0006-2952(93)90087-D; PEGG AE, 1986, BIOCHEM J, V234, P249, DOI 10.1042/bj2340249; PEGG AE, 1987, BIOCHEM J, V241, P305, DOI 10.1042/bj2410305; Pennie WD, 1999, CELL GROWTH DIFFER, V10, P279; RADFORD DM, 1990, CANCER RES, V50, P6146; RIDEOUT WM, 1994, MOL CELL BIOL, V14, P6143, DOI 10.1128/MCB.14.9.6143; Rofstad EK, 2000, INT J RADIAT BIOL, V76, P589, DOI 10.1080/095530000138259; ROMANO M, 1986, INT J BIOL MARKER, V2, P77; Salzberg A, 1996, GENETICS, V144, P183; SAPIENZA C, 1991, BIOCHIM BIOPHYS ACTA, V1072, P51, DOI 10.1016/0304-419X(91)90006-7; Sark MWJ, 1998, J BIOL CHEM, V273, P24683, DOI 10.1074/jbc.273.38.24683; SEILER N, 1985, J CHROMATOGR, V339, P45, DOI 10.1016/S0378-4347(00)84626-5; SHIN DM, 1990, CANCER RES, V50, P2505; SUN Y, 1995, J BIOL CHEM, V270, P19312, DOI 10.1074/jbc.270.33.19312; TABOR CW, 1984, ANNU REV BIOCHEM, V53, P747; Takaoka AS, 1998, J BIOL CHEM, V273, P33848, DOI 10.1074/jbc.273.50.33848; TAKIGAWA M, 1983, CANCER RES, V43, P3732; TAMORI A, 1994, HEPATOLOGY, V20, P1179, DOI 10.1002/hep.1840200512; TOMAYKO MM, 1989, CANCER CHEMOTH PHARM, V24, P148, DOI 10.1007/BF00300234; Tsuji T, 1998, ONCOGENE, V16, P3379, DOI 10.1038/sj.onc.1201887; Tulchinsky EM, 1996, ONCOGENE, V12, P1737; VERES DA, 1989, J INVEST DERMATOL, V93, P687, DOI 10.1111/1523-1747.ep12319883; VERMA AK, 1980, CANCER RES, V40, P308; Waltz DA, 1997, J CLIN INVEST, V100, P58, DOI 10.1172/JCI119521; WEEKS CE, 1982, P NATL ACAD SCI-BIOL, V79, P6028, DOI 10.1073/pnas.79.19.6028; WETTERS TV, 1989, NUCLEIC ACIDS RES, V17, P9843, DOI 10.1093/nar/17.23.9843; WILLIAMS HK, 1995, J ORAL PATHOL MED, V24, P322, DOI 10.1111/j.1600-0714.1995.tb01193.x; YEBRA MJ, 1995, BIOCHEMISTRY-US, V34, P14752, DOI 10.1021/bi00045a016; Zhang M, 1997, CELL GROWTH DIFFER, V8, P179	83	44	49	0	0	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 4	2001	20	1					24	33		10.1038/sj.onc.1204051	http://dx.doi.org/10.1038/sj.onc.1204051			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	391NE	11244502				2022-12-25	WOS:000166361400004
J	Dhordain, P; Albagli, O; Honore, N; Guidez, F; Lantoine, D; Schmid, M; De The, H; Zelent, A; Koken, MHM				Dhordain, P; Albagli, O; Honore, N; Guidez, F; Lantoine, D; Schmid, M; De The, H; Zelent, A; Koken, MHM			Colocalization and heteromerization between the two human oncogene POZ/zinc finger proteins, LAZ3 (BCL6) and PLZF	ONCOGENE			English	Article						nuclear body; PML; APL; non Hodgkin lymphoma	ACUTE PROMYELOCYTIC LEUKEMIA; ALPHA FUSION PROTEIN; GERMINAL-CENTER FORMATION; B-CELL LYMPHOMA; PML-RAR-ALPHA; RETINOIC ACID; TRANSCRIPTIONAL REPRESSION; POZ-DOMAIN; HISTONE DEACETYLASE; BTB/POZ DOMAIN	Most acute promyelocytic leukemia (APL) cases are associated with recurrent translocations between the gene of retinoic receptor alpha and that of PML (t(15;17)) or PLZF (t(11;17)), PML localizes onto discrete intranuclear domains, the PML-nuclear bodies, and displays anti-oncogenic and pro-apoptotic properties. PLZF encodes a transcription factor belonging to the (PO) under barZ/domain and Kruppel zinc finger (POK) family which interacts directly with PML, PLZF is related to another POK protein, LAZ3(BCL6), which is structurally altered, and presumably misexpressed, in many non-Hodgkin lymphoma (NHL) cases. PLZF and LAZ3 share many functional properties: both inhibit cell growth, concentrate into punctated nuclear subdomains and are sequence-specific transcriptional repressors recruiting a histone deacetylase-repressing complex. Given these similarities, we tested whether both proteins could be targeted by each other, Here, LAZ3 and PLZF are shown to colocalize onto nuclear dots. Moreover, truncated derivatives of one protein, which display a diffuse nuclear localization, are recruited onto nuclear dots by the full-length other. The colocalization and the reciprocal 'rescue' is the result of a direct interaction between LAZ3 and PLZF, as indicated by yeast two hybrid assays, in vitro immunoprecipitations, and GST pull down experiments. In contrast to LAZ3 homomerization, LAZ3/PLZF heteromerization in yeast does not solely depend on POZ/POZ contacts but rather also relies on interactions between the two zinc finger regions and 'cross' contacts between the zinc finger region and the POZ domain of each partner, Likewise, LAZ3 shows some colocalization with the PLZF partner PML upon stable overexpression of both proteins in CHO cells and interacts with PML in yeast. Finally, endogenous LAZ3 and PLZF are co-induced and partially colocalized in myeloid MDS cells, These data indicate that a physical interaction between LAZ3 and PLZF underlies their simultaneous recruitment onto multiproteic nuclear complexes, presumably involved in transcriptional silencing and whose integrity (for APL) and/or function (for APL and NHL) may be altered in oncogenesis.	Univ Paris 07, CNRS UPR 9051, Unite Conventionnee, Hop St Louis, F-75475 Paris 10, France; IRCL, INSERM U524, F-59045 Lille, France; Inst Canc Res, Chester Beatty Labs, Leukaemia Res Fund Ctr, London SW3 6JB, England; Hop St Louis, INSERM U462, F-75475 Paris 10, France; UPR 1983, F-94801 Villejuif, France; MNHN, Stn Biol Marine, F-29182 Concarneau, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Museum National d'Histoire Naturelle (MNHN)	Koken, MHM (corresponding author), Univ Paris 07, CNRS UPR 9051, Unite Conventionnee, Hop St Louis, 1 Ave Claude Vellefaux, F-75475 Paris 10, France.		koken, marcel/J-8154-2012; Zelent, Arthur/B-3532-2009; koken, marcel/N-1349-2019; Guidez, Fabien/B-3750-2009; Guidez, Fabien/P-4220-2019	koken, marcel/0000-0002-0839-0125; Guidez, Fabien/0000-0003-1380-4473; Zelent, Arthur/0000-0002-7968-9888				Albagli O, 1999, ONCOGENE, V18, P5063, DOI 10.1038/sj.onc.1202892; Albagli O, 1996, BIOCHEM BIOPH RES CO, V220, P911, DOI 10.1006/bbrc.1996.0505; ALBAGLI O, 1995, CELL GROWTH DIFFER, V6, P1193; Albagli-Curiel O, 1998, DIFFERENTIATION, V64, P33, DOI 10.1046/j.1432-0436.1998.6410033.x; Aoki K, 1998, J BIOL CHEM, V273, P26698, DOI 10.1074/jbc.273.41.26698; BANERJEE R, 1992, P NATL ACAD SCI USA, V89, P9996, DOI 10.1073/pnas.89.21.9996; BARDWELL VJ, 1994, GENE DEV, V8, P1664, DOI 10.1101/gad.8.14.1664; Barna M, 2000, NAT GENET, V25, P166, DOI 10.1038/76014; Baron BW, 1997, GENE CHROMOSOME CANC, V19, P14, DOI 10.1002/(SICI)1098-2264(199705)19:1<14::AID-GCC3>3.0.CO;2-3; Brown KE, 1997, CELL, V91, P845, DOI 10.1016/S0092-8674(00)80472-9; CATTORETTI G, 1995, BLOOD, V86, P45, DOI 10.1182/blood.V86.1.45.bloodjournal86145; Chang CC, 1996, P NATL ACAD SCI USA, V93, P6947, DOI 10.1073/pnas.93.14.6947; CHEN Z, 1994, P NATL ACAD SCI USA, V91, P1178, DOI 10.1073/pnas.91.3.1178; David G, 1998, ONCOGENE, V16, P2549, DOI 10.1038/sj.onc.1202043; Davies JM, 1999, ONCOGENE, V18, P365, DOI 10.1038/sj.onc.1202332; Dent AL, 1997, SCIENCE, V276, P589, DOI 10.1126/science.276.5312.589; DETHE H, 1991, CELL, V66, P675, DOI 10.1016/0092-8674(91)90113-D; Dhordain P, 1997, P NATL ACAD SCI USA, V94, P10762, DOI 10.1073/pnas.94.20.10762; Dhordain P, 1998, NUCLEIC ACIDS RES, V26, P4645, DOI 10.1093/nar/26.20.4645; Dhordain P, 1995, ONCOGENE, V11, P2689; Dong S, 1996, P NATL ACAD SCI USA, V93, P3624, DOI 10.1073/pnas.93.8.3624; Doucas V, 1999, P NATL ACAD SCI USA, V96, P2627, DOI 10.1073/pnas.96.6.2627; Ferrucci PF, 1997, P NATL ACAD SCI USA, V94, P10901, DOI 10.1073/pnas.94.20.10901; Gietz RD, 1995, METHOD MOL CELL BIOL, V5, P255; Grignani F, 1998, NATURE, V391, P815, DOI 10.1038/35901; Guidez F, 1998, BLOOD, V91, P2634, DOI 10.1182/blood.V91.8.2634.2634_2634_2642; He LZ, 1999, BLOOD, V94, p368A; Hong SH, 1997, P NATL ACAD SCI USA, V94, P9028, DOI 10.1073/pnas.94.17.9028; Hummel JL, 1999, ONCOGENE, V18, P633, DOI 10.1038/sj.onc.1202357; Huynh KD, 1998, ONCOGENE, V17, P2473, DOI 10.1038/sj.onc.1202197; James P, 1996, GENETICS, V144, P1425; KERCKAERT JP, 1993, NAT GENET, V5, P66, DOI 10.1038/ng0993-66; Koipally J, 1999, EMBO J, V18, P3090, DOI 10.1093/emboj/18.11.3090; Koken MHM, 1999, ONCOGENE, V18, P1113, DOI 10.1038/sj.onc.1202414; KOKEN MHM, 1995, ONCOGENE, V10, P1315; Koken MHM, 1997, P NATL ACAD SCI USA, V94, P10255, DOI 10.1073/pnas.94.19.10255; Li JY, 1997, J BIOL CHEM, V272, P22447, DOI 10.1074/jbc.272.36.22447; Li SH, 1997, CELL, V90, P469, DOI 10.1016/S0092-8674(00)80507-3; Li XM, 1997, J BIOL CHEM, V272, P27324, DOI 10.1074/jbc.272.43.27324; Li XM, 1999, CANCER RES, V59, P5275; Licht JD, 1996, ONCOGENE, V12, P323; Lin RJ, 1998, NATURE, V391, P811, DOI 10.1038/35895; Lorick KL, 1999, P NATL ACAD SCI USA, V96, P11364, DOI 10.1073/pnas.96.20.11364; MACLEY JP, 1998, TIBS, V23, P1; MIKI T, 1994, BLOOD, V83, P26; Morrison DJ, 1999, NUCLEIC ACIDS RES, V27, P1251, DOI 10.1093/nar/27.5.1251; Niu HF, 1999, BLOOD, V94, p693A; Numoto M, 1999, BIOCHEM BIOPH RES CO, V256, P573, DOI 10.1006/bbrc.1999.0375; Okabe S, 1998, MOL CELL BIOL, V18, P4235, DOI 10.1128/MCB.18.7.4235; Quignon F, 1998, NAT GENET, V20, P259, DOI 10.1038/3068; Rose MD., 1990, METHODS YEAST GENETI; Seeler JS, 1998, P NATL ACAD SCI USA, V95, P7316, DOI 10.1073/pnas.95.13.7316; Seyfert VL, 1996, ONCOGENE, V12, P2331; Shaknovich R, 1998, MOL CELL BIOL, V18, P5533, DOI 10.1128/MCB.18.9.5533; Sitterlin D, 1997, ONCOGENE, V14, P1067, DOI 10.1038/sj.onc.1200916; Tang AH, 1997, CELL, V90, P459, DOI 10.1016/S0092-8674(00)80506-1; Wang ZG, 1998, NAT GENET, V20, P266, DOI 10.1038/3073; Wong CW, 1998, J BIOL CHEM, V273, P27695, DOI 10.1074/jbc.273.42.27695; Ye BH, 1997, NAT GENET, V16, P161, DOI 10.1038/ng0697-161; Ye BH, 1995, EMBO J, V14, P6209, DOI 10.1002/j.1460-2075.1995.tb00311.x; YE BH, 1993, SCIENCE, V262, P747, DOI 10.1126/science.8235596; Yeyati PL, 1999, ONCOGENE, V18, P925, DOI 10.1038/sj.onc.1202375	62	61	62	0	10	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 14	2000	19	54					6240	6250		10.1038/sj.onc.1203976	http://dx.doi.org/10.1038/sj.onc.1203976			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	388YK	11175338				2022-12-25	WOS:000166210500007
J	Swank, DM; Bartoo, ML; Knowles, AF; Iliffe, C; Bernstein, SI; Molloy, JE; Sparrow, JC				Swank, DM; Bartoo, ML; Knowles, AF; Iliffe, C; Bernstein, SI; Molloy, JE; Sparrow, JC			Alternative exon-encoded regions of Drosophila myosin heavy chain modulate ATPase rates and actin sliding velocity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SKELETAL-MUSCLE MYOSIN; INDIRECT FLIGHT-MUSCLE; VITRO MOTILITY ASSAY; SMOOTH-MUSCLE; LIGHT-CHAIN; MOTOR DOMAIN; IN-VITRO; SHORTENING VELOCITY; FUNCTIONAL DOMAINS; INVITRO MOTILITY	To investigate the molecular functions of the regions encoded by alternative exons from the single Drosophila myosin heavy chain gene, we made the first kinetic measurements of two muscle myosin isoforms that differ in all alternative regions. Myosin was purified from the indirect flight muscles of wild-type and transgenic flies expressing a major embryonic isoform. The in vitro actin sliding velocity on the flight muscle isoform (6.4 mum.s(-1) at 22 degreesC) is among the fastest reported for a type II myosin and was g-fold faster than with the embryonic isoform. With smooth muscle tropomyosin bound to actin, the actin sliding velocity on the embryonic isoform increased 6-fold, whereas that on the flight muscle myosin slightly decreased. No difference in the step sizes of Drosophila and rabbit skeletal myosins were found using optical tweezers, suggesting that the slower in vitro velocity with the embryonic isoform is due to altered kinetics. Basal ATPase rates for flight muscle myosin are higher than those of embryonic and rabbit myosin. These differences explain why the embryonic myosin cannot functionally substitute in vivo for the native flight muscle isoform, and demonstrate that one or more of the five myosin heavy chain alternative exons must influence Drosophila myosin kinetics.	San Diego State Univ, Dept Biol, San Diego, CA 92182 USA; San Diego State Univ, Inst Mol Biol, San Diego, CA 92182 USA; San Diego State Univ, Dept Chem, San Diego, CA 92182 USA; Univ York, Dept Biol, York YO1 5YW, N Yorkshire, England	California State University System; San Diego State University; California State University System; San Diego State University; California State University System; San Diego State University; University of York - UK	Swank, DM (corresponding author), San Diego State Univ, Dept Biol, San Diego, CA 92182 USA.	dswank@sciences.sdsu.edu		Bernstein, Sanford/0000-0001-7094-5390; Molloy, Justin/0000-0002-8307-2450	NIGMS NIH HHS [GM32443] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032443] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BALL E, 1987, CELL, V51, P221, DOI 10.1016/0092-8674(87)90149-8; BERNSTEIN SI, 1983, NATURE, V302, P393, DOI 10.1038/302393a0; BERNSTEIN SI, 1993, INT REV CYTOL, V143, P63; Bernstein SI, 1997, J MOL BIOL, V271, P1, DOI 10.1006/jmbi.1997.1160; Bing W, 1998, J BIOL CHEM, V273, P15016, DOI 10.1074/jbc.273.24.15016; Bobkov AA, 1996, P NATL ACAD SCI USA, V93, P2285, DOI 10.1073/pnas.93.6.2285; BULLARD B, 1973, BIOCHEM J, V135, P277, DOI 10.1042/bj1350277; Chan WP, 1996, J EXP BIOL, V199, P2767; COLLIER VL, 1990, GENE DEV, V4, P885, DOI 10.1101/gad.4.6.885; Dickinson MH, 1997, BIOPHYS J, V73, P3122, DOI 10.1016/S0006-3495(97)78338-3; Dominguez R, 1998, CELL, V94, P559, DOI 10.1016/S0092-8674(00)81598-6; FALKENTHAL S, 1985, P NATL ACAD SCI USA, V82, P449, DOI 10.1073/pnas.82.2.449; FINER JT, 1994, NATURE, V368, P113, DOI 10.1038/368113a0; Geeves MA, 1999, ANNU REV BIOCHEM, V68, P687, DOI 10.1146/annurev.biochem.68.1.687; GEORGE EL, 1989, MOL CELL BIOL, V9, P2957, DOI 10.1128/MCB.9.7.2957; Gordon AM, 2000, PHYSIOL REV, V80, P853, DOI 10.1152/physrev.2000.80.2.853; GREENE LE, 1978, P NATL ACAD SCI USA, V75, P54, DOI 10.1073/pnas.75.1.54; HASTINGS GA, 1991, J CELL BIOL, V114, P263, DOI 10.1083/jcb.114.2.263; HOMSHER E, 1992, AM J PHYSIOL, V262, P714; HYNES TR, 1987, CELL, V48, P953, DOI 10.1016/0092-8674(87)90704-5; KRON SJ, 1991, METHOD ENZYMOL, V196, P399; KRONERT WA, 1991, EMBO J, V10, P2479, DOI 10.1002/j.1460-2075.1991.tb07787.x; Kurzawa-Goertz SE, 1998, BIOCHEMISTRY-US, V37, P7517, DOI 10.1021/bi972844+; Lauzon AM, 1998, J MUSCLE RES CELL M, V19, P825, DOI 10.1023/A:1005489501357; LEHMAN W, 1974, J GEN PHYSIOL, V63, P553, DOI 10.1085/jgp.63.5.553; LEVINE JD, 1973, P NATL ACAD SCI USA, V70, P1050, DOI 10.1073/pnas.70.4.1050; LOWEY S, 1993, NATURE, V365, P454, DOI 10.1038/365454a0; LOWEY S, 1993, J BIOL CHEM, V268, P20414; MARGOSSIAN SS, 1982, METHOD ENZYMOL, V85, P55; Miller CJ, 1996, BIOCHEMISTRY-US, V35, P16557, DOI 10.1021/bi962388+; MILLER RC, 1993, J MUSCLE RES CELL M, V14, P85, DOI 10.1007/BF00132183; Molloy J. E., 1995, Biophysical Journal, V68, P298; MOLLOY JE, 1987, NATURE, V328, P449, DOI 10.1038/328449a0; MOLLOY JE, 1995, NATURE, V378, P209, DOI 10.1038/378209a0; Moore JR, 2000, BIOPHYS J, V78, P1431, DOI 10.1016/S0006-3495(00)76696-3; MOSS RL, 1986, J PHYSIOL-LONDON, V377, P487, DOI 10.1113/jphysiol.1986.sp016199; Murphy CT, 1998, BIOCHEMISTRY-US, V37, P6738, DOI 10.1021/bi972903j; PARDEE JD, 1982, METHOD CELL BIOL, V24, P271; PECKHAM M, 1990, J MUSCLE RES CELL M, V11, P203, DOI 10.1007/BF01843574; PULLMAN ME, 1967, METHOD ENZYMOL, V10, P57; RAYMENT I, 1993, SCIENCE, V261, P50, DOI 10.1126/science.8316857; Razzaq A, 1999, J BIOL CHEM, V274, P28321, DOI 10.1074/jbc.274.40.28321; ROOT DD, 1994, BIOCHEMISTRY-US, V33, P12581, DOI 10.1021/bi00208a008; Rovner AS, 1997, J MUSCLE RES CELL M, V18, P103, DOI 10.1023/A:1018689102122; ROZEK CE, 1983, CELL, V32, P23, DOI 10.1016/0092-8674(83)90493-2; Ruppel KM, 1996, ANNU REV CELL DEV BI, V12, P543, DOI 10.1146/annurev.cellbio.12.1.543; Schmitz S, 2000, J MOL BIOL, V295, P1201, DOI 10.1006/jmbi.1999.3407; SELLERS JR, 1993, METHOD CELL BIOL, V39, P23, DOI 10.1016/S0091-679X(08)60159-4; Swank DM, 2000, MICROSC RES TECHNIQ, V50, P430, DOI 10.1002/1097-0029(20000915)50:6<430::AID-JEMT2>3.0.CO;2-E; Sweeney HL, 1998, J BIOL CHEM, V273, P6262, DOI 10.1074/jbc.273.11.6262; TAKAHASHI S, 1987, ZOOL SCI, V4, P833; TAKAHASHI S, 1990, COMP BIOCHEM PHYS B, V95, P183, DOI 10.1016/0305-0491(90)90268-X; TAKIGUCHI K, 1990, J BIOCHEM-TOKYO, V107, P671, DOI 10.1093/oxfordjournals.jbchem.a123106; Tanaka H, 1998, BIOPHYS J, V75, P1886, DOI 10.1016/S0006-3495(98)77629-5; Thedinga E, 1999, J MUSCLE RES CELL M, V20, P785, DOI 10.1023/A:1005658825375; TOYOSHIMA YY, 1987, NATURE, V328, P536, DOI 10.1038/328536a0; UMEMOTO S, 1990, J BIOL CHEM, V265, P14864; VANBUREN P, 1995, CIRC RES, V77, P439, DOI 10.1161/01.RES.77.2.439; Veigel C, 1998, BIOPHYS J, V75, P1424, DOI 10.1016/S0006-3495(98)74061-5; WANG F, 1993, BIOPHYS J, V64, pA359; Wells L, 1996, EMBO J, V15, P4454, DOI 10.1002/j.1460-2075.1996.tb00822.x; WHITE DCS, 1986, J MUSCLE RES CELL M, V7, P179, DOI 10.1007/BF01753419; Zhang SX, 2001, MECH DEVELOP, V101, P35, DOI 10.1016/S0925-4773(00)00549-9	63	56	57	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 4	2001	276	18					15117	15124		10.1074/jbc.M008379200	http://dx.doi.org/10.1074/jbc.M008379200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	429QQ	11134017	hybrid			2022-12-25	WOS:000168528800079
J	Duan, RQ; Xie, W; Burghardt, RC; Safe, S				Duan, RQ; Xie, W; Burghardt, RC; Safe, S			Estrogen receptor-mediated activation of the serum response element in MCF-7 cells through MAPK-dependent phosphorylation of Elk-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BREAST-CANCER-CELLS; TERNARY COMPLEX FACTORS; C-FOS TRANSCRIPTION; PROTEIN-KINASE-C; GROWTH FACTOR-I; SIGNAL-TRANSDUCTION; CROSS-TALK; PROTOONCOGENE EXPRESSION; CELLULAR PROLIFERATION; GENE-TRANSCRIPTION	17 beta -Estradiol (E2) induces c-fos protooncogene expression in MCF-7 human breast cancer cells, and deletion analysis of the c-fas promoter showed that the serum response element (SRE) at -325 to -296 was E2-responsive. The mechanism of ligand-activated estrogen receptor alpha (ER alpha)-dependent activation of gene expression through the SRE was determined by mutational analysis of the promoter, analysis of mitogen-activated protein kinase (MAPK) pathway activation by E2, and transforming growth factor alpha (TGF-alpha) as a positive control. In addition, ER alpha -negative MDA-MB-231 breast cancer and Chinese hamster ovary cells were used as reference cell lines, The results showed that transcriptional activation of the SRE by E2 was due to ER alpha activation of the MAPK pathway and increased binding of the serum response factor and Elk-1 to the SRE. Subsequent studies with dominant negative Elk-1, wild type, and variant GAL4-Elk-1. fusion proteins confirmed that phosphorylation of Elk-1 at serines 383 and 389 in the C-terminal region of Elk-1 is an important downstream target associated with activation of an SRE by E2. Both E2 (ER alpha -dependent) and,growth factors (ER alpha -independent) activated the SRE in breast cancer cells via the Ras/MAPK pathway; however, in ER-negative CHO cells that do not express a receptor for TGF-alpha, only hormone-induced activation was observed in cells transfected with ER alpha.	Texas A&M Univ, Dept Vet Physiol & Pharmacol, College Stn, TX 77843 USA	Texas A&M University System; Texas A&M University College Station	Safe, S (corresponding author), Texas A&M Univ, Dept Vet Physiol & Pharmacol, College Stn, TX 77843 USA.	ssafe@cvm.tamu.edu	xu, huanfang/I-4315-2012; Burghardt, Robert C./AAF-4847-2021	Burghardt, Robert C./0000-0003-1021-8444	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES009253, P30ES009106] Funding Source: NIH RePORTER; NIEHS NIH HHS [ES09253, ES09106] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ARONICA SM, 1994, P NATL ACAD SCI USA, V91, P8517, DOI 10.1073/pnas.91.18.8517; ARONICA SM, 1993, MOL ENDOCRINOL, V7, P743, DOI 10.1210/me.7.6.743; Bonapace IM, 1996, ONCOGENE, V12, P753; CANDELIERE GA, 1991, MOL ENDOCRINOL, V5, P1780, DOI 10.1210/mend-5-12-1780; Candeliere GA, 1996, MOL CELL BIOL, V16, P584; CAVIGELLI M, 1995, EMBO J, V14, P5957, DOI 10.1002/j.1460-2075.1995.tb00284.x; Chen DS, 1999, MOL CELL BIOL, V19, P1002; CHO H, 1993, MOL ENDOCRINOL, V7, P441, DOI 10.1210/me.7.3.441; COHEN D R, 1989, Critical Reviews in Oncogenesis, V1, P65; CURRAN T, 1988, CELL, V55, P395, DOI 10.1016/0092-8674(88)90024-4; Curran T, 1988, ONCOGENE HDB, P307; Darnell JE, 1996, RECENT PROG HORM RES, V51, P391; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; De Cesare D, 1998, P NATL ACAD SCI USA, V95, P12202, DOI 10.1073/pnas.95.21.12202; DICKSON RB, 1995, ENDOCR REV, V16, P559, DOI 10.1210/er.16.5.559; DICKSON RB, 1991, BREAST, P363; DICKSON RB, 1988, BREAST CANCER CELLUL, P119; DOUCAS V, 1991, EMBO J, V10, P2237, DOI 10.1002/j.1460-2075.1991.tb07760.x; Duan R, 1998, ENDOCRINOLOGY, V139, P1981, DOI 10.1210/en.139.4.1981; ETHIER SP, 1995, J NATL CANCER I, V87, P964, DOI 10.1093/jnci/87.13.964; GILLE H, 1995, CURR BIOL, V5, P1191, DOI 10.1016/S0960-9822(95)00235-1; GINTY DD, 1994, CELL, V77, P713, DOI 10.1016/0092-8674(94)90055-8; HILL CS, 1995, EMBO J, V14, P5037, DOI 10.1002/j.1460-2075.1995.tb00186.x; Hodge C, 1998, J BIOL CHEM, V273, P31327, DOI 10.1074/jbc.273.47.31327; Improta-Brears T, 1999, P NATL ACAD SCI USA, V96, P4686, DOI 10.1073/pnas.96.8.4686; INCE BA, 1994, MOL ENDOCRINOL, V8, P1397, DOI 10.1210/me.8.10.1397; Joel PB, 1998, MOL CELL BIOL, V18, P1978, DOI 10.1128/MCB.18.4.1978; JOHNSON RS, 1992, CELL, V71, P577, DOI 10.1016/0092-8674(92)90592-Z; Kahlert S, 2000, J BIOL CHEM, V275, P18447, DOI 10.1074/jbc.M910345199; KARIN M, 1995, CURR BIOL, V5, P747, DOI 10.1016/S0960-9822(95)00151-5; KARIN M, 1994, CURR OPIN CELL BIOL, V6, P415, DOI 10.1016/0955-0674(94)90035-3; KATO S, 1995, SCIENCE, V270, P1491, DOI 10.1126/science.270.5241.1491; Kato S, 1998, ONCOLOGY-BASEL, V55, P5, DOI 10.1159/000055253; LEE K, 1994, ENDOCRINOLOGY, V134, P441, DOI 10.1210/en.134.1.441; Liao JF, 1997, J BIOL CHEM, V272, P25951, DOI 10.1074/jbc.272.41.25951; LIPPMAN ME, 1989, RECENT PROG HORM RES, V45, P383; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; Marino M, 1998, BIOCHEM BIOPH RES CO, V245, P254, DOI 10.1006/bbrc.1998.8413; MCDONNELL SE, 1990, MOL CELL BIOL, V10, P4284, DOI 10.1128/MCB.10.8.4284; MEYER DJ, 1993, P NATL ACAD SCI USA, V90, P6721, DOI 10.1073/pnas.90.14.6721; Migliaccio A, 1996, EMBO J, V15, P1292, DOI 10.1002/j.1460-2075.1996.tb00471.x; Migliaccio A, 1998, EMBO J, V17, P2008, DOI 10.1093/emboj/17.7.2008; MULLER R, 1985, BIOCHIM BIOPHYS ACTA, V823, P207; PIETRZKOWSKI Z, 1992, CANCER RES, V52, P6447; Price MA, 1996, EMBO J, V15, P6552, DOI 10.1002/j.1460-2075.1996.tb01046.x; Razandi M, 1999, MOL ENDOCRINOL, V13, P307, DOI 10.1210/me.13.2.307; RIVERA VM, 1990, GENE DEV, V4, P255, DOI 10.1101/gad.4.2.255; Shaul PW, 1999, STEROIDS, V64, P28, DOI 10.1016/S0039-128X(98)00105-6; SHENG M, 1991, SCIENCE, V252, P1427, DOI 10.1126/science.1646483; Smith CL, 1998, BIOL REPROD, V58, P627, DOI 10.1095/biolreprod58.3.627; Soh JW, 1999, MOL CELL BIOL, V19, P1313; Treisman R, 1990, Semin Cancer Biol, V1, P47; TREISMAN R, 1995, EMBO J, V14, P4905, DOI 10.1002/j.1460-2075.1995.tb00173.x; TREISMAN R, 1986, CELL, V46, P567, DOI 10.1016/0092-8674(86)90882-2; TREISMAN R, 1994, CURR OPIN GENET DEV, V4, P96, DOI 10.1016/0959-437X(94)90097-3; VANDERBURG B, 1991, J STEROID BIOCHEM, V40, P215, DOI 10.1016/0960-0760(91)90185-8; VANDERBURG B, 1990, MOL ENDOCRINOL, V4, P1720, DOI 10.1210/mend-4-11-1720; VANDERBURG B, 1989, MOL CELL ENDOCRINOL, V64, P223, DOI 10.1016/0303-7207(89)90149-4; Wang Y, 1998, CELL GROWTH DIFFER, V9, P513; Watters JJ, 1997, ENDOCRINOLOGY, V138, P4030, DOI 10.1210/en.138.9.4030; WEBSTER N, 1988, CELL, V52, P169, DOI 10.1016/0092-8674(88)90505-3; Weigel NL, 1998, J MOL MED, V76, P469, DOI 10.1007/s001090050241; WEISZ A, 1993, CRIT REV ONCOGENESIS, V4, P361; WILDING G, 1988, CANCER RES, V48, P802	64	124	130	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 13	2001	276	15					11590	11598		10.1074/jbc.M005492200	http://dx.doi.org/10.1074/jbc.M005492200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	421UK	11145955	hybrid			2022-12-25	WOS:000168081800025
J	Park, KM; Chen, A; Bonventre, JV				Park, KM; Chen, A; Bonventre, JV			Prevention of kidney ischemia/reperfusion-induced functional injury and JNK, p38, and MAPK kinase activation by remote ischemic pretreatment	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACUTE-RENAL-FAILURE; INDUCED CELL-DEATH; PROTEIN-KINASE; HEAT-SHOCK; C-JUN; REPERFUSION INJURY; SIGNAL-TRANSDUCTION; PROXIMAL TUBULES; RAT-KIDNEY; STRESS	MAPK activities, including JNK, p38, and ERK, are markedly enhanced after ischemia in vivo and chemical anoxia in vitro. The relative extent of JNK, p38, or ERK activation has been proposed to determine cell fate after injury. A mouse model was established in which prior exposure to ischemia protected against a second ischemic insult imposed 8 or 15 days later, In contrast to what was observed after 30 min of bilateral ischemia, when a second period of ischemia of 30- or 35-min duration was imposed 8 days later, there was no subsequent increase in plasma creatinine, decrease in glomerular filtration rate, or increase in fractional excretion of sodium. A shorter period of prior ischemia (15 min) was partially protective against subsequent ischemic injury 8 days later. Unilateral ischemia was also protective against a subsequent ischemic insult to the same kidney, revealing that systemic uremia is not necessary for protection. The ischemia-related activation of JNK and p38 and outer medullary vascular congestion were markedly mitigated by prior exposure to ischemia, whereas preconditioning had no effect on post-ischemic activation of ERK1/2. The phosphorylation of MKK7, MKK4, and MKK3/6, upstream activators of JNK and p38, was markedly reduced by ischemic preconditioning, whereas the post-ischemic phosphorylation of MEK1/2, the upstream activator of ERK1/2, was unaffected by preconditioning. Pre- and post-ischemic HSP-25 levels were much higher in the preconditioned kidney. In summary, post-ischemic JNK and p38 (but not ERK1/2) activation was markedly reduced in a model of kidney ischemic preconditioning that was established in the mouse. The reduction in JNK and p38 activation can be accounted for by reduced activation of upstream MAPK kinases. The post-ischemic activation patterns of MAPKs may explain the remarkable protection against ischemic injury observed in this model.	Massachusetts Gen Hosp E, Med Serv, Charlestown, MA 02129 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02114 USA; Harvard MIT Div Hlth Sci & Technol, Boston, MA 02115 USA	Harvard University; Harvard Medical School; Harvard University	Bonventre, JV (corresponding author), Massachusetts Gen Hosp E, Med Serv, Suite 4002,149 13th St, Charlestown, MA 02129 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK038452, R37DK039773, R01DK039773] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS010828, P50NS010828] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK38452, DK39773] Funding Source: Medline; NINDS NIH HHS [NS10828] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Abbate M, 1999, AM J PHYSIOL-RENAL, V277, pF454, DOI 10.1152/ajprenal.1999.277.3.F454; Behrens A, 1999, NAT GENET, V21, P326, DOI 10.1038/6854; Bogoyevitch MA, 1996, CIRC RES, V79, P162, DOI 10.1161/01.RES.79.2.162; Brown D, 1997, AM J PHYSIOL-RENAL, V273, pF1003, DOI 10.1152/ajprenal.1997.273.6.F1003; Cochrane J, 1999, RENAL FAILURE, V21, P135, DOI 10.3109/08860229909066978; Conger J, 1997, Adv Ren Replace Ther, V4, P25; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; Di Mari JF, 1999, AM J PHYSIOL-RENAL, V277, pF195, DOI 10.1152/ajprenal.1999.277.2.F195; Ehrnsperger M, 1997, EMBO J, V16, P221, DOI 10.1093/emboj/16.2.221; FINN WF, 1984, J LAB CLIN MED, V103, P193; He HP, 1999, CELL DEATH DIFFER, V6, P987, DOI 10.1038/sj.cdd.4400572; Holtmann H, 1999, MOL CELL BIOL, V19, P6742; HONDA N, 1987, KIDNEY INT, V31, P1233, DOI 10.1038/ki.1987.136; Huot J, 1996, CANCER RES, V56, P273; Islam CF, 1997, BRIT J UROL, V79, P842, DOI 10.1046/j.1464-410X.1997.00209.x; Jefayri MK, 2000, BJU INT, V85, P1007, DOI 10.1046/j.1464-410x.2000.00678.x; Lee HT, 2000, AM J PHYSIOL-RENAL, V278, pF380, DOI 10.1152/ajprenal.2000.278.3.F380; Mehlen P, 1996, J BIOL CHEM, V271, P16510, DOI 10.1074/jbc.271.28.16510; Mehlen P, 1996, EMBO J, V15, P2695, DOI 10.1002/j.1460-2075.1996.tb00630.x; Meng XZ, 1999, ANN NY ACAD SCI, V874, P69, DOI 10.1111/j.1749-6632.1999.tb09226.x; MOLITORIS BA, 1992, AM J PHYSIOL, V263, pF488, DOI 10.1152/ajprenal.1992.263.3.F488; Nakano A, 2000, CIRC RES, V86, P144, DOI 10.1161/01.RES.86.2.144; POMBO CM, 1994, J BIOL CHEM, V269, P26545; Read MA, 1997, J BIOL CHEM, V272, P2753, DOI 10.1074/jbc.272.5.2753; Safirstein R, 1998, SEMIN NEPHROL, V18, P519; Saurin AT, 2000, FASEB J, V14, P2237, DOI 10.1096/fj.99-0671com; Schwarz ER, 1997, CURR OPIN CARDIOL, V12, P475, DOI 10.1097/00001573-199712050-00007; Smoyer WE, 2000, J AM SOC NEPHROL, V11, P211, DOI 10.1681/ASN.V112211; Srivastava S, 1999, J CLIN INVEST, V104, P503, DOI 10.1172/JCI7094; Swantek JL, 1997, MOL CELL BIOL, V17, P6274, DOI 10.1128/MCB.17.11.6274; Tournier C, 2000, SCIENCE, V288, P870, DOI 10.1126/science.288.5467.870; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Yamashita N, 1998, J MOL CELL CARDIOL, V30, P1181, DOI 10.1006/jmcc.1998.0682; ZAGER RA, 1985, AM J PHYSIOL, V249, pF148, DOI 10.1152/ajprenal.1985.249.1.F148; ZAGER RA, 1994, KIDNEY INT, V45, P1760, DOI 10.1038/ki.1994.229; ZAGER RA, 1995, KIDNEY INT, V47, P628, DOI 10.1038/ki.1995.80; ZAGER RA, 1995, LAB INVEST, V72, P592; ZAGER RA, 1984, KIDNEY INT, V26, P689, DOI 10.1038/ki.1984.204	38	258	269	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 13	2001	276	15					11870	11876		10.1074/jbc.M007518200	http://dx.doi.org/10.1074/jbc.M007518200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	421UK	11150293	hybrid			2022-12-25	WOS:000168081800060
J	Swain, JF; Gierasch, LM				Swain, JF; Gierasch, LM			Signal peptides bind and aggregate RNA - An alternative explanation for GTPase inhibition in the signal recognition particle	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							METHIONINE-RICH DOMAIN; ESCHERICHIA-COLI SRP; ENDOPLASMIC-RETICULUM; CRYSTAL-STRUCTURE; PROTEIN TRANSLOCATION; SEQUENCE RECOGNITION; SECONDARY STRUCTURE; TARGETING PATHWAYS; MEMBRANE-PROTEIN; INVIVO FUNCTION	N-terminal signal sequences can direct nascent protein chains to the inner membrane of prokaryotes and the endoplasmic reticulum of eukaryotes by interacting with the signal recognition particle. In this study, we show that isolated peptides corresponding to several bacterial signal sequences inhibit the GTPase activity of the Escherichia coli signal recognition particle, as previously reported (Miller, J. D., Bernstein, H. D., and Waiter, P. (1994) Nature 367, 657-659), but not by the direct mechanism proposed. Instead, isolated signal peptides bind nonspecifically to the RNA component and aggregate the entire signal recognition particle, leading to a loss of its intrinsic GTPase activity. Surprisingly, only "functional" peptide sequences aggregate RNA;the peptides in general use as "nonfunctional" negative controls (e.g. those with deletions or charged substitutions within the hydrophobic core), are sufficiently different in physical character that they do not aggregate RNA and thus have no effect on the GTPase activity of the signal recognition particle. We propose that the reported effect of functional signal peptides on the GTPase activity of the signal recognition particle is an artifact of the high peptide concentrations and low salt conditions used in these in vitro studies and that signal sequences at the N terminus of nascent chains in vivo do not exhibit this activity.	Univ Massachusetts, Dept Biochem & Mol Biol, Amherst, MA 01003 USA; Univ Massachusetts, Dept Chem, Amherst, MA 01003 USA	University of Massachusetts System; University of Massachusetts Amherst; University of Massachusetts System; University of Massachusetts Amherst	Gierasch, LM (corresponding author), Univ Massachusetts, Dept Biochem & Mol Biol, Amherst, MA 01003 USA.	gierasch@biochem.umass.edu	Gierasch, Lila M/D-1494-2009		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM019573, R01GM034962] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM34962, F32 GM19573] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bacher G, 1996, NATURE, V381, P248, DOI 10.1038/381248a0; BATENBURG AM, 1988, BIOCHEMISTRY-US, V27, P5678, DOI 10.1021/bi00415a043; Batey RT, 2000, SCIENCE, V287, P1232, DOI 10.1126/science.287.5456.1232; BERNSTEIN HD, 1989, NATURE, V340, P482, DOI 10.1038/340482a0; Bernstein HD, 1998, CURR BIOL, V8, pR715, DOI 10.1016/S0960-9822(98)70456-7; BIANCHI F, 1994, BIOCHEM BIOPH RES CO, V201, P1197, DOI 10.1006/bbrc.1994.1832; BRIGGS MS, 1985, SCIENCE, V228, P1096, DOI 10.1126/science.3158076; CARLSON JH, 1993, J BACTERIOL, V175, P3327, DOI 10.1128/jb.175.11.3327-3334.1993; Clemons WM, 1999, J MOL BIOL, V292, P697, DOI 10.1006/jmbi.1999.3090; deGier JWL, 1996, FEBS LETT, V399, P307, DOI 10.1016/S0014-5793(96)01354-3; Duong F, 1997, CELL, V91, P567, DOI 10.1016/S0092-8674(00)80444-4; EMR SD, 1983, P NATL ACAD SCI-BIOL, V80, P4599, DOI 10.1073/pnas.80.15.4599; FIDELIO GD, 1987, BIOCHEM J, V244, P295, DOI 10.1042/bj2440295; GIERASCH LM, 1989, BIOCHEMISTRY-US, V28, P923, DOI 10.1021/bi00429a001; HIGH S, 1991, J CELL BIOL, V113, P229, DOI 10.1083/jcb.113.2.229; HOYT DW, 1991, BIOCHEMISTRY-US, V30, P10155, DOI 10.1021/bi00106a012; HUD NV, 1994, BIOCHEMISTRY-US, V33, P7528, DOI 10.1021/bi00190a005; JONES JD, 1994, BIOPHYS J, V67, P1534, DOI 10.1016/S0006-3495(94)80627-7; Keenan RJ, 1998, CELL, V94, P181, DOI 10.1016/S0092-8674(00)81418-X; Koch HG, 1999, MOL BIOL CELL, V10, P2163, DOI 10.1091/mbc.10.7.2163; MACFARLANE J, 1995, EUR J BIOCHEM, V233, P766, DOI 10.1111/j.1432-1033.1995.766_3.x; MCKNIGHT CJ, 1989, J BIOL CHEM, V264, P17293; MILLER JD, 1994, NATURE, V367, P657, DOI 10.1038/367657a0; MILLER JD, 1993, NATURE, V366, P351, DOI 10.1038/366351a0; Rapiejko PJ, 1997, CELL, V89, P703, DOI 10.1016/S0092-8674(00)80253-6; ROMISCH K, 1989, NATURE, V340, P478, DOI 10.1038/340478a0; ROMISCH K, 1990, J CELL BIOL, V111, P1793, DOI 10.1083/jcb.111.5.1793; Saenger W., 1984, PRINCIPLES NUCL ACID, P399; SHINNAR AE, 1984, J AM CHEM SOC, V106, P5006, DOI 10.1021/ja00329a063; SUAU P, 1977, J MOL BIOL, V117, P909, DOI 10.1016/S0022-2836(77)80005-3; Ulbrandt ND, 1997, CELL, V88, P187, DOI 10.1016/S0092-8674(00)81839-5; Valent QA, 1998, EMBO J, V17, P2504, DOI 10.1093/emboj/17.9.2504; WALTER P, 1994, ANNU REV CELL BIOL, V10, P87, DOI 10.1146/annurev.cb.10.110194.000511; WANG ZL, 1993, BIOCHEMISTRY-US, V32, P13991, DOI 10.1021/bi00213a032; WARRANT RW, 1978, NATURE, V271, P130, DOI 10.1038/271130a0; Zheng N, 1997, MOL CELL, V1, P79, DOI 10.1016/S1097-2765(00)80009-X; Zheng T, 1999, J BIOL CHEM, V274, P36623, DOI 10.1074/jbc.274.51.36623; ZOPF D, 1990, EMBO J, V9, P4511, DOI 10.1002/j.1460-2075.1990.tb07902.x; [No title captured]	39	7	8	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 13	2001	276	15					12222	12227		10.1074/jbc.M011128200	http://dx.doi.org/10.1074/jbc.M011128200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	421UK	11148214	hybrid			2022-12-25	WOS:000168081800105
J	Zhang, YN; Wang, PG; Brew, K				Zhang, YN; Wang, PG; Brew, K			Specificity and mechanism of metal ion activation in UDP-galactose :beta-Galactoside-alpha-1,3-galactosyltransferase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN SECONDARY STRUCTURE; ALPHA-GALACTOSYL EPITOPES; PURPLE ACID-PHOSPHATASE; STRUCTURE PREDICTION; HUMAN ALPHA-1,3-FUCOSYL-TRANSFERASE-V; CHEMOENZYMATIC SYNTHESIS; HOMOLOGOUS SEQUENCES; CIRCULAR-DICHROISM; EXPRESSION CLONING; RECOMBINANT ENZYME	UDP-galactose:beta -galactosyl-alpha1,3-galactosyltransferase (alpha 3GT) catalyzes the synthesis of galactosyl-alpha -1,3-beta -galactosyl structures in mammalian glycoconjugates. In humans the gene for a3GT is inactivated, and its product, the alpha -Gal epitope, is the target of a large fraction of natural antibodies. alpha 3GT is a member of a family of metal-dependent-retaining glycosyltransferases that includes the histo blood group A and B enzymes. Mn2+ activates the catalytic domain of alpha 3GT (alpha 3GTcd), but the affinity reported for this ion is very low relative to physiological levels. Enzyme activity over a wide range of metal ion concentrations indicates a dependence on Mn2+ binding to two sites. At physiological metal ion concentrations, Zn2+ gives higher levels of activity and may be the natural cofactor. To determine the role of the cation, metal activation was perturbed by substituting Co2+ and Zn2+ for Mn2+ and by mutagenesis of a conserved (DVD151)-V-149 sequence motif that is considered to act in cation binding in many glycosyltransferases. The aspartates of this motif were found to be essential for activity, and the kinetic properties of a Val(150) to Ala mutant with reduced activity were determined. The results indicate that the cofactor is involved in binding UDP-galactose and has a crucial influence on catalytic efficiency for galactose transfer and for the low endogenous UDP-galactose hydrolase activity. It may therefore interact with one or more phosphates of UDP-galactose in the Michaelis complex and in the transition state for cleavage of the UDP to galactose bond. The DXD motif conserved in many glycosyltransferases appears to have a key role in metal-mediated donor substrate binding and phosphate-sugar bond cleavage.	Univ Miami, Sch Med, Dept Biochem & Mol Biol, Miami, FL 33101 USA; Wayne State Univ, Dept Chem, Detroit, MI 48202 USA	University of Miami; Wayne State University	Brew, K (corresponding author), Florida Atlantic Univ, Dept Biomed Sci, 777 Glades Rd, Boca Raton, FL 33431 USA.		Brew, Keith/A-6746-2009; Brew, Keith/W-1643-2019	Brew, Keith/0000-0003-1306-1032; 	NIGMS NIH HHS [GM 58773] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM058773] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDRADE MA, 1993, PROTEIN ENG, V6, P383, DOI 10.1093/protein/6.4.383; BEESE LS, 1991, EMBO J, V10, P25, DOI 10.1002/j.1460-2075.1991.tb07917.x; BLANKEN WM, 1985, J BIOL CHEM, V260, P2927; Breton C, 1998, J BIOCHEM, V123, P1000; BURGNER JW, 1984, BIOCHEMISTRY-US, V23, P3636, DOI 10.1021/bi00311a010; Busch C, 1998, J BIOL CHEM, V273, P19566, DOI 10.1074/jbc.273.31.19566; CASEY CE, 1985, AM J CLIN NUTR, V41, P1193, DOI 10.1093/ajcn/41.6.1193; COLLINS BH, 1995, J IMMUNOL, V154, P5500; Cornish-Bowden A., 1995, FUNDAMENTALS ENZYME, P129; DiFrancesco V, 1996, PROTEIN SCI, V5, P106; Fang JW, 1998, J AM CHEM SOC, V120, P6635, DOI 10.1021/ja9808898; Frishman D, 1996, PROTEIN ENG, V9, P133, DOI 10.1093/protein/9.2.133; Frishman D, 1997, PROTEINS, V27, P329, DOI 10.1002/(SICI)1097-0134(199703)27:3<329::AID-PROT1>3.0.CO;2-8; GALILI U, 1988, J BIOL CHEM, V263, P17755; GALILI U, 1991, P NATL ACAD SCI USA, V88, P7401, DOI 10.1073/pnas.88.16.7401; GALILI U, 1993, SPRINGER SEMIN IMMUN, V15, P155; Gastinel LN, 1999, EMBO J, V18, P3546, DOI 10.1093/emboj/18.13.3546; Hagen FK, 1999, J BIOL CHEM, V274, P6797, DOI 10.1074/jbc.274.10.6797; Haslam DB, 1996, P NATL ACAD SCI USA, V93, P10697, DOI 10.1073/pnas.93.20.10697; Hayashi T, 1997, BIOORGAN MED CHEM, V5, P497, DOI 10.1016/S0968-0896(96)00263-5; HENION TR, 1994, GLYCOBIOLOGY, V4, P193, DOI 10.1093/glycob/4.2.193; Huang W, 1997, J BIOL CHEM, V272, P22086, DOI 10.1074/jbc.272.35.22086; Imberty A, 1999, GLYCOBIOLOGY, V9, P713, DOI 10.1093/glycob/9.7.713; JOZIASSE DH, 1990, EUR J BIOCHEM, V191, P75, DOI 10.1111/j.1432-1033.1990.tb19095.x; JOZIASSE DH, 1989, J BIOL CHEM, V264, P14290; KHATRA BS, 1974, EUR J BIOCHEM, V44, P537, DOI 10.1111/j.1432-1033.1974.tb03513.x; KIM EE, 1991, J MOL BIOL, V218, P449, DOI 10.1016/0022-2836(91)90724-K; KIM SC, 1988, ARCH BIOCHEM BIOPHYS, V267, P54, DOI 10.1016/0003-9861(88)90007-0; LARSEN RD, 1989, P NATL ACAD SCI USA, V86, P8227, DOI 10.1073/pnas.86.21.8227; Murray BW, 1997, BIOCHEMISTRY-US, V36, P823, DOI 10.1021/bi962284z; Murray BW, 1996, BIOCHEMISTRY-US, V35, P11183, DOI 10.1021/bi961065a; PAULSON JC, 1989, J BIOL CHEM, V264, P17615; POWELL JT, 1976, J BIOL CHEM, V251, P3645; ROST B, 1993, J MOL BIOL, V232, P584, DOI 10.1006/jmbi.1993.1413; SARKAR G, 1990, BIOTECHNIQUES, V8, P404; STRAHAN KM, 1995, IMMUNOGENETICS, V41, P101, DOI 10.1007/BF00182319; STRATER N, 1995, SCIENCE, V268, P1489, DOI 10.1126/science.7770774; SUERBAUM H, 1993, EUR J BIOCHEM, V214, P313, DOI 10.1111/j.1432-1033.1993.tb17926.x; VANDENEIJNDEN DH, 1983, EUR J BIOCHEM, V134, P523; VINCENT JB, 1992, BIOCHEMISTRY-US, V31, P3033, DOI 10.1021/bi00127a001; VUILLEUMIER S, 1993, BIOCHEMISTRY-US, V32, P10303, DOI 10.1021/bi00090a005; Walker KW, 1998, PROTEIN SCI, V7, P2684, DOI 10.1002/pro.5560071224; Watson KA, 1999, EMBO J, V18, P4619, DOI 10.1093/emboj/18.17.4619; Wiggins CAR, 1998, P NATL ACAD SCI USA, V95, P7945, DOI 10.1073/pnas.95.14.7945; WITSELL DL, 1990, J BIOL CHEM, V265, P15731; YAMAMOTO F, 1990, NATURE, V345, P229, DOI 10.1038/345229a0; Zhang J, 1996, BIOCHEMISTRY-US, V35, P6276, DOI 10.1021/bi952954l; Zhang YN, 1999, GLYCOBIOLOGY, V9, P815, DOI 10.1093/glycob/9.8.815	48	48	57	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 13	2001	276	15					11567	11574		10.1074/jbc.M006530200	http://dx.doi.org/10.1074/jbc.M006530200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	421UK	11133981	hybrid			2022-12-25	WOS:000168081800022
J	Emoto, M; Langille, SE; Czech, MP				Emoto, M; Langille, SE; Czech, MP			A role for kinesin in insulin-stimulated GLUT4 glucose transporter translocation in 3T3-L1 adipocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHATIDYLINOSITOL 3-KINASE; DEPENDENT TRAFFICKING; VESICLE TRAFFICKING; ORGANELLE MOVEMENT; RAT ADIPOCYTES; TAU-PROTEIN; ACTIN; MOTILITY; OVEREXPRESSION; MICROTUBULES	Insulin regulates glucose uptake in adipocytes and muscle by stimulating the movement of sequestered glucose transporter 4 (GLUT4) proteins from intracellular membranes to the cell surface. Here we report that optimal insulin-mediated GLUT4 translocation is dependent upon both microtubule and actin-based cytoskeletal structures in cultured adipocytes, Depolymerization of microtubules and F-actin in 3T3-L1 adipocytes causes the dispersion of perinuclear GLUT4-containing membranes and abolishes insulin action on GLUT4 movements to the plasma membrane. Furthermore, heterologous expression in 3T3-L1 adipocytes of the microtubule-binding protein hTau40, which impairs kinesin motors that move toward the plus ends of microtubules, markedly delayed the appearance of GLUT4 at the plasma membrane in response to insulin, The hTau40 protein had no detectable effect on microtubule structure or perinuclear GLUT4 localization under these conditions. These results are consistent with the hypothesis that both the actin and microtubule-based cytoskeleton, as well as a kinesin motor, direct the translocation of GLUT4 to the plasma membrane in response to insulin.	Univ Massachusetts, Sch Med, Program Mol Med, Worcester, MA 01605 USA; Univ Massachusetts, Sch Med, Dept Mol Pharmacol & Biochem, Worcester, MA 01605 USA	University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester	Czech, MP (corresponding author), Univ Massachusetts, Sch Med, Program Mol Med, 373 Plantat St, Worcester, MA 01605 USA.	Michael.Czech@umassmed.edu			NIDDK NIH HHS [DK30898] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK030898, R37DK030898] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bi GQ, 1997, J CELL BIOL, V138, P999, DOI 10.1083/jcb.138.5.999; Burkhardt JK, 1997, J CELL BIOL, V139, P469, DOI 10.1083/jcb.139.2.469; Burkhardt JK, 1998, BBA-MOL CELL RES, V1404, P113, DOI 10.1016/S0167-4889(98)00052-4; CHEATHAM B, 1994, MOL CELL BIOL, V14, P4902, DOI 10.1128/MCB.14.7.4902; CUSHMAN SW, 1980, J BIOL CHEM, V255, P4758; CZECH MP, 1993, J BIOL CHEM, V268, P9187; Ebneth A, 1998, J CELL BIOL, V143, P777, DOI 10.1083/jcb.143.3.777; Fletcher LM, 2000, BIOCHEM J, V352, P267, DOI 10.1042/0264-6021:3520267; Guilherme A, 2000, J BIOL CHEM, V275, P38151, DOI 10.1074/jbc.M003432200; Harada A, 1998, J CELL BIOL, V141, P51, DOI 10.1083/jcb.141.1.51; HARING HU, 1979, FEBS LETT, V105, P329, DOI 10.1016/0014-5793(79)80641-9; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Hirokawa N, 1998, SCIENCE, V279, P519, DOI 10.1126/science.279.5350.519; Illenberger S, 1998, MOL BIOL CELL, V9, P1495, DOI 10.1091/mbc.9.6.1495; JHUN BH, 1992, J BIOL CHEM, V267, P17710; Khayat ZA, 2000, J CELL SCI, V113, P279; KUZNETSOV SA, 1992, NATURE, V356, P722, DOI 10.1038/356722a0; Martin LB, 1998, J BIOL CHEM, V273, P1444, DOI 10.1074/jbc.273.3.1444; Nielsen E, 1999, NAT CELL BIOL, V1, P376, DOI 10.1038/14075; OKADA T, 1994, J BIOL CHEM, V269, P3568; Omata W, 2000, BIOCHEM J, V346, P321, DOI 10.1042/0264-6021:3460321; Pessin JE, 1999, J BIOL CHEM, V274, P2593, DOI 10.1074/jbc.274.5.2593; Reilein AR, 1998, J CELL BIOL, V142, P803, DOI 10.1083/jcb.142.3.803; Rodionov VI, 1998, CURR BIOL, V8, P165, DOI 10.1016/S0960-9822(98)70064-8; Rogers SL, 1997, P NATL ACAD SCI USA, V94, P3720, DOI 10.1073/pnas.94.8.3720; Rogers SL, 1998, CURR BIOL, V8, P161, DOI 10.1016/S0960-9822(98)70063-6; SCHLIWA M, 1981, P NATL ACAD SCI-BIOL, V78, P1037, DOI 10.1073/pnas.78.2.1037; Sharma PM, 1998, J BIOL CHEM, V273, P18528, DOI 10.1074/jbc.273.29.18528; Tanaka Y, 1998, CELL, V93, P1147, DOI 10.1016/S0092-8674(00)81459-2; Trinczek B, 1999, J CELL SCI, V112, P2355; Wu XF, 2000, CURR OPIN CELL BIOL, V12, P42, DOI 10.1016/S0955-0674(99)00055-1; YANG J, 1993, J BIOL CHEM, V268, P4600	32	85	91	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 6	2001	276	14					10677	10682		10.1074/jbc.M010785200	http://dx.doi.org/10.1074/jbc.M010785200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	420AC	11145966	hybrid			2022-12-25	WOS:000167980900017
J	Akiyoshi, Y; Clayton, J; Phan, L; Yamamoto, M; Hinnebusch, AG; Watanabe, Y; Asano, K				Akiyoshi, Y; Clayton, J; Phan, L; Yamamoto, M; Hinnebusch, AG; Watanabe, Y; Asano, K			Fission yeast homolog of murine int-6 protein, encoded by mouse mammary tumor virus integration site, is associated with the conserved core subunits of eukaryotic translation initiation factor 3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WD-REPEAT PROTEIN; SACCHAROMYCES-CEREVISIAE; SCHIZOSACCHAROMYCES-POMBE; FACTOR EIF-3; RNA-BINDING; CELL-PROLIFERATION; COMPLEX-FORMATION; NUCLEAR-BODIES; WHEAT-GERM; GENE	The murine int-6 locus, identified as a frequent integration site of mouse mammary tumor viruses, encodes the 48-kDa eIF3e subunit of translation initiation factor eIF3, Previous studies indicated that the catalytically active core of budding yeast eIF3 consists of five subunits, all conserved in eukaryotes, but does not contain a protein closely related to eIF3e/Int-6, Whereas the budding yeast genome does not encode a protein closely related to murine Int-6, fission yeast does encode an Int-6 ortholog, designated here Int6, We found that fission yeast Int6/eIF3e is a cytoplasmic protein associated with 40 S ribosomes, FLAG epitope-tagged Tif35,a putative core eIF3g subunit, copurified with Int6 and all five orthologs of core eIF3 subunits, An int6 deletion (int6 Delta) mutant was viable but grew slowly in minimal medium. This slow growth phenotype was accompanied by a reduction in the amount of polyribosomes engaged in translation and was complemented by expression of human Int-6 protein. These findings support the idea that human and Schizosaccharomyces pombe Int-6 homologs are involved in translation. Interestingly, haploid int6 Delta cells showed unequal nuclear partitioning, possibly because of a defect in tubulin function, and diploid int6 Delta cells formed abnormal spores. We propose that Int6 is not an essential subunit of eIF3 but might be involved in regulating the activity of eIF3 for translation of specific mRNAs in S. pombe.	Univ Tokyo, Grad Sch Sci, Dept Biophys & Biochem, Tokyo 1130033, Japan; NICHD, Lab Eukaryot Gene Regulat, NIH, Bethesda, MD 20892 USA; Japan Sci & Technol Corp, PRESTO, Kawaguchi, Saitama 3320012, Japan	University of Tokyo; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); Japan Science & Technology Agency (JST)	Watanabe, Y (corresponding author), Univ Tokyo, Grad Sch Sci, Dept Biophys & Biochem, Tokyo 1130033, Japan.			Watanabe, Yoshinori/0000-0002-5488-4812	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [ZIAHD001004] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD001004] Funding Source: NIH RePORTER	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Asano K, 2000, GENE DEV, V14, P2534, DOI 10.1101/gad.831800; Asano K, 1998, J BIOL CHEM, V273, P18573, DOI 10.1074/jbc.273.29.18573; Asano K, 1999, EMBO J, V18, P1673, DOI 10.1093/emboj/18.6.1673; Asano K, 1997, J BIOL CHEM, V272, P23477, DOI 10.1074/jbc.272.38.23477; Asano K, 1997, J BIOL CHEM, V272, P27042, DOI 10.1074/jbc.272.43.27042; Bahler J, 1998, YEAST, V14, P943, DOI 10.1002/(SICI)1097-0061(199807)14:10<943::AID-YEA292>3.0.CO;2-Y; Bandyopadhyay A, 2000, MOL BIOL CELL, V11, P4005, DOI 10.1091/mbc.11.11.4005; BENNE R, 1978, J BIOL CHEM, V253, P3078; Block KL, 1998, J BIOL CHEM, V273, P31901, DOI 10.1074/jbc.273.48.31901; Burks EA, 2001, J BIOL CHEM, V276, P2122, DOI 10.1074/jbc.M007236200; BUSCHMAN JL, 1993, MOL CELL BIOL, V13, P4618; Callahan R, 2000, ONCOGENE, V19, P992, DOI 10.1038/sj.onc.1203276; CHECKLEY JW, 1981, J BIOL CHEM, V256, P1582; Chen CR, 1999, P NATL ACAD SCI USA, V96, P517, DOI 10.1073/pnas.96.2.517; CIGAN AM, 1991, MOL CELL BIOL, V11, P3217, DOI 10.1128/MCB.11.6.3217; Crane R, 2000, MOL BIOL CELL, V11, P3993, DOI 10.1091/mbc.11.11.3993; Craven RA, 1998, GENE, V221, P59, DOI 10.1016/S0378-1119(98)00434-X; DANAIE P, 1995, J BIOL CHEM, V270, P4288, DOI 10.1074/jbc.270.9.4288; Desbois C, 1996, SCIENCE, V273, P951, DOI 10.1126/science.273.5277.951; Duesberg P, 1998, P NATL ACAD SCI USA, V95, P13692, DOI 10.1073/pnas.95.23.13692; Greenberg JR, 1998, J BIOL CHEM, V273, P23485, DOI 10.1074/jbc.273.36.23485; Guo JJ, 2000, J VIROL, V74, P1892, DOI 10.1128/JVI.74.4.1892-1899.2000; Hanachi P, 1999, J BIOL CHEM, V274, P8546, DOI 10.1074/jbc.274.13.8546; HANICJOYCE PJ, 1987, J BIOL CHEM, V262, P2845; HANNIG EM, 1993, MOL CELL BIOL, V13, P506, DOI 10.1128/MCB.13.1.506; Humphrey T, 1998, GENETICS, V148, P1731; Kondoh H, 2000, GENES CELLS, V5, P525, DOI 10.1046/j.1365-2443.2000.00344.x; Kovarik P, 1998, CURR GENET, V33, P100, DOI 10.1007/s002940050314; LAUER SJ, 1985, BIOCHEMISTRY-US, V24, P2924, DOI 10.1021/bi00333a016; Li Y, 2000, ONCOGENE, V19, P1002, DOI 10.1038/sj.onc.1203273; MARCHETTI A, 1995, J VIROL, V69, P1932, DOI 10.1128/JVI.69.3.1932-1938.1995; MAUNDRELL K, 1993, GENE, V123, P127, DOI 10.1016/0378-1119(93)90551-D; Morris-Desbois C, 1999, J CELL SCI, V112, P3331; NARANDA T, 1994, J BIOL CHEM, V269, P32286; Naranda T, 1997, MOL CELL BIOL, V17, P145, DOI 10.1128/MCB.17.1.145; Phan L, 1998, MOL CELL BIOL, V18, P4935, DOI 10.1128/MCB.18.8.4935; Radcliffe PA, 1999, MOL BIOL CELL, V10, P2987, DOI 10.1091/mbc.10.9.2987; Shinozaki-Yabana S, 2000, MOL CELL BIOL, V20, P1234, DOI 10.1128/MCB.20.4.1234-1242.2000; TRACHSEL H, 1979, BIOCHIM BIOPHYS ACTA, V565, P305, DOI 10.1016/0005-2787(79)90207-7; Verlhac MH, 1997, EMBO J, V16, P6812, DOI 10.1093/emboj/16.22.6812; Yahalom A, 2001, J BIOL CHEM, V276, P334, DOI 10.1074/jbc.M006721200; YOON HJ, 1992, MOL CELL BIOL, V12, P248, DOI 10.1128/MCB.12.1.248; Zhong S, 2000, NAT CELL BIOL, V2, pE85, DOI 10.1038/35010583	43	47	54	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 30	2001	276	13					10056	10062		10.1074/jbc.M010188200	http://dx.doi.org/10.1074/jbc.M010188200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	420GC	11134033	hybrid			2022-12-25	WOS:000167996400065
J	Gao, Y; Wells, L; Comer, FI; Parker, GJ; Hart, GW				Gao, Y; Wells, L; Comer, FI; Parker, GJ; Hart, GW			Dynamic O-glycosylation of nuclear and cytosolic proteins - Cloning and characterization of a neutral, cytosolic beta-N-acetylglucosaminidase from human brain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLCNAC TRANSFERASE; INSULIN-RESISTANCE; D-GLUCOSAMINIDASE; SKELETAL-MUSCLE; RAT-BRAIN; LOCALIZATION; PHOSPHORYLATION; PURIFICATION; ACETYLHEXOSAMINIDASES; AMIDOTRANSFERASE	Dynamic modification of cytoplasmic and nuclear proteins by O-linked N-acetylglucosamine (O-GlcNAc) on Ser/Thr residues is ubiquitous in higher eukaryotes and is analogous to protein phosphorylation, The enzyme for the addition of this modification, O-GlcNAc transferase, has been cloned from several species. Here, we have cloned a human brain O-GlcNAcase that cleaves O-GlcNAc off proteins. The cloned cDNA encodes a polypeptide of 916 amino acids with a predicted molecular mass of 103 kDa and a pi value of 4.63, but the protein migrates as a 130-kDa band on SDS-polyacrylamide gel electrophoresis. The cloned O-GlcNAcase has a pH optimum of 5.5-7.0 and is inhibited by GlcNAc but not by GalNAc, p-Nitrophenyl (pNP)-beta -GlcNAc, but not pNP-beta -GalNAc or pNP-alpha -GlcNAc, is a substrate. The cloned enzyme cleaves GlcNAc, but not GalNAc, from glycopeptides. Cell fractionation suggests that the overexpressed protein is mostly localized in the cytoplasm, It therefore has all the expected characteristics of O-GlcNAcase and is distinct from lysosomal hexosaminidases, Northern blots show that the transcript is expressed in every human tissue examined but is the highest in the brain, placenta, and pancreas. An understanding of O-GlcNAc dynamics and O-GlcNAcase may be key to elucidating the relationships between O-phosphate and O-GlcNAc and to the understanding of the molecular mechanisms of diseases such as diabetes, cancer, and neurodegeneration.	Johns Hopkins Univ, Sch Med, Dept Biol Chem, Baltimore, MD 21205 USA; Univ Utah, Dept Internal Med, Div Endocrinol Diabet & Metab, Salt Lake City, UT 84132 USA	Johns Hopkins University; Utah System of Higher Education; University of Utah	Hart, GW (corresponding author), Johns Hopkins Univ, Sch Med, Dept Biol Chem, 725 N Wolfe St, Baltimore, MD 21205 USA.	gwhart@jhmi.edu	Wells, Lance/H-3118-2013	Wells, Lance/0000-0003-4956-5363; Hart, Gerald/0000-0001-7812-4351	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD013563, R37HD013563] Funding Source: NIH RePORTER; NICHD NIH HHS [HD13563] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Akimoto Y, 1999, DIABETES, V48, P2407, DOI 10.2337/diabetes.48.12.2407; Arnold CS, 1996, J BIOL CHEM, V271, P28741, DOI 10.1074/jbc.271.46.28741; Baron AD, 1995, J CLIN INVEST, V96, P2792, DOI 10.1172/JCI118349; Cheng XG, 2000, BIOCHEMISTRY-US, V39, P11609, DOI 10.1021/bi000755i; CHOU TY, 1995, J BIOL CHEM, V270, P18961, DOI 10.1074/jbc.270.32.18961; Cole RN, 1999, J NEUROCHEM, V73, P418, DOI 10.1046/j.1471-4159.1999.0730418.x; Comer FI, 2000, J BIOL CHEM, V275, P29179, DOI 10.1074/jbc.R000010200; Cooksey RC, 1999, ENDOCRINOLOGY, V140, P1151, DOI 10.1210/en.140.3.1151; DONG DLY, 1993, J BIOL CHEM, V268, P16679; DONG DLY, 1994, J BIOL CHEM, V269, P19321; Du XL, 2000, P NATL ACAD SCI USA, V97, P12222, DOI 10.1073/pnas.97.22.12222; Ducret A, 1998, PROTEIN SCI, V7, P706, DOI 10.1002/pro.5560070320; EMILIANI C, 1990, BIOCHIM BIOPHYS ACTA, V1037, P265, DOI 10.1016/0167-4838(90)90024-A; Gharahdaghi F, 1999, ELECTROPHORESIS, V20, P601, DOI 10.1002/(SICI)1522-2683(19990301)20:3<601::AID-ELPS601>3.0.CO;2-6; Griffith LS, 1999, EUR J BIOCHEM, V262, P824, DOI 10.1046/j.1432-1327.1999.00439.x; GRIFFITH LS, 1995, J NEUROSCI RES, V41, P270, DOI 10.1002/jnr.490410214; HALTIWANGER RS, 1992, J BIOL CHEM, V267, P9005; Han I, 1997, MOL CELL BIOL, V17, P2550, DOI 10.1128/MCB.17.5.2550; Hanover JA, 1999, ARCH BIOCHEM BIOPHYS, V362, P38, DOI 10.1006/abbi.1998.1016; Hart GW, 1997, ANNU REV BIOCHEM, V66, P315, DOI 10.1146/annurev.biochem.66.1.315; Hebert LF, 1996, J CLIN INVEST, V98, P930, DOI 10.1172/JCI118876; Heckel D, 1998, HUM MOL GENET, V7, P1859, DOI 10.1093/hmg/7.12.1859; IZUMI T, 1980, BIOCHIM BIOPHYS ACTA, V615, P402, DOI 10.1016/0005-2744(80)90507-0; IZUMI T, 1983, J BIOL CHEM, V258, P6991; JACKSON SP, 1988, CELL, V55, P125, DOI 10.1016/0092-8674(88)90015-3; Jiang MS, 1997, J BIOL CHEM, V272, P2421; KELLY WG, 1989, CELL, V57, P243, DOI 10.1016/0092-8674(89)90962-8; KELLY WG, 1993, J BIOL CHEM, V268, P10416; Kreppel LK, 1997, J BIOL CHEM, V272, P9308; KUSTERMANNKUHN B, 1983, HUM GENET, V65, P172, DOI 10.1007/BF00286657; Lefebvre T, 1999, BBA-GEN SUBJECTS, V1472, P71, DOI 10.1016/S0304-4165(99)00105-1; Lubas WA, 1997, J BIOL CHEM, V272, P9316; McClain DA, 1996, DIABETES, V45, P1003, DOI 10.2337/diabetes.45.8.1003; NEUFELD EF, 1989, J BIOL CHEM, V264, P10927; OVERDIJK B, 1981, BIOCHIM BIOPHYS ACTA, V659, P255, DOI 10.1016/0005-2744(81)90052-8; OVERDIJK B, 1975, BIOCHEM J, V151, P257, DOI 10.1042/bj1510257; POENARU L, 1973, BIOMED EXPRESS, V19, P538; REASON AJ, 1992, J BIOL CHEM, V267, P16911; ROQUEMORE EP, 1994, METHOD ENZYMOL, V230, P443; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Shafi R, 2000, P NATL ACAD SCI USA, V97, P5735, DOI 10.1073/pnas.100471497; Snow DM, 1998, INT REV CYTOL, V181, P43, DOI 10.1016/S0074-7696(08)60416-7; TORRES CR, 1984, J BIOL CHEM, V259, P3308; Yao PJ, 1998, J NEUROSCI, V18, P2399; Yki-Jarvinen H, 1998, METABOLISM, V47, P449, DOI 10.1016/S0026-0495(98)90058-0	45	496	526	1	29	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 30	2001	276	13					9838	9845		10.1074/jbc.M010420200	http://dx.doi.org/10.1074/jbc.M010420200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	420GC	11148210	hybrid			2022-12-25	WOS:000167996400036
J	Yu, LC; Twu, YC; Chang, CY; Lin, M				Yu, LC; Twu, YC; Chang, CY; Lin, M			Molecular basis of the Kell-null phenotype - A mutation at the splice site of human Kel gene abolishes the expression of Kell blood group antigens	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROUP PROTEIN; GROUP SYSTEM; DISEASE; XK; IDENTIFICATION; ANTIBODIES; DEFICIENCY; COLLAGEN; VARIANT	The Kell blood group system is polymorphic, and 23 antigens have been defined to date. The Kell antigens are located on a single red cell transmembrane glyco-protein, encoded by the 19 exons of the KEL gene. The different Kell phenotypes result from point mutations leading to amino acid changes in the Kell glycoprotein. An unusual phenotype, which is defined as the complete lack of all of the Kell antigens, has been identified and designated as the Kell-null or Ko phenotype, The coding region of the KEL gene of the Ko individual showed a normal KEL2/KEL4/KEL7 gene sequence; nevertheless, a G to C mutation at the splice donor site (5' splice site) of intron 3 was found to be present as a homozygote in the individual. The mutation destroys the conserved GT sequence of the splice donor site. Reverse transcription-polymerase chain reaction analysis showed the absence of the complete KEL mRNA. Instead, a major transcript with the exon 3 region skipped was found. The exon 3 of the KEL gene encodes the transmembrane domain of the Kell glycoprotein, and a transcript without exon 3 is predicted to have a premature stop codon that abolishes the translation of C-terminal segment. The segment contains all of the known positions responsible for characterizing different Kell antigens, and this explains the lack of all Kell antigens in Ko red cells.	Mackay Mem Hosp, Transfus Med Lab, Dept Med Res, Tamsui 251, Taipei, Taiwan; Mackay Mem Hosp, Immunohematol Reference Lab, Tamsui 251, Taipei, Taiwan	Mackay Memorial Hospital; Mackay Memorial Hospital	Lin, M (corresponding author), Mackay Mem Hosp, Transfus Med Lab, Dept Med Res, 45 Ming San Rd, Tamsui 251, Taipei, Taiwan.	marilin@ms2.mmh.org.tw						CHOWN B, 1957, NATURE, V180, P711, DOI 10.1038/180711a0; Condino-Neto A, 2000, BLOOD, V95, P3548, DOI 10.1182/blood.V95.11.3548.011k36_3548_3554; COOMBS RRA, 1946, LANCET, V250, P264; DANIELS G, 1995, HUMAN BLOOD GROUPS; Harteveld CL, 2000, BRIT J HAEMATOL, V110, P694, DOI 10.1046/j.1365-2141.2000.02225.x; ISSITT PD, 1998, APPL BLOOD GROUP SER, P609; JABER A, 1991, BRIT J HAEMATOL, V79, P311, DOI 10.1111/j.1365-2141.1991.tb04539.x; KRAWCZAK M, 1992, HUM GENET, V90, P41; LEE S, 1995, BLOOD, V85, P1364, DOI 10.1182/blood.V85.5.1364.bloodjournal8551364; Lee S, 2000, SEMIN HEMATOL, V37, P113, DOI 10.1016/S0037-1963(00)90036-2; Lee S, 1999, BLOOD, V94, P1440, DOI 10.1182/blood.V94.4.1440.416k01_1440_1450; Lee S, 1997, TRANSFUSION, V37, P1117, DOI 10.1046/j.1537-2995.1997.37111298088039.x; Lee S, 1997, VOX SANG, V73, P1, DOI 10.1046/j.1423-0410.1997.7310001.x; LEE S, 1991, P NATL ACAD SCI USA, V88, P6353, DOI 10.1073/pnas.88.14.6353; LEE S, 1995, TRANSFUSION, V35, P822, DOI 10.1046/j.1537-2995.1995.351096026362.x; Lee S, 1996, TRANSFUSION, V36, P490, DOI 10.1046/j.1537-2995.1996.36696269505.x; Lee S, 2000, TRANSFUS MED REV, V14, P93, DOI 10.1016/S0887-7963(00)80001-2; LEE SH, 1995, BLOOD, V85, P912, DOI 10.1182/blood.V85.4.912.bloodjournal854912; LEVINE P, 1949, SCIENCE, V109, P464, DOI 10.1126/science.109.2836.464; McVey JH, 1998, BLOOD, V92, P920, DOI 10.1182/blood.V92.3.920.415a18_920_926; NAKAI K, 1994, GENE, V141, P171, DOI 10.1016/0378-1119(94)90567-3; Ohno K, 1999, AM J HUM GENET, V65, P635, DOI 10.1086/302551; Okubo M, 2000, AM J MED GENET, V93, P211, DOI 10.1002/1096-8628(20000731)93:3<211::AID-AJMG10>3.0.CO;2-Z; REDMAN CM, 1986, J BIOL CHEM, V261, P9521; REDMAN CM, 1988, BRIT J HAEMATOL, V68, P131, DOI 10.1111/j.1365-2141.1988.tb04191.x; Redman Colvin M., 1995, V6, P227; REID ME, 1997, BLOOD GROUP ANTIGEN, P175; ROBBERSON BL, 1990, MOL CELL BIOL, V10, P84, DOI 10.1128/MCB.10.1.84; Russo D, 2000, BLOOD, V96, P340, DOI 10.1182/blood.V96.1.340.013k45_340_346; Russo D, 1999, BBA-BIOMEMBRANES, V1461, P10, DOI 10.1016/S0005-2736(99)00148-0; Russo D, 1998, J BIOL CHEM, V273, P13950, DOI 10.1074/jbc.273.22.13950; SCHENKELBRUNNER H, 2000, HUMAN BLOOD GROUPS C, P485; Schwarze U, 1999, AM J HUM GENET, V65, P336, DOI 10.1086/302512; THIERFELDER L, 1994, CELL, V77, P701, DOI 10.1016/0092-8674(94)90054-X; UCHIKAWA M, 2000, VOX SANG, V78, P11; Wagner T, 2000, NEW ENGL J MED, V343, P72, DOI 10.1056/NEJM200007063430120; Winberg JO, 1997, HUM MOL GENET, V6, P1125, DOI 10.1093/hmg/6.7.1125; Wyatt J, 2000, THROMB HAEMOSTASIS, V84, P449; Yazdanbakhsh K, 1999, BLOOD, V94, P310, DOI 10.1182/blood.V94.1.310.413k12_310_318	39	30	33	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 30	2001	276	13					10247	10252		10.1074/jbc.M009879200	http://dx.doi.org/10.1074/jbc.M009879200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	420GC	11134029	hybrid			2022-12-25	WOS:000167996400089
J	Tam, WF; Sen, RJ				Tam, WF; Sen, RJ			I kappa B family members function by different mechanisms	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR EXPORT SIGNAL; REL PROTEINS; ALPHA; LOCALIZATION; IMPORT; SEQUENCES; COMPLEXES; PATHWAY; MICE	The I kappaB family of proteins regulates NF-kappaB-dependent transcription by inhibiting DNA binding and localizing these factors to the cell cytoplasm, I kappaB alpha does this by shifting the balance between nuclear import of Rel proteins and their export from the nucleus. Here we show that, unlike I kappaB alpha, I kappaB beta and I kappaB beta appear to sequester p65 or c-Rel in the cytoplasm by inhibiting nuclear import. Furthermore, because I kappaB beta does not undergo nucleocytoplasmic shuttling, it cannot remove nuclear proteins like I kappaB alpha does. We conclude that the mechanism of action differs among I kappaB family members.	Brandeis Univ, Rosenstiel Basic Med Sci Res Ctr, Waltham, MA 02454 USA; Brandeis Univ, Dept Biol, Waltham, MA 02454 USA	Brandeis University; Brandeis University	Sen, RJ (corresponding author), Brandeis Univ, Rosenstiel Basic Med Sci Res Ctr, 415 South St, Waltham, MA 02454 USA.							BEG AA, 1992, GENE DEV, V6, P1899, DOI 10.1101/gad.6.10.1899; BEG AA, 1995, GENE DEV, V9, P2736, DOI 10.1101/gad.9.22.2736; Cheng JD, 1998, J EXP MED, V188, P1055, DOI 10.1084/jem.188.6.1055; Feske S, 2000, J IMMUNOL, V165, P297, DOI 10.4049/jimmunol.165.1.297; Foo SY, 1999, TRENDS GENET, V15, P229; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Huang TT, 2000, P NATL ACAD SCI USA, V97, P1014, DOI 10.1073/pnas.97.3.1014; Johnson C, 1999, EMBO J, V18, P6682, DOI 10.1093/emboj/18.23.6682; Klement JF, 1996, MOL CELL BIOL, V16, P2341; May MJ, 1997, SEMIN CANCER BIOL, V8, P63, DOI 10.1006/scbi.1997.0057; OssarehNazari B, 1997, SCIENCE, V278, P141, DOI 10.1126/science.278.5335.141; Prigent M, 2000, J BIOL CHEM, V275, P36441, DOI 10.1074/jbc.M004751200; Rayet B, 1999, ONCOGENE, V18, P6938, DOI 10.1038/sj.onc.1203221; Sachdev S, 2000, MOL CELL BIOL, V20, P1571, DOI 10.1128/MCB.20.5.1571-1582.2000; Sachdev S, 1998, MOL CELL BIOL, V18, P2524, DOI 10.1128/MCB.18.5.2524; Tam WF, 2000, MOL CELL BIOL, V20, P2269, DOI 10.1128/MCB.20.6.2269-2284.2000; Turpin P, 1999, J BIOL CHEM, V274, P6804, DOI 10.1074/jbc.274.10.6804; Whiteside ST, 1997, SEMIN CANCER BIOL, V8, P75, DOI 10.1006/scbi.1997.0058; ZABEL U, 1993, EMBO J, V12, P201, DOI 10.1002/j.1460-2075.1993.tb05646.x	19	91	95	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 16	2001	276	11					7701	7704		10.1074/jbc.C000916200	http://dx.doi.org/10.1074/jbc.C000916200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	411AA	11152669	hybrid			2022-12-25	WOS:000167474900004
J	Li, YQ; Kuwahara, H; Ren, J; Wen, GY; Kufe, D				Li, YQ; Kuwahara, H; Ren, J; Wen, GY; Kufe, D			The c-Src tyrosine kinase regulates signaling of the human DF3/MUC1 carcinoma-associated antigen with GSK3 beta and beta-catenin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR LEF-1; TUMOR-SUPPRESSOR PROTEIN; MONOCLONAL-ANTIBODY DF3; CELL-CELL ADHESION; GROWTH-FACTOR; HUMAN CANCER; RECEPTOR; REACTIVITY; BINDING; COMPLEXES	The DF3/MUC1 mucin-like glycoprotein is aberrantly overexpressed in most human carcinomas. The cytoplasmic domain of MUC1 interacts with glycogen synthase kinase 3 beta (GSK3 beta) and thereby decreases binding of MUC1 and beta -catenin. The present studies demonstrate that MUC1 associates with the c-Src tyrosine kinase. c-Src phosphorylates the MUC1 cytoplasmic domain at a YEKV motif located between sites involved in interactions with GSK3 beta and beta -catenin. The results demonstrate that the c-Src SH2 domain binds directly to pYEKV and inhibits the interaction between MUC1 and GSK3 beta. Moreover and in contrast to GSK3 beta, in vitro and in vivo studies demonstrate that c-Src-mediated phosphorylation of MUC1 increases binding of MUC1 and beta -catenin. The findings support a novel role for c-Src in regulating interactions of MUC1 with GSK3 beta and beta -catenin.	Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School	Kufe, D (corresponding author), Harvard Univ, Sch Med, Dana Farber Canc Inst, 44 Binney St, Boston, MA 02115 USA.	donald_kufe@dfci.harvard.edu			NATIONAL CANCER INSTITUTE [R21CA087421] Funding Source: NIH RePORTER; NCI NIH HHS [CA87421] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797; Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; Biscardi JS, 1999, ADV CANCER RES, V76, P61; Brunner E, 1997, NATURE, V385, P829, DOI 10.1038/385829a0; FRIEDMAN EL, 1986, CANCER RES, V46, P5189; GENDLER S, 1988, J BIOL CHEM, V263, P12820; Hansen K, 1996, EMBO J, V15, P5299, DOI 10.1002/j.1460-2075.1996.tb00915.x; Holmes TC, 1996, J NEUROSCI, V16, P1581; Huber O, 1996, MECH DEVELOP, V59, P3, DOI 10.1016/0925-4773(96)00597-7; JOU TS, 1995, P NATL ACAD SCI USA, V92, P5067, DOI 10.1073/pnas.92.11.5067; KAMPS MP, 1986, MOL CELL BIOL, V6, P751, DOI 10.1128/MCB.6.3.751; KAWANISHI J, 1995, MOL CELL BIOL, V15, P1175; KUFE D, 1984, HYBRIDOMA, V3, P223, DOI 10.1089/hyb.1984.3.223; Li YQ, 1998, MOL CELL BIOL, V18, P7216, DOI 10.1128/MCB.18.12.7216; LIGHTENBERG M, 1992, CANCER RES, V52, P223; MAA MC, 1995, P NATL ACAD SCI USA, V92, P6981, DOI 10.1073/pnas.92.15.6981; MALARKEY K, 1995, BIOCHEM J, V309, P361, DOI 10.1042/bj3090361; Molenaar M, 1996, CELL, V86, P391, DOI 10.1016/S0092-8674(00)80112-9; MUNEMITSU S, 1995, P NATL ACAD SCI USA, V92, P3046, DOI 10.1073/pnas.92.7.3046; Orford K, 1997, J BIOL CHEM, V272, P24735, DOI 10.1074/jbc.272.40.24735; PEREY L, 1992, CANCER RES, V52, P2563; RUBINFELD B, 1993, SCIENCE, V262, P1731, DOI 10.1126/science.8259518; RUBINFELD B, 1995, J BIOL CHEM, V270, P5549, DOI 10.1074/jbc.270.10.5549; Rubinfeld B, 1996, SCIENCE, V272, P1023, DOI 10.1126/science.272.5264.1023; Salomon D, 1997, J CELL BIOL, V139, P1325, DOI 10.1083/jcb.139.5.1325; SHIUE L, 1995, J BIOL CHEM, V270, P10498, DOI 10.1074/jbc.270.18.10498; SIDDIQUI J, 1988, P NATL ACAD SCI USA, V85, P2320, DOI 10.1073/pnas.85.7.2320; SU LK, 1993, SCIENCE, V262, P1734, DOI 10.1126/science.8259519; TAKEICHI M, 1990, ANNU REV BIOCHEM, V59, P237, DOI 10.1146/annurev.biochem.59.1.237; vanHoek ML, 1997, BIOCHEM J, V326, P271, DOI 10.1042/bj3260271; WENG ZG, 1995, MOL CELL BIOL, V15, P5627; Yamamoto M, 1997, J BIOL CHEM, V272, P12492, DOI 10.1074/jbc.272.19.12492; Yu SP, 1997, SCIENCE, V278, P114, DOI 10.1126/science.278.5335.114; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	34	198	221	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 2	2001	276	9					6061	6064		10.1074/jbc.C000754200	http://dx.doi.org/10.1074/jbc.C000754200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	407FF	11152665	hybrid			2022-12-25	WOS:000167261000002
J	Mukherjee, S; Casanova, JE; Hunzicker-Dunn, M				Mukherjee, S; Casanova, JE; Hunzicker-Dunn, M			Desensitization of the luteinizing hormone/choriogonadotropin receptor in ovarian follicular membranes is inhibited by catalytically inactive ARNO(+)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE EXCHANGE FACTOR; PLECKSTRIN-HOMOLOGY DOMAINS; ADP-RIBOSYLATION FACTOR-6; ADENYLYL CYCLASE; ACTIN CYTOSKELETON; PLASMA-MEMBRANE; HORMONE; CELLS; BETA; ARF	We have investigated the participation of endogenous ADP-ribosylation factor (ARF) nucleotide-binding site opener (ARNO) in desensitization of the luteinizing hormone/choriogonadotropin (LH/CG) receptor, independent of receptor internalization, using a cell-free plasma membrane model. We recently showed that the addition of recombinant ARNO promotes binding of beta -arrestin1 to the third intracellular (3i) loop of the active LH/CG receptor, thereby reducing the ability of the receptor to activate the stimulatory G protein and signal to adenylyl cyclase. In the present report we determined whether ARNO is detectable in follicular membranes and whether the catalytically inactive E156K ARNO mutant, containing a mutation in the Sec7 domain, can act in a dominant negative manner to block LH/CG receptor desensitization. Results show that ARNO is readily detected in follicular membranes and that levels of membrane-associated ARNO increase with follicular maturation. The addition of catalytically inactive E156K ARNO blocks both the release of beta -arrestin1 from its membrane docking site, based on Western blot analysis, and development of LH/CG receptor desensitization. We also investigated whether a point mutation in the pleckstrin homology (PH) domain of ARNO (R280D), which blocks binding of phosphoinositides like phosphatidylinositol 3,4,5-trisphosphate and phosphatidylinositol 4,5-bisphosphate (PIP2) but not catalytic activity, disrupts LH/CG receptor desensitization. R280D ARNO neither promotes nor inhibits LH/CG receptor desensitization, consistent with a requirement of the PH domain of ARNO for its association with the plasma membrane. LH/CG receptor activation of ARNO is not mediated by activation of phosphatidylinositol 3-kinase (PI 3-kinase) or by G protein beta gamma subunits. Taken together, these results suggest that LH/CG receptor promotes beta -arrestin1 release from its membrane docking site to bind to the 3i loop of the LH/CG receptor via activation of membrane delimited endogenous ARNO. As ARNO activation is independent of PI 3-kinase and G beta gamma, our results are consistent with a role for PIP2 in receptor-stimulated ARNO activation.	Northwestern Univ, Sch Med, Dept Cell & Mol Biol, Chicago, IL 60611 USA; Univ Virginia, Hlth Sci Ctr, Dept Cell Biol, Charlottesville, VA 22908 USA	Northwestern University; University of Virginia	Hunzicker-Dunn, M (corresponding author), Northwestern Univ, Sch Med, Dept Cell & Mol Biol, 303 E Chicago Ave, Chicago, IL 60611 USA.				EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD038060] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI032991] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI 32991] Funding Source: Medline; NICHD NIH HHS [R01 HD/DK 38060] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BENDER FE, 1982, STAT METHODS FOOD AG; BOCKAERT J, 1976, J BIOL CHEM, V251, P2653; Bottomley MJ, 1998, BBA-MOL CELL BIOL L, V1436, P165, DOI 10.1016/S0005-2760(98)00141-6; Caumon AS, 2000, J BIOL CHEM, V275, P15637, DOI 10.1074/jbc.M908347199; CHANNING CP, 1974, BIOL REPROD, V10, P179, DOI 10.1095/biolreprod10.2.179; Chardin P, 1996, NATURE, V384, P481, DOI 10.1038/384481a0; CHEN JQ, 1995, SCIENCE, V268, P1166, DOI 10.1126/science.7761832; Cullen PJ, 2000, CURR BIOL, V10, pR876, DOI 10.1016/S0960-9822(00)00818-6; DAVIS JS, 1987, J BIOL CHEM, V262, P8515; DIMINO MJ, 1987, BIOL REPROD, V36, P97, DOI 10.1095/biolreprod36.1.97; EKSTROM RC, 1989, ENDOCRINOLOGY, V125, P2470, DOI 10.1210/endo-125-5-2470; EKSTROM RC, 1989, ENDOCRINOLOGY, V124, P956, DOI 10.1210/endo-124-2-956; EZRA E, 1980, J BIOL CHEM, V255, P653; EZRA E, 1981, J BIOL CHEM, V256, P5377; Franco M, 1999, EMBO J, V18, P1480, DOI 10.1093/emboj/18.6.1480; Franco M, 1998, P NATL ACAD SCI USA, V95, P9926, DOI 10.1073/pnas.95.17.9926; Frank S, 1998, J BIOL CHEM, V273, P23, DOI 10.1074/jbc.273.1.23; Frank SR, 1998, MOL BIOL CELL, V9, P3133, DOI 10.1091/mbc.9.11.3133; Godi A, 1999, NAT CELL BIOL, V1, P280, DOI 10.1038/12993; HAUSDORFF WP, 1990, FASEB J, V4, P2881, DOI 10.1096/fasebj.4.11.2165947; Honda A, 1999, CELL, V99, P521, DOI 10.1016/S0092-8674(00)81540-8; HSUEH AJW, 1984, ENDOCR REV, V5, P76, DOI 10.1210/edrv-5-1-76; Jackson CL, 2000, TRENDS CELL BIOL, V10, P60, DOI 10.1016/S0962-8924(99)01699-2; KHARLUND JK, 1998, J BIOL CHEM, V273, P1859; Kim HS, 1998, FEBS LETT, V433, P312, DOI 10.1016/S0014-5793(98)00937-5; Klarlund JK, 2000, J BIOL CHEM, V275, P32816, DOI 10.1074/jbc.M002435200; Klarlund JK, 1997, SCIENCE, V275, P1927, DOI 10.1126/science.275.5308.1927; Langille SE, 1999, J BIOL CHEM, V274, P27099, DOI 10.1074/jbc.274.38.27099; Moss J, 1998, J BIOL CHEM, V273, P21431, DOI 10.1074/jbc.273.34.21431; Mukherjee S, 1999, J BIOL CHEM, V274, P12984, DOI 10.1074/jbc.274.19.12984; Mukherjee S, 1999, P NATL ACAD SCI USA, V96, P493, DOI 10.1073/pnas.96.2.493; Mukherjee S, 2000, P NATL ACAD SCI USA, V97, P5901, DOI 10.1073/pnas.100127097; Nagel W, 1998, J BIOL CHEM, V273, P14853, DOI 10.1074/jbc.273.24.14853; Nagel WG, 1998, MOL BIOL CELL, V9, P1981, DOI 10.1091/mbc.9.8.1981; Ogasawara M, 2000, J BIOL CHEM, V275, P3221, DOI 10.1074/jbc.275.5.3221; Paris S, 1997, J BIOL CHEM, V272, P22221, DOI 10.1074/jbc.272.35.22221; Rajagopalan-Gupta RM, 1999, ENDOCRINOLOGY, V140, P1612, DOI 10.1210/en.140.4.1612; RajagopalanGupta RM, 1997, MOL ENDOCRINOL, V11, P538, DOI 10.1210/me.11.5.538; Roth MG, 1999, CELL, V97, P149, DOI 10.1016/S0092-8674(00)80723-0; Santy LC, 1999, CURR BIOL, V9, P1173, DOI 10.1016/S0960-9822(00)80019-6; Venkateswarlu K, 1998, CURR BIOL, V8, P463, DOI 10.1016/S0960-9822(98)70181-2	41	21	21	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 2	2001	276	9					6524	6528		10.1074/jbc.C000725200	http://dx.doi.org/10.1074/jbc.C000725200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	407FF	11139567	hybrid			2022-12-25	WOS:000167261000061
J	Liu, YY; Han, TY; Giuliano, AE; Cabot, MC				Liu, YY; Han, TY; Giuliano, AE; Cabot, MC			Ceramide glycosylation potentiates cellular multidrug resistance	FASEB JOURNAL			English	Article						glucosylceramide synthase; antisense; breast cancer; apoptosis; chemotherapy	BREAST-CANCER-CELLS; GLUCOSYLCERAMIDE SYNTHASE; P-GLYCOPROTEIN; INDUCED APOPTOSIS; GLYCOSPHINGOLIPID SYNTHESIS; ADRIAMYCIN RESISTANCE; GLUCOSPHINGOLIPID SYNTHESIS; GENE-EXPRESSION; CYCLOSPORINE-A; SDZ PSC-833	Ceramide glycosylation, through glucosylceramide synthase (GCS), allows cellular escape from ceramide-induced programmed cell death. This glycosylation event confers cancer cell resistance to cytotoxic anticancer agents [Liu, Y. Y., Han, T. Y., Giuliano, A. E., and M. C. Cabot. (1999) J. Biol. Qlem. 274, 1140-1146]. We previously found that glucosylceramide, the glycosylated form of ceramide, accumulates in adriamycin-resistant breast carcinoma cells, in vinblastine-resistant epithelioid carcinoma cells, and in tumor specimens from patients showing poor response to chemotherapy, Here we show that multidrug resistance can be increased over baseline and then totally reversed in human breast cancer cells by GCS gene targeting. In adriamycin-resistant MCF-7-AdrR cells, transfection of GCS upgraded multidrug resistance, whereas transfection of GCS antisense markedly restored cellular sensitivity to anthracyclines, Vinca alkaloids, taxanes, and other anticancer drugs. Sensitivity to the various drugs by GCS antisense transfection increased 7- to 240-fold and was consistent with the resumption of ceramide-caspase-apoptotic signaling. CCS targeting had Little influence on cellular sensitivity to either 5-FU or cisplatin, nor did it modify P-glyco-protein expression or rhodamine-123 efflux, GCS antisense transfection did enhance rhodamine-123 uptake compared with parent MCF-7-AdrR cells. This study reveals that GCS is a novel mechanism of multidrug resistance and positions GCS antisense as an innovative force to overcome multidrug resistance in cancer chemotherapy.-Liu, Y.-Y., Han, T.-Y., Giuliano, A. E., and Cabot, M, C, Ceramide glycosylation potentiates cellular multidrug resistance.	St Johns Hlth Ctr, John Wayne Canc Inst, Santa Monica, CA 90404 USA	John Wayne Cancer Institute	Cabot, MC (corresponding author), St Johns Hlth Ctr, John Wayne Canc Inst, 2200 Santa Monica Blvd, Santa Monica, CA 90404 USA.	Cabot@jwci.org		Liu, Yong-Yu/0000-0002-7968-0162	NATIONAL CANCER INSTITUTE [R01CA077632] Funding Source: NIH RePORTER; NCI NIH HHS [CA77632] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BASU S, 1968, J BIOL CHEM, V243, P5802; BATIST G, 1986, J BIOL CHEM, V261, P5544; Birkle S, 2000, J NEUROCHEM, V74, P547, DOI 10.1046/j.1471-4159.2000.740547.x; BONFOCO E, 1995, P NATL ACAD SCI USA, V92, P7162, DOI 10.1073/pnas.92.16.7162; BOSE R, 1995, CELL, V82, P405, DOI 10.1016/0092-8674(95)90429-8; BROUTYBOYE D, 1995, CANCER RES, V55, P1633; Cabot MC, 1999, CANCER RES, V59, P880; Cabot MC, 1998, FEBS LETT, V431, P185, DOI 10.1016/S0014-5793(98)00744-3; CABOT MC, 1997, BREAST CANC RES TREA, V46, P283; Chen JH, 1998, P NATL ACAD SCI USA, V95, P2648, DOI 10.1073/pnas.95.5.2648; COWAN KH, 1986, P NATL ACAD SCI USA, V83, P9328, DOI 10.1073/pnas.83.24.9328; DARVIS WD, 1998, CURR OPIN ONCOL, V10, P552; DATTA SC, 1988, LIPIDS, V23, P508, DOI 10.1007/BF02535529; Dbaibo GS, 1998, J CLIN INVEST, V102, P329, DOI 10.1172/JCI1180; DECKER DA, 1995, ANN CLIN LAB SCI, V25, P52; FAIRCHILD CR, 1990, MOL PHARMACOL, V37, P801; FAIRCHILD CR, 1987, CANCER RES, V47, P5141; Ferte J, 2000, EUR J BIOCHEM, V267, P277, DOI 10.1046/j.1432-1327.2000.01046.x; Fukumoto H, 1996, INT J CANCER, V67, P676, DOI 10.1002/(SICI)1097-0215(19960904)67:5<676::AID-IJC14>3.0.CO;2-3; GOTTESMAN MM, 1993, ANNU REV BIOCHEM, V62, P385, DOI 10.1146/annurev.bi.62.070193.002125; Hakamori S, 1998, ACTA ANAT, V161, P79; Hannun YA, 1996, SCIENCE, V274, P1855, DOI 10.1126/science.274.5294.1855; Hannun YA, 2000, TRENDS CELL BIOL, V10, P73, DOI 10.1016/S0962-8924(99)01694-3; Harder T, 1997, CURR OPIN CELL BIOL, V9, P534, DOI 10.1016/S0955-0674(97)80030-0; Ichikawa S, 1996, P NATL ACAD SCI USA, V93, P4638, DOI 10.1073/pnas.93.10.4638; INOKUCHI J, 1990, CANCER RES, V50, P6731; Iwabuchi K, 1998, J BIOL CHEM, V273, P9130, DOI 10.1074/jbc.273.15.9130; JONES JB, 1985, CIBA F SYMP, V111, P3; Kim HM, 1997, FEBS LETT, V412, P201, DOI 10.1016/S0014-5793(97)00777-1; Kok JW, 2000, INT J CANCER, V87, P172, DOI 10.1002/1097-0215(20000715)87:2<172::AID-IJC3>3.0.CO;2-K; Kolesnick RN, 1998, ANNU REV PHYSIOL, V60, P643, DOI 10.1146/annurev.physiol.60.1.643; Kolter T, 1998, BRAIN PATHOL, V8, P79; Kyogashima M, 1996, CANCER LETT, V101, P25, DOI 10.1016/0304-3835(95)04106-0; Lala P, 2000, J BIOL CHEM, V275, P6246, DOI 10.1074/jbc.275.9.6246; Lavie Y, 1999, LIPIDS, V34, pS57, DOI 10.1007/BF02562229; Lavie Y, 1997, J BIOL CHEM, V272, P1682, DOI 10.1074/jbc.272.3.1682; Lavie Y, 1996, J BIOL CHEM, V271, P19530, DOI 10.1074/jbc.271.32.19530; Lehnert M, 1996, EUR J CANCER, V32A, P912, DOI 10.1016/0959-8049(96)00069-X; Liu YY, 2000, J BIOL CHEM, V275, P7138, DOI 10.1074/jbc.275.10.7138; Liu YY, 1999, EXP CELL RES, V252, P464, DOI 10.1006/excr.1999.4649; Liu YY, 1999, J BIOL CHEM, V274, P1140, DOI 10.1074/jbc.274.2.1140; Luberto C, 1998, J BIOL CHEM, V273, P14550, DOI 10.1074/jbc.273.23.14550; Lucci A, 1999, INT J ONCOL, V15, P541; Lucci A, 1999, CANCER-AM CANCER SOC, V86, P300, DOI 10.1002/(SICI)1097-0142(19990715)86:2<300::AID-CNCR14>3.0.CO;2-H; Lucci A, 1998, ANTICANCER RES, V18, P475; MARSH NL, 1995, J CLIN INVEST, V95, P2903, DOI 10.1172/JCI117997; Mizutani A, 1996, BIOCHEM BIOPH RES CO, V222, P494, DOI 10.1006/bbrc.1996.0772; Mutoh T, 1998, J BIOL CHEM, V273, P26001, DOI 10.1074/jbc.273.40.26001; Myrick D, 1999, LEUKEMIA RES, V23, P569, DOI 10.1016/S0145-2126(99)00048-X; Nicholson KM, 1999, BRIT J CANCER, V81, P423, DOI 10.1038/sj.bjc.6690711; Perales M, 1998, LEUKEMIA LYMPHOMA, V31, P609, DOI 10.3109/10428199809057621; PETERSON RHF, 1983, CANCER RES, V43, P222; Radford IR, 1999, INT J RADIAT BIOL, V75, P521, DOI 10.1080/095530099140168; Radin NS, 1999, BIOCHEM PHARMACOL, V57, P589; RANI CSS, 1995, J BIOL CHEM, V270, P2859, DOI 10.1074/jbc.270.6.2859; RIORDAN JR, 1979, J BIOL CHEM, V254, P2701; ROSENWALD AG, 1994, J LIPID RES, V35, P1232; SCHNEIDER J, 1995, ANTICANCER RES, V15, P1117; SHUKLA GS, 1990, ARCH BIOCHEM BIOPHYS, V283, P372, DOI 10.1016/0003-9861(90)90657-K; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; Stein U, 1997, INT J CANCER, V72, P885, DOI 10.1002/(SICI)1097-0215(19970904)72:5<885::AID-IJC28>3.0.CO;2-6; Watanabe R, 1998, J BIOL CHEM, V273, P9651, DOI 10.1074/jbc.273.16.9651; Wyllie A H, 1980, Int Rev Cytol, V68, P251; Yamashita T, 1999, P NATL ACAD SCI USA, V96, P9142, DOI 10.1073/pnas.96.16.9142; Yokoyama K, 1997, EUR J BIOCHEM, V249, P450, DOI 10.1111/j.1432-1033.1997.00450.x	65	233	252	0	15	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2001	15	3					719	730		10.1096/fj.00-0223com	http://dx.doi.org/10.1096/fj.00-0223com			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	410BE	11259390				2022-12-25	WOS:000167419500029
J	Massfelder, T; Taesch, N; Endlich, N; Eichinger, A; Escande, B; Endlich, K; Barthelmebs, M; Helwig, JJ				Massfelder, T; Taesch, N; Endlich, N; Eichinger, A; Escande, B; Endlich, K; Barthelmebs, M; Helwig, JJ			Paradoxical actions of exogenous and endogenous parathyroid hormone-related protein on renal vascular smooth muscle cell proliferation: reversion in the SHR model of genetic hypertension	FASEB JOURNAL			English	Article						mitogenesis; intracrine; nucleolus	PTH/PTHRP RECEPTOR; BLOOD-PRESSURE; MESSENGER-RNA; PEPTIDE; EXPRESSION; PTHRP; ARTERIES; KIDNEY; RATS; BINDING	In previous studies, added parathyroid hormone-related protein (PTHrP) inhibits whereas transfected PTHrP stimulates the proliferation of A10 aortic smooth muscle cells by nuclear translocation of the peptide. In the present studies, we asked whether these paradoxical trophic actions of PTHrP occur in smooth muscle cells (SMC) cultured from small intrarenal arteries of, and whether they are altered in, 12-wk-old spontaneously hypertensive rats (SHR) as compared to normotensive Wistar-Kyoto (WKY) rats, SHR cells grew faster than WKY cells. PTHrP transcript was increased in SHR-derived cells whereas PTH1 receptor (PTH1R) transcripts were similar in both cell Lines. In both strains of cells, stable transfection with human PTHrP(1-139) cDNA did not further induce proliferation, suggesting maximal effect of endogenous PTHrP in wild cells. In contrast, transfection with antisense hPTHrP(1-139) DNA, which abolished PTHrP mRNA, decreased WKY but increased SHR cell proliferation. Added PTHrP(1-36) (1-100 pM) decreased WKY and increased SHR cell proliferation, Additional studies indicated that the preferential coupling of PTH1-R to G-protein Gi was responsible for the proliferative effect of exogenous PTHrP in SHR cells. Moreover, PTHrP was detected in the nucleolus of a fraction of WKY and SHR renal SMC, in vitro as well as in situ, suggesting that the nucleolar translocation of PTHrP might be involved in the proliferative effects of endogenous PTHrP. In renovascular SMC, added PTHrP is antimitogenic, whereas endogenously produced PTHrP is mitogenic, These paradoxical effects of PTHrP on renovascular SMC proliferation appear to be reversed in the SHR model of genetic hypertension, A new concept emerges from these results, according to which a single molecule may have opposite effects on VSMC proliferation under physiological and pathophysiological conditions.-Mass-felder, T., Taesch, N., Endlich, N., Eichinger, A., Escande, B., Endlich, K., Barthelmebs, M., Helwig, J.-J. Paradoxical actions of exogenous and endogenous parathyroid hormone-related protein on renal vascular smooth muscle cell proliferation: reversion in the SHR model of genetic hypertension.	Univ Louis Pasteur Strasbourg 1, Sect Renovasc Pharmacol & Physiol, INSERM, Sch Med, Strasbourg, France	CHU Strasbourg; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Universite de Franche-Comte	Helwig, JJ (corresponding author), INSERM, Equipe 0015, MENRT, Equipe 2307, 11 Rue Humann,Batiment 4,1 Etage, F-67085 Strasbourg, France.	Jean-Jacques.Helwig@pharmaco-ulp.u-strasbg.fr	Massfelder, Thierry/I-1260-2016; Endlich, Karlhans/G-5485-2013	Endlich, Karlhans/0000-0001-6052-6061				Aarts MM, 1999, J BONE MINER RES, V14, P1493, DOI 10.1359/jbmr.1999.14.9.1493; Aarts MM, 1999, J BIOL CHEM, V274, P4832, DOI 10.1074/jbc.274.8.4832; ABOUSAMRA AB, 1989, ENDOCRINOLOGY, V125, P2594; ANANDSRIVASTAVA MB, 1992, BIOCHEM J, V288, P79, DOI 10.1042/bj2880079; Broadus Arthur E., 1994, P259; BUKOSKI RD, 1990, J HYPERTENS, V8, P37, DOI 10.1097/00004872-199001000-00007; Celic S, 1996, J ENDOCRINOL, V150, P299, DOI 10.1677/joe.0.1500299; Diez J, 1998, EUR HEART J, V19, pG29; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; Endlich N, 2000, KIDNEY INT, V57, P2468, DOI 10.1046/j.1523-1755.2000.00105.x; Fiaschi-Taesch N, 1998, KIDNEY INT, V54, pS207, DOI 10.1046/j.1523-1755.1998.06749.x; HADRAVA V, 1992, BIOCHEM CELL BIOL, V70, P599, DOI 10.1139/o92-091; HENDERSON JE, 1995, MOL CELL BIOL, V15, P4064; Ishikawa M, 1998, ATHEROSCLEROSIS, V136, P59, DOI 10.1016/S0021-9150(97)00187-1; JIANG BB, 1995, MINER ELECTROL METAB, V21, P157; Joun H, 1997, ENDOCRINOLOGY, V138, P1742, DOI 10.1210/en.138.4.1742; JUPPNER H, 1991, SCIENCE, V254, P1024, DOI 10.1126/science.1658941; KARAPLIS AC, 1994, GENE DEV, V8, P277, DOI 10.1101/gad.8.3.277; Kett MM, 1996, CLIN EXP PHARMACOL P, V23, pS132, DOI 10.1111/j.1440-1681.1996.tb03074.x; Lam MHC, 1999, J BIOL CHEM, V274, P7391, DOI 10.1074/jbc.274.11.7391; LAM MHC, 1999, ASBMR ANN M ST LOUIS; Lanske B, 1996, SCIENCE, V273, P663, DOI 10.1126/science.273.5275.663; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Maeda S, 1996, ENDOCRINOLOGY, V137, P3154, DOI 10.1210/en.137.8.3154; Maeda S, 1999, ENDOCRINOLOGY, V140, P1815, DOI 10.1210/en.140.4.1815; Massfelder T, 1998, CURR OPIN NEPHROL HY, V7, P27, DOI 10.1097/00041552-199801000-00005; Massfelder T, 1996, BRIT J PHARMACOL, V118, P1995, DOI 10.1111/j.1476-5381.1996.tb15635.x; Massfelder T, 1999, ENDOCRINOLOGY, V140, P1507, DOI 10.1210/en.140.4.1507; Massfelder T, 1996, KIDNEY INT, V50, P1591, DOI 10.1038/ki.1996.475; Massfelder T, 1997, P NATL ACAD SCI USA, V94, P13630, DOI 10.1073/pnas.94.25.13630; MASSFELDER T, 1995, J PHYSIOL-LONDON, V483, P481; NAKAYAMA T, 1994, BIOCHEM BIOPH RES CO, V200, P1028, DOI 10.1006/bbrc.1994.1553; NICKOLS GA, 1990, ENDOCRINOLOGY, V126, P721, DOI 10.1210/endo-126-2-721; Noda M, 1997, HYPERTENSION, V30, P1284, DOI 10.1161/01.HYP.30.5.1284; ORLOFF JJ, 1995, ENDOCRINOLOGY, V136, P3016, DOI 10.1210/en.136.7.3016; Orloff JJ, 1996, ENDOCRINOLOGY, V137, P5376, DOI 10.1210/en.137.12.5376; Ozeki S, 1996, ARTERIOSCL THROM VAS, V16, P565, DOI 10.1161/01.ATV.16.4.565; Pederson T, 1998, J CELL BIOL, V143, P279, DOI 10.1083/jcb.143.2.279; Pederson T, 1998, NUCLEIC ACIDS RES, V26, P3871, DOI 10.1093/nar/26.17.3871; Philbrick WM, 1996, PHYSIOL REV, V76, P127, DOI 10.1152/physrev.1996.76.1.127; PIROLA CJ, 1994, ENDOCRINOLOGY, V134, P2230, DOI 10.1210/en.134.5.2230; PIROLA CJ, 1993, J BIOL CHEM, V268, P1987; Qian J, 1999, ENDOCRINOLOGY, V140, P1826, DOI 10.1210/en.140.4.1826; Rettig R, 1996, J HUM HYPERTENS, V10, P641; RETTIG R, 1990, CLIN EXP HYPERTENS A, V12, P957, DOI 10.3109/10641969009073513; RETTIG R, 1993, J HUM HYPERTENS, V7, P177; SAUSSINE C, 1993, KIDNEY INT, V44, P764, DOI 10.1038/ki.1993.311; Schwindinger WF, 1998, ENDOCRINE, V8, P201, DOI 10.1385/ENDO:8:2:201; STUART WD, 1999, ASBMR ANN M ST LOUIS; TAKAHASHI K, 1995, BIOCHEM BIOPH RES CO, V208, P447, DOI 10.1006/bbrc.1995.1358; TREMBLAY J, 1992, CAN J PHYSIOL PHARM, V70, P565, DOI 10.1139/y92-071; Valin A, 1997, J CELL PHYSIOL, V170, P209, DOI 10.1002/(SICI)1097-4652(199702)170:2<209::AID-JCP13>3.3.CO;2-Y; Vasavada RC, 1998, RECENT PROG HORM RES, V53, P305; Wu TL, 1996, J BIOL CHEM, V271, P24371, DOI 10.1074/jbc.271.40.24371; Wysolmerski JJ, 1998, ANNU REV PHYSIOL, V60, P431, DOI 10.1146/annurev.physiol.60.1.431; YANG TX, 1997, AM J PHYSIOL, V41, pF751	56	18	18	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2001	15	3					707	718		10.1096/fj.00-0053com	http://dx.doi.org/10.1096/fj.00-0053com			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	410BE	11259389				2022-12-25	WOS:000167419500028
J	Fruhbeck, G; Gomez-Ambrosi, J; Salvador, J				Fruhbeck, G; Gomez-Ambrosi, J; Salvador, J			Leptin-induced lipolysis opposes the tonic inhibition of endogenous adenosine in white adipocytes	FASEB JOURNAL			English	Article						OB protein; catecholamines; G-proteins; obesity; lipid metabolism	ADENYLATE-CYCLASE ACTIVITY; DEPENDENT PROTEIN-KINASE; FAT-CELLS; IN-VIVO; RAT ADIPOCYTES; OB/OB MICE; BROWN FAT; OBESE; ACTIVATION; GTP	The aim of the present study was to gain insight into the signaling pathway used by leptin to stimulate lipolysis. The lipolytic rate of white adipocytes from sex- and age-matched lean (+/+) and fa/fa rats was determined in the absence or presence of leptin together with a number of agents acting at different levels of the signaling cascade. Leptin did not modify FSK-, dbcAMP-, and IBMX-stimulated lipolysis. Lipolysis can also be maximally stimulated by lowering media adenosine levels with adenosine deaminase (ADA), i.e., in the ligand-free state. Although ADA produced near maximal lipolysis in adipocytes of lean animals, only half of the maximal lipolytic rate (50.9+/-3.2%) was achieved in fat cells from fa/fa rats (P=0.0034). In adipocytes from lean animals preincubated with ADA, leptin caused a concentration-related stimulation of lipolysis (P=0.0001). However, leptin had no effect on the lipolytic activity of adipocytes in the ligand-free state from fa/fa rats. The adenosine A(1) receptor agonist CPA effectively inhibited basal lipolysis in both lean and obese adipocytes (P=0.0001 and P=0.0090, respectively). Leptin had no effect on the lipolytic rate of adipocytes isolated from fa/fa rats and preincubated with CPA. When adipocytes were incubated with the A(1) receptor antagonist DPCPX, a significant increase in glycerol release was observed in fa/fa fat cells (P=0.009), whereas cells isolated from lean rats showed no differences to ADA-stimulated lipolysis. After pretreatment with PTX, which inactivates receptor-mediated G(i) function, adipocytes of obese rats became as responsive to the stimulatory actions of ISO as cells from lean rats (P=0.0090 vs. ISO in fa/fa rats; P=0.2416 vs. lean rats, respectively). PTX treatment of lean cells, however, did not alter their response to this lipolytic agent. It can be concluded that the lipolytic effect of leptin is located at the adenylate cyclase/G(i) proteins level and that leptin-induced lipolysis opposes the tonic inhibition of endogenous adenosine in white adipocytes.	Univ Navarra, Metab Res Lab, Pamplona 31008, Spain; Univ Navarra Clin, Dept Endocrinol, Pamplona 31008, Spain	University of Navarra; University of Navarra	Fruhbeck, G (corresponding author), Univ Navarra Clin, Dept Endocrinol, Pamplona 31008, Spain.	gfruhbeck@unav.es	Gómez-Ambrosi, Javier/D-2984-2017	Gómez-Ambrosi, Javier/0000-0001-5601-1604				BEGINHEICK N, 1985, J BIOL CHEM, V260, P6187; BEGINHEICK N, 1990, BIOCHEM J, V268, P83, DOI 10.1042/bj2680083; BEGINHEICK N, 1992, AM J PHYSIOL, V263, pC121, DOI 10.1152/ajpcell.1992.263.1.C121; BERKICH DA, 1995, AM J PHYSIOL-ENDOC M, V268, pE693, DOI 10.1152/ajpendo.1995.268.4.E693; Bottini E, 1999, METABOLISM, V48, P949, DOI 10.1016/S0026-0495(99)90187-7; Bray G, 1997, FASEB J, V11, P937, DOI 10.1096/fasebj.11.12.9337146; CARO JF, 1994, J CELL BIOCHEM, V54, P309, DOI 10.1002/jcb.240540307; Chagnon YC, 2000, OBES RES, V8, P89, DOI 10.1038/oby.2000.12; Chehab FE, 1996, NAT GENET, V12, P318, DOI 10.1038/ng0396-318; Chen GX, 1996, P NATL ACAD SCI USA, V93, P14795, DOI 10.1073/pnas.93.25.14795; Cheng JT, 2000, DIABETES, V49, P20, DOI 10.2337/diabetes.49.1.20; Cioffi JA, 1996, NAT MED, V2, P585, DOI 10.1038/nm0596-585; Crist GH, 1998, FASEB J, V12, P1301, DOI 10.1096/fasebj.12.13.1301; DOLE VP, 1960, J BIOL CHEM, V235, P2595; Fruhbeck G, 1999, DIABETES, V48, P903, DOI 10.2337/diabetes.48.4.903; Fruhbeck G, 2000, DIABETOLOGIA, V43, P3, DOI 10.1007/s001250050002; Fruhbeck G, 1998, BIOCHEM BIOPH RES CO, V250, P99, DOI 10.1006/bbrc.1998.9277; Fruhbeck G, 1997, BIOCHEM BIOPH RES CO, V240, P590, DOI 10.1006/bbrc.1997.7716; GALITZKY J, 1993, AM J PHYSIOL, V264, pE403, DOI 10.1152/ajpendo.1993.264.3.E403; GETTYS TW, 1991, J BIOL CHEM, V266, P15949; GREENBERG AS, 1987, J BIOL CHEM, V262, P4564; HONNOR RC, 1985, J BIOL CHEM, V260, P5122; HONNOR RC, 1985, J BIOL CHEM, V260, P5130; KAARTINEN JM, 1994, BBA-GEN SUBJECTS, V1201, P69, DOI 10.1016/0304-4165(94)90153-8; Kenan Y, 1997, AM J PHYSIOL-ENDOC M, V272, pE1043, DOI 10.1152/ajpendo.1997.272.6.E1043; LAFONTAN M, 1993, J LIPID RES, V34, P1057; LANOUE KF, 1994, FASEB J, V8, P72, DOI 10.1096/fasebj.8.1.8299893; Lord GM, 1998, NATURE, V394, P897, DOI 10.1038/29795; MALBON CC, 1985, J BIOL CHEM, V260, P2558; MARTIN LF, 1990, SURGERY, V108, P228; MILLIGAN G, 1990, BIOCHEM J, V270, P765, DOI 10.1042/bj2700765; Moxham CM, 1996, NATURE, V379, P840, DOI 10.1038/379840a0; MOXHAM CM, 1993, DEV GENET, V14, P266, DOI 10.1002/dvg.1020140404; OHISALO JJ, 1989, BIOCHEM J, V260, P843, DOI 10.1042/bj2600843; Rice AM, 2000, ENDOCRINOLOGY, V141, P1442, DOI 10.1210/en.141.4.1442; RODBELL M, 1964, J BIOL CHEM, V239, P375; Shimabukuro M, 1997, P NATL ACAD SCI USA, V94, P4637, DOI 10.1073/pnas.94.9.4637; Siegrist-Kaiser CA, 1997, J CLIN INVEST, V100, P2858, DOI 10.1172/JCI119834; Sierra-Honigmann MR, 1998, SCIENCE, V281, P1683, DOI 10.1126/science.281.5383.1683; Vaisse C, 1996, NAT GENET, V14, P95, DOI 10.1038/ng0996-95; VANNUCCI SJ, 1990, INT J OBESITY, V14, P125; VANNUCCI SJ, 1989, AM J PHYSIOL, V257, pE871, DOI 10.1152/ajpendo.1989.257.6.E871; Wang MY, 1999, J BIOL CHEM, V274, P17541, DOI 10.1074/jbc.274.25.17541; Wang ZW, 1999, BIOCHEM BIOPH RES CO, V260, P653, DOI 10.1006/bbrc.1999.0918; WIELAND O, 1957, BIOCHEM Z, V329, P313; Xu BY, 1998, AM J PHYSIOL-ENDOC M, V274, pE271, DOI 10.1152/ajpendo.1998.274.2.E271; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0; Zhao AZ, 1998, J CLIN INVEST, V102, P869, DOI 10.1172/JCI3920	48	83	86	0	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2001	15	2					333	340		10.1096/fj.00-0249com	http://dx.doi.org/10.1096/fj.00-0249com			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	400LK	11156949				2022-12-25	WOS:000166872900015
J	L'Heureux, N; Stoclet, JC; Auger, FA; Lagaud, GJL; Germain, L; Andriantsitohaina, R				L'Heureux, N; Stoclet, JC; Auger, FA; Lagaud, GJL; Germain, L; Andriantsitohaina, R			A human tissue-engineered vascular media: a new model for pharmacological studies of contractile responses	FASEB JOURNAL			English	Article						tissue engineering; blood vessel; pharmacol; calcium; purinoceptors; cyclic nucleotides; contraction	SMOOTH-MUSCLE-CELLS; DEPENDENT PROTEIN-KINASE; NITRIC-OXIDE; ISOMETRIC CONTRACTION; NUCLEOTIDE RECEPTOR; CYCLIC-GMP; EXPRESSION; ATP; CULTURE; MECHANISM	Our method for producing tissue-engineered blood vessels based exclusively on the use of human cells, i.e., without artificial scaffolding, has previously been described (1). In this report, a tissue-engineered vascular media (TEVM) was specifically produced for pharmacological studies from cultured human vascular smooth muscle cells (VSMC). The VSMC displayed a differentiated phenotype as demonstrated by the re-expression of VSMC-specific markers and actual tissue contraction in response to physiological stimuli. Because of their physiological shape and mechanical strength, rings of human TEVM could be mounted on force transducers in organ baths to perform standard pharmacological experiments. Concentration-response curves to vasoconstrictor agonists (histamine, bradykinin, ATP, and UTP) were established, with or without selective antagonists, allowing pharmacological characterization of receptors (H-1, B-2, and P-2Y1, and pyrimidinoceptors). Sustained agonist-induced contractions were associated with transient increases in cytosolic Ca2+ concentration, suggesting sensitization of the contractile machinery to Ca2+.ATP caused both Ca2+ entry and Ca2+ release from a ryanodine- and caffeine-sensitive store. Increased cyclic AMP or cyclic GMP levels caused relaxation. This human TEVM displays many of functional characters of the normal vessel from which the cells were originally isolated, including contractile/relaxation responses, cyclic nucleotide sensitivity, and Ca2+ handling mechanisms comparable to those of the normal vessel from which the cells were originally isolated. These results demonstrate the potential of this human model as a versatile new tool for pharmacological research.	Hop St Sacrament CHA, Lab Organogenese Expt, Ste Foy, PQ G1S 4L8, Canada; Univ Laval, Dept Surg, Quebec City, PQ, Canada; Univ Strasbourg 1, Fac Pharm, Lab Pharmacol & Physicochim Interact Cellulaires, UMR CNRS 7034, F-67401 Illkirch Graffenstaden, France	Laval University; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Germain, L (corresponding author), Hop St Sacrament CHA, Lab Organogenese Expt, 1050 Chemin, Ste Foy, PQ G1S 4L8, Canada.	Lucie.germain@chg.ulaval.ca	ANDRIANTSITOHAINA, Ramaroson/H-5286-2018; L'Heureux, Nicolas/K-8669-2015	L'Heureux, Nicolas/0000-0001-8602-3948; Germain, Lucie/0000-0001-8883-6491; andriantsitohaina, ramaroson/0000-0002-4770-3585				ALLEN BG, 1994, TRENDS BIOCHEM SCI, V19, P362, DOI 10.1016/0968-0004(94)90112-0; ALTURA BM, 1972, AM J PHYSIOL, V222, P345, DOI 10.1152/ajplegacy.1972.222.2.345; ANDRIANTSITOHAINA R, 1995, AM J PHYSIOL-HEART C, V268, pH1223, DOI 10.1152/ajpheart.1995.268.3.H1223; BIRUKOV KG, 1993, EXP CELL RES, V204, P46, DOI 10.1006/excr.1993.1007; Bo XN, 1998, EUR J PHARMACOL, V353, P59, DOI 10.1016/S0014-2999(98)00383-5; Boerth NJ, 1997, J VASC RES, V34, P245, DOI 10.1159/000159231; BOSWELL CA, 1992, MICROVASC RES, V43, P178, DOI 10.1016/0026-2862(92)90015-H; BRINER VA, 1993, AM J HYPERTENS, V6, P268, DOI 10.1093/ajh/6.4.268; Brown C, 1999, CIRC RES, V84, P655, DOI 10.1161/01.RES.84.6.655; CAILLA HL, 1976, ANAL BIOCHEM, V70, P195, DOI 10.1016/S0378-5173(83)90100-X; CHAMLEYCAMPBELL J, 1979, PHYSIOL REV, V59, P1, DOI 10.1152/physrev.1979.59.1.1; Charlton SJ, 1996, BRIT J PHARMACOL, V119, P1301, DOI 10.1111/j.1476-5381.1996.tb16038.x; CHEN TR, 1977, EXP CELL RES, V104, P255, DOI 10.1016/0014-4827(77)90089-1; Communi D, 1995, J BIOL CHEM, V270, P30849, DOI 10.1074/jbc.270.52.30849; CORNWELL TL, 1994, J VASC RES, V31, P330, DOI 10.1159/000159061; Delaey C, 1997, EUR J PHARMACOL, V325, P41, DOI 10.1016/S0014-2999(97)00097-6; DRUMMOND GR, 1995, BRIT J PHARMACOL, V116, P2746; DUBEY RK, 1995, J CLIN INVEST, V96, P141, DOI 10.1172/JCI118014; DUBEY RK, 1992, CIRC RES, V71, P1143, DOI 10.1161/01.RES.71.5.1143; EASTWOOD M, 1994, BBA-GEN SUBJECTS, V1201, P186, DOI 10.1016/0304-4165(94)90040-X; Erlinge D, 1998, GEN PHARMACOL-VASC S, V31, P1, DOI 10.1016/S0306-3623(97)00420-5; Erlinge D, 1998, BIOCHEM BIOPH RES CO, V248, P864, DOI 10.1006/bbrc.1998.9083; FELETOU M, 1995, EUR J PHARMACOL, V274, P57, DOI 10.1016/0014-2999(94)00709-G; FUKURODA T, 1994, J APPL PHYSIOL, V76, P1976, DOI 10.1152/jappl.1994.76.5.1976; Gessi S, 1997, BRIT J PHARMACOL, V122, P1450, DOI 10.1038/sj.bjp.0701536; Groschner K, 1996, BIOCHEM J, V318, P513, DOI 10.1042/bj3180513; GRYNKIEWICZ G, 1985, J BIOL CHEM, V360, P3110; Harper S, 1998, BRIT J PHARMACOL, V124, P703, DOI 10.1038/sj.bjp.0701895; JIANG H, 1992, J BIOL CHEM, V267, P1015; Kleschyov AL, 1998, BRIT J PHARMACOL, V124, P623, DOI 10.1038/sj.bjp.0701916; KOLODNEY MS, 1992, J CELL BIOL, V117, P73, DOI 10.1083/jcb.117.1.73; Kunapuli SP, 1998, BIOCHEM J, V336, P513, DOI 10.1042/bj3360513; L'Heureux N, 1998, FASEB J, V12, P47, DOI 10.1096/fasebj.12.1.47; Lagaud GJL, 1996, J PHYSIOL-LONDON, V492, P689, DOI 10.1113/jphysiol.1996.sp021338; LHEUREUX N, 1993, J VASC SURG, V17, P499, DOI 10.1016/0741-5214(93)90150-K; LINCOLN TM, 1991, BLOOD VESSELS, V28, P129; LOIRAND G, 1995, PFLUG ARCH EUR J PHY, V430, P429, DOI 10.1007/BF00373919; MARCEAU F, 1995, IMMUNOPHARMACOLOGY, V30, P1, DOI 10.1016/0162-3109(95)00011-H; Moy AB, 1996, J CLIN INVEST, V97, P1020, DOI 10.1172/JCI118493; MURRAY TR, 1990, J CELL PHYSIOL, V143, P26, DOI 10.1002/jcp.1041430105; Murthy KS, 1998, J BIOL CHEM, V273, P4695, DOI 10.1074/jbc.273.8.4695; Nguyen T, 1995, J BIOL CHEM, V270, P30845, DOI 10.1074/jbc.270.52.30845; Nicholas RA, 1996, J AUTON PHARMACOL, V16, P319, DOI 10.1111/j.1474-8673.1996.tb00044.x; Nicholas RA, 1996, MOL PHARMACOL, V50, P224; Niklason LE, 1999, SCIENCE, V284, P489, DOI 10.1126/science.284.5413.489; OKADA K, 1991, AM J PHYSIOL, V260, pF39, DOI 10.1152/ajprenal.1991.260.1.F39; OSOL G, 1995, J VASC RES, V32, P275, DOI 10.1159/000159102; OWENS GK, 1995, PHYSIOL REV, V75, P487; PACAUD P, 1995, AM J PHYSIOL-HEART C, V269, pH30, DOI 10.1152/ajpheart.1995.269.1.H30; PARR CE, 1994, P NATL ACAD SCI USA, V91, P13067, DOI 10.1073/pnas.91.26.13067; PARR CE, 1994, P NATL ACAD SCI USA, V91, P3275, DOI 10.1073/pnas.91.8.3275; Petitclerc E, 1996, J IMMUNOL, V156, P3426; Pfitzer G, 1998, ACTA PHYSIOL SCAND, V164, P449, DOI 10.1111/j.1365-201X.1998.tb10698.x; PILCHER BK, 1995, PLAST RECONSTR SURG, V96, P1188, DOI 10.1097/00006534-199510000-00029; RICHARD S, 1992, BIOCHIM BIOPHYS ACTA, V1160, P95, DOI 10.1016/0167-4838(92)90042-C; Robaye B, 1997, EUR J PHARMACOL, V329, P231, DOI 10.1016/S0014-2999(97)89184-4; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; SHIRINSKY VP, 1992, AM J HYPERTENS, V5, pS124, DOI 10.1093/ajh/5.6.124S; SKALLI O, 1986, J CELL BIOL, V103, P2787, DOI 10.1083/jcb.103.6.2787; SOMLYO AP, 1994, NATURE, V372, P231, DOI 10.1038/372231a0; Strobaek D, 1996, BRIT J PHARMACOL, V118, P1645, DOI 10.1111/j.1476-5381.1996.tb15587.x; THYBERG J, 1990, ARTERIOSCLEROSIS, V10, P966, DOI 10.1161/01.ATV.10.6.966; Zhao M, 1996, PULM PHARMACOL THER, V9, P167, DOI 10.1006/pulp.1996.0019	63	129	132	0	15	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2001	15	2					515	524		10.1096/fj.00-0283com	http://dx.doi.org/10.1096/fj.00-0283com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	400LK	11156967				2022-12-25	WOS:000166872900033
J	Kamencic, H; Griebel, RW; Lyon, AW; Paterson, PG; Juurlink, BHJ				Kamencic, H; Griebel, RW; Lyon, AW; Paterson, PG; Juurlink, BHJ			Promoting glutathione synthesis after spinal cord trauma decreases secondary damage and promotes retention of function	FASEB JOURNAL			English	Article						central nervous system; functional recovery; neurotrauma; oxidative stress; paraplegia	RANDOMIZED CONTROLLED TRIAL; LIPID-PEROXIDATION PRODUCT; TIRILAZAD MESYLATE; OXIDATIVE STRESS; ISOLATED HEPATOCYTES; N-ACETYLCYSTEINE; INJURY; RAT; METHYLPREDNISOLONE; REDUCTASE	The study aimed to 1) quantify oxidative stress in spinal cord after crush injury at T6, 2) determine whether the administration of the procysteine compound L-2-oxothiazolidine-4-carboxylate (OTC) would up-regulate glutathione (GSH) synthesis and decrease oxidative stress, and 3) determine whether decreased oxidative stress results in better tissue and function retention. We demonstrate that spinal cord compression (5 s with a 50 g aneurysm clip) at T6 in rats results in oxidative stress that is extensive (significant increases in oxidative stress seen at C3 and L4) and rapid in onset. Indices of oxidative stress used were GSH content, protein carbonyl content, and inactivation of glutathione reductase. Administration of OTC resulted in a marked decrease in oxidative stress associated with a sparing of white matter at T6 (16 +/-1.9% retained in OTC-treated animals vs, less than 1% in saline-treated). Behavioral indices in control, saline-treated, and OTC-treated animals after 6 wk were respectively: angle board scores (59 degrees, 32 degrees, and 42 degrees), modified Tarlov score (7, 2.4, and 4.1), and Basso-Beattie-Bresnahan score (21, 5.3, and 12.9). We conclude that administration of OTC after spinal cord trauma greatly decreases oxidative stress and allows tissue preservation, thereby enabling otherwise paraplegic animals to locomote.	Univ Saskatchewan, Dept Anat & Cell Biol, Saskatoon, SK S7N 5E5, Canada; Univ Saskatchewan, Dept Surg Neurosurg, Saskatoon, SK S7N 5E5, Canada; Univ Saskatchewan, Dept Pathol, Saskatoon, SK S7N 5E5, Canada; Univ Saskatchewan, Coll Pharm & Nutr, Saskatoon, SK S7N 5E5, Canada	University of Saskatchewan; University of Saskatchewan; University of Saskatchewan; University of Saskatchewan	Juurlink, BHJ (corresponding author), Univ Saskatchewan, Dept Anat & Cell Biol, 107 Wiggins Rd, Saskatoon, SK S7N 5E5, Canada.							ANDERSON DK, 1993, ANN EMERG MED, V22, P987, DOI 10.1016/S0196-0644(05)82739-8; ANDERSON ME, 1989, FASEB J, V3, P1632, DOI 10.1096/fasebj.3.5.2920877; Barker JE, 1996, BRAIN RES, V716, P118, DOI 10.1016/0006-8993(96)00003-0; BARTHOLDI D, 1995, BRAIN RES, V672, P177, DOI 10.1016/0006-8993(94)01410-J; BASSO DM, 1995, J NEUROTRAUM, V12, P1, DOI 10.1089/neu.1995.12.1; BELLOMO G, 1987, BIOCHEM PHARMACOL, V36, P1313, DOI 10.1016/0006-2952(87)90087-6; Bernard GR, 1997, CHEST, V112, P164, DOI 10.1378/chest.112.1.164; Bethea JR, 1998, J NEUROSCI, V18, P3251; Blakeman DP, 1998, J BIOCHEM MOL TOXIC, V12, P185, DOI 10.1002/(SICI)1099-0461(1998)12:3<185::AID-JBT7>3.0.CO;2-H; BLAKYTNY R, 1992, BIOCHEM J, V288, P303, DOI 10.1042/bj2880303; Bracken MB, 1998, J NEUROSURG, V89, P699, DOI 10.3171/jns.1998.89.5.0699; Bracken MB, 1997, JAMA-J AM MED ASSOC, V277, P1597, DOI 10.1001/jama.277.20.1597; BROWN SA, 1992, J AM VET MED ASSOC, V200, P1849; Burcham PC, 1996, BIOCHEM BIOPH RES CO, V220, P996, DOI 10.1006/bbrc.1996.0521; Carlson SL, 1998, EXP NEUROL, V151, P77, DOI 10.1006/exnr.1998.6785; Christman JW, 2000, BRAIN PATHOL, V10, P153; EKLOW L, 1984, EUR J BIOCHEM, V138, P459, DOI 10.1111/j.1432-1033.1984.tb07938.x; FEHLINGS MG, 1995, EXP NEUROL, V132, P220, DOI 10.1016/0014-4886(95)90027-6; GALANDIUK S, 1993, ANN SURG, V218, P419, DOI 10.1097/00000658-199310000-00003; HALL ED, 1992, J NEUROSURG, V76, P13, DOI 10.3171/jns.1992.76.1.0013; Huang DW, 1999, NEURON, V24, P639, DOI 10.1016/S0896-6273(00)81118-6; Juurlink B H, 1998, J Spinal Cord Med, V21, P309; Juurlink BHJ, 1999, NEUROTOX RES, V1, P119, DOI 10.1007/BF03033276; Juurlink BHJ, 1998, GLIA, V22, P371, DOI 10.1002/(SICI)1098-1136(199804)22:4<371::AID-GLIA6>3.0.CO;2-6; KALAYJIAN RC, 1994, J ACQ IMMUN DEF SYND, V7, P369; KHAN M, 1983, CAN J NEUROL SCI, V10, P161, DOI 10.1017/S031716710004484X; Koc RK, 1999, SPINAL CORD, V37, P29, DOI 10.1038/sj.sc.3100732; KOMURO C, 1985, J CHROMATOGR, V338, P209, DOI 10.1016/0378-4347(85)80087-6; LEVINE RL, 1990, METHOD ENZYMOL, V186, P464; Lucas JH, 1998, J NEUROPATH EXP NEUR, V57, P937, DOI 10.1097/00005072-199810000-00006; McDonald JW, 1999, NAT MED, V5, P1410, DOI 10.1038/70986; MCLELLAN LI, 1995, CARCINOGENESIS, V16, P2099, DOI 10.1093/carcin/16.9.2099; MEISTER A, 1989, GLUTATHIONE CHEM BIO, VA, P367; MESINA JE, 1989, BRAIN RES, V478, P181, DOI 10.1016/0006-8993(89)91494-7; Miyata T, 1998, FEBS LETT, V437, P24, DOI 10.1016/S0014-5793(98)01079-5; Nesathurai S, 1998, J TRAUMA, V45, P1088, DOI 10.1097/00005373-199812000-00021; Popovich PG, 1999, EXP NEUROL, V158, P351, DOI 10.1006/exnr.1999.7118; RIVLIN AS, 1977, J NEUROSURG, V47, P577, DOI 10.3171/jns.1977.47.4.0577; RIVLIN AS, 1979, SURG NEUROL, V9, P39; SCHUPPE I, 1992, BIOCHEM PHARMACOL, V44, P1757, DOI 10.1016/0006-2952(92)90069-U; SHIVAKUMAR BR, 1995, J PHARMACOL EXP THER, V274, P1167; Springer JE, 1997, J NEUROCHEM, V68, P2469; TABATABAIE T, 1994, ARCH BIOCHEM BIOPHYS, V314, P112, DOI 10.1006/abbi.1994.1418; Taoka Y, 1997, NEUROSCIENCE, V79, P1177, DOI 10.1016/S0306-4522(97)00011-0; Tariq M, 1998, J NEUROTRAUM, V15, P239, DOI 10.1089/neu.1998.15.239; Vita JA, 1998, J CLIN INVEST, V101, P1408, DOI 10.1172/JCI1155	46	89	91	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JAN	2001	15	1					243	250		10.1096/fj.00-0228com	http://dx.doi.org/10.1096/fj.00-0228com			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	390TH	11149912				2022-12-25	WOS:000166312400033
J	Gudi, T; Casteel, DE; Vinson, C; Boss, GR; Pilz, RB				Gudi, T; Casteel, DE; Vinson, C; Boss, GR; Pilz, RB			NO activation of fos promoter elements requires nuclear translocation of G-kinase I and CREB phosphorylation but is independent of MAP kinase activation	ONCOGENE			English	Article						nitric oxide; cGMP-dependent protein kinase; c-fos; CREB	DEPENDENT PROTEIN-KINASE; MULTIPLE SEQUENCE ELEMENTS; SOLUBLE GUANYLATE-CYCLASE; SMOOTH-MUSCLE CELLS; NITRIC-OXIDE; CYCLIC-GMP; C-FOS; GENE-EXPRESSION; BINDING PROTEIN; DNA-BINDING	We have shown that nitric oxide (NO) regulates c-fos gene expression via cGMP-dependent protein kinase (G-kinase), but NO's precise mechanism of action is unclear, We now demonstrate that: (1) NO targets two transcriptional elements in the fos promoter, i,e., the fos AP-1 binding site and the cAMP-response element (CRE); (2) NO activation of these two enhancer elements requires the CRE binding protein CREB because a dominant negative CREB fully inhibits NO transactivation of reporter genes whereas dominant negative Fos or CCAAT enhancer binding proteins have no effect; (3) CREB is phosphorylated by G-kinase in vitro and its phosphorylation increases in vivo when G-kinase is activated either directly by cGMP or indirectly by NO via soluble guanylate cyclase; (4) NO activation of fos promoter elements requires nuclear translocation of G-kinase but not activation of mitogen-activated protein kinases.	Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA; Univ Calif San Diego, Ctr Canc, La Jolla, CA 92093 USA; NCI, Met Lab, NIH, Bethesda, MD 20892 USA	University of California System; University of California San Diego; University of California System; University of California San Diego; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Pilz, RB (corresponding author), Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA.			Boss, Gerry/0000-0002-9758-8714	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007233] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM055586] Funding Source: NIH RePORTER; NIDDK NIH HHS [5T32DK07233-24] Funding Source: Medline; NIGMS NIH HHS [R01GM055586] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ahn S, 1998, MOL CELL BIOL, V18, P967, DOI 10.1128/MCB.18.2.967; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; ARIAS J, 1994, NATURE, V370, P226, DOI 10.1038/370226a0; BERKOWITZ LA, 1989, MOL CELL BIOL, V9, P4272, DOI 10.1128/MCB.9.10.4272; BOSCOFELLEY E, 1994, AM J RESP CELL MOL B, V11, P159; Browning DD, 2000, J BIOL CHEM, V275, P2811, DOI 10.1074/jbc.275.4.2811; Callsen D, 1998, J IMMUNOL, V161, P4852; Chiche JD, 1998, J BIOL CHEM, V273, P34263, DOI 10.1074/jbc.273.51.34263; COLBRAN JL, 1992, BIOCHEM CELL BIOL, V70, P1277, DOI 10.1139/o92-174; Collins SP, 1999, J BIOL CHEM, V274, P8391, DOI 10.1074/jbc.274.13.8391; EIGENTHALER M, 1998, REV PHYSL BIOCH PHAR, V135, P174; ENSLEN H, 1994, J BIOL CHEM, V269, P15520; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; Finkbeiner S, 1997, NEURON, V19, P1031, DOI 10.1016/S0896-6273(00)80395-5; FISCH TM, 1989, GENE DEV, V3, P198, DOI 10.1101/gad.3.2.198; GAUTHIERROUVIERE C, 1992, ONCOGENE, V7, P363; GINTY DD, 1993, SCIENCE, V260, P238, DOI 10.1126/science.8097062; Gonzalez-Zulueta M, 2000, P NATL ACAD SCI USA, V97, P436, DOI 10.1073/pnas.97.1.436; GRUSSENMEYER T, 1985, P NATL ACAD SCI USA, V82, P7952, DOI 10.1073/pnas.82.23.7952; Gudi T, 1996, J BIOL CHEM, V271, P4597; Gudi T, 1997, MOL CELL BIOL, V17, P5244, DOI 10.1128/MCB.17.9.5244; Gudi T, 1999, FASEB J, V13, P2143, DOI 10.1096/fasebj.13.15.2143; HABY C, 1994, J NEUROCHEM, V62, P496; HAGIWARA M, 1993, MOL CELL BIOL, V13, P4852, DOI 10.1128/MCB.13.8.4852; Idriss SD, 1999, J BIOL CHEM, V274, P9489, DOI 10.1074/jbc.274.14.9489; Impey S, 1998, NEURON, V21, P869, DOI 10.1016/S0896-6273(00)80602-9; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; Klatt P, 1999, J BIOL CHEM, V274, P15857, DOI 10.1074/jbc.274.22.15857; Komalavilas P, 1999, J BIOL CHEM, V274, P34301, DOI 10.1074/jbc.274.48.34301; Lander HM, 1997, J BIOL CHEM, V272, P4323, DOI 10.1074/jbc.272.7.4323; LevRam V, 1997, NEURON, V18, P1025, DOI 10.1016/S0896-6273(00)80340-2; Lu YF, 1999, J NEUROSCI, V19, P10250; MARKERT T, 1995, J CLIN INVEST, V96, P822, DOI 10.1172/JCI118128; Matthews JR, 1996, NUCLEIC ACIDS RES, V24, P2236, DOI 10.1093/nar/24.12.2236; MATTHEWS RP, 1994, MOL CELL BIOL, V14, P6107, DOI 10.1128/MCB.14.9.6107; MEINKOTH JL, 1990, P NATL ACAD SCI USA, V87, P9595, DOI 10.1073/pnas.87.24.9595; METZ R, 1991, ONCOGENE, V6, P2165; METZ R, 1991, GENE DEV, V5, P1754, DOI 10.1101/gad.5.10.1754; Moon C, 1999, P NATL ACAD SCI USA, V96, P14605, DOI 10.1073/pnas.96.25.14605; MORRIS BJ, 1995, J BIOL CHEM, V270, P24740; NAKANE M, 1990, J BIOL CHEM, V265, P16841; Olive M, 1997, J BIOL CHEM, V272, P18586, DOI 10.1074/jbc.272.30.18586; Parenti A, 1998, J BIOL CHEM, V273, P4220, DOI 10.1074/jbc.273.7.4220; PEUNOVA N, 1993, NATURE, V364, P450, DOI 10.1038/364450a0; PILZ RB, 1995, FASEB J, V9, P552, DOI 10.1096/fasebj.9.7.7737465; PRYZWANSKY KB, 1995, J LEUKOCYTE BIOL, V57, P670, DOI 10.1002/jlb.57.4.670; Qiang M, 1999, BEHAV PHARMACOL, V10, P215, DOI 10.1097/00008877-199903000-00010; Roberson ED, 1999, J NEUROSCI, V19, P4337; ROTHMAN A, 1992, CIRCULATION, V86, P1977, DOI 10.1161/01.CIR.86.6.1977; SASSONECORSI P, 1990, ONCOGENE, V5, P427; SCHMIDT HHHW, 1993, BIOCHIM BIOPHYS ACTA, V1178, P153, DOI 10.1016/0167-4889(93)90006-B; Seternes OM, 1999, MOL ENDOCRINOL, V13, P1071, DOI 10.1210/me.13.7.1071; Shaywitz AJ, 1999, ANNU REV BIOCHEM, V68, P821, DOI 10.1146/annurev.biochem.68.1.821; Suhasini M, 1998, MOL CELL BIOL, V18, P6983, DOI 10.1128/MCB.18.12.6983; SUN PQ, 1994, GENE DEV, V8, P2527, DOI 10.1101/gad.8.21.2527; VELCICH A, 1990, MOL CELL BIOL, V10, P6273, DOI 10.1128/MCB.10.12.6273; Wang X, 1999, EMBO J, V18, P4549, DOI 10.1093/emboj/18.16.4549; Wang Y, 2000, ONCOGENE, V19, P1379, DOI 10.1038/sj.onc.1203443; Wisdom R, 1999, EXP CELL RES, V253, P180, DOI 10.1006/excr.1999.4685; WYATT TA, 1991, J BIOL CHEM, V266, P21274; ZHUO M, 1994, NATURE, V368, P635, DOI 10.1038/368635a0	61	75	80	0	3	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 14	2000	19	54					6324	6333		10.1038/sj.onc.1204007	http://dx.doi.org/10.1038/sj.onc.1204007			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	388YK	11175347				2022-12-25	WOS:000166210500016
J	Hara, K; Kudoh, H; Enomoto, T; Hashimoto, Y; Masuko, T				Hara, K; Kudoh, H; Enomoto, T; Hashimoto, Y; Masuko, T			Enhanced tumorigenicity caused by truncation of the extracellular domain of GP125/CD98 heavy chain	ONCOGENE			English	Article						CD98; transfectant; extracellular domain	AMINO-ACID-TRANSPORT; GROWTH-FACTOR RECEPTOR; MONOCLONAL-ANTIBODY 4F2; CELL-SURFACE ANTIGEN; XENOPUS-LAEVIS OOCYTES; ACTIVATED LYMPHOCYTES; INTEGRIN ACTIVATION; RAS TRANSFORMATION; INHIBIT ACTIVATION; MEMBRANE-PROTEIN	GP125/CD98 is a heterodimeric 125-kDa glycoprotein, which consists of an 85-kDa heavy chain the) and a 40-kDa light chain (Ic), and is strongly expressed on the cell surface of various tumor cells, irrespective of their tissue of origin. We have recently demonstrated that over-expression of the CD98hc cDNA causes malignant transformation of NIH3T3 cells. To investigate the function of the extracellular domain of CD98hc in cell proliferation and malignant transformation, we established two NIH3T3-derived clones transfected with human truncated CD98hc cDNAs, and compared their characteristics with parental NIH3T3 and clones transfected with full-length CD98hc cDNA, Truncated as well as full-length CD98hc-transfected clones grew to a higher saturation density than control cells. Efficiency of colony formation in soft agar was augmented in all CD98hc-transfected clones, and the degrees of augmented colony formation of the transfectants expressing full-length CD98hc of 529 a.a. or truncated CD98hc of 418 a,a, were reduced by anti-human CD98hc antibodies, while that of the transfectant expressing truncated CD98hc of 237 a,a, lacking the epitopes recognized by anti-human CD98hc antibodies was not affected by the addition of antibodies. CD98hc-transfected clones developed tumors in athymic mice, and tumor growth of truncated CD98hc-transfected clones was faster than that of full-length CD98hc-transfected clones.	Kinki Univ, Sch Pharmaceut Sci, Cell Biol Lab, Higashiosaka, Osaka 5778502, Japan; Tohoku Univ, Grad Sch Pharmaceut Sci, Mol Cell Biol Lab, Aoba Ku, Sendai, Miyagi 9808578, Japan; Sasaki Inst, Chikusa Ku, Tokyo 101, Japan	Kindai University (Kinki University); Tohoku University	Masuko, T (corresponding author), Kinki Univ, Sch Pharmaceut Sci, Cell Biol Lab, 4-1 Kowakae 3 Chome, Higashiosaka, Osaka 5778502, Japan.							BERTRAN J, 1992, P NATL ACAD SCI USA, V89, P5606, DOI 10.1073/pnas.89.12.5606; Bouck N, 1979, Methods Enzymol, V58, P296; Broer S, 1995, BIOCHEM J, V312, P863, DOI 10.1042/bj3120863; COOPER GM, 1980, NATURE, V284, P418, DOI 10.1038/284418a0; DIXON WT, 1990, INT J CANCER, V45, P59, DOI 10.1002/ijc.2910450113; Dong S, 1996, FEBS LETT, V395, P165, DOI 10.1016/0014-5793(96)01031-9; DOWNWARD J, 1984, NATURE, V307, P521, DOI 10.1038/307521a0; Fenczik CA, 1997, NATURE, V390, P81, DOI 10.1038/36349; Hara K, 1999, BIOCHEM BIOPH RES CO, V262, P720, DOI 10.1006/bbrc.1999.1051; Hashimoto Y, 1983, Gan, V74, P819; HAYNES BF, 1981, J IMMUNOL, V126, P1409; Hughes PE, 1997, CELL, V88, P521, DOI 10.1016/S0092-8674(00)81892-9; KAMMA H, 1989, CANCER RES, V49, P5118; Kanai Y, 1998, J BIOL CHEM, V273, P23629, DOI 10.1074/jbc.273.37.23629; KHOSRAVIFAR R, 1995, MOL CELL BIOL, V15, P6443; KROUS MH, 1987, EMBO J, V6, P605; LUMADUE JA, 1987, P NATL ACAD SCI USA, V84, P9204, DOI 10.1073/pnas.84.24.9204; MACLEOD CL, 1994, J EXP BIOL, V196, P109; Mannion BA, 1998, J BIOL CHEM, V273, P33127, DOI 10.1074/jbc.273.50.33127; MARTIN GS, 1986, CANCER SURV, V5, P199; Mastroberardino L, 1998, NATURE, V395, P288, DOI 10.1038/26246; MASUKO T, 1985, JPN J CANCER RES, V76, P386; MICHALAK M, 1986, J BIOL CHEM, V261, P92; Nakamura E, 1999, J BIOL CHEM, V274, P3009, DOI 10.1074/jbc.274.5.3009; NISHIKAWA R, 1994, P NATL ACAD SCI USA, V91, P7727, DOI 10.1073/pnas.91.16.7727; OHGIMOTO S, 1995, J IMMUNOL, V155, P3585; PARMACEK MS, 1989, NUCLEIC ACIDS RES, V17, P1915, DOI 10.1093/nar/17.5.1915; PATTERSON JAK, 1984, J INVEST DERMATOL, V83, P210, DOI 10.1111/1523-1747.ep12263581; Pfeiffer R, 1999, EMBO J, V18, P49, DOI 10.1093/emboj/18.1.49; Pineda M, 1999, J BIOL CHEM, V274, P19738, DOI 10.1074/jbc.274.28.19738; PLOWMAN GD, 1993, P NATL ACAD SCI USA, V90, P1746, DOI 10.1073/pnas.90.5.1746; POSILLICO JT, 1987, J CLIN ENDOCR METAB, V64, P43, DOI 10.1210/jcem-64-1-43; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; QUACKENBUSH E, 1987, P NATL ACAD SCI USA, V84, P6526, DOI 10.1073/pnas.84.18.6526; QUACKENBUSH E, 1987, P NATL ACAD SCI USA, V84, P8618; QUACKENBUSH EJ, 1986, J IMMUNOL, V136, P118; Radeva G, 1997, J BIOL CHEM, V272, P13937, DOI 10.1074/jbc.272.21.13937; Rajan DP, 1999, J BIOL CHEM, V274, P29005, DOI 10.1074/jbc.274.41.29005; Rossier G, 1999, J BIOL CHEM, V274, P34948, DOI 10.1074/jbc.274.49.34948; SANG JS, 1995, CANCER RES, V55, P1152; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Sato H, 1999, J BIOL CHEM, V274, P11455, DOI 10.1074/jbc.274.17.11455; Schwartz MA, 1997, J CELL BIOL, V139, P575, DOI 10.1083/jcb.139.3.575; Schwartz MA, 1996, EMBO J, V15, P6525, DOI 10.1002/j.1460-2075.1996.tb01043.x; Shin S, 1979, Methods Enzymol, V58, P370; Shishido T, 2000, INT J CANCER, V87, P311, DOI 10.1002/1097-0215(20000801)87:3<311::AID-IJC1>3.0.CO;2-W; TANAKA T, 1989, JPN J CANCER RES, V80, P380, DOI 10.1111/j.1349-7006.1989.tb02323.x; TANAKA T, 1988, J BIOCHEM-TOKYO, V103, P644, DOI 10.1093/oxfordjournals.jbchem.a122322; TEIXEIRA S, 1987, J BIOL CHEM, V262, P9574; Tsurudome M, 1999, J IMMUNOL, V162, P2462; Warren AP, 1996, BLOOD, V87, P3676, DOI 10.1182/blood.V87.9.3676.bloodjournal8793676; WELLS RG, 1992, J BIOL CHEM, V267, P15285; YAGITA H, 1986, J IMMUNOL, V136, P2062; YAGITA H, 1986, CANCER RES, V46, P1478; YAGITA H, 1986, J IMMUNOL, V136, P2055; YAMAZAKI H, 1988, MOL CELL BIOL, V8, P1816, DOI 10.1128/MCB.8.4.1816	56	24	26	0	3	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 14	2000	19	54					6209	6215		10.1038/sj.onc.1204019	http://dx.doi.org/10.1038/sj.onc.1204019			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	388YK	11175335				2022-12-25	WOS:000166210500004
J	He, HL; McColl, K; Distelhorst, CW				He, HL; McColl, K; Distelhorst, CW			Involvement of c-Fos in signaling grp78 induction following ER calcium release	ONCOGENE			English	Article						GRP78; c-Fos; calcium; thapsigargin	ENDOPLASMIC-RETICULUM STRESS; PROGRAMMED CELL-DEATH; CA2+-ATPASE INHIBITOR THAPSIGARGIN; UNFOLDED PROTEIN RESPONSE; MOUSE LYMPHOMA-CELLS; TRANSCRIPTION FACTOR; INDUCED APOPTOSIS; GLUCOCORTICOID RECEPTOR; DNA-BINDING; IN-VIVO	Release of calcium from the endoplasmic reticulum (ER) signals an increase in transcription of both the early response gene, c-fos, and the late response gene, grp78. We hale used thapsigargin (TG), an ER calcium-ATPase pump inhibitor that induces calcium release from the ER, to investigate the possible involvement of c-Fos, a component of the AP-1 transcription factor, in grp78 induction. Tno cell lines with markedly different responses to TG treatment were employed: the WEHI7,2 mouse lymphoma line in which TG fails to induce grp78, and the MDA-MB-468 mammary epithelial line in which TG induces grp78. In WEHI7,2 cells, TG-induced calcium release triggers a rapid increase in c-fos mRNA, but the level of c-Fos protein decreases due to degradation by the multicatalytic proteasome, C-Fos DeltaC, a proteasome resistant c-Fos mutant with AP-1 activity similar to that of wild type c-Pos, restores grp78 induction in WEHI7.2 cells, detected by both Northern hybridization and a grp78 promoter-luciferase reporter assay. In MDA-MB-468 cells, TG-mediated calcium release induces a sustained elevation of c-Fos protein that precedes grp78 induction. A region of the grp78 promoter containing both ERSE and CORE regions, but missing TRE and CRE regions, is sufficient to mediate induction of reporter luciferase activity, Induction of this reporter was blocked by A-Fos, a dominant negative inhibitor of c-Fos, Also, the induction of grp78-luciferase reporter activity was inhibited by c-fos antisense mRNA. In summary, the findings indicate that c-Fos is involved in signaling grp78 induction following TG treatment, and that grp78 induction is inhibited by proteasome-mediated c-Fos degradation.	Case Western Reserve Univ, Div Hematol Oncol, Dept Med, Cleveland, OH 44106 USA; Case Western Reserve Univ, Dept Pharmacol, Cleveland, OH 44106 USA	Case Western Reserve University; Case Western Reserve University	Distelhorst, CW (corresponding author), Case Western Reserve Univ, Div Hematol Oncol, Dept Med, BRB 329,10900 Euclid Ave, Cleveland, OH 44106 USA.				NATIONAL CANCER INSTITUTE [R01CA079806] Funding Source: NIH RePORTER; NCI NIH HHS [CA79806] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANGEL P, 1987, MOL CELL BIOL, V7, P2256, DOI 10.1128/MCB.7.6.2256; BARBER JR, 1987, MOL CELL BIOL, V7, P2201, DOI 10.1128/MCB.7.6.2201; Berridge MJ, 1998, NATURE, V395, P645, DOI 10.1038/27094; BROSTROM CO, 1990, ANNU REV PHYSIOL, V52, P577; BUTTYAN R, 1988, MOL ENDOCRINOL, V2, P650, DOI 10.1210/mend-2-7-650; Chapman R, 1998, ANNU REV CELL DEV BI, V14, P459, DOI 10.1146/annurev.cellbio.14.1.459; Chen LY, 2000, J CELL BIOCHEM, V78, P404, DOI 10.1002/1097-4644(20000901)78:3<404::AID-JCB6>3.0.CO;2-8; CLAPHAM DE, 1995, CELL, V80, P259, DOI 10.1016/0092-8674(95)90408-5; COLOTTA F, 1992, J BIOL CHEM, V267, P18278; Cox JS, 1996, CELL, V87, P391, DOI 10.1016/S0092-8674(00)81360-4; Duval DL, 1997, MOL ENDOCRINOL, V11, P1814, DOI 10.1210/me.11.12.1814; Foti DM, 1999, J BIOL CHEM, V274, P30402, DOI 10.1074/jbc.274.43.30402; Hafezi F, 1997, NAT MED, V3, P346, DOI 10.1038/nm0397-346; Haze K, 1999, MOL BIOL CELL, V10, P3787, DOI 10.1091/mbc.10.11.3787; He HL, 1998, J BIOL CHEM, V273, P25015, DOI 10.1074/jbc.273.39.25015; He HL, 1997, J CELL BIOL, V138, P1219, DOI 10.1083/jcb.138.6.1219; HELMBERG A, 1995, EMBO J, V14, P452, DOI 10.1002/j.1460-2075.1995.tb07021.x; HERSCHMAN HR, 1991, ANNU REV BIOCHEM, V60, P281, DOI 10.1146/annurev.biochem.60.1.281; Ivanov VN, 1997, J BIOL CHEM, V272, P8558; JONAT C, 1990, CELL, V62, P1189, DOI 10.1016/0092-8674(90)90395-U; Kaina B, 1997, CANCER RES, V57, P2721; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; Kaufman RJ, 1999, GENE DEV, V13, P1211, DOI 10.1101/gad.13.10.1211; KERPPOLA TK, 1993, MOL CELL BIOL, V13, P3782, DOI 10.1128/MCB.13.6.3782; LAM M, 1993, MOL ENDOCRINOL, V7, P686, DOI 10.1210/me.7.5.686; LAM M, 1994, P NATL ACAD SCI USA, V91, P6569, DOI 10.1073/pnas.91.14.6569; Li MQ, 2000, MOL CELL BIOL, V20, P5096, DOI 10.1128/MCB.20.14.5096-5106.2000; LI WW, 1994, MOL CELL BIOL, V14, P5533, DOI 10.1128/MCB.14.8.5533; LI WWF, 1993, J BIOL CHEM, V268, P12003; Lievremont JP, 1997, J BIOL CHEM, V272, P30873, DOI 10.1074/jbc.272.49.30873; LITTLE E, 1995, J BIOL CHEM, V270, P9526, DOI 10.1074/jbc.270.16.9526; Liu H, 1998, J BIOL CHEM, V273, P12858, DOI 10.1074/jbc.273.21.12858; LODISH HF, 1992, J BIOL CHEM, V267, P12753; McColl KS, 1998, MOL CELL ENDOCRINOL, V139, P229, DOI 10.1016/S0303-7207(98)00051-3; McCormick TS, 1997, J BIOL CHEM, V272, P6087, DOI 10.1074/jbc.272.9.6087; Mery L, 1996, J BIOL CHEM, V271, P9332, DOI 10.1074/jbc.271.16.9332; Morris JA, 1997, J BIOL CHEM, V272, P4327, DOI 10.1074/jbc.272.7.4327; Olive M, 1997, J BIOL CHEM, V272, P18586, DOI 10.1074/jbc.272.30.18586; Pahl HL, 1999, PHYSIOL REV, V79, P683, DOI 10.1152/physrev.1999.79.3.683; Preston GA, 1996, MOL CELL BIOL, V16, P211; Qi XM, 1997, ONCOGENE, V15, P2849, DOI 10.1038/sj.onc.1201463; Qi XM, 1997, ONCOGENE, V15, P1207, DOI 10.1038/sj.onc.1201290; RESENDEZ E, 1988, MOL CELL BIOL, V8, P4579, DOI 10.1128/MCB.8.10.4579; RofflerTarlov S, 1996, DEVELOPMENT, V122, P1; ROSEN LB, 1995, ADV SEC MESS PHOSPH, V30, P225; Roy B, 1999, NUCLEIC ACIDS RES, V27, P1437, DOI 10.1093/nar/27.6.1437; SCHONTHAL A, 1991, P NATL ACAD SCI USA, V88, P7096, DOI 10.1073/pnas.88.16.7096; SCHREIBER M, 1995, EMBO J, V14, P5338, DOI 10.1002/j.1460-2075.1995.tb00218.x; SHORT AD, 1993, P NATL ACAD SCI USA, V90, P4986, DOI 10.1073/pnas.90.11.4986; SMEYNE RJ, 1993, NATURE, V363, P166, DOI 10.1038/363166a0; Tabuchi A, 1996, J BIOL CHEM, V271, P31061, DOI 10.1074/jbc.271.49.31061; Wang XZ, 1998, EMBO J, V17, P5708, DOI 10.1093/emboj/17.19.5708; Wisdom R, 1999, EXP CELL RES, V253, P180, DOI 10.1006/excr.1999.4685; WOODEN SK, 1991, MOL CELL BIOL, V11, P5612, DOI 10.1128/MCB.11.11.5612; Yoshida H, 1998, J BIOL CHEM, V273, P33741, DOI 10.1074/jbc.273.50.33741; Yu ZF, 1999, EXP NEUROL, V155, P302, DOI 10.1006/exnr.1998.7002; Zhu C, 1997, MOL CELL BIOL, V17, P4957, DOI 10.1128/MCB.17.9.4957	57	23	23	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 30	2000	19	51					5936	5943		10.1038/sj.onc.1203994	http://dx.doi.org/10.1038/sj.onc.1203994			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	378CA	11127825				2022-12-25	WOS:000165563100013
J	MacLaren, A; Clark, W; Gillespie, DAF				MacLaren, A; Clark, W; Gillespie, DAF			v-Jun sensitizes cells to apoptosis by a mechanism involving mitochondrial cytochrome C release	ONCOGENE			English	Article						v-Jun; apoptosis; p53; cytochrome C	MYC-INDUCED APOPTOSIS; TRANSCRIPTION FACTOR; CYCLE PROGRESSION; TUMOR-SUPPRESSOR; DEATH; BCL-2; KINASE; FIBROBLASTS; INDUCTION; PROTEASES	v-Jun shares the ability of the Myc, E1A, and E2F oncogenes to both sustain cell cycle progression and promote apoptosis in the absence of mitogenic stimulation. To gain an insight into the mechanism of apoptosis sensitization,,ve examined the possible involvement of key regulatory proteins previously implicated in oncogene-induced cell death during v-Jun-induced apoptosis triggered by serum, withdrawal, We observed that ectopic expression of the anti-apoptotic Bcl-2 protein, or of two downstream effecters of growth factor signalling, v-PI 3-Kinase and v-Src, partially or completely suppressed apoptosis, Apoptosis was also observed in the presence of serum growth factors when endogenous PI3K activity was blocked using the synthetic inhibitor LY294002, further suggesting an important role for PI3-K in cell survival, Cytochrome C was released into the cytosol of apoptotic v-Jun expressing cells, and this release was inhibited by Bcl-2, suggesting an important role for mitochondrial dysfunction in v-Jun induced apoptosis, In contrast, inhibition of Fas signalling using dominant negative FADD did not inhibit apoptosis, nor was there any evidence for accumulation or activation of p53 in v-Jun transformed cells. Consistent with this latter observation, inhibition of p53 function by HPV16 E6 protein had no effect on v-Jun induced cell death. Taken together, these results suggest that mitochondrial dysfunction is an important component of the mechanism through which v-Jun sensitizes cells to apoptosis, but that the apoptotic signals elicited by v-Jun upstream of the mitochondria do not depend on increased levels of p53 activity or Fas signalling.	Beatson Inst Canc Res, Canc Res Campaign, Beatson Labs, Glasgow G61 1BD, Lanark, Scotland	Beatson Institute	MacLaren, A (corresponding author), Beatson Inst Canc Res, Canc Res Campaign, Beatson Labs, Garscube Estate,Switchback Rd, Glasgow G61 1BD, Lanark, Scotland.		Gillespie, David/R-4771-2019	Gillespie, David/0000-0002-6338-0544				Bates S, 1999, CELL MOL LIFE SCI, V55, P28, DOI 10.1007/s000180050267; BossyWetzel E, 1997, EMBO J, V16, P1695, DOI 10.1093/emboj/16.7.1695; BROWN JP, 1997, BIOCHIM BIOPHYS ACTA, V1332, P1; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Carpenter CL, 1996, CURR OPIN CELL BIOL, V8, P153, DOI 10.1016/S0955-0674(96)80060-3; Clark W, 2000, MOL CELL BIOL, V20, P2529, DOI 10.1128/MCB.20.7.2529-2542.2000; Clark W, 1997, CELL GROWTH DIFFER, V8, P371; Crouch DH, 1996, ONCOGENE, V12, P2689; Dang CV, 1999, TRENDS BIOCHEM SCI, V24, P68, DOI 10.1016/S0968-0004(98)01344-9; de Stanchina E, 1998, GENE DEV, V12, P2434, DOI 10.1101/gad.12.15.2434; DeGregori J, 1997, P NATL ACAD SCI USA, V94, P7245, DOI 10.1073/pnas.94.14.7245; ELLIS RE, 1991, ANNU REV CELL BIOL, V7, P663, DOI 10.1146/annurev.cb.07.110191.003311; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; GORCZYCA W, 1993, CANCER RES, V53, P3186; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; HARRINGTON EA, 1994, CURR OPIN GENET DEV, V4, P120, DOI 10.1016/0959-437X(94)90100-7; Hoffman B, 1998, ONCOGENE, V17, P3351, DOI 10.1038/sj.onc.1202592; Hueber AO, 1997, SCIENCE, V278, P1305, DOI 10.1126/science.278.5341.1305; Juin P, 1999, GENE DEV, V13, P1367, DOI 10.1101/gad.13.11.1367; Kennedy SG, 1999, MOL CELL BIOL, V19, P5800; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; Kilbey A, 1996, ONCOGENE, V12, P2409; Lenahan MK, 1996, ONCOGENE, V12, P1847; McCarthy NJ, 1997, J CELL BIOL, V136, P215, DOI 10.1083/jcb.136.1.215; Nunez G, 1998, ONCOGENE, V17, P3237, DOI 10.1038/sj.onc.1202581; Papas KK, 1999, FEBS LETT, V446, P338, DOI 10.1016/S0014-5793(99)00240-9; Prendergast GC, 1999, ONCOGENE, V18, P2967, DOI 10.1038/sj.onc.1202727; RAFF MC, 1993, SCIENCE, V262, P695, DOI 10.1126/science.8235590; Reed JC, 1998, ONCOGENE, V17, P3225, DOI 10.1038/sj.onc.1202591; Reed John C., 1999, Current Opinion in Oncology, V11, P68, DOI 10.1097/00001622-199901000-00014; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Schreiber M, 1999, GENE DEV, V13, P607, DOI 10.1101/gad.13.5.607; Schwartzberg PL, 1998, ONCOGENE, V17, P1463, DOI 10.1038/sj.onc.1202176; Sherr CJ, 1998, GENE DEV, V12, P2984, DOI 10.1101/gad.12.19.2984; Shimizu Y, 1996, IMMUNOL TODAY, V17, P565, DOI 10.1016/S0167-5699(96)10061-X; Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135; Vercammen D, 1998, J EXP MED, V188, P919, DOI 10.1084/jem.188.5.919; Vogt P K, 1990, Adv Cancer Res, V55, P1, DOI 10.1016/S0065-230X(08)60466-2; Wajant H, 1998, CURR BIOL, V8, P113, DOI 10.1016/S0960-9822(98)70042-9; WELHAM MJ, 1988, J VIROL, V62, P1898, DOI 10.1128/JVI.62.6.1898-1906.1988; White E, 1996, GENE DEV, V10, P1, DOI 10.1101/gad.10.1.1; Wisdom R, 1999, EMBO J, V18, P188, DOI 10.1093/emboj/18.1.188; Xiang JL, 1996, P NATL ACAD SCI USA, V93, P14559, DOI 10.1073/pnas.93.25.14559; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; YAO RJ, 1995, SCIENCE, V267, P2003, DOI 10.1126/science.7701324; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424	47	8	8	0	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 30	2000	19	51					5906	5918		10.1038/sj.onc.1203954	http://dx.doi.org/10.1038/sj.onc.1203954			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	378CA	11127822				2022-12-25	WOS:000165563100010
J	Aguilar, RC; Boehm, M; Gorshkova, I; Crouch, RJ; Tomita, K; Saito, T; Ohno, H; Bonifacino, JS				Aguilar, RC; Boehm, M; Gorshkova, I; Crouch, RJ; Tomita, K; Saito, T; Ohno, H; Bonifacino, JS			Signal-binding specificity of the mu 4 subunit of the adaptor protein complex AP-4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HERMANSKY-PUDLAK-SYNDROME; SORTING SIGNALS; MEDIUM CHAINS; CLATHRIN; DISTINCT; RECOGNITION; TGN38; REQUIREMENTS; TRANSPORT; SEQUENCE	The medium (p) chains of the adaptor protein (AP) complexes AP-1, AP-2, and AP-3 recognize distinct subsets of tyrosine-based (YXX phi) sorting signals found within the cytoplasmic domains of integral membrane proteins. Here, we describe the signal-binding specificity and affinity of the medium subunit mu4 of the recently described adaptor protein complex AP-4. To elucidate the determinants of specificity, we screened a two-hybrid combinatorial peptide library using mu4 as a selector protein. Statistical analyses of the results revealed that mu4 prefers aspartic acid at position Y+1, proline or arginine at Y+2, and phenylalanine at Y-1 and Y+3 (phi). In addition, we examined the interaction of mu4 with naturally occurring YXX phi signals by both two-hybrid and in vitro binding analyses. These experiments showed that mu4 recognized the tyrosine signal from the human lysosomal protein LAMP-2, HTGYEQF. Using surface plasmon resonance measurements, we determined the apparent dissociation constant for the mu4-YXX phi interaction to be in the micromolar range. To gain insight into a possible role of AP-4 in intracellular trafficking, we constructed a Tac chimera bearing a mu4-specific YXX phi signal. This chimera was targeted to the endosomal-lysosomal system without being internalized from the plasma membrane.	NICHD, Cell Biol & Metab Branch, NIH, Bethesda, MD 20892 USA; NICHD, Mol Genet Lab, NIH, Bethesda, MD 20892 USA; Chiba Univ, Grad Sch Med, Dept Mol Genet, Chuo Ku, Chiba 2608670, Japan; Kanazawa Univ, Canc Res Inst, Div Mol Membrane Biol, Kanazawa, Ishikawa 9200934, Japan	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); Chiba University; Kanazawa University	Bonifacino, JS (corresponding author), NICHD, Cell Biol & Metab Branch, NIH, Bldg 18T,Rm 101, Bethesda, MD 20892 USA.		Ohno, Hiroshi/L-7899-2014; Saito, Takashi/C-9684-2009	Ohno, Hiroshi/0000-0001-8776-9661; Saito, Takashi/0000-0001-9495-3547; Bonifacino, Juan S./0000-0002-5673-6370	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [ZIAHD000068, ZIAHD001607] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD001607, Z01HD000068] Funding Source: NIH RePORTER	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		AGUILAR RC, 1997, J BIOL CHEM, V272, P2760; Boll W, 1996, EMBO J, V15, P5789, DOI 10.1002/j.1460-2075.1996.tb00965.x; Bonifacino JS, 1996, P ASSOC AM PHYSICIAN, V108, P285; Bonifacino JS, 1999, J CELL BIOL, V145, P923, DOI 10.1083/jcb.145.5.923; Dell'Angelica EC, 2000, J BIOL CHEM, V275, P1300, DOI 10.1074/jbc.275.2.1300; Dell'Angelica EC, 1999, MOL CELL, V3, P11, DOI 10.1016/S1097-2765(00)80170-7; Dell'Angelica EC, 1998, SCIENCE, V280, P431, DOI 10.1126/science.280.5362.431; Feng LJ, 1999, HUM MOL GENET, V8, P323, DOI 10.1093/hmg/8.2.323; GALLUSSER A, 1993, EMBO J, V12, P5237, DOI 10.1002/j.1460-2075.1993.tb06219.x; Hirst J, 1999, MOL BIOL CELL, V10, P2787, DOI 10.1091/mbc.10.8.2787; Hirst J, 1998, BBA-MOL CELL RES, V1404, P173, DOI 10.1016/S0167-4889(98)00056-1; HUMPHREY JS, 1993, J CELL BIOL, V120, P1123, DOI 10.1083/jcb.120.5.1123; JONSSON U, 1991, BIOTECHNIQUES, V11, P620; Kantheti P, 1998, NEURON, V21, P111, DOI 10.1016/S0896-6273(00)80519-X; Kirchhausen T, 1999, ANNU REV CELL DEV BI, V15, P705, DOI 10.1146/annurev.cellbio.15.1.705; Le Borgne R, 1998, J BIOL CHEM, V273, P29451, DOI 10.1074/jbc.273.45.29451; Lewin DA, 1998, BBA-MOL CELL RES, V1401, P129, DOI 10.1016/S0167-4889(97)00130-4; Marks MS, 1997, TRENDS CELL BIOL, V7, P124, DOI 10.1016/S0962-8924(96)10057-X; Meyer C, 2000, EMBO J, V19, P2193, DOI 10.1093/emboj/19.10.2193; Mullins C, 2000, MOL GEN GENET, V263, P1003, DOI 10.1007/PL00008688; Ohno H, 1999, FEBS LETT, V449, P215, DOI 10.1016/S0014-5793(99)00432-9; Ohno H, 1998, J BIOL CHEM, V273, P25915, DOI 10.1074/jbc.273.40.25915; Ohno H, 1996, J BIOL CHEM, V271, P29009, DOI 10.1074/jbc.271.46.29009; OHNO H, 1995, SCIENCE, V269, P1872, DOI 10.1126/science.7569928; Owen DJ, 1998, SCIENCE, V282, P1327, DOI 10.1126/science.282.5392.1327; Owen DJ, 2000, CURR OPIN CELL BIOL, V12, P467, DOI 10.1016/S0955-0674(00)00118-6; Rapoport I, 1998, EMBO J, V17, P2148, DOI 10.1093/emboj/17.8.2148; Shih W, 1995, J BIOL CHEM, V270, P31083, DOI 10.1074/jbc.270.52.31083; Shim J, 2000, MOL BIOL CELL, V11, P2743, DOI 10.1091/mbc.11.8.2743; Stephens DJ, 1997, J BIOL CHEM, V272, P14104, DOI 10.1074/jbc.272.22.14104; Stephens DJ, 1998, BIOCHEM J, V335, P567, DOI 10.1042/bj3350567; Storch S, 2001, J BIOL CHEM, V276, P4298, DOI 10.1074/jbc.M005548200; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; Wang XL, 1997, FEBS LETT, V402, P57, DOI 10.1016/S0014-5793(96)01500-1	34	103	107	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 20	2001	276	16					13145	13152		10.1074/jbc.M010591200	http://dx.doi.org/10.1074/jbc.M010591200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	423VN	11139587	hybrid			2022-12-25	WOS:000168198600095
J	Cruz, WS; Kwon, G; Marshall, CA; McDaniel, ML; Semenkovich, CF				Cruz, WS; Kwon, G; Marshall, CA; McDaniel, ML; Semenkovich, CF			Glucose and insulin stimulate heparin-releasable lipoprotein lipase activity in mouse islets and INS-1 cells - A potential link between insulin resistance and beta-cell dysfunction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; FATTY-ACID CYCLE; PROTEIN-KINASE-C; ENZYME-ACTIVITY; DEVELOPMENTAL REGULATION; HEPATIC LIPASE; OBESE RATS; SECRETION; EXPRESSION; ADIPOCYTES	Lipoprotein lipase (LpL) provides tissues with triglyceride-derived fatty acids. Fatty acids affect beta -cell function, and LpL overexpression decreases insulin secretion in cell lines, but whether LpL is regulated in beta -cells is unknown. To test the hypothesis that glucose and insulin regulate LpL activity in beta -cells, we studied pancreatic islets and INS-1 cells. Acute exposure of beta -cells to physiological concentrations of glucose stimulated both total cellular LpL activity and heparin-releasable LpL activity. Glucose had no effect on total LpL protein mass but instead promoted the appearance of LpL protein in a heparin-releasable fraction, suggesting that glucose stimulates the translocation of LpL hom intracellular to extracellular sites in beta -cells. The induction of heparin-releasable LpL activity was unaffected by treatment with diazoxide, an inhibitor of insulin exocytosis that does not alter glucose metabolism but was blocked by conditions that inhibit glucose metabolism. In vitro hyperinsulinemia had no effect; on LpL activity in the presence of low concentrations of glucose but increased LpL activity in the presence of 20 mM glucose. Using dual-laser confocal microscopy, we detected intracellular LpL in vesicles distinct from those containing insulin. LpL was also detected at the cell surface and was displaced from this site by heparin in dispersed islets and INS-1 cells. These results show that glucose metabolism controls the trafficking of LpL activity in beta -cells independent of insulin secretion. They suggest that hyperglycemia and hyperinsulinemia associated with insulin resistance may contribute to progressive beta -cell dysfunction by increasing LpL-mediated delivery of lipid to islets.	Washington Univ, Sch Med, Div Atherosclerosis Nutr & Lipid Res, Dept Med, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Pathol & Immunol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Cell Biol & Physiol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Cardiovasc Res Ctr, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL)	Semenkovich, CF (corresponding author), Washington Univ, Sch Med, Div Atherosclerosis Nutr & Lipid Res, Dept Med, Campus Box 8046,660 S Euclid Ave, St Louis, MO 63110 USA.			Semenkovich, Clay/0000-0003-1163-1871	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL058427] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK056341, R01DK006181, R56DK006181, R01DK053198, T32DK007296] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL58427] Funding Source: Medline; NIDDK NIH HHS [T32 DK07296, DK53198, DK56341, DK06181] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ASFARI M, 1992, ENDOCRINOLOGY, V130, P167, DOI 10.1210/en.130.1.167; BASSO L V, 1970, Journal of Clinical Investigation, V49, P537, DOI 10.1172/JCI106264; BEHR SR, 1986, BIOCHIM BIOPHYS ACTA, V889, P346, DOI 10.1016/0167-4889(86)90197-7; BENGTSSON G, 1982, FEBS LETT, V147, P183, DOI 10.1016/0014-5793(82)81038-7; BENGTSSON G, 1980, EUR J BIOCHEM, V106, P549, DOI 10.1111/j.1432-1033.1980.tb04602.x; BENGTSSON G, 1983, BIOCHIM BIOPHYS ACTA, V751, P254, DOI 10.1016/0005-2760(83)90180-7; BENZEEV O, 1994, J LIPID RES, V35, P1511; Bollheimer LC, 1998, J CLIN INVEST, V101, P1094, DOI 10.1172/JCI420; CAMPILLO JE, 1979, DIABETOLOGIA, V16, P267, DOI 10.1007/BF01221954; COLEMAN T, 1995, J BIOL CHEM, V270, P12518, DOI 10.1074/jbc.270.21.12518; CORNELIUS P, 1988, BIOCHEM J, V249, P765, DOI 10.1042/bj2490765; CRESPIN SR, 1969, J CLIN INVEST, V48, P1934, DOI 10.1172/JCI106160; ELKS ML, 1993, ENDOCRINOLOGY, V133, P208, DOI 10.1210/en.133.1.208; Ewart HS, 1999, BIOCHEM J, V340, P485, DOI 10.1042/0264-6021:3400485; Ewart HS, 1999, CAN J PHYSIOL PHARM, V77, P571, DOI 10.1139/cjpp-77-8-571; Goldberg IJ, 1996, J LIPID RES, V37, P693; Hirsch D, 1998, P NATL ACAD SCI USA, V95, P8625, DOI 10.1073/pnas.95.15.8625; KERN PA, 1987, DIABETES, V36, P1238, DOI 10.2337/diabetes.36.11.1238; Kraemer FB, 1998, METABOLISM, V47, P555, DOI 10.1016/S0026-0495(98)90239-6; Kwon G, 1999, J BIOL CHEM, V274, P18702, DOI 10.1074/jbc.274.26.18702; LARNKJAER A, 1995, BIOCHEM J, V307, P205, DOI 10.1042/bj3070205; Lee Y, 1997, DIABETES, V46, P408, DOI 10.2337/diabetes.46.3.408; LEE Y, 1994, P NATL ACAD SCI USA, V91, P10878, DOI 10.1073/pnas.91.23.10878; Liang Y, 1997, DIABETOLOGIA, V40, P1018, DOI 10.1007/s001250050783; Marshall BA, 1999, J BIOL CHEM, V274, P27426, DOI 10.1074/jbc.274.39.27426; MCDANIEL ML, 1983, METHOD ENZYMOL, V98, P182; MILBURN JL, 1995, J BIOL CHEM, V270, P1295, DOI 10.1074/jbc.270.3.1295; MONTAGUE W, 1968, NATURE, V217, P853, DOI 10.1038/217853a0; Mulder H, 1999, DIABETES, V48, P228, DOI 10.2337/diabetes.48.1.228; ONG JM, 1989, J BIOL CHEM, V264, P3177; OSBORNE JC, 1985, BIOCHEMISTRY-US, V24, P5606, DOI 10.1021/bi00341a048; Randle PJ, 1998, DIABETES METAB REV, V14, P263, DOI 10.1002/(SICI)1099-0895(199812)14:4&lt;263::AID-DMR233&gt;3.0.CO;2-C; Ranganathan G, 1999, J BIOL CHEM, V274, P9122, DOI 10.1074/jbc.274.13.9122; SAKO Y, 1990, ENDOCRINOLOGY, V127, P1580, DOI 10.1210/endo-127-4-1580; Sartippour MR, 1998, DIABETES, V47, P431, DOI 10.2337/diabetes.47.3.431; Sartippour MR, 2000, DIABETES, V49, P597, DOI 10.2337/diabetes.49.4.597; SEIP RL, 1995, AM J PHYSIOL-ENDOC M, V268, pE229, DOI 10.1152/ajpendo.1995.268.2.E229; SEMB H, 1987, BIOCHIM BIOPHYS ACTA, V921, P104, DOI 10.1016/0005-2760(87)90176-7; SEMENKOVICH CF, 1989, J BIOL CHEM, V264, P9030; Semenkovich CF, 1998, J LIPID RES, V39, P1141; SEMENKOVICH CF, 1989, J LIPID RES, V30, P423; Semenkovich CF, 1997, PROG LIPID RES, V36, P43, DOI 10.1016/S0163-7827(97)00003-9; SEMENKOVICH CF, 1990, J BIOL CHEM, V265, P5429; Shimabukuro M, 1998, P NATL ACAD SCI USA, V95, P2498, DOI 10.1073/pnas.95.5.2498; Shimabukuro M, 1998, J BIOL CHEM, V273, P3547, DOI 10.1074/jbc.273.6.3547; SINGHBIST A, 1994, BIOCHEM BIOPH RES CO, V202, P838, DOI 10.1006/bbrc.1994.2006; Stein DT, 1996, J CLIN INVEST, V97, P2728, DOI 10.1172/JCI118727; TAVANGAR K, 1992, AM J PHYSIOL, V262, pE330, DOI 10.1152/ajpendo.1992.262.3.E330; Weinstock PH, 1997, P NATL ACAD SCI USA, V94, P10261, DOI 10.1073/pnas.94.19.10261; Yaney GC, 2000, ENDOCRINOLOGY, V141, P1989, DOI 10.1210/en.141.6.1989; ZHOU YP, 1994, J CLIN INVEST, V93, P870, DOI 10.1172/JCI117042	51	42	49	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 13	2001	276	15					12162	12168		10.1074/jbc.M010707200	http://dx.doi.org/10.1074/jbc.M010707200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	421UK	11154699	hybrid			2022-12-25	WOS:000168081800098
J	Deak, PM; Wolf, DH				Deak, PM; Wolf, DH			Membrane topology and function of Der3/Hrd1p as a ubiquitin-protein ligase (E3) involved in endoplasmic reticulum degradation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANAPHASE-PROMOTING COMPLEX; PROTEASOME PATHWAY; 3-HYDROXY-3-METHYLGLUTARYL-COA REDUCTASE; SACCHAROMYCES-CEREVISIAE; UNCONVENTIONAL ROUTE; SECRETORY PATHWAY; RING-H2 FINGER; ER DEGRADATION; FAMILIAR FATE; IN-VIVO	The endoplasmic reticulum contains a protein quality control system that discovers malfolded or unassembled secretory proteins and subjects them to degradation in the cytosol, This requires retrograde transport of the respective proteins from the endoplasmic reticulum back to the cytosol via the Sec61 translocon. In addition, a fully competent ubiquitination machinery and the 26 S proteasome are necessary for retrotranslocation and degradation. Ubiquitination of mutated and malfolded proteins of the endoplasmic reticulum is dependent mainly on the ubiquitin conjugating enzyme Ubc7p. In addition, several new membrane components of the endoplasmic reticulum are required for degradation. Here we present the topology of the previously discovered RING-MS finger protein Der3/Hrd1p, one of the new components of the endoplasmic reticulum membrane. The protein spans the membrane six times. The amino terminus and the carboxyl terminus containing the RING finger domain face the cytoplasm. Altogether, RING finger-dependent ubiquitination of malfolded carboxypeptidase yscY in vivo, as well as of Der3/Hrd1p itself in vitro and RING finger dependent binding of Ubc7p, uncovers Der3/Hrd1p as the ubiquitin-protein ligase (E3) of the endoplasmic reticulum-associated protein degradation process.	Univ Stuttgart, Inst Biochem, D-70569 Stuttgart, Germany	University of Stuttgart	Wolf, DH (corresponding author), Univ Stuttgart, Inst Biochem, Pfaffenwaldring 55, D-70569 Stuttgart, Germany.	dieter.wolf@po.uni-stuttgart.de						[Anonymous], 1991, Methods Enzymol, V194, P1; Biederer T, 1997, SCIENCE, V278, P1806, DOI 10.1126/science.278.5344.1806; Biederer T, 1996, EMBO J, V15, P2069, DOI 10.1002/j.1460-2075.1996.tb00560.x; Bordallo J, 1999, FEBS LETT, V448, P244, DOI 10.1016/S0014-5793(99)00362-2; Bordallo J, 1998, MOL BIOL CELL, V9, P209, DOI 10.1091/mbc.9.1.209; Deshaies RJ, 1999, ANNU REV CELL DEV BI, V15, P435, DOI 10.1146/annurev.cellbio.15.1.435; DESHAIES RJ, 1987, J CELL BIOL, V105, P633, DOI 10.1083/jcb.105.2.633; Ellgaard L, 1999, SCIENCE, V286, P1882, DOI 10.1126/science.286.5446.1882; Fang SY, 2000, J BIOL CHEM, V275, P8945, DOI 10.1074/jbc.275.12.8945; FRANZUSOFF A, 1991, METHOD ENZYMOL, V194, P662; Gardner RG, 2000, J CELL BIOL, V151, P69, DOI 10.1083/jcb.151.1.69; Hampton RY, 1997, P NATL ACAD SCI USA, V94, P12944, DOI 10.1073/pnas.94.24.12944; Hampton RY, 1996, MOL BIOL CELL, V7, P2029, DOI 10.1091/mbc.7.12.2029; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Hiller MM, 1996, SCIENCE, V273, P1725, DOI 10.1126/science.273.5282.1725; HOCHSTRASSER M, 1991, P NATL ACAD SCI USA, V88, P4606, DOI 10.1073/pnas.88.11.4606; Huppa JB, 1997, IMMUNITY, V7, P113, DOI 10.1016/S1074-7613(00)80514-2; JENSEN TJ, 1995, CELL, V83, P129, DOI 10.1016/0092-8674(95)90241-4; Joazeiro CAP, 1999, SCIENCE, V286, P309, DOI 10.1126/science.286.5438.309; JOHNSSON N, 1994, P NATL ACAD SCI USA, V91, P10340, DOI 10.1073/pnas.91.22.10340; Knop M, 1996, EMBO J, V15, P753, DOI 10.1002/j.1460-2075.1996.tb00411.x; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; Lorick KL, 1999, P NATL ACAD SCI USA, V96, P11364, DOI 10.1073/pnas.96.20.11364; McCracken AA, 1998, ADV MOL CEL, V27, P165, DOI 10.1016/S1569-2558(08)60461-0; Plemper RK, 1999, J CELL SCI, V112, P4123; Plemper RK, 1999, TRENDS BIOCHEM SCI, V24, P266, DOI 10.1016/S0968-0004(99)01420-6; Plemper RK, 1999, FEBS LETT, V443, P241, DOI 10.1016/S0014-5793(98)01724-4; Plemper RK, 1998, J BIOL CHEM, V273, P32848, DOI 10.1074/jbc.273.49.32848; SIKORSKI RS, 1989, GENETICS, V122, P19; Sommer T, 1997, FASEB J, V11, P1227, DOI 10.1096/fasebj.11.14.9409541; Strahl-Bolsinger S, 1999, J BIOL CHEM, V274, P9068, DOI 10.1074/jbc.274.13.9068; WARD CL, 1995, CELL, V83, P121, DOI 10.1016/0092-8674(95)90240-6; Werner ED, 1996, P NATL ACAD SCI USA, V93, P13797, DOI 10.1073/pnas.93.24.13797; Wittke S, 1999, MOL BIOL CELL, V10, P2519, DOI 10.1091/mbc.10.8.2519; Xie YM, 1999, EMBO J, V18, P6832, DOI 10.1093/emboj/18.23.6832; Yang Y, 2000, SCIENCE, V288, P874, DOI 10.1126/science.288.5467.874; Yokouchi M, 1999, J BIOL CHEM, V274, P31707, DOI 10.1074/jbc.274.44.31707; Yu H, 1997, J BIOL CHEM, V272, P20800, DOI 10.1074/jbc.272.33.20800; Yu HT, 1998, SCIENCE, V279, P1219, DOI 10.1126/science.279.5354.1219; Zachariae W, 1998, SCIENCE, V279, P1216, DOI 10.1126/science.279.5354.1216; Zheng N, 2000, CELL, V102, P533, DOI 10.1016/S0092-8674(00)00057-X	41	143	147	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 6	2001	276	14					10663	10669		10.1074/jbc.M008608200	http://dx.doi.org/10.1074/jbc.M008608200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	420AC	11139575	hybrid			2022-12-25	WOS:000167980900015
J	Medvedev, AV; Snedden, SK; Raimbault, S; Ricquier, D; Collins, S				Medvedev, AV; Snedden, SK; Raimbault, S; Ricquier, D; Collins, S			Transcriptional regulation of the mouse uncoupling protein-2 gene - Double E-Box motif is required for peroxisome proliferator-activated receptor-gamma-dependent activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELEMENT-BINDING PROTEINS; FATTY-ACIDS; PPAR-GAMMA; SKELETAL-MUSCLE; ADIPOSE-TISSUE; IN-VIVO; GLUCOSE REGULATION; STEROL REGULATION; RESPONSE ELEMENT; SYNTHASE GENE	Uncoupling protein-2 (UCP2) is present in many tissues with relevance to fuel metabolism, and its expression is increased in fat and muscle in response to elevated circulating free fatty acids resulting from fasting and high fat feeding. We proposed a role for peroxisome proliferator-activated receptor-gamma (PPAR gamma) as a mediator of these physiological changes in UCP2, because thiazolidinediones also increase expression of UCP2 in these cell types (1), To determine the molecular basis for this regulation, we isolated the 7.3-kilobase promoter region of the mouse UCP2 gene. The -7.3-kilobase/+12-base pair fragment activates transcription of a reporter gene by 50-100-fold. Deletion and point mutation analysis, coupled with gel shift assays, indicate the presence of a 43-base pair enhancer (-86/-44) that is responsible for the majority of both basal and PPAR gamma -dependent transcriptional activity. The distal (-86/-76) part of the enhancer specifically binds Sp1, Sp2, and Sp3 and is indistinguishable from a consensus Sp1 element in competition experiments. Point mutation in this sequence reduces basal activity by 75%. A second region (-74/-66) is identical to the sterol response element consensus and specifically binds ADD1/SREBP1. However, deletion of this sequence does not affect basal transcriptional activity or the response to PPAR gamma, The proximal portion of the enhancer contains a direct repeat of two E-Box motifs, which contributes most strongly to basal and PPAR gamma -dependent transcription of the UCP2 promoter. Deletion of this region results in a 10-20-fold reduction of transcriptional activity and complete loss of PPAR gamma responsiveness. Point mutations in either E-Box, but not in the spacer region between them, eliminate the stimulatory response to PPAR gamma, However, gel shift assays show that PPAR gamma does not bind to this region. Taken together, these data indicate that PPAR gamma activates the UCP2 gene indirectly by altering the activity or expression of other transcription factors that bind to the UCP2 promoter.	Duke Univ, Med Ctr, Dept Psychiat & Behav Sci, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Pharmacol, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Canc Biol, Durham, NC 27710 USA; CNRS, Ctr Rech Endocrinol Mol & Dev, UPR 9078, F-92190 Meudon, France	Duke University; Duke University; Duke University; Centre National de la Recherche Scientifique (CNRS)	Collins, S (corresponding author), Duke Univ, Med Ctr, Dept Psychiat & Behav Sci, Box 3557, Durham, NC 27710 USA.			Medvedev, Alexander/0000-0001-6983-1687	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [F31DK009812, R01DK054024] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01-DK54024, F31-DK09812] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Arnone MI, 1997, DEVELOPMENT, V124, P1851; Arsenijevic D, 2000, NAT GENET, V26, P435, DOI 10.1038/82565; Aubert J, 1997, BIOCHEM BIOPH RES CO, V238, P606, DOI 10.1006/bbrc.1997.7348; Austin S, 1998, CELL GROWTH DIFFER, V9, P267; Bennett MK, 1999, J BIOL CHEM, V274, P13025, DOI 10.1074/jbc.274.19.13025; BENNETT MK, 1995, J BIOL CHEM, V270, P25578, DOI 10.1074/jbc.270.43.25578; Boss O, 1997, FEBS LETT, V412, P111, DOI 10.1016/S0014-5793(97)00755-2; Brun RP, 1997, CURR OPIN LIPIDOL, V8, P212, DOI 10.1097/00041433-199708000-00004; Camirand A, 1998, ENDOCRINOLOGY, V139, P428, DOI 10.1210/en.139.1.428; Casado M, 1999, J BIOL CHEM, V274, P2009, DOI 10.1074/jbc.274.4.2009; COLLINS S, 1988, J BIOL CHEM, V263, P9067; COLLINS S, 1994, MOL ENDOCRINOL, V8, P518, DOI 10.1210/me.8.4.518; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Dooley KA, 1998, J BIOL CHEM, V273, P1349, DOI 10.1074/jbc.273.3.1349; El-Jack AK, 1999, J BIOL CHEM, V274, P7946, DOI 10.1074/jbc.274.12.7946; Fleury C, 1997, NAT GENET, V15, P269, DOI 10.1038/ng0397-269; Forman BM, 1997, P NATL ACAD SCI USA, V94, P4312, DOI 10.1073/pnas.94.9.4312; Kelly LJ, 1998, ENDOCRINOLOGY, V139, P4920, DOI 10.1210/en.139.12.4920; KIM JB, 1995, MOL CELL BIOL, V15, P2582; Kliewer SA, 1997, P NATL ACAD SCI USA, V94, P4318, DOI 10.1073/pnas.94.9.4318; Koo SH, 2000, J BIOL CHEM, V275, P5200, DOI 10.1074/jbc.275.7.5200; LEHMANN JM, 1995, J BIOL CHEM, V270, P12953, DOI 10.1074/jbc.270.22.12953; Millet L, 1997, J CLIN INVEST, V100, P2665, DOI 10.1172/JCI119811; MIYAMOTO NG, 1987, NUCLEIC ACIDS RES, V15, P9095, DOI 10.1093/nar/15.21.9095; Monsalve M, 2000, MOL CELL, V6, P307, DOI 10.1016/S1097-2765(00)00031-9; Osborne TF, 2000, J BIOL CHEM, V275, P32379, DOI 10.1074/jbc.R000017200; Pecqueur C, 1999, BIOCHEM BIOPH RES CO, V255, P40, DOI 10.1006/bbrc.1998.0146; Puigserver P, 1999, SCIENCE, V286, P1368, DOI 10.1126/science.286.5443.1368; Puigserver P, 1998, CELL, V92, P829, DOI 10.1016/S0092-8674(00)81410-5; Rosen ED, 2000, GENE DEV, V14, P1293; Samec S, 1999, DIABETES, V48, P436, DOI 10.2337/diabetes.48.2.436; Samec S, 1998, DIABETES, V47, P1693, DOI 10.2337/diabetes.47.11.1693; Samec S, 1998, FASEB J, V12, P715, DOI 10.1096/fasebj.12.9.715; SCHOONJANS K, 1995, J BIOL CHEM, V270, P19269, DOI 10.1074/jbc.270.33.19269; Schoonjans K, 1996, EMBO J, V15, P5336, DOI 10.1002/j.1460-2075.1996.tb00918.x; SMITH JR, 1990, J BIOL CHEM, V265, P2306; Surwit RS, 1998, P NATL ACAD SCI USA, V95, P4061, DOI 10.1073/pnas.95.7.4061; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; TONTONOZ P, 1995, MOL CELL BIOL, V15, P351, DOI 10.1128/MCB.15.1.351; TONTONOZ P, 1994, GENE DEV, V8, P1224, DOI 10.1101/gad.8.10.1224; TONTONOZ P, 1994, CELL, V79, P1147, DOI 10.1016/0092-8674(94)90006-X; TUGWOOD JD, 1992, EMBO J, V11, P433, DOI 10.1002/j.1460-2075.1992.tb05072.x; Vaulont S, 2000, J BIOL CHEM, V275, P31555, DOI 10.1074/jbc.R000016200; Werman A, 1997, J BIOL CHEM, V272, P20230, DOI 10.1074/jbc.272.32.20230	45	90	90	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 6	2001	276	14					10817	10823		10.1074/jbc.M010587200	http://dx.doi.org/10.1074/jbc.M010587200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	420AC	11150307	hybrid			2022-12-25	WOS:000167980900036
J	Rho, J; Choi, S; Seong, YR; Cho, WK; Kim, SH; Im, DS				Rho, J; Choi, S; Seong, YR; Cho, WK; Kim, SH; Im, DS			PRMT5, which forms distinct homo-oligomers, is a member of the protein-arginine methyltransferase family	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPATITIS-C VIRUS; MYELIN BASIC-PROTEIN; N-METHYLTRANSFERASE; DEPENDENT METHYLTRANSFERASES; SUBSTRATE-SPECIFICITY; FISSION YEAST; NS3 PROTEIN; IN-VIVO; IDENTIFICATION; DOMAIN	We found that JBP1, known as a human homolog (Skb1Hs) of Skb1 of fission yeast, interacts with NS3 of the hepatitis C virus in a yeast two-hybrid screen. Amino acid sequence analysis revealed that Skb1Hs/JBP1 contains conserved motifs of S-adenosyl-L-methionine-dependent protein-arginine methyltransferases (PRMTs). Here, we demonstrate that Skb1Hs/JBP1, named PRMT5, is a distinct member of the PRMT family. Recombinant PRMT5 protein purified from human cells methylated myelin basic protein, histone, and the amino terminus of fibrillarin fused to glutathione S-transferase. Myelin basic protein methylated by PRMT5 contained monomethylated and dimethylated arginine residues. Recombinant glutathione S-transferase-PRMT5 protein expressed in Escherichia coli also contained the catalytic activity. Sedimentation analysis of purified PRMT5 on a sucrose density gradient indicated that PRMT5 formed distinct homooligomeric complexes, including a dimer and tetramer, that comigrated with the enzyme activity. The PRMT5 homo-oligomers were dissociated into a monomer in the presence of a reducing agent, whereas a monomer, dimer, and multimer were detected in the absence or at low concentrations of a reducing agent. The results indicate that both covalent linkage by a disulfide bond and noncovalent association are involved in the formation of PRMT5 homo oligomers. Western blot analysis of sedimentation fractions suggests that endogenous PRMT5 is present as a homo-oligomer in a 293T cell extract, PRMT5 appears to have lower specific enzyme activity than PRMT1. Although PRMT1 is known to be mainly located in the nucleus, human PRMT5 is predominantly localized in the cytoplasm.	Korea Res Inst Biosci & Biotechnol, Cell Biol Lab, Taejon 305333, South Korea; Korea Basic Sci Inst, Biomol Res Team, Taejon 305333, South Korea	Korea Research Institute of Bioscience & Biotechnology (KRIBB); Korea Basic Science Institute (KBSI)	Im, DS (corresponding author), Korea Res Inst Biosci & Biotechnol, Cell Biol Lab, Taejon 305333, South Korea.	imdongsu@mail.kribb.re.kr		Rho, Jaerang/0000-0002-0019-4939				Abramovich C, 1997, EMBO J, V16, P260, DOI 10.1093/emboj/16.2.260; BALDWIN GS, 1971, SCIENCE, V171, P579, DOI 10.1126/science.171.3971.579; BARTENSCHLAGER R, 1993, J VIROL, V67, P3835, DOI 10.1128/JVI.67.7.3835-3844.1993; Brahms H, 2000, J BIOL CHEM, V275, P17122, DOI 10.1074/jbc.M000300200; Chao L, 1999, J VIROL, V73, P8798, DOI 10.1128/JVI.73.10.8798-8807.1999; Chen DG, 1999, SCIENCE, V284, P2174, DOI 10.1126/science.284.5423.2174; CHOO QL, 1989, SCIENCE, V244, P359, DOI 10.1126/science.2523562; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Frankel A, 2000, J BIOL CHEM, V275, P32974, DOI 10.1074/jbc.M006445200; Fujita T, 1996, BIOCHEM BIOPH RES CO, V229, P825, DOI 10.1006/bbrc.1996.1887; Gary JD, 1998, PROG NUCLEIC ACID RE, V61, P65, DOI 10.1016/S0079-6603(08)60825-9; Gary JD, 1996, J BIOL CHEM, V271, P12585, DOI 10.1074/jbc.271.21.12585; GHOSH SK, 1988, J BIOL CHEM, V263, P19024; Gilbreth M, 1998, P NATL ACAD SCI USA, V95, P14781, DOI 10.1073/pnas.95.25.14781; Gilbreth M, 1996, P NATL ACAD SCI USA, V93, P13802, DOI 10.1073/pnas.93.24.13802; GRAKOUI A, 1993, J VIROL, V67, P2832, DOI 10.1128/JVI.67.5.2832-2843.1993; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; HEINE MA, 1993, MOL BIOL CELL, V4, P1189, DOI 10.1091/mbc.4.11.1189; HIJIKATA M, 1993, J VIROL, V67, P4665, DOI 10.1128/JVI.67.8.4665-4675.1993; Ihle JN, 1995, ADV IMMUNOL, V60, P1, DOI 10.1016/S0065-2776(08)60582-9; KAGAN RM, 1994, ARCH BIOCHEM BIOPHYS, V310, P417, DOI 10.1006/abbi.1994.1187; Katsanis N, 1997, MAMM GENOME, V8, P526, DOI 10.1007/s003359900491; Kim DW, 1997, J VIROL, V71, P9400, DOI 10.1128/JVI.71.12.9400-9409.1997; Kim S, 1997, BIOCHEMISTRY-US, V36, P5185, DOI 10.1021/bi9625509; Kim S, 1997, INT J BIOCHEM CELL B, V29, P743, DOI 10.1016/S1357-2725(97)00009-5; KOONIN EV, 1993, J GEN VIROL, V74, P733, DOI 10.1099/0022-1317-74-4-733; Krapivinsky G, 1998, J BIOL CHEM, V273, P10811, DOI 10.1074/jbc.273.18.10811; KRAPIVINSKY GB, 1994, CELL, V76, P439, DOI 10.1016/0092-8674(94)90109-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAPEYRE B, 1985, NUCLEIC ACIDS RES, V13, P5805, DOI 10.1093/nar/13.16.5805; Lin WJ, 1996, J BIOL CHEM, V271, P15034, DOI 10.1074/jbc.271.25.15034; LISCHWE MA, 1985, BIOCHEMISTRY-US, V24, P6025, DOI 10.1021/bi00343a001; LIU Q, 1995, MOL CELL BIOL, V15, P2800; Matsumoto M, 1996, VIROLOGY, V218, P43, DOI 10.1006/viro.1996.0164; Montagnoli A, 1996, CELL GROWTH DIFFER, V7, P1327; Muramatsu S, 1997, J VIROL, V71, P4954, DOI 10.1128/JVI.71.7.4954-4961.1997; NAJBAUER J, 1993, J BIOL CHEM, V268, P10501; PAIK WK, 1967, BIOCHEM BIOPH RES CO, V29, P14, DOI 10.1016/0006-291X(67)90533-5; PAIK WK, 1968, J BIOL CHEM, V243, P2108; Pollack BP, 1999, J BIOL CHEM, V274, P31531, DOI 10.1074/jbc.274.44.31531; RAWAL N, 1994, BIOCHEM J, V300, P483, DOI 10.1042/bj3000483; Rouault JP, 1996, NAT GENET, V14, P482, DOI 10.1038/ng1296-482; SAITO I, 1990, P NATL ACAD SCI USA, V87, P6547, DOI 10.1073/pnas.87.17.6547; SAKAMURO D, 1995, J VIROL, V69, P3893, DOI 10.1128/JVI.69.6.3893-3896.1995; SCHLUCKEBIER G, 1995, J MOL BIOL, V247, P16, DOI 10.1006/jmbi.1994.0117; Scott HS, 1998, GENOMICS, V48, P330, DOI 10.1006/geno.1997.5190; Smith JJ, 1999, J BIOL CHEM, V274, P13229, DOI 10.1074/jbc.274.19.13229; Stallcup MR, 2000, BIOCHEM SOC T, V28, P415, DOI 10.1042/0300-5127:0280415; STONER GL, 1984, J NEUROCHEM, V43, P433, DOI 10.1111/j.1471-4159.1984.tb00919.x; Tang J, 2000, J BIOL CHEM, V275, P19866, DOI 10.1074/jbc.M000023200; Tang J, 1998, J BIOL CHEM, V273, P16935, DOI 10.1074/jbc.273.27.16935; Tang J, 2000, J BIOL CHEM, V275, P7723, DOI 10.1074/jbc.275.11.7723; TOMEI L, 1993, J VIROL, V67, P4017, DOI 10.1128/JVI.67.7.4017-4026.1993; WINSTONLA, 1996, CELL SIGNAL, V7, P739	54	119	126	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 6	2001	276	14					11393	11401		10.1074/jbc.M008660200	http://dx.doi.org/10.1074/jbc.M008660200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	420AC	11152681	hybrid			2022-12-25	WOS:000167980900111
J	Hanson, PK; Nichols, JW				Hanson, PK; Nichols, JW			Energy-dependent flip of fluorescence-labeled phospholipids is regulated by nutrient starvation and transcription factors, PDR1 and PDR3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-ERYTHROCYTE MEMBRANE; PLASMA-MEMBRANE; TRANSBILAYER MOVEMENT; SACCHAROMYCES-CEREVISIAE; ASYMMETRIC DISTRIBUTION; MULTIDRUG-RESISTANCE; MAMMALIAN-CELLS; BLOOD-CELLS; RED-CELL; YEAST	The yeast Saccharomyces cerevisiae readily accumulates short-chain, fluorescent 7-nitrobenz-2-oxa-1,3-diazol-4-yl (NBD)-labebd phosphatidylcholine and phosphatidylethanolamine at the nuclear envelope/endoplasmic reticulum and mitochondria. The net intracellular accumulation reflects the sum of their inwardly and outwardly directed transbilayer translocation across the plasma membrane (flip and flop, respectively). The rate of flop is negligible in energy-depleted cells as well as at low temperature (2 degreesC), Although flip is reduced at 2 degreesC, it can still be measured by now cytometry, allowing the rate of flip, independent of flop, to be characterized at this temperature. Flip requires the energy of the plasma membrane proton electrochemical gradient and is down-regulated as cells pass through the diauxic shift and enter stationary phase. Furthermore, drug-resistant, gain-of-function mutations in the transcription factors, PDR1 and PDR3, result in a dramatic downregulation of flip in addition to their already established up-regulation of flop. These results imply that down-regulation of the NBD-phospholipid flip pathway is a physiological response to environmental stress.	Emory Univ, Sch Med, Dept Physiol, Atlanta, GA 30322 USA	Emory University	Nichols, JW (corresponding author), Emory Univ, Sch Med, Dept Physiol, 1648 Pierce Dr, Atlanta, GA 30322 USA.	wnichols@physio.emory.edu		Hanson, Pamela/0000-0002-9312-1682	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008367, R21GM052410] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM52410, GM08367] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AULAND ME, 1994, P NATL ACAD SCI USA, V91, P10938, DOI 10.1073/pnas.91.23.10938; BALZI E, 1995, J BIOENERG BIOMEMBR, V27, P71, DOI 10.1007/BF02110333; Basse F, 1996, J BIOL CHEM, V271, P17205, DOI 10.1074/jbc.271.29.17205; Beck T, 1999, J CELL BIOL, V146, P1227, DOI 10.1083/jcb.146.6.1227; Bevers EM, 1999, BBA-MOL CELL BIOL L, V1439, P317, DOI 10.1016/S1388-1981(99)00110-9; BRETSCHER MS, 1972, J MOL BIOL, V71, P523, DOI 10.1016/0022-2828(72)90028-4; CONNOR J, 1987, BIOCHEMISTRY-US, V26, P5099, DOI 10.1021/bi00390a031; CONNOR J, 1994, J BIOL CHEM, V269, P2399; Daleke DL, 2000, BBA-MOL CELL BIOL L, V1486, P108, DOI 10.1016/S1388-1981(00)00052-4; DALEKE DL, 1985, BIOCHEMISTRY-US, V24, P5406, DOI 10.1021/bi00341a019; Decottignies A, 1998, J BIOL CHEM, V273, P12612, DOI 10.1074/jbc.273.20.12612; DEVAUX PF, 1994, CHEM PHYS LIPIDS, V73, P107, DOI 10.1016/0009-3084(94)90177-5; Egner R, 1998, MOL BIOL CELL, V9, P523, DOI 10.1091/mbc.9.2.523; Fadeel B, 1999, BIOCHEM BIOPH RES CO, V266, P504, DOI 10.1006/bbrc.1999.1820; FADOK VA, 1992, J IMMUNOL, V148, P2207; Fadok VA, 1998, CELL DEATH DIFFER, V5, P551, DOI 10.1038/sj.cdd.4400404; Farge E, 1999, AM J PHYSIOL-CELL PH, V276, pC725, DOI 10.1152/ajpcell.1999.276.3.C725; FOX TD, 1991, METHOD ENZYMOL, V194, P149; Grant AM, 2001, TRAFFIC, V2, P37, DOI 10.1034/j.1600-0854.2001.020106.x; JULIEN M, 1993, EXP CELL RES, V208, P387, DOI 10.1006/excr.1993.1260; KATZMANN DJ, 1995, MOL CELL BIOL, V15, P6875; KEAN LS, 1993, J CELL BIOL, V123, P1403, DOI 10.1083/jcb.123.6.1403; Kean LS, 1997, J CELL BIOL, V138, P255, DOI 10.1083/jcb.138.2.255; Mahe Y, 1996, MOL MICROBIOL, V20, P109, DOI 10.1111/j.1365-2958.1996.tb02493.x; Marx U, 1999, EUR J BIOCHEM, V263, P254, DOI 10.1046/j.1432-1327.1999.00497.x; Merkel O, 1999, J BIOL CHEM, V274, P28121, DOI 10.1074/jbc.274.40.28121; MORROT G, 1990, FEBS LETT, V266, P29, DOI 10.1016/0014-5793(90)81498-D; MULLER K, 1994, BIOCHEMISTRY-US, V33, P9968; Muller P, 1996, HEPATOLOGY, V24, P1497; NOLAN JP, 1995, BIOCHEMISTRY-US, V34, P3907, DOI 10.1021/bi00012a006; PAGANO RE, 1985, SCIENCE, V229, P1051, DOI 10.1126/science.4035344; Pomorski T, 1996, J CELL SCI, V109, P687; Pomorski T, 1999, BIOCHEMISTRY-US, V38, P142, DOI 10.1021/bi981244n; PRINGLE JR, 1989, METHOD CELL BIOL, V31, P357; Raggers RJ, 2000, TRAFFIC, V1, P226, DOI 10.1034/j.1600-0854.2000.010305.x; RIEZMAN H, 1986, TRENDS BIOCHEM SCI, V11, P325, DOI 10.1016/0968-0004(86)90290-2; RIEZMAN H, 1985, CELL, V40, P1001, DOI 10.1016/0092-8674(85)90360-5; ROSING J, 1985, BLOOD, V65, P1557, DOI 10.1182/blood.V65.6.1557.bloodjournal6561557; SCHROIT AJ, 1987, BIOCHEMISTRY-US, V26, P1812, DOI 10.1021/bi00381a004; SCHROIT AJ, 1991, BIOCHIM BIOPHYS ACTA, V1071, P313, DOI 10.1016/0304-4157(91)90019-S; SEIGNEURET M, 1984, P NATL ACAD SCI-BIOL, V81, P3751, DOI 10.1073/pnas.81.12.3751; SHERMAN F, 1986, METHODS YEAST GENETI, P181; Siegmund A, 1998, J BIOL CHEM, V273, P34399, DOI 10.1074/jbc.273.51.34399; SLEIGHT RG, 1989, J CELL SCI, V93, P363; SLEIGHT RG, 1985, J BIOL CHEM, V260, P1146; SMEETS EF, 1994, BBA-BIOMEMBRANES, V1195, P281, DOI 10.1016/0005-2736(94)90268-2; Tang XJ, 1996, SCIENCE, V272, P1495, DOI 10.1126/science.272.5267.1495; TILLEY L, 1986, FEBS LETT, V194, P21, DOI 10.1016/0014-5793(86)80044-8; van den Hazel HB, 1999, J BIOL CHEM, V274, P1934, DOI 10.1074/jbc.274.4.1934; vanHelvoort A, 1996, CELL, V87, P507, DOI 10.1016/S0092-8674(00)81370-7; VERKLEIJ AJ, 1973, BIOCHIM BIOPHYS ACTA, V323, P178, DOI 10.1016/0005-2736(73)90143-0; VIDA TA, 1995, J CELL BIOL, V128, P779, DOI 10.1083/jcb.128.5.779; WILLIAMSON P, 1992, BIOCHEMISTRY-US, V31, P6355, DOI 10.1021/bi00142a027; WILLIAMSON P, 1994, MOL MEMBR BIOL, V11, P199, DOI 10.3109/09687689409160430; ZACHOWSKI A, 1987, BIOCHIM BIOPHYS ACTA, V897, P197, DOI 10.1016/0005-2736(87)90328-2; Zhao J, 1998, J BIOL CHEM, V273, P6603, DOI 10.1074/jbc.273.12.6603; Zhou QS, 1997, J BIOL CHEM, V272, P18240, DOI 10.1074/jbc.272.29.18240; ZIMMERMAN ML, 1993, BIOCHEMISTRY-US, V32, P12257, DOI 10.1021/bi00096a040; Zwaal RFA, 1997, BLOOD, V89, P1121, DOI 10.1182/blood.V89.4.1121	59	37	37	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 30	2001	276	13					9861	9867		10.1074/jbc.M009065200	http://dx.doi.org/10.1074/jbc.M009065200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	420GC	11136727	hybrid			2022-12-25	WOS:000167996400039
J	Lemmens, R; Larsson, O; Berggren, PO; Islam, MS				Lemmens, R; Larsson, O; Berggren, PO; Islam, MS			Ca2+-induced Ca2+ release from the endoplasmic reticulum amplifies the Ca2+ signal mediated by activation of voltage-gated L-type Ca2+ channels in pancreatic beta-cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INOSITOL 1,4,5-TRISPHOSPHATE RECEPTOR; ADRENAL GLOMERULOSA CELLS; PHOSPHOLIPASE-C ACTIVITY; CYCLIC ADP-RIBOSE; RYANODINE RECEPTOR; CALCIUM-RELEASE; CATION SENSITIVITY; RINM5F CELLS; THAPSIGARGIN; ISLETS	Stimulus-secretion coupling in pancreatic beta -cells involves membrane depolarization and Ca2+ entry through voltage-gated L-type Ca2+ channels, which is one determinant of increases in the cytoplasmic free Ca2+ concentration ([Ca2+](i)). We investigated how the endoplasmic reticulum (ER)-associated Ca2+ apparatus further modifies this Ca2+ signal. When fura-2-loaded mouse beta -cells were depolarized by KCI in the presence of 3 mM glucose, [Ca2+](i) increased to a peak in two phases. The second phase of the [Ca2+](i) increase was abolished when ER Ca2+ stores were depleted by thapsigargin, The steady-state [Ca2+]i measured at 300 s of depolarization was higher in control cells compared with cells in which the ER Ca2+ pools were depleted. The amount of Ca2+ presented to the cytoplasm during depolarization as estimated from the integral of the increment in [Ca2+](i) over time (integral Delta [Ca2+](i)dt) was similar to 30% higher compared with that in the Ca pool-depleted cells. neothapsigargin, an inactive analog, did not affect [Ca2+](i) response. Using Sr2+ in the extracellular medium and exploiting the differences in the fluorescence properties of Ca2+- and Sr2+-bound fluo-3, we found that the incoming Sr2+ triggered Ca2+ release from the ER, Depolarization-induced [Ca2+](i) response was not altered by U73122, an inhibitor of phosphatidylinositol-specific phospholipase C, suggesting that stimulation of the enzyme by Ca2+ is not essential for amplification of Ca2+ signaling, [Ca2+](i) response was enhanced when cells were depolarized in the presence of 3 mM glucose, forskolin, and caffeine, suggesting involvement of ryanodine receptors in the amplification process. Pretreatment with ryanodine (100 muM) diminished the second phase of the depolarization-induced increase in [Ca2+](i). We conclude that Ca2+ entry through L-type voltage-gated Ca2+ channels triggers Ca2+ release from the ER and that such a process amplifies depolarization-induced Ca2+ signaling in beta -cells.	Karolinska Inst, Rolf Luft Ctr Diabet Res, Dept Mol Med, Endocrine & Diabet Unit,Karolinska Hosp, S-17176 Stockholm, Sweden	Karolinska Institutet; Karolinska University Hospital	Islam, MS (corresponding author), Karolinska Inst, Rolf Luft Ctr Diabet Res, Dept Mol Med, Endocrine & Diabet Unit,Karolinska Hosp, S-17176 Stockholm, Sweden.		Islam, Shahidul/K-3295-2019	Islam, Shahidul/0000-0002-9016-1881; Berggren, Per-Olof/0000-0001-8991-413X				ANDERSEN A, 1994, ACTA CHEM SCAND, V48, P340, DOI 10.3891/acta.chem.scand.48-0340; BALLA T, 1994, J BIOL CHEM, V269, P16101; BECKER PL, 1989, SCIENCE, V244, P211, DOI 10.1126/science.2704996; BIDEN TJ, 1987, J BIOL CHEM, V262, P3567; Bird GSJ, 1997, CELL CALCIUM, V21, P253, DOI 10.1016/S0143-4160(97)90049-X; CHRISTENSEN SB, 1993, FEBS LETT, V335, P345, DOI 10.1016/0014-5793(93)80416-R; DUARTE CB, 1993, EUR J PHARM-MOLEC PH, V244, P259, DOI 10.1016/0922-4106(93)90151-X; EVTODIENKO YV, 1994, CELL CALCIUM, V15, P143, DOI 10.1016/0143-4160(94)90053-1; FINCH EA, 1991, SCIENCE, V252, P443, DOI 10.1126/science.2017683; Gafni J, 1997, NEURON, V19, P723, DOI 10.1016/S0896-6273(00)80384-0; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HAIN J, 1995, J BIOL CHEM, V270, P2074, DOI 10.1074/jbc.270.5.2074; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HEDESKOV CJ, 1991, MOL CELL ENDOCRINOL, V78, P187, DOI 10.1016/0303-7207(91)90122-9; Holz GG, 1999, J BIOL CHEM, V274, P14147, DOI 10.1074/jbc.274.20.14147; IINO M, 1992, NATURE, V360, P76, DOI 10.1038/360076a0; ISLAM MS, 1992, FEBS LETT, V296, P287, DOI 10.1016/0014-5793(92)80306-2; ISLAM MS, 1995, BIOCHEM J, V306, P679, DOI 10.1042/bj3060679; Islam MS, 1997, BIOCHEM J, V321, P347, DOI 10.1042/bj3210347; ISLAM MS, 1993, BIOCHEM J, V293, P423, DOI 10.1042/bj2930423; ISLAM MS, 1993, SCIENCE, V262, P584, DOI 10.1126/science.8211188; Islam MS, 1998, P NATL ACAD SCI USA, V95, P6145, DOI 10.1073/pnas.95.11.6145; ISLAM MS, 1994, THESIS KAROLINSKA I; Lee B, 1998, J MOL ENDOCRINOL, V21, P31, DOI 10.1677/jme.0.0210031; Liu YJ, 1996, ARCH BIOCHEM BIOPHYS, V334, P295, DOI 10.1006/abbi.1996.0458; Marchant JS, 1997, CURR BIOL, V7, P510, DOI 10.1016/S0960-9822(06)00222-3; Maruyama T, 1997, J BIOCHEM-TOKYO, V122, P498; Marx SO, 2000, CELL, V101, P365, DOI 10.1016/S0092-8674(00)80847-8; Missiaen L, 1998, J BIOL CHEM, V273, P8983, DOI 10.1074/jbc.273.15.8983; MONTAGUE W, 1985, BIOCHEM J, V227, P483, DOI 10.1042/bj2270483; POWIS G, 1992, CANCER RES, V52, P2835; ROSSIER MF, 1993, BIOCHEM J, V296, P309, DOI 10.1042/bj2960309; Sitsapesan R, 1997, J MEMBRANE BIOL, V159, P179, DOI 10.1007/s002329900281; Takasawa S, 1998, J BIOL CHEM, V273, P2497, DOI 10.1074/jbc.273.5.2497; TAYLOR CW, 1986, BIOCHEM J, V238, P765, DOI 10.1042/bj2380765; Treiman M, 1998, TRENDS PHARMACOL SCI, V19, P131, DOI 10.1016/S0165-6147(98)01184-5; Velez P, 1997, BIOPHYS J, V72, pTH157; WALENGA R, 1980, J BIOL CHEM, V255, P6024; Zawalich WS, 1997, AM J PHYSIOL-ENDOC M, V272, pE671, DOI 10.1152/ajpendo.1997.272.4.E671; ZAWALICH WS, 1995, ENDOCRINOLOGY, V136, P4903, DOI 10.1210/en.136.11.4903	40	75	75	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 30	2001	276	13					9971	9977		10.1074/jbc.M009463200	http://dx.doi.org/10.1074/jbc.M009463200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	420GC	11139580	hybrid			2022-12-25	WOS:000167996400054
J	Gardner, RG; Shan, H; Matsuda, SPT; Hampton, RY				Gardner, RG; Shan, H; Matsuda, SPT; Hampton, RY			An oxysterol-derived positive signal for 3-hydroxy-3-methylglutaryl-CoA reductase degradation in yeast	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COENZYME-A REDUCTASE; HMG-COA REDUCTASE; 2,3-OXIDOSQUALENE-LANOSTEROL CYCLASE INHIBITOR; STEROL-ENHANCED DEGRADATION; RETICULUM MEMBRANE-PROTEIN; GREEN FLUORESCENT PROTEIN; REGULATED DEGRADATION; ENDOPLASMIC-RETICULUM; SACCHAROMYCES-CEREVISIAE; CHOLESTEROL-BIOSYNTHESIS	Sterol synthesis by the mevalonate pathway is modulated, in part, through feedback-regulated degradation of 3-hydroxy-3-methylglutaryl-CoA reductase (HMGR). In mammals, both a non-sterol isoprenoid signal derived from farnesyl diphosphate (FPP) and a sterol-derived signal appear to act together to positively regulate the rate of HMGR degradation. Although the nature and number of sterol-derived signals are not clear, there is growing evidence that oxysterols can serve in this capacity. In yeast, a similar non-sterol isoprenoid signal generated from FPP acts to positively regulate HMGR degradation, but the existence of any sterol-derived signal has thus far not been revealed. We now demonstrate, through the use of genetic and pharmacological manipulation of oxidosqualene-lanosterol cyclase, that an oxysterol-derived signal positively regulated HMGR degradation in yeast. The oxysterol-derived signal acted by specifically modulating HMGR stability, not endoplasmic reticulum-associated degradation in general. Direct biochemical labeling of mevalonate pathway products confirmed that oxysterols were produced endogenously in yeast and that their levels varied appropriately in response to genetic or pharmacological manipulations that altered HMGR stability. Genetic manipulation of oxidosqualene-lanosterol cyclase did result in the buildup of detectable levels of 24,25-oxidolanosterol by gas chromatography, gas chromatography-mass spectroscopy, and MMR analyses, whereas no detectable amounts were observed in wild-type cells or cells with squalene epoxidase down-regulated. In contrast to mammalian cells, the yeast oxysterol-derived signal was not required for HMGR degradation in yeast, Rather, the function of this second signal was to enhance the ability of the FPP-derived signal to promote HMGR degradation. Thus, although differences do exist, both yeast and mammalian cells employ a similar strategy of multiinput regulation of HMGR degradation.	Univ Calif San Diego, Div Biol, Sect Cell & Dev Biol, La Jolla, CA 92093 USA; Rice Univ, Dept Biochem & Cell Biol, Houston, TX 77005 USA; Rice Univ, Dept Chem, Houston, TX 77005 USA	University of California System; University of California San Diego; Rice University; Rice University	Hampton, RY (corresponding author), Univ Calif San Diego, Div Biol, Sect Cell & Dev Biol, La Jolla, CA 92093 USA.			Gardner, Richard/0000-0003-2162-6275	NHLBI NIH HHS [HL49122] Funding Source: Medline; NIDDK NIH HHS [DK5199601] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL049122] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK051996] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BAI M, 1992, BIOCHEM BIOPH RES CO, V185, P323, DOI 10.1016/S0006-291X(05)90003-X; Bays NW, 2001, NAT CELL BIOL, V3, P24, DOI 10.1038/35050524; BITTER GA, 1984, GENE, V32, P263, DOI 10.1016/0378-1119(84)90002-7; BOUTAUD O, 1992, BIOCHEM BIOPH RES CO, V188, P898, DOI 10.1016/0006-291X(92)91140-L; BRADFUTE DL, 1994, J BIOL CHEM, V269, P6645; BRODERICK G, 1991, NEUROUROL URODYNAM, V10, P507, DOI 10.1002/nau.1930100507; CHEREST H, 1985, GENE, V34, P269; CHIN DJ, 1985, MOL CELL BIOL, V5, P634, DOI 10.1128/MCB.5.4.634; CHUN KT, 1990, J BIOL CHEM, V265, P22004; CORRELL CC, 1994, J BIOL CHEM, V269, P17390; Cronin SR, 1999, METHOD ENZYMOL, V302, P58, DOI 10.1016/S0076-6879(99)02010-8; Cronin SR, 2000, J CELL BIOL, V148, P915, DOI 10.1083/jcb.148.5.915; DOLLIS D, 1994, BIOCHEM PHARMACOL, V48, P49, DOI 10.1016/0006-2952(94)90222-4; Du EZ, 1999, J BIOL CHEM, V274, P1856, DOI 10.1074/jbc.274.3.1856; FAUST JR, 1982, P NATL ACAD SCI-BIOL, V79, P5205, DOI 10.1073/pnas.79.17.5205; FIELD RB, 1979, LIPIDS, V14, P741, DOI 10.1007/BF02533900; FIELD RB, 1977, ARCH BIOCHEM BIOPHYS, V180, P465, DOI 10.1016/0003-9861(77)90061-3; FUNG B, 1976, BIOCHEM PHARMACOL, V25, P1249, DOI 10.1016/0006-2952(76)90086-1; Gardner R, 1998, MOL BIOL CELL, V9, P2611, DOI 10.1091/mbc.9.9.2611; Gardner RG, 2000, J CELL BIOL, V151, P69, DOI 10.1083/jcb.151.1.69; Gardner RG, 1999, EMBO J, V18, P5994, DOI 10.1093/emboj/18.21.5994; Gardner RG, 1999, J BIOL CHEM, V274, P31671, DOI 10.1074/jbc.274.44.31671; GIL G, 1985, CELL, V41, P249, DOI 10.1016/0092-8674(85)90078-9; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; Hampton RY, 1996, P NATL ACAD SCI USA, V93, P828, DOI 10.1073/pnas.93.2.828; Hampton RY, 1997, P NATL ACAD SCI USA, V94, P12944, DOI 10.1073/pnas.94.24.12944; HAMPTON RY, 1994, J CELL BIOL, V125, P299, DOI 10.1083/jcb.125.2.299; Hampton RY, 1996, MOL BIOL CELL, V7, P2029, DOI 10.1091/mbc.7.12.2029; Hua XX, 1996, CELL, V87, P415, DOI 10.1016/S0092-8674(00)81362-8; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JANDROSITZ A, 1991, GENE, V107, P155, DOI 10.1016/0378-1119(91)90310-8; JINGAMI H, 1987, J CELL BIOL, V104, P1693, DOI 10.1083/jcb.104.6.1693; KUMAGAI H, 1995, J BIOL CHEM, V270, P19107, DOI 10.1074/jbc.270.32.19107; Lopez D, 1997, ARCH BIOCHEM BIOPHYS, V343, P118, DOI 10.1006/abbi.1997.0162; Mark M, 1996, J LIPID RES, V37, P148; Meigs TE, 1997, ARCH BIOCHEM BIOPHYS, V345, P1, DOI 10.1006/abbi.1997.0200; Meigs TE, 1996, J BIOL CHEM, V271, P7916, DOI 10.1074/jbc.271.14.7916; MEIGS TE, 1992, J BIOL CHEM, V267, P13547; Morand OH, 1997, J LIPID RES, V38, P373; MOUNTAIN HA, 1991, YEAST, V7, P781, DOI 10.1002/yea.320070804; NAKANISHI M, 1988, J BIOL CHEM, V263, P8929; NI Y, 1993, TETRAHEDRON LETT, V34, P3687, DOI 10.1016/S0040-4039(00)79201-X; PANINI SR, 1986, J LIPID RES, V27, P1190; PANINI SR, 1992, J BIOL CHEM, V267, P12647; Peffley DM, 1997, ARCH BIOCHEM BIOPHYS, V337, P251, DOI 10.1006/abbi.1996.9796; Peffley DM, 1998, BIOCHEM PHARMACOL, V56, P439, DOI 10.1016/S0006-2952(98)00083-5; Ravid T, 2000, J BIOL CHEM, V275, P35840, DOI 10.1074/jbc.M004793200; ROITELMAN J, 1992, J BIOL CHEM, V267, P25264; RYDER NS, 1992, BRIT J DERMATOL, V126, P2, DOI 10.1111/j.1365-2133.1992.tb00001.x; RYDER NS, 1989, CLIN EXP DERMATOL, V14, P98, DOI 10.1111/j.1365-2230.1989.tb00900.x; Schroepfer GJ, 2000, PHYSIOL REV, V80, P361, DOI 10.1152/physrev.2000.80.1.361; SKALNIK DG, 1988, J BIOL CHEM, V263, P6836	52	45	46	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 23	2001	276	12					8681	8694		10.1074/jbc.M007888200	http://dx.doi.org/10.1074/jbc.M007888200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	413HV	11134013	hybrid			2022-12-25	WOS:000167607700011
J	Iwasaki, K; Morimatsu, M; Inanami, O; Uchida, E; Syuto, B; Kuwabara, M; Niiyama, M				Iwasaki, K; Morimatsu, M; Inanami, O; Uchida, E; Syuto, B; Kuwabara, M; Niiyama, M			Isolation, characterization, and cDNA cloning of chicken turpentine-induced protein, a new member of the scavenger receptor cysteine-rich (SRCR) family of proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEUKOCYTE NADPH OXIDASE; MOLECULAR-CLONING; FREE-RADICALS; HUMAN-NEUTROPHILS; LYMPHOCYTES-T; CELL-SURFACE; ACTIVATION; CONTAINS; DOMAIN; DIFFERENTIATION	Acute-phase serum proteins were induced by administrating a chicken with turpentine oil. One of these proteins was a new protein that appeared in front of albumin in polyacrylamide disc gel electrophoresis using a 4.5-16% gel. To purify this protein, turpentine-administrated chicken serum was fractionated by ammonium sulfate precipitation at 50% saturation, and the supernatant fraction was chromatographed on a DEAE-Toyopearl 650S column. The purified protein is a mannose-glycoprotein, and its N-terminal sequence, determined by the Edoman method, is not homologous from that of other reported acute-phase proteins. An analysis of physiological function with two different test systems, chemiluminescence measurement and electron spin resonance spectroscopy, showed that the purified protein has antioxidant, activity and inhibits superoxide (O-2(radical anion)) mediated by activation of the receptor. In support of these results, the complete amino acid sequence of 18-B is homologous to the scavenger receptor cysteine-rich (SRCR) family of proteins that participate in the regulation of leukocyte function. 18-B is composed of four SRCR domains, which is different from the previously characterized SRCR family of proteins such as Sp alpha, CD6, and CD163. These findings indicate that turpentine-induced 18-B, a new member of scavenger receptor cysteine-rich family, may be implicated in regulation of cell function in a manner of inhibition of the overproduction of the reactive oxygen species.	Rakuno Gakuen Univ, Sch Vet Med, Dept Vet Internal Med 2, Ebetsu, Hokkaido 0698501, Japan; Iwate Univ, Fac Agr, Dept Vet Physiol, Morioka, Iwate 0208550, Japan; Hokkaido Univ, Grad Sch Vet Med, Dept Environm Vet Med, Sapporo, Hokkaido 0600818, Japan	Rakuno Gakuen University; Iwate University; Hokkaido University	Niiyama, M (corresponding author), Rakuno Gakuen Univ, Sch Vet Med, Dept Vet Internal Med 2, Ebetsu, Hokkaido 0698501, Japan.		Inanami, Osamu/A-5197-2012; Morimatsu, Masami/A-6698-2012	Inanami, Osamu/0000-0001-7895-3918; Morimatsu, Masami/0000-0003-0740-0157				AMRANI DL, 1986, BIOCHEM J, V238, P365, DOI 10.1042/bj2380365; ARUFFO A, 1991, J EXP MED, V174, P949, DOI 10.1084/jem.174.4.949; Aruffo A, 1997, IMMUNOL TODAY, V18, P498, DOI 10.1016/S0167-5699(97)01130-4; BABIOR BM, 1973, J CLIN INVEST, V52, P741, DOI 10.1172/JCI107236; BRITIGAN BE, 1987, J LEUKOCYTE BIOL, V41, P349, DOI 10.1002/jlb.41.4.349; BRITIGAN BE, 1986, J BIOL CHEM, V261, P4426; Chamulitrat W, 1999, FREE RADICAL BIO MED, V27, P411, DOI 10.1016/S0891-5849(99)00088-X; Cheng H, 1996, ANAT REC, V244, P327; DELERS E, 1983, COMP BIOCH PHYSL, V74, P619; DUBOIS M, 1956, ANAL CHEM, V28, P350, DOI 10.1021/ac60111a017; FELGENHAUER K, 1970, Clinica Chimica Acta, V27, P305, DOI 10.1016/0009-8981(70)90349-9; Gebe JA, 1997, J BIOL CHEM, V272, P6151, DOI 10.1074/jbc.272.10.6151; GRIENINGER G, 1989, ANN NY ACAD SCI, V557, P257; GRIENINGER G, 1986, J BIOL CHEM, V261, P5719; HALLQUIST NA, 1994, COMP BIOCHEM PHYS B, V108, P375, DOI 10.1016/0305-0491(94)90089-2; HUANG HJS, 1987, P NATL ACAD SCI USA, V84, P204, DOI 10.1073/pnas.84.1.204; Inanami O, 1998, ARCH BIOCHEM BIOPHYS, V350, P36, DOI 10.1006/abbi.1997.0484; Inanami O, 1998, J BIOL CHEM, V273, P9539, DOI 10.1074/jbc.273.16.9539; JAIN NK, 1982, VET REC, V110, P421, DOI 10.1136/vr.110.18.421; JONES NH, 1986, NATURE, V323, P346, DOI 10.1038/323346a0; KLASING KC, 1991, POULTRY SCI, V70, P1176, DOI 10.3382/ps.0701176; KODAMA T, 1990, NATURE, V343, P531, DOI 10.1038/343531a0; Krieger M, 1997, CURR OPIN LIPIDOL, V8, P275, DOI 10.1097/00041433-199710000-00006; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAW SKA, 1993, EUR J IMMUNOL, V23, P2320, DOI 10.1002/eji.1830230940; LI XJ, 1995, J BIOL CHEM, V270, P17674, DOI 10.1074/jbc.270.30.17674; LOWRY OH, 1951, J BIOL CHEM, V193, P265; PATTERSON LT, 1965, TEX REP BIOL MED, V23, P600; SINHA BK, 1987, RES VET SCI, V42, P365, DOI 10.1016/S0034-5288(18)30720-3; SYUTO B, 1981, JPN J VET SCI, V43, P71; Takito J, 1999, AM J PHYSIOL-RENAL, V277, pF277, DOI 10.1152/ajprenal.1999.277.2.F277; THIES ES, 1983, AM J VET RES, V44, P288; TOHJO H, 1995, POULTRY SCI, V74, P648, DOI 10.3382/ps.0740648; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; URBAN J, 1979, J BIOL CHEM, V254, P565; VAN DE VELDE H, 1991, NATURE, V351, P662; Vijayakumar S, 1999, J CELL BIOL, V144, P1057, DOI 10.1083/jcb.144.5.1057; WHITNEY GS, 1995, J BIOL CHEM, V270, P18187, DOI 10.1074/jbc.270.31.18187; WIJNGAARD PLJ, 1992, J IMMUNOL, V149, P3273; Yamamori T, 2000, FEBS LETT, V467, P253, DOI 10.1016/S0014-5793(00)01167-4	40	24	24	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 23	2001	276	12					9400	9405		10.1074/jbc.M011713200	http://dx.doi.org/10.1074/jbc.M011713200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	413HV	11136738	hybrid			2022-12-25	WOS:000167607700104
J	Wooten, MW; Seibenhener, ML; Mamidipudi, V; Diaz-Meco, MT; Barker, PA; Moscat, J				Wooten, MW; Seibenhener, ML; Mamidipudi, V; Diaz-Meco, MT; Barker, PA; Moscat, J			The atypical protein kinase C-interacting protein p62 is a scaffold for NF-kappa B activation by nerve growth factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PC12 CELLS; NEUROTROPHIN RECEPTOR; SIGNAL-TRANSDUCTION; SURVIVAL; APOPTOSIS; PKC; DIFFERENTIATION; ISOFORMS; PATHWAY; FAMILY	Nerve growth factor (NGF) binding to both p75 and TrkA neurotrophin receptors activates the transcription factor nuclear factor kappaB (NF-kappaB). Here we show that the atypical protein kinase C-interacting protein, p62, which binds TRAF6, selectively interacts with TrkA but not p75. In contrast, TRAF6 interacts with p75 but not TrkA. We demonstrate the formation of a TRAF6-p62 complex that serves as a bridge linking both p75 and TrkA signaling. Of functional relevance, transfection of antisense p62-enhanced p75-mediated cell death and diminished NGF-induced differentiation occur through a mechanism involving inhibition of IKK activity. These findings reveal a new function for p62 as a common platform for communication of both p75-TRAF6 and TrkA signals. Moreover, we demonstrated that p62 serves as a scaffold for activation of the NF-kappaB pathway, which mediates NGF survival and differentiation responses.	Auburn Univ, Dept Biol Sci, Program Cell & Mol Biosci, Auburn, AL 36849 USA; Univ Autonoma Madrid, Ctr Biol Mol Severo Ochoa, CSIC, E-28049 Madrid, Spain; McGill Univ, Montreal Neurol Inst, Ctr Neuronal Survival, Montreal, PQ H3A 2B4, Canada	Auburn University System; Auburn University; Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Biologia Molecular Severo Ochoa (CBM); McGill University	Wooten, MW (corresponding author), Auburn Univ, Dept Biol Sci, Program Cell & Mol Biosci, 331 Funchess Hall, Auburn, AL 36849 USA.		Moscat, Jorge/A-7011-2009	Diaz-Meco, Maria/0000-0003-0147-0998				Arch RH, 1998, GENE DEV, V12, P2821, DOI 10.1101/gad.12.18.2821; Casaccia-Bonnefil P, 1998, CELL DEATH DIFFER, V5, P357, DOI 10.1038/sj.cdd.4400377; Feng ZW, 1999, J BIOL CHEM, V274, P30341, DOI 10.1074/jbc.274.43.30341; Foehr ED, 2000, J NEUROSCI, V20, P7556; Gentry JJ, 2000, J BIOL CHEM, V275, P7558, DOI 10.1074/jbc.275.11.7558; Jiang H, 1999, J BIOL CHEM, V274, P26209, DOI 10.1074/jbc.274.37.26209; Kaplan DR, 1998, PROG BRAIN RES, V117, P35; Khursigara G, 1999, J BIOL CHEM, V274, P2597, DOI 10.1074/jbc.274.5.2597; Klesse LJ, 1999, MICROSC RES TECHNIQ, V45, P210, DOI 10.1002/(SICI)1097-0029(19990515/01)45:4/5<210::AID-JEMT4>3.3.CO;2-6; Lallena MJ, 1999, MOL CELL BIOL, V19, P2180; Li QT, 2000, GENE DEV, V14, P1729; Lomaga MA, 2000, J NEUROSCI, V20, P7384; Puls A, 1997, P NATL ACAD SCI USA, V94, P6191, DOI 10.1073/pnas.94.12.6191; Sanchez P, 1998, MOL CELL BIOL, V18, P3069, DOI 10.1128/MCB.18.5.3069; Sanz L, 2000, EMBO J, V19, P1576, DOI 10.1093/emboj/19.7.1576; Wang YM, 1999, J NEUROSCI RES, V55, P293, DOI 10.1002/(SICI)1097-4547(19990201)55:3<293::AID-JNR4>3.3.CO;2-0; Wooten MW, 2000, MOL CELL BIOL, V20, P4494, DOI 10.1128/MCB.20.13.4494-4504.2000; Wooten MW, 1999, CELL DEATH DIFFER, V6, P753, DOI 10.1038/sj.cdd.4400548; Wooten MW, 1999, J NEUROSCI RES, V58, P607, DOI 10.1002/(SICI)1097-4547(19991201)58:5<607::AID-JNR1>3.0.CO;2-M; Yamashita T, 1999, NEURON, V24, P585, DOI 10.1016/S0896-6273(00)81114-9; Ye X, 1999, J BIOL CHEM, V274, P30202, DOI 10.1074/jbc.274.42.30202	21	144	158	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 16	2001	276	11					7709	7712		10.1074/jbc.C000869200	http://dx.doi.org/10.1074/jbc.C000869200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	411AA	11244088	hybrid			2022-12-25	WOS:000167474900006
J	Sun, RG; Chen, XM; Yang, VW				Sun, RG; Chen, XM; Yang, VW			Intestinal-enriched Kruppel-like factor (Kruppel-like factor 5) is a positive regulator of cellular proliferation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE CELLS; TRANSCRIPTION FACTOR; BIOLOGICAL ASSAYS; EPITHELIAL-CELLS; NUCLEAR PROTEINS; GENE; EXPRESSION; GROWTH; FINGER; FAMILY	Intestinal-enriched Kruppel-like factor (IKLF or KLF5) belongs to the family of mammalian Kruppel-like transcription factors. Previous studies indicate that expression of IKLF is enriched in the proliferating crypt epithelial cells of the intestinal tract. However, the biological function of IKLF is unknown. In the current study, we have shown that the level of IKLF mRNA was nearly undetectable in serum-deprived NIH3T3 fibroblasts but became acutely and significantly increased upon the addition of fetal bovine serum or the phorbol ester, PMA. This induction required protein synthesis because it was prevented by cycloheximide. Transfection of IKLF into NIH3T3 cells resulted in the formation of foci in a manner similar to that caused by the activated Ha-ras oncogene. Constitutive expression of IKLF in transfected NIH3T3 cells significantly increased the rate of proliferation when compared with cells transfected with an empty vector. The growth of IKLF-transfected cells was no longer inhibited by cell-cell contact or by low serum content. Moreover, these cells proliferated in an anchorage-independent fashion. We conclude that IKLF encodes a delayed early response gene product that positively regulates cellular proliferation and may give rise to a transformed phenotype when overexpressed.	Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Biol Chem, Baltimore, MD 21205 USA	Johns Hopkins University; Johns Hopkins University	Yang, VW (corresponding author), Johns Hopkins Univ, Sch Med, Dept Med, Ross 918,720 Rutland Ave, Baltimore, MD 21205 USA.				NCI NIH HHS [R01 CA084197-02, CA84197, R01 CA084197] Funding Source: Medline; NIDDK NIH HHS [DK52230, R01 DK052230-04, R01 DK052230] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA084197] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK052230] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Adam PJ, 2000, J BIOL CHEM, V275, P37798, DOI 10.1074/jbc.M006323200; CLARK GJ, 1995, METHOD ENZYMOL, V255, P395; Conkright MD, 1999, NUCLEIC ACIDS RES, V27, P1263, DOI 10.1093/nar/27.5.1263; COX AD, 1994, METHOD ENZYMOL, V238, P277; Dang DT, 2000, INT J BIOCHEM CELL B, V32, P1103, DOI 10.1016/S1357-2725(00)00059-5; GarrettSinha LA, 1996, J BIOL CHEM, V271, P31384, DOI 10.1074/jbc.271.49.31384; Gebelein B, 1998, J CLIN INVEST, V102, P1911, DOI 10.1172/JCI1919; GORDON JI, 1994, CURR OPIN CELL BIOL, V6, P795, DOI 10.1016/0955-0674(94)90047-7; Hoshino Y, 2000, CIRCULATION, V102, P2528, DOI 10.1161/01.CIR.102.20.2528; KADONAGA JT, 1987, CELL, V51, P1079, DOI 10.1016/0092-8674(87)90594-0; Kawai-Kowase K, 1999, CIRC RES, V85, P787, DOI 10.1161/01.RES.85.9.787; LANAHAN A, 1992, MOL CELL BIOL, V12, P3919, DOI 10.1128/MCB.12.9.3919; MILLER IJ, 1993, MOL CELL BIOL, V13, P2776, DOI 10.1128/MCB.13.5.2776; Ogata T, 2000, J THORAC CARDIOV SUR, V119, P983, DOI 10.1016/S0022-5223(00)70093-6; Ohnishi S, 2000, DEV DYNAM, V217, P421, DOI 10.1002/(SICI)1097-0177(200004)217:4<421::AID-DVDY9>3.0.CO;2-1; Philipsen S, 1999, NUCLEIC ACIDS RES, V27, P2991, DOI 10.1093/nar/27.15.2991; SCHUH R, 1986, CELL, V47, P1025, DOI 10.1016/0092-8674(86)90817-2; Shi HP, 1999, NUCLEIC ACIDS RES, V27, P4807, DOI 10.1093/nar/27.24.4807; Shie JL, 2000, AM J PHYSIOL-GASTR L, V279, pG806, DOI 10.1152/ajpgi.2000.279.4.G806; Shie JL, 2000, NUCLEIC ACIDS RES, V28, P2969, DOI 10.1093/nar/28.15.2969; Shields JM, 1996, J BIOL CHEM, V271, P20009, DOI 10.1074/jbc.271.33.20009; SOGAWA K, 1993, NUCLEIC ACIDS RES, V21, P1527, DOI 10.1093/nar/21.7.1527; Stappenbeck TS, 1998, CURR OPIN CELL BIOL, V10, P702, DOI 10.1016/S0955-0674(98)80110-5; Turner J, 1999, TRENDS BIOCHEM SCI, V24, P236, DOI 10.1016/S0968-0004(99)01406-1; Watanabe N, 1999, CIRC RES, V85, P182, DOI 10.1161/01.RES.85.2.182; White JA, 1997, GENOMICS, V45, P468, DOI 10.1006/geno.1997.4979; Winkles JA, 1998, PROG NUCLEIC ACID RE, V58, P41	27	135	143	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 9	2001	276	10					6897	6900		10.1074/jbc.C000870200	http://dx.doi.org/10.1074/jbc.C000870200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	410MC	11152667	Green Accepted, hybrid			2022-12-25	WOS:000167442900005
J	Fessele, S; Boehlk, S; Mojaat, A; Miyamoto, NG; Werner, T; Nelson, EL; Schlondorff, D; Nelson, PJ				Fessele, S; Boehlk, S; Mojaat, A; Miyamoto, NG; Werner, T; Nelson, EL; Schlondorff, D; Nelson, PJ			Molecular and in silico characterization of a promoter module and C/EBP element that mediate LPS-induced RANTES/CCL5 expression in monocytic cells	FASEB JOURNAL			English	Article									Univ Munich, Klinikum Innenstadt, Med Poliklin, D-8000 Munich, Germany; Beriex Biosci, Dept Immunol, Richmond, CA USA; GSF, Natl Res Ctr Environm & Hlth, Inst Mammalian Genet, Neuherberg, Germany; Genomatix Software GmbH, Munich, Germany; NCI, Frederick Canc Res & Dev Ctr, Frederick, MD USA	University of Munich; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick	Nelson, PJ (corresponding author), Univ Munich, Med Poliklin, Schillerstr 42, D-80336 Munich, Germany.			Nelson, Edward/0000-0001-7887-032X; Fessele, Sabine/0000-0002-5399-3574					0	48	48	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAR	2001	15	3					577	579						3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	410BE	11259372				2022-12-25	WOS:000167419500010
J	Oviedo-Orta, E; Gasque, P; Evans, WH				Oviedo-Orta, E; Gasque, P; Evans, WH			Immunoglobulin and cytokine expression in mixed lymphocyte cultures is reduced by disruption of gap junction intercellular communication	FASEB JOURNAL			English	Article						connexins; intercellular communication; interleukins; mimetic peptides; interferon gamma	ENDOTHELIUM-DEPENDENT RELAXATIONS; ADHESION MOLECULES; PERIPHERAL-BLOOD; IMMUNE-SYSTEM; CELL-ADHESION; B-CELLS; INHIBITION; IL-2; PROTEINS; CONNEXIN-43	Connexins (Cx), the protein subunits assembled into gap junction intercellular communication channels, are expressed in primary lymphoid or organs and by circulating leukocytes, Human tonsil-derived T and B lymphocytes express Cx40 and 43; circulating human T, B, and NK lymphocytes express Cx43 and directly transfer between each other a low molecular dye indicative that functional gap junctions exist. We now identify specific properties in the immune system underwritten by gap junctions. Mixed lymphocytes cultured in the presence of two reagents with independent inhibitory action on gap junction communication, a connexin mimetic peptide and 18-alpha -glycyrrhetinic acid, markedly reduced the secretion of IgM, Igc, and IgA. The secretion of these immunoglobulins by purified B cells was also reduced by the two classes of gap junction inhibitors. Complex temporal inhibitory effects on the expression of mRNA encoding interleukins, especially IL-10, were also observed, The results indicate that intercellular signaling across gap junctions is an important component of the mechanisms underlying metabolic cooperation in the immune system.	Univ Wales Coll Cardiff, Coll Med, Dept Biochem Med, Cardiff CF14 4XN, S Glam, Wales; Wales Heart Res Inst, Cardiff CF14 4XN, S Glam, Wales	Cardiff University; Cardiff University	Oviedo-Orta, E (corresponding author), Bristol Royal Infirm & Gen Hosp, Bristol Heart Inst, Level 7,Upper Maudlin St, Bristol BS2 8HW, Avon, England.	e.oviedo-orta@bristol.ac.uk	OVIEDO-ORTA, Ernesto/L-4846-2018	OVIEDO-ORTA, Ernesto/0000-0003-1323-3316				AbouHashieh I, 1996, J HEPATOL, V24, P360; Alves LA, 1998, IMMUNOL TODAY, V19, P269, DOI 10.1016/S0167-5699(98)01256-0; Angelopoulou MK, 1999, SEMIN HEMATOL, V36, P178; Bain G, 1998, SEMIN IMMUNOL, V10, P143, DOI 10.1006/smim.1998.0116; BASTIDE B, 1995, PFLUG ARCH EUR J PHY, V429, P386, DOI 10.1007/BF00374154; BASTIDE B, 1993, CIRC RES, V73, P1138, DOI 10.1161/01.RES.73.6.1138; Bayon Y, 1998, CYTOKINES CELL MOL T, V4, P275; BECK E, 1995, BOT ACTA, V108, P1; BENNETT MVL, 1991, NEURON, V6, P305, DOI 10.1016/0896-6273(91)90241-Q; BEREK C, 1993, IMMUNOL TODAY, V14, P400, DOI 10.1016/0167-5699(93)90143-9; Boitano S, 2000, AM J PHYSIOL-LUNG C, V279, pL623, DOI 10.1152/ajplung.2000.279.4.L623; Briscoe DM, 1998, CURR OPIN IMMUNOL, V10, P525, DOI 10.1016/S0952-7915(98)80218-5; Buckley CD, 1998, MOL MEMBR BIOL, V15, P167, DOI 10.3109/09687689709044318; CALLAGHAN M, 1993, CLIN EXP IMMUNOL, V93, P212; Chaytor AT, 1997, J PHYSIOL-LONDON, V503, P99, DOI 10.1111/j.1469-7793.1997.099bi.x; Chaytor AT, 1998, J PHYSIOL-LONDON, V508, P561, DOI 10.1111/j.1469-7793.1998.561bq.x; Chaytor AT, 1999, J PHYSIOL-LONDON, V520, P539, DOI 10.1111/j.1469-7793.1999.00539.x; Chaytor AT, 1997, J PHYSIOL-LONDON, V503, P699; Chia MC, 1998, CRIT REV CL LAB SCI, V35, P573, DOI 10.1080/10408369891234282; Cooper EL, 1999, MICROSC RES TECHNIQ, V44, P237, DOI 10.1002/(SICI)1097-0029(19990215)44:4<237::AID-JEMT4>3.0.CO;2-0; DAVIDSON JS, 1988, J PHARMACOL EXP THER, V246, P1104; DEUTSCH DE, 1995, AM J PHYSIOL-GASTR L, V269, pG779, DOI 10.1152/ajpgi.1995.269.5.G779; Dora KA, 1999, BIOCHEM BIOPH RES CO, V254, P27, DOI 10.1006/bbrc.1998.9877; EVANS WH, 1988, BIOESSAYS, V8, P3; Fabbri M, 1999, INFLAMM RES, V48, P239, DOI 10.1007/s000110050454; Freitas AA, 1999, CURR OPIN IMMUNOL, V11, P152, DOI 10.1016/S0952-7915(99)80026-0; Gonzalez-Amaro R, 1998, DRUGS, V56, P977, DOI 10.2165/00003495-199856060-00003; Goodenough DA, 1996, ANNU REV BIOCHEM, V65, P475, DOI 10.1146/annurev.bi.65.070196.002355; GUO YH, 1999, AM J PHYSIOL, V20, pL1018; He DS, 1998, MOL BIOL CELL, V9, p325A; HULSER DF, 1972, EXP CELL RES, V74, P319, DOI 10.1016/0014-4827(72)90383-7; JARA PI, 1995, P NATL ACAD SCI USA, V92, P7011, DOI 10.1073/pnas.92.15.7011; JAVID PJ, 1995, FASEB J, V9, pA914; KAUL R, 1995, CLIN IMMUNOL IMMUNOP, V74, P271, DOI 10.1006/clin.1995.1039; KRENACS T, 1995, J HISTOCHEM CYTOCHEM, V43, P1125, DOI 10.1177/43.11.7560895; Krenacs T, 1997, EUR J IMMUNOL, V27, P1489, DOI 10.1002/eji.1830270627; Kwak BR, 1999, J PHYSIOL-LONDON, V516, P679, DOI 10.1111/j.1469-7793.1999.0679u.x; Mambetisaeva ET, 1999, J NEUROSCI RES, V57, P166, DOI 10.1002/(SICI)1097-4547(19990715)57:2<166::AID-JNR2>3.3.CO;2-P; Martin PEM, 1998, J BIOL CHEM, V273, P1719, DOI 10.1074/jbc.273.3.1719; MILSTEIN C, 1991, IMMUNOL TODAY, V12, P93, DOI 10.1016/0167-5699(91)90164-O; MIYAJIMA H, 1991, J IMMUNOL, V146, P457; NONOYAMA S, 1994, CLIN IMMUNOL IMMUNOP, V72, P373, DOI 10.1006/clin.1994.1155; Oviedo-Orta E, 2000, IMMUNOLOGY, V99, P578, DOI 10.1046/j.1365-2567.2000.00991.x; REVEL JP, 1986, TRENDS BIOCHEM SCI, V11, P375, DOI 10.1016/0968-0004(86)90208-2; Taylor HJ, 1998, BRIT J PHARMACOL, V125, P1, DOI 10.1038/sj.bjp.0702078; WARNER A, 1995, J PHYSIOL-LONDON, V488, P721, DOI 10.1113/jphysiol.1995.sp021003	46	71	74	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2001	15	3					768	774		10.1096/fj.00-0288com	http://dx.doi.org/10.1096/fj.00-0288com			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	410BE	11259395				2022-12-25	WOS:000167419500034
J	Watanabe, H; Tran, QK; Takeuchi, K; Fukao, M; Liu, MY; Kanno, M; Hayashi, T; Iguchi, A; Seto, M				Watanabe, H; Tran, QK; Takeuchi, K; Fukao, M; Liu, MY; Kanno, M; Hayashi, T; Iguchi, A; Seto, M			Myosin light-chain kinase regulates endothelial calcium entry and endothelium-dependent vasodilation	FASEB JOURNAL			English	Article									Hamamatsu Univ Sch Med, Dept Clin Pharmacol & Therapeut, Hamamatsu, Shizuoka 4313192, Japan; Hokkaido Univ, Sch Med, Dept Pharmacol, Sapporo, Hokkaido 0608638, Japan; Asahi Chem Ind Co Ltd, Life Sci Res Ctr, Fuji, Shizuoka 4160934, Japan; Nagoya Univ, Sch Med, Dept Geriatr Med, Nagoya, Aichi 4668560, Japan	Hamamatsu University School of Medicine; Hokkaido University; Nagoya University	Watanabe, H (corresponding author), Hamamatsu Univ Sch Med, Dept Clin Pharmacol & Therapeut, 3600 Handa Cho, Hamamatsu, Shizuoka 4313192, Japan.	hwat@hama-med.ac.jp		Tran, Kim/0000-0003-1881-1357					0	24	25	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2001	15	2					282	284		10.1096/fj.00-0587fje	http://dx.doi.org/10.1096/fj.00-0587fje			3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	400LK	11156937				2022-12-25	WOS:000166872900003
J	Lehembre, F; Muller, S; Pandolfi, PP; Dejean, A				Lehembre, F; Muller, S; Pandolfi, PP; Dejean, A			Regulation of Pax3 transcriptional activity by SUMO-1-modified PML	ONCOGENE			English	Article						PML; SUMO; Pax3; Daxx; nuclear bodies	TUMOR ALVEOLAR RHABDOMYOSARCOMA; PROMYELOCYTIC LEUKEMIA FUSES; NUCLEAR-PORE COMPLEX; PAIRED BOX GENE; COVALENT MODIFICATION; WAARDENBURG SYNDROME; INTERACTING PROTEIN; BINDING PROTEIN; DOMAIN GENE; RAR-ALPHA	Pax3 is an evolutionarily conserved transcription factor that plays a major role in a variety of developmental processes, Mutations in Pax3 lead to severe malformations as seen in human Waardenburg syndrome and in the Splotch mutant mice. The transcriptional activity of Pax3 was recently shown to be repressed by Daxx whereas the oncogenic fusion protein Pax3-FKHR is unresponsive to this repressive action. Here we demonstrate that Daxx-mediated repression of Pax3 can be inhibited by the nuclear body (NB)-associated protein PML, Interestingly, this suppression of Daxx properties correlates with its recruitment to the NBs, Factors such as arsenicals and interferons that enhance NE formation, trigger both the targeting of Daxx to these nuclear structures and the relief of the repressive activity of Daxx, Conversely, lack of structurally intact NBs profoundly impairs Pax3 transcriptional activity, likely by increasing the pool of available nucleoplasmic Daxx, Moreover, a PML mutant that can not be modified by the ubiquitin-related SUMO-1 modifier is no more able to interact with Daxx, Consistently, such a mutant fails both to inhibit the Daxx repressing effect on Pax3 and to induce its accumulation into the NBs, Taken together, these results argue that SUMO-I modified PML can derepress Pax3 transcriptional activity through sequestration of the Daxx repressor into the NBs and suggest a role for these nuclear structures in the transcriptional control by Pax proteins.	Inst Pasteur, INSERM, U163, Unite Recombinaison & Express Genet, F-75724 Paris 15, France; Cornell Univ, Mem Sloan Kettering Canc Ctr, Dept Human Genet, New York, NY 10021 USA; Cornell Univ, Mem Sloan Kettering Canc Ctr, Program Mol Biol, New York, NY 10021 USA	Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Cornell University; Memorial Sloan Kettering Cancer Center; Cornell University; Memorial Sloan Kettering Cancer Center	Dejean, A (corresponding author), Inst Pasteur, INSERM, U163, Unite Recombinaison & Express Genet, 28 Rue Dr Roux, F-75724 Paris 15, France.		Dejean, Anne/L-5145-2018	Muller, Stefan/0000-0002-8792-7700				Alcalay M, 1998, MOL CELL BIOL, V18, P1084, DOI 10.1128/MCB.18.2.1084; Ausubel FM., 1992, CURRENT PROTOCOLS MO, V3; BALDWIN CT, 1992, NATURE, V355, P637, DOI 10.1038/355637a0; BARR FG, 1993, NAT GENET, V3, P113, DOI 10.1038/ng0293-113; Boisvert FM, 2000, J CELL BIOL, V148, P283, DOI 10.1083/jcb.148.2.283; BORDEN KLB, 1995, EMBO J, V14, P1532, DOI 10.1002/j.1460-2075.1995.tb07139.x; CHALEPAKIS G, 1994, P NATL ACAD SCI USA, V91, P12745, DOI 10.1073/pnas.91.26.12745; Chang HY, 1998, SCIENCE, V281, P1860, DOI 10.1126/science.281.5384.1860; Desterro JMP, 1998, MOL CELL, V2, P233, DOI 10.1016/S1097-2765(00)80133-1; DETHE H, 1990, NATURE, V347, P558, DOI 10.1038/347558a0; Doucas V, 1999, P NATL ACAD SCI USA, V96, P2633, DOI 10.1073/pnas.96.6.2633; DYCK JA, 1994, CELL, V76, P333, DOI 10.1016/0092-8674(94)90340-9; EPSTEIN DJ, 1991, CELL, V67, P767, DOI 10.1016/0092-8674(91)90071-6; FREDERICKS WJ, 1995, MOL CELL BIOL, V15, P1522; GALILI N, 1993, NAT GENET, V5, P230, DOI 10.1038/ng1193-230; GULDNER HH, 1992, J IMMUNOL, V149, P4067; Hendzel MJ, 1998, MOL BIOL CELL, V9, P2491, DOI 10.1091/mbc.9.9.2491; Hollenbach AD, 1999, EMBO J, V18, P3702, DOI 10.1093/emboj/18.13.3702; Ishov AM, 1999, J CELL BIOL, V147, P221, DOI 10.1083/jcb.147.2.221; Jentsch S, 2000, TRENDS CELL BIOL, V10, P335, DOI 10.1016/S0962-8924(00)01785-2; KAKIZUKA A, 1991, CELL, V66, P663, DOI 10.1016/0092-8674(91)90112-C; Kamitani T, 1998, J BIOL CHEM, V273, P3117, DOI 10.1074/jbc.273.6.3117; Kiriakidou M, 1997, DNA CELL BIOL, V16, P1289, DOI 10.1089/dna.1997.16.1289; KOKEN MHM, 1994, EMBO J, V13, P1073, DOI 10.1002/j.1460-2075.1994.tb06356.x; LAVAU C, 1995, ONCOGENE, V11, P871; Li H, 2000, MOL CELL BIOL, V20, P1784, DOI 10.1128/MCB.20.5.1784-1796.2000; Magnaghi P, 1998, NAT GENET, V20, P74, DOI 10.1038/1739; Mahajan R, 1997, CELL, V88, P97, DOI 10.1016/S0092-8674(00)81862-0; Mansouri A, 1996, CURR OPIN CELL BIOL, V8, P851, DOI 10.1016/S0955-0674(96)80087-1; Matunis MJ, 1996, J CELL BIOL, V135, P1457, DOI 10.1083/jcb.135.6.1457; MAULBECKER CC, 1993, EMBO J, V12, P2361, DOI 10.1002/j.1460-2075.1993.tb05890.x; Michaelson JS, 1999, GENE DEV, V13, P1918, DOI 10.1101/gad.13.15.1918; Muller S, 1998, EMBO J, V17, P61, DOI 10.1093/emboj/17.1.61; Pluta AF, 1998, J CELL SCI, V111, P2029; Schul W, 1998, J CELL BIOCHEM, V70, P159, DOI 10.1002/(SICI)1097-4644(19980801)70:2<159::AID-JCB2>3.0.CO;2-N; Seeler JS, 1999, CURR OPIN GENET DEV, V9, P362, DOI 10.1016/S0959-437X(99)80054-9; Seeler JS, 1998, P NATL ACAD SCI USA, V95, P7316, DOI 10.1073/pnas.95.13.7316; SHAPIRO DN, 1993, CANCER RES, V53, P5108; Shen ZX, 1997, BLOOD, V89, P3354, DOI 10.1182/blood.V89.9.3354; Stadler M, 1995, ONCOGENE, V11, P2565; Sternsdorf T, 1997, J CELL BIOL, V139, P1621, DOI 10.1083/jcb.139.7.1621; STUURMAN N, 1992, J CELL SCI, V101, P773; TASSABEHJI M, 1992, NATURE, V355, P635, DOI 10.1038/355635a0; Torii S, 1999, EMBO J, V18, P6037, DOI 10.1093/emboj/18.21.6037; WEIS K, 1994, CELL, V76, P345, DOI 10.1016/0092-8674(94)90341-7; Wiggan O, 1998, ONCOGENE, V16, P227, DOI 10.1038/sj.onc.1201534; Yang XL, 1997, CELL, V89, P1067, DOI 10.1016/S0092-8674(00)80294-9; Yeh ETH, 2000, GENE, V248, P1, DOI 10.1016/S0378-1119(00)00139-6; Zhong S, 2000, NAT CELL BIOL, V2, pE85, DOI 10.1038/35010583; Zhong S, 2000, BLOOD, V95, P2748, DOI 10.1182/blood.V95.9.2748.009k31a_2748_2752	50	92	95	0	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 4	2001	20	1					1	9		10.1038/sj.onc.1204063	http://dx.doi.org/10.1038/sj.onc.1204063			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	391NE	11244500				2022-12-25	WOS:000166361400001
J	Kosako, H; Yoshida, T; Matsumura, F; Ishizaki, T; Narumiya, S; Inagaki, M				Kosako, H; Yoshida, T; Matsumura, F; Ishizaki, T; Narumiya, S; Inagaki, M			Rho-kinase/ROCK is involved in cytokinesis through the phosphorylation of myosin light chain and not ezrin/radixin/moesin proteins at the cleavage furrow	ONCOGENE			English	Article						cell cycle; cytokinesis; Rho-kinase; myosin light chain; ERM proteins	ERM PROTEINS; CULTURED-CELLS; ACTIN CYTOSKELETON; SMALL GTPASE; ADHESION; ASSOCIATION; PHOSPHATASE; FILAMENTS; ACTIVATION; MOESIN	The small GTPase Rho and one of its targets, Rho-kinase (also termed ROK or ROCK), are implicated in various cellular functions including stress fiber formation, smooth muscle contraction, tumor cell invasion and cell motility, We have previously reported that Rho-kinase accumulates at the cleavage furrow during cytokinesis in several cultured cells. Here, using Rho-kinase inhibitors, Y-27632 and HA1077, we found that Rho-kinase is responsible for the phosphorylation of myosin regulatory light chain at Ser(19) in the cleavage furrow during cytokinesis. On the other hand, phosphorylation of ezrin/radixin/moesin (ERM) proteins at the cleavage furrow was enhanced by the addition of the above Rho-kinase inhibitors, Treatment with Y-27632 strongly enhanced the accumulation of Rho-kinase but not RhoA and citron kinase at the cleavage furrow. Furthermore, the furrow ingression in cytokinesis was significantly prolonged in the presence of Y-27632, These results suggest that Rho-kinase is involved in the progression of cytokinesis through the phosphorylation of several proteins including myosin light chain at the cleavage furrow.	Univ Tokyo, Grad Sch Med, Dept Neurobiol, Bunkyo Ku, Tokyo 1130033, Japan; Aichi Canc Ctr, Res Inst, Biochem Lab, Nagoya, Aichi 4648681, Japan; Mie Univ, Sch Med, Dept Pathol, Tsu, Mie 5148507, Japan; Rutgers State Univ, Dept Mol Biol & Biochem, Piscataway, NJ 08855 USA; Kyoto Univ, Fac Med, Dept Pharmacol, Kyoto 6068315, Japan	University of Tokyo; Aichi Cancer Center; Mie University; Rutgers State University New Brunswick; Kyoto University	Kosako, H (corresponding author), Univ Tokyo, Grad Sch Med, Dept Neurobiol, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1130033, Japan.		Inagaki, Masaki/B-9920-2016; Yoshida, Toshimichi/H-6204-2013	Yoshida, Toshimichi/0000-0001-8935-8217; Matsumura, Fumio/0000-0002-8204-153X				Amano M, 1996, J BIOL CHEM, V271, P20246, DOI 10.1074/jbc.271.34.20246; Fukata Y, 1998, J CELL BIOL, V141, P409, DOI 10.1083/jcb.141.2.409; Gerisch G, 2000, CURR OPIN CELL BIOL, V12, P126, DOI 10.1016/S0955-0674(99)00066-6; Hales KG, 1999, CURR OPIN CELL BIOL, V11, P717, DOI 10.1016/S0955-0674(99)00042-3; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Hayashi K, 1999, J CELL SCI, V112, P1149; HUTTENLOCHER A, 1995, CURR OPIN CELL BIOL, V7, P697, DOI 10.1016/0955-0674(95)80112-X; Kaibuchi K, 1999, ANNU REV BIOCHEM, V68, P459, DOI 10.1146/annurev.biochem.68.1.459; Kimura K, 1996, SCIENCE, V273, P245, DOI 10.1126/science.273.5272.245; Kimura K, 1998, J BIOL CHEM, V273, P5542, DOI 10.1074/jbc.273.10.5542; Kosako H, 1999, ONCOGENE, V18, P2783, DOI 10.1038/sj.onc.1202633; Lim L, 1996, EUR J BIOCHEM, V242, P171, DOI 10.1111/j.1432-1033.1996.0171r.x; Madaule P, 1998, NATURE, V394, P491, DOI 10.1038/28873; Mangeat P, 1999, TRENDS CELL BIOL, V9, P187, DOI 10.1016/S0962-8924(99)01544-5; Matsui T, 1999, CURR BIOL, V9, P1259, DOI 10.1016/S0960-9822(99)80508-9; Matsui T, 1998, J CELL BIOL, V140, P647, DOI 10.1083/jcb.140.3.647; Matsumura F, 1998, J CELL BIOL, V140, P119, DOI 10.1083/jcb.140.1.119; Narumiya S, 1997, FEBS LETT, V410, P68, DOI 10.1016/S0014-5793(97)00317-7; O'Connell CB, 1999, J CELL BIOL, V144, P305, DOI 10.1083/jcb.144.2.305; Oshiro N, 1998, J BIOL CHEM, V273, P34663, DOI 10.1074/jbc.273.52.34663; TAKAI Y, 1995, TRENDS BIOCHEM SCI, V20, P227, DOI 10.1016/S0968-0004(00)89022-2; TAKAISHI K, 1995, ONCOGENE, V11, P39; Tsukita S, 1999, J BIOL CHEM, V274, P34507, DOI 10.1074/jbc.274.49.34507; Uehata M, 1997, NATURE, V389, P990, DOI 10.1038/40187; VanAelst L, 1997, GENE DEV, V11, P2295, DOI 10.1101/gad.11.18.2295; Watanabe N, 1997, EMBO J, V16, P3044, DOI 10.1093/emboj/16.11.3044; Yasui Y, 1998, J CELL BIOL, V143, P1249, DOI 10.1083/jcb.143.5.1249	27	176	181	0	3	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 7	2000	19	52					6059	6064		10.1038/sj.onc.1203987	http://dx.doi.org/10.1038/sj.onc.1203987			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	382MY	11146558				2022-12-25	WOS:000165827900013
J	Klein, ATJ; Barnett, P; Bottger, G; Konings, D; Tabak, HF; Distel, B				Klein, ATJ; Barnett, P; Bottger, G; Konings, D; Tabak, HF; Distel, B			Recognition of peroxisomal targeting signal type 1 by the import receptor Pex5p	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE-PROTEIN PEX13P; TETRATRICOPEPTIDE REPEAT-DOMAIN; SACCHAROMYCES-CEREVISIAE; PTS1 RECEPTOR; 3-KETOACYL-COA THIOLASE; DNA-POLYMERASE; SH3 DOMAIN; TPR DOMAIN; YEAST; IDENTIFICATION	We have studied how Pex5p recognizes peroxisomal targeting signal type I (PTS1)-containing proteins. A randomly mutagenized pex5 library was screened in a two-hybrid setup for mutations that disrupted the interaction with the PTS1 protein Mdh3p or for suppressor mutations that could restore the interaction with Mdh3p containing a mutation in its PTS1. All mutations localized in the tetratricopeptide repeat (TPR) domain of Pex5p. The Pex5p TPR domain was modeled based on the crystal structure of a related TPR protein. Mapping of the mutations on this structural model revealed that some of the loss-of-interaction mutations consisted of substitutions in alpha -helices of TPRs with bulky amino acids, probably resulting in local misfolding and thereby indirectly preventing binding of PTS1 proteins. The other loss-of-interaction mutations and most suppressor mutations localized in short, exposed, intra-repeat loops of TPR2, TPR3, and TPR6, which are predicted to mediate direct interaction with PTS1 amino acids. Additional site-directed mutants at conserved positions in intra-repeat loops underscored the importance of the loops of TPR2 and TPR3 for PTS1 interaction. Based on the mutational analysis and the structural model, we put forward a model as to how PTS1 proteins are selected by Pex5p.	Univ Amsterdam, Acad Med Ctr, Dept Biochem, NL-1105 AZ Amsterdam, Netherlands	University of Amsterdam; Academic Medical Center Amsterdam	Distel, B (corresponding author), Univ Amsterdam, Acad Med Ctr, Dept Biochem, Meibergdreef 15, NL-1105 AZ Amsterdam, Netherlands.		Barnett, Phil/F-6153-2011	Barnett, Phil/0000-0001-7420-6106				Albertini M, 1997, CELL, V89, P83, DOI 10.1016/S0092-8674(00)80185-3; Barnett P, 2000, EMBO J, V19, P6382, DOI 10.1093/emboj/19.23.6382; Bottger G, 2000, MOL BIOL CELL, V11, P3963, DOI 10.1091/mbc.11.11.3963; BROCARD C, 1994, BIOCHEM BIOPH RES CO, V204, P1016, DOI 10.1006/bbrc.1994.2564; Brocard C, 1997, EMBO J, V16, P5491, DOI 10.1093/emboj/16.18.5491; CHEVRAY PM, 1992, P NATL ACAD SCI USA, V89, P5789, DOI 10.1073/pnas.89.13.5789; Conti E, 1998, CELL, V94, P193, DOI 10.1016/S0092-8674(00)81419-1; Das AK, 1998, EMBO J, V17, P1192, DOI 10.1093/emboj/17.5.1192; DODT G, 1995, NAT GENET, V9, P115, DOI 10.1038/ng0295-115; Eckert K A, 1991, PCR Methods Appl, V1, P17; ELGERSMA Y, 1995, EMBO J, V14, P3472, DOI 10.1002/j.1460-2075.1995.tb07353.x; Elgersma Y, 1996, J CELL BIOL, V135, P97, DOI 10.1083/jcb.135.1.97; Elgersma Y, 1996, J BIOL CHEM, V271, P26375, DOI 10.1074/jbc.271.42.26375; Erdmann R, 1996, J CELL BIOL, V135, P111, DOI 10.1083/jcb.135.1.111; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; Fransen M, 1998, P NATL ACAD SCI USA, V95, P8087, DOI 10.1073/pnas.95.14.8087; FRANSEN M, 1995, J BIOL CHEM, V270, P7731, DOI 10.1074/jbc.270.13.7731; Gatto GJ, 2000, PROTEINS, V38, P241, DOI 10.1002/(SICI)1097-0134(20000215)38:3<241::AID-PROT1>3.0.CO;2-1; GIETL C, 1994, P NATL ACAD SCI USA, V91, P3151, DOI 10.1073/pnas.91.8.3151; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; Girzalsky W, 1999, J CELL BIOL, V144, P1151, DOI 10.1083/jcb.144.6.1151; GLOVER JR, 1994, J BIOL CHEM, V269, P7558; GOEBL M, 1991, TRENDS BIOCHEM SCI, V16, P173, DOI 10.1016/0968-0004(91)90070-C; Gould SJ, 1996, J CELL BIOL, V135, P85, DOI 10.1083/jcb.135.1.85; GOULD SJ, 1989, J CELL BIOL, V108, P1657, DOI 10.1083/jcb.108.5.1657; Guex N, 1999, TRENDS BIOCHEM SCI, V24, P364, DOI 10.1016/S0968-0004(99)01427-9; Hettema EH, 1999, BBA-MOL CELL RES, V1451, P17, DOI 10.1016/S0167-4889(99)00087-7; Huhse B, 1998, J CELL BIOL, V140, P49, DOI 10.1083/jcb.140.1.49; Kunau WH, 1998, CURR OPIN MICROBIOL, V1, P232, DOI 10.1016/S1369-5274(98)80016-7; Lametschwandtner G, 1998, J BIOL CHEM, V273, P33635, DOI 10.1074/jbc.273.50.33635; Lapouge K, 2000, MOL CELL, V6, P899, DOI 10.1016/S1097-2765(00)00087-3; MARZIOCH M, 1994, EMBO J, V13, P4908, DOI 10.1002/j.1460-2075.1994.tb06818.x; MCCOLLUM D, 1993, J CELL BIOL, V121, P761, DOI 10.1083/jcb.121.4.761; Miller J.H., 1972, EXPT MOL GENETICS; Otera H, 1998, MOL CELL BIOL, V18, P388, DOI 10.1128/MCB.18.1.388; Purdue PE, 1996, J CELL BIOL, V134, P849, DOI 10.1083/jcb.134.4.849; Rehling P, 2000, J BIOL CHEM, V275, P3593, DOI 10.1074/jbc.275.5.3593; Sambrook J., 2002, MOL CLONING LAB MANU; Scheufler C, 2000, CELL, V101, P199, DOI 10.1016/S0092-8674(00)80830-2; Schliebs W, 1999, J BIOL CHEM, V274, P5666, DOI 10.1074/jbc.274.9.5666; STERN LJ, 1994, NATURE, V368, P215, DOI 10.1038/368215a0; Subramani S, 2000, ANNU REV BIOCHEM, V69, P399, DOI 10.1146/annurev.biochem.69.1.399; SWINKELS BW, 1992, FEBS LETT, V305, P133, DOI 10.1016/0014-5793(92)80880-P; SWINKELS BW, 1991, EMBO J, V10, P3255, DOI 10.1002/j.1460-2075.1991.tb04889.x; Szilard RK, 2000, BIOCHEM J, V346, P177, DOI 10.1042/0264-6021:3460177; Tabak HF, 1995, COLD SPRING HARB SYM, V60, P649, DOI 10.1101/SQB.1995.060.01.069; TERLECKY SR, 1995, EMBO J, V14, P3627, DOI 10.1002/j.1460-2075.1995.tb00032.x; VRIEND G, 1990, J MOL GRAPHICS, V8, P526; WIEMER EAC, 1995, J CELL BIOL, V130, P51, DOI 10.1083/jcb.130.1.51; ZHANG JW, 1995, J CELL BIOL, V129, P65, DOI 10.1083/jcb.129.1.65; ZHOU YH, 1991, NUCLEIC ACIDS RES, V19, P6052, DOI 10.1093/nar/19.21.6052	51	40	41	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 4	2001	276	18					15034	15041		10.1074/jbc.M010776200	http://dx.doi.org/10.1074/jbc.M010776200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	429QQ	11154700	hybrid			2022-12-25	WOS:000168528800069
J	Bonini, MG; Augusto, O				Bonini, MG; Augusto, O			Carbon dioxide stimulates the production of thiyl, sulfinyl, and disulfide radical anion from thiol oxidation by peroxynitrite	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ONE-ELECTRON OXIDATION; BOVINE SERUM-ALBUMIN; NITRIC-OXIDE; SPIN-TRAP; MEDIATED OXIDATION; TYROSINE NITRATION; PULSE-RADIOLYSIS; DECOMPOSITION; GLUTATHIONE; RESONANCE	Reaction of peroxynitrite with the biological ubiquitous CO2 produces about 35% yields of two relatively strong one-electron oxidants, CO3. and (NO2)-N-.,, but the remaining of peroxynitrite is isomerized to the innocuous nitrate. Partial oxidant deactivation may confound interpretation of the effects of HCO3-/CO2 on the oxidation of targets that react with peroxynitrite by both one- and two-electron mechanisms. Thiols are example of such targets, and previous studies have reported that HCO3-/ CO, partially inhibits GSH oxidation by peroxynitrite at pH 7,4. To differentiate the effects of HCO3-/CO2 on twoand one-electron thiol oxidation, we monitored GSH, cysteine, and albumin oxidation by peroxynitrite at pH 5.4 and 7.4 by thiol disappearance, oxygen consumption, fast flow EPR, and EPR spin trapping. Our results demonstrate that HCO3-/CO2 diverts thiol oxidation by peroxynitrite from two- to one-electron mechanisms particularly at neutral pH. At acid pH values, thiol oxidation to free radicals predominates even in the absence of HCO3-/CO2. In addition to the previously characterized thiyl radicals (RS'), we also characterized radicals derived from them such as the corresponding sulfinyl (RSO.) and disulfide anion radical (RSSR.-) of both GSH and cysteine, Thiyl, RSO. and RSSR.- are reactive radicals that may contribute to the biodamaging and bioregulatory actions of peroxynitrite.	Univ Sao Paulo, Inst Quim, Dept Quim, BR-05513970 Sao Paulo, Brazil	Universidade de Sao Paulo	Augusto, O (corresponding author), Univ Sao Paulo, Inst Quim, Dept Quim, Caixa Postal 26077, BR-05513970 Sao Paulo, Brazil.	oaugusto@iq.usp.br	Augusto, Ohara/D-3839-2012	Augusto, Ohara/0000-0002-7220-4286				Alvarez B, 1999, J BIOL CHEM, V274, P842, DOI 10.1074/jbc.274.2.842; Aslund F, 1999, CELL, V96, P751, DOI 10.1016/S0092-8674(00)80584-X; AUGUSTO O, 1994, ARCH BIOCHEM BIOPHYS, V310, P118, DOI 10.1006/abbi.1994.1147; Balazy M, 1998, J BIOL CHEM, V273, P32009, DOI 10.1074/jbc.273.48.32009; Barton J.P., 1970, INT J RADIAT PHYS CH, V2, P159; BECKMAN JS, 1990, P NATL ACAD SCI USA, V87, P1620, DOI 10.1073/pnas.87.4.1620; Bisby RH, 1998, J CHEM SOC FARADAY T, V94, P2069, DOI 10.1039/a801239c; Bonini MG, 1999, J BIOL CHEM, V274, P10802, DOI 10.1074/jbc.274.16.10802; Borg D.C., 1976, FREE RADICALS BIOL, P69; CHEN SN, 1975, RADIAT RES, V62, P18, DOI 10.2307/3574180; CHEN SN, 1973, RADIAT RES, V56, P40, DOI 10.2307/3573789; Coddington JW, 1999, J AM CHEM SOC, V121, P2438, DOI 10.1021/ja982887t; DAVIES MJ, 1993, FREE RADICAL RES COM, V18, P353, DOI 10.3109/10715769309147502; Denicola A, 1996, ARCH BIOCHEM BIOPHYS, V333, P49, DOI 10.1006/abbi.1996.0363; DULING DR, 1994, J MAGN RESON SER B, V104, P105, DOI 10.1006/jmrb.1994.1062; FORNI LG, 1996, J CHEM SOC P2, P1; Gatti RM, 1998, ARCH BIOCHEM BIOPHYS, V349, P36, DOI 10.1006/abbi.1997.0451; GATTI RM, 1994, FEBS LETT, V348, P287, DOI 10.1016/0014-5793(94)00625-3; Gerasimov OV, 1999, INORG CHEM, V38, P4317, DOI 10.1021/ic990384y; GILBERT BC, 1972, J CHEM SOC PERK T 2, P1272, DOI 10.1039/p29720001272; GILBERT BC, 1975, J CHEM SOC PERK T 2, P892, DOI 10.1039/p29750000892; Giorgio S, 1998, INFECT IMMUN, V66, P807, DOI 10.1128/IAI.66.2.807-814.1998; Goldstein S, 1999, J AM CHEM SOC, V121, P2444, DOI 10.1021/ja9822254; GOLSTEIN S, 2000, J BIOL CHEM, V275, P3031; GRACEFFA P, 1983, ARCH BIOCHEM BIOPHYS, V225, P802, DOI 10.1016/0003-9861(83)90092-9; Groves JT, 1999, CURR OPIN CHEM BIOL, V3, P226, DOI 10.1016/S1367-5931(99)80036-2; Hodges GR, 1999, J AM CHEM SOC, V121, P10695, DOI 10.1021/ja991077u; HOFFMAN MZ, 1973, J PHYS CHEM-US, V77, P990, DOI 10.1021/j100627a005; HUIE RE, 1991, RADIAT PHYS CHEM, V38, P477; Hurst JK, 1999, ACCOUNTS CHEM RES, V32, P520, DOI 10.1021/ar9703488; Ischiropoulos H, 1998, ARCH BIOCHEM BIOPHYS, V356, P1, DOI 10.1006/abbi.1998.0755; Karoui H, 1996, J BIOL CHEM, V271, P6000, DOI 10.1074/jbc.271.11.6000; Kirsch M, 2000, J BIOL CHEM, V275, P16702, DOI 10.1074/jbc.M909228199; Kissner R, 1997, CHEM RES TOXICOL, V10, P1285, DOI 10.1021/tx970160x; KOPPENOL WH, 1992, CHEM RES TOXICOL, V5, P834, DOI 10.1021/tx00030a017; Kuhn DM, 1999, J NEUROSCI, V19, P10289; Kuhn DM, 1999, J BIOL CHEM, V274, P29726, DOI 10.1074/jbc.274.42.29726; Lehnig M, 1999, ARCH BIOCHEM BIOPHYS, V368, P303, DOI 10.1006/abbi.1999.1268; LI ASW, 1988, J MAGN RESON, V79, P140, DOI 10.1016/0022-2364(88)90329-0; Lymar SV, 2000, RADIAT PHYS CHEM, V59, P387, DOI 10.1016/S0969-806X(00)00277-2; LYMAR SV, 1995, J AM CHEM SOC, V117, P8867, DOI 10.1021/ja00139a027; Lymar SV, 1996, BIOCHEMISTRY-US, V35, P7855, DOI 10.1021/bi960331h; Lymar SV, 1998, INORG CHEM, V37, P294, DOI 10.1021/ic970946i; Merenyi G, 1998, CHEM RES TOXICOL, V11, P712, DOI 10.1021/tx980043h; MISIK V, 1993, FREE RADICAL BIO MED, V15, P611, DOI 10.1016/0891-5849(93)90164-P; NUCIFORA G, 1972, RADIAT RES, V49, P96, DOI 10.2307/3573375; Pfeiffer S, 2000, J BIOL CHEM, V275, P6346, DOI 10.1074/jbc.275.9.6346; Pietraforte D, 1997, BIOCHEM J, V321, P743, DOI 10.1042/bj3210743; PRUTZ WA, 1989, INT J RADIAT BIOL, V55, P539, DOI 10.1080/09553008914550591; Quijano C, 1997, BIOCHEM J, V322, P167, DOI 10.1042/bj3220167; QUINTILIANI M, 1977, INT J RADIAT BIOL, V32, P195, DOI 10.1080/09553007714550891; RADI R, 1991, J BIOL CHEM, V266, P4244; Radi R, 1996, CHEM RES TOXICOL, V9, P828, DOI 10.1021/tx950176s; RADI R, 1990, METHOD ENZYMOL, V269, P354; RAO DNR, 1990, J BIOL CHEM, V265, P844; Richeson CE, 1998, J AM CHEM SOC, V120, P7211, DOI 10.1021/ja980871x; Santos CXC, 2000, ARCH BIOCHEM BIOPHYS, V377, P146, DOI 10.1006/abbi.2000.1751; Scorza G, 1998, BIOCHEM J, V329, P405, DOI 10.1042/bj3290405; SEALY RC, 1985, J AM CHEM SOC, V107, P3401, DOI 10.1021/ja00298a001; SEVILLA MD, 1987, BIOCHEM BIOPH RES CO, V144, P1037, DOI 10.1016/S0006-291X(87)80068-2; Squadrito GL, 1998, FREE RADICAL BIO MED, V25, P392, DOI 10.1016/S0891-5849(98)00095-1; van der Vliet A, 1998, J BIOL CHEM, V273, P30255, DOI 10.1074/jbc.273.46.30255; Winterbourn CC, 1999, FREE RADICAL BIO MED, V27, P322, DOI 10.1016/S0891-5849(99)00051-9; Zhang HW, 1997, ARCH BIOCHEM BIOPHYS, V339, P183, DOI 10.1006/abbi.1996.9863; ZHAO R, 1994, J AM CHEM SOC, V116, P12010, DOI 10.1021/ja00105a048	65	148	148	1	29	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 30	2001	276	13					9749	9754		10.1074/jbc.M008456200	http://dx.doi.org/10.1074/jbc.M008456200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	420GC	11134018	hybrid			2022-12-25	WOS:000167996400024
J	Chen, SC; Yen, CH; Yeh, MS; Huang, CJ; Liu, TY				Chen, SC; Yen, CH; Yeh, MS; Huang, CJ; Liu, TY			Biochemical properties and cDNa cloning of two new lectins from the plasma of Tachypleus tridentatus - Tachypleus plasma lectin 1 and 2+	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-REACTIVE PROTEIN; HORSESHOE-CRAB HEMOLYMPH; INNATE IMMUNITY; LIMULUS-POLYPHEMUS; INHIBITORY-ACTIVITY; BINDING PROTEIN; PURIFICATION; LIPOPOLYSACCHARIDE; AMEBOCYTES; SYSTEM	A Sepharose CL-4B-binding protein, Tachypleus plasma lectin 1 (TPL-1), and a lipopolysaccharide (LPS)binding protein, Tachypleus plasma lectin-2 (TPL-2), have been isolated from the plasma of Tachypleus tri-dentatus and biochemically characterized, Each protein is coded by a homologous family of multigenes, TPL-1 binds to Sepharose CL-4B and was eluted with buffer containing 0.4 M GlcNAc, The deduced amino acid sequence of TPL-1 consisted of 232 amino acids with an N-glycosylation site, Asn-Gly-Ser at residues 74-76. It shares a 65% sequence identity and similar internal repeats of about 20 amino acid motifs with tachylectin-1. Tachylectin-1 was identified as a lipopolysaccharideagarose binding nonglycosylated protein from the amebocytes of T, tridentatus, TPL-8 was eluted from the LPS-Sepbarose CL-4B affinity column in buffer containing 0.4 M GlcNAc and 2 M KCI, The deduced amino acid sequence of TPL-2 consisted of 128 amino acids with an N-glycosylation site, Asn-Cys-Thr, at positions 3-5, It shares an 80% sequence identity with tachylectin-3, isolated from the amebocytes of T, tridentatus, TPL-2 purified by LPS-affinity column from the plasma predominantly exists as a dimer of a glycoprotein with an apparent molecular mass of 36 kDa, Tachylectin-3 is an intracellular nonglycosylated protein that also exists as a dimer in solution with an apparent molecular mass of 29 kDa, It recognizes Gram-negative bacteria through the 0-antigen of LPS, Western blot analyses showed that, in the plasma, TPL-1 and TPL-2 exist predominantly as oligomers with molecular masses above 60 kDa, They both bind to Gram-positive and Gram-negative bacteria, and this binding is inhibited by GlcNAc, Possible binding site of TPL-1 and TPL-8 to the bacteria could be at the NAc moiety of GlcNAc-MurNAc of the peptidoglycan, The physiological function of TPL-1 and TPL-2 is most likely related to their ability to form a cluster of interlocking molecules to immobilize and entrap invading organisms.	Acad Sinica, Inst Biol Chem, Taipei 115, Taiwan	Academia Sinica - Taiwan	Liu, TY (corresponding author), OriGene Technol Inc, 6 Taft Ct,Suite 300, Rockville, MD 20850 USA.	dliu@origene.com						Carroll MC, 1998, CURR OPIN IMMUNOL, V10, P36; Chiou ST, 2000, J BIOL CHEM, V275, P1630, DOI 10.1074/jbc.275.3.1630; ENGHILD JJ, 1990, BIOCHEMISTRY-US, V29, P10070, DOI 10.1021/bi00495a009; Fearon DT, 1996, SCIENCE, V272, P50, DOI 10.1126/science.272.5258.50; FORTESDIAS CL, 1993, COMP BIOCHEM PHYS B, V105, P79, DOI 10.1016/0305-0491(93)90171-Z; FREUDENBERG MA, 1989, INFECTION, V17, P322, DOI 10.1007/BF01650719; Gokudan S, 1999, P NATL ACAD SCI USA, V96, P10086, DOI 10.1073/pnas.96.18.10086; Hoffmann JA, 1996, CURR OPIN IMMUNOL, V8, P8, DOI 10.1016/S0952-7915(96)80098-7; HONG TH, 1989, J IMMUNOL METHODS, V120, P151, DOI 10.1016/0022-1759(89)90236-6; Huh CG, 1998, J BIOL CHEM, V273, P6565, DOI 10.1074/jbc.273.11.6565; Inamori K, 1999, J BIOL CHEM, V274, P3272, DOI 10.1074/jbc.274.6.3272; Iwaki D, 1999, EUR J BIOCHEM, V264, P314, DOI 10.1046/j.1432-1327.1999.00588.x; Iwanaga S, 1998, J BIOCHEM, V123, P1; KAPITANY RA, 1973, ANAL BIOCHEM, V56, P361, DOI 10.1016/0003-2697(73)90202-9; Kawabata S, 1999, DEV COMP IMMUNOL, V23, P391, DOI 10.1016/S0145-305X(99)00019-1; Lemaitre B, 1996, CELL, V86, P973, DOI 10.1016/S0092-8674(00)80172-5; LIU T, 1991, J BIOL CHEM, V266, P14813; MANIATIS T, 1982, MOL CLONING LABORATO, P280; Medzhitov R, 1998, CURR OPIN IMMUNOL, V10, P12, DOI 10.1016/S0952-7915(98)80024-1; Medzhitov R, 1997, CELL, V91, P295, DOI 10.1016/S0092-8674(00)80412-2; MINETTI CASA, 1991, J BIOL CHEM, V266, P20773; MURER EH, 1975, J CELL PHYSIOL, V86, P533, DOI 10.1002/jcp.1040860310; Muta T, 1996, CURR OPIN IMMUNOL, V8, P41, DOI 10.1016/S0952-7915(96)80103-8; Nagai T, 1999, J BIOL CHEM, V274, P37673, DOI 10.1074/jbc.274.53.37673; NGUYEN NY, 1986, J BIOL CHEM, V261, P450; Okino N, 1995, J BIOL CHEM, V270, P31008, DOI 10.1074/jbc.270.52.31008; PORATH J, 1971, J CHROMATOGR, V60, P167, DOI 10.1016/S0021-9673(00)95547-X; ROBEY FA, 1981, J BIOL CHEM, V256, P969; SAITO T, 1995, J BIOL CHEM, V270, P14493, DOI 10.1074/jbc.270.24.14493; SCHUMANN RR, 1990, SCIENCE, V249, P1429, DOI 10.1126/science.2402637; VOLANAKI.JE, 1971, P SOC EXP BIOL MED, V136, P612	31	36	38	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 30	2001	276	13					9631	9639		10.1074/jbc.M008414200	http://dx.doi.org/10.1074/jbc.M008414200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	420GC	11133989	hybrid, Green Published			2022-12-25	WOS:000167996400009
J	Komatsu, M; Tanida, I; Ueno, T; Ohsumi, M; Ohsumi, Y; Kominami, E				Komatsu, M; Tanida, I; Ueno, T; Ohsumi, M; Ohsumi, Y; Kominami, E			The C-terminal region of an Apg7p/Cvt2p is required for homodimerization and is essential for its E1 activity and E1-E2 complex formation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UBIQUITIN-ACTIVATING ENZYME; PROTEIN CONJUGATION SYSTEM; SACCHAROMYCES-CEREVISIAE; AUTOPHAGIC PROCESS; TARGETING PATHWAY; YEAST VACUOLE; CYTOPLASM; GENE; DEGRADATION; MECHANISMS	Apg7p/Cvt2p, a protein-activating enzyme, is essential for both the Apg12p-Apg5p conjugation system and the Apg8p membrane targeting in autophagy and cytoplasm-to-vacuole targeting in the yeast Saccharomyces cerevisiae, Similar to the ubiquitin-conjugating system, both Apg12p and Apg8p are activated by Apg7p, an El-like enzyme. Apg12p is then transferred to Apg10p, an E2-like enzyme, and conjugated with Apg5p, whereas Apg8p is transferred to Apg3p, another E2-like enzyme, followed by conjugation with phosphatidylethanoiamine. Evidence is presented here that Apg7p forms a homodimer with two active-site cysteine residues via the C-terminal region, The dimerization of Apg7p is independent of the other Apg proteins and facilitated by overexpressed Apg12p, The C-terminal 123 amino acids of Apg7p (residues 508 to 630 out of 630 amino acids) are sufficient for its dimerization, where there is neither an ATP binding domain nor an active-site cysteine essential for its El activity, The deletion of its carboxyl 40 amino acids (residues 591-630 out of 630 amino acids) results in several defects of not only Apg7p dimerization but also interactions with two substrates, Apg12p and Apg8p and Apg12p-Apg5p conjugation, whereas the mutant Apg7p contains both an ATP binding domain and an active-site cysteine. Furthermore, the carboxyl 40 amino acids of Apg7p are also essential for the interaction of Apg7p with Apg3p to form the E1-E2 complex for Apg8p. These results suggest that Apg7p forms a homodimer via the C-terminal region and that the C-terminal region is essential for both the activity of the El enzyme for Apg12p and Apg8p as well as the formation of an E1-E2 complex for Apg8p.	Juntendo Univ, Sch Med, Dept Biochem, Tokyo 1138421, Japan; Teikyo Univ Sci & Technol, Dept Biosci, Yamanashi 4090193, Japan; Natl Inst Basic Biol, Dept Cell Biol, Okazaki, Aichi 4448501, Japan	Juntendo University; National Institutes of Natural Sciences (NINS) - Japan; National Institute for Basic Biology (NIBB)	Kominami, E (corresponding author), Juntendo Univ, Sch Med, Dept Biochem, Tokyo 1138421, Japan.		Komatsu, Masaaki/B-8321-2011; Ohsumi, Yoshinori/C-6449-2009; Kominami, Eiki/D-3802-2009; Tanida, Isei/C-8277-2009	Komatsu, Masaaki/0000-0001-7672-7722; Ohsumi, Yoshinori/0000-0003-2384-2166; Tanida, Isei/0000-0001-8999-3990				Ausubel FM, 1995, SHORT PROTOCOLS MOL, V3rd; Baba M, 1997, J CELL BIOL, V139, P1687, DOI 10.1083/jcb.139.7.1687; Baba M, 1995, CELL STRUCT FUNCT, V20, P465, DOI 10.1247/csf.20.465; BABA M, 1994, J CELL BIOL, V124, P903, DOI 10.1083/jcb.124.6.903; Bonifacino JS, 1998, ANNU REV CELL DEV BI, V14, P19, DOI 10.1146/annurev.cellbio.14.1.19; CIECHANOVER A, 1982, J BIOL CHEM, V257, P2537; Ciechanover A, 1998, EMBO J, V17, P7151, DOI 10.1093/emboj/17.24.7151; DOHMEN RJ, 1995, J BIOL CHEM, V270, P18099, DOI 10.1074/jbc.270.30.18099; Dunn William A. Jr., 1994, Trends in Cell Biology, V4, P139, DOI 10.1016/0962-8924(94)90069-8; Funakoshi T, 1997, GENE, V192, P207, DOI 10.1016/S0378-1119(97)00031-0; Furukawa K, 2000, J BIOL CHEM, V275, P7462, DOI 10.1074/jbc.275.11.7462; Harding TM, 1996, J BIOL CHEM, V271, P17621, DOI 10.1074/jbc.271.30.17621; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Huang WP, 2000, J BIOL CHEM, V275, P5845, DOI 10.1074/jbc.275.8.5845; Ichimura Y, 2000, NATURE, V408, P488, DOI 10.1038/35044114; James P, 1996, GENETICS, V144, P1425; Johnson ES, 1999, J CELL BIOL, V147, P981, DOI 10.1083/jcb.147.5.981; Johnson ES, 1997, J BIOL CHEM, V272, P26799, DOI 10.1074/jbc.272.43.26799; Johnson ES, 1997, EMBO J, V16, P5509, DOI 10.1093/emboj/16.18.5509; Kaiser C., 1994, METHODS YEAST GENETI; Kametaka S, 1996, GENE, V178, P139, DOI 10.1016/0378-1119(96)00354-X; Kametaka S, 1998, J BIOL CHEM, V273, P22284, DOI 10.1074/jbc.273.35.22284; Kim J, 1999, MOL BIOL CELL, V10, P1337, DOI 10.1091/mbc.10.5.1337; Kirisako T, 2000, J CELL BIOL, V151, P263, DOI 10.1083/jcb.151.2.263; Kirisako T, 1999, J CELL BIOL, V147, P435, DOI 10.1083/jcb.147.2.435; Klionsky DT, 1999, ANNU REV CELL DEV BI, V15, P1, DOI 10.1146/annurev.cellbio.15.1.1; Lammer D, 1998, GENE DEV, V12, P914, DOI 10.1101/gad.12.7.914; Lang T, 2000, J BACTERIOL, V182, P2125, DOI 10.1128/JB.182.8.2125-2133.2000; Lang T, 1998, EMBO J, V17, P3597, DOI 10.1093/emboj/17.13.3597; Legesse-Miller A, 2000, J BIOL CHEM, V275, P32966, DOI 10.1074/jbc.M000917200; Liakopoulos D, 1998, EMBO J, V17, P2208, DOI 10.1093/emboj/17.8.2208; Matsuura A, 1997, GENE, V192, P245, DOI 10.1016/S0378-1119(97)00084-X; MCGRATH JP, 1991, EMBO J, V10, P227, DOI 10.1002/j.1460-2075.1991.tb07940.x; Mizushima N, 1998, NATURE, V395, P395, DOI 10.1038/26506; Mizushima N, 1998, J BIOL CHEM, V273, P33889, DOI 10.1074/jbc.273.51.33889; Mizushima N, 1999, EMBO J, V18, P3888, DOI 10.1093/emboj/18.14.3888; Noda T, 2000, J CELL BIOL, V148, P465, DOI 10.1083/jcb.148.3.465; Scott SV, 2000, J BIOL CHEM, V275, P25840, DOI 10.1074/jbc.M002813200; Scott SV, 1996, P NATL ACAD SCI USA, V93, P12304, DOI 10.1073/pnas.93.22.12304; SEGLEN PO, 1992, EXPERIENTIA, V48, P158, DOI 10.1007/BF01923509; Shintani T, 1999, EMBO J, V18, P5234, DOI 10.1093/emboj/18.19.5234; SIKORSKI RS, 1989, GENETICS, V122, P19; Straub M, 1997, J BACTERIOL, V179, P3875, DOI 10.1128/jb.179.12.3875-3883.1997; TAKESHIGE K, 1992, J CELL BIOL, V119, P301, DOI 10.1083/jcb.119.2.301; Tanida I, 1999, MOL BIOL CELL, V10, P1367, DOI 10.1091/mbc.10.5.1367; Tanida I, 2001, J BIOL CHEM, V276, P1701, DOI 10.1074/jbc.C000752200; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Uetz P, 2000, NATURE, V403, P623, DOI 10.1038/35001009; Varshavsky A, 1997, TRENDS BIOCHEM SCI, V22, P383, DOI 10.1016/S0968-0004(97)01122-5; Yuan WP, 1999, MOL BIOL CELL, V10, P1353, DOI 10.1091/mbc.10.5.1353	50	76	82	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 30	2001	276	13					9846	9854		10.1074/jbc.M007737200	http://dx.doi.org/10.1074/jbc.M007737200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	420GC	11139573	hybrid			2022-12-25	WOS:000167996400037
J	Schroder, NW; Pfeil, D; Opitz, B; Michelsen, KS; Amberger, J; Zahringer, U; Gobel, UB; Schumann, RR				Schroder, NW; Pfeil, D; Opitz, B; Michelsen, KS; Amberger, J; Zahringer, U; Gobel, UB; Schumann, RR			Activation of mitogen-activated protein kinases p42/44, p38, and stress-activated protein kinases in myelo-monocytic cells by Treponema lipoteichoic acid	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TOLL-LIKE RECEPTOR-4; BORRELIA-BURGDORFERI LIPOPROTEINS; LIPOPOLYSACCHARIDE-BINDING-PROTEIN; NECROTIZING ULCERATIVE GINGIVITIS; BACTERIAL LIPOPOLYSACCHARIDE; MAP KINASE; TYROSINE PHOSPHORYLATION; CUTTING EDGE; PERIODONTAL-DISEASE; MONOKINE PRODUCTION	We have shown previously that phenol/water extracts derived from two novel Treponema species, Treponema maltophilum, and Treponema brennaborense, resembling lipoteichoic acid (LTA), induce cytokines in mononuclear cells. This response was lipopolysaccharide binding-protein (LBP)-dependent and involved Toll-like receptors (TLRs), Here we show that secretion of tumor necrosis factor-alpha induced by Treponema culture supernatants and extracted LTA was paralleled by an LBP-dependent phosphorylation of mitogen-activated protein kinases (MAPKs) p42 and p44, and p38, as well as the stress-activated protein kinases c-Jun N-terminal kinases 1 and 2, Phosphorylation of p42/44 correlated with an increase of activity, and tumor necrosis factor-cu levels were significantly reduced by addition of inhibitors of p42/44 and p38, PD 98059 and SE 203580, respectively. Treponeme LTA differed from bacterial lipopolysaccharide regarding time course of p42/44 phosphorylation, exhibiting a prolonged activation of MAPKs. Furthermore, MAPK activation and cytokine induction failed to be strictly correlated. Involvement of TLR-4 for phosphorylation of p42/44 was shown employing the neutralizing anti-murine TLR-4 antibody MTS 510, In TLR-2-negative U373 cells, the compounds studied differed regarding MAPK activation with T. maltophilum leading to a stronger activation, In summary, the data presented here show that treponeme LTA are able to activate the MAPK and stress-activated protein kinase pathway involving LBP and TLR-4.	Humboldt Univ, Fak Med, Klinikum Charite, Inst Mikrobiol & Hyg, D-10117 Berlin, Germany; Forschungsinst Borstel, Labor Immunchem, D-23845 Borstel, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Forschungszentrum Borstel	Schumann, RR (corresponding author), Humboldt Univ, Fak Med, Klinikum Charite, Inst Mikrobiol & Hyg, Dorotheenstr 96, D-10117 Berlin, Germany.			Opitz, Bastian/0000-0003-1276-836X				Akashi S, 2000, J IMMUNOL, V164, P3471, DOI 10.4049/jimmunol.164.7.3471; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Beutler B, 2000, CURR OPIN MICROBIOL, V3, P23, DOI 10.1016/S1369-5274(99)00046-6; BHAKDI S, 1991, INFECT IMMUN, V59, P4614, DOI 10.1128/IAI.59.12.4614-4620.1991; Brightbill HD, 1999, SCIENCE, V285, P732, DOI 10.1126/science.285.5428.732; BRUNET A, 1994, FEBS LETT, V346, P299, DOI 10.1016/0014-5793(94)00475-7; CHOI BK, 1994, INFECT IMMUN, V62, P1889, DOI 10.1128/IAI.62.5.1889-1895.1994; Choi BK, 1997, INT J SYST BACTERIOL, V47, P175, DOI 10.1099/00207713-47-1-175; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; DING A, 1993, J IMMUNOL, V151, P5596; Fraser CM, 1998, SCIENCE, V281, P375, DOI 10.1126/science.281.5375.375; FREED E, 1994, COLD SPRING HARB SYM, V59, P187, DOI 10.1101/SQB.1994.059.01.023; FU H, 1994, SCIENCE, V266, P126, DOI 10.1126/science.7939632; GARDNER AM, 1994, MOL BIOL CELL, V5, P193, DOI 10.1091/mbc.5.2.193; GENG Y, 1994, P NATL ACAD SCI USA, V91, P8602, DOI 10.1073/pnas.91.18.8602; GEPPERT TD, 1994, MOL MED, V1, P93; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; HAN JH, 1995, BBA-MOL CELL RES, V1265, P224, DOI 10.1016/0167-4889(95)00002-A; HARDY PH, 1983, P SOC EXP BIOL MED, V174, P47; HERSKOWITZ I, 1995, CELL, V80, P187, DOI 10.1016/0092-8674(95)90402-6; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; Hirschfeld M, 1999, J IMMUNOL, V163, P2382; Hoshino K, 1999, J IMMUNOL, V162, P3749; KELLER R, 1992, INFECT IMMUN, V60, P3664, DOI 10.1128/IAI.60.9.3664-3672.1992; Kirschning CJ, 1998, J EXP MED, V188, P2091, DOI 10.1084/jem.188.11.2091; Kotlyarov A, 1999, NAT CELL BIOL, V1, P94, DOI 10.1038/10061; Lamping N, 1998, J CLIN INVEST, V101, P2065, DOI 10.1172/JCI2338; LIU F, 1990, CELL, V61, P1217, DOI 10.1016/0092-8674(90)90686-9; LIU MK, 1994, J IMMUNOL, V153, P2642; LUKEHART SA, 1994, HARRISONS PRINCIPLES, P726; Means TK, 2000, CYTOKINE GROWTH F R, V11, P219, DOI 10.1016/S1359-6101(00)00006-X; Means TK, 1999, J IMMUNOL, V163, P6748; Moter A, 1998, J CLIN MICROBIOL, V36, P1399, DOI 10.1128/JCM.36.5.1399-1403.1998; Muzio M, 1998, J EXP MED, V187, P2097, DOI 10.1084/jem.187.12.2097; NATHAN CF, 1987, J CLIN INVEST, V79, P319, DOI 10.1172/JCI112815; Nocton J J, 1995, Adv Intern Med, V40, P69; Norgard MV, 1996, INFECT IMMUN, V64, P3845, DOI 10.1128/IAI.64.9.3845-3852.1996; OFFENBACHER S, 1993, J PERIODONTOL, V64, P432, DOI 10.1902/jop.1993.64.5s.432; Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085; Qureshi ST, 1999, J EXP MED, V189, P615, DOI 10.1084/jem.189.4.615; RADOLF JD, 1991, J IMMUNOL, V147, P1968; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; REIMANN T, 1994, J IMMUNOL, V153, P5740; Rietschel ET, 1996, CURR TOP MICROBIOL, V216, P39; RIVIERE GR, 1991, NEW ENGL J MED, V325, P539, DOI 10.1056/NEJM199108223250803; RIVIERE GR, 1991, INFECT IMMUN, V59, P2653, DOI 10.1128/IAI.59.8.2653-2657.1991; Rosen G, 1999, INFECT IMMUN, V67, P1180, DOI 10.1128/IAI.67.3.1180-1186.1999; Sanghera JS, 1996, J IMMUNOL, V156, P4457; Schroder NWJ, 2000, J IMMUNOL, V165, P2683, DOI 10.4049/jimmunol.165.5.2683; Schultz CP, 1998, J BIOL CHEM, V273, P15661, DOI 10.1074/jbc.273.25.15661; SCHUMANN RR, 1990, SCIENCE, V249, P1429, DOI 10.1126/science.2402637; SCHUMANN RR, 1994, MED MICROBIOL IMMUN, V183, P279; Schwandner R, 1999, J BIOL CHEM, V274, P17406, DOI 10.1074/jbc.274.25.17406; SEGER R, 1992, J BIOL CHEM, V267, P14373; Sellati TJ, 1998, J IMMUNOL, V160, P5455; SHAPIRA L, 1994, ORAL MICROBIOL IMMUN, V9, P112, DOI 10.1111/j.1399-302X.1994.tb00044.x; Shimazu R, 1999, J EXP MED, V189, P1777, DOI 10.1084/jem.189.11.1777; TAKAYAMA K, 1987, INFECT IMMUN, V55, P2311, DOI 10.1128/IAI.55.9.2311-2313.1987; Takeuchi O, 1999, IMMUNITY, V11, P443, DOI 10.1016/S1074-7613(00)80119-3; ULEVITCH RJ, 1995, ANNU REV IMMUNOL, V13, P437, DOI 10.1146/annurev.iy.13.040195.002253; Vossler MR, 1997, CELL, V89, P73, DOI 10.1016/S0092-8674(00)80184-1; WEIDEMANN B, 1994, INFECT IMMUN, V62, P4709, DOI 10.1128/IAI.62.11.4709-4715.1994; WEINSTEIN SL, 1992, J BIOL CHEM, V267, P14955; WEINSTEIN SL, 1991, P NATL ACAD SCI USA, V88, P4148, DOI 10.1073/pnas.88.10.4148; WESTPHAL O., 1965, METHOD CARBOHYD CHEM, V5, P83; WRIGHT SD, 1990, SCIENCE, V249, P1431, DOI 10.1126/science.1698311; Wyss C, 1996, INT J SYST BACTERIOL, V46, P745, DOI 10.1099/00207713-46-3-745; Yang RB, 1998, NATURE, V395, P284, DOI 10.1038/26239	70	35	35	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 30	2001	276	13					9713	9719		10.1074/jbc.M008954200	http://dx.doi.org/10.1074/jbc.M008954200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	420GC	11134043	hybrid			2022-12-25	WOS:000167996400019
J	Meijers, R; Morris, RJ; Adolph, HW; Merli, A; Lamzin, VS; Cedergren-Zeppezauer, ES				Meijers, R; Morris, RJ; Adolph, HW; Merli, A; Lamzin, VS; Cedergren-Zeppezauer, ES			On the enzymatic activation of NADH	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIVER ALCOHOL-DEHYDROGENASE; HORSE LIVER; SUBSTITUTED COBALT(II); COORDINATION GEOMETRY; PROTEIN CONFORMATION; BINDING; MECHANISM; ISOZYMES; CRYSTALLINE; RESOLUTION	Atomic (1 Angstrom) resolution x-ray structures of horse liver alcohol dehydrogenase in complex with NADH revealed the formation of an adduct in the active site between a metal-bound water and NADH. Furthermore, a pronounced distortion of the pyridine ring of NADH was observed, A series of quantum chemical calculations on the water-nicotinamide adduct showed that the puckering of the pyridine ring in the crystal structures can only be reproduced when the water is considered a hydroxide ion, These observations provide fundamental insight into the enzymatic activation of NADH for hydride transfer.	DESY, European Mol Biol Lab, D-22603 Hamburg, Germany; Univ Saarlandes, Fachrichtung 124, D-66041 Saarbrucken, Germany; Univ Parma, Inst Sci Biochim, I-43000 Parma, Italy; Univ Lund, Kemicentrum, S-22100 Lund, Sweden	European Molecular Biology Laboratory (EMBL); Helmholtz Association; Deutsches Elektronen-Synchrotron (DESY); Saarland University; University of Parma; Lund University	Lamzin, VS (corresponding author), DESY, European Mol Biol Lab, Notkestr 85, D-22603 Hamburg, Germany.		Adolph, Hans W/A-2104-2008; Meijers, Rob/D-5521-2011	Morris, Richard/0000-0003-3080-2613; Lamzin, Victor/0000-0002-6058-7793; Meijers, Rob/0000-0003-2872-6279				Adolph HW, 1997, BIOCHEMISTRY-US, V36, P8743, DOI 10.1021/bi970398k; AL-KARADAGHI S, 1994, ACTA CRYSTALLOGR D, V50, P793, DOI 10.1107/S0907444994005263; ALMARSSON O, 1993, J AM CHEM SOC, V115, P2125, DOI 10.1021/ja00059a005; Bader R. F. W., 1990, QUANTUM THEORY; BERTINI I, 1986, ZINC ENZYMES, P377; BURKE JR, 1993, BIOCHEMISTRY-US, V32, P13220, DOI 10.1021/bi00211a034; Coleman JE, 1998, CURR OPIN CHEM BIOL, V2, P222, DOI 10.1016/S1367-5931(98)80064-1; Cruickshank DWJ, 1999, ACTA CRYSTALLOGR D, V55, P583, DOI 10.1107/S0907444998012645; Dauter Z, 1997, CURR OPIN STRUC BIOL, V7, P681, DOI 10.1016/S0959-440X(97)80078-4; Deng Z, 1999, NAT STRUCT BIOL, V6, P847; DUNN MF, 1982, BIOCHEMISTRY-US, V21, P354, DOI 10.1021/bi00531a024; DWORSCHACK RT, 1977, BIOCHEMISTRY-US, V16, P111, DOI 10.1021/bi00620a018; Eklund H., 1987, BIOL MACROMOL, V3, P73; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; FERSHT A, 1999, STRUCTURE MECHANISM, P460; Foglio MH, 1999, BBA-PROTEIN STRUCT M, V1432, P239, DOI 10.1016/S0167-4838(99)00104-1; HEMMINGSEN L, 1995, BIOCHEMISTRY-US, V34, P7145, DOI 10.1021/bi00021a028; Hemmingsen L, 1996, EUR J BIOCHEM, V241, P546, DOI 10.1111/j.1432-1033.1996.00546.x; HUBATSCH I, 1995, J CHROMATOGR A, V711, P105, DOI 10.1016/0021-9673(95)00227-E; JORNVALL H, 1987, EUR J BIOCHEM, V167, P195, DOI 10.1111/j.1432-1033.1987.tb13323.x; Kachalova GS, 1999, SCIENCE, V284, P473, DOI 10.1126/science.284.5413.473; KVASSMAN J, 1980, EUR J BIOCHEM, V103, P565, DOI 10.1111/j.1432-1033.1980.tb05981.x; LOEWUS FA, 1953, J AM CHEM SOC, V75, P5018, DOI 10.1021/ja01116a039; MAHLER HR, 1957, J AM CHEM SOC, V79, P1159, DOI 10.1021/ja01562a035; Mantle D., 1999, Adverse Drug Reactions and Toxicological Reviews, V18, P235; MARET W, 1979, EUR J BIOCHEM, V98, P501, DOI 10.1111/j.1432-1033.1979.tb13211.x; MARET W, 1989, BIOCHEMISTRY-US, V28, P9944, DOI 10.1021/bi00452a011; Merli A, 1996, J BIOL CHEM, V271, P9177, DOI 10.1074/jbc.271.16.9177; Murshudov GN, 1999, ACTA CRYSTALLOGR D, V55, P247, DOI 10.1107/S090744499801405X; Northrop DB, 2000, BIOPHYS J, V79, P1621, DOI 10.1016/S0006-3495(00)76412-5; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Sawaya MR, 1997, BIOCHEMISTRY-US, V36, P586, DOI 10.1021/bi962337c; Schaftenaar G, 2000, J COMPUT AID MOL DES, V14, P123, DOI 10.1023/A:1008193805436; SCHMIDT MW, 1993, J COMPUT CHEM, V14, P1347, DOI 10.1002/jcc.540141112; Sheldrick GM, 1997, METHOD ENZYMOL, V277, P319, DOI 10.1016/S0076-6879(97)77018-6; SLOAN DL, 1975, BIOCHEMISTRY-US, V14, P1998, DOI 10.1021/bi00680a030	36	99	99	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 23	2001	276	12					9316	9321		10.1074/jbc.M010870200	http://dx.doi.org/10.1074/jbc.M010870200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	413HV	11134046	hybrid			2022-12-25	WOS:000167607700093
J	Nakatsukasa, K; Nishikawa, S; Hosokawa, N; Nagata, K; Endo, T				Nakatsukasa, K; Nishikawa, S; Hosokawa, N; Nagata, K; Endo, T			Mnl1p, an alpha-mannosidase-like protein in yeast Saccharomyces cerevisiae, is required for endoplasmic reticulum-associated degradation of glycoproteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SECRETORY PATHWAY; QUALITY-CONTROL; GENE DELETION; PROTEASOME; ER; MEMBRANE; GLYCOSYLATION; TRANSLOCATION; BIOSYNTHESIS; TRANSPORT	The endoplasmic reticulum (ER) has a mechanism to block the exit of misfolded or unassembled proteins from the ER for the downstream organelles in the secretory pathway. Misfolded proteins retained in the ER are subjected to proteasome-dependent degradation in the cytosol when they cannot achieve correct folding and/or assembly within an appropriate time window. Although specific mannose trimming of the protein-bound oligosaccharide is essential for the degradation of misfolded glycoproteins, the precise mechanism for this recognition remains obscure. Here we report a new alpha -mannosidase-like protein, Mnl1p (mannosidase-like protein), in the yeast ER. Mnl1p is unlikely to exhibit alpha1,2-mannosidase activity, because it lacks cysteine residues that are essential for alpha1,2-mannosidase. However deletion of the MNL1 gene causes retardation of the degradation of misfolded carboxypeptidase Y, but not of the unglycosylated mutant form of the yeast alpha -mating pheromone. Possible roles of Mnl1p in the degradation and in the ER-retention of misfolded glycoproteins are discussed.	Nagoya Univ, Grad Sch Sci, Dept Chem, Chikusa Ku, Nagoya, Aichi 4648602, Japan; Kyoto Univ, Inst Frontier Med Sci, Dept Mol & Cellular Biol, Kyoto 6068507, Japan; Japan Sci & Technol Corp, CREST, Wako, Saitama, Japan	Nagoya University; Kyoto University; Japan Science & Technology Agency (JST)	Endo, T (corresponding author), Nagoya Univ, Grad Sch Sci, Dept Chem, Chikusa Ku, Nagoya, Aichi 4648602, Japan.							BAUDIN A, 1993, NUCLEIC ACIDS RES, V21, P3329, DOI 10.1093/nar/21.14.3329; Brodsky JL, 1999, SEMIN CELL DEV BIOL, V10, P507, DOI 10.1006/scdb.1999.0321; CAPLAN S, 1991, J BACTERIOL, V173, P627, DOI 10.1128/jb.173.2.627-635.1991; DESHAIES RJ, 1987, J CELL BIOL, V105, P633, DOI 10.1083/jcb.105.2.633; Ellgaard L, 1999, SCIENCE, V286, P1882, DOI 10.1126/science.286.5446.1882; FRANZUSOFF A, 1989, EMBO J, V8, P2695, DOI 10.1002/j.1460-2075.1989.tb08410.x; HAMMOND C, 1995, CURR OPIN CELL BIOL, V7, P523, DOI 10.1016/0955-0674(95)80009-3; HEMMINGS BA, 1981, P NATL ACAD SCI-BIOL, V78, P435, DOI 10.1073/pnas.78.1.435; HERSCOVICS A, 1993, FASEB J, V7, P540, DOI 10.1096/fasebj.7.6.8472892; HOSOKAWA N, 2001, IN PRESS EMBO REP; Jakob CA, 1998, J CELL BIOL, V142, P1223, DOI 10.1083/jcb.142.5.1223; KITADA K, 1995, GENE, V165, P203, DOI 10.1016/0378-1119(95)00552-H; Knop M, 1996, EMBO J, V15, P753, DOI 10.1002/j.1460-2075.1996.tb00411.x; Knop M, 1996, YEAST, V12, P1229, DOI 10.1002/(SICI)1097-0061(19960930)12:12<1229::AID-YEA15>3.0.CO;2-H; Lipari F, 1996, J BIOL CHEM, V271, P27615, DOI 10.1074/jbc.271.44.27615; Liu Y, 1999, J BIOL CHEM, V274, P5861, DOI 10.1074/jbc.274.9.5861; McCracken AA, 1996, J CELL BIOL, V132, P291, DOI 10.1083/jcb.132.3.291; NISHIKAWA S, 1994, MOL BIOL CELL, V5, P1129, DOI 10.1091/mbc.5.10.1129; Nishikawa S, 1997, J BIOL CHEM, V272, P12889, DOI 10.1074/jbc.272.20.12889; NISHIKAWA S, 1991, BIOCHIM BIOPHYS ACTA, V1093, P135, DOI 10.1016/0167-4889(91)90114-D; Pilon M, 1997, EMBO J, V16, P4540, DOI 10.1093/emboj/16.15.4540; Plemper RK, 1999, TRENDS BIOCHEM SCI, V24, P266, DOI 10.1016/S0968-0004(99)01420-6; QADOTA H, 1992, YEAST, V8, P735, DOI 10.1002/yea.320080906; ROBINSON JS, 1988, MOL CELL BIOL, V8, P4936, DOI 10.1128/MCB.8.11.4936; Romisch K, 1999, J CELL SCI, V112, P4185; ROTHBLATT JA, 1989, J CELL BIOL, V109, P2641, DOI 10.1083/jcb.109.6.2641; Sommer T, 1997, FASEB J, V11, P1227, DOI 10.1096/fasebj.11.14.9409541; STEVENS TH, 1986, J CELL BIOL, V102, P1551, DOI 10.1083/jcb.102.5.1551; SU K, 1993, J BIOL CHEM, V268, P14301; Vallee F, 2000, EMBO J, V19, P581, DOI 10.1093/emboj/19.4.581; Werner ED, 1996, P NATL ACAD SCI USA, V93, P13797, DOI 10.1073/pnas.93.24.13797; Wiertz EJHJ, 1996, NATURE, V384, P432, DOI 10.1038/384432a0; Winzeler EA, 1999, SCIENCE, V285, P901, DOI 10.1126/science.285.5429.901; Zhou MY, 1999, MOL CELL, V4, P925, DOI 10.1016/S1097-2765(00)80222-1	34	145	148	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 23	2001	276	12					8635	8638		10.1074/jbc.C100023200	http://dx.doi.org/10.1074/jbc.C100023200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	413HV	11254655	hybrid			2022-12-25	WOS:000167607700004
J	Lavigne, MC; Malech, HL; Holland, SM; Leto, TL				Lavigne, MC; Malech, HL; Holland, SM; Leto, TL			Genetic requirement of p47phox for superoxide production by murine microglia	FASEB JOURNAL			English	Article									NIAID, Host Def Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Leto, TL (corresponding author), NIH, Bldg 10,Room 11N106, Bethesda, MD 20982 USA.			Malech, Harry/0000-0001-5874-5775	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [ZIAAI000614, ZIAAI000646, Z01AI000614, ZIAAI000644, Z01AI000646, Z01AI000644] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))			0	48	50	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	FEB	2001	15	2					285	287						3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	400LK	11156938				2022-12-25	WOS:000166872900004
J	Takacs, P; Kauma, SW; Sholley, MM; Walsh, SW; Dinsmoor, MJ; Green, K				Takacs, P; Kauma, SW; Sholley, MM; Walsh, SW; Dinsmoor, MJ; Green, K			Increased circulating lipid peroxides in severe preeclampsia activate NF-kappa B and upregulate ICAM-1 in vascular endothelial cells	FASEB JOURNAL			English	Article									Virginia Commonwealth Univ, Med Coll Virginia, Dept Obstet & Gynecol, Richmond, VA 23298 USA; Virginia Commonwealth Univ, Med Coll Virginia, Dept Microbiol & Immunol, Richmond, VA 23298 USA; Virginia Commonwealth Univ, Med Coll Virginia, Dept Physiol, Richmond, VA 23298 USA; Virginia Commonwealth Univ, Med Coll Virginia, Dept Anat, Richmond, VA 23298 USA	Virginia Commonwealth University; Virginia Commonwealth University; Virginia Commonwealth University; Virginia Commonwealth University	Kauma, SW (corresponding author), Virginia Commonwealth Univ, Med Coll Virginia, Dept Obstet & Gynecol, 1101 E Marshal St,Sanger Hall,Rm 11-029,Box 98003, Richmond, VA 23298 USA.								0	81	98	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	FEB	2001	15	2					279	281						3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	400LK	11156936				2022-12-25	WOS:000166872900002
J	Balana, ME; Labriola, L; Salatino, M; Movsichoff, F; Peters, G; Charreau, EH; Elizalde, PV				Balana, ME; Labriola, L; Salatino, M; Movsichoff, F; Peters, G; Charreau, EH; Elizalde, PV			Activation of ErbB-2 via a hierarchical interaction between ErbB-2 and type I insulin-like growth factor receptor in mammary tumor cells	ONCOGENE			English	Article						ErbB receptors; mammary tumorigenesis; progestin; type I insulin-like growth factor receptor	HUMAN-BREAST-CANCER; MEDROXYPROGESTERONE-ACETATE; CARCINOMA-CELLS; SIGNAL-TRANSDUCTION; ESTROGEN-RECEPTOR; PROGESTIN REGULATION; BALB/C MICE; EXPRESSION; PROLIFERATION; PROTEIN	The present study focused on interactions between signaling pathways activated by progestins and by type I and II receptor tyrosine kinases (RTKs) in mammary tumors. An experimental model in which the synthetic progestin medroxyprogesterone acetate (MPA) induced mammary adenocarcinomas in Balb/c mice was used. MPA-stimulated proliferation, both in vivo and in vitro, of progestin-dependent tumors induced up-regulation of ErbB-2 protein levels and tyrosine phosphorylation of this receptor. Combinations of antisense oligodeoxynucleotides (ASODNs) directed to ErbB-2 mRNA with ASODNs directed to the insulin-like growth factor-I receptor (IGF-IR) were used to study the effect of the simultaneous block of these receptors on the MPA-induced proliferation of epithelial cells from the progestin-dependent C4HD line. Neither synergistic nor additive effects on the inhibition of MPA-induced proliferation of C4HD cells were observed as a result of the combination of these ASODNs, Suppression of IGF-IR expression by ASODNs resulted in complete abrogation of MPA-induced phosphorylation of ErbB-2 in C4HD cells, whereas blockage of ErbB-2 did not affect ICF-IR phosphorylation, These results show the existence of a hierarchical interaction between IGF-IR and ErbB-2, by means of which IGF-IR directs ErbB-2 phosphorylation, We demonstrated, for the first time, that this hierarchical interaction involves physical association of both receptors, resulting in the formation of a heteromeric complex, Furthermore, confocal laser microscopy experiments demonstrated that MPA was able to induce co-localization of ErbB-2 and IGF-IR, This hetero-oligomer was also found in MCF-7 human breast cancer cells in which association of IGF-IR and Erbs-2 was induced by heregulin and IGF-I.	Inst Biol & Med Expt, RA-1428 Buenos Aires, DF, Argentina; Univ Buenos Aires, Fac Ciencias Exactas & Nat, RA-1053 Buenos Aires, DF, Argentina	Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET); Institute of Biology & Experimental Medicine; University of Buenos Aires	Elizalde, PV (corresponding author), Inst Biol & Med Expt, Obligado 2490, RA-1428 Buenos Aires, DF, Argentina.		Labriola, Leticia/ABF-9079-2020; Labriola, Leticia/E-9059-2012	Labriola, Leticia/0000-0003-3899-6088; Labriola, Leticia/0000-0003-3899-6088; Peters, Maria/0000-0002-9271-4590; Elizalde, Patricia V./0000-0002-5923-9898				BACKER JM, 1993, J BIOL CHEM, V268, P8204; Balana ME, 1999, ONCOGENE, V18, P6370, DOI 10.1038/sj.onc.1203028; BASERGA R, 1995, CANCER RES, V55, P249; BRAUNSBERG H, 1987, EUR J CANCER CLIN ON, V23, P563, DOI 10.1016/0277-5379(87)90321-X; CARRAWAY KL, 1994, CELL, V78, P5, DOI 10.1016/0092-8674(94)90564-9; CLARKE CL, 1990, ENDOCR REV, V11, P266, DOI 10.1210/edrv-11-2-266; COHEN GB, 1995, CELL, V80, P237, DOI 10.1016/0092-8674(95)90406-9; COLOMER R, 1994, BRIT J CANCER, V70, P819, DOI 10.1038/bjc.1994.405; COPPOLA D, 1994, MOL CELL BIOL, V14, P4588, DOI 10.1128/MCB.14.7.4588; DATI C, 1990, ONCOGENE, V5, P1001; De Bortoli M, 1997, J MAMMARY GLAND BIOL, V2, P175, DOI 10.1023/A:1026308015763; DICKSON RB, 1995, ENDOCR REV, V16, P559, DOI 10.1210/er.16.5.559; DRAN G, 1995, BREAST CANCER RES TR, V35, P173, DOI 10.1007/BF00668207; EGAN SE, 1993, NATURE, V365, P781, DOI 10.1038/365781a0; ELIZALDE PV, 1990, J EXP CLIN CANC RES, V9, P193; Elizalde PV, 1998, J STEROID BIOCHEM, V67, P305, DOI 10.1016/S0960-0760(98)00123-X; FEDI P, 1994, MOL CELL BIOL, V14, P492, DOI 10.1128/MCB.14.1.492; GrausPorta D, 1997, EMBO J, V16, P1647, DOI 10.1093/emboj/16.7.1647; Groshong SD, 1997, MOL ENDOCRINOL, V11, P1593, DOI 10.1210/me.11.11.1593; GRUNT TW, 1995, INT J CANCER, V63, P560, DOI 10.1002/ijc.2910630417; HOLMES WE, 1992, SCIENCE, V256, P1205, DOI 10.1126/science.256.5060.1205; KAVANAUGH WM, 1994, SCIENCE, V266, P1862, DOI 10.1126/science.7527937; KISS R, 1986, JNCI-J NATL CANCER I, V77, P173; KORDON EC, 1994, INT J CANCER, V59, P196, DOI 10.1002/ijc.2910590210; KRAUS MH, 1989, P NATL ACAD SCI USA, V86, P9193, DOI 10.1073/pnas.86.23.9193; LANARI C, 1989, INT J CANCER, V43, P845, DOI 10.1002/ijc.2910430518; Lange CA, 1998, J BIOL CHEM, V273, P31308, DOI 10.1074/jbc.273.47.31308; LEROITH D, 1995, ENDOCR REV, V16, P143, DOI 10.1210/er.16.2.143; Lewis GD, 1996, CANCER RES, V56, P1457; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; LUPU R, 1993, BREAST CANCER RES TR, V27, P83, DOI 10.1007/BF00683195; MANNI A, 1987, CANCER RES, V47, P3066; Migliaccio A, 1996, EMBO J, V15, P1292, DOI 10.1002/j.1460-2075.1996.tb00471.x; Migliaccio A, 1998, EMBO J, V17, P2008, DOI 10.1093/emboj/17.7.2008; MING XF, 1994, NATURE, V371, P426, DOI 10.1038/371426a0; MODIANO JF, 1991, J CELL BIOCHEM, V45, P196, DOI 10.1002/jcb.240450211; MOLINOLO AA, 1987, J NATL CANCER I, V79, P1341; MURPHY LC, 1988, CANCER RES, V48, P4555; MURPHY LJ, 1986, CANCER RES, V46, P728; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; Pinkas-Kramarski R, 1997, J MAMMARY GLAND BIOL, V2, P97, DOI 10.1023/A:1026343528967; PLOWMAN GD, 1993, P NATL ACAD SCI USA, V90, P1746, DOI 10.1073/pnas.90.5.1746; PLOWMAN GD, 1990, P NATL ACAD SCI USA, V87, P4905, DOI 10.1073/pnas.87.13.4905; RAM TG, 1995, J CELL PHYSIOL, V163, P589, DOI 10.1002/jcp.1041630320; Ram TG, 1996, MOL CARCINOGEN, V15, P227, DOI 10.1002/(SICI)1098-2744(199603)15:3<227::AID-MC8>3.0.CO;2-E; READ LD, 1990, CANCER RES, V50, P3947; Richer JK, 1998, J BIOL CHEM, V273, P31317, DOI 10.1074/jbc.273.47.31317; Riese DJ, 1998, BIOESSAYS, V20, P41, DOI 10.1002/(SICI)1521-1878(199801)20:1<41::AID-BIES7>3.0.CO;2-V; SARUP JC, 1988, CANCER RES, V48, P5071; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; STEWART AJ, 1990, J BIOL CHEM, V265, P21172; Swantek JL, 1999, ENDOCRINOLOGY, V140, P3163, DOI 10.1210/en.140.7.3163; TAVERNA D, 1994, INT J CANCER, V56, P522, DOI 10.1002/ijc.2910560411; Tzahar E, 1996, MOL CELL BIOL, V16, P5276; ULLRICH A, 1984, NATURE, V309, P418, DOI 10.1038/309418a0; ULLRICH A, 1986, EMBO J, V5, P2503, DOI 10.1002/j.1460-2075.1986.tb04528.x; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; Woods Ignatoski Kathleen M., 1999, Endocrinology, V140, P3615; YAMAMOTO T, 1986, NATURE, V319, P230, DOI 10.1038/319230a0	59	101	105	0	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 4	2001	20	1					34	47		10.1038/sj.onc.1204050	http://dx.doi.org/10.1038/sj.onc.1204050			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	391NE	11244498	Green Published			2022-12-25	WOS:000166361400005
J	Dabbeni-Sala, F; Di Santo, S; Franceschini, D; Skaper, SD; Giusti, P				Dabbeni-Sala, F; Di Santo, S; Franceschini, D; Skaper, SD; Giusti, P			Melatonin protects against 6-OHDA-induced neurotoxicity in rats: a role for mitochondrial complex I activity	FASEB JOURNAL			English	Article						Parkinson's disease; neurodegeneration; pineal hormone; neuroprotection; oxidative phosphorylation	KAINATE-INDUCED EXCITOTOXICITY; DEPENDENT LIPID-PEROXIDATION; PARKINSONS-DISEASE; CELL-DEATH; ROTATIONAL BEHAVIOR; SUBSTANTIA-NIGRA; OXIDATIVE STRESS; ACTIVITY RHYTHMS; ANIMAL-MODELS; VITAMIN-E	Unilateral injection into the right substantia nigra of the catecholaminergic neurotoxin 6-hydroxydopamine (6-OHDA) produces extensive loss of dopaminergic cells ('hemi-parkinsonian rat'). The pineal hormone melatonin, which is a potent antioxidant against different reactive oxygen species and has been reported to be neuroprotective in vivo and in vitro, was evaluated for potential anti-Parkinson effects in this model. Imbalance in dopaminergic innervation between the striata produced by intranigral administration of 6-OHDA results in a postural asymmetry causing rotation away from the nonlesioned side. Melatonin given systemically prevented apomorphine-induced circling behavior in 6-OHDA-lesioned rats. Reduced activity of mitochondrial oxidative phosphorylation enzymes has been suggested in some neurodegenerative diseases; in particular, selective decrease in complex I activity is observed in the substantia nigra of Parkinson's disease patients. Analysis of mitochondrial oxidative phosphorylation enzyme activities in nigral tissue from 6-OHDA-lesioned rats by a novel BN-PAGE histochemical procedure revealed a clear loss of complex I activity, which was protected against in melatonin-treated animals. A good correlation between behavioral parameters and enzymatic (complex I) analysis was observed independent of melatonin administration. A deficit in mitochondrial complex I could conceivably contribute to cell death in parkinsonism via free radical mechanisms, both directly via reactive oxygen species production and by decreased ATP synthesis and energy failure. Melatonin may have potential utility in the treatment of neurodegenerative disorders where oxidative stress is a participant.	Univ Padua, Dept Pharmacol, I-35131 Padua, Italy; SmithKline Beecham Pharmaceut, Dept Neurosci Res, Harlow CM19 5AW, Essex, England	University of Padua; GlaxoSmithKline	Giusti, P (corresponding author), Univ Padua, Dept Pharmacol, Largo E Meneghetti 2, I-35131 Padua, Italy.	giusti@uxl.unipd.it		GIUSTi, Pietro/0000-0001-9352-4046				Acuna-Castroviejo Dario, 1997, Life Sciences, V60, pPL23; ADAMS JD, 1993, FREE RADICAL BIO MED, V15, P181, DOI 10.1016/0891-5849(93)90057-2; ANDREW R, 1993, NEUROCHEM RES, V18, P1175, DOI 10.1007/BF00978370; ANTONTAY F, 1971, LIFE SCI, V10, P841, DOI 10.1016/0024-3205(71)90155-X; Beal MF, 1999, BIOFACTORS, V9, P261, DOI 10.1002/biof.5520090222; BENSHACHAR D, 1991, J NEUROCHEM, V57, P1609, DOI 10.1111/j.1471-4159.1991.tb06358.x; BENSHACHAR D, 1995, J NEUROCHEM, V64, P718, DOI 10.1046/j.1471-4159.1995.64020718.x; BURTON S, 1991, EXPERIENTIA, V47, P466, DOI 10.1007/BF01959946; CAGNOLI CM, 1995, J PINEAL RES, V18, P222, DOI 10.1111/j.1600-079X.1995.tb00163.x; CARMAN LS, 1991, BRAIN RES, V553, P275, DOI 10.1016/0006-8993(91)90835-J; Chanut E, 1998, J CHROMATOGR B, V709, P11, DOI 10.1016/S0378-4347(98)00041-3; CHESWORTH MJ, 1987, AM J PHYSIOL, V253, pR101, DOI 10.1152/ajpregu.1987.253.1.R101; COSTALL B, 1975, PSYCHOPHARMACOLOGIA, V43, P53, DOI 10.1007/BF00437615; COTZIAS GC, 1971, SCIENCE, V173, P450, DOI 10.1126/science.173.3995.450; COYLE JT, 1993, SCIENCE, V262, P689, DOI 10.1126/science.7901908; Davey GP, 1998, J BIOL CHEM, V273, P12753, DOI 10.1074/jbc.273.21.12753; Ebadi M, 1996, PROG NEUROBIOL, V48, P1, DOI 10.1016/0301-0082(95)00029-1; Floreani M, 1997, FASEB J, V11, P1309, DOI 10.1096/fasebj.11.14.9409550; Gerlach M, 1996, J NEURAL TRANSM, V103, P987, DOI 10.1007/BF01291788; GIUSTI P, 1995, EXP NEUROL, V131, P39, DOI 10.1016/0014-4886(95)90005-5; Giusti P, 1996, FASEB J, V10, P891, DOI 10.1096/fasebj.10.8.8666166; Giusti P, 1996, J PINEAL RES, V20, P226, DOI 10.1111/j.1600-079X.1996.tb00263.x; GLINKA YY, 1995, EUR J PHARM-ENVIRON, V292, P329, DOI 10.1016/0926-6917(95)90040-3; Gu M, 1998, ANN NEUROL, V44, P177, DOI 10.1002/ana.410440207; HASEGAWA E, 1990, BIOCHEM BIOPH RES CO, V170, P1049, DOI 10.1016/0006-291X(90)90498-C; HEFFNER TG, 1980, PHARMACOL BIOCHEM BE, V13, P453, DOI 10.1016/0091-3057(80)90254-3; HODGSON EK, 1975, BIOCHEMISTRY-US, V14, P5299, DOI 10.1021/bi00695a011; Hou JGG, 1997, J NEUROCHEM, V69, P76; ICHITANI Y, 1994, EXP NEUROL, V130, P269, DOI 10.1006/exnr.1994.1205; Jenner P, 1996, NEUROLOGY, V47, pS161, DOI 10.1212/WNL.47.6_Suppl_3.161S; JENNER P, 1992, NEUROLOGY, V42, P2241, DOI 10.1212/WNL.42.12.2241; Kim YS, 1998, NEUROREPORT, V9, P2387, DOI 10.1097/00001756-199807130-00043; KUMAR R, 1995, J NEUROCHEM, V64, P1703; Maney H., 1995, Society for Neuroscience Abstracts, V21, P1518; Matuszak Z, 1997, FREE RADICAL BIO MED, V23, P367, DOI 10.1016/S0891-5849(96)00614-4; Mayo JC, 1998, J PINEAL RES, V24, P179, DOI 10.1111/j.1600-079X.1998.tb00531.x; Melchiorri D, 1996, BIOCHEM PHARMACOL, V51, P1095, DOI 10.1016/0006-2952(96)00055-X; MELCHIORRI D, 1995, FASEB J, V9, P1205, DOI 10.1096/fasebj.9.12.7672513; MONTEIRO HP, 1989, BIOCHEM PHARMACOL, V38, P4177, DOI 10.1016/0006-2952(89)90512-1; NAVEILHAN P, 1994, J NEUROCHEM, V62, P2178; Offen D, 1996, EXP NEUROL, V141, P32, DOI 10.1006/exnr.1996.0136; OGAWA N, 1993, ADV NEUROL, V60, P242; Olanow CW, 1999, ANNU REV NEUROSCI, V22, P123, DOI 10.1002/mds.23732; PAPAVASILIOU PS, 1972, J AMER MED ASSOC, V221, P88, DOI 10.1001/jama.221.1.88; PERUMAL AS, 1992, BRAIN RES BULL, V29, P699, DOI 10.1016/0361-9230(92)90142-K; PIERI C, 1994, LIFE SCI, V55, pPL271, DOI 10.1016/0024-3205(94)00666-0; PIERREFICHE G, 1995, EXP GERONTOL, V30, P213, DOI 10.1016/0531-5565(94)00036-3; PRZEDBORSKI S, 1993, ANN NEUROL, V34, P715, DOI 10.1002/ana.410340515; PYCOCK CJ, 1980, NEUROSCIENCE, V5, P461, DOI 10.1016/0306-4522(80)90048-2; REDMAN J, 1983, SCIENCE, V219, P1089, DOI 10.1126/science.6823571; Reiter R, 1997, LIFE SCI, V60, P2255, DOI 10.1016/S0024-3205(97)00030-1; Reiter RJ, 1998, PROG NEUROBIOL, V56, P359, DOI 10.1016/S0301-0082(98)00052-5; Reiter RJ, 1996, TRENDS ENDOCRIN MET, V7, P22, DOI 10.1016/1043-2760(95)00192-1; Rojas P, 1996, NEUROTOXICOLOGY, V17, P323; SCHAGGER H, 1991, ANAL BIOCHEM, V199, P223, DOI 10.1016/0003-2697(91)90094-A; Schapira AHV, 1998, BBA-BIOENERGETICS, V1364, P261, DOI 10.1016/S0005-2728(98)00032-2; Schapira AHV, 1999, BBA-BIOENERGETICS, V1410, P159, DOI 10.1016/S0005-2728(98)00164-9; SEWERYNEK E, 1995, J PINEAL RES, V19, P51, DOI 10.1111/j.1600-079X.1995.tb00170.x; SHAW KM, 1973, LANCET, V1, P271; SILVERMAN PB, 1993, EUR J PHARMACOL, V242, P31, DOI 10.1016/0014-2999(93)90006-4; SWANSON LW, 1980, NEUROENDOCRINOLOGY, V31, P410, DOI 10.1159/000123111; Tenn CC, 1997, NEUROPHARMACOLOGY, V36, P1659, DOI 10.1016/S0028-3908(97)00165-2; UNGERSTEDT U, 1971, ACTA PHYSIOL SCAND, P69; Willis GL, 1999, PHYSIOL BEHAV, V66, P785, DOI 10.1016/S0031-9384(99)00023-2; Wolden-Hanson T, 2000, ENDOCRINOLOGY, V141, P487, DOI 10.1210/en.141.2.487; Yeleswaram K, 1997, J PINEAL RES, V22, P45, DOI 10.1111/j.1600-079X.1997.tb00302.x; Zamostiano R, 1999, NEUROSCI LETT, V264, P9, DOI 10.1016/S0304-3940(99)00168-8; Zerbetto E, 1997, ELECTROPHORESIS, V18, P2059, DOI 10.1002/elps.1150181131; ZIV I, 1994, NEUROSCI LETT, V170, P136, DOI 10.1016/0304-3940(94)90258-5	69	159	166	0	13	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2001	15	1					164	170		10.1096/fj.00-0129com	http://dx.doi.org/10.1096/fj.00-0129com			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	390TH	11149904				2022-12-25	WOS:000166312400025
J	Laflamme, N; Rivest, S				Laflamme, N; Rivest, S			Toll-like receptor 4: the missing link of the cerebral innate immune response triggered by circulating gram-negative bacterial cell wall components	FASEB JOURNAL			English	Article						circumventricular organs; innate immune response; in situ hybridization histochemistry; inflammation; lipopolysaccharide; proinflammatory cytokines; microglia; macrophages; NF-kappa B; septic shock	RAT-BRAIN; LIPOPOLYSACCHARIDE; ENDOTOXIN; MICE; CD14; POPULATIONS	The recent characterization of human homologues of Toll may be the missing link for the transduction events leading to NF-kappaB activity and proinflammatory gene transcription during innate immune response. Indeed, CD14 is not thought to participate directly in the cell signaling, but rather one or more of the mammalian Toll-like receptors (TLRs) acts in concert with the lipopolysaccharide (LPS) receptor to discriminate between microbial pathogens or their products and initiate transmembrane signaling. Mammalian cells may express as many as 10 distinct TLRs, although the importance of TLR4 in response to gram-negative bacteria and LPS is now supported by the fact that TLR4-mutated mice are LPS resistant. We investigated the expression of TLR4 across the rat brain under basal conditions and in response to systemic LPS and IL-1 beta injection. We first cloned the rat TLR4 cDNA via RNA isolation and polymerase chain reaction (PCR) amplification with a proofreading polymerase. Total RNA was isolated from the rat liver tissue using Tri-Reagent and reverse transcribed into cDNA using Superscript II reverse transcriptase and an oligonucleotide primer with a degenerate 3' end of sequence 5'-T12(GAC)N-3'. Positive hybridization signal was found in the leptomeninges, choroid plexus (chp), subfornical organ, organum vasculosum of the lamina terminalis, median eminence, and area postrema. Scattered small cells also displayed a convincing hybridization signal within the brain parenchyma. Few well-defined nuclei exhibited positive TLR4 transcript: the supramamillary nucleus, cochlear nucleus, and the lateral reticular nucleus. The circumventricular organs, the leptomeninges, and chp also exhibited constitutive expression of the LPS receptor mCD14. In contrast to the strong up-regulation of the gene encoding mCD14 during endotoxemia, neither LPS nor IL-1 beta caused a convincing increase in the TLR4 mRNA levels across the CNS. A down-regulation of the gene encoding TLR4 was found in the cerebral tissue of immune-challenged animals. The constitutive expression of both mCD 14 and TLR4 may explain the innate immune response in the brain, which originates from the structures devoid of blood-brain barrier in presence of circulating LPS.	Univ Laval, CHUL, Res Ctr, Mol Endocrinol Lab, Quebec City, PQ G1V 4G2, Canada; Univ Laval, Dept Anat & Physiol, Quebec City, PQ G1V 4G2, Canada	Laval University; Laval University	Rivest, S (corresponding author), Univ Laval, CHUL, Res Ctr, Mol Endocrinol Lab, 2705 Boul Laurier, Quebec City, PQ G1V 4G2, Canada.			Rivest, Serge/0000-0002-6082-770X				Anderson KV, 2000, CURR OPIN IMMUNOL, V12, P13, DOI 10.1016/S0952-7915(99)00045-X; ANDERSSON J, 1992, IMMUNOL REV, V127, P69, DOI 10.1111/j.1600-065X.1992.tb01409.x; Beutler B, 2000, CURR OPIN IMMUNOL, V12, P20, DOI 10.1016/S0952-7915(99)00046-1; Haziot A, 1996, IMMUNITY, V4, P407, DOI 10.1016/S1074-7613(00)80254-X; Kawai T, 1999, IMMUNITY, V11, P115, DOI 10.1016/S1074-7613(00)80086-2; Lacroix S, 1998, BRAIN PATHOL, V8, P625, DOI 10.1111/j.1750-3639.1998.tb00189.x; Laflamme N, 1999, J NEUROCHEM, V73, P309, DOI 10.1046/j.1471-4159.1999.0730309.x; Laflamme N, 1999, J NEUROSCI, V19, P10923, DOI 10.1523/JNEUROSCI.19-24-10923.1999; Muzio M, 2000, J LEUKOCYTE BIOL, V67, P450, DOI 10.1002/jlb.67.4.450; Nadeau S, 1999, J NEUROPATH EXP NEUR, V58, P61, DOI 10.1097/00005072-199901000-00008; Nadeau S, 2000, J NEUROSCI, V20, P3456, DOI 10.1523/JNEUROSCI.20-09-03456.2000; Nomura F, 2000, J IMMUNOL, V164, P3476, DOI 10.4049/jimmunol.164.7.3476; Oldfield Brian J., 1995, P391; Perera PY, 1997, J IMMUNOL, V158, P4422; Quan N, 1998, NEUROSCIENCE, V83, P281, DOI 10.1016/S0306-4522(97)00350-3; Takeuchi O, 1999, IMMUNITY, V11, P443, DOI 10.1016/S1074-7613(00)80119-3; Vallieres L, 1997, J NEUROCHEM, V69, P1668, DOI 10.1046/j.1471-4159.1997.69041668.x; Wright SD, 1999, J EXP MED, V189, P605, DOI 10.1084/jem.189.4.605; WRIGHT SD, 1990, SCIENCE, V249, P1431, DOI 10.1126/science.1698311	19	395	431	1	35	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JAN	2001	15	1					155	163		10.1096/fj.00-0339com	http://dx.doi.org/10.1096/fj.00-0339com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	390TH	11149903				2022-12-25	WOS:000166312400024
J	Virag, L; Szabo, C				Virag, L; Szabo, C			Purines inhibit poly(ADP-ribose) polymerase activation and modulate oxidant-induced cell death	FASEB JOURNAL			English	Article						nitric oxide; free radicals; antioxidants; shock; knockout; ADP-RT	PERFORMANCE LIQUID-CHROMATOGRAPHY; INDUCED BACTERIAL TRANSLOCATION; ISCHEMIA-REPERFUSION INJURY; ADENOSINE RECEPTOR AGONISTS; ADP-RIBOSE POLYMERASE; NITRIC-OXIDE; XANTHINE-OXIDASE; URIC-ACID; SYNTHETASE ACTIVATION; ADENINE-NUCLEOTIDES	Purines such as adenosine, inosine, and hypoxanthine are known to have potent antiinflammatory effects. These effects generally are believed to be mediated by cell surface adenosine receptors. Here we provide evidence that purines protect against oxidant-induced cell injury by inhibiting the activation of the nuclear enzyme poly(ADP-ribose) polymerase (PARP). Upon binding to broken DNA, PARP cleaves NAD(+) into nicotinamide and ADP-ribose and polymerizes the latter on nuclear acceptor tor proteins such as histones and PARP itself. Overactivation of PARP depletes cellular NAD(+) and ATP stores and causes necrotic cell death. We have identified some purines (hypoxanthine, inosine, and adenosine) as potential endogenous PARP inhibitors, We have found that purines (hypoxanthine > inosine > adenosine) dose-dependently inhibited PARP activation in peroxynitrite-treated macrophages and also inhibited the activity of the purified PARP enzyme. Consistently with their PARP inhibitory effects, the purines also protected interferon gamma + endotoxin (IFN/LPS) -stimulated RAW macrophages from the inhibition of mitochondrial respiration and inhibited nitrite production from IFN/LPS-stimulated macrophages. We have selected hypoxanthine as the most potent cytoprotective agent and PARP inhibitor among the three purine compounds, and investigated the mechanism of its cytoprotective effect. We have found that hypoxanthine protects thymocytes from death induced by the cytotoxic oxidant peroxynitrite, In line with the PARP inhibitory effect of purines, hypoxanthine has prevented necrotic cell death while increasing caspase activity and DNA fragmentation, As previously shown with other PARP inhibitors, hypoxanthine acted proximal to mitochondrial alterations as hypoxanthine inhibited the peroxynitrite-induced mitochondrial depolarization and secondary superoxide production. Our data imply that purines may serve as endogenous PARP inhibitors. We propose that, by affecting PARP activation, purines may modulate the pattern of cell death during shock, inflammation, and reperfusion injury.	Inotek Corp, Cummings Ctr 100, Beverly, MA 01915 USA	Inotek Pharmaceuticals	Szabo, C (corresponding author), Inotek Corp, Cummings Ctr 100, Suite 419E, Beverly, MA 01915 USA.	szabocsaba@aol.com	Szabo, Csaba/ABG-2644-2021; Virag, Laszlo/E-6124-2010; Szabo, Csaba/D-1882-2013	Virag, Laszlo/0000-0002-7099-6718	NIGMS NIH HHS [R01-GM60915] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM060915] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AASEN AO, 1979, CIRC SHOCK, V6, P277; Ar'Rajab A, 1996, New Horiz, V4, P224; Bell MJ, 1998, J NEUROTRAUM, V15, P163, DOI 10.1089/neu.1998.15.163; Bouma MG, 1997, SHOCK, V8, P313, DOI 10.1097/00024382-199711000-00001; COCHRANE CG, 1991, MOL ASPECTS MED, V12, P137, DOI 10.1016/0098-2997(91)90009-B; CRONSTEIN BN, 1995, J INVEST MED, V43, P50; CRONSTEIN BN, 1994, J APPL PHYSIOL, V76, P5, DOI 10.1152/jappl.1994.76.1.5; Degenring F H, 1975, Recent Adv Stud Cardiac Struct Metab, V10, P455; DEITCH EA, 1988, SURGERY, V104, P191; DEITCH EA, 1992, J TRAUMA, V32, P141; DEMURCIA G, 1994, TRENDS BIOCHEM SCI, V19, P172, DOI 10.1016/0968-0004(94)90280-1; DEVOUS MD, 1979, CARDIOLOGY, V64, P149; Dougherty C, 1998, FASEB J, V12, P1785, DOI 10.1096/fasebj.12.15.1785; Eliasson MJL, 1997, NAT MED, V3, P1089, DOI 10.1038/nm1097-1089; Fujimura M, 1997, NEUROSCI LETT, V228, P107, DOI 10.1016/S0304-3940(97)00373-X; Gizzi F, 1998, ADV EXP MED BIOL, V431, P777; GUDBJORNSSON B, 1991, ANN RHEUM DIS, V50, P669, DOI 10.1136/ard.50.10.669; Ha HC, 1999, P NATL ACAD SCI USA, V96, P13978, DOI 10.1073/pnas.96.24.13978; HARKNESS RA, 1988, J CHROMATOGR-BIOMED, V429, P255, DOI 10.1016/S0378-4347(00)83873-6; Hasko G, 2000, J IMMUNOL, V164, P1013, DOI 10.4049/jimmunol.164.2.1013; Hasko G, 1996, J IMMUNOL, V157, P4634; Hassa PO, 1999, BIOL CHEM, V380, P953, DOI 10.1515/BC.1999.118; HAUSCHILDT S, 1992, BIOCHEM J, V288, P255, DOI 10.1042/bj2880255; KLEIN HH, 1981, BASIC RES CARDIOL, V76, P612, DOI 10.1007/BF01908051; KOGURE K, 1980, ANN NEUROL, V8, P278, DOI 10.1002/ana.410080310; Krump E, 1999, ADV EXP MED BIOL, V447, P107; Maguire MH, 1998, J CHROMATOGR B, V707, P33, DOI 10.1016/S0378-4347(97)00581-1; MAINOUS MR, 1993, CIRC SHOCK, V40, P99; MARAK GE, 1988, OPHTHALMIC RES, V20, P220; Mei DA, 1996, ANAL BIOCHEM, V238, P34, DOI 10.1006/abio.1996.0246; MIRASPORTUGAL MT, 1986, J BIOL CHEM, V261, P1712; MORIMOTO K, 1982, J NEUROCHEM, V38, P833, DOI 10.1111/j.1471-4159.1982.tb08706.x; NISHINO T, 1994, J BIOCHEM, V116, P1; Nyce JW, 1999, TRENDS PHARMACOL SCI, V20, P79, DOI 10.1016/S0165-6147(99)01305-X; Oldner A, 1999, CRIT CARE MED, V27, P790, DOI 10.1097/00003246-199904000-00037; Oliver FJ, 1999, EMBO J, V18, P4446, DOI 10.1093/emboj/18.16.4446; Perretti M, 1997, TRENDS PHARMACOL SCI, V18, P418; Pieper AA, 1999, TRENDS PHARMACOL SCI, V20, P171, DOI 10.1016/S0165-6147(99)01292-4; POELSTRA K, 1992, LAB INVEST, V66, P555; POLASEK PM, 1989, J PHARM PHARMACOL, V41, P216, DOI 10.1111/j.2042-7158.1989.tb06437.x; Quinlan GJ, 1999, J CARDIOVASC SURG, V40, P65; SAUGSTAD OD, 1977, SCAND J CLIN LAB INV, V37, P517, DOI 10.3109/00365517709101840; Sitkovsky M V, 1998, Nihon Ika Daigaku Zasshi, V65, P351; SMISETH OA, 1983, CARDIOVASC RES, V17, P192, DOI 10.1093/cvr/17.4.192; STIPEK S, 1989, BIOMED BIOCHIM ACTA, V48, pS194; Stover JF, 1997, NEUROSCI LETT, V238, P25, DOI 10.1016/S0304-3940(97)00840-9; Szabo C, 1998, TRENDS PHARMACOL SCI, V19, P287, DOI 10.1016/S0165-6147(98)01193-6; Szabo C, 1998, EUR J PHARMACOL, V350, P1, DOI 10.1016/S0014-2999(98)00249-0; Szabo C, 1998, BRIT J PHARMACOL, V125, P379, DOI 10.1038/sj.bjp.0702040; Szabo C, 1997, J EXP MED, V186, P1041, DOI 10.1084/jem.186.7.1041; Szabo C, 1998, P NATL ACAD SCI USA, V95, P3867, DOI 10.1073/pnas.95.7.3867; Szabo C, 1996, SHOCK, V6, P79, DOI 10.1097/00024382-199608000-00001; Szabo C., 2000, CELL DEATH ROLE PARP; TARANTOLA M, 1991, J MOL CELL CARDIOL, V23, P77, DOI 10.1016/0022-2828(91)90040-S; THIRINGER K, 1983, ACTA PAEDIATR SCAND, V72, P231, DOI 10.1111/j.1651-2227.1983.tb09703.x; Tighe D, 1996, New Horiz, V4, P426; TRAUT TW, 1994, MOL CELL BIOCHEM, V140, P1, DOI 10.1007/BF00928361; VanWay CW, 1996, J SURG RES, V66, P159; Virag L, 1998, FREE RADICAL BIO MED, V25, P1075, DOI 10.1016/S0891-5849(98)00139-7; Virag L, 1999, MOL PHARMACOL, V56, P824; Virag L, 1999, BRIT J PHARMACOL, V126, P769, DOI 10.1038/sj.bjp.0702332; Virag L, 1998, J IMMUNOL, V161, P3753; Virag L, 1998, IMMUNOLOGY, V94, P345, DOI 10.1046/j.1365-2567.1998.00534.x; Zingarelli B, 1996, J IMMUNOL, V156, P350	64	100	113	0	10	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2001	15	1					99	107		10.1096/fj.00-0299com	http://dx.doi.org/10.1096/fj.00-0299com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	390TH	11149897				2022-12-25	WOS:000166312400018
J	Pages, C; Daviaud, D; An, SZ; Krief, S; Lafontan, M; Valet, P; Saulnier-Blache, JS				Pages, C; Daviaud, D; An, SZ; Krief, S; Lafontan, M; Valet, P; Saulnier-Blache, JS			Endothelial differentiation gene-2 receptor is involved in lysophosphatidic acid-dependent control of 3T3F442A preadipocyte proliferation and spreading	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTOR; MOLECULAR-CLONING; XENOPUS OOCYTES; GROWTH-FACTORS; MEDIATOR; IDENTIFICATION; EXPRESSION; ADIPOCYTES; EDG-1; CELLS	EDG-2, EDG-4, EDG-7, and PSP24 genes encode distinct lysophosphatidic acid (LPA) receptors, The aim of the present study was to determine which receptor subtype is involved in the biological responses generated by LPA in preadipocytes, Growing 3T3F442A preadipocytes express EDG-2 and EDG-4 mRNAs, with no expression of EDG-7 or PSP24 mRNAs. Quantitative reverse transcriptase-polymerase chain reaction revealed that EDG-2 transcripts were 10-fold more abundant than that of EDG-4. To determine the involvement of the EDG-2 receptor in the responses of growing preadipocytes to LPA, stable transfection of antisense EDG-2 cDNA was performed in growing 3T3F442A preadipocytes. This procedure, led to a significant and specific reduction in EDG-2 mRNA and protein. This was associated with a significant alteration in the effect of LPA on both cell proliferation and cell spreading, Finally, the differentiation of growing preadipocytes into quiescent adipocytes led to a strong reduction in the level of EDG-2 transcripts. Results demonstrate the significant contribution of the EDG-2 receptor in the biological responses generated by LPA in 3T3F442A preadipocytes.	Univ Toulouse 3, CHU Rangueil, Inst Louis Burnard, INSERM,U317, F-31403 Toulouse 04, France; Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA; SmithKline Beecham Labs Pharmaceut, F-35762 St Gregoire, France	CHU de Toulouse; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Toulouse; Universite Toulouse III - Paul Sabatier; University of California System; University of California San Francisco; GlaxoSmithKline	Saulnier-Blache, JS (corresponding author), Univ Toulouse 3, CHU Rangueil, Inst Louis Burnard, INSERM,U317, Batiment L3, F-31403 Toulouse 04, France.		Saulnier-Blache, Jean Sebastien/X-7729-2018; Valet, Philippe/N-7472-2017	Valet, Philippe/0000-0001-6520-7393; Saulnier-Blache, Jean Sebastien/0000-0002-8971-7723; Krief, Stephane/0000-0002-5543-731X				An SZ, 1998, J BIOL CHEM, V273, P7906, DOI 10.1074/jbc.273.14.7906; An SZ, 1997, BIOCHEM BIOPH RES CO, V231, P619, DOI 10.1006/bbrc.1997.6150; Bandoh K, 1999, J BIOL CHEM, V274, P27776, DOI 10.1074/jbc.274.39.27776; BERNLOHR DA, 1984, P NATL ACAD SCI-BIOL, V81, P5468, DOI 10.1073/pnas.81.17.5468; Betuing S, 1996, ENDOCRINOLOGY, V137, P5220, DOI 10.1210/en.137.12.5220; Betuing S, 1997, BIOCHEM BIOPH RES CO, V235, P765, DOI 10.1006/bbrc.1997.6887; BOULOUMIE A, 1994, J BIOL CHEM, V269, P30254; Chun Jerold, 1999, Cell Biochemistry and Biophysics, V30, P213, DOI 10.1007/BF02738068; Contos JJA, 2000, GENOMICS, V64, P155, DOI 10.1006/geno.2000.6122; EICHHOLTZ T, 1993, BIOCHEM J, V291, P677, DOI 10.1042/bj2910677; Gaits F, 1997, FEBS LETT, V410, P54, DOI 10.1016/S0014-5793(97)00411-0; Goetzl EJ, 1998, FASEB J, V12, P1589, DOI 10.1096/fasebj.12.15.1589; GOETZL EJ, 1994, J BIOL CHEM, V269, P809; Guo Z, 1996, P NATL ACAD SCI USA, V93, P14367, DOI 10.1073/pnas.93.25.14367; Hecht JH, 1996, J CELL BIOL, V135, P1071, DOI 10.1083/jcb.135.4.1071; JALINK K, 1994, BBA-REV CANCER, V1198, P185, DOI 10.1016/0304-419X(94)90013-2; Kawasawa Y, 2000, BIOCHEM BIOPH RES CO, V276, P952, DOI 10.1006/bbrc.2000.3569; Lee MJ, 1998, SCIENCE, V279, P1552, DOI 10.1126/science.279.5356.1552; Liu CH, 1997, GENOMICS, V43, P15, DOI 10.1006/geno.1997.4759; Pages C, 1999, BIOCHEM BIOPH RES CO, V265, P572, DOI 10.1006/bbrc.1999.1726; Pages C, 2000, ANN NY ACAD SCI, V905, P159; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Sasagawa T, 1998, J NUTR SCI VITAMINOL, V44, P809, DOI 10.3177/jnsv.44.809; Saulnier-Blache JS, 2000, J LIPID RES, V41, P1947; TIGYI G, 1992, J BIOL CHEM, V267, P21360; TOKUMURA A, 1994, AM J PHYSIOL, V267, pC204, DOI 10.1152/ajpcell.1994.267.1.C204; Valet P, 1998, J CLIN INVEST, V101, P1431, DOI 10.1172/JCI806	27	39	44	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 13	2001	276	15					11599	11605		10.1074/jbc.M010111200	http://dx.doi.org/10.1074/jbc.M010111200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	421UK	11152468	hybrid, Green Published			2022-12-25	WOS:000168081800026
J	D'Angelo, M; Billings, PC; Pacifici, M; Leboy, PS; Kirsch, T				D'Angelo, M; Billings, PC; Pacifici, M; Leboy, PS; Kirsch, T			Authentic matrix vesicles contain active metalloproteases (MMP) - A role for matrix vesicle-associated MMP-13 in activation of transforming growth factor-beta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXTRACELLULAR-MATRIX; MEDIATED MINERALIZATION; NUCLEATIONAL CORE; BINDING PROTEINS; TGF-BETA; CHONDROCYTES; CARTILAGE; MECHANISMS; COLLAGEN; CULTURES	Matrix vesicles (MV) play a key role in the initiation of cartilage mineralization. Although many components in these microstructures have been identified, the specific function of each component is still poorly understood. In this study, we show that metalloproteases (MMP), MMP-2, -9, and -13 are associated with MV isolated from growth plate cartilage. In addition, we provide evidence that MV contain transforming growth factor-beta (TGF-beta) and that MV-associated MMP-13 is capable of activating latent TGF-beta. To determine whether MMPs are associated directly with MV, vesicles isolated from growth plate cartilage were sequentially treated with hyaluronidase, NaCl, and bacterial collagenase to remove matrix proteins and other components attached to their outer surface. Finally, the vesicles were incubated with detergent to rupture the MCV membrane and expose components that are inside the vesicles. Each treated MV fraction was subjected to substrate zymography, immunoblotting, and substrate activity assay. Whereas active MMP-13 was lost after combined treatment with hyaluronidase and Nacl, MMP-8 and -9 activities were still retained in the pellet fraction even after detergent treatment, suggesting that the gelatinases, MMP-2 and -9, are integral components of MV. In addition, MV contain TGF-beta in the small latent complex, and MMP-13 associated with the MV surface was responsible for activation of TGF-beta. Since the amount of TGF-beta activated by hypertrophic chondrocytes increased with mineral appearance in serum-free chondrocyte cultures, a role for active MV-associated MMPs is suggested in activation of TGF-beta seen during late chondrocyte hypertrophy and mineralization of growth plate cartilage.	Univ Penn, Sch Dent Med, Dept Biochem, Hershey, PA 17033 USA; Univ Penn, Sch Dent Med, Dept Anat & Histol, Hershey, PA 17033 USA	University of Pennsylvania; University of Pennsylvania	Kirsch, T (corresponding author), Penn State Univ, Milton S Hershey Med Ctr, Dept Orthopaed & Rehabil, Coll Med, H089,500 Univ Dr, Hershey, PA 17033 USA.	tkirsch@psu.edu	D'Angelo, Maria Grazia/K-4685-2016; Leboy, Phoebe/A-1062-2007	D'Angelo, Maria Grazia/0000-0003-1241-4350; 	NIAMS NIH HHS [AR 46245, AR 43732, AR 40075] Funding Source: Medline; NIDCR NIH HHS [DE 11876, DE 05676] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR040075, R29AR043732, R01AR046245] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R03DE011876] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		ABE M, 1994, ANAL BIOCHEM, V216, P276, DOI 10.1006/abio.1994.1042; ANDERSON HC, 1995, CLIN ORTHOP RELAT R, P266; ANDERSON HC, 1969, J CELL BIOL, V41, P59, DOI 10.1083/jcb.41.1.59; BONAVENTURE J, 1994, EXP CELL RES, V212, P97, DOI 10.1006/excr.1994.1123; BONEWALD LF, 1994, J CELL BIOCHEM, V55, P350, DOI 10.1002/jcb.240550312; BOYAN BD, 1994, J BIOL CHEM, V269, P28374; Choi JY, 1996, J CELL BIOCHEM, V61, P609, DOI 10.1002/(SICI)1097-4644(19960616)61:4<609::AID-JCB15>3.3.CO;2-Q; D'Angelo M, 2000, J CELL BIOCHEM, V77, P678, DOI 10.1002/(SICI)1097-4644(20000615)77:4<678::AID-JCB15>3.3.CO;2-G; DAngelo M, 1997, J BONE MINER RES, V12, P1368, DOI 10.1359/jbmr.1997.12.9.1368; DANGELO M, 1998, T 44 ANN M ORTH RES, V23, P497; DEAN DD, 1992, CALCIFIED TISSUE INT, V50, P342, DOI 10.1007/BF00301632; Fosang AJ, 1996, FEBS LETT, V380, P17, DOI 10.1016/0014-5793(95)01539-6; GENGE BR, 1989, J BIOL CHEM, V264, P10917; HALE JE, 1987, J BIOL CHEM, V262, P1916; HAUSELMANN HJ, 1992, MATRIX, V12, P116; Jeffrey JJ, 1998, BIOL EXTRAC, P15; KIRSCH T, 1994, J BIOL CHEM, V269, P11462; Kirsch T, 2000, J BONE MINER RES, V15, P261, DOI 10.1359/jbmr.2000.15.2.261; Kirsch T, 2000, J BIOL CHEM, V275, P35577, DOI 10.1074/jbc.M005648200; Kirsch T, 1997, J CELL BIOL, V137, P1149, DOI 10.1083/jcb.137.5.1149; Knauper V, 1996, J BIOL CHEM, V271, P17124, DOI 10.1074/jbc.271.29.17124; Miyazono K., 1991, CIBA F SYMP, V157, P89; Munger JS, 1997, KIDNEY INT, V51, P1376, DOI 10.1038/ki.1997.188; Sasaki T, 1999, ANN NY ACAD SCI, V878, P347, DOI 10.1111/j.1749-6632.1999.tb07694.x; Schmitz JP, 1996, J CELL BIOCHEM, V61, P375, DOI 10.1002/(SICI)1097-4644(19960601)61:3<375::AID-JCB5>3.3.CO;2-I; SHIBATA Y, 1993, INT J BIOCHEM, V25, P239, DOI 10.1016/0020-711X(93)90012-4; Takai H, 1998, J BIOL CHEM, V273, P27091, DOI 10.1074/jbc.273.42.27091; TSCHAN T, 1990, J CELL BIOL, V111, P257, DOI 10.1083/jcb.111.1.257; WU LNY, 1993, J BIOL CHEM, V268, P25084; WU LNY, 1991, J BIOL CHEM, V266, P1195; WU LNY, 1991, J BIOL CHEM, V266, P1187; Wu LNY, 1997, J BIOL CHEM, V272, P4404, DOI 10.1074/jbc.272.7.4404	32	144	153	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 6	2001	276	14					11347	11353		10.1074/jbc.M009725200	http://dx.doi.org/10.1074/jbc.M009725200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	420AC	11145962	hybrid			2022-12-25	WOS:000167980900104
J	Dormeyer, M; Reckenfelderbaumer, N; Ludemann, H; Krauth-Siegel, RL				Dormeyer, M; Reckenfelderbaumer, N; Ludemann, H; Krauth-Siegel, RL			Trypanothione-dependent synthesis of deoxyribonucleotides by Trypanosoma brucei ribonucleotide reductase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; CRITHIDIA-FASCICULATA; FUNCTIONAL-CHARACTERIZATION; CYSTEINE RESIDUES; THIOREDOXIN; TRYPAREDOXIN; GLUTATHIONE; METABOLISM; CLONING; PURIFICATION	Trypanosoma brucei, the causative agent of African sleeping sickness, synthesizes deoxyribonucleotides via a classical eukaryotic class I ribonucleotide reductase, The unique thiol metabolism of trypanosomatids in which the nearly ubiquitous glutathione reductase is replaced by a trypanothione reductase prompted us to study the nature of thiols providing reducing equivalents for the parasite synthesis of DNA precursors. Here we show that the dithiol trypanothione (bis(glutathionyl)spermidine), in contrast to glutathione, is a direct reductant of T. brucei ribonucleotide reductase with a K-m value of 2 mM, This is the first example of a natural low molecular mass thiol directly delivering reducing equivalents for ribonucleotide reduction. At submillimolar concentrations, the reaction is strongly accelerated by tryparedoxin, a 16-kDa parasite protein with a WCPPC active site motif, The K-m value of T, brucei ribonucleotide reductase for T. brucei tryparedoxin is about 4 muM. The disulfide form of trypanothione is a powerful inhibitor of the tryparedoxin-mediated reaction that may represent a physiological regulation of deoxyribonucleotide synthesis by the redox state of the cell. The trypanothione/tryparedoxin system is a new system providing electrons for a class I ribonucleotide reductase, in addition to the well known thioredoxin and glutaredoxin systems described in other organisms.	Heidelberg Univ, Zentrum Biochem, D-69120 Heidelberg, Germany	Ruprecht Karls University Heidelberg	Krauth-Siegel, RL (corresponding author), Heidelberg Univ, Zentrum Biochem, Neuenheimer Feld 328, D-69120 Heidelberg, Germany.	krauth-siegel@urz.uni-heidelberg.de						ASLUND F, 1994, P NATL ACAD SCI USA, V91, P9813, DOI 10.1073/pnas.91.21.9813; Breidbach T, 2000, FEBS LETT, V473, P212, DOI 10.1016/S0014-5793(00)01533-7; CARNIERI EGS, 1993, MOL BIOCHEM PARASIT, V61, P79, DOI 10.1016/0166-6851(93)90160-Y; Dormeyer M, 1997, FEBS LETT, V414, P449, DOI 10.1016/S0014-5793(97)01036-3; ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6; ENGSTROM Y, 1979, BIOCHEMISTRY-US, V18, P2941, DOI 10.1021/bi00581a004; Eriksson M, 1997, STRUCTURE, V5, P1077, DOI 10.1016/S0969-2126(97)00259-1; FAIRLAMB AH, 1992, ANNU REV MICROBIOL, V46, P695, DOI 10.1146/annurev.micro.46.1.695; Flohe L, 1999, FREE RADICAL BIO MED, V27, P966, DOI 10.1016/S0891-5849(99)00172-0; GILBERT HF, 1990, ADV ENZYMOL RAMB, V63, P69; Gommel DU, 1997, EUR J BIOCHEM, V248, P913, DOI 10.1111/j.1432-1033.1997.t01-1-00913.x; Hofer A, 1997, P NATL ACAD SCI USA, V94, P6959, DOI 10.1073/pnas.94.13.6959; Hofer A, 1998, J BIOL CHEM, V273, P34098, DOI 10.1074/jbc.273.51.34098; HOLMGREN A, 1985, ANNU REV BIOCHEM, V54, P237, DOI 10.1146/annurev.bi.54.070185.001321; HOLMGREN A, 1979, J BIOL CHEM, V254, P3672; HOLMGREN A, 1979, J BIOL CHEM, V254, P3664; HOLMGREN A, 1989, J BIOL CHEM, V264, P13963; Jordan A, 1998, ANNU REV BIOCHEM, V67, P71, DOI 10.1146/annurev.biochem.67.1.71; KALLIS GB, 1980, J BIOL CHEM, V255, P261; Krauth-Siegel RL, 1999, PARASITOL TODAY, V15, P404, DOI 10.1016/S0169-4758(99)01516-1; KRAUTHSIEGEL RL, 1993, FEBS LETT, V317, P105, DOI 10.1016/0014-5793(93)81501-P; KrauthSiegel RL, 1996, MOL BIOCHEM PARASIT, V80, P203, DOI 10.1016/0166-6851(96)02689-8; KRAUTHSIEGEL RL, 1995, FASEB J, V9, P1138, DOI 10.1096/fasebj.9.12.7672506; Krieger S, 2000, MOL MICROBIOL, V35, P542, DOI 10.1046/j.1365-2958.2000.01721.x; Ludemann H, 1998, FEBS LETT, V431, P381, DOI 10.1016/S0014-5793(98)00793-5; MAO SS, 1992, BIOCHEMISTRY-US, V31, P9733, DOI 10.1021/bi00155a029; Miranda-Vizuete A, 1997, J BIOL CHEM, V272, P30841, DOI 10.1074/jbc.272.49.30841; Montemartini M, 1998, BIOL CHEM, V379, P1137, DOI 10.1515/bchm.1998.379.8-9.1137; Montemartini M, 1999, EUR J BIOCHEM, V264, P516, DOI 10.1046/j.1432-1327.1999.00656.x; MOUTIEZ M, 1994, CHEM PHARM BULL, V42, P2641; Nogoceke E, 1997, BIOL CHEM, V378, P827, DOI 10.1515/bchm.1997.378.8.827; Reckenfelderbaumer N, 2000, J BIOL CHEM, V275, P7547, DOI 10.1074/jbc.275.11.7547; Sjoberg B. M., 1995, NUCLEIC ACIDS MOL BI, V9, P192; SULLIVAN FX, 1991, MOL BIOCHEM PARASIT, V44, P145, DOI 10.1016/0166-6851(91)90231-T; THELANDER L, 1979, ANNU REV BIOCHEM, V48, P133, DOI 10.1146/annurev.bi.48.070179.001025; WILLING A, 1988, EUR J BIOCHEM, V170, P603, DOI 10.1111/j.1432-1033.1988.tb13740.x	36	98	104	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 6	2001	276	14					10602	10606		10.1074/jbc.M010352200	http://dx.doi.org/10.1074/jbc.M010352200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	420AC	11150302	hybrid			2022-12-25	WOS:000167980900006
J	Fried, MG; Daugherty, MA				Fried, MG; Daugherty, MA			In vitro interaction of the Escherichia coli cyclic AMP receptor protein with the lactose repressor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE ACTIVATOR PROTEIN; LAC REPRESSOR; DNA-BINDING; OPERATOR DNA; TRANSCRIPTION; PROMOTER; OPERON; 3',5'-MONOPHOSPHATE; EQUILIBRIUM; INDUCER	Sedimentation equilibrium studies show that the Escherichia coli cyclic AMP receptor protein (CAP) and lactose repressor associate to form a 2:1 complex in vitro. This is, to our knowledge, the first demonstration of a direct interaction of these proteins in the absence of DNA. No 1:1 complex was detected over a wide range of CAP concentrations, suggesting that binding is highly cooperative. Complex formation is stimulated by cAMP, with a net uptake of 1 equivalent of cAMP per molecule of CAP bound. Substitution of the dimeric lacI-18 mutant repressor for tetrameric wild-type repressor completely eliminates detectable binding. We therefore propose that CAP binds the cleft between dimeric units in the repressor tetramer. CAP-lac repressor interactions may play important roles in regulatory events that take place at overlapping CAP and repressor binding sites in the lactose promoter.	Penn State Univ, Milton S Hershey Med Ctr, Coll Med, Dept Biochem & Mol Biol, Hershey, PA 17033 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health	Fried, MG (corresponding author), Penn State Univ, Milton S Hershey Med Ctr, Coll Med, Dept Biochem & Mol Biol, Hershey, PA 17033 USA.							ANDERSON WB, 1971, J BIOL CHEM, V246, P5929; Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235; BUTLER AP, 1977, BIOCHEMISTRY-US, V16, P4757, DOI 10.1021/bi00641a001; CHAKERIAN AE, 1992, MOL MICROBIOL, V6, P963, DOI 10.1111/j.1365-2958.1992.tb02162.x; CHEN J, 1992, J BIOL CHEM, V267, P13843; CHEN J, 1994, BIOCHEMISTRY-US, V33, P1234, DOI 10.1021/bi00171a025; EBRIGHT RH, 1993, MOL MICROBIOL, V8, P797, DOI 10.1111/j.1365-2958.1993.tb01626.x; FRIED MG, 1984, J MOL BIOL, V172, P241, DOI 10.1016/S0022-2836(84)80025-X; Fried MG, 1996, SCIENCE, V274, P1930, DOI 10.1126/science.274.5294.1930; GALAS DJ, 1978, NUCLEIC ACIDS RES, V5, P3157, DOI 10.1093/nar/5.9.3157; HUANG CY, 1982, METHOD ENZYMOL, V87, P509; HUDSON JM, 1990, J MOL BIOL, V214, P381, DOI 10.1016/0022-2836(90)90188-R; JOHNSON ML, 1981, BIOPHYS J, V36, P575, DOI 10.1016/S0006-3495(81)84753-4; KOLB A, 1993, ANNU REV BIOCHEM, V62, P749, DOI 10.1146/annurev.bi.62.070193.003533; KRAMER H, 1987, EMBO J, V6, P1481, DOI 10.1002/j.1460-2075.1987.tb02390.x; Laue TM, 1999, ANNU REV BIOPH BIOM, V28, P75, DOI 10.1146/annurev.biophys.28.1.75; LEE JY, 1991, CELL, V66, P793, DOI 10.1016/0092-8674(91)90122-F; Lewis M, 1996, SCIENCE, V271, P1247, DOI 10.1126/science.271.5253.1247; MAJORS J, 1977, THESIS HARVARD U; MALAN TP, 1984, CELL, V39, P173, DOI 10.1016/0092-8674(84)90203-4; McRorie D. K., 1993, SELF ASS SYSTEMS ANA; Mller-Hill B., 1996, LAC OPERON; OEHLER S, 1994, EMBO J, V13, P3348, DOI 10.1002/j.1460-2075.1994.tb06637.x; OGORMAN RB, 1980, J BIOL CHEM, V255, P100; REZNIKOFF WS, 1992, J BACTERIOL, V174, P655, DOI 10.1128/jb.174.3.655-658.1992; REZNIKOFF WS, 1992, MOL MICROBIOL, V6, P2419; SCHLAX PJ, 1995, J MOL BIOL, V245, P331, DOI 10.1006/jmbi.1994.0028; SCHMITZ A, 1981, NUCLEIC ACIDS RES, V9, P277, DOI 10.1093/nar/9.2.277; SOGAARDANDERSEN L, 1991, P NATL ACAD SCI USA, V88, P4921, DOI 10.1073/pnas.88.11.4921; STICKLE DF, 1994, EUR J BIOCHEM, V226, P869, DOI 10.1111/j.1432-1033.1994.00869.x; STRANEY SB, 1987, CELL, V51, P699, DOI 10.1016/0092-8674(87)90093-6; TAKAHASHI M, 1980, BIOCHEMISTRY-US, V19, P5124, DOI 10.1021/bi00563a029; Vossen KM, 1996, J MOL BIOL, V255, P44, DOI 10.1006/jmbi.1996.0005; Wyman J., 1990, BINDING LINKAGE FUNC, P63	34	9	9	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 6	2001	276	14					11226	11229		10.1074/jbc.M009087200	http://dx.doi.org/10.1074/jbc.M009087200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	420AC	11152685	hybrid			2022-12-25	WOS:000167980900087
J	Neve, EPA; Ingelman-Sundberg, M				Neve, EPA; Ingelman-Sundberg, M			Identification and characterization of a mitochondrial targeting signal in rat cytochrome P450 2E1 (CYP2E1)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM MEMBRANE; PROTEIN IMPORT; PROCESSING PEPTIDASE; RECOGNITION; LIVER; TRANSLOCATION; RETENTION; PRECURSOR; RECEPTOR; DOMAINS	Cytochrome P450 2E1 (CYP2E1) lacking the hydrophobic NH2-terminal hydrophobic transmembrane domain is specifically targeted to mitochondria, where it is processed to a soluble and catalytically active form (Delta 2E1) with a mass of about 40 kDa. Small amounts of Delta 2E1 were also observed in mitochondria isolated from rat liver, indicating that this form of CYP2E1 is also present in vivo. In the present study the mitochondrial targeting signal was identified and characterized by the use of several NH2-terminally truncated and mutated forms of CYP2E1 that were expressed in the mouse H2.35 hepatoma cell line. Two potential mitochondrial targeting sequences were identified in the NH2 terminus of CYP2E1. Deletion of the first potential mitochondrial targeting sequence located between amino acids 50 and 65, as in Delta (2-64)2E1, still resulted in mitochondrial targeting and processing, but when, in addition to the first, the second potential mitochondrial targeting sequence located between amino acids 74 and 95 was also deleted, as in Delta (2-95)2E1, the mitochondrial targeting was abolished. Mutation of the four positively charged Arg and Lys residues present in this sequence to neutral Ala residues resulted in the abrogation of mitochondrial targeting. Deletion of a hydrophobic stretch of amino acids between residues 76 and 83 also abolished mitochondrial targeting and import. Once imported in the mitochondria, these constructs were further processed to the mature protein Delta 2E1. It is concluded that mitochondrial targeting of CYP2E1 is mediated through a sequence located between residues 74 and 95 and that positively charged residues as well as a hydrophobic stretch present in the beginning of this sequence are essential for this process.	Karolinska Inst, Inst Environm Med, Div Mol Toxicol, S-17177 Stockholm, Sweden	Karolinska Institutet	Ingelman-Sundberg, M (corresponding author), Karolinska Inst, Inst Environm Med, Div Mol Toxicol, Box 210, S-17177 Stockholm, Sweden.	magnus.ingelman-sundberg@imm.ki.se	Ingelman-Sundberg, Magnus/ABD-9302-2021					Abe Y, 2000, CELL, V100, P551, DOI 10.1016/S0092-8674(00)80691-1; Addya S, 1997, J CELL BIOL, V139, P589, DOI 10.1083/jcb.139.3.589; AHN KS, 1993, J BIOL CHEM, V268, P18726; Anandatheerthavarada HK, 1999, EMBO J, V18, P5494, DOI 10.1093/emboj/18.20.5494; Bauer MF, 1996, CELL, V87, P33, DOI 10.1016/S0092-8674(00)81320-3; Bauer MF, 2000, TRENDS CELL BIOL, V10, P25, DOI 10.1016/S0962-8924(99)01684-0; BOHNI PC, 1983, J BIOL CHEM, V258, P4937; Bondoc FY, 1999, BIOCHEM PHARMACOL, V58, P461, DOI 10.1016/S0006-2952(99)00111-2; Brix J, 1997, J BIOL CHEM, V272, P20730, DOI 10.1074/jbc.272.33.20730; Chen Q, 1998, MOL PHARMACOL, V53, P638, DOI 10.1124/mol.53.4.638; ELIASSON E, 1990, P NATL ACAD SCI USA, V87, P3225, DOI 10.1073/pnas.87.8.3225; Eliasson E, 1996, MOL PHARMACOL, V50, P573; French SW, 1997, J NUTR, V127, pS907, DOI 10.1093/jn/127.5.907S; HAWLITSCHEK G, 1988, CELL, V53, P795, DOI 10.1016/0092-8674(88)90096-7; Hettema EH, 1999, BBA-MOL CELL RES, V1451, P17, DOI 10.1016/S0167-4889(99)00087-7; INGELMANSUNDBERG M, 1993, ALCOHOL, V10, P447, DOI 10.1016/0741-8329(93)90063-T; Ito A, 1999, BIOCHEM BIOPH RES CO, V265, P611, DOI 10.1006/bbrc.1999.1703; Komiya T, 1998, EMBO J, V17, P3886, DOI 10.1093/emboj/17.14.3886; Lee CM, 1999, J BIOL CHEM, V274, P20937, DOI 10.1074/jbc.274.30.20937; Marks MS, 1997, TRENDS CELL BIOL, V7, P124, DOI 10.1016/S0962-8924(96)10057-X; MONIER S, 1988, J CELL BIOL, V107, P457, DOI 10.1083/jcb.107.2.457; Mori M, 1998, BBA-MOL CELL RES, V1403, P12, DOI 10.1016/S0167-4889(98)00021-4; MURAKAMI K, 1994, J BIOCHEM, V116, P164, DOI 10.1093/oxfordjournals.jbchem.a124489; Neupert W, 1997, ANNU REV BIOCHEM, V66, P863, DOI 10.1146/annurev.biochem.66.1.863; Neve EPA, 1999, FEBS LETT, V460, P309, DOI 10.1016/S0014-5793(99)01361-7; Neve EPA, 2000, J BIOL CHEM, V275, P17130, DOI 10.1074/jbc.M000957200; Neve EPA, 1996, ARCH BIOCHEM BIOPHYS, V333, P459, DOI 10.1006/abbi.1996.0415; OGISHIMA T, 1985, J BIOCHEM, V98, P781, DOI 10.1093/oxfordjournals.jbchem.a135335; OMURA T, 1991, METHOD ENZYMOL, V206, P75; Pahan K, 1997, FREE RADICAL BIO MED, V23, P963, DOI 10.1016/S0891-5849(97)00017-8; Pfanner N, 2000, CURR BIOL, V10, pR412, DOI 10.1016/S0960-9822(00)00507-8; PFANNER N, 1987, J BIOL CHEM, V262, P14851; RAMAGE L, 1993, EMBO J, V12, P4115, DOI 10.1002/j.1460-2075.1993.tb06095.x; ROISE D, 1988, J BIOL CHEM, V263, P4509; RONIS MJJ, 1991, EUR J BIOCHEM, V198, P383, DOI 10.1111/j.1432-1033.1991.tb16026.x; Ronis MJJ, 1996, CYTOCHROMES P450 MET, P211; SAKAGUCHI M, 1984, P NATL ACAD SCI-BIOL, V81, P3361, DOI 10.1073/pnas.81.11.3361; Schleiff E, 1999, FEBS LETT, V461, P9, DOI 10.1016/S0014-5793(99)01415-5; Szczesna-Skorupa E, 2000, ARCH BIOCHEM BIOPHYS, V374, P128, DOI 10.1006/abbi.1999.1628; Szczesna-Skorupa E, 2000, J BIOL CHEM, V275, P19409, DOI 10.1074/jbc.M002394200; VONHEIJNE G, 1986, EMBO J, V5, P1335, DOI 10.1002/j.1460-2075.1986.tb04364.x; Voos W, 1999, BBA-REV BIOMEMBRANES, V1422, P235, DOI 10.1016/S0304-4157(99)00007-6; WALTER P, 1994, ANNU REV CELL BIOL, V10, P87, DOI 10.1146/annurev.cb.10.110194.000511	43	43	44	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 6	2001	276	14					11317	11322		10.1074/jbc.M008640200	http://dx.doi.org/10.1074/jbc.M008640200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	420AC	11133991	hybrid			2022-12-25	WOS:000167980900100
J	Eicken, C; Sharma, V; Klabunde, T; Owens, RT; Pikas, DS; Hook, M; Sacchettini, JC				Eicken, C; Sharma, V; Klabunde, T; Owens, RT; Pikas, DS; Hook, M; Sacchettini, JC			Crystal structure of Lyme disease antigen outer surface protein C from Borrelia burgdorferi	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVE IMMUNIZATION; ASPARTATE RECEPTOR; PROTECTIVE EPITOPE; OSPC; MICE; SEQUENCE; SPIROCHETE; EXPRESSION; CHALLENGE; INFECTION	The outer surface protein C (OspC) is one of the major host-induced antigens of Borrelia burgdorferi, the causative agent of Lyme disease. We have solved the crystal structure of recombinant OspC to a resolution of 2.5 Angstrom OspC, a largely alpha -helical protein, is a dimer with a characteristic central four-helical bundle formed by association of the two longest helices from each subunit, OspC is very different from OspA and similar to the extracellular domain of the bacterial aspartate receptor and the variant surface glycoprotein from Trypanosoma brucei, Most of the surface-exposed residues of OspC are highly variable among different OspC isolates. The membrane proximal halves of the two long alpha -helices are the only conserved regions that are solvent accessible. As vaccination with recombinant OspC has been shown to elicit a protective immune response in mice, these regions are candidates for peptide-based vaccines.	Texas A&M Univ, Dept Biochem & Biophys, College Stn, TX 77843 USA; Albert B Alkek Inst Biosci & Technol, Ctr Struct Biol, Houston, TX 77030 USA; Texas A&M Univ, Hlth Sci Ctr, Ctr Extracellular Matrix Biol, Albert B Alkek Inst Biosci & Technol, College Stn, TX 77843 USA	Texas A&M University System; Texas A&M University College Station; Texas A&M University System; Texas A&M University College Station; Texas A&M Health Science Center	Sacchettini, JC (corresponding author), Texas A&M Univ, Dept Biochem & Biophys, College Stn, TX 77843 USA.	sacchett@tamu.edu						BARTON GJ, 1993, PROTEIN ENG, V6, P37, DOI 10.1093/protein/6.1.37; BLUM ML, 1993, NATURE, V362, P603, DOI 10.1038/362603a0; Bockenstedt LK, 1997, INFECT IMMUN, V65, P4661, DOI 10.1128/IAI.65.11.4661-4667.1997; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; BURGDORFER W, 1982, SCIENCE, V216, P1317, DOI 10.1126/science.7043737; BURMAN N, 1990, MOL MICROBIOL, V4, P1715, DOI 10.1111/j.1365-2958.1990.tb00549.x; Cadavid D, 1997, INFECT IMMUN, V65, P3352, DOI 10.1128/IAI.65.8.3352-3360.1997; Casjens S, 2000, MOL MICROBIOL, V35, P490, DOI 10.1046/j.1365-2958.2000.01698.x; Chervitz SA, 1996, P NATL ACAD SCI USA, V93, P2545, DOI 10.1073/pnas.93.6.2545; Cowtan K., 1994, JOINT CCP4 ESF EACBM, V31, P34; Davies C, 2000, STRUCTURE, V8, P185, DOI 10.1016/S0969-2126(00)00094-0; Gilmore RD, 1999, INFECT IMMUN, V67, P5463, DOI 10.1128/IAI.67.10.5463-5469.1999; Gilmore RD, 2000, INFECT IMMUN, V68, P411, DOI 10.1128/IAI.68.1.411-414.2000; Gilmore RD, 1996, INFECT IMMUN, V64, P2234, DOI 10.1128/IAI.64.6.2234-2239.1996; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; HENDRICKSON WA, 1990, EMBO J, V9, P1665, DOI 10.1002/j.1460-2075.1990.tb08287.x; Huang XL, 1999, J BIOMOL NMR, V14, P283, DOI 10.1023/A:1008398527355; JAURISHEIPKE S, 1993, MED MICROBIOL IMMUN, V182, P37; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Li H, 1997, P NATL ACAD SCI USA, V94, P3584, DOI 10.1073/pnas.94.8.3584; Mathiesen MJ, 1998, INFECT IMMUN, V66, P4073; Montgomery RR, 1996, J EXP MED, V183, P261, DOI 10.1084/jem.183.1.261; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PREACMURSIC V, 1992, INFECTION, V20, P342, DOI 10.1007/BF01710681; PROBERT WS, 1994, INFECT IMMUN, V62, P1920, DOI 10.1128/IAI.62.5.1920-1926.1994; SCHWAN TG, 1995, P NATL ACAD SCI USA, V92, P2909, DOI 10.1073/pnas.92.7.2909; Schwan TG, 1998, SCIENCE, V280, P1938, DOI 10.1126/science.280.5371.1938; Schwan TG, 2000, J CLIN MICROBIOL, V38, P382; STEVENSON B, 1994, FEMS MICROBIOL LETT, V124, P367, DOI 10.1111/j.1574-6968.1994.tb07310.x; STEVENSON B, 1994, INFECT IMMUN, V62, P3568, DOI 10.1128/IAI.62.8.3568-3571.1994; STEVENSON B, 1995, INFECT IMMUN, V63, P4535, DOI 10.1128/IAI.63.11.4535-4539.1995; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; THEISEN M, 1993, J CLIN MICROBIOL, V31, P2570, DOI 10.1128/JCM.31.10.2570-2576.1993; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; WILSKE B, 1993, INFECT IMMUN, V61, P2182, DOI 10.1128/IAI.61.5.2182-2191.1993; WILSKE B, 1986, ZBL BAKT-INT J MED M, V263, P92; Yeh JI, 1996, J MOL BIOL, V262, P186, DOI 10.1006/jmbi.1996.0507; Zhong WM, 1997, P NATL ACAD SCI USA, V94, P12533, DOI 10.1073/pnas.94.23.12533; Zucker WR, 2001, J BIOL CHEM, V276, P457, DOI 10.1074/jbc.M008449200; [No title captured]	41	73	76	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 30	2001	276	13					10010	10015		10.1074/jbc.M010062200	http://dx.doi.org/10.1074/jbc.M010062200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	420GC	11139584	hybrid			2022-12-25	WOS:000167996400059
J	Hagedorn, M; Zilberberg, L; Lozano, RM; Cuevas, P; Canron, X; Redondo-Horcajo, M; Gimenez-Gallego, G; Bikfalvi, A				Hagedorn, M; Zilberberg, L; Lozano, RM; Cuevas, P; Canron, X; Redondo-Horcajo, M; Gimenez-Gallego, G; Bikfalvi, A			A short peptide domain of platelet factor 4 blocks angiogenic key events induced by FGF-2	FASEB JOURNAL			English	Article									Univ Bordeaux 1, Growth Factor & Cell Differentiat Lab, F-33405 Talence, France; CSIC, Lab Estructura & Func Prot, E-28006 Madrid, Spain; Hosp Ramon y Cajal, Dept Hist, E-28034 Madrid, Spain	UDICE-French Research Universities; Universite de Bordeaux; Consejo Superior de Investigaciones Cientificas (CSIC); Hospital Universitario Ramon y Cajal	Bikfalvi, A (corresponding author), Univ Bordeaux 1, Growth Factor & Cell Differentiat Lab, F-33405 Talence, France.		Hagedorn, Martin/B-4272-2008	Hagedorn, Martin/0000-0002-0960-5116; Lozano, Rosa Maria/0000-0003-2762-6938					0	60	70	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAR	2001	15	3					550	552						3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	410BE	11259363				2022-12-25	WOS:000167419500001
J	Chapman, RS; Duff, EK; Lourenco, PC; Tonner, E; Flint, DJ; Clarke, AR; Watson, CJ				Chapman, RS; Duff, EK; Lourenco, PC; Tonner, E; Flint, DJ; Clarke, AR; Watson, CJ			A novel role for IRF-1 as a suppressor of apoptosis	ONCOGENE			English	Article						IRF-1; apoptosis; mammary gland; involution	MAMMARY-GLAND INVOLUTION; TRANSCRIPTION FACTOR IRF-1; CELL-DEATH; MICE; ACTIVATION; PATHWAYS; PROTEINS; BINDING; TISSUE	The tumour suppressor IRF-1 is a transcription factor involved in the induction of apoptosis in several in vitro systems, Post-lactational involution of the mammary gland is characterized by extensive apoptosis of the epithelial cells, We have previously shown that signal transducer and activator of transcription (Stat) 3 drives apoptosis and involution in the mouse mammary gland, Since one of the downstream targets of the Stat signalling pathway is IRF-1, we have used IRF-1 knockout mice to address the potential role of this transcription factor in involution, Surprisingly, in the absence of IRF-1 significantly higher numbers of apoptotic cells were found in involuting glands at 48 h compared to control glands, In addition, the alveolar structure in IRF-1 null mammary glands had collapsed whereas in control glands the alveoli remained intact and distended. However, by 72 h control and null glands were morphologically similar suggesting that IRF-1 suppresses apoptosis only during the early, reversible, stage of involution, This suggests a survival role for IRF-1 in mammary epithelia and demonstrates a novel role for IRF-1 in vivo - suppression of premature epithelial apoptosis during mammary gland involution.	Univ Cambridge, Dept Pathol, Cambridge CB2 1QP, England; Univ Edinburgh, Sch Med, Dept Pathol, Canc Res Campaign Labs, Edinburgh EH8 9AG, Midlothian, Scotland; Hannah Res Inst, Ayr KA6 5HL, Scotland; Univ Wales Coll Cardiff, Sch Biosci, Cardiff CF10 3US, S Glam, Wales	University of Cambridge; University of Edinburgh; Cardiff University	Watson, CJ (corresponding author), Univ Cambridge, Dept Pathol, Tennis Court Rd, Cambridge CB2 1QP, England.		clarke, alan r/P-2820-2014; watson, Christine J/B-1431-2012; Clarke, Alan R/A-6256-2008	Chapman, Rachel/0000-0001-5786-1918; Clarke, Alan/0000-0002-4281-426X				Chapman RS, 1999, GENE DEV, V13, P2604, DOI 10.1101/gad.13.19.2604; Heermeier K, 1996, MECH DEVELOP, V56, P197, DOI 10.1016/0925-4773(96)88032-4; Horiuchi M, 1997, J BIOL CHEM, V272, P11952, DOI 10.1074/jbc.272.18.11952; HOSSENLOPP P, 1986, ANAL BIOCHEM, V154, P138, DOI 10.1016/0003-2697(86)90507-5; Jager R, 1997, ONCOGENE, V15, P1787, DOI 10.1038/sj.onc.1201353; Jerry DJ, 1998, ONCOGENE, V17, P2305, DOI 10.1038/sj.onc.1202157; Kirchhoff S, 1999, ONCOGENE, V18, P3725, DOI 10.1038/sj.onc.1202704; Kumar A, 1997, SCIENCE, V278, P1630, DOI 10.1126/science.278.5343.1630; Li ML, 1997, P NATL ACAD SCI USA, V94, P3425, DOI 10.1073/pnas.94.7.3425; Li ML, 1996, CELL GROWTH DIFFER, V7, P13; Liu XW, 1996, MOL ENDOCRINOL, V10, P1496, DOI 10.1210/me.10.12.1496; Lund LR, 1996, DEVELOPMENT, V122, P181; MATSUYAMA T, 1993, CELL, V75, P83, DOI 10.1016/S0092-8674(05)80086-8; Meraro D, 1999, J IMMUNOL, V163, P6468; Nguyen H, 1997, ONCOGENE, V15, P1425, DOI 10.1038/sj.onc.1201318; Nozawa H, 1999, GENE DEV, V13, P1240, DOI 10.1101/gad.13.10.1240; Ogasawara K, 1998, NATURE, V391, P700, DOI 10.1038/35636; Philp JAC, 1996, FEBS LETT, V396, P77, DOI 10.1016/0014-5793(96)01069-1; STRANGE R, 1992, DEVELOPMENT, V115, P49; TAMURA T, 1995, NATURE, V376, P596, DOI 10.1038/376596a0; TANAKA N, 1994, CELL, V77, P829, DOI 10.1016/0092-8674(94)90132-5; Taniguchi T, 1997, BBA-REV CANCER, V1333, pM9, DOI 10.1016/S0304-419X(97)00014-0; Tonner E, 1997, ENDOCRINOLOGY, V138, P5101, DOI 10.1210/en.138.12.5101; WALKER NI, 1989, AM J ANAT, V185, P19, DOI 10.1002/aja.1001850104; YUAN JP, 1994, MOL CELL BIOL, V14, P1657, DOI 10.1128/MCB.14.3.1657	25	36	39	0	4	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 14	2000	19	54					6386	6391		10.1038/sj.onc.1204016	http://dx.doi.org/10.1038/sj.onc.1204016			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	388YK	11175354				2022-12-25	WOS:000166210500023
J	Cascio, M; Shenkel, S; Grodzicki, RL; Sigworth, FJ; Fox, RO				Cascio, M; Shenkel, S; Grodzicki, RL; Sigworth, FJ; Fox, RO			Functional reconstitution and characterization of recombinant human alpha(1)-glycine receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NICOTINIC ACETYLCHOLINE-RECEPTOR; PROTEIN SECONDARY STRUCTURE; HUMAN GLYCINE RECEPTOR; GATED ION CHANNELS; CIRCULAR-DICHROISM; TRANSMEMBRANE DOMAINS; CHLORIDE CONDUCTANCE; GLUTAMATE-RECEPTOR; AGONIST BINDING; BETA-ALANINE	By utilizing a baculoviral expression system described previously (Cascio, M., Schoppa, N. E., Grodzicki, R. L., Sigworth, F. J., and Fox, R. O. (1993) J. Biol. Chem. 268, 22135-22142), functional recombinant homomeric human alpha (1)-glycine receptors (GlyR) were overexpressed in insect cell culture, solubilized, purified, and reconstituted into lipid vesicles via gel filtration. Reconstituted GlyR channels were observed to retain native-like activity in single channel recordings of planar bilayers and in flux assays of small unilamellar vesicles, providing evidence that the recombinant homomeric receptor may be functionally reconstituted. This reconstitution is significant in that it indicates that the overexpressed homomeric receptor is an appropriate substrate for subsequent biophysical characterization aimed at the general elucidation of structure function, Circular dichroism spectroscopy of reconstituted GlyR indicated a low alpha -helical content and a significant fraction of polyproline structure. The small fraction of observed alpha -helix is insufficient to accommodate the four helical transmembrane domains proposed in models for this receptor. By inference, other members of the homologous ligand-gated channel superfamily, which include the ionotropic gamma -aminobutyric acid, acetylcholine, and serotonin receptors, may also be erroneously modeled, and alternate models should be considered.	Univ Texas, Med Branch, Dept Human Biol Chem & Genet, Galveston, TX 77555 USA; Yale Univ, Dept Mol Biophys & Biochem, New Haven, CT 06511 USA; Yale Univ, Howard Hughes Med Inst, New Haven, CT 06511 USA; Yale Univ, Sch Med, Dept Cellular & Mol Physiol, New Haven, CT 06510 USA; Univ Pittsburgh, Sch Med, Dept Mol Genet & Biochem, Pittsburgh, PA 15261 USA	University of Texas System; University of Texas Medical Branch Galveston; Yale University; Howard Hughes Medical Institute; Yale University; Yale University; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Fox, RO (corresponding author), Univ Texas, Med Branch, Dept Human Biol Chem & Genet, 6-658 Basic Sci Bldg, Galveston, TX 77555 USA.	fox@bloch.utmb.edu			NIGMS NIH HHS [GM51911, GM55851] Funding Source: Medline; NINDS NIH HHS [NS21501] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM051911, R01GM055851] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS021501] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ADZHUBEI AA, 1993, J MOL BIOL, V229, P472, DOI 10.1006/jmbi.1993.1047; Barrantes FJ, 2000, J BIOL CHEM, V275, P37333, DOI 10.1074/jbc.M005246200; BENNETT JA, 1995, NEURON, V14, P373, DOI 10.1016/0896-6273(95)90293-7; BETZ H, 1990, NEURON, V5, P383, DOI 10.1016/0896-6273(90)90077-S; Blanton MP, 1998, J BIOL CHEM, V273, P8659, DOI 10.1074/jbc.273.15.8659; BLANTON MP, 1994, BIOCHEMISTRY-US, V33, P2859, DOI 10.1021/bi00176a016; BLANTON MP, 1992, BIOCHEMISTRY-US, V31, P3738, DOI 10.1021/bi00130a003; Boileau AJ, 1999, J NEUROSCI, V19, P4847; BORMANN J, 1993, EMBO J, V12, P3729, DOI 10.1002/j.1460-2075.1993.tb06050.x; CASCIO M, 1993, J BIOL CHEM, V268, P22135; CASCIO M, 1995, METH NEUROSCI, V25, P175; CHANG CT, 1978, ANAL BIOCHEM, V91, P13, DOI 10.1016/0003-2697(78)90812-6; COHEN GB, 1995, CELL, V80, P237, DOI 10.1016/0092-8674(95)90406-9; Corringer PJ, 2000, ANNU REV PHARMACOL, V40, P431, DOI 10.1146/annurev.pharmtox.40.1.431; DEVILLERSTHIERY A, 1993, J MEMBRANE BIOL, V136, P97, DOI 10.1007/BF02505755; Fiske CH, 1925, J BIOL CHEM, V66, P375; GARCIACALVO M, 1989, BIOCHEMISTRY-US, V28, P6405, DOI 10.1021/bi00441a037; Gomperts SN, 1996, CELL, V84, P659, DOI 10.1016/S0092-8674(00)81043-0; GORNETSCHELNOKOW U, 1994, EMBO J, V13, P338, DOI 10.1002/j.1460-2075.1994.tb06266.x; Green T, 1998, NEURON, V20, P427, DOI 10.1016/S0896-6273(00)80986-1; GRENNINGLOH G, 1990, NEURON, V4, P963, DOI 10.1016/0896-6273(90)90149-A; GRENNINGLOH G, 1990, EMBO J, V9, P771, DOI 10.1002/j.1460-2075.1990.tb08172.x; HOLLMANN M, 1994, NEURON, V13, P1331, DOI 10.1016/0896-6273(94)90419-7; HUCHO F, 1994, TRENDS BIOCHEM SCI, V19, P383, DOI 10.1016/0968-0004(94)90116-3; ILLSLEY NP, 1987, BIOCHEMISTRY-US, V26, P1215, DOI 10.1021/bi00379a002; ISHII T, 1993, J BIOL CHEM, V268, P2836; JOHNSON WC, 1990, PROTEINS, V7, P205, DOI 10.1002/prot.340070302; Karlin A, 1998, METHOD ENZYMOL, V293, P123; KIRSCH J, 1993, NATURE, V366, P745, DOI 10.1038/366745a0; KIRSCH J, 1995, J NEUROSCI, V15, P4148; KUBO T, 1985, EUR J BIOCHEM, V149, P5, DOI 10.1111/j.1432-1033.1985.tb08885.x; KUHSE J, 1990, J BIOL CHEM, V265, P22317; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANGOSCH D, 1994, EMBO J, V13, P4223, DOI 10.1002/j.1460-2075.1994.tb06742.x; LANGOSCH D, 1988, P NATL ACAD SCI USA, V85, P7394, DOI 10.1073/pnas.85.19.7394; Le Novere N, 1999, BIOPHYS J, V76, P2329, DOI 10.1016/S0006-3495(99)77390-X; Leite JF, 2000, J BIOL CHEM, V275, P13683, DOI 10.1074/jbc.275.18.13683; LIM WA, 1994, NATURE, V372, P375, DOI 10.1038/372375a0; MACKINNON R, 1990, SCIENCE, V250, P276, DOI 10.1126/science.2218530; MALOSIO ML, 1991, J BIOL CHEM, V266, P2048; MANAVALAN P, 1987, ANAL BIOCHEM, V167, P76, DOI 10.1016/0003-2697(87)90135-7; MAO D, 1984, BIOCHEMISTRY-US, V23, P2667, DOI 10.1021/bi00307a020; MAO D, 1982, BIOCHEMISTRY-US, V21, P4960, DOI 10.1021/bi00263a020; MAYO KH, 1991, BIOCHEMISTRY-US, V30, P8251, DOI 10.1021/bi00247a022; MEYER G, 1995, NEURON, V15, P563, DOI 10.1016/0896-6273(95)90145-0; MIELKE DL, 1988, J BIOL CHEM, V263, P3177; Miyazawa A, 1999, J MOL BIOL, V288, P765, DOI 10.1006/jmbi.1999.2721; MORR J, 1995, FEBS LETT, V368, P495, DOI 10.1016/0014-5793(95)00721-K; Niethammer M, 1996, J NEUROSCI, V16, P2157; Olsen RW, 1998, TOXICOL LETT, V101, P193, DOI 10.1016/S0378-4274(98)00185-4; Ortells MO, 1997, PROTEINS, V29, P391, DOI 10.1002/(SICI)1097-0134(199711)29:3<391::AID-PROT12>3.0.CO;2-I; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; PFEIFFER F, 1982, J BIOL CHEM, V257, P9389; RAJENDRA S, 1995, EMBO J, V14, P2987, DOI 10.1002/j.1460-2075.1995.tb07301.x; RAJENDRA S, 1995, NEURON, V14, P169, DOI 10.1016/0896-6273(95)90251-1; RIQUELME G, 1990, FEBS LETT, V276, P54, DOI 10.1016/0014-5793(90)80505-D; ROTIN D, 1994, EMBO J, V13, P4440, DOI 10.1002/j.1460-2075.1994.tb06766.x; SAVITZKY A, 1964, ANAL CHEM, V36, P1627, DOI 10.1021/ac60214a047; Schertler G. F. X., 1992, CURR OPIN STRUC BIOL, V2, P534, DOI DOI 10.1016/0959-440X(92)90083-J; SCHLOSS P, 1991, J NEUROCHEM, V57, P1556, DOI 10.1111/j.1471-4159.1991.tb06351.x; SCHMIEDEN V, 1993, SCIENCE, V262, P256, DOI 10.1126/science.8211147; SCHOFIELD PR, 1987, NATURE, V328, P221, DOI 10.1038/328221a0; SHENKEL S, 1989, P NATL ACAD SCI USA, V86, P9592, DOI 10.1073/pnas.86.23.9592; SKACH WR, 1993, J BIOL CHEM, V268, P6903; SREERAMA N, 1994, BIOCHEMISTRY-US, V33, P10022, DOI 10.1021/bi00199a028; Sullivan DA, 2000, J BIOL CHEM, V275, P12651, DOI 10.1074/jbc.275.17.12651; SUMMERS MD, 1987, TEXAS AGR EXPT STATI, V1555, P1; UNWIN N, 1995, NATURE, V373, P37, DOI 10.1038/373037a0; UNWIN N, 1993, J MOL BIOL, V229, P1101, DOI 10.1006/jmbi.1993.1107; VANDENBERG RJ, 1992, P NATL ACAD SCI USA, V89, P1765, DOI 10.1073/pnas.89.5.1765; WESSEL D, 1984, ANAL BIOCHEM, V138, P141, DOI 10.1016/0003-2697(84)90782-6; WU J, 1992, ANAL BIOCHEM, V200, P359, DOI 10.1016/0003-2697(92)90479-Q; Wyszynski M, 1997, NATURE, V385, P439, DOI 10.1038/385439a0; Yan D, 1999, J BIOL CHEM, V274, P5537, DOI 10.1074/jbc.274.9.5537	75	28	28	0	4	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 15	2001	276	24					20981	20988		10.1074/jbc.M010968200	http://dx.doi.org/10.1074/jbc.M010968200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	442RC	11145968	hybrid			2022-12-25	WOS:000169297900026
J	Ayvazian, L; Kerfelec, B; Granon, S; Foglizzo, E; Crenon, I; Dubois, C; Chapus, C				Ayvazian, L; Kerfelec, B; Granon, S; Foglizzo, E; Crenon, I; Dubois, C; Chapus, C			The lipase C-terminal domain - A novel unusual inhibitor of pancreatic lipase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROCOLIPASE COMPLEX; CRYSTAL-STRUCTURE; X-RAY; COLIPASE; ACTIVATION; ABILITY	In vertebrates, dietary fat digestion mainly results from the combined effect of pancreatic lipase, colipase, and bile. It has been proposed that in vivo lipase adsorption on oil-water emulsion is mediated by a preformed lipase-colipase-mixed micelle complex. The main lipase-colipase binding site is located on the C-terminal domain of the enzyme. We report here that in vitro the isolated C-terminal domain behaves as a potent noncovalent inhibitor of lipase and that the inhibitory effect is triggered by the presence of micelles, Lipase inhibition results from the formation of a nonproductive C-terminal domain-colipase-micelle ternary complex, which competes for colipase with the active lipase-colipase-micelle ternary complex, thus diverting colipase from its lipase-anchoring function. The formation of such a complex has been evidenced by molecular sieving experiments. This nonproductive complex lowers the amount of active lipase thus reducing lipolysis, Preliminary experiments performed in rats show that the C-terminal domain also behaves as an inhibitor in vivo and thus could be considered a potential new tool for specifically reducing intestinal lipolysis.	INSERM, U476, F-13009 Marseille, France; Lab LAPHAL, F-13718 Allauch, France	Institut National de la Sante et de la Recherche Medicale (Inserm)	Chapus, C (corresponding author), INSERM, U476, 18 Ave Mozart, F-13009 Marseille, France.							ABOUSALHAM K, 1991, PROT ENG, V5, P105; Ayvazian L, 1996, PROTEIN ENG, V9, P707, DOI 10.1093/protein/9.8.707; BOUCHIER IA, 1968, LANCET, V1, P340; BOURNE Y, 1994, J MOL BIOL, V238, P709, DOI 10.1006/jmbi.1994.1331; CHAPUS C, 1981, EUR J BIOCHEM, V115, P99; GUERCIOLINI R, 1997, INT J OBES S3, V21, P12; HADVARY P, 1988, BIOCHEM J, V256, P357, DOI 10.1042/bj2560357; Hermoso J, 1997, EMBO J, V16, P5531, DOI 10.1093/emboj/16.18.5531; Hermoso J, 1996, J BIOL CHEM, V271, P18007, DOI 10.1074/jbc.271.30.18007; LAB LAPHAL, 1998, Patent No. 9830588; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LARSSON A, 1986, BIOCHIM BIOPHYS ACTA, V664, P538; LOMBARDO D, 1989, J MOL BIOL, V205, P259, DOI 10.1016/0022-2836(89)90380-X; MAHEGOUHIER N, 1988, BIOCHIM BIOPHYS ACTA, V229, P286; Pignol D, 2000, J BIOL CHEM, V275, P4220, DOI 10.1074/jbc.275.6.4220; RATHELOT J, 1981, BIOCHIMIE, V63, P227, DOI 10.1016/S0300-9084(81)80196-4; STERNBY B, 1981, COMP BIOCHEM PHYS B, V68, P15, DOI 10.1016/0305-0491(81)90173-5; VANTILBEURGH H, 1993, NATURE, V362, P814, DOI 10.1038/362814a0; VANTILBEURGH H, 1992, NATURE, V359, P159, DOI 10.1038/359159a0; Winer BJ, 1971, STAT PRINCIPLES EXPT; WINKLER FK, 1990, NATURE, V343, P771, DOI 10.1038/343771a0	21	14	14	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 27	2001	276	17					14014	14018		10.1074/jbc.M010328200	http://dx.doi.org/10.1074/jbc.M010328200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	426PB	11154696	hybrid			2022-12-25	WOS:000168356600070
J	Korschineck, I; Ziegler, S; Breuss, J; Lang, I; Lorenz, M; Kaun, C; Ambros, PF; Binder, BR				Korschineck, I; Ziegler, S; Breuss, J; Lang, I; Lorenz, M; Kaun, C; Ambros, PF; Binder, BR			Identification of a novel exon in apolipoprotein E receptor 2 leading to alternatively spliced mRNAs found in cells of the vascular wall but not in neuronal tissue	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DENSITY-LIPOPROTEIN RECEPTOR; PROTEIN ALPHA-2-MACROGLOBULIN RECEPTOR; ACTIVATOR INHIBITOR TYPE-1; PLASMINOGEN-ACTIVATOR; LDL RECEPTOR; ENDOTHELIAL-CELLS; MESSENGER-RNA; VLDL RECEPTOR; SH3 DOMAINS; CLONING	Novel members of the low density lipoprotein receptor family were identified in human endothelial and vascular smooth muscle cells utilizing a homology-cloning strategy. Four novel mRNA transcripts could be identified as isoforms of the apolipoprotein E receptor 2 (apoEr2): one form lacking three ligand binding repeats (nucleotides 497-883) but containing a novel ligand binding repeat adjacent to a unique cysteine-rich domain preceding the epidermal growth factor precursor domain of apoEr2, forms lacking the O -linked sugar domain, and forms containing a 59-amino acid deletion within the cytoplasmic tail. By fluorescence in situ hybridization for chromosome mapping, we could confirm that the novel alternative forms of apoEr2 are splice variants of transcripts from a single copy gene on chromosome 1p34. To analyze whether the different splice variants of apoEra mRNA are expressed in a splice variant-specific pattern, we concentrated on the central nervous system, where high expression of apoEra has been described originally. By means of splice variant-specific in situ hybridization, we could confirm that apoEra mRNA is abundantly expressed in brain tissue and, with exception of the newly identified ligand binding domain, all mRNA splice variants exhibited a similar expression pattern. The mRNA of the newly identified ligand binding domain, however, was expressed in brain only in cells of the vascular wall, confirming data from Northern blotting, where the mRNA of the newly identified ligand binding domain was found in several tissues but was absent in brain tissue.	Univ Vienna, Dept Vasc Biol & Thrombosis Res, A-1090 Vienna, Austria; Univ Vienna, Vienna Gen Hosp, Dept Cardiol, A-1090 Vienna, Austria; St Anna Childrens Hosp, Childrens Canc Res Inst, A-1090 Vienna, Austria	University of Vienna; University of Vienna; Saint Anna Children's Hospital	Binder, BR (corresponding author), Univ Vienna, Dept Vasc Biol & Thrombosis Res, Schwarzspanierstr 17, A-1090 Vienna, Austria.		Winter, Max P/E-8456-2011; Ambros, Peter/AAA-1266-2021; Kaun, Christoph/L-7543-2015	Ambros, Peter/0000-0002-5507-7211; Kaun, Christoph/0000-0003-3873-7246; Lang, Irene/0000-0003-0485-2692; breuss, johannes/0000-0003-1312-3387				BREUSS JM, 1993, J HISTOCHEM CYTOCHEM, V41, P1521, DOI 10.1177/41.10.8245410; BROWN MS, 1986, SCIENCE, V232, P34, DOI 10.1126/science.3513311; BU GJ, 1992, P NATL ACAD SCI USA, V89, P7427, DOI 10.1073/pnas.89.16.7427; BUJO H, 1995, J BIOL CHEM, V270, P23546, DOI 10.1074/jbc.270.40.23546; CHEN WJ, 1990, J BIOL CHEM, V265, P3116; Clatworthy AE, 1999, NEUROSCIENCE, V90, P903, DOI 10.1016/S0306-4522(98)00489-8; GIMBRONE MA, 1974, J CELL BIOL, V60, P673, DOI 10.1083/jcb.60.3.673; HAJJAR DP, 1992, FASEB J, V6, P2933, DOI 10.1096/fasebj.6.11.1644257; HEEGAARD CW, 1995, J BIOL CHEM, V270, P20855, DOI 10.1074/jbc.270.35.20855; HERZ J, 1988, EMBO J, V7, P4119, DOI 10.1002/j.1460-2075.1988.tb03306.x; Hjalm G, 1996, EUR J BIOCHEM, V239, P132, DOI 10.1111/j.1432-1033.1996.0132u.x; Kim DH, 1997, J BIOL CHEM, V272, P8498, DOI 10.1074/jbc.272.13.8498; Kim DH, 1996, J BIOL CHEM, V271, P8373, DOI 10.1074/jbc.271.14.8373; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KRIEGER M, 1994, ANNU REV BIOCHEM, V63, P601, DOI 10.1146/annurev.bi.63.070194.003125; LICHTER P, 1990, SCIENCE, V247, P64, DOI 10.1126/science.2294592; MARCHUK D, 1991, NUCLEIC ACIDS RES, V19, P1154, DOI 10.1093/nar/19.5.1154; MOESTRUP SK, 1992, CELL TISSUE RES, V269, P375, DOI 10.1007/BF00353892; Novak S, 1996, J BIOL CHEM, V271, P11732, DOI 10.1074/jbc.271.20.11732; NYKJAER A, 1992, J BIOL CHEM, V267, P14543; ORTH K, 1992, P NATL ACAD SCI USA, V89, P7422, DOI 10.1073/pnas.89.16.7422; RUSSELL DW, 1989, J BIOL CHEM, V264, P21682; SAITO A, 1994, P NATL ACAD SCI USA, V91, P9725, DOI 10.1073/pnas.91.21.9725; Sambrook J., 2002, MOL CLONING LAB MANU; Schweizer D, 1994, Methods Mol Biol, V29, P97; STRICKLAND DK, 1994, FRIBRINOLYSIS, V8, P208; TAKAHASHI S, 1992, P NATL ACAD SCI USA, V89, P9252, DOI 10.1073/pnas.89.19.9252; Trommsdorff M, 1999, CELL, V97, P689, DOI 10.1016/S0092-8674(00)80782-5; Wyne KL, 1996, ARTERIOSCL THROM VAS, V16, P407, DOI 10.1161/01.ATV.16.3.407; YAMAMOTO T, 1984, CELL, V39, P27, DOI 10.1016/0092-8674(84)90188-0; YU HT, 1994, CELL, V76, P933, DOI 10.1016/0092-8674(94)90367-0	31	31	33	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 20	2001	276	16					13192	13197		10.1074/jbc.M011795200	http://dx.doi.org/10.1074/jbc.M011795200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	423VN	11152697	hybrid			2022-12-25	WOS:000168198600101
J	van Rossenberg, SMW; Sliedregt, LAJM; Autar, R; Piperi, C; Van der Merwe, AP; van Berkel, TJC; Kuiper, J; Biessen, EAL				van Rossenberg, SMW; Sliedregt, LAJM; Autar, R; Piperi, C; Van der Merwe, AP; van Berkel, TJC; Kuiper, J; Biessen, EAL			A structure-function study of ligand recognition by CD22 beta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPATIC ASIALOGLYCOPROTEIN RECEPTOR; MYELIN-ASSOCIATED GLYCOPROTEIN; ADHESION MOLECULE CD22-BETA; ACID-BINDING-SITE; SIALYL-LEWIS-X; B-CELL ANTIGEN; IMMUNOGLOBULIN SUPERFAMILY; NATURAL LIGANDS; HIGH-AFFINITY; E-SELECTIN	B-cell-specific CD22 is a member of a group of cell adhesion molecules within the immunoglobulin superfamily that display binding to glycans with terminal sialic acid residues. Binding of endogenous ligands to CD22 triggers B-cell activation and proliferation. It is therefore conceivable that high affinity ligands for CD22 may be of value as inhibitors of B-cell activation in allergy and chronic inflammation. In this study, we aimed to delineate the structural requirements for ligand binding to CD22. A library of 20 mono-, di-, and trisaccharide analogs of the basic binding motif Neu5Ac(alpha2,6)Lac was synthesized and screened for affinity for CD22 beta, In general, CD22 ligand recognition appeared to be rather tolerant with respect to structural modifications of the anomeric sugar on a mono-, di-, and trisaccharide level, although affinity was increased by the presence of a nitro aromatic group at C-2, The most potent monovalent ligand, Neu5Ac-4-nitrobenzoyl-Glc, was selected to generate multivalent ligands based on either a glutamate or Tris cluster core. All multivalent ligands displayed at least a 10-fold increased affinity for CD22 compared with the corresponding monovalent glycoside, Interestingly, a maximal gain in affinity was already obtained for bivalent ligands, regardless of the terminal glycoside, A trivalent Tris-based cluster of Neu5Ac-4-nitrobenzoyl-Glc displayed a 300-fold higher affinity compared with the basic binding motif, which makes it, to our knowledge, the most potent antagonist for CD22 yet synthesized. As our in vitro fluorescence-activated cell sorting studies demonstrated efficient cellular uptake of a CD22 substrate, the most potent ligand in this study may hold promise as a homing device for immunomodulatory compounds and cytostatics.	Leiden Univ, Sylvius Lab, Leiden Amsterdam Ctr Drug Res, Div Biopharmaceut, NL-2300 RA Leiden, Netherlands; Univ Oxford, Sir William Dunn Sch Pathol, Oxford OX1 3RE, England	Leiden University; Leiden University - Excl LUMC; University of Oxford	van Rossenberg, SMW (corresponding author), Leiden Univ, Sylvius Lab, Leiden Amsterdam Ctr Drug Res, Div Biopharmaceut, POB 9503, NL-2300 RA Leiden, Netherlands.		Van Berkel, Theo/ABD-7677-2021; Piperi, Christina/AAF-2009-2020	Piperi, Christina/0000-0002-2701-0618				ADLER P, 1995, J BIOL CHEM, V270, P5164, DOI 10.1074/jbc.270.10.5164; BIESSEN EAL, 1995, J MED CHEM, V38, P1846, DOI 10.1021/jm00011a003; BIESSEN EAL, 1995, J MED CHEM, V38, P1538, DOI 10.1021/jm00009a014; Biessen EAL, 1996, J BIOL CHEM, V271, P28024, DOI 10.1074/jbc.271.45.28024; Collins BE, 1997, J BIOL CHEM, V272, P16889, DOI 10.1074/jbc.272.27.16889; Crocker P R, 1998, Glycobiology, V8, pv; Crocker PR, 1997, GLYCOCONJUGATE J, V14, P601, DOI 10.1023/A:1018588526788; Doody GM, 1996, CURR OPIN IMMUNOL, V8, P378, DOI 10.1016/S0952-7915(96)80128-2; Hayashi M, 1996, J ORG CHEM, V61, P2938, DOI 10.1021/jo960125f; Kelm S, 1998, EUR J BIOCHEM, V255, P663, DOI 10.1046/j.1432-1327.1998.2550663.x; KELM S, 1994, GLYCOCONJUGATE J, V11, P576, DOI 10.1007/BF00731309; Kelm S, 1996, GLYCOCONJUGATE J, V13, P913, DOI 10.1007/BF01053186; KELM S, 1994, CURR BIOL, V4, P965, DOI 10.1016/S0960-9822(00)00220-7; LAW CL, 1994, IMMUNOL TODAY, V15, P442, DOI 10.1016/0167-5699(94)90275-5; LAW CL, 1995, J IMMUNOL, V155, P3368; Miyauchi H, 1997, BIOORG MED CHEM LETT, V7, P989, DOI 10.1016/S0960-894X(97)00156-X; NATH D, 1995, J BIOL CHEM, V270, P26184, DOI 10.1074/jbc.270.44.26184; NELSON RM, 1993, J CLIN INVEST, V91, P1157, DOI 10.1172/JCI116275; NIKRAD PV, 1993, CARBOHYD RES, V250, P145, DOI 10.1016/0008-6215(93)84162-Y; PEZZUTTO A, 1988, J IMMUNOL, V140, P1791; POWELL LD, 1993, J BIOL CHEM, V268, P7019; POWELL LD, 1995, J BIOL CHEM, V270, P7523, DOI 10.1074/jbc.270.13.7523; POWELL LD, 1994, J BIOL CHEM, V269, P10628; Ramphal JY, 1996, J MED CHEM, V39, P1357, DOI 10.1021/jm9600611; SGROI D, 1993, J BIOL CHEM, V268, P7011; Simanek EE, 1998, CHEM REV, V98, P833, DOI 10.1021/cr940226i; SJOBERG ER, 1994, J CELL BIOL, V126, P549, DOI 10.1083/jcb.126.2.549; Sliedregt LAJM, 2001, BIOORGAN MED CHEM, V9, P85, DOI 10.1016/S0968-0896(00)00224-8; Sliedregt LAJM, 1999, J MED CHEM, V42, P609, DOI 10.1021/jm981078h; STAMENKOVIC I, 1990, NATURE, V345, P74, DOI 10.1038/345074a0; Strenge K, 1998, EUR J BIOCHEM, V258, P677, DOI 10.1046/j.1432-1327.1998.2580677.x; Tedder TF, 1997, ANNU REV IMMUNOL, V15, P481, DOI 10.1146/annurev.immunol.15.1.481; TOOGOOD PL, 1991, J MED CHEM, V34, P3140; vanderMerwe PA, 1996, J BIOL CHEM, V271, P9273, DOI 10.1074/jbc.271.16.9273	34	17	20	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 20	2001	276	16					12967	12973		10.1074/jbc.M009276200	http://dx.doi.org/10.1074/jbc.M009276200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	423VN	11152460	hybrid			2022-12-25	WOS:000168198600073
J	Andrei-Selmer, C; Knuppel, A; Satyanarayana, C; Heese, C; Schu, PV				Andrei-Selmer, C; Knuppel, A; Satyanarayana, C; Heese, C; Schu, PV			A new class of mutants deficient in dodecamerization of aminopeptidase 1 and vacuolar transport	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN TARGETING PATHWAY; SACCHAROMYCES-CEREVISIAE; YEAST; CYTOPLASM; AUTOPHAGY; DEGRADATION; MECHANISM; MEMBRANE; CYTOSOL; ENZYME	Vacuolar aminopeptidase 1 is transported to the vacuole by cytoplasmic double-membrane vesicles, the nonclassic Cvt pathway The cytosolic protein dodecamerizes and is enclosed in a double-membrane vesicle, which is transported to and fuses with the vacuole releasing a single-membrane autophagic body into the vacuolar lumen. This is degraded and the precursor sequence of aminopeptidase 1 is removed. This pathway resembles autophagy, and most proteins identified to function in the Cvt pathway are also required for autophagy and vice versa. The cytosolic precursor protein and the matured vacuolar protein form a homododecameric complex, and only this complex has enzymatic activity. We developed a new genetic screen to isolate mutants in the biogenesis of vacuolar aminopeptidase 1 based on its enzymatic activity. The sensitivity of this assay made it possible for us to search for mutants under conditions where autophagy is down-regulated, and me describe two new mutants defective in the biogenesis pathway of vacuolar aminopeptidase 1. Mutants are defective in dodecamerization of pApe1p and in Cvt vesicle formation. Complex assembly and transport vesicle formation appear to be linked processes. This mechanism can control the potentially harmful cytoplasmic proteolytic activity and could be the driving force for this nonclassic mechanism of vacuolar enzyme transport.	Univ Gottingen, Dept Biochem 2, Zentrum Biochem & Mol Zellbiol, D-37073 Gottingen, Germany	University of Gottingen	Schu, PV (corresponding author), Univ Gottingen, Dept Biochem 2, Zentrum Biochem & Mol Zellbiol, Heinrich Duker Weg 12, D-37073 Gottingen, Germany.							AMMERER G, 1986, MOL CELL BIOL, V6, P2490, DOI 10.1128/MCB.6.7.2490; ANDREISELMER C, 1999, THESIS U GOTTINGEN; Baba M, 1997, J CELL BIOL, V139, P1687, DOI 10.1083/jcb.139.7.1687; Baba M, 1995, CELL STRUCT FUNCT, V20, P465, DOI 10.1247/csf.20.465; CHANG YH, 1989, J BIOL CHEM, V264, P6979; GUTHRIE C, 1991, METHOD ENZYMOL, V194, P77; HARDING TM, 1995, J CELL BIOL, V131, P591, DOI 10.1083/jcb.131.3.591; Harding TM, 1996, J BIOL CHEM, V271, P17621, DOI 10.1074/jbc.271.30.17621; Hoffman M, 1996, GENETICS, V143, P1555; Kim J, 1997, J CELL BIOL, V137, P609, DOI 10.1083/jcb.137.3.609; KLIONSKY DJ, 1992, J CELL BIOL, V119, P287, DOI 10.1083/jcb.119.2.287; Martinez E, 1997, J MOL BIOL, V267, P1124, DOI 10.1006/jmbi.1997.0925; Martinez E, 1999, MOL MICROBIOL, V33, P52, DOI 10.1046/j.1365-2958.1999.01446.x; METZ G, 1977, Z NATURFORSCH C, V32, P929; Oda MN, 1996, J CELL BIOL, V132, P999, DOI 10.1083/jcb.132.6.999; Philips J, 1997, J CELL BIOL, V138, P961, DOI 10.1083/jcb.138.5.961; Satyanarayana C, 2000, FEBS LETT, V470, P232, DOI 10.1016/S0014-5793(00)01324-7; SCHU P, 1991, EUR J BIOCHEM, V197, P1, DOI 10.1111/j.1432-1033.1991.tb15874.x; Scott SV, 1996, P NATL ACAD SCI USA, V93, P12304, DOI 10.1073/pnas.93.22.12304; Scott SV, 1997, J CELL BIOL, V138, P37, DOI 10.1083/jcb.138.1.37; Scott SV, 1998, CURR OPIN CELL BIOL, V10, P523, DOI 10.1016/S0955-0674(98)80068-9; SEGUIREAL B, 1995, EMBO J, V14, P5476, DOI 10.1002/j.1460-2075.1995.tb00234.x; TAKESHIGE K, 1992, J CELL BIOL, V119, P301, DOI 10.1083/jcb.119.2.301; TEICHERT U, 1989, J BIOL CHEM, V264, P16037; THUMM M, 1994, FEBS LETT, V349, P275, DOI 10.1016/0014-5793(94)00672-5; TRUMBLY RJ, 1983, J BACTERIOL, V156, P36, DOI 10.1128/JB.156.1.36-48.1983; TSUKADA M, 1993, FEBS LETT, V333, P169, DOI 10.1016/0014-5793(93)80398-E; YOSHIHISA T, 1990, J BIOL CHEM, V265, P22418	28	9	10	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 13	2001	276	15					11606	11614		10.1074/jbc.M003846200	http://dx.doi.org/10.1074/jbc.M003846200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	421UK	11152450	hybrid			2022-12-25	WOS:000168081800027
J	Ginger, ML; Chance, ML; Sadler, IH; Goad, LJ				Ginger, ML; Chance, ML; Sadler, IH; Goad, LJ			The biosynthetic incorporation of the intact leucine skeleton into sterol by the trypanosomatid Leishmania mexicana	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FATTY-ACIDS; 3-HYDROXY-3-METHYLGLUTARYL-COA REDUCTASE; SUBCELLULAR-LOCALIZATION; INTERMEDIARY METABOLISM; ENERGY-METABOLISM; AXENIC CULTURE; CARBON-SOURCES; CRUZI; PROMASTIGOTES; KETOCONAZOLE	The amino acid leucine is efficiently used by the trypanosomatid Leishmania mexicana for sterol biosynthesis. The incubation of [2-C-13]leucine with L. mexicana promastigotes in the presence of ketoconazole gave 14 alpha -methylergosta-8,24(24(1))-3 beta -ol as the major sterol, which was shown by mass spectrometry to contain up to six atoms of C-13 per molecule, C-13 NMR analysis of the 14 alpha -methylergosta-8,24(24(1))-3 beta -ol revealed that it was labeled in only six positions: C-2, C-6, C-11, C-12, C-16, and C-23, This established that the leucine skeleton is incorporated intact into the isoprenoid pathway leading to sterol; it is not converted first to acetyl CoA, as in animals and plants, with utilization of the acetyl-CoA to regenerate 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA). An inhibitor of HMG-CoA synthase (L-659,699) blocked the incorporation of [1-C-14]acetate into sterol but had no inhibitory effect on (U-C-14]leucine incorporation. The HMG-CoA reductase inhibitor lovastatin inhibited promastigote growth and [U-C-14]leucine incorporation into sterol, The addition of unlabeled mevalonic acid (MVA) overcame the lovastatin inhibition of growth and also diluted the incorporation of [1-C-14]leucine into sterol. These results are compatible with two routes by which the leucine skeleton may enter intact into the isoprenoid pathway. The catabolism of leucine could generate HMG-CoA that is then directly reduced to MVA for incorporation into sterol, Alternatively, a compound produced as an intermediate in leucine breakdown to HMG-CoA (e.g, dimethylcrotonyl-CoA) could be directly reduced to produce an isoprene alcohol followed by phosphorylation to enter the isoprenoid pathway post-MVA.	Univ Liverpool, Sch Biol Sci, Liverpool L69 7ZB, Merseyside, England; Univ Liverpool, Liverpool Sch Trop Med, Liverpool L3 5QA, Merseyside, England; Univ Edinburgh, Dept Chem, Edinburgh EH9 3JJ, Midlothian, Scotland	University of Liverpool; Liverpool School of Tropical Medicine; University of Liverpool; University of Edinburgh	Goad, LJ (corresponding author), Univ Liverpool, Sch Biol Sci, Life Sci Bldg,Crown St, Liverpool L69 7ZB, Merseyside, England.	ljgo@liv.ac.uk		Ginger, Michael/0000-0002-9643-8482				ANASTASIS P, 1985, J CHEM SOC CHEM COMM, P148, DOI 10.1039/c39850000148; ANASTASIS P, 1987, J CHEM SOC PERK T 1, P2427, DOI 10.1039/p19870002427; Anderson MD, 1998, PLANT PHYSIOL, V118, P1127, DOI 10.1104/pp.118.4.1127; BATES PA, 1993, PARASITOL TODAY, V9, P143, DOI 10.1016/0169-4758(93)90181-E; BEACH DH, 1986, BIOCHEM BIOPH RES CO, V136, P851, DOI 10.1016/0006-291X(86)90410-9; BERENS RL, 1976, J PARASITOL, V62, P360, DOI 10.2307/3279142; BERMAN JD, 1984, MOL BIOCHEM PARASIT, V12, P1, DOI 10.1016/0166-6851(84)90039-2; Bloch K, 1944, J BIOL CHEM, V155, P255; BLUM JJ, 1993, PARASITOL TODAY, V9, P118, DOI 10.1016/0169-4758(93)90168-F; BLUM JJ, 1991, J PROTOZOOL, V38, P527, DOI 10.1111/j.1550-7408.1991.tb06075.x; BLUM JJ, 1994, J BIOENERG BIOMEMBR, V26, P147, DOI 10.1007/BF00763063; Chance Michael L., 1997, P163; CHICHESTER CO, 1959, J BIOL CHEM, V234, P598; Concepcion JL, 1998, ARCH BIOCHEM BIOPHYS, V352, P114, DOI 10.1006/abbi.1998.0577; COPPENS I, 1995, MOL BIOCHEM PARASIT, V69, P29, DOI 10.1016/0166-6851(94)00192-P; Croft Simon L., 1997, P245; Domenech CE, 1996, EUR J BIOCHEM, V239, P720, DOI 10.1111/j.1432-1033.1996.0720u.x; EDMOND J, 1974, J BIOL CHEM, V249, P66; Ginger ML, 1999, BIOCHEM J, V342, P397, DOI 10.1042/0264-6021:3420397; Ginger ML, 2000, EUR J BIOCHEM, V267, P2555, DOI 10.1046/j.1432-1327.2000.01261.x; GOAD LJ, 1989, MOL BIOCHEM PARASIT, V32, P179, DOI 10.1016/0166-6851(89)90069-8; GOAD LJ, 1985, MOL BIOCHEM PARASIT, V15, P257, DOI 10.1016/0166-6851(85)90089-1; GOAD LJ, 1985, BIOCHEM PHARMACOL, V34, P3785, DOI 10.1016/0006-2952(85)90250-3; Goad LJ., 1997, ANAL STEROLS; Gonzalez-Pacanowska D., 1999, Memorias do Instituto Oswaldo Cruz, V94, P18; GREENSPAN MD, 1987, P NATL ACAD SCI USA, V84, P7488, DOI 10.1073/pnas.84.21.7488; GREENSPAN MD, 1993, BIOCHEM J, V289, P889, DOI 10.1042/bj2890889; Haughan P.A., 1991, P312; HAUGHAN PA, 1992, BIOCHEM PHARMACOL, V44, P2199, DOI 10.1016/0006-2952(92)90347-L; HAUGHAN PA, 1995, BIOCHEM J, V308, P31, DOI 10.1042/bj3080031; Hegardt FG, 1999, BIOCHEM J, V338, P569, DOI 10.1042/0264-6021:3380569; Heise N, 2000, Z NATURFORSCH C, V55, P473; Hida A, 1998, J BIOCHEM-TOKYO, V124, P648, DOI 10.1093/oxfordjournals.jbchem.a022161; MIETTINEN TA, 1971, ANN MED EXP BIOL FEN, V49, P20; Montalvetti A, 2000, BIOCHEM J, V349, P27, DOI 10.1042/0264-6021:3490027; MONTAMAT EE, 1987, MOL BIOCHEM PARASIT, V22, P185, DOI 10.1016/0166-6851(87)90049-1; PenaDiaz J, 1997, BIOCHEM J, V324, P619, DOI 10.1042/bj3240619; RIGHETTI M, 1976, J BIOL CHEM, V251, P2716; ROSENTHA.J, 1974, AM J PHYSIOL, V226, P411, DOI 10.1152/ajplegacy.1974.226.2.411; STEIGER RF, 1977, T ROY SOC TROP MED H, V71, P441, DOI 10.1016/0035-9203(77)90049-9; STILLWAY LW, 1977, LIPIDS, V12, P1012, DOI 10.1007/BF02533327; SUGA T, 1980, PHYTOCHEMISTRY, V19, P67, DOI 10.1016/0031-9422(80)85014-X; Tielens AGM, 1998, PARASITOL TODAY, V14, P265, DOI 10.1016/S0169-4758(98)01263-0; URBINA JA, 1993, ANTIMICROB AGENTS CH, V37, P580, DOI 10.1128/AAC.37.3.580; Urbina JA, 1996, SCIENCE, V273, P969, DOI 10.1126/science.273.5277.969; URBINA JA, 1994, PARASITOL TODAY, V10, P107, DOI 10.1016/0169-4758(94)90010-8; Van Hellemond JJ, 1998, P NATL ACAD SCI USA, V95, P3036, DOI 10.1073/pnas.95.6.3036; VANDENBOSSCHE H, 1993, MICROBIOL EUR    NOV, P20; VANDENBOSSCHE H, 1988, STEROL BIOSYNTHESIS, P79; WEINSTOCK SB, 1984, J BIOL CHEM, V259, P8939; Wilson WK, 1996, J LIPID RES, V37, P1529	51	57	60	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 13	2001	276	15					11674	11682		10.1074/jbc.M006850200	http://dx.doi.org/10.1074/jbc.M006850200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	421UK	11148203	hybrid			2022-12-25	WOS:000168081800035
J	Sato, Y; Takahashi, M; Shibukawa, Y; Jain, SK; Hamaoka, R; Miyagawa, J; Yaginuma, Y; Honke, K; Ishikawa, M; Taniguchi, N				Sato, Y; Takahashi, M; Shibukawa, Y; Jain, SK; Hamaoka, R; Miyagawa, J; Yaginuma, Y; Honke, K; Ishikawa, M; Taniguchi, N			Overexpression of N-acetylglucosaminyltransferase III enhances the epidermal growth factor-induced phosphorylation of ERK in HeLaS3 cells by up-regulation of the internalization rate of the receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CLATHRIN-MEDIATED ENDOCYTOSIS; ACTIVATED PROTEIN-KINASE; HIGH-AFFINITY BINDING; SIGNAL-TRANSDUCTION; EGF RECEPTOR; GENE TRANSFECTION; GLYCOSYLATION; DOMAIN; OLIGOSACCHARIDES; PROGRESSION	N-Acetylglucosaminyltransferase III (GnT-III) is a key enzyme that inhibits the extension of N-glycans by introducing a bisecting N-acetylglucosamine residue. In this study we investigated the effect of GnT-III on epidermal growth factor (EGF) signaling in HeLaS3 cells. Although the binding of EGF to the epidermal growth factor receptor (EGFR) was decreased in GnT-III transfectants to a level of about 60% of control cells, the EGF-induced activation of extracellular signal-regulated kinase (ERR) in GnT-III transfectants was enhanced to similar to1.4-fold that of the control cells. A binding analysis revealed that only low affinity binding of EGF was decreased in the GnT-III transfectants, whereas high affinity binding, which is considered to be responsible for the downstream signaling, was not altered, EGF-induced autophosphorylation and dimerization of the EGFR in the GnT-III transfectants were the same levels as found in the controls. The internalization rate of EGFR was, however, enhanced in the GnT-III transfectants as judged by the uptake of I-125-EGF and Oregon Green-labeled EGF. Then the EGFR internalization was delayed by dansylcadaverine, the up-regulation of ERK phosphorylation in GnT-III transfectants was completely suppressed to the same level as control cells. These results suggest that GnT-III overexpression in HeLaS3 cells resulted in an enhancement of EGF-induced ERR phosphorylation at least in part by the upregulation of the endocytosis of EGFR.	Osaka Univ, Grad Sch Med, Dept Biochem, Suita, Osaka 5650871, Japan; Asahikawa Med Coll, Dept Obstet & Gynecol, Asahikawa, Hokkaido 0788510, Japan; Osaka Univ, Grad Sch Med, Dept Internal Med & Mol Sci, Suita, Osaka 5650871, Japan	Osaka University; Asahikawa Medical College; Osaka University	Taniguchi, N (corresponding author), Osaka Univ, Grad Sch Med, Dept Biochem, B1,2-2 Yamadaoka, Suita, Osaka 5650871, Japan.		Taniguchi, Naoyuki/I-4182-2014; Taniguchi, Naoyuki/A-7086-2016; Takahashi, Motoko/I-3154-2013	Taniguchi, Naoyuki/0000-0001-5889-5968; Takahashi, Motoko/0000-0002-2112-6142				Altschuler Y, 2000, MOL BIOL CELL, V11, P819, DOI 10.1091/mbc.11.3.819; BELLOT F, 1990, J CELL BIOL, V110, P491, DOI 10.1083/jcb.110.2.491; Bhaumik M, 1998, CANCER RES, V58, P2881; Ceresa BP, 2000, CURR OPIN CELL BIOL, V12, P204, DOI 10.1016/S0955-0674(99)00077-0; Ceresa BP, 1998, MOL CELL BIOL, V18, P3862, DOI 10.1128/MCB.18.7.3862; CHEN WS, 1989, CELL, V59, P33, DOI 10.1016/0092-8674(89)90867-2; Chow JC, 1998, J BIOL CHEM, V273, P4672, DOI 10.1074/jbc.273.8.4672; Daaka Y, 1998, J BIOL CHEM, V273, P685, DOI 10.1074/jbc.273.2.685; DEFIZE LHK, 1989, J CELL BIOL, V109, P2495, DOI 10.1083/jcb.109.5.2495; Della Rocca GJ, 1999, J BIOL CHEM, V274, P4749, DOI 10.1074/jbc.274.8.4749; Dennis JW, 1999, BBA-GEN SUBJECTS, V1473, P21, DOI 10.1016/S0304-4165(99)00167-1; Di Fiore PP, 1999, CURR OPIN CELL BIOL, V11, P483, DOI 10.1016/S0955-0674(99)80069-6; DIGUGLIELMO GM, 1994, EMBO J, V13, P4269, DOI 10.1002/j.1460-2075.1994.tb06747.x; DWEK RA, 1995, SCIENCE, V269, P1234, DOI 10.1126/science.7652569; GAMOU S, 1988, J BIOCHEM-TOKYO, V104, P388, DOI 10.1093/oxfordjournals.jbchem.a122478; GOTOH N, 1992, BIOCHEM BIOPH RES CO, V186, P768, DOI 10.1016/0006-291X(92)90812-Y; HENEGOUWEN PMP, 1992, EXP CELL RES, V199, P90; Hobert ME, 1997, J BIOL CHEM, V272, P32901, DOI 10.1074/jbc.272.52.32901; Ihara Y, 1997, J BIOL CHEM, V272, P9629; KING AC, 1982, J BIOL CHEM, V257, P3053; LANDRETH GE, 1985, J CELL BIOL, V101, P1341, DOI 10.1083/jcb.101.4.1341; LIVNEH E, 1986, J BIOL CHEM, V261, P2490; MIYOSHI E, 1995, J BIOL CHEM, V270, P28311; NARASIMHAN S, 1982, J BIOL CHEM, V257, P235; Nesterov A, 1999, EMBO J, V18, P2489, DOI 10.1093/emboj/18.9.2489; NISHIKAWA A, 1992, J BIOL CHEM, V267, P18199; NISHIKAWA A, 1988, ANAL BIOCHEM, V170, P349, DOI 10.1016/0003-2697(88)90641-0; Oksvold MP, 2000, J HISTOCHEM CYTOCHEM, V48, P21, DOI 10.1177/002215540004800103; Rebbaa A, 1997, J BIOL CHEM, V272, P9275; Ringerike T, 1998, J BIOL CHEM, V273, P16639, DOI 10.1074/jbc.273.27.16639; ROY LM, 1989, J CELL PHYSIOL, V140, P295, DOI 10.1002/jcp.1041400215; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SCHACHTER H, 1986, BIOCHEM CELL BIOL, V64, P163, DOI 10.1139/o86-026; Sheng Y, 1997, INT J CANCER, V73, P850, DOI 10.1002/(SICI)1097-0215(19971210)73:6<850::AID-IJC15>3.0.CO;2-8; SODERQUIST AM, 1984, J BIOL CHEM, V259, P2586; SORKIN A, 1993, ONCOGENE, V8, P3021; Sorkina T, 1999, J CELL SCI, V112, P317; Taniguchi N, 1999, BBA-MOL BASIS DIS, V1455, P287, DOI 10.1016/S0925-4439(99)00066-6; TANIGUCHI N, 1995, GLYCOCONJUGATE J, V12, P733, DOI 10.1007/BF00731232; Tong XK, 2000, J BIOL CHEM, V275, P29894, DOI 10.1074/jbc.M004096200; Tsuda T, 2000, J BIOL CHEM, V275, P21988, DOI 10.1074/jbc.M003400200; VanderHeyden MAG, 1997, FEBS LETT, V410, P265, DOI 10.1016/S0014-5793(97)00599-1; WIEGANT FAC, 1986, J CELL BIOL, V103, P87, DOI 10.1083/jcb.103.1.87; WYSS DF, 1995, SCIENCE, V269, P1273, DOI 10.1126/science.7544493; Yang XP, 2000, CANCER RES, V60, P3313; Yoshimura M, 1996, CANCER RES, V56, P412; Yoshimura M, 1996, J BIOL CHEM, V271, P13811, DOI 10.1074/jbc.271.23.13811; YOSHIMURA M, 1995, P NATL ACAD SCI USA, V92, P8754, DOI 10.1073/pnas.92.19.8754	48	77	79	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 13	2001	276	15					11956	11962		10.1074/jbc.M008551200	http://dx.doi.org/10.1074/jbc.M008551200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	421UK	11134020	hybrid			2022-12-25	WOS:000168081800070
J	Kang, HG; Evers, MR; Xia, GQ; Baenziger, U; Schachner, M				Kang, HG; Evers, MR; Xia, GQ; Baenziger, U; Schachner, M			Molecular cloning and expression of an N-acetylgalactosamine-4-O-sulfotransferase that transfers sulfate to terminal and non-terminal beta 1,4-linked N-acetylgalactosamine	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ASPARAGINE-LINKED OLIGOSACCHARIDES; SIALYLATED OLIGOSACCHARIDES; CRYSTAL-STRUCTURE; HEPARAN-SULFATE; MONOCLONAL IGM; SULFOTRANSFERASE; CHONDROITIN; LUTROPIN; BOVINE; RECOGNITION	We have identified and characterized an N-acetyl-galaetosamine-4-O-sulfotransferase designated GalNAc-4-ST2 (GenBank(TM) accession number AF332472) based on its homology to HNK-1 sulfotransferase (HNK-1 ST). The cDNA predicts an open reading frame encoding a type II membrane protein of 443 amino acids with a 12-amino acid cytoplasmic domain, a 23-amino acid transmembrane domain, and a 408-amino acid luminal domain containing four potential N-linked glycosylation sites. GalNAc-4-ST2 displays a high degree of amino acid sequence identity with GalNAc-4-ST1 (46%), HNK-1 ST (23%), chondroitin 4-O-sulfotransferase-1 (C4ST-1) (27%), and chondroitin 4-O-sulfotransferase-2 (C4ST-2) (24%), GalNAc-4-ST2 transfers sulfate to the C-4 hydroxyl of terminal beta1,4-linked GalNAc in the sequence GalNAc beta1,4GlcNAc beta -R found on N-linked oligosaccharides and nonterminal beta1,4-linked GalNAc in chondroitin and dermatan. The translated region of GalNAc-4-ST2 is encoded by five exons located on human chromosome 18q11.2, Northern blot analysis reveals a 2.1-kilobase transcript. GalNAc-4-ST2 message is most highly expressed in trachea and to a lesser extent in heart, liver, pancreas, salivary gland, and testis. The I.M.A.G.E. cDNA clone 49547 contains a putative GalNAc-4-ST2 splice form with an open reading frame encoding a protein of 358 amino acids that lacks the transmembrane domain and the stem region. This form of GalNAc-4-ST2 is not retained by transfected cells and is active against chondroitin but not terminal beta1,4-linked GalNAc. Thus, as with GalNAc-4-ST1, sequences N-terminal to the catalytic domain contribute to the specificity of GalNAc-4-ST2 toward terminal beta1,4-linked GalNAc.	Univ Hamburg, Zentrum Mol Neurobiol, D-20246 Hamburg, Germany; Washington Univ, Sch Med, Dept Pathol, St Louis, MO 63110 USA	University of Hamburg; University Medical Center Hamburg-Eppendorf; Washington University (WUSTL)	Schachner, M (corresponding author), Univ Hamburg, Zentrum Mol Neurobiol, Martinistr 52, D-20246 Hamburg, Germany.	melitta.schachner@zmnh.uni-hamburg.de	Xia, Guoqing/C-2365-2015	Xia, Guoqing/0000-0003-4492-9156	NIDDK NIH HHS [R01-DK41738] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK041738] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; BAENZIGER JU, 1992, P NATL ACAD SCI USA, V89, P334, DOI 10.1073/pnas.89.1.334; BAENZIGER JU, 1991, BIOL CARBOHYDRATES, V3, P1; BAJT ML, 1990, J NEUROSCI RES, V27, P276, DOI 10.1002/jnr.490270306; Bakker H, 1997, J BIOL CHEM, V272, P29942, DOI 10.1074/jbc.272.47.29942; CHOU KH, 1985, BIOCHEM BIOPH RES CO, V128, P383, DOI 10.1016/0006-291X(85)91690-0; COLES P, 1997, CAMB LECT N PHYS, V7, P1; FAISSNER A, 1994, J CELL BIOL, V126, P783, DOI 10.1083/jcb.126.3.783; FIETE D, 1991, CELL, V67, P1103, DOI 10.1016/0092-8674(91)90287-9; GREEN ED, 1988, J BIOL CHEM, V263, P25; GREEN ED, 1988, J BIOL CHEM, V263, P36; GREEN ED, 1986, ANAL BIOCHEM, V158, P42, DOI 10.1016/0003-2697(86)90585-3; Hall T.A., 1999, NUCL ACIDS S SERIES, V41, P95, DOI [DOI 10.1021/BK-1999-0734.CH008, citeulike-article-id:691774, 10.12691/ajmr-6-4-3]; Hiraoka N, 2000, J BIOL CHEM, V275, P20188, DOI 10.1074/jbc.M002443200; Hooper LV, 1996, FASEB J, V10, P1137, DOI 10.1096/fasebj.10.10.8751716; HOOPER LV, 1995, J BIOL CHEM, V270, P5985, DOI 10.1074/jbc.270.11.5985; HOOPER LV, 1995, J BIOL CHEM, V270, P16327, DOI 10.1074/jbc.270.27.16327; JUNGALWALA FB, 1994, NEUROCHEM RES, V19, P945, DOI 10.1007/BF00968704; Kakuta Y, 1999, J BIOL CHEM, V274, P10673, DOI 10.1074/jbc.274.16.10673; Kakuta Y, 1998, TRENDS BIOCHEM SCI, V23, P129, DOI 10.1016/S0968-0004(98)01182-7; Kakuta Y, 1997, NAT STRUCT BIOL, V4, P904, DOI 10.1038/nsb1197-904; KOZAK M, 1978, CELL, V15, P1109, DOI 10.1016/0092-8674(78)90039-9; KRUSE J, 1984, NATURE, V311, P153, DOI 10.1038/311153a0; Lennon G, 1996, GENOMICS, V33, P151, DOI 10.1006/geno.1996.0177; MACCARANA M, 1993, J BIOL CHEM, V268, P23898; NAGASAWA K, 1979, J BIOCHEM-TOKYO, V86, P1323, DOI 10.1093/oxfordjournals.jbchem.a132648; Okuda T, 2000, J BIOL CHEM, V275, P40605, DOI 10.1074/jbc.M007983200; Ong E, 1998, J BIOL CHEM, V273, P5190, DOI 10.1074/jbc.273.9.5190; Roseman DS, 2000, P NATL ACAD SCI USA, V97, P9949, DOI 10.1073/pnas.170184597; Rosen SD, 1996, CURR BIOL, V6, P261, DOI 10.1016/S0960-9822(02)00473-6; Saghatelyan AK, 2000, EUR J NEUROSCI, V12, P3331, DOI 10.1046/j.1460-9568.2000.00216.x; Salamov AA, 2000, GENOME RES, V10, P516, DOI 10.1101/gr.10.4.516; SCHACHNER M, 1995, TRENDS NEUROSCI, V18, P183, DOI 10.1016/0166-2236(95)93899-9; SKELTON TP, 1991, J BIOL CHEM, V266, P17142; Sonnhammer E L, 1998, Proc Int Conf Intell Syst Mol Biol, V6, P175; STECK AJ, 1983, NEUROLOGY, V33, P19, DOI 10.1212/WNL.33.1.19; VLODAVSKY I, 1991, TRENDS BIOCHEM SCI, V16, P268, DOI 10.1016/0968-0004(91)90102-2; Vlodavsky I, 1996, CANCER METAST REV, V15, P177, DOI 10.1007/BF00437470; Voshol H, 1996, J BIOL CHEM, V271, P22957, DOI 10.1074/jbc.271.38.22957; Xia GQ, 2000, J BIOL CHEM, V275, P38402, DOI 10.1074/jbc.M007821200; Yamauchi S, 2000, J BIOL CHEM, V275, P8975, DOI 10.1074/jbc.275.12.8975	41	33	34	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 6	2001	276	14					10861	10869		10.1074/jbc.M011560200	http://dx.doi.org/10.1074/jbc.M011560200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	420AC	11139592	Green Published, hybrid			2022-12-25	WOS:000167980900042
J	Bonacchi, A; Romagnani, P; Romanelli, RG; Efsen, E; Annunziato, F; Lasagni, L; Francalanci, M; Serio, M; Laffi, G; Pinzani, M; Gentilini, P; Marra, F				Bonacchi, A; Romagnani, P; Romanelli, RG; Efsen, E; Annunziato, F; Lasagni, L; Francalanci, M; Serio, M; Laffi, G; Pinzani, M; Gentilini, P; Marra, F			Signal transduction by the chemokine receptor CXCR3 - Activation of Ras/ERK, Src, and phosphatidylinositol 3-kinase/Akt controls cell migration and proliferation in human vascular pericytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPATIC STELLATE CELLS; PROTEIN-COUPLED RECEPTORS; MONOCYTE CHEMOATTRACTANT PROTEIN-1; INTERFERON-INDUCIBLE PROTEIN-10; GROWTH-FACTOR RECEPTOR; SMOOTH-MUSCLE CELLS; FAT-STORING CELLS; TYROSINE KINASE; T-LYMPHOCYTES; CHEMOTACTIC PROTEIN-1	Hepatic stellate cells (HSC) and glomerular mesangial cells (MC) are tissue-specific pericytes involved in tissue repair, a process that is regulated by members of the chemokine family. In this study, we explored the signal transduction pathways activated by the chemokine receptor CXCR3 in vascular pericytes, In HSC, interaction of CXCR3 with its ligands resulted in increased chemotaxis and activation of the Ras/ERK cascade. Activation of CXCR3 also stimulated Src phosphorylation and kinase activity and increased the activity of phosphatidylinositol 3-kinase and its downstream pathway, Akt. The increase in ERK activity was inhibited by genistein and PP1, but not by wortmannin, indicating that Src activation is necessary for the activation of the Ras/ERK pathway by CXCR3. Inhibition of ERI( activation resulted in a decreased chemotactic and mitogenic effect of CXCR3 ligands. In MC, which respond to CXCR3 ligands with increased DNA synthesis, CXCR3 activation resulted in a biphasic stimulation of ERK activation, a pattern similar to the one observed in HSC exposed to platelet-derived growth factor, indicating that this type of response is related to the stimulation of cell proliferation. These data characterize CXCR3 signaling in pericytes and clarify the relevance of downstream pathways in the modulation of different biologic responses.	Univ Florence, Dipartimento Med Interna, I-50134 Florence, Italy; Univ Florence, Dipartimento Fisiopatol Clin, I-50134 Florence, Italy	University of Florence; University of Florence	Marra, F (corresponding author), Univ Florence, Dipartimento Med Interna, Viale Morgagni 85, I-50134 Florence, Italy.		Marra, Fabio/K-7263-2016; Lasagni, Laura/J-6856-2018; Romagnani, Paola/A-4309-2008; Annunziato, Francesco/C-1155-2013; ROMANELLI, Roberto Giulio/K-4406-2018	Marra, Fabio/0000-0001-8629-0878; Lasagni, Laura/0000-0001-6553-9160; Romagnani, Paola/0000-0002-1774-8088; ROMANELLI, Roberto Giulio/0000-0001-9219-8189; Laffi, Giacomo/0000-0001-6916-1134; Annunziato, Francesco/0000-0001-8798-7589; Bonacchi, Andrea/0000-0003-4703-4067				ABBOUD HE, 1995, ANNU REV PHYSIOL, V57, P297; Aronica SM, 1997, BLOOD, V89, P3582, DOI 10.1182/blood.V89.10.3582.3582_3582_3595; Banas B, 1999, J AM SOC NEPHROL, V10, P2314; Bonecchi R, 1998, J EXP MED, V187, P129, DOI 10.1084/jem.187.1.129; CASINI A, 1993, GASTROENTEROLOGY, V105, P245, DOI 10.1016/0016-5085(93)90033-9; CHOUDHURY GG, 1991, J BIOL CHEM, V266, P8068; Choudhury GG, 1997, AM J PHYSIOL-RENAL, V273, pF931, DOI 10.1152/ajprenal.1997.273.6.F931; Cole KE, 1998, J EXP MED, V187, P2009, DOI 10.1084/jem.187.12.2009; COLLINS T, 1999, ROBBINS PATHOLOGICAL; Cunnick JM, 1998, J BIOL CHEM, V273, P14468, DOI 10.1074/jbc.273.23.14468; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Daub H, 1996, NATURE, V379, P557, DOI 10.1038/379557a0; deRooij J, 1997, ONCOGENE, V14, P623, DOI 10.1038/sj.onc.1201005; Dikic I, 1996, NATURE, V383, P547, DOI 10.1038/383547a0; Friedman SL, 2000, J BIOL CHEM, V275, P2247, DOI 10.1074/jbc.275.4.2247; GharaeeKermani M, 1996, J BIOL CHEM, V271, P17779, DOI 10.1074/jbc.271.30.17779; Gutkind JS, 1998, J BIOL CHEM, V273, P1839, DOI 10.1074/jbc.273.4.1839; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; Hawes BE, 1996, J BIOL CHEM, V271, P12133, DOI 10.1074/jbc.271.21.12133; Holdsworth SR, 1999, KIDNEY INT, V55, P1198, DOI 10.1046/j.1523-1755.1999.00369.x; HU QJ, 1995, SCIENCE, V268, P100, DOI 10.1126/science.7701328; ISHIDA M, 1995, CIRC RES, V77, P1053, DOI 10.1161/01.RES.77.6.1053; LEVITZKI A, 1995, SCIENCE, V267, P1782, DOI 10.1126/science.7892601; Loetscher M, 1996, J EXP MED, V184, P963, DOI 10.1084/jem.184.3.963; Luster AD, 1998, NEW ENGL J MED, V338, P436, DOI 10.1056/NEJM199802123380706; Luttrell LM, 1996, J BIOL CHEM, V271, P19443, DOI 10.1074/jbc.271.32.19443; Marra F, 2000, GASTROENTEROLOGY, V119, P466, DOI 10.1053/gast.2000.9365; Marra F, 1999, HEPATOLOGY, V30, P951, DOI 10.1002/hep.510300406; Marra F, 1999, HEPATOLOGY, V29, P140, DOI 10.1002/hep.510290107; Marra F, 1998, AM J PATHOL, V152, P423; Marra F, 1996, J CLIN INVEST, V98, P1218, DOI 10.1172/JCI118905; Marra F, 1997, GASTROENTEROLOGY, V112, P1297, DOI 10.1016/S0016-5085(97)70144-6; Piali L, 1998, EUR J IMMUNOL, V28, P961, DOI 10.1002/(SICI)1521-4141(199803)28:03<961::AID-IMMU961>3.0.CO;2-4; PINZANI M, 1989, J CLIN INVEST, V84, P1786, DOI 10.1172/JCI114363; Pupilli C, 1999, J AM SOC NEPHROL, V10, P245; Robino G, 2000, J BIOL CHEM, V275, P40561, DOI 10.1074/jbc.M007694200; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; Romagnani P, 1999, J AM SOC NEPHROL, V10, P2518; Romagnani P, 2001, J CLIN INVEST, V107, P53, DOI 10.1172/JCI9775; Rossi D, 2000, ANNU REV IMMUNOL, V18, P217, DOI 10.1146/annurev.immunol.18.1.217; Schecter AD, 2000, J BIOL CHEM, V275, P5466, DOI 10.1074/jbc.275.8.5466; Schecter AD, 1997, J BIOL CHEM, V272, P28568, DOI 10.1074/jbc.272.45.28568; Shields PL, 1999, J IMMUNOL, V163, P6236; TAMEMOTO H, 1992, J BIOL CHEM, V267, P20293; Tilton B, 2000, J EXP MED, V192, P313, DOI 10.1084/jem.192.3.313; Treisman R, 1996, CURR OPIN CELL BIOL, V8, P205, DOI 10.1016/S0955-0674(96)80067-6; Venkatakrishnan G, 2000, J BIOL CHEM, V275, P6868, DOI 10.1074/jbc.275.10.6868; Wang XK, 1996, J BIOL CHEM, V271, P24286, DOI 10.1074/jbc.271.39.24286; Wright JH, 1999, P NATL ACAD SCI USA, V96, P11335, DOI 10.1073/pnas.96.20.11335; Wymann MP, 1998, BBA-MOL CELL BIOL L, V1436, P127, DOI 10.1016/S0005-2760(98)00139-8	51	256	264	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 30	2001	276	13					9945	9954		10.1074/jbc.M010303200	http://dx.doi.org/10.1074/jbc.M010303200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	420GC	11136732	hybrid			2022-12-25	WOS:000167996400051
J	Gampala, SSL; Hagenbeek, D; Rock, CD				Gampala, SSL; Hagenbeek, D; Rock, CD			Functional interactions of lanthanum and phospholipase D with the abscisic acid signaling effecters VP1 and ABI1-1 in rice protoplasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN PHOSPHATASE 2C; DNA-BINDING ACTIVITY; CONSERVED B3 DOMAIN; GENE-EXPRESSION; EM GENE; RESPONSIVE ELEMENT; VIVIPAROUS1 VP1; ANION CHANNELS; BZIP PROTEIN; GUARD-CELLS	cis,trans-Abscisic acid (ABA) plays an important role in plant growth and development, regulation of seed maturation, germination, and adaptation to environmental stresses. Knowledge of ABA mechanisms of action and the interactions of components required for ABA signal transduction is far from complete. Using transient gene expression in rice protoplasts, we observed additive and inhibitory effects between maize VP1 Viviparous-1, a transcriptional activator) and a dominant-negative mutant protein phosphatase, ABI1-1 (ABA-insensitive-1-1), from Arabidopsis. Lanthanide ions were shown to be specific agonists of ABA-inducible gene expression and to interact synergistically with ABA and overexpressed VP1, Both VP1 and lanthanum activities could be antagonized by coexpression of ABI1-1, which demonstrates the specific ABA dependence of these effecters on ABA-regulated gene expression. We obtained pharmacological evidence that phospholipase D (PLD) functions in ABA-inducible gene expression in rice, Antagonism of ABA, VP1, and lanthanum synergy by 1-butanol, a specific inhibitor of PLD, was similar to the inhibition by coexpression of ABI1-1, These results demonstrate that ABA,VP1, lanthanum, PLD, and ABI1 are all involved in ABA-regulated gene expression and are consistent with an integrated model whereby La3+ acts upstream of PLD.	Hong Kong Univ Sci & Technol, Dept Biol, Kowloon, Hong Kong, Peoples R China	Hong Kong University of Science & Technology	Rock, CD (corresponding author), Hong Kong Univ Sci & Technol, Dept Biol, Clear Water Bay, Kowloon, Hong Kong, Peoples R China.	borock@ust.hk		, Christopher/0000-0002-2090-0650				Albinsky D, 1999, PLANT J, V17, P73, DOI 10.1046/j.1365-313X.1999.00354.x; Bobb AJ, 1997, NUCLEIC ACIDS RES, V25, P641, DOI 10.1093/nar/25.3.641; BOSTOCK RM, 1992, PLANT PHYSIOL, V98, P1356, DOI 10.1104/pp.98.4.1356; Busk PK, 1999, PLANT MOL BIOL, V41, P529, DOI 10.1023/A:1006345113637; Carson CB, 1997, PLANT J, V12, P1231, DOI 10.1046/j.1365-313x.1997.12061231.x; Chak RKF, 2000, PLANTA, V210, P875, DOI 10.1007/s004250050692; Chiu WL, 1996, CURR BIOL, V6, P325, DOI 10.1016/S0960-9822(02)00483-9; Choi HI, 2000, J BIOL CHEM, V275, P1723, DOI 10.1074/jbc.275.3.1723; Christensen AH, 1996, TRANSGENIC RES, V5, P213, DOI 10.1007/BF01969712; Cross MJ, 1996, CURR BIOL, V6, P588, DOI 10.1016/S0960-9822(02)00545-6; Desikan R, 1999, FEBS LETT, V456, P257, DOI 10.1016/S0014-5793(99)00972-2; Fan L, 1997, PLANT CELL, V9, P2183, DOI 10.1105/tpc.9.12.2183; FINKELSTEIN RR, 1994, PLANT J, V5, P765, DOI 10.1046/j.1365-313X.1994.5060765.x; Finkelstein RR, 2000, PLANT CELL, V12, P599, DOI 10.1105/tpc.12.4.599; Gosti F, 1999, PLANT CELL, V11, P1897, DOI 10.1105/tpc.11.10.1897; Hagenbeek D, 2000, PLANT PHYSIOL, V123, P1553, DOI 10.1104/pp.123.4.1553; HEUSER J, 1971, PROC R SOC SER B-BIO, V179, P247, DOI 10.1098/rspb.1971.0096; Hill A, 1996, J BIOL CHEM, V271, P3366, DOI 10.1074/jbc.271.7.3366; HIRAYAMA T, 1995, P NATL ACAD SCI USA, V92, P3903, DOI 10.1073/pnas.92.9.3903; Hobo T, 1999, PLANT J, V19, P679, DOI 10.1046/j.1365-313x.1999.00565.x; Hobo T, 1999, P NATL ACAD SCI USA, V96, P15348, DOI 10.1073/pnas.96.26.15348; HOECKER U, 1995, GENE DEV, V9, P2459, DOI 10.1101/gad.9.20.2459; Hoecker U, 1999, PLANT J, V19, P371, DOI 10.1046/j.1365-313X.1999.00521.x; HORNBERG C, 1984, NATURE, V310, P321, DOI 10.1038/310321a0; HUANG JWW, 1994, P NATL ACAD SCI USA, V91, P3473, DOI 10.1073/pnas.91.8.3473; Jacob T, 1999, P NATL ACAD SCI USA, V96, P12192, DOI 10.1073/pnas.96.21.12192; Jones HD, 2000, PLANT J, V21, P133, DOI 10.1046/j.1365-313x.2000.00662.x; Kim SY, 1998, J PLANT PHYSIOL, V152, P607, DOI 10.1016/S0176-1617(98)80019-9; KOORNNEEF M, 1984, PHYSIOL PLANTARUM, V61, P377, DOI 10.1111/j.1399-3054.1984.tb06343.x; Kurup S, 2000, PLANT J, V21, P143, DOI 10.1046/j.1365-313x.2000.00663.x; Leung J, 1997, PLANT CELL, V9, P759, DOI 10.1105/tpc.9.5.759; Leung J, 1998, ANNU REV PLANT PHYS, V49, P199, DOI 10.1146/annurev.arplant.49.1.199; Li GF, 1999, P NATL ACAD SCI USA, V96, P7104, DOI 10.1073/pnas.96.12.7104; Li JX, 2000, SCIENCE, V287, P300, DOI 10.1126/science.287.5451.300; LU GH, 1992, P NATL ACAD SCI USA, V89, P11490, DOI 10.1073/pnas.89.23.11490; MARCOTTE WR, 1988, NATURE, V335, P454, DOI 10.1038/335454a0; MCCARTY DR, 1991, CELL, V66, P895, DOI 10.1016/0092-8674(91)90436-3; MCCARTY DR, 1995, ANNU REV PLANT PHYS, V46, P71, DOI 10.1146/annurev.pp.46.060195.000443; Munnik T, 1995, PLANT CELL, V7, P2197, DOI 10.1105/tpc.7.12.2197; Munnik T, 1998, BBA-LIPID LIPID MET, V1389, P222, DOI 10.1016/S0005-2760(97)00158-6; MURASHIGE T, 1962, PHYSIOL PLANTARUM, V15, P473, DOI 10.1111/j.1399-3054.1962.tb08052.x; Nakagawa H, 1996, PLANT J, V9, P217, DOI 10.1046/j.1365-313X.1996.09020217.x; Nantel A, 1996, J BIOL CHEM, V271, P31296, DOI 10.1074/jbc.271.49.31296; OEDA K, 1991, EMBO J, V10, P1793, DOI 10.1002/j.1460-2075.1991.tb07704.x; Pappan K, 1997, J BIOL CHEM, V272, P7048, DOI 10.1074/jbc.272.11.7048; Parcy F, 1997, PLANT J, V11, P693, DOI 10.1046/j.1365-313X.1997.11040693.x; Pei ZM, 1998, SCIENCE, V282, P287, DOI 10.1126/science.282.5387.287; Razik MA, 1997, PLANT CELL, V9, P1791, DOI 10.1105/tpc.9.10.1791; RICHIE S, 2000, PLANT PHYSIOL, V124, P693; RICHIE SM, 1998, P NATL ACAD SCI USA, V95, P2697; ROBERTSON M, 1995, PHYSIOL PLANTARUM, V94, P470, DOI 10.1111/j.1399-3054.1995.tb00956.x; ROCK CD, 1994, CURR BIOL, V4, P1013, DOI 10.1016/S0960-9822(00)00229-3; Rock CD, 1996, PLANT CELL REP, V15, P371, DOI 10.1007/BF00232374; Rock CD, 2000, NEW PHYTOL, V148, P357, DOI 10.1046/j.1469-8137.2000.00769.x; Rodriguez PL, 1998, FEBS LETT, V421, P185, DOI 10.1016/S0014-5793(97)01558-5; Rohde A, 1999, PLANT CELL ENVIRON, V22, P261, DOI 10.1046/j.1365-3040.1999.00428.x; Rohde A, 2000, PLANT CELL, V12, P35, DOI 10.1105/tpc.12.1.35; Rojas A, 1999, PLANT J, V20, P601, DOI 10.1046/j.1365-313X.1999.00635.x; Schultz CJ, 2000, PLANT CELL, V12, P1751, DOI 10.1105/tpc.12.9.1751; Schultz TF, 1998, PLANT CELL, V10, P837, DOI 10.1105/tpc.10.5.837; Schultz TF, 1996, J BIOL CHEM, V271, P25742, DOI 10.1074/jbc.271.42.25742; Sheen J, 1998, P NATL ACAD SCI USA, V95, P975, DOI 10.1073/pnas.95.3.975; Shen QX, 1997, PHYSIOL PLANTARUM, V101, P653, DOI 10.1111/j.1399-3054.1997.tb01050.x; Shinozaki K, 1997, PLANT PHYSIOL, V115, P327, DOI 10.1104/pp.115.2.327; Singh KB, 1998, PLANT PHYSIOL, V118, P1111, DOI 10.1104/pp.118.4.1111; Staxen I, 1999, P NATL ACAD SCI USA, V96, P1779, DOI 10.1073/pnas.96.4.1779; Suzuki M, 1997, PLANT CELL, V9, P799, DOI 10.1105/tpc.9.5.799; Svetek J, 1999, J BIOL CHEM, V274, P14724, DOI 10.1074/jbc.274.21.14724; Uno Y, 2000, P NATL ACAD SCI USA, V97, P11632, DOI 10.1073/pnas.190309197; VANSTEVENINCK RFM, 1976, PROTOPLASMA, V90, P89, DOI 10.1007/BF01276481; VASIL V, 1995, PLANT CELL, V7, P1511, DOI 10.1105/tpc.7.9.1511; WANG M, 1995, PLANTA, V196, P271, DOI 10.1007/BF00201384; Wang XM, 1999, PLANT PHYSIOL, V120, P645, DOI 10.1104/pp.120.3.645; Wu Y, 1997, SCIENCE, V278, P2126, DOI 10.1126/science.278.5346.2126; Xu LW, 1997, PLANT PHYSIOL, V115, P387, DOI 10.1104/pp.115.2.387; YANG SF, 1967, J BIOL CHEM, V242, P477; ZEEVAART JAD, 1988, ANNU REV PLANT PHYS, V39, P439, DOI 10.1146/annurev.pp.39.060188.002255	77	43	44	1	10	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 30	2001	276	13					9855	9860		10.1074/jbc.M009168200	http://dx.doi.org/10.1074/jbc.M009168200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	420GC	11139577	hybrid			2022-12-25	WOS:000167996400038
J	Zhang, BL; Gao, Y; Moon, SY; Zhang, YQ; Zheng, Y				Zhang, BL; Gao, Y; Moon, SY; Zhang, YQ; Zheng, Y			Oligomerization of Rac1 GTPase mediated by the carboxyl-terminal polybasic domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RHO GTPASES; INORGANIC-PHOSPHATE; ACTIVATING PROTEINS; CRYSTAL-STRUCTURE; CELL-ADHESION; BINDING; CDC42; RAS; EXPRESSION; ASSEMBLES	The Rho family GTPase Rad mediates a variety of signal transduction processes leading to activation of NADPH oxidase, actin cytoskeleton reorganization, transcription activation, and stimulation of DNA synthesis, In this study, Rad was found to form a reversible monomer and oligomer in both the GDP- and GTP-bound states in vitro and in cells. Mutational analysis and peptide competition experiments showed that the unique C-terminal domain of Rad consisting of six consecutive basic residues (amino acids 183-188) is required for the homophilic interaction. Oligomerization of Rac1-GTP led to a self-stimulatory GTPase-activating protein (GAP) activity, resulting in a significantly enhanced intrinsic GTP hydrolysis rate of Rac1-GTP, Deletion or mutation of the polybasic residues drastically decreased its intrinsic GTPase activity and resulted in a loss of the self-stimulatory GAP activity, In the oligomeric state, Rad became insensitive to the RhoGAP stimulation, albeit maintaining the responsiveness to the guanine nucleotide exchange factor. The ability of the Rad C-terminal mutants to activate the effector p21(cdc42/rac)-activated kinase-1 correlated with their oligomerization states, suggesting that oligomer formation potentiates effector activation. Furthermore, the oligomer-to-monomer transition of Rac1-GDP could be driven effectively by interaction with the Rho guanine nucleotide dissociation inhibitor. Building on previous characterizations of Rac1 interaction with regulatory proteins and effectors, these results suggest that Rad may employ yet another means of regulation by cycling between the monomeric and oligomeric states to effectively generate a transient and augmented signal.	Univ Tennessee, Ctr Hlth Sci, Dept Mol Sci, Memphis, TN 38163 USA	University of Tennessee System; University of Tennessee Health Science Center	Zhang, BL (corresponding author), Univ Tennessee, Ctr Hlth Sci, Dept Mol Sci, Memphis, TN 38163 USA.		Zheng, Yi/J-7235-2015	Zheng, Yi/0000-0001-7089-6074	NIGMS NIH HHS [GM 60523] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM060523] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bagrodia S, 1999, TRENDS CELL BIOL, V9, P350, DOI 10.1016/S0962-8924(99)01618-9; Bar-Sagi D, 2000, CELL, V103, P227, DOI 10.1016/S0092-8674(00)00115-X; Bishop AL, 2000, BIOCHEM J, V348, P241, DOI 10.1042/0264-6021:3480241; Bourne HR, 1997, NATURE, V389, P673, DOI 10.1038/39470; Carr JF, 1997, J BIOL CHEM, V272, P28030, DOI 10.1074/jbc.272.44.28030; del Pozo MA, 2000, EMBO J, V19, P2008, DOI 10.1093/emboj/19.9.2008; Feltham JL, 1997, BIOCHEMISTRY-US, V36, P8755, DOI 10.1021/bi970694x; Haataja L, 1997, J BIOL CHEM, V272, P20384, DOI 10.1074/jbc.272.33.20384; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; HANCOCK JF, 1990, CELL, V63, P133, DOI 10.1016/0092-8674(90)90294-O; HINSHAW JE, 1995, NATURE, V374, P190, DOI 10.1038/374190a0; Hirshberg M, 1997, NAT STRUCT BIOL, V4, P147, DOI 10.1038/nsb0297-147; Hoffman GR, 2000, CELL, V100, P345, DOI 10.1016/S0092-8674(00)80670-4; Inouye K, 2000, J BIOL CHEM, V275, P3737, DOI 10.1074/jbc.275.6.3737; JOSEPH G, 1995, J BIOL CHEM, V270, P29079, DOI 10.1074/jbc.270.49.29079; Kaibuchi K, 1999, ANNU REV BIOCHEM, V68, P459, DOI 10.1146/annurev.biochem.68.1.459; Kasper B, 2000, BLOOD, V95, P2947, DOI 10.1182/blood.V95.9.2947.009k10_2947_2953; Knaus UG, 1998, J BIOL CHEM, V273, P21512, DOI 10.1074/jbc.273.34.21512; Kraynov VS, 2000, SCIENCE, V290, P333, DOI 10.1126/science.290.5490.333; KRECK ML, 1994, J BIOL CHEM, V269, P4161; Kreck ML, 1996, BIOCHEMISTRY-US, V35, P15683, DOI 10.1021/bi962064l; Kurzchalia TV, 1999, CURR OPIN CELL BIOL, V11, P424, DOI 10.1016/S0955-0674(99)80061-1; Lei M, 2000, CELL, V102, P387, DOI 10.1016/S0092-8674(00)00043-X; Mackay DJG, 1998, J BIOL CHEM, V273, P20685, DOI 10.1074/jbc.273.33.20685; MOLL J, 1991, ONCOGENE, V6, P863; Morreale A, 2000, NAT STRUCT BIOL, V7, P384; NOELJP, 1997, NAT STRUCT BIOL, V277, P677; PAOLO C, 1999, J BIOL CHEM, V274, P32071; Roberts AW, 1999, IMMUNITY, V10, P183, DOI 10.1016/S1074-7613(00)80019-9; Sander EE, 1999, EUR J CANCER, V35, P1302, DOI 10.1016/S0959-8049(99)00145-8; Schumacher B, 1998, J BIOL CHEM, V273, P28365, DOI 10.1074/jbc.273.43.28365; Symons M, 2000, CURR BIOL, V10, pR535, DOI 10.1016/S0960-9822(00)00588-1; Uehata M, 1997, NATURE, V389, P990, DOI 10.1038/40187; WARNOCK DE, 1995, EMBO J, V14, P1322, DOI 10.1002/j.1460-2075.1995.tb07118.x; WEBB MR, 1992, P NATL ACAD SCI USA, V89, P4884, DOI 10.1073/pnas.89.11.4884; WEBB MR, 1992, BIOCHEM J, V287, P555, DOI 10.1042/bj2870555; Wei YY, 1997, NAT STRUCT BIOL, V4, P699, DOI 10.1038/nsb0997-699; Zhang BL, 1997, J BIOL CHEM, V272, P21999, DOI 10.1074/jbc.272.35.21999; Zhang BL, 1998, J BIOL CHEM, V273, P25728, DOI 10.1074/jbc.273.40.25728; Zhang BL, 1998, BIOCHEMISTRY-US, V37, P5249, DOI 10.1021/bi9718447; Zhang BL, 1999, J BIOL CHEM, V274, P2609, DOI 10.1074/jbc.274.5.2609; Zhao LY, 1997, P NATL ACAD SCI USA, V94, P4418, DOI 10.1073/pnas.94.9.4418; Zheng Y, 1996, J BIOL CHEM, V271, P33169, DOI 10.1074/jbc.271.52.33169; ZHENG Y, 1993, J BIOL CHEM, V268, P24629; Zhu KJ, 2000, J BIOL CHEM, V275, P25993, DOI 10.1074/jbc.M003780200; Zohn IM, 1998, ONCOGENE, V17, P1415, DOI 10.1038/sj.onc.1202181	46	35	35	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 23	2001	276	12					8958	8967		10.1074/jbc.M008720200	http://dx.doi.org/10.1074/jbc.M008720200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	413HV	11134022	hybrid			2022-12-25	WOS:000167607700048
J	Grichtchenko, II; Choi, IY; Zhong, XB; Bray-Ward, P; Russell, JM; Boron, WF				Grichtchenko, II; Choi, IY; Zhong, XB; Bray-Ward, P; Russell, JM; Boron, WF			Cloning, characterization, and chromosomal mapping of a human electroneutral Na+-driven Cl-NCO3 exchanger	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTRACELLULAR PH REGULATION; SODIUM-BICARBONATE COTRANSPORTER; PIG HIPPOCAMPAL SLICES; BARNACLE MUSCLE-FIBERS; SQUID GIANT-AXONS; TISSUE DISTRIBUTION; FUNCTIONAL-CHARACTERIZATION; NA+/HCO3 COTRANSPORTER; PYRAMIDAL NEURONS; CL-/HCO3 EXCHANGE	The electroneutral Na+-driven Cl-HCO3 exchanger is a key mechanism for regulating intracellular pH (pH(i)) in neurons, glia, and other cells, Here we report the cloning, tissue distribution, chromosomal location, and functional characterization of the cDNA of such a transporter (NDCBE1) from human brain (GenBank(TM) accession number AF069512). NDCBE1, which encodes 1044 amino acids, is 34% identical to the mammalian anion exchanger (AF2); similar to 50% to the electrogenic Na/HCO3 co-transporter (NBCe1) from salamander, rat, and humans; similar to 73% to mammalian electroneutral Na/HCO3 cotransporters (NBCn1); 71% to mouse NCBE; and 47% to a Na+-driven anion exchanger (NDAE1) from Drosophila, Northern blot analysis of NDCBE1 shows a robust similar to 12-kilobase signal in all major regions of human brain and in testis, and weaker signals in kidney and ovary. This human gene (SLC4A8) maps to chromosome 12q13. When expressed in Xenopus oocytes and running in the forward direction, NDCBE1 is electroneutral and mediates increases in both pH(i) and [Na+](i) (monitored with microelectrodes) that require HCO3- and are blocked by 4,4'-diisothiocyanostilbene-2,2'-disulfonic acid (DIDS). The pH(i) increase also requires extracellular Na+. The Na+:HCO3- stoichiometry is 1:2. Forward-running NDCBE1 mediates a Cl-36 efflux that requires extracellular Na+ and HCO3- and is blocked by DIDS. Running in reverse, NDCBE1 requires extracellular Cl-. Thus, NDCBE1 encodes a human, electroneutral Na+-driven ClHCO3 exchanger.	Yale Univ, Sch Med, Dept Cellular & Mol Physiol, New Haven, CT 06520 USA; Yale Univ, Sch Med, Dept Genet, New Haven, CT 06520 USA; Syracuse Univ, Dept Biol, Syracuse, NY 13244 USA	Yale University; Yale University; Syracuse University	Grichtchenko, II (corresponding author), Yale Univ, Sch Med, Dept Cellular & Mol Physiol, 333 Cedar St, New Haven, CT 06520 USA.		Boron, Walter/ABI-1564-2020; choi, inyeong/AAM-4826-2021	Boron, Walter/0000-0003-4741-7287; Grichtchenko, Irina/0000-0002-6708-6916	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS018400] Funding Source: NIH RePORTER; NINDS NIH HHS [NS18400] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AALKJAER C, 1991, J PHYSIOL-LONDON, V436, P57, DOI 10.1113/jphysiol.1991.sp018539; Abuladze N, 1998, J BIOL CHEM, V273, P17689, DOI 10.1074/jbc.273.28.17689; Amlal H, 1999, AM J PHYSIOL-RENAL, V276, pF903, DOI 10.1152/ajprenal.1999.276.6.F903; Bevensee MO, 2000, AM J PHYSIOL-CELL PH, V278, pC1200, DOI 10.1152/ajpcell.2000.278.6.C1200; Bonnet U, 2000, BRAIN RES, V872, P116, DOI 10.1016/S0006-8993(00)02350-7; Bonnet U, 1999, BRAIN RES, V840, P16, DOI 10.1016/S0006-8993(99)01687-X; BORON WF, 1976, NATURE, V259, P240, DOI 10.1038/259240a0; BORON WF, 1985, J GEN PHYSIOL, V85, P325, DOI 10.1085/jgp.85.3.325; BORON WF, 1978, NATURE, V276, P511, DOI 10.1038/276511a0; BORON WF, 1976, J GEN PHYSIOL, V67, P91, DOI 10.1085/jgp.67.1.91; BORON WF, 1977, AM J PHYSIOL, V233, pC61, DOI 10.1152/ajpcell.1977.233.3.C61; BORON WF, 1983, J GEN PHYSIOL, V81, P53, DOI 10.1085/jgp.81.1.53; BORON WF, 1983, J GEN PHYSIOL, V81, P373, DOI 10.1085/jgp.81.3.373; BOYARSKY G, 1988, AM J PHYSIOL, V255, pC857, DOI 10.1152/ajpcell.1988.255.6.C857; Bruzzone R, 1996, EUR J BIOCHEM, V238, P1, DOI 10.1111/j.1432-1033.1996.0001q.x; CHAO P, 1988, PFLUG ARCH EUR J PHY, V411, P216, DOI 10.1007/BF00582318; Choi I, 1999, AM J PHYSIOL-CELL PH, V276, pC576, DOI 10.1152/ajpcell.1999.276.3.C576; Choi I, 2000, NATURE, V405, P571, DOI 10.1038/35014615; CHURCH J, 1992, J PHYSIOL-LONDON, V455, P51, DOI 10.1113/jphysiol.1992.sp019290; Church J, 1998, J PHYSIOL-LONDON, V511, P119, DOI 10.1111/j.1469-7793.1998.119bi.x; DAUMAS P, 1993, J GEN PHYSIOL, V101, P27, DOI 10.1085/jgp.101.1.27; DIXON DB, 1993, NEURON, V11, P267, DOI 10.1016/0896-6273(93)90183-R; Faber S, 1998, CELL PHYSIOL BIOCHEM, V8, P202, DOI 10.1159/000016283; FRANCKE U, 1994, CYTOGENET CELL GENET, V65, P206, DOI 10.1159/000133633; FREY G, 1993, J MEMBRANE BIOL, V134, P131; Grichtchenko II, 2000, J GEN PHYSIOL, V115, P533, DOI 10.1085/jgp.115.5.533; Kiss L, 1999, J NEUROPHYSIOL, V81, P1839, DOI 10.1152/jn.1999.81.4.1839; Ko YP, 1999, CHINESE J PHYSIOL, V42, P237; KOPITO RR, 1985, NATURE, V316, P234, DOI 10.1038/316234a0; KOPITO RR, 1989, CELL, V59, P927, DOI 10.1016/0092-8674(89)90615-6; KOSTENKO MA, 1983, BRAIN RES, V276, P43, DOI 10.1016/0006-8993(83)90546-2; KOTTGEN M, 1994, PFLUG ARCH EUR J PHY, V428, P179, DOI 10.1007/BF00374856; LADOUX A, 1987, EUR J BIOCHEM, V170, P43, DOI 10.1111/j.1432-1033.1987.tb13665.x; Lane J, 2000, BIOPHYS J, V78, P2493, DOI 10.1016/S0006-3495(00)76794-4; Meyer TM, 2000, NEUROREPORT, V11, P33, DOI 10.1097/00001756-200001170-00007; Nagase T, 1998, DNA Res, V5, P355, DOI 10.1093/dnares/5.6.355; OKUBO K, 1994, J BIOL CHEM, V269, P1918; Pedersen KA, 2000, PFLUG ARCH EUR J PHY, V440, P153, DOI 10.1007/s004240051033; Pushkin A, 1999, GENOMICS, V57, P321, DOI 10.1006/geno.1999.5781; Pushkin A, 1999, J BIOL CHEM, V274, P16569, DOI 10.1074/jbc.274.23.16569; Romero M. F., 1998, Journal of the American Society of Nephrology, V9, p11A; Romero MF, 2000, J BIOL CHEM, V275, P24552, DOI 10.1074/jbc.M003476200; Romero MF, 1997, NATURE, V387, P409, DOI 10.1038/387409a0; Romero MF, 1998, AM J PHYSIOL-RENAL, V274, pF425, DOI 10.1152/ajprenal.1998.274.2.F425; ROOS A, 1981, PHYSIOL REV, V61, P296, DOI 10.1152/physrev.1981.61.2.296; Rozental R, 2000, BRAIN RES REV, V32, P11, DOI 10.1016/S0165-0173(99)00095-8; RUSSELL JM, 1976, NATURE, V264, P73, DOI 10.1038/264073a0; SCHWIENING CJ, 1994, J PHYSIOL-LONDON, V475, P59, DOI 10.1113/jphysiol.1994.sp020049; SHRODE LD, 1994, GLIA, V12, P196, DOI 10.1002/glia.440120305; SIEBENS AW, 1987, J GEN PHYSIOL, V90, P799, DOI 10.1085/jgp.90.6.799; Smith GAM, 1998, J PHYSIOL-LONDON, V512, P487, DOI 10.1111/j.1469-7793.1998.487be.x; SPRAY DC, 1981, SCIENCE, V211, P712, DOI 10.1126/science.6779379; Strazzabosco M, 1997, HEPATOLOGY, V25, P976, DOI 10.1002/hep.510250431; THOMAS RC, 1976, J PHYSIOL-LONDON, V255, P715, DOI 10.1113/jphysiol.1976.sp011305; THOMAS RC, 1976, NATURE, V262, P54, DOI 10.1038/262054a0; THOMAS RC, 1977, J PHYSIOL-LONDON, V273, P317, DOI 10.1113/jphysiol.1977.sp012096; Tombaugh GC, 1997, J NEUROPHYSIOL, V77, P639, DOI 10.1152/jn.1997.77.2.639; TRUDEAU MC, 1995, SCIENCE, V269, P92, DOI 10.1126/science.7604285; Wang CZ, 2000, J BIOL CHEM, V275, P35486, DOI 10.1074/jbc.C000456200; Wang XG, 1998, AM J PHYSIOL-CELL PH, V275, pC1384, DOI 10.1152/ajpcell.1998.275.5.C1384; Xiong ZQ, 2000, J NEUROSCI, V20, P1290; Xu HX, 2000, J PHYSIOL-LONDON, V524, P725, DOI 10.1111/j.1469-7793.2000.00725.x; Zeng Y, 1996, DEV BIOL, V173, P510, DOI 10.1006/dbio.1996.0044; Zhu GY, 2000, J CELL PHYSIOL, V183, P53, DOI 10.1002/(SICI)1097-4652(200004)183:1<53::AID-JCP7>3.3.CO;2-I	64	126	129	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 16	2001	276	11					8358	8363		10.1074/jbc.C000716200	http://dx.doi.org/10.1074/jbc.C000716200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	411AA	11133997	hybrid			2022-12-25	WOS:000167474900093
J	Vainshtein, I; Kovacina, KS; Roth, RA				Vainshtein, I; Kovacina, KS; Roth, RA			The insulin receptor substrate (IRS)-1 pleckstrin homology domain functions in downstream signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHATIDYLINOSITOL 3-KINASE; IN-VIVO; PROTEIN; BINDING; KINASE; IRS-1; REGION; AKT; LOCALIZATION; ADIPOCYTES	The pleckstrin homology (PH) domain of the insulin receptor substrate-1 (IRS-1) plays a role in directing this molecule to the insulin receptor, thereby regulating its tyrosine phosphorylation. In this work, the role of the PH domain in subsequent signaling was studied by constructing constitutively active forms of IRS-1 in which the inter-SH2 domain of the p85 subunit of phosphatidylinositol 3-kinase was fused to portions of the IRS-1 molecule. Chimeric molecules containing the PH domain were found to activate the downstream response of stimulating the Ser/Thr kinase Akt, A chimera containing point mutations in the PH domain that abolished the ability of this domain to bind phosphatidylinositol 4,5-bisphosphate prevented these molecules from activating Akt. These mutations also decreased by about 70% the amount of the constructs present in a particulate fraction of the cells. These results indicate that the PH domain of IRS-1, in addition to directing this protein to the receptor for tyrosine phosphorylation, functions in the ability of this molecule to stimulate subsequent responses. Thus, compromising the function of the PH domain, e.g. in insulin-resistant states, could decrease both the ability of IRS-1 to be tyrosine phosphorylated by the insulin receptor and to link to subsequent downstream targets.	Stanford Univ, Dept Mol Pharmacol, Sch Med, Stanford, CA 94305 USA	Stanford University	Roth, RA (corresponding author), Stanford Univ, Dept Mol Pharmacol, Sch Med, Stanford, CA 94305 USA.				NIDDK NIH HHS [DK 34926] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK034926, R01DK034926] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Burks DJ, 1998, J BIOL CHEM, V273, P31061, DOI 10.1074/jbc.273.47.31061; Burks DJ, 1997, J BIOL CHEM, V272, P27716, DOI 10.1074/jbc.272.44.27716; Clark SF, 1998, J CELL BIOL, V140, P1211, DOI 10.1083/jcb.140.5.1211; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Dhe-Paganon S, 1999, P NATL ACAD SCI USA, V96, P8378, DOI 10.1073/pnas.96.15.8378; ENDEMANN G, 1990, J BIOL CHEM, V265, P396; GUSTAFSON TA, 1995, MOL CELL BIOL, V15, P2500; He WM, 1996, J BIOL CHEM, V271, P11641, DOI 10.1074/jbc.271.20.11641; KLIPPEL A, 1993, MOL CELL BIOL, V13, P5560, DOI 10.1128/MCB.13.9.5560; Kohn AD, 1996, J BIOL CHEM, V271, P31372, DOI 10.1074/jbc.271.49.31372; Kohn AD, 1998, J BIOL CHEM, V273, P11937, DOI 10.1074/jbc.273.19.11937; Krook A, 1997, DIABETES, V46, P2110, DOI 10.2337/diabetes.46.12.2110; Margolis B, 1996, J LAB CLIN MED, V128, P235, DOI 10.1016/S0022-2143(96)90022-0; MYERS MG, 1992, P NATL ACAD SCI USA, V89, P10350, DOI 10.1073/pnas.89.21.10350; Paz K, 1996, J BIOL CHEM, V271, P6998, DOI 10.1074/jbc.271.12.6998; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; Pessin JE, 2000, J CLIN INVEST, V106, P165, DOI 10.1172/JCI10582; Razzini G, 2000, MOL ENDOCRINOL, V14, P823, DOI 10.1210/me.14.6.823; RUDERMAN NB, 1990, P NATL ACAD SCI USA, V87, P1411, DOI 10.1073/pnas.87.4.1411; SawkaVerhelle D, 1996, J BIOL CHEM, V271, P5980, DOI 10.1074/jbc.271.11.5980; Shaw G, 1996, BIOESSAYS, V18, P35, DOI 10.1002/bies.950180109; Shepherd PR, 1998, BIOCHEM J, V333, P471, DOI 10.1042/bj3330471; Takeuchi H, 1998, BIOCHEM J, V334, P211, DOI 10.1042/bj3340211; TOUHARA K, 1994, J BIOL CHEM, V269, P10217; Vanhaesebroeck B, 2000, BIOCHEM J, V346, P561, DOI 10.1042/0264-6021:3460561; VOLIOVITCH H, 1995, J BIOL CHEM, V270, P18083, DOI 10.1074/jbc.270.30.18083; White MF, 1998, CURR TOP MICROBIOL, V228, P179; WOLF G, 1995, J BIOL CHEM, V270, P27407, DOI 10.1074/jbc.270.46.27407; Yenush L, 1996, J BIOL CHEM, V271, P24300, DOI 10.1074/jbc.271.39.24300	29	22	22	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 16	2001	276	11					8073	8078		10.1074/jbc.M008436200	http://dx.doi.org/10.1074/jbc.M008436200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	411AA	11145958	hybrid			2022-12-25	WOS:000167474900057
J	Jo, DG; Kim, MJ; Choi, YH; Kim, IK; Song, YH; Woo, HN; Chung, CW; Jung, YK				Jo, DG; Kim, MJ; Choi, YH; Kim, IK; Song, YH; Woo, HN; Chung, CW; Jung, YK			Pro-apoptotic function of calsenilin/DREAM/KChIP3	FASEB JOURNAL			English	Article									Kwangju Inst Sci & Technol, Dept Life Sci, Puk Gu, Kwangju 500712, South Korea	Gwangju Institute of Science & Technology (GIST)	Jung, YK (corresponding author), Kwangju Inst Sci & Technol, Dept Life Sci, Puk Gu, 1 Oryong Dong, Kwangju 500712, South Korea.		Jo, Dong-Gyu/AAN-9278-2021	Jo, Dong-Gyu/0000-0003-2271-1076; Woo, Ha-Na/0000-0002-6771-8151; Jung, Yong-Keun/0000-0002-9686-3120					0	67	71	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAR	2001	15	3					589	591						3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	410BE	11259376				2022-12-25	WOS:000167419500014
J	Li, LH; McCarthy, P; Hui, SW				Li, LH; McCarthy, P; Hui, SW			High-efficiency electrotransfection of human primary hematopoietic stem cells	FASEB JOURNAL			English	Article									New York State Dept Hlth, Roswell Pk Canc Inst, Dept Mol & Cellular Biol, Buffalo, NY 14263 USA; New York State Dept Hlth, Roswell Pk Canc Inst, Dept Med, Buffalo, NY 14263 USA	Roswell Park Cancer Institute; Roswell Park Cancer Institute	Hui, SW (corresponding author), New York State Dept Hlth, Roswell Pk Canc Inst, Dept Mol & Cellular Biol, Buffalo, NY 14263 USA.	sekwen.hui@roswellpark.org							0	35	40	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2001	15	3					586	588		10.1096/fj.00-0447fje	http://dx.doi.org/10.1096/fj.00-0447fje			3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	410BE	11259375				2022-12-25	WOS:000167419500013
J	Thomsen, P; van Deurs, B; Norrild, B; Kayser, L				Thomsen, P; van Deurs, B; Norrild, B; Kayser, L			The HPV16 E5 oncogene inhibits endocytic trafficking	ONCOGENE			English	Article						cytoskeleton; endocytic; human; papillomavirus; trafficking	HUMAN-PAPILLOMAVIRUS; H+-ATPASE; ONCOPROTEIN; ENDOSOMES; ACIDIFICATION; BAFILOMYCINS; EXPRESSION; LYSOSOMES; TRANSPORT; PROTEINS	The small hydrophobic E5 protein of Human Papillomavirus type 16 (HPV16) binds to the 16-kDa subunit of the V-H+-ATPase, This binding has been suggested to interfere with acidification of late endocytic structures. We here used video microscopy, ratio imaging and confocal microscopy of living C127 fibroblasts to study the effects of E5, Various endocytic markers including the pH-sensitive probe DM-NERF coupled to dextran, TransFluoSpheres and TRITC-concanavalin A, were applied. In ES-transfected cells, none of these markers colocalized with the membrane permeable probe Lyso-Tracker Red, which accumulates in acidic, late endocytic structures, or with a green fluorescent version of the small GTPase Rab7 labeling late endocytic structures. Importantly, however, late endocytic structures accumulating LysoTracker were still present in the E5-transfected cells. It is therefore concluded that HPV16 E5 perturbs trafficking from early to late endocytic structures rather than acidification.	Univ Copenhagen, Panum Inst, Dept Med Anat, Struct Cell Biol Unit, DK-2200 Copenhagen N, Denmark; Univ Copenhagen, Panum Inst, Inst Mol Pathol, DK-2200 Copenhagen N, Denmark	University of Copenhagen; University of Copenhagen	van Deurs, B (corresponding author), Univ Copenhagen, Panum Inst, Dept Med Anat, Struct Cell Biol Unit, Blegdamsvej 3, DK-2200 Copenhagen N, Denmark.							Bar-Ziv R, 1999, P NATL ACAD SCI USA, V96, P10140, DOI 10.1073/pnas.96.18.10140; Barois N, 1998, J CELL SCI, V111, P1791; BERGMAN P, 1988, ONCOGENE, V2, P453; BOWMAN EJ, 1988, P NATL ACAD SCI USA, V85, P7972, DOI 10.1073/pnas.85.21.7972; BUBB V, 1988, VIROLOGY, V163, P243, DOI 10.1016/0042-6822(88)90259-0; Bucci C, 2000, MOL BIOL CELL, V11, P467, DOI 10.1091/mbc.11.2.467; CONRAD M, 1993, J VIROL, V67, P6170, DOI 10.1128/JVI.67.10.6170-6178.1993; CRIDER BP, 1994, J BIOL CHEM, V269, P17379; Critchley DR, 1999, BIOCHEM SOC SYMP, V65, P79; Crusius K, 1999, ONCOGENE, V18, P6714, DOI 10.1038/sj.onc.1203075; DePina AS, 1999, MICROSC RES TECHNIQ, V47, P93, DOI 10.1002/(SICI)1097-0029(19991015)47:2<93::AID-JEMT2>3.0.CO;2-P; DROSE S, 1993, BIOCHEMISTRY-US, V32, P3902, DOI 10.1021/bi00066a008; Drose S, 1997, J EXP BIOL, V200, P1; Evans LL, 1998, J CELL SCI, V111, P2055; FAGOTTO F, 1994, J CELL SCI, V107, P3325; Giancotti FG, 2000, NAT CELL BIOL, V2, pE13, DOI 10.1038/71397; GOLDSTEIN DJ, 1991, NATURE, V352, P347, DOI 10.1038/352347a0; HALBERT CL, 1988, J VIROL, V62, P1071, DOI 10.1128/JVI.62.3.1071-1075.1988; Harada M, 1997, LIVER, V17, P244; Huang JD, 1999, NATURE, V397, P267, DOI 10.1038/16722; Ishiguro H, 1996, J PHYSIOL-LONDON, V495, P179, DOI 10.1113/jphysiol.1996.sp021583; JANMEY PA, 1995, CURR OPIN CELL BIOL, V7, P111, DOI 10.1016/0955-0674(95)80052-2; Johnsen CK, 1995, INTERVIROLOGY, V38, P339, DOI 10.1159/000150461; Lee RJ, 1996, BBA-MOL CELL RES, V1312, P237, DOI 10.1016/0167-4889(96)00041-9; Lin HJ, 1999, ANAL BIOCHEM, V269, P162, DOI 10.1006/abio.1999.4011; LYASS LA, 1984, P NATL ACAD SCI-BIOL, V81, P3098, DOI 10.1073/pnas.81.10.3098; Magez S, 1997, J CELL BIOL, V137, P715, DOI 10.1083/jcb.137.3.715; MANABE T, 1993, J CELL PHYSIOL, V157, P445, DOI 10.1002/jcp.1041570303; MCCANCE DJ, 1994, INFECT DIS CLIN N AM, V8, P751; MCCANCE DJ, 1985, BRIT J OBSTET GYNAEC, V92, P1101, DOI 10.1111/j.1471-0528.1985.tb03019.x; Mizejewski GJ, 1999, P SOC EXP BIOL MED, V222, P124, DOI 10.1046/j.1525-1373.1999.d01-122.x; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P1068, DOI 10.1093/nar/18.4.1068; O'Neill GM, 2000, TRENDS CELL BIOL, V10, P111, DOI 10.1016/S0962-8924(99)01714-6; Raposo G, 1999, MOL BIOL CELL, V10, P1477, DOI 10.1091/mbc.10.5.1477; Rathman M, 1996, INFECT IMMUN, V64, P2765, DOI 10.1128/IAI.64.7.2765-2773.1996; SCHALLER MD, 1995, J CELL BIOL, V130, P1181, DOI 10.1083/jcb.130.5.1181; Schapiro F, 2000, J CELL BIOL, V148, P305, DOI 10.1083/jcb.148.2.305; Skinner MA, 1999, J BIOL CHEM, V274, P23119, DOI 10.1074/jbc.274.33.23119; SPARKOWSKI J, 1995, EMBO J, V14, P3055, DOI 10.1002/j.1460-2075.1995.tb07308.x; STANLEY MA, 1989, INT J CANCER, V43, P672, DOI 10.1002/ijc.2910430422; STRAIGHT SW, 1993, J VIROL, V67, P4521, DOI 10.1128/JVI.67.8.4521-4532.1993; STRAIGHT SW, 1995, J VIROL, V69, P3185, DOI 10.1128/JVI.69.5.3185-3192.1995; Syrjanen SM, 1999, ANN MED, V31, P175, DOI 10.3109/07853899909115976; Taunton J, 2000, J CELL BIOL, V148, P519, DOI 10.1083/jcb.148.3.519; Thomsen P, 1999, BBA-MOL CELL RES, V1452, P285, DOI 10.1016/S0167-4889(99)00132-9; Tong XA, 1997, P NATL ACAD SCI USA, V94, P4412, DOI 10.1073/pnas.94.9.4412; VALLE GF, 1995, J GEN VIROL, V76, P1239, DOI 10.1099/0022-1317-76-5-1239; VANDEURS B, 1995, EUR J CELL BIOL, V66, P309; Venuti A, 1998, VIROLOGY, V248, P1, DOI 10.1006/viro.1998.9227; VOUSDEN K, 1993, FASEB J, V7, P872, DOI 10.1096/fasebj.7.10.8393818; Wubbolts R, 1996, J CELL BIOL, V135, P611, DOI 10.1083/jcb.135.3.611; zur Hausen H, 1999, P ASSOC AM PHYSICIAN, V111, P581, DOI 10.1046/j.1525-1381.1999.99723.x	52	58	63	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 7	2000	19	52					6023	6032		10.1038/sj.onc.1204010	http://dx.doi.org/10.1038/sj.onc.1204010			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	382MY	11146554				2022-12-25	WOS:000165827900009
J	Yamashita, Y; Kumabe, T; Cho, YY; Watanabe, M; Kawagishi, J; Yoshimoto, T; Fujino, T; Kang, MJ; Yamamoto, TT				Yamashita, Y; Kumabe, T; Cho, YY; Watanabe, M; Kawagishi, J; Yoshimoto, T; Fujino, T; Kang, MJ; Yamamoto, TT			Fatty acid induced glioma cell growth is mediated by the acyl-CoA synthetase 5 gene located on chromosome 10q25.1-q25.2, a region frequently deleted in malignant gliomas	ONCOGENE			English	Article						acyl-CoA synthetase; fatty acid; glioma; growth stimulation	PROTEIN; HETEROZYGOSITY; EXPRESSION; REPLICATION; THIOESTERS; TRANSPORT; COENZYME; CLONING; GENOME; ACS2	Acyl-CoA synthetase (ACS) ligates fatty acid and CoA to produce acyl-CoA, an essential molecule in fatty acid metabolism and cell proliferation. ACS5 is a recently characterized ACS isozyme highly expressed in proliferating 3T3-L1 cells. Molecular characterization of the human ACS5 gene revealed that the gene is located on chromosome 10q25.1-q25.2, spans approximately 46 kb, comprises 21 exons and 22 introns, and encodes a 683 amino acid protein, Two major ACS5 transcripts of 2,5-and 3,7-kb are distributed in a wide range of tissues with the highest expression in uterus and spleen. Markedly increased levels of ACS5 transcripts were detected in a glioma line, A172 cells, and primary gliomas of grade IV malignancy,,while ACS5 expression was found to be low in normal brain. Immunohistochemical analysis also revealed strong immunostaining with an anti-ACS5 antibody in glioblastomas. U87MG glioma cells infected with an adenovirus encoding ACS5 displayed induced cell growth on exposure to palmitate, Consistent with the induction of cell growth, the virus infected cells displayed induced uptake of palmitate, These results demonstrate a novel fatty acid-induced glioma cell growth mediated by ACS5.	Tohoku Univ, Ctr Gene Res, Sendai, Miyagi 9818555, Japan; Tohoku Univ, Sch Med, Dept Neurosurg, Sendai, Miyagi 9808574, Japan; Tohoku Univ, Sch Med, Dept Pathol, Sendai, Miyagi 9808574, Japan	Tohoku University; Tohoku University; Tohoku University	Yamamoto, TT (corresponding author), Tohoku Univ, Ctr Gene Res, 1-1 Tsutsumidori Amamiya, Sendai, Miyagi 9818555, Japan.			Cho, Yong-Yeon/0000-0003-1107-2651				BERGERHEIM USR, 1991, GENE CHROMOSOME CANC, V3, P215, DOI 10.1002/gcc.2870030308; BRONFMAN M, 1989, BIOCHEM BIOPH RES CO, V159, P1026, DOI 10.1016/0006-291X(89)92211-0; Coe NR, 1999, J BIOL CHEM, V274, P36300, DOI 10.1074/jbc.274.51.36300; COHEN D, 1993, NATURE, V366, P698, DOI 10.1038/366698a0; Fujino T, 1996, J BIOL CHEM, V271, P16748, DOI 10.1074/jbc.271.28.16748; FUJINO T, 1992, J BIOCHEM-TOKYO, V111, P197, DOI 10.1093/oxfordjournals.jbchem.a123737; GLICK BS, 1987, NATURE, V326, P309, DOI 10.1038/326309a0; GRAND RJA, 1989, BIOCHEM J, V258, P625, DOI 10.1042/bj2580625; Harlow E., 1988, ANTIBODIES LAB MANUA; HENRY MF, 1992, CELL, V70, P671, DOI 10.1016/0092-8674(92)90435-F; HERBST RA, 1994, CANCER RES, V54, P3111; Hertz R, 1998, NATURE, V392, P512, DOI 10.1038/33185; Iijima H, 1996, EUR J BIOCHEM, V242, P186, DOI 10.1111/j.1432-1033.1996.0186r.x; Kang MJ, 1997, P NATL ACAD SCI USA, V94, P2880, DOI 10.1073/pnas.94.7.2880; KARLBOM AE, 1993, HUM GENET, V92, P169; KUHAJDA FP, 1994, P NATL ACAD SCI USA, V91, P6379, DOI 10.1073/pnas.91.14.6379; Miyake S, 1996, P NATL ACAD SCI USA, V93, P1320, DOI 10.1073/pnas.93.3.1320; Oikawa E, 1998, J BIOCHEM, V124, P679, DOI 10.1093/oxfordjournals.jbchem.a022165; PEIFFER SL, 1995, CANCER RES, V55, P1922; Pizer ES, 1998, CANCER RES, V58, P4611; RASHEED BKA, 1992, GENE CHROMOSOME CANC, V5, P75, DOI 10.1002/gcc.2870050111; RASHEED BKA, 1995, ONCOGENE, V10, P2243; Sambrook J., 2002, MOL CLONING LAB MANU; SCHAFFER JE, 1994, CELL, V79, P427, DOI 10.1016/0092-8674(94)90252-6; SUZUKI H, 1990, J BIOL CHEM, V265, P8681; TOMODA H, 1991, J BIOL CHEM, V266, P4214; Yagasaki F, 1999, GENE CHROMOSOME CANC, V26, P192, DOI 10.1002/(SICI)1098-2264(199911)26:3<192::AID-GCC2>3.0.CO;2-E	27	63	67	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 30	2000	19	51					5919	5925		10.1038/sj.onc.1203981	http://dx.doi.org/10.1038/sj.onc.1203981			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	378CA	11127823				2022-12-25	WOS:000165563100011
J	Crespo, NC; Ohkanda, J; Yen, TJ; Hamilton, AD; Sebti, SM				Crespo, NC; Ohkanda, J; Yen, TJ; Hamilton, AD; Sebti, SM			The farnesyltransferase inhibitor, FTI-2153, blocks bipolar spindle formation and chromosome alignment and causes prometaphase accumulation during mitosis of human lung cancer cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN TUMOR-GROWTH; CENP-E; GERANYLGERANYLTRANSFERASE-I; TRANSFERASE INHIBITORS; MITOTIC CHECKPOINT; RAS PRENYLATION; K-RAS; PROTEIN; FARNESYLATION; KINETOCHORES	Even though farnesyltransferase inhibitors (FTIs), a novel class of therapeutic agents presently in clinical trials, have preclinically outstanding anticancer activity and impressive lack of toxicity, their mechanism of action is not well understood. To enhance our understanding of how FTIs inhibit the growth of tumors, we have investigated their effects on eel cycle progression of two human lung cancer cell lines, A-549 and Calu-1. In this report, we show in synchronized A-549 and Calu-1 cells that FTI-2153 treatment resulted in a large accumulation of cells in the mitosis phase of the cell division cycle, with some cells in the G(0)/G(1) phase. Furthermore, microtubule immunostaining and 4,6-diamidino-2-phenylindole DNA staining demonstrated that the FTI-2153-induced accumulation in mitosis is due to the inability of these cells to progress from prophase to metaphase. FTI-2153 inhibited the ability of A-549 and Calu-1 cells to form bipolar spindles and caused formation of monoasteral spindles. Furthermore, FTI-2153 induced a ring-shaped chromosome morphology and inhibited chromosome alignment. Time-lapse videomicroscopy confirmed this result by showing that FTI-2153-treated cells are unable to align their chromosomes at the metaphase plate. FTI-2153 did not affect the localization to the kinetochores of two farnesylated centromeric proteins, CENP-E and CENP-F. Thus, a mechanism by which FTIs inhibit progression through mitosis and tumor growth is by blocking bipolar spindle formation and chromosome alignment.	Univ S Florida, H Lee Moffitt Canc Ctr & Res Inst, Dept Oncol, Drug Discovery Program,MRC,DRDIS, Tampa, FL 33612 USA; Univ S Florida, H Lee Moffitt Canc Ctr & Res Inst, Dept Biochem & Mol Biol, Drug Discovery Program, Tampa, FL 33612 USA; Yale Univ, Dept Chem, New Haven, CT 06520 USA; Fox Chase Canc Ctr, Program Cell & Dev Biol, Philadelphia, PA 19111 USA	H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; Yale University; Fox Chase Cancer Center	Sebti, SM (corresponding author), Univ S Florida, H Lee Moffitt Canc Ctr & Res Inst, Dept Oncol, Drug Discovery Program,MRC,DRDIS, 12902 Magnolia Dr, Tampa, FL 33612 USA.		Ohkanda, Junko/I-6102-2019	Ohkanda, Junko/0000-0001-9663-5104; Yen, Tim/0000-0003-2159-0997	NCI NIH HHS [CA67771] Funding Source: Medline; NATIONAL CANCER INSTITUTE [U19CA067771] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abrieu A, 2000, CELL, V102, P817, DOI 10.1016/S0092-8674(00)00070-2; Ashar HR, 2000, J BIOL CHEM, V275, P30451, DOI 10.1074/jbc.M003469200; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; Blangy A, 1995, CELL, V83, P1159, DOI 10.1016/0092-8674(95)90142-6; Campbell SL, 1998, ONCOGENE, V17, P1395, DOI 10.1038/sj.onc.1202174; Chan GKT, 1998, J CELL BIOL, V143, P49, DOI 10.1083/jcb.143.1.49; Chen Z, 2000, J BIOL CHEM, V275, P17974, DOI 10.1074/jbc.C000145200; Gibbs JB, 1997, ANNU REV PHARMACOL, V37, P143, DOI 10.1146/annurev.pharmtox.37.1.143; HUANG CC, 2000, FARNESYLTRANSFERASE, P21; Jiang K, 2000, MOL CELL BIOL, V20, P139, DOI 10.1128/MCB.20.1.139-148.2000; JORDAN MA, 1991, CANCER RES, V51, P2212; JORDAN MA, 1993, P NATL ACAD SCI USA, V90, P9552, DOI 10.1073/pnas.90.20.9552; Lebowitz PF, 1998, ONCOGENE, V17, P1439, DOI 10.1038/sj.onc.1202175; LIAO H, 1994, SCIENCE, V265, P394, DOI 10.1126/science.8023161; LIAO H, 1995, J CELL BIOL, V130, P507, DOI 10.1083/jcb.130.3.507; Mayer TU, 1999, SCIENCE, V286, P971, DOI 10.1126/science.286.5441.971; MCCORMICK F, 1993, NATURE, V363, P15, DOI 10.1038/363015a0; PATNAIK A, 2000, FARNESYLTRANSFERASE, P233; PRENDERGAST GC, 1994, MOL CELL BIOL, V14, P4193, DOI 10.1128/MCB.14.6.4193; Rowell CA, 1997, J BIOL CHEM, V272, P14093, DOI 10.1074/jbc.272.22.14093; Schaar BT, 1997, J CELL BIOL, V139, P1373, DOI 10.1083/jcb.139.6.1373; Sebti S. M., 2000, FARNESYLTRANSFERASE, P197; Sebti SM, 1997, PHARMACOL THERAPEUT, V74, P103, DOI 10.1016/S0163-7258(97)00014-4; SEPPLORENZINO L, 1995, CANCER RES, V55, P5302; Sun JZ, 1999, CANCER RES, V59, P4919; Sun JZ, 1998, ONCOGENE, V16, P1467, DOI 10.1038/sj.onc.1201656; VAISBERG EA, 1993, J CELL BIOL, V123, P849, DOI 10.1083/jcb.123.4.849; Vogt A, 1997, J BIOL CHEM, V272, P27224, DOI 10.1074/jbc.272.43.27224; Vogt A, 1996, ONCOGENE, V13, P1991; Whyte DB, 1997, J BIOL CHEM, V272, P14459, DOI 10.1074/jbc.272.22.14459; Wood KW, 1997, CELL, V91, P357, DOI 10.1016/S0092-8674(00)80419-5; Yao XB, 2000, NAT CELL BIOL, V2, P484, DOI 10.1038/35019518; Zhang FL, 1996, ANNU REV BIOCHEM, V65, P241, DOI 10.1146/annurev.bi.65.070196.001325	33	112	118	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 11	2001	276	19					16161	16167		10.1074/jbc.M006213200	http://dx.doi.org/10.1074/jbc.M006213200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	431GH	11154688	hybrid			2022-12-25	WOS:000168623100080
J	Richman, JG; Brady, AE; Wang, Q; Hensel, JL; Colbran, RJ; Limbird, LE				Richman, JG; Brady, AE; Wang, Q; Hensel, JL; Colbran, RJ; Limbird, LE			Agonist-regulated interaction between alpha(2)-adrenergic receptors and spinophilin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; FILAMENT-BINDING PROTEIN; 3RD INTRACELLULAR LOOP; CANINE KIDNEY-CELLS; ADRENERGIC-RECEPTORS; ALPHA-2-ADRENERGIC RECEPTOR; ALPHA(2A)-ADRENERGIC RECEPTOR; BASOLATERAL MEMBRANE; COUPLED RECEPTORS; SUBTYPES	Previously, we demonstrated that the third intracellular (3i) loop of the heptahelical alpha (2A)-adrenergic receptor (alpha (2A)AAR) is critical for retention at the basolateral surface of polarized Madin-Darby canine kidney II (MDCKII) cells following their direct targeting to this surface, Findings that the 3i loops of the D-2 dopamine receptors interact with spinophilin (Smith, F. D., Oxford, G. S., and Milgram, S. L. (1999) J. Biol. Chem. 274, 19894-19900) and that spinophilin is enriched beneath the basolateral surface of polarized MDCK cells prompted us to assess whether alpha (2)AR subtypes might also interact with spinophilin. [S-35]Met-labeled 3i loops of the alpha (2A)AR (Val(217)-Ala(377)), alpha (2B)AR (Lys(210)-Trp(354)), and alpha (2C)AR (Arg(248)-Val(363)) subtypes interacted with glutathione S-transferase-spinophilin fusion proteins. These interactions could be refined to spinophilin amino acid residues 169-255, in a region between spinophilin's F-actin binding and phosphatase 1 regulatory domains. Furthermore, these interactions occur in intact cells in an agonist regulated fashion, because alpha (2A)AR and spinophilin coimmunoprecipitation from cells is enhanced by prior treatment with agonist. These findings suggest that spinophilin may contribute not only to alpha (2)AR localization but also to agonist modulation of alpha (2)AR signaling.	Vanderbilt Univ, Med Ctr, Dept Pharmacol, Nashville, TN 37232 USA; Vanderbilt Univ, Med Ctr, Dept Physiol & Mol Biophys, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University	Limbird, LE (corresponding author), Vanderbilt Univ, Med Ctr, Dept Pharmacol, Rm 464, Nashville, TN 37232 USA.		Colbran, Roger/AAU-7708-2021	Colbran, Roger/0000-0001-7401-8244; Wang, Qin/0000-0002-1079-5914	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043879, T32DK007563] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS037508] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK43879, T32DK07563] Funding Source: Medline; NINDS NIH HHS [NS37508] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALBLAS J, 1993, J BIOL CHEM, V268, P22235; Allen PB, 1997, P NATL ACAD SCI USA, V94, P9956, DOI 10.1073/pnas.94.18.9956; Brakeman PR, 1997, NATURE, V386, P284, DOI 10.1038/386284a0; Cao TT, 1999, NATURE, V401, P286, DOI 10.1038/45816; Daunt DA, 1997, MOL PHARMACOL, V51, P711, DOI 10.1124/mol.51.5.711; Daviet L, 1999, J BIOL CHEM, V274, P17058, DOI 10.1074/jbc.274.24.17058; DeGraff JL, 1999, J BIOL CHEM, V274, P11253, DOI 10.1074/jbc.274.16.11253; EASON MG, 1992, J BIOL CHEM, V267, P25473; FLORDELLIS CS, 1995, J BIOL CHEM, V270, P3491, DOI 10.1074/jbc.270.8.3491; GUYER CA, 1990, J BIOL CHEM, V265, P17307; Hall RA, 1998, NATURE, V392, P626, DOI 10.1038/33458; Heuss C, 2000, TRENDS NEUROSCI, V23, P469, DOI 10.1016/S0166-2236(00)01643-X; Hsieh-Wilson LC, 1999, BIOCHEMISTRY-US, V38, P4365, DOI 10.1021/bi982900m; Jinsi A, 1996, EUR J PHARMACOL, V302, P183, DOI 10.1016/0014-2999(96)00049-0; JONES SB, 1990, J PHARMACOL EXP THER, V254, P294; KEEFER JR, 1993, J BIOL CHEM, V268, P11340; KEEFER JR, 1994, J BIOL CHEM, V269, P16425; Klein U, 1997, J BIOL CHEM, V272, P19099, DOI 10.1074/jbc.272.31.19099; KOBILKA B, 1992, ANNU REV NEUROSCI, V15, P87, DOI 10.1146/annurev.ne.15.030192.000511; KOCH WJ, 1994, P NATL ACAD SCI USA, V91, P12706, DOI 10.1073/pnas.91.26.12706; KUROSE H, 1994, J BIOL CHEM, V269, P10093; LANIER SM, 1991, J BIOL CHEM, V266, P10470; Lezcano N, 2000, SCIENCE, V287, P1660, DOI 10.1126/science.287.5458.1660; LIMBIRD LE, 1988, FASEB J, V2, P2686, DOI 10.1096/fasebj.2.11.2840317; MacMillan LB, 1999, J BIOL CHEM, V274, P35845, DOI 10.1074/jbc.274.50.35845; MACNULTY EE, 1992, J BIOL CHEM, V267, P2149; Mani SK, 2000, SCIENCE, V287, P1053, DOI 10.1126/science.287.5455.1053; Nakanishi H, 1997, J CELL BIOL, V139, P951, DOI 10.1083/jcb.139.4.951; Olli-Lahdesmaki T, 1999, J NEUROSCI, V19, P9281; Petosa C, 1998, J BIOL CHEM, V273, P16305, DOI 10.1074/jbc.273.26.16305; Prezeau L, 1999, J BIOL CHEM, V274, P13462, DOI 10.1074/jbc.274.19.13462; RICHMAN JG, 1998, AM J PHYSIOL, V43, pC654; Satoh A, 1998, J BIOL CHEM, V273, P3470, DOI 10.1074/jbc.273.6.3470; Saunders C, 2000, MOL PHARMACOL, V57, P44; Schramm NL, 1999, J BIOL CHEM, V274, P24935, DOI 10.1074/jbc.274.35.24935; Smith FD, 1999, J BIOL CHEM, V274, P19894, DOI 10.1074/jbc.274.28.19894; SMITH SK, 1981, P NATL ACAD SCI-BIOL, V78, P4026, DOI 10.1073/pnas.78.7.4026; Snyder GL, 1998, J NEUROSCI, V18, P10297; Tai AW, 1999, CELL, V97, P877, DOI 10.1016/S0092-8674(00)80800-4; VONZASTROW M, 1993, J BIOL CHEM, V268, P763; VONZASTROW M, 1994, J BIOL CHEM, V269, P15448; WADE SM, 1994, MOL PHARMACOL, V45, P1191; Wilson M, 1996, J BIOL CHEM, V271, P8537, DOI 10.1074/jbc.271.15.8537; Wozniak M, 1996, J BIOL CHEM, V271, P5017; Wu GY, 1997, J BIOL CHEM, V272, P17836, DOI 10.1074/jbc.272.28.17836; Yan Z, 1999, NAT NEUROSCI, V2, P13, DOI 10.1038/4516; ZENG DW, 1990, P NATL ACAD SCI USA, V87, P3102, DOI 10.1073/pnas.87.8.3102; Zitzer H, 1999, J BIOL CHEM, V274, P18153, DOI 10.1074/jbc.274.26.18153	48	101	104	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 4	2001	276	18					15003	15008		10.1074/jbc.M011679200	http://dx.doi.org/10.1074/jbc.M011679200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	429QQ	11154706	hybrid			2022-12-25	WOS:000168528800065
J	Cherqui, S; Kalatzis, V; Trugnan, G; Antignac, C				Cherqui, S; Kalatzis, V; Trugnan, G; Antignac, C			The targeting of cystinosin to the lysosomal membrane requires a tyrosine-based signal and a novel sorting motif	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR RECEPTORS; INTRACELLULAR TRAFFICKING; NEPHROPATHIC CYSTINOSIS; CYTOPLASMIC TAIL; TRANSPORT; ENDOCYTOSIS; DELIVERY; PROTEINS; GLYCOPROTEINS; PROTEOLYSIS	Cystinosis is a lysosomal transport disorder characterized by an accumulation of intra-lysosomal cystine, Biochemical studies showed that the lysosomal cystine transporter was distinct from the plasma membrane cystine transporters and that it exclusively transported cystine. The gene underlying cystinosis, CTNS, encodes a predicted seven-transmembrane domain protein called cystinosin, which is highly glycosylated at the N-terminal end and carries a GY-XX-Phi (where Phi is a hydrophobic residue) lysosomal-targeting motif in its carboxyl tail. We constructed cystinosin-green fluorescent protein fusion proteins to determine the subcellular localization of cystinosin in transfected cell lines and showed that cystinosin-green fluorescent protein colocalizes with lysosomal-associated membrane protein 2 (LAMP-S) to lysosomes. Deletion of the GY-XX-Phi motif resulted in a partial redirection to the plasma membrane as well as sorting to lysosomes, demonstrating that this motif is only partially responsible for the lysosomal targeting of cystinosin and suggesting the existence of a second sorting signal. A complete relocalization of cystinosin to the plasma membrane was obtained after deletion of half of the third cytoplasmic loop (amino acids 280-288) coupled with the deletion of the GY-DQ-L motif, demonstrating the presence of the second signal within this loop. Using site-directed mutagenesis studies we identified a novel conformational lysosomal-sorting motif, the core of which was delineated to YF-PQA (amino acids 281-285).	Hop Necker Enfants Malad, INSERM, U423, F-75015 Paris, France; Ctr Hosp Univ St Antoine, INSERM, U538, F-75012 Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite	Antignac, C (corresponding author), Hop Necker Enfants Malad, INSERM, U423, 149 Rue Sevres, F-75015 Paris, France.		Kalatzis, Vasiliki/F-6170-2019; ANTIGNAC, Corinne/H-8945-2017	Kalatzis, Vasiliki/0000-0002-9626-8807; ANTIGNAC, Corinne/0000-0002-9934-4940; Cherqui, Stephanie/0000-0003-1240-5219				Alpy F, 2001, J BIOL CHEM, V276, P4261, DOI 10.1074/jbc.M006279200; BANNAI S, 1980, J BIOL CHEM, V255, P2372; Blagoveshchenskaya AD, 1998, J BIOL CHEM, V273, P2729, DOI 10.1074/jbc.273.5.2729; Bonifacino JS, 1999, J CELL BIOL, V145, P923, DOI 10.1083/jcb.145.5.923; Calvo PA, 1999, J BIOL CHEM, V274, P12780, DOI 10.1074/jbc.274.18.12780; DICE JF, 1990, TRENDS BIOCHEM SCI, V15, P305, DOI 10.1016/0968-0004(90)90019-8; FELDER S, 1990, CELL, V61, P623, DOI 10.1016/0092-8674(90)90474-S; FUKUDA M, 1991, J BIOL CHEM, V266, P21327; GAHL WA, 1983, BIOCHEM J, V216, P393, DOI 10.1042/bj2160393; GAHL WA, 1982, SCIENCE, V217, P1263, DOI 10.1126/science.7112129; Gahl WASJ, 1995, METABOLIC MOL BASIS, V7th, P3763; GUARNIERI FG, 1993, J BIOL CHEM, V268, P1941; HONING S, 1995, J CELL BIOL, V128, P321, DOI 10.1083/jcb.128.3.321; Hunziker W, 1996, BIOESSAYS, V18, P379, DOI 10.1002/bies.950180508; Kornilova E, 1996, J BIOL CHEM, V271, P30340, DOI 10.1074/jbc.271.48.30340; Mancini GMS, 2000, J INHERIT METAB DIS, V23, P278, DOI 10.1023/A:1005640214408; MARKELLO TC, 1993, NEW ENGL J MED, V328, P1157, DOI 10.1056/NEJM199304223281604; MELLMAN I, 1986, ANNU REV BIOCHEM, V55, P663, DOI 10.1146/annurev.biochem.55.1.663; NABI IR, 1991, J CELL BIOL, V115, P1573, DOI 10.1083/jcb.115.6.1573; NEUFELD EF, 1991, ANNU REV BIOCHEM, V60, P257, DOI 10.1146/annurev.biochem.60.1.257; Odorizzi G, 1998, TRENDS CELL BIOL, V8, P282, DOI 10.1016/S0962-8924(98)01295-1; OPRESKO LK, 1995, J BIOL CHEM, V270, P4325, DOI 10.1074/jbc.270.9.4325; Patterson GH, 1997, BIOPHYS J, V73, P2782, DOI 10.1016/S0006-3495(97)78307-3; PEARSE BMF, 1990, ANNU REV CELL BIOL, V6, P151, DOI 10.1146/annurev.cb.06.110190.001055; PISONI RL, 1990, J CELL BIOL, V110, P327, DOI 10.1083/jcb.110.2.327; ROBINSON MS, 1994, CURR OPIN CELL BIOL, V6, P538, DOI 10.1016/0955-0674(94)90074-4; Schekman R, 1996, SCIENCE, V271, P1526, DOI 10.1126/science.271.5255.1526; SEGLEN PO, 1992, EXPERIENTIA, V48, P158, DOI 10.1007/BF01923509; TATE SS, 1992, P NATL ACAD SCI USA, V89, P1, DOI 10.1073/pnas.89.1.1; Thoene J, 1999, MOL GENET METAB, V67, P283, DOI 10.1006/mgme.1999.2876; THOENE JG, 1976, J CLIN INVEST, V58, P180, DOI 10.1172/JCI108448; Touchman JW, 2000, GENOME RES, V10, P165, DOI 10.1101/gr.10.2.165; Town M, 1998, NAT GENET, V18, P319, DOI 10.1038/ng0498-319; WILLIAMS MA, 1990, J CELL BIOL, V111, P955, DOI 10.1083/jcb.111.3.955	34	97	100	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 20	2001	276	16					13314	13321		10.1074/jbc.M010562200	http://dx.doi.org/10.1074/jbc.M010562200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	423VN	11150305	hybrid			2022-12-25	WOS:000168198600117
J	Ghosh, D; Sawicki, M; Lala, P; Erman, M; Pangborn, W; Eyzaguirre, J; Gutierrez, R; Jornvall, H; Thiel, DJ				Ghosh, D; Sawicki, M; Lala, P; Erman, M; Pangborn, W; Eyzaguirre, J; Gutierrez, R; Jornvall, H; Thiel, DJ			Multiple conformations of catalytic serine and histidine in acetylxylan esterase at 0.90 angstrom	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELLULOSE-BINDING DOMAIN; X-RAY-DIFFRACTION; XYLAN ESTERASE; PENICILLIUM-PURPUROGENUM; TRICHODERMA-REESEI; SYSTEMS	Acetylxylan esterase (AXEII; 207 amino acids) from Penicillium purpurogenum has substrate specificities toward acetate esters of D-xylopyranose residues in xylan and belongs to a new class of alpha/beta hydrolases. The crystal structure of AXEII has been determined by single isomorphous replacement and anomalous scattering, and refined at 0.90- and 1.10-Angstrom resolutions with data collected at 85 K and 295 K, respectively. The tertiary structure consists of a doubly wound alpha/beta sandwich, having a central six-stranded parallel beta -sheet flanked by two parallel ol-helices on each side. The catalytic residues Ser(90), His(187), and Ap(175) are located at the C-terminal end of the sheet, an exposed region of the molecule. The serine and histidine side chains in the 295 K structure show the frequently observed conformations in which Ser(90) is trans and the hydroxyl group is in the plane of the imidazole ring of His(187), However, the structure at 85 K displays an additional conformation in which Ser(90) side-chain hydroxyl is away from the plane of the imidazole ring of His(187). The His(187) side chain forms a hydrogen bond with a sulfate ion and adopts an altered conformation. The only other known hydrolase that has a similar tertiary structure is Fusarium solani cutinase, The exposed nature of the catalytic triad suggests that AXEII is a pure esterase, i.e. an alpha/beta hydrolase with specificity for nonlipidic polar substrates.	Hauptmann Woodward Med Res Inst, Buffalo, NY 14203 USA; Roswell Pk Canc Inst, Buffalo, NY 14263 USA; Pontificia Univ Catolica Chile, Santiago, Chile; Karolinska Inst, SE-17177 Stockholm, Sweden; Cornell High Energy Synchotron Source, Ithaca, NY 14853 USA	Hauptman Woodward Medical Research Institute; Roswell Park Cancer Institute; Pontificia Universidad Catolica de Chile; Karolinska Institutet; Cornell University	Ghosh, D (corresponding author), Hauptmann Woodward Med Res Inst, 73 High St, Buffalo, NY 14203 USA.	ghosh@hwi.buffalo.edu	Gutierrez, Rodrigo/ABA-9285-2020; Gutiérrez, Rodrigo A/C-2611-2008	Gutierrez, Rodrigo/0000-0002-5961-5005; Gutiérrez, Rodrigo A/0000-0002-5961-5005				BIELY P, 1985, FEBS LETT, V186, P80, DOI 10.1016/0014-5793(85)81343-0; BIELY P, 1985, TRENDS BIOTECHNOL, V3, P286, DOI 10.1016/0167-7799(85)90004-6; BRUNGER AT, 1997, XPLOR MANUAL 3 8; CHRISTOV LP, 1993, ENZYME MICROB TECH, V15, P460, DOI 10.1016/0141-0229(93)90078-G; Egana L, 1996, BIOTECHNOL APPL BIOC, V24, P33; EVANS SV, 1993, J MOL GRAPHICS, V11, P134, DOI 10.1016/0263-7855(93)87009-T; EYZAGUIRRE J, 1999, SPECIAL PUBLICATION, V246, P117; Ghosh D, 1999, ACTA CRYSTALLOGR D, V55, P779, DOI 10.1107/S0907444999000244; GHOSH D, 1995, STRUCTURE, V3, P279, DOI 10.1016/S0969-2126(01)00158-7; Gutierrez R, 1998, FEBS LETT, V423, P35, DOI 10.1016/S0014-5793(98)00055-6; Hakulinen N, 1998, ACTA CRYSTALLOGR D, V54, P430, DOI 10.1107/S0907444997012213; JOSELEAU JP, 1992, PROGR BIOTECHNOL, V7, P1; Longhi S, 1997, J MOL BIOL, V268, P779, DOI 10.1006/jmbi.1997.1000; MargollesClark E, 1996, EUR J BIOCHEM, V237, P553, DOI 10.1111/j.1432-1033.1996.0553p.x; OLLIS DL, 1992, PROTEIN ENG, V5, P197, DOI 10.1093/protein/5.3.197; Otwinowski Z, 1995, HKL MANUAL; Pangborn W, 1996, PROTEINS, V24, P523, DOI 10.1002/(SICI)1097-0134(199604)24:4<523::AID-PROT13>3.0.CO;2-N; POUTANEN K, 1988, APPL MICROBIOL BIOT, V28, P419, DOI 10.1007/BF00268207; ROE SM, 1993, J MOL BIOL, V229, P419, DOI 10.1006/jmbi.1993.1043; SACK JS, 1988, J MOL GRAPHICS, V6, P224, DOI 10.1016/S0263-7855(98)80040-4; Sheldrick G.M., 1997, SHELX 97 MANUAL; Williamson G, 1998, MICROBIOL-SGM, V144, P2011, DOI 10.1099/00221287-144-8-2011; WONG KKY, 1993, PORT PR R M, V4, P127	23	58	62	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 6	2001	276	14					11159	11166		10.1074/jbc.M008831200	http://dx.doi.org/10.1074/jbc.M008831200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	420AC	11134051				2022-12-25	WOS:000167980900078
J	Bleijs, DA; van Duijnhoven, GCF; van Vliet, SJ; Thijssen, JPH; Figdor, CG; van Kooyk, Y				Bleijs, DA; van Duijnhoven, GCF; van Vliet, SJ; Thijssen, JPH; Figdor, CG; van Kooyk, Y			A single amino acid in the cytoplasmic domain of the beta(2) integrin lymphocyte function-associated antigen-1 regulates avidity-dependent inside-out signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CD11/CD18 LEUKOCYTE INTEGRINS; PROTEIN-KINASE-C; PHORBOL ESTER; CELL-ADHESION; CYTOSKELETAL ASSOCIATION; MONOCLONAL-ANTIBODY; ACTIN CYTOSKELETON; ALPHA-ACTININ; SMALL GTPASE; LFA-1	The leukocyte-specific beta (2) integrin lymphocyte function-associated antigen-1 (LFA-1) (alpha (L)/beta (2)) mediates activation-dependent adhesion to intercellular adhesion molecule (ICAM)-1, In leukocytes, LFA-1 requires activation by intracellular messengers to bind ICAM-1, We observed malfunctioning of LFA-1 activation in leukemic T cells and K562-transfected cells. This defective inside-out integrin activation is only restricted to beta (2) integrins, since beta (1) integrins expressed in KS62 readily respond to activation signals, such as phorbol la-myristate 13-acetate, To unravel these differences in inside-out signaling between beta (1) and beta (2) integrins, we searched for amino acids in the p, cytoplasmic domain that are critical in the activation of LFA-1, We provide evidence that substitution of a single amino acid (L732R) in the beta (2) cytoplasmic DLRE motif, creating the DRRE motif, is sufficient to completely restore PMA responsiveness of LFA-1 expressed in K562. In addition, an intact TTT motif in the C-terminal domain is necessary for the acquired PMA responsiveness. We observed that restoration of the PMA response altered neither LFA-1 affinity nor the phosphorylation status of LFA-1. In contrast, strong differences were observed in the capacity of LFA-1 to form clusters, which indicates that inside-out activation of LFA-1 strongly depends on cytoskeletal induced receptor reorganization that was induced by activation of the Ca2+-dependent protease calpain.	UMC Nijmegen, Dept Tumor Immunol, NL-6525 EX Nijmegen, Netherlands	Radboud University Nijmegen	van Kooyk, Y (corresponding author), UMC Nijmegen, Dept Tumor Immunol, Philips van Leydenlaan 25, NL-6525 EX Nijmegen, Netherlands.		Figdor, Carl G/A-4232-2010	Figdor, Carl G/0000-0002-2366-9212; van Vliet, Sandra/0000-0003-1811-2687				ANDREW D, 1993, EUR J IMMUNOL, V23, P2217, DOI 10.1002/eji.1830230925; BEATTY PG, 1983, J IMMUNOL, V131, P2913; BURN P, 1988, P NATL ACAD SCI USA, V85, P497, DOI 10.1073/pnas.85.2.497; DRANSFIELD I, 1992, J CELL BIOL, V116, P219, DOI 10.1083/jcb.116.1.219; DUSTIN ML, 1989, NATURE, V341, P619, DOI 10.1038/341619a0; FIGDOR CG, 1990, IMMUNOL TODAY, V11, P277, DOI 10.1016/0167-5699(90)90112-M; Geiger C, 2000, EMBO J, V19, P2525, DOI 10.1093/emboj/19.11.2525; Geijtenbeek TBH, 1999, BLOOD, V94, P754, DOI 10.1182/blood.V94.2.754.414k11_754_764; HIBBS ML, 1991, J EXP MED, V174, P1227, DOI 10.1084/jem.174.5.1227; HIBBS ML, 1991, SCIENCE, V251, P1611, DOI 10.1126/science.1672776; Hughes PE, 1996, J BIOL CHEM, V271, P6571, DOI 10.1074/jbc.271.12.6571; IMHOF BA, 1995, ADV IMMUNOL, V58, P345, DOI 10.1016/S0065-2776(08)60623-9; Jones SL, 1998, P NATL ACAD SCI USA, V95, P9331, DOI 10.1073/pnas.95.16.9331; Katagiri K, 2000, MOL CELL BIOL, V20, P1956, DOI 10.1128/MCB.20.6.1956-1969.2000; KEIZER GD, 1987, EUR J IMMUNOL, V17, P1317, DOI 10.1002/eji.1830170915; KEIZER GD, 1988, J IMMUNOL, V140, P1393; Kolanus W, 1996, CELL, V86, P233, DOI 10.1016/S0092-8674(00)80095-1; Krauss K, 1999, J BIOL CHEM, V274, P36921, DOI 10.1074/jbc.274.52.36921; KRENSKY AM, 1983, J IMMUNOL, V131, P611; Li JX, 1996, J BIOL CHEM, V271, P12985, DOI 10.1074/jbc.271.22.12985; Liliental J, 1998, J BIOL CHEM, V273, P2379, DOI 10.1074/jbc.273.4.2379; Lobb RR, 1995, CELL ADHES COMMUN, V3, P385, DOI 10.3109/15419069509081293; Lub M, 1997, MOL BIOL CELL, V8, P341, DOI 10.1091/mbc.8.2.341; Lub M, 1997, MOL BIOL CELL, V8, P719, DOI 10.1091/mbc.8.4.719; MARTZ E, 1987, HUM IMMUNOL, V18, P3, DOI 10.1016/0198-8859(87)90110-8; Pande G, 2000, CURR OPIN CELL BIOL, V12, P569, DOI 10.1016/S0955-0674(00)00133-2; PARDI R, 1995, J IMMUNOL, V155, P1252; PAVALKO FM, 1993, J IMMUNOL, V151, P3795; PETER K, 1995, J EXP MED, V181, P315, DOI 10.1084/jem.181.1.315; Reedquist KA, 2000, J CELL BIOL, V148, P1151, DOI 10.1083/jcb.148.6.1151; RESZKA AA, 1992, J CELL BIOL, V117, P1321, DOI 10.1083/jcb.117.6.1321; ROTHLEIN R, 1986, J EXP MED, V163, P1132, DOI 10.1084/jem.163.5.1132; Sampath R, 1998, J BIOL CHEM, V273, P33588, DOI 10.1074/jbc.273.50.33588; SANCHEZMADRID F, 1982, P NATL ACAD SCI-BIOL, V79, P7489, DOI 10.1073/pnas.79.23.7489; SCHALLER MD, 1995, J CELL BIOL, V130, P1181, DOI 10.1083/jcb.130.5.1181; Schoenwaelder SM, 1999, J BIOL CHEM, V274, P14359, DOI 10.1074/jbc.274.20.14359; SHARMA CP, 1995, J IMMUNOL, V154, P3461; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; Stewart MP, 1998, J CELL BIOL, V140, P699, DOI 10.1083/jcb.140.3.699; Valmu L, 1999, EUR J IMMUNOL, V29, P2107, DOI 10.1002/(SICI)1521-4141(199907)29:07<2107::AID-IMMU2107>3.0.CO;2-T; VALMU L, 1995, J IMMUNOL, V155, P1175; van Kooyk Y, 1999, J BIOL CHEM, V274, P26869, DOI 10.1074/jbc.274.38.26869; VANKOOYK Y, 1994, J CELL BIOL, V124, P1061, DOI 10.1083/jcb.124.6.1061; VANKOOYK Y, 1993, J EXP MED, V177, P185, DOI 10.1084/jem.177.1.185; WACHOLTZ MC, 1989, J EXP MED, V170, P431, DOI 10.1084/jem.170.2.431; Zhou XM, 2000, J BIOL CHEM, V275, P20217, DOI 10.1074/jbc.M909129199	46	23	29	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 30	2001	276	13					10338	10346		10.1074/jbc.M008967200	http://dx.doi.org/10.1074/jbc.M008967200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	420GC	11134023	hybrid, Green Published			2022-12-25	WOS:000167996400100
J	Chambenoit, O; Hamon, Y; Marguet, D; Rigneault, H; Rosseneu, M; Chimini, G				Chambenoit, O; Hamon, Y; Marguet, D; Rigneault, H; Rosseneu, M; Chimini, G			Specific docking of apolipoprotein A-I at the cell surface requires a functional ABCA1 transporter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FLUORESCENCE CORRELATION SPECTROSCOPY; BINDING CASSETTE TRANSPORTER-1; DENSITY-LIPOPROTEIN DEFICIENCY; CHOLESTEROL EFFLUX; TANGIER-DISEASE; PLASMA-MEMBRANE; APOPTOTIC CELLS; GENE; MUTATIONS; CAMP	The identification of defects in ABCA1 as the molecular basis of Tangier disease has highlighted its crucial role in the loading with phospholipids and cholesterol of nascent apolipoprotein particles. Indeed the expression of ABCA1 affects apolipoprotein A-I (apoA-I)-mediated removal of lipids from cell membranes, and the possible role of ABCA1 as an apoA-I surface receptor has been recently suggested, In the present study, we have investigated the role of the ABCA1 transporter as an apoA-I receptor with the analysis of a panel of transfectants expressing functional or mutant forms of ABCA1, We provide experimental evidence that the forced expression of a functional ABCA1 transporter confers surface competence for apoA-I binding. This, however, appears to be dependent on ABCA1 function. Structurally intact but ATPase-deficient forms of the transporter fail to elicit a specific cell association of the ligand, In addition the diffusion parameters of membrane-associated apoA-I indicate an interaction with membrane lipids rather than proteins. These results do not support a direct molecular interaction between ABCA1 and apoA-I, but rather suggest that the ABCA1-induced modification of the lipid distribution in the membrane, evidenced by the phosphatidylserine exofacial flopping, generates a biophysical microenvironment required for the docking of apoA-I at the cell surface.	CNRS Marseille Luminy, Ctr Immunol, INSERM, F-13288 Marseille 09, France; Ecole Normale Super Phys Marseille, Inst Fresnel, F-13397 Marseille, France; State Univ Ghent, Dept Biochem, B-9000 Ghent, Belgium	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite; UDICE-French Research Universities; Aix-Marseille Universite; Ghent University	Chimini, G (corresponding author), CNRS Marseille Luminy, Ctr Immunol, INSERM, Parc Sci Luminy Case 906, F-13288 Marseille 09, France.		HAMON, Yannick YH/N-5372-2016; RIGNEAULT, Hervé/L-6303-2017; Marguet, Didier/B-9946-2008; HAMON, Yannick/S-3118-2019; Marguet, Didier/AGO-5421-2022	HAMON, Yannick YH/0000-0002-7636-2310; RIGNEAULT, Hervé/0000-0001-6007-0631; HAMON, Yannick/0000-0002-7636-2310; Marguet, Didier/0000-0003-3198-5095				Abe-Dohmae S, 2000, BIOCHEMISTRY-US, V39, P11092, DOI 10.1021/bi0008175; Becq F, 1997, J BIOL CHEM, V272, P2695, DOI 10.1074/jbc.272.5.2695; Bergeron J, 1997, BBA-LIPID LIPID MET, V1344, P139, DOI 10.1016/S0005-2760(96)00136-1; Bevers EM, 1999, BBA-MOL CELL BIOL L, V1439, P317, DOI 10.1016/S1388-1981(99)00110-9; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Bodzioch M, 1999, NAT GENET, V22, P347, DOI 10.1038/11914; Bortnick AE, 2000, J BIOL CHEM, V275, P28634, DOI 10.1074/jbc.M003407200; Brooks-Wilson A, 1999, NAT GENET, V22, P336, DOI 10.1038/11905; Fielding PE, 2000, BIOCHEMISTRY-US, V39, P14113, DOI 10.1021/bi0004192; Gillotte KL, 1999, J BIOL CHEM, V274, P2021, DOI 10.1074/jbc.274.4.2021; Hamon Y, 2000, NAT CELL BIOL, V2, P399, DOI 10.1038/35017029; Ito J, 2000, J LIPID RES, V41, P894; Korlach J, 1999, P NATL ACAD SCI USA, V96, P8461, DOI 10.1073/pnas.96.15.8461; Lauffenburger D, 1993, RECEPTORS MODELS BIN, P9; Lawn RM, 1999, J CLIN INVEST, V104, pR25, DOI 10.1172/JCI8119; LUCIANI MF, 1994, GENOMICS, V21, P150, DOI 10.1006/geno.1994.1237; Marcil M, 1999, LANCET, V354, P1341, DOI 10.1016/S0140-6736(99)07026-9; Marguet D, 1999, NAT CELL BIOL, V1, P454, DOI 10.1038/15690; Martin C, 2000, BIOCHEMISTRY-US, V39, P11901, DOI 10.1021/bi000559b; McNeish J, 2000, P NATL ACAD SCI USA, V97, P4245, DOI 10.1073/pnas.97.8.4245; Oram JF, 2000, CURR OPIN LIPIDOL, V11, P253, DOI 10.1097/00041433-200006000-00005; Oram JF, 2000, J BIOL CHEM, V275, P34508, DOI 10.1074/jbc.M006738200; Orso E, 2000, NAT GENET, V24, P192, DOI 10.1038/72869; Peelman F, 1997, EUR J BIOCHEM, V249, P708, DOI 10.1111/j.1432-1033.1997.t01-2-00708.x; Rothblat GH, 1999, J LIPID RES, V40, P781; Rust S, 1999, NAT GENET, V22, P352, DOI 10.1038/11921; Sakr SW, 1999, BBA-MOL CELL BIOL L, V1438, P85, DOI 10.1016/S1388-1981(99)00041-4; Saxton MJ, 1996, BIOPHYS J, V70, P1250, DOI 10.1016/S0006-3495(96)79682-0; Schwille P, 1999, BIOPHYS J, V77, P2251, DOI 10.1016/S0006-3495(99)77065-7; Schwille P, 2000, P NATL ACAD SCI USA, V97, P151, DOI 10.1073/pnas.97.1.151; Schwille P, 1999, CYTOMETRY, V36, P176, DOI 10.1002/(SICI)1097-0320(19990701)36:3<176::AID-CYTO5>3.0.CO;2-F; VANLOO B, 1995, J LIPID RES, V36, P1686; Wang N, 2000, J BIOL CHEM, V275, P33053, DOI 10.1074/jbc.M005438200; Yokoyama S, 1998, BBA-LIPID LIPID MET, V1392, P1, DOI 10.1016/S0005-2760(98)00032-0	34	166	175	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 30	2001	276	13					9955	9960		10.1074/jbc.M010265200	http://dx.doi.org/10.1074/jbc.M010265200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	420GC	11150301	hybrid			2022-12-25	WOS:000167996400052
J	Cui, Y; Konig, J; Leier, I; Buchholz, U; Keppler, D				Cui, Y; Konig, J; Leier, I; Buchholz, U; Keppler, D			Hepatic uptake of bilirubin and its conjugates by the human organic anion transporter SLC21A6	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN LIVER; SUBSTRATE-SPECIFICITY; RAT; GLUCURONIDES; POLYPEPTIDE; ALBUMIN; ACID	Bilirubin, the end product of heme catabolism, is taken up from the blood circulation into the liver. This work identifies a high-affinity transport protein mediating the uptake of bilirubin and its conjugates into human hepatocytes. Human embryonic kidney cells (HEK293) permanently expressing the recombinant organic anion-transporting polypeptide 2 (human OATP2, also known as LST-1 or OATP-C; symbol SLC21A6) showed uptake of [H-3]monoglucuronosyl bilirubin, [H-3]bisglucuronosyl bilirubin, and [H-3]sulfobromophthalein with X, values of 0,10, 0,28, and 0.14,muM, respectively. High-affinity uptake of unconjugated [H-3]bilirubin by OATP2 occurred in the presence of albumin and was not mediated by another basolateral hepatic uptake transporter, human OATP8 (symbol SLC21A8), OATP2 and OATP8 differed by their capacity to extract substrates from albumin before transport. In comparison to the high-affinity transport by OATP8, OATP8 transported [H-3]sulfobromophthalein and [H-3]monoglucuronosyl bilirubin with lower affinity, with K-m values of 3.3 and 0.5 muM. respectively. The organic anion indocyanine green potently inhibited transport mediated by OATP2, with a Ki value of 112 nM, but did not inhibit transport mediated by OATP8, Human OATP2 may play a key role in the prevention of hyperbilirubinemia by facilitating the selective entry of unconjugated bilirubin and its glucuronate conjugates into human hepatocytes.	Deutsch Krebsforschungszentrum, Div Tumor Biochem, D-69120 Heidelberg, Germany	Helmholtz Association; German Cancer Research Center (DKFZ)	Cui, Y (corresponding author), Deutsch Krebsforschungszentrum, Div Tumor Biochem, Neuenheimer Feld 280, D-69120 Heidelberg, Germany.		Cui, Yunhai/AAP-7670-2021; Keppler, Dietrich/A-5528-2013	Cui, Yunhai/0000-0003-4969-072X; Keppler, Dietrich/0000-0003-2964-2333; Koenig, Joerg/0000-0001-7016-5482				Abe T, 1999, J BIOL CHEM, V274, P17159, DOI 10.1074/jbc.274.24.17159; ARIAS IA, 1961, AM J PHYSIOL, V200, P1091, DOI 10.1152/ajplegacy.1961.200.5.1091; BLACK M, 1969, NEW ENGL J MED, V280, P1266, DOI 10.1056/NEJM196906052802303; BRODERSEN R, 1990, ACTA PAEDIATR SCAND, V79, P12, DOI 10.1111/j.1651-2227.1990.tb11323.x; Chowdhury Jayanta Roy, 1994, P471; CRAWFORD JM, 1987, J CLIN INVEST, V79, P1172, DOI 10.1172/JCI112934; Hsiang BN, 1999, J BIOL CHEM, V274, P37161, DOI 10.1074/jbc.274.52.37161; JACQUEMIN E, 1994, P NATL ACAD SCI USA, V91, P133, DOI 10.1073/pnas.91.1.133; Jedlitschky G, 1997, BIOCHEM J, V327, P305, DOI 10.1042/bj3270305; Kamisako T, 1999, HEPATOLOGY, V30, P485, DOI 10.1002/hep.510300220; Konig J, 2000, J BIOL CHEM, V275, P23161, DOI 10.1074/jbc.M001448200; Konig J, 2000, AM J PHYSIOL-GASTR L, V278, pG156, DOI 10.1152/ajpgi.2000.278.1.G156; KULLAKUBLICK GA, 1995, GASTROENTEROLOGY, V109, P1274, DOI 10.1016/0016-5085(95)90588-X; LEHMANN WD, 1984, J LABELLED COMPD RAD, V21, P455, DOI 10.1002/jlcr.2580210508; MARTIN JF, 1976, GASTROENTEROLOGY, V70, P385; Mediavilla MG, 1999, FEBS LETT, V463, P143, DOI 10.1016/S0014-5793(99)01606-3; Meier PJ, 1997, HEPATOLOGY, V26, P1667, DOI 10.1002/hep.510260641; OKUDA K, 1976, GUT, V17, P588, DOI 10.1136/gut.17.8.588; Pascolo L, 1996, BIOCHEM J, V316, P999, DOI 10.1042/bj3160999; SCHARSCHMIDT BF, 1975, J CLIN INVEST, V56, P1280, DOI 10.1172/JCI108204; SENAFI SB, 1994, BIOCHEM J, V303, P233, DOI 10.1042/bj3030233; WEISIGER RA, 1985, P NATL ACAD SCI USA, V82, P1563, DOI 10.1073/pnas.82.5.1563	22	374	389	2	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 30	2001	276	13					9626	9630		10.1074/jbc.M004968200	http://dx.doi.org/10.1074/jbc.M004968200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	420GC	11134001	hybrid			2022-12-25	WOS:000167996400008
J	Finazzi, G; Zito, F; Barbagallo, RP; Wollman, FA				Finazzi, G; Zito, F; Barbagallo, RP; Wollman, FA			Contrasted effects of inhibitors of cytochrome b(6)f complex on state transitions in Chlamydomonas reinhardtii - The role of Q(o) site occupancy in LHCII kinase activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHLOROPLAST PROTEIN-PHOSPHORYLATION; LIGHT ENERGY-DISTRIBUTION; BC(1) COMPLEX; CHLOROPHYLL FLUORESCENCE; DOMAIN MOVEMENT; BF COMPLEX; BINDING; PHOTOSYNTHESIS; PLASTOQUINONE; DEACTIVATION	We have investigated the relationship between the occupancy of the Q(o) site in the cytochrome b(6)f complex and the activation of the LHCII protein kinase that controls state transitions. To this aim, fluorescence emission and LHCII phosphorylation patterns were studied in whole cells of Chlamydomonas reinhardtii treated with different plastoquinone analogues. The analysis of fluorescence induction at room temperature indicates that stigmatellin consistently prevented transition to State 2, whereas 2,5-dibromo-3-methyl-6-isopropyl-p-benzoquinone behaved as an inhibitor of state transitions only after the cells were preilluminated, The same effects were observed on the phosphorylation patterns of the LHCII proteins, while subunit V of the cytochrome b(6)f complex showed a different behavior. These findings are discussed on the basis of a dynamic structural model of cytochrome b(6)f that relates the activation of the LHCII kinase to the occupancy of the Q(o) site and the movement of the Rieske protein.	Univ Milan, Ctr Studio Biol Cellulare & Mol Piante, CNR, I-20133 Milan, Italy; CNRS, Inst Biol Physicochim, UPR 9050, F-75005 Paris, France; CNRS, Inst Biol Physicochim, UPR 1261, F-75005 Paris, France	Consiglio Nazionale delle Ricerche (CNR); University of Milan; Centre National de la Recherche Scientifique (CNRS); Centre National de la Recherche Scientifique (CNRS)	Finazzi, G (corresponding author), Univ Milan, Ctr Studio Biol Cellulare & Mol Piante, CNR, Via Celoria 26, I-20133 Milan, Italy.	giovanni.finazzi@unimi.it		Zito, Francesca/0000-0003-1783-5090				ALLEN JF, 1981, NATURE, V291, P25, DOI 10.1038/291025a0; ALLEN JF, 1981, BIOCHIM BIOPHYS ACTA, V638, P290, DOI 10.1016/0005-2728(81)90239-5; Barbagallo RP, 1999, BIOCHEMISTRY-US, V38, P12814, DOI 10.1021/bi990424+; BENNETT J, 1991, ANNU REV PLANT PHYS, V42, P281, DOI 10.1146/annurev.pp.42.060191.001433; BENNOUN P, 1986, PLANT MOL BIOL, V6, P151, DOI 10.1007/BF00021484; BONAVENTURA C, 1969, BIOCHIM BIOPHYS ACTA, V189, P366, DOI 10.1016/0005-2728(69)90168-6; Breyton C, 2000, J BIOL CHEM, V275, P13195, DOI 10.1074/jbc.275.18.13195; Brugna M, 2000, P NATL ACAD SCI USA, V97, P2069, DOI 10.1073/pnas.030539897; BULTE L, 1990, BIOCHIM BIOPHYS ACTA, V1020, P72, DOI 10.1016/0005-2728(90)90095-L; BUTLER WL, 1978, ANNU REV PLANT PHYS, V29, P345, DOI 10.1146/annurev.pp.29.060178.002021; Crofts AR, 1999, BIOCHEMISTRY-US, V38, P15807, DOI 10.1021/bi990962m; Crofts AR, 1998, CURR OPIN STRUC BIOL, V8, P501, DOI 10.1016/S0959-440X(98)80129-2; DEBUS RJ, 1992, BIOCHIM BIOPHYS ACTA, V1102, P269, DOI 10.1016/0005-2728(92)90133-M; DEKOUCHKOVSKY Y, 1975, BIOCHIM BIOPHYS ACTA, V376, P259, DOI 10.1016/0005-2728(75)90018-3; DELOSME R, 1994, BBA-BIOENERGETICS, V1185, P56, DOI 10.1016/0005-2728(94)90193-7; Delosme R, 1996, BBA-BIOENERGETICS, V1273, P150, DOI 10.1016/0005-2728(95)00143-3; DING HG, 1992, BIOCHEMISTRY-US, V31, P3144, DOI 10.1021/bi00127a015; Elich TD, 1997, FEBS LETT, V411, P236, DOI 10.1016/S0014-5793(97)00698-4; FRANK K, 1995, PHOTOCHEM PHOTOBIOL, V61, P2, DOI 10.1111/j.1751-1097.1995.tb09237.x; Fulgosi H, 1998, EMBO J, V17, P1577, DOI 10.1093/emboj/17.6.1577; GAL A, 1990, J BIOL CHEM, V265, P19742; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; Hamel P, 2000, J BIOL CHEM, V275, P17072, DOI 10.1074/jbc.M001468200; HORTON P, 1981, BIOCHIM BIOPHYS ACTA, V635, P53, DOI 10.1016/0005-2728(81)90006-2; Iwata S, 1998, SCIENCE, V281, P64, DOI 10.1126/science.281.5373.64; RICH PR, 1991, BIOCHIM BIOPHYS ACTA, V1058, P312, DOI 10.1016/S0005-2728(05)80252-X; Schoepp B, 1999, FEBS LETT, V450, P245, DOI 10.1016/S0014-5793(99)00511-6; SUEOKA N, 1965, P NATL ACAD SCI USA, V54, P1665; Vener AV, 1998, CURR OPIN PLANT BIOL, V1, P217, DOI 10.1016/S1369-5266(98)80107-6; Vener AV, 1997, P NATL ACAD SCI USA, V94, P1585, DOI 10.1073/pnas.94.4.1585; VENER AV, 1995, J BIOL CHEM, V270, P25225, DOI 10.1074/jbc.270.42.25225; WOLLMAN FA, 1984, J CELL BIOL, V98, P1, DOI 10.1083/jcb.98.1.1; WOLLMAN FA, 1988, BIOCHIM BIOPHYS ACTA, V933, P85, DOI 10.1016/0005-2728(88)90058-8; Zhang ZL, 1998, NATURE, V392, P677, DOI 10.1038/33612; Zito F, 1999, EMBO J, V18, P2961, DOI 10.1093/emboj/18.11.2961	35	61	69	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 30	2001	276	13					9770	9774		10.1074/jbc.M010092200	http://dx.doi.org/10.1074/jbc.M010092200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	420GC	11134032	hybrid			2022-12-25	WOS:000167996400027
J	Depoix, C; Delmotte, MH; Formstecher, P; Lefebvre, P				Depoix, C; Delmotte, MH; Formstecher, P; Lefebvre, P			Control of retinoic acid receptor heterodimerization by ligand-induced structural transitions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THYROID-HORMONE RECEPTOR; EMBRYONAL CARCINOMA-CELLS; HUMAN ESTROGEN-RECEPTOR; DNA-BINDING; X-RECEPTOR; HOMODIMER FORMATION; NUCLEAR RECEPTORS; IN-VIVO; BETA-2 PROMOTER; DIMERIZATION	Heterodimerization of retinoic acid receptors (RARs) with 9-cis-retinoic receptors (RXRs) is a prerequisite for binding of RXR.RAR dimers to DNA and for retinoic acid-induced gene regulation. Whether retinoids control RXR/RAR solution interaction remains a debated question, and we have used in vitro and in vivo protein interaction assays to investigate the role of ligand in modulating RXR/RAR interaction in the absence of DNA. Two-hybrid assay in mammalian cells demonstrated that only RAR agonists were able to increase significantly RAR interaction with RXR, whereas RAR antagonists inhibited RXR binding to RAR, Quantitative glutathione S-transferase pull-dawn assays established that there was a strict correlation between agonist binding affinity for the RAR monomer and the affinity of RXR for liganded RAR, but RAR antagonists were inactive in inducing RXR recruitment to RAR in vitro, Alteration of coactivator- or corepressor-binding interfaces of RXR or RAR did not alter ligand-enhanced dimerization. In contrast, preventing the formation of a stable holoreceptor structure upon agonist binding strongly altered RXR.RAR dimerization, Finally, we observed that RAR interaction with RXR silenced RXR ligand-dependent activation function. We propose that ligand-controlled dimerization of RAR with RXR is an important step in the RXR.RAR activation process. This interaction is dependent upon adequate remodeling of the AF-2 structure and amenable to pharmacological inhibition by structurally modified retinoids.	Fac Med Henri Warembourg, INSERM, U459, F-59045 Lille, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Lille - ISITE; Universite de Lille	Lefebvre, P (corresponding author), Fac Med Henri Warembourg, INSERM, U459, 1 Pl Verdun, F-59045 Lille, France.		Lefebvre, Philippe/F-2685-2010	Lefebvre, Philippe/0000-0002-9366-5129; depoix, christophe/0000-0003-2826-3075				APFEL C, 1992, P NATL ACAD SCI USA, V89, P7129, DOI 10.1073/pnas.89.15.7129; ARCHER TK, 1992, SCIENCE, V255, P1573, DOI 10.1126/science.1347958; ARNOLD SF, 1995, P NATL ACAD SCI USA, V92, P7475, DOI 10.1073/pnas.92.16.7475; Ausubel FM., 2006, ENZYMATIC MANIPULATI; BAIN G, 1994, BIOESSAYS, V16, P343, DOI 10.1002/bies.950160509; Benkoussa M, 1997, RECEPT SIGNAL TRANS, V7, P257; Bhattacharyya N, 1997, MOL CELL BIOL, V17, P6481, DOI 10.1128/MCB.17.11.6481; Bourguet W, 2000, MOL CELL, V5, P289, DOI 10.1016/S1097-2765(00)80424-4; Chen JY, 1996, NATURE, V382, P819, DOI 10.1038/382819a0; Cheskis B, 1996, BIOCHEMISTRY-US, V35, P3309, DOI 10.1021/bi952283r; Collingwood TN, 1997, J BIOL CHEM, V272, P13060, DOI 10.1074/jbc.272.20.13060; Delmotte MH, 1999, J BIOL CHEM, V274, P38225, DOI 10.1074/jbc.274.53.38225; DEMARZO AM, 1991, P NATL ACAD SCI USA, V88, P72, DOI 10.1073/pnas.88.1.72; DEY A, 1994, MOL CELL BIOL, V14, P8191, DOI 10.1128/MCB.14.12.8191; Dong D, 1998, BIOCHEMISTRY-US, V37, P10691, DOI 10.1021/bi980561r; DROUIN J, 1992, MOL ENDOCRINOL, V6, P1299, DOI 10.1210/me.6.8.1299; Dudley MW, 2000, P NATL ACAD SCI USA, V97, P3696, DOI 10.1073/pnas.040558197; FAWELL SE, 1990, P NATL ACAD SCI USA, V87, P6883, DOI 10.1073/pnas.87.17.6883; FURLOW JD, 1993, J BIOL CHEM, V268, P12519; Glass CK, 2000, GENE DEV, V14, P121; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; Kakizawa T, 1997, J BIOL CHEM, V272, P23799, DOI 10.1074/jbc.272.38.23799; Klein ES, 1996, J BIOL CHEM, V271, P22692, DOI 10.1074/jbc.271.37.22692; KLIEWER SA, 1992, NATURE, V355, P446, DOI 10.1038/355446a0; LEES JA, 1990, MOL CELL BIOL, V10, P5529, DOI 10.1128/MCB.10.10.5529; LEFEBVRE B, 1995, BIOCHEMISTRY-US, V34, P5477, DOI 10.1021/bi00016a019; Lefebvre B, 1998, MOL CELL ENDOCRINOL, V139, P161, DOI 10.1016/S0303-7207(98)00065-3; Lefebvre P, 1998, J BIOL CHEM, V273, P12288, DOI 10.1074/jbc.273.20.12288; LEFEBVRE P, 1995, J BIOL CHEM, V270, P10806, DOI 10.1074/jbc.270.18.10806; Leonhardt SA, 1998, MOL ENDOCRINOL, V12, P1914, DOI 10.1210/me.12.12.1914; MCBURNEY MW, 1993, INT J DEV BIOL, V37, P135; Mouchon A, 1999, MOL CELL BIOL, V19, P3073; PERLMANN T, 1995, GENE DEV, V9, P769, DOI 10.1101/gad.9.7.769; Rachez C, 1996, J BIOL CHEM, V271, P17996, DOI 10.1074/jbc.271.30.17996; Rachez C, 2000, GENE, V246, P9, DOI 10.1016/S0378-1119(00)00052-4; Schulman IG, 1996, MOL CELL BIOL, V16, P3807; Tanenbaum DM, 1998, P NATL ACAD SCI USA, V95, P5998, DOI 10.1073/pnas.95.11.5998; Tate BF, 1996, FASEB J, V10, P1524, DOI 10.1096/fasebj.10.13.8940298; Vega Diaz Barbara, 2000, Journal of Biological Chemistry, V275, P642; WANG H, 1995, J BIOL CHEM, V270, P23322, DOI 10.1074/jbc.270.40.23322; Westin S, 1998, NATURE, V395, P199, DOI 10.1038/26040; ZECHEL C, 1994, EMBO J, V13, P1414, DOI 10.1002/j.1460-2075.1994.tb06395.x; ZELENT A, 1991, EMBO J, V10, P71, DOI 10.1002/j.1460-2075.1991.tb07922.x; ZHANG XK, 1992, NATURE, V358, P587, DOI 10.1038/358587a0	44	30	31	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 23	2001	276	12					9452	9459		10.1074/jbc.M008004200	http://dx.doi.org/10.1074/jbc.M008004200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	413HV	11254657	hybrid			2022-12-25	WOS:000167607700110
J	Mueller, GA; Smith, AM; Chapman, MD; Rule, GS; Benjamin, DC				Mueller, GA; Smith, AM; Chapman, MD; Rule, GS; Benjamin, DC			Hydrogen exchange nuclear magnetic resonance spectroscopy mapping of antibody epitopes on the house dust mite allergen Der p 2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROUP-II DERMATOPHAGOIDES; PROTEIN ANTIGEN; P 2; IGE; MUTAGENESIS; BINDING; SURFACE	New strategies for allergen-specific immunotherapy have focused on reducing IgE reactivity of purified recombinant allergens while maintaining T-cell epitopes. Previously, we showed that disrupting the disulfide bonds of the major house dust mite allergen Der p 2 resulted in 10-100-fold less skin test reactivity in mite-allergic subjects but did not change in vitro T-cell proliferative responses. To provide a more complete picture of the antigenic surface of Der p 2, we report here the identification of three epitopes using hydrogen protection nuclear magnetic resonance spectroscopy. The epitopes are defined by monoclonal antibodies that are able to inhibit IgE antibody binding to the allergen. Each monoclonal antibody affected the amide exchange rate of 2-3 continuous residues in different regions of Der p 2. Based on these data, a number of other residues were predicted to belong to each epitope, and this prediction was tested for monoclonal antibody 7A1 by generating alanine point mutants. The results indicate that only a small number of residues within the predicted epitope are functionally important for antibody binding. The molecular definition of these three epitopes will enable us to target limited positions for mutagenesis and to expand our studies of hypoallergenic variants for immunotherapy.	Univ Virginia, Asthma & Allerg Dis Ctr, Biophys Program, Charlottesville, VA 22908 USA; Univ Virginia, Asthma & Allerg Dis Ctr, Dept Med, Charlottesville, VA 22908 USA; Univ Virginia Hlth Syst, Beirne B Carter Ctr Immunol, Charlottesville, VA 22908 USA; Carnegie Mellon Univ, Div Biol Sci, Pittsburgh, PA 15213 USA	University of Virginia; University of Virginia; University of Virginia; Carnegie Mellon University	Benjamin, DC (corresponding author), Univ Virginia Hlth Syst, Beirne B Carter Ctr Immunol, POB 801386, Charlottesville, VA 22908 USA.	dcb@virginia.edu	Mueller, Geoffrey A/I-2909-2017; Rule, Gordon S/Q-2422-2015	Mueller, Geoffrey A/0000-0001-8361-5323; Rule, Gordon S/0000-0002-4396-3363; Chapman, Martin/0000-0002-0845-3632	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI034607, U19AI034607, R37AI020565, R01AI020565] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 34607, AI-20565] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Benjamin David C., 1996, Methods (Orlando), V9, P508, DOI 10.1006/meth.1996.0058; BENJAMIN DC, 1992, BIOCHEMISTRY-US, V31, P9539, DOI 10.1021/bi00155a005; BODENHAUSEN G, 1980, CHEM PHYS LETT, V69, P185, DOI 10.1016/0009-2614(80)80041-8; Chua KY, 1996, CLIN EXP ALLERGY, V26, P829, DOI 10.1111/j.1365-2222.1996.tb00615.x; Dall'Acqua W, 1998, BIOCHEMISTRY-US, V37, P7981, DOI 10.1021/bi980148j; DAVIES DR, 1990, ANNU REV BIOCHEM, V59, P439, DOI 10.1146/annurev.bi.59.070190.002255; Hakkaart GAJ, 1998, CLIN EXP ALLERGY, V28, P169, DOI 10.1046/j.1365-2222.1998.00205.x; HEYMANN PW, 1989, J ALLERGY CLIN IMMUN, V83, P1055, DOI 10.1016/0091-6749(89)90447-8; JIN L, 1992, J MOL BIOL, V226, P851, DOI 10.1016/0022-2836(92)90636-X; LOMBARDERO M, 1990, J IMMUNOL, V144, P1353; MARION D, 1989, BIOCHEMISTRY-US, V28, P6150, DOI 10.1021/bi00441a004; Mueller GA, 1998, BIOCHEMISTRY-US, V37, P12707, DOI 10.1021/bi980578+; Mueller GA, 1997, J BIOL CHEM, V272, P26893, DOI 10.1074/jbc.272.43.26893; Nishiyama C, 1999, MOL IMMUNOL, V36, P53, DOI 10.1016/S0161-5890(98)00112-6; NOVOTNY J, 1986, P NATL ACAD SCI USA, V83, P226, DOI 10.1073/pnas.83.2.226; OVSYANNIKOVA IG, 1994, J ALLERGY CLIN IMMUN, V94, P537, DOI 10.1016/0091-6749(94)90211-9; PATERSON Y, 1990, SCIENCE, V249, P755, DOI 10.1126/science.1697101; Platts-Mills TAE, 1997, J ALLERGY CLIN IMMUN, V100, pS2, DOI 10.1016/S0091-6749(97)70292-6; PRASAD L, 1993, J BIOL CHEM, V268, P10705; Schuurman J, 1997, J ALLERGY CLIN IMMUN, V99, P545, DOI 10.1016/S0091-6749(97)70083-6; Smith AM, 1997, CLIN EXP ALLERGY, V27, P593, DOI 10.1111/j.1365-2222.1997.tb00750.x; Smith AM, 1996, MOL IMMUNOL, V33, P399, DOI 10.1016/0161-5890(95)00150-6; SMITH AM, 1991, J IMMUNOL, V146, P1254; SMITH AM, 1999, IMMUNOTHERAPY ASTHMA; SMITHGILL SJ, 1990, FASEB J, V4, P2276; SPORIK R, 1992, CLIN EXP ALLERGY, V22, P897, DOI 10.1111/j.1365-2222.1992.tb02062.x; VANDERZEE JS, 1988, J ALLERGY CLIN IMMUN, V81, P884, DOI 10.1016/0091-6749(88)90946-3; Williams DC, 1996, J MOL BIOL, V257, P866, DOI 10.1006/jmbi.1996.0207	28	57	69	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 23	2001	276	12					9359	9365		10.1074/jbc.M010812200	http://dx.doi.org/10.1074/jbc.M010812200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	413HV	11134039	hybrid			2022-12-25	WOS:000167607700099
J	Mojena, M; Hortelano, S; Castrillo, A; Diaz-Guerra, MJM; Garcia-Barchino, MJ; Saez, GT; Bosca, L				Mojena, M; Hortelano, S; Castrillo, A; Diaz-Guerra, MJM; Garcia-Barchino, MJ; Saez, GT; Bosca, L			Protection by nitric oxide against liver inflammatory injury in animals carrying a nitric oxide synthase-2 transgene	FASEB JOURNAL			English	Article									Univ Complutense Madrid, Fac Farm, CSIC, Inst Bioquim, E-28040 Madrid, Spain; Merck Sharp & Dohme Ltd, CIBE, Madrid, Spain; Fac Med, Dept Bioquim, Albacete 02071, Spain; Univ Valencia, Fac Med, Dept Bioquim & Biol Mol, Valencia 46010, Spain	Complutense University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); Merck & Company; University of Valencia	Bosca, L (corresponding author), Univ Complutense Madrid, Fac Farm, CSIC, Inst Bioquim, E-28040 Madrid, Spain.		Bosca, Lisardo/A-2059-2008; Díaz-Guerra, María José M/M-2855-2014; Hortelano, Sonsoles/A-7954-2010	Bosca, Lisardo/0000-0002-0253-5469; Díaz-Guerra, María José M/0000-0003-3843-3912; Hortelano, Sonsoles/0000-0003-2528-0072; Saez, Guillermo/0000-0002-8164-4048; Mojena, Marina/0000-0002-5371-8118					0	44	46	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAR	2001	15	3					583	585						3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	410BE	11259374				2022-12-25	WOS:000167419500012
J	Ticchioni, M; Raimondi, V; Lamy, L; Wijdenes, J; Lindberg, FP; Brown, EJ; Bernard, A				Ticchioni, M; Raimondi, V; Lamy, L; Wijdenes, J; Lindberg, FP; Brown, EJ; Bernard, A			Integrin-associated protein (CD47/IAP) contributes to T cell arrest on inflammatory vascular endothelium under flow	FASEB JOURNAL			English	Article						adhesion; T cell circulation; integrin	NEURAL ADHESION MOLECULE; RED-BLOOD-CELLS; L-SELECTIN; SIGNAL-TRANSDUCTION; IMMOBILIZED THROMBOSPONDIN; HUMAN MONOCYTES; BINDING DOMAIN; SHEAR-FLOW; RECEPTOR; EXPRESSION	Integrin-associated protein (CD47/IAP) is a pentaspan molecule that regulates integrin functions. We prepared a CD47-deficient Jurkat T cell line to assess its role in the arrest of T cells on inflammatory endothelium. Under flow conditions, constitutive arrest of CD47-deficient cells is strongly decreased as compared to the original cell line, whereas reexpression of CD47 reestablishes their ability to stop. Moreover, cells transfected with a chimera made with the extracellular portion of CD47 and the transmembrane domain of CD7 or several truncated forms of CD47 show that the first transmembrane domain and a short cytoplasmic loop are sufficient for this process. CD47 effect is indirect and depends mainly on the alpha4 beta1/VCAM-1 pathway, as shown by blocking antibodies. We detected on endothelium the two CD47 counter receptors known to date: thrombospondin and SIRP1 alpha, Blocking experiments show that both are involved. Overall, CD47 participates in the constitutive arrest of T lymphocytes on inflamed vascular endothelium by up-regulating alpha 4 beta1 integrins.	Hop Archet, Unite INERM U343, F-06202 Nice 3, France; Immunol Lab, F-06202 Nice, France; Diaclone Res, F-25020 Besancon, France; Washington Univ, Sch Med, Div Infect Dis, St Louis, MO 63110 USA; Univ Calif San Francisco, San Francisco, CA 94143 USA	CHU Nice; Institut National de la Sante et de la Recherche Medicale (Inserm); Washington University (WUSTL); University of California System; University of California San Francisco	Bernard, A (corresponding author), Hop Archet, Unite INERM U343, Route St Antoine Ginestiere,BP 3079, F-06202 Nice 3, France.		Ticchioni, Michel/P-8095-2016		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM057573] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM57573-01] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abe Y, 1996, J IMMUNOL, V157, P5061; ADAMS J, 1993, CURR BIOL, V3, P188, DOI 10.1016/0960-9822(93)90270-X; ALON R, 1995, J CELL BIOL, V128, P1243, DOI 10.1083/jcb.128.6.1243; Aplin AE, 1998, PHARMACOL REV, V50, P197; Babic I, 2000, J IMMUNOL, V164, P3652, DOI 10.4049/jimmunol.164.7.3652; Baggiolini M, 1998, NATURE, V392, P565, DOI 10.1038/33340; Barabino GA, 1997, BLOOD, V89, P2560, DOI 10.1182/blood.V89.7.2560; BERLIN C, 1995, CELL, V80, P413, DOI 10.1016/0092-8674(95)90491-3; Blanks JE, 1998, EUR J IMMUNOL, V28, P433, DOI 10.1002/(SICI)1521-4141(199802)28:02<433::AID-IMMU433>3.0.CO;2-U; BLYSTONE SD, 1995, J CELL BIOL, V130, P745, DOI 10.1083/jcb.130.3.745; BLYSTONE SD, 1994, J CELL BIOL, V127, P1129, DOI 10.1083/jcb.127.4.1129; BORNSTEIN P, 1995, J CELL BIOL, V130, P503, DOI 10.1083/jcb.130.3.503; BORNSTEIN P, 1992, FASEB J, V6, P3290, DOI 10.1096/fasebj.6.14.1426766; BROWN EJ, 1990, J CELL BIOL, P2785; Butcher EC, 1996, SCIENCE, V272, P60, DOI 10.1126/science.272.5258.60; CAMPBELL IG, 1992, CANCER RES, V52, P5416; Chen C, 1999, J IMMUNOL, V162, P1084; Chung J, 1997, J BIOL CHEM, V272, P14740, DOI 10.1074/jbc.272.23.14740; Chung J, 1999, BLOOD, V94, P642, DOI 10.1182/blood.V94.2.642.414k35_642_648; Comu S, 1997, J NEUROSCI, V17, P8702; COOKE BM, 1994, BRIT J HAEMATOL, V87, P162, DOI 10.1111/j.1365-2141.1994.tb04887.x; COOPER D, 1995, P NATL ACAD SCI USA, V92, P3978, DOI 10.1073/pnas.92.9.3978; EDGELL CJ, 1983, P NATL ACAD SCI-BIOL, V80, P3734, DOI 10.1073/pnas.80.12.3734; Frazier WA, 1999, J BIOL CHEM, V274, P8554, DOI 10.1074/jbc.274.13.8554; Furusawa T, 1998, J BIOCHEM-TOKYO, V123, P101; Gao AG, 1996, J CELL BIOL, V135, P533, DOI 10.1083/jcb.135.2.533; GAO AG, 1994, J BIOL CHEM, V269, P29650; GAO AG, 1996, J BIOL CHEM, V271, P12; Giblin PA, 1997, J IMMUNOL, V159, P3498; Gopalan PK, 1997, J IMMUNOL, V158, P367; Green JM, 1999, J CELL BIOL, V146, P673, DOI 10.1083/jcb.146.3.673; GRESHAM HD, 1992, J BIOL CHEM, V267, P13885; Hermann P, 1999, J CELL BIOL, V144, P767, DOI 10.1083/jcb.144.4.767; Huang AM, 1998, J NEUROSCI, V18, P4305; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; Imhof BA, 1997, EUR J IMMUNOL, V27, P3242, DOI 10.1002/eji.1830271223; JAKUBOWSKI A, 1995, CELL ADHES COMMUN, V3, P131, DOI 10.3109/15419069509081282; Jiang PH, 1999, J BIOL CHEM, V274, P559, DOI 10.1074/jbc.274.2.559; Joneckis CC, 1996, BLOOD, V87, P4862, DOI 10.1182/blood.V87.11.4862.bloodjournal87114862; KANSAS GS, 1993, J EXP MED, V177, P833, DOI 10.1084/jem.177.3.833; KOSFELD MD, 1993, J BIOL CHEM, V268, P8808; Li XP, 1996, AM J RESP CELL MOL, V14, P398, DOI 10.1165/ajrcmb.14.4.8600945; Lindberg FP, 1996, J CELL BIOL, V134, P1313, DOI 10.1083/jcb.134.5.1313; Lindberg FP, 1996, SCIENCE, V274, P795, DOI 10.1126/science.274.5288.795; LINDBERG FP, 1993, J CELL BIOL, V123, P485, DOI 10.1083/jcb.123.2.485; MACKINNON M, 1990, DIABETIC MED, V7, P171, DOI 10.1111/j.1464-5491.1990.tb01356.x; MASUMOTO A, 1993, J BIOL CHEM, V268, P228; MCPHERSON J, 1981, J BIOL CHEM, V256, P1330; Mi ZP, 2000, J COMP NEUROL, V416, P335; MODDERMAN PW, 1992, LEUKOCYTE TYPING 4, P1025; MOSHER DF, 1982, J CELL BIOL, V93, P343, DOI 10.1083/jcb.93.2.343; MURPHYULLRICH JE, 1987, J CELL BIOL, V105, P1603, DOI 10.1083/jcb.105.4.1603; OSBORN L, 1989, CELL, V59, P1203, DOI 10.1016/0092-8674(89)90775-7; Parkos CA, 1996, J CELL BIOL, V132, P437, DOI 10.1083/jcb.132.3.437; Pettersen RD, 1999, J IMMUNOL, V162, P7031; PICKER LJ, 1992, ANNU REV IMMUNOL, V10, P561, DOI 10.1146/annurev.immunol.10.1.561; PITZALIS C, 1991, EUR J IMMUNOL, V21, P369, DOI 10.1002/eji.1830210218; Porter JC, 1997, J CELL BIOL, V138, P1437, DOI 10.1083/jcb.138.6.1437; Reinhold MI, 1997, J EXP MED, V185, P1, DOI 10.1084/jem.185.1.1; Reinhold MI, 1999, INT IMMUNOL, V11, P707, DOI 10.1093/intimm/11.5.707; REINHOLD MI, 1995, J CELL SCI, V108, P3419; ROSALES C, 1995, J LEUKOCYTE BIOL, V57, P189, DOI 10.1002/jlb.57.2.189; Saginario C, 1998, MOL CELL BIOL, V18, P6213, DOI 10.1128/MCB.18.11.6213; SALTINI C, 1990, J EXP MED, V171, P1123, DOI 10.1084/jem.171.4.1123; SCHON P, 1992, EUR J CELL BIOL, V59, P329; SCHWARTZ MA, 1993, J BIOL CHEM, V268, P19931; Seiffert M, 1999, BLOOD, V94, P3633, DOI 10.1182/blood.V94.11.3633.423k01_3633_3643; SHIMIZU Y, 1990, NATURE, V345, P250, DOI 10.1038/345250a0; SIMON SI, 1995, J IMMUNOL, V155, P1502; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; Steeber DA, 1997, J IMMUNOL, V159, P952; TANAKA Y, 1993, NATURE, V361, P79, DOI 10.1038/361079a0; TAUB DD, 1993, SCIENCE, V260, P355, DOI 10.1126/science.7682337; TAUB DD, 1993, J EXP MED, V177, P1809, DOI 10.1084/jem.177.6.1809; Ticchioni M, 1997, J IMMUNOL, V158, P677; TSAO PW, 1995, J BIOL CHEM, V270, P23747, DOI 10.1074/jbc.270.40.23747; Vallejo AN, 2000, J IMMUNOL, V164, P2947, DOI 10.4049/jimmunol.164.6.2947; VISCHER P, 1988, EUR J CELL BIOL, V47, P36; Waclavicek M, 1997, J IMMUNOL, V159, P5345; Ward SG, 1998, IMMUNITY, V9, P1, DOI 10.1016/S1074-7613(00)80583-X; ZHOU MJ, 1993, J EXP MED, V178, P1165, DOI 10.1084/jem.178.4.1165	81	47	48	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	FEB	2001	15	2					341	350		10.1096/fj.99-0833com	http://dx.doi.org/10.1096/fj.99-0833com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	400LK	11156950				2022-12-25	WOS:000166872900016
J	Jafrezou, JP; Bruno, AP; Moisand, A; Levade, T; Laurent, G				Jafrezou, JP; Bruno, AP; Moisand, A; Levade, T; Laurent, G			Activation of a nuclear sphingomyelinase in radiation-induced apoptosis	FASEB JOURNAL			English	Article						myeloid cells; nuclear signaling; ionizing radiation; resistance	CERAMIDE-INDUCED APOPTOSIS; IONIZING-RADIATION; NEUTRAL SPHINGOMYELINASE; RAT-LIVER; ACID SPHINGOMYELINASE; CONFERS RESISTANCE; DNA FRAGMENTATION; CELLS; GENERATION; DISEASE	The subcellular origin of ceramide signaling in ionizing radiation-triggered apoptosis was investigated using two previously described subclones of the autonomous erythro-myeloblastic cell line TF-1, radio-resistant and -sensitive TF-1-34 and TF-1-33, respectively. We show in nuclei-free lysates and cytoplasts that both cell lines failed to generate ceramide in response to ionizing radiation, Moreover, whereas cytoplasts did respond to anti-Fas stimulation through phosphatidylserine externalization, no effect was observed with ionizing radiation. Only in highly purified nuclei preparations did we observe ceramide generation, neutral sphingomyelinase activation, and apoptotic features (PARP cleavage, nuclear fragmentation, DNA laddering) in TF-1-33, but not in TF-1-34 cells, These observations suggest that nuclear sphingomyelinase and ceramide formation may contribute to ionizing radiation-triggered apoptosis.	Inst Claudius Regaud, INSERM E9910, F-31052 Toulouse, France; CNRS, UPR 9062, Inst Pharmacol & Biol Struct, Toulouse, France; CHU Rangueil, INSERM, U466, Lab Biochim Med, F-31403 Toulouse, France; CHU Purpan, Serv Hematol, F-31059 Toulouse, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Institut Claudius Regaud; Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS); CHU de Toulouse; Institut National de la Sante et de la Recherche Medicale (Inserm); CHU de Toulouse	Jafrezou, JP (corresponding author), Inst Claudius Regaud, INSERM E9910, 20 Rue Pont St Pierre, F-31052 Toulouse, France.	jaffrezou@icr.fnclcc.fr	Levade, Thierry/O-8948-2014					Albi E, 1997, BIOCHEM BIOPH RES CO, V236, P29, DOI 10.1006/bbrc.1997.6803; ALESSENKO A, 1995, MOL CELL BIOCHEM, V143, P169, DOI 10.1007/BF01816950; Andrieu N, 1996, EUR J BIOCHEM, V236, P738, DOI 10.1111/j.1432-1033.1996.00738.x; Bezombes C, 1998, FASEB J, V12, P101, DOI 10.1096/fasebj.12.1.101; BRACH MA, 1991, J CLIN INVEST, V88, P691, DOI 10.1172/JCI115354; Bruno AP, 1998, CELL DEATH DIFFER, V5, P172, DOI 10.1038/sj.cdd.4400330; BSTTCHER CJF, 1961, ANAL CHIM ACTA, V699, P57; CHEN RH, 1992, MOL CELL BIOL, V12, P915, DOI 10.1128/MCB.12.3.915; Chmura SJ, 1997, CANCER RES, V57, P1270; COCCO L, 1980, BIOCHEM BIOPH RES CO, V96, P890, DOI 10.1016/0006-291X(80)91439-4; DATTA R, 1995, CELL GROWTH DIFFER, V6, P363; DEWEY WC, 1995, INT J RADIAT ONCOL, V33, P781, DOI 10.1016/0360-3016(95)00214-8; DUVE CD, 1955, BIOCHEM J, V60, P604, DOI 10.1042/bj0600604; ESCARGUEILBLANC I, 1994, FASEB J, V8, P1075, DOI 10.1096/fasebj.8.13.7926374; FISHER DE, 1994, CELL, V78, P539, DOI 10.1016/0092-8674(94)90518-5; FOLCH J, 1957, J BIOL CHEM, V226, P497; GarciaRuiz C, 1997, J BIOL CHEM, V272, P11369; GONG JP, 1994, ANAL BIOCHEM, V218, P314, DOI 10.1006/abio.1994.1184; HAIMOVITZFRIEDMAN A, 1994, J EXP MED, V180, P525, DOI 10.1084/jem.180.2.525; Hannun YA, 1996, SCIENCE, V274, P1855, DOI 10.1126/science.274.5294.1855; HEALD R, 1993, CELL, V74, P463, DOI 10.1016/0092-8674(93)80048-J; Jaffrezou JP, 1996, EMBO J, V15, P2417, DOI 10.1002/j.1460-2075.1996.tb00599.x; KAPUSCINSKI J, 1977, ANAL BIOCHEM, V83, P252, DOI 10.1016/0003-2697(77)90533-4; KASTAN MB, 1991, CANCER RES, V51, P6304; Kharbanda S, 1996, CANCER RES, V56, P3617; KITAMURA T, 1989, J CELL PHYSIOL, V140, P323, DOI 10.1002/jcp.1041400219; LEHNERT S, 1995, RADIAT RES, V141, P108; Levade T, 1999, BBA-MOL CELL BIOL L, V1438, P1, DOI 10.1016/S1388-1981(99)00038-4; Levade T, 1996, J LIPID RES, V37, P2525; LEVADE T, 1993, FEBS LETT, V329, P306, DOI 10.1016/0014-5793(93)80243-N; LINARDIC CM, 1994, J BIOL CHEM, V269, P23530; LING CC, 1994, RADIOTHER ONCOL, V32, P129; MARTIN SJ, 1995, J EXP MED, V182, P1545, DOI 10.1084/jem.182.5.1545; MARTIN SJ, 1995, CELL DEATH DIFFER, V2, P253; MEYN RE, 1993, INT J RADIAT BIOL, V64, P583, DOI 10.1080/09553009314551801; Michael JM, 1997, CANCER RES, V57, P3600; MORRE DJ, 1971, METHOD ENZYMOL, V22, P130; OJCIUS DM, 1991, MOL IMMUNOL, V28, P1011, DOI 10.1016/0161-5890(91)90187-O; PENNINGTON R, 1961, BIOCHEM J, V80, P649, DOI 10.1042/bj0800649; QuilletMary A, 1997, J BIOL CHEM, V272, P21388, DOI 10.1074/jbc.272.34.21388; RADFORD IR, 1986, INT J RADIAT BIOL, V49, P611; RADFORD JR, 1994, INT J RADIAT BIOL, V66, P329; Rusakov S A, 1993, Biokhimiia, V58, P724; Santana P, 1996, CELL, V86, P189, DOI 10.1016/S0092-8674(00)80091-4; SCHULZEOSTHOFF K, 1994, J CELL BIOL, V127, P15, DOI 10.1083/jcb.127.1.15; SHERMAN ML, 1990, P NATL ACAD SCI USA, V87, P5663, DOI 10.1073/pnas.87.15.5663; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SPANGLER M, 1975, CANCER RES, V35, P3131; Susin SA, 1997, J EXP MED, V186, P25, DOI 10.1084/jem.186.1.25; TAMIYAKOIZUMI K, 1989, J BIOCHEM, V106, P593, DOI 10.1093/oxfordjournals.jbchem.a122901; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; Tsugane K, 1999, J HEPATOL, V31, P8, DOI 10.1016/S0168-8278(99)80158-5; WENGER DA, 1976, LIFE SCI, V19, P413, DOI 10.1016/0024-3205(76)90047-3; Zhang JD, 1996, P NATL ACAD SCI USA, V93, P5325, DOI 10.1073/pnas.93.11.5325	54	44	46	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2001	15	1					123	133		10.1096/fj.00-0305com	http://dx.doi.org/10.1096/fj.00-0305com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	390TH	11149900	Bronze			2022-12-25	WOS:000166312400021
J	Lim, SJ; Lopez-Berestein, G; Hung, MC; Lupu, R; Tari, AM				Lim, SJ; Lopez-Berestein, G; Hung, MC; Lupu, R; Tari, AM			Grb2 downregulation leads to Akt inactivation in heregulin-stimulated and ErbB2-overexpressing breast cancer cells	ONCOGENE			English	Article						Grb2; heregulin; ErbB2; Akt; breast cancer	PROTEIN-KINASE-B; RECEPTOR TYROSINE KINASES; MAMMARY EPITHELIAL-CELLS; MAP KINASE; PHOSPHATIDYLINOSITOL 3-KINASE; SIGNAL-TRANSDUCTION; GROWTH-FACTOR; TUMOR-CELLS; ACTIVATION; RAS	ErbB2 can be activated by its own overexpression or be transactivated by the heregulin polypeptide growth factor. Activation of ErbB2 leads to breast cancer cell proliferation, presumably by inducing the activation of extracellular signal-regulated kinases 1,2 (Erk1,2) and Akt. We have previously reported that the growth factor receptor bound protein-2 (Grb2) is required for the proliferation of ErbB2-overexpressing breast cancer cells. We investigated here whether Grb2 protein plays a role in heregulin-stimulated proliferation. Grb2 protein inhibition led to growth inhibition of heregulin-stimulated breast cancer cells, but not Erk1,2 inactivation. These findings are similar to our earlier observations in ErbB2-overexpressing cells. Since Akt can also be activated by heregulin, the effects of Grb2 inhibition on Akt were examined. Akt was inactivated following Grb2 downregulation in heregulin-stimulated breast cancer cells. We then examined the effects of Grb2 downregulation on Akt in ErbB2-overexpressing cells in the absence of heregulin, Similar to heregulin-stimulated cells, Grb2 inhibition also led to Akt inactivation in ErbB2-over-expressing breast cancer cells. Our results indicate that the activation of ErbB2 by heregulin or by its overexpression requires Grb2 to stimulate the Akt pathway to propagate mitogenic signals.	Univ Texas, MD Anderson Canc Ctr, Dept Bioimmunotherapy, Sect Immunobiol & Drug Carriers, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, Houston, TX 77030 USA; Univ Calif Berkeley, Lawrence Berkeley Lab, Berkeley, CA 94720 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley	Tari, AM (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Bioimmunotherapy, Sect Immunobiol & Drug Carriers, Box 60, Houston, TX 77030 USA.		Hung, Mien-Chie/ABD-5911-2021	Hung, Mien-Chie/0000-0003-4317-4740				Alessi DR, 1998, CURR OPIN GENET DEV, V8, P55, DOI 10.1016/S0959-437X(98)80062-2; ALIMANDI M, 1995, ONCOGENE, V10, P1813; BONFINI L, 1992, SCIENCE, V255, P603, DOI 10.1126/science.1736363; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; CARRAWAY KL, 1995, J BIOL CHEM, V270, P7111, DOI 10.1074/jbc.270.13.7111; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; Daly JM, 1999, ONCOGENE, V18, P3440, DOI 10.1038/sj.onc.1202700; DEVRIESSMITS AMM, 1992, NATURE, V357, P602, DOI 10.1038/357602a0; DICKSON B, 1992, NATURE, V360, P600, DOI 10.1038/360600a0; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; FIDDES RJ, 1995, CELL GROWTH DIFFER, V6, P1567; Filippa N, 1999, MOL CELL BIOL, V19, P4989; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Franke TF, 1997, CELL, V88, P435, DOI 10.1016/S0092-8674(00)81883-8; HAZAN R, 1990, CELL GROWTH DIFFER, V1, P3; HolgadoMadruga M, 1996, NATURE, V379, P560, DOI 10.1038/379560a0; HolgadoMadruga M, 1997, P NATL ACAD SCI USA, V94, P12419, DOI 10.1073/pnas.94.23.12419; HOLMES WE, 1992, SCIENCE, V256, P1206; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; Lewis GD, 1996, CANCER RES, V56, P1457; Li J, 1998, CANCER RES, V58, P5667; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; Liu W, 1999, BIOCHEM BIOPH RES CO, V261, P897, DOI 10.1006/bbrc.1999.1144; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; LUPU R, 1992, P NATL ACAD SCI USA, V89, P2287, DOI 10.1073/pnas.89.6.2287; Majeti R, 1998, SCIENCE, V279, P88, DOI 10.1126/science.279.5347.88; Marais R, 1996, CANCER SURV, V27, P101; MARTE BM, 1995, ONCOGENE, V10, P167; MCCANN AH, 1991, CANCER RES, V51, P3296; MEYER S, 1994, MOL CELL BIOL, V14, P3253, DOI 10.1128/MCB.14.5.3253; Muthuswamy SK, 1999, MOL CELL BIOL, V19, P6845; PATERSON MC, 1991, CANCER RES, V51, P556; PELES E, 1992, CELL, V69, P205, DOI 10.1016/0092-8674(92)90131-U; PIERCE JH, 1991, ONCOGENE, V6, P1189; PLOWMAN GD, 1993, P NATL ACAD SCI USA, V90, P1746, DOI 10.1073/pnas.90.5.1746; PLOWMAN GD, 1993, NATURE, V366, P473, DOI 10.1038/366473a0; RAVICHANDRAN KS, 1995, MOL CELL BIOL, V15, P593; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; RodriguezViciana P, 1996, EMBO J, V15, P2442, DOI 10.1002/j.1460-2075.1996.tb00602.x; SEGATTO O, 1993, ONCOGENE, V8, P2105; SeppLorenzino L, 1996, ONCOGENE, V12, P1679; SIMON MA, 1993, CELL, V73, P169, DOI 10.1016/0092-8674(93)90169-Q; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; SLIWKOWSKI MX, 1994, J BIOL CHEM, V269, P14661; TANG C, 1996, CANCER RES, P3350; TANG M, 1999, CANCER RES, V59, P1620; Tari AM, 1997, BIOCHEM BIOPH RES CO, V235, P383, DOI 10.1006/bbrc.1997.6791; Tari AM, 1999, ONCOGENE, V18, P1325, DOI 10.1038/sj.onc.1202422; Tari AM, 2000, INT J CANCER, V86, P295, DOI 10.1002/(SICI)1097-0215(20000415)86:2<295::AID-IJC22>3.0.CO;2-K; Treisman R, 1996, CURR OPIN CELL BIOL, V8, P205, DOI 10.1016/S0955-0674(96)80067-6; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WANG J, 1995, J BIOL CHEM, V270, P12774, DOI 10.1074/jbc.270.21.12774; Xie YM, 1995, J BIOL CHEM, V270, P30717, DOI 10.1074/jbc.270.51.30717	54	34	38	0	3	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 14	2000	19	54					6271	6276		10.1038/sj.onc.1204014	http://dx.doi.org/10.1038/sj.onc.1204014			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	388YK	11175341				2022-12-25	WOS:000166210500010
J	Zamzami, N; El Hamel, C; Maisse, C; Brenner, C; Munoz-Pinedo, C; Belzacq, AS; Costantini, P; Vieira, H; Loeffler, M; Molle, G; Kroemer, G				Zamzami, N; El Hamel, C; Maisse, C; Brenner, C; Munoz-Pinedo, C; Belzacq, AS; Costantini, P; Vieira, H; Loeffler, M; Molle, G; Kroemer, G			Bid acts on the permeability transition pore complex to induce apoptosis	ONCOGENE			English	Article						apoptosis; Bcl-2; mitochondria; permeability transition; t-Bid	DEPENDENT ANION CHANNEL; CYTOCHROME-C RELEASE; MITOCHONDRIAL CONTROL; BAX; BCL-2; MEMBRANES; PROTEINS; YEAST; PURIFICATION	Similar to most if not all pro-apoptotic members of the Bcl-2 family, Bid land its truncated product t-Bid) triggers cell death via mitochondrial membrane permeabilization (MMP). This effect can be monitored in intact cells, upon microinjection of recombinant Bid protein into the cytoplasm, as well as in purified mitochondria, upon addition of Bid protein. Here we show that Bid-induced MMP can be inhibited, both in cells and in the cell-free system, by three pharmacological inhibitors of the permeability transiton pore complex (PTPC), namely cyclosporin A, N-methyl-4-Val-cyclosporin A, and bongkrekic acid (a ligand of the adenine nucleotide translocase, ANT, one of the PTPC components). Bid effects on synthetic membranes were studied either in proteoliposomes or in synthetic bilayers subjected to electrophysiological measurements. Full length Bid preferentially permeabilizes membranes and induces the formation of large conductance channels at neutral pH, when added to liposomes or bilayers containing both purified ANT and Bax, yet has no or little effect combined with ANT or Bax alone. t-Bid acts on membranes containing ANT alone with the same efficiency as on those containing both ANT and Bax. These results suggest that the proapoptotic effects of Bid are mediated, at least in part, by its functional interaction with ANT, one of the major components of PTPC.	Inst Gustave Roussy, CNRS, UMR 1599, F-94805 Villejuif, France; Univ Technol Compiegne, UMR 6022, CNRS, F-60205 Compiegne, France; Fac Sci, IFRMP23, UMR 6522, CNRS, F-76821 Mont St Aignan, France; CSIC, Inst Parasitol & Biomed, Granada 18001, Spain	Centre National de la Recherche Scientifique (CNRS); UNICANCER; Gustave Roussy; Picardie Universites; Universite de Technologie de Compiegne; Centre National de la Recherche Scientifique (CNRS); Centre National de la Recherche Scientifique (CNRS); Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Parasitologia y Biomedicina Lopez-Neyra (IPBLN)	Kroemer, G (corresponding author), Inst Gustave Roussy, CNRS, UMR 1599, 39 Rue Camille Desmoulins, F-94805 Villejuif, France.		KROEMER, Guido/B-4263-2013; brenner, catherine/AAE-8632-2020; Munoz-Pinedo, Cristina/B-6118-2008; Vieira, Helena/AAZ-9562-2021; Kroemer, Guido/AAY-9859-2020	KROEMER, Guido/0000-0002-9334-4405; Munoz-Pinedo, Cristina/0000-0002-9120-664X; Vieira, Helena/0000-0001-9415-3742; Maisse, Carine/0000-0003-2848-1638				Antonsson B, 1997, SCIENCE, V277, P370, DOI 10.1126/science.277.5324.370; Basanez G, 1999, P NATL ACAD SCI USA, V96, P5492, DOI 10.1073/pnas.96.10.5492; BERNARDI P, 1993, J BIOL CHEM, V268, P1005; Brenner C, 2000, METHOD ENZYMOL, V322, P243; Brenner C, 2000, ONCOGENE, V19, P329, DOI 10.1038/sj.onc.1203298; Chou JJ, 1999, CELL, V96, P615, DOI 10.1016/S0092-8674(00)80572-3; Costantini P, 2000, ONCOGENE, V19, P307, DOI 10.1038/sj.onc.1203299; Crompton M, 1998, EUR J BIOCHEM, V258, P729, DOI 10.1046/j.1432-1327.1998.2580729.x; Desagher S, 1999, J CELL BIOL, V144, P891, DOI 10.1083/jcb.144.5.891; Eskes R, 1998, J CELL BIOL, V143, P217, DOI 10.1083/jcb.143.1.217; Eskes R, 2000, MOL CELL BIOL, V20, P929, DOI 10.1128/MCB.20.3.929-935.2000; Feldmann G, 2000, HEPATOLOGY, V31, P674, DOI 10.1002/hep.510310318; Goldmacher VS, 1999, P NATL ACAD SCI USA, V96, P12536, DOI 10.1073/pnas.96.22.12536; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; Gross A, 2000, MOL CELL BIOL, V20, P3125, DOI 10.1128/MCB.20.9.3125-3136.2000; Harris MH, 2000, MOL CELL BIOL, V20, P3590, DOI 10.1128/MCB.20.10.3590-3596.2000; Hatano E, 2000, J BIOL CHEM, V275, P11814, DOI 10.1074/jbc.275.16.11814; Jurgensmeier JM, 1998, P NATL ACAD SCI USA, V95, P4997, DOI 10.1073/pnas.95.9.4997; Kroemer G, 1997, NAT MED, V3, P614, DOI 10.1038/nm0697-614; Kroemer G, 2000, NAT MED, V6, P513, DOI 10.1038/74994; Kudla G, 2000, J BIOL CHEM, V275, P22713, DOI 10.1074/jbc.M003807200; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Marzo I, 1998, SCIENCE, V281, P2027, DOI 10.1126/science.281.5385.2027; Marzo I, 1998, J EXP MED, V187, P1261, DOI 10.1084/jem.187.8.1261; McDonnell JM, 1999, CELL, V96, P625, DOI 10.1016/S0092-8674(00)80573-5; Minn AJ, 1997, NATURE, V385, P353, DOI 10.1038/385353a0; MONTAL M, 1972, P NATL ACAD SCI USA, V69, P3561, DOI 10.1073/pnas.69.12.3561; Narita M, 1998, P NATL ACAD SCI USA, V95, P14681, DOI 10.1073/pnas.95.25.14681; Pastorino JG, 1998, J BIOL CHEM, V273, P7770, DOI 10.1074/jbc.273.13.7770; Pastorino JG, 1999, J BIOL CHEM, V274, P31734, DOI 10.1074/jbc.274.44.31734; Priault M, 1999, FEBS LETT, V456, P232, DOI 10.1016/S0014-5793(99)00957-6; Priault M, 1999, EUR J BIOCHEM, V260, P684, DOI 10.1046/j.1432-1327.1999.00198.x; Reed JC, 1997, NATURE, V387, P773, DOI 10.1038/42867; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Scaffidi C, 1999, CURR OPIN IMMUNOL, V11, P277, DOI 10.1016/S0952-7915(99)80045-4; Schendel SL, 1997, P NATL ACAD SCI USA, V94, P5113, DOI 10.1073/pnas.94.10.5113; Schendel SL, 1999, J BIOL CHEM, V274, P21932, DOI 10.1074/jbc.274.31.21932; Schlesinger PH, 1997, P NATL ACAD SCI USA, V94, P11357, DOI 10.1073/pnas.94.21.11357; Shimizu S, 1999, NATURE, V399, P483, DOI 10.1038/20959; Shimizu S, 2000, P NATL ACAD SCI USA, V97, P3100, DOI 10.1073/pnas.97.7.3100; Shimizu S, 2000, J BIOL CHEM, V275, P12321, DOI 10.1074/jbc.275.16.12321; Shimizu S, 1998, P NATL ACAD SCI USA, V95, P1455, DOI 10.1073/pnas.95.4.1455; Shimizu S, 2000, P NATL ACAD SCI USA, V97, P577, DOI 10.1073/pnas.97.2.577; Susin SA, 2000, METHOD ENZYMOL, V322, P205; Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135; Vander Heiden MG, 2000, P NATL ACAD SCI USA, V97, P4666, DOI 10.1073/pnas.090082297; Vander Heiden MG, 1999, NAT CELL BIOL, V1, pE209, DOI 10.1038/70237; Yin XM, 1999, NATURE, V400, P886, DOI 10.1038/23730; Zamzami N, 1998, ONCOGENE, V16, P2265, DOI 10.1038/sj.onc.1201989; ZORATTI M, 1995, BBA-REV BIOMEMBRANES, V1241, P139, DOI 10.1016/0304-4157(95)00003-A	51	164	169	1	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 14	2000	19	54					6342	6350		10.1038/sj.onc.1204030	http://dx.doi.org/10.1038/sj.onc.1204030			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	388YK	11175349				2022-12-25	WOS:000166210500018
J	Schoenfeld, AR; Parris, T; Eisenberger, A; Davidowitz, EJ; De Leon, M; Talasazan, F; Devarajan, P; Burk, RD				Schoenfeld, AR; Parris, T; Eisenberger, A; Davidowitz, EJ; De Leon, M; Talasazan, F; Devarajan, P; Burk, RD			The von Hippel-Lindau tumor suppressor gene protects cells from UV-mediated apoptosis	ONCOGENE			English	Article						VHL; von Hippel-Lindau; renal cell carcinoma; apoptosis; UV	BIOLOGICALLY-ACTIVE PRODUCT; CARCINOMA-CELLS; VHL GENE; P53; PHOSPHORYLATION; IDENTIFICATION; INITIATION; INHIBITION; COMPLEX; PATHWAY	The familial cancer syndrome, von Hlippel-Lindau (VHL) disease, characterized by a predisposition to renal cell carcinoma and certain other tumor types, is caused by mutational inactivation of the VHL tumor suppressor gene. Loss of VHL gene function is detected also in the vast majority of sporadic renal cell carcinomas. Previous reports have determined a protective role for VHL in response to serum withdrawal and glucose deprivation, In this study, the effect of UV irradiation on VHL-negative and VHL-positive renal carcinoma cells was examined, VHL-negative 786-O renal carcinoma cells underwent apoptosis following UV irradiation, In contrast, reintroduction of wild-type VHL expression protected 786-O cells from UV-mediated cell death, p53 and Bax levels were equivalent in VHL-negative and VHL-positive 786-O cells. Strikingly, cyclin-dependent kinase? inhibitors p21 and p27 underwent proteasome-dependent degradation in VHL-negative 786-O cells following UV treatment. However, p21 and p27 protein levels were stable in VHL-positive cells. Also, levels of the anti-apoptotic proteins, Bcl-2 and Bcl-xL were elevated in VH L-positive cells, consistent with the protection from apoptotic stimuli, UV treatment led to increased S phase in VHL-negative, but not VHL-positive cells, Thus, following UV irradiation, diminution of p21 and p27 levels resulted in a hyperproliferative state in VHL-negative cells, leading to apoptosis, These results suggest that loss of VHL function promotes apoptosis and may provide selective pressure toward cells that are able to escape apoptosis, leading to tumorigenesis.	Albert Einstein Coll Med, Marion Bessin Liver Res Ctr, Dept Microbiol & Immunol, Bronx, NY 10461 USA; Albert Einstein Coll Med, Albert Einstein Comprehens Canc Ctr, Bronx, NY 10461 USA; Albert Einstein Coll Med, Marion Bessin Liver Res Ctr, Dept Pediat, Bronx, NY 10461 USA; Albert Einstein Coll Med, Marion Bessin Liver Res Ctr, Dept Epidemiol & Social Med, Bronx, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine	Burk, RD (corresponding author), Albert Einstein Coll Med, Marion Bessin Liver Res Ctr, Dept Microbiol & Immunol, Ullmann Bldg,Rm 515,1300 Morris Pk Ave, Bronx, NY 10461 USA.			Schoenfeld, Alan R./0000-0002-6778-1548	NIDDK NIH HHS [DK 07218] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007218] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Agarwal ML, 1998, J BIOL CHEM, V273, P1, DOI 10.1074/jbc.273.1.1; Blagosklonny MV, 1996, BIOCHEM BIOPH RES CO, V227, P564, DOI 10.1006/bbrc.1996.1546; Blankenship C, 1999, ONCOGENE, V18, P1529, DOI 10.1038/sj.onc.1202473; Di Cristofano A, 2000, CELL, V100, P387, DOI 10.1016/S0092-8674(00)80674-1; DUAN DR, 1995, P NATL ACAD SCI USA, V92, P6459, DOI 10.1073/pnas.92.14.6459; Gorospe M, 1999, MOL CELL BIOL, V19, P1289; Iliopoulos O, 1996, P NATL ACAD SCI USA, V93, P10595, DOI 10.1073/pnas.93.20.10595; Iliopoulos O, 1998, P NATL ACAD SCI USA, V95, P11661, DOI 10.1073/pnas.95.20.11661; ILIOPOULOS O, 1995, NAT MED, V1, P822, DOI 10.1038/nm0895-822; Iwai K, 1999, P NATL ACAD SCI USA, V96, P12436, DOI 10.1073/pnas.96.22.12436; LATIF F, 1993, SCIENCE, V260, P1317, DOI 10.1126/science.8493574; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Lieubeau-Teillet B, 1998, CANCER RES, V58, P4957; LINEHAN WM, 1995, JAMA-J AM MED ASSOC, V273, P564; Lisztwan J, 1999, GENE DEV, V13, P1822, DOI 10.1101/gad.13.14.1822; Lowe SW, 2000, CARCINOGENESIS, V21, P485, DOI 10.1093/carcin/21.3.485; Lu X, 1996, ONCOGENE, V13, P413; Lubensky IA, 1996, AM J PATHOL, V149, P2089; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; Morimoto M, 2000, BIOCHEM BIOPH RES CO, V270, P1093, DOI 10.1006/bbrc.2000.2576; Ohh M, 2000, NAT CELL BIOL, V2, P423, DOI 10.1038/35017054; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; Pause A, 1998, P NATL ACAD SCI USA, V95, P993, DOI 10.1073/pnas.95.3.993; Ramaswamy S, 1999, P NATL ACAD SCI USA, V96, P2110, DOI 10.1073/pnas.96.5.2110; Schoenfeld A, 1998, P NATL ACAD SCI USA, V95, P8817, DOI 10.1073/pnas.95.15.8817; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Shieh SY, 1999, EMBO J, V18, P1815, DOI 10.1093/emboj/18.7.1815; Siliciano JD, 1997, GENE DEV, V11, P3471, DOI 10.1101/gad.11.24.3471	28	55	55	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 30	2000	19	51					5851	5857		10.1038/sj.onc.1203985	http://dx.doi.org/10.1038/sj.onc.1203985			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	378CA	11127815				2022-12-25	WOS:000165563100003
J	Mok, YK; Lo, KWH; Zhang, MJ				Mok, YK; Lo, KWH; Zhang, MJ			Structure of Tctex-1 and its interaction with cytoplasmic dynein intermediate chain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGHT-CHAIN; NMR-SPECTROSCOPY; LARGE PROTEINS; TRANSPORT; DYNACTIN; ASSIGNMENT; COMPLEXES; KINASE; FAMILY; MOUSE	The minus-ended microtubule motor cytoplasmic dynein contains a number of low molecular weight light chains including the 14-kDa Tctex-1. The assembly of Tctex-1 in the dynein complex and its function are largely unknown. Using partially deuterated, N-15,C-13-labeled protein samples and transverse relaxation-optimized NMR spectroscopic techniques, the secondary structure and overall topology of Tctex-1 were determined based on the backbone nuclear Overhauser effect pattern and the chemical shift values of the protein. The data showed that Tctex-1 adopts a structure remarkably similar to that of the 8-kDa light chain of the motor complex (DLC8), although the two light chains share no amino acid sequence homology, We further demonstrated that Tctex-1 binds directly to the intermediate chain (DIC) of dynein, The Tctex-1 binding site on DIC was mapped to a 19-residue fragment immediately following the second alternative splicing site of DIG. Titration of Tctex-1 with a peptide derived from DIG, which contains a consensus sequence R/KR/KXYR/K found in various Tctex-1 target proteins, indicated that Tctex-1 binds to its targets in a manner similar to that of DLC8. The experimental results presented in this study suggest that Tctex-1 is likely to be a specific cargo adaptor for the dynein motor complex.	Hong Kong Univ Sci & Technol, Dept Biochem, Kowloon, Hong Kong, Peoples R China	Hong Kong University of Science & Technology	Zhang, MJ (corresponding author), Hong Kong Univ Sci & Technol, Dept Biochem, Clear Water Bay, Kowloon, Hong Kong, Peoples R China.		Mok, Yu Keung/H-8019-2012	Mok, Yu Keung/0000-0002-2829-4878; Zhang, Mingjie/0000-0001-9404-0190				Bauch A, 1998, EUR J IMMUNOL, V28, P2167, DOI 10.1002/(SICI)1521-4141(199807)28:07<2167::AID-IMMU2167>3.0.CO;2-L; Campbell KS, 1998, J IMMUNOL, V161, P1728; Clore GM, 1998, TRENDS BIOTECHNOL, V16, P22, DOI 10.1016/S0167-7799(97)01135-9; Crackower MA, 1999, GENOMICS, V55, P257, DOI 10.1006/geno.1998.5665; Fan JS, 2001, J MOL BIOL, V306, P97, DOI 10.1006/jmbi.2000.4374; GRZESIEK S, 1993, J AM CHEM SOC, V115, P4369, DOI 10.1021/ja00063a068; Harrison A, 1998, J CELL BIOL, V140, P1137, DOI 10.1083/jcb.140.5.1137; Hirokawa N, 1998, SCIENCE, V279, P519, DOI 10.1126/science.279.5350.519; IKURA M, 1990, J AM CHEM SOC, V112, P9020, DOI 10.1021/ja00180a080; Karki S, 1999, CURR OPIN CELL BIOL, V11, P45, DOI 10.1016/S0955-0674(99)80006-4; Kay LE, 1997, BIOCHEM CELL BIOL, V75, P1, DOI 10.1139/o97-023; Kay LE, 1997, CURR OPIN STRUC BIOL, V7, P722, DOI 10.1016/S0959-440X(97)80084-X; King SM, 2000, BBA-MOL CELL RES, V1496, P60, DOI 10.1016/S0167-4889(00)00009-4; King SM, 1996, J BIOL CHEM, V271, P32281, DOI 10.1074/jbc.271.50.32281; King SM, 1998, BIOCHEMISTRY-US, V37, P15033, DOI 10.1021/bi9810813; LADER E, 1989, CELL, V58, P969, DOI 10.1016/0092-8674(89)90948-3; Liang J, 1999, NAT STRUCT BIOL, V6, P735; Lo KWH, 2001, J BIOL CHEM, V276, P14059, DOI 10.1074/jbc.M010320200; Ma S, 1999, J CELL BIOL, V147, P1261, DOI 10.1083/jcb.147.6.1261; Nagano F, 1998, J BIOL CHEM, V273, P30065, DOI 10.1074/jbc.273.46.30065; Nurminsky DI, 1998, MOL CELL BIOL, V18, P6816, DOI 10.1128/MCB.18.11.6816; Pervushin K, 2000, J BIOMOL NMR, V17, P195, DOI 10.1023/A:1008399320576; Rosen MK, 1996, J MOL BIOL, V263, P627, DOI 10.1006/jmbi.1996.0603; Susalka SJ, 2000, BBA-MOL CELL RES, V1496, P76, DOI 10.1016/S0167-4889(00)00010-0; Tai AW, 1999, CELL, V97, P877, DOI 10.1016/S0092-8674(00)80800-4; Tai AW, 1998, J BIOL CHEM, V273, P19639, DOI 10.1074/jbc.273.31.19639; Vallee RB, 1996, SCIENCE, V271, P1539, DOI 10.1126/science.271.5255.1539; VAUGHAN KT, 1995, J CELL BIOL, V131, P1507, DOI 10.1083/jcb.131.6.1507; WISHART DS, 1992, BIOCHEMISTRY-US, V31, P1647, DOI 10.1021/bi00121a010; YAMAZAKI T, 1994, J AM CHEM SOC, V116, P11655, DOI 10.1021/ja00105a005; Zhang OW, 1997, J BIOMOL NMR, V9, P181, DOI 10.1023/A:1018658305040	31	96	98	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 27	2001	276	17					14067	14074		10.1074/jbc.M011358200	http://dx.doi.org/10.1074/jbc.M011358200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	426PB	11148215	hybrid			2022-12-25	WOS:000168356600077
J	Selmi, B; Boretto, J; Navarro, JM; Sire, J; Longhi, S; Guerreiro, C; Mulard, L; Sarfati, S; Canard, B				Selmi, B; Boretto, J; Navarro, JM; Sire, J; Longhi, S; Guerreiro, C; Mulard, L; Sarfati, S; Canard, B			The valine-to-threonine 75 substitution in human immunodeficiency virus type 1 reverse transcriptase and its relation with stavudine resistance	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRE-STEADY-STATE; MECHANISM; 3'-AZIDO-3'-DEOXYTHYMIDINE; INHIBITION; MUTANTS; AZT; 2,3-DIDEHYDRO-2,3-DIDEOXYTHYMIDINE; 5'-TRIPHOSPHATE; PHOSPHORYLATION; PYROPHOSPHATE	The amino acid change V75T in human immunodeficiency virus type 1 reverse transcriptase confers a low level of 2',3'-didehydro-2',3'-dideoxythymidine (stavudine, d4T) resistance in vivo and in vitro, Valine 75 is located at the basis of the fingers subdomain of reverse transcriptase between the template contact point and the nucleotide-binding pocket. V75T reverse transcriptase discriminates 3.6-fold d4T 5'-triphosphate relative to dTTP, as judged by pre-steady state kinetics of incorporation of a single nucleotide into DNA, In addition, V75T increases the DNA polymerization rate up to 5-fold by facilitating translocation along nucleic acid single-stranded templates. V75T also increases the reverse transcriptase-mediated repair of the d4TMP-terminated DNA by pyrophosphate but not by ATP. The V75T/Y146F double substitution partially suppressed both increases in rate of polymerization and pyrophosphorolysis, indicating that the hydroxyl group of Thr-75 interacts with that of Tyr-146. V75T recombinant virus was 3-4-fold d4T-resistant and 3-fold resistant to phosphonoformic acid relative to wild type, confirming that the pyrophosphate traffic is affected in V75T reverse transcriptase. Thus, in addition to nucleotide selectivity V75T defines a type of amino acid change conferring resistance to nucleoside analogues that links translocation rate to the traffic of pyrophosphate at the reverse transcriptase active site.	CNRS, F-13288 Marseille 9, France; Univ Aix Marseille 1, UMR 6098, F-13288 Marseille 9, France; Univ Aix Marseille 2, UMR 6098, F-13288 Marseille 9, France; INSERM, U372, F-13288 Marseille 9, France; Inst Pasteur, F-75724 Paris 15, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Aix-Marseille Universite; UDICE-French Research Universities; Aix-Marseille Universite; Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Canard, B (corresponding author), CNRS, ESIL Case 925,163 Ave Luminy, F-13288 Marseille 9, France.	bruno@esil.univ-mrs.fr	LONGHI, Sonia/M-5305-2014	LONGHI, Sonia/0000-0002-6829-6771; Canard, Bruno/0000-0003-4924-1991				Ahluwalia GS, 1996, MOL PHARMACOL, V50, P160; Arion D, 1998, BIOCHEMISTRY-US, V37, P15908, DOI 10.1021/bi981200e; BALZARINI J, 1989, J BIOL CHEM, V264, P6127; Balzarini J, 1999, BIOCHEM PHARMACOL, V58, P1; BARSHOP BA, 1991, ANAL BIOCHEM, V197, P266, DOI 10.1016/0003-2697(91)90387-9; BRUNVEZINET F, 2000, ANTIVIR THER S, V5, P78; Canard B, 1999, J BIOL CHEM, V274, P35768, DOI 10.1074/jbc.274.50.35768; Canard B, 1998, J BIOL CHEM, V273, P14596, DOI 10.1074/jbc.273.23.14596; CARROLL SS, 1994, BIOCHEMISTRY-US, V33, P2113, DOI 10.1021/bi00174a018; Coakley EP, 2000, AIDS, V14, pF9, DOI 10.1097/00002030-200001280-00002; FURMAN PA, 1986, P NATL ACAD SCI USA, V83, P8333, DOI 10.1073/pnas.83.21.8333; Hashimoto K, 1997, AIDS RES HUM RETROV, V13, P193, DOI 10.1089/aid.1997.13.193; Huang HF, 1998, SCIENCE, V282, P1669, DOI 10.1126/science.282.5394.1669; HUANG P, 1992, J BIOL CHEM, V267, P2817; KATI WM, 1992, J BIOL CHEM, V267, P25988; Kim B, 1996, J BIOL CHEM, V271, P4872, DOI 10.1074/jbc.271.9.4872; Krebs R, 1997, BIOCHEMISTRY-US, V36, P10292, DOI 10.1021/bi970512z; LACEY SF, 1994, ANTIMICROB AGENTS CH, V38, P1428, DOI 10.1128/AAC.38.6.1428; LARDER B, 1992, REVERSE TRANSCRIPTAS, P205; Lavie A, 1997, NAT STRUCT BIOL, V4, P601, DOI 10.1038/nsb0897-601; LENNERSTRAND J, 2000, ANTIVIR THER S, V5, P14; LIGHTFOOTE MM, 1986, J VIROL, V60, P771, DOI 10.1128/JVI.60.2.771-775.1986; Lin PF, 1999, ANTIVIR THER, V4, P21; Meyer P, 2000, EMBO J, V19, P3520, DOI 10.1093/emboj/19.14.3520; Meyer PR, 1999, MOL CELL, V4, P35, DOI 10.1016/S1097-2765(00)80185-9; MITSUYA H, 1985, P NATL ACAD SCI USA, V82, P7096, DOI 10.1073/pnas.82.20.7096; MORENO S, 2000, ANTIVIR THER S3, V5, P19; REARDON JE, 1992, BIOCHEMISTRY-US, V31, P4473, DOI 10.1021/bi00133a013; Rigourd M, 2000, J BIOL CHEM, V275, P26944; ROSS LL, 2000, ANTIVIR THER S, V5, P38; ROUSSEL A, 1991, SILICON GRAPHICS DIR, P97; SALAHUDDIN SZ, 1983, VIROLOGY, V129, P51, DOI 10.1016/0042-6822(83)90395-1; Schinazi R.F., 2000, INT ANTIVIRAL NEWS, V8, P65; Schneider B, 1998, J BIOL CHEM, V273, P11491, DOI 10.1074/jbc.273.19.11491; Schneider B, 2000, MOL PHARMACOL, V57, P948; Soriano V, 1997, AIDS, V11, P696; Theodore TS, 1996, AIDS RES HUM RETROV, V12, P191, DOI 10.1089/aid.1996.12.191; UENO T, 1995, J BIOL CHEM, V270, P23605, DOI 10.1074/jbc.270.40.23605; Vaccaro JA, 2000, ANTIMICROB AGENTS CH, V44, P217, DOI 10.1128/AAC.44.1.217-221.2000; Wohrl BM, 1999, J MOL BIOL, V292, P333, DOI 10.1006/jmbi.1999.3057	40	34	35	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 27	2001	276	17					13965	13974		10.1074/jbc.M009837200	http://dx.doi.org/10.1074/jbc.M009837200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	426PB	11134027	hybrid			2022-12-25	WOS:000168356600064
J	Paik, JH; Chae, SS; Lee, MJ; Thangada, S; Hla, T				Paik, JH; Chae, SS; Lee, MJ; Thangada, S; Hla, T			Sphingosine 1-phosphate-induced endothelial cell migration requires the expression of EDG-1 and EDG-3 receptors and Rho-dependent activation of alpha(v)beta(3)- and beta(1)-containing integrins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTOR; LYSOPHOSPHATIDIC ACID; ALPHA(5)BETA(1) INTEGRINS; EXTRACELLULAR-MATRIX; SIGNALING PATHWAYS; GROWTH-FACTORS; SPHINGOSINE-1-PHOSPHATE; ANGIOGENESIS; ADHESION; DIFFERENTIATION	Sphingosine 1-phosphate (SPP), a platelet-derived bioactive lysophospholipid, is a regulator of angiogenesis. However, molecular mechanisms involved in SPP-induced angiogenic responses are not fully defined. Here we report the molecular mechanisms involved in SPP-induced human umbilical vein endothelial cell (HUVEC) adhesion and migration. SPP-induced HUVEC migration is potently inhibited by antisense phosphothioate oligonucleotides against EDG-1 as well as EDG-3 receptors, In addition, C3 exotoxin blocked SPP-induced cell attachment, spreading and migration on fibronectin-, vitronectin- and Matrigel-coated surfaces, suggesting that endothelial differentiation gene receptor signaling via the Rho pathway is critical for SPP-induced cell migration. Indeed, SPP induced Rho activation in an adherence-independent manner, whereas Rac activation was dispensible for cell attachment and focal contact formation. Interestingly, both EDG-1 and -3 receptors were required for Rho activation. Since integrins are critical for cell adhesion, migration, and angiogenesis, we examined the effects of blocking antibodies against alpha (v)beta (3), beta (1), or beta (3) integrins. SPP induced Rho-dependent integrin clustering into focal contact sites, which was essential for cell adhesion, spreading and migration. Blockage of alpha (v)beta (3)- or beta (1)-containing integrins inhibited SPP-induced HUVEC migration. Together our results suggest that endothelial differentiation gene receptor-mediated Rho signaling is required for the activation of integrin alpha (v)beta (3) as well as beta (1)-containing integrins, leading to the formation of initial focal contacts and endothelial cell migration.	Univ Connecticut, Ctr Hlth, Dept Physiol, Ctr Vasc Biol, Farmington, CT 06030 USA	University of Connecticut	Hla, T (corresponding author), Univ Connecticut, Ctr Hlth, Dept Physiol, Ctr Vasc Biol, 263 Farmington Ave, Farmington, CT 06030 USA.		Hla, Timothy/G-5873-2012	Hla, Timothy/0000-0001-8355-4065	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK045659] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-45659] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		An SZ, 1998, MOL PHARMACOL, V54, P881, DOI 10.1124/mol.54.5.881; Ancellin N, 1999, J BIOL CHEM, V274, P18997, DOI 10.1074/jbc.274.27.18997; Bayless KJ, 2000, AM J PATHOL, V156, P1673, DOI 10.1016/S0002-9440(10)65038-9; Bloch W, 1997, J CELL BIOL, V139, P265, DOI 10.1083/jcb.139.1.265; del Pozo MA, 2000, EMBO J, V19, P2008, DOI 10.1093/emboj/19.9.2008; Eliceiri BP, 1999, J CLIN INVEST, V103, P1227, DOI 10.1172/JCI6869; English D, 2000, FASEB J, V14, P2255, DOI 10.1096/fj.00-0134com; English D, 1999, J HEMATOTH STEM CELL, V8, P627, DOI 10.1089/152581699319795; FOLKMAN J, 1992, J BIOL CHEM, V267, P10931; GAMBLE JR, 1993, J CELL BIOL, V121, P931, DOI 10.1083/jcb.121.4.931; Goetzl EJ, 1998, FASEB J, V12, P1589, DOI 10.1096/fasebj.12.15.1589; Gonda K, 1999, BIOCHEM J, V337, P67, DOI 10.1042/0264-6021:3370067; GRANT DS, 1989, CELL, V58, P933, DOI 10.1016/0092-8674(89)90945-8; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; HLA T, 1990, J BIOL CHEM, V265, P9308; Hla T, 1999, BIOCHEM PHARMACOL, V58, P201; Hodivala-Dilke KM, 1999, J CLIN INVEST, V103, P229, DOI 10.1172/JCI5487; Im DS, 2000, J BIOL CHEM, V275, P14281, DOI 10.1074/jbc.275.19.14281; IruelaArispe ML, 1997, THROMB HAEMOSTASIS, V78, P672; Kanda S, 1999, EXP CELL RES, V248, P203, DOI 10.1006/excr.1999.4400; Kimura T, 2000, BIOCHEM J, V348, P71, DOI 10.1042/0264-6021:3480071; Kon J, 1999, J BIOL CHEM, V274, P23940, DOI 10.1074/jbc.274.34.23940; Kupperman E, 2000, NATURE, V406, P192, DOI 10.1038/35018092; Lee H, 2000, AM J PHYSIOL-CELL PH, V278, pC612, DOI 10.1152/ajpcell.2000.278.3.C612; Lee MJ, 1998, SCIENCE, V279, P1552, DOI 10.1126/science.279.5356.1552; Lee MJ, 1999, CELL, V99, P301, DOI 10.1016/S0092-8674(00)81661-X; Lee OH, 1999, BIOCHEM BIOPH RES CO, V264, P743, DOI 10.1006/bbrc.1999.1586; Liu YJ, 2000, J CLIN INVEST, V106, P951, DOI 10.1172/JCI10905; Murphy G, 1999, CURR OPIN CELL BIOL, V11, P614, DOI 10.1016/S0955-0674(99)00022-8; Panetti TS, 2000, ARTERIOSCL THROM VAS, V20, P1013, DOI 10.1161/01.ATV.20.4.1013; Pyne S, 2000, BIOCHEM J, V349, P385, DOI 10.1042/0264-6021:3490385; Ren XD, 1999, EMBO J, V18, P578, DOI 10.1093/emboj/18.3.578; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; SADAHIRA Y, 1992, P NATL ACAD SCI USA, V89, P9686, DOI 10.1073/pnas.89.20.9686; Sander EE, 1999, J CELL BIOL, V147, P1009, DOI 10.1083/jcb.147.5.1009; Schneller M, 1997, EMBO J, V16, P5600, DOI 10.1093/emboj/16.18.5600; Schoenwaelder SM, 1999, CURR OPIN CELL BIOL, V11, P274, DOI 10.1016/S0955-0674(99)80037-4; Soldi R, 1999, EMBO J, V18, P882, DOI 10.1093/emboj/18.4.882; Spiegel S, 2000, FEBS LETT, V476, P55, DOI 10.1016/S0014-5793(00)01670-7; Spiegel S, 2000, BBA-MOL CELL BIOL L, V1484, P107, DOI 10.1016/S1388-1981(00)00010-X; Van Brocklyn JR, 2000, BLOOD, V95, P2624; Van Brocklyn JR, 1999, J BIOL CHEM, V274, P4626, DOI 10.1074/jbc.274.8.4626; Varner JA, 1996, CURR OPIN CELL BIOL, V8, P724, DOI 10.1016/S0955-0674(96)80115-3; Wang F, 1999, J BIOL CHEM, V274, P35343, DOI 10.1074/jbc.274.50.35343; Wang F, 1999, CANCER RES, V59, P6185; Wang F, 1997, BIOCHEM J, V324, P481, DOI 10.1042/bj3240481; Wierzbicka-Patynowski I, 1999, J BIOL CHEM, V274, P37809, DOI 10.1074/jbc.274.53.37809; Windh RT, 1999, J BIOL CHEM, V274, P27351, DOI 10.1074/jbc.274.39.27351	48	248	254	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 13	2001	276	15					11830	11837		10.1074/jbc.M009422200	http://dx.doi.org/10.1074/jbc.M009422200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	421UK	11150298	hybrid			2022-12-25	WOS:000168081800055
J	Shui, Z; Khan, IA; Haga, T; Benovic, JL; Boyett, MR				Shui, Z; Khan, IA; Haga, T; Benovic, JL; Boyett, MR			Control of the cardiac muscarinic K+ channel by beta-arrestin 2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; DEPENDENT DESENSITIZATION; ACETYLCHOLINE-RECEPTOR; IONIC BASIS; RAT; ARRESTIN; KINASE; PHOSPHORYLATION; HYDROLYSIS; ACTIVATION	Control of the cardiac muscarinic K+ current (i(K,ACh)) by beta -arrestin 2 has been studied. In Chinese hamster ovary cells transfected with m2 muscarinic receptor, muscarinic K+ channel, receptor kinase (GRK2), and beta -arrestin 2, desensitization of i(K,ACh) during a 3-min application of 10 muM ACh was significantly increased as compared with that in cells transfected with receptor, channel, and GRK2 only (fade in current increased from 45 to 78%). The effect of beta -arrestin 2 was lost if cells were not co-transfected with GRK2, Resensitization (recovery from desensitization) of i(K,ACh) in cells transfected with beta -arrestin 2 was significantly slowed (time constant increased from 34 to 232 s), Activation and deactivation of i(K,ACh) on application and wash-off of ACh in cells transfected with beta -arrestin 2 were significantly slowed from 0.9 to 3.1 s (time to half peak i(K,ACh)) and from 6.2 to 13.8 s (time to half-deactivation), respectively. In cells transfected with a constitutively active beta -arrestin 2 mutant, desensitization occurred in the absence of agonist (peak current significantly decreased from 0.4 +/- 0.05 to 0.1 +/- 0.01 nA), We conclude that beta -arrestin 2 has the potential to play a major role in desensitization and other aspects of the functioning of the muscarinic K+ channel.	Univ Leeds, Sch Biomed Sci, Leeds LS2 9JT, W Yorkshire, England; Univ Tokyo, Fac Med, Dept Neurochem, Tokyo 1130033, Japan; Thomas Jefferson Univ, Kimmel Canc Inst, Philadelphia, PA 19107 USA	University of Leeds; University of Tokyo; Jefferson University	Boyett, MR (corresponding author), Univ Leeds, Sch Biomed Sci, Leeds LS2 9JT, W Yorkshire, England.	m.r.boyett@leeds.ac.uk		Boyett, Mark/0000-0003-3931-2020				Appleyard SM, 1999, J BIOL CHEM, V274, P23802, DOI 10.1074/jbc.274.34.23802; BOYETT MR, 1995, CARDIOVASC RES, V29, P867, DOI 10.1016/S0008-6363(96)88625-1; BOYETT MR, 1987, J PHYSIOL-LONDON, V393, P171, DOI 10.1113/jphysiol.1987.sp016818; BOYETT MR, 1988, J PHYSIOL-LONDON, V404, P613, DOI 10.1113/jphysiol.1988.sp017309; BOYETT MR, 1999, J PHYSL, V521, P23; Chuang HH, 1998, P NATL ACAD SCI USA, V95, P11727, DOI 10.1073/pnas.95.20.11727; Feron O, 1997, J BIOL CHEM, V272, P17744, DOI 10.1074/jbc.272.28.17744; GUREVICH VV, 1993, J BIOL CHEM, V268, P11628; Gurevich VV, 1997, J BIOL CHEM, V272, P28849, DOI 10.1074/jbc.272.46.28849; GUREVICH VV, 1995, J BIOL CHEM, V270, P720, DOI 10.1074/jbc.270.2.720; HAGA T, 1994, J NEUROCHEM, V63, P400; HARRISON SM, 1992, J PHYSIOL-LONDON, V449, P517, DOI 10.1113/jphysiol.1992.sp019100; Hong SG, 1996, AM J PHYSIOL-HEART C, V270, pH526, DOI 10.1152/ajpheart.1996.270.2.H526; HONJO H, 1992, AM J PHYSIOL, V263, pH1779, DOI 10.1152/ajpheart.1992.263.6.H1779; KAMEYAMA K, 1993, J BIOL CHEM, V268, P7753; KIM D, 1991, J PHYSIOL-LONDON, V437, P133, DOI 10.1113/jphysiol.1991.sp018588; KIM DH, 1993, CIRC RES, V73, P89, DOI 10.1161/01.RES.73.1.89; Kobrinsky E, 2000, NAT CELL BIOL, V2, P507, DOI 10.1038/35019544; Krupnick JG, 1998, ANNU REV PHARMACOL, V38, P289, DOI 10.1146/annurev.pharmtox.38.1.289; KWATRA MM, 1987, J BIOL CHEM, V262, P16314; Lefkowitz RJ, 1998, J BIOL CHEM, V273, P18677, DOI 10.1074/jbc.273.30.18677; LOHSE MJ, 1995, TRENDS CARDIOVAS MED, V5, P63, DOI 10.1016/1050-1738(94)00034-4; MARTIN P, 1982, AM J PHYSIOL, V243, pH219, DOI 10.1152/ajpheart.1982.243.2.H219; MARTIN P, 1983, AM J PHYSIOL, V245, pH584, DOI 10.1152/ajpheart.1983.245.4.H584; NISHIMURA M, 1988, AM J PHYSIOL, V255, pH7, DOI 10.1152/ajpheart.1988.255.1.H7; PalsRylaarsdam R, 1997, J BIOL CHEM, V272, P14152, DOI 10.1074/jbc.272.22.14152; PalsRylaarsdam R, 1997, J BIOL CHEM, V272, P23682, DOI 10.1074/jbc.272.38.23682; REUVENY E, 1994, NATURE, V370, P143, DOI 10.1038/370143a0; Saitoh O, 1997, NATURE, V390, P525, DOI 10.1038/37385; Santini F, 2000, J CELL SCI, V113, P2463; Shui Z, 1997, J PHYSIOL-LONDON, V505, P77, DOI 10.1111/j.1469-7793.1997.077bc.x; Shui Z, 1998, J PHYSIOL-LONDON, V507, P325, DOI 10.1111/j.1469-7793.1998.325bt.x; SHUI Z, 1995, J PHYSIOL-LONDON, V487, P359, DOI 10.1113/jphysiol.1995.sp020885; THOMPSON AK, 1991, J BIOL CHEM, V266, P23856; TSUGA H, 1994, J BIOL CHEM, V269, P32522; ZANG WJ, 1993, J PHYSIOL-LONDON, V464, P649, DOI 10.1113/jphysiol.1993.sp019656	36	7	7	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 13	2001	276	15					11691	11697		10.1074/jbc.M011007200	http://dx.doi.org/10.1074/jbc.M011007200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	421UK	11152693	hybrid			2022-12-25	WOS:000168081800037
J	Zhao, KH; Chai, XM; Johnston, K; Clements, A; Marmorstein, R				Zhao, KH; Chai, XM; Johnston, K; Clements, A; Marmorstein, R			Crystal structure of the mouse p53 core DNA-binding domain at 2.7 angstrom resolution	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TETRAMERIZATION DOMAIN; TUMOR-SUPPRESSOR; PROTEIN; OLIGOMERIZATION; REFINEMENT; PATHWAY; REGIONS	The p53 tumor suppressor is a sequence-specific DNA-binding protein that activates transcription in response to DNA damage to promote cell cycle arrest or apoptosis, The p53 protein functions in a tetrameric form in vivo and contains four domains including an N-terminal transcriptional activation domain, a C-terminal regulatory domain, a tetramerization domain, and a central core DNA-binding domain that is the site of the majority of tumor-derived mutations. Here we report the 2.7-Angstrom crystal structure of the mouse p53 core domain. Like the human p53 core domain in complex with DNA, the mouse p53 core domain adopts an immunoglobulin-like beta sandwich architecture with a series of loops and short helices at opposite ends of the beta sandwich. Comparison of the DNA-bound and DNA-free p53 core domains reveals that while the central beta sandwich architecture remains largely unchanged, a loop region important for DNA binding undergoes significant rearrangement. Although this loop region mediates major groove DNA contacts in the DNA-bound structure, it adopts a conformation that is incompatible with DNA binding in the DNA-free structure. Interestingly, crystals of the DNA-free core domain contain a noncrystallographic trimer with three nearly identical subunit-subunit (dimer) contacts. These dimer contacts align the p53 core domains in a way that is incompatible with simultaneous DNA binding by both protomers of the dimer. Surprisingly, similar dimer contacts are observed in crystals of the human p53 core domain with DNA in which only one of the three p53 protomers in the asymmetric unit cell is specifically bound to DNA. We propose that the p53 core domain dimer that: is seen in the crystals described here represents a physiologically relevant inactive form of p53 that must undergo structural rearrangement for sequence-specific DNA binding.	Univ Penn, Wistar Inst, Philadelphia, PA 19104 USA; Univ Penn, Dept Chem, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Biochem & Biophys, Philadelphia, PA 19104 USA	The Wistar Institute; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania	Marmorstein, R (corresponding author), Univ Penn, Wistar Inst, 3601 Spruce St, Philadelphia, PA 19104 USA.							BRUNGER AT, 1990, ACTA CRYSTALLOGR A, V46, P585, DOI 10.1107/S0108767390002355; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Burns TF, 1999, J CELL PHYSIOL, V181, P231, DOI 10.1002/(SICI)1097-4652(199911)181:2<231::AID-JCP5>3.0.CO;2-L; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; CLORE GM, 1995, NAT STRUCT BIOL, V2, P253; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FRIEDMAN PN, 1993, P NATL ACAD SCI USA, V90, P3319, DOI 10.1073/pnas.90.8.3319; HALAZONETIS TD, 1993, EMBO J, V12, P5057, DOI 10.1002/j.1460-2075.1993.tb06199.x; JEFFREY PD, 1995, SCIENCE, V267, P1498, DOI 10.1126/science.7878469; JIANG JS, 1994, J MOL BIOL, V243, P100, DOI 10.1006/jmbi.1994.1633; JOHNSON ML, 1981, BIOPHYS J, V36, P575, DOI 10.1016/S0006-3495(81)84753-4; JONES TA, 1978, J APPL CRYSTALLOGR, V11, P268, DOI 10.1107/S0021889878013308; Laue T.M., 1992, ANAL ULTRACENTRIFUGA, P90; LEE WT, 1994, NAT STRUCT BIOL, V1, P877, DOI 10.1038/nsb1294-877; Leslie A.G.W., 1992, CCP4 ESF EACMB NEWSL; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; PAVLETICH NP, 1993, GENE DEV, V7, P2556, DOI 10.1101/gad.7.12b.2556; Prives C, 1999, J PATHOL, V187, P112; RICE LM, 1994, PROTEINS, V19, P277, DOI 10.1002/prot.340190403; STENGER JE, 1994, EMBO J, V13, P6011, DOI 10.1002/j.1460-2075.1994.tb06947.x; TOKINO T, 1994, HUM MOL GENET, V3, P1537, DOI 10.1093/hmg/3.9.1537; WANG Y, 1993, GENE DEV, V7, P2575, DOI 10.1101/gad.7.12b.2575; WATERMAN JLF, 1995, EMBO J, V14, P512, DOI 10.1002/j.1460-2075.1995.tb07027.x; YPHANTIS DA, 1964, BIOCHEMISTRY-US, V3, P297, DOI 10.1021/bi00891a003	27	70	73	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 13	2001	276	15					12120	12127		10.1074/jbc.M011644200	http://dx.doi.org/10.1074/jbc.M011644200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	421UK	11152481	hybrid			2022-12-25	WOS:000168081800092
J	Ame, JC; Schreiber, V; Fraulob, V; Dolle, P; de Murcia, G; Niedergang, CP				Ame, JC; Schreiber, V; Fraulob, V; Dolle, P; de Murcia, G; Niedergang, CP			Bidirectional promoter connects the poly(ADP-ribose) polymerase 2 (PARP-2) gene to the gene for RNase P RNA - Structure and expression of the mouse PARP-2 gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							T-CELL RECEPTOR; SERINE PROTEASE GENES; CIS-ACTING ELEMENTS; ALPHA-CHAIN; TRANSCRIPTION FACTORS; III TRANSCRIPTION; DNA-POLYMERASE; H1 RNA; REGION; SEQUENCES	Poly(ADP-ribose) polymerase 2 (PARP-2) is a DNA damage-dependent enzyme that belongs to a growing family of enzymes seemingly involved in genome protection. To gain insight into the physiological role of PARP-2 and to investigate mechanisms of PARP-2 gene regulation, we cloned and characterized the murine PARP-2 gene. The PARP-2 gene consists of 16 exons and 15 introns spanning about 13 kilobase pairs. Interestingly, the PARP-2 gene lies head to head with the gene encoding the mouse RNase P RNA subunit. The distance between the transcription start sites of the PARP-2 and RNase P RNA genes is 114 base pairs. This suggested that regulation of the expression of both genes may be coordinated through a bi-directional promoter. The PARP-2/RNase P RNA gene organization is conserved in the human. To our knowledge, this is the first report of a RNA polymerase II gene and an RNA polymerase III gene sharing the same promoter region and potentially the same transcriptional control elements. Reporter gene constructs showed that the 113-base pair intergenic region was indeed sufficient for the expression of both genes and revealed the importance of both the TATA and the DSE/Oct-1 expression control elements for the PARP-2 gene transcription. The expression of both genes is clearly independently regulated. PARP-2 is expressed only in certain tissues, and RNase P RNA is ex pressed in all tissues, This suggests that both genes may be subjected to multiple levels of control and may be regulated by different factors in different cellular contexts.	ULP, Ecole Super Biotechnol Strasbourg, CNRS,UPR 9003, Lab Conventionne Commissariat Energie Atom, F-67400 Illkirch, France; ULP, CNRS,INSERM, Coll France, Inst Genet & Biol Mol & Cellulaire, F-67404 Illkirch, France	CEA; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; College de France; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	de Murcia, G (corresponding author), ULP, Ecole Super Biotechnol Strasbourg, CNRS,UPR 9003, Lab Conventionne Commissariat Energie Atom, Blvd Sebastien Brant, F-67400 Illkirch, France.		Schreiber, Valérie/M-5007-2016; Dolle, Pascal/A-8037-2010	Schreiber, Valérie/0000-0003-0507-639X; Dolle, Pascal/0000-0002-9294-9090				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Ame JC, 1999, J BIOL CHEM, V274, P17860, DOI 10.1074/jbc.274.25.17860; Antonson P, 1996, GENOMICS, V35, P30, DOI 10.1006/geno.1996.0319; Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; BAER M, 1990, NUCLEIC ACIDS RES, V18, P97, DOI 10.1093/nar/18.1.97; BANERJI J, 1981, CELL, V27, P299, DOI 10.1016/0092-8674(81)90413-X; Berghammer H, 1999, FEBS LETT, V449, P259, DOI 10.1016/S0014-5793(99)00448-2; BERGHAMMER H, 1992, ADP RIBOSYLATION REA, P69; BOEHM T, 1988, EMBO J, V7, P385, DOI 10.1002/j.1460-2075.1988.tb02825.x; COLLINS MKL, 1985, NATURE, V314, P273, DOI 10.1038/314273a0; CROCE CM, 1985, SCIENCE, V227, P1044, DOI 10.1126/science.3919442; CROSBY JL, 1990, GENOMICS, V6, P252, DOI 10.1016/0888-7543(90)90564-B; D'Amours D, 1999, BIOCHEM J, V342, P249, DOI 10.1042/0264-6021:3420249; Dantzer F, 2000, BIOCHEMISTRY-US, V39, P7559, DOI 10.1021/bi0003442; DAS G, 1988, EMBO J, V7, P503, DOI 10.1002/j.1460-2075.1988.tb02838.x; DEMURCIA G, 1994, TRENDS BIOCHEM SCI, V19, P172, DOI 10.1016/0968-0004(94)90280-1; DeMurcia G., 2000, DNA DAMAGE STRESS SI; EDELHOFF S, 1995, MAMM GENOME, V6, P111, DOI 10.1007/BF00303253; Gibson L, 1996, ONCOGENE, V13, P665; HANNON GJ, 1991, J BIOL CHEM, V266, P22796; HANSON RD, 1990, P NATL ACAD SCI USA, V87, P960, DOI 10.1073/pnas.87.3.960; HERNANDEZ N, 1990, MOL BIOL REP, V14, P167, DOI 10.1007/BF00360460; HUPPI K, 1989, NUCLEIC ACIDS RES, V17, P3387, DOI 10.1093/nar/17.9.3387; Jacobson MK, 1999, TRENDS BIOCHEM SCI, V24, P415, DOI 10.1016/S0968-0004(99)01481-4; Johansson M, 1999, GENOMICS, V57, P442, DOI 10.1006/geno.1999.5799; Kickhoefer VA, 1999, J CELL BIOL, V146, P917, DOI 10.1083/jcb.146.5.917; LOBO SM, 1990, NUCLEIC ACIDS RES, V18, P2891, DOI 10.1093/nar/18.10.2891; Matz MV, 1999, NAT BIOTECHNOL, V17, P969, DOI 10.1038/13657; MCCAW BK, 1975, P NATL ACAD SCI USA, V72, P2071, DOI 10.1073/pnas.72.6.2071; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; MURPHY S, 1989, CELL, V59, P1071, DOI 10.1016/0092-8674(89)90763-0; MURPHY S, 1987, CELL, V51, P81, DOI 10.1016/0092-8674(87)90012-2; Niederreither K, 1998, METH MOL B, V89, P247; Oei SL, 1998, J BIOL CHEM, V273, P31644, DOI 10.1074/jbc.273.48.31644; OGURA T, 1990, BIOCHEM BIOPH RES CO, V167, P701, DOI 10.1016/0006-291X(90)92082-B; PARRY HD, 1989, TRENDS BIOCHEM SCI, V14, P15, DOI 10.1016/0968-0004(89)90083-2; POTVIN F, 1992, FEBS LETT, V302, P269, DOI 10.1016/0014-5793(92)80457-R; ROBSON CN, 1992, NUCLEIC ACIDS RES, V20, P4417, DOI 10.1093/nar/20.17.4417; Saito T, 1997, GENOMICS, V46, P46, DOI 10.1006/geno.1997.5005; Sambrook J., 2002, MOL CLONING LAB MANU; SANGER F, 1975, J MOL BIOL, V94, P441, DOI 10.1016/0022-2836(75)90213-2; SHALL S, 1999, MUTAT RES, V460, P1; Smith S, 1998, SCIENCE, V282, P1484, DOI 10.1126/science.282.5393.1484; SWAROOP A, 1992, P NATL ACAD SCI USA, V89, P266, DOI 10.1073/pnas.89.1.266; SWAROOP A, 1991, NUCLEIC ACIDS RES, V19, P1954, DOI 10.1093/nar/19.8.1954; TOPPER JN, 1990, NUCLEIC ACIDS RES, V18, P793, DOI 10.1093/nar/18.4.793; WIDEN SG, 1988, J BIOL CHEM, V263, P16992; YUAN Y, 1991, BIOCHIM BIOPHYS ACTA, V1089, P33, DOI 10.1016/0167-4781(91)90081-V	48	42	44	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 6	2001	276	14					11092	11099		10.1074/jbc.M007870200	http://dx.doi.org/10.1074/jbc.M007870200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	420AC	11133988	hybrid			2022-12-25	WOS:000167980900071
J	Chen, F; Lu, YJ; Zhang, Z; Vallyathan, V; Ding, M; Castranova, V; Shi, XL				Chen, F; Lu, YJ; Zhang, Z; Vallyathan, V; Ding, M; Castranova, V; Shi, XL			Opposite effect of NF-kappa B and c-Jun N-terminal kinase on p53-independent GADD45 induction by arsenite	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BRONCHIAL EPITHELIAL-CELLS; TRANSCRIPTION FACTOR; SIGNAL-TRANSDUCTION; INDUCED APOPTOSIS; GENE-EXPRESSION; IKK-BETA; ACTIVATION; JNK; P53; ALPHA	Cell cycle checkpoint, a major genomic surveillance mechanism,is an important step in maintaining genomic stability and integrity in response to environmental stresses. Using cells derived from human bronchial epithelial cells, we demonstrate that NF-kappaB and c-Jun N-terminal kinase (JNK) reciprocally regulate arsenic trioxide (arsenite)-induced, p53-independent expression of GADD45 protein, a cell cycle checkpoint protein that arrests cells at the G(2)/M phase transition. Inhibition of NF-kappaB activation by stable expression of a kinase-mutated form of I kappaB kinase caused increased and prolonged induction of GADD45 by arsenite. In contrast, the induction of GADD45 by arsenite was transient and less potent in cells where the NF-kappaB activation pathway was normal. Analysis of the cell cycle profile by flow cytometry indicated that NF-kappaB inhibition potentiates arsenite-induced G(2)/M cell cycle arrest. Abrogation of JNK activation, on the other hand, decreased GADD45 expression induced by arsenite, suggesting a role for JNK activation in GADD45 induction. These results indicate a molecular mechanism by which NF-kappaB and JNK may differentially contribute to cell cycle regulation in response to arsenite.	NIOSH, Pathol & Physiol Res Branch, Morgantown, WV 26505 USA	Centers for Disease Control & Prevention - USA; National Institute for Occupational Safety & Health (NIOSH)	Shi, XL (corresponding author), NIOSH, Pathol & Physiol Res Branch, 1095 Willowdale Rd, Morgantown, WV 26505 USA.	lfd3@cdc.gov; Xshi@cdc.gov	Shi, Xianglin/B-8588-2012; Zhang, Zhuo/B-8601-2012					Akao Y, 2000, LEUKEMIA LYMPHOMA, V37, P53, DOI 10.3109/10428190009057628; Ashcroft M, 1999, MOL CELL BIOL, V19, P1751; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Cavigelli M, 1996, EMBO J, V15, P6269, DOI 10.1002/j.1460-2075.1996.tb01017.x; Chan TA, 1999, NATURE, V401, P616, DOI 10.1038/44188; Chen F, 1999, CLIN CHEM, V45, P7; Chen F, 1999, J BIOL CHEM, V274, P20307, DOI 10.1074/jbc.274.29.20307; Chu WM, 1999, IMMUNITY, V11, P721, DOI 10.1016/S1074-7613(00)80146-6; Dickens M, 1997, SCIENCE, V277, P693, DOI 10.1126/science.277.5326.693; Du J, 2000, J BIOL CHEM, V275, P19661, DOI 10.1074/jbc.M907258199; Estrov Z, 1999, BLOOD, V94, P2844, DOI 10.1182/blood.V94.8.2844.420k43_2844_2853; FORNACE AJ, 1988, P NATL ACAD SCI USA, V85, P8800, DOI 10.1073/pnas.85.23.8800; Gebel T, 2000, TOXICOLOGY, V144, P155, DOI 10.1016/S0300-483X(99)00202-4; Geleziunas R, 1998, MOL CELL BIOL, V18, P5157, DOI 10.1128/MCB.18.9.5157; GERWIN BI, 1992, P NATL ACAD SCI USA, V89, P2759, DOI 10.1073/pnas.89.7.2759; Guttridge DC, 2000, SCIENCE, V289, P2363, DOI 10.1126/science.289.5488.2363; Hayes RB, 1997, CANCER CAUSE CONTROL, V8, P371, DOI 10.1023/A:1018457305212; Huang CS, 1999, CANCER RES, V59, P3053; Ip YT, 1998, CURR OPIN CELL BIOL, V10, P205, DOI 10.1016/S0955-0674(98)80143-9; Jin SQ, 2000, ONCOGENE, V19, P4050, DOI 10.1038/sj.onc.1203759; Kapahi P, 2000, J BIOL CHEM, V275, P36062, DOI 10.1074/jbc.M007204200; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Karin M, 1998, P NATL ACAD SCI USA, V95, P9067, DOI 10.1073/pnas.95.16.9067; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; Kayajanian GM, 2000, ECOTOX ENVIRON SAFE, V45, P195, DOI 10.1006/eesa.1999.1865; LEHMAN TA, 1993, CARCINOGENESIS, V14, P833, DOI 10.1093/carcin/14.5.833; Li QT, 1999, SCIENCE, V284, P321, DOI 10.1126/science.284.5412.321; Lubin JH, 2000, AM J EPIDEMIOL, V151, P554, DOI 10.1093/oxfordjournals.aje.a010243; Manna SK, 1998, J BIOL CHEM, V273, P13245, DOI 10.1074/jbc.273.21.13245; O'Reilly MA, 2000, AM J PHYSIOL-LUNG C, V278, pL552, DOI 10.1152/ajplung.2000.278.3.L552; Piwnica-Worms H, 1999, NATURE, V401, P535, DOI 10.1038/44029; Porter AC, 1999, ONCOGENE, V18, P7794, DOI 10.1038/sj.onc.1203214; Roussel RR, 2000, ARCH BIOCHEM BIOPHYS, V377, P204, DOI 10.1006/abbi.2000.1770; Samet JM, 1998, AM J PHYSIOL-LUNG C, V275, pL551, DOI 10.1152/ajplung.1998.275.3.L551; Shaulian E, 1999, J BIOL CHEM, V274, P29595, DOI 10.1074/jbc.274.42.29595; Simeonova PP, 2000, CANCER RES, V60, P3445; Takekawa M, 1998, CELL, V95, P521, DOI 10.1016/S0092-8674(00)81619-0; Wang XT, 1999, J BIOL CHEM, V274, P29599, DOI 10.1074/jbc.274.42.29599; Wang XW, 1999, P NATL ACAD SCI USA, V96, P3706, DOI 10.1073/pnas.96.7.3706; Woronicz JD, 1997, SCIENCE, V278, P866, DOI 10.1126/science.278.5339.866; Yu J, 1999, P NATL ACAD SCI USA, V96, P14517, DOI 10.1073/pnas.96.25.14517; ZHAN QM, 1993, MOL CELL BIOL, V13, P4242, DOI 10.1128/MCB.13.7.4242; Zhao RB, 2000, GENE DEV, V14, P981; Zhu XH, 1999, J NATL CANCER I, V91, P772, DOI 10.1093/jnci/91.9.772	44	88	91	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 6	2001	276	14					11414	11419		10.1074/jbc.M011682200	http://dx.doi.org/10.1074/jbc.M011682200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	420AC	11150309	hybrid			2022-12-25	WOS:000167980900114
J	Hoch, U; de Montellano, PRO				Hoch, U; de Montellano, PRO			Covalently linked heme in cytochrome P4504A fatty acid hydroxylases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MECHANISM-BASED INACTIVATION; LAURIC ACID; OMEGA-HYDROXYLATION; CATALYTIC SITE; RAT; PROTEINS; (OMEGA-1)-HYDROXYLATION; CYP4A11; BINDING	Three independent experimental methods, liquid chromatography, denaturing gel electrophoresis with heme staining, and mass spectrometry, establish that the CYP4A class of enzymes has a covalently bound heme group even though the heme is not cross-linked to the protein in other P450 enzymes. Covalent binding has been demonstrated for CYP4A1, -4A2, -4A3, -4A8, and -4A11 heterologously expressed in Escherichia coli. However, the covalent link is also present in CYP4A1 isolated from rat liver and is not an artifact of heterologous expression. The extent of heme covalent binding in the proteins as isolated varies and is substoichiometric. In CYP4A3, the heme is attached to the protein via an ester link to glutamic acid residue 318, which is on the I-helix, and is predicted to be within the active site. This is the first demonstration that a class of cytochrome P450 enzymes covalently binds their prosthetic heme group.	Univ Calif San Francisco, Sch Pharm, Dept Pharmaceut Chem, San Francisco, CA 94143 USA	University of California System; University of California San Francisco	de Montellano, PRO (corresponding author), Univ Calif San Francisco, Sch Pharm, Dept Pharmaceut Chem, San Francisco, CA 94143 USA.	ortiz@cgl.ucsf.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM025515, R01GM025515] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM25515] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMET Y, 1994, BIOCHEM BIOPH RES CO, V203, P1168, DOI 10.1006/bbrc.1994.2305; Barker PD, 1999, STRUCTURE, V7, pR281, DOI 10.1016/S0969-2126(00)88334-3; BARNES HJ, 1991, P NATL ACAD SCI USA, V88, P5597, DOI 10.1073/pnas.88.13.5597; BASILE G, 1980, J BIOL CHEM, V255, P7181; BONFILS C, 1995, ANAL BIOCHEM, V226, P302, DOI 10.1006/abio.1995.1229; CAJACOB CA, 1988, J BIOL CHEM, V263, P18640; CASTLE PJ, 1995, DRUG METAB DISPOS, V23, P1037; Chang YT, 1999, PROTEINS, V34, P403, DOI 10.1002/(SICI)1097-0134(19990215)34:3<403::AID-PROT12>3.0.CO;2-D; de Montellano P. R. O., 1995, CYTCOCHROME P450 STR, P245; DePillis GD, 1997, J BIOL CHEM, V272, P8857; Dierks EA, 1998, J BIOL CHEM, V273, P23055, DOI 10.1074/jbc.273.36.23055; Dierks EA, 1998, BIOCHEMISTRY-US, V37, P1839, DOI 10.1021/bi972458s; DORWARD DW, 1993, ANAL BIOCHEM, V209, P219, DOI 10.1006/abio.1993.1110; Fayadat L, 1999, J BIOL CHEM, V274, P10533, DOI 10.1074/jbc.274.15.10533; FENNA R, 1995, ARCH BIOCHEM BIOPHYS, V316, P653, DOI 10.1006/abbi.1995.1086; FUKUDA T, 1994, J BIOCHEM-TOKYO, V115, P338, DOI 10.1093/oxfordjournals.jbchem.a124339; Helvig C, 1998, BIOCHEMISTRY-US, V37, P12546, DOI 10.1021/bi981048g; Hoch U, 2000, ARCH BIOCHEM BIOPHYS, V373, P63, DOI 10.1006/abbi.1999.1504; Hoch U, 2000, J BIOL CHEM, V275, P26952; IMAOKA S, 1989, BIOCHEM INT, V18, P731; Koenigs LL, 1999, BIOCHEMISTRY-US, V38, P2312, DOI 10.1021/bi9823030; Koenigs LL, 1998, BIOCHEMISTRY-US, V37, P13184, DOI 10.1021/bi981198r; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; OMURA T, 1964, J BIOL CHEM, V239, P2370; Orrenius S, 1972, Biochem Soc Symp, V34, P55; Oxvig C, 1999, J BIOL CHEM, V274, P16953, DOI 10.1074/jbc.274.24.16953; Rae TD, 1996, J AM CHEM SOC, V118, P2103, DOI 10.1021/ja952650m; Rae TD, 1998, J BIOL CHEM, V273, P27968, DOI 10.1074/jbc.273.43.27968; Regal KA, 2000, CHEM RES TOXICOL, V13, P262, DOI 10.1021/tx990195s; TAYLOR KL, 1995, ARCH BIOCHEM BIOPHYS, V316, P635, DOI 10.1006/abbi.1995.1083; THONYMEYER L, 1994, BBA-BIOENERGETICS, V1187, P260, DOI 10.1016/0005-2728(94)90123-6; VISCO C, 1985, J BIOL CHEM, V260, P6133; Vuletich JL, 1998, ANAL BIOCHEM, V265, P375, DOI 10.1006/abio.1998.2926; Xie ZY, 1996, J BIOL CHEM, V271, P4632; ZENG J, 1992, J MOL BIOL, V226, P185, DOI 10.1016/0022-2836(92)90133-5	35	61	68	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 6	2001	276	14					11339	11346		10.1074/jbc.M009969200	http://dx.doi.org/10.1074/jbc.M009969200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	420AC	11139583	hybrid			2022-12-25	WOS:000167980900103
J	Hirase, T; Kawashima, S; Wong, EYM; Ueyama, T; Rikitake, Y; Tsukita, S; Yokoyama, M; Staddon, JM				Hirase, T; Kawashima, S; Wong, EYM; Ueyama, T; Rikitake, Y; Tsukita, S; Yokoyama, M; Staddon, JM			Regulation of tight junction permeability and occludin phosphorylation by RhoA-p160ROCK-dependent and -independent mechanisms	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGHT-CHAIN PHOSPHATASE; RHO-ASSOCIATED KINASE; ENDOTHELIAL-CELLS; LYSOPHOSPHATIDIC ACID; ACTIN CYTOSKELETON; POSSIBLE INVOLVEMENT; EPITHELIAL-CELLS; BINDING PROTEIN; ZO-1; IDENTIFICATION	In epithelial and endothelial cells, tight junctions regulate the paracellular permeability of ions and proteins. Disruption of tight junctions by inflammation is often associated with tissue edema, but regulatory mechanisms are not fully understood. Using ECV304 cells as a model system, lysophosphatidic acid and histamine were found to increase the paracellular permeability of the tracer horseradish peroxidase. Cytoskeletal changes induced by these agents included stimulation of stress fiber formation and myosin light chain phosphorylation, Additionally, occludin, a tight junction protein, was a target for signaling events triggered by lysophosphatidic acid and histamine, events that resulted in its phosphorylation, A dominant-negative mutant of RhoA, RhoA T19N, or a specific inhibitor of Rho-activated kinases, Y-27632, prevented stress fiber formation, myosin light chain phosphorylation, occludin phosphorylation, and the increase in tracer flux in response to lysophosphatidic acid. In contrast, although RhoA T19N and Y-27632 blocked the cytoskeletal events induced by histamine, they had no effect on the stimulation of occludin phosphorylation or increased tracer flux, indicating that occludin phosphorylation may regulate tight junction permeability independently of cytoskeletal events. Thus, occludin is a target for receptor-initiated signaling events regulating its phosphorylation, and this phosphorylation may be a key regulator of tight junction permeability.	Kobe Univ, Sch Med, Dept Internal Med 1, Chuo Ku, Kobe, Hyogo 6500017, Japan; Kyoto Univ, Fac Med, Dept Cell Biol, Sakyo Ku, Kyoto 6068501, Japan; UCL, Eisai London Res Labs Ltd, London WC1E 6BT, England	Kobe University; Kyoto University; Eisai Co Ltd; University of London; University College London	Hirase, T (corresponding author), Kobe Univ, Sch Med, Dept Internal Med 1, Chuo Ku, 7-5-2 Kusunoki Cho, Kobe, Hyogo 6500017, Japan.	hirase@med.kobe-u.ac.jp						ANDERSON JM, 1995, AM J PHYSIOL-GASTR L, V269, pG467, DOI 10.1152/ajpgi.1995.269.4.G467; Antonetti DA, 1999, J BIOL CHEM, V274, P23463, DOI 10.1074/jbc.274.33.23463; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; CITI S, 1988, NATURE, V333, P272, DOI 10.1038/333272a0; Cordenonsi M, 1997, J CELL SCI, V110, P3131; Essler M, 1998, J BIOL CHEM, V273, P21867, DOI 10.1074/jbc.273.34.21867; Essler M, 1998, J IMMUNOL, V161, P5640; Fanning AS, 1998, J BIOL CHEM, V273, P29745, DOI 10.1074/jbc.273.45.29745; FURUSE M, 1993, J CELL BIOL, V123, P1777, DOI 10.1083/jcb.123.6.1777; Furuse M, 1998, J CELL BIOL, V141, P1539, DOI 10.1083/jcb.141.7.1539; FURUSE M, 1994, J CELL BIOL, V127, P1617, DOI 10.1083/jcb.127.6.1617; Gebbink MFBG, 1997, J CELL BIOL, V137, P1603, DOI 10.1083/jcb.137.7.1603; GOECKELER ZM, 1995, J CELL BIOL, V130, P613, DOI 10.1083/jcb.130.3.613; GUMBINER B, 1987, AM J PHYSIOL, V253, pC749, DOI 10.1152/ajpcell.1987.253.6.C749; GUMBINER B, 1991, P NATL ACAD SCI USA, V88, P3460, DOI 10.1073/pnas.88.8.3460; GUMBINER BM, 1993, J CELL BIOL, V123, P1631, DOI 10.1083/jcb.123.6.1631; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Haskins J, 1998, J CELL BIOL, V141, P199, DOI 10.1083/jcb.141.1.199; Hirase T, 1997, J CELL SCI, V110, P1603; Ishizaki T, 1997, FEBS LETT, V404, P118, DOI 10.1016/S0014-5793(97)00107-5; Itoh M, 1999, J BIOL CHEM, V274, P5981, DOI 10.1074/jbc.274.9.5981; Jou TS, 1998, J CELL BIOL, V142, P101, DOI 10.1083/jcb.142.1.101; Keon BH, 1996, J CELL BIOL, V134, P1003, DOI 10.1083/jcb.134.4.1003; Kimura K, 1996, SCIENCE, V273, P245, DOI 10.1126/science.273.5272.245; Kranenburg O, 1997, J CELL SCI, V110, P2417; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Madara JL, 1998, ANNU REV PHYSIOL, V60, P143, DOI 10.1146/annurev.physiol.60.1.143; Matsui T, 1996, EMBO J, V15, P2208, DOI 10.1002/j.1460-2075.1996.tb00574.x; McDonald DM, 1999, MICROCIRCULATION, V6, P7; MEISENHELDER J, 1991, METHOD ENZYMOL, V197, P288; Miyake S, 1996, P NATL ACAD SCI USA, V93, P1320, DOI 10.1073/pnas.93.3.1320; MOOLENAAR WH, 1995, J BIOL CHEM, V270, P12949, DOI 10.1074/jbc.270.22.12949; Morita K, 1999, P NATL ACAD SCI USA, V96, P511, DOI 10.1073/pnas.96.2.511; Narumiya S, 1997, FEBS LETT, V410, P68, DOI 10.1016/S0014-5793(97)00317-7; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; NUSRAT A, 1995, P NATL ACAD SCI USA, V92, P10629, DOI 10.1073/pnas.92.23.10629; Ratcliffe MJ, 1999, BIOCHEM J, V338, P471, DOI 10.1042/0264-6021:3380471; Sahai E, 1999, CURR BIOL, V9, P136, DOI 10.1016/S0960-9822(99)80067-0; Saitou M, 1997, EUR J CELL BIOL, V73, P222; Sakakibara A, 1997, J CELL BIOL, V137, P1393, DOI 10.1083/jcb.137.6.1393; SCHNEEBERGER EE, 1992, AM J PHYSIOL, V262, pL647, DOI 10.1152/ajplung.1992.262.6.L647; Schulze C, 1997, J NEUROCHEM, V68, P991; SELDEN SC, 1981, J CELL PHYSIOL, V108, P195, DOI 10.1002/jcp.1041080210; Siess W, 1999, P NATL ACAD SCI USA, V96, P6931, DOI 10.1073/pnas.96.12.6931; STADDON JM, 1995, J CELL SCI, V108, P609; Staddon JM, 1996, CURR OPIN NEUROBIOL, V6, P622, DOI 10.1016/S0959-4388(96)80094-8; STEVENSON BR, 1986, J CELL BIOL, V103, P755, DOI 10.1083/jcb.103.3.755; Tsukita S, 1999, TRENDS CELL BIOL, V9, P268, DOI 10.1016/S0962-8924(99)01578-0; Uehata M, 1997, NATURE, V389, P990, DOI 10.1038/40187; WEBER E, 1994, J CELL BIOL, V125, P583, DOI 10.1083/jcb.125.3.583; ZHONG Y, 1993, J CELL BIOL, V120, P477, DOI 10.1083/jcb.120.2.477	51	243	261	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 30	2001	276	13					10423	10431		10.1074/jbc.M007136200	http://dx.doi.org/10.1074/jbc.M007136200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	420GC	11139571	hybrid			2022-12-25	WOS:000167996400109
J	Miyadera, H; Amino, H; Hiraishi, A; Taka, H; Murayama, K; Miyoshi, H; Sakamoto, K; Ishii, N; Hekimi, S; Kita, K				Miyadera, H; Amino, H; Hiraishi, A; Taka, H; Murayama, K; Miyoshi, H; Sakamoto, K; Ishii, N; Hekimi, S; Kita, K			Altered quinone biosynthesis in the long-lived clk-1 mutants of Caenorhabditis elegans	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; LIFE-SPAN; COQ7 GENE; MITOCHONDRIA; COMPLEX; NEMATODE; RESPIRATION; PROTEIN; MOUSE	Mutations in the clk-1 gene of Caenorhabditis elegans result in an extended life span and an average slowing down of developmental and behavioral rates. However, it has not been possible to identify biochemical changes that might underlie the extension of life span observed in clk-1 mutants, and therefore the function of CLK-1 in C. elegans remains unknown. In this report, we analyzed the effect of clk-1 mutation on ubiquinone (UQ(9)) biosynthesis and show that clk-1 mutants mitochondria do not contain detectable levels of UQ(9). Instead, the UQ(9) biosynthesis intermediate, demethoxyubiquinone (DMQ(9)), is present at high levels. This result demonstrates that CLK-1 is absolutely required for the biosynthesis of UQ(9) in C. elegans. Interestingly, the activity levels of NADH-cytochrome c reductase and succinate-cytochrome c reductase in mutant mitochondria are very similar to those in the wild-type, suggesting that DMQ(9) can function as an electron carrier in the respiratory chain. To test this possibility, the short side chain derivative DMQ(2) was chemically synthesized. We find that DMQ(2) can act as an electron acceptor for both complex I and complex II in clk-1 mutant mitochondria, while another ubiquinone biosynthesis precursor, 3-hydroxy-UQ(2), cannot. The accumulation of DMQ(9) and its use in mutant mitochondria indicate, for the first time in any organism, a link between the alteration in the quinone species used in respiration and life span.	Univ Tokyo, Grad Sch Med, Dept Biomed Chem, Bunkyo Ku, Tokyo 1130033, Japan; Toyohashi Univ Technol, Dept Ecol Engn, Toyohashi, Aichi 4418580, Japan; Juntendo Univ, Sch Med, Cent Lab Med Sci, Tokyo 1138421, Japan; Kyoto Univ, Grad Sch Agr, Div Appl Life Sci, Kyoto 6068502, Japan; Tokai Univ, Sch Med, Dept Mol Life Sci, Kanagawa 2591193, Japan; McGill Univ, Dept Biol, Montreal, PQ H3A 1B1, Canada	University of Tokyo; Toyohashi University of Technology; Juntendo University; Kyoto University; Tokai University; McGill University	Kita, K (corresponding author), Univ Tokyo, Grad Sch Med, Dept Biomed Chem, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1130033, Japan.	kitak@m.u-tokyo.ac.jp	Sakamoto, Kimitoshi/G-4539-2014	Hiraishi, Akira/0000-0001-5556-344X; Kita, Kiyoshi/0000-0002-0426-4308				Asaumi S, 1999, GENOMICS, V58, P293, DOI 10.1006/geno.1999.5838; Beckman KB, 1998, PHYSIOL REV, V78, P547, DOI 10.1152/physrev.1998.78.2.547; Braeckman BP, 1999, CURR BIOL, V9, P493, DOI 10.1016/S0960-9822(99)80216-4; Branicky R, 2000, BIOESSAYS, V22, P48, DOI 10.1002/(SICI)1521-1878(200001)22:1&lt;48::AID-BIES9&gt;3.0.CO;2-F; Ewbank JJ, 1997, SCIENCE, V275, P980, DOI 10.1126/science.275.5302.980; Felkai S, 1999, EMBO J, V18, P1783, DOI 10.1093/emboj/18.7.1783; Finkel T, 2000, NATURE, V408, P239, DOI 10.1038/35041687; Gems D, 1999, CURR BIOL, V9, pR614, DOI 10.1016/S0960-9822(99)80387-X; Hekimi S, 1998, TRENDS GENET, V14, P14, DOI 10.1016/S0168-9525(97)01299-7; HEKIMI S, 2000, MOL GENETICS AGING, P81; HIRAISHI A, 1984, J GEN APPL MICROBIOL, V30, P435, DOI 10.2323/jgam.30.435; Hsu AY, 2000, BBA-MOL CELL BIOL L, V1484, P287, DOI 10.1016/S1388-1981(00)00019-6; Jonassen T, 1996, ARCH BIOCHEM BIOPHYS, V330, P285, DOI 10.1006/abbi.1996.0255; Jonassen T, 1998, J BIOL CHEM, V273, P3351, DOI 10.1074/jbc.273.6.3351; KITA K, 1989, J BIOL CHEM, V264, P2672; Kwon O, 2000, FEMS MICROBIOL LETT, V186, P157, DOI 10.1016/S0378-1097(00)00134-8; Lakowski B, 1998, P NATL ACAD SCI USA, V95, P13091, DOI 10.1073/pnas.95.22.13091; Lakowski B, 1996, SCIENCE, V272, P1010, DOI 10.1126/science.272.5264.1010; LESTER RL, 1959, BIOCHIM BIOPHYS ACTA, V33, P169, DOI 10.1016/0006-3002(59)90511-6; Marbois BN, 1996, J BIOL CHEM, V271, P2995, DOI 10.1074/jbc.271.6.2995; MURFITT RR, 1976, COMP BIOCHEM PHYS B, V53, P423, DOI 10.1016/0305-0491(76)90191-7; OGASAHARA S, 1989, P NATL ACAD SCI USA, V86, P2379, DOI 10.1073/pnas.86.7.2379; Ohshima M, 1998, BIOCHEMISTRY-US, V37, P6436, DOI 10.1021/bi9800202; Raha S, 2000, TRENDS BIOCHEM SCI, V25, P502, DOI 10.1016/S0968-0004(00)01674-1; SCHEFFLER IE, 1999, MITOCHONDRIA, P235; TAKAMIYA S, 1984, MOL BIOCHEM PARASIT, V13, P121, DOI 10.1016/0166-6851(84)90107-5; TRUMPOWER BL, 1974, CHEM PHYS LIPIDS, V13, P123, DOI 10.1016/0009-3084(74)90027-9; Vajo Z, 1999, MAMM GENOME, V10, P1000, DOI 10.1007/s003359901147; Vanfleteren JR, 1999, NEUROBIOL AGING, V20, P487, DOI 10.1016/S0197-4580(99)00087-1; WALLACE BJ, 1977, BIOCHIM BIOPHYS ACTA, V461, P75, DOI 10.1016/0005-2728(77)90070-6; WONG A, 1995, GENETICS, V139, P1247	31	164	174	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 16	2001	276	11					7713	7716		10.1074/jbc.C000889200	http://dx.doi.org/10.1074/jbc.C000889200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	411AA	11244089	hybrid			2022-12-25	WOS:000167474900007
J	Hu, JX; Reyes-Cruz, G; Goldsmith, PK; Spiegel, AM				Hu, JX; Reyes-Cruz, G; Goldsmith, PK; Spiegel, AM			The venus's-flytrap and cysteine-rich domains of the human Ca2+ receptor are not linked by disulfide bonds	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							METABOTROPIC GLUTAMATE-RECEPTOR; CALCIUM-SENSING RECEPTOR; CELL-SURFACE EXPRESSION; SIGNAL-TRANSDUCTION; EXTRACELLULAR DOMAIN; IDENTIFICATION; DIMERIZATION; CLONING	The extracellular N-terminal domain of the human Ca2+ receptor (hCaR) consists of a Venus's-flytrap (VFT) domain and a cysteine-rich (Cys-rich) domain. We have shown earlier that the Cys-rich domain is critical for signal transmission from the VFT domain to the seven-transmembrane domain. The VFT domain contains 10 cysteines: two of them (Cys(129) and Cys(131)) were identified as involved in intermolecular disulfide bonds necessary for homodimerization, and six others (Cys(60)- Cys(101), Cys(358)-Cys(395), and Cys(437)-Cys(449)) are predicted to form three intramolecular disulfide bonds. The Cys-rich domain contains nine cysteines, the involvement of which in disulfide bond formation has not been defined. In this work, we asked whether the remaining cysteines in the hCaR VFT, namely Cys(236) and Cys(482), form disulfide bond(s) with cysteines in the Cys-rich domain. We constructed mutant hCaRs with a unique tobacco etch virus (TEV) protease recognition site inserted between the VFT domain and the Cys-rich domain. These mutant hCaRs remain fully functional compared with the wild type hCaR. After TEV protease digestion of the mutant hCaR proteins, dimers of the VFT were identified on Western blot under nonreducing conditions. We concluded that there is no disulfide bond between the VFT and the Cys-rich domains in the hCaR.	NIDCD, Mol Pathophysiol Sect, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute on Deafness & Other Communication Disorders (NIDCD)	Hu, JX (corresponding author), NIDCD, Mol Pathophysiol Sect, NIH, Bldg 10,Rm 8C-101,9000 Rockville Pike, Bethesda, MD 20892 USA.		Centeno, Patricia Pacios/O-8368-2016		NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [Z01DC000061] Funding Source: NIH RePORTER	NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		Bai M, 1996, J BIOL CHEM, V271, P19537, DOI 10.1074/jbc.271.32.19537; Bockaert J, 1999, EMBO J, V18, P1723, DOI 10.1093/emboj/18.7.1723; Brauner-Osborne H, 1999, J BIOL CHEM, V274, P18382, DOI 10.1074/jbc.274.26.18382; Brown EM, 1999, AM J MED, V106, P238, DOI 10.1016/S0002-9343(98)00418-5; Brown EM, 1998, ANNU REV MED, V49, P15, DOI 10.1146/annurev.med.49.1.15; DOUGHERTY WG, 1993, MICROBIOL REV, V57, P781, DOI 10.1128/MMBR.57.4.781-822.1993; Fan GF, 1998, FEBS LETT, V436, P353, DOI 10.1016/S0014-5793(98)01165-X; GARRETT JE, 1995, J BIOL CHEM, V270, P12919, DOI 10.1074/jbc.270.21.12919; Hammerland LG, 1999, MOL PHARMACOL, V55, P642; Hoon MA, 1999, CELL, V96, P541, DOI 10.1016/S0092-8674(00)80658-3; Hu JX, 2000, J BIOL CHEM, V275, P16382, DOI 10.1074/jbc.M000277200; Kaupmann K, 1997, NATURE, V386, P239, DOI 10.1038/386239a0; Kunishima N, 2000, NATURE, V407, P971, DOI 10.1038/35039564; MASU M, 1991, NATURE, V349, P760, DOI 10.1038/349760a0; Ray K, 1998, J BIOL CHEM, V273, P34558, DOI 10.1074/jbc.273.51.34558; Ray K, 1999, J BIOL CHEM, V274, P27642, DOI 10.1074/jbc.274.39.27642; Ray K, 1997, J BIOL CHEM, V272, P31355, DOI 10.1074/jbc.272.50.31355; Ryba NJP, 1997, NEURON, V19, P371, DOI 10.1016/S0896-6273(00)80946-0; Tsuji Y, 2000, J BIOL CHEM, V275, P28144	19	18	18	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 9	2001	276	10					6901	6904		10.1074/jbc.C000865200	http://dx.doi.org/10.1074/jbc.C000865200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	410MC	11238442	hybrid			2022-12-25	WOS:000167442900006
J	Ho, MCY; Lo, ACY; Kurihara, H; Yu, ACH; Chung, SSM; Chung, SK				Ho, MCY; Lo, ACY; Kurihara, H; Yu, ACH; Chung, SSM; Chung, SK			Endothelin-1 protects astrocytes from hypoxic/ischemic injury	FASEB JOURNAL			English	Article						Endothelin-3; endothelin receptors; cell survival; lactate dehydrogenase; ET-1-deficient mice	TRANSIENT FOREBRAIN ISCHEMIA; RECEPTOR-DEFICIENT MICE; SMOOTH-MUSCLE CELLS; ETB RECEPTORS; DNA-SYNTHESIS; GLIAL-CELLS; RAT; EXPRESSION; VASOCONSTRICTOR; BRAIN	Under pathological conditions such as ischemia (I), subarachnoid hemorrhage, and Alzheimer's disease, astrocytes show a large increase in endothelin (ET) -like immunoreactivity. However, it is not clear whether ET is protective or destructive to these cells during brain injury. Using astrocytes from ET-1-deficient mice, we determined the effect of ET-1 on these cells under normal, hypoxic (H), and hypoxic/ ischemic (H/I) conditions. Under normal culture conditions, astrocytes from wild-type and ET-l-deficient mice showed no difference in their morphology and cell proliferation rates. ET-3 and ETA receptor mRNAs were up-regulated whereas ETB receptor mRNA was down-regulated in ET-1-deficient astrocytes, suggesting that ET-1 and ET-3 may complement each other's functions and that the expressions of these endothelins and their receptors are regulated by a complex feedback mechanism. Under H and H/I conditions, ET-1 peptide and mRNA were up-regulated in wild-type astrocytes, and the astrocytes without ET-1 died faster than the wild-type astrocytes, as indicated by greater efflux of lactate dehydrogenase, The present study suggests that astrocytes without ET-1 are more vulnerable to H and H/I injuries and that the up-regulation of astrocytic ET-1 is essential for the survival of astrocytes.-Ho, M. C. Y., Lo, A. C. Y., Kurihara, H., Yu, A. C. H., Chung, S. S. M., Chung, S. K. Endothelin-1 protects astrocytes from hypoxic/ischemic injury.	Univ Hong Kong, Inst Mol Biol, Hong Kong, Hong Kong, Peoples R China; Hong Kong Univ Sci & Technol, Dept Biol, Hong Kong, Hong Kong, Peoples R China; Univ Tokyo, Grad Sch Med, Dept Cardiovasc Res, Tokyo, Japan	University of Hong Kong; Hong Kong University of Science & Technology; University of Tokyo	Chung, SK (corresponding author), Univ Hong Kong, Inst Mol Biol, South Wing,8-F Kadoorie,Biol Sci Bldg,Pokfulam Rd, Hong Kong, Hong Kong, Peoples R China.		Lo, Amy C. Y./C-1195-2009	Lo, Amy C. Y./0000-0003-4239-6851; Kurihara, Hiroki/0000-0002-6476-5593				ARAI H, 1990, NATURE, V348, P730, DOI 10.1038/348730a0; Chan TSK, 1995, EUR J BIOCHEM, V234, P819, DOI 10.1111/j.1432-1033.1995.819_a.x; CLARKE JG, 1989, AM J PHYSIOL, V257, pH2033, DOI 10.1152/ajpheart.1989.257.6.H2033; Clouthier DE, 1998, DEVELOPMENT, V125, P813; Clouthier DE, 2000, DEV BIOL, V217, P10, DOI 10.1006/dbio.1999.9527; DENUCCI G, 1988, P NATL ACAD SCI USA, V85, P9797; DUGAN LL, 1995, J NEUROSCI, V15, P4545; FUXE K, 1991, NEUROSCI LETT, V123, P107, DOI 10.1016/0304-3940(91)90169-T; HIRATA Y, 1989, ATHEROSCLEROSIS, V78, P225, DOI 10.1016/0021-9150(89)90227-X; Hu J, 1998, BIOCHEM BIOPH RES CO, V245, P894, DOI 10.1006/bbrc.1998.8543; INOUE A, 1989, P NATL ACAD SCI USA, V86, P2863, DOI 10.1073/pnas.86.8.2863; Ishikawa N, 1997, EUR J NEUROSCI, V9, P895, DOI 10.1111/j.1460-9568.1997.tb01440.x; JIANG MH, 1993, NEUROREPORT, V4, P935, DOI 10.1097/00001756-199307000-00024; KAKU DA, 1991, BRAIN RES, V554, P344, DOI 10.1016/0006-8993(91)90214-G; KURIHARA Y, 1994, NATURE, V368, P703, DOI 10.1038/368703a0; Kuwaki T, 1997, PROG NEUROBIOL, V51, P545, DOI 10.1016/S0301-0082(96)00063-9; LEE ME, 1990, J CLIN INVEST, V86, P141, DOI 10.1172/JCI114677; MACCUMBER MW, 1990, P NATL ACAD SCI USA, V87, P2359, DOI 10.1073/pnas.87.6.2359; MACNULTY EE, 1990, BIOCHEM J, V272, P761, DOI 10.1042/bj2720761; MAKAR TK, 1994, J NEUROCHEM, V62, P45; NAKAMURA S, 1993, ENDOCRINOLOGY, V132, P530, DOI 10.1210/en.132.2.530; Pluta RM, 1997, J NEUROSURG, V87, P287, DOI 10.3171/jns.1997.87.2.0287; RANSOM BR, 1992, PROG BRAIN RES, V94, P37; RAPS SP, 1989, BRAIN RES, V493, P398, DOI 10.1016/0006-8993(89)91178-5; ROSENBERG PA, 1990, NEUROSCI LETT, V116, P399; ROSENBERG PA, 1989, NEUROSCI LETT, V103, P162, DOI 10.1016/0304-3940(89)90569-7; Ruffolo RR., 1995, ENDOTHELIN RECEPTORS; SAKURAI T, 1990, NATURE, V348, P732, DOI 10.1038/348732a0; Sasaki Y, 1998, EUR J NEUROSCI, V10, P2984, DOI 10.1111/j.1460-9568.1998.00305.x; Shichiri M, 1998, J CARDIOVASC PHARM, V31, pS138, DOI 10.1097/00005344-199800001-00041; Shichiri M, 1997, HYPERTENSION, V30, P1198, DOI 10.1161/01.HYP.30.5.1198; SIMONSON MS, 1989, J CLIN INVEST, V83, P708, DOI 10.1172/JCI113935; SUPATTAPONE S, 1989, BIOCHEM BIOPH RES CO, V165, P1115, DOI 10.1016/0006-291X(89)92718-6; TSANG M, 1995, NEUR ABSTR, V22; VIGNE P, 1990, BIOCHEM J, V266, P415, DOI 10.1042/bj2660415; Wu-Wong JR, 1997, BIOCHEM J, V328, P733, DOI 10.1042/bj3280733; YAMASHITA K, 1993, CELL MOL NEUROBIOL, V13, P15, DOI 10.1007/BF00712986; YAMASHITA K, 1994, J NEUROCHEM, V63, P1042; Yamashita Kimihiro, 1995, Clinical and Experimental Pharmacology and Physiology, V22, pS277, DOI 10.1111/j.1440-1681.1995.tb02915.x; YANAGISAWA M, 1988, NATURE, V332, P411, DOI 10.1038/332411a0; Yu ACH, 2000, NEUROCHEM INT, V36, P369, DOI 10.1016/S0197-0186(99)00145-X; YU ACH, 1993, J NEUROSCI RES, V34, P295, DOI 10.1002/jnr.490340306; ZHANG WW, 1994, J NEUROL SCI, V122, P90, DOI 10.1016/0022-510X(94)90057-4	43	49	51	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAR	2001	15	3					618	626		10.1096/fj.99-1022com	http://dx.doi.org/10.1096/fj.99-1022com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	410BE	11259380				2022-12-25	WOS:000167419500019
J	Schaefer, L; Raslik, I; Grone, HJ; Schonherr, E; Macakova, K; Ugorcakova, J; Budny, S; Schaefer, RM; Kresse, H				Schaefer, L; Raslik, I; Grone, HJ; Schonherr, E; Macakova, K; Ugorcakova, J; Budny, S; Schaefer, RM; Kresse, H			Small proteoglycans in human diabetic nephropathy: Discrepancy between glomerular expression and protein accumulation of decorin, biglycan, lumican, and fibromodulin	FASEB JOURNAL			English	Article									Univ Munster, Dept Internal Med, D-4400 Munster, Germany; Univ Munster, Dept Physiol Chem & Pathobiochem, D-4400 Munster, Germany; German Canc Res Ctr, Dept Cellular & Mol Pathol, D-6900 Heidelberg, Germany; Slovak Acad Sci, Inst Mol Biol, Bratislava 84251, Slovakia	University of Munster; University of Munster; Helmholtz Association; German Cancer Research Center (DKFZ); Slovak Academy of Sciences	Schaefer, L (corresponding author), Med Poliklin, Albert Schweitzer Str 33, D-48129 Munster, Germany.			Ugorcakova, Jana/0000-0003-4019-9221					0	117	123	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAR	2001	15	3					559	561						3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	410BE	11259366				2022-12-25	WOS:000167419500004
J	Watchorn, TM; Waddell, I; Dowidar, N; Ross, JA				Watchorn, TM; Waddell, I; Dowidar, N; Ross, JA			Proteolysis-inducing factor regulates hepatic gene expression via the transcription factors NF-kappa B and STAT3	FASEB JOURNAL			English	Article									Univ Edinburgh, Dept Clin & Surg Sci, Mol Immunol Grp, Edinburgh EH8 9YL, Midlothian, Scotland; Astrazeneca, Cardiovasc & Gastrointestinal Discovery Dept, Macclesfield, Cheshire, England	University of Edinburgh; AstraZeneca	Waddell, I (corresponding author), RIE, Lister Res Labs, Lauriston Pl, Edinburgh EH3 9YW, Midlothian, Scotland.								0	75	85	0	9	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAR	2001	15	3					562	564						3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	410BE	11259367				2022-12-25	WOS:000167419500005
J	Baker, D; Pryce, G; Croxford, JL; Brown, P; Pertwee, RG; Makriyannis, A; Khanolkar, A; Layward, L; Fezza, F; Bisogno, T; Di Marzo, V				Baker, D; Pryce, G; Croxford, JL; Brown, P; Pertwee, RG; Makriyannis, A; Khanolkar, A; Layward, L; Fezza, F; Bisogno, T; Di Marzo, V			Endocannabinoids control spasticity in a multiple sclerosis model	FASEB JOURNAL			English	Article									CNR, Ist Chim Mol Interesse Biol, Endocannabinoid Res Grp, I-80072 Arco Felice Napoli, Naples, Italy; UCL, Inst Neurol, Neuroinflammat Grp, London, England; Natl Hosp Neurol & Neurosurg, MRC, Human Movement & Balance Unit, London WC1N 3BG, England; Univ Aberdeen, Inst Med Sci, Aberdeen AB9 1FX, Scotland; Univ Connecticut, Dept Pharmaceut Sci & Mol & Cell Biol, Ctr Drug Discovery, Storrs, CT USA; Multiple Sclerosis Soc Great Britain & No Ireland, London, England	Consiglio Nazionale delle Ricerche (CNR); University of London; King's College London; University College London; University of London; University College London; UCL Medical School; University College London Hospitals NHS Foundation Trust; University of Aberdeen; University of Connecticut	Di Marzo, V (corresponding author), CNR, Ist Chim Mol Interesse Biol, Endocannabinoid Res Grp, Via Toiano 6, I-80072 Arco Felice Napoli, Naples, Italy.	vdimarzo@icmib.na.cnr.it	Brown, Peter/J-4307-2016; Pertwee, Roger Guy/E-1312-2011; Di Marzo, Vincenzo/AAD-7742-2019; Bisogno, Tiziana/B-7891-2015; Makriyannis, Alexandros/GRF-1518-2022	Brown, Peter/0000-0002-5201-3044; Di Marzo, Vincenzo/0000-0002-1490-3070; Makriyannis, Alexandros/0000-0003-3272-3687; Pertwee, Roger/0000-0003-3227-2783	Multiple Sclerosis Society [541] Funding Source: Medline	Multiple Sclerosis Society(National Multiple Sclerosis Society)			0	314	337	0	13	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	FEB	2001	15	2					300	302		10.1096/fj.00-0399fje	http://dx.doi.org/10.1096/fj.00-0399fje			3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	400LK	11156943				2022-12-25	WOS:000166872900009
J	Smith, U; Gogg, S; Johansson, A; Olausson, T; Rotter, V; Svalstedt, B				Smith, U; Gogg, S; Johansson, A; Olausson, T; Rotter, V; Svalstedt, B			Thiazolidinediones (PPAR gamma agonists) but not PPAR alpha agonists increase IRS-2 gene expression in 3T3-L1 and human adipocytes	FASEB JOURNAL			English	Article; Proceedings Paper	60th Annual Meeting of the American-Diabetes-Association	JUN 09-13, 2000	SAN ANTONIO, TEXAS	Amer Diabet Assoc		insulin signaling; insulin action; gene transcription; IRS-2; PPAR	INSULIN-RECEPTOR SUBSTRATE-2; OBESE ZUCKER RATS; TYROSINE PHOSPHORYLATION; ADIPOSE-TISSUE; C/EBP-ALPHA; PATHWAY; ORGANIZATION; TROGLITAZONE; SENSITIVITY; FIBROBLASTS	Thiazolidinediones (TZD) improve insulin sensitivity in human as well as in different animal models of insulin resistance and Type 2 diabetes. However, no clear link to the insulin signaling events has been identified, Using differentiated 3T3-L1 adipocytes, we found that TZD rapidly and markedly increased IRS-2 gene expression. This effect was specific for PPAR gamma agonists and was not seen with PPAR alpha agonists. It was rapidly induced (within 4 h) and maintained throughout the observation period of 48 h. It was also concentration dependent (EC50 similar to 50 nM) and not inhibited by cycloheximide, suggesting a direct effect on the IRS-2 promoter. There was no evidence that TZD altered IRS-2 mRNA stability, supporting that the increased mRNA levels were due to an increased gene transcription. IRS-2 protein expression was increased similar to 30% after 48 h and similar to 50% after 96 h. No effects of TZD were seen on IRS-1, PKB/Akt, or GLUT4 gene expression. TZD also increased IRS-2 mRNA levels in cultured human adipose tissue. These data show the first direct Link between TZD and a critical molecule in insulin's signaling cascade in both 3T3-L1 and human adipocytes, and indicate a novel mode of action of these compounds.	Univ Gothenburg, Sahlgrenska Hosp, Dept Internal Med, Lundberg Lab Diabet Res, S-41345 Gothenburg, Sweden	Sahlgrenska University Hospital; University of Gothenburg	Smith, U (corresponding author), Univ Gothenburg, Sahlgrenska Hosp, Dept Internal Med, Lundberg Lab Diabet Res, Guldhetsgatan, S-41345 Gothenburg, Sweden.		Gogg, Silvia/R-4549-2019					BOWEN L, 1991, METABOLISM, V40, P1025, DOI 10.1016/0026-0495(91)90124-F; CHAIKEN RL, 1995, DIABETOLOGIA, V38, P1307; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CIGOLINI M, 1979, METABOLISM, V28, P502, DOI 10.1016/0026-0495(79)90189-6; El-Jack AK, 1999, J BIOL CHEM, V274, P7946, DOI 10.1074/jbc.274.12.7946; Fajas L, 1997, J BIOL CHEM, V272, P18779, DOI 10.1074/jbc.272.30.18779; FUJIWARA T, 1988, DIABETES, V37, P1549, DOI 10.2337/diabetes.37.11.1549; Lefebvre AM, 1997, ARTERIOSCL THROM VAS, V17, P1756, DOI 10.1161/01.ATV.17.9.1756; Li JP, 1999, J BIOL CHEM, V274, P9351, DOI 10.1074/jbc.274.14.9351; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; Mastick CC, 1997, J BIOL CHEM, V272, P20706, DOI 10.1074/jbc.272.33.20706; NOLAN JJ, 1994, NEW ENGL J MED, V331, P1188, DOI 10.1056/NEJM199411033311803; Okuno A, 1998, J CLIN INVEST, V101, P1354, DOI 10.1172/JCI1235; Peraldi P, 1997, J CLIN INVEST, V100, P1863, DOI 10.1172/JCI119715; Ribon V, 1998, P NATL ACAD SCI USA, V95, P14751, DOI 10.1073/pnas.95.25.14751; RICORT JM, 1995, DIABETOLOGIA, V38, P1148, DOI 10.1007/s001250050406; Rondinone CM, 1997, P NATL ACAD SCI USA, V94, P4171, DOI 10.1073/pnas.94.8.4171; RUBIN CS, 1977, J BIOL CHEM, V252, P3554; SMITH U, 1976, DIABETOLOGIA, V12, P137, DOI 10.1007/BF00428979; Spiegelman BM, 1998, DIABETES, V47, P507, DOI 10.2337/diabetes.47.4.507; Sun XJ, 1999, DIABETES, V48, P1359, DOI 10.2337/diabetes.48.7.1359; TOBACK FG, 1974, J CLIN INVEST, V54, P91, DOI 10.1172/JCI107754; Vassen L, 1999, MOL ENDOCRINOL, V13, P485; Vassen L, 1999, DIABETES, V48, P1877, DOI 10.2337/diabetes.48.9.1877; Withers DJ, 1999, NAT GENET, V23, P32, DOI 10.1038/12631; Wu ZD, 1998, J CLIN INVEST, V101, P22, DOI 10.1172/JCI1244; Zierath JR, 1998, ENDOCRINOLOGY, V139, P5034, DOI 10.1210/en.139.12.5034	27	108	114	1	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JAN	2001	15	1					215	220		10.1096/fj.00-0020com	http://dx.doi.org/10.1096/fj.00-0020com			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	390TH	11149909				2022-12-25	WOS:000166312400030
J	Kitamura, E; Su, GF; Sossey-Alaoui, K; Malaj, E; Lewis, J; Pan, HQ; Hawthorn, L; Roe, B; Cowell, JK				Kitamura, E; Su, GF; Sossey-Alaoui, K; Malaj, E; Lewis, J; Pan, HQ; Hawthorn, L; Roe, B; Cowell, JK			A transcription map of the minimally deleted region from 13q14 in B-cell chronic lymphocytic leukemia as defined by large scale sequencing of the 650 kb critical region	ONCOGENE			English	Article						B-CLL; genomic sequence; transcript map; 13q14; gene annotation	CHROMOSOME-ABNORMALITIES; D13S25 LOCUS; L1 ELEMENT; GENE; INSERTION; TRANSLOCATION; BREAKPOINT; PROTEINS; CLONING; CONTIG	Extensive analysis of tumors has demonstrated homozygous and heterozygous deletions in chromosome region 13q14.3 in B-cell chronic lymphocytic leukemia (B-CLL), suggesting the site of a tumor suppressor gene. Since previous searches for this gene have not yielded any viable candidates, we now present the sequence of the BACs which span the minimally deleted approximately 650 kb region between markers D13S319 and D13S25, This sequence has allowed us to create the definitive transcription map for the region which reveals 93 ESTs and 12 Unigene clusters in this region. Using gene prediction programs, a further 19 potential genes are also identified. The genes show an asymmetrical distribution throughout the region with most of them clustering at the extreme ends. This sequencing effort provides for the definitive structure of the B-CLL deletion region and the identification of the vast majority of the potential candidate genes. Of all the genes identified, only three have homologies to known genes: two LL repeat genes and rabbit epididymal protein 52, This 13q14.3 sequence provides the final substrate from which to characterize the B-CLL tumor suppressor gene.	Cleveland Clin Fdn, Ctr Mol Genet, Lerner Res Inst, Cleveland, OH 44195 USA; Univ Oklahoma, Dept Chem, Norman, OK 73019 USA	Cleveland Clinic Foundation; University of Oklahoma System; University of Oklahoma - Norman	Cowell, JK (corresponding author), Roswell Pk Canc Inst, Dept Canc Genet, Elm & Carlton St, Buffalo, NY 14263 USA.			Pan, Huaqin/0000-0002-7166-108X; Cowell, John/0000-0002-2079-5950; Hawthorn, Lesleyann/0000-0001-8179-0937; Koculi, Eda/0000-0001-9477-555X	NATIONAL CANCER INSTITUTE [R01CA074190] Funding Source: NIH RePORTER; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R01HG001604, R01HG000313] Funding Source: NIH RePORTER; NCI NIH HHS [CA74190] Funding Source: Medline; NHGRI NIH HHS [HG00313, HG01604] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Bezieau S, 1998, GENOMICS, V52, P369, DOI 10.1006/geno.1998.5464; BIENZ N, 1993, BRIT J HAEMATOL, V85, P819, DOI 10.1111/j.1365-2141.1993.tb03233.x; Bodenteich A, 1993, AUTOMATED DNA SEQUEN, P42; BouygeMoreau I, 1997, GENOMICS, V46, P183, DOI 10.1006/geno.1997.5008; Brandon CI, 1999, THERIOGENOLOGY, V52, P863, DOI 10.1016/S0093-691X(99)00178-8; BROWN AG, 1993, NAT GENET, V3, P67, DOI 10.1038/ng0193-67; Bullrich F, 1996, BLOOD, V88, P3109, DOI 10.1182/blood.V88.8.3109.bloodjournal8883109; Burge C, 1997, J MOL BIOL, V268, P78, DOI 10.1006/jmbi.1997.0951; CHAPMAN RM, 1994, ONCOGENE, V9, P1289; CHISSOE SL, 1995, GENOMICS, V27, P67, DOI 10.1006/geno.1995.1008; ESCUDIER SM, 1993, BLOOD, V81, P2702; Ewing B, 1998, GENOME RES, V8, P186, DOI 10.1101/gr.8.3.186; Ewing B, 1998, GENOME RES, V8, P175, DOI 10.1101/gr.8.3.175; FITCHETT M, 1987, CANCER GENET CYTOGEN, V24, P143, DOI 10.1016/0165-4608(87)90091-4; Gordon D, 1998, GENOME RES, V8, P195, DOI 10.1101/gr.8.3.195; Hawthorn L, 1995, GENOMICS, V30, P425, DOI 10.1006/geno.1995.1260; HAWTHORN LA, 1993, ONCOGENE, V8, P1415; Hawthorn LA, 1998, ANN HUM GENET, V62, P401, DOI 10.1046/j.1469-1809.1998.6250401.x; HENIKOFF S, 1994, GENOMICS, V19, P97, DOI 10.1006/geno.1994.1018; HOLMES SE, 1994, NAT GENET, V7, P143, DOI 10.1038/ng0694-143; IULIUSSON G, 1988, CANCER, V62, P500; Kalachikov S, 1997, GENOMICS, V42, P369, DOI 10.1006/geno.1997.4747; KAZAZIAN HH, 1988, NATURE, V332, P164, DOI 10.1038/332164a0; KILLIAN GJ, 1993, BIOL REPROD, V49, P1202, DOI 10.1095/biolreprod49.6.1202; Kooy R F, 1994, Eur J Hum Genet, V2, P228; MIKI Y, 1992, CANCER RES, V52, P643; MORSE B, 1988, NATURE, V333, P87, DOI 10.1038/333087a0; NARITA N, 1993, J CLIN INVEST, V91, P1862, DOI 10.1172/JCI116402; PAN HQ, 1994, GENET ANAL-BIOMOL E, V11, P181; PETERSON LC, 1992, GENE CHROMOSOME CANC, V4, P273, DOI 10.1002/gcc.2870040402; PITTMAN S, 1983, CANCER GENET CYTOGEN, V9, P355, DOI 10.1016/0165-4608(83)90084-5; Roberts T, 1998, HUM MOL GENET, V7, P1169, DOI 10.1093/hmg/7.7.1169; ROE BA, 1996, DNA ISOLATION SEQUEN; Sassaman DM, 1997, NAT GENET, V16, P37, DOI 10.1038/ng0597-37; Schuler GD, 1996, SCIENCE, V274, P540, DOI 10.1126/science.274.5287.540; WORLEY KC, 1995, GENOME RES, V5, P173, DOI 10.1101/gr.5.2.173; XU Y, 1994, 2 INT C INT SYST MOL	38	13	13	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 23	2000	19	50					5772	5780		10.1038/sj.onc.1203978	http://dx.doi.org/10.1038/sj.onc.1203978			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	376VP	11126364				2022-12-25	WOS:000165477700009
J	Dalgleish, G; Veyrune, JL; Blanchard, JM; Hesketh, J				Dalgleish, G; Veyrune, JL; Blanchard, JM; Hesketh, J			mRNA localization by a 145-nucleotide region of the c-fos 3 '-untranslated region - Links to translation but not stability	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOSKELETAL-BOUND POLYSOMES; MESSENGER-RNA DEGRADATION; 3' UNTRANSLATED REGION; INTRACELLULAR-LOCALIZATION; SEQUENCES; GENE; MYC; EXPRESSION; PROTEIN; CELLS	The presence of a localization signal in the 3'-untranslated region of c-fos mRNA was investigated by in situ hybridization and cell fractionation techniques. Cells were transfected with chimeric gene constructs in which the beta -globin coding region was used as a reporter and linked to either its own 3'-untranslated region, the c-fos 3'-untranslated region, or the c-fos 3'-untranslated region containing different deletions. Replacement of the endogenous beta -globin 3'-untranslated region by that from c-fos caused a redistribution of the transcripts so that they were recovered in cytoskeletal-bound polysomes and seen localized in the perinuclear cytoplasm, Deletion of the AU-rich instability region did not affect transcript localization, but removal of a distinct 145-nucleotide region of the 3'-untranslated region abolished it. The prevention of transcript translation by desferrioxamine led to a marked loss of transcript localization, independent of mRNA instability. The data show that the 3'-untranslated region of c-fos mRNA, as c-myc, contains a localization signal, which targets the mRNA to the perinuclear cytoskeleton. We propose that this is important to ensure efficient nuclear import of these key regulatory proteins. mRNA localization by the fos 3'-untranslated region is independent of mRNA instability, and the two are determined by different regulatory elements.	Rowett Res Inst, Aberdeen AB21 9SB, Scotland; Inst Genet Mol, CNRS, UMR 5535, F-34293 Montpellier 5, France; Univ Newcastle Upon Tyne, Dept Biol & Nutr Sci, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England	University of Aberdeen; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Montpellier; Newcastle University - UK	Hesketh, J (corresponding author), Rowett Res Inst, Aberdeen AB21 9SB, Scotland.							Bassell G, 1997, CURR OPIN CELL BIOL, V9, P109, DOI 10.1016/S0955-0674(97)80159-7; BIRD RC, 1986, BIOCHIM BIOPHYS ACTA, V868, P215, DOI 10.1016/0167-4781(86)90057-6; BONNIEU A, 1989, ONCOGENE, V4, P881; CAPUT D, 1986, P NATL ACAD SCI USA, V83, P1670, DOI 10.1073/pnas.83.6.1670; CARILLO S, 1994, ONCOGENE, V9, P1679; CHEN CYA, 1994, MOL CELL BIOL, V14, P8471, DOI 10.1128/MCB.14.12.8471; CHEN CYA, 1992, MOL CELL BIOL, V12, P5748, DOI 10.1128/MCB.12.12.5748; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CURRAN T, 1982, J VIROL, V44, P674, DOI 10.1128/JVI.44.2.674-682.1982; ERICKSON JM, 1981, GENE, V16, P1, DOI 10.1016/0378-1119(81)90055-X; FORT P, 1987, NUCLEIC ACIDS RES, V15, P5657, DOI 10.1093/nar/15.14.5657; Gavis ER, 1997, TRENDS CELL BIOL, V7, P485, DOI 10.1016/S0962-8924(97)01162-8; HESKETH J, 1994, BIOCHEM J, V298, P143, DOI 10.1042/bj2980143; Hesketh JE, 1996, EXP CELL RES, V225, P219, DOI 10.1006/excr.1996.0172; HESKETH JE, 1991, BIOCHEM J, V274, P607, DOI 10.1042/bj2740607; HOVLAND R, 1995, BIOCHEM J, V310, P193, DOI 10.1042/bj3100193; KISLAUSKIS EH, 1994, J CELL BIOL, V127, P441, DOI 10.1083/jcb.127.2.441; KRUIJER W, 1984, NATURE, V312, P711, DOI 10.1038/312711a0; LATHAM VM, 1994, J CELL BIOL, V126, P1211, DOI 10.1083/jcb.126.5.1211; Levadoux M, 1999, J BIOL CHEM, V274, P34961, DOI 10.1074/jbc.274.49.34961; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P1068, DOI 10.1093/nar/18.4.1068; MULLER R, 1984, NATURE, V312, P716, DOI 10.1038/312716a0; Sambrook J., 2002, MOL CLONING LAB MANU; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SHYU AB, 1989, GENE DEV, V3, P60, DOI 10.1101/gad.3.1.60; STJOHNSTON D, 1995, CELL, V81, P161, DOI 10.1016/0092-8674(95)90324-0; TREISMAN R, 1985, CELL, V42, P889, DOI 10.1016/0092-8674(85)90285-5; VEDELER A, 1991, MOL CELL BIOCHEM, V100, P183; Veyrune JL, 1996, J CELL SCI, V109, P1185; VEYRUNE JL, 1995, ONCOGENE, V11, P2127; WILSON IA, 1995, BIOCHEM J, V308, P599, DOI 10.1042/bj3080599; WILSON T, 1988, NATURE, V336, P396, DOI 10.1038/336396a0; WINSTALL E, 1995, MOL CELL BIOL, V15, P3796; ZAMBETTI G, 1990, EXP CELL RES, V191, P246, DOI 10.1016/0014-4827(90)90011-X	34	28	28	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 27	2001	276	17					13593	13599		10.1074/jbc.M001141200	http://dx.doi.org/10.1074/jbc.M001141200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	426PB	11139568	hybrid, Green Published			2022-12-25	WOS:000168356600014
J	Becamel, C; Figge, A; Poliak, S; Dumuis, A; Peles, E; Bockaert, J; Lubbert, H; Ullmer, C				Becamel, C; Figge, A; Poliak, S; Dumuis, A; Peles, E; Bockaert, J; Lubbert, H; Ullmer, C			Interaction of serotonin 5-hydroxytryptamine type 2C receptors with PDZ10 of the multi-PDZ domain protein MUPP1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXCHANGER REGULATORY FACTOR; CHOROID-PLEXUS; BETA(2)-ADRENERGIC RECEPTOR; 5-HT2C RECEPTORS; IMMUNOHISTOCHEMICAL LOCALIZATION; MOLECULAR CHARACTERIZATION; SYNAPTIC PROTEINS; MESSENGER-RNAS; FAMILY; RAT	By using the yeast two-hybrid system, we previously isolated a cDNA clone encoding a novel member of the multivalent PDZ protein family called MUPP1 containing 13 PDZ domains. Here we report that the C terminus of the Fi-hydroxytryptamine type 2C (5-HT2C) receptor selectively interacts with the 10th PDZ domain of MUPP1. Mutations in the extreme C terminal SSV sequence of the 5-HT2C receptor confirmed that the SXV motif is critical for the interaction, Co-immunoprecipitations of MUPP1 and 5-HT2C receptors from transfected COS-7 cells and from rat choroid plexus verified this interaction in vivo. Immunocytochemistry revealed an SXV motif-dependent co-clustering of both proteins in transfected COS-7 cells as well as a colocalization in rat choroid plexus. A 5-HT2C receptor-dependent unmasking of a C-terminal vesicular stomatitis virus epitope of MUPP1 suggests that the interaction triggers a conformational change within the MUPP1 protein. Moreover, 5-HT2A and 5-HT2B, sharing the C-terminal EX(V/I)SXV sequence with 5-HT2C receptors, also bind MUPP1 PDZ domains in vitro. The highest MUPP1 mRNA levels were found in all cerebral cortical layers, the hippocampus, the granular layer of the dentate gyrus, as well as the choroid plexus, where 5-HT2C receptors are highly enriched. We propose that MUPP1 may serve as a multivalent scaffold protein that selectively assembles and targets signaling complexes.	Biofrontera Pharmaceut AG, D-51377 Leverkusen, Germany; Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel; CNRS UPR 9023, INSERM, F-34094 Montpellier 05, France; Ruhr Univ Bochum, Dept Anim Physiol, D-44780 Bochum, Germany	Weizmann Institute of Science; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); Ruhr University Bochum	Ullmer, C (corresponding author), Biofrontera Pharmaceut AG, Hemmelratherweg 201, D-51377 Leverkusen, Germany.	ullmer@biofrontera.de		Peles, Elior/0000-0002-3325-0597; Luebbert, Herrmann/0000-0003-3429-5233				Abramowski D, 1995, NEUROPHARMACOLOGY, V34, P1635, DOI 10.1016/0028-3908(95)00138-7; ABRAMOWSKI D, 1995, J NEUROCHEM, V65, P782; ANNWEILER A, 1991, NUCLEIC ACIDS RES, V19, P3750, DOI 10.1093/nar/19.13.3750; Backstrom JR, 2000, J BIOL CHEM, V275, P23620, DOI 10.1074/jbc.M000922200; BARTSCH S, 1992, J NEUROSCI, V12, P736; Berg KA, 1996, MOL PHARMACOL, V50, P1017; BERRIDGE MJ, 1983, BIOCHEM J, V212, P473, DOI 10.1042/bj2120473; Boeckers TM, 1999, BIOCHEM BIOPH RES CO, V264, P247, DOI 10.1006/bbrc.1999.1489; BONHAUS DW, 1995, BRIT J PHARMACOL, V115, P622, DOI 10.1111/j.1476-5381.1995.tb14977.x; Cao TT, 1999, NATURE, V401, P286, DOI 10.1038/45816; Choi DS, 1996, FEBS LETT, V391, P45, DOI 10.1016/0014-5793(96)00695-3; Claeysen S, 1996, FEBS LETT, V398, P19, DOI 10.1016/S0014-5793(96)01132-5; Clemett DA, 2000, NEUROPHARMACOLOGY, V39, P123, DOI 10.1016/S0028-3908(99)00086-6; Doyle DA, 1996, CELL, V85, P1067, DOI 10.1016/S0092-8674(00)81307-0; Du YR, 1998, MOL CELL BIOL, V18, P5838, DOI 10.1128/MCB.18.10.5838; Duxon MS, 1997, NEUROSCIENCE, V76, P323, DOI 10.1016/S0306-4522(96)00480-0; FEILOTTER HE, 1994, NUCLEIC ACIDS RES, V22, P1502, DOI 10.1093/nar/22.8.1502; Fone KCF, 1998, BRIT J PHARMACOL, V123, P1707, DOI 10.1038/sj.bjp.0701798; Fredericks ZL, 1996, J BIOL CHEM, V271, P13796, DOI 10.1074/jbc.271.23.13796; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; Hall RA, 1998, NATURE, V392, P626, DOI 10.1038/33458; Hall RA, 1998, P NATL ACAD SCI USA, V95, P8496, DOI 10.1073/pnas.95.15.8496; HARTIG PR, 1989, SEROTONIN ACTIONS RE, P180; JULIUS D, 1988, SCIENCE, V241, P558, DOI 10.1126/science.3399891; Kaufman MJ, 1996, NEUROSCI LETT, V206, P153, DOI 10.1016/S0304-3940(96)12461-7; KAUFMAN MJ, 1995, J NEUROCHEM, V64, P199; KIM E, 1995, NATURE, V378, P85, DOI 10.1038/378085a0; KLUXEN FW, 1992, P NATL ACAD SCI USA, V89, P4618, DOI 10.1073/pnas.89.10.4618; KORNAU HC, 1995, SCIENCE, V269, P1737, DOI 10.1126/science.7569905; Kurschner C, 1998, MOL CELL NEUROSCI, V11, P161, DOI 10.1006/mcne.1998.0679; Lim S, 1999, J BIOL CHEM, V274, P29510, DOI 10.1074/jbc.274.41.29510; LUCKI I, 1989, J PHARMACOL EXP THER, V249, P155; Manivet P, 2000, J BIOL CHEM, V275, P9324, DOI 10.1074/jbc.275.13.9324; Marcoli M, 1998, J PHARMACOL EXP THER, V285, P983; Millan MJ, 1997, NEUROPHARMACOLOGY, V36, P743, DOI 10.1016/S0028-3908(97)00071-3; MURPHY DL, 1991, PHARMACOL REV, V43, P527; Naisbitt S, 1999, NEURON, V23, P569, DOI 10.1016/S0896-6273(00)80809-0; PAZOS A, 1984, EUR J PHARMACOL, V106, P539, DOI 10.1016/0014-2999(84)90057-8; Philipp S, 1997, FEBS LETT, V413, P243, DOI 10.1016/S0014-5793(97)00877-6; POMPEIANO M, 1994, MOL BRAIN RES, V23, P163, DOI 10.1016/0169-328X(94)90223-2; RAMSAY G, 1984, P NATL ACAD SCI-BIOL, V81, P7742, DOI 10.1073/pnas.81.24.7742; Reczek D, 1997, J CELL BIOL, V139, P169, DOI 10.1083/jcb.139.1.169; SCHMUCK K, 1994, FEBS LETT, V342, P85, DOI 10.1016/0014-5793(94)80590-3; Schmuck K, 1996, EUR J NEUROSCI, V8, P959, DOI 10.1111/j.1460-9568.1996.tb01583.x; Schultz J, 1998, NAT STRUCT BIOL, V5, P19, DOI 10.1038/nsb0198-19; Simpson EH, 1999, GENOMICS, V59, P102, DOI 10.1006/geno.1999.5853; Songyang Z, 1997, SCIENCE, V275, P73, DOI 10.1126/science.275.5296.73; SWANSON LW, 1980, NEUROENDOCRINOLOGY, V31, P410, DOI 10.1159/000123111; TECOTT LH, 1995, NATURE, V374, P542, DOI 10.1038/374542a0; Ullmer C, 1998, FEBS LETT, V424, P63, DOI 10.1016/S0014-5793(98)00141-0; ULLMER C, 1995, FEBS LETT, V370, P215, DOI 10.1016/0014-5793(95)00828-W; YAGALOFF KA, 1985, J NEUROSCI, V5, P3178; Zitzer H, 1999, J BIOL CHEM, V274, P18153, DOI 10.1074/jbc.274.26.18153; Zitzer H, 1999, J BIOL CHEM, V274, P32997, DOI 10.1074/jbc.274.46.32997	54	121	129	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 20	2001	276	16					12974	12982		10.1074/jbc.M008089200	http://dx.doi.org/10.1074/jbc.M008089200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	423VN	11150294	hybrid			2022-12-25	WOS:000168198600074
J	Daoud, R; Julien, M; Gros, P; Georges, E				Daoud, R; Julien, M; Gros, P; Georges, E			Major photoaffinity drug binding sites in multidrug resistance protein 1 (MRP1) are within transmembrane domains 10-11 and 16-17	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN P-GLYCOPROTEIN; CONJUGATE EXPORT PUMP; QUINOLINE-BASED DRUG; LEUKOTRIENE C-4; VINCRISTINE TRANSPORT; INCREASED SENSITIVITY; DEPENDENT TRANSPORT; EPITOPE INSERTION; TUMOR-CELLS; GLUTATHIONE	MRP1 is an ABC (or ATP binding cassette) membrane transport protein shown to confer resistance to structurally dissimilar drugs, Studies of MRP1 topology suggested the presence of a hydrophobic N-domain with five potential membrane-spanning domains linked to an MDR1-like core (MSD1-NBD1-L1-MSD2-NBD2) by an intracellular linker domain (LO). MRP1-mediated multidrug resistance is thought to be due to enhanced drug efflux. However, little is known about MRP1-drug interaction and its drug binding site(s). We previously developed several photoreactive probes to study MRP1-drug interactions. In this report, we have used eight MRP1-HA variants that were modified to have hemagglutinin A (HA) epitopes inserted at different sites in MRP1 sequence. Exhaustive in-gel digestion of all IAARh123 photoaffinity-labeled MRP1-HA variants revealed the same profile of photolabeled peptides as seen for wild type MRP1. Photolabeling of the different MRP1-HA variants followed by digestion with increasing concentrations of trypsin or Staphylococcus aureus V8 protease (1:800 to 1:5 w/w) and immunoprecipitation with anti-HA mAb identified two small photolabeled peptides (similar to6-7 kDa) from MRP1-HA(574) and MRP1-HA(1222). Based on the location of the HA epitopes in the latter variants together with molecular masses of the two peptides, the photolabeled amino acid residues were localized to MRP1 sequences encoding transmembranes 10 and 11 of MSD1 (Ser(542)-Arg(593)) and transmembranes 16 and 17 of MSD2 (Cys(1205)-Glu(1253)). Interestingly, the same sequences in MRP1 were also photolabeled with a structurally different photoreactive drug, IACI, confirming the significance of transmembranes 10, 11, 16 and 17 in MRP1 drug binding. Taken together, the results in this study provide the first delineation of the drug binding site(s) of MRP1. Furthermore, our findings suggest the presence of common drug binding site(s) for structurally dissimilar drugs.	McGill Univ, Inst Parasitol, Ste Anne De Bellevue, PQ H9X 3V9, Canada; McGill Univ, Dept Biochem, Ste Anne De Bellevue, PQ H9X 3V9, Canada	McGill University; McGill University	Georges, E (corresponding author), McGill Univ, Inst Parasitol, 21111 Lakeshore Rd, Ste Anne De Bellevue, PQ H9X 3V9, Canada.	Elias.Georges@McGill.CA						Bakos E, 1996, J BIOL CHEM, V271, P12322, DOI 10.1074/jbc.271.21.12322; Bakos E, 1998, J BIOL CHEM, V273, P32167, DOI 10.1074/jbc.273.48.32167; BRADLEY G, 1994, CANCER METAST REV, V13, P223, DOI 10.1007/BF00689638; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; Cole SPC, 1998, BIOESSAYS, V20, P931, DOI 10.1002/(SICI)1521-1878(199811)20:11<931::AID-BIES8>3.0.CO;2-J; COLE SPC, 1992, SCIENCE, V258, P1650, DOI 10.1126/science.1360704; Daoud R, 2000, BIOCHEMISTRY-US, V39, P15344, DOI 10.1021/bi0020574; Daoud R, 2000, BIOCHEMISTRY-US, V39, P6094, DOI 10.1021/bi9922188; Dey S, 1997, P NATL ACAD SCI USA, V94, P10594, DOI 10.1073/pnas.94.20.10594; Draper MP, 1997, EUR J BIOCHEM, V243, P219, DOI 10.1111/j.1432-1033.1997.0219a.x; Evers R, 1997, FEBS LETT, V419, P112, DOI 10.1016/S0014-5793(97)01442-7; FAIRBANKS G, 1971, BIOCHEMISTRY-US, V10, P2606, DOI 10.1021/bi00789a030; FELLER N, 1995, BRIT J CANCER, V72, P543, DOI 10.1038/bjc.1995.371; Gao M, 1998, J BIOL CHEM, V273, P10733, DOI 10.1074/jbc.273.17.10733; GEORGES E, 1991, J CELL PHYSIOL, V148, P479, DOI 10.1002/jcp.1041480321; GREENBERGER LM, 1993, J BIOL CHEM, V268, P11417; Hipfner DR, 1997, J BIOL CHEM, V272, P23623, DOI 10.1074/jbc.272.38.23623; Hipfner DR, 1996, CANCER RES, V56, P3307; Hipfner DR, 1999, BBA-BIOMEMBRANES, V1461, P359, DOI 10.1016/S0005-2736(99)00168-6; ISHIKAWA T, 1992, TRENDS BIOCHEM SCI, V17, P463, DOI 10.1016/0968-0004(92)90489-V; Jedlitschky G, 1996, CANCER RES, V56, P988; KAJIJI S, 1993, BIOCHEMISTRY-US, V32, P4185, DOI 10.1021/bi00067a005; Kast C, 1997, J BIOL CHEM, V272, P26479, DOI 10.1074/jbc.272.42.26479; Kast C, 1998, BIOCHEMISTRY-US, V37, P2305, DOI 10.1021/bi972332v; Klein I, 1999, BBA-BIOMEMBRANES, V1461, P237, DOI 10.1016/S0005-2736(99)00161-3; Leier I, 1996, BIOCHEM J, V314, P433, DOI 10.1042/bj3140433; LEIER I, 1994, J BIOL CHEM, V269, P27807; Loe DW, 1997, MOL PHARMACOL, V51, P1034, DOI 10.1124/mol.51.6.1034; Loe DW, 1998, CANCER RES, V58, P5130; Loe DW, 1996, J BIOL CHEM, V271, P9675, DOI 10.1074/jbc.271.16.9675; Loo TW, 1997, J BIOL CHEM, V272, P31945, DOI 10.1074/jbc.272.51.31945; Loo TW, 1999, BIOCHEMISTRY-US, V38, P5124, DOI 10.1021/bi982525y; LOWRY OH, 1951, J BIOL CHEM, V193, P265; RAO US, 1994, MOL PHARMACOL, V45, P773; Rappa G, 1997, CANCER RES, V57, P5232; Renes J, 1999, BRIT J PHARMACOL, V126, P681, DOI 10.1038/sj.bjp.0702360; SCHINKEL AH, 1994, CELL, V77, P491, DOI 10.1016/0092-8674(94)90212-7; Shapiro AB, 1999, EUR J BIOCHEM, V259, P841, DOI 10.1046/j.1432-1327.1999.00098.x; Shapiro AB, 1998, ACTA PHYSIOL SCAND, V163, P227; Shen HX, 1996, BIOCHEMISTRY-US, V35, P5719, DOI 10.1021/bi960098n; Stride BD, 1999, J BIOL CHEM, V274, P22877, DOI 10.1074/jbc.274.32.22877; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VERSANTVOORT CHM, 1995, BRIT J CANCER, V72, P82, DOI 10.1038/bjc.1995.281; Vezmar M, 1998, BIOCHEM PHARMACOL, V56, P733, DOI 10.1016/S0006-2952(98)00217-2; Vezmar M, 2000, BIOCHEM PHARMACOL, V59, P1245, DOI 10.1016/S0006-2952(00)00270-7; Vezmar M, 1997, BIOCHEM BIOPH RES CO, V241, P104, DOI 10.1006/bbrc.1997.7634; Wijnholds J, 1997, NAT MED, V3, P1275, DOI 10.1038/nm1197-1275; ZAMAN GJR, 1996, MULTIDRUG RESISTANCE, P95	48	60	62	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 13	2001	276	15					12324	12330		10.1074/jbc.M009782200	http://dx.doi.org/10.1074/jbc.M009782200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	421UK	11152467	hybrid			2022-12-25	WOS:000168081800118
J	An, J; Li, YZ; van de Werve, G; Newgard, CB				An, J; Li, YZ; van de Werve, G; Newgard, CB			Overexpression of the P46 (T1) translocase component of the glucose-6-phosphatase complex in hepatocytes impairs glycogen accumulation via hydrolysis of glucose 1-phosphate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENOVIRUS-MEDIATED TRANSFER; STORAGE-DISEASE; CATALYTIC SUBUNIT; GENE-EXPRESSION; MICROSOMAL GLUCOSE-6-PHOSPHATASE; LIVER GLUCOSE-6-PHOSPHATASE; INSULIN; GLUCOKINASE; TRANSPORT; PROTEIN	The final step of gluconeogenesis and glycogenolysis is catalyzed by the glucose-6-phosphatase (Glc-6-Pase) enzyme complex, located in the endoplasmic reticulum, The complex consists of a 36-kDa catalytic subunit (P36), a 46-kDa glucose 6-phosphate translocase (P46), and putative glucose and inorganic phosphate transporters. Mutations in the genes encoding P36 or P46 have been linked:to glycogen storage diseases type Ia and type Tb, respectively. However, the relative roles of these two proteins in control of the rate of glucose 6-phosphate hydrolysis have not been defined. To gain insight into this area, we have constructed a recombinant adenovirus containing the cDNA encoding human P46 (AdCMV-P46) and treated rat hepatocytes with this virus, or a virus encoding P36 (AdCMV-P36), or the combination of both viruses, resulting in large and equivalent increases in expression of the transgenes within 8-24 h of viral treatment. The overexpressed P46 protein was appropriately targeted to hepatocyte microsomes and caused a 58% increase in glucose 6-phosphate hydrolysis in nondetergent-treated (intact) microsomal preparations relative to controls, whereas overexpression of P36 caused a 3.6-fold increase. Overexpression of P46 caused a 50% inhibition of glycogen accumulation in hepatocytes from fasted rats incubated at 25 mM glucose relative to cells treated with a control virus (AdCMV-beta GAL), Furthermore, in hepatocytes from fed rats cultured at 25 mM glucose and then exposed to 15 nM glucose, AdCMV-P46 treatment activated glycogenolysis, as indicated by a 50% reduction in glycogen content relative to AdCMV-beta GAL-treated controls. In contrast, overexpression of P46 had only small effects on glycolysis, whereas overexpression of P36 had large effects on both glycogen metabolism and glycolysis, even in the presence of co-overexpressed glucokinase, Finally, P46 overexpression enhanced glucose 1-phosphate but not fructose 6-phosphhate hydrolysis in intact microsomes, providing a mechanism by which P46 overexpression may exert its preferential effects on glycogen metabolism.	Univ Texas, SW Med Ctr, Touchstone Ctr Diabet Res, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Biochem, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Internal Med, Dallas, TX 75390 USA; Univ Montreal, Dept Nutr, Montreal, PQ H2L 4M1, Canada; Univ Montreal, Dept Biochem, Montreal, PQ H2L 4M1, Canada; CHUM, Ctr Rech, Lab Endocrinol Metab, Montreal, PQ H2L 4M1, Canada	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Universite de Montreal; Universite de Montreal; Universite de Montreal	Newgard, CB (corresponding author), Univ Texas, SW Med Ctr, Touchstone Ctr Diabet Res, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	newgard@utsw.swmed.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK058398] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 58398] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AGIUS L, 1993, BIOCHEM J, V296, P785, DOI 10.1042/bj2960785; Argaud D, 1997, J BIOL CHEM, V272, P12854, DOI 10.1074/jbc.272.19.12854; ARION WJ, 1980, J BIOL CHEM, V255, P396; BECKER TC, 1994, METHOD CELL BIOL, V43, P161; Becker TC, 1996, J BIOL CHEM, V271, P390, DOI 10.1074/jbc.271.1.390; BERTELOOT A, 1991, J BIOL CHEM, V266, P5497; Brown KS, 1997, DIABETES, V46, P179, DOI 10.2337/diabetes.46.2.179; Burchell A, 1998, BIOCHEM J, V331, P973, DOI 10.1042/bj3310973; CLINE GW, 1994, J CLIN INVEST, V94, P2369, DOI 10.1172/JCI117602; FernandezNovell JM, 1997, BIOCHEM J, V321, P227, DOI 10.1042/bj3210227; FernandezNovell JM, 1996, EUR J BIOCHEM, V238, P570, DOI 10.1111/j.1432-1033.1996.0570z.x; Gerin I, 1997, FEBS LETT, V419, P235, DOI 10.1016/S0014-5793(97)01463-4; GOMEZFOIX AM, 1992, J BIOL CHEM, V267, P25129; HABER BA, 1995, J CLIN INVEST, V95, P832, DOI 10.1172/JCI117733; HERZ J, 1993, P NATL ACAD SCI USA, V90, P2812, DOI 10.1073/pnas.90.7.2812; HUGHES SD, 1993, J BIOL CHEM, V268, P15205; LANGE AJ, 1994, BIOCHEM BIOPH RES CO, V201, P302, DOI 10.1006/bbrc.1994.1702; LANGE AJ, 1980, J BIOL CHEM, V255, P8381; LEI KJ, 1993, SCIENCE, V262, P580, DOI 10.1126/science.8211187; Lei KJ, 1996, NAT GENET, V13, P203, DOI 10.1038/ng0696-203; Li YZ, 1999, J BIOL CHEM, V274, P33866, DOI 10.1074/jbc.274.48.33866; Li YZ, 2000, BIOCHEM BIOPH RES CO, V272, P41, DOI 10.1006/bbrc.2000.2734; MAGNUSSON I, 1992, J CLIN INVEST, V90, P1323, DOI 10.1172/JCI115997; MASSAGUE J, 1978, BIOCHIM BIOPHYS ACTA, V543, P269, DOI 10.1016/0304-4165(78)90073-9; Massillon D, 1997, DIABETES, V46, P153, DOI 10.2337/diabetes.46.1.153; Massillon D, 1996, J BIOL CHEM, V271, P9871, DOI 10.1074/jbc.271.17.9871; Mechin MC, 2000, METABOLISM, V49, P1200, DOI 10.1053/meta.2000.7714; Mevorach M, 1998, J CLIN INVEST, V102, P744, DOI 10.1172/JCI2720; NARISAWA K, 1987, ENZYME, V38, P177, DOI 10.1159/000469203; NEWGARD CB, 1983, J BIOL CHEM, V258, P8046; Newgard CB, 2000, DIABETES, V49, P1967, DOI 10.2337/diabetes.49.12.1967; Nordlie R C, 1974, Curr Top Cell Regul, V8, P33; Scott DK, 1998, J BIOL CHEM, V273, P24145, DOI 10.1074/jbc.273.37.24145; Seoane J, 1997, J BIOL CHEM, V272, P26972, DOI 10.1074/jbc.272.43.26972; SHELLY LL, 1993, J BIOL CHEM, V268, P21482; Shi YG, 1999, J BIOL CHEM, V274, P5723, DOI 10.1074/jbc.274.9.5723; SRERE PA, 1987, ANNU REV BIOCHEM, V56, P89, DOI 10.1146/annurev.bi.56.070187.000513; Trinh K, 1997, J BIOL CHEM, V272, P24837, DOI 10.1074/jbc.272.40.24837; Trinh KY, 1998, J BIOL CHEM, V273, P31615, DOI 10.1074/jbc.273.47.31615; van de Werve G, 2000, EUR J BIOCHEM, V267, P1533, DOI 10.1046/j.1432-1327.2000.01160.x; Van Schaftingen E, 2000, FRONT DIABETES, V15, P136; VANSCHAFTINGEN E, 1994, FASEB J, V8, P414, DOI 10.1096/fasebj.8.6.8168691; Veiga-da-Cunha M, 1998, AM J HUM GENET, V63, P976, DOI 10.1086/302068; Velho G, 1996, J CLIN INVEST, V98, P1755, DOI 10.1172/JCI118974; WADDELL ID, 1992, BIOCHEM J, V286, P173, DOI 10.1042/bj2860173; WEINHOUSE S, 1976, CURR TOP CELL REGUL, V11, P1	46	20	21	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 6	2001	276	14					10722	10729		10.1074/jbc.M009525200	http://dx.doi.org/10.1074/jbc.M009525200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	420AC	11148207	hybrid			2022-12-25	WOS:000167980900023
J	Kwon, YG; Min, JK; Kim, KM; Lee, DJ; Billiar, TR; Kim, YM				Kwon, YG; Min, JK; Kim, KM; Lee, DJ; Billiar, TR; Kim, YM			Sphingosine 1-phosphate protects human umbilical vein endothelial cells from serum-deprived apoptosis by nitric oxide production	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; INHIBITS APOPTOSIS; CYTOCHROME-C; TYROSINE PHOSPHORYLATION; SUPPRESSES APOPTOSIS; MEDIATED APOPTOSIS; CASPASE ACTIVATION; RAT HEPATOCYTES; SYNTHASE GENE; SHEAR-STRESS	Sphingosine 1-phosphate (S1P) can prevent endothelial cell apoptosis. We investigated the molecular mechanisms and signaling pathways by which S1P protects endothelial cells from serum deprivation-induced apoptosis. We show here that human umbilical vein endothelial cells (HUVECs) undergo apoptosis associated with increased DEVDase activity, caspase-3 activation, cytochrome c release, and DNA fragmentation after 24 h of serum deprivation. These apoptotic markers were suppressed by the addition of S1P, the NO donor S-nitroso-N-acetylpenicillamine (100 muM), or caspase-3 inhibitor z-VAD-fmk. The protective effects of S1P were reversed by the nitric-oxide synthase (NOS) inhibitor N-monomethyl-L-arginine, but not by the soluble guanylyl cyclase inhibitor 1H-(1,2,4)oxadiazolo[4,3-a]-quanoxaline-1-one, suggesting that NO, but not cGMP, is responsible for S1P protection from apoptosis. Furthermore, S1P increased NO production by enhancing Ca2+ sensitive NOS activity without changes in the eNOS protein level. S1P-mediated cell survival and NO production were suppressed significantly by pretreatment with antisense oligonucleotide of EDG-1 and partially by EDG-3 antisense. S1P-mediated NO production was suppressed by the addition of pertussis toxin, an inhibitor of G(i) proteins, the specific inhibitor of phospholipase C (PLC), U73122, and the Ca2+ chelator BAPTA-AM. These findings indicate that S1P protects HUVECs from apoptosis through the activation of eNOS activity mainly through an EDG-1 and -3/G(i)/PLC/Ca2+ signaling pathway.	Kangwon Natl Univ, Coll Nat Sci, Dept Biochem, Kangwon Do 200701, South Korea; Kangwon Natl Univ, Sch Med, Dept Mol & Cellular Biochem, Kangwon Do 200701, South Korea; Univ Pittsburgh, Sch Med, Dept Surg, Pittsburgh, PA 15213 USA	Kangwon National University; Kangwon National University; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Kwon, YG (corresponding author), Kangwon Natl Univ, Coll Nat Sci, Dept Biochem, Kangwon Do 200701, South Korea.			Min, Jeong-Ki/0000-0003-4924-8739				An SZ, 2000, J BIOL CHEM, V275, P288, DOI 10.1074/jbc.275.1.288; BUCKLEY BJ, 1995, AM J PHYSIOL-CELL PH, V269, pC757, DOI 10.1152/ajpcell.1995.269.3.C757; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; Ceneviva GD, 1998, AM J PHYSIOL-LUNG C, V275, pL717, DOI 10.1152/ajplung.1998.275.4.L717; CHUN SY, 1995, ENDOCRINOLOGY, V136, P3120, DOI 10.1210/en.136.7.3120; Clapham DE, 1997, ANNU REV PHARMACOL, V37, P167, DOI 10.1146/annurev.pharmtox.37.1.167; Cuvillier O, 1996, NATURE, V381, P800, DOI 10.1038/381800a0; Cuvillier O, 1998, J BIOL CHEM, V273, P2910, DOI 10.1074/jbc.273.5.2910; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Deora AA, 1998, J BIOL CHEM, V273, P29923, DOI 10.1074/jbc.273.45.29923; Dimmeler S, 1997, J EXP MED, V185, P601, DOI 10.1084/jem.185.4.601; Estevez AG, 1998, J NEUROSCI, V18, P3708; Feron O, 1996, J BIOL CHEM, V271, P22810, DOI 10.1074/jbc.271.37.22810; Fisslthaler B, 2000, ACTA PHYSIOL SCAND, V168, P81; Fulton D, 1999, NATURE, V399, P597, DOI 10.1038/21218; Garcia-Cardena G, 1998, NATURE, V392, P821, DOI 10.1038/33934; GarciaCardena G, 1996, J BIOL CHEM, V271, P27237, DOI 10.1074/jbc.271.44.27237; GarciaCardena G, 1996, P NATL ACAD SCI USA, V93, P6448, DOI 10.1073/pnas.93.13.6448; GENARO AM, 1995, J CLIN INVEST, V95, P1884, DOI 10.1172/JCI117869; Goetzl EJ, 1999, J IMMUNOL, V162, P2049; GRANGER DL, 1980, J CLIN INVEST, V65, P357, DOI 10.1172/JCI109679; Gupta K, 1999, EXP CELL RES, V247, P495, DOI 10.1006/excr.1998.4359; Hebestreit H, 1998, J EXP MED, V187, P415, DOI 10.1084/jem.187.3.415; Heneka MT, 1998, J NEUROCHEM, V71, P88; Hisano N, 1999, BLOOD, V93, P4293, DOI 10.1182/blood.V93.12.4293.412k26_4293_4299; HUANG PL, 1995, NATURE, V377, P239, DOI 10.1038/377239a0; Igarashi J, 2000, J BIOL CHEM, V275, P32363, DOI 10.1074/jbc.M003075200; JAMES NL, 1995, FASEB J, V9, P968, DOI 10.1096/fasebj.9.10.7615166; Kawahara A, 1998, J CELL BIOL, V143, P1353, DOI 10.1083/jcb.143.5.1353; Kim YM, 1998, J BIOL CHEM, V273, P31437, DOI 10.1074/jbc.273.47.31437; Kim YM, 1997, J BIOL CHEM, V272, P1402, DOI 10.1074/jbc.272.2.1402; Kim YM, 1997, J BIOL CHEM, V272, P31138, DOI 10.1074/jbc.272.49.31138; Kim YM, 1998, MOL MED, V4, P179, DOI 10.1007/BF03401915; KIM YM, 1995, FEBS LETT, V374, P228, DOI 10.1016/0014-5793(95)01115-U; Kim YM, 1999, J NEUROSCI, V19, P6740, DOI 10.1523/JNEUROSCI.19-16-06740.1999; Kuida K, 1998, CELL, V94, P325, DOI 10.1016/S0092-8674(00)81476-2; KWON NS, 1991, J EXP MED, V174, P761, DOI 10.1084/jem.174.4.761; Lee MJ, 1999, CELL, V99, P301, DOI 10.1016/S0092-8674(00)81661-X; Lee OH, 1999, BIOCHEM BIOPH RES CO, V264, P743, DOI 10.1006/bbrc.1999.1586; Lee OH, 2000, BIOCHEM BIOPH RES CO, V268, P47, DOI 10.1006/bbrc.2000.2087; Lee PC, 1999, AM J PHYSIOL-HEART C, V277, pH1600, DOI 10.1152/ajpheart.1999.277.4.H1600; Leist M, 1997, J EXP MED, V185, P1481, DOI 10.1084/jem.185.8.1481; Li JR, 1999, J BIOL CHEM, V274, P17325, DOI 10.1074/jbc.274.24.17325; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Mannick JB, 1999, SCIENCE, V284, P651, DOI 10.1126/science.284.5414.651; Mannick JB, 1997, J BIOL CHEM, V272, P24125, DOI 10.1074/jbc.272.39.24125; MANNICK JB, 1994, CELL, V79, P1137, DOI 10.1016/0092-8674(94)90005-1; Michel JB, 1997, J BIOL CHEM, V272, P25907, DOI 10.1074/jbc.272.41.25907; Michel T, 1997, J CLIN INVEST, V100, P2146, DOI 10.1172/JCI119750; Mignon A, 1999, AM J RESP CRIT CARE, V159, P1308, DOI 10.1164/ajrccm.159.4.9712012; NATHAN C, 1992, FASEB J, V6, P3051, DOI 10.1096/fasebj.6.12.1381691; Okada S, 1998, J IMMUNOL, V160, P2590; Okamoto H, 1998, J BIOL CHEM, V273, P27104, DOI 10.1074/jbc.273.42.27104; Ozes ON, 1999, NATURE, V401, P82; Papapetropoulos A, 1997, J CLIN INVEST, V100, P3131, DOI 10.1172/JCI119868; Prabhakar P, 1998, J BIOL CHEM, V273, P27383, DOI 10.1074/jbc.273.42.27383; Rodriguez I, 1996, J EXP MED, V184, P2067, DOI 10.1084/jem.184.5.2067; Rudic RD, 1998, J CLIN INVEST, V101, P731, DOI 10.1172/JCI1699; Sato K, 1998, BIOCHEM BIOPH RES CO, V253, P253, DOI 10.1006/bbrc.1998.9745; Shears LL, 1997, J CLIN INVEST, V100, P2035, DOI 10.1172/JCI119736; Tamir S, 1996, CHEM RES TOXICOL, V9, P821, DOI 10.1021/tx9600311; Teubl M, 1999, J BIOL CHEM, V274, P29529, DOI 10.1074/jbc.274.41.29529; Tzeng E, 1998, SURGERY, V124, P278, DOI 10.1067/msy.1998.90569; Wang F, 1999, J BIOL CHEM, V274, P35343, DOI 10.1074/jbc.274.50.35343; Xia P, 1999, J BIOL CHEM, V274, P34499, DOI 10.1074/jbc.274.48.34499; Xiao ZS, 1997, J CELL PHYSIOL, V171, P205, DOI 10.1002/(SICI)1097-4652(199705)171:2<205::AID-JCP11>3.3.CO;2-3	67	175	190	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 6	2001	276	14					10627	10633		10.1074/jbc.M011449200	http://dx.doi.org/10.1074/jbc.M011449200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	420AC	11134047	hybrid			2022-12-25	WOS:000167980900010
J	Pirneskoski, A; Ruddock, LW; Klappa, P; Freedman, RB; Kivirikko, KI; Koivunen, P				Pirneskoski, A; Ruddock, LW; Klappa, P; Freedman, RB; Kivirikko, KI; Koivunen, P			Domains b ' and a ' of protein disulfide isomerase fulfill the minimum requirement for function as a subunit of prolyl 4-hydroxylase - The N-terminal domains a and b enhance this function and can be substituted in part by those of ERp57	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PEPTIDE-BINDING-SITE; BETA-SUBUNIT; ALPHA-SUBUNIT; BACULOVIRUS EXPRESSION; CHAPERONE ACTIVITIES; TETRAMER; CLONING; COLLAGEN; LYSOZYME; ISOFORM	Protein disulfide isomerase (PDI) is a modular polypeptide consisting of four domains, a, b, b' and a', plus an acidic C-terminal extension, c. PDI carries out multiple functions, acting as the beta subunit in the animal prolyl 4-hydroxylases and in the microsomal triglyceride transfer protein and independently acting as a protein folding catalyst. We report here that the minimum sequence requirement for the assembly of an active prolyl 4-hydroxylase alpha (2)beta (2) tetramer in insect cell coexpression experiments is fulfilled by the PDI domain construct b'a' but that the sequential addition of the b and a domains greatly increases the level of enzyme activity obtained. In the assembly of active prolyl 4-hydroxylase tetramers, the a and b domains of PDI, but not b' and a', can in part be substituted by the corresponding domains of ERp57, a PDI isoform that functions naturally in association with the lectins calnexin and calreticulin. The a' domain of PDI could not be substituted by the PDI a domain, suggesting that both b' and a' domains contain regions critical for prolyl 4-hydroxylase assembly. All PDI domain constructs and PDI/ERp57 hybrids that contain the b' domain can bind the 14-amino acid peptide Delta -somatostatin, as measured by cross-linking; however, binding of the misfolded protein "scrambled" RNase required the addition of domains ab or a' of PDI. The human prolyl 4-hydroxylase alpha subunit has at least two isoforms, alpha (I) and alpha (II), which form with the PDI polypeptide the (alpha (I))(2)beta (2) and (alpha (II))(2)beta (2) tetramers. We report here that all the PDI domain constructs and PDI/ERp57 hybrid polypeptides tested were more effectively associated with the alpha (II) subunit than the alpha (I) subunit.	Univ Oulu, Bioctr, Collagen Res Unit, FIN-90014 Oulu, Finland; Univ Oulu, Dept Med Biochem, FIN-90014 Oulu, Finland; Univ Kent, Dept Biosci, Canterbury CT2 7NJ, Kent, England	University of Oulu; University of Oulu; University of Kent	Koivunen, P (corresponding author), Univ Oulu, Bioctr, Collagen Res Unit, POB 5000, FIN-90014 Oulu, Finland.			Ruddock, Lloyd/0000-0002-6247-686X				Annunen P, 1997, J BIOL CHEM, V272, P17342, DOI 10.1074/jbc.272.28.17342; CAI H, 1994, J BIOL CHEM, V269, P24550; Darby NJ, 1998, J MOL BIOL, V276, P239, DOI 10.1006/jmbi.1997.1504; Dijkstra K, 1999, J BIOMOL NMR, V14, P195, DOI 10.1023/A:1008331225208; Freedman RB, 1998, BIOL CHEM, V379, P321, DOI 10.1515/bchm.1998.379.3.321; FREEDMAN RB, 1994, TRENDS BIOCHEM SCI, V19, P331, DOI 10.1016/0968-0004(94)90072-8; FREEDMAN RB, 1999, MOL CHAPERONES PROTE, P437; GRUENWALD S, 1994, BACULOVIRUS EXPRESSI; Hayano T, 1995, FEBS LETT, V377, P505, DOI 10.1016/0014-5793(95)01410-1; HELAAKOSKI T, 1995, P NATL ACAD SCI USA, V92, P4427, DOI 10.1073/pnas.92.10.4427; JOHN DCA, 1993, EMBO J, V12, P1587, DOI 10.1002/j.1460-2075.1993.tb05803.x; Kemmink J, 1999, J BIOMOL NMR, V13, P357, DOI 10.1023/A:1008341820489; Kemmink J, 1997, CURR BIOL, V7, P239, DOI 10.1016/S0960-9822(06)00119-9; Kivirikko KI, 1998, MATRIX BIOL, V16, P357, DOI 10.1016/S0945-053X(98)90009-9; KIVIRIKKO KI, 1982, METHOD ENZYMOL, V82, P245; Kivirikko KI, 1998, ADV ENZYMOL RAMB, V72, P325; Klappa P, 2000, J BIOL CHEM, V275, P13213, DOI 10.1074/jbc.275.18.13213; Klappa P, 1997, EUR J BIOCHEM, V248, P37, DOI 10.1111/j.1432-1033.1997.t01-1-00037.x; Klappa P, 1998, EMBO J, V17, P927, DOI 10.1093/emboj/17.4.927; KLAPPA P, 1991, EMBO J, V10, P2795, DOI 10.1002/j.1460-2075.1991.tb07828.x; Koivunen P, 1999, EMBO J, V18, P65, DOI 10.1093/emboj/18.1.65; Koivunen P, 1996, BIOCHEM J, V316, P599, DOI 10.1042/bj3160599; LAMANTIA ML, 1993, CELL, V74, P899, DOI 10.1016/0092-8674(93)90469-7; Lamberg A, 1996, BIOCHEM J, V315, P533, DOI 10.1042/bj3150533; Myllyharju J, 1999, EMBO J, V18, P306, DOI 10.1093/emboj/18.2.306; Oliver JD, 1999, MOL BIOL CELL, V10, P2573, DOI 10.1091/mbc.10.8.2573; Oliver JD, 1997, SCIENCE, V275, P86, DOI 10.1126/science.275.5296.86; OTSU M, 1994, J BIOL CHEM, V269, P6874; PIHLAJANIEMI T, 1987, EMBO J, V6, P643, DOI 10.1002/j.1460-2075.1987.tb04803.x; PROCKOP DJ, 1995, ANNU REV BIOCHEM, V64, P403, DOI 10.1146/annurev.biochem.64.1.403; PUIG A, 1994, J BIOL CHEM, V269, P7764; PUIG A, 1994, J BIOL CHEM, V269, P19128; RUPP K, 1994, J BIOL CHEM, V269, P2501; VUORI K, 1992, P NATL ACAD SCI USA, V89, P7467, DOI 10.1073/pnas.89.16.7467; VUORI K, 1992, EMBO J, V11, P4213, DOI 10.1002/j.1460-2075.1992.tb05515.x; WETTERAU JR, 1991, BIOCHEMISTRY-US, V30, P9728, DOI 10.1021/bi00104a023; WETTERAU JR, 1990, J BIOL CHEM, V265, P9801; Yao Y, 1997, EMBO J, V16, P651, DOI 10.1093/emboj/16.3.651	38	46	47	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 6	2001	276	14					11287	11293		10.1074/jbc.M010656200	http://dx.doi.org/10.1074/jbc.M010656200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	420AC	11134056	hybrid			2022-12-25	WOS:000167980900096
J	Slotboom, DJ; Konings, WN; Lolkema, JS				Slotboom, DJ; Konings, WN; Lolkema, JS			Cysteine-scanning mutagenesis reveals a highly amphipathic, pore-lining membrane-spanning helix in the glutamate transporter GltT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REENTRANT LOOP; RAT-BRAIN; BACILLUS-STEAROTHERMOPHILUS; SUBSTRATE-BINDING; HIGH-AFFINITY; TOPOLOGY; ACCESSIBILITY; FAMILY; SELECTIVITY; PROTEINS	The carboxyl terminal membrane-spanning segment 8 of the glutamate transporter GltT of Bacillus stearothermophilus was studied by cysteine-scanning mutagenesis. 21 single cysteine mutants were constructed in a stretch ranging from Gly-574 to Gln-404, Two mutants were not expressed, four were inactive, and two showed severely reduced glutamate transport activity. Cysteine mutations at the other positions were well tolerated. Only the two most amino- and carboxyl-terminal mutants (G374C, I375C, S399C, and Q404C) could be labeled with the large thiol reagent fluorescein maleimide, indicating unrestricted access and a location in a loop structure outside the membrane. The labeling pattern of these mutants using membrane- permeable and -impermeable thiol reagents showed that the N and C termini of the mutated stretch are located extra- and intracellularly, respectively. Thus, the location of the membrane-spanning segment was confined to a stretch of 23 residues between Gly-374 and Ser-399. Cysteine residues in three mutants in the central part of the segment (M381C, V388C, and N391C) could be labeled with the small and flexible reagent a-aminoethyl methanethiosulfonate hydrobromide only, suggesting accessibility via a narrow aqueous pore. When the region was modeled as an cu-helix, all positions at which cysteine mutations lead to inactive or severely impaired transporters cluster on one face of this helix, The inactive mutants showed neither proton motive force-driven uptake activity nor exchange activity nor glutamate binding. The results indicate that transmembrane segment 8 forms an amphipathic alpha -helix, The hydrophilic face of the helix lines an aqueous pore and contains many residues that are important for activity.	Univ Groningen, Dept Microbiol, Groningen Biomol Sci & Biotechnol Inst, NL-9751 NN Haren, Netherlands	University of Groningen	Lolkema, JS (corresponding author), Univ Groningen, Dept Microbiol, Groningen Biomol Sci & Biotechnol Inst, Kerklaan 30, NL-9751 NN Haren, Netherlands.		Konings, Wilhelmus N./C-7063-2013					AKABAS MH, 1992, SCIENCE, V258, P307, DOI 10.1126/science.1384130; Bendahan A, 2000, J BIOL CHEM, V275, P37436, DOI 10.1074/jbc.M006536200; CONRADT M, 1995, J BIOL CHEM, V270, P25207, DOI 10.1074/jbc.270.42.25207; Eskandari S, 2000, P NATL ACAD SCI USA, V97, P8641, DOI 10.1073/pnas.97.15.8641; Gaillard I, 1996, BIOCHEMISTRY-US, V35, P6150, DOI 10.1021/bi953005v; Grunewald M, 1998, NEURON, V21, P623, DOI 10.1016/S0896-6273(00)80572-3; Grunewald M, 2000, J BIOL CHEM, V275, P9684, DOI 10.1074/jbc.275.13.9684; GUZMAN LM, 1995, J BACTERIOL, V177, P4121, DOI 10.1128/jb.177.14.4121-4130.1995; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; Kaback H. R., 1971, METHOD ENZYMOL, V22, P99, DOI DOI 10.1016/0076-6879(71)22015-2; Karlin A, 1998, METHOD ENZYMOL, V293, P123; Kavanaugh MP, 1997, J BIOL CHEM, V272, P1703, DOI 10.1074/jbc.272.3.1703; Lolkema JS, 1998, MOL MEMBR BIOL, V15, P33, DOI 10.3109/09687689809027516; MENNERICK S, 1994, NATURE, V368, P59, DOI 10.1038/368059a0; Mitrovic AD, 1998, J BIOL CHEM, V273, P14698, DOI 10.1074/jbc.273.24.14698; NICHOLLS D, 1990, TRENDS PHARMACOL SCI, V11, P462, DOI 10.1016/0165-6147(90)90129-V; Otis TS, 1997, SCIENCE, V277, P1515, DOI 10.1126/science.277.5331.1515; PINES G, 1995, J BIOL CHEM, V270, P17093, DOI 10.1074/jbc.270.29.17093; Sambrook J., 2002, MOL CLONING LAB MANU; Seal RP, 2000, NEURON, V25, P695, DOI 10.1016/S0896-6273(00)81071-5; Seal RP, 1998, NEURON, V21, P1487, DOI 10.1016/S0896-6273(00)80666-2; Slotboom DJ, 1999, MICROBIOL MOL BIOL R, V63, P293, DOI 10.1128/MMBR.63.2.293-307.1999; Slotboom DJ, 1999, P NATL ACAD SCI USA, V96, P14282, DOI 10.1073/pnas.96.25.14282; Slotboom DJ, 1996, J BIOL CHEM, V271, P31317, DOI 10.1074/jbc.271.49.31317; Tanaka K, 1997, SCIENCE, V276, P1699, DOI 10.1126/science.276.5319.1699; TOLNER B, 1995, MOL MICROBIOL, V18, P123, DOI 10.1111/j.1365-2958.1995.mmi_18010123.x; VANDENBERG RJ, 1995, J BIOL CHEM, V270, P17668, DOI 10.1074/jbc.270.30.17668; Wahle S, 1996, J CELL BIOL, V135, P1867, DOI 10.1083/jcb.135.6.1867; Zarbiv R, 1998, J BIOL CHEM, V273, P14231, DOI 10.1074/jbc.273.23.14231; Zhang YM, 1999, P NATL ACAD SCI USA, V96, P1710, DOI 10.1073/pnas.96.4.1710; Zhang YM, 1998, P NATL ACAD SCI USA, V95, P751, DOI 10.1073/pnas.95.2.751	31	50	50	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 6	2001	276	14					10775	10781		10.1074/jbc.M011064200	http://dx.doi.org/10.1074/jbc.M011064200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	420AC	11148213	Green Published, hybrid			2022-12-25	WOS:000167980900030
J	Walter, W; Scheuer, C; Loos, M; Reichert, TE; Maeurer, MJ				Walter, W; Scheuer, C; Loos, M; Reichert, TE; Maeurer, MJ			H2-M beta 1 and H2-M beta 2 heterodimers equally promote CLIP removal in I-A(q) molecules from autoimmune-prone DBA/1 mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MHC CLASS-II; COLLAGEN-INDUCED ARTHRITIS; ANTIGEN PRESENTATION; INVARIANT CHAIN; DENDRITIC CELLS; HLA-DM; PEPTIDE; H2-M; EXPRESSION; POLYMORPHISM	Antigen-presenting cells degrade endocytosed antigens, e.g. collagen type II, into peptides that are bound and presented to arthritogenic CD4(+) helper T cells by major histocompatibility complex (MHC) class II molecules. Efficient loading of many MHC class II alleles with peptides requires the assistance of H2-M (HLA-DM in humans), a heterodimeric MHC class II-like molecule that facilitates CLIP removal from MHC class II molecules and aids to shape the peptide repertoire presented by MHC class II to CD4(+) T cells. In contrast to the KLA-DM region in humans, the beta -chain locus is duplicated in mice, with the H2-Mb1 beta-chain distal to H2-Mb2 and the H2-Ma alpha-chain gene. H2-M alleles appear to be associated with the development of autoimmune diseases. Recent data showed that M beta1 and M beta2 isoforms are differentially expressed in isolated macrophages and B cells, respectively. The tissue expression and functional role of these heterodimers in promoting CLIP removal and peptide selection have not been addressed. We utilized the human T2 cell line, which lacks part of chromosome 6 encompassing the MHC class II and DM genes, to construct transgenic cell lines expressing the MHC class II heterodimer I-A(q) alone or in the presence of H2-M alpha beta1 or H2-M alpha beta2 heterodimers, Both H2-M isoforms facilitate the exchange of CLIP for cognate peptides on I-Aq molecules from arthritis-susceptible DBA/1 mice and induce a conformational change in I-A(q) molecules. Moreover, I-A(q) cell-surface expression is not absolutely dependent on H2-M molecules. These data suggest that I-A(q) exhibits a high affinity for CLIP since virtually all I-A(q) molecules on T2 cells were found to be associated with CLIP in the absence of both H2-M isoforms.	Johannes Gutenberg Univ Mainz, Dept Med Microbiol, D-55101 Mainz, Germany; Johannes Gutenberg Univ Mainz, Dept Oral & Maxillofacial Surg, D-55101 Mainz, Germany	Johannes Gutenberg University of Mainz; Johannes Gutenberg University of Mainz	Maeurer, MJ (corresponding author), Johannes Gutenberg Univ Mainz, Dept Med Microbiol, D-55101 Mainz, Germany.	maeurer@mail.uni-mainz.de		Maeurer, Markus/0000-0002-8436-8077				Alfonso C, 2000, ANNU REV IMMUNOL, V18, P113, DOI 10.1146/annurev.immunol.18.1.113; BOUABOULA M, 1992, J BIOL CHEM, V267, P21830; BRICKELL PM, 1981, IMMUNOLOGY, V43, P493; CHIOCCHIA G, 1993, EUR J IMMUNOL, V23, P327, DOI 10.1002/eji.1830230204; CHO SG, 1991, NATURE, V353, P573, DOI 10.1038/353573a0; CHO SG, 1991, P NATL ACAD SCI USA, V88, P5197, DOI 10.1073/pnas.88.12.5197; COURTENAY JS, 1980, NATURE, V283, P666, DOI 10.1038/283666a0; DANOS O, 1988, P NATL ACAD SCI USA, V85, P6460, DOI 10.1073/pnas.85.17.6460; DENZIN LK, 1994, IMMUNITY, V1, P595, DOI 10.1016/1074-7613(94)90049-3; DRANOFF G, 1993, P NATL ACAD SCI USA, V90, P3539, DOI 10.1073/pnas.90.8.3539; FungLeung WP, 1996, SCIENCE, V271, P1278, DOI 10.1126/science.271.5253.1278; Germain RN, 1996, IMMUNOL REV, V151, P5, DOI 10.1111/j.1600-065X.1996.tb00701.x; HASENKRUG KJ, 1987, IMMUNOGENETICS, V25, P136, DOI 10.1007/BF00364282; HERMEL E, 1995, IMMUNOGENETICS, V42, P136, DOI 10.1007/BF00178588; HOLMDAHL R, 1986, AGENTS ACTIONS, V19, P295, DOI 10.1007/BF01971231; KARLSSON L, 1994, SCIENCE, V266, P1569, DOI 10.1126/science.7985028; KERWAR SS, 1983, ARTHRITIS RHEUM, V26, P1120, DOI 10.1002/art.1780260910; Kim KJ, 1996, MOL CELLS, V6, P684; Korganow AS, 1999, IMMUNITY, V10, P451, DOI 10.1016/S1074-7613(00)80045-X; KYHSEANDERSEN J, 1984, J BIOCHEM BIOPH METH, V10, P203, DOI 10.1016/0165-022X(84)90040-X; Maeurer MJ, 1996, J CLIN INVEST, V98, P1633, DOI 10.1172/JCI118958; ManourySchwartz B, 1995, EUR J IMMUNOL, V25, P3235, DOI 10.1002/eji.1830251206; Martin WD, 1996, CELL, V84, P543, DOI 10.1016/S0092-8674(00)81030-2; MICHAELSSON E, 1995, EUR J IMMUNOL, V25, P2234, DOI 10.1002/eji.1830250818; Miyazaki T, 1996, CELL, V84, P531, DOI 10.1016/S0092-8674(00)81029-6; MORRIS P, 1994, NATURE, V368, P551, DOI 10.1038/368551a0; MYERS LK, 1992, J IMMUNOL, V149, P1439; NIJMAN HW, 1995, J EXP MED, V182, P163, DOI 10.1084/jem.182.1.163; Osman GE, 1998, INT IMMUNOL, V10, P1613, DOI 10.1093/intimm/10.11.1613; SALTER RD, 1985, IMMUNOGENETICS, V21, P235, DOI 10.1007/BF00375376; SANDERSON F, 1994, SCIENCE, V266, P1566, DOI 10.1126/science.7985027; SEKI N, 1988, J IMMUNOL, V140, P1477; SETTE A, 1995, J EXP MED, V181, P677, DOI 10.1084/jem.181.2.677; SLOAN JH, 1992, J IMMUNOL, V148, P2591; Stebbins CC, 1996, J IMMUNOL, V157, P4892; TERATO K, 1985, J EXP MED, V162, P637, DOI 10.1084/jem.162.2.637; URBAN RG, 1994, J EXP MED, V180, P751, DOI 10.1084/jem.180.2.751; vanHam SM, 1996, J EXP MED, V184, P2019, DOI 10.1084/jem.184.5.2019; Villadangos JA, 1997, J EXP MED, V186, P549, DOI 10.1084/jem.186.4.549; Walter W, 2000, BRIT J CANCER, V83, P1192, DOI 10.1054/bjoc.2000.1415; Walter W, 1996, IMMUNOGENETICS, V44, P19, DOI 10.1007/s002510050085; Walter W, 2000, IMMUNOGENETICS, V51, P794, DOI 10.1007/s002510000210; Walter W, 1999, MOL IMMUNOL, V36, P733, DOI 10.1016/S0161-5890(99)00089-9; Weber DA, 1996, SCIENCE, V274, P618, DOI 10.1126/science.274.5287.618; Wolf PR, 1998, EUR J IMMUNOL, V28, P2605, DOI 10.1002/(SICI)1521-4141(199809)28:09<2605::AID-IMMU2605>3.0.CO;2-B; Wolf PR, 1995, ANNU REV CELL DEV BI, V11, P267, DOI 10.1146/annurev.cb.11.110195.001411; WOOLEY PH, 1981, J EXP MED, V154, P688, DOI 10.1084/jem.154.3.688; Young AJ, 1999, SEMIN IMMUNOL, V11, P73, DOI 10.1006/smim.1999.0163	48	12	12	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 6	2001	276	14					11086	11091		10.1074/jbc.M006521200	http://dx.doi.org/10.1074/jbc.M006521200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	420AC	11148202				2022-12-25	WOS:000167980900070
J	Yoshikawa, DM; Bresciano, K; Hatwar, M; Smrcka, AV				Yoshikawa, DM; Bresciano, K; Hatwar, M; Smrcka, AV			Characterization of a phospholipase C beta 2-binding site near the amino-terminal coiled-coil of G protein beta gamma subunits	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YEAST G-PROTEIN; ADENYLYL-CYCLASE; ACTIVATION; BINDING	In previous work (Sankaran, B., Osterhout, J., Wu, D., and Smrcka, A. V. (1998) J. Biol. Chem. 273, 7148-7154), we showed that overlapping peptides, N20K (Asn(564)- Lys(583)) and E20K (Glu(574)-Lys(593)), from the catalytic domain of phospholipase C (PLC) beta2 block G beta gamma -dependent activation of PLC beta2, The peptides could also be directly cross-linked to beta gamma subunits with a heterobifunctional cross-linker succinimidyl 4-[N-maleimidomethyl]-cyclohexane-1-carboxylate. Cross-linking of peptides to G beta (1) was inhibited by PLC beta2 but not by alpha (i1)(GDP), indicating that the peptide-binding site on beta (1) represents a binding site for PLC beta2 that does not overlap with the alpha (i1)-binding site. Here we identify the site of peptide cross-linking and thereby define a site for PLC beta2 interaction with beta subunits. Each of the 14 cysteine residues in beta (1) were altered to alanine. The ability of the PLC beta2-derived peptide to cross-link to each beta gamma mutant was then analyzed to identify the reactive sulfhydryl moiety on the beta subunit required for the cross-linking reaction. We find that C25A was the only mutation that significantly affected peptide cross-linking. This indicates that the peptide is specifically binding to a region near cysteine 25 of beta (1) which is located in the amino-terminal coiled-coil region of beta (1), and identifies a PLC-binding site distinct from the alpha subunit interaction site.	Univ Rochester, Sch Med & Dent, Dept Physiol & Pharmacol, Rochester, NY 14642 USA	University of Rochester	Smrcka, AV (corresponding author), Univ Rochester, Sch Med & Dent, Dept Physiol & Pharmacol, 601 Elmwood Ave, Rochester, NY 14642 USA.				NIGMS NIH HHS [GM 53536] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Buck E, 1999, SCIENCE, V283, P1332, DOI 10.1126/science.283.5406.1332; Dowell SJ, 1998, GENETICS, V150, P1407; Ford CE, 1998, SCIENCE, V280, P1271, DOI 10.1126/science.280.5367.1271; GarciaHiguera I, 1996, J BIOL CHEM, V271, P528, DOI 10.1074/jbc.271.1.528; Hamm HE, 1998, J BIOL CHEM, V273, P669, DOI 10.1074/jbc.273.2.669; KOZASA T, 1995, J BIOL CHEM, V270, P1734, DOI 10.1074/jbc.270.4.1734; Lambright DG, 1996, NATURE, V379, P311, DOI 10.1038/379311a0; LEBERER E, 1992, EMBO J, V11, P4805, DOI 10.1002/j.1460-2075.1992.tb05586.x; Leeuw T, 1998, NATURE, V391, P191, DOI 10.1038/34448; Li Y, 1998, J BIOL CHEM, V273, P16265, DOI 10.1074/jbc.273.26.16265; Means GE, 1990, BIOCONJUGATE CHEM, V1, P2, DOI 10.1021/bc00001a001; MUMBY SM, 1994, METHOD ENZYMOL, V237, P254; Panchenko MP, 1998, J BIOL CHEM, V273, P28298, DOI 10.1074/jbc.273.43.28298; Pellegrino S, 1997, J BIOL CHEM, V272, P25360, DOI 10.1074/jbc.272.40.25360; Romoser V, 1996, J BIOL CHEM, V271, P25071, DOI 10.1074/jbc.271.41.25071; Runnels LW, 1998, BIOCHEMISTRY-US, V37, P15563, DOI 10.1021/bi9811258; Sankaran B, 1998, J BIOL CHEM, V273, P7148, DOI 10.1074/jbc.273.12.7148; SMRCKA AV, 1993, J BIOL CHEM, V268, P9667; THOMAS TC, 1993, BIOCHEMISTRY-US, V32, P8628, DOI 10.1021/bi00084a034; WALL MA, 1995, CELL, V83, P1047, DOI 10.1016/0092-8674(95)90220-1	20	17	17	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 6	2001	276	14					11246	11251		10.1074/jbc.M006073200	http://dx.doi.org/10.1074/jbc.M006073200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	420AC	11145956	hybrid			2022-12-25	WOS:000167980900090
J	Lindenthal, B; Holleran, AL; Aldaghlas, TA; Ruan, BF; Schroepfer, GJ; Wilson, WK; Kelleher, JK				Lindenthal, B; Holleran, AL; Aldaghlas, TA; Ruan, BF; Schroepfer, GJ; Wilson, WK; Kelleher, JK			Progestins block cholesterol synthesis to produce meiosis-activating sterols	FASEB JOURNAL			English	Article						progesterone; 17-hydroxyprogesterone; cholesterol precursors; GC-MS; isotopomer spectral analysis; HepG2 cells	PLASMA-MEMBRANE CHOLESTEROL; EMPTY FOLLICLE SYNDROME; RECEPTOR LXR-ALPHA; ENDOPLASMIC-RETICULUM; DOCOSAHEXAENOIC ACID; GRANULOSA-CELLS; OOCYTE MEIOSIS; CULTURED-CELLS; CACO-2 CELLS; IN-VITRO	The resumption of meiosis is regulated by meiosis-preventing and meiosis-activating substances in testes and ovaries. Certain C-29 precursors of cholesterol are present at elevated levels in gonadal tissue, but the mechanism by which these meiosis-activating sterols (MAS) accumulate has remained an unresolved question. Here we report that progestins alter cholesterol synthesis in HepG2 cells and rat testes to increase levels of major MAS (FF-MAS and T-MAS), These C-29 sterols accumulated as a result of inhibition of Delta 24-reduction and 4 alpha -demethylation, Progesterone, pregnenolone, and 17 alpha -OH-pregnenolone were potent inhibitors of Delta 24-reduction in an in vitro cell assay and led to the accumulation of desmosterol, a Delta5,24 sterol precursor of cholesterol, A markedly different effect was observed for 17 alpha -OH-progesterone, which caused the accumulation of sterols associated with inhibition of 4 alpha -demethylation. The flux of C-13-acetate into lathosterol and cholesterol was decreased by progestins as measured by isotopomer spectral analysis, whereas newly synthesized MAS accumulated, The combined evidence that MAS concentrations can be regulated by physiological levels of progestins and their specific combination provides a plausible explanation for the elevated concentration of MAS in gonads and suggests a new role for progestins in fertility.	George Washington Univ, Sch Med & Hlth Sci, Dept Physiol & Expt Med, Washington, DC 20037 USA; Univ Bonn, Dept Clin Pharmacol, D-53105 Bonn, Germany; Rice Univ, Dept Chem, Houston, TX 77251 USA; Rice Univ, Dept Biochem & Cell Biol, Houston, TX 77251 USA	George Washington University; University of Bonn; Rice University; Rice University	Lindenthal, B (corresponding author), Schering AG, Female Hlth Care Res, Muellerstr 170-178, D-13342 Berlin, Germany.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL049122] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK045164] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-49122] Funding Source: Medline; NIDDK NIH HHS [DK-45164] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDERSEN CY, 1992, HUM REPROD, V7, P765, DOI 10.1093/oxfordjournals.humrep.a137734; BRAILLY S, 1981, J CLIN ENDOCR METAB, V53, P128, DOI 10.1210/jcem-53-1-128; Byskov AG, 1999, J EXP ZOOL, V285, P237, DOI 10.1002/(SICI)1097-010X(19991015)285:3&lt;237::AID-JEZ6&gt;3.0.CO;2-S; BYSKOV AG, 1995, NATURE, V374, P559, DOI 10.1038/374559a0; BYSKOV AG, 1976, DEV BIOL, V52, P193, DOI 10.1016/0012-1606(76)90239-6; Byskov AG, 1998, J MOL MED-JMM, V76, P818, DOI 10.1007/s001090050286; CHANNING CP, 1978, CLIN ENDOCRINOL META, V7, P601, DOI 10.1016/S0300-595X(78)80011-5; Connor WE, 1997, J CLIN ENDOCR METAB, V82, P1911, DOI 10.1210/jc.82.6.1911; Enien WM, 1995, HUM REPROD, V10, P2840, DOI 10.1093/oxfordjournals.humrep.a135804; FIELD FJ, 1995, J LIPID RES, V36, P1533; Field FJ, 1998, J LIPID RES, V39, P333; Forman BM, 1997, P NATL ACAD SCI USA, V94, P10588, DOI 10.1073/pnas.94.20.10588; Gerst N, 1997, J LIPID RES, V38, P1685; Gondos B, 1996, ANN CLIN LAB SCI, V26, P421; Grondahl C, 1998, BIOL REPROD, V58, P1297, DOI 10.1095/biolreprod58.5.1297; HAKSAR A, 1967, STEROIDS, V9, P405, DOI 10.1016/0039-128X(67)90028-1; HASHIMOTO F, 1991, BIOCHIM BIOPHYS ACTA, V1086, P115, DOI 10.1016/0005-2760(91)90162-B; Holleran AL, 1998, METABOLISM, V47, P1504, DOI 10.1016/S0026-0495(98)90078-6; Janowski BA, 1996, NATURE, V383, P728, DOI 10.1038/383728a0; KALLIO MJT, 1989, AM J CLIN NUTR, V50, P782, DOI 10.1093/ajcn/50.4.782; KASE NG, 1983, J REPROD MED, V28, P239; KELLEHER JK, 1994, AM J PHYSIOL, V266, pE384, DOI 10.1152/ajpendo.1994.266.3.E384; KRITCHEVSKY D, 1965, J AM OIL CHEM SOC, V42, P1024, DOI 10.1007/BF02636896; LANGE Y, 1994, J BIOL CHEM, V269, P3411; LANGE Y, 1994, J BIOL CHEM, V269, P29371; LANGE Y, 1988, ENDOCRINOLOGY, V123, P81, DOI 10.1210/endo-123-1-81; LEINONEN P, 1981, J CLIN ENDOCR METAB, V53, P569, DOI 10.1210/jcem-53-3-569; LEINONEN P, 1980, J CLIN ENDOCR METAB, V51, P423, DOI 10.1210/jcem-51-3-423; LIN DS, 1993, J LIPID RES, V34, P491; LISCUM L, 1995, J BIOL CHEM, V270, P15443, DOI 10.1074/jbc.270.26.15443; MCNATTY KP, 1979, J CLIN ENDOCR METAB, V49, P687, DOI 10.1210/jcem-49-5-687; Metherall JE, 1996, J BIOL CHEM, V271, P2627, DOI 10.1074/jbc.271.5.2627; Metherall JE, 1996, J BIOL CHEM, V271, P2634, DOI 10.1074/jbc.271.5.2634; Nikkila K, 1996, J LIPID RES, V37, P2687; PANINI SR, 1987, J BIOL CHEM, V262, P14435; RODRIGUEZRIGAU LJ, 1978, ACTA ENDOCRINOL-COP, V87, P400, DOI 10.1530/acta.0.0870400; Ruan BF, 1998, J LIPID RES, V39, P2005; SCHUETZ AW, 1977, ANN NY ACAD SCI, V286, P408, DOI 10.1111/j.1749-6632.1977.tb29433.x; SEIBEL MM, 1982, AM J OBSTET GYNECOL, V142, P568, DOI 10.1016/0002-9378(82)90763-3; Stromstedt M, 1998, ENDOCRINOLOGY, V139, P2314, DOI 10.1210/en.139.5.2314; TSUIKI A, 1988, FERTIL STERIL, V49, P104; WESTERGAARD L, 1984, FERTIL STERIL, V41, P377; Yoshida Y, 1996, BIOCHEM BIOPH RES CO, V223, P534, DOI 10.1006/bbrc.1996.0929; ZEGERSHOCHSCHILD F, 1995, HUM REPROD, V10, P2262	44	44	45	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAR	2001	15	3					775	784		10.1096/fj.00-0214com	http://dx.doi.org/10.1096/fj.00-0214com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	410BE	11259396				2022-12-25	WOS:000167419500035
J	Arlt, A; Grobe, O; Sieke, A; Kruse, ML; Folsch, UR; Schmidt, WE; Schafer, H				Arlt, A; Grobe, O; Sieke, A; Kruse, ML; Folsch, UR; Schmidt, WE; Schafer, H			Expression of the NF-kappa B target gene IEX-1 (p22/PRG1) does not prevent cell death but instead triggers apoptosis in Hela cells	ONCOGENE			English	Article						programmed cell death; NF-kappa B; early response gene; cell cycle	EARLY-RESPONSE GENE; ALPHA-INDUCED APOPTOSIS; TRANSCRIPTIONAL REGULATION; CYCLIN D1; C-MYC; INHIBITOR; PROTEIN; ACTIVATION; PROMOTER; GROWTH	P22(PRG1/IEX-1) is putative NF-kappaB target gene implicated in the regulation of cellular viability. Here, we show that in HeLa cells TNF alpha induces expression of p22(PRG1/IEX-1) in an NF-kappaB dependent fashion. Blockade of NF-kappaB activation by various NF-kappaB inhibitors abolished TNF alpha -induced p22(PRG1/IEX-1) expression and increased the sensitivity to apoptosis induced by TNF alpha, an activating Fas-antibody or the anti-cancer drug etoposide, Surprisingly, ectopic expression of p22(PRG1/IEX-1) in HeLa cells transfected with an inducible p22(PRG1/IEX-1)-expression vector augments the susceptibility to apoptosis initiated by death-receptor ligands or by etoposide, In addition, p22(PRG1/IEX-1) expressing HeLa cells exhibit an accelerated progression through the cell cycle. Transfection of an antisense hammerhead ribozyme targeted to p22(PRG1/IEX-1) reduced the speed in cell cycle progression and decreased the apoptotic response to death ligands. Our data demonstrate that p22(PRG1/IEX-1) is specifically induced during NF-kappaB activation, but this seems not to be related to the anti-apoptotic actions of NF-kappaB, Instead, NF-kappaB dependent recruitment of p22(PRG1/IEX-1) might be related to a modulation in the cell cycle, and hereby, p22(PRG1/IEX-1) accelerate cell growth on the one hand, but may trigger apoptosis on the other.	Univ Kiel, Dept Med 1, Lab Mol Gastroenterol, D-24105 Kiel, Germany; Ruhr Univ Bochum, St Josef Hosp, Dept Med 1, D-4630 Bochum, Germany	University of Kiel; Ruhr University Bochum	Schafer, H (corresponding author), Univ Kiel, Dept Med 1, Lab Mol Gastroenterol, Schittenhelmstr 12, D-24105 Kiel, Germany.		Schäfer, Heiner/C-1055-2011; Arlt, Alexander/G-7308-2019	Arlt, Alexander/0000-0002-6160-1059				ABBADIE C, 1993, CELL, V75, P899, DOI 10.1016/0092-8674(93)90534-W; Barkett M, 1999, ONCOGENE, V18, P6910, DOI 10.1038/sj.onc.1203238; Chan H, 1999, MOL CELL BIOL, V19, P2098, DOI 10.1128/mcb.19.3.2098; CHARLES CH, 1993, ONCOGENE, V8, P797; Chen CL, 2000, MOL CELL BIOL, V20, P2687, DOI 10.1128/MCB.20.8.2687-2695.2000; Dudley E, 1999, EUR J IMMUNOL, V29, P878, DOI 10.1002/(SICI)1521-4141(199903)29:03<878::AID-IMMU878>3.0.CO;2-9; Evan G, 1998, SCIENCE, V281, P1317, DOI 10.1126/science.281.5381.1317; Gibson SB, 2000, MOL CELL BIOL, V20, P205, DOI 10.1128/MCB.20.1.205-212.2000; Guttridge DC, 1999, MOL CELL BIOL, V19, P5785; Hellerbrand C, 1998, HEPATOLOGY, V27, P1285, DOI 10.1002/hep.510270514; Hinz M, 1999, MOL CELL BIOL, V19, P2690; Jiang MC, 1996, ONCOGENE, V13, P609; Kaltschmidt B, 2000, EUR J BIOCHEM, V267, P3828, DOI 10.1046/j.1432-1327.2000.01421.x; Kaltschmidt B, 1999, ONCOGENE, V18, P3213, DOI 10.1038/sj.onc.1202657; Kobayashi T, 1998, BIOCHEM BIOPH RES CO, V251, P868, DOI 10.1006/bbrc.1998.9556; Kondratyev AD, 1996, CANCER RES, V56, P1498; Kroll M, 1999, CHEM BIOL, V6, P689, DOI 10.1016/S1074-5521(00)80016-2; Lee HH, 1999, P NATL ACAD SCI USA, V96, P9136, DOI 10.1073/pnas.96.16.9136; Lin BH, 1999, CELL DEATH DIFFER, V6, P570, DOI 10.1038/sj.cdd.4400528; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; Okamoto K, 1999, ONCOGENE, V18, P4606, DOI 10.1038/sj.onc.1202821; Pahl HL, 1996, J EXP MED, V183, P1829, DOI 10.1084/jem.183.4.1829; Pietzsch A, 1998, BIOCHEM BIOPH RES CO, V245, P651, DOI 10.1006/bbrc.1998.8500; Qin JZ, 1999, J BIOL CHEM, V274, P37957, DOI 10.1074/jbc.274.53.37957; Rayet B, 1999, ONCOGENE, V18, P6938, DOI 10.1038/sj.onc.1203221; Ryan KM, 2000, NATURE, V404, P892, DOI 10.1038/35009130; Sakamuro D, 1995, ONCOGENE, V11, P2411; Schafer H, 1999, BIOCHEM BIOPH RES CO, V262, P139, DOI 10.1006/bbrc.1999.1131; Schafer H, 1998, FEBS LETT, V436, P139, DOI 10.1016/S0014-5793(98)01109-0; Schafer H, 1996, CANCER RES, V56, P2641; Schafer H, 1998, ONCOGENE, V16, P2479, DOI 10.1038/sj.onc.1201788; Segev DL, 2000, J BIOL CHEM, V275, P28371, DOI 10.1074/jbc.M004554200; Stehlik C, 1998, J EXP MED, V188, P211, DOI 10.1084/jem.188.1.211; Usami I, 1998, BIOCHEM PHARMACOL, V55, P185, DOI 10.1016/S0006-2952(97)00429-2; VAN AD, 1996, SCIENCE, V274, P787; Wahl C, 1998, J CLIN INVEST, V101, P1163, DOI 10.1172/JCI992; Wang CY, 1999, MOL CELL BIOL, V19, P5923; Wang CY, 1999, NAT MED, V5, P412, DOI 10.1038/7410; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Wolff B, 1999, ONCOGENE, V18, P2663, DOI 10.1038/sj.onc.1202617; Wu MX, 1998, SCIENCE, V281, P998, DOI 10.1126/science.281.5379.998; You MJ, 1997, MOL CELL BIOL, V17, P7328, DOI 10.1128/MCB.17.12.7328; Zong WX, 1999, GENE DEV, V13, P382, DOI 10.1101/gad.13.4.382	43	72	76	0	2	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 4	2001	20	1					69	76		10.1038/sj.onc.1204061	http://dx.doi.org/10.1038/sj.onc.1204061			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	391NE	11244505				2022-12-25	WOS:000166361400008
J	See, V; Boutiller, AL; Bito, H; Loeffler, JP				See, V; Boutiller, AL; Bito, H; Loeffler, JP			Calcium/calmodulin-dependent protein kinase type IV (CaMKIV) inhibits apoptosis induced by potassium deprivation in cerebellar granule neurons	FASEB JOURNAL			English	Article						CPP32/caspase-3; cAMP-responsive element binding protein (CREB); calcium channels; nuclear condensation; gene transfer	GENE-EXPRESSION; SIGNALING PATHWAY; TRANSGENIC MICE; CELL-SURVIVAL; MESSENGER-RNA; CALCIUM; CREB; ACTIVATION; TRANSCRIPTION; DEATH	The neuroprotective mechanisms of the Ca2+/calmodulin kinase (CaMK) signaling pathway were studied in primary cerebellar neurons in vitro. When switched from depolarizing culture conditions HX (extracellular Kf 30 mM) to LK (Kf 5 mM), these neurons rapidly undergo nuclear fragmentation, a typical feature of apoptosis. We present evidence that blockade of L-type Ca2+ channels (nifedipine sensitive) but not N/P/Q-type Ca2+ channels (omega-conotoxin MVIIC sensitive) triggered apoptosis and CPP32/ caspase-3-like activity. The entry into apoptosis was associated with a progressive caspase-3-dependent cleavage of CaMKIV, but not of CaMKII. CaMKIV function in neuronal apoptosis was further investigated by overexpression of CaMKIV mutants by gene transfer. A dominant-active CaMKIV mutant inhibited LK-induced apoptosis whereas a dominant-negative form induced apoptosis in HK, suggesting that CaMKIV exerts neuroprotective effects. The transcription factor CREB is a well-described nuclear target of CaMKIV in neurons. When switched to LK, the level of phosphorylation of CREB, after an initial drop, further declined progressively with kinetics comparable to those of CaMKIV degradation. This decrease was abolished by caspase-3 inhibitor. These data are compatible with a model where Ca2+ influx via L-type Ca2+ channels prevents caspase-dependent cleavage of CaMKIV and promotes neuronal survival by maintaining a constitutive level of CaMKIV/CREB-dependent gene expression.	Univ Strasbourg, UMR 7519, CNRS, IPCB, F-67084 Strasbourg, France; Kyoto Univ, Fac Med, Dept Pharmacol, Sakyo Ku, Kyoto 6068315, Japan	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Kyoto University	Loeffler, JP (corresponding author), Univ Strasbourg, UMR 7519, CNRS, IPCB, 21 Rue Rene Descartes, F-67084 Strasbourg, France.	loeffler@neurochem.u-strasbg.fr	LOEFFLER, Jean-Philippe/AAS-4401-2020; Bito, Haruhiko/A-8635-2008	Bito, Haruhiko/0000-0001-6315-9594				Alnemri ES, 1996, CELL, V87, P171, DOI 10.1016/S0092-8674(00)81334-3; Anderson KA, 1997, MOL ENDOCRINOL, V11, P725, DOI 10.1210/me.11.6.725; Armstrong RC, 1997, J NEUROSCI, V17, P553; Barthel F, 1996, NEUROSCIENCE, V70, P1053, DOI 10.1016/0306-4522(95)00411-4; Bito H, 1996, CELL, V87, P1203, DOI 10.1016/S0092-8674(00)81816-4; Bito H, 1997, CURR OPIN NEUROBIOL, V7, P419, DOI 10.1016/S0959-4388(97)80072-4; BOUSSIF O, 1995, P NATL ACAD SCI USA, V92, P7297, DOI 10.1073/pnas.92.16.7297; Boutillier AL, 1999, EUR J NEUROSCI, V11, P441, DOI 10.1046/j.1460-9568.1999.00451.x; Brugg B, 1996, J NEUROCHEM, V66, P733; Campard PK, 1997, DNA CELL BIOL, V16, P323, DOI 10.1089/dna.1997.16.323; CHURN SB, 1993, STROKE, V24, P271, DOI 10.1161/01.STR.24.2.271; D'MELLO SR, 1993, P NATL ACAD SCI USA, V90, P10989, DOI 10.1073/pnas.90.23.10989; Eldadah BA, 1997, J NEUROSCI, V17, P6105; ELLIS RE, 1991, ANNU REV CELL BIOL, V7, P663, DOI 10.1146/annurev.cb.07.110191.003311; Finkbeiner S, 1997, NEURON, V19, P1031, DOI 10.1016/S0896-6273(00)80395-5; Finkbeiner S, 1996, NEURON, V16, P233, DOI 10.1016/S0896-6273(00)80040-9; GALLO V, 1987, J NEUROSCI, V7, P2203; HACK N, 1993, NEUROSCIENCE, V57, P9, DOI 10.1016/0306-4522(93)90108-R; HAJIMOHAMMADREZA I, 1995, J NEUROSCI, V15, P4093; Hardingham GE, 1999, NEURON, V22, P789, DOI 10.1016/S0896-6273(00)80737-0; Heist EK, 1998, CELL CALCIUM, V23, P103; Kohara K, 1998, BRAIN RES, V809, P231, DOI 10.1016/S0006-8993(98)00894-4; LOO DT, 1993, P NATL ACAD SCI USA, V90, P7951, DOI 10.1073/pnas.90.17.7951; Marks N, 1999, NEUROCHEM INT, V35, P195, DOI 10.1016/S0197-0186(99)00061-3; MARTIN SJ, 1995, CELL, V82, P349, DOI 10.1016/0092-8674(95)90422-0; MATTHEWS RP, 1994, MOL CELL BIOL, V14, P6107, DOI 10.1128/MCB.14.9.6107; McGinnis KM, 1998, J BIOL CHEM, V273, P19993, DOI 10.1074/jbc.273.32.19993; Mermelstein PG, 2000, J NEUROSCI, V20, P266, DOI 10.1523/JNEUROSCI.20-01-00266.2000; Moran J, 1999, J NEUROCHEM, V73, P568, DOI 10.1046/j.1471-4159.1999.0730568.x; Murray KD, 1998, EUR J NEUROSCI, V10, P377, DOI 10.1046/j.1460-9568.1998.00019.x; Nardi N, 1997, J NEUROCHEM, V68, P750; Ono T, 1997, NEUROSCI LETT, V228, P123, DOI 10.1016/S0304-3940(97)00383-2; PORTERA CC, 1995, J NEUROSCI, P3775; Przywara DA, 1998, J NEUROCHEM, V71, P1889; RANDALL A, 1995, J NEUROSCI, V15, P2995; ROY N, 1995, CELL, V80, P167, DOI 10.1016/0092-8674(95)90461-1; Schousboe A., 1989, DISSECTION TISSUE CU, P203; Schulman H, 1993, CURR OPIN CELL BIOL, V5, P247, DOI 10.1016/0955-0674(93)90111-3; Schulz JB, 1996, J NEUROSCI, V16, P4696; SHENG M, 1990, NEURON, V4, P571, DOI 10.1016/0896-6273(90)90115-V; Shieh PB, 1998, NEURON, V20, P727, DOI 10.1016/S0896-6273(00)81011-9; Soderling TR, 1999, TRENDS BIOCHEM SCI, V24, P232, DOI 10.1016/S0968-0004(99)01383-3; SUN PQ, 1994, GENE DEV, V8, P2527, DOI 10.1101/gad.8.21.2527; Tanabe H, 1997, EUR J NEUROSCI, V9, P848, DOI 10.1111/j.1460-9568.1997.tb01434.x; Tanabe H, 1998, EUR J NEUROSCI, V10, P1403, DOI 10.1046/j.1460-9568.1998.00148.x; Tao X, 1998, NEURON, V20, P709, DOI 10.1016/S0896-6273(00)81010-7; VILLARROEL A, 1997, TRENDS GENET, V13, P164; Widmann C, 1998, J BIOL CHEM, V273, P7141, DOI 10.1074/jbc.273.12.7141; Wright SC, 1997, FASEB J, V11, P843, DOI 10.1096/fasebj.11.11.9285482; Yano S, 1998, NATURE, V396, P584, DOI 10.1038/25147	50	123	129	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2001	15	1					134	144		10.1096/fj.00-0106com	http://dx.doi.org/10.1096/fj.00-0106com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	390TH	11149901				2022-12-25	WOS:000166312400022
J	Tomatis, L; Melnick, RL; Haseman, J; Barrett, JC; Huff, J				Tomatis, L; Melnick, RL; Haseman, J; Barrett, JC; Huff, J			Alleged 'misconceptions' distort perceptions of environmental cancer risks	FASEB JOURNAL			English	Article						environmental carcinogens; assessment of risks; cancer prevention; carcinogenesis bioassay	CARCINOGENIC POTENCY; AVOIDABLE RISKS; LUNG-CANCER; PREVENTION; CHEMICALS; PESTICIDES; POLLUTION; EXPOSURE; TESTS	In a series of papers, Ames and col leagues allege that the scientific and public health communities have perpetuated a series of 'misconceptions' that resulted in inaccurate identification of chemicals that pose potential human cancer risks, and misguided cancer prevention strategies and regulatory policies. They conclude that exposures to industrial and synthetic chemicals represent negligible cancer risks and that animal studies have little or no scientific value for assessing human risks, Their conclusions are based on flawed and untested assumptions. For instance, they claim that synthetic residues on food can be ignored because 99.99% of pesticides humans eat are natural, chemicals in plants are pesticides, and their potential to cause cancer equals that of synthetic pesticides. Similarly, Ames does not offer any convincing scientific evidence to justify discrediting bioassays for identifying human carcinogens. Ironically, their arguments center on a ranking procedure that relies on the same experimental data and extrapolation methods they criticize as being unreliable for evaluating cancer risks. We address their inconsistencies and flaws, and present scientific facts and our perspectives surrounding Ames' nine alleged misconceptions. Our conclusions agree with the International Agency for Research on Cancer, the National Toxicology Program, and other respected scientific organizations: in the absence of human data, animal studies are the most definitive for assessing human cancer risks, Animal data should not be ignored, and precautions should be taken to lessen human exposures, Dismissing animal carcinogenicity findings would lead to human cancer cases as the only means of demonstrating carcinogenicity of environmental agents. This is unacceptable public health policy.	NIEHS, Res Triangle Pk, NC 27709 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Huff, J (corresponding author), NIEHS, 111 Alexander Dr, Res Triangle Pk, NC 27709 USA.	huffl@niehs.nih.gov			NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [ZIAES045004, Z01ES045004] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Alpha-Tocopherol Beta Carotene Cancer Prevention Study Group, 1994, N Engl J Med, V330, P1029, DOI 10.1056/NEJM199404143301501; *AM CANC SOC, 2000, ACS CANC FACTS FIG; AMES BN, 1995, P NATL ACAD SCI USA, V92, P5258, DOI 10.1073/pnas.92.12.5258; AMES BN, 1990, P NATL ACAD SCI USA, V87, P7772, DOI 10.1073/pnas.87.19.7772; AMES BN, 1987, SCIENCE, V236, P271, DOI 10.1126/science.3563506; Ames BN, 2000, MUTAT RES-FUND MOL M, V447, P3, DOI 10.1016/S0027-5107(99)00194-3; AMES BN, 1990, MED ONCOL TUMOR PHAR, V7, P69; Ames BN, 1997, FASEB J, V11, P1041, DOI 10.1096/fasebj.11.13.9367339; AMES BN, 1990, P NATL ACAD SCI USA, V87, P7777, DOI 10.1073/pnas.87.19.7777; Ames BN, 1997, ENVIRON HEALTH PERSP, V105, P865, DOI 10.2307/3433296; AMES BN, 1976, SCREENING TESTS CHEM, V12, P493; Bailar JC, 1997, NEW ENGL J MED, V336, P1569, DOI 10.1056/NEJM199705293362206; Bartsch H, 1996, EUR J CANCER PREV, V5, P11, DOI 10.1097/00008469-199609001-00003; BLUM A, 1977, SCIENCE, V195, P17, DOI 10.1126/science.831254; DOLL R, 1981, JNCI-J NATL CANCER I, V66, P1191, DOI 10.1093/jnci/66.6.1192; Doll R, 1967, PREVENTION CANC POIN; *EPA, 1997, CHEM PROG, V18, P1; FUNG VA, 1993, FUND APPL TOXICOL, V20, P413, DOI 10.1006/faat.1993.1053; FUNG VA, 1995, ENVIRON HEALTH PERSP, V103, P680, DOI 10.2307/3432858; Gold L.S., 1997, HDB CARCINOGENIC POT; GOLD LS, 1992, SCIENCE, V258, P261, DOI 10.1126/science.1411524; GOLD LS, 1984, ENVIRON HEALTH PERSP, V58, P9, DOI 10.2307/3429857; Gold LS, 1998, DRUG METAB REV, V30, P359, DOI 10.3109/03602539808996318; Greenlee RT, 2000, CA-CANCER J CLIN, V50, P7, DOI 10.3322/canjclin.50.1.7; Herbst A. L., 1981, DEV EFFECTS DIETHYLS; HIGGINSON J, 1979, JNCI-J NATL CANCER I, V63, P1291; Huff J, 1999, CARCINOGENICITY, P21; HUFF J, 1993, ENVIRON HEALTH PERSP, V100, P201, DOI 10.2307/3431526; HUFF JE, 1994, CARCINOGENESIS, P35; *IARC, 1987, MON EV CARC RISK H S, V7; IARC, 1993, IARC MON EV CARC RIS, V56; *IARC, 1995, MON EV CARC RISK HUM, V63; *IARC PREAMBL, 2000, IARC MON EV CARC RIS, V77; Jasny BR, 1998, SCIENCE, V280, P1507; McCann J., 1977, ORIGINS HUMAN CANCER, P1431; McMichael AJ, 1992, IARC SCI PUBL, V116; National Toxicology Program, 2000, 9 NAT TOX PROGR; NRC National Research Council, 1993, PEST DIETS INF CHILD; Omenn GS, 1996, NEW ENGL J MED, V334, P1150, DOI 10.1056/NEJM199605023341802; PETO R, 1984, ENVIRON HEALTH PERSP, V58, P1, DOI 10.2307/3429856; SCHMAHL D, 1989, KLIN WOCHENSCHR, V67, P1169, DOI 10.1007/BF01716203; SUGIMURA T, 1992, SCIENCE, V258, P603, DOI 10.1126/science.1411570; TOMATIS L, 1993, NEW FRONTIERS IN CANCER CAUSATION, P371; Tomatis L, 1997, CARCINOGENESIS, V18, P97, DOI 10.1093/carcin/18.1.97; TOMATIS L, 1979, ANNU REV PHARMACOL, V19, P511, DOI 10.1146/annurev.pa.19.040179.002455; TOMATIS L, 1990, IARC SCI PUB, V100; Wingo PA, 1999, J NATL CANCER I, V91, P675, DOI 10.1093/jnci/91.8.675; WYNDER EL, 1977, JNCI-J NATL CANCER I, V58, P825, DOI 10.1093/jnci/58.4.825; 1990, WASHINGTON POST 0831, pA3; 1991, FOOD CHEM NEWS  0805, P6; 1993, FORBES          1025, P104; 1991, FOOD CHEM NEWS  0826, P23; 1990, BUSINESS WEEK   1015, P58	53	36	36	1	14	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2001	15	1					195	203		10.1096/fj.99-1056com	http://dx.doi.org/10.1096/fj.99-1056com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	390TH	11149907				2022-12-25	WOS:000166312400028
J	Rodicio, R; Strauss, A; Heinisch, JJ				Rodicio, R; Strauss, A; Heinisch, JJ			Single point mutations in either gene encoding the subunits of the heterooctameric yeast phosphofructokinase abolish allosteric inhibition by ATP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; FRUCTOSE 2,6-BISPHOSPHATE; ESCHERICHIA-COLI; MUTANTS; SITES; DUPLICATION; ACTIVATION; DISRUPTION	Yeast phosphofructokinase is a heterooctameric enzyme subject to a complex allosteric regulation. A mutation in the PFK1 gene, encoding the larger cy-subunits, rendering the enzyme insensitive to allosteric inhibition by ATP was found to be caused by an exchange of proline 728 for a leucine residue. By in vitro mutagenesis, we introduced this mutation in either PFK1 or PFK2 and found that the exchange in either subunit drastically reduced the sensitivity of the holoenzyme to ATP inhibition. This was accompanied by a lack of allosteric activation by AMP, fructose a,6-bisphosphate, or ammonium and an increased resistance to heat inactivation. Yeast cells carrying either one mutation or both in conjunction did not display a strong phenotype when grown on fermentable carbon sources and did not show any significant changes in intermediary metabolites. Growth on non-fermentable carbon sources was clearly impaired. The strain carrying both mutant alleles was more sensitive to Congo Red than the wildtype strain or the single mutants indicating differences in cell wall composition. In addition, we found single pfk null mutants to be less viable than wild type at different storage temperatures and a pfk2 null mutant to be temperature-sensitive for growth at 37 degreesC. The latter mutant was shown to be respiration-dependent for growth on glucose.	Univ Dusseldorf, Inst Mikrobiol, D-40225 Dusseldorf, Germany; Univ Oviedo, Dept Bioquim & Biol Mol, E-33006 Oviedo, Spain	Heinrich Heine University Dusseldorf; University of Oviedo	Heinisch, JJ (corresponding author), Univ Dusseldorf, Inst Mikrobiol, Univ Str 1,Gebaude 26-12, D-40225 Dusseldorf, Germany.		Heinisch, Juergen J./G-3801-2017	Rodicio Rodicio, Rosaura/0000-0002-3862-9619				ARVANITIDIS A, 1994, J BIOL CHEM, V269, P8911; AVIGAD G, 1981, BIOCHEM BIOPH RES CO, V102, P985, DOI 10.1016/0006-291X(81)91635-1; BANUELOS M, 1977, J BIOL CHEM, V252, P6394; BERBEN G, 1991, YEAST, V7, P475, DOI 10.1002/yea.320070506; CLIFTON D, 1982, BIOCHEMISTRY-US, V21, P1935, DOI 10.1021/bi00537a037; CLIFTON D, 1978, GENETICS, V88, P1; EBERHARDT I, 1995, CURR GENET, V27, P306, DOI 10.1007/BF00352097; EVANS PR, 1979, NATURE, V279, P500, DOI 10.1038/279500a0; FRENZEL J, 1984, BIOMED BIOCHIM ACTA, V43, P413; GALAZZO JL, 1990, ENZYME MICROB TECH, V12, P162, DOI 10.1016/0141-0229(90)90033-M; GANCEDO JM, 1973, BIOCHIMIE, V55, P205, DOI 10.1016/S0300-9084(73)80393-1; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; Gonzalez B, 1997, YEAST, V13, P1347, DOI 10.1002/(SICI)1097-0061(199711)13:14<1347::AID-YEA176>3.0.CO;2-O; HEINISCH J, 1989, GENE, V78, P309; HEINISCH J, 1986, CURR GENET, V11, P227, DOI 10.1007/BF00420611; HEINISCH JJ, 1993, YEAST, V9, P1103, DOI 10.1002/yea.320091010; Heinisch JJ, 1996, J BIOL CHEM, V271, P15928, DOI 10.1074/jbc.271.27.15928; Kirchberger J, 1999, BIOCHEM J, V341, P15, DOI 10.1042/0264-6021:3410015; KLEBE RJ, 1983, GENE, V25, P333, DOI 10.1016/0378-1119(83)90238-X; KOPPERSCHLAGER G, 1993, EUR J BIOCHEM, V217, P527, DOI 10.1111/j.1432-1033.1993.tb18273.x; KOPPERSCHLAGER G, 1977, EUR J BIOCHEM, V81, P317, DOI 10.1111/j.1432-1033.1977.tb11954.x; KOPPERSCHLAGER G, 1982, ANAL BIOCHEM, V124, P117, DOI 10.1016/0003-2697(82)90228-7; Kopperschlager G, 1997, YEAST SUGAR METABOLI, P97; KRETSCHMER M, 1991, EUR J BIOCHEM, V197, P367, DOI 10.1111/j.1432-1033.1991.tb15920.x; LAURENT M, 1978, BIOCHEM BIOPH RES CO, V80, P646, DOI 10.1016/0006-291X(78)91617-0; LISOWSKY T, 1988, MOL GEN GENET, V214, P218, DOI 10.1007/BF00337714; LLOYD D, 1992, YEAST, V8, P291, DOI 10.1002/yea.320080406; LOBO Z, 1982, FEBS LETT, V139, P93, DOI 10.1016/0014-5793(82)80494-8; LOBO Z, 1983, J BIOL CHEM, V258, P1444; NADKARNI M, 1984, FEBS LETT, V175, P294, DOI 10.1016/0014-5793(84)80754-1; NISSLER K, 1983, BIOCHEM BIOPH RES CO, V111, P294, DOI 10.1016/S0006-291X(83)80150-8; Obmolova G, 1998, ACTA CRYSTALLOGR D, V54, P96, DOI 10.1107/S0907444997007555; Palkova Z, 1997, NATURE, V390, P532, DOI 10.1038/37398; POORMAN RA, 1984, NATURE, V309, P467, DOI 10.1038/309467a0; RABEN N, 1995, AM J HUM GENET, V56, P131; RILEY BB, 1990, P NATL ACAD SCI USA, V87, P4746, DOI 10.1073/pnas.87.12.4746; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; Sambrook J., 2002, MOL CLONING LAB MANU; SCHIRMER T, 1990, NATURE, V343, P140, DOI 10.1038/343140a0; Sherman F., 1983, LAB MANUAL; SHIRAKIHARA Y, 1988, J MOL BIOL, V204, P973, DOI 10.1016/0022-2836(88)90056-3; SOLS A, 1981, CURR TOP CELL REGUL, V19, P77; Varon M, 2000, J BACTERIOL, V182, P3877, DOI 10.1128/JB.182.13.3877-3880.2000; WESTERHOFF HV, 1995, TRENDS BIOTECHNOL, V13, P242, DOI 10.1016/S0167-7799(00)88955-6; ZIMMERMANN FK, 1977, MOL GEN GENET, V154, P75, DOI 10.1007/BF00265579	45	27	32	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 29	2000	275	52					40952	40960		10.1074/jbc.M007131200	http://dx.doi.org/10.1074/jbc.M007131200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	387GJ	11221662	hybrid			2022-12-25	WOS:000166114600040
J	Reinstein, E; Scheffner, M; Oren, M; Ciechanover, A; Schwartz, A				Reinstein, E; Scheffner, M; Oren, M; Ciechanover, A; Schwartz, A			Degradation of the E7 human papillomavirus oncoprotein by the ubiquitin-proteasome system: targeting via ubiquitination of the N-terminal residue	ONCOGENE			English	Article						human papilloma-virus (HPV); E7; ubiquitin; proteolysis; N-terminus	TRANSGENIC MICE; END RULE; TYPE-16; PROTEIN; EXPRESSION; GENE; E6; TRANSFORMATION; CONJUGATION; CELLS	The E7 oncoprotein of the high risk human papillomavirus type 16 (HPV-16), which is etiologically associated with uterine cervical cancer, is a potent immortalizing and transforming agent, It probably exerts its oncogenic functions by interacting and altering the normal activity of cell cycle control proteins such as p21(WAF1), p27(KIP1) pRb, transcriptional activators such as TBP and AP-1, and metabolic regulators such as M2-pyruvate kinase (M2-PK), Here we show that E7 is a short-lived protein and its degradation both in vitro and in vivo is mediated by the ubiquitin-proteasome pathway. interestingly; ubiquitin does not attach to any of the two internal Lysine residues of E7, Substitution of these residues with Arg does not affect the ability of the protein to be conjugated and degraded; in contrast, addition of a MSc tag to the N-terminal but not to the C-terminal residue, stabilizes the protein. Also, deletion of the first If amino acid residues stabilizes the protein in cells, Taken together, these findings strongly suggest that, like MyoD and the Epstein Barr Virus (EBV) transforming Latent Membrane Protein 1 (LMP1), the first ubiquitin moiety is attached linearly to the free N-terminal residue of E7, Additional ubiquitin moieties are then attached to an internal Lys residue of the previously conjugated molecule, The involvement of E7 in many diverse and apparently unrelated processes requires tight regulation of its function and cellular level, which is controlled in this case by ubiquitin-mediated proteolysis.	Technion Israel Inst Technol, Bruce Rappaport Fac Med, Dept Biochem, IL-30196 Haifa, Israel; Technion Israel Inst Technol, Bruce Rappaport Fac Med, Rappaport Family Inst Res Med Sci, IL-30196 Haifa, Israel; Univ Cologne, Fak Med, Inst Biochem, D-50931 Cologne, Germany; Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel; Washington Univ, Sch Med, Dept Pediat, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Mol Biol & Pharmacol, St Louis, MO 63110 USA; St Louis Childrens Hosp, St Louis, MO 63110 USA	Technion Israel Institute of Technology; Rappaport Faculty of Medicine; Technion Israel Institute of Technology; Rappaport Faculty of Medicine; University of Cologne; Weizmann Institute of Science; Washington University (WUSTL); Washington University (WUSTL); St. Louis Children's Hospital; Washington University (WUSTL)	Ciechanover, A (corresponding author), Technion Israel Inst Technol, Bruce Rappaport Fac Med, Dept Biochem, POB 9649,Efron St, IL-30196 Haifa, Israel.		高, 雨莉/HGU-8187-2022; Ciechanover, Aaron J/C-9166-2017; Scheffner, Martin/K-2940-2012	Scheffner, Martin/0000-0003-2229-0128; Oren, Moshe/0000-0003-4311-7172				Antinore MJ, 1996, EMBO J, V15, P1950, DOI 10.1002/j.1460-2075.1996.tb00546.x; ARBEIT JM, 1993, AM J PATHOL, V142, P1187; ARROYO M, 1993, MOL CELL BIOL, V13, P6537, DOI 10.1128/MCB.13.10.6537; AUEWARAKUL P, 1994, MOL CELL BIOL, V14, P8250, DOI 10.1128/MCB.14.12.8250; Aviel S, 2000, J BIOL CHEM, V275, P23491, DOI 10.1074/jbc.M002052200; BLUMENFELD N, 1994, J BIOL CHEM, V269, P9574; BOISSEL JP, 1988, J BIOL CHEM, V263, P8443; Boyer SN, 1996, CANCER RES, V56, P4620; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Breitschopf K, 1998, EMBO J, V17, P5964, DOI 10.1093/emboj/17.20.5964; CHEN LP, 1993, P NATL ACAD SCI USA, V90, P6523, DOI 10.1073/pnas.90.14.6523; CROOK T, 1989, EMBO J, V8, P513, DOI 10.1002/j.1460-2075.1989.tb03405.x; DAVIES R, 1993, J VIROL, V67, P2521, DOI 10.1128/JVI.67.5.2521-2528.1993; Funk JO, 1997, GENE DEV, V11, P2090, DOI 10.1101/gad.11.16.2090; Govers R, 1999, EMBO J, V18, P28, DOI 10.1093/emboj/18.1.28; GREENHALGH DA, 1994, CELL GROWTH DIFFER, V5, P667; HAWLEYNELSON P, 1989, EMBO J, V8, P3905, DOI 10.1002/j.1460-2075.1989.tb08570.x; HERSHKO A, 1985, BIOCHEM BIOPH RES CO, V128, P1079, DOI 10.1016/0006-291X(85)91050-2; HERSHKO A, 1983, J BIOL CHEM, V258, P8206; HERSHKO A, 1987, P NATL ACAD SCI USA, V84, P1829, DOI 10.1073/pnas.84.7.1829; HU TH, 1995, INT J ONCOL, V6, P167; HUANG S, 1987, BIOCHEMISTRY-US, V26, P8242, DOI 10.1021/bi00399a033; JOHNSTON NL, 1991, BIOCHEMISTRY-US, V30, P7514, DOI 10.1021/bi00244a021; JORNVALL H, 1975, J THEOR BIOL, V55, P1, DOI 10.1016/S0022-5193(75)80105-6; KANDA T, 1988, J VIROL, V62, P610, DOI 10.1128/JVI.62.2.610-613.1988; Kornitzer D, 2000, J CELL PHYSIOL, V182, P1, DOI 10.1002/(SICI)1097-4652(200001)182:1<1::AID-JCP1>3.0.CO;2-V; MUNGER K, 1989, J VIROL, V63, P4417; Orian A, 2000, EMBO J, V19, P2580, DOI 10.1093/emboj/19.11.2580; PAN HC, 1994, GENE DEV, V8, P1285, DOI 10.1101/gad.8.11.1285; PHELPS WC, 1988, CELL, V53, P539, DOI 10.1016/0092-8674(88)90570-3; Polevoda B, 1999, EMBO J, V18, P6155, DOI 10.1093/emboj/18.21.6155; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SELVEY LA, 1994, J GEN VIROL, V75, P1647, DOI 10.1099/0022-1317-75-7-1647; Sheaff RJ, 2000, MOL CELL, V5, P403, DOI 10.1016/S1097-2765(00)80435-9; Varshavsky A, 1996, P NATL ACAD SCI USA, V93, P12142, DOI 10.1073/pnas.93.22.12142; Voges D, 1999, ANNU REV BIOCHEM, V68, P1015, DOI 10.1146/annurev.biochem.68.1.1015; Yu H, 1999, J BIOL CHEM, V274, P36852, DOI 10.1074/jbc.274.52.36852; ZerfassThome K, 1996, ONCOGENE, V13, P2323; Zwerschke W, 1999, P NATL ACAD SCI USA, V96, P1291, DOI 10.1073/pnas.96.4.1291	39	149	157	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 30	2000	19	51					5944	5950		10.1038/sj.onc.1203989	http://dx.doi.org/10.1038/sj.onc.1203989			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	378CA	11127826				2022-12-25	WOS:000165563100014
J	Farrant, RD; Walker, V; Mills, GA; Mellor, JM; Langley, GJ				Farrant, RD; Walker, V; Mills, GA; Mellor, JM; Langley, GJ			Pyridoxal phosphate de-activation by pyrroline-5-carboxylic acid - Increased risk of vitamin B-6 deficiency and seizures in hyperprolinemia type II	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUTAMIC GAMMA-SEMIALDEHYDE; DELTA-1-PYRROLINE-5-CARBOXYLIC ACID; 5-CARBOXYLATE DEHYDROGENASE; PYRROLINE 5-CARBOXYLATE; DIFFUSION; IDENTIFICATION; SPECTROSCOPY; PURIFICATION; PROLINE; LIVER	We previously identified vitamin B-6 deficiency in a child presenting with seizures whose primary diagnosis was the inherited disorder hyperprolinemia type II. This is an unrecognized association, which was not explained by diet or medication. We hypothesized that pyridoxal phosphate (vitamin B-6 coenzyme) was de-activated by L-Delta (1)-pyrroline-5-carboxylic acid, the major intermediate that accumulates endogenously in hyperprolinemia type II. The proposed interaction has now been investigated in vitro with high resolution H-1 nuclear magnetic resonance spectroscopy and mass spectrometry at a pH of 7.4 and temperature of 310 K. Three novel adducts were identified. These were the result of a Claisen condensation (or Knoevenagel type of reaction) of the activated C-4 carbon of the pyrroline ring with the aldehyde carbon of pyridoxal phosphate. The structures of the adducts were confirmed by a combination of high performance liquid chromatography, nuclear magnetic resonance, and mass spectrometry. This interaction has not been reported before. From preliminary observations, pyrroline-5-carboxylic acid also condenses with other aromatic and aliphatic aldehydes and ketones, and this may be a previously unsuspected generic addition reaction. Pyrroline-5 carboxylic acid is thus found to be a unique endogenous vitamin antagonist. Vitamin B-6 de-activation may contribute to seizures in hyperprolinemia type II, which are so far unexplained, but they may be preventable with long term vitamin B-6 supplementation.	Glaxo Wellcome Med Res Ctr, Stevenage SG1 2NY, Herts, England; Southampton Gen Hosp, Dept Chem Pathol, Southampton SO16 6YD, Hants, England; Univ Portsmouth, Sch Pharm & Biomed Sci, Portsmouth PO1 2DT, Hants, England; Univ Southampton, Dept Chem, Southampton SO17 1BJ, Hants, England	GlaxoSmithKline; University of Southampton; University of Portsmouth; University of Southampton	Farrant, RD (corresponding author), Glaxo Wellcome Med Res Ctr, Gunnels Wood Rd, Stevenage SG1 2NY, Herts, England.	rdf17079@glaxowellcome.co.uk	Langley, Graham J/B-5320-2008	Langley, Graham J/0000-0002-8323-7235				ALVAREZ FG, 1995, INTENS CARE MED, V21, P641, DOI 10.1007/BF01711541; BARJAT H, 1995, J MAGN RESON SER B, V108, P170, DOI 10.1006/jmrb.1995.1118; Bates CJ, 1997, ANN CLIN BIOCHEM, V34, P599, DOI 10.1177/000456329703400604; BOSRON WF, 1978, J BIOL CHEM, V253, P1488; Coburn S P, 1996, Adv Food Nutr Res, V40, P107, DOI 10.1016/S1043-4526(08)60023-6; COBURN SP, 1981, J NUTR, V111, P391, DOI 10.1093/jn/111.2.391; DARNELL J, 1986, MOL CELL BIOL, P32; EBADI M, 1986, COENZYMES COFACTOR B, V1, P449; Emery F A, 1968, J Ment Defic Res, V12, P187; FLEMING GA, 1984, METABOLISM, V33, P739, DOI 10.1016/0026-0495(84)90215-4; FLYNN MP, 1989, ARCH DIS CHILD, V64, P1699, DOI 10.1136/adc.64.12.1699; FORTEMCROBBIE CM, 1986, J BIOL CHEM, V261, P2154; Geraghty MT, 1998, HUM MOL GENET, V7, P1411, DOI 10.1093/hmg/7.9.1411; GIBBS SJ, 1991, J MAGN RESON, V93, P395, DOI 10.1016/0022-2364(91)90014-K; GYORGY P, 1968, VITAMINS, V2, P90; HAGEDORN CH, 1986, ARCH BIOCHEM BIOPHYS, V248, P166, DOI 10.1016/0003-9861(86)90413-3; HOLTZ P, 1964, PHARMACOL REV, V16, P113; INK SL, 1984, ANNU REV NUTR, V4, P455, DOI 10.1146/annurev.nu.04.070184.002323; KLOSTERMAN HJ, 1986, COENZYMES COFACTORS, V1, P392; KLOSTERMAN HJ, 1979, METHOD ENZYMOL, V72, P483; MCCOY EE, 1986, COENZYMES COFACTORS, V1, P573; MEZL VA, 1976, ANAL BIOCHEM, V74, P430, DOI 10.1016/0003-2697(76)90223-2; MINNS R, 1980, DEV MED CHILD NEUROL, V22, P795; Nabbout R, 1999, ARCH DIS CHILD-FETAL, V81, pF125, DOI 10.1136/fn.81.2.F125; NICHOLSON JK, 1995, ANAL CHEM, V67, P793, DOI 10.1021/ac00101a004; RICHTER W, 1967, HELV CHIM ACTA, V50, P364, DOI 10.1002/hlca.19670500204; SAUBERLICH HE, 1968, VITAMINS, V2, P33; SIMILA S, 1970, Annals of Clinical Research, V2, P143; SMALL WC, 1990, J BIOL CHEM, V265, P18668; SNELL EE, 1968, PYRIDOXAL CATALYSIS, P770; STEJSKAL EO, 1965, J CHEM PHYS, V42, P288, DOI 10.1063/1.1695690; Stott K, 1997, J MAGN RESON, V125, P302, DOI 10.1006/jmre.1997.1110; STRECKER HJ, 1960, J BIOL CHEM, V235, P3218; Stryer L., 1988, BIOCHEMISTRY-US, P496; TRYFIATES GP, 1986, COENZYMES COFACTOR B, V1, P421; Valle, 1995, METABOLIC MOL BASES, P1125; VOGEL HJ, 1952, J AM CHEM SOC, V74, P109, DOI 10.1021/ja01121a025; WAJNER M, 1990, CLIN GENET, V37, P485; Walker V, 2000, ARCH DIS CHILD, V82, P236, DOI 10.1136/adc.82.3.236; YEH GC, 1988, J BIOL CHEM, V263, P13083	40	77	78	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 4	2001	276	18					15107	15116		10.1074/jbc.M010860200	http://dx.doi.org/10.1074/jbc.M010860200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	429QQ	11134058	hybrid			2022-12-25	WOS:000168528800078
J	Huang, LM; Chao, MF; Chen, MY; Shih, HM; Chiang, YP; Chuang, CY; Lee, CY				Huang, LM; Chao, MF; Chen, MY; Shih, HM; Chiang, YP; Chuang, CY; Lee, CY			Reciprocal regulatory interaction between human herpesvirus 8 and human immunodeficiency virus type 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SARCOMA-ASSOCIATED HERPESVIRUS; PRIMARY EFFUSION LYMPHOMA; KAPOSIS-SARCOMA; DNA-SEQUENCES; TAT PROTEIN; T-CELLS; HIV-1; AIDS; IDENTIFICATION; EPIDEMIOLOGY	Human herpesvirus 8 (HHV8) is the primary viral etiologic agent in Kaposi's sarcoma (KS). However, individuals dually infected with both HHV8 and human immunodeficiency virus type 1 (HIV-1) show an enhanced prevalence of KS when compared with those singularly infected with HHV8. Host immune suppression conferred by HIV infection cannot wholly explain this increased presentation of KS. To better understand how HHV8 and HIV 1 might interact directly in the pathogenesis of KS, we queried for potential regulatory interactions between the two viruses. Here, we report that HHV8 and HIV-1 reciprocally up-regulate the gene expression of each other. We found that the KIE2 immediate-early gene product of HHV8 interacted synergistically with Tat in activating expression from the HIV-1 long terminal repeat. On the other hand, HIV-1 encoded Tat and Vpr proteins increased intracellular HHV8-specific expression. These results provide molecular insights correlating coinfection with HHV8 and HIV-1 with an unusually high incidence of KS.	Natl Taiwan Univ Hosp, Dept Pediat, Taipei 100, Taiwan; Natl Taiwan Univ Hosp, Dept Internal Med, Taipei 100, Taiwan; Natl Hlth Res Inst, Div Mol & Genom Med, Taipei 100, Taiwan	National Taiwan University; National Taiwan University Hospital; National Taiwan University; National Taiwan University Hospital; National Health Research Institutes - Taiwan	Huang, LM (corresponding author), Natl Taiwan Univ Hosp, Dept Pediat, 7 Chung Shan S Rd, Taipei 100, Taiwan.	lmhuang@ha.mc.ntu.edu.tw	Shih, Hsiu-Ming/S-7023-2018	LEE, CHIN-YUN/0000-0002-3938-377X; HUANG, LI-MIN/0000-0002-9291-260X				Asada H, 1999, J VIROL, V73, P4019, DOI 10.1128/JVI.73.5.4019-4028.1999; BERAL V, 1990, LANCET, V335, P123, DOI 10.1016/0140-6736(90)90001-L; Biggar RJ, 1996, HEMATOL ONCOL CLIN N, V10, P997, DOI 10.1016/S0889-8588(05)70380-4; Blauvelt A, 1999, Adv Dermatol, V14, P167; Boccuni MC, 1998, AIDS, V12, P365, DOI 10.1097/00002030-199804000-00004; Buonaguro FM, 1996, INT J CANCER, V65, P25, DOI 10.1002/(SICI)1097-0215(19960103)65:1&lt;25::AID-IJC5&gt;3.0.CO;2-3; BUONAGURO L, 1994, ANTIBIOT CHEMOTHER, V46, P62; CARRIGAN DR, 1990, J INFECT DIS, V162, P844, DOI 10.1093/infdis/162.4.844; Cathomas G, 2000, VIRCHOWS ARCH, V436, P195, DOI 10.1007/s004280050031; Cathomas G, 1996, J CLIN PATHOL, V49, P631, DOI 10.1136/jcp.49.8.631; CESARMAN E, 1995, NEW ENGL J MED, V332, P1186, DOI 10.1056/NEJM199505043321802; CHANG Y, 1994, SCIENCE, V266, P1865, DOI 10.1126/science.7997879; CLOUSE KA, 1989, J IMMUNOL, V142, P431; Conti L, 2000, J VIROL, V74, P10207, DOI 10.1128/JVI.74.21.10207-10211.2000; Crowley RW, 1996, J IMMUNOL, V156, P2004; ENSOLI B, 1994, NATURE, V371, P674, DOI 10.1038/371674a0; ENSOLI B, 1991, HEMATOL ONCOL CLIN N, V5, P281, DOI 10.1016/S0889-8588(18)30441-6; Flore O, 1997, AIDS RES HUM RETROV, V13, P1229, DOI 10.1089/aid.1997.13.1229; FOLKS TM, 1989, P NATL ACAD SCI USA, V86, P2365, DOI 10.1073/pnas.86.7.2365; Foreman K, 1999, J INVEST DERMATOL, V112, P603; GENG YQ, 1992, J VIROL, V66, P1564, DOI 10.1128/JVI.66.3.1564-1570.1992; Graves JD, 1998, EMBO J, V17, P2224, DOI 10.1093/emboj/17.8.2224; Guan MX, 1996, J VIROL, V70, P7341, DOI 10.1128/JVI.70.10.7341-7346.1996; Harrington W, 1997, LANCET, V349, P774; HUANG YQ, 1995, LANCET, V345, P759, DOI 10.1016/S0140-6736(95)90641-X; Iscovich J, 2000, CANCER-AM CANCER SOC, V88, P500, DOI 10.1002/(SICI)1097-0142(20000201)88:3<500::AID-CNCR3>3.3.CO;2-0; Jacobson LP, 2000, J INFECT DIS, V181, P1940, DOI 10.1086/315503; Jeang KT, 1999, J BIOL CHEM, V274, P28837, DOI 10.1074/jbc.274.41.28837; JEANG KT, 1988, J VIROL, V62, P3874, DOI 10.1128/JVI.62.10.3874-3878.1988; Kelly GO, 1998, AIDS, V12, P1753, DOI 10.1097/00002030-199814000-00006; Kim JM, 2000, J GEN VIROL, V81, P37, DOI 10.1099/0022-1317-81-1-37; Li LH, 1999, GENE THER, V6, P364, DOI 10.1038/sj.gt.3300828; Martin JC, 1999, J ACQ IMMUN DEF SYND, V22, P413; Martin JN, 1998, NEW ENGL J MED, V338, P948, DOI 10.1056/NEJM199804023381403; Mercader M, 2000, AM J PATHOL, V156, P1961, DOI 10.1016/S0002-9440(10)65069-9; Moir S, 1999, J VIROL, V73, P7972, DOI 10.1128/JVI.73.10.7972-7980.1999; MOORE PS, 1995, NEW ENGL J MED, V332, P1181, DOI 10.1056/NEJM199505043321801; Morini M, 2000, BIOCHEM BIOPH RES CO, V273, P267, DOI 10.1006/bbrc.2000.2941; MOSES SV, 1999, J ACQ IMMUN DEF SYND, V21, pA28; Nador RG, 1996, BLOOD, V88, P645, DOI 10.1182/blood.V88.2.645.bloodjournal882645; NAKAMURA S, 1988, SCIENCE, V242, P426, DOI 10.1126/science.3262925; Noel JC, 1996, CANCER, V77, P2132, DOI 10.1002/(SICI)1097-0142(19960515)77:10<2132::AID-CNCR26>3.0.CO;2-V; NOORE PS, 1996, J VIROL, V70, P549; POMERANTZ RJ, 1990, CELL, V61, P1271, DOI 10.1016/0092-8674(90)90691-7; Quinto I, 1999, J BIOL CHEM, V274, P17567, DOI 10.1074/jbc.274.25.17567; Renne R, 1996, J VIROL, V70, P8151, DOI 10.1128/JVI.70.11.8151-8154.1996; Renne R, 1996, NAT MED, V2, P342, DOI 10.1038/nm0396-342; Romano G, 1997, VIROLOGY, V237, P23, DOI 10.1006/viro.1997.8764; Russo JJ, 1996, P NATL ACAD SCI USA, V93, P14862, DOI 10.1073/pnas.93.25.14862; Sarid R, 1999, ADV VIRUS RES, V52, P139, DOI 10.1016/S0065-3527(08)60299-7; Secchiero P, 1998, BLOOD, V92, P4521, DOI 10.1182/blood.V92.12.4521.424k38_4521_4528; SOULIER J, 1995, BLOOD, V86, P1276, DOI 10.1182/blood.V86.4.1276.bloodjournal8641276; Varthakavi V, 1999, J VIROL, V73, P10329, DOI 10.1128/JVI.73.12.10329-10338.1999; Weiss RA, 2000, TROP MED INT HEALTH, V5, pA10, DOI 10.1046/j.1365-3156.2000.00591.x; Yurochko AD, 1999, J HUMAN VIROL, V2, P81; Zhu FX, 1999, J VIROL, V73, P5556, DOI 10.1128/JVI.73.7.5556-5567.1999	56	67	81	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 20	2001	276	16					13427	13432		10.1074/jbc.M011314200	http://dx.doi.org/10.1074/jbc.M011314200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	423VN	11154704	hybrid			2022-12-25	WOS:000168198600131
J	Egawa, K; Maegawa, H; Shimizu, S; Morino, K; Nishio, Y; Bryer-Ash, M; Cheung, AT; Kolls, JK; Kikkawa, R; Kashiwagi, A				Egawa, K; Maegawa, H; Shimizu, S; Morino, K; Nishio, Y; Bryer-Ash, M; Cheung, AT; Kolls, JK; Kikkawa, R; Kashiwagi, A			Protein-tyrosine phosphatase-1B negatively regulates insulin signaling in L6 myocytes and Fao hepatoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SKELETAL-MUSCLE; RECEPTOR SUBSTRATE-1; INCREASED ABUNDANCE; GLUCOSE-TRANSPORT; ADIPOSE-TISSUE; RESISTANT; MICE; SENSITIVITY; ADIPOCYTES; OBESITY	Insulin signaling is regulated by tyrosine phosphorylation of the signaling molecules, such as the insulin receptor and insulin receptor substrates (IRSs), Therefore, the balance between protein-tyrosine kinases and protein-tyrosine phosphatase activities is thought to be important in the modulation of insulin signaling in insulin-resistant states. We thus employed the adenovirus-mediated gene transfer technique, and we analyzed the effect of overexpression of a wild-type protein-tyrosine phosphatase-1B (PTP1B) on insulin signaling in both L6 myocytes and Fao cells. In both cells, PTP1B overexpression blocked insulin-stimulated tyrosine phosphorylation of the insulin receptor and IRS-1 by more than 70% and resulted in a significant inhibition of the association between IRS-1 and the p85 subunit of phosphatidylinositol 3-kinase and Akt phosphorylation as well as mitogen-activated protein kinase phosphorylation, Moreover, insulin-stimulated glycogen synthesis was also inhibited by PTP1B overexpression in both cells. These effects were specific for insulin signaling, because platelet-derived growth factor (PDGF)-stimulated PDGF receptor tyrosine phosphorylation and Akt phosphorylation were not inhibited by PTP1B overexpression. The present findings demonstrate that PTP1B negatively regulates insulin signaling in L6 and Fao cells, suggesting that PTP1B plays an important role in insulin resistance in muscle and liver.	Shiga Univ Med Sci, Dept Med 3, Otsu, Shiga 5202192, Japan; Univ Tennessee, Dept Med, Memphis, TN 38104 USA; Vet Affairs Med Ctr, Res Serv, Memphis, TN 38104 USA; Tulane Univ, Dept Physiol, New Orleans, LA 70112 USA; Louisiana State Univ, Dept Med, New Orleans, LA 70112 USA	Shiga University of Medical Science; University of Tennessee System; University of Tennessee Health Science Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); Memphis VA Medical Center; Tulane University; Louisiana State University System	Maegawa, H (corresponding author), Shiga Univ Med Sci, Dept Med 3, Otsu, Shiga 5202192, Japan.		Kashiwagi, Atsunori/H-8712-2019; Kolls, Jay/AAH-1829-2019; MORINO, KATSUTARO/I-3207-2019	Kolls, Jay/0000-0001-5151-6304; MORINO, KATSUTARO/0000-0003-2420-3817; Maegawa, Hiroshi/0000-0002-4611-8149	NCRR NIH HHS [RR-00211] Funding Source: Medline	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Ahmad F, 1997, METABOLISM, V46, P1140, DOI 10.1016/S0026-0495(97)90206-7; Ahmad F, 1997, J CLIN INVEST, V100, P449, DOI 10.1172/JCI119552; AHMAD F, 1995, J CLIN INVEST, V95, P2806, DOI 10.1172/JCI117985; AHMAD F, 1995, METABOLISM, V44, P1175, DOI 10.1016/0026-0495(95)90012-8; Chen H, 1997, J BIOL CHEM, V272, P8026, DOI 10.1074/jbc.272.12.8026; Egawa K, 1999, J BIOL CHEM, V274, P14306, DOI 10.1074/jbc.274.20.14306; Elchebly M, 1999, SCIENCE, V283, P1544, DOI 10.1126/science.283.5407.1544; FRANGIONI JV, 1992, CELL, V68, P545, DOI 10.1016/0092-8674(92)90190-N; FRANGIONI JV, 1993, EMBO J, V12, P4843, DOI 10.1002/j.1460-2075.1993.tb06174.x; Gluzman Y., 1982, EUKARYOTIC VIRAL VEC, P187; Goldstein BJ, 2000, J BIOL CHEM, V275, P4283, DOI 10.1074/jbc.275.6.4283; Kaburagi Y, 1997, J BIOL CHEM, V272, P25839, DOI 10.1074/jbc.272.41.25839; Klaman LD, 2000, MOL CELL BIOL, V20, P5479, DOI 10.1128/MCB.20.15.5479-5489.2000; KOLLS J, 1994, P NATL ACAD SCI USA, V91, P215, DOI 10.1073/pnas.91.1.215; MAEGAWA H, 1986, AM J PHYSIOL, V251, pE616, DOI 10.1152/ajpendo.1986.251.5.E616; MAEGAWA H, 1995, J BIOL CHEM, V270, P7724, DOI 10.1074/jbc.270.13.7724; MCGRORY WJ, 1988, VIROLOGY, V163, P614, DOI 10.1016/0042-6822(88)90302-9; MCGUIRE MC, 1991, DIABETES, V40, P939, DOI 10.2337/diabetes.40.7.939; MEYEROVITCH J, 1989, J CLIN INVEST, V84, P976, DOI 10.1172/JCI114261; Seely BL, 1996, DIABETES, V45, P1379, DOI 10.2337/diabetes.45.10.1379; Venable CL, 2000, J BIOL CHEM, V275, P18318, DOI 10.1074/jbc.M908392199; Wang H, 1999, TALANTA, V48, P1, DOI 10.1016/S0039-9140(97)00360-3; WHITE MF, 1994, J BIOL CHEM, V269, P1; Withers DJ, 1998, NATURE, V391, P900, DOI 10.1038/36116; Yamauchi T, 1996, MOL CELL BIOL, V16, P3074	25	126	134	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 30	2001	276	13					10207	10211		10.1074/jbc.M009489200	http://dx.doi.org/10.1074/jbc.M009489200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	420GC	11136729	hybrid			2022-12-25	WOS:000167996400083
J	Hildebrand, D; Tiefenbach, J; Heinzel, T; Grez, M; Maurer, AB				Hildebrand, D; Tiefenbach, J; Heinzel, T; Grez, M; Maurer, AB			Multiple regions of ETO cooperate in transcriptional repression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACUTE MYELOID-LEUKEMIA; HISTONE DEACETYLASE ACTIVITY; N-COR; SIGNALING PATHWAYS; FUSION TRANSCRIPT; COREPRESSOR; T(8-21); COMPLEX; AML1; PROTEIN	In acute myeloid leukemias (AMLs) with t(8;21), the transcription factor AML1 is juxtaposed to the zinc finger nuclear protein ETO (Eight-Twenty-One), resulting in transcriptional repression of AML1 target genes. ETO has been shown to interact with corepressors, such as N-CoR and mSin3A to form complexes containing histone deacetylases. To define regions of ETO required for maximal repressor activity, we analyzed amino-terminal deletions in a transcriptional repression assay. We found that ETO mutants lacking the first 236 amino acids were not affected in their repressor activity, whereas a further deletion of 85 amino acids drastically reduced repressor function and high molecular weight complex formation. This latter mutant can still homodimerize and bind to N-CoR but shows only weak binding to mSin3A. Furthermore, we could show that a "core repressor domain" comprising nervy homology region 2 and its amino- and carboxyl-terminal flanking sequences recruits mSin3A and induces transcriptional repression. These results suggest that mSin3A and N-CoR bind to ETO independently and that both binding sites cooperate to maximize ETO-mediated transcriptional repression. Thus, ETO has a modular structure, and the interaction between the individual elements is essential for the formation of a stable repressor complex and efficient transcriptional repression.	Inst Biomed Res, D-60596 Frankfurt, Germany		Maurer, AB (corresponding author), Inst Biomed Res, Georg Speyer Haus,Paul Ehrlich Str 42-44, D-60596 Frankfurt, Germany.		Heinzel, Thorsten/B-1013-2015					Alland L, 1997, NATURE, V387, P49, DOI 10.1038/387049a0; ARCHER TK, 1992, SCIENCE, V255, P1573, DOI 10.1126/science.1347958; Ayer DE, 1999, TRENDS CELL BIOL, V9, P193, DOI 10.1016/S0962-8924(99)01536-6; Behre G, 1999, METHODS, V17, P231, DOI 10.1006/meth.1998.0733; Davie JR, 1999, BIOCHEM CELL BIOL, V77, P265, DOI 10.1139/bcb-77-4-265; Dikstein R, 1996, CELL, V87, P137, DOI 10.1016/S0092-8674(00)81330-6; ERICKSON P, 1992, BLOOD, V80, P1825; ERICKSON PF, 1994, CANCER RES, V54, P1782; Gelmetti V, 1998, MOL CELL BIOL, V18, P7185, DOI 10.1128/MCB.18.12.7185; Glass CK, 2000, GENE DEV, V14, P121; Hassig CA, 1998, P NATL ACAD SCI USA, V95, P3519, DOI 10.1073/pnas.95.7.3519; Hassig CA, 1997, CELL, V89, P341, DOI 10.1016/S0092-8674(00)80214-7; Heinzel T, 1997, NATURE, V387, P43, DOI 10.1038/387043a0; HOEY T, 1993, CELL, V72, P247, DOI 10.1016/0092-8674(93)90664-C; Imhof A, 1997, CURR BIOL, V7, P689, DOI 10.1016/S0960-9822(06)00296-X; Kitabayashi I, 1998, EMBO J, V17, P2994, DOI 10.1093/emboj/17.11.2994; Kitabayashi I, 1998, MOL CELL BIOL, V18, P846, DOI 10.1128/MCB.18.2.846; Laherty CD, 1997, CELL, V89, P349, DOI 10.1016/S0092-8674(00)80215-9; Lavinsky RM, 1998, P NATL ACAD SCI USA, V95, P2920, DOI 10.1073/pnas.95.6.2920; Lutterbach B, 1998, MOL CELL BIOL, V18, P7176, DOI 10.1128/MCB.18.12.7176; Lutterbach B, 1998, MOL CELL BIOL, V18, P3604, DOI 10.1128/MCB.18.6.3604; Mao SF, 1999, MOL CELL BIOL, V19, P3635; Melnick AM, 2000, MOL CELL BIOL, V20, P2075, DOI 10.1128/MCB.20.6.2075-2086.2000; Minucci S, 2000, MOL CELL, V5, P811, DOI 10.1016/S1097-2765(00)80321-4; Morohoshi F, 2000, GENE, V241, P287, DOI 10.1016/S0378-1119(99)00481-3; Nagy L, 1997, CELL, V89, P373, DOI 10.1016/S0092-8674(00)80218-4; NUCIFORA G, 1994, LEUKEMIA LYMPHOMA, V14, P353, DOI 10.3109/10428199409049690; NUCIFORA G, 1995, BLOOD, V86, P1; SCHREIBERAGUS N, 1995, CELL, V80, P777, DOI 10.1016/0092-8674(95)90356-9; Wang JX, 1998, P NATL ACAD SCI USA, V95, P10860, DOI 10.1073/pnas.95.18.10860; Xu L, 1999, CURR OPIN GENET DEV, V9, P140, DOI 10.1016/S0959-437X(99)80021-5; Zhang JS, 2001, MOL CELL BIOL, V21, P156, DOI 10.1128/MCB.21.1.156-163.2001	32	76	83	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 30	2001	276	13					9889	9895		10.1074/jbc.M010582200	http://dx.doi.org/10.1074/jbc.M010582200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	420GC	11150306	hybrid			2022-12-25	WOS:000167996400043
J	Kim, SW; Muise, AM; Lyons, PJ; Ro, HS				Kim, SW; Muise, AM; Lyons, PJ; Ro, HS			Regulation of adipogenesis by a transcriptional repressor that modulates MAPK activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE-PHOSPHATASE; KINASE-MEDIATED PHOSPHORYLATION; ADIPOCYTIC DIFFERENTIATION; RECEPTOR-GAMMA; GROWTH-FACTOR; CATALYTIC ACTIVATION; SIGNAL-TRANSDUCTION; RAF-1 KINASE; 3T3-L1 CELLS; PPAR-GAMMA	Mitogen-activated protein kinase (MAPK) is required for cell growth and cell differentiation. In adipogenesis, MAPK activation opposes the differentiation process. The regulatory mechanisms or the cellular factors that regulate the switch between growth and differentiation in the adipogenic lineage have been largely unelucidated. We show here that AEBP1, a transcriptional repressor that is down-regulated during adipogenesis, complexes and protects MAPK from its specific phosphatase in mammalian cells. We further show evidence that the modulation of MAPK activation by AEBP1 is a biologically relevant process in adipogenesis. Our results suggest that modulation of MAPK activation by the protective effect of AEBP1 may constitute a critical part in the determination between cell growth and differentiation in the adipogenic lineage. The proposed mode of action by which a transcription factor regulates MAPK activation is novel.	Dalhousie Univ, Dept Biochem & Mol Biol, Fac Med, Halifax, NS B3H 4H7, Canada	Dalhousie University	Ro, HS (corresponding author), Dalhousie Univ, Dept Biochem & Mol Biol, Fac Med, Sir Charles Tupper Med Bldg, Halifax, NS B3H 4H7, Canada.			Ro, Hyo-Sung/0000-0003-4411-0386; Lyons, Peter/0000-0001-5214-5445				Adachi M, 1999, EMBO J, V18, P5347, DOI 10.1093/emboj/18.19.5347; Adams M, 1997, J BIOL CHEM, V272, P5128, DOI 10.1074/jbc.272.8.5128; ALESSI DR, 1995, CURR BIOL, V5, P283, DOI 10.1016/S0960-9822(95)00059-5; BENITO M, 1991, SCIENCE, V253, P565, DOI 10.1126/science.1857988; Brondello JM, 1997, J BIOL CHEM, V272, P1368, DOI 10.1074/jbc.272.2.1368; CAMP HS, 1997, J BIOL CHEM, V272, P13452; Camps M, 1998, SCIENCE, V280, P1262, DOI 10.1126/science.280.5367.1262; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; deMora JF, 1997, MOL CELL BIOL, V17, P6068, DOI 10.1128/MCB.17.10.6068; Elion EA, 1998, SCIENCE, V281, P1625, DOI 10.1126/science.281.5383.1625; FREYTAG SO, 1994, GENE DEV, V8, P1654, DOI 10.1101/gad.8.14.1654; Grammer TC, 1997, ONCOGENE, V14, P1635, DOI 10.1038/sj.onc.1201000; Gregoire FM, 1998, PHYSIOL REV, V78, P783, DOI 10.1152/physrev.1998.78.3.783; Groom LA, 1996, EMBO J, V15, P3621, DOI 10.1002/j.1460-2075.1996.tb00731.x; He GP, 1999, J BIOL CHEM, V274, P14678, DOI 10.1074/jbc.274.21.14678; HE GP, 1995, NATURE, V378, P92, DOI 10.1038/378092a0; Hu ED, 1996, SCIENCE, V274, P2100, DOI 10.1126/science.274.5295.2100; Ito T, 1996, MOL CELL BIOL, V16, P943; Jacobs D, 1999, GENE DEV, V13, P163, DOI 10.1101/gad.13.2.163; Lenormand P, 1998, J CELL BIOL, V142, P625, DOI 10.1083/jcb.142.3.625; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MELOCHE S, 1992, MOL ENDOCRINOL, V6, P845, DOI 10.1210/me.6.5.845; Mourey RJ, 1996, J BIOL CHEM, V271, P3795; Muda M, 1996, J BIOL CHEM, V271, P4319; Muda M, 1998, J BIOL CHEM, V273, P9323, DOI 10.1074/jbc.273.15.9323; Muise AM, 1999, BIOCHEM J, V343, P341, DOI 10.1042/0264-6021:3430341; Myers MG, 1996, ANNU REV PHARMACOL, V36, P615, DOI 10.1146/annurev.pa.36.040196.003151; NAVRE M, 1989, J CELL BIOL, V109, P1857, DOI 10.1083/jcb.109.4.1857; Nichols A, 2000, J BIOL CHEM, V275, P24613, DOI 10.1074/jbc.M001515200; Park JG, 1999, EMBO J, V18, P4004, DOI 10.1093/emboj/18.14.4004; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; PORRAS A, 1994, J BIOL CHEM, V269, P12741; Porras A, 1996, INT J OBESITY, V20, pS43; Reginato MJ, 1998, J BIOL CHEM, V273, P1855, DOI 10.1074/jbc.273.4.1855; RON D, 1992, J CLIN INVEST, V89, P223, DOI 10.1172/JCI115566; SALE EM, 1995, EMBO J, V14, P674, DOI 10.1002/j.1460-2075.1995.tb07046.x; SELLS MA, 1995, GENE, V152, P187, DOI 10.1016/0378-1119(94)00685-L; SERRERO G, 1991, P NATL ACAD SCI USA, V88, P3912, DOI 10.1073/pnas.88.9.3912; Shao DL, 1998, NATURE, V396, P377, DOI 10.1038/24634; Tanoue T, 2000, NAT CELL BIOL, V2, P110, DOI 10.1038/35000065; TONTONOZ P, 1994, GENE DEV, V8, P1224, DOI 10.1101/gad.8.10.1224; TONTONOZ P, 1994, CELL, V79, P1147, DOI 10.1016/0092-8674(94)90006-X; Yang SH, 1998, EMBO J, V17, P1740, DOI 10.1093/emboj/17.6.1740; Yang SH, 1998, MOL CELL BIOL, V18, P710, DOI 10.1128/MCB.18.2.710; Zhang B, 1996, J BIOL CHEM, V271, P31771, DOI 10.1074/jbc.271.50.31771	47	99	102	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 30	2001	276	13					10199	10206		10.1074/jbc.M010640200	http://dx.doi.org/10.1074/jbc.M010640200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	420GC	11152475	hybrid			2022-12-25	WOS:000167996400082
J	Luo, X; Choi, JY; Ko, SBH; Pushkin, A; Kurtz, I; Ahn, W; Lee, MG; Muallem, S				Luo, X; Choi, JY; Ko, SBH; Pushkin, A; Kurtz, I; Ahn, W; Lee, MG; Muallem, S			HCO3- salvage mechanisms in the submandibular gland acinar and duct cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SODIUM-BICARBONATE COTRANSPORTER; PH-REGULATORY MECHANISMS; VASCULAR SMOOTH-MUSCLE; GUINEA-PIG PANCREAS; INTRACELLULAR PH; MEMBRANE LOCALIZATION; TARGETED DISRUPTION; TISSUE DISTRIBUTION; INTERLOBULAR DUCTS; NA+/H+ EXCHANGER	In the present work, we characterized H+ and HCO3- transport mechanisms in the submandibular salivary gland (SMG) ducts of wild type, NHE2-/-, NHE3-/-, and NHE2-/-;NHES-/- double knock-out mice. The bulk of recovery from an acid load across the luminal membrane (LM) of the duct was mediated by a Na+-dependent HOE and ethyl-isopropyl-amiloride (EIPA)-inhibitable and 4,4'-diisothiocyanostilbene-2,2'-disulfonic acid (DIDS)-insensitive mechanism. HCO3- increased the rate of luminal Na+-dependent pH(i) recovery but did not change inhibition by HOE and EIPA or the insensitivity to DIDS. Despite expression of NHE2 and NHE3 in the LM of the duct, the same activity was observed in ducts from wild type and all mutant mice. Measurements of Na+-dependent OH- and/or HCO3- cotransport (NBC) activities in SMG acinar and duct cells showed separate DIDS-sensitive/EIPA-insensitive and DIDS-insensitive/ EIPA-sensitive NBC activities in both cell types. Functional and immunocytochemical localization of these activities in the perfused duct indicated that pNBC1 probably mediates the DIDS-sensitive/EIPA-insensitive transport in the basolateral membrane, and splice variants of NBC3 probably mediate the DIDS-insensitive/ EIPA-sensitive NBC activity in the LM of duct and acinar cells. Notably, the acinar cell NBCS variants transported HCO, but not OH-. By contrast, duct cell NBC3 transported both OH- and HCO3-. Accordingly, reverse transcription-polymerase chain reaction analysis revealed that both cell types expressed mRNA for pNBC1, However, the acini expressed mRNA for the NBC3 splice variants NBCn1C and NBCn1D, whereas the ducts expressed mRNA for NCBn1B, Based on these findings we propose that the luminal NBCs in the HCO3- secreting SMG acinar and duct cells function as HCO3- salvage mechanisms at the resting state, These studies emphasize the complexity but also begin to clarify the mechanism of HCO3- homeostasis in secretory epithelia.	Yonsei Univ, Coll Med, Dept Pharmacol, Seoul 120752, South Korea; Univ Texas, SW Med Ctr, Dept Physiol, Dallas, TX 75235 USA; Univ Calif Los Angeles, Dept Med, Div Nephrol, Los Angeles, CA 90024 USA; Yonsei Univ, Coll Med, Brain Korea Project Med Sci 21, Seoul 120752, South Korea	Yonsei University; Yonsei University Health System; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of California System; University of California Los Angeles; Yonsei University; Yonsei University Health System	Lee, MG (corresponding author), Yonsei Univ, Coll Med, Dept Pharmacol, 134 Sinchon Dong, Seoul 120752, South Korea.		Ko, Shigeru/H-3450-2012; Lee, Min Goo/AAS-4636-2020; Lee, Min Goo/D-5635-2012	Ko, Shigeru/0000-0003-1913-6357; Lee, Min Goo/0000-0001-7436-012X; Lee, Min Goo/0000-0001-7436-012X	NIDCR NIH HHS [DE12309] Funding Source: Medline; NIDDK NIH HHS [DK46976, DK38938] Funding Source: Medline; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE012309] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK046976, R01DK038938] Funding Source: NIH RePORTER	NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abuladze N, 1998, J BIOL CHEM, V273, P17689, DOI 10.1074/jbc.273.28.17689; ARGENT BE, 1994, PHYSL GASTROINTESTIN, P1478; BOBIK A, 1990, CLIN EXP PHARMACOL P, V17, P297, DOI 10.1111/j.1440-1681.1990.tb01324.x; Chaturapanich G, 1997, J PHYSIOL-LONDON, V503, P583, DOI 10.1111/j.1469-7793.1997.583bg.x; Choi I, 2000, NATURE, V405, P571, DOI 10.1038/35014615; Choi JY, 2000, J CLIN INVEST, V105, P1141, DOI 10.1172/JCI9260; Cook D. I., 1994, P1061; Evans RL, 1999, J BIOL CHEM, V274, P29025, DOI 10.1074/jbc.274.41.29025; Grubb Barbara R., 1999, Physiological Reviews, V79, pS193; Ishiguro H, 1998, J PHYSIOL-LONDON, V511, P407, DOI 10.1111/j.1469-7793.1998.407bh.x; Ishiguro H, 1996, J PHYSIOL-LONDON, V495, P169, DOI 10.1113/jphysiol.1996.sp021582; JOHANSEN PG, 1968, LANCET, V1, P455; KOPELMAN H, 1988, GASTROENTEROLOGY, V95, P349, DOI 10.1016/0016-5085(88)90490-8; Lee MG, 1999, J BIOL CHEM, V274, P3414, DOI 10.1074/jbc.274.6.3414; Lee MG, 2000, J CLIN INVEST, V105, P1651, DOI 10.1172/JCI9207; Lee MG, 1998, J PHYSIOL-LONDON, V513, P341, DOI 10.1111/j.1469-7793.1998.341bb.x; Lee MG, 1999, J BIOL CHEM, V274, P14670, DOI 10.1074/jbc.274.21.14670; Lerch MM, 2000, MED CLIN N AM, V84, P549, DOI 10.1016/S0025-7125(05)70239-X; LITTLE PJ, 1995, CARDIOVASC RES, V29, P239, DOI 10.1016/0008-6363(96)88576-2; MARINO GR, 1999, AM J PHYSIOL, V277, pG487; MUALLEM S, 1990, J BIOL CHEM, V265, P12813; MUALLEM S, 1990, J BIOL CHEM, V265, P12806; NOEL J, 1995, AM J PHYSIOL-CELL PH, V268, pC283, DOI 10.1152/ajpcell.1995.268.2.C283; Park K, 1999, AM J PHYSIOL-GASTR L, V276, pG470, DOI 10.1152/ajpgi.1999.276.2.G470; PAULAIS M, 1994, AM J PHYSIOL, V266, pC1594, DOI 10.1152/ajpcell.1994.266.6.C1594; Pilewski Joseph M., 1999, Physiological Reviews, V79, pS215; Pushkin A, 1999, J BIOL CHEM, V274, P16569, DOI 10.1074/jbc.274.23.16569; Romero MF, 1999, ANNU REV PHYSIOL, V61, P699, DOI 10.1146/annurev.physiol.61.1.699; Romero MF, 1997, NATURE, V387, P409, DOI 10.1038/387409a0; Schultheis PJ, 1998, NAT GENET, V19, P282, DOI 10.1038/969; Schultheis PJ, 1998, J CLIN INVEST, V101, P1243, DOI 10.1172/JCI1249; Thevenod F, 1999, BIOCHEM BIOPH RES CO, V264, P291, DOI 10.1006/bbrc.1999.1484; ZHAO H, 1994, J GEN PHYSIOL, V104, P57, DOI 10.1085/jgp.104.1.57; ZHAO H, 1995, J BIOL CHEM, V270, P19599, DOI 10.1074/jbc.270.33.19599	34	69	70	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 30	2001	276	13					9808	9816		10.1074/jbc.M008548200	http://dx.doi.org/10.1074/jbc.M008548200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	420GC	11139574	hybrid			2022-12-25	WOS:000167996400032
J	Kimura, K; Cuvier, O; Hirano, T				Kimura, K; Cuvier, O; Hirano, T			Chromosome condensation by a human condensin complex in Xenopus egg extracts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							13S CONDENSIN; PROTEIN COMPLEXES; HEAT REPEATS; IN-VITRO; HOMOLOG; DNA; PHOSPHORYLATION; IDENTIFICATION; SEGREGATION; SEPARATION	13S condensin is a five-subunit protein complex that plays a central role in mitotic chromosome condensation. The condensin complex was originally identified and purified from Xenopus egg extracts and shown to have an ATP-dependent positive supercoiling activity in vitro. We report here the characterization of a human condensin complex purified from HeLa cell nuclear extracts. The human 13S complex has exactly the same composition as its Xenopus counterpart, being composed of two structural maintenance of chromosomes (human chromosome-associated polypeptide (hCAP)-C and hCAP-E) subunits and three non-structural maintenance of chromosomes (hCAP-D2/CNAP1, hCAP-G, and hCAP-H/BRRN) subunits. Human condensin purified from asynchronous HeLa cell cultures fails to reconfigure DNA structure in vitro. When phosphorylated by purified cdc2-cyclin B, however, it gains the ability to introduce positive supercoils into DNA in the presence of ATP and topoisomerase I. Strikingly, human condensin can induce chromosome condensation when added back into a Xenopus egg extract that has been immunodepleted of endogenous condensin. Thus, the structure and function of the condensin complex are highly conserved between Xenopus and humans, underscoring its fundamental importance in mitotic chromosome dynamics in eukaryotic cells.	Cold Spring Harbor Lab, Cold Spring Harbor, NY 11724 USA	Cold Spring Harbor Laboratory	Hirano, T (corresponding author), Cold Spring Harbor Lab, 1 Bungtown Rd,POB 100, Cold Spring Harbor, NY 11724 USA.		CUVIER, Olivier/AAC-4693-2019; Hirano, Tatsuya/F-6008-2011; Cuvier, Olivier/ADO-0657-2022	CUVIER, Olivier/0000-0003-0644-2734; Hirano, Tatsuya/0000-0002-4219-6473; 	NIGMS NIH HHS [R01-GM153926] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDRADE MA, 1995, NAT GENET, V11, P115, DOI 10.1038/ng1095-115; Cabello OA, 1997, GENOMICS, V46, P311, DOI 10.1006/geno.1997.5021; Freeman L, 2000, J CELL BIOL, V149, P811, DOI 10.1083/jcb.149.4.811; Hirano T, 2000, ANNU REV BIOCHEM, V69, P115, DOI 10.1146/annurev.biochem.69.1.115; Hirano T, 1997, CELL, V89, P511, DOI 10.1016/S0092-8674(00)80233-0; HIRANO T, 1994, CELL, V79, P449, DOI 10.1016/0092-8674(94)90254-2; Jager D, 2000, CANCER RES, V60, P3584; Kimura K, 1999, CELL, V98, P239, DOI 10.1016/S0092-8674(00)81018-1; Kimura K, 1997, CELL, V90, P625, DOI 10.1016/S0092-8674(00)80524-3; Kimura K, 1998, SCIENCE, V282, P487, DOI 10.1126/science.282.5388.487; Kimura K, 2000, P NATL ACAD SCI USA, V97, P11972, DOI 10.1073/pnas.220326097; Koshland D, 1996, ANNU REV CELL DEV BI, V12, P305, DOI 10.1146/annurev.cellbio.12.1.305; Lavoie BD, 2000, MOL BIOL CELL, V11, P1293, DOI 10.1091/mbc.11.4.1293; Neuwald AF, 2000, GENOME RES, V10, P1445, DOI 10.1101/gr.147400; Ouspenski II, 2000, MOL BIOL CELL, V11, P1305, DOI 10.1091/mbc.11.4.1305; SAKA Y, 1994, EMBO J, V13, P4938, DOI 10.1002/j.1460-2075.1994.tb06821.x; Schmiesing JA, 1998, P NATL ACAD SCI USA, V95, P12906, DOI 10.1073/pnas.95.22.12906; Schmiesing JA, 2000, MOL CELL BIOL, V20, P6996, DOI 10.1128/MCB.20.18.6996-7006.2000; STRUNNIKOV AV, 1995, GENE DEV, V9, P587, DOI 10.1101/gad.9.5.587; Sutani T, 1999, GENE DEV, V13, P2271, DOI 10.1101/gad.13.17.2271	21	143	152	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 23	2001	276	8					5417	5420		10.1074/jbc.C000873200	http://dx.doi.org/10.1074/jbc.C000873200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	404RU	11136719	hybrid			2022-12-25	WOS:000167115100002
J	Nishioka, M; Kohno, T; Takahashi, M; Niki, T; Yamada, T; Sone, S; Yokota, J				Nishioka, M; Kohno, T; Takahashi, M; Niki, T; Yamada, T; Sone, S; Yokota, J			Identification of a 428-kb homozygously deleted region disrupting the SEZ6L gene at 22q12.1 in a lung cancer cell line	ONCOGENE			English	Article						lung cancer; tumor suppressor gene; chromosomal deletion; chromosome 22q; SEZ6L	TUMOR-SUPPRESSOR GENE; NEUROFIBROMATOSIS TYPE-2; POLYPYRIMIDINE TRACT; CARCINOMA; DNA; SEQUENCE; FREQUENT; METHYLATION; PREDICTION; EXPRESSION	Frequent allelic losses on chromosome 22q in small cell lung carcinomas (SCLCs) and advanced non-small cell lung carcinomas indicate the presence of tumor suppressor gene(s) on this chromosome arm. We detected a homozygous deletion at 22q12.1 in a SCLC cell line, Lu24. Cloning of the breakpoints of the Lu24 deletion revealed that the deletion was interstitial and 428, 131 bp in size. The deleted region contained the SEZ6L (Seizure 6-like) gene, whose structure had been partially determined by the chromosome 22 sequencing project, We determined the full length cDNA sequence for the SEZ6L gene based on the genomic sequence for the SEZ6L locus using the GENSCAN program and the RT-PCR method. The deduced SEZ6L protein was a transmembrane protein of 1024 amino acids with multiple domains involved in protein-protein interaction and signal transduction, SEZ6L expression was detected in a variety of human tissues, including lung, while its expression was detected in 14 (30%) of 46 lung cancer cell lines examined, Missense mutations were detected in three (7%) of the 46 cell lines, and a 1 bp deletion in the polypyrimidine tract preceding exon 4 was detected in one (2%) of 46 primary lung cancers. Therefore, it is possible that genetic and/or epigenetic SEZ6L alterations are involved in the development and/or progression in a subset of lung cancer, although functional analysis of the SEZ6L gene as well as molecular analysis of other genes in the homozygously deleted region is necessary to understand the pathogenetic significance of 220 deletions in human lung carcinogenesis.	Natl Canc Ctr, Res Inst, Div Biol, Chuo Ku, Tokyo 1040045, Japan; Natl Canc Ctr, Res Inst, Div Pathol, Chuo Ku, Tokyo 1040045, Japan; Univ Tokushima, Sch Med, Dept Internal Med 3, Tokushima 7708503, Japan	National Cancer Center - Japan; National Cancer Center - Japan; Tokushima University	Yokota, J (corresponding author), Natl Canc Ctr, Res Inst, Div Biol, Chuo Ku, 1-1 Tsukiji 5 Chome, Tokyo 1040045, Japan.		niki, toshiro/K-8917-2012					Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Anami Y, 2000, INT J CANCER, V89, P19, DOI 10.1002/(SICI)1097-0215(20000120)89:1<19::AID-IJC4>3.0.CO;2-3; Burge C, 1997, J MOL BIOL, V268, P78, DOI 10.1006/jmbi.1997.0951; CANNING S, 1989, P NATL ACAD SCI USA, V86, P5044, DOI 10.1073/pnas.86.13.5044; Castells A, 2000, CANCER RES, V60, P2836; Chen C, 1998, MOL CELL, V2, P9, DOI 10.1016/S1097-2765(00)80109-4; Dunham I, 1999, NATURE, V402, P489, DOI 10.1038/990031; Gayther SA, 2000, NAT GENET, V24, P300, DOI 10.1038/73536; Hamada K, 1998, GENE CHROMOSOME CANC, V22, P232, DOI 10.1002/(SICI)1098-2264(199807)22:3<232::AID-GCC9>3.0.CO;2-X; Herbst R, 1997, MOL BRAIN RES, V44, P309, DOI 10.1016/S0169-328X(96)00274-4; HERMAN JG, 1994, P NATL ACAD SCI USA, V91, P9700, DOI 10.1073/pnas.91.21.9700; Hirokawa T, 1998, BIOINFORMATICS, V14, P378, DOI 10.1093/bioinformatics/14.4.378; Inoue H, 1997, P NATL ACAD SCI USA, V94, P14584, DOI 10.1073/pnas.94.26.14584; Kawanishi M, 1997, CARCINOGENESIS, V18, P2057, DOI 10.1093/carcin/18.11.2057; Kohno T, 1999, CARCINOGENESIS, V20, P1403, DOI 10.1093/carcin/20.8.1403; Kohno T, 1996, DNA Res, V3, P421, DOI 10.1093/dnares/3.6.421; Kohno T, 1998, GENE CHROMOSOME CANC, V22, P152, DOI 10.1002/(SICI)1098-2264(199806)22:2<152::AID-GCC10>3.0.CO;2-S; Kohno T, 1999, CANCER RES, V59, P4170; Kukita Y, 1997, HUM MUTAT, V10, P400, DOI 10.1002/(SICI)1098-1004(1997)10:5<400::AID-HUMU11>3.3.CO;2-1; LEVIN NA, 1994, CANCER RES, V54, P5086; Magnusson KP, 2000, GENE, V246, P247, DOI 10.1016/S0378-1119(00)00068-8; Manda R, 2000, CANCER LETT, V153, P57, DOI 10.1016/S0304-3835(00)00342-6; MERLO A, 1995, NAT MED, V1, P686, DOI 10.1038/nm0795-686; Mertens F, 1997, CANCER RES, V57, P2765; NORTON PA, 1994, NUCLEIC ACIDS RES, V22, P3854, DOI 10.1093/nar/22.19.3854; POMYKALA HM, 1994, MOL CELL BIOL, V14, P7604, DOI 10.1128/MCB.14.11.7604; ROSCIGNO RF, 1993, J BIOL CHEM, V268, P11222; ROULEAU GA, 1993, NATURE, V363, P515, DOI 10.1038/363515a0; Sekido Y, 1998, ONCOGENE, V16, P3151, DOI 10.1038/sj.onc.1201858; SEKIDO Y, 1995, CANCER RES, V55, P1227; SHIMIZUNISHIKAWA K, 1995, MOL BRAIN RES, V28, P201, DOI 10.1016/0169-328X(94)00203-Q; SHISEKI M, 1994, CANCER RES, V54, P5643; Shiseki M, 1996, GENE CHROMOSOME CANC, V17, P71, DOI 10.1002/(SICI)1098-2264(199610)17:2<71::AID-GCC1>3.0.CO;2-Y; Stanton SE, 2000, GENE CHROMOSOME CANC, V27, P323, DOI 10.1002/(SICI)1098-2264(200003)27:3<323::AID-GCC14>3.0.CO;2-P; Sudol M, 1998, ONCOGENE, V17, P1469, DOI 10.1038/sj.onc.1202182; TESTA JR, 1994, GENE CHROMOSOME CANC, V11, P178, DOI 10.1002/gcc.2870110307; TROFATTER JA, 1993, CELL, V72, P791, DOI 10.1016/0092-8674(93)90406-G; Ueda T, 1999, CANCER RES, V59, P6080; Ueki K, 1999, CANCER RES, V59, P5995; Versteege I, 1998, NATURE, V394, P203, DOI 10.1038/28212; Virmani AK, 1998, GENE CHROMOSOME CANC, V21, P308, DOI 10.1002/(SICI)1098-2264(199804)21:4<308::AID-GCC4>3.0.CO;2-2; Wilmotte R, 1999, BRIT J HAEMATOL, V104, P855, DOI 10.1046/j.1365-2141.1999.01271.x; Yamada T, 2000, CANCER GENET CYTOGEN, V120, P11, DOI 10.1016/S0165-4608(99)00240-X	43	43	46	0	3	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 14	2000	19	54					6251	6260		10.1038/sj.onc.1204031	http://dx.doi.org/10.1038/sj.onc.1204031			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	388YK	11175339				2022-12-25	WOS:000166210500008
J	Onodera, Y; Suzuki, A; Wu, CY; Washida, H; Takaiwa, F				Onodera, Y; Suzuki, A; Wu, CY; Washida, H; Takaiwa, F			A rice functional transcriptional activator, RISBZ1, responsible for endosperm-specific expression of storage protein genes through GCN4 motif	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING PROTEINS; GLUTELIN GENE; BZIP PROTEIN; PLANT EMBRYOGENESIS; BARLEY ENDOSPERM; GCN4-LIKE MOTIF; ZIPPER PROTEIN; LEUCINE ZIPPER; PROLAMIN-BOX; OPAQUE-2	The GCN4 motif, a cis-element that is highly conserved in the promoters of cereal seed storage protein genes, plays a central role in controlling endosperm-specific expression. This motif is the recognition site for a basic leucine zipper transcriptional factor that belongs to the group of maize Opaque-2 (O2)-like proteins. Five different basic leucine zipper cDNA clones, designated RISBZ1-5, have been isolated from a rice seed cDNA library. The predicted gene products can be divided into two groups based on their amino acid sequences. Although all the RISBZ proteins are able to interact with the GCN4 motif, only RISBZ1 is capable of activating (more than 100-fold expression) the expression of a reporter gene under a minimal promoter fused to a pentamer of the GCN4 motif, Loss-of-function and gain-of-function experiments using the yeast GAL4 DNA binding domain revealed that the proline-rich N-terminal domain (27 amino acids in length) is responsible for transactivation, The RISBZ1 protein is capable of forming homodimers as well as heterodimers with other RISBZ subunit proteins. RISBZ1 gene expression is restricted to the seed, where it precedes the expression of storage protein genes. When the RISBZ1 promoter was transcriptionally fused to the beta -glucuronidase reporter gene and the chimeric gene was introduced into rice, the beta -glucuronidase gene is specifically expressed in aleurone and subaleurone layer of the developing endosperm, These findings suggest that the specific expression of transcriptional activator RISBZ1 gene may determine the endosperm specificity of the storage protein genes.	Natl Inst Agrobiol Resources, Dept Biotechnol, Tsukuba, Ibaraki 3058602, Japan; Chiba Univ, Fac Hort, Matsudo, Chiba 2718510, Japan	National Institute of Agrobiological Sciences - Japan; Chiba University	Takaiwa, F (corresponding author), Natl Inst Agrobiol Resources, Dept Biotechnol, Kannondai 2-1-2, Tsukuba, Ibaraki 3058602, Japan.			Washida, Haruhiko/0000-0001-7372-9503				Albani D, 1997, PLANT CELL, V9, P171, DOI 10.1105/tpc.9.2.171; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; Ciceri P, 1997, PLANT CELL, V9, P97, DOI 10.1105/tpc.9.1.97; Conlan RS, 1999, PLANT J, V19, P173, DOI 10.1046/j.1365-313X.1999.00522.x; DAPATER S, 1993, PLANT CELL, V5, P877; DEPATER S, 1994, PLANT J, V6, P133, DOI 10.1046/j.1365-313X.1994.6020133.x; GOLDBERG RB, 1994, SCIENCE, V266, P605, DOI 10.1126/science.266.5185.605; HAMMONDKOSACK MCU, 1993, EMBO J, V12, P545, DOI 10.1002/j.1460-2075.1993.tb05686.x; HARTINGS H, 1989, EMBO J, V8, P2795, DOI 10.1002/j.1460-2075.1989.tb08425.x; Holdsworth MJ, 1995, PLANT MOL BIOL, V29, P711, DOI 10.1007/BF00041162; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; IZAWA T, 1994, PLANT CELL, V6, P1277, DOI 10.1105/tpc.6.9.1277; Jefferson RA, 1987, PLANT MOL BIOL REP, V5, P387, DOI [DOI 10.1007/BF02667740, 10.1007/bf02667740]; KIM SY, 1990, NUCLEIC ACIDS RES, V18, P6845, DOI 10.1093/nar/18.23.6845; KOUZARIDES T, 1988, NATURE, V336, P646, DOI 10.1038/336646a0; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LIU YG, 1995, PLANT J, V8, P457, DOI 10.1046/j.1365-313X.1995.08030457.x; LOHMER S, 1991, EMBO J, V10, P617, DOI 10.1002/j.1460-2075.1991.tb07989.x; LOHMER S, 1993, PLANT CELL, V5, P65, DOI 10.1105/tpc.5.1.65; Maddaloni M, 1996, MOL GEN GENET, V250, P647, DOI 10.1007/s004380050117; Marzabal P, 1998, PLANT J, V16, P41, DOI 10.1046/j.1365-313x.1998.00272.x; Mena M, 1998, PLANT J, V16, P53, DOI 10.1046/j.1365-313x.1998.00275.x; MENKENS AE, 1994, P NATL ACAD SCI USA, V91, P2522, DOI 10.1073/pnas.91.7.2522; MIKAELIAN I, 1992, NUCLEIC ACIDS RES, V20, P376, DOI 10.1093/nar/20.2.376; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MORTON RL, 1995, SEED DEV GERMINATION, P103; MULLER M, 1993, PLANT J, V4, P343, DOI 10.1046/j.1365-313X.1993.04020343.x; Nakase M, 1997, PLANT MOL BIOL, V33, P513, DOI 10.1023/A:1005784717782; Nakayama T, 1997, MOL GEN GENET, V253, P553, DOI 10.1007/s004380050357; NETO GC, 1995, PLANT MOL BIOL, V27, P1015, DOI 10.1007/BF00037028; Onate L, 1999, J BIOL CHEM, V274, P9175, DOI 10.1074/jbc.274.14.9175; PIROVANO L, 1994, PLANT MOL BIOL, V24, P515, DOI 10.1007/BF00024119; PYSH LD, 1993, PLANT CELL, V5, P227, DOI 10.1105/tpc.5.2.227; Sambrook J., 2002, MOL CLONING LAB MANU; SCHINDLER U, 1992, EMBO J, V11, P1275, DOI 10.1002/j.1460-2075.1992.tb05171.x; SCHMIDT RJ, 1992, PLANT CELL, V4, P689, DOI 10.1105/tpc.4.6.689; Schmitz D, 1997, NUCLEIC ACIDS RES, V25, P756, DOI 10.1093/nar/25.4.756; Suzuki A, 1998, PLANT CELL PHYSIOL, V39, P555, DOI 10.1093/oxfordjournals.pcp.a029404; TAKAIWA F, 1987, MOL GEN GENET, V208, P15, DOI 10.1007/BF00330416; Takaiwa F, 1996, PLANT MOL BIOL, V30, P1207, DOI 10.1007/BF00019553; THOMAS TL, 1993, PLANT CELL, V5, P1401, DOI 10.1105/tpc.5.10.1401; TOPFER R, 1987, NUCLEIC ACIDS RES, V15, P5890, DOI 10.1093/nar/15.14.5890; VARAGONA MJ, 1992, PLANT CELL, V4, P1213, DOI 10.1105/tpc.4.10.1213; Vettore AL, 1998, PLANT MOL BIOL, V36, P249, DOI 10.1023/A:1005995806897; Vicente-Carbajosa J, 1998, PLANT J, V13, P629, DOI 10.1111/j.1365-313X.1998.00068.x; VicenteCarbajosa J, 1997, P NATL ACAD SCI USA, V94, P7685, DOI 10.1073/pnas.94.14.7685; WEINBERGER J, 1986, NATURE, V322, P846, DOI 10.1038/322846a0; Wu CY, 1998, PLANT J, V14, P673, DOI 10.1046/j.1365-313x.1998.00167.x; Wu CY, 2000, PLANT J, V23, P415, DOI 10.1046/j.1365-313x.2000.00797.x; Yoshihara T, 1996, FEBS LETT, V383, P213, DOI 10.1016/0014-5793(96)00233-5; ZHENG ZW, 1993, PLANT J, V4, P357, DOI 10.1046/j.1365-313X.1993.04020357.x	53	125	143	1	23	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 27	2001	276	17					14139	14152		10.1074/jbc.M007405200	http://dx.doi.org/10.1074/jbc.M007405200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	426PB	11133985	hybrid			2022-12-25	WOS:000168356600086
J	Kieschnick, H; Wakefield, T; Narducci, CA; Beckers, C				Kieschnick, H; Wakefield, T; Narducci, CA; Beckers, C			Toxoplasma gondii attachment to host cells is regulated by a calmodulin-like domain protein kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-BINDING PROPERTIES; PLASMODIUM-FALCIPARUM; PARAMECIUM-TETRAURELIA; INTRACELLULAR CALCIUM; INVASION; EXPRESSION; MOBILIZATION; PURIFICATION; FAMILY; CA2+	The role of calcium-dependent protein kinases in the invasion of Toxoplasma gondii into its animal host cells was analyzed. KT5926, an inhibitor of calcium-dependent protein kinases in other systems, is known to block. the motility of Toxoplasma tachyzoites and their attachment to host cells. lit vivo, KT5926 blocks the phosphorylation of only three parasite proteins, and in parasite extracts only a single KT5926-sensitive protein kinase activity was detected. This activity was calcium-dependent but did not require calmodulin, In a search for calcium-dependent protein kinases in Toxoplasma, two members of the class of calmodulin-like domain protein kinases (CDPKs) were detected. TgCDPK2 was only expressed at the mRNA level in tachyzoites, but no protein was detected, TgCDPK1 protein was expressed in Toxoplasma tachyzoites and cofractionated precisely with the peak of KT5926-sensitive protein kinase activity. TgCDPK1 kinase activity was calcium-dependent but did not require calmodulin or phospholipids. TgCDPK1 was found to be inhibited effectively by KT5926 at concentrations that block parasite attachment to host cells. In vitro, TgCDPK1 phosphorylated three parasite proteins that migrated identical to the three KT5926-sensitive phosphoproteins detected in vivo, Based on these observations, a central role is suggested for TgCDPK1 in regulating Toxoplasma motility and host cell invasion.	Univ Alabama Birmingham, Div Geog Med, BBRB 206, Birmingham, AL 35294 USA; Univ Alabama Birmingham, Dept Cell Biol, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham	Beckers, C (corresponding author), Univ Alabama Birmingham, Div Geog Med, BBRB 206, 845 19th St S, Birmingham, AL 35294 USA.	cbeckers@uab.edu			NIAID NIH HHS [AI41765] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI041765, R01AI041765] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BECKERS CJM, 1994, J CELL BIOL, V127, P947, DOI 10.1083/jcb.127.4.947; Bohne W, 1999, IMMUNOBIOLOGY, V201, P248, DOI 10.1016/S0171-2985(99)80065-5; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Carruthers VB, 1999, MOL MICROBIOL, V31, P421, DOI 10.1046/j.1365-2958.1999.01174.x; Dobrowolski JM, 1997, MOL MICROBIOL, V26, P163, DOI 10.1046/j.1365-2958.1997.5671913.x; Dunn PPJ, 1996, PARASITOLOGY, V113, P439, DOI 10.1017/S0031182000081506; FABIATO A, 1988, METHOD ENZYMOL, V157, P378; FRENKEL JK, 1988, PARASITOL TODAY, V4, P273, DOI 10.1016/0169-4758(88)90018-X; GUNDERSEN RE, 1987, J BIOL CHEM, V262, P4602; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HARMON AC, 1987, PLANT PHYSIOL, V83, P830, DOI 10.1104/pp.83.4.830; HARMON AC, 1994, BIOCHEMISTRY-US, V33, P7278, DOI 10.1021/bi00189a032; HARPER JF, 1991, SCIENCE, V252, P951, DOI 10.1126/science.1852075; HASHIMOTO Y, 1991, BIOCHEM BIOPH RES CO, V181, P423, DOI 10.1016/S0006-291X(05)81436-6; Hwang I, 2000, P NATL ACAD SCI USA, V97, P6224, DOI 10.1073/pnas.97.11.6224; Kim K, 1998, EUR J BIOCHEM, V251, P605, DOI 10.1046/j.1432-1327.1998.2510605.x; Knoll LJ, 1998, MOL CELL BIOL, V18, P807, DOI 10.1128/MCB.18.2.807; Lee JY, 1998, BIOCHEMISTRY-US, V37, P6801, DOI 10.1021/bi980062q; Li JL, 2000, BBA-GENE STRUCT EXPR, V1491, P341, DOI 10.1016/S0167-4781(00)00032-4; Li JX, 1998, PLANT PHYSIOL, V116, P785, DOI 10.1104/pp.116.2.785; MCCURDY DW, 1992, PLANTA, V188, P54, DOI 10.1007/BF00198939; Pei ZM, 1996, EMBO J, V15, P6564, DOI 10.1002/j.1460-2075.1996.tb01047.x; Pezzella N, 1997, EUR J CELL BIOL, V74, P92; Pfefferkorn E.R., 1990, P26; PUTNAMEVANS CL, 1990, BIOCHEMISTRY-US, V29, P2488, DOI 10.1021/bi00462a008; Romeis T, 2000, PLANT CELL, V12, P803, DOI 10.1105/tpc.12.5.803; Saijo Y, 2000, PLANT J, V23, P319, DOI 10.1046/j.1365-313x.2000.00787.x; SHAW MK, 1995, EUR J CELL BIOL, V68, P78; SON M, 1993, J BIOL CHEM, V268, P5940; SWOFFORD DL, 2001, PHYLOGENETIC ANAL US; Vieira MCF, 2000, MOL BIOCHEM PARASIT, V106, P157, DOI 10.1016/S0166-6851(99)00182-6; Wasserman M, 1996, PARASITOL RES, V82, P102, DOI 10.1007/s004360050078; Yang SM, 1997, GENE, V184, P1, DOI 10.1016/S0378-1119(96)00566-5; YUASA T, 1992, ARCH BIOCHEM BIOPHYS, V296, P175, DOI 10.1016/0003-9861(92)90560-J; ZHAO Y, 1994, BIOCHEMISTRY-US, V33, P3714, DOI 10.1021/bi00178a031; ZHAO Y, 1993, J BIOL CHEM, V268, P4347	36	119	133	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 13	2001	276	15					12369	12377		10.1074/jbc.M011045200	http://dx.doi.org/10.1074/jbc.M011045200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	421UK	11154702	hybrid			2022-12-25	WOS:000168081800124
J	Kominami, S; Owaki, A; Iwanaga, T; Tagashira-Ikushiro, H; Yamazaki, T				Kominami, S; Owaki, A; Iwanaga, T; Tagashira-Ikushiro, H; Yamazaki, T			The rate-determining step in P450C21-catalyzing reactions in a membrane-reconstituted system	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME P-450 REDUCTASE; PIG ADRENAL MICROSOMES; NADPH-CYTOCHROME-P-450 REDUCTASE; ADRENOCORTICAL MICROSOMES; PHOSPHOLIPID-VESICLES; SUCCESSIVE REACTIONS; YEAST MICROSOMES; P450 REDUCTASE; ENZYME SYSTEM; ROTATION	Adrenal cytochrome P450 C21 in a membrane-reconstituted system catalyzed 21-hydroxylation of 17 alpha -hydroxyprogesterone at a rate higher than that for progesterone in the steady state at 37 degreesC, The rate of product formation in the steady state increased with the concentration of the complex between P450 C21 and the reductase in the membranes. The complex formation was independent of the volume of the reaction, showing that the effective concentrations of the membrane proteins should be defined with the volume of the lipid phase. The rates of conversion of progesterone and 17 alpha -hydroxyprogesterone to the product in a single cycle of the P450 C21 reaction were measured with a reaction rapid quenching device. The first-order rate constant for the conversion of progesterone by P450 C21 was 4.3 +/- 0.7 s(-1), and that for 17 alpha -hydroxyprogesterone was 1.8 +/- 0.5 s(-1) at 37 degreesC, It was found from the analysis of kinetic data that the rate-determining step in 21-hydroxylation of progesterone in the steady state was the dissociation of product from P450 C21, whereas the conversion to deoxycortisol was the rate-determining step in the reaction of 17 alpha -hydroxyprogesterone. The difference in the rate-determining steps in the reactions for the two substrates was clearly demonstrated in the pre-steady-state kinetics.	Hiroshima Univ, Fac Integrated Arts & Sci, Higashihiroshima 7398521, Japan	Hiroshima University	Kominami, S (corresponding author), Hiroshima Univ, Fac Integrated Arts & Sci, 1-7-1 Kagamiyama, Higashihiroshima 7398521, Japan.							ALGAILANY KAS, 1978, BIOCHEM PHARMACOL, V27, P783, DOI 10.1016/0006-2952(78)90521-X; BACKES WL, 1989, J BIOL CHEM, V264, P6252; BACKES WL, 1981, J BIOL CHEM, V256, P7213; BARSHOP BA, 1983, ANAL BIOCHEM, V130, P134, DOI 10.1016/0003-2697(83)90660-7; Bell LC, 1997, J BIOL CHEM, V272, P29643, DOI 10.1074/jbc.272.47.29643; Bell-Parikh LC, 1999, J BIOL CHEM, V274, P23833, DOI 10.1074/jbc.274.34.23833; BENDER ML, 1966, J AM CHEM SOC, V88, P5890, DOI 10.1021/ja00976a034; ETTER HU, 1991, J BIOL CHEM, V266, P18600; FRENCH JS, 1980, J BIOL CHEM, V255, P4112; FRIEDEN C, 1993, TRENDS BIOCHEM SCI, V18, P58, DOI 10.1016/0968-0004(93)90056-S; Guengerich FP, 1997, BIOCHEMISTRY-US, V36, P14741, DOI 10.1021/bi9719399; GUT J, 1982, J BIOL CHEM, V257, P7030; HIGUCHI A, 1991, BIOCHIM BIOPHYS ACTA, V1084, P240, DOI 10.1016/0005-2760(91)90064-O; HUANG C, 1978, P NATL ACAD SCI USA, V75, P308, DOI 10.1073/pnas.75.1.308; Imai T, 1998, BIOCHEMISTRY-US, V37, P8097, DOI 10.1021/bi9802768; Iwanaga T, 1999, BIOCHEMISTRY-US, V38, P16629, DOI 10.1021/bi991277i; IWASE T, 1991, BIOCHEMISTRY-US, V30, P8347, DOI 10.1021/bi00098a010; KAWATO S, 1982, J BIOL CHEM, V257, P7023; KOMINAMI S, 1982, BIOCHEM BIOPH RES CO, V109, P916, DOI 10.1016/0006-291X(82)92027-7; KOMINAMI S, 1989, BIOCHIM BIOPHYS ACTA, V985, P293, DOI 10.1016/0005-2736(89)90415-X; KOMINAMI S, 1980, J BIOL CHEM, V255, P3386; KOMINAMI S, 1987, BIOCHIM BIOPHYS ACTA, V905, P143, DOI 10.1016/0005-2736(87)90018-6; KOMINAMI S, 1982, BIOCHIM BIOPHYS ACTA, V709, P147, DOI 10.1016/0167-4838(82)90454-X; KOMINAMI S, 1986, J BIOL CHEM, V261, P2077; KOMINAMI S, 1984, J BIOL CHEM, V259, P2991; MIWA GT, 1984, ARCH BIOCHEM BIOPHYS, V234, P161, DOI 10.1016/0003-9861(84)90337-0; MIWA GT, 1979, J BIOL CHEM, V254, P5695; MULLERENOCH D, 1984, J BIOL CHEM, V259, P8174; OHTA Y, 1992, BIOCHEMISTRY-US, V31, P12680, DOI 10.1021/bi00165a019; OMURA T, 1964, J BIOL CHEM, V239, P2370; OPRIAN DD, 1979, J BIOL CHEM, V254, P8895; ROBERTS DV, 1977, ENZYME KINETICS, P35; SCHEN S, 1994, BIOCHEMISTRY-US, V33, P8807; SEVRUKOVA IF, 1994, ARCH BIOCHEM BIOPHYS, V311, P133, DOI 10.1006/abbi.1994.1218; SHINZAWA K, 1985, BIOCHIM BIOPHYS ACTA, V833, P151; TAGASHIRA H, 1995, BIOCHEMISTRY-US, V34, P10939, DOI 10.1021/bi00034a028; TAKEMORI S, 1984, TRENDS BIOCHEM SCI, V9, P393, DOI 10.1016/0968-0004(84)90223-8; TAKEMORI S, 1982, OXYGENASES OXYGEN ME, P403; VOZNESENSKY AI, 1992, J BIOL CHEM, V267, P14669; WHITE RE, 1980, ANNU REV BIOCHEM, V49, P315, DOI 10.1146/annurev.bi.49.070180.001531; Yamada M, 1999, BIOCHEMISTRY-US, V38, P9465, DOI 10.1021/bi990648s; Yamazaki T, 1998, BIOCHEMISTRY-US, V37, P2800, DOI 10.1021/bi9715066; YOSHIOKA H, 1986, J BIOL CHEM, V261, P4106	43	9	9	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 6	2001	276	14					10753	10758		10.1074/jbc.M006043200	http://dx.doi.org/10.1074/jbc.M006043200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	420AC	11154687	hybrid			2022-12-25	WOS:000167980900027
J	Nadler, LS; Kumar, G; Nathanson, NM				Nadler, LS; Kumar, G; Nathanson, NM			Identification of a basolateral sorting signal for the m(3) muscarinic acetylcholine receptor in Madin-Darby canine kidney cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLARIZED EPITHELIAL-CELLS; PROTEIN-COUPLED RECEPTORS; GROWTH-FACTOR RECEPTOR; MDCK CELLS; STRUCTURAL REQUIREMENTS; CYTOPLASMIC TAIL; HIPPOCAMPAL-NEURONS; MOLECULAR-CLONING; XENOPUS OOCYTES; ACINAR-CELLS	Muscarinic acetylcholine receptors (mAChRs) can be differentially localized in polarized cells. To identify potential sorting signals that mediate mAChR targeting, we examined the sorting of mAChRs in Madin-Darby canine kidney cells, a widely used model system. Expression of FLAG-tagged mAChRs in polarized Madin-Darby canine kidney cells demonstrated that the M-2 subtype is sorted apically, whereas M-3 is targeted basolaterally, Expression of M-2/M-3 receptor chimeras revealed that a al-residue sequence, Ser(271)-Ser(291), from the M-3 third intracellular loop contains a basolateral sorting signal. Substitution of sequences containing the M-3 sorting signal into the homologous regions of M-2 was sufficient to confer basolateral localization to this apical receptor. Sequences containing the M-3 sorting signal also conferred basolateral targeting to M-2 when added to either the third intracellular loop or the C-terminal cytoplasmic tail. Furthermore, addition of a sequence containing the M-3 basolateral sorting signal to the cytoplasmic tail of the interleukin-2 receptor alpha -chain caused significant basolateral targeting of this heterologous apical protein. The results indicate that the M-3 basolateral sorting signal is dominant over apical signals in M-2 and acts in a position-independent manner. The M-3 sorting signal represents a novel basolateral targeting motif for G protein-coupled receptors.	Univ Washington, Sch Med, Dept Pharmacol, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle	Nathanson, NM (corresponding author), Univ Washington, Sch Med, Dept Pharmacol, POB 357750, Seattle, WA 98195 USA.				NINDS NIH HHS [NS26920] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS026920] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Beau I, 1998, J BIOL CHEM, V273, P18610, DOI 10.1074/jbc.273.29.18610; BLIN N, 1995, J BIOL CHEM, V270, P17741, DOI 10.1074/jbc.270.30.17741; BONNER TI, 1987, SCIENCE, V237, P527, DOI 10.1126/science.3037705; BONNER TI, 1988, NEURON, V1, P403, DOI 10.1016/0896-6273(88)90190-0; CAULFIELD MP, 1993, PHARMACOL THERAPEUT, V58, P319, DOI 10.1016/0163-7258(93)90027-B; Chuang JZ, 1998, J CELL BIOL, V142, P1245, DOI 10.1083/jcb.142.5.1245; DAVIDSON A, 1991, FEBS LETT, V284, P252, DOI 10.1016/0014-5793(91)80697-2; Distel B, 1998, J BIOL CHEM, V273, P186, DOI 10.1074/jbc.273.1.186; DOTTI CG, 1990, CELL, V62, P63, DOI 10.1016/0092-8674(90)90240-F; EDLUND T, 1985, SCIENCE, V230, P912, DOI 10.1126/science.3904002; Ghavami A, 1999, J CELL SCI, V112, P967; Goldman PS, 1996, J BIOL CHEM, V271, P4215; Hajos N, 1998, NEUROSCIENCE, V82, P355; Hobert ME, 1997, J BIOL CHEM, V272, P32901, DOI 10.1074/jbc.272.52.32901; HUNZIKER W, 1991, CELL, V66, P907, DOI 10.1016/0092-8674(91)90437-4; Jacob R, 1999, J BIOL CHEM, V274, P8061, DOI 10.1074/jbc.274.12.8061; Jareb M, 1998, NEURON, V20, P855, DOI 10.1016/S0896-6273(00)80468-7; JONES DT, 1987, J BIOL CHEM, V262, P14241; KEEFER JR, 1994, J BIOL CHEM, V269, P16425; Kostenis E, 1997, J BIOL CHEM, V272, P23675, DOI 10.1074/jbc.272.38.23675; Kundu A, 1996, J VIROL, V70, P6508, DOI 10.1128/JVI.70.9.6508-6515.1996; LEBIVIC A, 1991, J CELL BIOL, V115, P607, DOI 10.1083/jcb.115.3.607; LeGall AH, 1997, J BIOL CHEM, V272, P4559, DOI 10.1074/jbc.272.7.4559; LEONARD WJ, 1984, NATURE, V311, P626, DOI 10.1038/311626a0; LEVEY AI, 1995, J NEUROSCI, V15, P4077; LEVEY AI, 1994, NEUROSCIENCE, V63, P207, DOI 10.1016/0306-4522(94)90017-5; LISANTI MP, 1989, J CELL BIOL, V109, P2145, DOI 10.1083/jcb.109.5.2145; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Maisner A, 1996, J BIOL CHEM, V271, P18853, DOI 10.1074/jbc.271.31.18853; MATTER K, 1994, CURR OPIN CELL BIOL, V6, P545, DOI 10.1016/0955-0674(94)90075-2; MATTER K, 1994, J CELL BIOL, V126, P991, DOI 10.1083/jcb.126.4.991; MATTER K, 1992, CELL, V71, P741, DOI 10.1016/0092-8674(92)90551-M; MATUSLEIBOVITCH N, 1990, PFLUG ARCH EUR J PHY, V417, P194, DOI 10.1007/BF00370699; MELLON PL, 1989, P NATL ACAD SCI USA, V86, P4887, DOI 10.1073/pnas.86.13.4887; MIGEON JC, 1995, J BIOL CHEM, V270, P16070, DOI 10.1074/jbc.270.27.16070; MIGEON JC, 1994, J BIOL CHEM, V269, P9767; MONLAUZEUR L, 1995, J BIOL CHEM, V270, P12219, DOI 10.1074/jbc.270.20.12219; MORO O, 1994, J BIOL CHEM, V269, P6651; MORO O, 1993, J BIOL CHEM, V268, P6862; Muth TR, 1998, J BIOL CHEM, V273, P25616, DOI 10.1074/jbc.273.40.25616; Nadler LS, 1999, AM J PHYSIOL-CELL PH, V277, pC1220, DOI 10.1152/ajpcell.1999.277.6.C1220; Odorizzi G, 1997, J CELL BIOL, V137, P1255, DOI 10.1083/jcb.137.6.1255; Odorizzi G, 1997, J BIOL CHEM, V272, P11757, DOI 10.1074/jbc.272.18.11757; PERALTA EG, 1987, SCIENCE, V236, P600, DOI 10.1126/science.3107123; Renold A, 2000, J BIOL CHEM, V275, P9290, DOI 10.1074/jbc.275.13.9290; Rodionov DG, 2000, J BIOL CHEM, V275, P8279, DOI 10.1074/jbc.275.12.8279; Rouse ST, 1997, LIFE SCI, V60, P1031, DOI 10.1016/S0024-3205(97)00044-1; Rouse ST, 1998, NEUROSCIENCE, V86, P221, DOI 10.1016/S0306-4522(97)00681-7; Sambrook J., 2002, MOL CLONING LAB MANU; Saunders C, 1998, J BIOL CHEM, V273, P24196, DOI 10.1074/jbc.273.37.24196; SCHEIFFELE P, 1995, NATURE, V378, P96, DOI 10.1038/378096a0; Schlador ML, 2000, J BIOL CHEM, V275, P23295, DOI 10.1074/jbc.M002380200; Schlador ML, 1997, J BIOL CHEM, V272, P18882, DOI 10.1074/jbc.272.30.18882; SHAPIRO RA, 1988, J BIOL CHEM, V263, P18397; Simmen T, 1999, MOL CELL BIOL, V19, P3136; SIMON SA, 1992, ARCH ORAL BIOL, V37, P685, DOI 10.1016/0003-9969(92)90072-G; Stowell JN, 1999, NEURON, V22, P525, DOI 10.1016/S0896-6273(00)80707-2; TAN YP, 1992, P NATL ACAD SCI USA, V89, P11229, DOI 10.1073/pnas.89.23.11229; TOESCU EC, 1992, EMBO J, V11, P1623, DOI 10.1002/j.1460-2075.1992.tb05208.x; Tugizov S, 1998, J VIROL, V72, P7374, DOI 10.1128/JVI.72.9.7374-7386.1998; Wess J, 1996, CRIT REV NEUROBIOL, V10, P69, DOI 10.1615/CritRevNeurobiol.v10.i1.40; Wozniak M, 1998, BRAIN RES, V780, P311, DOI 10.1016/S0006-8993(97)01216-X; Yeaman C, 1996, AM J PHYSIOL-CELL PH, V270, pC753, DOI 10.1152/ajpcell.1996.270.3.C753; Yeaman C, 1999, PHYSIOL REV, V79, P73, DOI 10.1152/physrev.1999.79.1.73	64	18	18	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 30	2001	276	13					10539	10547		10.1074/jbc.M007190200	http://dx.doi.org/10.1074/jbc.M007190200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	420GC	11136723	hybrid			2022-12-25	WOS:000167996400123
J	Osman, A; Niles, EG; LoVerde, PT				Osman, A; Niles, EG; LoVerde, PT			Identification and characterization of a Smad2 homologue from Schistosoma mansoni, a transforming growth factor-beta signal transducer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAD-RELATED PROTEIN; FAMILY MEDIATOR SMAD1; TUMOR-SUPPRESSOR; RECEPTOR HOMOLOG; MOUSE EMBRYO; PHOSPHORYLATION; KINASE; SMAD4/DPC4; ACTIVATION; PATHWAYS	Smad proteins are essential intracellular signal transducers of the transforming growth factor-beta (TGF-beta) superfamily, The TGF-beta superfamily signals through phosphorylation and activation of R-Smad proteins, receptor-regulated Smads, by heteromeric complexes of ligand-specific type I and type II serine/threonine kinase receptors, R-Smads receive a signal from the activated receptor complex and transmit it to the nucleus. A cDNA was isolated that encodes a 649-amino acid protein found to be homologous to members of R-Smad subfamily with highest homology scored to clawed African frog and human Smads, The Schistosoma mansoni homologue (SmSmad2) was overexpressed in bacteria as a Sj26-GST fusion protein and used to raise specific antibodies. The IgG fraction of the immunized rabbit serum identified 70- and 72-kDa protein bands in Western analysis of schistosome extracts. Treatment with alkaline phosphatase removed the 72-kDa band, which indicates that this band represents the phosphorylated form of schistosome Smad2, SmSmad2 was localized in the subtegument, parenchymal cells, and sex organs in both male and female worm cryosections. Similar results were also obtained from the analysis of the Smad2 mRNA distribution pattern revealed by in situ hybridization of adult worm pair paraffin sections, SmSmad2 mRNA levels were determined by reverse transcriptase-polymerase chain reaction in different mammalian host developmental stages and found to be constitutively expressed, SmSmad2 was also found to interact with a previously identified SmT betaR-I, a serine/threonine type I kinase receptor. Furthermore, SmSmad2 was shown to undergo phosphorylation by constitutively active forms of SmT betaR-I in uitro, In addition, SmSmad2 localized in the nuclei of mink lung epithelial cells upon treatment with TGF-beta (1), These data indicate that the SmSmad2 responds to the TGF-beta signals by interaction with receptor I, which phosphorylates it, whereupon it translocates into the nucleus presumably to regulate target gene transcription and consequently elicit a specific TGF-beta effect.	SUNY Buffalo, Sch Med & Biomed Sci, Dept Microbiol, Buffalo, NY 14214 USA; SUNY Buffalo, Sch Med & Biomed Sci, Ctr Microbial Pathogenesis, Buffalo, NY 14214 USA	State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo	LoVerde, PT (corresponding author), SUNY Buffalo, Sch Med & Biomed Sci, Dept Microbiol, 138 Farber Hall, Buffalo, NY 14214 USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI046762] Funding Source: NIH RePORTER; NIAID NIH HHS [AI46762] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Abdollah S, 1997, J BIOL CHEM, V272, P27678, DOI 10.1074/jbc.272.44.27678; Baker JC, 1996, GENE DEV, V10, P1880, DOI 10.1101/gad.10.15.1880; BOBEK L, 1986, P NATL ACAD SCI USA, V83, P5544, DOI 10.1073/pnas.83.15.5544; BOROS DL, 1989, CLIN MICROBIOL REV, V2, P250, DOI 10.1128/CMR.2.3.250-269.1989; Calonge MJ, 1999, J BIOL CHEM, V274, P33637, DOI 10.1074/jbc.274.47.33637; Chen TP, 1998, CANCER RES, V58, P4805; Chen Y, 1996, P NATL ACAD SCI USA, V93, P12992, DOI 10.1073/pnas.93.23.12992; Davies SJ, 1998, J BIOL CHEM, V273, P11234, DOI 10.1074/jbc.273.18.11234; Derynck R, 1998, NATURE, V393, P737, DOI 10.1038/31593; Engers HD, 1996, DEV BIOL STAND, V87, P73; Eppert K, 1996, CELL, V86, P543, DOI 10.1016/S0092-8674(00)80128-2; Feng XH, 1997, EMBO J, V16, P3912, DOI 10.1093/emboj/16.13.3912; Freebern WJ, 1999, J BIOL CHEM, V274, P4577, DOI 10.1074/jbc.274.8.4577; Graff JM, 1996, CELL, V85, P479, DOI 10.1016/S0092-8674(00)81249-0; Hayashi H, 1997, CELL, V89, P1165, DOI 10.1016/S0092-8674(00)80303-7; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Hoodless PA, 1996, CELL, V85, P489, DOI 10.1016/S0092-8674(00)81250-7; Kim J, 1997, NATURE, V388, P304, DOI 10.1038/40906; Kretzschmar M, 1999, GENE DEV, V13, P804, DOI 10.1101/gad.13.7.804; Kretzschmar M, 1997, NATURE, V389, P618, DOI 10.1038/39348; Kretzschmar M, 1997, GENE DEV, V11, P984, DOI 10.1101/gad.11.8.984; Lagna G, 1996, NATURE, V383, P832, DOI 10.1038/383832a0; LAIHO M, 1990, CELL, V62, P175, DOI 10.1016/0092-8674(90)90251-9; Liu F, 1997, GENE DEV, V11, P3157, DOI 10.1101/gad.11.23.3157; Liu F, 1996, NATURE, V381, P620, DOI 10.1038/381620a0; Lo RS, 1998, EMBO J, V17, P996, DOI 10.1093/emboj/17.4.996; LOVERDE PT, 1991, PARASITOL TODAY, V7, P303, DOI 10.1016/0169-4758(91)90263-N; MaciasSilva M, 1996, CELL, V87, P1215, DOI 10.1016/S0092-8674(00)81817-6; Massague J, 2000, EMBO J, V19, P1745, DOI 10.1093/emboj/19.8.1745; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Meersseman G, 1997, MECH DEVELOP, V61, P127, DOI 10.1016/S0925-4773(96)00629-6; Nakao A, 1997, J BIOL CHEM, V272, P2896, DOI 10.1074/jbc.272.5.2896; Nakao A, 1997, EMBO J, V16, P5353, DOI 10.1093/emboj/16.17.5353; Nellen D, 1996, CELL, V85, P357, DOI 10.1016/S0092-8674(00)81114-9; Neumann C, 1997, BIOESSAYS, V19, P721, DOI 10.1002/bies.950190813; Nomura M, 1998, NATURE, V393, P786, DOI 10.1038/31693; Osman A, 1999, MOL BIOCHEM PARASIT, V100, P27, DOI 10.1016/S0166-6851(99)00029-8; Ramachandran H, 1996, MOL BIOCHEM PARASIT, V83, P1, DOI 10.1016/S0166-6851(96)02731-4; Riggins GJ, 1996, NAT GENET, V13, P347, DOI 10.1038/ng0796-347; SEKELSKY JJ, 1995, GENETICS, V139, P1347; Shi YG, 1998, CELL, V94, P585, DOI 10.1016/S0092-8674(00)81600-1; SILVA EE, 1993, J IMMUNOL, V151, P7057; Sirard C, 1998, GENE DEV, V12, P107, DOI 10.1101/gad.12.1.107; Smithers S. R., 1982, Immunology of parasitic infections.  2nd edition., P527; Tsukazaki T, 1998, CELL, V95, P779, DOI 10.1016/S0092-8674(00)81701-8; Waldrip WR, 1998, CELL, V92, P797, DOI 10.1016/S0092-8674(00)81407-5; WIESER R, 1995, EMBO J, V14, P2199, DOI 10.1002/j.1460-2075.1995.tb07214.x; Willis SA, 1996, MOL ENDOCRINOL, V10, P367, DOI 10.1210/me.10.4.367; Wu G, 2000, SCIENCE, V287, P92, DOI 10.1126/science.287.5450.92; Zhang Y, 1997, CURR BIOL, V7, P270, DOI 10.1016/S0960-9822(06)00123-0; Zhang Y, 1996, NATURE, V383, P168, DOI 10.1038/383168a0	51	62	66	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 30	2001	276	13					10072	10082		10.1074/jbc.M005933200	http://dx.doi.org/10.1074/jbc.M005933200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	420GC	11152451	hybrid			2022-12-25	WOS:000167996400067
J	Pedarzani, P; Mosbacher, J; Rivard, A; Cingolani, LA; Oliver, D; Stocker, M; Adelman, JP; Fakler, B				Pedarzani, P; Mosbacher, J; Rivard, A; Cingolani, LA; Oliver, D; Stocker, M; Adelman, JP; Fakler, B			Control of electrical activity in central neurons by modulating the gating of small conductance Ca2+-activated K+ channels	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED POTASSIUM CHANNELS; CA1 PYRAMIDAL NEURONS; INTERMEDIATE-CONDUCTANCE; CALCIUM CHANNELS; EPILEPTIFORM ACTIVITY; HIPPOCAMPAL-NEURONS; EPITHELIAL-CELLS; CALMODULIN; INACTIVATION; RECEPTORS	In most central neurons, action potentials are followed by an afterhyperpolarization (AHP) that controls firing pattern and excitability, The medium and slow components of the AHP have been ascribed to the activation of small conductance Ca2+-activated potassium (SK) channels. Cloned SK channels are heteromeric complexes of SK alpha -subunits and calmodulin, The channels are activated by Ca2+ binding to calmodulin that induces conformational changes resulting in channel opening, and channel deactivation is the reverse process brought about by dissociation of Ca2+ Rom calmodulin, Here we show that SK channel gating is effectively modulated by 1-ethyl-2-benzimidazolinone (EBIO). Application of EBIO to cloned SK channels shifts the Ca2+ concentration-response relation into the lower nanomolar range and slows channel deactivation by almost 10-fold. In hippocampal CA1 neurons, EBIO increased both the medium and slow AHP, strongly reducing electrical activity. Moreover, EBIO suppressed the hyperexcitability induced by low Mg2+ in cultured cortical neurons. These results underscore the importance of SK channels for shaping the electrical response patterns of central neurons and suggest that modulating SK channel gating is a potent mechanism for controlling excitability in the central nervous system.	Univ Tubingen, Dept Physiol 2, D-72074 Tubingen, Germany; Oregon Hlth & Sci Univ, Vollum Inst, Portland, OR 97201 USA; Novartis Pharma AG, TA Nervous Syst, CH-4002 Basel, Switzerland; Max Planck Inst Expt Med, D-37075 Gottingen, Germany	Eberhard Karls University of Tubingen; Oregon Health & Science University; Novartis; Max Planck Society	Fakler, B (corresponding author), Univ Tubingen, Dept Physiol 2, Ob Himmelreich 7, D-72074 Tubingen, Germany.	bernd.fakler@uni-tuebingen.de	Oliver, Dominik/F-5845-2013; Cingolani, Lorenzo A/ABH-1364-2021; Cingolani, Lorenzo/J-1530-2012; Stocker, Martin/C-1844-2008	Oliver, Dominik/0000-0002-8368-0923; Cingolani, Lorenzo A/0000-0001-9538-1659; 				Adeagbo ASO, 1999, EUR J PHARMACOL, V379, P151, DOI 10.1016/S0014-2999(99)00489-6; Adkins CE, 2000, BIOCHEM J, V345, P357, DOI 10.1042/0264-6021:3450357; BLANTON MG, 1989, J NEUROSCI METH, V30, P203, DOI 10.1016/0165-0270(89)90131-3; BRUGNARA C, 1995, J MEMBRANE BIOL, V147, P71, DOI 10.1007/BF00235398; Devor DC, 1999, J GEN PHYSIOL, V113, P743, DOI 10.1085/jgp.113.5.743; Devor DC, 1996, AM J PHYSIOL-LUNG C, V271, pL775, DOI 10.1152/ajplung.1996.271.5.L775; Dzhura I, 2000, NAT CELL BIOL, V2, P173, DOI 10.1038/35004052; FABIATO A, 1988, METHOD ENZYMOL, V157, P378; FAKLER B, 1995, CELL, V80, P149, DOI 10.1016/0092-8674(95)90459-X; Fanger CM, 1999, J BIOL CHEM, V274, P5746, DOI 10.1074/jbc.274.9.5746; Gardener MJ, 1999, BRIT J PHARMACOL, V128, P1064, DOI 10.1038/sj.bjp.0702916; HAIECH J, 1991, J BIOL CHEM, V266, P3427; Hamilton KL, 1999, PFLUG ARCH EUR J PHY, V439, P158, DOI 10.1007/s004240051140; Hille B., 1992, IONIC CHANNELS EXCIT; Hirschberg B, 1998, J GEN PHYSIOL, V111, P565, DOI 10.1085/jgp.111.4.565; Hirschberg B, 1999, BIOPHYS J, V77, P1905, DOI 10.1016/S0006-3495(99)77032-3; Ishii TM, 1997, P NATL ACAD SCI USA, V94, P11651, DOI 10.1073/pnas.94.21.11651; Jensen BS, 1998, AM J PHYSIOL-CELL PH, V275, pC848, DOI 10.1152/ajpcell.1998.275.3.C848; Jensen BS, 1999, P NATL ACAD SCI USA, V96, P10917, DOI 10.1073/pnas.96.19.10917; Joiner WJ, 1997, P NATL ACAD SCI USA, V94, P11013, DOI 10.1073/pnas.94.20.11013; Keen JE, 1999, J NEUROSCI, V19, P8830, DOI 10.1523/JNEUROSCI.19-20-08830.1999; Kohler M, 1996, SCIENCE, V273, P1709, DOI 10.1126/science.273.5282.1709; Lee A, 1999, NATURE, V399, P155, DOI 10.1038/20194; Logsdon NJ, 1997, J BIOL CHEM, V272, P32723, DOI 10.1074/jbc.272.52.32723; MADISON DV, 1986, J PHYSIOL-LONDON, V372, P221, DOI 10.1113/jphysiol.1986.sp016006; MAHAUTSMITH MP, 1995, J PHYSIOL-LONDON, V484, P15, DOI 10.1113/jphysiol.1995.sp020644; Marrion NV, 1998, NATURE, V395, P900, DOI 10.1038/27674; Michikawa T, 1999, NEURON, V23, P799, DOI 10.1016/S0896-6273(01)80037-4; Mirzoeva S, 1999, BIOCHEMISTRY-US, V38, P14117, DOI 10.1021/bi9950894; MODY I, 1987, J NEUROPHYSIOL, V57, P869, DOI 10.1152/jn.1987.57.3.869; NICOLL RA, 1988, SCIENCE, V241, P545, DOI 10.1126/science.2456612; Oliver D, 2000, NEURON, V26, P595, DOI 10.1016/S0896-6273(00)81197-6; OLWIN BB, 1985, BIOCHEMISTRY-US, V24, P8081, DOI 10.1021/bi00348a037; OLWIN BB, 1984, J BIOL CHEM, V259, P949; OZAWA T, 1999, BIOCHIM BIOPHYS ACTA, V1432, P254; PEDARZANI P, 1993, NEURON, V11, P1023, DOI 10.1016/0896-6273(93)90216-E; Pedersen KA, 1999, BBA-BIOMEMBRANES, V1420, P231, DOI 10.1016/S0005-2736(99)00110-8; Peterson BZ, 1999, NEURON, V22, P549, DOI 10.1016/S0896-6273(00)80709-6; Sah P, 1996, TRENDS NEUROSCI, V19, P150, DOI 10.1016/S0166-2236(96)80026-9; Schlossmann J, 2000, NATURE, V404, P197, DOI 10.1038/35004606; Schwab A, 1999, PFLUG ARCH EUR J PHY, V438, P330, DOI 10.1007/s004240050917; SCHWINDT PC, 1992, J NEUROPHYSIOL, V67, P216, DOI 10.1152/jn.1992.67.1.216; STANTON PK, 1987, EPILEPSY RES, V1, P53, DOI 10.1016/0920-1211(87)90051-9; Stocker M, 1999, P NATL ACAD SCI USA, V96, P4662, DOI 10.1073/pnas.96.8.4662; Stocker M, 2000, MOL CELL NEUROSCI, V15, P476, DOI 10.1006/mcne.2000.0842; STORM JF, 1990, PROG BRAIN RES, V83, P161; Syme CA, 2000, AM J PHYSIOL-CELL PH, V278, pC570, DOI 10.1152/ajpcell.2000.278.3.C570; Trost C, 1999, FEBS LETT, V451, P257, DOI 10.1016/S0014-5793(99)00588-8; Wang XS, 1997, BRAIN RES, V767, P239, DOI 10.1016/S0006-8993(97)00585-4; Warth R, 1999, PFLUG ARCH EUR J PHY, V438, P437, DOI 10.1007/s004240051059; WOLFART J, 2000, SOC NEUR ABSTR, V26, P1401; Xia XM, 1998, NATURE, V395, P503, DOI 10.1038/26758; ZAGOTTA WN, 1994, J GEN PHYSIOL, V103, P321, DOI 10.1085/jgp.103.2.321; ZAGOTTA WN, 1994, J GEN PHYSIOL, V103, P279, DOI 10.1085/jgp.103.2.279; Zuhlke RD, 1999, NATURE, V399, P159, DOI 10.1038/20200	55	191	199	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 30	2001	276	13					9762	9769		10.1074/jbc.M010001200	http://dx.doi.org/10.1074/jbc.M010001200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	420GC	11134030	hybrid			2022-12-25	WOS:000167996400026
J	Tretter, V; Hauer, B; Nusser, Z; Mihalek, RM; Hoger, H; Homanics, GE; Somogyi, P; Sieghart, W				Tretter, V; Hauer, B; Nusser, Z; Mihalek, RM; Hoger, H; Homanics, GE; Somogyi, P; Sieghart, W			Targeted disruption of the GABA(A) receptor delta subunit gene leads to an up-regulation of gamma(2) subunit-containing receptors in cerebellar granule cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINOBUTYRIC ACID(A) RECEPTORS; A RECEPTOR; RAT-BRAIN; ALPHA-6 SUBUNIT; ALCOHOL ANTAGONIST; SUBTYPES; MICE; PHARMACOLOGY; EXPRESSION; BINDING	GABA(A) receptors are chloride channels composed of five subunits. Cerebellar granule cells express abundantly six subunits belonging to four subunit classes. These are assembled into a number of distinct receptors, but the regulation of their relative proportions is yet unknown. Here, we studied the composition of cerebellar GABA(A) receptors after targeted disruption of the delta subunit gene, In membranes and extracts of delta-/- cerebellum, [H-3]muscimol binding was not significantly changed, whereas [H-3]Ro15-4513 binding was increased by 52% due to an increase in diazepam-insensitive binding. Immunocytochemical and Western blot analysis revealed no change in alpha (6) subunits but an increased expression of gamma (2) subunits in delta-/- cerebellum. Immunoaffinity chromatography of cerebellar extracts indicated there was an increased coassembly of alpha (6) and gamma (2) subunits and that 24% of all receptors in delta-/- cerebellum did not contain a gamma subunit, Because 97% of delta subunits are coassembled with alpha (6) subunits in the cerebellum of wild-type mice, these results indicated that, in delta-/- mice, alpha (6)beta gamma (2) and alpha beta receptors replaced delta subunit-containing receptors, The availability of the delta subunit, thus, influences the level of expression or the extent of assembly of the gamma (2) subunit, although these two subunits do not occur in the same receptor.	Univ Vienna, Brain Res Inst, A-1090 Vienna, Austria; Univ Vienna, Sect Biochem Psychiat, Psychiat Clin, A-1090 Vienna, Austria; MRC, Anat Neuropharmacol Unit, Oxford OX1 3TH, England; Univ Pittsburgh, Sch Med, Dept Anesthesiol Crit Care Med, Pittsburgh, PA 15261 USA; Univ Pittsburgh, Sch Med, Dept Pharmacol, Pittsburgh, PA 15261 USA; Res Inst Lab Anim Breeding, A-2325 Himberg, Austria	University of Vienna; University of Vienna; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Sieghart, W (corresponding author), Univ Vienna, Brain Res Inst, Spitalgasse 4, A-1090 Vienna, Austria.		Sieghart, Werner/A-4877-2013; Nusser, Zoltan/K-8587-2014	Sieghart, Werner/0000-0002-0443-0302; Nusser, Zoltan/0000-0001-7004-4111; Homanics, Gregg/0000-0003-3641-8153	NIAAA NIH HHS [AA10422] Funding Source: Medline; NIGMS NIH HHS [GM52035] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052035] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R01AA010422, R37AA010422] Funding Source: NIH RePORTER	NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		ANGELOTTI TP, 1993, J NEUROSCI, V13, P1429; ANGELOTTI TP, 1993, J NEUROSCI, V13, P1418; Araujo F, 1998, EUR J PHARMACOL, V347, P347, DOI 10.1016/S0014-2999(98)00122-8; Barnard EA, 1998, PHARMACOL REV, V50, P291; Benke D, 1996, NEUROPHARMACOLOGY, V35, P1413, DOI 10.1016/S0028-3908(96)00068-8; BENKE D, 1991, FEBS LETT, V283, P145, DOI 10.1016/0014-5793(91)80573-L; BENKE D, 1991, J BIOL CHEM, V266, P4478; Bonnert TP, 1999, P NATL ACAD SCI USA, V96, P9891, DOI 10.1073/pnas.96.17.9891; Essrich C, 1998, NAT NEUROSCI, V1, P563, DOI 10.1038/2798; Gorrie GH, 1997, J NEUROSCI, V17, P6587; GUNTHER U, 1995, P NATL ACAD SCI USA, V92, P7749, DOI 10.1073/pnas.92.17.7749; Homanics GE, 1997, MOL PHARMACOL, V51, P588, DOI 10.1124/mol.51.4.588; Homanics GE, 1997, P NATL ACAD SCI USA, V94, P4143, DOI 10.1073/pnas.94.8.4143; Jechlinger M, 1998, J NEUROSCI, V18, P2449; Jones A, 1997, J NEUROSCI, V17, P1350; Khan ZU, 1996, J NEUROCHEM, V66, P685; KORPI ER, 1993, NEUROSCIENCE, V53, P483, DOI 10.1016/0306-4522(93)90212-X; LUDDENS H, 1990, NATURE, V346, P648, DOI 10.1038/346648a0; MACDONALD RL, 1994, ANNU REV NEUROSCI, V17, P569, DOI 10.1146/annurev.neuro.17.1.569; McKernan RM, 1996, TRENDS NEUROSCI, V19, P139, DOI 10.1016/S0166-2236(96)80023-3; Mihalek RM, 1999, P NATL ACAD SCI USA, V96, P12905, DOI 10.1073/pnas.96.22.12905; Mohler H, 1998, LIFE SCI, V62, P1611, DOI 10.1016/S0024-3205(98)00116-7; MOSSIER B, 1994, J BIOL CHEM, V269, P25777; Nusser Z, 1999, EUR J NEUROSCI, V11, P1685, DOI 10.1046/j.1460-9568.1999.00581.x; Nusser Z, 1998, J NEUROSCI, V18, P1693; Nusser Z, 1996, J NEUROSCI, V16, P103; PERSOHN E, 1992, J COMP NEUROL, V326, P193, DOI 10.1002/cne.903260204; POLLARD S, 1995, J BIOL CHEM, V270, P21285, DOI 10.1074/jbc.270.36.21285; QUIRK K, 1995, EUR J PHARM-MOLEC PH, V290, P175, DOI 10.1016/0922-4106(95)00061-5; Sieghart W, 1999, NEUROCHEM INT, V34, P379, DOI 10.1016/S0197-0186(99)00045-5; SIEGHART W, 1995, PHARMACOL REV, V47, P181; SIEGHART W, 1987, J NEUROCHEM, V48, P46, DOI 10.1111/j.1471-4159.1987.tb13125.x; STEPHENSON FA, 1995, BIOCHEM J, V310, P1; THOMPSON CL, 1994, J NEUROCHEM, V62, P2037; Tretter V, 1997, J NEUROSCI, V17, P2728; TURNER DM, 1991, J PHARMACOL EXP THER, V257, P1236; Wang HB, 1999, NATURE, V397, P69, DOI 10.1038/16264; Wisden W, 1996, NEUROPHARMACOLOGY, V35, P1139, DOI 10.1016/S0028-3908(96)00076-7; WISDEN W, 1992, J NEUROSCI, V12, P1040; ZEZULA J, 1991, BRAIN RES, V563, P325, DOI 10.1016/0006-8993(91)91556-G; Zezula J, 1996, EUR J PHARMACOL, V301, P207, DOI 10.1016/0014-2999(96)00066-0	41	76	76	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 30	2001	276	13					10532	10538		10.1074/jbc.M011054200	http://dx.doi.org/10.1074/jbc.M011054200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	420GC	11136737	hybrid			2022-12-25	WOS:000167996400122
J	Nardai, G; Braun, L; Csala, M; Mile, V; Csermely, P; Benedetti, A; Mandl, J; Banhegyi, G				Nardai, G; Braun, L; Csala, M; Mile, V; Csermely, P; Benedetti, A; Mandl, J; Banhegyi, G			Protein-disulfide isomerase- and protein thiol-dependent dehydroascorbate reduction and ascorbate accumulation in the lumen of the endoplasmic reticulum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIVER MICROSOMAL VESICLES; GLUTATHIONE-INSULIN TRANSHYDROGENASE; RIBONUCLEASE-REACTIVATING ENZYME; RAT-LIVER; TISSUE DISTRIBUTION; INTERCHANGE ENZYME; SECRETION GRANULES; PAROTID-GLAND; GLUCOSE-6-PHOSPHATASE; DEGRADATION	The transport and intraluminal reduction of dehydroascorbate was investigated in microsomal vesicles from various tissues. The highest rates of transport and intraluminal isotope accumulation (using radiolabeled compound and a rapid filtration technique) were found in hepatic microsomes. These microsomes contain the highest amount of protein-disulfide isomerase, which is known to have a dehydroascorbate reductase activity, The steady-state level of intraluminal isotope accumulation was more than a-fold higher in hepatic microsomes prepared from spontaneously diabetic BioBreeding/Worcester rats and was very low in fetal hepatic microsomes although the initial rate of transport was not changed. In these microsomes, the amount of protein-disulfide isomerase was similar, but the availability of protein thiols was different and correlated with dehydroascorbate uptake. The increased isotope accumulation was accompanied by a higher rate of dehydroascorbate reduction and increased protein thiol oxidation in microsomes from diabetic animals, The results suggest that both the activity of protein-disulfide isomerase and the availability of protein thiols as reducing equivalents can play a crucial role in the accumulation of ascorbate in the lumen of the endoplasmic reticulum, These findings also support the fact that dehydroascorbate can act as an oxidant in the protein-disulfide isomerase-catalyzed protein disulfide formation.	Semmelweis Univ, Dept Med Chem, H-1444 Budapest, Hungary; Univ Siena, Dipartimento Fisiopatol & Med Sperimentale, I-53100 Siena, Italy	Semmelweis University; University of Siena	Banhegyi, G (corresponding author), Semmelweis Univ, Dept Med Chem, POB 260, H-1444 Budapest, Hungary.	banhegyi@puskin.sote.hu	Csermely, Peter/J-2067-2017; Csala, Miklos/H-5369-2011; Bánhegyi, Gábor/A-1476-2014	Csermely, Peter/0000-0001-9234-0659; Csala, Miklos/0000-0002-3829-4361; 				Banhegyi G, 1998, J BIOL CHEM, V273, P2758, DOI 10.1074/jbc.273.5.2758; Banhegyi G, 1999, J BIOL CHEM, V274, P12213, DOI 10.1074/jbc.274.18.12213; BJELLAND S, 1987, COMP BIOCHEM PHYS B, V87, P907, DOI 10.1016/0305-0491(87)90411-1; BURCHELL A, 1988, CLIN CHIM ACTA, V173, P183, DOI 10.1016/0009-8981(88)90256-2; Csala M, 1999, FEBS LETT, V460, P539, DOI 10.1016/S0014-5793(99)01412-X; Csala M, 2000, BIOCHEM J, V349, P413, DOI 10.1042/0264-6021:3490413; DANIELS AJ, 1982, SCIENCE, V216, P737, DOI 10.1126/science.7079733; ELLMAN G, 1979, ANAL BIOCHEM, V93, P98, DOI 10.1016/S0003-2697(79)80122-0; Ferrari DM, 1999, BIOCHEM J, V339, P1, DOI 10.1042/0264-6021:3390001; FULCERI R, 1994, ARCH BIOCHEM BIOPHYS, V309, P43, DOI 10.1006/abbi.1994.1081; FULCERI R, 1993, BIOCHEM J, V289, P299, DOI 10.1042/bj2890299; Gamberucci A, 1996, MOL MEMBR BIOL, V13, P103, DOI 10.3109/09687689609160583; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; HENNE V, 1986, FEBS LETT, V202, P267, DOI 10.1016/0014-5793(86)80699-8; HERN EP, 1980, J BIOL CHEM, V255, P697; Heuck AP, 1997, ANAL BIOCHEM, V248, P94, DOI 10.1006/abio.1997.2123; HOLMGREN A, 1979, J BIOL CHEM, V254, P9627; HWANG C, 1992, SCIENCE, V257, P1496, DOI 10.1126/science.1523409; Marcus N, 1996, BBA-GENE STRUCT EXPR, V1309, P253, DOI 10.1016/S0167-4781(96)00133-9; Ngkeekwong FC, 1997, BIOCHEM J, V324, P225, DOI 10.1042/bj3240225; NIETO A, 1990, BIOCHEM J, V267, P317, DOI 10.1042/bj2670317; Omaye S T, 1979, Methods Enzymol, V62, P3, DOI 10.1016/0076-6879(79)62181-X; Puskas F, 1999, J BIOL CHEM, V274, P117, DOI 10.1074/jbc.274.1.117; SOM S, 1981, METABOLISM, V30, P572, DOI 10.1016/0026-0495(81)90133-5; THOMAS JH, 1979, BIOCHIM BIOPHYS ACTA, V567, P88, DOI 10.1016/0005-2744(79)90175-X; VARANDANI PT, 1985, DIABETOLOGIA, V28, P379; VENETIAN.P, 1965, ACTA PHYSIOL HUNG, V27, P303; VENETIANER P, 1964, BIOCHIM BIOPHYS ACTA, V89, P189, DOI 10.1016/0926-6569(64)90123-3; VONZASTROW M, 1986, P NATL ACAD SCI USA, V83, P3297; VONZASTROW M, 1984, J BIOL CHEM, V259, P1746; WELLS WW, 1994, J BIOENERG BIOMEMBR, V26, P369, DOI 10.1007/BF00762777; WELLS WW, 1990, J BIOL CHEM, V265, P15361; WHITEHEAD TP, 1979, CLIN CHEM, V25, P1531; WILLIAMSON JR, 1993, DIABETES, V42, P801, DOI 10.2337/diabetes.42.6.801	34	49	59	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 23	2001	276	12					8825	8828		10.1074/jbc.M010563200	http://dx.doi.org/10.1074/jbc.M010563200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	413HV	11136734	hybrid			2022-12-25	WOS:000167607700030
J	Yart, A; Laffargue, M; Mayeux, P; Chretien, S; Peres, C; Tonks, N; Roche, S; Payrastre, B; Chap, H; Raynal, P				Yart, A; Laffargue, M; Mayeux, P; Chretien, S; Peres, C; Tonks, N; Roche, S; Payrastre, B; Chap, H; Raynal, P			A critical pole for phosphoinositide 3-kinase upstream of Gab1 and SHP2 in the activation of Ras and mitogen-activated protein kinases by epidermal growth factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-REGULATED KINASE; PHOSPHATIDYLINOSITOL 3-KINASE; LYSOPHOSPHATIDIC ACID; DOCKING PROTEIN; RECEPTOR; DOMAIN; PHOSPHORYLATION; PHOSPHATASE; INHIBITION; BINDING	Although the mechanisms involved in the activation of mitogen-activated protein kinases (MAPK) by receptor tyrosine kinases do not display an obvious role for phosphoinositide 3-kinases (PI3Ks), we have observed in the nontransformed cell line Vero stimulated with epidermal growth factor (EGF) that wortmannin and LY294002 nearly abolished MAPK activation. The effect was observed under strong stimulation and was independent of EGF concentration. In addition, three mutants of class Is PI3Ks were found to inhibit MAPK activation to an extent similar to their effect on Akt/protein kinase B activation. To determine the importance of PI3K lipid kinase activity in MAPK activation, we have used the phosphatase PTEN and the pleckstrin homology domain of Tec kinase, Overexpression of these proteins, but not control mutants, was found to inhibit MAPK activation, suggesting that the lipid products of class Ia PI3K are necessary for MAPK signaling. We next investigated the location of PI3K in the MAPK cascade. Pharmacological inhibitors and dominant negative forms of PI3K were found to block the activation of Pas induced by EGF, Upstream from Pas, although association of Grb2 with its conventional effectors was independent of PI3K we have observed that the recruitment of the tyrosine phosphatase SHP2 required PI3K, Because SHP2 was also essential for Ras activation, this suggested the:existence of a PI3K/SHP2 pathway leading to the activation of Pas. In addition, we have observed that the docking protein Gab1, which is involved in PI3K activation during EGF stimulation, is also implicated in this pathway downstream of PI3K, Indeed, the association of Gab1 with SHP2 was blocked by PI3K inhibitors, and expression of Gab1 mutant deficient for binding to SHPS was found to inhibit Ras stimulation without interfering with PI3K activation. These results show that, in addition to Shc and Grb2, a PI3K-dependent pathway involving Gab1 and SHP2 is essential for Ras activation under EGF stimulation.	Hop Purpan, IFR 30, INSERM, U326, F-31059 Toulouse, France; Hop Cochin, INSERM, U363, F-75014 Paris, France; CNRS, UPR 1086, F-34293 Montpellier, France; Cold Spring Harbor Lab, Cold Spring Harbor, NY 11724 USA	CHU de Toulouse; Institut National de la Sante et de la Recherche Medicale (Inserm); Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Centre National de la Recherche Scientifique (CNRS); Cold Spring Harbor Laboratory	Raynal, P (corresponding author), Hop Purpan, IFR 30, INSERM, U326, F-31059 Toulouse, France.	raynal@purpan.inserm.fr	Laffargue, Muriel/AAE-7849-2021; Peres, Carlos A./B-1276-2013; Chretien, Stany/M-5166-2018; Raynal, Patrick/O-1926-2018; Peres, Carlos A./ABE-8361-2020; YART, Armelle/A-5656-2016; Peres, Carlos Augusto/N-8275-2019	Peres, Carlos A./0000-0002-1588-8765; Peres, Carlos A./0000-0002-1588-8765; YART, Armelle/0000-0002-2412-9840; Laffargue, Muriel/0000-0003-1833-639X; Raynal, Patrick/0000-0002-6731-3007; roche, serge/0000-0003-3413-3859; , Bernard/0000-0002-8693-0190	NATIONAL CANCER INSTITUTE [R01CA053840] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		August A, 1997, P NATL ACAD SCI USA, V94, P11227, DOI 10.1073/pnas.94.21.11227; Bennett AM, 1996, MOL CELL BIOL, V16, P1189; Bi L, 1999, J BIOL CHEM, V274, P10963, DOI 10.1074/jbc.274.16.10963; Bondeva T, 1998, SCIENCE, V282, P293, DOI 10.1126/science.282.5387.293; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; BURGERING BMT, 1993, MOL CELL BIOL, V13, P7248, DOI 10.1128/MCB.13.12.7248; CROSS MJ, 1995, J BIOL CHEM, V270, P25352, DOI 10.1074/jbc.270.43.25352; Cunnick JM, 2000, J BIOL CHEM, V275, P13842, DOI 10.1074/jbc.275.18.13842; deRooij J, 1997, ONCOGENE, V14, P623, DOI 10.1038/sj.onc.1201005; Duckworth BC, 1997, J BIOL CHEM, V272, P27665, DOI 10.1074/jbc.272.44.27665; Frost JA, 1997, EMBO J, V16, P6426, DOI 10.1093/emboj/16.21.6426; Gu JG, 1998, J CELL BIOL, V143, P1375, DOI 10.1083/jcb.143.5.1375; HARA K, 1994, P NATL ACAD SCI USA, V91, P7415, DOI 10.1073/pnas.91.16.7415; HolgadoMadruga M, 1996, NATURE, V379, P560, DOI 10.1038/379560a0; HU P, 1994, MOL CELL BIOL, V14, P2577, DOI 10.1128/MCB.14.4.2577; HUNTER T, 1995, CELL, V83, P1, DOI 10.1016/0092-8674(95)90225-2; Isakoff SJ, 1998, EMBO J, V17, P5374, DOI 10.1093/emboj/17.18.5374; Itoh M, 2000, MOL CELL BIOL, V20, P3695, DOI 10.1128/MCB.20.10.3695-3704.2000; King AJ, 1998, NATURE, V396, P180, DOI 10.1038/24184; Klippel A, 1997, MOL CELL BIOL, V17, P338, DOI 10.1128/MCB.17.1.338; Le Good JA, 1998, SCIENCE, V281, P2042, DOI 10.1126/science.281.5385.2042; Leevers SJ, 1999, CURR OPIN CELL BIOL, V11, P219, DOI 10.1016/S0955-0674(99)80029-5; LI W, 1994, MOL CELL BIOL, V14, P509, DOI 10.1128/MCB.14.1.509; Luttrell LM, 1997, J BIOL CHEM, V272, P31648, DOI 10.1074/jbc.272.50.31648; MARRA F, 1995, FEBS LETT, V376, P141, DOI 10.1016/0014-5793(95)01261-0; MCCORMICK F, 1993, NATURE, V363, P15, DOI 10.1038/363015a0; Myers MP, 1998, P NATL ACAD SCI USA, V95, P13513, DOI 10.1073/pnas.95.23.13513; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; Ramaswamy S, 1999, P NATL ACAD SCI USA, V96, P2110, DOI 10.1073/pnas.96.5.2110; Rameh LE, 1997, J BIOL CHEM, V272, P22059, DOI 10.1074/jbc.272.35.22059; Rameh LE, 1999, J BIOL CHEM, V274, P8347, DOI 10.1074/jbc.274.13.8347; ROCHE S, 1994, P NATL ACAD SCI USA, V91, P9185, DOI 10.1073/pnas.91.19.9185; Roche S, 1998, MOL CELL BIOL, V18, P7119, DOI 10.1128/MCB.18.12.7119; Rodrigues GA, 2000, MOL CELL BIOL, V20, P1448, DOI 10.1128/MCB.20.4.1448-1459.2000; Sajan MP, 1999, J BIOL CHEM, V274, P30495, DOI 10.1074/jbc.274.43.30495; Salim K, 1996, EMBO J, V15, P6241, DOI 10.1002/j.1460-2075.1996.tb01014.x; Schaeffer HJ, 1999, MOL CELL BIOL, V19, P2435; Schonwasser DC, 1998, MOL CELL BIOL, V18, P790, DOI 10.1128/MCB.18.2.790; Shi ZQ, 2000, MOL CELL BIOL, V20, P1526, DOI 10.1128/MCB.20.5.1526-1536.2000; Tamura M, 1998, SCIENCE, V280, P1614, DOI 10.1126/science.280.5369.1614; TOKER A, 1994, J BIOL CHEM, V269, P32358; Vanhaesebroeck B, 1999, EMBO J, V18, P1292, DOI 10.1093/emboj/18.5.1292; Weidner KM, 1996, NATURE, V384, P173, DOI 10.1038/384173a0; Wennstrom S, 1999, MOL CELL BIOL, V19, P4279	44	122	126	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 23	2001	276	12					8856	8864		10.1074/jbc.M006966200	http://dx.doi.org/10.1074/jbc.M006966200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	413HV	11134009	hybrid			2022-12-25	WOS:000167607700035
J	Harvey, KF; Dinudom, A; Cook, DI; Kumar, S				Harvey, KF; Dinudom, A; Cook, DI; Kumar, S			The Nedd4-like protein KIAA0439 is a potential regulator of the epithelial sodium channel	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OOCYTE EXPRESSION SYSTEM; NA+-CHANNEL; LIDDLES-SYNDROME; LIGASE NEDD4; BETA-SUBUNIT; WW DOMAINS; SUBCELLULAR-LOCALIZATION; MISSENSE MUTATION; XENOPUS-LAEVIS; C2 DOMAIN	The amiloride-sensitive epithelial sodium channel (ENaC) plays a critical role in fluid and electrolyte homeostasis and consists of alpha, beta, and gamma subunits. The carboxyl terminus of each ENaC subunit contains a PPxY, motif which is believed to be important for interaction with the WW domains of the ubiquitin-protein ligase, Nedd4, Disruption of this interaction, as in Liddle's syndrome, where mutations delete or alter the PPxY motif of either the beta or gamma subunits, has been proposed to result in increased ENaC activity, Here we present evidence that KIAA0439 protein, a close relative of Nedd4, is also a potential regulator of ENaC, We demonstrate that KTAA0439 WW domains bind all three ENaC subunits. We show that a recombinant KIAA0439 WW domain protein acts as a dominant negative mutant that can interfere with the Na+-dependent feedback inhibition of ENaC in whole-cell patch clamp experiments. We propose that KIAA0439 and Nedd4 proteins either play a redundant role in ENaC regulation or function in a tissue- and/or signal-specific manner to down-regulate ENaC.	Inst Med & Vet Sci, Hanson Ctr Canc Res, Adelaide, SA 5000, Australia; Univ Sydney, Dept Physiol, Sydney, NSW 2006, Australia	Institute Medical & Veterinary Science Australia; University of Sydney	Kumar, S (corresponding author), Inst Med & Vet Sci, Hanson Ctr Canc Res, POB 14,Rundle Mall,Frome Rd, Adelaide, SA 5000, Australia.		Harvey, Kieran/AAD-5268-2022; Kumar, Sharad/AAX-7787-2020	Kumar, Sharad/0000-0001-7126-9814; Harvey, Kieran/0000-0001-7845-369X				Abriel H, 2000, FEBS LETT, V466, P377, DOI 10.1016/S0014-5793(00)01098-X; Abriel H, 1999, J CLIN INVEST, V103, P667, DOI 10.1172/JCI5713; Anan T, 1998, GENES CELLS, V3, P751, DOI 10.1046/j.1365-2443.1998.00227.x; Awayda MS, 1997, AM J PHYSIOL-CELL PH, V273, pC1889; de la Rosa DA, 2000, ANNU REV PHYSIOL, V62, P573, DOI 10.1146/annurev.physiol.62.1.573; DINUDOM A, 1995, J PHYSIOL-LONDON, V487, P549, DOI 10.1113/jphysiol.1995.sp020899; Dinudom A, 1998, P NATL ACAD SCI USA, V95, P7169, DOI 10.1073/pnas.95.12.7169; DINUDOM A, 1993, PFLUG ARCH EUR J PHY, V344, P33; DUC C, 1994, J CELL BIOL, V127, P1907, DOI 10.1083/jcb.127.6.1907; Farman N, 1997, AM J PHYSIOL-CELL PH, V272, pC131, DOI 10.1152/ajpcell.1997.272.1.C131; Farr TJ, 2000, BIOCHEM J, V345, P503, DOI 10.1042/0264-6021:3450503; Firsov D, 1998, EMBO J, V17, P344, DOI 10.1093/emboj/17.2.344; Firsov D, 1996, P NATL ACAD SCI USA, V93, P15370, DOI 10.1073/pnas.93.26.15370; Goulet CC, 1998, J BIOL CHEM, V273, P30012, DOI 10.1074/jbc.273.45.30012; HANSSON JH, 1995, P NATL ACAD SCI USA, V92, P11495, DOI 10.1073/pnas.92.25.11495; HANSSON JH, 1995, NAT GENET, V11, P76, DOI 10.1038/ng0995-76; Harvey KF, 1999, TRENDS CELL BIOL, V9, P166, DOI 10.1016/S0962-8924(99)01541-X; Harvey KF, 1999, J BIOL CHEM, V274, P12525, DOI 10.1074/jbc.274.18.12525; Hatakeyama S, 1997, J BIOL CHEM, V272, P15085, DOI 10.1074/jbc.272.24.15085; Jeunemaitre X, 1997, J HYPERTENS, V15, P1091, DOI 10.1097/00004872-199715100-00007; Jolliffe CN, 2000, BIOCHEM J, V351, P557, DOI 10.1042/0264-6021:3510557; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; Kellenberger S, 1998, J CLIN INVEST, V101, P2741, DOI 10.1172/JCI2837; Kosari F, 1998, J BIOL CHEM, V273, P13469, DOI 10.1074/jbc.273.22.13469; KUMAR S, 1992, BIOCHEM BIOPH RES CO, V185, P1155, DOI 10.1016/0006-291X(92)91747-E; Kumar S, 1997, GENOMICS, V40, P435, DOI 10.1006/geno.1996.4582; Matsushita K, 1996, AM J PHYSIOL-LUNG C, V271, pL332, DOI 10.1152/ajplung.1996.271.2.L332; Plant PJ, 1997, J BIOL CHEM, V272, P32329, DOI 10.1074/jbc.272.51.32329; Plant PJ, 2000, J CELL BIOL, V149, P1473, DOI 10.1083/jcb.149.7.1473; Rebhun JF, 1998, DNA SEQUENCE, V9, P295, DOI 10.3109/10425179809008468; SCHILD L, 1995, P NATL ACAD SCI USA, V92, P5699, DOI 10.1073/pnas.92.12.5699; Schild L, 1996, EMBO J, V15, P2381, DOI 10.1002/j.1460-2075.1996.tb00594.x; SHIMKETS RA, 1994, CELL, V79, P407, DOI 10.1016/0092-8674(94)90250-X; Shimkets RA, 1997, J BIOL CHEM, V272, P25537, DOI 10.1074/jbc.272.41.25537; SNYDER PM, 1995, CELL, V83, P969, DOI 10.1016/0092-8674(95)90212-0; Staub O, 1996, EMBO J, V15, P2371, DOI 10.1002/j.1460-2075.1996.tb00593.x; Staub O, 1997, EMBO J, V16, P6325, DOI 10.1093/emboj/16.21.6325; Staub O, 1997, AM J PHYSIOL-CELL PH, V272, pC1871, DOI 10.1152/ajpcell.1997.272.6.C1871; Tamura H, 1996, J CLIN INVEST, V97, P1780, DOI 10.1172/JCI118606	39	126	137	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 16	2001	276	11					8597	8601		10.1074/jbc.C000906200	http://dx.doi.org/10.1074/jbc.C000906200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	411AA	11244092	hybrid			2022-12-25	WOS:000167474900123
J	Panka, DJ; Mano, T; Suhara, T; Walsh, K; Mier, JW				Panka, DJ; Mano, T; Suhara, T; Walsh, K; Mier, JW			Phosphatidylinositol 3-kinase/Akt activity regulates c-FLIP expression in tumor cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; NF-KAPPA-B; TRAIL-INDUCED APOPTOSIS; MEDIATED APOPTOSIS; ANTIGEN RECEPTOR; GROWTH-FACTOR; LIGAND TRAIL; DEATH DOMAIN; FAS; INHIBITION	The caspase-8 homologue FLICE-inhibitory protein (FLIP) functions as a caspase-8 dominant negative, blocking apoptosis induced by the oligomerization of the adapter protein FADD/MORT-1. FLIP expression correlates with resistance to apoptosis induced by various members of the tumor necrosis factor family such as TRAIL. Furthermore, forced expression of FLIP renders cells resistant to Fas-mediated apoptosis. Although FLIP expression is regulated primarily by MEK1 activity in activated T cells, the oncogenic signaling pathways that regulate FLIP expression in tumor cells are largely unknown. In this report, we examined the roles of the MAP kinase and phosphatidylinositol (PI) 3-kinase signaling pathways in the regulation of FLIP expression in tumor cells. We observed that the MEK1 inhibitor PD98059 reduced FLIP levels in only 2 of 11 tumor cell lines tested. In contrast, disruption of the PI 3-kinase pathway with the specific inhibitor LY294002 reduced Akt (protein kinase B) phosphorylation and the levels of FLIP protein and mRNA in all cell lines evaluated. The introduction of a dominant negative Akt adenoviral construct also consistently reduced FLIP expression as well as the phosphorylation of the Akt target glycogen synthase kinase-3. In addition, infection of the same cell lines with a constitutively active Akt adenovirus increased FLIP expression and the phosphorylation of GSK-5, These data add FLIP to the growing list of apoptosis inhibitors in which expression or function is regulated by the PI 3-kinase-Akt pathway.	Harvard Univ, Inst Med, Beth Israel Deaconess Med Ctr, Dept Hematol & Oncol, Boston, MA 02115 USA; St Elizabeth Hosp, Boston, MA 02135 USA	Harvard University; Beth Israel Deaconess Medical Center	Mier, JW (corresponding author), Harvard Univ, Inst Med, Beth Israel Deaconess Med Ctr, Dept Hematol & Oncol, Rm 309,4 Blackfan Cr, Boston, MA 02115 USA.	jmier@caregroup.harvard.edu			NCI NIH HHS [CA74401] Funding Source: Medline; NIA NIH HHS [AG15051] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA074401] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Algeciras-Schimnich A, 1999, J IMMUNOL, V162, P5205; Barton K, 1996, NATURE, V379, P81, DOI 10.1038/379081a0; Berra E, 1998, J BIOL CHEM, V273, P10792, DOI 10.1074/jbc.273.17.10792; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Capodici C, 1998, J IMMUNOL, V160, P1901; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; Chen RH, 1998, ONCOGENE, V17, P1959, DOI 10.1038/sj.onc.1202111; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4961; Du KY, 1998, J BIOL CHEM, V273, P32377, DOI 10.1074/jbc.273.49.32377; Duckworth BC, 1997, J BIOL CHEM, V272, P27665, DOI 10.1074/jbc.272.44.27665; Duronio V, 1998, CELL SIGNAL, V10, P233, DOI 10.1016/S0898-6568(97)00129-0; Ebert AD, 1999, CANCER RES, V59, P4502; ETTINGER R, 1995, J IMMUNOL, V154, P4302; Fujio Y, 1999, J BIOL CHEM, V274, P16349, DOI 10.1074/jbc.274.23.16349; Gibbs BF, 1999, J LEUKOCYTE BIOL, V65, P883, DOI 10.1002/jlb.65.6.883; Griffith TS, 1998, J IMMUNOL, V161, P2833; Hitoshi Y, 1998, IMMUNITY, V8, P461, DOI 10.1016/S1074-7613(00)80551-8; Houghton JA, 1997, CLIN CANCER RES, V3, P2205; Hsu SY, 1997, MOL ENDOCRINOL, V11, P1858, DOI 10.1210/me.11.12.1858; Hu SM, 1997, J BIOL CHEM, V272, P17255, DOI 10.1074/jbc.272.28.17255; Hu WH, 2000, J BIOL CHEM, V275, P10838, DOI 10.1074/jbc.275.15.10838; Irmler M, 1997, NATURE, V388, P190, DOI 10.1038/40657; Jaattela M, 1999, EXP CELL RES, V248, P30, DOI 10.1006/excr.1999.4455; Jiang YP, 1999, SCIENCE, V283, P543, DOI 10.1126/science.283.5401.543; Kane LP, 1999, CURR BIOL, V9, P601, DOI 10.1016/S0960-9822(99)80265-6; Kataoka T, 1998, J IMMUNOL, V161, P3936; Micheau O, 1999, J BIOL CHEM, V274, P7987, DOI 10.1074/jbc.274.12.7987; Pugazhenthi S, 2000, J BIOL CHEM, V275, P10761, DOI 10.1074/jbc.275.15.10761; Rasper DM, 1998, CELL DEATH DIFFER, V5, P271, DOI 10.1038/sj.cdd.4400370; Refaeli Y, 1998, IMMUNITY, V8, P615, DOI 10.1016/S1074-7613(00)80566-X; ROTHSTEIN TL, 1995, NATURE, V374, P163, DOI 10.1038/374163a0; Sata M, 1998, J BIOL CHEM, V273, P33103, DOI 10.1074/jbc.273.50.33103; SATO T, 1995, SCIENCE, V268, P411, DOI 10.1126/science.7536343; Scaffidi C, 1999, J BIOL CHEM, V274, P1541, DOI 10.1074/jbc.274.3.1541; Takahashi R, 1998, J BIOL CHEM, V273, P7787, DOI 10.1074/jbc.273.14.7787; Tamm I, 1998, CANCER RES, V58, P5315; THORNE M, 1997, NATURE, V386, P517; Tschopp J, 1999, CURR BIOL, V9, pR381, DOI 10.1016/S0960-9822(99)80233-4; Tschopp J, 1998, CURR OPIN IMMUNOL, V10, P552, DOI 10.1016/S0952-7915(98)80223-9; Vassilev A, 1999, J BIOL CHEM, V274, P1646, DOI 10.1074/jbc.274.3.1646; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Wang J, 2000, EUR J IMMUNOL, V30, P155, DOI 10.1002/1521-4141(200001)30:1<155::AID-IMMU155>3.3.CO;2-O; Wennstrom S, 1999, MOL CELL BIOL, V19, P4279; Yeh JH, 1998, J EXP MED, V188, P1795, DOI 10.1084/jem.188.10.1795; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3; Zha JP, 1997, J BIOL CHEM, V272, P24101, DOI 10.1074/jbc.272.39.24101; Zhang XD, 2000, J IMMUNOL, V164, P3961, DOI 10.4049/jimmunol.164.8.3961; Zhang XD, 1999, CANCER RES, V59, P2747	50	233	237	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 9	2001	276	10					6893	6896		10.1074/jbc.C000569200	http://dx.doi.org/10.1074/jbc.C000569200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	410MC	11145953	hybrid			2022-12-25	WOS:000167442900004
J	Izzotti, A; Cartiglia, C; Lewtas, J; De Flora, S				Izzotti, A; Cartiglia, C; Lewtas, J; De Flora, S			Increased DNA alterations in atherosclerotic lesions of individuals lacking the GSTM1 genotype	FASEB JOURNAL			English	Article						metabolic polymorphisms; glutathione S-transferases; smooth muscle cells; DNA adducts	TRANSFERASE M1 GSTM1; GLUTATHIONE S-TRANSFERASES; LUNG-CANCER PATIENTS; ADDUCT LEVELS; SUPERGENE FAMILY; SUSCEPTIBILITY; POLYMORPHISMS; RISK; GENE; SMOKING	Reduced glutathione (GSH) plays a critical role as an intracellular defense system providing detoxification of a broad spectrum of reactive species and their excretion as water-soluble conjugates, Conjugation of GSH with electrophiles is catalyzed by GSH S-transferases (GST), which constitute a broad family of phase II isoenzymes, Two of the GST encoding genes, GSTM1 (mu) and GSTT1 (0), have a null genotype due to their homozygous deletion that results in lack of active protein, Polymorphisms within GSTT1 and especially GSTM1 have often been associated with cancer in various organs as well as with elevated levels of DNA adducts in various cell types. We recently demonstrated that DNA adducts are consistently detectable in smooth muscle cells (SMC) of human abdominal aorta affected by atherosclerotic lesions. Here we provide evidence that levels: of adducts to SMC DNA from atherosclerotic lesions are consistently increased in individuals having the null GSTM1 genotype, whereas no association was established with the GSTT1 polymorphism. The influence of GSTM1 deletion was better expressed in never-smokers and ex-smokers than in current smokers. These findings bear relevance to the epidemiology of atherosclerosis and suggest that metabolic polymorphisms may contribute to the interindividual variability in susceptibility not only to carcinogens, but also to DNA binding atherogens.	Univ Genoa, Dept Hlth Sci, I-16132 Genoa, Italy; US EPA, Seattle, WA USA	University of Genoa; United States Environmental Protection Agency	De Flora, S (corresponding author), Univ Genoa, Dept Hlth Sci, Via A Pastore 1, I-16132 Genoa, Italy.	sdf@unige.it		izzotti, alberto/0000-0002-8588-0347				ANTTILA S, 1995, CANCER RES, V55, P3305; BELL DA, 1993, J NATL CANCER I, V85, P1159, DOI 10.1093/jnci/85.14.1159; BINKOVA B, 1999, HOMEOSTASIS HLTH DIS, V39, P168; BRIDGES B A, 1990, Mutation Research, V239, P143, DOI 10.1016/0165-1110(90)90002-S; Butkiewicz D, 1999, EUR J CANCER PREV, V8, P315, DOI 10.1097/00008469-199908000-00008; Chasseaud L F, 1979, Adv Cancer Res, V29, P175, DOI 10.1016/S0065-230X(08)60848-9; Chen L, 1996, HUM GENET, V98, P551, DOI 10.1007/s004390050258; DeFlora S, 1997, FASEB J, V11, P1021, DOI 10.1096/fasebj.11.12.9337155; DeFlora S, 1996, MUTAT RES-REV GENET, V366, P197, DOI 10.1016/S0165-1110(96)00043-7; dErrico A, 1996, BIOMARKERS, V1, P149, DOI 10.3109/13547509609079352; GUPTA RC, 1988, CARCINOGENESIS, V9, P1687, DOI 10.1093/carcin/9.9.1687; Hayes JD, 1995, CRIT REV BIOCHEM MOL, V30, P445, DOI 10.3109/10409239509083491; He NG, 1999, TOXICOL APPL PHARM, V158, P177, DOI 10.1006/taap.1999.8700; He NG, 1998, TOXICOL APPL PHARM, V152, P83, DOI 10.1006/taap.1998.8511; Hou SM, 2000, CARCINOGENESIS, V21, P49, DOI 10.1093/carcin/21.1.49; Izzotti A, 1998, FREE RADICAL RES, V28, P165, DOI 10.3109/10715769809065802; KATO S, 1995, J NATL CANCER I, V87, P902, DOI 10.1093/jnci/87.12.902; KETTERER B, 1992, ENVIRON HEALTH PERSP, V98, P87, DOI 10.2307/3431252; Kleyn PW, 1998, SCIENCE, V281, P1820, DOI 10.1126/science.281.5384.1820; Li RL, 2000, ATHEROSCLEROSIS, V149, P451, DOI 10.1016/S0021-9150(99)00483-9; Margaglione M, 1996, ARTERIOSCL THROM VAS, V16, P304, DOI 10.1161/01.ATV.16.2.304; MCWILLIAMS JE, 1995, CANCER EPIDEM BIOMAR, V4, P589; Meister A., 1989, GLUTATHIONE CHEM BIO, P361; Mooney LA, 1997, CARCINOGENESIS, V18, P503, DOI 10.1093/carcin/18.3.503; NELSON HH, 1995, CARCINOGENESIS, V16, P1243, DOI 10.1093/carcin/16.5.1243; PEMBLE S, 1994, BIOCHEM J, V300, P271, DOI 10.1042/bj3000271; Perera FP, 1997, SCIENCE, V278, P1068, DOI 10.1126/science.278.5340.1068; PESSAHRASMUSSEN H, 1990, INT ANGIOL, V9, P70; Peyser PA, 1997, EPIDEMIOL REV, V19, P80, DOI 10.1093/oxfordjournals.epirev.a017949; Rojas M, 2000, CARCINOGENESIS, V21, P35, DOI 10.1093/carcin/21.1.35; Rollinson S, 2000, CARCINOGENESIS, V21, P43, DOI 10.1093/carcin/21.1.43; SEIDEGARD J, 1988, P NATL ACAD SCI USA, V85, P7293, DOI 10.1073/pnas.85.19.7293; SHIELDS PG, 1993, CANCER RES, V53, P3486; SING CF, 1985, AM J HUM GENET, V37, P268; Taningher M, 1999, MUTAT RES-REV MUTAT, V436, P227, DOI 10.1016/S1383-5742(99)00005-8; ToFigueras J, 1997, CARCINOGENESIS, V18, P1529, DOI 10.1093/carcin/18.8.1529; Van Schooten FJ, 1998, FASEB J, V12, P1409, DOI 10.1096/fasebj.12.13.1409; Wilson MH, 2000, FASEB J, V14, P791, DOI 10.1096/fasebj.14.5.791; ZHONG S, 1993, CARCINOGENESIS, V14, P1821, DOI 10.1093/carcin/14.9.1821	39	74	76	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2001	15	3					752	757		10.1096/fj.00-0312com	http://dx.doi.org/10.1096/fj.00-0312com			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	410BE	11259393				2022-12-25	WOS:000167419500032
J	Tonko, M; Ausserlechner, MJ; Bernhard, D; Helmberg, A; Kofler, R				Tonko, M; Ausserlechner, MJ; Bernhard, D; Helmberg, A; Kofler, R			Gene expression profiles of proliferating vs. G1/G0 arrested human leukemia cells suggest a mechanism for glucocorticoid-induced apoptosis	FASEB JOURNAL			English	Article						glucocorticoid-induced gene regulation; DNA chip expression profiling; acute lymphoid leukemia; pathophysiology	RECEPTOR EXPRESSION; T-CELLS; LYMPHOBLASTS; METABOLISM; RESISTANCE; BCL-2; LINES	Glucocorticoids (GC) have pronounced effects on metabolism, differentiation, proliferation, and cell survival (1). In certain lymphocytes and lymphocyte-related malignancies, GC inhibit proliferation and induce apoptotic cell. death, which has led to their extensive use in the therapy of malignant lymphoproliferative disorders (2). Most of these effects result from regulation of gene expression via the GC receptor (GI), a ligand-activated transcription factor (3). Although hundreds of genes are regulated by GC (1), how certain biological GC effects relate to individual gene regulation remains enigmatic. To address this question with respect to GC-induced cell cycle arrest and apoptosis, we applied DNA chip technology (4, 5) to determine gene expression profiles in proliferating and G1/G0-arrested (by conditional expression of the CDK inhibitor p16/INK4a) acute lymphoblastic T cells undergoing GC-induced apoptosis. Of 7074 genes tested, 163 were found to be regulated by dexamethasone in the first 8 h in proliferating cells and 66 genes in G1/G0-arrested cells. An almost nonoverlapping set of genes (i.e., only eight genes) was coordinately regulated in proliferating and arrested cells. Analysis of the regulated genes supports the concept that GC-induced apoptosis results from positive GR autoregulation entailing persistent down-regulation of metabolic pathways critical for survival.-Tonko, Ml, Ausserlechner, M. J., Bernhard, D., Helmberg, A., Kofler, R. Gene expression profiles of proliferating vs. G1/G0 arrested human leukemia cells suggest a mechanism for glucocorticoid-induced apoptosis.	Univ Innsbruck, Tyrolean Canc Res Inst, A-6020 Innsbruck, Austria; Univ Innsbruck, Inst Gen & Expt Pathol, Div Mol Pathophysiol, A-6020 Innsbruck, Austria	University of Innsbruck; University of Innsbruck	Kofler, R (corresponding author), Univ Innsbruck, Tyrolean Canc Res Inst, Innrain 66, A-6020 Innsbruck, Austria.	Reinhard.Kofler@uibk.ac.at		Ausserlechner, Michael/0000-0002-1015-2302; Bernhard, David/0000-0002-2383-6607				Alizadeh AA, 2000, NATURE, V403, P503, DOI 10.1038/35000501; AUSSERLECHNER MJ, 2001, IN PRESS J BIOL CHEM; BANSAL N, 1991, FASEB J, V5, P211, DOI 10.1096/fasebj.5.2.2004665; Bernhard D, 1999, FASEB J, V13, P1991, DOI 10.1096/fasebj.13.14.1991; Dang CV, 1999, TRENDS BIOCHEM SCI, V24, P68, DOI 10.1016/S0968-0004(98)01344-9; EISEN LP, 1988, J BIOL CHEM, V263, P12044; FOLEY GE, 1965, CANCER, V18, P522, DOI 10.1002/1097-0142(196504)18:4<522::AID-CNCR2820180418>3.0.CO;2-J; Geley S, 1996, REV PHYSIOL BIOCH P, V128, P1; Geley S, 1996, CANCER RES, V56, P5033; Hartmann BL, 1999, ONCOGENE, V18, P713, DOI 10.1038/sj.onc.1202339; HELMBERG A, 1990, J IMMUNOL, V145, P4332; HOLLENBERG SM, 1988, CELL, V55, P899, DOI 10.1016/0092-8674(88)90145-6; Iyer VR, 1999, SCIENCE, V283, P83, DOI 10.1126/science.283.5398.83; Kalenik JL, 1997, NUCLEIC ACIDS RES, V25, P843, DOI 10.1093/nar/25.4.843; Marine JC, 1999, CELL, V98, P609, DOI 10.1016/S0092-8674(00)80048-3; Mellitzer G, 1999, NATURE, V400, P77, DOI 10.1038/21907; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; Ramdas J, 1999, CANCER RES, V59, P1378; SCHMIDT TJ, 1994, RECEPTOR, V4, P229; Shim H, 1997, P NATL ACAD SCI USA, V94, P6658, DOI 10.1073/pnas.94.13.6658; SIMONET WS, 1989, J BIOL CHEM, V264, P569; STEPHENS JL, 1984, BIOCHEM J, V219, P689, DOI 10.1042/bj2190689; STOOLMAN LM, 1993, J CELL PHYSIOL, V154, P593, DOI 10.1002/jcp.1041540318; Strasser-Wozak EMC, 1998, CELL DEATH DIFFER, V5, P687, DOI 10.1038/sj.cdd.4400402; STRASSERWOZAK EMC, 1995, CANCER RES, V55, P348; Vogel P, 1996, BBA-GENE STRUCT EXPR, V1309, P200, DOI 10.1016/S0167-4781(96)00177-7; WARBURG O, 1926, METABOLISM TUMORS	27	94	96	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAR	2001	15	3					693	699		10.1096/fj.00-0327com	http://dx.doi.org/10.1096/fj.00-0327com			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	410BE	11259387				2022-12-25	WOS:000167419500026
J	Wei, L; Wang, L; Carson, JA; Agan, JE; Imanaka-Yoshida, K; Schwartz, RJ				Wei, L; Wang, L; Carson, JA; Agan, JE; Imanaka-Yoshida, K; Schwartz, RJ			beta 1 integrin and organized actin filaments facilitate cardiomyocyte-specific RhoA-dependent activation of the skeletal alpha-actin promoter	FASEB JOURNAL			English	Article						serum response factor; cardiac hypertrophy; actin polymerization	SERUM RESPONSE FACTOR; CARDIAC MYOCYTE HYPERTROPHY; RAT VENTRICULAR MYOCYTES; BINDING PROTEIN-RHO; GENE-TRANSCRIPTION; FOCAL ADHESIONS; CELL-ADHESION; STRESS FIBERS; F-ACTIN; GROWTH	Activation of RhoA GTPase causes actin filament bundling into stress fibers, integrin clustering, and focal adhesion formation through its action on actin cytoskeleton organization, RhoA also regulates transcriptional activity of serum response factor (SRF), Recent studies in NM 3T3 fibroblasts have shown that SRF activation by RhoA does not require an organized cytoskeleton and may be regulated by G-actin level, In cardiac myocytes, the organization of actin fibers into myofibrils is one of the primary characteristics of cardiac differentiation and hypertrophy, The primary purpose of this study was to examine if RhoA regulates SRF-dependent gene expression in neonatal cardiomyocytes in a manner different from that observed in fibroblasts, Our results show that RhoA-dependent skeletal alpha -actin promoter activation requires beta1 integrin and a functional cytoskeleton in cardiomyocytes but not in NM 3T3 fibroblasts, Activation of the alpha -actin promoter by RhoA is greatly potentiated (up to 15-fold) by coexpression of the integrin beta 1A or beta 1D isoform but is significantly reduced by 70% with a coexpressed dominant negative mutant of beta1 integrin, Furthermore, clustering of beta1 integrin with anti-beta1 integrin antibodies potentiates synergistic RhoA and beta1 integrin activation of the alpha -actin promoter. Cytochalasin D and latrunculin B, inhibitors of actin polymerization, significantly reduced RhoA-induced activation of the alpha -actin promoter, Jasplakinolide, an actin polymerizing agent, mimics the synergistic effect of RhoA and beta1 integrin on the actin promoter, These observations support the concept that RhoA regulates SRF-dependent cardiac gene expression through cross-talk with beta1 integrin signal pathway via an organized actin cytoskeleton.	Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA; Univ S Carolina, Sch Publ Hlth, Dept Exercise Sci, Columbia, SC 29208 USA; Mie Univ, Sch Med, Dept Pathol, Tsu, Mie 514, Japan	Baylor College of Medicine; University of South Carolina; University of South Carolina System; University of South Carolina Columbia; Mie University	Schwartz, RJ (corresponding author), Baylor Coll Med, Dept Cell Biol, 1 Baylor Plaza,Room 145E, Houston, TX 77030 USA.		Carson, James/Q-5693-2019	Carson, James/0000-0003-3733-8796	NHLBI NIH HHS [R01 HL50422, P01 HL49953] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL049953] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Aikawa R, 1999, CIRC RES, V84, P458, DOI 10.1161/01.RES.84.4.458; AKIYAMA SK, 1994, J BIOL CHEM, V269, P15961; Aoki H, 1998, CIRC RES, V82, P666, DOI 10.1161/01.RES.82.6.666; Arsenian S, 1998, EMBO J, V17, P6289, DOI 10.1093/emboj/17.21.6289; BELAGULI NS, 2000, IN PRESS MOL CELL BI; Belkin AM, 1996, J CELL BIOL, V132, P211, DOI 10.1083/jcb.132.1.211; BOXER LM, 1989, MOL CELL BIOL, V9, P515, DOI 10.1128/MCB.9.2.515; BUBB MR, 1994, J BIOL CHEM, V269, P14869; Burridge K, 1996, ANNU REV CELL DEV BI, V12, P463, DOI 10.1146/annurev.cellbio.12.1.463; Chen CY, 1996, MOL CELL BIOL, V16, P6372; CHIEN KR, 1993, ANNU REV PHYSIOL, V55, P77, DOI 10.1146/annurev.ph.55.030193.000453; CHOW KL, 1990, MOL CELL BIOL, V10, P528, DOI 10.1128/MCB.10.2.528; Cone M, 1987, FEBS LETT, V213, P316; Dabiri GA, 1997, P NATL ACAD SCI USA, V94, P9493, DOI 10.1073/pnas.94.17.9493; DLUGOSZ AA, 1984, J CELL BIOL, V99, P2268, DOI 10.1083/jcb.99.6.2268; FLANAGAN MD, 1980, J BIOL CHEM, V255, P835; Groisman R, 1996, J BIOL CHEM, V271, P5258; GROUX H, 1989, NATURE, V339, P152, DOI 10.1038/339152a0; HALL A, 1994, ANNU REV CELL BIOL, V10, P31, DOI 10.1146/annurev.cb.10.110194.000335; HILENSKI LL, 1992, CELL MOTIL CYTOSKEL, V21, P87, DOI 10.1002/cm.970210202; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; Hoshijima M, 1998, J BIOL CHEM, V273, P7725, DOI 10.1074/jbc.273.13.7725; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; KARNS LR, 1995, J BIOL CHEM, V270, P410, DOI 10.1074/jbc.270.1.410; LAFLAMME SE, 1992, J CELL BIOL, V117, P437, DOI 10.1083/jcb.117.2.437; LEE TC, 1991, MOL CELL BIOL, V11, P5090, DOI 10.1128/MCB.11.10.5090; LUKASHEV ME, 1994, J BIOL CHEM, V269, P18311; MACLELLAN WR, 1994, J BIOL CHEM, V269, P16754; MUSCAT GEO, 1987, MOL CELL BIOL, V7, P4089, DOI 10.1128/MCB.7.11.4089; Narumiya S, 1997, FEBS LETT, V410, P68, DOI 10.1016/S0014-5793(97)00317-7; Paradis P, 1996, J BIOL CHEM, V271, P10827, DOI 10.1074/jbc.271.18.10827; PARKER TG, 1992, J BIOL CHEM, V267, P3343; Parsons JT, 1996, CURR OPIN CELL BIOL, V8, P146, DOI 10.1016/S0955-0674(96)80059-7; Ren XD, 1999, EMBO J, V18, P578, DOI 10.1093/emboj/18.3.578; RHEE D, 1994, CELL MOTIL CYTOSKEL, V28, P1, DOI 10.1002/cm.970280102; Richardson A, 1996, NATURE, V380, P538, DOI 10.1038/380538a0; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Ridley AJ, 1999, NAT CELL BIOL, V1, pE64, DOI 10.1038/11034; Ross RS, 1998, CIRC RES, V82, P1160, DOI 10.1161/01.RES.82.11.1160; Sah VP, 1996, J BIOL CHEM, V271, P31185, DOI 10.1074/jbc.271.49.31185; SCHWARTZ K, 1986, CIRC RES, V59, P551, DOI 10.1161/01.RES.59.5.551; Sharp WW, 1997, AM J PHYSIOL-HEART C, V273, pH546, DOI 10.1152/ajpheart.1997.273.2.H546; SIMPSON PC, 1989, J MOL CELL CARDIOL, V21, P79, DOI 10.1016/0022-2828(89)90774-8; Sotiropoulos A, 1999, CELL, V98, P159, DOI 10.1016/S0092-8674(00)81011-9; Takahashi K, 1997, J BIOL CHEM, V272, P23371, DOI 10.1074/jbc.272.37.23371; Takano H, 1998, MOL CELL BIOL, V18, P1580, DOI 10.1128/MCB.18.3.1580; Taylor JM, 2000, J BIOL CHEM, V275, P19250, DOI 10.1074/jbc.M909099199; TERRACIO L, 1991, CIRC RES, V68, P734, DOI 10.1161/01.RES.68.3.734; VanAelst L, 1997, GENE DEV, V11, P2295, DOI 10.1101/gad.11.18.2295; VanderFlier A, 1997, DEV DYNAM, V210, P472, DOI 10.1002/(SICI)1097-0177(199712)210:4<472::AID-AJA10>3.0.CO;2-9; Wei L, 1998, J BIOL CHEM, V273, P30287, DOI 10.1074/jbc.273.46.30287; ZHANG SJ, 1995, J BIOL CHEM, V270, P23934, DOI 10.1074/jbc.270.41.23934	52	62	65	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAR	2001	15	3					785	796		10.1096/fj.00-026com	http://dx.doi.org/10.1096/fj.00-026com			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	410BE	11259397				2022-12-25	WOS:000167419500036
J	Andley, UP; Song, Z; Wawrousek, EF; Brady, JP; Bassnett, S; Fleming, TP				Andley, UP; Song, Z; Wawrousek, EF; Brady, JP; Bassnett, S; Fleming, TP			Lens epithelial cells derived from alpha B-crystallin knockout mice demonstrate hyperproliferation and genomic instability	FASEB JOURNAL			English	Article						molecular chaperone; nuclear; immortalization; ploidy	NIH 3T3 FIBROBLASTS; LARGE-T-ANTIGEN; A-CRYSTALLIN; MOLECULAR CHAPERONE; SPINDLE CHECKPOINT; CYCLE REGULATION; MOUSE LENS; HA-RAS; V-MOS; EXPRESSION	alphaB-crystallin is a member of the small heat shock protein family and can act as a molecular chaperone preventing the in vitro aggregation of other proteins denatured by heat or other stress conditions. Expression of alphaB-crystallin increases in cells exposed to stress and enhanced in tumors of neuroectodermal origin and in many neurodegenerative diseases. In the present study, we examined the properties of lens epithelial cells derived from mice in which the alphaB-crystallin gene had been knocked out. Primary rodent cells immortalize spontaneously in tissue culture with a frequency of 10(-5) to 10(-6). Primary lens epithelial cells derived from alphaB-crystallin(-/-) mice produced hyperproliferative clones at a frequency of 7.6 x 10(-2), four orders of magnitude greater than predicted by spontaneous immortalization (1), Hyperproliferative alphaB-crystallin(-/-) cells were shown to be truly immortal since they have been passaged for more than 100 population doublings without any diminution in growth potential. In striking contrast to the wild-type cells, which were diploid, the alphaB-crystallin(-/-) cultures had a high proportion of tetraploid and higher ploidy cells, indicating that the loss of alphaB-crystallin is associated with an increase in genomic instability. Further evidence of genomic instability of alphaB-crystallin(-/-) cells was observed when primary cultures were infected with Ad12SV40 hybrid virus. In striking contrast to wild-type cells, alphaB-crystallin(-/-) cells expressing SV40 T antigen exhibited a widespread cytocidal response 2 to 3 days after attaining confluence, indicating that SV40 T antigen enhanced the intrinsic genomic instability of alphaB-crystallin(-/-) lens epithelial cells. These observations suggest that the widely distributed molecular chaperone alphaB-crystallin may play an important nuclear role in maintaining genomic integrity.	Washington Univ, Sch Med, Dept Ophthalmol & Visual Sci, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Biochem & Mol Biophys, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Cell Biol & Physiol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Genet, St Louis, MO 63110 USA; NEI, NIH, Bethesda, MD 20892 USA	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); National Institutes of Health (NIH) - USA; NIH National Eye Institute (NEI)	Andley, UP (corresponding author), Washington Univ, Sch Med, Dept Ophthalmol & Visual Sci, 660 S Euclid Ave,Campus Box 8096, St Louis, MO 63110 USA.		Wawrousek, Eric/A-4547-2008	Bassnett, Steven/0000-0002-8337-2760; Andley, Usha/0000-0001-7049-7591	NATIONAL EYE INSTITUTE [R01EY009852, Z01EY000286, P30EY002687, R01EY005681] Funding Source: NIH RePORTER; NEI NIH HHS [R01EY05681, P30 EY002687, EY02687, R01EY09852] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Andley UP, 1998, J BIOL CHEM, V273, P31252, DOI 10.1074/jbc.273.47.31252; ANDLEY UP, 1994, INVEST OPHTH VIS SCI, V35, P3094; Arrigo AP, 1995, NEUROPATH APPL NEURO, V21, P488, DOI 10.1111/j.1365-2990.1995.tb01094.x; BASSNETT S, 1994, J CELL SCI, V107, P799; Bhat SP, 1999, EUR J CELL BIOL, V78, P143, DOI 10.1016/S0171-9335(99)80016-8; BHAT SP, 1989, BIOCHEM BIOPH RES CO, V158, P319, DOI 10.1016/S0006-291X(89)80215-3; Brady JP, 1997, P NATL ACAD SCI USA, V94, P884, DOI 10.1073/pnas.94.3.884; CHIESA R, 1989, BIOCHEM BIOPH RES CO, V162, P1494, DOI 10.1016/0006-291X(89)90843-7; CROSS SM, 1995, SCIENCE, V267, P1353, DOI 10.1126/science.7871434; DEJONG WW, 1993, MOL BIOL EVOL, V10, P103; Djabali K, 1999, EXP CELL RES, V253, P649, DOI 10.1006/excr.1999.4679; DUBIN RA, 1989, MOL CELL BIOL, V9, P1083, DOI 10.1128/MCB.9.3.1083; Fleming TP, 1998, INVEST OPHTH VIS SCI, V39, P1387; Gennarelli M, 1998, CELL BIOCHEM FUNCT, V16, P117, DOI 10.1002/(SICI)1099-0844(199806)16:2<117::AID-CBF776>3.0.CO;2-X; Gonin S, 1997, CELL STRESS CHAPERON, V2, P238, DOI 10.1379/1466-1268(1997)002<0238:TBTAAO>2.3.CO;2; GRIEP AE, 1993, J VIROL, V67, P1373, DOI 10.1128/JVI.67.3.1373-1384.1993; GRIEP AE, 1989, GENE DEV, V3, P1075, DOI 10.1101/gad.3.7.1075; Gualberto A, 1998, P NATL ACAD SCI USA, V95, P5166, DOI 10.1073/pnas.95.9.5166; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; Hopfer U, 1996, AM J PHYSIOL-CELL PH, V270, pC1, DOI 10.1152/ajpcell.1996.270.1.C1; HORWITZ J, 1992, P NATL ACAD SCI USA, V89, P10449, DOI 10.1073/pnas.89.21.10449; Iwaki A, 1997, GENOMICS, V45, P386, DOI 10.1006/geno.1997.4956; IWAKI T, 1991, AM J PATHOL, V139, P1303; IWAKI T, 1991, CANCER, V68, P2230, DOI 10.1002/1097-0142(19911115)68:10<2230::AID-CNCR2820681023>3.0.CO;2-7; KANTOROW M, 1995, J BIOL CHEM, V270, P17215, DOI 10.1074/jbc.270.29.17215; Kappler R, 1999, CARCINOGENESIS, V20, P1433, DOI 10.1093/carcin/20.8.1433; KLEMENZ R, 1991, MOL CELL BIOL, V11, P803, DOI 10.1128/MCB.11.2.803; KLEMENZ R, 1989, ONCOGENE, V4, P799; Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292; MORGENBESSER SD, 1994, NATURE, V371, P72, DOI 10.1038/371072a0; Peterson W D Jr, 1979, Methods Enzymol, V58, P164; PIATIGORSKY J, 1994, EXS, V71, P241; Rakic JM, 1997, EXP EYE RES, V64, P67, DOI 10.1006/exer.1996.0179; Reddan J R, 1989, Lens Eye Toxic Res, V6, P687; REDDAN JR, 1982, CELL BIOL EYE, P299; Renkawek K, 1999, NEUROREPORT, V10, P2273, DOI 10.1097/00001756-199908020-00009; RHIM JS, 1993, CRIT REV ONCOGENESIS, V4, P313; Robinson ML, 1996, INVEST OPHTH VIS SCI, V37, P2276; RUSSELL P, 1977, INVEST OPHTH VIS SCI, V21, P169; Sax C M, 1994, Adv Enzymol Relat Areas Mol Biol, V69, P155; Schmutte C, 1999, ANTICANCER RES, V19, P4665; SEABRIGH.M, 1971, LANCET, V2, P971; SPECTOR A, 1985, P NATL ACAD SCI USA, V82, P4712, DOI 10.1073/pnas.82.14.4712; Thornton C, 1999, SEMIN NEUROL, V19, P25, DOI 10.1055/s-2008-1040823; Tlsty TD, 1998, CURR OPIN CELL BIOL, V10, P647, DOI 10.1016/S0955-0674(98)80041-0; VANNOORT JM, 1995, NATURE, V375, P798, DOI 10.1038/375798a0; Vicart P, 1998, NAT GENET, V20, P92, DOI 10.1038/1765; Wawrousek E. F., 1998, IOVS, V39, pS523; WHITE AE, 1994, GENE DEV, V8, P666, DOI 10.1101/gad.8.6.666; YAMADA T, 1990, CURR EYE RES, V9, P31, DOI 10.3109/02713689009000052; Yin XY, 1999, ONCOGENE, V18, P1177, DOI 10.1038/sj.onc.1202410; Zelenka PS, 1997, PROG RETIN EYE RES, V16, P303, DOI 10.1016/S1350-9462(96)00024-9	52	60	62	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JAN	2001	15	1					221	229		10.1096/fj.00-0296com	http://dx.doi.org/10.1096/fj.00-0296com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	390TH	11149910				2022-12-25	WOS:000166312400031
J	Scott, GK; Chang, CH; Erny, KM; Xu, F; Fredericks, WJ; Rauscher, FJ; Thor, AD; Benz, CC				Scott, GK; Chang, CH; Erny, KM; Xu, F; Fredericks, WJ; Rauscher, FJ; Thor, AD; Benz, CC			Ets regulation of the erbB2 promoter	ONCOGENE			English	Article						erbB2(HER2/neu) promoter; Ets binding site; Ets candidates	TRANSCRIPTION FACTOR; HER2/NEU PROMOTER; DOWN-REGULATION; DNA; PROTEIN; C-ERBB-2; EXPRESSION; BINDING; OVEREXPRESSION; INHIBITION	Evaluating the chromatinized erbB2 gene in nuclei from breast cancer cells expressing varying levels of ErbB2 transcripts, we identified a nuclease-sensitive site within a 0.22 kb region of maximum enhancer activity centered over a conserved 28 bp polypurine(GGA)-polypyrimidine(TCC) mirror-repeat and an adjacent essential Ets binding site (EBS), Promoter footprinting with nuclear extracts reveals an intense Ets hypersensitivity site at the EBS whose degree of intensity correlates with the Level of cellular ErbB2 expression. In vitro mapping assays show that the supercoiled erbB2 promoter forms an internal tripler structure (Hr-DNA) at the mirror-repeat element. Mutations preventing Hr-DNA formation can enhance erbB2 promoter activity in human breast cancer cells, a result consistent with previous demonstration that Ets-erbB2 promoter complexes cannot form when the mirror-repeat is engaged in tripler binding, and new results suggesting that Ets binding induces severe promoter bending that may restrict local tripler formation. In addition to previously described erbB2-regulating breast cancer Ets factors (PEA3, ESX/Elf-3), Elf-1 is now shown to be another endogenously expressed Ets candidate capable of binding to and upregulating the erbB2 promoter. Given current strategies to transcriptionally inhibit ErbB2 overexpression, including development of novel erbB2 promoter-targeted therapeutics, an EBS-targeted approach is presented using chimeric Ets proteins that strongly repress erbB2 promoter activity.	Univ Calif San Francisco, Dept Med, Div Hematol Oncol, San Francisco, CA 94143 USA; Wistar Inst Anat & Biol, Mol Genet Program, Philadelphia, PA 19104 USA; Wistar Inst Anat & Biol, Ctr Canc, Philadelphia, PA 19104 USA; Northwestern Univ, Evanston Hosp, Dept Pathol, Evanston, IL 60201 USA	University of California System; University of California San Francisco; The Wistar Institute; The Wistar Institute; NorthShore University Health System; Northwestern University	Benz, CC (corresponding author), Buck Inst Age Res, 8001 Redwood Blvd, Novato, CA 94945 USA.			Erny-Albrecht, Katrina/0000-0003-3538-1475	NATIONAL CANCER INSTITUTE [P50CA058207, R01CA036773, P01CA044768] Funding Source: NIH RePORTER; NCI NIH HHS [P01-CA44768, R01-CA36773, P50-CA58207, R01 CA036773, P50 CA058207] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Beerli RR, 1998, P NATL ACAD SCI USA, V95, P14628, DOI 10.1073/pnas.95.25.14628; BENZ C, 2000, J WOMENS CANC, V2, P33; Benz CC, 1998, ENDOCR-RELAT CANCER, V5, P271, DOI 10.1677/erc.0.0050271; Benz CC, 1997, ONCOGENE, V15, P1513, DOI 10.1038/sj.onc.1201331; BOSHER JM, 1995, P NATL ACAD SCI USA, V92, P744, DOI 10.1073/pnas.92.3.744; Bosher JM, 1996, ONCOGENE, V13, P1701; BredemeierErnst I, 1997, FEBS LETT, V408, P47, DOI 10.1016/S0014-5793(97)00387-6; Chang CH, 1999, ONCOGENE, V18, P3682, DOI 10.1038/sj.onc.1202674; Chang CH, 1997, ONCOGENE, V14, P1617, DOI 10.1038/sj.onc.1200978; Chen H, 1997, ONCOGENE, V14, P1965, DOI 10.1038/sj.onc.1201030; Chen S, 1997, MOL ENDOCRINOL, V11, P3, DOI 10.1210/me.11.1.3; Chen YY, 1997, J BIOL CHEM, V272, P14110, DOI 10.1074/jbc.272.22.14110; Chen YY, 1996, J BIOL CHEM, V271, P5183; CHEN YY, 1994, ONCOGENE, V9, P2269; Chiang SY, 2000, J BIOL CHEM, V275, P24246, DOI 10.1074/jbc.M000820200; COLOMER R, 1994, BRIT J CANCER, V70, P819, DOI 10.1038/bjc.1994.405; Czubayko F, 1997, GENE THER, V4, P943, DOI 10.1038/sj.gt.3300483; EBBINGHAUS SW, 1993, J CLIN INVEST, V92, P2433, DOI 10.1172/JCI116850; EBBINGHAUS SW, 1999, PERSPECT ANTISEN SCI, P117; GROOTECLAES M, 1994, CANCER RES, V54, P4193; GUIEYSSE AL, 1999, PERSPECT ANTISEN SCI, P223; HOLLYWOOD DP, 1993, EMBO J, V12, P2369, DOI 10.1002/j.1460-2075.1993.tb05891.x; HOLLYWOOD DP, 1995, BRIT J CANCER, V71, P753, DOI 10.1038/bjc.1995.146; HORWITZ EM, 1994, J BIOL CHEM, V269, P14130; HTUN H, 1988, SCIENCE, V241, P1791, DOI 10.1126/science.3175620; HTUN H, 1989, SCIENCE, V243, P1571, DOI 10.1126/science.2648571; HUDSON LG, 1990, J BIOL CHEM, V265, P4389; Hung M C, 2000, Breast Dis, V11, P133; ISHII S, 1987, P NATL ACAD SCI USA, V84, P4374, DOI 10.1073/pnas.84.13.4374; Kodandapani R, 1996, NATURE, V380, P456, DOI 10.1038/380456a0; KRAUS MH, 1987, EMBO J, V6, P605, DOI 10.1002/j.1460-2075.1987.tb04797.x; Krauss W C, 2000, Breast Dis, V11, P113; MARDEN C, 2000, IN PRESS ENCY MOL ME; MARGOLIN JF, 1994, P NATL ACAD SCI USA, V91, P4509, DOI 10.1073/pnas.91.10.4509; McCormick RJ, 1996, P NATL ACAD SCI USA, V93, P14434, DOI 10.1073/pnas.93.25.14434; MIRKIN SM, 1999, PERSPECT ANTISEN SCI, P193; MIZUGUCHI G, 1994, FEBS LETT, V348, P80, DOI 10.1016/0014-5793(94)00578-8; NOONBERG SB, 1994, GENE, V149, P123, DOI 10.1016/0378-1119(94)90420-0; PANAYOTATOS N, 1981, NATURE, V289, P466, DOI 10.1038/289466a0; Porumb H, 1996, CANCER RES, V56, P515; Raziuddin A, 1997, J BIOL CHEM, V272, P15715, DOI 10.1074/jbc.272.25.15715; Roh H, 2000, CANCER RES, V60, P560; Sacco MG, 1998, GENE THER, V5, P388, DOI 10.1038/sj.gt.3300592; SCOTT GK, 1994, J BIOL CHEM, V269, P19848; SUEN TC, 1990, MOL CELL BIOL, V10, P6306, DOI 10.1128/MCB.10.12.6306; Suzuki T, 2000, GENE THER, V7, P241, DOI 10.1038/sj.gt.3301065; TAL M, 1987, MOL CELL BIOL, V7, P2597, DOI 10.1128/MCB.7.7.2597; THOMPSON JF, 1988, NUCLEIC ACIDS RES, V16, P9687, DOI 10.1093/nar/16.20.9687; VAUGHN JP, 1995, P NATL ACAD SCI USA, V92, P8338, DOI 10.1073/pnas.92.18.8338; VERRIJZER CP, 1991, EMBO J, V10, P3007, DOI 10.1002/j.1460-2075.1991.tb07851.x; WECHSLER DS, 1992, P NATL ACAD SCI USA, V89, P7635, DOI 10.1073/pnas.89.16.7635; Werner MH, 1997, J BIOMOL NMR, V10, P317, DOI 10.1023/A:1018399711996; Xing XM, 2000, NAT MED, V6, P189, DOI 10.1038/72294	53	67	68	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 18	2000	19	55					6490	6502		10.1038/sj.onc.1204041	http://dx.doi.org/10.1038/sj.onc.1204041			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	395RL	11175365				2022-12-25	WOS:000166595000011
J	Ogawa, K; Pasqualini, R; Lindberg, RA; Kain, R; Freeman, AL; Pasquale, EB				Ogawa, K; Pasqualini, R; Lindberg, RA; Kain, R; Freeman, AL; Pasquale, EB			The ephrin-A1 ligand and its receptor, EphA2, are expressed during tumor neovascularization	ONCOGENE			English	Article						Eph receptor tyrosine kinases; angiogenesis; endothelial cells	PROTEIN-TYROSINE KINASE; BLOOD-VESSEL FORMATION; VASCULAR DEVELOPMENT; CARDIOVASCULAR DEVELOPMENT; MELANOMA PROGRESSION; RESPONSE GENE; CELL-LINES; ANGIOGENESIS; B61; ECK	Eph receptor tyrosine kinases and their ephrin ligands have been implicated in embryonic vascular development and in in vivo models of angiogenesis. Eph proteins may also regulate tumor neovascularization, but this role has not been previously investigated. To screen for Eph proteins expressed in tumor blood vessels, we used tumor xenografts grown in nude mice from MDA-MB-435 human breast cancer cells or KS1767 human Kaposi's sarcoma cells, By immunohistochemistry, the ephrin-A1 ligand and one of its receptors, EphA2, were detected throughout tumor vasculature. Double-labeling with anti-CD34 antibodies demonstrated that both ephrin-A1 and EphA2 were expressed in xenograft endothelial cells and also tumor cells. Furthermore, EphA2 was tyrosine-phosphorylated in the xenograft tumors, indicating that it was activated, presumably by interacting with ephrin-A1. Ephrin-A1 and EphA2 were also detected in both the vasculature and tumor cells of surgically removed human cancers. In an in vitro angiogenesis model, a dominant negative form of EphA2 inhibited capillary tube-like formation by human umbilical vein endothelial cells (HUVECs), demonstrating a requirement for EphA receptor signaling, These data suggest that ephrin-A1 and EphA2 play a role in human cancers, at least in part by influencing tumor neovascularization. Eph proteins may represent promising new targets for antiangiogenic cancer treatments.	Burnham Inst, La Jolla, CA 92037 USA; Iwate Univ, Fac Agr, Dept Vet Anat, Morioka, Iwate 2028550, Japan; Amgen Inc, Amgen Ctr, Thousand Oaks, CA 91320 USA; Univ Vienna, AK Hosp, Inst Clin Pathol, A-1090 Vienna, Austria	Sanford Burnham Prebys Medical Discovery Institute; Iwate University; Amgen; University of Vienna	Pasquale, EB (corresponding author), Burnham Inst, 10901 N Torrey Pines Rd, La Jolla, CA 92037 USA.		Kain, Renate/ACR-4709-2022	Kain, Renate/0000-0002-2428-543X	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R29HD026351, R01HD026351] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [P01CA082713] Funding Source: NIH RePORTER; NCI NIH HHS [CA82713] Funding Source: Medline; NICHD NIH HHS [HD26351] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Adams RH, 1999, GENE DEV, V13, P295, DOI 10.1101/gad.13.3.295; ANDRES AC, 1994, ONCOGENE, V9, P1461; Asahara T, 1997, SCIENCE, V275, P964, DOI 10.1126/science.275.5302.964; BARTLEY TD, 1994, NATURE, V368, P558, DOI 10.1038/368558a0; BAUMHUETER S, 1993, SCIENCE, V262, P436, DOI 10.1126/science.7692600; Berclaz G, 1996, BIOCHEM BIOPH RES CO, V226, P869, DOI 10.1006/bbrc.1996.1442; Bobik A, 1997, TUMOUR ANGIOGENESIS, P169; BROOKS PC, 1994, SCIENCE, V264, P569, DOI 10.1126/science.7512751; DANIEL TO, 1996, KIDNEY INT S, V57, P73; Davy A, 1999, GENE DEV, V13, P3125, DOI 10.1101/gad.13.23.3125; DODELET VC, 2000, IN PRESS ONCOGENE; EASTY DJ, 1995, INT J CANCER, V60, P129, DOI 10.1002/ijc.2910600119; Easty DJ, 1999, INT J CANCER, V84, P494, DOI 10.1002/(SICI)1097-0215(19991022)84:5<494::AID-IJC8>3.3.CO;2-F; Eberhart J, 2000, DEV NEUROSCI-BASEL, V22, P237, DOI 10.1159/000017446; Flanagan JG, 1998, ANNU REV NEUROSCI, V21, P309, DOI 10.1146/annurev.neuro.21.1.309; Flanagan JG, 1997, CELL, V90, P403; Flenniken AM, 1996, DEV BIOL, V179, P382, DOI 10.1006/dbio.1996.0269; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; Folkman J, 1996, CELL, V87, P1153, DOI 10.1016/S0092-8674(00)81810-3; FOX SB, 1995, J PATHOL, V177, P369, DOI 10.1002/path.1711770407; FRIEDLANDER M, 1995, SCIENCE, V270, P1500, DOI 10.1126/science.270.5241.1500; Gale NW, 1999, GENE DEV, V13, P1055, DOI 10.1101/gad.13.9.1055; Gasparini G, 1997, TUMOUR ANGIOGENESIS, P29; Gerety SS, 1999, MOL CELL, V4, P403, DOI 10.1016/S1097-2765(00)80342-1; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; Hanahan D, 1997, SCIENCE, V277, P48, DOI 10.1126/science.277.5322.48; HERNDIER BG, 1994, AIDS, V8, P575, DOI 10.1097/00002030-199405000-00002; HIRAI H, 1987, SCIENCE, V238, P1717, DOI 10.1126/science.2825356; Holash JA, 1995, DEV BIOL, V172, P683, DOI 10.1006/dbio.1995.8039; HOLZMAN LB, 1990, MOL CELL BIOL, V10, P5830, DOI 10.1128/MCB.10.11.5830; Huynh-Do U, 1999, EMBO J, V18, P2165, DOI 10.1093/emboj/18.8.2165; Kalo MS, 1999, CELL TISSUE RES, V298, P1, DOI 10.1007/PL00008807; KIYOKAWA E, 1994, CANCER RES, V54, P3645; LINDBERG RA, 1990, MOL CELL BIOL, V10, P6316, DOI 10.1128/MCB.10.12.6316; Magal E, 1996, J NEUROSCI RES, V43, P735, DOI 10.1002/(SICI)1097-4547(19960315)43:6<735::AID-JNR10>3.0.CO;2-X; MARU Y, 1988, MOL CELL BIOL, V8, P3770, DOI 10.1128/MCB.8.9.3770; MARU Y, 1990, ONCOGENE, V5, P445; McBride JL, 1998, MECH DEVELOP, V77, P201, DOI 10.1016/S0925-4773(98)00142-7; Mellitzer G, 1999, NATURE, V400, P77, DOI 10.1038/21907; Merenmies J, 1997, CELL GROWTH DIFFER, V8, P3; Miao H, 2000, NAT CELL BIOL, V2, P62, DOI 10.1038/35000008; PANDEY A, 1995, SCIENCE, V268, P567, DOI 10.1126/science.7536959; Pasqualini R, 1997, NAT BIOTECHNOL, V15, P542, DOI 10.1038/nbt0697-542; PRICE JE, 1990, CANCER RES, V50, P717; Risau W, 1995, ANNU REV CELL DEV BI, V11, P73, DOI 10.1146/annurev.cb.11.110195.000445; Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0; SARMA V, 1992, J IMMUNOL, V148, P3302; SATO TN, 1995, NATURE, V376, P70, DOI 10.1038/376070a0; SOANS C, 1994, ONCOGENE, V9, P3353; Soans C, 1996, J CELL BIOL, V135, P781, DOI 10.1083/jcb.135.3.781; Stein E, 1998, GENE DEV, V12, P667, DOI 10.1101/gad.12.5.667; Suri C, 1996, CELL, V87, P1171, DOI 10.1016/S0092-8674(00)81813-9; TAKAHASHI H, 1995, ONCOGENE, V11, P879; UICC/AJCC, 1997, TNM CLASS MAL TUM; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; Walker-Daniels J, 1999, PROSTATE, V41, P275, DOI 10.1002/(SICI)1097-0045(19991201)41:4<275::AID-PROS8>3.0.CO;2-T; Wang HU, 1998, CELL, V93, P741, DOI 10.1016/S0092-8674(00)81436-1; Xu QL, 1999, NATURE, V399, P267, DOI 10.1038/20452; Zisch AH, 2000, ONCOGENE, V19, P177, DOI 10.1038/sj.onc.1203304	59	309	344	0	15	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 7	2000	19	52					6043	6052		10.1038/sj.onc.1204004	http://dx.doi.org/10.1038/sj.onc.1204004			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	382MY	11146556				2022-12-25	WOS:000165827900011
J	Asaad, NA; Zeng, ZC; Guan, J; Thacker, J; Iliakis, G				Asaad, NA; Zeng, ZC; Guan, J; Thacker, J; Iliakis, G			Homologous recombination as a potential target for caffeine radiosensitization in mammalian cells: reduced caffeine radiosensitization in XRCC2 and XRCC3 mutants	ONCOGENE			English	Article						caffeine; DNA; Double Strand Breaks (DSB); repair; homologous recombination; non-homologous end joining	IRRADIATED HELA-CELLS; DOUBLE-STRAND BREAKS; RADIATION-SENSITIVE MUTANT; INDUCED CHROMOSOMAL-ABERRATIONS; INDUCED G2 DELAY; ATAXIA-TELANGIECTASIA; DNA-DAMAGE; IONIZING-RADIATION; CHO-CELLS; PROTEIN-KINASE	The radiosensitizing effect of caffeine has been associated with the disruption of multiple DNA damage-responsive cell cycle checkpoints, but several lines of evidence also implicate inhibition of DNA repair. The role of DNA repair inhibition in caffeine radiosensitization remains uncharacterized, and it is unknown which repair process, or lesion, is affected. We show that a radiosensitive cell line, mutant for the RAD51 homolog XRCC2 and defective in homologous recombination repair (HRR), displays significantly diminished caffeine radiosensitization that can be restored by expression of XRCC2, Despite the reduced radiosensitization, caffeine effectively abrogates checkpoints in S and G2 phases in XRCC2 mutant cells indicating that checkpoint abrogation is not sufficient for radiosensitization, Another radiosensitive line, mutant for XRCC3 and defective in HRR, similarly shows reduced caffeine radiosensitization, On the other hand, a radiosensitive mutant (irs-20) of DNA-PKcs with a defect in non-homologous end-joining (NHEJ) is radiosensitized by caffeine to an extent comparable to wild-type cells. In addition, rejoining of radiation-induced DNA DSBs, that mainly reflects NHEJ, remains unaffected by caffeine in XRCC2 and XRCC3 mutants, or their wild-type counterparts. These observations suggest that caffeine targets steps in HRR but not in NHEJ and that abrogation of checkpoint response is not sufficient to explain radiosensitization, Indeed, immortalized fibroblasts from AT patients show caffeine radiosensitization despite the checkpoint defects associated with ATM mutation. We propose that caffeine radiosensitization is mediated by inhibition of stages in DNA DSB repair requiring HRR and that checkpoint disruption contributes by allowing these DSBs to transit into irreparable states. Thus, checkpoints may contribute to genomic stability by promoting error-free HRR.	Thomas Jefferson Univ, Dept Radiat Oncol, Kimmel Canc Ctr, Jefferson Med Coll, Philadelphia, PA 19107 USA; MRC, Radiat & Genome Stabil Unit, Harwell OX11 0RD, Berks, England	Jefferson University	Iliakis, G (corresponding author), Thomas Jefferson Univ, Dept Radiat Oncol, Kimmel Canc Ctr, Jefferson Med Coll, Thompson Bldg,Rm B-1, Philadelphia, PA 19107 USA.				NATIONAL CANCER INSTITUTE [P30CA056036, R01CA042026] Funding Source: NIH RePORTER; NCI NIH HHS [2RO1 CA42026, P30-CA56036] Funding Source: Medline; PHS HHS [56706] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BATES PR, 1985, INT J RADIAT BIOL, V47, P713, DOI 10.1080/09553008514550951; Bebb DG, 1998, MUTAT RES-FUND MOL M, V401, P27, DOI 10.1016/S0027-5107(97)00214-5; BEETHAM KL, 1982, RADIAT RES, V91, P199, DOI 10.2307/3575827; BEETHAM KL, 1984, RADIAT RES, V100, P104, DOI 10.2307/3576526; BEETHAM KL, 1986, RADIAT RES, V107, P272, DOI 10.2307/3576814; Bernhard EJ, 1996, INT J RADIAT BIOL, V69, P575, DOI 10.1080/095530096145580; Blasina A, 1999, CURR BIOL, V9, P1135, DOI 10.1016/S0960-9822(99)80486-2; BUSSE PM, 1977, RADIAT RES, V71, P666, DOI 10.2307/3574634; BUSSE PM, 1978, RADIAT RES, V76, P292, DOI 10.2307/3574780; CARR AM, 1995, SEMIN CELL BIOL, V6, P65, DOI 10.1016/1043-4682(95)90002-0; Cartwright R, 1998, NUCLEIC ACIDS RES, V26, P3084, DOI 10.1093/nar/26.13.3084; CHEONG N, 1994, MUTAT RES, V314, P77, DOI 10.1016/0921-8777(94)90063-9; CHEONG N, 1992, MUTAT RES, V274, P111, DOI 10.1016/0921-8777(92)90058-B; Dibiase SJ, 2000, CANCER RES, V60, P1245; DOMON M, 1969, RADIAT RES, V39, P207, DOI 10.2307/3572642; FABRE F, 1972, MOL GEN GENET, V117, P153, DOI 10.1007/BF00267612; FAN SJ, 1995, CANCER RES, V55, P1649; FRANKENBERGSCHWAGER M, 1989, RADIOTHER ONCOL, V14, P307, DOI 10.1016/0167-8140(89)90143-6; FULLER LF, 1988, MUTAT RES, V193, P109, DOI 10.1016/0167-8817(88)90041-7; FURCINITTI PS, 1993, RADIAT RES, V95, P197; GARATTINI S, 1993, CAFFEINE COFFEE HLTH, P1; GENTNER NE, 1981, MOL GEN GENET, V181, P283, DOI 10.1007/BF00425598; GENTNER NE, 1978, MOL GEN GENET, V167, P43, DOI 10.1007/BF00270320; GRIFFITHS TD, 1978, INT J RADIAT BIOL, V33, P493, DOI 10.1080/09553007814550401; Guan J, 2000, NUCLEIC ACIDS RES, V28, P1183, DOI 10.1093/nar/28.5.1183; Hall-Jackson CA, 1999, ONCOGENE, V18, P6707, DOI 10.1038/sj.onc.1203077; HANSSON K, 1984, HUM GENET, V67, P329, DOI 10.1007/BF00291363; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; HARVEY AN, 1994, MUTAT RES, V304, P203, DOI 10.1016/0027-5107(94)90212-7; ILIAKIS G, 1983, INT J RADIAT BIOL, V43, P649, DOI 10.1080/09553008314550741; ILIAKIS G, 1983, RADIAT RES, V95, P87, DOI 10.2307/3576074; ILIAKIS G, 1991, BIOESSAYS, V13, P641; ILIAKIS G, 1988, INT J RADIAT BIOL, V53, P541, DOI 10.1080/09553008814550901; ILIAKIS GE, 1991, INT J RADIAT BIOL, V59, P343, DOI 10.1080/09553009114550321; ILIAKIS GE, 1991, INT J RADIAT BIOL, V59, P321, DOI 10.1080/09553009114550311; Jeggo PA, 1998, ADV GENET, V38, P185, DOI 10.1016/S0065-2660(08)60144-3; Johnson RD, 1999, NATURE, V401, P397, DOI 10.1038/43935; JONES NJ, 1990, MUTAGENESIS, V5, P15, DOI 10.1093/mutage/5.1.15; JONES NJ, 1987, MUTAT RES, V183, P279, DOI 10.1016/0167-8817(87)90011-3; JUNG T, 1992, INT J RADIAT BIOL, V62, P161, DOI 10.1080/09553009214551971; KASTAN MB, 1991, CANCER RES, V51, P6304; KIMLER BF, 1982, INT J RADIAT BIOL, V41, P47, DOI 10.1080/09553008214550041; LAU CC, 1982, P NATL ACAD SCI-BIOL, V79, P2942, DOI 10.1073/pnas.79.9.2942; LEHMANN AR, 1972, BIOPHYS J, V12, P1316, DOI 10.1016/S0006-3495(72)86165-4; Lehmann AR, 1996, MUTAT RES-DNA REPAIR, V363, P147, DOI 10.1016/0921-8777(96)00017-1; Liu N, 1998, MOL CELL, V1, P783, DOI 10.1016/S1097-2765(00)80078-7; LOPRIENO N, 1973, MUTAT RES, V21, P275; LOPRIENO N, 1974, MUTAT RES, V26, P83, DOI 10.1016/S0027-5107(74)80038-2; LOPRIENO N, 1971, MOL GEN GENET, V110, P348, DOI 10.1007/BF00438276; LUCKEHUHLE C, 1982, RADIAT RES, V89, P298, DOI 10.2307/3575776; Morrison C, 2000, EMBO J, V19, P463, DOI 10.1093/emboj/19.3.463; Moser BA, 2000, MOL CELL BIOL, V20, P4288, DOI 10.1128/MCB.20.12.4288-4294.2000; MURNANE JP, 1980, NATURE, V285, P326, DOI 10.1038/285326a0; MURNANE JP, 1995, CANCER METAST REV, V14, P17, DOI 10.1007/BF00690208; MUSK SRR, 1991, RADIAT RES, V125, P262, DOI 10.2307/3578108; MUSK SRR, 1990, INT J RADIAT BIOL, V57, P1105, DOI 10.1080/09553009014551221; NASIM A, 1974, MOL GEN GENET, V132, P13, DOI 10.1007/BF00268226; NATARAJAN AT, 1980, HUM GENET, V54, P183, DOI 10.1007/BF00278969; Nevaldine B, 1997, RADIAT RES, V147, P535, DOI 10.2307/3579619; Osman F, 1998, MOL GEN GENET, V260, P319, DOI 10.1007/s004380050901; PAINTER RB, 1980, J MOL BIOL, V143, P289, DOI 10.1016/0022-2836(80)90191-6; PALAYOOR ST, 1995, RADIAT RES, V141, P235, DOI 10.2307/3579000; PAWLAK AL, 1990, MUTAT RES, V230, P197, DOI 10.1016/0027-5107(90)90057-B; Pierce AJ, 1999, GENE DEV, V13, P2633, DOI 10.1101/gad.13.20.2633; POWELL SN, 1995, CANCER RES, V55, P1643; Priestley A, 1998, NUCLEIC ACIDS RES, V26, P1965, DOI 10.1093/nar/26.8.1965; Ribeiro JCC, 1999, INT J RADIAT BIOL, V75, P481, DOI 10.1080/095530099140410; Rowley R, 1999, GENETICS, V152, P61; ROWLEY R, 1992, RADIAT RES, V129, P224, DOI 10.2307/3578161; RUSSELL KJ, 1995, CANCER RES, V55, P1639; Sarkaria JN, 1999, CANCER RES, V59, P4375; SCHLEGEL R, 1986, SCIENCE, V232, P1264, DOI 10.1126/science.2422760; Shinomiya N, 1997, CYTOMETRY, V27, P365, DOI 10.1002/(SICI)1097-0320(19970401)27:4<365::AID-CYTO8>3.3.CO;2-F; SIEDE W, 1985, RADIAT ENVIRON BIOPH, V24, P1, DOI 10.1007/BF01212648; Smith GCM, 1999, GENE DEV, V13, P916, DOI 10.1101/gad.13.8.916; STACKHOUSE MA, 1993, RADIAT RES, V136, P241, DOI 10.2307/3578617; STACKHOUSE MA, 1994, INT J RADIAT BIOL, V65, P571, DOI 10.1080/09553009414550661; STACKHOUSE MA, 1993, RADIAT RES, V136, P250, DOI 10.2307/3578618; Takata M, 1998, EMBO J, V17, P5497, DOI 10.1093/emboj/17.18.5497; Tambini CE, 1997, GENOMICS, V41, P84, DOI 10.1006/geno.1997.4636; TATSUMI K, 1979, J MOL BIOL, V135, P435, DOI 10.1016/0022-2836(79)90445-5; TAYLOR YC, 1993, INT J RADIAT BIOL, V64, P57, DOI 10.1080/09553009314551111; Thacker J, 1999, TRENDS GENET, V15, P166, DOI 10.1016/S0168-9525(99)01733-3; THACKER J, 1990, MUTAT RES, V235, P49, DOI 10.1016/0921-8777(90)90057-C; Thompson LH, 1999, BIOCHIMIE, V81, P87, DOI 10.1016/S0300-9084(99)80042-X; TIMSON J, 1977, MUTAT RES, V47, P1, DOI 10.1016/0165-1110(77)90016-1; TOLMACH LJ, 1980, RADIAT RES, V82, P374, DOI 10.2307/3575387; TOLMACH LJ, 1977, RADIAT RES, V71, P653, DOI 10.2307/3574633; TOMASOVIC SP, 1978, RADIAT RES, V74, P112, DOI 10.2307/3574761; TSO POP, 1964, P NATL ACAD SCI USA, V51, P17, DOI 10.1073/pnas.51.1.17; Valenzuela MT, 2000, RADIOTHER ONCOL, V54, P261, DOI 10.1016/S0167-8140(99)00180-2; WALDREN CA, 1978, RADIAT RES, V73, P95, DOI 10.2307/3574576; WALTERS RA, 1974, BIOPHYS J, V14, P99, DOI 10.1016/S0006-3495(74)70002-9; WANG H, 2000, UNPUB; Wang SW, 1999, J CELL SCI, V112, P927; WARD JF, 1985, RADIAT RES, V104, pS103, DOI 10.2307/3576637; Yao SL, 1996, NAT MED, V2, P1140, DOI 10.1038/nm1096-1140; ZAMPETTIBOSSELER F, 1985, MUTAT RES, V143, P251, DOI 10.1016/0165-7992(85)90089-2; Zhou BBS, 2000, J BIOL CHEM, V275, P10342, DOI 10.1074/jbc.275.14.10342	100	92	95	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 23	2000	19	50					5788	5800		10.1038/sj.onc.1203953	http://dx.doi.org/10.1038/sj.onc.1203953			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	376VP	11126366				2022-12-25	WOS:000165477700011
J	Zheng, YM; Liu, CD; Chen, H; Locke, D; Ryan, JC; Kahn, ML				Zheng, YM; Liu, CD; Chen, H; Locke, D; Ryan, JC; Kahn, ML			Expression of the platelet receptor GPVI confers signaling via the Fc receptor gamma-chain in response to the snake venom convulxin but not to collagen	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPSILON-RI-GAMMA; GLYCOPROTEIN-VI; IMMUNOGLOBULIN SUPERFAMILY; FUNCTIONAL ASSOCIATION; I COLLAGEN; ACTIVATION; ADHESION; IGE; INTEGRIN; PROTEIN	The mechanism of signal transduction underlying the activation of platelets by collagen has been actively investigated for over 30 years, but the receptors involved remain incompletely understood. Studies of human platelets, which are unresponsive to collagen, mouse knockout models, and platelet biochemical studies support the hypothesis that the recently cloned platelet surface protein GPVI functions as a signaling receptor for collagen. To directly test this hypothesis, we have expressed wild-type and mutant forms of GPVI in RBL-2H3 cells, which express the Fee receptor gamma -chain (Fc R gamma), the putative signaling co-receptor for GPVI in platelets, but lack GPVI itself. Expression of GPVI in RBL-2H3 cells confers strong adhesive and signaling responses to convulxin (a snake venom protein that directly binds GPVI) and weak responsiveness to collagen-related peptide but no responsiveness to collagen, To elucidate the mechanism of GPVI intracellular signaling, mutations were introduced in the receptor's transmembrane domain and C-terminal tail. Unlike reported studies of other Fc R gamma partners, these studies reveal that both the GPVI transmembrane arginine and intracellular C-tail are necessary for coupling to Fc R gamma and for signal transduction. To our knowledge, these studies are the first to demonstrate a direct signaling role for GPVI and the first to directly test the role of GPVI as a collagen receptor. Our results suggest that GPVI may be necessary but not sufficient for collagen signaling and that a distinct ligand-binding collagen receptor such as the alpha (2)beta (1) integrin is likely to play a necessary role for collagen signaling as well as adhesion in platelets.	Univ Penn, Dept Med, Philadelphia, PA 19104 USA; Vet Adm Med Ctr, San Francisco, CA 94121 USA; Univ Calif San Francisco, Dept Med, San Francisco, CA 94121 USA	University of Pennsylvania; US Department of Veterans Affairs; Veterans Health Administration (VHA); University of California System; University of California San Francisco	Kahn, ML (corresponding author), Univ Penn, Dept Med, 421 Curie Blvd,BRB 2-3,Rm 952, Philadelphia, PA 19104 USA.							ALBER G, 1991, J BIOL CHEM, V266, P22613; Bakker ABH, 1999, P NATL ACAD SCI USA, V96, P9792, DOI 10.1073/pnas.96.17.9792; BARSUMIAN EL, 1981, EUR J IMMUNOL, V11, P317, DOI 10.1002/eji.1830110410; Chiang TM, 1997, J CLIN INVEST, V100, P514, DOI 10.1172/JCI119560; Clemetson JM, 1999, J BIOL CHEM, V274, P29019, DOI 10.1074/jbc.274.41.29019; CLEMETSON KJ, 1982, J CLIN INVEST, V70, P304, DOI 10.1172/JCI110618; Connolly AJ, 1996, NATURE, V381, P516, DOI 10.1038/381516a0; DU XP, 1994, J BIOL CHEM, V269, P18287; Francischetti IMB, 1997, TOXICON, V35, P1217, DOI 10.1016/S0041-0101(97)00021-4; Hamawy MM, 1997, J BIOL CHEM, V272, P30498, DOI 10.1074/jbc.272.48.30498; Jandrot-Perrus M, 2000, BLOOD, V96, P1798, DOI 10.1182/blood.V96.5.1798.h8001798_1798_1807; JandrotPerrus M, 1997, J BIOL CHEM, V272, P27035, DOI 10.1074/jbc.272.43.27035; Kahn ML, 1999, J CLIN INVEST, V103, P879, DOI 10.1172/JCI6042; Keely PJ, 1996, J BIOL CHEM, V271, P26668, DOI 10.1074/jbc.271.43.26668; LANIER LL, 1991, J IMMUNOL, V146, P1571; LECONIAT M, 1990, IMMUNOGENETICS, V32, P183, DOI 10.1007/BF02114971; Monnet E, 2000, THROMB RES, V98, P423, DOI 10.1016/S0049-3848(00)00199-7; MOROI M, 1992, BIOCHIM BIOPHYS ACTA, V1137, P1, DOI 10.1016/0167-4889(92)90092-P; MOROI M, 1989, J CLIN INVEST, V84, P1440, DOI 10.1172/JCI114318; MORTON HC, 1995, J BIOL CHEM, V270, P29781; MORTON LF, 1995, BIOCHEM J, V306, P337, DOI 10.1042/bj3060337; Nakamura T, 1998, J BIOL CHEM, V273, P4338, DOI 10.1074/jbc.273.8.4338; Nieswandt B, 2000, J BIOL CHEM, V275, P23998, DOI 10.1074/jbc.M003803200; NIEUWENHUIS HK, 1985, NATURE, V318, P470, DOI 10.1038/318470a0; Ono M, 1999, J BIOL CHEM, V274, P30288, DOI 10.1074/jbc.274.42.30288; Polgar J, 1997, J BIOL CHEM, V272, P13576, DOI 10.1074/jbc.272.21.13576; Poole A, 1997, EMBO J, V16, P2333, DOI 10.1093/emboj/16.9.2333; POSNER RG, 1995, J IMMUNOL, V155, P3601; SANTORO SA, 1986, CELL, V46, P913, DOI 10.1016/0092-8674(86)90073-5; Strouse RJ, 1996, THROMB RES, V82, P485, DOI 10.1016/0049-3848(96)00099-0; SUGIYAMA T, 1987, BLOOD, V69, P1712; Taylor LS, 1999, BLOOD, V94, P1790, DOI 10.1182/blood.V94.5.1790.417k16_1790_1796; Tsuji M, 1997, J BIOL CHEM, V272, P23528, DOI 10.1074/jbc.272.38.23528; Watson SP, 1999, THROMB HAEMOSTASIS, V82, P365; WILNER GD, 1968, J CLIN INVEST, V47, P2616, DOI 10.1172/JCI105944	36	64	71	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 20	2001	276	16					12999	13006		10.1074/jbc.M009344200	http://dx.doi.org/10.1074/jbc.M009344200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	423VN	11152687	hybrid			2022-12-25	WOS:000168198600077
J	Sauna, ZE; Ambudkar, SV				Sauna, ZE; Ambudkar, SV			Characterization of the catalytic cycle of ATP hydrolysis by human P-glycoprotein - The two ATP hydrolysis events in a single catalytic cycle are kinetically similar but affect different functional outcomes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTIDRUG-RESISTANCE PROTEIN; HAMSTER OVARY CELLS; CRYSTAL-STRUCTURE; TRANSITION-STATE; WALKER-A; NUCLEOTIDE; SITES; BINDING; PURIFICATION; TRANSPORTER	P-glycoprotein (Pgp) is a plasma membrane protein whose overexpression confers multidrug resistance to tumor cells by extruding amphipathic natural product cytotoxic drugs using the energy of ATP, An elucidation of the catalytic cycle of Pgp would help design rational strategies to combat multidrug resistance and to further our understanding of the mechanism of ATP-binding cassette transporters. We have recently reported (Sauna, Z, E,, and Ambudkar, S, V. (2000) Proc. Natl, Acad Sci, U.S.A. 97, 2515-2520) that there are two independent ATP hydrolysis events in a single catalytic cycle of Pgp, In this study we exploit the vanadate (Vi)induced transition state conformation of Pgp (Pgp ADP Vi) to address the question of what are the effects of ATP hydrolysis on the nucleotide-binding site, We find that at the end of the first hydrolysis event there is a drastic decrease in the affinity of nucleotide for Pgp coincident with decreased substrate binding. Release of occluded dinucleotide is adequate for the next hydrolysis event to occur but is not sufficient for the recovery of substrate binding. Whereas the two hydrolysis events have different functional outcomes vis a vis the substrate, they show comparable t(1/2), for both incorporation and release of nucleotide, and the affinities for [alpha-P-32]8-azido-ATP during Vi induced trapping are identical. In addition, the incorporation of [alpha-P-32]8-azido-ADP in two ATP sites during both hydrolysis events is also similar. These data demonstrate that during individual hydrolysis events, the ATP sites are recruited in a random manner, and only one site is utilized at any given time because of the conformational change in the catalytic site that drastically reduces the affinity of the second ATP site for nucleotide binding. In aggregate, these findings provide an explanation for the alternate catalysis of ATP hydrolysis and offer a mechanistic framework to elucidate events at both the substrate- and nucleotide-binding sites in the catalytic cycle of Pgp.	NCI, Cell Biol Lab, Div Basic Sci, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Ambudkar, SV (corresponding author), NCI, Cell Biol Lab, Div Basic Sci, NIH, Bldg 37,Rm 1B-22,37 Convent Dr, Bethesda, MD 20892 USA.	ambudkar@helix.nih.gov	Ambudkar, Suresh V/B-5964-2008; Ambudkar, Suresh V/L-1317-2016; Sauna, Zuben E./AAA-7149-2019					ALSHAWI MK, 1993, J BIOL CHEM, V268, P4197; ALSHAWI MK, 1994, J BIOL CHEM, V269, P8986; Ambudkar SV, 1997, J BIOL CHEM, V272, P21160, DOI 10.1074/jbc.272.34.21160; Ambudkar SV, 1999, ANNU REV PHARMACOL, V39, P361, DOI 10.1146/annurev.pharmtox.39.1.361; AMBUDKAR SV, 1992, P NATL ACAD SCI USA, V89, P8472, DOI 10.1073/pnas.89.18.8472; Dey S, 1997, P NATL ACAD SCI USA, V94, P10594, DOI 10.1073/pnas.94.20.10594; Diederichs K, 2000, EMBO J, V19, P5951, DOI 10.1093/emboj/19.22.5951; FORD JM, 1990, PHARMACOL REV, V42, P155; GOTTESMAN MM, 1993, ANNU REV BIOCHEM, V62, P385, DOI 10.1146/annurev.bi.62.070193.002125; Gottesman MM, 1996, CURR OPIN GENET DEV, V6, P610, DOI 10.1016/S0959-437X(96)80091-8; HIRATSUKA T, 1973, BIOCHIM BIOPHYS ACTA, V320, P635, DOI 10.1016/0304-4165(73)90143-8; Hrycyna CA, 1999, BIOCHEMISTRY-US, V38, P13887, DOI 10.1021/bi991115m; Kerr KM, 2001, J BIOL CHEM, V276, P8657, DOI 10.1074/jbc.M010044200; Lamers MH, 2000, NATURE, V407, P711, DOI 10.1038/35037523; Lerner-Marmarosh N, 1999, J BIOL CHEM, V274, P34711, DOI 10.1074/jbc.274.49.34711; Liu RH, 1997, BIOCHEMISTRY-US, V36, P2836, DOI 10.1021/bi9627119; Liu RH, 1996, BIOCHEMISTRY-US, V35, P11865, DOI 10.1021/bi960823u; LOO TW, 1995, J BIOL CHEM, V270, P21449, DOI 10.1074/jbc.270.37.21449; LOO TW, 1995, J BIOL CHEM, V270, P22957, DOI 10.1074/jbc.270.39.22957; Muller M, 1996, J BIOL CHEM, V271, P1877; Obmolova G, 2000, NATURE, V407, P703, DOI 10.1038/35037509; Ramachandra M, 1998, BIOCHEMISTRY-US, V37, P5010, DOI 10.1021/bi973045u; Sankaran B, 1997, BIOCHEMISTRY-US, V36, P6847, DOI 10.1021/bi970034s; SARKADI B, 1992, J BIOL CHEM, V267, P4854; Sauna ZE, 2000, P NATL ACAD SCI USA, V97, P2515, DOI 10.1073/pnas.97.6.2515; SCARBOROUGH GA, 1995, J BIOENERG BIOMEMBR, V27, P37, DOI 10.1007/BF02110329; SCHAFFNE.W, 1973, ANAL BIOCHEM, V56, P502, DOI 10.1016/0003-2697(73)90217-0; SENIOR AE, 1995, J BIOENERG BIOMEMBR, V27, P31, DOI 10.1007/BF02110328; Senior AE, 1995, FEBS LETT, V377, P285, DOI 10.1016/0014-5793(95)01345-8; Senior AE, 1998, BIOCHEMISTRY-US, V37, P831, DOI 10.1021/bi9719962; Senior AE, 1997, SEMIN CANCER BIOL, V8, P143, DOI 10.1006/scbi.1997.0065; Senior AE, 1998, ACTA PHYSIOL SCAND, V163, P213; Shapiro AB, 1998, EUR J BIOCHEM, V254, P189, DOI 10.1046/j.1432-1327.1998.2540189.x; SHAROM FJ, 1995, BIOCHEM J, V308, P381, DOI 10.1042/bj3080381; Urbatsch IL, 2000, J BIOL CHEM, V275, P25031, DOI 10.1074/jbc.M003962200; Urbatsch IL, 2000, BIOCHEMISTRY-US, V39, P11921, DOI 10.1021/bi001220s; URBATSCH IL, 1995, J BIOL CHEM, V270, P19383, DOI 10.1074/jbc.270.33.19383; Urbatsch IL, 1998, BIOCHEMISTRY-US, V37, P4592, DOI 10.1021/bi9728001; URBATSCH IL, 1994, BIOCHEMISTRY-US, V33, P7069, DOI 10.1021/bi00189a008; URBATSCH IL, 1995, J BIOL CHEM, V270, P26956, DOI 10.1074/jbc.270.45.26956; Zhou TQ, 2000, EMBO J, V19, P4838, DOI 10.1093/emboj/19.17.4838	41	147	148	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 13	2001	276	15					11653	11661		10.1074/jbc.M011294200	http://dx.doi.org/10.1074/jbc.M011294200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	421UK	11154703	hybrid			2022-12-25	WOS:000168081800033
J	Sharkov, NA; Davis, RM; Reidhaar-Olson, JF; Navre, M; Cai, D				Sharkov, NA; Davis, RM; Reidhaar-Olson, JF; Navre, M; Cai, D			Reaction kinetics of protease with substrate phage - Kinetic model developed using stromelysin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PEPTIDE LIBRARIES; PLASMINOGEN-ACTIVATOR; DISPLAY; SPECIFICITY; SELECTION; IDENTIFICATION; STABILITY; PROTEINS; LIGANDS	Peptide libraries generated using phage display have been widely applied to proteolytic enzymes for substrate selection and optimization, but the reaction kinetics between the enzyme and substrate phage are not well understood. Using a quantitative ELISA assay to monitor the disappearance of substrate, we have been able to follow the course of reaction between stromelysin, a metalloprotease, and its substrate phage, We found that under the proteolytic conditions where the enzyme was present in nanomolar concentration or higher, in excess over the substrate, the proteolysis of substrate phage was a single exponential event and the observed rate linear with respect to enzyme concentration. The enzyme concentration dependence could be described by pseudo first-order kinetic equations. Our data suggest that substrate binding is slow relative to the subsequent hydrolysis step, implying that the phage display selection process enriches clones that have high binding affinity to the protease, and the selection may not discriminate those of different chemical reactivity toward the enzyme. Considering that multiple substrate molecules may be present on a single phage particle, we regard the substrate phage reaction kinetic model as empirical. The validity of the model was ascertained when we successfully applied it to determine the binding affinity of a competitive inhibitor of stromelysin.	Affymax Res Inst, Santa Clara, CA 95051 USA		Cai, D (corresponding author), 3410 Cent Expressway, Santa Clara, CA 95051 USA.							Cochran AG, 2000, CHEM BIOL, V7, pR85, DOI 10.1016/S1074-5521(00)00106-X; Coombs GS, 1998, CHEM BIOL, V5, P475, DOI 10.1016/S1074-5521(98)90004-7; CWIRLA SE, 1990, P NATL ACAD SCI USA, V87, P6378, DOI 10.1073/pnas.87.16.6378; Dente L, 1997, J MOL BIOL, V269, P694, DOI 10.1006/jmbi.1997.1073; DEVLIN JJ, 1990, SCIENCE, V249, P404, DOI 10.1126/science.2143033; DING L, 1995, P NATL ACAD SCI USA, V92, P7627, DOI 10.1073/pnas.92.17.7627; Finucane MD, 1999, BIOCHEMISTRY-US, V38, P11604, DOI 10.1021/bi990765n; Gram H, 1999, COMB CHEM HIGH T SCR, V2, P19; Harris JL, 1998, J BIOL CHEM, V273, P27364, DOI 10.1074/jbc.273.42.27364; Hervio LS, 2000, CHEM BIOL, V7, P443, DOI 10.1016/S1074-5521(00)00125-3; Kay BK, 1998, DRUG DISCOV TODAY, V3, P370, DOI 10.1016/S1359-6446(98)01220-3; Ke SH, 1997, J BIOL CHEM, V272, P16603, DOI 10.1074/jbc.272.26.16603; Kristensen P, 1998, FOLD DES, V3, P321, DOI 10.1016/S1359-0278(98)00044-3; Lowman HB, 1997, ANNU REV BIOPH BIOM, V26, P401, DOI 10.1146/annurev.biophys.26.1.401; MATTHEWS DJ, 1993, SCIENCE, V260, P1113, DOI 10.1126/science.8493554; MATTHEWS DJ, 1994, PROTEIN SCI, V3, P1197, DOI 10.1002/pro.5560030805; OBoyle DR, 1997, VIROLOGY, V236, P338, DOI 10.1006/viro.1997.8746; Ruan B, 1998, PROTEIN SCI, V7, P2345, DOI 10.1002/pro.5560071111; Schmitz R, 1996, J MOL BIOL, V260, P664, DOI 10.1006/jmbi.1996.0429; SCOTT JK, 1990, SCIENCE, V249, P386, DOI 10.1126/science.1696028; Sieber V, 1998, NAT BIOTECHNOL, V16, P955, DOI 10.1038/nbt1098-955; SMITH MM, 1995, J BIOL CHEM, V270, P6440, DOI 10.1074/jbc.270.12.6440; Souroujon MC, 1998, NAT BIOTECHNOL, V16, P919, DOI 10.1038/nbt1098-919; Webster Robert E., 1996, P1, DOI 10.1016/B978-012402380-2/50003-4; Zwick MB, 1998, CURR OPIN BIOTECH, V9, P427, DOI 10.1016/S0958-1669(98)80017-7	25	6	6	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 6	2001	276	14					10788	10793		10.1074/jbc.M011772200	http://dx.doi.org/10.1074/jbc.M011772200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	420AC	11152696	hybrid			2022-12-25	WOS:000167980900032
J	Han, GS; Johnston, CN; Chen, XM; Athenstaedt, K; Daum, G; Carman, GM				Han, GS; Johnston, CN; Chen, XM; Athenstaedt, K; Daum, G; Carman, GM			Regulation of the Saccharomyces cerevisiae DPP1-encoded diacylglycerol pyrophosphate phosphatase by zinc	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOLIPID BIOSYNTHESIS; GENE ENCODES; SHUTTLE VECTORS; SEQUENCE MOTIF; H+-ATPASE; YEAST; IDENTIFICATION; TRANSPORTER; PROTEIN; PURIFICATION	The DPP1 gene, encoding diacylglycerol pyrophosphate (DGPP) phosphatase from Saccharomyces cerevisiae, has recently been identified as a zinc-regulated gene, and it contains a putative zinc-responsive element (UAS(ZRE)) in its promoter. In this work we examined the hypothesis that expression of DGPP phosphatase was regulated by zinc availability. The deprivation of zinc from the growth medium resulted in a time- and dose-dependent induction of beta -galactosidase activity driven by a P-DPP1-lacZ reporter gene, This regulation was dependent on the UAS(ZRE) in the DPP1 promoter and was mediated by the Zap1p transcriptional activator. Induction of the DGPP phosphatase protein and activity by zinc deprivation was demonstrated by immunoblot analysis and measurement of the dephosphorylation of DGPP, The regulation pattern of DGPP phosphatase in mutants defective in plasma membrane (Zrt1p and Zrt2p) and vacuolar membrane (Zrt3p) zinc transporters indicated that enzyme expression was sensitive to the cytoplasmic levels of zinc. DGPP phosphatase activity was inhibited by zinc by a mechanism that involved formation of DGPP-zinc complexes, Studies with well characterized subcellular fractions and by indirect immunofluorescence microscopy revealed that the DGPP phosphatase enzyme was localized to the vacuolar membrane.	Rutgers State Univ, Dept Food Sci, Cook Coll, New Jersey Agr Expt Stn, New Brunswick, NJ 08901 USA; Graz Univ Technol, Inst Biochem, A-8010 Graz, Austria	Rutgers State University New Brunswick; Graz University of Technology	Carman, GM (corresponding author), Rutgers State Univ, Dept Food Sci, Cook Coll, New Jersey Agr Expt Stn, 65 Dudley Rd, New Brunswick, NJ 08901 USA.	carman@aesop.rutgers.edu		Athenstaedt, Karin/0000-0001-7198-3989	NIGMS NIH HHS [GM-28140] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM028140, R01GM028140] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Balboa MA, 1999, J BIOL CHEM, V274, P522, DOI 10.1074/jbc.274.1.522; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brindley DN, 1998, J BIOL CHEM, V273, P24281, DOI 10.1074/jbc.273.38.24281; Carman GM, 1999, PROG LIPID RES, V38, P361, DOI 10.1016/S0163-7827(99)00010-7; CARMAN GM, 1989, ANNU REV BIOCHEM, V58, P635, DOI 10.1146/annurev.biochem.58.1.635; Chen HM, 1996, J AGR FOOD CHEM, V44, P2619, DOI 10.1021/jf950833m; CRAVEN GR, 1965, J BIOL CHEM, V240, P2468; DAUM G, 1982, J BIOL CHEM, V257, P3028; Dawson R. M. C., 1986, DATA BIOCH RES, V3rd; Dillon DA, 1997, J BIOL CHEM, V272, P10361; Dillon DA, 1996, J BIOL CHEM, V271, P30548, DOI 10.1074/jbc.271.48.30548; Faulkner A, 1999, J BIOL CHEM, V274, P14831, DOI 10.1074/jbc.274.21.14831; Gitan RS, 1998, J BIOL CHEM, V273, P28617, DOI 10.1074/jbc.273.44.28617; Gitan RS, 2000, BIOCHEM J, V346, P329, DOI 10.1042/0264-6021:3460329; Greenberg ML, 1996, MICROBIOL REV, V60, P1; Guerinot ML, 1999, CURR OPIN PLANT BIOL, V2, P244, DOI 10.1016/S1369-5266(99)80042-9; HAID A, 1983, METHOD ENZYMOL, V96, P192; Hemrika W, 1997, P NATL ACAD SCI USA, V94, P2145, DOI 10.1073/pnas.94.6.2145; HILL JE, 1986, YEAST, V2, P163, DOI 10.1002/yea.320020304; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HUNT JB, 1985, ANAL BIOCHEM, V146, P150, DOI 10.1016/0003-2697(85)90409-9; Innis MA, 1990, PCR PROTOCOLS GUIDE, P3; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; KLIG LS, 1985, J BACTERIOL, V162, P1135, DOI 10.1128/JB.162.3.1135-1141.1985; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEBER R, 1994, YEAST, V10, P1421, DOI 10.1002/yea.320101105; Li LT, 1998, J BIOL CHEM, V273, P22181, DOI 10.1074/jbc.273.35.22181; Lyons TJ, 2000, P NATL ACAD SCI USA, V97, P7957, DOI 10.1073/pnas.97.14.7957; MacDiarmid CW, 2000, EMBO J, V19, P2845, DOI 10.1093/emboj/19.12.2845; Mandala SM, 1998, P NATL ACAD SCI USA, V95, P150, DOI 10.1073/pnas.95.1.150; Mao CG, 1997, J BIOL CHEM, V272, P28690, DOI 10.1074/jbc.272.45.28690; Munnik T, 2000, PLANT J, V22, P147, DOI 10.1046/j.1365-313x.2000.00725.x; Munnik T, 1996, J BIOL CHEM, V271, P15708, DOI 10.1074/jbc.271.26.15708; Munnik T, 1998, BBA-LIPID LIPID MET, V1389, P222, DOI 10.1016/S0005-2760(97)00158-6; Neuwald AF, 1997, PROTEIN SCI, V6, P1764, DOI 10.1002/pro.5560060817; NIES DH, 1995, J IND MICROBIOL, V14, P186, DOI 10.1007/BF01569902; NOVICK P, 1980, CELL, V21, P205, DOI 10.1016/0092-8674(80)90128-2; Oshiro J, 2000, J BIOL CHEM, V275, P40887, DOI 10.1074/jbc.M008144200; PALMITER RD, 1995, EMBO J, V14, P639, DOI 10.1002/j.1460-2075.1995.tb07042.x; Palmiter RD, 1998, P NATL ACAD SCI USA, V95, P8428, DOI 10.1073/pnas.95.15.8428; PALTAUF F, 1992, MOL CELLULAR BIOL YE, P415; Pical C, 1999, J BIOL CHEM, V274, P38232, DOI 10.1074/jbc.274.53.38232; PRINGLE JR, 1991, METHOD ENZYMOL, V194, P565; Riedel B, 1997, PLANT SCI, V128, P1, DOI 10.1016/S0168-9452(97)00120-9; Rose MD., 1990, METHODS YEAST GENETI; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SCHWABE JWR, 1994, NAT STRUCT BIOL, V1, P345, DOI 10.1038/nsb0694-345; SERRANO R, 1988, METHOD ENZYMOL, V157, P533; SIKORSKI RS, 1989, GENETICS, V122, P19; Stukey J, 1997, PROTEIN SCI, V6, P469; THOMAS BJ, 1989, CELL, V56, P619, DOI 10.1016/0092-8674(89)90584-9; Toke DA, 1998, J BIOL CHEM, V273, P3278, DOI 10.1074/jbc.273.6.3278; Toke DA, 1998, J BIOL CHEM, V273, P14331, DOI 10.1074/jbc.273.23.14331; Toke DA, 1999, BIOCHEMISTRY-US, V38, P14606, DOI 10.1021/bi991472x; UCHIDA E, 1988, METHOD ENZYMOL, V157, P544; VALLEE BL, 1993, PHYSIOL REV, V73, P79, DOI 10.2466/pr0.1993.73.1.79; VIDA TA, 1995, J CELL BIOL, V128, P779, DOI 10.1083/jcb.128.5.779; WISSING JB, 1993, PLANT PHYSIOL, V102, P1243, DOI 10.1104/pp.102.4.1243; WISSING JB, 1993, FEBS LETT, V315, P95, DOI 10.1016/0014-5793(93)81141-L; Wu WI, 1996, J BIOL CHEM, V271, P1868, DOI 10.1074/jbc.271.4.1868; Yuan DS, 2000, GENETICS, V156, P45; Zhao H, 1998, J BIOL CHEM, V273, P28713, DOI 10.1074/jbc.273.44.28713; Zhao H, 1997, MOL CELL BIOL, V17, P5044, DOI 10.1128/MCB.17.9.5044; Zhao H, 1996, J BIOL CHEM, V271, P23203, DOI 10.1074/jbc.271.38.23203; Zhao H, 1996, P NATL ACAD SCI USA, V93, P2454, DOI 10.1073/pnas.93.6.2454; ZINSER E, 1991, J BACTERIOL, V173, P2026, DOI 10.1128/jb.173.6.2026-2034.1991; ZINSER E, 1995, YEAST, V11, P493, DOI 10.1002/yea.320110602	67	53	54	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 30	2001	276	13					10126	10133		10.1074/jbc.M011421200	http://dx.doi.org/10.1074/jbc.M011421200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	420GC	11139591	hybrid			2022-12-25	WOS:000167996400073
J	Zhang, ZL; Oliver, P; Lancaster, JR; Schwarzenberger, PO; Joshi, MS; Cork, J; Kolls, JK				Zhang, ZL; Oliver, P; Lancaster, JR; Schwarzenberger, PO; Joshi, MS; Cork, J; Kolls, JK			Reactive oxygen species mediate tumor necrosis factor alpha-converting, enzyme-dependent ectodomain shedding induced by phorbol myristate acetate	FASEB JOURNAL			English	Article									Tulane Univ, Sch Med, LSUMC Gene Therapy Program, New Orleans, LA 70112 USA; Tulane Univ, Sch Med, Dept Pediat, New Orleans, LA 70112 USA; Tulane Univ, Sch Med, Dept Physiol, New Orleans, LA 70112 USA; Tulane Univ, Sch Med, Dept Med, New Orleans, LA 70112 USA; Tulane Univ, Sch Med, Dept Surg, New Orleans, LA 70112 USA; Tulane Univ, Sch Med, Dept Anat & Cell Biol, New Orleans, LA 70112 USA	Tulane University; Tulane University; Tulane University; Tulane University; Tulane University; Tulane University	Kolls, JK (corresponding author), 533 Bolivar St,Room 601, New Orleans, LA 70112 USA.		Schwarzenberger, Paul/AAZ-2174-2021; Kolls, Jay/AAH-1829-2019	Kolls, Jay/0000-0001-5151-6304					0	152	163	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	FEB	2001	15	2					303	305						3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	400LK	11156944				2022-12-25	WOS:000166872900010
J	Ladanyi, M; Lui, MY; Antonescu, CR; Krause-Boehm, A; Meindl, A; Argani, P; Healey, JH; Ueda, T; Yoshikawa, H; Meloni-Ehrig, A; Sorensen, PHB; Mertens, F; Mandahl, N; van den Berghe, H; Sciot, R; Dal Cin, P; Bridge, J				Ladanyi, M; Lui, MY; Antonescu, CR; Krause-Boehm, A; Meindl, A; Argani, P; Healey, JH; Ueda, T; Yoshikawa, H; Meloni-Ehrig, A; Sorensen, PHB; Mertens, F; Mandahl, N; van den Berghe, H; Sciot, R; Dal Cin, P; Bridge, J			The der(17)t(X;17)(p11;q25) of human alveolar soft part sarcoma fuses the TFE3 transcription factor gene to ASPL, a novel gene at 17q25	ONCOGENE			English	Article						chromosomal translocation; gene fusion; molecular diagnosis; UBX domain; soft tissue sarcoma	RENAL-CELL CARCINOMA; SKELETAL-MUSCLE DIFFERENTIATION; REGULATORY PROTEIN EXPRESSION; ACTIVATOR INHIBITOR-1 GENE; BETA-INDUCED TRANSCRIPTION; CRYPTIC INTRON; SMAD PROTEINS; DOMAIN; ORGANIZATION; INVOLVEMENT	Alveolar soft part sarcoma (ASPS) is an unusual tumor with highly characteristic histopathology and ultrastructure, controversial histogenesis, and enigmatic clinical behavior. Recent cytogenetic studies have identified a recurrent der(17) due to non-reciprocal t(X;17)(p11.2;q25) in this sarcoma, To define the interval containing the Xp11,2 break, we first performed FISH on ASPS cases using YAC probes for OA TLI (Xp11,23) and OATL2 (Xp11,21), and cosmid probes from the intervening genomic region. This localized the breakpoint to a 160 kb interval. The prime candidate within this previously fully sequenced region was TFE3, a transcription factor gene known to be fused to translocation partners on 1 and X in some papillary renal cell carcinomas. Southern blotting using a TFE3 genomic probe identified non-germline bands in several ASPS cases, consistent with rearrangement and possible fusion of TFE3 with a gene on 17q25, Amplification of the 5' portion of cDNAs containing the 3' portion of TFE3 in two different ASPS cases identified a novel sequence, designated ASPL, fused in-frame to TFE3 exon 4 (type 1 fusion) or exon 3 (type 2 fusion), Reverse transcriptase PCR using a forward primer from ASPL and a TFE3 exon 4 reverse primer detected an ASPL-TFE3 fusion transcript in all ASPS cases (12/12: 9 type 1, 3 type 2), establishing the utility of this assay in the diagnosis of ASPS. Using appropriate primers, the reciprocal fusion transcript, TFE3-ASPL, was detected in only one of 12 cases, consistent with the non-reciprocal nature of the translocation in most cases, and supporting ASPL-TFE3 as its oncogenically significant fusion product. ASPL maps to chromosome 17, is ubiquitously expressed, and matches numerous ESTs (Unigene cluster Hs.84128) but no named genes. The ASPL cDNA open reading frame encodes a predicted protein of 476 amino acids that contains within its carboxy-terminal portion of a UBX-like domain that shows significant similarity to predicted proteins of unknown function in several model organisms. The ASPL-TFE3 fusion replaces the N-terminal portion of TFE3 by the fused ASPL sequences, while retaining the TFE3 DNA-binding domain, implicating transcriptional deregulation in the pathogenesis of this tumor, consistent with the biology of several other translocation-associated sarcomas.	Mem Sloan Kettering Canc Ctr, Dept Pathol, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Dept Human Genet, New York, NY 10021 USA; Univ Nebraska, Med Ctr, Dept Pathol, CGMG MMI, Omaha, NE USA; Univ Munich, Dept Med Genet, Munich, Germany; Johns Hopkins Hosp, Dept Pathol, Baltimore, MD 21287 USA; Mem Sloan Kettering Canc Ctr, Dept Surg, New York, NY 10021 USA; Osaka Med Ctr Canc & Cardiovasc Dis, Dept Orthoped Surg, Osaka, Japan; Univ Utah, Med Ctr, Huntsman Canc Inst, Dept Human Genet, Salt Lake City, UT USA; British Columbia Childrens Hosp, Dept Pathol, Vancouver, BC V6H 3V4, Canada; Univ Lund Hosp, Dept Clin Genet, S-22185 Lund, Sweden; Univ Leuven, Ctr Human Genet, Louvain, Belgium; Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA; Univ Nebraska, Med Ctr, Dept Pediat, CHMG MMI, Omaha, NE USA; Univ Nebraska, Med Ctr, Dept Orthoped Surg, CHMG MMI, Omaha, NE USA	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; University of Nebraska System; University of Nebraska Medical Center; University of Munich; Johns Hopkins University; Johns Hopkins Medicine; Memorial Sloan Kettering Cancer Center; Osaka Medical Center for Cancer & Cardiovascular Diseases; Huntsman Cancer Institute; Utah System of Higher Education; University of Utah; BC Childrens Hospital; University of British Columbia; Lund University; Skane University Hospital; KU Leuven; Harvard University; Brigham & Women's Hospital; University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center	Ladanyi, M (corresponding author), Mem Sloan Kettering Canc Ctr, Dept Pathol, 1275 York Ave, New York, NY 10021 USA.		Ladanyi, Marc/AAG-8585-2019; Meloni-Ehrig, Aurelia/AAF-9248-2020	Healey, John/0000-0002-0802-1186; Mertens, Fredrik/0000-0002-6278-5232; sciot, raf/0000-0003-2244-5839	NCI NIH HHS [P01 CA47179] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA047179] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARTANDI SE, 1994, MOL CELL BIOL, V14, P7704, DOI 10.1128/MCB.14.12.7704; BECKMANN H, 1990, GENE DEV, V4, P167, DOI 10.1101/gad.4.2.167; Bruce SR, 1999, NUCLEIC ACIDS RES, V27, P3446, DOI 10.1093/nar/27.17.3446; CHRISTOPHERSON WM, 1952, CANCER, V5, P100, DOI 10.1002/1097-0142(195201)5:1<100::AID-CNCR2820050112>3.0.CO;2-K; Clark J, 1997, ONCOGENE, V15, P2233, DOI 10.1038/sj.onc.1201394; Golub TR, 1997, CURR TOP MICROBIOL, V220, P67; Gomez JA, 1999, ARCH PATHOL LAB MED, V123, P503; Haseloff J, 1997, P NATL ACAD SCI USA, V94, P2122, DOI 10.1073/pnas.94.6.2122; Heimann P, 1998, GENE CHROMOSOME CANC, V23, P194, DOI 10.1002/(SICI)1098-2264(199810)23:2<194::AID-GCC14>3.3.CO;2-O; HEMESATH TJ, 1994, GENE DEV, V8, P2770, DOI 10.1101/gad.8.22.2770; HERNANDEZMARTI MJ, 1995, CANCER GENET CYTOGEN, V83, P82, DOI 10.1016/0165-4608(94)00184-7; Hofmann K, 1996, TRENDS BIOCHEM SCI, V21, P172, DOI 10.1016/0968-0004(96)30015-7; Hua XX, 1999, P NATL ACAD SCI USA, V96, P13130, DOI 10.1073/pnas.96.23.13130; Hua XX, 1998, GENE DEV, V12, P3084, DOI 10.1101/gad.12.19.3084; Joyama S, 1999, CANCER, V86, P1246, DOI 10.1002/(SICI)1097-0142(19991001)86:7<1246::AID-CNCR20>3.3.CO;2-W; Kiuru-Kuhlefelt S, 1998, MODERN PATHOL, V11, P227; KOZAK M, 1991, J BIOL CHEM, V266, P19867; Ladanyi M, 2000, HUM PATHOL, V31, P532, DOI 10.1053/hp.2000.6706; LIEBERMAN PH, 1989, CANCER-AM CANCER SOC, V63, P1, DOI 10.1002/1097-0142(19890101)63:1<1::AID-CNCR2820630102>3.0.CO;2-E; MACCHI P, 1995, GENOMICS, V28, P491, DOI 10.1006/geno.1995.1179; Ordonez NG, 1999, ADV ANAT PATHOL, V6, P125, DOI 10.1097/00125480-199905000-00001; Rehli M, 1999, GENOMICS, V56, P111, DOI 10.1006/geno.1998.5588; ROMAN C, 1991, SCIENCE, V254, P94, DOI 10.1126/science.1840705; ROSAI J, 1991, AM J SURG PATHOL, V15, P974, DOI 10.1097/00000478-199110000-00008; Schindelhauer D, 1996, GENOME RES, V6, P1056, DOI 10.1101/gr.6.11.1056; SCIOT R, 1993, HISTOPATHOLOGY, V23, P439, DOI 10.1111/j.1365-2559.1993.tb00492.x; Sidhar SK, 1996, HUM MOL GENET, V5, P1333, DOI 10.1093/hmg/5.9.1333; TALLINI G, 1994, AM J PATHOL, V144, P693; Tian G, 1999, MOL CELL BIOL, V19, P2946; TOMLINSON GE, 1991, CANCER GENET CYTOGEN, V57, P11, DOI 10.1016/0165-4608(91)90184-V; Verastegui C, 2000, MOL ENDOCRINOL, V14, P449, DOI 10.1210/me.14.3.449; Wang NP, 1996, MODERN PATHOL, V9, P496; Weterman MAJ, 1996, P NATL ACAD SCI USA, V93, P15294, DOI 10.1073/pnas.93.26.15294; Weterman MAJ, 2000, ONCOGENE, V19, P69, DOI 10.1038/sj.onc.1203255; WONG SC, 1995, J NEUROCHEM, V65, P23	35	393	426	1	9	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 4	2001	20	1					48	57		10.1038/sj.onc.1204074	http://dx.doi.org/10.1038/sj.onc.1204074			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	391NE	11244503	Green Published			2022-12-25	WOS:000166361400006
J	Tan, C; Costello, P; Sanghera, J; Dominguez, D; Baulida, J; de Herreros, AG; Dedhar, S				Tan, C; Costello, P; Sanghera, J; Dominguez, D; Baulida, J; de Herreros, AG; Dedhar, S			Inhibition of integrin linked kinase (ILK) suppresses beta-catenin-Lef/Tcf-dependent transcription and expression of the E-cadherin repressor, snail, in APC-/- human colon carcinoma cells	ONCOGENE			English	Article						cyclin D1; E-cadherin; GSK-3; colon cancer	GLYCOGEN-SYNTHASE KINASE; CYCLIN D1; ADHESION; ACTIVATION; TARGET; CANCER; B/AKT; GENE	Loss of functional adenomatous polyposis coli (APC) protein results in the stabilization of cytosolic beta -catenin and activation of genes that are responsive to Lef/Tcf family transcription factors. We have recently shown that an independent cell adhesion and integrin linked kinase (ILK)-dependent pathway can also activate beta -catenin/LEF mediated gene transcription and downregulate E-cadherin expression. In addition, ILK activity and expression are elevated in adenomatous polyposis and colon carcinomas. To examine the role of this pathway in the background of APC mutations we inhibited ILK activity in APC-/- human colon carcinoma cell lines. In all cases, inhibition of ILK resulted in substantial inhibition of TCF mediated gene transcription and inhibition of transcription and expression of the TCF regulated gene, cyclin D1, Inhibition of ILK resulted in decreased nuclear beta-catenin expression, and in the inhibition of phosphorylation of GSK-3 and stimulation of its activity, leading to accelerated degradation of beta -catenin. In addition, inhibition of ILK suppressed cell growth in culture as well as growth of human colon carcinoma cells in SCID mice. Strikingly, inhibition of ILK also resulted in the transcriptional stimulation of E-cadherin expression and correlated with the inhibition of gene transcription of snail, a repressor of E-cadherin gene expression. Overexpression of ILK caused a stimulation of expression of snail, but snail expression was found not to be regulated by beta -catenin/ Tcf, These data demonstrate that ILK can regulate beta -catenin/TCF and snail transcription factors by distinct pathways. We propose that inhibition of ILK may be a useful strategy in the control of progression of colon as well as other carcinomas.	British Columbia Canc Agcy, Vancouver, BC V6H 3Z6, Canada; Jack Bell Res Ctr, Vancouver, BC V6H 3Z6, Canada; Univ British Columbia, Dept Biochem & Mol Biol, Vancouver, BC V5Z 1M9, Canada; Kinetek Pharmceut Inc, Vancouver, BC V6P 6P2, Canada; Univ Pompeu Fabra, Inst Municipal Invest Med, Unitat Biol Cellular & Mol, Barcelona, Spain	British Columbia Cancer Agency; University of British Columbia; University of British Columbia; Pompeu Fabra University	Dedhar, S (corresponding author), British Columbia Canc Agcy, 2660 Oak St, Vancouver, BC V6H 3Z6, Canada.		de Herreros, A Garcia/H-3104-2014	de Herreros, A Garcia/0000-0001-5270-0808; Dominguez-Sola, David/0000-0001-9569-8402; Dedhar, Shoukat/0000-0003-4355-1657				Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797; Attwell S, 2000, ONCOGENE, V19, P3811, DOI 10.1038/sj.onc.1203711; Batlle E, 2000, NAT CELL BIOL, V2, P84, DOI 10.1038/35000034; Baulida J, 1999, BIOCHEM J, V344, P565, DOI 10.1042/0264-6021:3440565; Ben-Ze'ev A, 1998, CURR OPIN CELL BIOL, V10, P629, DOI 10.1016/S0955-0674(98)80039-2; Cano A, 2000, NAT CELL BIOL, V2, P76, DOI 10.1038/35000025; Christofori G, 1999, TRENDS BIOCHEM SCI, V24, P73, DOI 10.1016/S0968-0004(98)01343-7; Delcommenne M, 1998, P NATL ACAD SCI USA, V95, P11211, DOI 10.1073/pnas.95.19.11211; Hannigan GE, 1996, NATURE, V379, P91, DOI 10.1038/379091a0; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Janji B, 2000, ONCOGENE, V19, P3069, DOI 10.1038/sj.onc.1203640; Janji B, 1999, INT J CANCER, V83, P255, DOI 10.1002/(SICI)1097-0215(19991008)83:2<255::AID-IJC18>3.3.CO;2-O; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Li FG, 1999, J CELL SCI, V112, P4589; Miller JR, 1996, GENE DEV, V10, P2527, DOI 10.1101/gad.10.20.2527; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; Mulrooney J, 2000, EXP CELL RES, V258, P332, DOI 10.1006/excr.2000.4964; Novak A, 1998, P NATL ACAD SCI USA, V95, P4374, DOI 10.1073/pnas.95.8.4374; Novak A, 1999, CELL MOL LIFE SCI, V56, P523, DOI 10.1007/s000180050449; Perl AK, 1998, NATURE, V392, P190, DOI 10.1038/32433; Persad S, 2000, P NATL ACAD SCI USA, V97, P3207, DOI 10.1073/pnas.060579697; Popov Z, 2000, BRIT J CANCER, V83, P209; Radeva G, 1997, J BIOL CHEM, V272, P13937, DOI 10.1074/jbc.272.21.13937; Shtutman M, 1999, P NATL ACAD SCI USA, V96, P5522, DOI 10.1073/pnas.96.10.5522; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; Troussard AA, 1999, MOL CELL BIOL, V19, P7420; Wu CY, 1998, J BIOL CHEM, V273, P528, DOI 10.1074/jbc.273.1.528	27	208	230	0	9	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 4	2001	20	1					133	140		10.1038/sj.onc.1204052	http://dx.doi.org/10.1038/sj.onc.1204052			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	391NE	11244511				2022-12-25	WOS:000166361400015
J	Frigeri, A; Nicchia, GP; Nico, B; Quondamatteo, F; Herken, R; Roncali, L; Svelto, M				Frigeri, A; Nicchia, GP; Nico, B; Quondamatteo, F; Herken, R; Roncali, L; Svelto, M			Aquaporin-4 deficiency in skeletal muscle and brain of dystrophic mdx mice	FASEB JOURNAL			English	Article						muscular dystrophy; aquaporins; orthogonal arrays of particles; AQP4; mdx mice; water channels	DUCHENNE MUSCULAR-DYSTROPHY; INSENSITIVE WATER CHANNEL; PLASMA-MEMBRANES; RAT-BRAIN; MOLECULAR CHARACTERIZATION; FREEZE-FRACTURE; EXPRESSION; PROTEIN; MOUSE; ASTROCYTES	We report a detailed study of AQP4 expression in the neuromuscular system of mdx mice. Immunocytochemical analysis performed by double immunostaining revealed that mdx mice manifest a progressive reduction in AQP4 at the sarcolemmal level of skeletal muscle fast fibers and that type IIB fibers are the first to manifest this reduction in AQP4 expression. No labeling was observed in the cytoplasm of muscle fibers, indicating that the reduction in sarcolemma staining is not associated with an intracellular compartmentalization of mistargeted protein. By Western blot and RT-PCR analysis, we found that whereas the total content of AQP4 protein decreased (by 90% in adult mdx mice), mRNA levels for AQP4 remained unchanged. A similar age-related reduction in AQP4 expression was found in brain astrocytic end-feet surrounding capillaries of mdx mice. Morphometric analysis performed after immunogold electron microscopy indicated a reduction of similar to 85% in gold particles (32 +/-2/mum vs. 4.7 +/-0.61/mum). Western blot experiments conducted using membrane fractions from brain cortex revealed a strong reduction (of 70%) in AQP4 protein in adult mdx mice, and RT-PCR experiments demonstrated that the reduction was not at transcription level. More interesting was the finding that AQP4 reduction was associated with swelling of astrocytic perivascular processes whose ultrastructural modifications are commonly indicated as an important and early event in the development of brain edema. No apparent reduction in AQP4 was found in mdx stomach and kidney. Our data provide evidence that dystrophin deficiency in mdx mice leads to disturbances in AQP4 assembly in the plasma membrane of fast skeletal muscle fibers and brain astrocytic end-feet, suggesting that changes in the osmotic equilibrium of the neuromuscular apparatus may be involved in the pathology of muscular dystrophy.	Univ Bari, Dipartimento Fisiol Gen & Ambientale, I-70126 Bari, Italy; Policlin Bari, Ist Anat Umana Normale, I-70124 Bari, Italy; Univ Gottingen, Zentrum Anat, Abt Histol, D-37075 Gottingen, Germany	Universita degli Studi di Bari Aldo Moro; Universita degli Studi di Bari Aldo Moro; University of Gottingen	Frigeri, A (corresponding author), Univ Bari, Dipartimento Fisiol Gen & Ambientale, Via Amendola 165-A, I-70126 Bari, Italy.		Svelto, Maria/P-6186-2014; frigeri, Antonio/AAC-6336-2022	Frigeri, Antonio/0000-0002-5284-2934; Svelto, Maria/0000-0002-5584-9541	Telethon [983] Funding Source: Medline	Telethon(Fondazione Telethon)		ADAMS ME, 1993, NEURON, V11, P531, DOI 10.1016/0896-6273(93)90157-M; Anderson LVB, 1999, HUM MOL GENET, V8, P855, DOI 10.1093/hmg/8.5.855; Brenman JE, 1996, CELL, V84, P757, DOI 10.1016/S0092-8674(00)81053-3; BULFIELD G, 1984, P NATL ACAD SCI-BIOL, V81, P1189, DOI 10.1073/pnas.81.4.1189; CAMPBELL KP, 1995, CELL, V80, P675, DOI 10.1016/0092-8674(95)90344-5; Culligan KG, 1998, INT J MOL MED, V2, P639; DeVries HE, 1997, PHARMACOL REV, V49, P143; Dunn JF, 1999, MUSCLE NERVE, V22, P1367, DOI 10.1002/(SICI)1097-4598(199910)22:10<1367::AID-MUS5>3.3.CO;2-8; EMERY AEH, 1987, OXFORD MONOGRAPHS ME, V15; ERVASTI JM, 1991, CELL, V66, P1121, DOI 10.1016/0092-8674(91)90035-W; Finn DM, 1998, BIOCHEM BIOPH RES CO, V249, P231, DOI 10.1006/bbrc.1998.9119; FRIGERI A, 1995, P NATL ACAD SCI USA, V92, P4328, DOI 10.1073/pnas.92.10.4328; Frigeri A, 1998, J CLIN INVEST, V102, P695, DOI 10.1172/JCI2545; FRIGERI A, 1995, J CELL SCI, V108, P2993; GORECKI DC, 1992, HUM MOL GENET, V1, P505, DOI 10.1093/hmg/1.7.505; HASEGAWA H, 1994, J BIOL CHEM, V269, P5497; HIRCHE H, 1980, PFLUG ARCH EUR J PHY, V387, P231, DOI 10.1007/BF00580975; HOFFMAN EP, 1988, NEURON, V1, P411, DOI 10.1016/0896-6273(88)90191-2; Jancsik V, 1999, BRAIN RES, V831, P200, DOI 10.1016/S0006-8993(99)01445-6; JUNG JS, 1994, P NATL ACAD SCI USA, V91, P13052, DOI 10.1073/pnas.91.26.13052; KOENIG M, 1988, CELL, V53, P219, DOI 10.1016/0092-8674(88)90383-2; KOWALCHUK JM, 1988, J APPL PHYSIOL, V65, P2080, DOI 10.1152/jappl.1988.65.5.2080; Ma TH, 1997, J CLIN INVEST, V100, P957, DOI 10.1172/JCI231; Manley GT, 2000, NAT MED, V6, P159, DOI 10.1038/72256; MEHTA JR, 1989, RES VET SCI, V47, P17, DOI 10.1016/S0034-5288(18)31225-6; MENKE A, 1991, NATURE, V349, P69, DOI 10.1038/349069a0; MISRA L K, 1982, Magnetic Resonance Imaging, V1, P75, DOI 10.1016/0730-725X(82)90222-3; Muntoni F, 1991, Neuromuscul Disord, V1, P121, DOI 10.1016/0960-8966(91)90059-2; Neely JD, 1999, BIOCHEMISTRY-US, V38, P11156, DOI 10.1021/bi990941s; Newman Eric A., 1995, P717; Nielsen S, 1997, J NEUROSCI, V17, P171; OZAWA E, 1995, HUM MOL GENET, V4, P1711, DOI 10.1093/hmg/4.suppl_1.1711; PONTING CP, 1995, TRENDS BIOCHEM SCI, V20, P102, DOI 10.1016/S0968-0004(00)88973-2; Rash JE, 1998, P NATL ACAD SCI USA, V95, P11981, DOI 10.1073/pnas.95.20.11981; SCHIAFFINO S, 1989, J MUSCLE RES CELL M, V10, P197, DOI 10.1007/BF01739810; SHIBUYA S, 1991, NEUROPATH APPL NEURO, V17, P335, DOI 10.1111/j.1365-2990.1991.tb00730.x; SJOGAARD G, 1985, AM J PHYSIOL, V248, P190; Straub V, 1997, J CELL BIOL, V139, P375, DOI 10.1083/jcb.139.2.375; Sun DD, 1995, AM J PHYSIOL-CELL PH, V269, pC1506, DOI 10.1152/ajpcell.1995.269.6.C1506; Tracey I, 1996, J NEUROL SCI, V141, P13, DOI 10.1016/0022-510X(96)00135-9; Tracey I, 1996, BRAIN, V119, P1039, DOI 10.1093/brain/119.3.1039; Tsukaguchi H, 1998, J BIOL CHEM, V273, P24737, DOI 10.1074/jbc.273.38.24737; Verbavatz JM, 1997, J CELL SCI, V110, P2855; Vizuete ML, 1999, NEUROBIOL DIS, V6, P245, DOI 10.1006/nbdi.1999.0246; WAKAYAMA Y, 1989, J NEUROL SCI, V91, P191, DOI 10.1016/0022-510X(89)90087-7; WALZ W, 1985, BRAIN RES, V343, P44, DOI 10.1016/0006-8993(85)91156-4; WEBSTER C, 1988, CELL, V52, P503, DOI 10.1016/0092-8674(88)90463-1; Wen H, 1999, EUR J NEUROSCI, V11, P935, DOI 10.1046/j.1460-9568.1999.00502.x; Yaffe D., 1996, Cellular Pharmacology, V3, P331; Yokota T, 2000, P JPN ACAD B-PHYS, V76, P22, DOI 10.2183/pjab.76.22	50	158	168	1	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JAN	2001	15	1					90	98		10.1096/fj.00-0260com	http://dx.doi.org/10.1096/fj.00-0260com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	390TH	11149896				2022-12-25	WOS:000166312400017
J	Chiu, IM; Touhalisky, K; Liu, Y; Yates, A; Frostholm, A				Chiu, IM; Touhalisky, K; Liu, Y; Yates, A; Frostholm, A			Tumorigenesis in transgenic mice in which the SV40 T antigen is driven by the brain-specific FGF1 promoter	ONCOGENE			English	Article						FGF1; brain tumor; gene expression; promoter regulation; neural stem cells	FIBROBLAST-GROWTH-FACTOR; PRIMITIVE NEUROECTODERMAL TUMORS; STEM-CELL; DIFFERENTIAL EXPRESSION; HEPARAN-SULFATE; MESSENGER-RNA; FIBROBLAST-GROWTH-FACTOR-1; ADULT; PROTEIN; IDENTIFICATION	Gene expression can be manipulated by the introduction of a hybrid gene formed by linking a highly tissue-specific regulatory element to a gene whose expression might be expected to alter cellular function. Previously, we have shown that the human FGF1 gene contains four distinct tissue-specific promoters. In an effort to perturb the programming of proliferation and differentiation in a subset of neural cells, we have produced transgenic mice bearing the brain-specific promoter of the human FGF1 gene joined to the SV40 immediate early gene, which encodes the large T antigen. The resulting mice, and offspring from four individual lines, developed brain tumors that originated in the pontine gray, just rostral to the fourth ventricle, Tumors were moderately vascularized, as demonstrated by staining with both hematoxylin and eosin and antibodies to three different endothelial cell markers, but vessels were histologically normal. Scattered tumor foci were present as early as postnatal day 26; and affected animals died between 5-8 months of age. In mature animals, tumors lacked terminal differentiation markers for astrocytes (glial fibrillary acidic protein) or neurons (synaptophysin and neuron-specific enolase). However, they expressed high levels of proliferating cell nuclear antigen and vimentin, markers for proliferating cells. This immunophenotype iis consistent with the tumor being at an early stage of differentiation. Therefore, these mice may provide a valuable tool for the study of tumorigenesis, replenishment and differentiation of neural stem cells.	Ohio State Univ, Dept Internal Med, Columbus, OH 43210 USA; Ohio State Univ, Dept Pathol, Columbus, OH 43210 USA; Ohio State Univ, Dept Pharmacol, Columbus, OH 43210 USA	University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University	Chiu, IM (corresponding author), Ohio State Univ, Dept Internal Med, 480 W 9th Ave, Columbus, OH 43210 USA.		Chiu, Ing-Ming/B-1534-2008					Alam KY, 1996, J BIOL CHEM, V271, P30263, DOI 10.1074/jbc.271.47.30263; Anderson DJ, 1999, CURR OPIN NEUROBIOL, V9, P517, DOI 10.1016/S0959-4388(99)00015-X; Barres BA, 1999, CELL, V97, P667, DOI 10.1016/S0092-8674(00)80777-1; Bergers G, 1999, SCIENCE, V284, P808, DOI 10.1126/science.284.5415.808; Black DL, 1998, NEURON, V20, P165, DOI 10.1016/S0896-6273(00)80444-4; Brustle O, 1999, SCIENCE, V285, P754, DOI 10.1126/science.285.5428.754; CHIU IM, 1990, ONCOGENE, V5, P755; Cho JY, 2000, GENE THER, V7, P740, DOI 10.1038/sj.gt.3301170; Chotani MA, 1997, CELL GROWTH DIFFER, V8, P999; DAVIS AA, 1994, NATURE, V372, P263, DOI 10.1038/372263a0; Doetsch F, 1999, CELL, V97, P703, DOI 10.1016/S0092-8674(00)80783-7; ECKENSTEIN FP, 1994, BIOCHEM PHARMACOL, V47, P103, DOI 10.1016/0006-2952(94)90442-1; ENG LF, 1994, BRAIN PATHOL, V4, P229, DOI 10.1111/j.1750-3639.1994.tb00838.x; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FRISEN J, 1995, J CELL BIOL, V131, P453, DOI 10.1083/jcb.131.2.453; FUNG KM, 1995, J NEUROPATH EXP NEUR, V54, P285, DOI 10.1097/00005072-199505000-00001; FUNG KM, 1994, LAB INVEST, V70, P114; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; HANAHAN D, 1985, NATURE, V315, P115, DOI 10.1038/315115a0; Johansson CB, 1999, CELL, V96, P25, DOI 10.1016/S0092-8674(00)80956-3; Liu Y, 1998, J BIOL CHEM, V273, P19269, DOI 10.1074/jbc.273.30.19269; Madiai F, 1999, J BIOL CHEM, V274, P11937, DOI 10.1074/jbc.274.17.11937; McKeehan WL, 1998, PROG NUCLEIC ACID RE, V59, P135; Mehta VB, 1998, J BIOL CHEM, V273, P4197, DOI 10.1074/jbc.273.7.4197; MESSING A, 1985, NATURE, V316, P461, DOI 10.1038/316461a0; MIGNATTI P, 1992, J CELL PHYSIOL, V151, P81, DOI 10.1002/jcp.1041510113; MYERS RL, 1995, ONCOGENE, V11, P785; MYERS RL, 1995, J BIOL CHEM, V270, P8257, DOI 10.1074/jbc.270.14.8257; MYERS RL, 1993, ONCOGENE, V8, P341; ORAITZ DM, 1996, J BIOL CHEM, V271, P15292; Ornitz DM, 2000, BIOESSAYS, V22, P108, DOI 10.1002/(SICI)1521-1878(200002)22:2<108::AID-BIES2>3.0.CO;2-M; Ornitz DM, 1996, J BIOL CHEM, V271, P15292, DOI 10.1074/jbc.271.25.15292; PALMITER RD, 1985, NATURE, V316, P457, DOI 10.1038/316457a0; Pekny M, 1999, J CELL BIOL, V145, P503, DOI 10.1083/jcb.145.3.503; Ray SK, 1997, J BIOL CHEM, V272, P7546, DOI 10.1074/jbc.272.11.7546; REIFENBERGER G, 1987, ACTA NEUROPATHOL, V74, P105, DOI 10.1007/BF00692841; Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0; SYMONDS H, 1994, CELL, V78, P703, DOI 10.1016/0092-8674(94)90534-7; TABERPIERCE E, 1966, J COMP NEUROL, V126, P219; TAKAHASHI K, 1994, J CLIN INVEST, V93, P2357, DOI 10.1172/JCI117241; Tarantini F, 1998, J BIOL CHEM, V273, P22209, DOI 10.1074/jbc.273.35.22209; Temple S, 1999, CURR OPIN NEUROBIOL, V9, P135, DOI 10.1016/S0959-4388(99)80017-8; TOOZE J, 1981, MOL BIOL TUMOR VIR 2; YACHNIS AT, 1994, J NEUROPATH EXP NEUR, V53, P61, DOI 10.1097/00005072-199401000-00008	44	30	32	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 14	2000	19	54					6229	6239		10.1038/sj.onc.1204021	http://dx.doi.org/10.1038/sj.onc.1204021			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	388YK	11175337				2022-12-25	WOS:000166210500006
J	Simoneau, M; LaRue, H; Aboulkassim, TO; Meyer, F; Moore, L; Fradet, Y				Simoneau, M; LaRue, H; Aboulkassim, TO; Meyer, F; Moore, L; Fradet, Y			Chromosome 9 deletions and recurrence of superficial bladder cancer: identification of four regions of prognostic interest	ONCOGENE			English	Article						bladder cancer; LOH; recurrence; prognostic; chromosome 9	TRANSITIONAL-CELL CARCINOMA; TUMOR-SUPPRESSOR LOCI; URINARY-BLADDER; HUMAN HOMOLOG; GENE; PROGRESSION; MUTATIONS; ANTIGENS; SMOKING; MARKERS	In a previous study, loss of heterozygosity (LOH) of 28 chromosome 9 microsatellite markers was assessed on 139 Ta/T1 bladder tumors. LOH at one or more loci was detected in 67 tumors, 62 presenting subchromosomal deletions. One hundred and thirty-three of these patients have now been followed for up to 8 years. The purpose of the present study was to evaluate the potential biological significance of chromosome 9 deletions in superficial bladder tumors at initial diagnosis. High grade was associated with LOH (P=0.004). Large tumors carried more frequently 9p deletions (P = 0.022). Female patients had more chromosome 9q LOH than male patients did (P = 0.010), Chromosome 9 LOH at all loci was associated with an elevated risk of recurrence but four regions were associated with a particularly high risk of recurrence. Multivariate analysis taking into account grade, stage, size and number of tumors showed that tumors deleted in the regions 9ptr-p22, 9q22.3, 9q33, and 9q34 recurred significantly more rapidly than those without deletions (Recurrence rate ratio=2.32, 2.53, 2.52 and 2.43 respectively). Log-rank statistics comparing Kaplan-Meier survival curves for the same chromosomal regions confirmed the correlation (P = 0.0002, 0.010, 0.002 and 0.009 respectively). Only four patients progressed to muscle-invasive disease. They all had extensive deletions on 9q but none had deletions at 9ptr-p22. This study suggests a link between chromosome 9 anomalies and recurrence of superficial bladder cancer.	Univ Laval, Ctr Hosp Univ Quebec, Ctr Rech Cancerol, Quebec City, PQ, Canada	Laval University	Fradet, Y (corresponding author), CHUQ LHotel Dieu Quebec, Ctr Rech, 11 Cote Palais, Quebec City, PQ G1R 2J6, Canada.			Fradet, Yves/0000-0002-7581-2500	NATIONAL CANCER INSTITUTE [R01CA047526, U01CA047526] Funding Source: NIH RePORTER; NCI NIH HHS [CA47526] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Allard P, 1998, BRIT J UROL, V81, P692; Allard P, 1995, CLIN CANCER RES, V1, P1195; Bartlett JMS, 1998, BRIT J CANCER, V77, P2193, DOI 10.1038/bjc.1998.365; Bartlett JMS, 1997, ANN HUM GENET, V61, P207; Czerniak B, 1999, ONCOGENE, V18, P1185, DOI 10.1038/sj.onc.1202385; DALBAGNI G, 1993, LANCET, V342, P469, DOI 10.1016/0140-6736(93)91595-D; Erbersdobler A, 1998, ONCOL RES, V10, P415; Gailani MR, 1996, NAT GENET, V14, P78, DOI 10.1038/ng0996-78; HABUCHI T, 1995, ONCOGENE, V11, P1671; Habuchi T, 1998, GENOMICS, V48, P277, DOI 10.1006/geno.1997.5165; Hills, 1993, STAT MODELS EPIDEMIO; Hornigold N, 1999, ONCOGENE, V18, P2657, DOI 10.1038/sj.onc.1202854; Johnson RL, 1996, SCIENCE, V272, P1668, DOI 10.1126/science.272.5268.1668; KEEN AJ, 1994, ONCOGENE, V9, P2083; Kleinbaum DG, 1987, APPL REGRESSION ANAL; LaRue H, 2000, CARCINOGENESIS, V21, P101, DOI 10.1093/carcin/21.1.101; Lee E, 1997, J UROLOGY, V157, P1070, DOI 10.1016/S0022-5347(01)65143-7; Liggett WH, 1998, J CLIN ONCOL, V16, P1197, DOI 10.1200/JCO.1998.16.3.1197; Micheli A, 1998, EUR J CANCER, V34, P2271, DOI 10.1016/S0959-8049(98)00324-4; Orlow I, 1999, AM J PATHOL, V155, P105, DOI 10.1016/S0002-9440(10)65105-X; POWELL I, 1990, CANCER GENET CYTOGEN, V50, P97, DOI 10.1016/0165-4608(90)90242-3; RAO JY, 1993, P NATL ACAD SCI USA, V90, P8287, DOI 10.1073/pnas.90.17.8287; SANDBERG AA, 1994, J UROLOGY, V151, P545, DOI 10.1016/S0022-5347(17)35014-0; Sharpless NE, 1999, CURR OPIN GENET DEV, V9, P22, DOI 10.1016/S0959-437X(99)80004-5; Simoneau AR, 1996, CANCER RES, V56, P5039; Simoneau M, 1999, ONCOGENE, V18, P157, DOI 10.1038/sj.onc.1202277; SPRUCK CH, 1994, CANCER RES, V54, P784; TSAI YC, 1990, CANCER RES, V50, P44; Uchida T, 1996, INT J CANCER, V69, P142, DOI 10.1002/(SICI)1097-0215(19960422)69:2<142::AID-IJC13>3.3.CO;2-N; Van Tilborg AAG, 1998, INT J CANCER, V75, P9, DOI 10.1002/(SICI)1097-0215(19980105)75:1<9::AID-IJC2>3.3.CO;2-I; ZHANG L, 1992, P NATL ACAD SCI USA, V89, P5847, DOI 10.1073/pnas.89.13.5847; Zhang ZF, 1997, CANCER EPIDEM BIOMAR, V6, P321; Zhang Zuo-Feng, 1997, P215; Zhao JM, 1999, CANCER RES, V59, P4658	34	53	54	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 14	2000	19	54					6317	6323		10.1038/sj.onc.1204022	http://dx.doi.org/10.1038/sj.onc.1204022			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	388YK	11175346				2022-12-25	WOS:000166210500015
J	Wykoff, CC; Pugh, CW; Maxwell, PH; Harris, AL; Ratcliffe, PJ				Wykoff, CC; Pugh, CW; Maxwell, PH; Harris, AL; Ratcliffe, PJ			Identification of novel hypoxia dependent and independent target genes of the von Hippel-Lindau (VHL) tumour suppressor by mRNA differential expression profiling	ONCOGENE			English	Article						VHL; hypoxia; HIF-1 alpha	RECEPTOR-RELATED PROTEIN; RENAL-CELL CARCINOMA; TISSUE TRANSGLUTAMINASE; INDUCIBLE GENES; DOWN-REGULATION; CYCLIN G2; C-FOS; ENDOTHELIN-1; ANGIOGENESIS; HIF-1-ALPHA	The von Hippel-Lindau tumour suppressor gene (VHL) targets hypoxia inducible factor (HIF)-alpha subunits for ubiquitin dependent proteolysis, To better understand the role of this and other putative pathways of gene regulation in VHL function we subjected mRNA from VHL defective renal carcinoma cells and transfectants re-expressing a wild type VHL allele to differential expression profiling, and analysed VHL target genes for oxygen regulated expression, Among a group of newly identified VHL target genes the majority but not all were regulated by oxygen, indicating that whilst dysregulation of the HIF system makes a dominant contribution to alterations in transcription, VHL has other influences on patterns of gene expression. Genes newly defined as targets of the VHL/hypoxia pathway (conditionally downregulated by VHL in normoxic cells) include aminopeptidase A, collagen type V, alpha 1, cyclin G2, DEC1/Stra13, endothelin 1, low density lipoprotein receptor-related protein 1, MIC2/CD99, and transglutaminase 2. These genes have a variety of functions relevant to tumour biology. However, not all are connected with the promotion of tumour growth, some being pro-apoptotic or growth inhibitory. We postulate that co-ordinate regulation as part of the HIF pathway may explain this paradox, and that evolution of anti; apoptotic pathways may be required for tumour growth under VHL-dysregulation, Our results indicate that it will be necessary to consider the effects of abnormal activity in integral regulatory pathways, as well as the effects of individual genes to understand the role of abnormal patterns of gene expression in cancer.	Wellcome Trust Ctr Human Genet, Oxford OX3 7BN, England; John Radcliffe Hosp, Inst Mol Med, Oxford OX3 9DS, England	University of Oxford; Wellcome Centre for Human Genetics; University of Oxford	Ratcliffe, PJ (corresponding author), Wellcome Trust Ctr Human Genet, Oxford OX3 7BN, England.		Harris, Adrian L/ABA-3343-2020; Maxwell, Patrick H/C-5557-2008	Harris, Adrian L/0000-0003-1376-8409; Maxwell, Patrick H/0000-0002-0338-2679; Pugh, Chris/0000-0002-5170-1662; Ratcliffe, Peter/0000-0002-2853-806X				Bates S, 1996, ONCOGENE, V13, P1103; Boudjelal M, 1997, GENE DEV, V11, P2052, DOI 10.1101/gad.11.16.2052; Carmeliet P, 1998, NATURE, V394, P485, DOI 10.1038/28867; Chazaud B, 2000, EXP CELL RES, V258, P237, DOI 10.1006/excr.2000.4934; Chen JSK, 1999, INT J BIOCHEM CELL B, V31, P817, DOI 10.1016/S1357-2725(99)00045-X; Cockman ME, 2000, J BIOL CHEM, V275, P25733, DOI 10.1074/jbc.M002740200; EBERT BL, 1995, J BIOL CHEM, V270, P29083, DOI 10.1074/jbc.270.49.29083; Fujimura H, 2000, ONCOLOGY-BASEL, V58, P342, DOI 10.1159/000012122; GNARRA JR, 1994, NAT GENET, V7, P85, DOI 10.1038/ng0594-85; GRAEBER TG, 1994, MOL CELL BIOL, V14, P6264, DOI 10.1128/MCB.14.9.6264; Hahn JH, 1997, J IMMUNOL, V159, P2250; HERMAN WH, 1995, J BIOL CHEM, V270, P11654, DOI 10.1074/jbc.270.19.11654; HIEDA HS, 1990, LIFE SCI, V47, P247, DOI 10.1016/0024-3205(90)90327-N; Horne MC, 1997, J BIOL CHEM, V272, P12650, DOI 10.1074/jbc.272.19.12650; Horne MC, 1996, J BIOL CHEM, V271, P6050, DOI 10.1074/jbc.271.11.6050; Hu J, 1998, BIOCHEM BIOPH RES CO, V245, P894, DOI 10.1006/bbrc.1998.8543; Iliopoulos O, 1996, P NATL ACAD SCI USA, V93, P10595, DOI 10.1073/pnas.93.20.10595; Ivanov SV, 1998, P NATL ACAD SCI USA, V95, P12596, DOI 10.1073/pnas.95.21.12596; Iwai K, 1999, P NATL ACAD SCI USA, V96, P12436, DOI 10.1073/pnas.96.22.12436; Iyer VR, 1999, SCIENCE, V283, P83, DOI 10.1126/science.283.5398.83; Kaelin WG, 1998, TRENDS GENET, V14, P423, DOI 10.1016/S0168-9525(98)01558-3; Koong AC, 2000, CANCER RES, V60, P883; Kozawa O, 2000, CELL SIGNAL, V12, P375, DOI 10.1016/S0898-6568(00)00061-9; Lisztwan J, 1999, GENE DEV, V13, P1822, DOI 10.1101/gad.13.14.1822; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; Maxwell PH, 1997, P NATL ACAD SCI USA, V94, P8104, DOI 10.1073/pnas.94.15.8104; Moch H, 1999, AM J PATHOL, V154, P981, DOI 10.1016/S0002-9440(10)65349-7; NANUS DM, 1993, P NATL ACAD SCI USA, V90, P7069, DOI 10.1073/pnas.90.15.7069; Ohh M, 1998, MOL CELL, V1, P959, DOI 10.1016/S1097-2765(00)80096-9; Okada SS, 1996, ARTERIOSCL THROM VAS, V16, P1269, DOI 10.1161/01.ATV.16.10.1269; Okuda Y, 1998, LIFE SCI, V63, P477, DOI 10.1016/S0024-3205(98)00296-3; Oliverio S, 1999, J BIOL CHEM, V274, P34123, DOI 10.1074/jbc.274.48.34123; Pasqualini R, 2000, CANCER RES, V60, P722; Pause A, 1998, P NATL ACAD SCI USA, V95, P993, DOI 10.1073/pnas.95.3.993; Ryan HE, 1998, EMBO J, V17, P3005, DOI 10.1093/emboj/17.11.3005; SCHENA M, 1995, SCIENCE, V270, P467, DOI 10.1126/science.270.5235.467; SEMENZA GL, 1994, J BIOL CHEM, V269, P23757; Shen M, 1997, BIOCHEM BIOPH RES CO, V236, P294, DOI 10.1006/bbrc.1997.6960; SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0; Soslow RA, 1997, HUM PATHOL, V28, P1158, DOI 10.1016/S0046-8177(97)90254-9; STRICKLAND DK, 1995, FASEB J, V9, P890, DOI 10.1096/fasebj.9.10.7615159; Sun H, 2000, P NATL ACAD SCI USA, V97, P4058, DOI 10.1073/pnas.070526297; Takahashi Y, 2000, J BIOL CHEM, V275, P14139, DOI 10.1074/jbc.275.19.14139; Wood SM, 1998, J BIOL CHEM, V273, P8360, DOI 10.1074/jbc.273.14.8360; YIN J, 1992, MOL BRAIN RES, V14, P213, DOI 10.1016/0169-328X(92)90176-C; Zhang PJ, 2000, MODERN PATHOL, V13, P452, DOI 10.1038/modpathol.3880077; ZOUBEK A, 1995, KLIN PADIATR, V207, P242, DOI 10.1055/s-2008-1046548	47	223	234	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 14	2000	19	54					6297	6305		10.1038/sj.onc.1204012	http://dx.doi.org/10.1038/sj.onc.1204012			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	388YK	11175344				2022-12-25	WOS:000166210500013
J	Zarich, N; Oliva, JL; Jorge, R; Santos, E; Rojas, JM				Zarich, N; Oliva, JL; Jorge, R; Santos, E; Rojas, JM			The isoform-specific stretch of hSos1 defines a new Grb2-binding domain	ONCOGENE			English	Article						hSos1; isoforms; Grb2; SH3 domains	NUCLEOTIDE EXCHANGE FACTOR; RECEPTOR TYROSINE KINASES; ACTIVATED PROTEIN-KINASE; SRC HOMOLOGY-3 DOMAINS; RAS SIGNALING PATHWAY; SH3 DOMAINS; FACTOR SON; SH3-LIGAND INTERACTIONS; STRUCTURAL BASIS; ADAPTER PROTEIN	hSos1 isoform II, defined by the presence of a 15 amino acid stretch in its carboxy-terminal region, exhibits higher Grb2 affinity than hSos1 isoform I. In this study, we investigated the cause for this difference and observed that, in addition to the four currently accepted Grb2-binding motifs, a number of additional, putative SH3-minimal binding sites (SH3-MBS) could be identified. The isoform II-specific 15 amino acid stretch contained one of them, Indeed, me demonstrated by site-directed mutagenesis that these SH3-MBS were responsible for the Grb2 interaction, and we found that C-terminal fragments of the two hSos1 isoforms (lacking the four cannonical Grb2-binding motifs, but containing the SH3-minimal binding sites) were able to bind Grb2, with the isoform II fragment showing higher Grb2 affinity than the corresponding isoform I fragment. Furthermore, we provide evidence that C-terminal truncated mutants of either hSos1 isoform, containing only the SH3-minimal binding sites, were able to originate in vivo stable complexes with Grb2, Although, Grb2-binding remains higher in both full-length isoforms, compared to the C-terminal truncated mutants, these mutants were also able to activate Ras, supporting a potential role of this C-terminal region as negative modulator of Sos1 activity. These findings document the existence of a new, functional, SH3-minimal binding site located in the specific stretch of hSos1 isoform II which may be responsible for the increased Grb2 affinity of this isoform in comparison to isoform I, and for the physiological properties differences between both isoforms, Moreover, these SH3-minimal binding sites may be sufficient to attain stable and functional hSos1-Grb2 complexes.	Inst Salud Carlos III, Ctr Nacl Biol Fundamental, Unidad Biol Celular, Madrid 28220, Spain; NCI, Cellular & Mol Biol Lab, NIH, Bethesda, MD 20892 USA	Instituto de Salud Carlos III; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Rojas, JM (corresponding author), Inst Salud Carlos III, Ctr Nacl Biol Fundamental, Unidad Biol Celular, Madrid 28220, Spain.		Rojas, José M./AAA-3354-2021; Rojas, José M/D-3718-2018	Rojas, José M./0000-0002-7547-2825; Rojas, José M/0000-0002-5383-3482; Zarich, Natasha/0000-0003-1058-6191				ARONHEIM A, 1994, CELL, V78, P949, DOI 10.1016/0092-8674(94)90271-2; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; Boriack-Sjodin PA, 1998, NATURE, V394, P337, DOI 10.1038/28548; Byrne JL, 1996, ONCOGENE, V13, P2055; CHARDIN P, 1995, FEBS LETT, V369, P47, DOI 10.1016/0014-5793(95)00578-W; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; CHERNIACK AD, 1994, J BIOL CHEM, V269, P4717; Corbalan-Garcia S, 1998, MOL CELL BIOL, V18, P880, DOI 10.1128/MCB.18.2.880; CorbalanGarcia S, 1996, MOL CELL BIOL, V16, P5674; Cussac D, 1999, FASEB J, V13, P31, DOI 10.1096/fasebj.13.1.31; CUSSAC D, 1994, EMBO J, V13, P4011, DOI 10.1002/j.1460-2075.1994.tb06717.x; DENHERTOG J, 1994, EMBO J, V13, P3020, DOI 10.1002/j.1460-2075.1994.tb06601.x; Douville E, 1997, ONCOGENE, V15, P373, DOI 10.1038/sj.onc.1201214; DOWNWARD J, 1994, FEBS LETT, V338, P113, DOI 10.1016/0014-5793(94)80346-3; EGAN SE, 1993, NATURE, V365, P781, DOI 10.1038/365781a0; FEIG LA, 1994, CURR OPIN CELL BIOL, V6, P204, DOI 10.1016/0955-0674(94)90137-6; FENG SB, 1994, SCIENCE, V266, P1241, DOI 10.1126/science.7526465; GOTOH T, 1995, MOL CELL BIOL, V15, P6746; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; Guerrero C, 1998, ONCOGENE, V16, P613, DOI 10.1038/sj.onc.1201569; HOLSINGER LJ, 1995, P NATL ACAD SCI USA, V92, P9810, DOI 10.1073/pnas.92.21.9810; Joneson T, 1997, J MOL MED-JMM, V75, P587, DOI 10.1007/s001090050143; KARLOVICH CA, 1995, SCIENCE, V268, P576, DOI 10.1126/science.7725106; Kim JH, 1998, ONCOGENE, V16, P2597, DOI 10.1038/sj.onc.1201822; Koshiba S, 1997, J MOL BIOL, V269, P579, DOI 10.1006/jmbi.1997.1041; LI BQ, 1995, BIOCHEM BIOPH RES CO, V216, P110, DOI 10.1006/bbrc.1995.2598; LI BQ, 1993, P NATL ACAD SCI USA, V90, P8504, DOI 10.1073/pnas.90.18.8504; Li BQ, 1996, P NATL ACAD SCI USA, V93, P1001, DOI 10.1073/pnas.93.3.1001; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LIM WA, 1994, NAT STRUCT BIOL, V1, P221, DOI 10.1038/nsb0494-221; Marinissen MJ, 1999, MOL CELL BIOL, V19, P4289; MAYER BJ, 1995, CURR BIOL, V5, P364, DOI 10.1016/S0960-9822(95)00073-X; MCCOLLAM L, 1995, J BIOL CHEM, V270, P15954, DOI 10.1074/jbc.270.27.15954; MCCORMICK F, 1993, NATURE, V363, P15, DOI 10.1038/363015a0; MCPHERSON PS, 1994, P NATL ACAD SCI USA, V91, P6486, DOI 10.1073/pnas.91.14.6486; Mendelsohn Andrew R., 1994, Current Opinion in Biotechnology, V5, P482, DOI 10.1016/0958-1669(94)90061-2; Nimnual AS, 1998, SCIENCE, V279, P560, DOI 10.1126/science.279.5350.560; PAWSON T, 1993, CURR BIOL, V3, P434, DOI 10.1016/0960-9822(93)90350-W; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; QUILLIAM LA, 1994, P NATL ACAD SCI USA, V91, P8512, DOI 10.1073/pnas.91.18.8512; QUILLIAM LA, 1995, BIOESSAYS, V17, P395, DOI 10.1002/bies.950170507; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; Rojas JM, 1996, ONCOGENE, V12, P2291; Rojas JM, 1999, ONCOGENE, V18, P1651, DOI 10.1038/sj.onc.1202483; ROZAKISADCOCK M, 1995, ONCOGENE, V11, P1417; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; SCHLESSINGER J, 1993, TRENDS BIOCHEM SCI, V18, P273, DOI 10.1016/0968-0004(93)90031-H; SIMON JA, 1995, CHEM BIOL, V2, P53, DOI 10.1016/1074-5521(95)90080-2; Soisson SM, 1998, CELL, V95, P259, DOI 10.1016/S0092-8674(00)81756-0; Sudol M, 1998, ONCOGENE, V17, P1469, DOI 10.1038/sj.onc.1202182; Taylor SJ, 1996, CURR BIOL, V6, P1621, DOI 10.1016/S0960-9822(02)70785-9; Tong XK, 2000, EMBO J, V19, P1263, DOI 10.1093/emboj/19.6.1263; WANG W, 1995, NAT GENET, V10, P294, DOI 10.1038/ng0795-294; YE ZS, 1994, P NATL ACAD SCI USA, V91, P12629, DOI 10.1073/pnas.91.26.12629; YU HT, 1994, CELL, V76, P933, DOI 10.1016/0092-8674(94)90367-0; Zohar M, 1998, ONCOGENE, V17, P991, DOI 10.1038/sj.onc.1202022	57	17	18	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 30	2000	19	51					5872	5883		10.1038/sj.onc.1203955	http://dx.doi.org/10.1038/sj.onc.1203955			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	378CA	11127818				2022-12-25	WOS:000165563100006
J	Cortajarena, AL; Goni, FM; Ostolaza, H				Cortajarena, AL; Goni, FM; Ostolaza, H			Glycophorin as a Receptor for Escherichia coli alpha-hemolysin in erythrocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN TOXIN; FATTY ACYLATION; SINGLE-HIT; RTX TOXINS; MEMBRANE; VESICLES; CELLS; MECHANISM; RELEASE; BINDING	Escherichia coli cu-hemolysin (HlyA) can lyse both red blood cells (RBC) and liposomes, However, the cells are lysed at HlyA concentrations 1-2 orders of magnitude lower than liposomes (large unilamellar vesicles). Treatment of RBC with trypsin, but not with chymotrypsin, reduces the sensitivity of RBC toward HlyA to the level of the liposomes, Since glycophorin, one of the main proteins in the RBC surface, can be hydrolyzed by trypsin much more readily than by chymotrypsin, the possibility was tested of a specific binding of HlyA to glycophorin, With this purpose, a number of experiments were performed. (a) HlyA was preincubated with purified glycophorin, after which it was found to be inactive against both RBC and liposomes, (b) Treatment of RBC with an anti-glycophorin antibody protected the cells against HlyA lysis, (c) Immobilized HlyA was able to bind glycophorin present in a detergent lysate of RBC ghosts. (d) Incorporation of glycophorin into pure phosphatidylcholine liposomes increased notoriously the sensitivity of the vesicles toward HlyA (e) Treatment of the glycophorin-containing liposomes with trypsin reverted the vesicles to their original low sensitivity, The above results are interpreted in terms of glycophorin acting as a receptor for HlyA in RBC. The binding constant of HlyA for glycophorin was estimated, in RBC at sublytic HlyA concentrations, to be 1.5 x 10(-9) M.	Univ Basque Country, Unidad Biofis, Consejo Super Invest Cient, E-48080 Bilbao, Spain; Univ Basque Country, Dept Bioquim, E-48080 Bilbao, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); University of Basque Country; CSIC - UPV EHU - Instituto Biofisika; University of Basque Country	Ostolaza, H (corresponding author), Univ Basque Country, Unidad Biofis, Consejo Super Invest Cient, Aptdo 644, E-48080 Bilbao, Spain.	gbzoseth@lg.ehu.es	Goni, Felix M/M-5425-2015; Cortajarena, Aitziber L/J-6202-2012; Fu, Lixia/B-7429-2009	Goni, Felix M/0000-0001-6270-9216; Cortajarena, Aitziber L/0000-0002-5331-114X; OSTOLAZA ECHABE, ELENA AMAYA/0000-0003-2933-9975				Bauer ME, 1996, INFECT IMMUN, V64, P4665, DOI 10.1128/IAI.64.11.4665-4672.1996; BENZ R, 1989, INFECT IMMUN, V57, P887, DOI 10.1128/IAI.57.3.887-895.1989; BHAKDI S, 1986, INFECT IMMUN, V52, P63, DOI 10.1128/IAI.52.1.63-69.1986; BHAKDI S, 1991, INFECT IMMUN, V59, P2955, DOI 10.1128/IAI.59.9.2955-2962.1991; BHAKDI S, 1990, J CLIN INVEST, V85, P1746, DOI 10.1172/JCI114631; Blumenfeld OO, 1997, TRANSFUS CLIN BIOL, V4, P357, DOI 10.1016/S1246-7820(97)80041-9; BRETSCHER MS, 1973, SCIENCE, V181, P622, DOI 10.1126/science.181.4100.622; CABANTCHIK ZI, 1974, J MEMBRANE BIOL, V15, P227, DOI 10.1007/BF01870089; CAVALIERI SJ, 1984, MICROBIOL REV, V48, P326, DOI 10.1128/MMBR.48.4.326-343.1984; CHALLOU N, 1994, BIOCHEMISTRY-US, V33, P6902, DOI 10.1021/bi00188a020; CHASIS JA, 1992, BLOOD, V80, P1869; COOTE JG, 1992, FEMS MICROBIOL LETT, V88, P137, DOI 10.1016/0378-1097(92)90688-K; COOTE JG, 1996, REV MED MICROBIOL, V7, P53, DOI [10.1097/00013542-199601000-00006, DOI 10.1097/00013542-199601000-00006]; CRUZ WT, 1990, MOL MICROBIOL, V4, P1933, DOI 10.1111/j.1365-2958.1990.tb02042.x; Duk M, 2000, ARCH BIOCHEM BIOPHYS, V375, P111, DOI 10.1006/abbi.1999.1637; EBERSPACHER B, 1989, INFECT IMMUN, V57, P983; ELLENS H, 1985, BIOCHEMISTRY-US, V24, P3099, DOI 10.1021/bi00334a005; GARLAND WJ, 1988, INFECT IMMUN, V56, P1249, DOI 10.1128/IAI.56.5.1249-1253.1988; Goni FM, 1998, BRAZ J MED BIOL RES, V31, P1019, DOI 10.1590/S0100-879X1998000800002; GRIMMINGER F, 1990, INFECT IMMUN, V58, P2659, DOI 10.1128/IAI.58.8.2659-2663.1990; GUTFREUND H, 1972, ENZYMES PHYSICAL PRI, P71; HAMAGUCHI H, 1972, BIOCHIM BIOPHYS ACTA, V278, P271, DOI 10.1016/0005-2795(72)90232-2; HOWARD SP, 1982, BIOCHEMISTRY-US, V21, P1662, DOI 10.1021/bi00536a029; Huang Pearl S., 1997, Current Opinion in Oncology, V9, P94; JORGENSEN SE, 1980, INFECT IMMUN, V27, P988, DOI 10.1128/IAI.27.3.988-994.1980; KEANE WF, 1987, AM J PATHOL, V126, P350; Lally ET, 1997, J BIOL CHEM, V272, P30463, DOI 10.1074/jbc.272.48.30463; Li J, 1999, VET MICROBIOL, V67, P91, DOI 10.1016/S0378-1135(99)00040-1; LUDWIG A, 1988, MOL GEN GENET, V214, P553, DOI 10.1007/BF00330494; MACDONALD RI, 1975, J BIOL CHEM, V250, P9206; MARCHESI VT, 1976, ANNU REV BIOCHEM, V45, P667, DOI 10.1146/annurev.bi.45.070176.003315; MAYER LD, 1986, BIOCHIM BIOPHYS ACTA, V858, P161, DOI 10.1016/0005-2736(86)90302-0; MENESTRINA G, 1988, FEBS LETT, V232, P217, DOI 10.1016/0014-5793(88)80420-4; Moayeri M, 1997, INFECT IMMUN, V65, P2233, DOI 10.1128/IAI.65.6.2233-2239.1997; Nimchuk Z, 2000, CELL, V101, P353, DOI 10.1016/S0092-8674(00)80846-6; OSTOLAZA H, 1993, BIOCHIM BIOPHYS ACTA, V1147, P81, DOI 10.1016/0005-2736(93)90318-T; Penninger JM, 1999, CELL, V96, P9, DOI 10.1016/S0092-8674(00)80954-X; Rivas S, 1997, J BIOL CHEM, V272, P25583, DOI 10.1074/jbc.272.41.25583; SCHEFFER J, 1985, INFECT IMMUN, V50, P271, DOI 10.1128/IAI.50.1.271-278.1985; SHAHINIAN S, 1995, BIOCHEMISTRY-US, V34, P3813, DOI 10.1021/bi00011a039; SMITH SO, 1995, P NATL ACAD SCI USA, V92, P488, DOI 10.1073/pnas.92.2.488; Soloaga A, 1998, BIOCHEMISTRY-US, V37, P6387, DOI 10.1021/bi9730994; Soloaga A, 1996, EUR J BIOCHEM, V238, P418, DOI 10.1111/j.1432-1033.1996.0418z.x; SPRINGER GF, 1966, BIOCHEMISTRY-US, V5, P3254, DOI 10.1021/bi00874a028; STANLEY P, 1994, SCIENCE, V266, P1992, DOI 10.1126/science.7801126; Stanley P, 1998, MICROBIOL MOL BIOL R, V62, P309, DOI 10.1128/MMBR.62.2.309-333.1998; STECK TL, 1976, BIOCHEMISTRY-US, V15, P1154, DOI 10.1021/bi00650a030; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VANZOELEN EJJ, 1978, EUR J BIOCHEM, V86, P539; WELCH RA, 1992, FEMS MICROBIOL IMMUN, V105, P29; Zhang DY, 1999, INFECT IMMUN, V67, P5332, DOI 10.1128/IAI.67.10.5332-5337.1999	51	61	62	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 20	2001	276	16					12513	12519		10.1074/jbc.M006792200	http://dx.doi.org/10.1074/jbc.M006792200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	423VN	11134007	hybrid			2022-12-25	WOS:000168198600009
J	Bodendorf, U; Fischer, F; Bodian, D; Multhaup, G; Paganetti, P				Bodendorf, U; Fischer, F; Bodian, D; Multhaup, G; Paganetti, P			A splice variant of beta-secretase deficient in the amyloidogenic processing of the amyloid precursor protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALZHEIMERS-DISEASE; GENERATION; PEPTIDE; PURIFICATION; ENDOCYTOSIS; MATURATION; CLEAVAGE; BACE	beta -Secretase (BACE) initiates the amyloidogenic processing of the amyloid precursor protein leading to the generation of the beta -amyloid, the main component of Alzheimer's disease senile plaques. BACE is a type I transmembrane aspartyl protease of 501 amino acids. Here we describe a novel BACE mRNA lacking 132 base pairs that is expressed in the pancreas but not in the brain. Sequence alignment indicates that the deleted fragment matches the terminal two-thirds of exon 3. The new BACE variant is short of a 44-amino acid region located between the two catalytic aspartyl residues. Accordingly, a 50-kDa form of BACE (BACE457) is detected in the human pancreas. When expressed in cells, BACE457 colocalizes with the marker for the endoplasmic reticulum BiP. Moreover, BACE457 remains in a proenzymatic and endoglycosidase H-sensitive state, suggesting that its transport along the secretory pathway is blocked at the level of the endoplasmic reticulum. Notably, this novel form of BACE does not contribute to the processing of the amyloid precursor protein. Our findings suggest that tissue-specific splicing of the BACE mRNA may explain the observation that in the human pancreas robust transcription of the BACE gene does not translate into recovered enzymatic activity.	Novartis Pharma AG, Nervous Syst, CH-4002 Basel, Switzerland; Novartis Pharmaceut Corp, Funct Gen, Summit, NJ 07901 USA; Univ Heidelberg, Ctr Mol Biol, D-69120 Heidelberg, Germany	Novartis; Novartis; Ruprecht Karls University Heidelberg	Paganetti, P (corresponding author), Novartis Pharma AG, Nervous Syst, WSJ-386-8-28, CH-4002 Basel, Switzerland.		Paganetti, Paolo/AAF-8039-2020	Paganetti, Paolo/0000-0003-1896-6324				CAI XD, 1993, SCIENCE, V259, P514, DOI 10.1126/science.8424174; Capell A, 2000, J BIOL CHEM, V275, P30849, DOI 10.1074/jbc.M003202200; Cescato R, 2000, J NEUROCHEM, V74, P1131; CITRON M, 1995, NEURON, V14, P661, DOI 10.1016/0896-6273(95)90323-2; CITRON M, 1992, NATURE, V360, P672, DOI 10.1038/360672a0; FAN W, 1999, SCIENCE, V286, P1255; GLENNER GG, 1984, BIOCHEM BIOPH RES CO, V120, P885, DOI 10.1016/S0006-291X(84)80190-4; GOLDE TE, 1992, SCIENCE, V255, P728, DOI 10.1126/science.1738847; HAASS C, 1993, J BIOL CHEM, V268, P3021; Haniu M, 2000, J BIOL CHEM, V275, P21099, DOI 10.1074/jbc.M002095200; Huse JT, 2000, J BIOL CHEM, V275, P33729, DOI 10.1074/jbc.M004175200; Hussain I, 1999, MOL CELL NEUROSCI, V14, P419, DOI 10.1006/mcne.1999.0811; Lin XL, 2000, P NATL ACAD SCI USA, V97, P1456, DOI 10.1073/pnas.97.4.1456; MASTERS CL, 1985, P NATL ACAD SCI USA, V82, P4245, DOI 10.1073/pnas.82.12.4245; Perez RG, 1999, J BIOL CHEM, V274, P18851, DOI 10.1074/jbc.274.27.18851; SAUDNERS AJ, 1999, SCIENCE, V286, P1255; SchraderFischer G, 1996, BRAIN RES, V716, P91, DOI 10.1016/0006-8993(96)00002-9; Selkoe DJ, 1998, TRENDS CELL BIOL, V8, P447, DOI 10.1016/S0962-8924(98)01363-4; SEUBERT P, 1993, NATURE, V361, P260, DOI 10.1038/361260a0; Sinha S, 1999, NATURE, V402, P537, DOI 10.1038/990114; Vassar R, 1999, SCIENCE, V286, P735, DOI 10.1126/science.286.5440.735; Yan RQ, 1999, NATURE, V402, P533, DOI 10.1038/990107	22	66	71	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 13	2001	276	15					12019	12023		10.1074/jbc.M008861200	http://dx.doi.org/10.1074/jbc.M008861200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	421UK	11152683	hybrid			2022-12-25	WOS:000168081800078
J	Mannering, DE; Sharma, S; Davidson, AL				Mannering, DE; Sharma, S; Davidson, AL			Demonstration of conformational changes associated with activation of the maltose transport complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING CASSETTE TRANSPORTER; SITE-DIRECTED FLUORESCENCE; ESCHERICHIA-COLI; ABC TRANSPORTER; NUCLEOTIDE-BINDING; P-GLYCOPROTEIN; ADENOSINE-TRIPHOSPHATASE; SALMONELLA-TYPHIMURIUM; MEMBRANE-COMPONENTS; CRYSTAL-STRUCTURE	In Escherichia coli, interaction of a periplasmic maltose-binding protein with a membrane-associated ATP-binding cassette transporter stimulates ATP hydrolysis, resulting in translocation of maltose into the cell. The maltose transporter contains two transmembrane subunits, MalF and MalG, and two copies of a nucleotide-hydrolyzing subunit, MalK. Mutant transport complexes that function in the absence of binding protein are thought to be stabilized in an ATPase-active conformation. To probe the conformation of the nucleotide-binding site and to gain an understanding of the nature of the conformational changes that lead to activation, cysteine 40 within the Walker A motif of the MalK subunit was modified by the fluorophore 2-(4'-maleimidoanilino)naphthalene-6-sulfonic acid. Fluorescence differences indicated that residues involved in nucleotide binding were less accessible to aqueous solvent in the binding protein independent transporter than in the wild-type transporter, Similar differences in fluorescence were seen when a vanadate-trapped transition state conformation was compared with the ground state in the wild-type transporter. Our results and recent crystal structures are consistent with a model in which activation of ATPase activity is associated with conformational changes that bring the two MalK subunits closer together, completing the nucleotide-binding sites and burying ATP in the interface.	Baylor Coll Med, Dept Mol Virol & Microbiol, MS BCM 280, Houston, TX 77030 USA	Baylor College of Medicine	Davidson, AL (corresponding author), Baylor Coll Med, Dept Mol Virol & Microbiol, MS BCM 280, 1 Baylor Plaza, Houston, TX 77030 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049261, R29GM049261] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM49261, GM08231] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BOOS W, 1996, ESCHERICHIA COLI SAL, P1197; CHEN CJ, 1986, CELL, V47, P381, DOI 10.1016/0092-8674(86)90595-7; CHEN J, 2001, IN PRESS P NATL ACAD; COVITZ KMY, 1994, EMBO J, V13, P1752, DOI 10.1002/j.1460-2075.1994.tb06439.x; DAHL MK, 1989, MOL GEN GENET, V218, P199, DOI 10.1007/BF00331269; DASSA E, 1985, EMBO J, V4, P2287, DOI 10.1002/j.1460-2075.1985.tb03928.x; DAVIDSON AL, 1991, J BIOL CHEM, V266, P8946; DAVIDSON AL, 1992, P NATL ACAD SCI USA, V89, P2360, DOI 10.1073/pnas.89.6.2360; DAVIDSON AL, 1990, J BIOL CHEM, V265, P4254; Davidson AL, 1997, J BACTERIOL, V179, P5458, DOI 10.1128/jb.179.17.5458-5464.1997; Davidson AL, 1996, J BIOL CHEM, V271, P4858; DEAN DA, 1992, MOL MICROBIOL, V6, P2033, DOI 10.1111/j.1365-2958.1992.tb01376.x; Diederichs K, 2000, EMBO J, V19, P5951, DOI 10.1093/emboj/19.22.5951; FERSHT A, 1985, ENZYME STRUCTURE MEC, P311; FROSHAUER S, 1984, J BIOL CHEM, V259, P896; GRANA D, 1988, GENETICS, V120, P319; GUPTE SS, 1979, J BIOL CHEM, V254, P362; HAUGLAND RP, 1983, EXCITED STATES BIOPO, P41; HIGGINS CF, 1990, RES MICROBIOL, V141, P353, DOI 10.1016/0923-2508(90)90011-E; HIRATSUKA T, 1992, J BIOL CHEM, V267, P14941; Holland IB, 1999, J MOL BIOL, V293, P381, DOI 10.1006/jmbi.1999.2993; Hopfner KP, 2000, CELL, V101, P789, DOI 10.1016/S0092-8674(00)80890-9; Hung LW, 1998, NATURE, V396, P703, DOI 10.1038/25393; Hunke S, 1999, FEBS LETT, V448, P131, DOI 10.1016/S0014-5793(99)00356-7; HUNKE S, 1995, BIOCHEM BIOPH RES CO, V216, P589, DOI 10.1006/bbrc.1995.2663; Jones PM, 1999, FEMS MICROBIOL LETT, V179, P187, DOI 10.1111/j.1574-6968.1999.tb08727.x; KSENZENKO MY, 1993, BIOCHEMISTRY-US, V32, P13362, DOI 10.1021/bi00211a051; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lakowicz JR, 1983, PRINCIPLES FLUORESCE, P260; Liu CE, 1997, J BIOL CHEM, V272, P21883, DOI 10.1074/jbc.272.35.21883; Liu RH, 1997, BIOCHEMISTRY-US, V36, P2836, DOI 10.1021/bi9627119; Liu RH, 1996, BIOCHEMISTRY-US, V35, P11865, DOI 10.1021/bi960823u; MANSON MD, 1985, J BIOL CHEM, V260, P9727; MORBACH S, 1993, J BIOL CHEM, V268, P18617; PANAGIOTIDIS CH, 1993, J BIOL CHEM, V268, P23685; RIORDAN JR, 1989, SCIENCE, V245, P1066; SCHAFFNE.W, 1973, ANAL BIOCHEM, V56, P502, DOI 10.1016/0003-2697(73)90217-0; Senior AE, 1998, BIOCHEMISTRY-US, V37, P831, DOI 10.1021/bi9719962; SHARFF AJ, 1992, BIOCHEMISTRY-US, V31, P10657, DOI 10.1021/bi00159a003; Sharma S, 2000, J BACTERIOL, V182, P6570, DOI 10.1128/JB.182.23.6570-6576.2000; SPURLINO JC, 1991, J BIOL CHEM, V266, P5202; TREPTOW NA, 1985, J BACTERIOL, V163, P654, DOI 10.1128/JB.163.2.654-660.1985; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WU JH, 1995, BIOCHEMISTRY-US, V34, P8257, DOI 10.1021/bi00026a007; WU JH, 1994, BIOCHEMISTRY-US, V33, P12166, DOI 10.1021/bi00206a020	45	41	41	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 13	2001	276	15					12362	12368		10.1074/jbc.M011686200	http://dx.doi.org/10.1074/jbc.M011686200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	421UK	11150310	hybrid			2022-12-25	WOS:000168081800123
J	Mironneau, J; Coussin, F; Jeyakumar, LH; Fleischer, S; Mironneau, C; Macrez, N				Mironneau, J; Coussin, F; Jeyakumar, LH; Fleischer, S; Mironneau, C; Macrez, N			Contribution of ryanodine receptor subtype 3 to Ca2+ responses in Ca2+-overloaded cultured rat portal vein myocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SARCOPLASMIC-RETICULUM; RELEASE CHANNEL; SKELETAL-MUSCLE; CALCIUM SPARKS; SMOOTH-MUSCLE; MICE LACKING; VASCULAR MYOCYTES; LUMINAL CA2+; ELEMENTARY EVENTS; CARDIAC MYOCYTES	Using an antisense strategy, we have previously shown that in vascular myocytes, subtypes 1 and 2 of ryanodine receptors (RYRs) are required for Ca2+ release during Ca2+ sparks and global Ca2+ responses, evoked by activation of voltage-gated Ca2+ channels, whereas RYR subtype 3 (RYR3) has no contribution. Here, we investigated the effects of increased Ca2+ loading of the sarcoplasmic reticulum (SR) on the RYR-mediated Ca2+ responses and the role of the RYR3 by injecting antisense oligonucleotides targeting the RYR subtypes, RYR3 expression was demonstrated by immunodetection in both freshly dissociated and cultured rat portal vein myocytes, Confocal Ca2+ measurements revealed that the number of cells showing spontaneous Ca2+ sparks was strongly increased by superfusing the vascular myocytes in 10 mM Ca2+-containing solution. These Ca2+ sparks were blocked after inhibition of RYR1 or RYR2 by treatment with antisense oligolucleotides but not after inhibition of RYR3, In contrast, inhibition of RYR3 reduced the global Ca2+ responses induced by caffeine and phenylephrine, indicating that RYR3 participated together with RYR1 and RYR2 to these Ca2+ responses in Ca2+-overloaded myocytes. Ca2+ transients evoked by photolysis of caged Ca2+ with increasing flash intensities were also reduced after inhibition of RYR3 and revealed that the [Ca2+](i) sensitivity of RYR3 would be similar to that of RYR1 and RYR2. Our results show that, under conditions of increased SR Ca2+ loading, the RYR3 becomes activable by caffeine and local increases in [Ca2+](i).	Univ Bordeaux 2, Lab Signalisat & Interact Cellulaires, CNRS, UMR 5017, F-33076 Bordeaux, France; Vanderbilt Univ, Dept Biol Sci, Nashville, TN 37235 USA	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite de Bordeaux; Vanderbilt University	Mironneau, J (corresponding author), Univ Bordeaux 2, Lab Signalisat & Interact Cellulaires, CNRS, UMR 5017, 146 Rue Leo Saignat, F-33076 Bordeaux, France.			MACREZ, Nathalie/0000-0002-3844-4403				Arnaudeau S, 1997, CELL CALCIUM, V22, P399, DOI 10.1016/S0143-4160(97)90024-5; Arnaudeau S, 1996, BIOCHEM BIOPH RES CO, V222, P809, DOI 10.1006/bbrc.1996.0808; Berridge MJ, 1997, J PHYSIOL-LONDON, V499, P291, DOI 10.1113/jphysiol.1997.sp021927; Bertocchini F, 1997, EMBO J, V16, P6956, DOI 10.1093/emboj/16.23.6956; Boittin FX, 1999, AM J PHYSIOL-CELL PH, V277, pC139, DOI 10.1152/ajpcell.1999.277.1.C139; Chen SRW, 1997, J BIOL CHEM, V272, P24234, DOI 10.1074/jbc.272.39.24234; Chen W, 1996, J BIOL CHEM, V271, P7398, DOI 10.1074/jbc.271.13.7398; CHENG H, 1993, SCIENCE, V262, P740, DOI 10.1126/science.8235594; CHU A, 1993, J MEMBRANE BIOL, V135, P49; Conklin MW, 1999, BIOPHYS J, V77, P1394, DOI 10.1016/S0006-3495(99)76988-2; Conklin MW, 2000, BIOPHYS J, V78, P1777, DOI 10.1016/S0006-3495(00)76728-2; Coussin F, 2000, J BIOL CHEM, V275, P9596, DOI 10.1074/jbc.275.13.9596; ENDO M, 1970, NATURE, V228, P34, DOI 10.1038/228034a0; FLEISCHER S, 1989, ANNU REV BIOPHYS BIO, V18, P333, DOI 10.1146/annurev.bb.18.060189.002001; Gyorke I, 1998, BIOPHYS J, V75, P2801, DOI 10.1016/S0006-3495(98)77723-9; HAKAMATA Y, 1992, FEBS LETT, V312, P229, DOI 10.1016/0014-5793(92)80941-9; Jeyakumar LH, 1998, J BIOL CHEM, V273, P16011, DOI 10.1074/jbc.273.26.16011; Lesh RE, 1998, CIRC RES, V82, P175; Lukyanenko V, 1999, J PHYSIOL-LONDON, V518, P173, DOI 10.1111/j.1469-7793.1999.0173r.x; Manunta M, 2000, FEBS LETT, V471, P256, DOI 10.1016/S0014-5793(00)01385-5; Mironneau J, 1996, CELL CALCIUM, V20, P153, DOI 10.1016/S0143-4160(96)90104-9; Miyatake R, 1996, FEBS LETT, V395, P123, DOI 10.1016/0014-5793(96)01022-8; Morel JL, 1996, BRIT J PHARMACOL, V118, P73, DOI 10.1111/j.1476-5381.1996.tb15368.x; Murayama T, 1999, J BIOL CHEM, V274, P17297, DOI 10.1074/jbc.274.24.17297; NELSON MT, 1995, SCIENCE, V270, P633, DOI 10.1126/science.270.5236.633; NEYLON CB, 1995, BIOCHEM BIOPH RES CO, V215, P814, DOI 10.1006/bbrc.1995.2536; Niggli E, 1999, ANNU REV PHYSIOL, V61, P311, DOI 10.1146/annurev.physiol.61.1.311; RIOS E, 1991, PHYSIOL REV, V71, P849, DOI 10.1152/physrev.1991.71.3.849; Satoh H, 1997, AM J PHYSIOL-HEART C, V272, pH657, DOI 10.1152/ajpheart.1997.272.2.H657; Sham JSK, 1998, P NATL ACAD SCI USA, V95, P15096, DOI 10.1073/pnas.95.25.15096; Shannon TR, 2000, BIOPHYS J, V78, P334, DOI 10.1016/S0006-3495(00)76596-9; SITSAPESAN R, 1994, J MEMBRANE BIOL, V137, P215; Sonnleitner A, 1998, EMBO J, V17, P2790, DOI 10.1093/emboj/17.10.2790; Takeshima H, 1998, EMBO J, V17, P3309, DOI 10.1093/emboj/17.12.3309; TAKESHIMA H, 1995, EMBO J, V14, P2999, DOI 10.1002/j.1460-2075.1995.tb07302.x; TAKESHIMA H, 1994, NATURE, V369, P556, DOI 10.1038/369556a0; Takeshima H, 1996, J BIOL CHEM, V271, P19649, DOI 10.1074/jbc.271.33.19649; TSUGORKA A, 1995, SCIENCE, V269, P1723, DOI 10.1126/science.7569901; VALDIVIA HH, 1995, SCIENCE, V267, P1997, DOI 10.1126/science.7701323; WIER WG, 1987, SCIENCE, V235, P325, DOI 10.1126/science.3798114; Yamazawa T, 1996, EMBO J, V15, P6172, DOI 10.1002/j.1460-2075.1996.tb01005.x; ZhuGe RH, 1999, J GEN PHYSIOL, V113, P215, DOI 10.1085/jgp.113.2.215	42	44	45	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 6	2001	276	14					11257	11264		10.1074/jbc.M005994200	http://dx.doi.org/10.1074/jbc.M005994200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	420AC	11150292	hybrid			2022-12-25	WOS:000167980900092
J	Napoli, A; Kvaratskelia, M; White, MF; Rossi, M; Ciaramella, M				Napoli, A; Kvaratskelia, M; White, MF; Rossi, M; Ciaramella, M			A novel member of the bacterial-archaeal regulator family is a nonspecific DNA-binding protein and induces positive supercoiling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HISTONE-LIKE PROTEIN; SULFOLOBUS-SHIBATAE; TRANSCRIPTIONAL REGULATOR; SMC PROTEINS; LRP; PURIFICATION; GENE; REPLICATION; COMPLEX; SOLFATARICUS	In hyperthermophilic Archaea genomic DNA is from relaxed to positively supercoiled in vivo because of the action of the enzyme reverse gyrase, and this peculiarity is believed to be related to stabilization of DNA against denaturation. We report the identification and characterization of Smj12, a novel protein of Sulfolobus solfataricus, which is homologous to members of the so-called Bacterial-Archaeal family of regulators, found in multiple copies in Eubacteria and Archaea. Whereas other members of the family are sequence-specific DNA-binding proteins and have been implicated in transcriptional regulation, Smj12 is a nonspecific DNA-binding protein that stabilizes the double helix and induces positive supercoiling. Smj12 is not abundant, suggesting that it is not a general architectural protein, but rather has a specialized function and/or localization. Smj12 is the first protein with the described features identified in Archaea and might participate in control of superhelicity during DNA transactions.	CNR, Inst Prot Biochem & Enzymol, I-80125 Naples, Italy; Univ St Andrews, Ctr Biomol Sci, St Andrews KY16 9ST, Fife, Scotland	Consiglio Nazionale delle Ricerche (CNR); Istituto di Biochimica delle Proteine (IBP-CNR); University of St Andrews	Ciaramella, M (corresponding author), CNR, Inst Prot Biochem & Enzymol, Via Marconi 10, I-80125 Naples, Italy.	ciaramel@dafne.ibpe.na.cnr.it	White, Malcolm F/A-6055-2010; Ciaramella, Maria/O-1152-2015	White, Malcolm F/0000-0003-1543-9342; Ciaramella, Maria/0000-0003-1583-1694				Akhmedov AT, 1998, J BIOL CHEM, V273, P24088, DOI 10.1074/jbc.273.37.24088; Azam TA, 1999, J BACTERIOL, V181, P6361, DOI 10.1128/JB.181.20.6361-6370.1999; BATES AD, 1993, DNA TOPOLOGY; BAUMANN H, 1994, NAT STRUCT BIOL, V1, P808, DOI 10.1038/nsb1194-808; Bell SD, 2000, J BIOL CHEM, V275, P31624, DOI 10.1074/jbc.M005422200; Bell SD, 1999, MOL CELL, V4, P971, DOI 10.1016/S1097-2765(00)80226-9; Bell SD, 1998, TRENDS MICROBIOL, V6, P222, DOI 10.1016/S0966-842X(98)01281-5; Bell SD, 1999, P NATL ACAD SCI USA, V96, P13662, DOI 10.1073/pnas.96.24.13662; Beloin C, 1997, MOL GEN GENET, V256, P63, DOI 10.1007/s004380050546; BERGERAT A, 1994, J BIOL CHEM, V269, P27663; Brinkman AB, 2000, J BIOL CHEM, V275, P38160, DOI 10.1074/jbc.M005916200; CALVO JM, 1994, MICROBIOL REV, V58, P466, DOI 10.1128/MMBR.58.3.466-490.1994; CHARBONNIER F, 1994, J BACTERIOL, V176, P1251, DOI 10.1128/jb.176.5.1251-1259.1994; CHOLI T, 1988, J BIOL CHEM, V263, P7087; Dennis PP, 1997, CELL, V89, P1007, DOI 10.1016/S0092-8674(00)80288-3; Enoru-Eta J, 2000, J BACTERIOL, V182, P3661, DOI 10.1128/JB.182.13.3661-3672.2000; Forterre P, 1999, MOL MICROBIOL, V32, P669, DOI 10.1046/j.1365-2958.1999.01366.x; Forterre P, 1996, FEMS MICROBIOL REV, V18, P237; GOULET I, 1987, NUCLEIC ACIDS RES, V15, P2803, DOI 10.1093/nar/15.7.2803; Grogan DW, 1998, MOL MICROBIOL, V28, P1043, DOI 10.1046/j.1365-2958.1998.00853.x; Holmes VF, 2000, P NATL ACAD SCI USA, V97, P1322, DOI 10.1073/pnas.040576797; Jessberger R, 1996, EMBO J, V15, P4061, DOI 10.1002/j.1460-2075.1996.tb00779.x; Jones KA, 2000, GENE DEV, V14, P1992; Kimura K, 1999, CELL, V98, P239, DOI 10.1016/S0092-8674(00)81018-1; Kornberg RD, 1999, CELL, V98, P285, DOI 10.1016/S0092-8674(00)81958-3; Kulms D, 1997, BIOL CHEM, V378, P545, DOI 10.1515/bchm.1997.378.6.545; Kvaratskhelia M, 2000, J BIOL CHEM, V275, P25540, DOI 10.1074/jbc.M003420200; Kvaratskhelia M, 2000, J MOL BIOL, V297, P923, DOI 10.1006/jmbi.2000.3624; Landgraf JR, 1996, J BACTERIOL, V178, P6930, DOI 10.1128/jb.178.23.6930-6936.1996; Lilley DMJ., 1995, NUCL ACIDS MOL BIOL, P84; Lopez-Delgado A, 1997, RRD MET MAT SCI, V1, P23; Lopez-Garcia P, 1999, J MOL EVOL, V49, P439, DOI 10.1007/PL00006567; Lopez-Garcia P, 1998, NUCLEIC ACIDS RES, V26, P2322, DOI 10.1093/nar/26.10.2322; Mai VQ, 1998, J BACTERIOL, V180, P2560, DOI 10.1128/JB.180.9.2560-2563.1998; Musgrave D, 2000, MOL MICROBIOL, V35, P341, DOI 10.1046/j.1365-2958.2000.01689.x; MUSGRAVE DR, 1991, P NATL ACAD SCI USA, V88, P10397, DOI 10.1073/pnas.88.23.10397; Napoli A, 1999, J BACTERIOL, V181, P1474, DOI 10.1128/JB.181.5.1474-1480.1999; Newlon CS, 1997, CELL, V91, P717, DOI 10.1016/S0092-8674(00)80459-6; Pisani FM, 1998, EXTREMOPHILES, V2, P171, DOI 10.1007/s007920050057; Pisani FM, 2000, J MOL BIOL, V301, P61, DOI 10.1006/jmbi.2000.3964; PRODROMOU C, 1992, PROTEIN ENG, V5, P827, DOI 10.1093/protein/5.8.827; REDDY TR, 1989, J BIOL CHEM, V264, P17298; Reeve JN, 1997, CELL, V89, P999, DOI 10.1016/S0092-8674(00)80286-X; Ridgway P, 2000, J CELL SCI, V113, P2647; Ritzi M, 2000, GENE, V245, P13, DOI 10.1016/S0378-1119(00)00020-2; Ronimus RS, 1996, MOL MICROBIOL, V20, P77, DOI 10.1111/j.1365-2958.1996.tb02490.x; ROUVIEREYANIV J, 1979, CELL, V17, P265, DOI 10.1016/0092-8674(79)90152-1; Sandman K, 2000, ARCH MICROBIOL, V173, P165, DOI 10.1007/s002039900122; Seitz EM, 1998, GENE DEV, V12, P1248, DOI 10.1101/gad.12.9.1248; SLESAREV AI, 1993, NATURE, V364, P735, DOI 10.1038/364735a0; Soppa J, 1999, MOL MICROBIOL, V31, P1295, DOI 10.1046/j.1365-2958.1999.01273.x; Struhl K, 1999, CELL, V98, P1, DOI 10.1016/S0092-8674(00)80599-1; Tapias A, 2000, NUCLEIC ACIDS RES, V28, P552, DOI 10.1093/nar/28.2.552; TOULME F, 1995, J BIOL CHEM, V270, P6286, DOI 10.1074/jbc.270.11.6286; TRAVERS AA, 1994, CELL, V77, P167, DOI 10.1016/0092-8674(94)90306-9; Van Komen S, 2000, MOL CELL, V6, P563, DOI 10.1016/S1097-2765(00)00055-1; Xue H, 2000, J BACTERIOL, V182, P3929, DOI 10.1128/JB.182.14.3929-3933.2000; ZIVANOVIC Y, 1988, J MOL BIOL, V200, P267, DOI 10.1016/0022-2836(88)90239-2; Zlatanova J, 1998, FASEB J, V12, P421, DOI 10.1096/fasebj.12.6.421	59	24	25	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 6	2001	276	14					10745	10752		10.1074/jbc.M010611200	http://dx.doi.org/10.1074/jbc.M010611200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	420AC	11148211	hybrid			2022-12-25	WOS:000167980900026
J	Aragones, J; Jones, DR; Martin, S; San Juan, MA; Alfranca, A; Vidal, F; Vara, A; Merida, I; Landazuri, MO				Aragones, J; Jones, DR; Martin, S; San Juan, MA; Alfranca, A; Vidal, F; Vara, A; Merida, I; Landazuri, MO			Evidence for the involvement of diacylglycerol. kinase in the activation of hypoxia-inducible transcription factor 1 by low oxygen tension	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR 1-ALPHA HIF-1-ALPHA; PHOSPHOLIPASE-D ACTIVITY; PHOSPHATIDIC-ACID; PROTEIN-KINASE; GENE-EXPRESSION; SIGNAL-TRANSDUCTION; ERYTHROPOIETIN PRODUCTION; MOLECULAR MECHANISMS; O-2 HOMEOSTASIS; ALPHA-SUBUNIT	Hypoxia-inducible factor 1 (HIF-1) induces a gene expression program essential for the cellular adaptation to lowered oxygen environments. The intracellular mechanisms by which hypoxia induces HIF-1 remain poorly understood. Here we show that exposure of various cell types to hypoxia raises the intracellular level of phosphatidic acid primarily through the action of diacylglycerol kinase (DGK), Pharmacological inhibition of DGK activity through use of the specific DGK inhibitors R59949 and R59022 abrogated specifically HIF-1-dependent transcription analyzed with a HIF-1-responsive reporter plasmid. A more detailed analysis revealed that pharmacological inhibition of DGK activity prevented the hypoxia-dependent accumulation of the HIF-1 alpha subunit and the subsequent HIF-1-DNA complex formation as well as hypoxia-induced activity of the HIF-1 transactivation domains localized to amino acids 530-582 and 775-826 of the HIF-1-alpha subunit. Our results demonstrate for the first time that accumulation of phosphatidic acid through DGK underlines oxygen sensing and provide evidence for the involvement of this lipid kinase in the intracellular signaling that leads to HIF-1 activation.	Univ Autonoma Madrid, Hosp Princesa, Serv Inmunol, Madrid 28006, Spain; CSIC, Ctr Nacl Biotecnol, Dept Inmunol & Oncol, Madrid 28049, Spain	Autonomous University of Madrid; Hospital de La Princesa; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro Nacional de Biotecnologia (CNB)	Landazuri, MO (corresponding author), Univ Autonoma Madrid, Hosp Princesa, Serv Inmunol, Diego Leon 62, Madrid 28006, Spain.	mortiz@hlpr.insalud.es	Merida, Isabel/A-9713-2014; Alfranca, Arantzazu/E-8804-2018; Sanjuán, Miguel AF/B-7709-2011	Merida, Isabel/0000-0003-2762-6241; Sanjuán, Miguel AF/0000-0003-3515-0837; Martin-Puig, Silvia/0000-0003-3048-6729; Aragones Lopez, Julian/0000-0002-0193-4679				AHMED S, 1991, BIOCHEM J, V280, P233, DOI 10.1042/bj2800233; BARTLETT GR, 1959, J BIOL CHEM, V234, P466; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Buck M, 1996, EMBO J, V15, P1753, DOI 10.1002/j.1460-2075.1996.tb00524.x; Bunn HF, 1996, PHYSIOL REV, V76, P839, DOI 10.1152/physrev.1996.76.3.839; Carmeliet P, 1998, NATURE, V394, P485, DOI 10.1038/28867; Chandel NS, 2000, J BIOL CHEM, V275, P25130, DOI 10.1074/jbc.M001914200; Chandel NS, 1998, P NATL ACAD SCI USA, V95, P11715, DOI 10.1073/pnas.95.20.11715; Conrad PW, 1999, J BIOL CHEM, V274, P23570, DOI 10.1074/jbc.274.33.23570; Cross MJ, 1996, CURR BIOL, V6, P588, DOI 10.1016/S0960-9822(02)00545-6; EDWARDS JS, 1995, BIOCHEM J, V308, P473, DOI 10.1042/bj3080473; Ema M, 1999, EMBO J, V18, P1905, DOI 10.1093/emboj/18.7.1905; Erickson RW, 1999, J BIOL CHEM, V274, P22243, DOI 10.1074/jbc.274.32.22243; Exton JH, 1997, PHYSIOL REV, V77, P303, DOI 10.1152/physrev.1997.77.2.303; Flores I, 1999, J IMMUNOL, V163, P708; Flores I, 1996, J BIOL CHEM, V271, P10334, DOI 10.1074/jbc.271.17.10334; Flores I, 1998, J IMMUNOL, V160, P3528; Forsythe JA, 1996, MOL CELL BIOL, V16, P4604; Frank C, 1999, BIOCHEMISTRY-US, V38, P11993, DOI 10.1021/bi982586w; FUKAMI K, 1992, J BIOL CHEM, V267, P10988; GASHLER A, 1995, PROG NUCLEIC ACID RE, V50, P191, DOI 10.1016/S0079-6603(08)60815-6; Gleadle JM, 1998, MOL MED TODAY, V4, P122, DOI 10.1016/S1357-4310(97)01198-2; Goldberg M, 1997, J CLIN INVEST, V99, P55, DOI 10.1172/JCI119133; Goto K, 1999, CHEM PHYS LIPIDS, V98, P109, DOI 10.1016/S0009-3084(99)00023-7; Gozal E, 1999, J NEUROCHEM, V73, P665, DOI 10.1046/j.1471-4159.1999.0730665.x; Guillemin K, 1997, CELL, V89, P9, DOI 10.1016/S0092-8674(00)80176-2; HA KS, 1993, J CELL BIOL, V123, P1789, DOI 10.1083/jcb.123.6.1789; Huang LE, 1996, J BIOL CHEM, V271, P32253, DOI 10.1074/jbc.271.50.32253; Huang LE, 1998, P NATL ACAD SCI USA, V95, P7987, DOI 10.1073/pnas.95.14.7987; HUG H, 1993, BIOCHEM J, V291, P329, DOI 10.1042/bj2910329; Iyer NV, 1998, GENE DEV, V12, P149, DOI 10.1101/gad.12.2.149; JENKINS GH, 1994, J BIOL CHEM, V269, P11547; Jiang BH, 1996, J BIOL CHEM, V271, P17771, DOI 10.1074/jbc.271.30.17771; Jiang BH, 1997, J BIOL CHEM, V272, P19253, DOI 10.1074/jbc.272.31.19253; Jiang Y, 2000, BIOCHEM PHARMACOL, V59, P763, DOI 10.1016/S0006-2952(99)00395-0; Jones DR, 1999, J BIOL CHEM, V274, P16846, DOI 10.1074/jbc.274.24.16846; Jones DR, 1998, FEBS LETT, V433, P23, DOI 10.1016/S0014-5793(98)00875-8; Kishikawa K, 1999, J BIOL CHEM, V274, P21335, DOI 10.1074/jbc.274.30.21335; LIMATOLA C, 1994, BIOCHEM J, V304, P1001, DOI 10.1042/bj3041001; LIU YX, 1995, CIRC RES, V77, P638, DOI 10.1161/01.RES.77.3.638; Luberto C, 1998, J BIOL CHEM, V273, P14550, DOI 10.1074/jbc.273.23.14550; Maltepe E, 1997, NATURE, V386, P403, DOI 10.1038/386403a0; Maxwell PH, 1997, P NATL ACAD SCI USA, V94, P8104, DOI 10.1073/pnas.94.15.8104; McPhail LC, 1999, BBA-MOL CELL BIOL L, V1439, P277, DOI 10.1016/S1388-1981(99)00100-6; Michell RH, 1997, ESSAYS BIOCHEM, V32, P31; Minet E, 2000, FEBS LETT, V468, P53, DOI 10.1016/S0014-5793(00)01181-9; MUKHOPADHYAY D, 1995, NATURE, V375, P577, DOI 10.1038/375577a0; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; OLSON EN, 1993, CELL GROWTH DIFFER, V4, P699; PLEVIN R, 1994, BRIT J PHARMACOL, V112, P311, DOI 10.1111/j.1476-5381.1994.tb13070.x; Pugh CW, 1997, J BIOL CHEM, V272, P11205; Raymond R, 1997, KIDNEY INT, V51, P536, DOI 10.1038/ki.1997.74; Richard DE, 1999, J BIOL CHEM, V274, P32631, DOI 10.1074/jbc.274.46.32631; Rizzo MA, 1999, J BIOL CHEM, V274, P1131, DOI 10.1074/jbc.274.2.1131; Ryan HE, 1998, EMBO J, V17, P3005, DOI 10.1093/emboj/17.11.3005; Sakane F, 1997, INT J BIOCHEM CELL B, V29, P1139, DOI 10.1016/S1357-2725(97)00037-X; Salceda S, 1997, J BIOL CHEM, V272, P22642, DOI 10.1074/jbc.272.36.22642; Salceda S, 1997, KIDNEY INT, V51, P556, DOI 10.1038/ki.1997.78; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Scott PH, 1998, AM J RESP CRIT CARE, V158, P958, DOI 10.1164/ajrccm.158.3.9712130; Seko Y, 1997, BIOCHEM BIOPH RES CO, V239, P840, DOI 10.1006/bbrc.1997.7570; Semenza GL, 1999, CELL, V98, P281, DOI 10.1016/S0092-8674(00)81957-1; SEMENZA GL, 1994, HEMATOL ONCOL CLIN N, V8, P863, DOI 10.1016/S0889-8588(18)30134-5; SEMENZA GL, 1994, J BIOL CHEM, V269, P23757; Semenza GL, 1998, CURR OPIN GENET DEV, V8, P588, DOI 10.1016/S0959-437X(98)80016-6; Sutter CH, 2000, P NATL ACAD SCI USA, V97, P4748, DOI 10.1073/pnas.080072497; Topham MK, 1999, J BIOL CHEM, V274, P11447, DOI 10.1074/jbc.274.17.11447; Topham MK, 1998, NATURE, V394, P697, DOI 10.1038/29337; van Blitterswijk WJ, 1999, CHEM PHYS LIPIDS, V98, P95, DOI 10.1016/S0009-3084(99)00022-5; Wakelam MJO, 1998, BBA-MOL CELL BIOL L, V1436, P117, DOI 10.1016/S0005-2760(98)00123-4; WANG GL, 1995, J BIOL CHEM, V270, P1230, DOI 10.1074/jbc.270.3.1230; WANG GL, 1995, BIOCHEM BIOPH RES CO, V216, P669, DOI 10.1006/bbrc.1995.2674; Wiesener MS, 1998, BLOOD, V92, P2260, DOI 10.1182/blood.V92.7.2260.2260_2260_2268; Yoshioka K, 1998, LIFE SCI, V63, P523, DOI 10.1016/S0024-3205(98)00303-8; Zundel W, 2000, GENE DEV, V14, P391	76	91	92	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 30	2001	276	13					10548	10555		10.1074/jbc.M006180200	http://dx.doi.org/10.1074/jbc.M006180200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	420GC	11136721	hybrid			2022-12-25	WOS:000167996400124
J	Bergum, PW; Cruikshank, A; Maki, SL; Kelly, CR; Ruf, W; Vlasuk, GP				Bergum, PW; Cruikshank, A; Maki, SL; Kelly, CR; Ruf, W; Vlasuk, GP			Role of zymogen and activated factor X as scaffolds for the inhibition of the blood coagulation factor VIIa-tissue factor complex by recombinant nematode anticoagulant protein c2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE PEPTIDE-BOND; SLOW-BINDING; RECOGNITION; HYDROLYSIS; THROMBOSIS; AFFINITY; SURFACE	Recombinant nematode anticoagulant protein c2 (rNAPc2) is a potent, factor Xa (Ma)-dependent small protein inhibitor of factor VIIa-tissue factor (fVIIa.TF), which binds to a site on fXa that is distinct from the catalytic center (exo-site), In the present study, the role of other M derivatives in presenting rNAPc2 to fVIIa.TF is investigated. Catalytically active and active site blocked fXa, as well as a plasma-derived and an activation-resistant mutant of zymogen M bound to rNAPc2 with comparable affinities (K-D = 1-10 nM), and similarly supported the inhibition of fVIIa.TF (K-i* = similar to 10 pM), The roles of phospholipid membrane composition in the inhibition of fVIIa TF by rNAPc2 were investigated using TF that was either detergent-solubilized (TFS), or reconstituted into membranes, containing phosphatidylcholine (TFPC) or a mixture of phosphatidylcholine and phosphatidylserine (TFPCPS). In the absence of the M derivative, inhibition of fVIIa TF was similar for all three conditions (K-i similar to1 muM), whereas the addition of the M derivative increased the respective inhibition by 35-, 150-, or 100,000-fold for TFS, TFPC, and TFPCPS. The removal of the gamma -carboxyglutamic acid-containing domain from the M derivative did not affect the binding to rNAPc2, but abolished the effect of factor Xa as a scaffold for the inhibition of fVIIa.TF by rNAPcQ, The overall. anticoagulant potency of rNAPc2, therefore, results from a coordinated recognition of an exo-site on fX/fXa and of the active site of fVIIa, both of which are properly positioned in the ternary fVIIa.TF.M(a) complex assembled on an appropriate phospholipid surface.	Corvas Int Inc, Epping, NSW 2121, Australia; Scripps Res Inst, Dept Immunol, La Jolla, CA 92037 USA	Scripps Research Institute	Bergum, PW (corresponding author), Corvas Int Inc, 3030 Sci Pk Rd, Epping, NSW 2121, Australia.	peter_bergum@corvas.com						ARDELT W, 1991, J MOL BIOL, V220, P1041, DOI 10.1016/0022-2836(91)90370-L; Baugh RJ, 2000, J BIOL CHEM, V275, P28826, DOI 10.1074/jbc.M005266200; Baugh RJ, 1998, J BIOL CHEM, V273, P4378, DOI 10.1074/jbc.273.8.4378; BOCK PE, 1989, ARCH BIOCHEM BIOPHYS, V273, P375, DOI 10.1016/0003-9861(89)90496-7; BODE W, 1989, EMBO J, V8, P3467, DOI 10.1002/j.1460-2075.1989.tb08511.x; BODE W, 1978, J MOL BIOL, V118, P99, DOI 10.1016/0022-2836(78)90246-2; BODE W, 1991, BIOMED BIOCHIM ACTA, V50, P437; BROZE GJ, 1995, ANNU REV MED, V46, P103, DOI 10.1146/annurev.med.46.1.103; CHA S, 1975, BIOCHEM PHARMACOL, V24, P2177, DOI 10.1016/0006-2952(75)90050-7; DISCIPIO RG, 1977, BIOCHEMISTRY-US, V16, P5253, DOI 10.1021/bi00643a015; DUNWIDDIE CT, 1992, ARCH BIOCHEM BIOPHYS, V294, P647, DOI 10.1016/0003-9861(92)90737-H; GIRARD TJ, 1989, NATURE, V338, P518, DOI 10.1038/338518a0; GIRARD TJ, 1990, SCIENCE, V248, P1421, DOI 10.1126/science.1972598; HAKANSSON K, 1995, BIOORGAN MED CHEM, V3, P1009, DOI 10.1016/0968-0896(95)00096-Y; Hirsh J, 1999, SEMIN HEMATOL, V36, P118; HUBER R, 1978, ACCOUNTS CHEM RES, V11, P114, DOI 10.1021/ar50123a006; JACKSON CM, 1984, PROG HEMOST THROMB, V7, P55; Jenny NS, 1998, THROMBOSIS HEMORRHAG, P3; Kelly CR, 1997, J BIOL CHEM, V272, P17467, DOI 10.1074/jbc.272.28.17467; KRISHNASWAMY S, 1992, J BIOL CHEM, V267, P26110; KRISHNASWAMY S, 1994, BIOCHEMISTRY-US, V33, P7897, DOI 10.1021/bi00191a017; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LASKOWSKI M, 1980, ANNU REV BIOCHEM, V49, P593, DOI 10.1146/annurev.bi.49.070180.003113; Lee A, 2000, BLOOD, V96, p491A; Mann KG, 1999, THROMB HAEMOSTASIS, V82, P165; MANN KG, 1992, SEMIN HEMATOL, V29, P213; Martin DMA, 1998, THROMB RES, V90, P1, DOI 10.1016/S0049-3848(98)00015-2; MORRISON JF, 1988, ADV ENZYMOL RAMB, V61, P201; MORRISON JF, 1982, TRENDS BIOCHEM SCI, V7, P102, DOI 10.1016/0968-0004(82)90157-8; MORRISON JF, 1969, BIOCHIM BIOPHYS ACTA, V185, P269, DOI 10.1016/0005-2744(69)90420-3; RAPAPORT SI, 1992, ARTERIOSCLER THROMB, V12, P1111, DOI 10.1161/01.ATV.12.10.1111; RUF W, 1994, BIOCHEMISTRY-US, V33, P11631, DOI 10.1021/bi00204a026; RUF W, 1992, J BIOL CHEM, V267, P6375; Ruf W, 1999, BIOCHEMISTRY-US, V38, P1957, DOI 10.1021/bi982254r; RUF W, 1993, METHOD ENZYMOL, V222, P209; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X; Shobe J, 1999, J BIOL CHEM, V274, P24171, DOI 10.1074/jbc.274.34.24171; Stanssens P, 1996, P NATL ACAD SCI USA, V93, P2149, DOI 10.1073/pnas.93.5.2149; Vlasuk GP, 1998, BLOOD, V92, p361A; Wei AZ, 1998, J MOL BIOL, V283, P147, DOI 10.1006/jmbi.1998.2069; Williams J W, 1979, Methods Enzymol, V63, P437	41	78	89	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 30	2001	276	13					10063	10071		10.1074/jbc.M009116200	http://dx.doi.org/10.1074/jbc.M009116200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	420GC	11139576	hybrid			2022-12-25	WOS:000167996400066
J	Mechaly, A; Fierobe, HP; Belaich, A; Belaich, JP; Lamed, R; Shoham, Y; Bayer, EA				Mechaly, A; Fierobe, HP; Belaich, A; Belaich, JP; Lamed, R; Shoham, Y; Bayer, EA			Cohesin-dockerin interaction in cellulosome assembly - A single hydroxyl group of a dockerin domain distinguishes between nonrecognition and high affinity recognition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; CLOSTRIDIUM-THERMOCELLUM CELLULOSOME; PROTEIN SECONDARY STRUCTURE; SCAFFOLDING PROTEIN; DUPLICATED SEGMENT; CRYSTAL-STRUCTURE; NEURAL NETWORKS; CELLULOLYTICUM; CELLULASES; BINDING	The assembly of enzyme components into the cellulosome complex is dictated by the cohesin-dockerin interaction. In a recent article (Mechaly, A, Yaron, S,, Lamed, R., Fierobe, H.-P., Belaich, A., Belaich, J.-P., Shoham, Y., and Bayer, E. A. (2000) Proteins 39, 170-177), we provided experimental evidence that four previously predicted dockerin residues play a decisive role in the specificity of this high affinity interaction, although additional residues were also implicated. In the present communication, we examine further the contributing factors for the recognition of a dockerin by a cohesin domain between the respective cellulosomal systems of Clostridium thermocellum and Clostridium cellulolyticum, In this context, the four confirmed residues were analyzed for their individual effect on selectivity, In addition, other dockerin residues were discerned that could conceivably contribute to the interaction, and the suspected residues were similarly modified by site-directed mutagenesis, The results indicate that mutation of a single residue from threonine to leucine at a given position of the C. thermocellum dockerin differentiates between its nonrecognition and high affinity recognition (K-a similar to 10(9) M-1) by a cohesin from C. cellulolyticum, This suggests that the presence or absence of a single decisive hydroxyl group is critical to the observed biorecognition, This study further implicates additional residues as secondary determinants in the specificity of interaction, because interconversion of selected residues reduced intraspecies self-recognition by at least three orders of magnitude. Nevertheless, as the latter mutageneses served to reduce but not annul the cohesin-dockerin interaction within this species, it follows that other subtle alterations play a comparatively minor role in the recognition between these two modules.	Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel; CNRS, IBSM, IFR1, F-13402 Marseille, France; Univ Aix Marseille 1, F-13331 Marseille, France; Tel Aviv Univ, Dept Mol Microbiol & Biotechnol, IL-69978 Tel Aviv, Israel; Technion Israel Inst Technol, Dept Food Engn & Biotechnol, IL-32000 Haifa, Israel; Technion Israel Inst Technol, Inst Catalysis Sci & Technol, IL-32000 Haifa, Israel	Weizmann Institute of Science; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Aix-Marseille Universite; Tel Aviv University; Technion Israel Institute of Technology; Technion Israel Institute of Technology	Bayer, EA (corresponding author), Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel.		FIEROBE, Henri-Pierre/P-4372-2019; Shoham, Yuval/M-4409-2013					Ausubel F.M., 1992, SHORT PROTOCOLS MOL; Bayer EA, 1998, J STRUCT BIOL, V124, P221, DOI 10.1006/jsbi.1998.4065; BAYER EA, 1990, METHOD ENZYMOL, V184, P138; Bayer EA, 1998, CURR OPIN STRUC BIOL, V8, P548, DOI 10.1016/S0959-440X(98)80143-7; BAYER EA, 1998, CARBOHYDRASES TRICHO, P39; Beguin P, 1996, CRIT REV BIOCHEM MOL, V31, P201, DOI 10.3109/10409239609106584; Belaich JP, 1997, J BIOTECHNOL, V57, P3, DOI 10.1016/S0168-1656(97)00085-0; CHAUVAUX S, 1990, BIOCHEM J, V265, P261, DOI 10.1042/bj2650261; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; Ding SY, 2000, J BACTERIOL, V182, P4915, DOI 10.1128/JB.182.17.4915-4925.2000; Ding SY, 1999, J BACTERIOL, V181, P6720, DOI 10.1128/JB.181.21.6720-6729.1999; DOI RH, 1994, CRIT REV MICROBIOL, V20, P87, DOI 10.3109/10408419409113548; FANUTTI C, 1995, J BIOL CHEM, V270, P29314, DOI 10.1074/jbc.270.49.29314; FELIX CR, 1993, ANNU REV MICROBIOL, V47, P791, DOI 10.1146/annurev.micro.47.1.791; Fierobe HP, 1999, BIOCHEMISTRY-US, V38, P12822, DOI 10.1021/bi9911740; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; LAMED R, 1988, ADV APPL MICROBIOL, V33, P1, DOI 10.1016/S0065-2164(08)70203-X; LAMED R, 1983, J BACTERIOL, V156, P828, DOI 10.1128/JB.156.2.828-836.1983; Lamed R, 1983, BIOTECHNOL BIOENG S, V13, P163; Li XL, 1997, APPL ENVIRON MICROB, V63, P4721, DOI 10.1128/AEM.63.12.4721-4728.1997; Lytle B, 1996, J BACTERIOL, V178, P1200, DOI 10.1128/jb.178.4.1200-1203.1996; Lytle B, 1998, J BACTERIOL, V180, P6581, DOI 10.1128/JB.180.24.6581-6585.1998; Lytle BL, 2000, ARCH BIOCHEM BIOPHYS, V379, P237, DOI 10.1006/abbi.2000.1882; Mechaly A, 2000, PROTEINS, V39, P170, DOI 10.1002/(SICI)1097-0134(20000501)39:2<170::AID-PROT7>3.0.CO;2-H; Meza R, 1996, FEMS MICROBIOL LETT, V145, P333, DOI 10.1111/j.1574-6968.1996.tb08597.x; Pages S, 1997, PROTEINS, V29, P517, DOI 10.1002/(SICI)1097-0134(199712)29:4<517::AID-PROT11>3.3.CO;2-I; Pages S, 1996, J BACTERIOL, V178, P2279, DOI 10.1128/jb.178.8.2279-2286.1996; ROST B, 1994, PROTEINS, V19, P55, DOI 10.1002/prot.340190108; ROST B, 1993, J MOL BIOL, V232, P584, DOI 10.1006/jmbi.1993.1413; Rost B, 1996, METHOD ENZYMOL, V266, P525; Sambrook J., 2002, MOL CLONING LAB MANU; Shimon LJW, 1997, STRUCTURE, V5, P381, DOI 10.1016/S0969-2126(97)00195-0; Shoham Y, 1999, TRENDS MICROBIOL, V7, P275, DOI 10.1016/S0966-842X(99)01533-4; Tavares GA, 1997, J MOL BIOL, V273, P701, DOI 10.1006/jmbi.1997.1326; TOKATLIDIS K, 1991, FEBS LETT, V291, P185, DOI 10.1016/0014-5793(91)81279-H; TOKATLIDIS K, 1993, PROTEIN ENG, V6, P947, DOI 10.1093/protein/6.8.947; Wilchek M, 1999, BIOMOL ENG, V16, P1; Wu J. H. D., 1988, Biochemistry and genetics of cellulose degradation, P117; WU JHD, 1988, BIOCHEMISTRY-US, V27, P1703, DOI 10.1021/bi00405a048; YARON S, 1995, FEBS LETT, V360, P121, DOI 10.1016/0014-5793(95)00074-J	40	85	87	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 30	2001	276	13					9883	9888		10.1074/jbc.M009237200	http://dx.doi.org/10.1074/jbc.M009237200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	420GC	11148206	hybrid			2022-12-25	WOS:000167996400042
J	Koyabu, Y; Nakata, K; Mizugishi, K; Aruga, J; Mikoshiba, K				Koyabu, Y; Nakata, K; Mizugishi, K; Aruga, J; Mikoshiba, K			Physical and functional interactions between Zic and Gli proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE CUBITUS-INTERRUPTUS; NEURAL CREST DEVELOPMENT; SONIC HEDGEHOG; FLOOR PLATE; MOUSE ZIC1; IN-VITRO; DROSOPHILA; EXPRESSION; ACTIVATION; FAMILY	Zic and Gli family proteins are transcription factors that share similar zinc finger domains. Recent studies indicate that Zic and Gli collaborate in neural and skeletal development. We provide evidence that the Zic and Gli proteins physically and functionally interact through their zinc finger domains. Moreover, Gli proteins were translocated to cell nuclei by coexpressed Zic proteins, and both proteins regulated each other's transcriptional activity. Our result suggests that the physical interaction between Zic and Gli is the molecular basis of their antagonistic or synergistic features in developmental contexts and that Zic proteins are potential modulators of the hedgehog-mediated signaling pathway.	RIKEN, Brain Sci Inst, Dev Neurobiol Lab, Wako, Saitama 3510198, Japan; Univ Tokyo, Inst Med Sci, Dept Basic Med Sci, Div Mol Neurobiol,Minato Ku, Tokyo 1088639, Japan	RIKEN; University of Tokyo	Aruga, J (corresponding author), RIKEN, Brain Sci Inst, Dev Neurobiol Lab, 2-1 Hirosawa, Wako, Saitama 3510198, Japan.		Mikoshiba, Katsuhiko/N-7943-2015; Aruga, Jun/H-5837-2011	Aruga, Jun/0000-0001-7936-1375				Alexandre C, 1996, GENE DEV, V10, P2003, DOI 10.1101/gad.10.16.2003; Altaba ARI, 1999, TRENDS GENET, V15, P418, DOI 10.1016/S0168-9525(99)01840-5; Aruga J, 1999, MECH DEVELOP, V89, P141, DOI 10.1016/S0925-4773(99)00220-8; Aruga J, 1998, J NEUROSCI, V18, P284; ARUGA J, 1994, J NEUROCHEM, V63, P1880; Aruga J, 1996, J BIOL CHEM, V271, P1043, DOI 10.1074/jbc.271.2.1043; BENEDYK MJ, 1994, GENE DEV, V8, P105, DOI 10.1101/gad.8.1.105; Brewster R, 1998, NATURE, V393, P579, DOI 10.1038/31242; Brown SA, 1998, NAT GENET, V20, P180, DOI 10.1038/2484; Dai P, 1999, J BIOL CHEM, V274, P8143, DOI 10.1074/jbc.274.12.8143; Ding Q, 1999, CURR BIOL, V9, P1119, DOI 10.1016/S0960-9822(99)80482-5; Gebbia M, 1997, NAT GENET, V17, P305, DOI 10.1038/ng1197-305; HUI CC, 1994, DEV BIOL, V162, P402, DOI 10.1006/dbio.1994.1097; HUI CC, 1993, NAT GENET, V3, P241, DOI 10.1038/ng0393-241; KINZLER KW, 1990, MOL CELL BIOL, V10, P634, DOI 10.1128/MCB.10.2.634; KINZLER KW, 1987, SCIENCE, V236, P70, DOI 10.1126/science.3563490; Kogerman P, 1999, NAT CELL BIOL, V1, P312, DOI 10.1038/13031; Lee J, 1997, DEVELOPMENT, V124, P2537; Marigo V, 1996, DEV BIOL, V180, P273, DOI 10.1006/dbio.1996.0300; Matise MP, 1998, DEVELOPMENT, V125, P2759; Mizugishi K, 2001, J BIOL CHEM, V276, P2180, DOI 10.1074/jbc.M004430200; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; Mo R, 1997, DEVELOPMENT, V124, P113; Nagai T, 2000, P NATL ACAD SCI USA, V97, P1618, DOI 10.1073/pnas.97.4.1618; Nagai T, 1997, DEV BIOL, V182, P299, DOI 10.1006/dbio.1996.8449; NAKAFUKU M, 1995, J NEUROSCI RES, V41, P153, DOI 10.1002/jnr.490410203; Nakagawa Y, 1996, DEVELOPMENT, V122, P2449; Nakata K, 1998, MECH DEVELOP, V75, P43, DOI 10.1016/S0925-4773(98)00073-2; Nakata K, 1997, P NATL ACAD SCI USA, V94, P11980, DOI 10.1073/pnas.94.22.11980; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; ORENIC TV, 1990, GENE DEV, V4, P1053, DOI 10.1101/gad.4.6.1053; Park HL, 2000, DEVELOPMENT, V127, P1593; Sasaki H, 1997, DEVELOPMENT, V124, P1313; VORTKAMP A, 1991, NATURE, V352, P539, DOI 10.1038/352539a0; Wang BL, 2000, CELL, V100, P423, DOI 10.1016/S0092-8674(00)80678-9	35	154	163	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 9	2001	276	10					6889	6892		10.1074/jbc.C000773200	http://dx.doi.org/10.1074/jbc.C000773200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	410MC	11238441	hybrid			2022-12-25	WOS:000167442900003
J	Nauenburg, S; Zwerschke, W; Jansen-Durr, P				Nauenburg, S; Zwerschke, W; Jansen-Durr, P			Induction of apoptosis in cervical carcinoma cells by peptide aptamers that bind to the HPV-16 E7 oncoprotein	FASEB JOURNAL			English	Article									Tiroler Krebsforschungsins, A-6020 Innsbruck, Austria; Austrian Acad Sci, Inst Biomed Alternsforsch, A-6020 Innsbruck, Austria; Deutsch Krebsforschungszentrum, Forschungsschewerpunket Angew Tumorvirol, D-69120 Heidelberg, Germany	Austrian Academy of Sciences; Helmholtz Association; German Cancer Research Center (DKFZ)	Zwerschke, W (corresponding author), Tiroler Krebsforschungsins, Innrain 66, A-6020 Innsbruck, Austria.		Jansen-Dürr, Pidder/ABG-2466-2020	Jansen-Dürr, Pidder/0000-0001-7771-3429; Zwerschke, Werner/0000-0003-1137-2953					0	39	45	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAR	2001	15	3					592	594						3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	410BE	11259377				2022-12-25	WOS:000167419500015
J	Misasi, R; Sorice, M; Di Marzio, L; Campana, WM; Molinari, S; Cifone, MG; Pavan, A; Pontieri, GM; O'Brien, JS				Misasi, R; Sorice, M; Di Marzio, L; Campana, WM; Molinari, S; Cifone, MG; Pavan, A; Pontieri, GM; O'Brien, JS			Prosaposin treatment induces PC12 entry in the S phase of the cell cycle and prevents apoptosis: activation of ERKs and sphingosine kinase	FASEB JOURNAL			English	Article						signal-regulated protein kinase; BrdU; S-1-P; PC12 cells	NERVE GROWTH-FACTOR; PROTEIN-DEPENDENT MECHANISM; SIGNAL-TRANSDUCTION; SCHWANN-CELLS; NEUROTROPHIC FACTOR; IN-VIVO; PROSAPTIDE; CERAMIDE; PATHWAY; SPHINGOSINE-1-PHOSPHATE	We report that prosaposin treatment induced extracellular signal-regulated kinases (ERKs) and sphingosine kinase activity, increased DNA synthesis, and prevented cell apoptosis. Prosaposin treatment induced pheochromocytoma cells (PC12) to enter the S phase of the cell cycle; this effect was inhibited by the MEK inhibitor PD98059, indicating that prosaposin-induced ERK phosphorylation is required for stimulation of DNA synthesis. The prosaposin effect was also inhibited by pertussis toxin, indicating that the prosaposin receptor is a G-protein-coupled receptor. Prosaposin rescued PC12 cells from apoptosis induced by staurosporine or ceramide. Sphingosine kinase activity was increased by prosaposin treatment. We propose that this effect is a mechanism underlying the proliferative and anti-apoptotic functions of prosaposin. Prosaposin appears to be a key regulatory factor in the ceramide-S-l-P rheostat, which regulates cell fate.	Univ Rome La Sapienza, Dipartimento Med Sperimentale & Patol, Policlin Umberto I, I-00161 Rome, Italy; Univ LAquila, Dipartimento Med Sperimentale, Laquila, Italy; Univ Calif San Diego, Dept Neurosci, Sch Med, Ctr Mol Genet, La Jolla, CA 92093 USA	Sapienza University Rome; University Hospital Sapienza Rome; University of L'Aquila; University of California System; University of California San Diego	Misasi, R (corresponding author), Univ Rome La Sapienza, Dipartimento Med Sperimentale & Patol, Policlin Umberto I, Viale Regina Elena 324, I-00161 Rome, Italy.		Sousa, Maria/HCI-9642-2022; Cifone, Maria Grazia/ABH-1984-2021; Di Marzio, Luisa/H-9969-2012; Di Marzio, Luisa/AAF-8052-2021; Sorice, Maurizio/Q-5079-2019; Cifone, Maria Grazia/I-3750-2019	Di Marzio, Luisa/0000-0002-2518-7188; Cifone, Maria Grazia/0000-0002-9923-5445; Sorice, Maurizio/0000-0003-3534-1502				ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; AZUMA N, 1994, ARCH BIOCHEM BIOPHYS, V311, P354, DOI 10.1006/abbi.1994.1248; BUEHRER BM, 1992, J BIOL CHEM, V267, P3154; Campana WM, 1999, J NEUROSCI RES, V57, P332; Campana WM, 1996, BIOCHEM BIOPH RES CO, V229, P706, DOI 10.1006/bbrc.1996.1869; Campana WM, 1998, FASEB J, V12, P307, DOI 10.1096/fasebj.12.3.307; Campana WM, 1998, NEUROTOXICOLOGY, V19, P237; CHAO MV, 1992, CELL, V68, P995, DOI 10.1016/0092-8674(92)90068-N; COLIGAN JE, 1990, CURRENT PROTOCOLS IM, V2; CONNOLLY JL, 1979, J CELL BIOL, V82, P820, DOI 10.1083/jcb.82.3.820; Cuvillier O, 1996, NATURE, V381, P800, DOI 10.1038/381800a0; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; FU Q, 1994, J MOL NEUROSCI, V5, P59, DOI 10.1007/BF02736694; GAVRIELI Y, 1992, J CELL BIOL, V119, P494; GREENE L, 1976, P NATL ACAD SCI USA, V3, P2424; GREENE LA, 1995, CURR OPIN NEUROBIOL, V5, P579, DOI 10.1016/0959-4388(95)80062-X; Hartfield PJ, 1997, FEBS LETT, V401, P148, DOI 10.1016/S0014-5793(96)01460-3; HINENO T, 1991, BIOCHEM BIOPH RES CO, V176, P668, DOI 10.1016/S0006-291X(05)80236-0; HIRAIWA M, 1993, ARCH BIOCHEM BIOPHYS, V304, P110, DOI 10.1006/abbi.1993.1328; Hiraiwa M, 1997, P NATL ACAD SCI USA, V94, P4778, DOI 10.1073/pnas.94.9.4778; Hiraiwa M, 1997, BIOCHEM BIOPH RES CO, V240, P415, DOI 10.1006/bbrc.1997.7673; Kaplan DR, 1997, CURR OPIN CELL BIOL, V9, P213, DOI 10.1016/S0955-0674(97)80065-8; KISHIMOTO Y, 1992, J LIPID RES, V33, P1255; Kotani Y, 1996, J NEUROCHEM, V66, P2019; Kruman I, 1998, J NEUROSCI RES, V51, P293, DOI 10.1002/(SICI)1097-4547(19980201)51:3<293::AID-JNR3>3.0.CO;2-B; LINDENBOIM L, 1995, CANCER RES, V55, P1242; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; OBRIEN JS, 1995, FASEB J, V9, P681, DOI 10.1096/fasebj.9.8.7768361; OBRIEN JS, 1994, P NATL ACAD SCI USA, V91, P9593, DOI 10.1073/pnas.91.20.9593; OBRIEN JS, 1991, FASEB J, V5, P301, DOI 10.1096/fasebj.5.3.2001789; Olivera A, 1999, J CELL BIOL, V147, P545, DOI 10.1083/jcb.147.3.545; PAGES G, 1993, P NATL ACAD SCI USA, V90, P8319, DOI 10.1073/pnas.90.18.8319; PUSHKAREVA M, 1995, IMMUNOL TODAY, V16, P294, DOI 10.1016/0167-5699(95)80184-7; Qi XY, 1996, J BIOL CHEM, V271, P6874, DOI 10.1074/jbc.271.12.6874; RIBONI L, 1995, J BIOL CHEM, V270, P26868, DOI 10.1074/jbc.270.45.26868; SANO A, 1994, BIOCHEM BIOPH RES CO, V204, P994, DOI 10.1006/bbrc.1994.2558; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; Spiegel S, 1996, FASEB J, V10, P1388, DOI 10.1096/fasebj.10.12.8903509; Spiegel S, 1999, J LEUKOCYTE BIOL, V65, P341, DOI 10.1002/jlb.65.3.341; SUGITA M, 1975, BIOCHIM BIOPHYS ACTA, V398, P125, DOI 10.1016/0005-2760(75)90176-9; TRAVERSE S, 1992, BIOCHEM J, V288, P351, DOI 10.1042/bj2880351; Tsuboi K, 1998, DEV BRAIN RES, V110, P249, DOI 10.1016/S0165-3806(98)00109-6; vanEchtenDeckert G, 1997, J BIOL CHEM, V272, P15825, DOI 10.1074/jbc.272.25.15825; vanGrunsven LA, 1996, ONCOGENE, V12, P855; WU J, 1995, J BIOL CHEM, V270, P11484, DOI 10.1074/jbc.270.19.11484; Xia P, 1998, P NATL ACAD SCI USA, V95, P14196, DOI 10.1073/pnas.95.24.14196; Yan LZ, 2000, NEUROSCI LETT, V278, P120, DOI 10.1016/S0304-3940(99)00902-7; YOUNG IT, 1977, J HISTOCHEM CYTOCHEM, V25, P935, DOI 10.1177/25.7.894009; ZHANG H, 1991, J CELL BIOL, V114, P155, DOI 10.1083/jcb.114.1.155	49	46	51	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	FEB	2001	15	2					467	474		10.1096/fj.00-0217com	http://dx.doi.org/10.1096/fj.00-0217com			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	400LK	11156962				2022-12-25	WOS:000166872900028
J	Scherpereel, A; Wiewrodt, R; Christofidou-Solomidou, M; Gervais, R; Murciano, JC; Albelda, SM; Muzykantov, VR				Scherpereel, A; Wiewrodt, R; Christofidou-Solomidou, M; Gervais, R; Murciano, JC; Albelda, SM; Muzykantov, VR			Cell-selective intracellular delivery of a foreign enzyme to endothelium in vivo using vascular immunotargeting	FASEB JOURNAL			English	Article						drug targeting; lung; PECAM-1; beta-galactosidase; streptavidin	HUMAN PECAM-1 CD31; ADHESION MOLECULE-1; MONOCLONAL-ANTIBODY; TRANSDUCTION; PROTEINS; STRATEGY; LUNGS	Vascular immunotargeting, the administration of drugs conjugated with antibodies to endothelial surface antigens, has the potential for drug delivery to the endothelium. Our previous cell culture studies showed that biotinylated antibodies to PECAM-1 (a highly expressed endothelial surface antigen) coupled with streptavidin (SA, a cross-linking protein that facilitates anti-PECAM internalization and targeting) may provide a carrier for the intracellular delivery of therapeutic enzymes. This paper describes the PECAM-directed vascular immunotargeting of a reporter enzyme (beta -galactosidase, beta -Gal) in intact animals. Intravenous injection of [(125)I]SA-beta -Gal conjugated with either anti-PECAM or IgG led to a high (125)I uptake in liver and spleen, yet beta -Gal activity in these organs rapidly declined to the background levels, suggesting rapid degradation of the conjugates. In contrast, anti-PECAM/[(125)I]SA-B-Gal, but not IgG/[(125)I]SA-beta -Gal, accumulated in the lungs (36.0+/-1.3 vs. 3.9+/-0.6% injected dose/g) and induced a marked elevation of beta -Gal activity in the lung tissue persisting for up to 8 h after injection (10-fold elevation 4 h postinjection). Using histochemical detection, the beta -Gal activity in the lungs was detected in the endothelial cells of capillaries and large vessels. The anti-PECAM carrier also provided (125)I uptake and beta -Gal activity in the renal glomeruli. Predominant intracellular localization of anti-PECAM/SA-beta -Gal was documented in the PECAM-expressing cells in culture by confocal microscopy and in the pulmonary endothelium by electron microscopy. Therefore, vascular immunotargeting is a feasible strategy for cell-selective, intracellular delivery of an active foreign enzyme to endothelial cells in vivo, and thus may be potentially useful for the treatment of acute pulmonary or vascular diseases.	Univ Penn, Med Ctr, Inst Environm Med, Philadelphia, PA 19104 USA; Univ Penn, Med Ctr, Dept Med, Pulm Allergy & Crit Care Div, Philadelphia, PA 19104 USA; Univ Penn, Med Ctr, Dept Pharmacol, Philadelphia, PA 19104 USA	University of Pennsylvania; University of Pennsylvania; University of Pennsylvania	Muzykantov, VR (corresponding author), Univ Penn, Med Ctr, Inst Environm Med, 1 John Morgan Bldg,36th St & Hamilton Walk, Philadelphia, PA 19104 USA.	muzykant@mail.med.upenn.edu	Murciano, Juan Carlos/AAG-6253-2021	Murciano, Juan Carlos/0000-0002-4894-046X	NHLBI NIH HHS [HL 60290] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL060290] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Atochina EN, 1998, AM J PHYSIOL-LUNG C, V275, pL806, DOI 10.1152/ajplung.1998.275.4.L806; Christofidou-Solomidou M, 2000, AM J PHYSIOL-LUNG C, V278, pL794, DOI 10.1152/ajplung.2000.278.4.L794; DANILOV SM, 1991, LAB INVEST, V64, P118; FAWELL S, 1994, P NATL ACAD SCI USA, V91, P664, DOI 10.1073/pnas.91.2.664; GOW A, 2000, AM J PHYSIOL, V277, pL271; Gurubhagavatula I, 1998, J CLIN INVEST, V101, P212, DOI 10.1172/JCI269; KUCHARCZUK JC, 1995, ANN THORAC SURG, V60, P593, DOI 10.1016/0003-4975(95)00507-H; Liu XY, 1996, P NATL ACAD SCI USA, V93, P11819, DOI 10.1073/pnas.93.21.11819; MARUYAMA K, 1990, P NATL ACAD SCI USA, V87, P5744, DOI 10.1073/pnas.87.15.5744; Muzykantov VR, 1999, P NATL ACAD SCI USA, V96, P2379, DOI 10.1073/pnas.96.5.2379; Muzykantov VR, 1996, P NATL ACAD SCI USA, V93, P5213, DOI 10.1073/pnas.93.11.5213; Muzykantov VR, 1998, PATHOPHYSIOLOGY, V5, P15; Nagahara H, 1998, NAT MED, V4, P1449, DOI 10.1038/4042; Newman PJ, 1997, J CLIN INVEST, V99, P3, DOI 10.1172/JCI119129; Schwarze SR, 1999, SCIENCE, V285, P1569, DOI 10.1126/science.285.5433.1569; Spragg DD, 1997, P NATL ACAD SCI USA, V94, P8795, DOI 10.1073/pnas.94.16.8795; VAPORCIYAN AA, 1993, SCIENCE, V262, P1580, DOI 10.1126/science.8248808; Wiewredt R, 1999, AM J RESP CRIT CARE, V159, pA347; YAN HC, 1995, CELL ADHES COMMUN, V3, P45, DOI 10.3109/15419069509081277	19	49	49	1	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	FEB	2001	15	2					416	426		10.1096/fj.00-0022com	http://dx.doi.org/10.1096/fj.00-0022com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	400LK	11156957				2022-12-25	WOS:000166872900023
J	Zhou, ZHL; Han, YL; Wei, T; Aras, S; Chaturvedi, P; Tyler, S; Rani, MRS; Ransohoff, RM				Zhou, ZHL; Han, YL; Wei, T; Aras, S; Chaturvedi, P; Tyler, S; Rani, MRS; Ransohoff, RM			Regulation of monocyte chemoattractant protein (MCP)-1 transcription by interferon-gamma (IFN-gamma) in human astrocytoma cells: postinduction refractory state of the gene, governed by its upstream elements	FASEB JOURNAL			English	Article						chemokine; gene expression; interferons; STAT factors; Sp1 transcriptions factor	MULTIPLE-SCLEROSIS LESIONS; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; IN-SITU HYBRIDIZATION; MESSENGER-RNA; GROWTH-FACTOR; JE GENE; EXPRESSION; INDUCTION; CHEMOKINES; MCP-1	Monocyte chemoattractant protein (MCP)-1 is expressed by astrocytes in diverse inflammatory states and is a key regulator of monocyte recruitment to the central nervous system (CNS). In the current study, we addressed mechanisms by which transcription of the human MCP-I. gene (hMCP-1) was terminated, after induction by interferon (IFN)-gamma. Our results demonstrated that IFN-gamma -induced transcription of hMCP-1 was followed by a refractory state, during which hMCP-1 was resistant to restimulation by either IFN-gamma or heterologous activators such as TNF-alpha. This refractory state affected the hMCP-1 gene selectively, as other IFN-gamma -inducible genes remained responsive to restimulation. The IFN-gamma -induced hMCP-1 refractory state was governed at the transcriptional level and was sensitive to protein synthesis inhibitors, suggesting a requirement for newly expressed components, A minimal 213 base pair hMCP-1 regulatory element directed both IFN-gamma -mediated transcription and the subsequent refractory state, We previously demonstrated that IFN-gamma treatment resulted in coordinate protein occupancy in vivo of two hMCP-1 promoter elements, a gamma-activated site (GAS) and a GC-rich element. During the refractory state, IFN-gamma treatment failed to induce protection of either the hMCP-1 GAS element or the GC box. These results furnish insight into the expression of hMCP-1 during CNS inflammation and provide the first delineation of an IFN-gamma -induced transcriptional refractory state.-Zhou, Z.-H. L., Han, Y., Wei, T., Aras, S., Chaturvedi, P., Tyler, S., Rani, M. R. S., Ransohoff, R. M. Regulation of monocyte chemoattractant protein (MCP)-1 transcription by interferon-gamma (IFN-gamma) in human astrocytoma cells: postinduction refractory state of the gene, governed by its upstream elements.	Cleveland Clin Fdn, Dept Neurosci, Lerner Res Inst, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Mellen Ctr Multiple Sclerosis Treatment & Res, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Dept Neurol, Cleveland, OH 44195 USA	Cleveland Clinic Foundation; Cleveland Clinic Foundation; Cleveland Clinic Foundation	Ransohoff, RM (corresponding author), Cleveland Clin Fdn, Dept Neurosci, Lerner Res Inst, 9500 Euclid Ave,NC30, Cleveland, OH 44195 USA.		Aras, Sumer/ABG-1206-2021		NCI NIH HHS [2PO1-CA62220] Funding Source: Medline; NINDS NIH HHS [2RO1-NS32151] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA062220] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS032151] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BARNA BP, 1989, J NEUROIMMUNOL, V23, P45, DOI 10.1016/0165-5728(89)90072-6; COCHRAN BH, 1983, CELL, V33, P939, DOI 10.1016/0092-8674(83)90037-5; Conant K, 1998, P NATL ACAD SCI USA, V95, P3117, DOI 10.1073/pnas.95.6.3117; FRETER RR, 1992, MOL CELL BIOL, V12, P5288, DOI 10.1128/MCB.12.12.5288; FRIEDMAN RL, 1984, CELL, V38, P745, DOI 10.1016/0092-8674(84)90270-8; Glabinski AR, 1996, J IMMUNOL, V156, P4363; GOODBOURN S, 1988, P NATL ACAD SCI USA, V85, P1447, DOI 10.1073/pnas.85.5.1447; Gosling J, 1999, J CLIN INVEST, V103, P773, DOI 10.1172/JCI5624; Gourmala NG, 1997, J NEUROIMMUNOL, V74, P35, DOI 10.1016/S0165-5728(96)00203-2; Gu L, 2000, NATURE, V404, P407, DOI 10.1038/35006097; Gu L, 1997, J LEUKOCYTE BIOL, V62, P577, DOI 10.1002/jlb.62.5.577; Gu L, 1998, MOL CELL, V2, P275, DOI 10.1016/S1097-2765(00)80139-2; KELLER AD, 1991, GENE DEV, V5, P868, DOI 10.1101/gad.5.5.868; LARNER AC, 1986, J BIOL CHEM, V261, P453; LI YS, 1993, MOL CELL BIOCHEM, V126, P61, DOI 10.1007/BF01772208; Lu B, 1998, J EXP MED, V187, P601, DOI 10.1084/jem.187.4.601; Majumder S, 1998, J IMMUNOL, V161, P4736; Majumder S, 1996, J NEUROSCI RES, V45, P758, DOI 10.1002/(SICI)1097-4547(19960915)45:6<758::AID-JNR12>3.0.CO;2-S; MANIATIS T, 1992, TRANSCRIPTIONAL REGU, P1193; McManus C, 1998, J NEUROIMMUNOL, V86, P20, DOI 10.1016/S0165-5728(98)00002-2; MUELLER PR, 1994, CURRENT PROTOCOLS MO, V2; NEISH AS, 1995, J BIOL CHEM, V270, P28903, DOI 10.1074/jbc.270.48.28903; Nicholson SE, 1998, J LEUKOCYTE BIOL, V63, P665, DOI 10.1002/jlb.63.6.665; PINE R, 1990, MOL CELL BIOL, V10, P2448, DOI 10.1128/MCB.10.6.2448; Ping DS, 2000, J BIOL CHEM, V275, P1708, DOI 10.1074/jbc.275.3.1708; Ping DS, 1996, IMMUNITY, V4, P455, DOI 10.1016/S1074-7613(00)80412-4; Ping DS, 1999, J BIOL CHEM, V274, P31909, DOI 10.1074/jbc.274.45.31909; RANSOHOFF RM, 1991, J NEUROIMMUNOL, V33, P103, DOI 10.1016/0165-5728(91)90054-B; Ransohoff RM, 1997, J LEUKOCYTE BIOL, V62, P645, DOI 10.1002/jlb.62.5.645; RANSOHOFF RM, 1993, FASEB J, V7, P592, DOI 10.1096/fasebj.7.6.8472896; Ransohoff RM, 1998, TRENDS NEUROSCI, V21, P154, DOI 10.1016/S0166-2236(97)01198-3; Rollins B, 1999, CHEMOKINES CANC; Rollins BJ, 1997, BLOOD, V90, P909, DOI 10.1182/blood.V90.3.909.909_909_928; ROLLINS BJ, 1989, MOL CELL BIOL, V9, P4687, DOI 10.1128/MCB.9.11.4687; Rollins BJ, 1996, MOL MED TODAY, V2, P198, DOI 10.1016/1357-4310(96)88772-7; Sakamoto H, 1998, BLOOD, V92, P1668, DOI 10.1182/blood.V92.5.1668.417k09_1668_1676; Simpson JE, 1998, J NEUROIMMUNOL, V84, P238, DOI 10.1016/S0165-5728(97)00208-7; Song MM, 1998, J BIOL CHEM, V273, P35056, DOI 10.1074/jbc.273.52.35056; Starr R, 1998, INT J BIOCHEM CELL B, V30, P1081, DOI 10.1016/S1357-2725(98)00067-3; Tani M, 1996, AM J PATHOL, V148, P889; Van der Voorn P, 1999, AM J PATHOL, V154, P45, DOI 10.1016/S0002-9440(10)65249-2; Zhou ZHL, 1998, J IMMUNOL, V160, P3908	42	21	22	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	FEB	2001	15	2					383	392		10.1096/fj.00-0373com	http://dx.doi.org/10.1096/fj.00-0373com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	400LK	11156954				2022-12-25	WOS:000166872900020
J	Yam, JWP; Chan, KW; Hsiao, WLW				Yam, JWP; Chan, KW; Hsiao, WLW			Suppression of the tumorigenicity of mutant p53-transformed rat embryo fibroblasts through expression of a newly cloned rat nonmuscle myosin heavy chain-B	ONCOGENE			English	Article						nmMHC; cytoskeletal protein; tumor suppression; Rat 6; mutant p53	PROTEIN KINASE-C; SMOOTH-MUSCLE; II-B; CELLS; CDNA; CLONING; ISOFORM; DISRUPTION; ANTIBODIES; TISSUES	In our previous study, a rat homolog of human nonmuscle myosin heavy chain-B (nmMHC-B) was identified by mRNA differential display comparing of transformed against nontransformed Rat 6 cells overexpressing mutant p53(val135) gene. The nmMHC-B was found to be expressed in normal Rat 6 embryo fibroblast cell line, but markedly suppressed in the mutant p53(val135) transformed Rat 6 cells. To examine the possible involvement of nmMHC-B in cell transformation, we first cloned and sequenced the full length cDNA of rat nmMHC-B, which was then cloned into an ecdysone-expression vector. The resulting construct was introduced into the T2 cell line, a mutant p53(val135)-transformed Rat 6 cells lacking the expression of the endogenous nmMHC-B, The clonal transfectants, expressing muristerone A-induced nmMHC-B, displayed a slightly flatter morphology and reached to a lower saturation density compared to the parental transformed cells. Reconstitution of actin filamental bundles was also clearly seen in cells overexpressing the nmMHC-B, In soft agar assays, nmMHC-B transfectants formed fewer and substantially smaller colonies than the parental cells in response to muristerone A induction. Moreover, it was strikingly effective in suppressing the tumorigenicity of the T2 cells when tested in nude mice. Thus, the nmMHC-B, known as a component of the cytoskeletal network, may act as a tumor suppressor gene. Our current finding may reveal a novel role of nmMHC-B in regulating cell growth and cell signaling in nonmuscle cells.	Hong Kong Univ Sci & Technol, Dept Biol, Kowloon, Hong Kong, Peoples R China	Hong Kong University of Science & Technology	Hsiao, WLW (corresponding author), Hong Kong Univ Sci & Technol, Dept Biol, Clear Water Bay, Kowloon, Hong Kong, Peoples R China.		Yam, Judy Wai Ping/C-4454-2009	Yam, Judy Wai Ping/0000-0002-5637-121X				BenZeev A, 1997, CURR OPIN CELL BIOL, V9, P99, DOI 10.1016/S0955-0674(97)80158-5; BHATIADEY N, 1993, P NATL ACAD SCI USA, V90, P2856, DOI 10.1073/pnas.90.7.2856; BOYD J, 1995, P NATL ACAD SCI USA, V92, P11534, DOI 10.1073/pnas.92.25.11534; Choi OH, 1996, J MUSCLE RES CELL M, V17, P69, DOI 10.1007/BF00140325; DELOZANNE A, 1987, SCIENCE, V236, P1086, DOI 10.1126/science.3576222; Esteve P, 1998, ONCOGENE, V17, P1855, DOI 10.1038/sj.onc.1202082; FERNANDEZ JLR, 1992, J CELL BIOL, V119, P427, DOI 10.1083/jcb.119.2.427; FREEMAN AE, 1967, P NATL ACAD SCI USA, V58, P1205, DOI 10.1073/pnas.58.3.1205; FUKUI Y, 1990, J CELL BIOL, V110, P367, DOI 10.1083/jcb.110.2.367; Gimona M, 1996, P NATL ACAD SCI USA, V93, P9618, DOI 10.1073/pnas.93.18.9618; GLUCK U, 1993, P NATL ACAD SCI USA, V90, P383, DOI 10.1073/pnas.90.2.383; Gulick AM, 1997, BIOESSAYS, V19, P561, DOI 10.1002/bies.950190707; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; HONER B, 1988, J CELL BIOL, V107, P2181, DOI 10.1083/jcb.107.6.2181; HOUSEY GM, 1988, CELL, V52, P343, DOI 10.1016/S0092-8674(88)80027-8; HSIAO WLW, 1986, MOL CELL BIOL, V6, P1943, DOI 10.1128/MCB.6.6.1943; HSIAO WLW, 1992, MOL CARCINOGEN, V5, P140, DOI 10.1002/mc.2940050210; Hunter T, 1997, CELL, V88, P333, DOI 10.1016/S0092-8674(00)81872-3; ITOH K, 1995, J BIOL CHEM, V270, P14533, DOI 10.1074/jbc.270.24.14533; KATSURAGAWA Y, 1989, EUR J BIOCHEM, V184, P611, DOI 10.1111/j.1432-1033.1989.tb15057.x; Kelley CA, 1996, J CELL BIOL, V134, P675, DOI 10.1083/jcb.134.3.675; LAMB NJC, 1988, J CELL BIOL, V106, P1955, DOI 10.1083/jcb.106.6.1955; LU X, 1992, CELL, V70, P153, DOI 10.1016/0092-8674(92)90541-J; LUDOWYKE RI, 1989, J BIOL CHEM, V264, P12492; MARTINEZ J, 1991, GENE DEV, V5, P151, DOI 10.1101/gad.5.2.151; Mummert CM, 1997, J NEUROCHEM, V68, P596; PHILLIPS CL, 1995, J MUSCLE RES CELL M, V16, P379, DOI 10.1007/BF00114503; ROVNER AS, 1986, J BIOL CHEM, V261, P4740; Sablina AA, 1999, CELL BIOL INT, V23, P323, DOI 10.1006/cbir.1999.0362; SAEZ CG, 1990, P NATL ACAD SCI USA, V87, P1164, DOI 10.1073/pnas.87.3.1164; Sanders LC, 1999, SCIENCE, V283, P2083, DOI 10.1126/science.283.5410.2083; SIMONS M, 1992, CIRC RES, V70, P835, DOI 10.1161/01.RES.70.4.835; SIMONS M, 1991, CIRC RES, V69, P530, DOI 10.1161/01.RES.69.2.530; STANBRIDGE EJ, 1980, INT J CANCER, V26, P1, DOI 10.1002/ijc.2910260102; TAKAHASHI M, 1992, J BIOL CHEM, V267, P17864; TSUKITA S, 1993, J CELL BIOL, V123, P1049, DOI 10.1083/jcb.123.5.1049; Tullio AN, 1997, P NATL ACAD SCI USA, V94, P12407, DOI 10.1073/pnas.94.23.12407; VERKHOVSKY AB, 1995, J CELL BIOL, V131, P989, DOI 10.1083/jcb.131.4.989; WARRICK HM, 1987, ANNU REV CELL BIOL, V3, P379, DOI 10.1146/annurev.cb.03.110187.002115; Weir L, 1996, GENE EXPRESSION, V6, P45; Yam JWP, 1999, BIOCHEM BIOPH RES CO, V266, P472, DOI 10.1006/bbrc.1999.1852	41	15	15	0	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 4	2001	20	1					58	68		10.1038/sj.onc.1203982	http://dx.doi.org/10.1038/sj.onc.1203982			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	391NE	11244504				2022-12-25	WOS:000166361400007
J	Rodier, F; Bertrand, R; Bossolasco, M; Mes-Masson, AM				Rodier, F; Bertrand, R; Bossolasco, M; Mes-Masson, AM			Polyomavirus large T-antigen protects mouse cells from Fas-, TNF-alpha- and taxol-induced apoptosis	ONCOGENE			English	Review						apoptosis; polyomavirus large T-antigen; Fas receptor; caspase-8; caspase-3	CHEMOTHERAPY-INDUCED APOPTOSIS; INTERLEUKIN-1-BETA CONVERTING-ENZYME; HEAT-SHOCK PROTEINS; RETINOBLASTOMA PROTEIN; MEDIATED APOPTOSIS; EXPRESSING MYOBLASTS; INTERACTING PROTEIN; TRANSGENIC MICE; DEATH RECEPTORS; MAMMALIAN-CELL	Polyomavirus large T-antigen (PyLT-Ag), a nucleophosphoprotein essential for regulating viral gene expression, modulates the cell cycle by binding to the Rb tumor suppressor gene product. PyLT-Ag/Rb binding is essential for in vitro immortalization. However, the effect of PyLT-Ag on apoptosis has not been extensively studied, We have previously reported that FasR agonist antibodies (FasR(Ab)) treatment of Sertoli cells derived from transgenic mice expressing PyLT-Ag induces the cells without concomitant apoptosis, Here we show that stable expression of PyLT-Ag in murine Sertoli TM4 and hybridoma NSO cell lines confers protection from FasR(Ab)-induced apoptosis, The protection was maintained up to 48 h when cells were grown continuously in the presence of FasR(Ab), Removal of the death stimulus after 24 h exposure was sufficient to allow full recovery of the PyLT-Ag expressing cells. The protective effect conferred by PyLT-Ag was associated with a delay in the sequential activation of caspase-8 and -3 after FasR(Ab) treatment. PyLT-Ag co-precipitated following immunoprecipitation of caspase-8 or FADD, both components of; the DISC, Based on these results we suggest that PyLT-Ag directly impedes the recruitment or activation of caspase-8 by the FasR, PyLT-Ag expression in TM4 cells was also associated with protection from TNF-chi -and taxol-induced apoptosis, In contrast, PyLT-Ag expression was not sufficient to confer protection from captothecin-induced apoptosis, Taken together, these results indicate that PyLT-Ag can be a potent inhibitor of Fas(R)(Ab)-, TNF-chi- and taxol-induced apoptosis.	CHUM, Ctr Rech, Hop Notre Dame, Montreal, PQ H2L 4M1, Canada; Inst Canc Montreal, Montreal, PQ H2L 4M1, Canada; Univ Montreal, Dept Med, Montreal, PQ H3C 3J7, Canada	Universite de Montreal; Universite de Montreal; Universite de Montreal	Mes-Masson, AM (corresponding author), CHUM, Ctr Rech, Hop Notre Dame, 1560 Rue Sherbrooke Est, Montreal, PQ H2L 4M1, Canada.			Rodier, Francis/0000-0003-2523-309X; Mes-Masson, Anne-Marie/0000-0002-6498-266X				Alnemri ES, 1997, J CELL BIOCHEM, V64, P33, DOI 10.1002/(SICI)1097-4644(199701)64:1<33::AID-JCB6>3.0.CO;2-0; Arrigo AP, 1998, BIOL CHEM, V379, P19; Baker SJ, 1998, ONCOGENE, V17, P3261, DOI 10.1038/sj.onc.1202568; Beere HM, 2000, NAT CELL BIOL, V2, P469, DOI 10.1038/35019501; BERTRAND R, 1995, DRUG DEVELOP RES, V34, P138, DOI 10.1002/ddr.430340206; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; BOYD JM, 1994, CELL, V79, P341, DOI 10.1016/0092-8674(94)90202-X; Brodsky JL, 1998, J VIROL, V72, P5329, DOI 10.1128/JVI.72.7.5329-5334.1998; Chen G, 1996, J BIOL CHEM, V271, P24221, DOI 10.1074/jbc.271.39.24221; Chinnaiyan A M, 1997, Semin Immunol, V9, P69, DOI 10.1006/smim.1996.0055; CHIOU SK, 1994, J VIROL, V68, P6553, DOI 10.1128/JVI.68.10.6553-6566.1994; Conzen SD, 1997, J VIROL, V71, P4536, DOI 10.1128/JVI.71.6.4536-4543.1997; Cryns V, 1998, GENE DEV, V12, P1551, DOI 10.1101/gad.12.11.1551; Decaudin D, 1998, INT J ONCOL, V12, P141; DOLE MG, 1995, CANCER RES, V55, P2576; EARNSHAW WC, 1995, CURR OPIN CELL BIOL, V7, P337, DOI 10.1016/0955-0674(95)80088-3; Endo T, 1998, J CELL SCI, V111, P1081; FernandesAlnemri T, 1996, P NATL ACAD SCI USA, V93, P7464, DOI 10.1073/pnas.93.15.7464; Fimia GM, 1998, MOL BIOL CELL, V9, P1449, DOI 10.1091/mbc.9.6.1449; Gonin S, 1999, ONCOGENE, V18, P8011, DOI 10.1038/sj.onc.1203319; Gottifredi V, 1999, J CELL SCI, V112, P2397; Han J, 1996, MOL CELL BIOL, V16, P5857; Han JH, 1998, MOL CELL BIOL, V18, P6052, DOI 10.1128/MCB.18.10.6052; Hirsch T, 1997, ONCOGENE, V15, P1573, DOI 10.1038/sj.onc.1201324; Hohfeld J, 1998, BIOL CHEM, V379, P269; Ibrado AM, 1996, CELL GROWTH DIFFER, V7, P1087; Imai Y, 1999, NATURE, V398, P777, DOI 10.1038/19709; Jaattela M, 1998, EMBO J, V17, P6124, DOI 10.1093/emboj/17.21.6124; Jung YK, 1997, ONCOGENE, V14, P1207, DOI 10.1038/sj.onc.1200943; Kelley WL, 1997, P NATL ACAD SCI USA, V94, P3679, DOI 10.1073/pnas.94.8.3679; KHANDJIAN EW, 1992, ONCOGENE, V7, P909; Kharbanda S, 1997, P NATL ACAD SCI USA, V94, P6939, DOI 10.1073/pnas.94.13.6939; Kidd VJ, 1998, ANNU REV PHYSIOL, V60, P533, DOI 10.1146/annurev.physiol.60.1.533; KINGSTON RE, 1986, MOL CELL BIOL, V6, P3180, DOI 10.1128/MCB.6.9.3180; LAROSE A, 1990, VIROLOGY, V176, P98, DOI 10.1016/0042-6822(90)90234-I; LAROSE A, 1991, J VIROL, V65, P2308, DOI 10.1128/JVI.65.5.2308-2313.1991; LAZEBNIK YA, 1995, P NATL ACAD SCI USA, V92, P9042, DOI 10.1073/pnas.92.20.9042; Lebel M, 1996, ONCOGENE, V12, P1127; LEBEL M, 1994, EXP CELL RES, V213, P12, DOI 10.1006/excr.1994.1167; Li CY, 2000, J BIOL CHEM, V275, P25665, DOI 10.1074/jbc.M906383199; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; MCBURNEY MW, 1991, NUCLEIC ACIDS RES, V19, P5755, DOI 10.1093/nar/19.20.5755; McCarthy NJ, 1997, J CELL BIOL, V136, P215, DOI 10.1083/jcb.136.1.215; Mountz JD, 1997, IMMUNOL REV, V160, P19, DOI 10.1111/j.1600-065X.1997.tb01024.x; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; OBERHAMMER FA, 1994, J CELL BIOL, V126, P827, DOI 10.1083/jcb.126.4.827; Oyaizu H, 1999, Mol Cell Biol Res Commun, V2, P36, DOI 10.1006/mcbr.1999.0146; Perkins CL, 2000, CANCER RES, V60, P1645; Pilon AA, 1996, J VIROL, V70, P4457, DOI 10.1128/JVI.70.7.4457-4465.1996; RASSOULZADEGAN M, 1983, P NATL ACAD SCI-BIOL, V80, P4354, DOI 10.1073/pnas.80.14.4354; RASSOULZADEGAN M, 1982, NATURE, V300, P713, DOI 10.1038/300713a0; RASSSOULZADEGAN M, 1983, P NATL ACAD SCI USA, V82, P4354; Rathmell JC, 1999, ANNU REV IMMUNOL, V17, P781, DOI 10.1146/annurev.immunol.17.1.781; RAY CA, 1992, CELL, V69, P597, DOI 10.1016/0092-8674(92)90223-Y; Reed JC, 1997, SEMIN HEMATOL, V34, P9; RESNICKSILVERMAN L, 1991, J VIROL, V65, P2845, DOI 10.1128/JVI.65.6.2845-2852.1991; Riley MI, 1997, J VIROL, V71, P6068, DOI 10.1128/JVI.71.8.6068-6074.1997; ROUQUET N, 1995, ONCOGENE, V11, P1061; Sakahira H, 1998, NATURE, V391, P96, DOI 10.1038/34214; Saleh A, 2000, NAT CELL BIOL, V2, P476, DOI 10.1038/35019510; Samali A, 1998, CELL STRESS CHAPERON, V3, P228, DOI 10.1054/csac.1998.0129; Sambrook J., 2002, MOL CLONING LAB MANU; Sane AT, 1999, CANCER RES, V59, P3565; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Schett G, 1999, FASEB J, V13, P833, DOI 10.1096/fasebj.13.8.833; Schmitt E, 1998, EXP CELL RES, V240, P107, DOI 10.1006/excr.1998.4003; Schmitt E, 1999, DRUG RESIST UPDATE, V2, P21, DOI 10.1054/drup.1999.0065; Sheng Q, 1997, J VIROL, V71, P9410, DOI 10.1128/JVI.71.12.9410-9416.1997; Siegel RM, 1999, J ALLERGY CLIN IMMUN, V103, P729, DOI 10.1016/S0091-6749(99)70412-4; SILVER J, 1978, CELL, V15, P485, DOI 10.1016/0092-8674(78)90018-1; Simonian PL, 1997, BLOOD, V90, P1208, DOI 10.1182/blood.V90.3.1208.1208_1208_1216; Slinskey A, 1999, J VIROL, V73, P6791, DOI 10.1128/JVI.73.8.6791-6799.1999; SOEDA E, 1980, NATURE, V283, P445, DOI 10.1038/283445a0; Stennicke HR, 1998, BBA-PROTEIN STRUCT M, V1387, P17, DOI 10.1016/S0167-4838(98)00133-2; SUBRAMANIAN T, 1995, CELL GROWTH DIFFER, V6, P131; Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135; TAKAHASHI H, 1995, J INVEST DERMATOL, V105, P810, DOI 10.1111/1523-1747.ep12326577; Teodoro JG, 1997, J VIROL, V71, P1739, DOI 10.1128/JVI.71.3.1739-1746.1997; TEWARI M, 1995, J BIOL CHEM, V270, P22705, DOI 10.1074/jbc.270.39.22705; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; Vaux DL, 1999, CELL, V96, P245, DOI 10.1016/S0092-8674(00)80564-4; Vayssier M, 1998, CELL STRESS CHAPERON, V3, P221, DOI 10.1379/1466-1268(1998)003<0221:HSPCLA>2.3.CO;2; Wallach D, 1999, ANNU REV IMMUNOL, V17, P331, DOI 10.1146/annurev.immunol.17.1.331; Weigel TL, 2000, J THORAC CARDIOV SUR, V119, P795, DOI 10.1016/S0022-5223(00)70016-X; Yasuda M, 1998, J BIOL CHEM, V273, P12415, DOI 10.1074/jbc.273.20.12415; YIN XM, 1994, NATURE, V369, P321, DOI 10.1038/369321a0; Young LS, 1997, BRIT MED BULL, V53, P509; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9; ZHENG DQ, 1994, ONCOGENE, V9, P3345; Zhou Q, 1997, J BIOL CHEM, V272, P7797, DOI 10.1074/jbc.272.12.7797	92	6	7	0	3	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 14	2000	19	54					6261	6270		10.1038/sj.onc.1204015	http://dx.doi.org/10.1038/sj.onc.1204015			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	388YK	11175340				2022-12-25	WOS:000166210500009
J	Doucet, C; Jasmin, C; Azzarone, B				Doucet, C; Jasmin, C; Azzarone, B			Unusual interleukin-4 and-13 signaling in human normal and tumor lung fibroblasts	ONCOGENE			English	Article						lung fibroblasts; myofibroblasts; IL-4/IL-13; signal transduction	INSULIN-RECEPTOR SUBSTRATE-1; ACTIVATED PROTEIN-KINASE; TYROSINE PHOSPHORYLATION; CELLS; TRANSDUCTION; IL-13; CHAIN; EXPRESSION; PATHWAYS; INVOLVEMENT	IL-4 and IL-13 act on human lung fibroblasts through specific receptors differing in their composition. Indeed, the gammac chain is constitutively expressed in tumor lung myofibroblast but not in normal cells, Here, we have analysed the signal transduction induced by IL-4 and IL-13 in both cell types, in order to better understand the molecular mechanisms underlying tumor stromal development. The IL-4R alpha chain is constitutively phosphorylated and pre-associated with the JAK1 protein in both cell types. In normal cells, we detected the activation of the classic IRS-2 or JAK1/STAT6 pathways, the phosphorylation of JAK2, while Tyk2 was constitutively phosphorylated and not modified by both cytokines, In addition to these pathways, in lung tumor myofibroblasts, IL-4 and IL-13 induced the phosphorylation of JAK3 and increased the phosphorylation of Tyk2, Interestingly, in both cell types IL-4 and IL-13 triggered an unusual pattern of STAT1 and STAT3 activation. These events probably correspond to a tissue-specific signaling important for the immunoregulatory functions of airways fibroblasts, Indeed, the inflammatory-like pattern of STATs signaling triggered by IL-4 and IL-13 in these cells may favor the homing of inflammatory and/or metastatic cells. In lung myofibroblasts, these properties could be modified through the different pattern of JAK activation.	Hop Paul Brousse, INSERM U268, F-94807 Villejuif, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Paul-Brousse - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm)	Azzarone, B (corresponding author), Hop Paul Brousse, INSERM U506, 16 Av PV Couturier, F-94807 Villejuif, France.		Azzarone, Bruno/AAH-9251-2019	Azzarone, Bruno/0000-0002-5962-3849				Aman MJ, 1996, J BIOL CHEM, V271, P29265, DOI 10.1074/jbc.271.46.29265; Aringer M, 1999, IMMUNOLOGIST, V7, P139; AZZARONE B, 1984, J CELL BIOL, V98, P1133, DOI 10.1083/jcb.98.3.1133; Brouty-Boye D, 2000, EUR J IMMUNOL, V30, P914, DOI 10.1002/1521-4141(200003)30:3<914::AID-IMMU914>3.0.CO;2-D; Callard RE, 1996, IMMUNOL TODAY, V17, P108, DOI 10.1016/0167-5699(96)80600-1; Chen XH, 1997, J BIOL CHEM, V272, P6556, DOI 10.1074/jbc.272.10.6556; Chuang LM, 1997, BIOCHEM BIOPH RES CO, V235, P317, DOI 10.1006/bbrc.1997.6771; Chuang LM, 1996, J BIOCHEM-TOKYO, V120, P111; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Demoulin JB, 1998, CYTOKINES CELL MOL T, V4, P243; Doucet C, 1998, INT IMMUNOL, V10, P1421, DOI 10.1093/intimm/10.10.1421; Doucet C, 1998, J CLIN INVEST, V101, P2129, DOI 10.1172/JCI741; Goebeler M, 1997, IMMUNOLOGY, V91, P450, DOI 10.1046/j.1365-2567.1997.00263.x; GUSCHIN D, 1995, EMBO J, V14, P1421, DOI 10.1002/j.1460-2075.1995.tb07128.x; IDZERDA RL, 1990, J EXP MED, V171, P861, DOI 10.1084/jem.171.3.861; IHLE JN, 1995, TRENDS GENET, V11, P69, DOI 10.1016/S0168-9525(00)89000-9; JOHNSTON JA, 1995, J BIOL CHEM, V270, P28527, DOI 10.1074/jbc.270.48.28527; LEFORT S, 1995, FEBS LETT, V366, P122, DOI 10.1016/0014-5793(95)00512-8; MINTY A, 1993, NATURE, V362, P248, DOI 10.1038/362248a0; Murata T, 1998, INT IMMUNOL, V10, P1103, DOI 10.1093/intimm/10.8.1103; Murata T, 1995, J BIOL CHEM, V270, P30829, DOI 10.1074/jbc.270.51.30829; Obiri NI, 1997, J BIOL CHEM, V272, P20251, DOI 10.1074/jbc.272.32.20251; PAUL WE, 1991, BLOOD, V77, P1859; ROLLING C, 1995, ONCOGENE, V10, P1757; Rolling C, 1996, FEBS LETT, V393, P53, DOI 10.1016/0014-5793(96)00835-6; SAPPINO AP, 1990, LAB INVEST, V63, P144; Schiemann WP, 1997, J BIOL CHEM, V272, P16631, DOI 10.1074/jbc.272.26.16631; SCHMITTGRAFF A, 1994, VIRCHOWS ARCH, V425, P3, DOI 10.1007/BF00193944; Schnyder B, 1996, BIOCHEM J, V315, P767, DOI 10.1042/bj3150767; SIRONI M, 1994, BLOOD, V84, P1913; SMEZBERTLING C, 1995, J BIOL CHEM, V270, P966; Smith RS, 1997, AM J PATHOL, V151, P317; SUN XJ, 1995, NATURE, V377, P173, DOI 10.1038/377173a0; Takeda K, 1996, J IMMUNOL, V157, P3220; TEPPER RI, 1990, CELL, V62, P457, DOI 10.1016/0092-8674(90)90011-3; WELHAM MJ, 1995, J BIOL CHEM, V270, P12286, DOI 10.1074/jbc.270.20.12286; Wery S, 1996, J BIOL CHEM, V271, P8529, DOI 10.1074/jbc.271.15.8529; WITTHUHN BA, 1994, NATURE, V370, P153, DOI 10.1038/370153a0	38	31	31	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 30	2000	19	51					5898	5905		10.1038/sj.onc.1203933	http://dx.doi.org/10.1038/sj.onc.1203933			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	378CA	11127821				2022-12-25	WOS:000165563100009
J	Hosaka, T; Kanoe, H; Nakayama, T; Murakami, H; Yamamoto, H; Nakamata, T; Tsuboyama, T; Oka, M; Kasai, M; Sasaki, MS; Nakamura, T; Toguchida, J				Hosaka, T; Kanoe, H; Nakayama, T; Murakami, H; Yamamoto, H; Nakamata, T; Tsuboyama, T; Oka, M; Kasai, M; Sasaki, MS; Nakamura, T; Toguchida, J			Translin binds to the sequences adjacent to the breakpoints of the TLS and CHOP genes in liposarcomas with translocation t(12;16)	ONCOGENE			English	Article						translin; liposarcoma; translocation; mobility-shift assay	CHROMOSOMAL TRANSLOCATIONS; TOPOISOMERASE-II; RECOMBINATION; PROTEIN; FUSION; REPAIR; MECHANISM; LEUKEMIA; ENDS	Myxoid and round-cell liposarcomas share the translocation t(12;16)(q13;p11) creating the TLS-CHOP fusion gene as a common genetic alteration. We previously reported several unique characteristics of genomic sequences around the breakpoints in the TLS and CHOP loci, and among them was the presence of consensus recognition motifs of Translin, a protein that associates with chromosomal translocations of lymphoid neoplasms. We further extended our search for Translin binding motifs in sequences adjacent to breakpoints and investigated,whether Translin binds to these sequences in vitro by mobility-shift assay. Computer-assisted search found sequences highly homologous (>70%) with Translin binding motifs adjacent to the breakpoints in 10 out of 11 liposarcomas,vith the TLS-CHOP fusion genes. All of 13 oligonucleotides corresponding to the putative binding sequences in these cases bind to Hela cell extract and also recombinant Translin protein, although the binding affinity of each motif showed considerable differences. The DNA-protein complex formation was inhibited by non-labeled competitor or anti-Translin antibody, suggesting the specificity of the complex formation. Considering the high incidence and specific binding property, the presence of Translin binding motif may be one of the important determinants for the location of breakpoints in the TLS and CHOP gents in liposarcomas.	Kyoto Univ, Inst Frontier Med Sci, Sakyo Ku, Kyoto 6068507, Japan; Kyoto Univ, Dept Orthopaed Surg, Kyoto 6068507, Japan; Kyoto Univ, Ctr Radiat Biol, Kyoto 6068507, Japan; Natl Inst Infect Dis, Dept Immunol, Tokyo 1628640, Japan	Kyoto University; Kyoto University; Kyoto University; National Institute of Infectious Diseases (NIID)	Toguchida, J (corresponding author), Kyoto Univ, Inst Frontier Med Sci, Sakyo Ku, 53 Kawahara Cho, Kyoto 6068507, Japan.							AOKI K, 1995, NAT GENET, V10, P167, DOI 10.1038/ng0695-167; Atlas M, 1998, LEUKEMIA, V12, P1895, DOI 10.1038/sj.leu.2401223; Badge RM, 2000, HUM MOL GENET, V9, P1239, DOI 10.1093/hmg/9.8.1239; Burden DA, 1998, BBA-GENE STRUCT EXPR, V1400, P139, DOI 10.1016/S0167-4781(98)00132-8; Chalk JG, 1997, ONCOGENE, V15, P1199, DOI 10.1038/sj.onc.1201285; CROZAT A, 1993, NATURE, V363, P640, DOI 10.1038/363640a0; Gillert E, 1999, ONCOGENE, V18, P4663, DOI 10.1038/sj.onc.1202842; Jeffs AR, 1998, HUM MOL GENET, V7, P767, DOI 10.1093/hmg/7.5.767; Kanoe H, 1999, ONCOGENE, V18, P721, DOI 10.1038/sj.onc.1202364; Kasai M, 1997, J BIOL CHEM, V272, P11402; Obata K, 1999, GENE CHROMOSOME CANC, V25, P6, DOI 10.1002/(SICI)1098-2264(199905)25:1<6::AID-GCC2>3.3.CO;2-D; PANAGOPOULOS I, 1994, CANCER RES, V54, P6500; RABBITTS TH, 1993, NAT GENET, V4, P175, DOI 10.1038/ng0693-175; RABBITTS TH, 1994, NATURE, V372, P143, DOI 10.1038/372143a0; ROTH DB, 1995, CURR BIOL, V5, P496, DOI 10.1016/S0960-9822(95)00101-1; SZOSTAK JW, 1983, CELL, V33, P25, DOI 10.1016/0092-8674(83)90331-8; Wu XQ, 1997, P NATL ACAD SCI USA, V94, P5640, DOI 10.1073/pnas.94.11.5640; Zucman-Rossi J, 1998, P NATL ACAD SCI USA, V95, P11786, DOI 10.1073/pnas.95.20.11786	18	24	26	0	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 23	2000	19	50					5821	5825		10.1038/sj.onc.1203943	http://dx.doi.org/10.1038/sj.onc.1203943			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	376VP	11126370	Green Submitted			2022-12-25	WOS:000165477700015
J	Poetsch, M; Dittberner, T; Cowell, JK; Woenckhaus, C				Poetsch, M; Dittberner, T; Cowell, JK; Woenckhaus, C			TTC4, a novel candidate tumor suppressor gene at 1p31 is often mutated in malignant melanoma of the skin	ONCOGENE			English	Article						TTC4; malignant melanoma; sequencing analysis	TETRATRICOPEPTIDE REPEAT MOTIFS; HUMAN PROTEIN; CELL-LINES; PROGRESSION; IDENTIFICATION; CYTOGENETICS; EXPRESSION; HOMOLOG	A novel candidate tumor suppressor gene, TTC4, on chromosome 1p31 has been described recently. Since aberrations in this region have been detected in malignant melanoma, we investigated DNA of paraffin-embedded sections from 16 typical naevi, 19 atypical naevi, 32 primary melanomas (15 superficial spreading melanomas, 17 nodular melanomas) and 25 metastases and DNA from four melanoma cell lines by PCR and direct sequencing analysis for mutations in all exons of TTC4. Tumors comprised a wide range of thickness (Breslow index) and Clark levels. No mutations could be detected in typical or atypical naevi, but we found se, cn different point mutations in the tumor samples, sis of them causing an amino acid change. Ten melanoma samples belonging to nine patients showed one or more of these mutations. In detail, in sis of 25 metastases, in two of 17 nodular melanomas and in two of 15 superficial spreading melanomas point mutations could be detected, In two cell lines, a loss of a whole exon could be demonstrated and in one cell line we found a point mutation. In addition, three polymorphisms were found. Our findings indicate that TTC4 may participate in the pathogenesis of malignant melanomas of the skin.	Univ Greifswald, Inst Forens Med, D-17489 Greifswald, Germany; Univ Greifswald, Dept Dermatol, D-17489 Greifswald, Germany; Univ Greifswald, Inst Pathol, D-17489 Greifswald, Germany; Cleveland Clin Fdn, Ctr Mol Genet, Cleveland, OH USA	Ernst Moritz Arndt Universitat Greifswald; Ernst Moritz Arndt Universitat Greifswald; Ernst Moritz Arndt Universitat Greifswald; Cleveland Clinic Foundation	Poetsch, M (corresponding author), Univ Greifswald, Inst Forens Med, Kuhstr 30, D-17489 Greifswald, Germany.			Cowell, John/0000-0002-2079-5950				ALBINO AP, 1981, J EXP MED, V154, P1764, DOI 10.1084/jem.154.6.1764; Ballinger CA, 1999, MOL CELL BIOL, V19, P4535; Blatch GL, 1999, BIOESSAYS, V21, P932, DOI 10.1002/(SICI)1521-1878(199911)21:11<932::AID-BIES5>3.0.CO;2-N; CHEN MX, 1994, EMBO J, V13, P4278, DOI 10.1002/j.1460-2075.1994.tb06748.x; DRACOPOLI NC, 1989, P NATL ACAD SCI USA, V86, P4614, DOI 10.1073/pnas.86.12.4614; FRANSEN M, 1995, J BIOL CHEM, V270, P7731, DOI 10.1074/jbc.270.13.7731; Heim S., 1995, CANC CYTOGENETICS CH, V2nd; HONORE B, 1992, J BIOL CHEM, V267, P8485; Isfort RJ, 1997, ONCOGENE, V15, P1797, DOI 10.1038/sj.onc.1201535; Koga H, 1999, J BIOL CHEM, V274, P25051, DOI 10.1074/jbc.274.35.25051; LAM E, 1995, GENE, V160, P297, DOI 10.1016/0378-1119(95)00216-S; Poetsch M, 1998, LAB INVEST, V78, P883; Poetsch M, 1999, VIRCHOWS ARCH, V435, P105, DOI 10.1007/s004280050406; POETSCH M, 2000, IN PRESS CANC GENET; SCHRICK JJ, 1995, HUM MOL GENET, V4, P559, DOI 10.1093/hmg/4.4.559; SIRACKY J, 1982, NEOPLASMA, V29, P661; Su GF, 1999, GENOMICS, V55, P157, DOI 10.1006/geno.1998.5633; Su GF, 2000, INT J MOL MED, V5, P197; THOMPSON FH, 1995, CANCER GENET CYTOGEN, V83, P93, DOI 10.1016/0165-4608(95)00057-V; WILTSHIRE RN, 1995, CANCER RES, V55, P3954; Zhang H, 1999, PROTEIN SCI, V8, P1658, DOI 10.1110/ps.8.8.1658	21	11	14	0	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 23	2000	19	50					5817	5820		10.1038/sj.onc.1203961	http://dx.doi.org/10.1038/sj.onc.1203961			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	376VP	11126369				2022-12-25	WOS:000165477700014
J	Barth, H; Pfeifer, G; Hofmann, F; Maier, E; Benz, R; Aktories, K				Barth, H; Pfeifer, G; Hofmann, F; Maier, E; Benz, R; Aktories, K			Low pH-induced formation of ion channels by Clostridium difficile toxin B in target cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOTULINUM C2 TOXIN; RHO-PROTEINS; RETROGRADE TRANSPORT; PROTECTIVE ANTIGEN; ESCHERICHIA-COLI; MAMMALIAN-CELLS; MEMBRANES; OLIGOMERIZATION; LOCALIZATION; INFECTION	Clostridium difficile toxin B (269 kDa), which is one of the causative agents of antibiotic-associated diarrhea and pseudomembranous colitis, inactivates Rho GTPase by glucosylation, Here we studied the uptake and membrane interaction of the toxin with eukaryotic target cells. Bafilomycin A1, which prevents acidification of endosomal compartments, blocked the cellular uptake of toxin B in Chinese hamster ovary cells cells. Extracellular acidification (pH less than or equal to 5.2) induced uptake of toxin B into the cytosol even in the presence of bafilomycin A1. Toxin B increased Rb-86(+) release when preloaded Chinese hamster ovary cells were exposed to low pH (pH less than or equal to 5.6) for 5 min. Release of Rb-86(+) depended on the concentration of toxin B and on the pH of the extracellular medium. An antibody directed against the holotoxin prevented channel formation, whereas an antibody against the N-terminal enzyme domain was without effect. The N-terminally truncated toxin B fragment consisting of amino acids 547-2366 increased Rb-86(+) efflux when cells were exposed to low pH, Toxin B also induced pH-dependent channel formation in artificial lipid bilayer membranes. Clostridium sordellii lethal toxin, another member of the family of large clostridial cytotoxins, also induced increased Rb-86(+) release at low pH, The results suggest that large clostridial cytotoxins including C. difficile toxin B and C, sordellii lethal toxin undergo structural changes at low pH of endosomes that are accompanied by membrane insertion and channel formation.	Univ Freiburg, Inst Expt & Klin Phamrakol & Toxikol, D-79104 Freiburg, Germany; Univ Wurzburg, Biozentrum, Theodor Boveri Inst, Lehrstuhl Biotechnol, D-97074 Wurzburg, Germany	University of Freiburg; University of Wurzburg	Aktories, K (corresponding author), Univ Freiburg, Inst Expt & Klin Phamrakol & Toxikol, Hermann Herder Str 5, D-79104 Freiburg, Germany.		Barth, Holger/E-7920-2013; Aktories, Klaus/CAJ-5682-2022	Aktories, Klaus/0000-0002-5397-0436; Benz, Roland/0000-0002-9510-9265				Aktories K, 1997, J CLIN INVEST, V99, P827, DOI 10.1172/JCI119245; BARROSO LA, 1994, MICROB PATHOGENESIS, V16, P297, DOI 10.1006/mpat.1994.1030; Barth H, 2000, J BIOL CHEM, V275, P18704, DOI 10.1074/jbc.M000596200; BENZ R, 1978, BIOCHIM BIOPHYS ACTA, V511, P305, DOI 10.1016/0005-2736(78)90269-9; BENZ R, 1994, EUR J BIOCHEM, V220, P339, DOI 10.1111/j.1432-1033.1994.tb18630.x; Borriello SP, 1998, J ANTIMICROB CHEMOTH, V41, P13, DOI 10.1093/jac/41.suppl_3.13; CHAUDHARY VK, 1990, P NATL ACAD SCI USA, V87, P308, DOI 10.1073/pnas.87.1.308; FREY SM, 1992, INFECT IMMUN, V60, P2488, DOI 10.1128/IAI.60.6.2488-2492.1992; Genth H, 2000, INFECT IMMUN, V68, P1094, DOI 10.1128/IAI.68.3.1094-1101.2000; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Hofmann F, 1997, J BIOL CHEM, V272, P11074; JUST I, 1995, J BIOL CHEM, V270, P13932, DOI 10.1074/jbc.270.23.13932; JUST I, 1995, NATURE, V375, P500, DOI 10.1038/375500a0; Just I., 1997, BACTERIAL TOXINS TOO, P159; Kelly CP, 1998, ANNU REV MED, V49, P375; KELLY CP, 1994, NEW ENGL J MED, V330, P257, DOI 10.1056/NEJM199401273300406; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lyerly David M., 1995, P867; MADSHUS IH, 1991, J BIOL CHEM, V266, P17446; Maier E, 1996, INFECT IMMUN, V64, P4415, DOI 10.1128/IAI.64.11.4415-4423.1996; Majoul I, 1998, J CELL BIOL, V143, P601, DOI 10.1083/jcb.143.3.601; MILNE JC, 1993, MOL MICROBIOL, V10, P647, DOI 10.1111/j.1365-2958.1993.tb00936.x; MONTECUCCO C, 1994, FEBS LETT, V346, P92, DOI 10.1016/0014-5793(94)00449-8; Qa'Dan M, 2000, INFECT IMMUN, V68, P2470, DOI 10.1128/IAI.68.5.2470-2474.2000; ROPELE M, 1989, BIOCHIM BIOPHYS ACTA, V985, P9, DOI 10.1016/0005-2736(89)90096-5; SANDVIG K, 1992, NATURE, V358, P510, DOI 10.1038/358510a0; SCHMID A, 1994, J BIOL CHEM, V269, P16706; Singh Y, 1999, INFECT IMMUN, V67, P1853; VONEICHELSTREIBER C, 1992, J BACTERIOL, V174, P6707, DOI 10.1128/JB.174.20.6707-6710.1992	29	123	128	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 6	2001	276	14					10670	10676		10.1074/jbc.M009445200	http://dx.doi.org/10.1074/jbc.M009445200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	420AC	11152463	hybrid			2022-12-25	WOS:000167980900016
J	Ceresa, BP; Lotscher, M; Schmid, SL				Ceresa, BP; Lotscher, M; Schmid, SL			Receptor and membrane recycling can occur with unaltered efficiency despite dramatic Rab5(Q79L)-induced changes in endosome geometry	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAB5; GTPASE; FUSION; TRANSFERRIN; PATHWAY	Current models for sorting in the endosomal compartment suggest that endosomal geometry plays a significant role as membrane-bound proteins accumulate in tubular regions for recycling, and lumenal markers accumulate in large vacuolar portions for delivery to lysosomes, Rab5, a small molecular weight GTPase, functions in the formation and maintenance of the early/sorting endosome, Overexpression of the constitutively active form, Rab5(Q79L), leads to enhanced endosome fusion resulting in the enlargement of early endosomes, Using an adenoviral expression system to regulate the time and level of Rab5(Q79L) overexpression in HeLa cells, we find that although endosomes are dramatically enlarged, the rates of transferrin receptor-mediated endocytosis and recycling are unaffected. Moreover, despite the enlarged endosome phenotype, neither the rate of internalization of a fluid phase marker nor the rate of recycling of a bulk lipid marker were affected. These results suggest that GTP hydrolysis by Rab5 is rate-limiting for endosome fusion but not for endocytic trafficking and that early endosome geometry may be a less critical determinant of sorting efficiencies than previously thought.	Scripps Res Inst, Dept Cell Biol, La Jolla, CA 92037 USA	Scripps Research Institute	Schmid, SL (corresponding author), Scripps Res Inst, Dept Cell Biol, La Jolla, CA 92037 USA.	slschmid@scripps.edu		Schmid, Sandra/0000-0002-1690-7024	NATIONAL CANCER INSTITUTE [P01CA058689] Funding Source: NIH RePORTER; NCI NIH HHS [CA58689] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARBIERI MA, 1994, J BIOL CHEM, V269, P18720; BUCCI C, 1992, CELL, V70, P715, DOI 10.1016/0092-8674(92)90306-W; DAMKE H, 1995, METHOD ENZYMOL, V257, P209; DAMKE H, 1994, J CELL BIOL, V127, P915, DOI 10.1083/jcb.127.4.915; DAUTRYVARSAT A, 1983, P NATL ACAD SCI-BIOL, V80, P2258, DOI 10.1073/pnas.80.8.2258; DUNN KW, 1989, J CELL BIOL, V109, P3303, DOI 10.1083/jcb.109.6.3303; GHOSH RN, 1995, J CELL BIOL, V128, P549, DOI 10.1083/jcb.128.4.549; GORVEL JP, 1991, CELL, V64, P915, DOI 10.1016/0092-8674(91)90316-Q; GRIFFITHS G, 1989, J CELL BIOL, V109, P2703, DOI 10.1083/jcb.109.6.2703; GRUENBERG J, 1995, CURR OPIN CELL BIOL, V7, P552, DOI 10.1016/0955-0674(95)80013-1; Hao MM, 2000, J BIOL CHEM, V275, P15279, DOI 10.1074/jbc.275.20.15279; Hardy S, 1997, J VIROL, V71, P1842, DOI 10.1128/JVI.71.3.1842-1849.1997; LI GP, 1993, J BIOL CHEM, V268, P24475; MARSH M, 1987, J CELL BIOL, V104, P875, DOI 10.1083/jcb.104.4.875; MAYOR S, 1993, J CELL BIOL, V121, P1257, DOI 10.1083/jcb.121.6.1257; Mellman I, 1996, ANNU REV CELL DEV BI, V12, P575, DOI 10.1146/annurev.cellbio.12.1.575; Mukherjee S, 1997, PHYSIOL REV, V77, P759, DOI 10.1152/physrev.1997.77.3.759; Presley JF, 1997, J BIOL CHEM, V272, P13929, DOI 10.1074/jbc.272.21.13929; Roberts RL, 1999, J CELL SCI, V112, P3667; Sheff DR, 1999, J CELL BIOL, V145, P123, DOI 10.1083/jcb.145.1.123; Sonnichsen B, 2000, J CELL BIOL, V149, P901, DOI 10.1083/jcb.149.4.901; STENMARK H, 1994, EMBO J, V13, P1287, DOI 10.1002/j.1460-2075.1994.tb06381.x; STENMARK H, 1994, EMBO J, V13, P575, DOI 10.1002/j.1460-2075.1994.tb06295.x; Stoorvogel W, 1996, J CELL BIOL, V132, P21, DOI 10.1083/jcb.132.1.21; VANDERBLIEK AM, 1993, J CELL BIOL, V122, P553, DOI 10.1083/jcb.122.3.553	25	48	49	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 30	2001	276	13					9649	9654		10.1074/jbc.M010387200	http://dx.doi.org/10.1074/jbc.M010387200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	420GC	11136733	hybrid			2022-12-25	WOS:000167996400011
J	Maruyama, M; Kumagai, T; Matoba, Y; Hayashida, M; Fujii, T; Hata, Y; Sugiyama, M				Maruyama, M; Kumagai, T; Matoba, Y; Hayashida, M; Fujii, T; Hata, Y; Sugiyama, M			Crystal structures of the transposon Tn5-carried bleomycin resistance determinant uncomplexed and complexed with bleomycin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DISTANCE GEOMETRY CALCULATIONS; X-RAY-DIFFRACTION; ESCHERICHIA-COLI; STREPTOMYCES-VERTICILLUS; STAPHYLOCOCCUS-AUREUS; ACTIVATED BLEOMYCIN; MOLECULAR-CLONING; FACTOR REFINEMENT; NMR-SPECTROSCOPY; BINDING PROTEIN	The transposon Tn5 carries a gene designated ble that confers resistance to bleomycin (Bm), In this study, we determined the x-ray crystal structures of the ble gene product, designated BLMT, uncomplexed and complexed with Bm at 1.7 and 2.5 Angstrom resolution, respectively. The structure of BLMT is a dimer with two Bm-binding pockets composed of two large concavities and two long grooves, This crystal structure of BLMT complexed with Bm gives a precise mode for binding of the antibiotic to BLMT. The conformational change of BLMT generated by binding to Bm occurs at a beta -turn composed of the residues from Gln(97) to Thr(102). Crystallographic analysis of Bm bound to BLMT shows that two thiazolium rings of the bithiazole moiety are in the trans conformation. The axial ligand, which binds a metal ion, seems to be the primary amine in the beta -aminoalanine moiety. This report, which is the first with regard to the x-ray crystal structure of Bm, shows that the bithiazole moiety of Bm is far from the metal-binding domain. That is, Bm complexed with BLMT takes a more extended form than the drug complexed with DNA.	Hiroshima Univ, Fac Med, Inst Pharmaceut Sci, Minami Ku, Hiroshima 7348551, Japan; Kyoto Univ, Inst Chem Res, Uji, Kyoto 6110011, Japan	Hiroshima University; Kyoto University	Sugiyama, M (corresponding author), Hiroshima Univ, Fac Med, Inst Pharmaceut Sci, Minami Ku, Kasumi 1-2-3, Hiroshima 7348551, Japan.							Adam E, 1998, MOL MICROBIOL, V28, P15, DOI 10.1046/j.1365-2958.1998.00755.x; AKKERMAN MAJ, 1990, J AM CHEM SOC, V112, P7462, DOI 10.1021/ja00177a003; AKKERMAN MAJ, 1988, EUR J BIOCHEM, V173, P211, DOI 10.1111/j.1432-1033.1988.tb13987.x; BERG DE, 1975, P NATL ACAD SCI USA, V72, P3628, DOI 10.1073/pnas.72.9.3628; BHUIYAN MZA, 1995, APPL MICROBIOL BIOT, V43, P65; BLOT M, 1991, P NATL ACAD SCI USA, V88, P9112, DOI 10.1073/pnas.88.20.9112; BLOT M, 1994, MOL GEN GENET, V242, P595, DOI 10.1007/BF00285283; BLUM RH, 1973, CANCER, V31, P903, DOI 10.1002/1097-0142(197304)31:4<903::AID-CNCR2820310422>3.0.CO;2-N; BrUnger A. T., 1992, X PLOR VERSION 3 1 S; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; BURGER RM, 1981, J BIOL CHEM, V256, P1636; CaceresCortes J, 1997, EUR J BIOCHEM, V244, P818, DOI 10.1111/j.1432-1033.1997.00818.x; CARTER BJ, 1990, P NATL ACAD SCI USA, V87, P9373, DOI 10.1073/pnas.87.23.9373; DUMAS P, 1994, EMBO J, V13, P2483, DOI 10.1002/j.1460-2075.1994.tb06535.x; FOX GC, 1966, ACTA CRYSTALLOGR, V20, P886, DOI 10.1107/S0365110X66002007; GATIGNOL A, 1988, FEBS LETT, V230, P171, DOI 10.1016/0014-5793(88)80665-3; GENILLOUD O, 1984, GENE, V32, P225, DOI 10.1016/0378-1119(84)90050-7; HIGASHI T, 1989, J APPL CRYSTALLOGR, V16, P542; HOLMES CE, 1993, BIOCHEMISTRY-US, V32, P4293, DOI 10.1021/bi00067a019; IITAKA Y, 1978, J ANTIBIOT, V31, P1070, DOI 10.7164/antibiotics.31.1070; JAMES MN, 1996, J CHEM SOC, V16, P1361; JIANG JS, 1994, J MOL BIOL, V243, P100, DOI 10.1006/jmbi.1994.1633; Kawano Y, 2000, J MOL BIOL, V295, P915, DOI 10.1006/jmbi.1999.3404; Kleywegt GJ, 1996, STRUCTURE, V4, P1395, DOI 10.1016/S0969-2126(96)00147-5; KONNERT JH, 1980, ACTA CRYSTALLOGR A, V36, P344, DOI 10.1107/S0567739480000794; Kumagai T, 1999, FEBS LETT, V442, P34, DOI 10.1016/S0014-5793(98)01613-5; Kumagai T, 1999, ACTA CRYSTALLOGR D, V55, P1095, DOI 10.1107/S0907444999002875; KURODA R, 1982, NUCLEIC ACIDS RES, V10, P4753, DOI 10.1093/nar/10.15.4753; Lehmann TE, 1997, BIOCHEMISTRY-US, V36, P2807, DOI 10.1021/bi962748t; LIN SY, 1981, BIOCHEMISTRY-US, V20, P7589, DOI 10.1021/bi00529a038; LUZZATI V, 1952, ACTA CRYSTALLOGR, V5, P802, DOI 10.1107/S0365110X52002161; MAGLIOZZO RS, 1989, MOL PHARMACOL, V35, P428; MATTHEWS BW, 1968, J MOL BIOL, V33, P491, DOI 10.1016/0022-2836(68)90205-2; MAZODIER P, 1985, NUCLEIC ACIDS RES, V13, P195, DOI 10.1093/nar/13.1.195; MCPHERSON A, 1982, PREPARATION ANAL PRO, P96; McRee DE, 1992, J MOL GRAPHICS, V10, P44, DOI DOI 10.1016/0263-7855(92)80022-6; Ramachandran G N, 1968, Adv Protein Chem, V23, P283, DOI 10.1016/S0065-3233(08)60402-7; SAKABE N, 1995, REV SCI INSTRUM, V66, P1276, DOI 10.1063/1.1146021; SAKAI TT, 1981, J MED CHEM, V24, P279, DOI 10.1021/jm00135a008; Sheldrick GM, 1997, METHOD ENZYMOL, V277, P319, DOI 10.1016/S0076-6879(97)77018-6; STUBBE J, 1987, CHEM REV, V87, P1107, DOI 10.1021/cr00081a011; SUGIYAMA M, 1994, GENE, V151, P11; SUGIYAMA M, 1995, FEBS LETT, V362, P80, DOI 10.1016/0014-5793(95)00218-X; UMEZAWA H, 1974, FED PROC, V33, P2296; Vanderwall DE, 1997, CHEM BIOL, V4, P373, DOI 10.1016/S1074-5521(97)90128-9; Wilson A. J. C., 1942, NATURE, V150, P152; Wu W, 1996, J AM CHEM SOC, V118, P1268, DOI 10.1021/ja9524964; Wu W, 1996, J AM CHEM SOC, V118, P1281, DOI 10.1021/ja952497w; XU RX, 1994, BIOCHEMISTRY-US, V33, P907, DOI 10.1021/bi00170a009	50	24	24	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 30	2001	276	13					9992	9999		10.1074/jbc.M009874200	http://dx.doi.org/10.1074/jbc.M009874200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	420GC	11134052	hybrid			2022-12-25	WOS:000167996400057
J	Suh, JH; Shigeno, ET; Morrow, JD; Cox, B; Rocha, AE; Frei, B; Hagen, TM				Suh, JH; Shigeno, ET; Morrow, JD; Cox, B; Rocha, AE; Frei, B; Hagen, TM			Oxidative stress in the aging rat heart is reversed by dietary supplementation with (R)-alpha-lipoic acid	FASEB JOURNAL			English	Article						aging; cardiac myocytes; oxidative stress; lipoic acid	LIPID-PEROXIDATION; ELECTROCHEMICAL DETECTION; PYRUVATE-DEHYDROGENASE; ALPHA-TOCOPHEROL; ASCORBIC-ACID; LIPOIC ACID; VITAMIN-E; OLD RATS; MYOCYTES; MITOCHONDRIA	Oxidative stress has been implicated as a causal factor in the aging process of the heart and other tissues. To determine the extent of age-related myocardial oxidative stress, oxidant production, antioxidant status, and oxidative DNA damage were measured in hearts of young (2 months) and old (28 months) male Fischer 344 rats. Cardiac myocytes isolated from old rats showed a nearly threefold increase in the rate of oxidant production compared to young rats, as measured by the rates of 2,7-dichlorofluorescin diacetate oxidation, Determination of myocardial antioxidant status revealed a significant twofold decline in the levels of ascorbic acid (P = 0.03), but not alpha -tocopherol, A significant age-related increase (P = 0.05) in steady-state levels of oxidative DNA damage was observed, as monitored by 8-oxo-2'-deoxyguanosine levels. To investigate whether dietary supplementation with (R)-alpha -lipoic acid (LA) was effective at reducing oxidative stress, young and old rats were fed an AIN-93M diet with or without 0.2% (w/w) LA for 2 wk before death. Cardiac myocytes from old, LA-supplemented rats exhibited a markedly lower rate of oxidant production that was no longer significantly different from that in cells from unsupplemented, young rats. Lipoic acid supplementation also restored myocardial ascorbic acid levels and reduced oxidative DNA damage, Our data indicate that the aging rat heart is under increased mitochondrial-induced oxidative stress, which is significantly attenuated by lipoic acid supplementation.-Suh, J. H., Shigeno, E. T., Merrow, J. D., Cox, B., Rocha, A. E., Frei, B., Hagen, T. M. Oxidative stress in the aging rat heart is reversed by dietary supplementation with (R)-alpha -lipoic acid.	Oregon State Univ, Linus Pauling Inst, Corvallis, OR 97331 USA; Oregon State Univ, Dept Biochem & Biophys, Corvallis, OR 97331 USA; Vanderbilt Univ, Sch Med, Dept Pharmacol, Nashville, TN 37212 USA	Oregon State University; Oregon State University; Vanderbilt University	Hagen, TM (corresponding author), Oregon State Univ, Linus Pauling Inst, 571 Weniger Hall, Corvallis, OR 97331 USA.				NCI NIH HHS [P01 CA077839, CA77839] Funding Source: Medline; NIA NIH HHS [R01 AG017141, RIAG17141A] Funding Source: Medline; NIDDK NIH HHS [R01 DK048831, P30 DK026657, DK26657, DK48831] Funding Source: Medline; NIGMS NIH HHS [R01 GM042056, GM42056, P50 GM015431, R37 GM042056, P01 GM015431, GM15431] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA077839] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK026657, R01DK048831] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042056, R37GM042056, P50GM015431, P01GM015431] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG017141] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		AWAD JA, 1994, J NUTR, V124, P810, DOI 10.1093/jn/124.6.810; BUETTNER GR, 1993, ARCH BIOCHEM BIOPHYS, V300, P535, DOI 10.1006/abbi.1993.1074; CHOU PP, 1985, CLIN CHEM, V31, P880; Cohn JN, 1997, CIRCULATION, V95, P766; FARMER BB, 1983, LIFE SCI, V33, P1, DOI 10.1016/0024-3205(83)90706-3; FREI B, 1989, P NATL ACAD SCI USA, V86, P6377, DOI 10.1073/pnas.86.16.6377; FROLKIS VV, 1988, GERONTOLOGY, V34, P64, DOI 10.1159/000212932; Hagen TM, 1997, P NATL ACAD SCI USA, V94, P3064, DOI 10.1073/pnas.94.7.3064; Hagen TM, 1998, P NATL ACAD SCI USA, V95, P9562, DOI 10.1073/pnas.95.16.9562; Han D, 1997, BIOFACTORS, V6, P321, DOI 10.1002/biof.5520060303; Hansford RG, 1997, J BIOENERG BIOMEMBR, V29, P89, DOI 10.1023/A:1022420007908; Haramaki N, 1997, FREE RADICAL BIO MED, V22, P535, DOI 10.1016/S0891-5849(96)00400-5; Helbock HJ, 1998, P NATL ACAD SCI USA, V95, P288, DOI 10.1073/pnas.95.1.288; HOCH FL, 1992, BIOCHIM BIOPHYS ACTA, V1113, P71, DOI 10.1016/0304-4157(92)90035-9; Humphries KM, 1998, BIOCHEMISTRY-US, V37, P15835, DOI 10.1021/bi981512h; KATZ AM, 1991, HOSP PRACT, V26, P78; Kozlov AV, 1999, ARCH BIOCHEM BIOPHYS, V363, P148, DOI 10.1006/abbi.1998.1064; Lodge JK, 1998, FREE RADICAL BIO MED, V25, P287, DOI 10.1016/S0891-5849(98)00048-3; Lykkesfeldt J, 1998, FASEB J, V12, P1183, DOI 10.1096/fasebj.12.12.1183; MORGAN JP, 1990, CIRCULATION, V81, P21; Morrow JD, 1998, ARCH BIOCHEM BIOPHYS, V353, P160, DOI 10.1006/abbi.1998.0645; MORROW JD, 1992, J CLIN INVEST, V90, P2502, DOI 10.1172/JCI116143; NAKAGAWA Y, 1991, BIOCHEM PHARMACOL, V42, P883, DOI 10.1016/0006-2952(91)90049-B; Nakai N, 1997, LIFE SCI, V60, P2309, DOI 10.1016/S0024-3205(97)00286-5; NEGRETTI N, 1993, CARDIOVASC RES, V27, P1826, DOI 10.1093/cvr/27.10.1826; NOHL H, 1978, EUR J BIOCHEM, V82, P563, DOI 10.1111/j.1432-1033.1978.tb12051.x; Roy Sashwati, 1998, Biofactors, V7, P263; SAWADA M, 1987, MECH AGEING DEV, V41, P125, DOI 10.1016/0047-6374(87)90057-1; SIRI FM, 1991, AM J PHYSIOL, V261, pH514, DOI 10.1152/ajpheart.1991.261.2.H514; SOHAL RS, 1994, MECH AGEING DEV, V74, P121, DOI 10.1016/0047-6374(94)90104-X; Souza-Pinto NC, 1999, NUCLEIC ACIDS RES, V27, P1935, DOI 10.1093/nar/27.8.1935; TYTGAT J, 1994, CARDIOVASC RES, V28, P280, DOI 10.1093/cvr/28.2.280; WANG Z, 1995, J PHARMACOL EXP THER, V363, P148	33	96	104	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAR	2001	15	3					700	706		10.1096/fj.00-0176com	http://dx.doi.org/10.1096/fj.00-0176com			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	410BE	11259388	Green Accepted			2022-12-25	WOS:000167419500027
J	Brunetti, A; Manfioletti, G; Chiefari, E; Goldfine, ID; Foti, D				Brunetti, A; Manfioletti, G; Chiefari, E; Goldfine, ID; Foti, D			Transcriptional regulation of human insulin receptor gene by the high-mobility group protein HMGI(Y)	FASEB JOURNAL			English	Article						insulin receptor promoter; transcription factors; CAT reporter gene	FIBROBLAST GROWTH-FACTOR; DNA-BINDING PROTEINS; IFN-BETA GENE; CULTURED LYMPHOCYTES; MOLECULAR MECHANISMS; PROMOTER REGION; MAMMALIAN-CELLS; VIRUS INDUCTION; BREAST-CANCER; EXPRESSION	We have previously identified two closely related nuclear binding proteins that specifically interact with two unique functional AT-rich sequences of the 5' regulatory region of the human insulin receptor gene, Expression of these nuclear binding proteins increases during myocyte and adipocyte differentiation, and in other tissues appears to correlate with insulin receptor content. We have hypothesized, therefore, that insulin receptor expression in the insulin target tissues is regulated at least in part by these nuclear proteins. Here we show data on purification and biochemical characterization of these DNA binding proteins. Using a conventional chromatographic purification procedure combined with electrophoresis mobility shift assay and immunoblot analyses, a unique similar to 15 kDa protein, either identical to or highly related to the architectural transcription factor HMGI(Y), has now been identified, suggesting an essential role for HMGI(Y) in regulating insulin receptor gene transcription. Direct evidence of HMGI(Y) insulin receptor promoter interactions is provided by functional analysis with the GAT reporter gene and by hormone binding studies in cells expressing HMGI(Y) antisense RNA. In these experiments, antisense HMGI(Y) specifically inhibits insulin receptor promoter function and insulin receptor protein expression, indicating that HMGI(Y) is required for proper transcription of insulin receptor gene, Moreover, our data consistently support the hypothesis that a putative defect in this nuclear binding protein may cause insulin receptor dysfunction with subsequent impairment of insulin signaling and action.	Policlin Mater Domini, Cattedra Endocrinol, Dipartimento Med Sperimentale & Clin G Salvatore, I-88100 Catanzaro, Italy; Univ Trieste, Dipartimento Biochim Biofis & Chim Macromol, Trieste, Italy; Univ Calif San Francisco, Dept Med, Div Diabet & Endocrine Res, Mt Zion Med Ctr, San Francisco, CA 94120 USA; Univ Catanzaro Magna Graecia, Cattedra Med Interna, Dipartimento Med Sperimentale & Clin G Salvatore, Catanzaro, Italy	University of Trieste; University of California System; University of California San Francisco; UCSF Medical Center; UCSF Medical Center at Mount Zion; Magna Graecia University of Catanzaro	Brunetti, A (corresponding author), Policlin Mater Domini, Cattedra Endocrinol, Dipartimento Med Sperimentale & Clin G Salvatore, Via T Campanella 115, I-88100 Catanzaro, Italy.		Brunetti, Antonio/K-7756-2016; Foti, Daniela P/K-8038-2016; Chiefari, Eusebio/Y-2558-2019	Chiefari, Eusebio/0000-0001-5329-3124; Brunetti, Antonio/0000-0003-1533-8779; Foti, Daniela/0000-0002-9536-5736; MANFIOLETTI, GUIDALBERTO/0000-0001-7913-2601	Telethon [E.0613, GGP04245] Funding Source: Medline; Fondazione Telethon Funding Source: Custom	Telethon(Fondazione Telethon); Fondazione Telethon(Fondazione Telethon)		Allemann RK, 1997, CHEM BIOL, V4, P643, DOI 10.1016/S1074-5521(97)90218-0; AMFO K, 1995, ONCOGENE, V11, P351; ARAKI E, 1987, J BIOL CHEM, V262, P16186; Bergmann U, 1996, BIOCHEM BIOPH RES CO, V220, P886, DOI 10.1006/bbrc.1996.0500; BIANCHI ME, 1989, SCIENCE, V243, P1056, DOI 10.1126/science.2922595; BODNER M, 1988, CELL, V55, P505, DOI 10.1016/0092-8674(88)90037-2; BRUNETTI A, 1989, J CLIN INVEST, V83, P192, DOI 10.1172/JCI113858; BRUNETTI A, 1990, MOL ENDOCRINOL, V4, P880, DOI 10.1210/mend-4-6-880; BRUNETTI A, 1990, J BIOL CHEM, V265, P5960; BRUNETTI A, 1993, J CLIN INVEST, V92, P1288, DOI 10.1172/JCI116702; Bustin M, 1996, PROG NUCLEIC ACID RE, V54, P35, DOI 10.1016/S0079-6603(08)60360-8; CELENZA JL, 1986, SCIENCE, V233, P1175, DOI 10.1126/science.3526554; CHLAPPETTA G, 1995, ONCOGENE, V10, P1307; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FOX SR, 1990, MOL ENDOCRINOL, V4, P1069, DOI 10.1210/mend-4-7-1069; GARTENBERG MR, 1991, J MOL BIOL, V219, P217, DOI 10.1016/0022-2836(91)90563-L; GOLDFINE ID, 1987, ENDOCR REV, V8, P235, DOI 10.1210/edrv-8-3-235; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HAWLEY DM, 1989, J BIOL CHEM, V264, P2438; HOYER D, 1999, ANN NY ACAD SCI, V893, P301; JOHNSON KR, 1989, MOL CELL BIOL, V9, P2114, DOI 10.1128/MCB.9.5.2114; KADONAGA JT, 1986, P NATL ACAD SCI USA, V83, P5889, DOI 10.1073/pnas.83.16.5889; KAHN CR, 1985, ANNU REV MED, V36, P429; LEE JK, 1992, J BIOL CHEM, V267, P4638; LEVY JR, 1993, DIABETES, V42, P66, DOI 10.2337/diabetes.42.1.66; Longo VD, 1999, NEUROBIOL AGING, V20, P479, DOI 10.1016/S0197-4580(99)00089-5; MAMULA PW, 1990, DIABETES CARE, V13, P288, DOI 10.2337/diacare.13.3.288; MAMULA PW, 1989, DIABETES, V37, P1241; Mantovani F, 1998, NUCLEIC ACIDS RES, V26, P1433, DOI 10.1093/nar/26.6.1433; MCDONALD AR, 1988, J CLIN INVEST, V81, P499, DOI 10.1172/JCI113347; MCKEON C, 1990, MOL ENDOCRINOL, V4, P647, DOI 10.1210/mend-4-4-647; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; NELSON HCM, 1987, NATURE, V330, P221, DOI 10.1038/330221a0; OLEFSKY JM, 1981, DIABETES, V30, P148, DOI 10.2337/diab.30.2.148; PAPA V, 1990, J CLIN INVEST, V86, P1503, DOI 10.1172/JCI114868; Pellacani A, 1999, J BIOL CHEM, V274, P1525, DOI 10.1074/jbc.274.3.1525; PETRUZZELLI L, 1986, P NATL ACAD SCI USA, V83, P4710, DOI 10.1073/pnas.83.13.4710; PODSKALNY JM, 1985, EUR J BIOCHEM, V150, P401, DOI 10.1111/j.1432-1033.1985.tb09034.x; Polonsky KS, 1996, NEW ENGL J MED, V334, P777, DOI 10.1056/NEJM199603213341207; QUEEN C, 1983, CELL, V33, P741, DOI 10.1016/0092-8674(83)90016-8; ROUILLER DG, 1985, J CLIN INVEST, V76, P645, DOI 10.1172/JCI112017; RUSSELL DW, 1983, NATURE, V304, P652, DOI 10.1038/304652a0; Sambrook J., 2002, MOL CLONING LAB MANU; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHLEIF R, 1988, SCIENCE, V241, P1182, DOI 10.1126/science.2842864; SEINO S, 1989, P NATL ACAD SCI USA, V86, P114, DOI 10.1073/pnas.86.1.114; Shain DH, 1998, NUCLEIC ACIDS RES, V26, P1019, DOI 10.1093/nar/26.4.1019; SIBLEY E, 1989, P NATL ACAD SCI USA, V86, P9732, DOI 10.1073/pnas.86.24.9732; STANDAERT ML, 1984, J BIOL CHEM, V259, P2337; STRUHL K, 1985, P NATL ACAD SCI USA, V82, P8419, DOI 10.1073/pnas.82.24.8419; SUNG CK, 1992, BIOCHEMISTRY-US, V31, P168, DOI 10.1021/bi00116a025; TAYLOR SI, 1992, DIABETES, V41, P1473, DOI 10.2337/diabetes.41.11.1473; Taylor SI, 1999, CELL, V97, P9, DOI 10.1016/S0092-8674(00)80709-6; TEWARI DS, 1989, J BIOL CHEM, V264, P16238; Thanos D, 1995, CELL, V83, P1091, DOI 10.1016/0092-8674(95)90136-1; THANOS D, 1992, CELL, V71, P777, DOI 10.1016/0092-8674(92)90554-P; TRISCHITTA V, 1989, J BIOL CHEM, V264, P5041; Virkamaki A, 1999, J CLIN INVEST, V103, P931, DOI 10.1172/JCI6609; Webster NJG, 1996, CANCER RES, V56, P2781; WEBSTER NJG, 1994, DIABETES, V43, P305, DOI 10.2337/diabetes.43.2.305; WHITE MF, 1994, J BIOL CHEM, V269, P1; YAMAMOTO KR, 1985, ANNU REV GENET, V19, P209, DOI 10.1146/annurev.genet.19.1.209	62	81	87	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	FEB	2001	15	2					492	500		10.1096/fj.00-0190com	http://dx.doi.org/10.1096/fj.00-0190com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	400LK	11156965				2022-12-25	WOS:000166872900031
J	Balaban, N; Goldkorn, T; Gov, Y; Hirshberg, M; Koyfman, N; Matthews, HR; Nhan, RT; Singh, B; Uziel, O				Balaban, N; Goldkorn, T; Gov, Y; Hirshberg, M; Koyfman, N; Matthews, HR; Nhan, RT; Singh, B; Uziel, O			Regulation of Staphylococcus aureus pathogenesis via target of RNAIII-activating protein (TRAP)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AGR; VIRULENCE; SYSTEMS; LOCUS; GENE; SAR; MOLECULE; TOXIN	Staphylococcus aureus can cause disease through the production of toxins. Toxin production is autoinduced by the protein RNAIII-activating protein (RAP) and by the autoinducing peptide (AIP), and is inhibited by RNAIII-inhibiting peptide (RIP) and by inhibitory AIPs. RAP has been shown to be a useful vaccine target site, and RIP and inhibitory AIPs as therapeutic molecules to prevent and suppress S. aureus infections. Development of therapeutic strategies based on these molecules has been hindered by a lack of knowledge of the molecular mechanisms by which they activate or inhibit virulence. Here, we show that RAP specifically induces the phosphorylation of a novel 21-kDa protein, whereas RIP inhibits its phosphorylation. This protein was termed target of RAP (TRAP). The synthesis of the virulence regulatory molecule, RNAIII, is not activated by RAP in the trap mutant strain, suggesting that RAP activates RNAIII synthesis via TRAP. Phosphoamino acid analysis shows that TRAP is histidine-phosphorylated, suggesting that TRAP may be a sensor of RAP. AIPs upregulate the synthesis of RNAIII also in trap mutant strains, suggesting that TRAP and AIPs activate RNAIII synthesis via distinct signal transduction pathways. Furthermore, TRAP phosphorylation is down-regulated in the presence of AIP, suggesting that a network of signal transduction pathways regulate S. aureus pathogenesis.	Univ Calif Davis, Dept Pathol, Davis, CA 95616 USA; Univ Calif Davis, Dept Internal Med, Davis, CA 95616 USA; Univ Calif Davis, Dept Biol Chem, Davis, CA 95616 USA; Tel Aviv Univ, Sackler Sch Med, Dept Human Microbiol, IL-69978 Tel Aviv, Israel; Univ Cambridge, Dept Biochem, Cambridge CB2 1GA, England	University of California System; University of California Davis; University of California System; University of California Davis; University of California System; University of California Davis; Tel Aviv University; Sackler Faculty of Medicine; University of Cambridge	Balaban, N (corresponding author), Univ Calif Davis, Med Ctr, Dept Pathol, Res Bldg 3, Sacramento, CA 95817 USA.	nbalaban@ucdavis.edu						ABDELNOUR A, 1993, INFECT IMMUN, V61, P3879, DOI 10.1128/IAI.61.9.3879-3885.1993; Balaban N, 2000, PEPTIDES, V21, P1301, DOI 10.1016/S0196-9781(00)00272-2; BALABAN N, 1995, FEMS MICROBIOL LETT, V133, P155, DOI 10.1016/0378-1097(95)00356-A; BALABAN N, 1995, P NATL ACAD SCI USA, V92, P1619, DOI 10.1073/pnas.92.5.1619; Balaban N, 1998, SCIENCE, V280, P438, DOI 10.1126/science.280.5362.438; BALABAN N, 2000, SCIENCE, V287, pA391; Bayer MG, 1996, J BACTERIOL, V178, P4563, DOI 10.1128/jb.178.15.4563-4570.1996; Cheung AL, 1997, J BACTERIOL, V179, P3963, DOI 10.1128/jb.179.12.3963-3971.1997; Chien YT, 1998, J BIOL CHEM, V273, P2645, DOI 10.1074/jbc.273.5.2645; GILLASPY AF, 1995, INFECT IMMUN, V63, P3373, DOI 10.1128/IAI.63.9.3373-3380.1995; Giraudo AT, 1999, FEMS MICROBIOL LETT, V177, P15, DOI 10.1016/S0378-1097(99)00282-7; Ji GY, 1995, P NATL ACAD SCI USA, V92, P12055, DOI 10.1073/pnas.92.26.12055; Ji GY, 1997, SCIENCE, V276, P2027, DOI 10.1126/science.276.5321.2027; Kleerebezem M, 1997, MOL MICROBIOL, V24, P895, DOI 10.1046/j.1365-2958.1997.4251782.x; LEE CY, 1991, GENE, V103, P101, DOI 10.1016/0378-1119(91)90399-V; Lina G, 1998, MOL MICROBIOL, V28, P655, DOI 10.1046/j.1365-2958.1998.00830.x; Lowy FD, 1998, NEW ENGL J MED, V339, P520, DOI 10.1056/NEJM199808203390806; Mayville P, 1999, P NATL ACAD SCI USA, V96, P1218, DOI 10.1073/pnas.96.4.1218; MOERFELDT E, 1995, EMBO J, V14, P4569; Moreau JM, 1997, CURR EYE RES, V16, P1221, DOI 10.1076/ceyr.16.12.1221.5022; Morfeldt E, 1996, FEMS MICROBIOL LETT, V143, P195, DOI 10.1016/0378-1097(96)00310-2; NOVICK RP, 1995, MOL GEN GENET, V248, P446, DOI 10.1007/BF02191645; NOVICK RP, 1993, EMBO J, V12, P3967, DOI 10.1002/j.1460-2075.1993.tb06074.x; NOVICK RP, 1991, METHOD ENZYMOL, V204, P587; NOVICK RP, 2000, SCIENCE, V287, pA391; Perraud AL, 1999, TRENDS MICROBIOL, V7, P115, DOI 10.1016/S0966-842X(99)01458-4; POPHAM DL, 1993, J BACTERIOL, V175, P4870, DOI 10.1128/JB.175.15.4870-4876.1993; ROST B, 1993, J MOL BIOL, V232, P584, DOI 10.1006/jmbi.1993.1413; Russo F D, 1993, Trends Microbiol, V1, P306, DOI 10.1016/0966-842X(93)90007-E; SCHENK S, 1992, FEMS MICROBIOL LETT, V94, P133; Schmitt CK, 1999, EMERG INFECT DIS, V5, P224, DOI 10.3201/eid0502.990206; WEI YF, 1991, METHOD ENZYMOL, V200, P388	32	122	141	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 26	2001	276	4					2658	2667		10.1074/jbc.M005446200	http://dx.doi.org/10.1074/jbc.M005446200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	398YV	11160124	hybrid			2022-12-25	WOS:000166784800051
J	Jabbur, JR; Huang, P; Zhang, W				Jabbur, JR; Huang, P; Zhang, W			DNA damage-induced phosphorylation of p53 at serine 20 correlates with p21 and Mdm-2 induction in vivo	ONCOGENE			English	Article						phosphorylation; ionizing radiation; p53; p21	TUMOR-SUPPRESSOR PROTEIN; ONCOPROTEIN MDM2; KINASE; ACTIVATION; STABILITY; APOPTOSIS; RADIATION; DEGRADATION; TERMINUS; DOMAIN	We investigated the induction and physiological role of Ser20 phosphorylation of p53 in response to DNA damage caused by ionizing radiation (IR) or ultraviolet radiation (UV), A polyclonal antibody that specifically recognizes a p53 peptide containing phosphorylated Ser20 was generated and used to detect p53 phosphorylation at Ser20, Western blot analyses of p53 in four cell lines with this antibody revealed that the p53 protein was phosphorylated at Ser20 to a different extent after treatment with IR or UV, The phosphorylation of Ser20 of wild-type p53 correlated with enhanced induction of the p53 downstream target genes p21(WAF1/Cip1) (p21) and mdm-2. These results suggest that DNA damage-induced phosphorylation of p53 at Ser20 enhances the transactivation function of p53 for p21 and mdm-2 in vivo.	Univ Texas, MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Canc Biol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Clin Invest, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Zhang, W (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Pathol, Box 85,1515 Holcombe Blvd, Houston, TX 77030 USA.				NCI NIH HHS [CA55164, CA16672, CA77339, CA67987] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA016672, R29CA077339, P01CA055164, R29CA067987] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ashcroft M, 1999, MOL CELL BIOL, V19, P1751; Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; Bulavin DV, 1999, EMBO J, V18, P6845, DOI 10.1093/emboj/18.23.6845; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; Chehab NH, 2000, GENE DEV, V14, P278; Chehab NH, 1999, P NATL ACAD SCI USA, V96, P13777, DOI 10.1073/pnas.96.24.13777; Chen JD, 1996, MOL CELL BIOL, V16, P2445; Dumaz N, 1999, FEBS LETT, V463, P312, DOI 10.1016/S0014-5793(99)01647-6; El-Deiry WS, 1998, SEMIN CANCER BIOL, V8, P345, DOI 10.1006/scbi.1998.0097; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; Gu JJ, 2000, MOL CELL BIOL, V20, P1243, DOI 10.1128/MCB.20.4.1243-1253.2000; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Higashimoto Y, 2000, J BIOL CHEM, V275, P23199, DOI 10.1074/jbc.M002674200; Hirao A, 2000, SCIENCE, V287, P1824, DOI 10.1126/science.287.5459.1824; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; Hsieh JK, 1999, MOL CELL, V3, P181, DOI 10.1016/S1097-2765(00)80309-3; Huang CS, 1999, J BIOL CHEM, V274, P12229, DOI 10.1074/jbc.274.18.12229; Kapoor M, 1998, P NATL ACAD SCI USA, V95, P2834, DOI 10.1073/pnas.95.6.2834; Keller D, 1999, BIOCHEM BIOPH RES CO, V261, P464, DOI 10.1006/bbrc.1999.1023; Khosravi R, 1999, P NATL ACAD SCI USA, V96, P14973, DOI 10.1073/pnas.96.26.14973; Ko LJ, 1997, MOL CELL BIOL, V17, P7220, DOI 10.1128/MCB.17.12.7220; Kobayashi T, 1998, CELL DEATH DIFFER, V5, P584, DOI 10.1038/sj.cdd.4400382; Kubbutat MHG, 1998, MOL CELL BIOL, V18, P5690, DOI 10.1128/MCB.18.10.5690; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Kussie PH, 1996, SCIENCE, V274, P948, DOI 10.1126/science.274.5289.948; Lambert PF, 1998, J BIOL CHEM, V273, P33048, DOI 10.1074/jbc.273.49.33048; LU H, 1995, P NATL ACAD SCI USA, V92, P5154, DOI 10.1073/pnas.92.11.5154; Lu H, 1998, P NATL ACAD SCI USA, V95, P6399, DOI 10.1073/pnas.95.11.6399; Mayo LD, 1997, CANCER RES, V57, P5013; MEEK DW, 1990, EMBO J, V9, P3253, DOI 10.1002/j.1460-2075.1990.tb07524.x; MILNE DM, 1995, J BIOL CHEM, V270, P5511, DOI 10.1074/jbc.270.10.5511; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; Prives C, 1998, CELL, V95, P5, DOI 10.1016/S0092-8674(00)81774-2; Sakaguchi K, 1998, GENE DEV, V12, P2831, DOI 10.1101/gad.12.18.2831; Sakaguchi K, 1997, BIOCHEMISTRY-US, V36, P10117, DOI 10.1021/bi970759w; Sakaguchi K, 2000, J BIOL CHEM, V275, P9278, DOI 10.1074/jbc.275.13.9278; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Shieh SY, 1999, EMBO J, V18, P1815, DOI 10.1093/emboj/18.7.1815; Shieh SY, 2000, GENE DEV, V14, P289; Siliciano JD, 1997, GENE DEV, V11, P3471, DOI 10.1101/gad.11.24.3471; THUT CJ, 1995, SCIENCE, V267, P100, DOI 10.1126/science.7809597; Tibbetts RS, 1999, GENE DEV, V13, P152, DOI 10.1101/gad.13.2.152; Uesugi M, 1999, P NATL ACAD SCI USA, V96, P14801, DOI 10.1073/pnas.96.26.14801; Unger T, 1999, EMBO J, V18, P1805, DOI 10.1093/emboj/18.7.1805; WATTHEW JF, 1998, NAT GENET, V19, P175; Woo RA, 1998, NATURE, V394, P700, DOI 10.1038/29343; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; ZHANG W, 1994, EMBO J, V13, P2535, DOI 10.1002/j.1460-2075.1994.tb06543.x	48	46	46	0	3	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 14	2000	19	54					6203	6208		10.1038/sj.onc.1204017	http://dx.doi.org/10.1038/sj.onc.1204017			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	388YK	11175334				2022-12-25	WOS:000166210500003
J	Leonidas, DD; Boix, E; Prill, R; Suzuki, M; Turton, R; Minson, K; Swaminathan, GJ; Youle, RJ; Acharya, KR				Leonidas, DD; Boix, E; Prill, R; Suzuki, M; Turton, R; Minson, K; Swaminathan, GJ; Youle, RJ; Acharya, KR			Mapping the ribonucleolytic active site of eosinophil-derived neurotoxin (EDN) - High resolution crystal structures of EDN complexes with adenylic nucleotide inhibitors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							X-RAY-DIFFRACTION; CATIONIC PROTEIN; SUBSTRATE; BINDING; RIBONUCLEASES; MECHANISM; HYDRATION; SUBSITE; RESIDUE; LINKAGE	Eosinophil-derived neurotoxin (EDN), a basic ribonuclease found in the large specific granules of eosinophils, belongs to the pancreatic RNase A family. Although its physiological function is still unclear, it has been shown that EDN is a neurotoxin capable of inducing the Gordon phenomenon in rabbits. EDN is also a potent helminthotoxin and can mediate antiviral activity of eosinophils against isolated virions of the respiratory syncytial virus. EDN is a catalytically efficient RNase sharing similar substrate specificity with pancreatic RNase A with its ribonucleolytic activity being absolutely essential for its neurotoxic, helminthotoxic, and antiviral activities. The crystal structure of recombinant human EDN in the unliganded form has been determined previously (Mosimann, S. C., Newton, D. L., Youle, R. J., and James, M. N. G. (1996) J. Mol. Biol. 260, 540-552). We have now determined high resolution (1.8 Angstrom) crystal structures for EDN in complex with adenosine-3',5'-diphosphate (3',5'-ADP), adenosine-2',5'-diphosphate (2',5'-ADP), adenosine-5'-diphosphate (5'-ADP) as well as for a native structure in the presence of sulfate refined at 1.6 Angstrom. The inhibition constant of these mononucleotides for EDN has been determined. The structures present the first detailed picture of differences between EDN and RNase A in substrate recognition at the ribonucleolytic active site. They also provide a starting point for the design of tight-binding inhibitors, which may be used to restrain the RNase activity of EDN.	Univ Bath, Dept Biol & Biochem, Bath BA2 7AY, Avon, England; NINDS, Biochem Sect, Surg Neurol Branch, NIH, Bethesda, MD 20892 USA	University of Bath; National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS)	Acharya, KR (corresponding author), Univ Bath, Dept Biol & Biochem, Claverton Down, Bath BA2 7AY, Avon, England.	K.R.Acharya@bath.ac.uk	Boix, Ester/B-9038-2012; Leonidas, Demetres/F-7228-2013; Leonidas, Demetres/AAE-9296-2021	Boix, Ester/0000-0003-1790-2142; Leonidas, Demetres/0000-0002-3874-2523; Leonidas, Demetres/0000-0002-3874-2523; Swaminathan, Jawahar/0000-0002-0215-4084; Turton, Kathryn/0000-0002-1421-3504; Acharya, K. Ravi/0000-0002-3009-4058	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [Z01NS002674, ZIANS002674] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ACKERMAN SJ, 1983, J IMMUNOL, V52, P611; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BEINTEMA JJ, 1988, PROG BIOPHYS MOL BIO, V51, P165, DOI 10.1016/0079-6107(88)90001-6; Berisio R, 1999, J MOL BIOL, V292, P845, DOI 10.1006/jmbi.1999.3093; BIRDSALL DL, 1992, J BIOL CHEM, V267, P22230; Boix E, 1999, BIOCHEMISTRY-US, V38, P16794, DOI 10.1021/bi9919145; Boix E, 1999, J BIOL CHEM, V274, P15605, DOI 10.1074/jbc.274.22.15605; BOIX E, 1994, J BIOL CHEM, V269, P2529; BORKAKOTI N, 1983, EUR J BIOCHEM, V132, P89, DOI 10.1111/j.1432-1033.1983.tb07329.x; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; Cuchillo C. M., 1997, RIBONUCLEASES STRUCT, P271; DEMEL VSJ, 1992, J BIOL CHEM, V267, P247; DIXON M, 1953, BIOCHEM J, V55, P170, DOI 10.1042/bj0550170; Domachowske JB, 1998, J INFECT DIS, V177, P1458, DOI 10.1086/515322; DURACK DT, 1981, P NATL ACAD SCI-BIOL, V78, P5165, DOI 10.1073/pnas.78.8.5165; EFTINK MR, 1987, HYDROLYTIC ENZYMES, V7, P333; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; Esposito L, 2000, J MOL BIOL, V297, P713, DOI 10.1006/jmbi.2000.3597; Fedorov AA, 1996, BIOCHEMISTRY-US, V35, P15962, DOI 10.1021/bi961533g; Fisher BM, 1998, J BIOL CHEM, V273, P34134, DOI 10.1074/jbc.273.51.34134; FONTECILLACAMPS JC, 1994, J BIOL CHEM, V269, P21526; FREDENS K, 1982, J ALLERGY CLIN IMMUN, V70, P361, DOI 10.1016/0091-6749(82)90025-2; FRENCH S, 1978, ACTA CRYSTALLOGR A, V34, P517, DOI 10.1107/S0567739478001114; GILLILAND GL, 1997, RIBONUCLEASES STRUCT, P305; GLEICH GJ, 1986, ADV IMMUNOL, V39, P177; HOFSTEENGE J, 1994, BIOCHEMISTRY-US, V33, P13524, DOI 10.1021/bi00250a003; IMAZAWA M, 1968, J BIOCHEM-TOKYO, V64, P595, DOI 10.1093/oxfordjournals.jbchem.a128936; JIANG JS, 1994, J MOL BIOL, V243, P100, DOI 10.1006/jmbi.1994.1633; Kelemen BR, 1999, NUCLEIC ACIDS RES, V27, P3696, DOI 10.1093/nar/27.18.3696; Krieg J, 1998, MOL BIOL CELL, V9, P301, DOI 10.1091/mbc.9.2.301; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Leonidas DD, 1997, BIOCHEMISTRY-US, V36, P5578, DOI 10.1021/bi9700330; Leonidas DD, 1999, BIOCHEMISTRY-US, V38, P10287, DOI 10.1021/bi990900w; LOFFLER A, 1998, BIOCHEMISTRY-US, V35, P12005; MATTOS C, 1994, NAT STRUCT BIOL, V1, P55, DOI 10.1038/nsb0194-55; MCDONALD IK, 1994, J MOL BIOL, V238, P777, DOI 10.1006/jmbi.1994.1334; MCPHERSON A, 1986, SCIENCE, V232, P765, DOI 10.1126/science.3961503; MOISEEV GP, 1982, BIOORG KHIM+, V8, P1197; MOODIE SL, 1993, NUCLEIC ACIDS RES, V21, P1369, DOI 10.1093/nar/21.6.1369; Mosimann SC, 1996, J MOL BIOL, V260, P540, DOI 10.1006/jmbi.1996.0420; NEWTON DL, 1994, J BIOL CHEM, V269, P26739; NEWTON DL, 1994, J NEUROSCI, V14, P538; NICHOLLS A, 1991, J COMPUT CHEM, V12, P435, DOI 10.1002/jcc.540120405; Nogues MV, 1998, CELL MOL LIFE SCI, V54, P766, DOI 10.1007/s000180050205; OIKONOMAKOS NG, 1995, J MOL BIOL, V254, P900, DOI 10.1006/jmbi.1995.0665; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Raines RT, 1998, CHEM REV, V98, P1045, DOI 10.1021/cr960427h; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; RICHARDS FM, 1971, ENZYMES, V4, P647; Rosenberg HF, 1998, CELL MOL LIFE SCI, V54, P795, DOI 10.1007/s000180050208; ROSENBERG HF, 1989, P NATL ACAD SCI USA, V86, P4460, DOI 10.1073/pnas.86.12.4460; Russo N, 1999, J BIOL CHEM, V274, P14902, DOI 10.1074/jbc.274.21.14902; Russo N, 1997, BIOCHEM BIOPH RES CO, V231, P671, DOI 10.1006/bbrc.1997.6167; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SLIFMAN NR, 1986, J IMMUNOL, V137, P2913; SNYDER MR, 1997, RIBONUCLEASES STRUCT, P425; SORRENTINO S, 1992, J BIOL CHEM, V267, P14859; SORRENTINO S, 1994, ARCH BIOCHEM BIOPHYS, V312, P340, DOI 10.1006/abbi.1994.1318; Toiron C, 1996, PROTEIN SCI, V5, P1633, DOI 10.1002/pro.5560050817; ZEGERS I, 1994, PROTEIN SCI, V3, P2322, DOI 10.1002/pro.5560031217	61	39	41	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 4	2001	276	18					15009	15017		10.1074/jbc.M010585200	http://dx.doi.org/10.1074/jbc.M010585200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	429QQ	11154698	hybrid			2022-12-25	WOS:000168528800066
J	Medina, M; Luquita, A; Tejero, J; Hermoso, J; Mayoral, T; Sanz-Aparicio, J; Grever, K; Gomez-Moreno, C				Medina, M; Luquita, A; Tejero, J; Hermoso, J; Mayoral, T; Sanz-Aparicio, J; Grever, K; Gomez-Moreno, C			Probing the determinants of coenzyme specificity in ferredoxin-NADP(+) reductase by site-directed mutagenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; PHTHALATE DIOXYGENASE REDUCTASE; ANABAENA SP PCC-7119; NADP+ REDUCTASE; ELECTRON-TRANSFER; SPINACH FERREDOXIN; ISOCITRATE DEHYDROGENASE; LACTATE-DEHYDROGENASE; COFACTOR SPECIFICITY; CATALYTIC MECHANISM	On the basis of sequence and three-dimensional structure comparison between Anabaena PCC7119 ferredoxin-NADP(+) reductase (FNR) and other reductases from its structurally related family that bind either NADP(+)/H or NAD(+)/H, a set of amino acid residues that might determine the FNR coenzyme specificity can be assigned, These residues include Thr-155, Ser-223, Arg-224, Arg-233 and Tyr-285. Systematic replacement of these amino acids was done to identify which of them are the main determinants of coenzyme specificity. Our data indicate that all of the residues interacting with the 2'-phosphate of NADP(+)/H in Anabaena FNR are not involved to the same extent in determining coenzyme specificity and affinity. Thus, it is found that Ser-223 and Tyr-235 are important for determining NADP(+)/H specificity and orientation with respect to the protein, whereas Arg-224 and Arg-233 provide only secondary interactions in Anabaena FNR. The analysis of the T155G FNR form also indicates that the determinants of coenzyme specificity are not only situated in the 2'-phosphate NADP(+)/H interacting region but that other regions of the protein must be involved. These regions, although not interacting directly with the coenzyme, must produce specific structural arrangements of the backbone chain that determine coenzyme specificity. The loop formed by residues 261-268 in Anabaena FNR must be one of these regions.	Univ Zaragoza, Fac Ciencias, Dept Bioquim & Biol Mol & Celular, E-50009 Zaragoza, Spain; CSIC, Inst Quim Fis Rocasolano, Grp Cristalog Macromol & Biol Estructural, E-28006 Madrid, Spain	University of Zaragoza; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Quimica Fisica Rocasolano (IQFR)	Medina, M (corresponding author), Univ Zaragoza, Fac Ciencias, Dept Bioquim & Biol Mol & Celular, Pedro Cerbuna 12, E-50009 Zaragoza, Spain.	mmedina@posta.unizar.es	Medina, Milagros/F-8310-2012; Tejero, Jesus/G-3953-2017; Hermoso, Juan/J-3433-2012; Sanz-Aparicio, Julia/F-6201-2013	Medina, Milagros/0000-0001-8743-0182; Tejero, Jesus/0000-0003-3245-9978; Hermoso, Juan/0000-0002-1862-8950; Sanz-Aparicio, Julia/0000-0002-6849-8621				Aliverti A, 1998, J BIOL CHEM, V273, P34008, DOI 10.1074/jbc.273.51.34008; ALIVERTI A, 1991, J BIOL CHEM, V266, P17760; ALIVERTI A, 1995, BIOCHEMISTRY-US, V34, P8371, DOI 10.1021/bi00026a019; Arakaki AK, 1997, FASEB J, V11, P133, DOI 10.1096/fasebj.11.2.9039955; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BATIE CJ, 1984, J BIOL CHEM, V259, P1976; BATIE CJ, 1986, J BIOL CHEM, V261, P1214; Brunger A. T., 1993, XPLOR SYSTEM XRAY CR; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; BRUNS CM, 1995, J MOL BIOL, V247, P125, DOI 10.1006/jmbi.1994.0127; CASTELLANO EE, 1992, J APPL CRYSTALLOGR, V25, P281, DOI 10.1107/S0021889891012773; Chen RD, 1996, P NATL ACAD SCI USA, V93, P12171, DOI 10.1073/pnas.93.22.12171; CHEN Z, 1991, EUR J BIOCHEM, V202, P263, DOI 10.1111/j.1432-1033.1991.tb16371.x; CLARKE AR, 1989, TRENDS BIOCHEM SCI, V14, P101, DOI 10.1016/0968-0004(89)90131-X; CORRELL CC, 1992, SCIENCE, V258, P1604, DOI 10.1126/science.1280857; CORRELL CC, 1993, PROTEIN SCI, V2, P2112, DOI 10.1002/pro.5560021212; Deng Z, 1999, NAT STRUCT BIOL, V6, P847; Didierjean C, 1997, J MOL BIOL, V268, P739, DOI 10.1006/jmbi.1997.0998; FAN F, 1991, BIOCHEMISTRY-US, V30, P6397, DOI 10.1021/bi00240a008; FILLAT MF, 1990, NUCLEIC ACIDS RES, V18, P7161, DOI 10.1093/nar/18.23.7161; Friesen JA, 1996, BIOCHEMISTRY-US, V35, P11945, DOI 10.1021/bi9609937; GOMEZMORENO C, 1995, PHOT LIGHT BIOSPH, P627; HALL AV, 1994, J BIOL CHEM, V269, P33082; HEDSTROM L, 1994, CURR OPIN STRUC BIOL, V4, P608, DOI 10.1016/S0959-440X(94)90225-9; Holmberg N, 1999, PROTEIN ENG, V12, P851, DOI 10.1093/protein/12.10.851; Hurley JH, 1996, BIOCHEMISTRY-US, V35, P5670, DOI 10.1021/bi953001q; Hurley JK, 1997, BIOCHEMISTRY-US, V36, P11100, DOI 10.1021/bi9709001; Hurley JK, 1996, J AM CHEM SOC, V118, P5526, DOI 10.1021/ja953662a; HYDE GE, 1990, BIOCHEM BIOPH RES CO, V168, P1285, DOI 10.1016/0006-291X(90)91168-R; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KARPLUS PA, 1991, SCIENCE, V251, P60, DOI 10.1126/science.1986412; KARPLUS PA, 1984, BIOCHEMISTRY-US, V23, P6576, DOI 10.1021/bi00321a046; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LESLIE AGW, 1987, P CCP4 STUD WEEK SER, P39; LONG DM, 1992, PHYSIOL PLANTARUM, V85, P561, DOI 10.1111/j.1399-3054.1992.tb04755.x; Madoz-Gurpide J, 2000, J AM CHEM SOC, V122, P9808, DOI 10.1021/ja001365m; Martinez-Julvez M, 1998, BIOCHEMISTRY-US, V37, P17680, DOI 10.1021/bi981718i; Medina M, 1998, BIOCHEMISTRY-US, V37, P2715, DOI 10.1021/bi971795y; MEDINA M, 1992, FEBS LETT, V298, P25, DOI 10.1016/0014-5793(92)80014-8; MEDINA M, 1992, ARCH BIOCHEM BIOPHYS, V299, P281, DOI 10.1016/0003-9861(92)90276-3; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; Morales R, 2000, EMBO REP, V1, P271, DOI 10.1093/embo-reports/kvd057; Nakanishi M, 1997, J BIOL CHEM, V272, P2218, DOI 10.1074/jbc.272.4.2218; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; NEWMAN BJ, 1988, PLANT MOL BIOL, V10, P511, DOI 10.1007/BF00033606; NISHIDA H, 1995, BIOCHEMISTRY-US, V34, P2763, DOI 10.1021/bi00009a004; ORELLANO EG, 1993, J BIOL CHEM, V268, P19267; OSTROWSKI J, 1989, J BIOL CHEM, V264, P15796; OZOLS J, 1985, J BIOL CHEM, V260, P1953; Piubelli L, 2000, J BIOL CHEM, V275, P10472, DOI 10.1074/jbc.275.14.10472; PORTER TD, 1985, P NATL ACAD SCI USA, V82, P973, DOI 10.1073/pnas.82.4.973; PUEYO JJ, 1991, PREP BIOCHEM, V21, P191, DOI 10.1080/10826069108018571; ROSSMANN MG, 1974, NATURE, V250, P194, DOI 10.1038/250194a0; SANCHO J, 1991, ARCH BIOCHEM BIOPHYS, V288, P231, DOI 10.1016/0003-9861(91)90189-P; SCRUTTON NS, 1990, NATURE, V343, P38, DOI 10.1038/343038a0; SEM DS, 1993, BIOCHEMISTRY-US, V32, P11548, DOI 10.1021/bi00094a011; Serre L, 1996, J MOL BIOL, V263, P20, DOI 10.1006/jmbi.1996.0553; WALKER MC, 1991, ARCH BIOCHEM BIOPHYS, V287, P351, DOI 10.1016/0003-9861(91)90489-6; YAOI T, 1994, FEBS LETT, V355, P171, DOI 10.1016/0014-5793(94)01191-5; ZANETTI G, 1979, BIOCHIM BIOPHYS ACTA, V568, P127, DOI 10.1016/0005-2744(79)90280-8; ZANETTI G, 1976, BIOCHIM BIOPHYS ACTA, V445, P14, DOI 10.1016/0005-2744(76)90157-1; Zubay G, 1998, BIOCHEMISTRY	62	54	61	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 13	2001	276	15					11902	11912		10.1074/jbc.M009287200	http://dx.doi.org/10.1074/jbc.M009287200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	421UK	11152461	hybrid			2022-12-25	WOS:000168081800064
J	Tamar, S; Papadopoulou, B				Tamar, S; Papadopoulou, B			A telomere-mediated chromosome fragmentation approach to assess mitotic stability and ploidy alterations of Leishmania chromosomes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOUBLE-STRAND BREAKS; MAMMALIAN ARTIFICIAL CHROMOSOMES; CHAIN DEHYDROGENASE GENE; HOMOLOGOUS RECOMBINATION; TRYPANOSOMA-BRUCEI; SACCHAROMYCES-CEREVISIAE; METHOTREXATE RESISTANCE; TRYPANOTHIONE REDUCTASE; PARASITIC PROTOZOA; DNA-SEQUENCE	We have used a telomere-associated chromosome fragmentation strategy to induce internal chromosome-specific breakage of Leishmania chromosomes. The integration of telomeric repeats from the kinetoplastid Trypanosoma brucei into defined positions of the Leishmania genome by homologous recombination can induce chromosome breakage accompanied by the deletion of the chromosomal part that is distal to the site of the break. The cloned telomeric DNA at the end of the truncated chromosomes is functional and it can seed the formation of new telomeric repeats. We found that genome ploidy is often altered upon telomere-mediated chromosome fragmentation events resulting in large chromosomal deletions. In most cases diploidy is either preserved, or partial trisomic cells are observed, but interestingly we report here the generation of partial haploid mutants in this diploid organism. Partial haploid Leishmania mutants should facilitate studies on the function of chromosome-assigned genes. We also present several lines of evidence for the presence of sequences involved in chromosome mitotic stability and segregation during cell cycle in this parasitic protozoan. Telomere-directed chromosome fragmentation studies in Leishmania may constitute a useful tool to assay for centromere function.	CHU Laval, CHUQ, Ctr Rech, Ctr Rech Infectiol, Ste Foy, PQ G1V 4G2, Canada; Univ Laval, Fac Med, Dept Med Biol, Quebec City, PQ G1V 4G2, Canada	Laval University; Laval University	Papadopoulou, B (corresponding author), CHU Laval, CHUQ, Ctr Rech, Ctr Rech Infectiol, 2705 Blvd Laurier, Ste Foy, PQ G1V 4G2, Canada.	Papadopoulou@crchul.ulaval.ca						BARNETT MA, 1993, NUCLEIC ACIDS RES, V21, P27, DOI 10.1093/nar/21.1.27; BELMAAZA A, 1994, MUTAT RES, V314, P199, DOI 10.1016/0921-8777(94)90065-5; BERINSTEIN N, 1992, MOL CELL BIOL, V12, P360, DOI 10.1128/MCB.12.1.360; BERNARDS A, 1983, NATURE, V303, P592, DOI 10.1038/303592a0; BERNARDS A, 1981, CELL, V27, P497, DOI 10.1016/0092-8674(81)90391-3; Blackburn EH, 2000, NATURE, V408, P53, DOI 10.1038/35040500; BLACKBURN EH, 1984, CELL, V36, P447, DOI 10.1016/0092-8674(84)90238-1; Brown W, 1996, CURR OPIN GENET DEV, V6, P281, DOI 10.1016/S0959-437X(96)80003-7; Brown WRA, 1992, CURR OPIN GENET DEV, V2, P479, DOI 10.1016/S0959-437X(05)80161-3; Cahill DP, 1998, NATURE, V392, P300, DOI 10.1038/32688; CALLAHAN HL, 1992, J BIOL CHEM, V267, P24165; Cano MIN, 1999, P NATL ACAD SCI USA, V96, P3616, DOI 10.1073/pnas.96.7.3616; CAPECCHI MR, 1989, SCIENCE, V244, P1288, DOI 10.1126/science.2660260; Chiurillo MA, 2000, EXP PARASITOL, V94, P248, DOI 10.1006/expr.2000.4499; CROSS S, 1990, NUCLEIC ACIDS RES, V18, P6649, DOI 10.1093/nar/18.22.6649; CRUZ A, 1991, P NATL ACAD SCI USA, V88, P7170, DOI 10.1073/pnas.88.16.7170; CRUZ A, 1990, NATURE, V348, P171, DOI 10.1038/348171a0; CUNNINGHAM ML, 1995, EUR J BIOCHEM, V230, P460, DOI 10.1111/j.1432-1033.1995.tb20583.x; Diede SJ, 1999, CELL, V99, P723, DOI 10.1016/S0092-8674(00)81670-0; Dumas C, 1997, EMBO J, V16, P2590, DOI 10.1093/emboj/16.10.2590; ELLIS J, 1988, MOL BIOCHEM PARASIT, V29, P9, DOI 10.1016/0166-6851(88)90114-4; FARR C, 1991, P NATL ACAD SCI USA, V88, P7006, DOI 10.1073/pnas.88.16.7006; FARR CJ, 1992, NAT GENET, V2, P275, DOI 10.1038/ng1292-275; FARR CJ, 1995, EMBO J, V14, P5444, DOI 10.1002/j.1460-2075.1995.tb00228.x; Farr CJ, 1996, SEMIN CELL DEV BIOL, V7, P41, DOI 10.1006/scdb.1996.0007; FLINT J, 1994, AM J HUM GENET, V55, P505; Fu GL, 1998, NUCLEIC ACIDS RES, V26, P2161, DOI 10.1093/nar/26.9.2161; Harrington JJ, 1997, NAT GENET, V15, P345, DOI 10.1038/ng0497-345; HARRINGTON LA, 1991, NATURE, V353, P451, DOI 10.1038/353451a0; Heller R, 1996, P NATL ACAD SCI USA, V93, P7125, DOI 10.1073/pnas.93.14.7125; Ikeno M, 1998, NAT BIOTECHNOL, V16, P431, DOI 10.1038/nbt0598-431; ITZHAKI JE, 1992, NAT GENET, V2, P283, DOI 10.1038/ng1292-283; Ivens AC, 1998, GENOME RES, V8, P135, DOI 10.1101/gr.8.2.135; Khodjakov A, 1996, J CELL BIOL, V132, P1093, DOI 10.1083/jcb.132.6.1093; Koehler KE, 1996, HUM MOL GENET, V5, P1495, DOI 10.1093/hmg/5.Supplement_1.1495; KRAMER KM, 1993, GENE DEV, V7, P2345, DOI 10.1101/gad.7.12a.2345; Kundig C, 1999, EMBO J, V18, P2342, DOI 10.1093/emboj/18.9.2342; LABAN A, 1990, NATURE, V343, P572, DOI 10.1038/343572a0; Lamontagne J, 1999, J BIOL CHEM, V274, P6602, DOI 10.1074/jbc.274.10.6602; LANZER M, 1995, MOL BIOCHEM PARASIT, V70, P1, DOI 10.1016/0166-6851(95)00021-R; LARSON DD, 1987, CELL, V50, P477, DOI 10.1016/0092-8674(87)90501-0; Lee MGS, 1995, NUCLEIC ACIDS RES, V23, P4893, DOI 10.1093/nar/23.23.4893; LEGARE D, 1994, MOL BIOCHEM PARASIT, V68, P81, DOI 10.1016/0166-6851(94)00156-1; MA DP, 1992, GENE, V119, P253, DOI 10.1016/0378-1119(92)90279-X; Marcand S, 2000, CURR BIOL, V10, P487, DOI 10.1016/S0960-9822(00)00450-4; McEachern MJ, 2000, ANNU REV GENET, V34, P331, DOI 10.1146/annurev.genet.34.1.331; MEYNE J, 1989, P NATL ACAD SCI USA, V86, P7049, DOI 10.1073/pnas.86.18.7049; Mills W, 1999, HUM MOL GENET, V8, P751, DOI 10.1093/hmg/8.5.751; Morrow DM, 1997, GENETICS, V147, P371; Mottram JC, 1996, P NATL ACAD SCI USA, V93, P6008, DOI 10.1073/pnas.93.12.6008; MURNANE JP, 1993, MOL CELL BIOL, V13, P977, DOI 10.1128/MCB.13.2.977; MURRAY AW, 1983, NATURE, V305, P189, DOI 10.1038/305189a0; Muyombwe A, 1997, EXP PARASITOL, V85, P35, DOI 10.1006/expr.1996.4115; Myler PJ, 1999, P NATL ACAD SCI USA, V96, P2902, DOI 10.1073/pnas.96.6.2902; PAPADOPOULOU B, 1992, EMBO J, V11, P3601, DOI 10.1002/j.1460-2075.1992.tb05444.x; PAPADOPOULOU B, 1994, MOL BIOCHEM PARASIT, V65, P39, DOI 10.1016/0166-6851(94)90113-9; Papadopoulou B, 1996, BIOCHEM BIOPH RES CO, V224, P772, DOI 10.1006/bbrc.1996.1098; PAPADOPOULOU B, 1993, NUCLEIC ACIDS RES, V21, P4305, DOI 10.1093/nar/21.18.4305; PAPADOPOULOU B, 1994, J BIOL CHEM, V269, P7310; Patnaik PK, 1996, NUCLEIC ACIDS RES, V24, P668, DOI 10.1093/nar/24.4.668; PATNAIK PK, 1993, EMBO J, V12, P2529, DOI 10.1002/j.1460-2075.1993.tb05908.x; PAYS E, 1983, NUCLEIC ACIDS RES, V11, P8137, DOI 10.1093/nar/11.23.8137; PENNINGTON SL, 1991, P NATL ACAD SCI USA, V88, P9498, DOI 10.1073/pnas.88.21.9498; PLASTERK RHA, 1992, EMBO J, V11, P287, DOI 10.1002/j.1460-2075.1992.tb05051.x; Puchta H, 1996, P NATL ACAD SCI USA, V93, P5055, DOI 10.1073/pnas.93.10.5055; RAMIREZSOLIS R, 1995, NATURE, V378, P720, DOI 10.1038/378720a0; Ravel C, 1995, MOL BIOCHEM PARASIT, V74, P31, DOI 10.1016/0166-6851(95)02480-8; RIEDER CL, 1986, J CELL BIOL, V103, P581, DOI 10.1083/jcb.103.2.581; ROUET P, 1994, MOL CELL BIOL, V14, P8096, DOI 10.1128/MCB.14.12.8096; Sambrook J., 2002, MOL CLONING LAB MANU; SANDELL LL, 1993, CELL, V75, P729, DOI 10.1016/0092-8674(93)90493-A; SMITH DR, 1992, METHOD ENZYMOL, V216, P603; SUROSKY RT, 1985, P NATL ACAD SCI USA, V82, P2106, DOI 10.1073/pnas.82.7.2106; Tamar S, 2000, MOL BIOCHEM PARASIT, V111, P401, DOI 10.1016/S0166-6851(00)00337-6; TOBIN JF, 1991, P NATL ACAD SCI USA, V88, P864, DOI 10.1073/pnas.88.3.864; VANDERPLOEG LHT, 1984, CELL, V36, P459, DOI 10.1016/0092-8674(84)90239-3; VOLLRATH D, 1988, P NATL ACAD SCI USA, V85, P6027, DOI 10.1073/pnas.85.16.6027; WELLINGER RJ, 1993, CELL, V72, P51, DOI 10.1016/0092-8674(93)90049-V; WHITE TC, 1988, J BIOL CHEM, V263, P16977; WILKIE AOM, 1990, NATURE, V346, P868, DOI 10.1038/346868a0	80	21	21	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 13	2001	276	15					11662	11673		10.1074/jbc.M009006200	http://dx.doi.org/10.1074/jbc.M009006200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	421UK	11152684	hybrid			2022-12-25	WOS:000168081800034
J	Darling, RJ; Wilken, JA; Miller-Lindbolm, AK; Urlacher, TM; Ruddon, RW; Sherman, SA; Bedows, E				Darling, RJ; Wilken, JA; Miller-Lindbolm, AK; Urlacher, TM; Ruddon, RW; Sherman, SA; Bedows, E			Functional contributions of noncysteine residues within the cystine knots of human chorionic gonadotropin subunits	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; HAMSTER OVARY CELLS; ALPHA-BETA-DIMER; DISULFIDE FOLDING PATHWAY; CYSTEINE RESIDUES; GROWTH-FACTOR; BIOLOGICAL-ACTIVITY; SECRETORY PATHWAY; CRYSTAL-STRUCTURE; MUTATIONS AFFECT	Human chorionic gonadotropin (hCG) is a heterodimeric member of a family of cystine knot-containing proteins that contain the consensus sequences Cys-X-1-Gly-X-2-Cys and Cys-X-3-Cys. Previously, we characterized the contributions that cystine residues of the hCG subunit cystine knots make in folding, assembly, and bioactivity. Here, we determined the contributions that noncysteine residues make in hCG folding, secretion, and assembly. When the X-1, X-2, and X-3 residues of hGC-alpha and -beta were substituted by swapping their respective cystine knot moths, the resulting chimeras appeared to fold correctly and were efficiently secreted. However, assembly of the chimeras with their wild type partner was almost completely abrogated. No single amino acid substitution completely accounted for the assembly inhibition, although the X-2 residue made the greatest individual contribution. Analysis by tryptic mapping, high performance liquid chromatography, and SDS-polyacrylamide gel electrophoresis revealed that substitution of the central Gly in the Cys-X-1-Gly-X-2-Cys sequence of either the alpha- or beta -subunit cystine knot resulted in non-native disulfide bond formation and subunit misfolding. This occurred even when the most conservative change possible (Gly --> Ala) was made. From these studies we conclude that all three "X" residues within the hCG cystine knots are collectively, but not individually, required for the formation of assembly-competent hCG subunits and that the invariant Gly residue is required for efficient cystine knot formation and subunit folding.	Univ Nebraska, Med Ctr, Eppley Inst Res Canc & Allied Dis, Omaha, NE 68198 USA; Univ Nebraska, Med Ctr, Dept Pharmacol, Omaha, NE 68198 USA; Univ Nebraska, Med Ctr, Dept Biochem & Mol Biol, Omaha, NE 68198 USA; Univ Nebraska, Med Ctr, Dept Obstet & Gynecol, Omaha, NE 68198 USA	University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center	Bedows, E (corresponding author), Univ Nebraska, Med Ctr, Eppley Inst Res Canc & Allied Dis, 986805 Nebraska Med Ctr, Omaha, NE 68198 USA.			Lindholm-Perry, Amanda/0000-0002-5555-118X	NATIONAL CANCER INSTITUTE [P30CA036727, R01CA032949] Funding Source: NIH RePORTER; NCI NIH HHS [CA32949, P30 CA36727] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AZUMA C, 1990, J MOL ENDOCRINOL, V5, P97, DOI 10.1677/jme.0.0050097; BEDOWS E, 1992, J BIOL CHEM, V267, P8880; BEDOWS E, 1994, J BIOL CHEM, V269, P10574; BEDOWS E, 1993, J BIOL CHEM, V268, P11655; BEEBE JS, 1990, J BIOL CHEM, V265, P312; Brewer JW, 1996, J CELL SCI, V109, P2383; BRUNNER AM, 1992, MOL ENDOCRINOL, V6, P1691, DOI 10.1210/me.6.10.1691; CHANG JY, 1995, J BIOL CHEM, V270, P9207, DOI 10.1074/jbc.270.16.9207; CHANG JY, 1994, J BIOL CHEM, V269, P22087; COHEN SA, 1993, ANAL BIOCHEM, V211, P279, DOI 10.1006/abio.1993.1270; CORLESS CL, 1987, J BIOL CHEM, V262, P14197; Darling RJ, 2000, J BIOL CHEM, V275, P15413, DOI 10.1074/jbc.275.20.15413; Ellgaard L, 1999, SCIENCE, V286, P1882, DOI 10.1126/science.286.5446.1882; Erbel PJA, 1999, EUR J BIOCHEM, V260, P490, DOI 10.1046/j.1432-1327.1999.00188.x; FARLING RJ, 2001, BIOCHEMISTRY-US, V40, P577; FURUHASHI M, 1994, J BIOL CHEM, V269, P25543; GIESE NA, 1987, SCIENCE, V236, P1315, DOI 10.1126/science.3035718; HAYASHIZAKI Y, 1989, EMBO J, V8, P2291, DOI 10.1002/j.1460-2075.1989.tb08355.x; HUTH JR, 1992, J BIOL CHEM, V267, P8870; HUTH JR, 1993, J BIOL CHEM, V268, P16472; ISAACS NW, 1995, CURR OPIN STRUC BIOL, V5, P391, DOI 10.1016/0959-440X(95)80102-2; Jackson AM, 1999, MOL ENDOCRINOL, V13, P2175, DOI 10.1210/me.13.12.2175; KIKUCHI T, 1994, MOL CELL ENDOCRINOL, V102, P1, DOI 10.1016/0303-7207(94)90090-6; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAPTHORN AJ, 1994, NATURE, V369, P455, DOI 10.1038/369455a0; Liu Y, 1999, J BIOL CHEM, V274, P5861, DOI 10.1074/jbc.274.9.5861; MCDONALD NQ, 1993, CELL, V73, P421, DOI 10.1016/0092-8674(93)90127-C; Miyai K, 1998, ENDOCR J, V45, P467, DOI 10.1507/endocrj.45.467; Muller YA, 1997, STRUCTURE, V5, P1325, DOI 10.1016/S0969-2126(97)00284-0; MURRAYRUST J, 1993, STRUCTURE, V1, P153, DOI 10.1016/0969-2126(93)90029-G; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; PETERS BP, 1989, ENDOCRINOLOGY, V124, P1602, DOI 10.1210/endo-124-4-1602; PIERCE JG, 1981, ANNU REV BIOCHEM, V50, P465, DOI 10.1146/annurev.bi.50.070181.002341; Ramachandran G N, 1968, Adv Protein Chem, V23, P283, DOI 10.1016/S0065-3233(08)60402-7; SARKAR G, 1990, BIOTECHNIQUES, V8, P404; Sato A, 1997, J BIOL CHEM, V272, P18098, DOI 10.1074/jbc.272.29.18098; SUGANUMA N, 1989, J BIOL CHEM, V264, P19302; SUN PD, 1995, ANNU REV BIOPH BIOM, V24, P269, DOI 10.1146/annurev.bb.24.060195.001413; WU H, 1994, STRUCTURE, V2, P545, DOI 10.1016/S0969-2126(00)00054-X	39	7	7	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 6	2001	276	14					10692	10699		10.1074/jbc.M010168200	http://dx.doi.org/10.1074/jbc.M010168200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	420AC	11134053	hybrid			2022-12-25	WOS:000167980900019
J	Krishna, S; Woodrow, C; Webb, R; Penny, J; Takeyasu, K; Kimura, M; East, JM				Krishna, S; Woodrow, C; Webb, R; Penny, J; Takeyasu, K; Kimura, M; East, JM			Expression and functional characterization of a Plasmodium falciparum Ca2+-ATPase (PfATP4) belonging to a subclass unique to apicomplexan organisms	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SARCOPLASMIC-RETICULUM CA2+-ATPASE; MEMBRANE CA2+ PUMP; P-TYPE ATPASE; CALCIUM PUMPS; INFECTED ERYTHROCYTES; TRANSMEMBRANE DOMAIN; CYCLOPIAZONIC ACID; CATION ATPASE; AMINO-ACIDS; THAPSIGARGIN	We have obtained a full-length P type ATPase sequence (PfATP4) encoded by Plasmodium falciparum and expressed PfATP4 in Xenopus laevis oocytes to study its function. Comparison of the hitherto incomplete open reading frame with other Ca2+-ATPase sequences reveals that PfATP4 differs significantly from previously defined categories. The Ca2+-dependent ATPase activity of PfATP4 is stimulated by a much broader: range of [Ca2+](free) (3.2-320 muM) than are an avian SERCA1 pump or rabbit SERCA 1a (maximal activity < 10 <mu>M). The activity of PfATP4 is resistant to inhibition by ouabain (200 muM) or thapsigargin (0.8 muM) but is inhibited by vanadate (1 mM) or cyclopiazonic acid (1 muM). We used a quantitative polymerase chain reaction to assay expression of mRNA encoding PfATP4 relative to that for beta -tubulin in synchronized asexual stages and found variable expression throughout the life cycle with a maximal 5-fold increase in meronts compared with ring stages. This analysis suggests that PfATP4 defines a novel subclass of Ca2+-ATPases unique to apicomplexan organisms and therefore offers potential as a drug target.	St George Hosp, Sch Med, Dept Infect Dis, London SW17 0RE, England; Kyoto Univ, Fac Integrated Human Studies, Sakyo Ku, Kyoto 606, Japan; Osaka City Univ, Sch Med, Biophys Lab, Abeno Ku, Osaka 5458585, Japan; Univ Southampton, Sch Biol Sci, Div Biochem & Mol Biol, Southampton S016 7PX, Hants, England	St Georges University London; Kyoto University; Osaka Metropolitan University; University of Southampton	Krishna, S (corresponding author), St George Hosp, Sch Med, Dept Infect Dis, Cranmer Terrace, London SW17 0RE, England.	s.krishna@sghms.ac.uk		Woodrow, Charles/0000-0002-5134-7165; Krishna, Sanjeev/0000-0003-0066-0634				ADOVELANDE J, 1993, EXP PARASITOL, V76, P247, DOI 10.1006/expr.1993.1030; ALLEVA LM, 2000, MOL APPROACHES MALAR, P54; ANSAH TA, 1984, J BIOL CHEM, V259, P3442; Axelsen KB, 1998, J MOL EVOL, V46, P84, DOI 10.1007/PL00006286; Bowman S, 1999, NATURE, V400, P532, DOI 10.1038/22964; CLARKE DM, 1989, NATURE, V339, P476, DOI 10.1038/339476a0; Curran AC, 2000, J BIOL CHEM, V275, P30301, DOI 10.1074/jbc.M002047200; Dyer M, 1996, MOL BIOCHEM PARASIT, V78, P1, DOI 10.1016/S0166-6851(96)02593-5; East J M, 1994, Methods Mol Biol, V27, P87; Garcia CRS, 1996, EUR J CELL BIOL, V71, P409; GEERING K, 1989, AM J PHYSIOL, V257, pC851, DOI 10.1152/ajpcell.1989.257.5.C851; Guerini D, 1996, BIOCHEMISTRY-US, V35, P3290, DOI 10.1021/bi952572f; ISHII T, 1993, P NATL ACAD SCI USA, V90, P8881, DOI 10.1073/pnas.90.19.8881; ISHII T, 1994, P NATL ACAD SCI USA, V91, P6103, DOI 10.1073/pnas.91.13.6103; KIMURA M, 1993, J CELL SCI, V104, P1129; KRISHNA S, 1990, PARASITOL TODAY, V6, P196, DOI 10.1016/0169-4758(90)90356-9; KRISHNA S, 1994, EXP PARASITOL, V78, P113, DOI 10.1006/expr.1994.1011; Krishna S, 1997, BMJ-BRIT MED J, V315, P730, DOI 10.1136/bmj.315.7110.730; KRISHNA S, 1993, J CELL BIOL, V120, P385, DOI 10.1083/jcb.120.2.385; KRISHNA S, 1999, TRANSPORT TRAFFICKIN, V226, P126; LAFAIRE AV, 1986, J MEMBRANE BIOL, V91, P43, DOI 10.1007/BF01870213; LYTTON J, 1992, J BIOL CHEM, V267, P14483; LYTTON J, 1991, J BIOL CHEM, V266, P17067; Ma HL, 1999, BIOCHEMISTRY-US, V38, P15522, DOI 10.1021/bi991523q; NORREGAARD A, 1994, J BIOL CHEM, V269, P26598; Pittman JK, 1999, GENE, V236, P137, DOI 10.1016/S0378-1119(99)00242-5; SAGARA Y, 1991, J BIOL CHEM, V266, P13503; SEIDLER NW, 1989, J BIOL CHEM, V264, P17816; Sorin A, 1997, J BIOL CHEM, V272, P9895; Staines HM, 1999, J MEMBRANE BIOL, V172, P13, DOI 10.1007/s002329900579; Tiffert T, 2000, J PHYSIOL-LONDON, V525, P125, DOI 10.1111/j.1469-7793.2000.00125.x; Toyoshima C, 2000, NATURE, V405, P647, DOI 10.1038/35015017; TROTTEIN F, 1995, GENE, V158, P133, DOI 10.1016/0378-1119(95)00158-3; TROTTEIN F, 1995, EUR J BIOCHEM, V227, P214, DOI 10.1111/j.1432-1033.1995.tb20379.x; Webb RJ, 2000, J BIOL CHEM, V275, P977, DOI 10.1074/jbc.275.2.977; White N, 1999, PHILOS T R SOC B, V354, P739, DOI 10.1098/rstb.1999.0426; Woodrow CJ, 1999, J BIOL CHEM, V274, P7272, DOI 10.1074/jbc.274.11.7272; Zhu G, 1997, MOL BIOCHEM PARASIT, V90, P307, DOI 10.1016/S0166-6851(97)00168-0	38	76	80	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 6	2001	276	14					10782	10787		10.1074/jbc.M010554200	http://dx.doi.org/10.1074/jbc.M010554200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	420AC	11145964	hybrid			2022-12-25	WOS:000167980900031
J	Gangar, A; Karande, AA; Rajasekharan, R				Gangar, A; Karande, AA; Rajasekharan, R			Isolation and localization of a cytosolic 10 S triacylglycerol biosynthetic multienzyme complex from oleaginous yeast	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACYL CARRIER PROTEIN; SACCHAROMYCES-CEREVISIAE; DIHYDROXYACETONE PHOSPHATE; ACID-PHOSPHATASE; ESCHERICHIA-COLI; RAT-LIVER; ACYLTRANSFERASE; PURIFICATION; METABOLISM; MEMBRANES	Triacylglycerol is one of the major storage forms of metabolic energy in eukaryotic cells. Biosynthesis of triacylglycerol is known to occur in membranes. We report here the isolation, purification, and characterization of a catalytically active cytosolic 10 S multienzyme complex for triacylglycerol biosynthesis from Rhodotorula glutinis during exponential growth. The complex was characterized and was found to contain lysophosphatidic acid acyltransferase, phosphatidic acid phosphatase, diacylglycerol acyltransferase, acyl-acyl carrier protein synthetase, and acyl carrier protein. The 10 S triacylglycerol biosynthetic complex rapidly incorporates free fatty acids as well as fatty acyl-coenzyme A into triacylglycerol and its biosynthetic intermediates, Lysophosphatidic acid acyltransferase, phosphatidic acid phosphatase, and diacylglycerol acyltransferase from the complex were microsequenced. Antibodies were raised against the synthetic peptides corresponding to lysophosphatidic acid acyltransferase and phosphatidic acid phosphatase sequences. Immunoprecipitation and immunolocalization studies show the presence of a cytosolic multienzyme complex for triacylglycerol biosynthesis, Chemical cross-linking studies revealed that the 10 S multienzyme complex was held together by protein-protein interactions. These results demonstrate that the cytosol is one of the sites for triacylglycerol biosynthesis in oleaginous yeast.	Indian Inst Sci, Dept Biochem, Bangalore 560012, Karnataka, India	Indian Institute of Science (IISC) - Bangalore	Rajasekharan, R (corresponding author), Indian Inst Sci, Dept Biochem, Bangalore 560012, Karnataka, India.		R, Rajasekharan/D-3420-2009; Rajasekharan, Ram/R-2257-2019	Rajasekharan, Ram/0000-0002-2124-6013				AbuElheiga L, 1997, J BIOL CHEM, V272, P10669; Athenstaedt K, 1999, J BACTERIOL, V181, P1458, DOI 10.1128/JB.181.5.1458-1463.1999; BERGFELD R, 1978, PLANTA, V143, P297, DOI 10.1007/BF00392002; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; COOPER CL, 1989, J BIOL CHEM, V264, P7384; Dahlqvist A, 2000, P NATL ACAD SCI USA, V97, P6487, DOI 10.1073/pnas.120067297; Engvall E, 1980, Methods Enzymol, V70, P419; FRITZ PJ, 1986, J BIOL CHEM, V261, P194; GREEN N, 1982, CELL, V28, P477, DOI 10.1016/0092-8674(82)90202-1; Hiroyama R, 1999, J BIOL CHEM, V274, P29172, DOI 10.1074/jbc.274.41.29172; HOSAKA K, 1984, BIOCHIM BIOPHYS ACTA, V796, P110; HUANG AHC, 1992, ANNU REV PLANT PHYS, V43, P177, DOI 10.1146/annurev.pp.43.060192.001141; ICHIHARA K, 1990, BIOCHIM BIOPHYS ACTA, V1043, P227, DOI 10.1016/0005-2760(90)90021-O; JACKOWSKI S, 1992, METHOD ENZYMOL, V209, P111; JAMAL Z, 1991, J BIOL CHEM, V266, P2988; Kai M, 1996, J BIOL CHEM, V271, P18931, DOI 10.1074/jbc.271.31.18931; KANOH H, 1983, J BIOL CHEM, V258, P1767; Kates M., 1986, TECHNIQUES LIPIDOLOG, P100; KENNEDY EP, 1961, FED PROC, V20, P934; Kent C, 1999, TRENDS BIOCHEM SCI, V24, P146, DOI 10.1016/S0968-0004(99)01365-1; KENT C, 1991, FASEB J, V5, P2258, DOI 10.1096/fasebj.5.9.1860617; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEPETINA EG, 1971, BIOCHEM J, V122, P171; MURPHY DJ, 1988, LIPIDS, V23, P157, DOI 10.1007/BF02535452; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; NOVICK D, 1987, J BIOL CHEM, V262, P8483; Oelkers P, 2000, J BIOL CHEM, V275, P15609, DOI 10.1074/jbc.C000144200; PALTAUF F, 1992, MOL CELLULAR BIOL YE, V2, P415; PELECH SL, 1989, TRENDS BIOCHEM SCI, V14, P28, DOI 10.1016/0968-0004(89)90086-8; Pillai MG, 1998, BBA-LIPID LIPID MET, V1393, P128, DOI 10.1016/S0005-2760(98)00069-1; RAETZ CRH, 1990, J BIOL CHEM, V265, P1235; ROCK CO, 1980, ANAL BIOCHEM, V102, P362, DOI 10.1016/0003-2697(80)90168-2; SOMERVILLE C, 1991, SCIENCE, V252, P80, DOI 10.1126/science.252.5002.80; Stymne S., 1987, Biochemistry of Plants, V9, P175; SUNDLER R, 1975, J BIOL CHEM, V250, P8585; SUZUKI O, 1988, P WORLD C BIOT FATS, P110; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WAKIL SJ, 1983, ANNU REV BIOCHEM, V52, P537, DOI 10.1146/annurev.bi.52.070183.002541; WEBBER KO, 1992, METHOD ENZYMOL, V209, P92; WEETE JD, 1980, LIPID BIOCH FUNGI OT, P16; ZINSER E, 1991, J BACTERIOL, V173, P2026, DOI 10.1128/jb.173.6.2026-2034.1991	41	35	39	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 30	2001	276	13					10290	10298		10.1074/jbc.M009550200	http://dx.doi.org/10.1074/jbc.M009550200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	420GC	11139581	hybrid			2022-12-25	WOS:000167996400094
J	Pak, J; Pu, YB; Zhang, ZT; Hasty, DL; Wu, XR				Pak, J; Pu, YB; Zhang, ZT; Hasty, DL; Wu, XR			Tamm-Horsfall protein binds to type 1 fimbriated Escherichia coli and prevents E. coli from binding to uroplakin Ia and Ib receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							URINARY-TRACT INFECTION; ASYMMETRIC UNIT MEMBRANE; UROTHELIAL DIFFERENTIATION; FUNCTIONAL-HETEROGENEITY; UROEPITHELIAL CELLS; STRUCTURAL-ANALYSIS; MUCOSAL DEFENSE; MOLECULAR-BASIS; FIMH-ADHESIN; GLYCOPROTEIN	The adherence of uropathogenic Escherichia coli to the urothelial surface, a critical first step in the pathogenesis of urinary tract infection (UTI), is controlled by three key elements: E, coli adhesins, host receptors, and host defense mechanisms. Although much has been learned about E. coli adhesins and their urothelial receptors, little is known about the role of host defense in the adherence process, Here we show that Tamm-Horsfall protein (THP) is the principal urinary protein that binds specifically to type 1 fimbriated E. coli, the main cause of UTI, The binding was highly specific and saturable and could be inhibited by D-mannose and abolished by endoglycosidase H treatment of THP, suggesting that the binding is mediated by the high-mannose moieties of THP, It is species-conserved, occurring in both human and mouse THPs. In addition, the binding to THP was much greater with an E, coli strain bearing a phenotypic variant of the type 1 fimbrial FimH adhesin characteristic of those prevalent in UTI isolates compared with the one prevalent in isolates from the large intestine of healthy individuals, Finally, a physiological concentration of THP completely abolished the binding of type 1 fimbriated E. coli to uroplakins Ia and Ib, two putative urothelial receptors for type 1 fimbriae, These results establish, on a functional level, that THP contains conserved high-mannose moieties capable of specific interaction with type 1 fimbriae and strongly suggest that this major urinary glycoprotein is a key urinary anti-adherence factor serving to prevent type 1 fimbriated E, coli from binding to the urothelial receptors.	NYU, Sch Med, Kaplan Comprehens Canc Ctr, Dept Urol, New York, NY 10016 USA; Vet Affairs Med Ctr, New York, NY 10010 USA; NYU, Sch Med, Kaplan Comprehens Canc Ctr, Dept Microbiol, New York, NY 10016 USA; Univ Tennessee, Dept Anat & Neurobiol, Memphis, TN 38163 USA; Vet Affairs Med Ctr, Memphis, TN 38104 USA	New York University; US Department of Veterans Affairs; Veterans Health Administration (VHA); New York University; University of Tennessee System; University of Tennessee Health Science Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); Memphis VA Medical Center	Wu, XR (corresponding author), NYU, Sch Med, Kaplan Comprehens Canc Ctr, Dept Urol, 550 1st Ave,Rm Skirball 10U, New York, NY 10016 USA.	xue-ru.wu@med.ny.edu		Wu, Xue-Ru/0000-0001-6058-6291	NIAID NIH HHS [1R01AI42886-01A1] Funding Source: Medline; NIDDK NIH HHS [1R01DK56903-01A1] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI042886] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK056903] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AFONSO AMM, 1981, CARBOHYD RES, V89, P309, DOI 10.1016/S0008-6215(00)85256-8; CLEGG S, 1982, INFECT IMMUN, V38, P739, DOI 10.1128/IAI.38.2.739-744.1982; Connell H, 1996, P NATL ACAD SCI USA, V93, P9827, DOI 10.1073/pnas.93.18.9827; DALLOLIO F, 1988, CARBOHYD RES, V178, P327, DOI 10.1016/0008-6215(88)80123-X; EISENSTEIN BI, 1988, REV INFECT DIS, V10, pS341; FLETCHER AP, 1970, BIOCHEM J, V120, P417, DOI 10.1042/bj1200417; FOXMAN B, 1995, J INFECT DIS, V171, P1514, DOI 10.1093/infdis/171.6.1514; FU DT, 1994, CARBOHYD RES, V261, P173, DOI 10.1016/0008-6215(94)84015-6; FUJITA K, 1989, INFECT IMMUN, V57, P2574, DOI 10.1128/IAI.57.8.2574-2579.1989; HARD K, 1992, EUR J BIOCHEM, V209, P895, DOI 10.1111/j.1432-1033.1992.tb17362.x; HICKS RM, 1969, NATURE, V224, P1304, DOI 10.1038/2241304a0; HICKS RM, 1965, J CELL BIOL, V26, P25, DOI 10.1083/jcb.26.1.25; HICKS RM, 1975, BIOL REV, V50, P215, DOI 10.1111/j.1469-185X.1975.tb01057.x; HULL RA, 1981, INFECT IMMUN, V33, P933, DOI 10.1128/IAI.33.3.933-938.1981; IWAHI T, 1983, INFECT IMMUN, V39, P1307, DOI 10.1128/IAI.39.3.1307-1315.1983; Kachar B, 1999, J MOL BIOL, V285, P595, DOI 10.1006/jmbi.1998.2304; KEITH BR, 1986, INFECT IMMUN, V53, P693, DOI 10.1128/IAI.53.3.693-696.1986; KLEMM P, 1996, ANTIADHESIN THERAPY, P81; KOSS LG, 1969, LAB INVEST, V21, P154; KUMAR S, 1990, KIDNEY INT, V37, P1395, DOI 10.1038/ki.1990.128; LAMONT JT, 1992, ANN NY ACAD SCI, V664, P190, DOI 10.1111/j.1749-6632.1992.tb39760.x; Langermann S, 1997, SCIENCE, V276, P607, DOI 10.1126/science.276.5312.607; Leeker A, 1997, EXP NEPHROL, V5, P38; LIN JH, 1994, J BIOL CHEM, V269, P1775; MEASLEY RE, 1991, MED CLIN N AM, V75, P275, DOI 10.1016/S0025-7125(16)30453-9; MOBLEY HLT, 1995, METHOD ENZYMOL, V253, P360; Mulvey MA, 1998, SCIENCE, V282, P1494, DOI 10.1126/science.282.5393.1494; OHANLEY P, 1985, J CLIN INVEST, V75, P347, DOI 10.1172/JCI111707; ORSKOV I, 1980, LANCET, V1, P887; PARKKINEN J, 1988, INFECT IMMUN, V56, P2623, DOI 10.1128/IAI.56.10.2623-2630.1988; PAULI BU, 1983, PATHOLOGY BLADDER CA, P42; PORTER KR, 1963, INTRO FINE STRUCTURE; REINHART HH, 1990, J INFECT DIS, V162, P1335, DOI 10.1093/infdis/162.6.1335; ROBERTS JA, 1996, ADV EXP MED BIOL, V462, P325; SCHAEFFER AJ, 1991, INFECTION, V19, pS144, DOI 10.1007/BF01643685; Schoolnik G K, 1987, Adv Exp Med Biol, V224, P53; SERAFINICESSI F, 1993, BIOCHEM BIOPH RES CO, V194, P784, DOI 10.1006/bbrc.1993.1890; SERAFINICESSI F, 1984, BIOSCIENCE REP, V4, P269, DOI 10.1007/BF01119663; Slomiany B L, 1991, J Physiol Pharmacol, V42, P147; SMAGULA RM, 1997, INFECT DIS CLIN N AM, V11, P531; Sokurenko EV, 1997, J BIOL CHEM, V272, P17880, DOI 10.1074/jbc.272.28.17880; SOKURENKO EV, 1994, J BACTERIOL, V176, P748, DOI 10.1128/jb.176.3.748-755.1994; SOKURENKO EV, 1995, J BACTERIOL, V177, P3680, DOI 10.1128/jb.177.13.3680-3686.1995; SOKURENKO EV, 1992, INFECT IMMUN, V60, P4709, DOI 10.1128/IAI.60.11.4709-4719.1992; Sokurenko EV, 1998, P NATL ACAD SCI USA, V95, P8922, DOI 10.1073/pnas.95.15.8922; STAEHELIN LA, 1972, J CELL BIOL, V53, P73, DOI 10.1083/jcb.53.1.73; STAMM WE, 1989, J INFECT DIS, V159, P400, DOI 10.1093/infdis/159.3.400; STROMBERG N, 1990, EMBO J, V9, P2001, DOI 10.1002/j.1460-2075.1990.tb08328.x; van Rooijen JJM, 1999, GLYCOBIOLOGY, V9, P21, DOI 10.1093/glycob/9.1.21; VERGARA J, 1969, J MOL BIOL, V46, P593, DOI 10.1016/0022-2836(69)90200-9; Wallace JL, 1996, FASEB J, V10, P731, DOI 10.1096/fasebj.10.7.8635690; WILLIAMS J, 1984, CARBOHYD RES, V134, P141, DOI 10.1016/0008-6215(84)85029-6; WU XR, 1993, J CELL SCI, V106, P31; WU XR, 1995, J BIOL CHEM, V270, P29752; Wu XR, 1996, P NATL ACAD SCI USA, V93, P9630, DOI 10.1073/pnas.93.18.9630; WU XR, 1994, J BIOL CHEM, V269, P13716; WU XR, 1990, J BIOL CHEM, V265, P19170; YU J, 1990, J CELL BIOL, V111, P1207, DOI 10.1083/jcb.111.3.1207; YU J, 1994, J CELL BIOL, V125, P171, DOI 10.1083/jcb.125.1.171	59	206	216	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 30	2001	276	13					9924	9930		10.1074/jbc.M008610200	http://dx.doi.org/10.1074/jbc.M008610200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	420GC	11134021	hybrid			2022-12-25	WOS:000167996400048
J	Kawai, H; Allende, ML; Wada, R; Kono, M; Sango, K; Deng, CX; Miyakawa, T; Crawley, JN; Werth, N; Bierfreund, U; Sandhoff, K; Proia, RL				Kawai, H; Allende, ML; Wada, R; Kono, M; Sango, K; Deng, CX; Miyakawa, T; Crawley, JN; Werth, N; Bierfreund, U; Sandhoff, K; Proia, RL			Mice expressing only monosialoganglioside GM3 exhibit lethal audiogenic seizures	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							B-SERIES GANGLIOSIDES; COMPLEX GANGLIOSIDES; NEURONAL DIFFERENTIATION; SYNTHASE; GENE; GLYCOSPHINGOLIPIDS; MODULATORS; METABOLISM; LACKING; DEFECTS	Gangliosides are a family of glycosphingolipids that contain sialic acid. Although they are abundant on neuronal cell membranes, their precise functions and importance in the central nervous system (CNS) remain largely undefined. We have disrupted the gene encoding GD3 synthase (GD3S), a sialyltransferase expressed in the CNS that is responsible for the synthesis of b-series gangliosides. GD3S-/- mice, even with an absence of b-series gangliosides, appear to undergo normal development and have a normal life span. To further restrict the expression of gangliosides, the GD3S mutant mice were crossbred with mice carrying a disrupted GalNAcT gene encoding beta1,4-N-acetylgalactosaminyltransferase. These double mutant mice expressed GM3 as their major ganglioside. In contrast to the single mutant mice, the double mutants displayed a sudden death phenotype and were extremely susceptible to induction of lethal seizures by sound stimulus. These results demonstrate unequivocally that gangliosides play an essential role in the proper functioning of the CNS.	NIDDKD, Genet Dev & Dis Branch, NIH, Bethesda, MD 20892 USA; NIMH, Sect Behav Neuropharmacol, Expt Therapeut Branch, Bethesda, MD 20892 USA; Univ Bonn, Kekule Inst Organ Chem & Biochem, D-53121 Bonn, Germany	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH); University of Bonn	Proia, RL (corresponding author), NIDDKD, Genet Dev & Dis Branch, NIH, Bldg 10,Rm 9N-314, Bethesda, MD 20892 USA.		Miyakawa, Tsuyoshi/A-7741-2008; deng, chuxia/N-6713-2016; Proia, Richard L/A-7908-2012	Miyakawa, Tsuyoshi/0000-0003-0137-8200; Kono, Mari/0000-0003-2447-4350; Proia, Richard/0000-0003-0456-1270	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK056001, ZIADK056001] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [Z01MH002177] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Chiavegatto S, 2000, EXP NEUROL, V166, P227, DOI 10.1006/exnr.2000.7504; Datta AK, 1998, J BIOL CHEM, V273, P9608, DOI 10.1074/jbc.273.16.9608; DeMaria R, 1997, SCIENCE, V277, P1652, DOI 10.1126/science.277.5332.1652; Futerman AH, 1998, ACTA BIOCHIM POL, V45, P469, DOI 10.18388/abp.1998_4240; Hakomori S, 1998, GLYCOBIOLOGY, V8, pXI; HAKOMORI SI, 1990, J BIOL CHEM, V265, P18713; Huwiler A, 2000, BBA-MOL CELL BIOL L, V1485, P63, DOI 10.1016/S1388-1981(00)00042-1; IBER H, 1992, GLYCOBIOLOGY, V2, P137, DOI 10.1093/glycob/2.2.137; Kasahara K, 1997, J BIOL CHEM, V272, P29947, DOI 10.1074/jbc.272.47.29947; Kasahara K, 2000, J BIOL CHEM, V275, P34701, DOI 10.1074/jbc.M003163200; Kawai H, 1998, J BIOL CHEM, V273, P19634, DOI 10.1074/jbc.273.31.19634; Kono M, 1998, BIOCHEM BIOPH RES CO, V253, P170, DOI 10.1006/bbrc.1998.9768; Ledeen RW, 1998, ANN NY ACAD SCI, V845, P161, DOI 10.1111/j.1749-6632.1998.tb09669.x; Liu YJ, 1999, J CLIN INVEST, V103, P497, DOI 10.1172/JCI5542; Matsuda Y, 1996, GENOMICS, V32, P137, DOI 10.1006/geno.1996.0090; MIETTINEN T, 1959, ACTA CHEM SCAND, V13, P856, DOI 10.3891/acta.chem.scand.13-0856; MIYAKAWA T, 1995, MOL BRAIN RES, V28, P349, DOI 10.1016/0169-328X(94)00251-9; Nehls M, 1996, SCIENCE, V272, P886, DOI 10.1126/science.272.5263.886; Puranam RS, 1999, CURR OPIN NEUROBIOL, V9, P281, DOI 10.1016/S0959-4388(99)80041-5; Sango K, 1996, NAT GENET, V14, P348, DOI 10.1038/ng1196-348; SANGO K, 1995, GENOMICS, V27, P362, DOI 10.1006/geno.1995.1058; Schnaar RL, 1998, ANN NY ACAD SCI, V845, P92, DOI 10.1111/j.1749-6632.1998.tb09664.x; Seyfried T N, 1999, Adv Neurol, V79, P279; Sheikh KA, 1999, P NATL ACAD SCI USA, V96, P7532, DOI 10.1073/pnas.96.13.7532; SVENNERHOLM L, 1957, BIOCHIM BIOPHYS ACTA, V24, P604, DOI 10.1016/0006-3002(57)90254-8; SVENNERHOLM L, 1994, PROG BRAIN RES, V101, pR10; Takamiya K, 1996, P NATL ACAD SCI USA, V93, P10662, DOI 10.1073/pnas.93.20.10662; Takamiya K, 1998, P NATL ACAD SCI USA, V95, P12147, DOI 10.1073/pnas.95.21.12147; Takashima S, 2000, J BIOCHEM-TOKYO, V128, P1033, DOI 10.1093/oxfordjournals.jbchem.a022831; Walkley SU, 2000, CEREB CORTEX, V10, P1028, DOI 10.1093/cercor/10.10.1028; Yamashita T, 1999, P NATL ACAD SCI USA, V96, P9142, DOI 10.1073/pnas.96.16.9142; YAO JK, 1985, ANAL BIOCHEM, V150, P111, DOI 10.1016/0003-2697(85)90447-6; YU RK, 1994, PROG BRAIN RES, V101, P31	33	189	191	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 9	2001	276	10					6885	6888		10.1074/jbc.C000847200	http://dx.doi.org/10.1074/jbc.C000847200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	410MC	11133999	hybrid			2022-12-25	WOS:000167442900002
J	Deigner, HP; Claus, R; Bonaterra, GA; Gehrke, C; Bibak, N; Blaess, M; Cantz, M; Metz, J; Kinscherf, R				Deigner, HP; Claus, R; Bonaterra, GA; Gehrke, C; Bibak, N; Blaess, M; Cantz, M; Metz, J; Kinscherf, R			Ceramide induces aSMase expression: implications for oxLDL-induced apoptosis	FASEB JOURNAL			English	Article						acid sphingomyelinase; macrophages; Niemann-Pick; programmed cell death; C-6-ceramide	LOW-DENSITY-LIPOPROTEIN; MANGANESE SUPEROXIDE-DISMUTASE; RADIATION-INDUCED APOPTOSIS; THERAPY-INDUCED APOPTOSIS; CELL-DEATH; ACID SPHINGOMYELINASE; ENDOTHELIAL-CELLS; SIGNAL-TRANSDUCTION; HUMAN LYMPHOBLASTS; DNA-BINDING	Sphingomyelinase (SMase) stimulation and subsequent ceramide generation are suggested to be involved in signal transduction of stress-induced apoptosis, We now show that apoptosis of human macrophages (M phi) and fibroblasts initiated by oxidized low density lipoproteins (minimally modified LDL, mmLDL) is associated with an increase in acid SMase (aSMase, E.C, 3.1.4.12) expression and ceramide concentration. Application of a novel, potent, and specific inhibitor of aSMase expression (NB6) diminished the effects of mmLDL and C-6-ceramide treatment by inhibiting transcription via Sp1 and AP-2. Moreover, apoptosis was abolished after mmLDL and C-6-ceramide treatment of hereditary aSMase-deficient fibroblasts (from Niemann-Pick patients), We suggest that in mmLDL-initiated apoptosis 1) enhanced ceramide generation via aSMase appears to be required as well as 2) a positive feedback control of aSMase expression by the increase in intracellular ceramide concentration.	Univ Jena, Clin Anaesthesiol, D-07740 Jena, Germany; Univ Jena, Clin Intens Care Med, D-07740 Jena, Germany; Univ Jena, Inst Pharmaceut Chem, D-07740 Jena, Germany; Univ Heidelberg, Dept Anat & Cell Biol 3, D-69120 Heidelberg, Germany; Univ Heidelberg, Inst Pathochem & Neurochem, D-69120 Heidelberg, Germany	Friedrich Schiller University of Jena; Friedrich Schiller University of Jena; Friedrich Schiller University of Jena; Ruprecht Karls University Heidelberg; Ruprecht Karls University Heidelberg	Deigner, HP (corresponding author), Univ Jena, Clin Anaesthesiol, D-07740 Jena, Germany.		Kinscherf, Ralf/AAV-7164-2021; Blaess, Markus/AAU-9572-2021; Claus, Ralf A./Q-4035-2016	Blaess, Markus/0000-0002-5860-2878; Claus, Ralf A./0000-0001-7232-4088				Auge N, 1998, J BIOL CHEM, V273, P12893, DOI 10.1074/jbc.273.21.12893; BOSE R, 1995, CELL, V82, P405, DOI 10.1016/0092-8674(95)90429-8; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; Chatelut M, 1998, FEBS LETT, V426, P102, DOI 10.1016/S0014-5793(98)00325-1; CHEN GL, 1986, ARCH BIOCHEM BIOPHYS, V245, P66, DOI 10.1016/0003-9861(86)90190-6; CIFONE MG, 1994, J EXP MED, V180, P1547, DOI 10.1084/jem.180.4.1547; Claus R, 1996, BIOCHEMISTRY-US, V35, P4911, DOI 10.1021/bi952036n; Claus R., 2000, Current Drug Targets, V1, P185, DOI 10.2174/1389450003349272; Deigner HP, 1999, CURR MED CHEM, V6, P399; Deiss LP, 1996, EMBO J, V15, P3861, DOI 10.1002/j.1460-2075.1996.tb00760.x; ELSAADANI M, 1989, J LIPID RES, V30, P627; Farina F, 2000, J HISTOCHEM CYTOCHEM, V48, P57, DOI 10.1177/002215540004800106; FOSSEL ET, 1994, CANCER RES, V54, P1240; GEHLER J, 1974, HUMANGENETIK, V23, P149; Grassme H, 1997, CELL, V91, P605, DOI 10.1016/S0092-8674(00)80448-1; HAIMOVITZFRIEDMAN A, 1994, J EXP MED, V180, P525, DOI 10.1084/jem.180.2.525; Hannun YA, 2000, TRENDS CELL BIOL, V10, P73, DOI 10.1016/S0962-8924(99)01694-3; Harada-Shiba M, 1998, J BIOL CHEM, V273, P9681, DOI 10.1074/jbc.273.16.9681; HAVEL RJ, 1955, J CLIN INVEST, V34, P1345, DOI 10.1172/JCI103182; Heinrich M, 1999, EMBO J, V18, P5252, DOI 10.1093/emboj/18.19.5252; Herr I, 1997, EMBO J, V16, P6200, DOI 10.1093/emboj/16.20.6200; HIMBER J, 1995, INT J VITAM NUTR RES, V65, P137; Huang Y, 1998, BIOCHEM BIOPH RES CO, V249, P307, DOI 10.1006/bbrc.1998.9139; Hueber AO, 2000, NAT CELL BIOL, V2, pE23, DOI 10.1038/35000092; IDZIOREK T, 1995, J IMMUNOL METHODS, V185, P249, DOI 10.1016/0022-1759(95)00172-7; Jaffrezou JP, 1998, FASEB J, V12, P999, DOI 10.1096/fasebj.12.11.999; JARVIS WD, 1994, P NATL ACAD SCI USA, V91, P73, DOI 10.1073/pnas.91.1.73; Kinscherf R, 1997, FEBS LETT, V405, P55, DOI 10.1016/S0014-5793(97)00157-9; Kinscherf R, 1998, FASEB J, V12, P461, DOI 10.1096/fasebj.12.6.461; Kinscherf R, 1997, J LEUKOCYTE BIOL, V62, P719, DOI 10.1002/jlb.62.6.719; Kockx MM, 2000, CARDIOVASC RES, V45, P736, DOI 10.1016/S0008-6363(99)00235-7; Langmann T, 1999, J LIPID RES, V40, P870; Lepple-Wienhues A, 1999, P NATL ACAD SCI USA, V96, P13795, DOI 10.1073/pnas.96.24.13795; MAOR I, 1994, J LIPID RES, V35, P803; Mathias S, 1998, BIOCHEM J, V335, P465, DOI 10.1042/bj3350465; Pena LA, 2000, CANCER RES, V60, P321; Perry DK, 1999, TRENDS BIOCHEM SCI, V24, P226, DOI 10.1016/S0968-0004(99)01407-3; Perry DK, 1998, BBA-MOL CELL BIOL L, V1436, P233, DOI 10.1016/S0005-2760(98)00145-3; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; REID VC, 1993, J PATHOL, V171, P321, DOI 10.1002/path.1711710413; Sandhoff K., 1999, ANGEW CHEM GER ED, V111, P1632, DOI [10.1002/(SICI)1521-3757(19990601)111:113.0.CO;2-A, DOI 10.1002/(SICI)1521-3757(19990601)111:113.0.CO;2-A]; Santana P, 1996, CELL, V86, P189, DOI 10.1016/S0092-8674(00)80091-4; Separovic D, 1999, BIOCHEM BIOPH RES CO, V258, P506, DOI 10.1006/bbrc.1999.0670; Seve M, 1999, ARCH BIOCHEM BIOPHYS, V361, P165, DOI 10.1006/abbi.1998.0942; Simon CG, 1999, BIOCHEMISTRY-US, V38, P14676, DOI 10.1021/bi991537w; Strelow A, 2000, J EXP MED, V192, P601, DOI 10.1084/jem.192.5.601; SUZUKI YJ, 1994, J IMMUNOL, V153, P5008; Tanaka T, 2000, ARTERIOSCL THROM VAS, V20, P392, DOI 10.1161/01.ATV.20.2.392; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; Watson AD, 1995, J CLIN INVEST, V96, P2882, DOI 10.1172/JCI118359; Yakes FM, 1997, P NATL ACAD SCI USA, V94, P514, DOI 10.1073/pnas.94.2.514; Yuan XM, 2000, FREE RADICAL BIO MED, V28, P208, DOI 10.1016/S0891-5849(99)00220-8	52	79	81	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAR	2001	15	3					807	814		10.1096/fj.15.3.807	http://dx.doi.org/10.1096/fj.15.3.807			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	410BE	11259399				2022-12-25	WOS:000167419500038
J	Ray, PS; Martin, JL; Swanson, EA; Otani, H; Dillmann, WH; Das, DK				Ray, PS; Martin, JL; Swanson, EA; Otani, H; Dillmann, WH; Das, DK			Transgene overexpression of alpha B crystallin confers simultaneous protection against cardiomyocyte apoptosis and necrosis during myocardial ischemia and reperfusion	FASEB JOURNAL			English	Article						alpha B crystallin; transgenic; ischemia/reperfusion; oxidative stress	HEAT-SHOCK-PROTEIN; RAT-HEART; RABBIT CARDIOMYOCYTES; OXIDATIVE STRESS; MOUSE HEART; INJURY; EXPRESSION; TISSUE; INDUCTION; HSP27	We investigated whether enhanced expression of alphaB crystallin, a stress-inducible molecular chaperone of the small heat shock family, can protect myocardial contractile apparatus against ischemia reperfusion (I/R) injury. Transgenic mice overexpressing alphaB crystallin were generated using the 0.76 kb rat alphaB crystallin cDNA cloned into a pCAGGS plasmid driven by a human cytomegalovirus expression system. Southern analysis confirmed transgene integration and Northern and Western blotting characterized expression (3.1-fold and 6.9-fold elevations in myocardial mRNA and protein levels, respectively). Extent of functional recovery over a 3 h reperfusion period following a 20 min ischemic period in transgenic and wild-type mouse hearts was assessed using an ex vivo work-performing heart preparation. The transgenic group displayed significantly higher values of DP at R45 min (29.14+/-1.9 mm Hg vs. 17.6+/-0.7 mm Hg), R60 min (31.56+/-1.7 mm Hg vs. 17.8+/-0.8 mm Hg), and R75 min (32.5+/-2.2 mm Hg vs. 16.9+/-0.9 mm Hg), and of dLVP/dt at R45 min (1740.2+/-111.5 mm Hg.s(-1) vs. 548.7+/-82.2 mm Hg.s(-1)) and R60 min (1199.8+/-104.6 mm Hg.s(-1) vs. 466.9+/-61.1 mm Hg.s(-1)). The transgenic group also displayed development of less oxidative stress, decreased extent of infarction, and attenuated cardiomyocyte apoptotic cell death. Transgene overexpression of alphaB crystallin was therefore successful in diminishing the independent contributory effects of both necrosis and apoptosis on I/R-induced cell death.	Univ Connecticut, Ctr Hlth, Dept Surg, Cardiovasc Res Ctr, Farmington, CT 06030 USA; Univ Calif San Diego, Dept Med, San Diego, CA 92103 USA	University of Connecticut; University of California System; University of California San Diego	Das, DK (corresponding author), Univ Connecticut, Ctr Hlth, Dept Surg, Cardiovasc Res Ctr, 263 Farmington Ave, Farmington, CT 06030 USA.				NHLBI NIH HHS [HL 49434, HL 34360, HL22559] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL022559, R01HL034360, R01HL049434, R37HL049434] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AOYAMA A, 1993, MOL CELL BIOL, V13, P1824, DOI 10.1128/MCB.13.3.1824; Armstrong SC, 1999, J MOL CELL CARDIOL, V31, P555, DOI 10.1006/jmcc.1998.0891; ASIMAKIS GK, 1992, AM J PHYSIOL, V263, pH887, DOI 10.1152/ajpheart.1992.263.3.H887; Barbato R, 1996, CIRC RES, V78, P821, DOI 10.1161/01.RES.78.5.821; Benjamin IJ, 1997, DEV DYNAM, V208, P75; BENNARDINI F, 1992, CIRC RES, V71, P288, DOI 10.1161/01.RES.71.2.288; BLUHM JF, 1998, AM J PHYSIOL, V275, pH2243; Bluhm WF, 1998, AM J PHYSIOL, V275, P2243; CHIEN KR, 1981, CIRC RES, V48, P711, DOI 10.1161/01.RES.48.5.711; CORDIS GA, 1995, J MOL CELL CARDIOL, V27, P1645, DOI 10.1016/S0022-2828(95)90656-8; Das DK, 1998, BIOLOGICAL OXIDANTS AND ANTIOXIDANTS: MOLECULAR MECHANISMS AND HEALTH EFFECTS, P165; Das DK, 1999, MOL CELL BIOCHEM, V196, P59, DOI 10.1023/A:1006966128795; DAS DK, 1994, METHOD ENZYMOL, V233, P601; DONNELLY TJ, 1992, CIRCULATION, V85, P769, DOI 10.1161/01.CIR.85.2.769; DUBLIN RA, 1989, MOL CELL BIOL, V9, P1083; Fliss H, 1996, CIRC RES, V79, P949, DOI 10.1161/01.RES.79.5.949; Gauthier NS, 1998, J MOL CELL CARDIOL, V30, P453, DOI 10.1006/jmcc.1997.0610; Golenhofen N, 1998, AM J PHYSIOL-HEART C, V274, pH1457, DOI 10.1152/ajpheart.1998.274.5.H1457; GOTTLIEB RA, 1994, J CLIN INVEST, V94, P1621, DOI 10.1172/JCI117504; GRUPP IL, 1993, AM J PHYSIOL, V265, pH1401, DOI 10.1152/ajpheart.1993.265.4.H1401; HEAD MW, 1994, J CELL PHYSIOL, V159, P41, DOI 10.1002/jcp.1041590107; HEIKKILA JJ, 1993, DEV GENET, V14, P87, DOI 10.1002/dvg.1020140202; Hogan B., 1986, MANIPULATING MOUSE E, P332; HORWITZ J, 1992, P NATL ACAD SCI USA, V89, P10449, DOI 10.1073/pnas.89.21.10449; IWAKI T, 1994, J CELL BIOL, V125, P1385, DOI 10.1083/jcb.125.6.1385; Kajstura J, 1996, LAB INVEST, V74, P86; KANTOROW M, 1994, P NATL ACAD SCI USA, V91, P3112, DOI 10.1073/pnas.91.8.3112; KATO K, 1991, BIOCHIM BIOPHYS ACTA, V1074, P201, DOI 10.1016/0304-4165(91)90062-L; KLEMENZ R, 1991, P NATL ACAD SCI USA, V88, P3652, DOI 10.1073/pnas.88.9.3652; LI GC, 1990, CIRCULATION, V82, P609, DOI 10.1161/01.CIR.82.2.609; MARBER MS, 1995, J CLIN INVEST, V95, P1446, DOI 10.1172/JCI117815; Martin JL, 1997, CIRCULATION, V96, P4343; MAULIK N, 1995, CIRCULATION, V92, P381, DOI 10.1161/01.CIR.92.9.381; Maulik N, 1998, AM J PHYSIOL-HEART C, V274, pH242, DOI 10.1152/ajpheart.1998.274.1.H242; Maulik N, 1998, FREE RADICAL BIO MED, V24, P869, DOI 10.1016/S0891-5849(97)00388-2; Maulik N, 1999, MOL CELL BIOCHEM, V196, P13, DOI 10.1023/A:1006905910140; MAULIK N, 1993, CIRCULATION, V88, P387; MAULIK N, 1999, HEART FAIL REV, V4, P165; Maulik N, 1998, AM J PHYSIOL, V275, P1857; MESTRIL R, 1994, J CLIN INVEST, V93, P759, DOI 10.1172/JCI117030; MIYAMAE M, 1996, AM J PHYSIOL, V271, pH1245; Neufer PD, 1998, AM J PHYSIOL-CELL PH, V274, pC341, DOI 10.1152/ajpcell.1998.274.2.C341; Qian YZ, 1999, AM J PHYSIOL-HEART C, V276, pH224, DOI 10.1152/ajpheart.1999.276.1.H224; SAGE MD, 1988, AM J PATHOL, V133, P327; Sharov VG, 1996, AM J PATHOL, V148, P141; van de Klundert FAJM, 1998, EUR J CELL BIOL, V75, P38, DOI 10.1016/S0171-9335(98)80044-7	46	199	211	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	FEB	2001	15	2					393	402		10.1096/fj.00-0199com	http://dx.doi.org/10.1096/fj.00-0199com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	400LK	11156955				2022-12-25	WOS:000166872900021
J	Imai, Y; Kurokawa, M; Izutsu, K; Hangaishi, A; Maki, K; Ogawa, S; Chiba, S; Mitani, K; Hirai, H				Imai, Y; Kurokawa, M; Izutsu, K; Hangaishi, A; Maki, K; Ogawa, S; Chiba, S; Mitani, K; Hirai, H			Mutations of the Smad4 gene in acute myelogeneous leukemia and their functional implications in leukemogenesis	ONCOGENE			English	Article						Smad; mutation; acute myelogeneous leukemia; leukemogenesis; transforming growth factor-beta	GROWTH-FACTOR-BETA; TUMOR-SUPPRESSOR; TRANSCRIPTIONAL ACTIVATION; DPC4 GENE; CELLS; PROTEINS; PROMOTER; RECEPTOR; BINDING; TRANSACTIVATION	The Smad family proteins are critical components of the transforming growth factor (TGF)-beta signaling pathway, TGF-beta is a multipotent cytokine that elicits many biological functions. In particular, TGF-beta exhibits effects on the cell cycle manifested by G1-phase arrest, differentiation, or apoptosis of several target cells, suggesting that disruption of TGF-beta signaling pathway could be involved in cancer formation, Here we show one missense mutation of the Smad4 gene in the MH1 domain (P102L) and one frame shift mutation resulting in termination in the MH2 domain (Delta (483-552)) in acute myelogeneous leukemia, Both of the mutated Smad4 proteins lack transcriptional activities, Concomitant expression of the P102L mutant with wild-type Smad4 inactivates wild-type Smad4 through inhibiting its DNA-binding ability. The Delta (483-552) mutant blocks nuclear translocation of wild-type Smad4 and thus disrupts TGF-beta signaling. This is the first report showing that mutations in the Smad4 gene are associated with the pathogenesis of acute myelogeneous leukemia and the obtained results should provide useful insights into the mechanism whereby disruption of TGF-beta signaling pathway could lead to acute myelogeneous leukemia.	Univ Tokyo, Grad Sch Med, Dept Hematol & Oncol, Bunkyo Ku, Tokyo 1138655, Japan	University of Tokyo	Hirai, H (corresponding author), Univ Tokyo, Grad Sch Med, Dept Hematol & Oncol, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1138655, Japan.		Izutsu, Koji/AAI-1125-2019	Izutsu, Koji/0000-0001-9129-8057; Imai, Yoichi/0000-0002-2938-6133				BENNETT JM, 1991, BRIT J HAEMATOL, V78, P325, DOI 10.1111/j.1365-2141.1991.tb04444.x; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; deWinter JP, 1997, ONCOGENE, V14, P1891, DOI 10.1038/sj.onc.1201017; Drexler H G, 1986, Tumour Biol, V6, P503; Feng XH, 1998, GENE DEV, V12, P2153, DOI 10.1101/gad.12.14.2153; Hahn SA, 1996, SCIENCE, V271, P350, DOI 10.1126/science.271.5247.350; Hangaishi A, 1996, BLOOD, V87, P4949, DOI 10.1182/blood.V87.12.4949.bloodjournal87124949; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Hua XX, 1998, GENE DEV, V12, P3084, DOI 10.1101/gad.12.19.3084; Imai Y, 1998, BIOCHEM BIOPH RES CO, V252, P582, DOI 10.1006/bbrc.1998.9705; Jonk LJC, 1998, J BIOL CHEM, V273, P21145, DOI 10.1074/jbc.273.33.21145; Kaneko H, 1998, ACTA HAEMATOL-BASEL, V99, P187, DOI 10.1159/000040837; Kawabata M, 1998, EMBO J, V17, P4056, DOI 10.1093/emboj/17.14.4056; Kurokawa M, 1998, NATURE, V394, P92, DOI 10.1038/27945; Kurokawa M, 1998, BLOOD, V92, P4003, DOI 10.1182/blood.V92.11.4003.423a56_4003_4012; Lagna G, 1996, NATURE, V383, P832, DOI 10.1038/383832a0; LEDAI J, 1998, CANCER RES, V58, P4592; Liu F, 1997, GENE DEV, V11, P3157, DOI 10.1101/gad.11.23.3157; LIU YC, 1993, P NATL ACAD SCI USA, V90, P8957, DOI 10.1073/pnas.90.19.8957; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Nakao A, 1997, EMBO J, V16, P5353, DOI 10.1093/emboj/16.17.5353; OGAWA S, 1994, BLOOD, V84, P2431, DOI 10.1182/blood.V84.8.2431.bloodjournal8482431; OHTA M, 1987, NATURE, V329, P539, DOI 10.1038/329539a0; PIACIBELLO W, 1991, HAEMATOLOGICA, V76, P460; Schutte M, 1996, CANCER RES, V56, P2527; Shi YG, 1997, NATURE, V388, P87, DOI 10.1038/40431; Stroschein SL, 1999, J BIOL CHEM, V274, P9431, DOI 10.1074/jbc.274.14.9431; TANAKA T, 1995, EMBO J, V14, P341, DOI 10.1002/j.1460-2075.1995.tb07008.x; TANAKA T, 1995, MOL CELL BIOL, V15, P2383; TANAKA T, 1994, J BIOL CHEM, V269, P24020; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0; Wu RY, 1997, MOL CELL BIOL, V17, P2521, DOI 10.1128/MCB.17.5.2521; Zawel L, 1998, MOL CELL, V1, P611, DOI 10.1016/S1097-2765(00)80061-1; Zhang Y, 1997, CURR BIOL, V7, P270, DOI 10.1016/S0960-9822(06)00123-0; Zhang Y, 1999, TRENDS CELL BIOL, V9, P274, DOI 10.1016/S0962-8924(99)01579-2; Zhang Y, 1998, NATURE, V394, P909, DOI 10.1038/29814; Zhang Y, 1996, NATURE, V383, P168, DOI 10.1038/383168a0; Zhou SB, 1998, P NATL ACAD SCI USA, V95, P2412, DOI 10.1073/pnas.95.5.2412	38	62	71	0	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 4	2001	20	1					88	96		10.1038/sj.onc.1204057	http://dx.doi.org/10.1038/sj.onc.1204057			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	391NE	11244507				2022-12-25	WOS:000166361400010
J	Koegel, H; Alzheimer, C				Koegel, H; Alzheimer, C			Expression and biological significance of Ca2+-activated ion channels in human keratinocytes	FASEB JOURNAL			English	Article						ATP-evoked change of membrane potential; P2Y2 receptor and intracellular Ca2+ release; Ca2+-activated Cl- channels; hSK4 proliferation and differentiation of keratinocytes	CULTURED HUMAN KERATINOCYTES; K+ CHANNELS; INTRACELLULAR CALCIUM; POTASSIUM CHANNELS; CHLORIDE TRANSPORT; EXTRACELLULAR ATP; CL SECRETION; DIFFERENTIATION; PROLIFERATION; CELLS	In whole-cell recording from HaCaT keratinocytes, ATP, bradykinin, and histamine caused a biphasic change of the membrane potential consisting of an initial transient depolarization, followed by a pronounced and long-lasting hyperpolarization. Flash photolysis of caged IP3 mimicked the agonist-induced voltage response, suggesting that intracellular Ca2+ release and subsequent opening of Ca2+-activated ion channels serve as the common transduction mechanism. In contrast, cAMP- and PKC-dependent pathways were not involved in the electrophysiological effects of the extracellular signaling molecules. The depolarization was predominantly mediated by a DIDS- and niflumic acid-sensitive Cl- current, whereas a charybdotoxin- and clotrimazole-sensitive K+ current underlay the prominent hyperpolarization. Consistent with the electrophysiological data, RT-PCR showed that HaCaT keratinocytes express two types of Ca2+-activated Cl- channels, CaCC2 and CaCC3 (CLCA2), as well as the Ca2+-activated K+ channel hSK4. That the pronounced hSK4-mediated hyperpolarization bears significance on the growth and differentiation properties of keratinocytes is suggested by RNase protection assays showing that hSK4 mRNA expression is strongly down-regulated under conditions that allow keratinocyte differentiation, hSK4 might thus play a role in linking changes in membrane potential to the biological fate of keratinocytes.	Univ Munich, Dept Physiol, D-80336 Munich, Germany	University of Munich	Alzheimer, C (corresponding author), Univ Munich, Dept Physiol, Pettenkoferstr 12, D-80336 Munich, Germany.							Agnel M, 1999, FEBS LETT, V455, P295, DOI 10.1016/S0014-5793(99)00891-1; Biro T, 1998, ARCH DERMATOL RES, V290, P270, DOI 10.1007/s004030050303; BOUKAMP P, 1988, J CELL BIOL, V106, P761, DOI 10.1083/jcb.106.3.761; Chan HC, 1997, J MEMBRANE BIOL, V156, P45; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COOK PW, 1995, J INVEST DERMATOL, V104, P976, DOI 10.1111/1523-1747.ep12606228; DeRoos ADG, 1997, J CELL PHYSIOL, V170, P166, DOI 10.1002/(SICI)1097-4652(199702)170:2<166::AID-JCP8>3.0.CO;2-M; Devor DC, 1996, AM J PHYSIOL-LUNG C, V271, pL775, DOI 10.1152/ajplung.1996.271.5.L775; Dixon CJ, 1999, BRIT J PHARMACOL, V127, P1680, DOI 10.1038/sj.bjp.0702653; FUCHS E, 1988, TRENDS GENET, V4, P277, DOI 10.1016/0168-9525(88)90169-2; GALIETTA LJV, 1991, PFLUG ARCH EUR J PHY, V418, P18, DOI 10.1007/BF00370447; GORDON JL, 1986, BIOCHEM J, V233, P309, DOI 10.1042/bj2330309; Gruber AD, 1999, AM J PHYSIOL-CELL PH, V276, pC1261; Gruber AD, 1998, HISTOCHEM CELL BIOL, V110, P43, DOI 10.1007/s004180050263; Gruber AD, 1998, GENOMICS, V54, P200, DOI 10.1006/geno.1998.5562; Huber SM, 1999, PFLUG ARCH EUR J PHY, V438, P53, DOI 10.1007/s004240050879; Jensen BS, 1998, AM J PHYSIOL-CELL PH, V275, pC848, DOI 10.1152/ajpcell.1998.275.3.C848; Joiner WJ, 1997, P NATL ACAD SCI USA, V94, P11013, DOI 10.1073/pnas.94.20.11013; JONES KT, 1994, EXP CELL RES, V212, P409, DOI 10.1006/excr.1994.1161; KAM E, 1987, EXP CELL RES, V173, P431, DOI 10.1016/0014-4827(87)90283-7; KANSEN M, 1992, BIOCHIM BIOPHYS ACTA, V1139, P49, DOI 10.1016/0925-4439(92)90081-W; Khanna R, 1999, J BIOL CHEM, V274, P14838, DOI 10.1074/jbc.274.21.14838; KYROZIS A, 1995, J NEUROSCI METH, V57, P27, DOI 10.1016/0165-0270(94)00116-X; Marty Alain, 1995, P31; MASTROCOLA T, 1991, BIOCHIM BIOPHYS ACTA, V1097, P275, DOI 10.1016/0925-4439(91)90081-J; Mauro T, 1997, J INVEST DERMATOL, V108, P864, DOI 10.1111/1523-1747.ep12292585; MAURO TM, 1990, J CELL PHYSIOL, V143, P13, DOI 10.1002/jcp.1041430103; MAURO TM, 1993, J MEMBRANE BIOL, V132, P201; NILIUS B, 1995, AM J PHYSIOL-CELL PH, V269, pC376, DOI 10.1152/ajpcell.1995.269.2.C376; Nilius B, 1997, J PHYSIOL-LONDON, V498, P381, DOI 10.1113/jphysiol.1997.sp021865; NILIUS B, 1994, NEWS PHYSIOL SCI, V9, P105; PILLAI S, 1992, J CLIN INVEST, V90, P42, DOI 10.1172/JCI115854; Ralevic V, 1998, PHARMACOL REV, V50, P413; ROSENBACH T, 1993, ARCH DERMATOL RES, V285, P393, DOI 10.1007/BF00372131; RYLE CM, 1989, DIFFERENTIATION, V40, P42, DOI 10.1111/j.1432-0436.1989.tb00812.x; Strobaek D, 1996, AM J PHYSIOL-CELL PH, V271, pC1463, DOI 10.1152/ajpcell.1996.271.5.C1463; SUTER MM, 1991, J INVEST DERMATOL, V97, P223, DOI 10.1111/1523-1747.ep12480162; TALWAR HS, 1989, J INVEST DERMATOL, V93, P241, DOI 10.1111/1523-1747.ep12277581; WERNER S, 1992, P NATL ACAD SCI USA, V89, P6896, DOI 10.1073/pnas.89.15.6896; WHITE MM, 1990, MOL PHARMACOL, V37, P720; Wonderlin WF, 1996, J MEMBRANE BIOL, V154, P91, DOI 10.1007/s002329900135; ZegarraMoran O, 1997, J MEMBRANE BIOL, V156, P297, DOI 10.1007/s002329900209	42	41	46	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JAN	2001	15	1					145	154		10.1096/fj.00-0055com	http://dx.doi.org/10.1096/fj.00-0055com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	390TH	11149902				2022-12-25	WOS:000166312400023
J	Mechtcheriakova, D; Schabbauer, G; Lucerna, M; Clauss, M; De Martin, R; Binder, BR; Hofer, E				Mechtcheriakova, D; Schabbauer, G; Lucerna, M; Clauss, M; De Martin, R; Binder, BR; Hofer, E			Specificity, diversity, and convergence in VEGF and TNF-alpha signaling events leading to tissue factor up-regulation via EGR-1 in endothelial cells	FASEB JOURNAL			English	Article						endothelium; tissue factor; MAP kinases; inflammatory cytokines; angiogenic growth factors	NF-KAPPA-B; ACTIVATED PROTEIN-KINASE; TUMOR-NECROSIS-FACTOR; COLONY-STIMULATING FACTOR; RECEPTOR TYROSINE KINASES; GROWTH-FACTOR; MAP KINASE; TRANSCRIPTION FACTOR; NUCLEAR-FACTOR; FACTOR GENE	Tissue factor (TF) has been shown to be up-regulated in endothelial cells by the inflammatory cytokine tumor necrosis factor alpha (TNF-alpha) as well as by the main angiogenic factor VEGF. Since both stimuli induce the transcription factor EGR-1, which is critically involved in TF gene regulation, we used EGR-1-dependent TF induction as a model to identify potential cross-talks between the various signal transduction cascades initiated by VEGF and TNF-alpha. The data show that at the MAP kinase level, VEGF mainly activates ERK1/2 and p38 MAP kinases in human endothelial cells. TNF-alpha is able to activate all three MAP kinase cascades as well as the classical inflammatory I kappaB/NF kappaB pathway. Furthermore, the MEK-ERK module of MAP kinases appears to act as the convergence point of VEGF- and TNF-alpha -initiated signaling cascades, which lead to the activation of EGR-1 and subsequent TF expression, whereas the upstream signals are distinct. We found that induction of TF by VEGF via EGR-1 is strongly PKC dependent. The TNF-alpha -initiated MEK/ERK cascade connected to EGR-1 and TF expression is clearly less sensitive to PKC inhibition. TNF-ol-mediated activation of MEK/ERK and EGR-1 can be blocked by adenoviral expression of a dominant negative mutant of IKK2, whereas the VEGF signaling pathway is unaffected. Thus, our data demonstrate a new link between the classical inflammatory IKK/I kappaB and the MEK/ERK cascades triggered by TNF-alpha. The additional finding that EGF induces ERK and EGR-1 in a PKC- independent manner and that this signal is not sufficient to up-regulate TF emphasizes the importance of a VEGF-specific signaling pattern for the induction of TF.	Univ Vienna, VIRCC, Dept Vasc Biol & Thrombosis Res, A-1235 Vienna, Austria; Max Planck Inst Physiol & Clin Res, Dept Mol Cell Biol, D-61231 Bad Nauheim, Germany	University of Vienna; Max Planck Society	Hofer, E (corresponding author), Univ Vienna, VIRCC, Dept Vasc Biol & Thrombosis Res, Brunnerstr 59, A-1235 Vienna, Austria.	erhard.hofer@univie.ac.at		Mechtcheriakova, Diana/0000-0002-8737-3592; Clauss, Matthias/0000-0001-5180-3899; Schabbauer, Gernot/0000-0002-7490-8009				ALESSI DR, 1994, EMBO J, V13, P1610, DOI 10.1002/j.1460-2075.1994.tb06424.x; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Anda T, 1997, NEUROL RES, V19, P369, DOI 10.1080/01616412.1997.11758599; Armesilla AL, 1999, MOL CELL BIOL, V19, P2032; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; Barnes PJ, 1997, NEW ENGL J MED, V336, P1066, DOI 10.1056/NEJM199704103361506; Basu A, 1996, CELL GROWTH DIFFER, V7, P1507; Berra E, 1995, EMBO J, V14, P6157, DOI 10.1002/j.1460-2075.1995.tb00306.x; BUDWORTH J, 1995, FEBS LETT, V362, P139, DOI 10.1016/0014-5793(95)00227-Z; CAO XM, 1992, J BIOL CHEM, V267, P1345; Carmeliet P, 1996, NATURE, V383, P73, DOI 10.1038/383073a0; Cines DB, 1998, BLOOD, V91, P3527; Clauss M, 1996, J BIOL CHEM, V271, P17629, DOI 10.1074/jbc.271.30.17629; Clauss M, 1996, FEBS LETT, V390, P334, DOI 10.1016/0014-5793(96)00690-4; CLAUSS M, 1990, J EXP MED, V172, P1535, DOI 10.1084/jem.172.6.1535; Cohen P, 1996, Adv Pharmacol, V36, P15, DOI 10.1016/S1054-3589(08)60574-8; Contrino J, 1996, NAT MED, V2, P209, DOI 10.1038/nm0296-209; Corbit KC, 1999, MOL CELL BIOL, V19, P4209; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; deMartin R, 1997, GENE THER, V4, P493, DOI 10.1038/sj.gt.3300408; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; DIKIC I, 1994, CURR BIOL, V4, P702, DOI 10.1016/S0960-9822(00)00155-X; EDGINGTON TS, 1991, THROMB HAEMOSTASIS, V66, P67; English J, 1999, EXP CELL RES, V253, P255, DOI 10.1006/excr.1999.4687; FANTL WJ, 1993, ANNU REV BIOCHEM, V62, P453, DOI 10.1146/annurev.bi.62.070193.002321; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; Ferrara N, 1997, ENDOCR REV, V18, P4, DOI 10.1210/er.18.1.4; GASSON JC, 1991, BLOOD, V77, P1131, DOI 10.1182/blood.V77.6.1131.1131; HERSCHMAN HR, 1991, ANNU REV BIOCHEM, V60, P281, DOI 10.1146/annurev.biochem.60.1.281; Hirano M, 1996, J BIOL CHEM, V271, P13234, DOI 10.1074/jbc.271.22.13234; Hofer E, 1999, NATO ADV SCI I A-LIF, V308, P3; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; JAMIESON GA, 1989, J CELL PHYSIOL, V139, P262, DOI 10.1002/jcp.1041390207; KELLER JR, 1989, J IMMUNOL, V143, P4025; Keyt BA, 1996, J BIOL CHEM, V271, P5638, DOI 10.1074/jbc.271.10.5638; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; Lallena MJ, 1999, MOL CELL BIOL, V19, P2180; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; Lee FS, 1997, CELL, V88, P213, DOI 10.1016/S0092-8674(00)81842-5; Lim CP, 1998, ONCOGENE, V16, P2915, DOI 10.1038/sj.onc.1201834; MACKMAN N, 1991, J EXP MED, V174, P1517, DOI 10.1084/jem.174.6.1517; MACKMAN N, 1995, FASEB J, V9, P883, DOI 10.1096/fasebj.9.10.7615158; Mark KS, 1999, LIFE SCI, V64, P1941, DOI 10.1016/S0024-3205(99)00139-3; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MARTINYBARON G, 1993, J BIOL CHEM, V268, P9194; Mechtcheriakova D, 1999, BLOOD, V93, P3811, DOI 10.1182/blood.V93.11.3811.411k40_3811_3823; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; Meyer M, 1999, EMBO J, V18, P363, DOI 10.1093/emboj/18.2.363; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; MIYAJIMA A, 1992, ANNU REV IMMUNOL, V10, P295, DOI 10.1146/annurev.immunol.10.1.295; MOLL T, 1995, J BIOL CHEM, V270, P3849, DOI 10.1074/jbc.270.8.3849; MULLER G, 1995, EMBO J, V14, P1961, DOI 10.1002/j.1460-2075.1995.tb07188.x; Nakano H, 1998, P NATL ACAD SCI USA, V95, P3537, DOI 10.1073/pnas.95.7.3537; OKUDA K, 1992, BLOOD, V79, P2880; OShea JJ, 1997, IMMUNITY, V7, P1, DOI 10.1016/S1074-7613(00)80505-1; Ott I, 1998, J CELL BIOL, V140, P1241, DOI 10.1083/jcb.140.5.1241; PAYNE DM, 1991, EMBO J, V10, P885, DOI 10.1002/j.1460-2075.1991.tb08021.x; Petrova TV, 1999, EXP CELL RES, V253, P117, DOI 10.1006/excr.1999.4707; QIU ZH, 1994, J BIOL CHEM, V269, P19480; Qu ZC, 1998, J CELL BIOL, V142, P1075, DOI 10.1083/jcb.142.4.1075; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; RUF W, 1994, FASEB J, V8, P385, DOI 10.1096/fasebj.8.6.8168689; SAKAMOTO KM, 1994, MOL CELL BIOL, V14, P5975, DOI 10.1128/MCB.14.9.5975; Verma IM, 1997, P NATL ACAD SCI USA, V94, P11758, DOI 10.1073/pnas.94.22.11758; WALTENBERGER J, 1994, J BIOL CHEM, V269, P26988; Wesselborg S, 1997, J BIOL CHEM, V272, P12422, DOI 10.1074/jbc.272.19.12422; WOLFF B, 1995, EXP CELL RES, V217, P31, DOI 10.1006/excr.1995.1060; Yabkowitz R, 1999, BLOOD, V93, P1969, DOI 10.1182/blood.V93.6.1969.406k14_1969_1979; Yan SF, 1999, J BIOL CHEM, V274, P15030, DOI 10.1074/jbc.274.21.15030; Yoshiji H, 1999, CANCER RES, V59, P4413; Young PR, 1997, J BIOL CHEM, V272, P12116, DOI 10.1074/jbc.272.18.12116; ZHANG YM, 1994, J CLIN INVEST, V94, P1320, DOI 10.1172/JCI117451	74	173	186	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JAN	2001	15	1					230	242		10.1096/fj.00-0247com	http://dx.doi.org/10.1096/fj.00-0247com			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	390TH	11149911				2022-12-25	WOS:000166312400032
J	Vernucci, M; Cerrato, F; Besnard, N; Casola, S; Pedone, PV; Bruni, CB; Riccio, A				Vernucci, M; Cerrato, F; Besnard, N; Casola, S; Pedone, PV; Bruni, CB; Riccio, A			The H19 endodermal enhancer is required for Igf2 activation and tumor formation in experimental liver carcinogenesis	ONCOGENE			English	Article						genomic imprinting; hepatocarcinogenesis; insulin-like growth factor; apoptosis	GROWTH-FACTOR-II; INDUCED HEPATOCELLULAR CARCINOMAS; INSULIN-LIKE GROWTH-FACTOR-2; SV40 LARGE T; TRANSGENIC MICE; GENE; EXPRESSION; TUMORIGENESIS; APOPTOSIS; RAT	The expression of the linked but reciprocally imprinted Igf2 and H19 genes is activated in adult liver in the course of tumor development. By in situ hybridization analysis we have shown that both the Igf2 and H19 RNAs are expressed in the majority of the neoplastic nodules, and that hepatocellular carcinomas are developed in an experimental model of liver carcinogenesis. H19 is also highly activated in smaller and less distinct hyperplastic regions, The few neoplastic areas showing Igf2 but no H19 RNA display loss of the maternally inherited allele at the Igf2/H19 locus. These data are compatible with the existence of a common activation mechanism of these two genes during liver carcinogenesis and with a stronger H19 induction in the pre-neoplastic lesions. By using mice carrying a deletion of the H19 endodermal enhancer, we show that this regulatory element is necessary for the activation of the lgf2 and H19 genes upon induction of liver carcinogenesis. Furthermore, multiple sites of the H19 endodermal enhancer region become hypersensitive to DNase I when the carcinogenesis process is induced. Lastly, liver tumors developed in mice paternally inheriting the H19 enhancer deletion are found to have marked growth delays, increased frequency of apoptotic nuclei, and lack of Igf2 mRNA expression, thus indicating that this regulatory element plays a major role in the progression of liver carcinogenesis, since it is required for the activation of the anti-apoptotic lgf2 gene.	CNR, Ctr Endocrinol & Oncol Sperimentale G Salvatore, I-80131 Naples, Italy; Univ Naples Federico II, Dipartimento Biol & Patol Cellulare & Mol L Calif, Naples, Italy; CNR, Ctr Biocristallog, I-80125 Naples, Italy; Univ Naples 2, Dipartimento Sci Ambientali, Naples, Italy	Consiglio Nazionale delle Ricerche (CNR); University of Naples Federico II; Consiglio Nazionale delle Ricerche (CNR); Universita della Campania Vanvitelli	Riccio, A (corresponding author), CNR, Ctr Endocrinol & Oncol Sperimentale G Salvatore, Via S Pansini 5, I-80131 Naples, Italy.		Riccio, Andrea/AAY-7571-2020; Riccio, Andrea/A-4991-2015; Casola, Stefano/AAN-8319-2021; Casola, Stefano/O-3922-2014	Riccio, Andrea/0000-0001-7990-3576; Riccio, Andrea/0000-0001-7990-3576; Casola, Stefano/0000-0001-5580-0986; Pedone, Paolo Vincenzo/0000-0002-0828-5843				Allemand I, 1995, ONCOGENE, V11, P2583; Bell AC, 2000, NATURE, V405, P482, DOI 10.1038/35013100; BRUNKOW ME, 1991, GENE DEV, V5, P1092, DOI 10.1101/gad.5.6.1092; CARICASOLE A, 1993, NUCLEIC ACIDS RES, V21, P1873, DOI 10.1093/nar/21.8.1873; CASOLA S, 1995, ONCOGENE, V11, P711; CHIARIOTTI L, 1988, MOL ENDOCRINOL, V2, P1115, DOI 10.1210/mend-2-11-1115; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHRISTOFORI G, 1995, NAT GENET, V10, P196, DOI 10.1038/ng0695-196; CHRISTOFORI G, 1994, NATURE, V369, P414, DOI 10.1038/369414a0; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; DeCaprio JA, 1999, BIOLOGICALS, V27, P23, DOI 10.1006/biol.1998.0173; DECHIARA TM, 1990, NATURE, V345, P78, DOI 10.1038/345078a0; DRUMMOND IA, 1992, SCIENCE, V257, P674, DOI 10.1126/science.1323141; Dugimont T, 1998, ONCOGENE, V16, P2395, DOI 10.1038/sj.onc.1201742; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; FEINBERG AP, 1999, CANCER RES, V59, P1743; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; Haddad R, 1997, CANCER RES, V57, P4615; Hark AT, 2000, NATURE, V405, P486, DOI 10.1038/35013106; Harris TM, 1998, ONCOGENE, V16, P203, DOI 10.1038/sj.onc.1201519; Ishihara K, 2000, GENOME RES, V10, P664, DOI 10.1101/gr.10.5.664; KIM SJ, 1992, MOL CELL BIOL, V12, P2455, DOI 10.1128/MCB.12.6.2455; Lee YI, 1998, ONCOGENE, V16, P2367, DOI 10.1038/sj.onc.1201760; LEIGHTON PA, 1995, GENE DEV, V9, P2079, DOI 10.1101/gad.9.17.2079; Li M, 1998, AM J MED GENET, V79, P253; Morison IM, 1996, NAT MED, V2, P311, DOI 10.1038/nm0396-311; Naik P, 1996, GENE DEV, V10, P2105, DOI 10.1101/gad.10.17.2105; Nardone G, 1996, HEPATOLOGY, V23, P1304, DOI 10.1053/jhep.1996.v23.pm0008675143; NORSTEDT G, 1988, CARCINOGENESIS, V9, P209, DOI 10.1093/carcin/9.2.209; PACHNIS V, 1988, EMBO J, V7, P673, DOI 10.1002/j.1460-2075.1988.tb02862.x; PACHNIS V, 1984, P NATL ACAD SCI-BIOL, V81, P5523, DOI 10.1073/pnas.81.17.5523; Reik W, 1997, TRENDS GENET, V13, P330, DOI 10.1016/S0168-9525(97)01200-6; REITMAN M, 1993, MOL CELL BIOL, V13, P3990, DOI 10.1128/MCB.13.7.3990; RUBIN R, 1995, LAB INVEST, V73, P311; RUTHER U, 1993, ONCOGENE, V8, P87; Sambrook J., 2002, MOL CLONING LAB MANU; Sohda T, 1996, LAB INVEST, V75, P307; Sperandeo MP, 2000, AM J HUM GENET, V66, P841, DOI 10.1086/302811; TAKAGI H, 1992, CANCER RES, V52, P5171; Tilghman SM, 1999, CELL, V96, P185, DOI 10.1016/S0092-8674(00)80559-0; Toretsky JA, 1996, J ENDOCRINOL, V149, P367, DOI 10.1677/joe.0.1490367; UENO T, 1988, CARCINOGENESIS, V9, P1779, DOI 10.1093/carcin/9.10.1779; Ungaro P, 1997, MOL CELL ENDOCRINOL, V135, P153, DOI 10.1016/S0303-7207(97)00201-3; Webber AL, 1998, NATURE, V391, P711, DOI 10.1038/35655; Werner H, 1997, CRIT REV ONCOGENESIS, V8, P71, DOI 10.1615/CritRevOncog.v8.i1.40; YOOWARREN H, 1988, MOL CELL BIOL, V8, P4707, DOI 10.1128/MCB.8.11.4707; ZARRILLI R, 1994, MOL CELL ENDOCRINOL, V101, pR1, DOI 10.1016/0303-7207(94)90253-4; Zhang LJ, 1998, ONCOGENE, V17, P1261, DOI 10.1038/sj.onc.1202050; Zhang LJ, 1996, CANCER RES, V56, P1367	49	27	27	0	8	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 14	2000	19	54					6376	6385		10.1038/sj.onc.1204024	http://dx.doi.org/10.1038/sj.onc.1204024			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	388YK	11175353				2022-12-25	WOS:000166210500022
J	Liu, Y; Zacksenhaus, E				Liu, Y; Zacksenhaus, E			E2F1 mediates ectopic proliferation and stage-specific p53-dependent apoptosis but not aberrant differentiation in the ocular lens of Rb deficient fetuses	ONCOGENE			English	Article						Rb; p53; E2F1; lens; crystallins; filensin	SKELETAL-MUSCLE CELLS; RETINOBLASTOMA PROTEIN; GENE-EXPRESSION; MOUSE LENS; TRANSCRIPTION FACTORS; EYE DEVELOPMENT; GROWTH CONTROL; FIBER CELL; IN-VIVO; S-PHASE	The retinoblastoma tumor suppressor, Rb, is a transcription cofactor that controls cell proliferation, survival and differentiation. Mutant mouse embryos lacking Rb exhibit ectopic proliferation and apoptosis that are mediated in some tissues by E2F1, a major partner of Rb, and by the p53 tumor suppressor. Whether E2F1 and p53 also mediate the differentiation defects in Rb mutant embryos is, however, not clear. Here we show that partially rescued mgRb:Rb-/- mutant fetuses exhibit ectopic lens epithelial cell proliferation, apoptosis and severe cataract. The abnormal cell proliferation and apoptosis were significantly suppressed in the lens of compound mutant fetuses lacking both Rb and E2F1 at embryonic day (E) E15.5, Interestingly however, at E18.5, only ectopic proliferation, not apoptosis, was dramatically reduced in mgRb:Rb-/-:E2F1-/- lenses. In contrast, p53 did not exert such a stage-specific effect and apoptosis was invariably suppressed in mgRb:Rb-/-:p53-/- composite mutant lenses throughout embryogenesis. Using RT-PCR and iir situ hybridization analyses, me identified a subset of lens specific genes, most notably the late differentiation marker filensin, which were not properly induced during lens development in mgRb:Rb-/- fetuses. Remarkably, despite the inhibition of cell proliferation and apoptosis, the degeneration of lens fibers and aberrant expression of filensin were only marginally corrected in mgRb:Rb-/-:E2F1-/- fetuses at E15.5 but not at all at E18.5 or in mgRb:Rb-/-:p53-/- mutant fetuses. Thus, inactivation of E2F1 reduces ectopic cell proliferation and stage-specific p53-dependent apoptosis but does not rescue the differentiation defects associated with loss of Rb during lens development.	Univ Toronto, Toronto Gen Hosp, Dept Med, Univ Hlth Network, Toronto, ON M5G 2M1, Canada; Univ Toronto, Toronto Gen Hosp, Inst Res, Dept Med Biophys,Univ Hlth Network, Toronto, ON M5G 2M1, Canada	University of Toronto; University Toronto Affiliates; University Health Network Toronto; Toronto General Hospital; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Toronto General Hospital	Zacksenhaus, E (corresponding author), Univ Toronto, Toronto Gen Hosp, Dept Med, Univ Hlth Network, 67 Coll St, Toronto, ON M5G 2M1, Canada.		Zacksenhaus, Eldad/AAD-3584-2020					Agah R, 1997, J CLIN INVEST, V100, P2722, DOI 10.1172/JCI119817; Bates S, 1998, NATURE, V395, P124, DOI 10.1038/25867; CLARKE AR, 1992, NATURE, V359, P328, DOI 10.1038/359328a0; Cvekl A, 1999, INVEST OPHTH VIS SCI, V40, P1343; Cvekl A, 1996, BIOESSAYS, V18, P621, DOI 10.1002/bies.950180805; DeGregori J, 1997, P NATL ACAD SCI USA, V94, P7245, DOI 10.1073/pnas.94.14.7245; Du W, 2000, DEVELOPMENT, V127, P367; Du W, 1996, GENE DEV, V10, P1206, DOI 10.1101/gad.10.10.1206; DYNLACHT BD, 1994, P NATL ACAD SCI USA, V91, P6359, DOI 10.1073/pnas.91.14.6359; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Field SJ, 1996, CELL, V85, P549, DOI 10.1016/S0092-8674(00)81255-6; Francis PJ, 1999, TRENDS GENET, V15, P191, DOI 10.1016/S0168-9525(99)01738-2; Fromm L, 1996, ONCOGENE, V12, P69; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; Humbert PO, 2000, GENE DEV, V14, P690; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; Jiang Z, 1997, ONCOGENE, V14, P1789, DOI 10.1038/sj.onc.1201014; JIANG Z, 2000, IN PRESS DEV BIOL; JIANG Z, 2000, IN PRESS J BIOL CHEM; JOHNSON DG, 1993, NATURE, V365, P349, DOI 10.1038/365349a0; Kondoh H, 1999, CURR OPIN GENET DEV, V9, P301, DOI 10.1016/S0959-437X(99)80045-8; Kumar J, 1997, GENE DEV, V11, P2023, DOI 10.1101/gad.11.16.2023; LEE EYHP, 1992, NATURE, V359, P288, DOI 10.1038/359288a0; LEE EYHP, 1994, GENE DEV, V8, P2008, DOI 10.1101/gad.8.17.2008; Macleod KF, 1996, EMBO J, V15, P6178, DOI 10.1002/j.1460-2075.1996.tb01006.x; Masaki S, 1997, GENE, V201, P11, DOI 10.1016/S0378-1119(97)00419-8; McCaffrey J, 1999, MOL CELL BIOL, V19, P6458; MERDES A, 1991, J CELL BIOL, V115, P397, DOI 10.1083/jcb.115.2.397; MORGENBESSER SD, 1994, NATURE, V371, P72, DOI 10.1038/371072a0; MURERORLANDO M, 1987, DEV BIOL, V119, P260, DOI 10.1016/0012-1606(87)90227-2; Nevins JR, 1997, J CELL PHYSIOL, V173, P233, DOI 10.1002/(SICI)1097-4652(199711)173:2<233::AID-JCP27>3.0.CO;2-F; Novitch BG, 1996, J CELL BIOL, V135, P441, DOI 10.1083/jcb.135.2.441; Oliver G, 1997, TRENDS NEUROSCI, V20, P415, DOI 10.1016/S0166-2236(97)01082-5; Phillips AC, 1999, MOL CELL, V4, P771, DOI 10.1016/S1097-2765(00)80387-1; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; Rampalli AM, 1998, ONCOGENE, V16, P399, DOI 10.1038/sj.onc.1201546; Sawado T, 1998, BIOCHEM BIOPH RES CO, V251, P409, DOI 10.1006/bbrc.1998.9407; Sellers WR, 1998, GENE DEV, V12, P95, DOI 10.1101/gad.12.1.95; Sellers WR, 1996, BBA-REV CANCER, V1288, pM1, DOI 10.1016/0304-419X(96)00014-5; Tsai KY, 1998, MOL CELL, V2, P293, DOI 10.1016/S1097-2765(00)80274-9; Vitelli L, 2000, MOL CELL BIOL, V20, P5330, DOI 10.1128/MCB.20.14.5330-5342.2000; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Wigle JT, 1999, NAT GENET, V21, P318, DOI 10.1038/6844; WILLIAMS BO, 1994, NAT GENET, V7, P480, DOI 10.1038/ng0894-480; WU XW, 1994, P NATL ACAD SCI USA, V91, P3602, DOI 10.1073/pnas.91.9.3602; Zacksenhaus E, 1996, GENE DEV, V10, P3051, DOI 10.1101/gad.10.23.3051; ZACKSENHAUS E, 1993, ADV CANCER RES, V61, P115, DOI 10.1016/S0065-230X(08)60957-4; Zhang PM, 1998, GENE DEV, V12, P3162, DOI 10.1101/gad.12.20.3162; Zhu X, 1999, ONCOGENE, V18, P4940, DOI 10.1038/sj.onc.1202876	50	27	27	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 7	2000	19	52					6065	6073		10.1038/sj.onc.1203996	http://dx.doi.org/10.1038/sj.onc.1203996			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	382MY	11146559				2022-12-25	WOS:000165827900014
J	Morini, M; Astigiano, S; Mora, M; Ricotta, C; Ferrari, N; Mantero, S; Levi, G; Rossini, M; Barbieri, O				Morini, M; Astigiano, S; Mora, M; Ricotta, C; Ferrari, N; Mantero, S; Levi, G; Rossini, M; Barbieri, O			Hyperplasia and impaired involution in the mammary gland of transgenic mice expressing human FGF4	ONCOGENE			English	Article						transgenic mice; fibroblast growth factors; mammary gland	GROWTH-FACTOR FAMILY; BREAST-CANCER; EPITHELIAL-CELLS; GENE-EXPRESSION; K-FGF; PROVIRAL INSERTION; TUMOR VIRUS; MCF-7 CELLS; INT-2; HST	Fgf4, a member of the fibroblast growth factor family, is frequently amplified in a variety of human cancers, however, its expression in neoplastic tissues is rarely detectable, This makes uncertain its involvement in tumour aetiology, although several in-vitro studies link Fgf4 overexpression to malignant transformation and metastatization of culture cells, We generated a transgenic mouse model in which the whey acidic protein (WAP) promoter directs expression of human Fgf4 to mammary tissues during late pregnancy and throughout lactation, with the purpose of studying the involvement of this growth factor in mammary tumorigenesis, Expression of the transgene was specifically detected in lobular-alveolar cells of lactating mammary glands that, by histological analysis, displayed hyperplastic areas and a disorganized structure, This was accompanied by an increased number of red blood cells and expression, in alveolar epithelial cells, of the vascular endothelial growth factor, which is absent in wild type controls, The most striking effect caused by FGF4 overexpression was on the remodelling of mammary tissue at the end of lactation, Indeed, transgenic animals showed a delayed involution of the gland due to a dramatic reduction in the overall number of apoptotic cells, which are normally present in the organ after weaning, Nevertheless, none of the animals examined developed neoplastic lesions of the mammary gland even after several pregnancies and at old age. Our work represents the first in-vivo demonstration of the anti-apoptotic and angiogenic properties of FGF4.	Univ Genoa, Dipartimento Oncol Biol & Genet, I-16132 Genoa, Italy; Univ Siena, Dipartimento Fisiopatol & Med Sperimentale, I-53100 Siena, Italy; MNHN, URA CNRS 8572, Lab Physiol Gen & Comparee, Paris, France; Chiron SPA, Iris, Siena, Italy; Ist Nazl Ric Canc, Unita Morfogenesi Mol, I-16132 Genoa, Italy; Ist Nazl Ric Canc, Serv Biol Mol, I-16132 Genoa, Italy; Ist Nazl Ric Canc, Unita Transgenici, I-16132 Genoa, Italy	University of Genoa; University of Siena; Museum National d'Histoire Naturelle (MNHN); Novartis; University of Genoa; IRCCS AOU San Martino IST; University of Genoa; IRCCS AOU San Martino IST; University of Genoa; IRCCS AOU San Martino IST	Barbieri, O (corresponding author), Univ Genoa, Dipartimento Oncol Biol & Genet, Largo R Banzi 10, I-16132 Genoa, Italy.		Ferrari, Nicoletta/AAG-6049-2019; Barbieri, Ottavia/E-8768-2011; Mantero, Stefano/AAE-5515-2021; Astigiano, Simonetta/AAG-7766-2019	Ferrari, Nicoletta/0000-0002-6027-1035; Astigiano, Simonetta/0000-0002-8200-0666; Mantero, Stefano/0000-0003-0608-2724; Levi, Giovanni/0000-0002-7041-6787				ADNANE J, 1991, ONCOGENE, V6, P659; Baik MG, 1998, INT J MOL MED, V2, P39; BASILICO C, 1992, ADV CANCER RES, V59, P115, DOI 10.1016/S0065-230X(08)60305-X; BATES SE, 1988, MOL ENDOCRINOL, V2, P543, DOI 10.1210/mend-2-6-543; BOVI PD, 1987, CELL, V50, P729, DOI 10.1016/0092-8674(87)90331-X; BRUSTLE O, 1992, ONCOGENE, V7, P1177; Chodosh LA, 2000, DEV BIOL, V219, P259, DOI 10.1006/dbio.2000.9614; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COLEMANKRNACIK S, 1994, MOL ENDOCRINOL, V8, P218, DOI 10.1210/me.8.2.218; Daphna-Iken D, 1998, ONCOGENE, V17, P2711, DOI 10.1038/sj.onc.1202212; Deroanne CF, 1997, CANCER RES, V57, P5590; DICKSON C, 1984, CELL, V37, P529, DOI 10.1016/0092-8674(84)90383-0; DICKSON RB, 1991, BIOESSAYS, V13, P591, DOI 10.1002/bies.950131109; FANTL V, 1995, GENE DEV, V9, P2364, DOI 10.1101/gad.9.19.2364; Fukumura D, 1998, CELL, V94, P715, DOI 10.1016/S0092-8674(00)81731-6; GAVIN BJ, 1992, MOL CELL BIOL, V12, P2418, DOI 10.1128/MCB.12.5.2418; Hajitou A, 2000, BREAST CANCER RES TR, V60, P15, DOI 10.1023/A:1006302602261; Hennighausen L, 1998, GENE DEV, V12, P449, DOI 10.1101/gad.12.4.449; Hogan B, 1994, MANIPULATING MOUSE E; JAAKKOLA S, 1993, INT J CANCER, V54, P378, DOI 10.1002/ijc.2910540305; Jackson D, 1997, J CELL SCI, V110, P1261; Johnson MR, 1998, ONCOGENE, V16, P2647, DOI 10.1038/sj.onc.1201789; Kitsberg DI, 1996, ONCOGENE, V13, P2507; Kiuru-Kuhlefelt S, 2000, MODERN PATHOL, V13, P433, DOI 10.1038/modpathol.3880074; Labosky PA, 1997, DEVELOPMENT, V124, P1263; MACARTHUR CA, 1995, J VIROL, V69, P2501, DOI 10.1128/JVI.69.4.2501-2507.1995; Mangiarini L, 1996, CELL, V87, P493, DOI 10.1016/S0092-8674(00)81369-0; MCLESKEY SW, 1993, CANCER RES, V53, P2168; MERLO GR, 1994, ONCOGENE, V9, P443; MULLER WJ, 1990, EMBO J, V9, P907, DOI 10.1002/j.1460-2075.1990.tb08188.x; MURPHY LJ, 1986, MOL ENDOCRINOL, V46, P4555; Neuenschwander S, 1996, J CLIN INVEST, V97, P2225, DOI 10.1172/JCI118663; OBERHAMMER F, 1993, J CELL SCI, V104, P317; Ornitz DM, 1996, J BIOL CHEM, V271, P15292, DOI 10.1074/jbc.271.25.15292; ORNITZ DM, 1991, P NATL ACAD SCI USA, V88, P698, DOI 10.1073/pnas.88.3.698; Payson RA, 1996, ONCOGENE, V13, P47; PENAULTLLORCA F, 1995, INT J CANCER, V61, P170, DOI 10.1002/ijc.2910610205; PETERS G, 1989, P NATL ACAD SCI USA, V86, P5678, DOI 10.1073/pnas.86.15.5678; PITTIUS CW, 1988, MOL ENDOCRINOL, V2, P1027, DOI 10.1210/mend-2-11-1027; QUARTO N, 1989, ONCOGENE RES, V5, P101; ROBINSON GW, 1995, DEVELOPMENT, V121, P2079; SHACKLEFORD GM, 1993, P NATL ACAD SCI USA, V90, P740, DOI 10.1073/pnas.90.2.740; Shimon I, 1996, J CLIN INVEST, V97, P187, DOI 10.1172/JCI118388; Shimon I, 1998, CLIN ENDOCRINOL, V48, P23, DOI 10.1046/j.1365-2265.1998.00332.x; Souttou B, 1996, INT J CANCER, V68, P675, DOI 10.1002/(SICI)1097-0215(19961127)68:5<675::AID-IJC19>3.0.CO;2-0; TALARICO D, 1993, MOL CELL BIOL, V13, P1998, DOI 10.1128/MCB.13.4.1998; TAYLOR WR, 1993, EXP CELL RES, V204, P295, DOI 10.1006/excr.1993.1036; THEILLET C, 1989, ONCOGENE, V4, P915; Vaahtokari A, 1996, DEVELOPMENT, V122, P121; Yiangou C, 1997, BRIT J CANCER, V75, P28, DOI 10.1038/bjc.1997.5	50	10	10	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 7	2000	19	52					6007	6014		10.1038/sj.onc.1204011	http://dx.doi.org/10.1038/sj.onc.1204011			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	382MY	11146552				2022-12-25	WOS:000165827900007
J	De Luca, A; Arra, C; D'Antonio, A; Casamassimi, A; Losito, S; Ferraro, P; Ciardiello, F; Salomon, DS; Normanno, N				De Luca, A; Arra, C; D'Antonio, A; Casamassimi, A; Losito, S; Ferraro, P; Ciardiello, F; Salomon, DS; Normanno, N			Simultaneous blockade of different EGF-like growth factors results in efficient growth inhibition of human colon carcinoma xenografts	ONCOGENE			English	Article						TGF alpha; amphiregulin; cripto; colon carcinoma; antisense	MAMMARY EPITHELIAL-CELLS; PROTEIN-KINASE-A; FACTOR-ALPHA; IMMUNOHISTOCHEMICAL DETECTION; ANTISENSE OLIGONUCLEOTIDES; ANTITUMOR-ACTIVITY; COLORECTAL TUMORS; FACTOR FAMILY; CANCER CELLS; AMPHIREGULIN	A majority of human colon carcinomas coexpress the epidermal growth factor (ECF)-related peptides transforming growth factor alpha (TGF alpha), amphiregulin (AR) and CRIPTO-1 (CR). We have synthesized novel, antisense mixed backbone oligonucleotides (AS MBOs) directed against TGF alpha. AR and CR, We screened the EGF-related (AS MBOs) for their ability to inhibit the anchorage independent growth of GEO human colon carcinoma cells. Tbe MBOs that showed a high in vitro efficacy were then used for in vitro experiments. TGF alpha, AR and CR AS MBOs were able to inhibit the growth of CEO tumor xenografts in nude mice in a dose-dependent manner. Furthermore, the AS MBOs were able to specifically inhibit the expression of the target mRNAs and proteins in the tumor xenografts. A more significant tumor growth inhibition was observed when mice were treated with a combination of the three AS MBOs as compared to treatment with a single AS MBO, Finally, tumors from mice treated with TGF alpha, AR and CR AS MBOs showed a significant reduction of microvessel count, as compared with tumors from untreated mice or from mire treated with a single AS MBO, These data suggest that combinations of AS oligonucleotides directed against different growth factors might represent a novel, experimental therapy approach of colon carcinomas.	ITN Fdn Pascale, Novel Therapeut Approaches Sect Oncol Sperimental, I-80131 Naples, Italy; ITN Fdn Pascale, Anim Fac, I-80131 Naples, Italy; Anat Pathol ULSS 3, I-36061 Bassano Del Grappa, VI, Italy; ITN Fdn, Anat Patol, I-80131 Naples, Italy; Univ Naples Federico II, Dip Endocrinol & Oncol Mol & Clin, Cattedra Oncol Med, I-80131 Naples, Italy; NCI, LTIB, Tumor Growth Factor Sect, NIH, Bethesda, MD 20892 USA	IRCCS Fondazione Pascale; IRCCS Fondazione Pascale; University of Naples Federico II; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Normanno, N (corresponding author), ITN Fdn Pascale, Novel Therapeut Approaches Sect Oncol Sperimental, I-80131 Naples, Italy.		De Luca, Antonella/J-8737-2016; losito, Nunzia/Y-6339-2018; Casamassimi, Amelia/AAD-2816-2020; Normanno, Nicola/AAT-1107-2021	De Luca, Antonella/0000-0001-5762-447X; losito, Nunzia/0000-0001-9045-0328; Casamassimi, Amelia/0000-0002-6010-4261; Ciardiello, Fortunato/0000-0002-3369-4841; Normanno, Nicola/0000-0002-7158-2605; Arra, Claudio/0000-0003-3162-2091	NATIONAL CANCER INSTITUTE [ZIABC009003, Z01BC009003] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Agrawal S, 1996, TRENDS BIOTECHNOL, V14, P376, DOI 10.1016/0167-7799(96)10053-6; Agrawal S, 1998, CURR OPIN CHEM BIOL, V2, P519, DOI 10.1016/S1367-5931(98)80129-4; Agrawal S, 1998, ANTISENSE NUCLEIC A, V8, P135, DOI 10.1089/oli.1.1998.8.135; BARNARD JA, 1994, J BIOL CHEM, V269, P22817; BRANDT R, 1994, J BIOL CHEM, V269, P17320; Casamassimi A, 2000, ANN ONCOL, V11, P319, DOI 10.1023/A:1008350811639; CIARDIELLO F, 1991, P NATL ACAD SCI USA, V88, P7792, DOI 10.1073/pnas.88.17.7792; Ciardiello F, 1996, JNCI-J NATL CANCER I, V88, P1770, DOI 10.1093/jnci/88.23.1770; CIARDIELLO F, 1994, ONCOGENE, V9, P291; CIARDIELLO F, 1993, INT J CANCER, V54, P952, DOI 10.1002/ijc.2910540615; De Luca A, 1999, INT J CANCER, V80, P589, DOI 10.1002/(SICI)1097-0215(19990209)80:4<589::AID-IJC17>3.0.CO;2-D; Ebert AD, 1999, CANCER RES, V59, P4502; Fontanini G, 1998, CLIN CANCER RES, V4, P241; GAGLIARDI G, 1994, INT J ONCOL, V4, P865; Gibbs JB, 2000, J CLIN INVEST, V105, P9, DOI 10.1172/JCI9084; JOHNSON GR, 1992, J CELL BIOL, V118, P741, DOI 10.1083/jcb.118.3.741; Kannan S, 1997, J BIOL CHEM, V272, P3330, DOI 10.1074/jbc.272.6.3330; Ma L, 1999, ONCOGENE, V18, P6513, DOI 10.1038/sj.onc.1203042; MASSAGUE J, 1990, J BIOL CHEM, V265, P21393; MODRELL B, 1992, GROWTH FACTORS, V7, P195; NECKERS L, 1992, Critical Reviews in Oncogenesis, V3, P175; NORMANNO N, 1994, P NATL ACAD SCI USA, V91, P2790, DOI 10.1073/pnas.91.7.2790; NORMANNO N, 1995, BREAST CANCER RES TR, V35, P293, DOI 10.1007/BF00665981; NORMANNO N, 1993, INT J ONCOL, V2, P903; NORMANNO N, 1995, INT J CANCER, V62, P762, DOI 10.1002/ijc.2910620619; Normanno N, 1996, CLIN CANCER RES, V2, P601; Panico L, 1996, INT J CANCER, V65, P51, DOI 10.1002/(SICI)1097-0215(19960103)65:1<51::AID-IJC9>3.0.CO;2-0; Qi C., 1994, BRIT J CANCER, V69, P19896; SAEKI T, 1992, CANCER RES, V52, P3467; SALOMON DS, 1995, CRIT REV ONCOL HEMAT, V19, P183, DOI 10.1016/1040-8428(94)00144-I; SCHREIBER AB, 1986, SCIENCE, V232, P1250, DOI 10.1126/science.2422759; Seno M, 1998, GROWTH FACTORS, V15, P215, DOI 10.3109/08977199809002118; SHOYAB M, 1989, SCIENCE, V243, P1074, DOI 10.1126/science.2466334; SIZELAND AM, 1992, MOL BIOL CELL, V3, P1235, DOI 10.1091/mbc.3.11.1235; STROMBERG K, 1994, INT J GYNECOL PATHOL, V13, P342, DOI 10.1097/00004347-199410000-00008; Wang H, 1999, P NATL ACAD SCI USA, V96, P13989, DOI 10.1073/pnas.96.24.13989; WATKINS LF, 1991, INT J CANCER, V47, P455, DOI 10.1002/ijc.2910470325	37	52	53	0	5	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 30	2000	19	51					5863	5871		10.1038/sj.onc.1203979	http://dx.doi.org/10.1038/sj.onc.1203979			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	378CA	11127817	Bronze			2022-12-25	WOS:000165563100005
J	Ribeiro, RCJ; Feng, WJ; Wagner, RL; Costa, CHRM; Pereira, AC; Apriletti, JW; Fletterick, RJ; Baxter, JD				Ribeiro, RCJ; Feng, WJ; Wagner, RL; Costa, CHRM; Pereira, AC; Apriletti, JW; Fletterick, RJ; Baxter, JD			Definition of the surface in the thyroid hormone receptor ligand binding domain for association as homodimers and heterodimers with retinoid X receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING; CRYSTAL-STRUCTURE; DIMERIZATION ACTIVITIES; NUCLEAR RECEPTORS; MOLECULAR-BASIS; RXR; ESTROGEN; RAR; RECOGNITION; INTERFACES	Thyroid hormone receptors (TRs) bind as homodimers or heterodimers with retinoid X receptors (RXRs) to DNA elements with diverse orientations of AGGTCA half-sites. We performed a comprehensive x-ray crystal structure-guided mutation analysis of the TR ligand binding domain (TR LED) surface to map the functional interface for TR homodimers and heterodimers with RXR in the absence and/or in the presence of DNA. We also identified the molecular contacts in TR LBDs crystallized as dimers. The results show that crystal dimer contacts differ from those found in the functional studies. We found that identical TR LED residues found in helices 10 and 11 are involved in TR homodimerization and heterodimerization with RXR. Moreover, the same TR LED surface is operative for dimerization with direct repeats spaced by 4 base pairs (DR-4) and with the inverted palindrome spaced by 6 base pairs (F2), but not with TREpal (unspaced palindrome), where homodimers appear to be simply two monomers binding independently to DNA. We also demonstrate that interactions between the TR and RXR DNA binding domains stabilize TR-RXR heterodimers on DR-4. The dimer interface can be functional in the cell, because disruption of key residues impairs transcriptional activity of TRs mediated through association with RXR LED linked to GAL4 DNA-binding domain.	Univ Calif San Francisco, Dept Med, Metab Res Unit, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA 94143 USA; Univ Brasilia, Dept Pharmaceut Sci, BR-70910900 Brasilia, DF, Brazil	University of California System; University of California San Francisco; University of California System; University of California San Francisco; Universidade de Brasilia	Ribeiro, RCJ (corresponding author), Univ Brasilia, Fac Hlth Sci, Mol Pharmacol Lab, BR-70910900 Brasilia, DF, Brazil.	ralff@unb.br	Wood, David W/B-2992-2012		NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK041842, F32DK009516] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK09516, DK41842] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDERSSON ML, 1992, NUCLEIC ACIDS RES, V20, P4803, DOI 10.1093/nar/20.18.4803; AUFLIEGNER M, 1993, MOL CELL BIOL, V13, P5725, DOI 10.1128/MCB.13.9.5725; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Blumberg B, 1998, GENE DEV, V12, P3149, DOI 10.1101/gad.12.20.3149; Bourguet W, 2000, MOL CELL, V5, P289, DOI 10.1016/S1097-2765(00)80424-4; BOURGUET W, 1995, NATURE, V375, P377, DOI 10.1038/375377a0; Brzozowski AM, 1997, NATURE, V389, P753, DOI 10.1038/39645; Chen SC, 1999, J BIOL CHEM, V274, P11260, DOI 10.1074/jbc.274.16.11260; CLACKSON T, 1995, SCIENCE, V267, P383, DOI 10.1126/science.7529940; DeLano WL, 2000, SCIENCE, V287, P1279, DOI 10.1126/science.287.5456.1279; Egea PF, 2000, EMBO J, V19, P2592, DOI 10.1093/emboj/19.11.2592; EISENHABER F, 1995, J COMPUT CHEM, V16, P273, DOI 10.1002/jcc.540160303; EISENHABER F, 1993, J COMPUT CHEM, V14, P1272, DOI 10.1002/jcc.540141103; FAWELL SE, 1990, CELL, V60, P953, DOI 10.1016/0092-8674(90)90343-D; Feng WJ, 1998, SCIENCE, V280, P1747, DOI 10.1126/science.280.5370.1747; Gampe RT, 2000, MOL CELL, V5, P545, DOI 10.1016/S1097-2765(00)80448-7; Glass CK, 2000, GENE DEV, V14, P121; GLASS CK, 1994, ENDOCR REV, V15, P391, DOI 10.1210/er.15.3.391; JANIN J, 1988, J MOL BIOL, V204, P155, DOI 10.1016/0022-2836(88)90606-7; KITAJIMA K, 1995, THYROID, V5, P343, DOI 10.1089/thy.1995.5.343; KUROKAWA R, 1993, GENE DEV, V7, P1423, DOI 10.1101/gad.7.7b.1423; Lee SK, 1998, MOL ENDOCRINOL, V12, P325, DOI 10.1210/me.12.3.325; Leitman DC, 1996, J BIOL CHEM, V271, P21950, DOI 10.1074/jbc.271.36.21950; LUISI BF, 1991, NATURE, V352, P497, DOI 10.1038/352497a0; MADER S, 1993, EMBO J, V12, P5029, DOI 10.1002/j.1460-2075.1993.tb06196.x; MITCHELL JBO, 1994, J MOL BIOL, V239, P315, DOI 10.1006/jmbi.1994.1370; NAGAYA T, 1993, J BIOL CHEM, V268, P24278; NAGAYA T, 1993, J BIOL CHEM, V268, P15766; Nolte RT, 1998, NATURE, V395, P137, DOI 10.1038/25931; PERLMANN T, 1993, GENE DEV, V7, P1411, DOI 10.1101/gad.7.7b.1411; Perlmann T, 1996, MOL ENDOCRINOL, V10, P958, DOI 10.1210/me.10.8.958; Perlmann T, 1997, CELL, V90, P391, DOI 10.1016/S0092-8674(00)80498-5; Pike ACW, 1999, EMBO J, V18, P4608, DOI 10.1093/emboj/18.17.4608; RASTINEJAD F, 1995, NATURE, V375, P203, DOI 10.1038/375203a0; RIBEIRO RC, 1992, MOL ENDOCRINOL, V6, P1142, DOI 10.1210/me.6.7.1142; RIBEIRO RCJ, 1994, ENDOCRINOLOGY, V135, P2076, DOI 10.1210/en.135.5.2076; Ribeiro RCJ, 1998, RECENT PROG HORM RES, V53, P351; RIBEIRO RCJ, 1995, ANNU REV MED, V46, P443, DOI 10.1146/annurev.med.46.1.443; Tanenbaum DM, 1998, P NATL ACAD SCI USA, V95, P5998, DOI 10.1073/pnas.95.11.5998; Tetel MJ, 1997, MOL ENDOCRINOL, V11, P1114, DOI 10.1210/me.11.8.1114; WAGNER RL, 1995, NATURE, V378, P690, DOI 10.1038/378690a0; Wagner RL, 2001, MOL ENDOCRINOL, V15, P398, DOI 10.1210/me.15.3.398; Williams SP, 1998, NATURE, V393, P392, DOI 10.1038/30775; Xu HE, 1999, MOL CELL, V3, P397, DOI 10.1016/S1097-2765(00)80467-0; YEN PM, 1992, J BIOL CHEM, V267, P3565; ZECHEL C, 1994, EMBO J, V13, P1414, DOI 10.1002/j.1460-2075.1994.tb06395.x; ZHANG XK, 1994, MOL CELL BIOL, V14, P4311, DOI 10.1128/MCB.14.6.4311	47	40	41	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 4	2001	276	18					14987	14995		10.1074/jbc.M010195200	http://dx.doi.org/10.1074/jbc.M010195200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	429QQ	11145963	hybrid			2022-12-25	WOS:000168528800063
J	Gerlach, LO; Skerlj, RT; Bridger, GJ; Schwartz, TW				Gerlach, LO; Skerlj, RT; Bridger, GJ; Schwartz, TW			Molecular interactions of cyclam and bicyclam non-peptide antagonists with the CXCR4 chemokine receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; PHENYLENEBIS(METHYLENE)-LINKED BIS-TETRAAZAMACROCYCLES; SELECTIVE-INHIBITION; HIGHLY POTENT; REPLICATION; CORECEPTOR; BINDING; HIV-1; SITE; DERIVATIVES	The non-peptide CXCR4 receptor antagonist AMD3100, which is a potent blocker of human immunodeficiency virus cell entry, is a symmetrical bicyclam composed of two identical 1,4,8,11-tetraazacyclotetradecane (cyclam) moieties connected by a relatively rigid phenylenebismethylene linker. Based on the known strong propensity of the cyclam moiety to bind carboxylic acid groups, receptor mutagenesis identified Asp(171) and Asp(262), located in transmembrane domain (TM) TV and TM-VI, respectively, at each end of the main ligand-binding crevice of the CXCR4 receptor, as being essential for the ability of AMD3100 to block the binding of the chemokine ligand stromal cell-derived factor (SDF)-1 alpha as well as the binding of the receptor antibody 12G5. The free cyclam moiety had no effect on 12G5 binding, but blocked SDF-1 alpha binding with an affinity of 3 muM through interaction with Asp(171). The effect on SDF-1 alpha binding of a series of bicyclam analogs with variable chemical linkers was found to rely either only on Asp(171), i.e. the bicyclams acted as the isolated cyclam, or on both Asp(171) and Asp(262), i.e, they acted as AMD3100, depending on the length and the chemical nature of the linker between the two cyclam moieties. A positive correlation was found between the dependence of these compounds on Asp(262) for binding and their potency as anti-human immunodeficiency virus agents, It is concluded that AMD3100 acts on the CXCR4 receptor through binding to Asp(171), TM-IV and Asp(262) in TM-VI with each of its cyclam moieties, and it is suggested that part of its function is associated with a conformational constraint imposed upon the receptor by the connecting phenylenebismethylene linker.	Univ Copenhagen, Panum Inst 18 6 12, Mol Pharmacol Lab, DK-2200 Copenhagen, Denmark; AnorMED Inc, Langley, BC V2Y 1N5, Canada; 7TM Pharmaceut AS, DK-2100 Copenhagen, Denmark	University of Copenhagen; AnorMED Inc	Schwartz, TW (corresponding author), Univ Copenhagen, Panum Inst 18 6 12, Mol Pharmacol Lab, Blegdamsvej 3, DK-2200 Copenhagen, Denmark.			Schwartz, Thue W./0000-0002-0261-6904				ADAM KR, 1994, J CHEM SOC CHEM COMM, P1539, DOI 10.1039/c39940001539; Brelot A, 1997, J VIROL, V71, P4744, DOI 10.1128/JVI.71.6.4744-4751.1997; Bridger GJ, 1996, J MED CHEM, V39, P109, DOI 10.1021/jm950584t; BRIDGER GJ, 1995, J MED CHEM, V38, P366, DOI 10.1021/jm00002a019; BRIDGER GJ, 1999, ADV ANTIV D, V3, P161; Crump MP, 1997, EMBO J, V16, P6996, DOI 10.1093/emboj/16.23.6996; De Clercq E, 1999, Drugs R D, V2, P321, DOI 10.2165/00126839-199902050-00010; DE CLERCQ E, 1994, ANTIMICROB AGENTS CH, V38, P668, DOI 10.1128/AAC.38.4.668; De Clercq E, 2000, MOL PHARMACOL, V57, P833; DECLERCO E, 1992, P NATL ACAD SCI USA, V89, P5286, DOI 10.1073/pnas.89.12.5286; DeVreese K, 1996, J VIROL, V70, P689, DOI 10.1128/JVI.70.2.689-696.1996; Donzella GA, 1998, NAT MED, V4, P72, DOI 10.1038/nm0198-072; Elling CE, 1999, P NATL ACAD SCI USA, V96, P12322, DOI 10.1073/pnas.96.22.12322; ELLING CE, 1995, NATURE, V374, P74, DOI 10.1038/374074a0; Este JA, 1999, MOL PHARMACOL, V55, P67, DOI 10.1124/mol.55.1.67; GETHER U, 1993, J BIOL CHEM, V268, P7893; Hendrix CW, 2000, ANTIMICROB AGENTS CH, V44, P1667, DOI 10.1128/AAC.44.6.1667-1673.2000; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; IZATT RM, 1991, CHEM REV, V91, P1721, DOI 10.1021/cr00008a003; JOAO HC, 1995, J MED CHEM, V38, P3865, DOI 10.1021/jm00019a017; JOHANSEN TE, 1990, FEBS LETT, V267, P289, DOI 10.1016/0014-5793(90)80947-H; Labrosse B, 1998, J VIROL, V72, P6381, DOI 10.1128/JVI.72.8.6381-6388.1998; MCAULEY A, 1987, J CHEM SOC CHEM COMM, P539, DOI 10.1039/c39870000539; Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739; Schols D, 1997, ANTIVIR RES, V35, P147, DOI 10.1016/S0166-3542(97)00025-9; Schols D, 1997, J EXP MED, V186, P1383, DOI 10.1084/jem.186.8.1383; Schwartz Thue W., 1994, Current Opinion in Biotechnology, V5, P434, DOI 10.1016/0958-1669(94)90054-X; Signoret N, 1998, J CELL SCI, V111, P2819; Signoret N, 1997, J CELL BIOL, V139, P651, DOI 10.1083/jcb.139.3.651; TROUTNER DE, 1980, J NUCL MED, V21, P443	30	240	256	0	23	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 27	2001	276	17					14153	14160		10.1074/jbc.M010429200	http://dx.doi.org/10.1074/jbc.M010429200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	426PB	11154697	hybrid			2022-12-25	WOS:000168356600087
J	Mowla, SJ; Farhadi, HF; Pareek, S; Atwal, JK; Morris, SJ; Seidah, NG; Murphy, RA				Mowla, SJ; Farhadi, HF; Pareek, S; Atwal, JK; Morris, SJ; Seidah, NG; Murphy, RA			Biosynthesis and post-translational processing of the precursor to brain-derived neurotrophic factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NERVE GROWTH-FACTOR; REGULATED SECRETORY PATHWAY; HIPPOCAMPAL-NEURONS; PROTEIN SULFATION; PROPROTEIN; CELLS; SPECIFICITY; CONVERTASES; EXPRESSION; TRANSPORT	We examined the biosynthesis and post-translational processing of the brain-derived neurotrophic factor precursor (pro-BDNF) in cells infected with a pro-BDNF-encoding vaccinia virus. Metabolic labeling, immunoprecipitation, and SDS-polyacrylamide gel electrophoresis reveal that pro-BDNF is generated as a 32-kDa precursor that is N-glycosylated and glycosulfated on a site, within the pro-domain. Some pro-BDNF is released extracellularly and is biologically active as demonstrated by its ability to mediate TrkB phosphorylation, The precursor undergoes N-terminal cleavage within the trans-Golgi network and/or immature secretory vesicles to generate mature BDNF (14 kDa), Small amounts of a 28-kDa protein that is immunoprecipitated with BDNF antibodies is also evident. This protein is generated in the endoplasmic reticulum through N-terminal cleavage of pro-BDNF at the Arg-Gly-Leu-Thr(57)- down arrow -Ser-Leu site. Cleavage is abolished when Arg(54) is changed to Ala (R54A) by in vitro mutagenesis. Blocking generation of 28-kDa BDNF has no effect on the level of mature BDNF and blocking generation of mature BDNF with alpha (1)-PDX, an inhibitor of furin-like enzymes, does not lead to accumulation of the 28-kDa form. These data suggest that 28-kDa pro-BDNF is not an obligatory intermediate in the formation of the 14-kDa form in the constitutive secretory pathway.	Salk Inst Biol Studies, La Jolla, CA 92037 USA; McGill Univ, Montreal Neurol Inst, Dept Neurol & Neurosurg, Ctr Neuronal Survival, Montreal, PQ H3A 2B4, Canada; Clin Res Inst Montreal, Biochem Neuroendocrinol Lab, Montreal, PQ H2W 1R7, Canada	Salk Institute; McGill University; Institut de Recherche Clinique de Montreal (IRCM); Universite de Montreal	Murphy, RA (corresponding author), Salk Inst Biol Studies, 10010 N Torrey Pines Rd, La Jolla, CA 92037 USA.		Farhadi, H. Francis/E-3051-2011; Seidah, Nabil/I-3596-2013	Seidah, Nabil/0000-0001-6503-9342; Mowla, Seyed Javad/0000-0002-3300-6332; Farhadi, H Francis/0000-0002-4668-8512				ANDERSON ED, 1993, J BIOL CHEM, V268, P24887; BAEUERLE PA, 1986, BIOCHEM BIOPH RES CO, V141, P870, DOI 10.1016/S0006-291X(86)80253-4; Barker PA, 1998, CELL DEATH DIFFER, V5, P346, DOI 10.1038/sj.cdd.4400375; BENJANNET S, 1992, J BIOL CHEM, V267, P11417; Brechler V, 1996, J BIOL CHEM, V271, P20636, DOI 10.1074/jbc.271.34.20636; BREWER GJ, 1993, J NEUROSCI RES, V35, P567, DOI 10.1002/jnr.490350513; Crino PB, 1996, NEURON, V17, P1173, DOI 10.1016/S0896-6273(00)80248-2; EDWARDS RH, 1988, J BIOL CHEM, V263, P6810; EDWARDS RH, 1988, MOL CELL BIOL, V8, P2456, DOI 10.1128/MCB.8.6.2456; Farhadi HF, 2000, J NEUROSCI, V20, P4059; Fawcett JP, 1997, J BIOL CHEM, V272, P8837; Fernandez CJ, 1997, MOL BIOL CELL, V8, P2171, DOI 10.1091/mbc.8.11.2171; HEMPSTEAD BL, 1992, NEURON, V9, P883, DOI 10.1016/0896-6273(92)90241-5; Jean F, 2000, P NATL ACAD SCI USA, V97, P2864, DOI 10.1073/pnas.050504297; KAPLAN DR, 1991, SCIENCE, V252, P545; KOLBECK R, 1994, EUR J BIOCHEM, V225, P995, DOI 10.1111/j.1432-1033.1994.0995b.x; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P5543; MAISONOPIERRE PC, 1990, SCIENCE, V247, P1373; MAISONPIERRE PC, 1991, GENOMICS, V10, P558, DOI 10.1016/0888-7543(91)90436-I; Mowla SJ, 1999, J NEUROSCI, V19, P2069; MOWLA SJ, 1999, SOC NEUR ABSTR, V709, P6; Seidah NG, 1999, BRAIN RES, V848, P45, DOI 10.1016/S0006-8993(99)01909-5; Seidah NG, 1996, BIOCHEM J, V314, P951, DOI 10.1042/bj3140951; Seidah NG, 1999, P NATL ACAD SCI USA, V96, P1321, DOI 10.1073/pnas.96.4.1321; SEIDAH NG, 1996, FEBS LETT, V379, P248; SNIDER DW, 1994, CELL, V77, P625; TAKAHASHI S, 1993, BIOCHEM BIOPH RES CO, V195, P1019, DOI 10.1006/bbrc.1993.2146; Tongiorgi E, 1997, J NEUROSCI, V17, P9492; van Kuppeveld FJM, 1997, MOL CELL ENDOCRINOL, V136, P29, DOI 10.1016/S0303-7207(97)00211-6; Yan Q, 1997, NEUROSCIENCE, V78, P431, DOI 10.1016/S0306-4522(96)00613-6	30	412	438	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 20	2001	276	16					12660	12666		10.1074/jbc.M008104200	http://dx.doi.org/10.1074/jbc.M008104200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	423VN	11152678	hybrid			2022-12-25	WOS:000168198600027
J	Chaturvedi, K; Bandari, P; Chinen, N; Howells, RD				Chaturvedi, K; Bandari, P; Chinen, N; Howells, RD			Proteasome involvement in agonist-induced down-regulation of mu and delta opioid receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MORPHINE-INDUCED ANALGESIA; FUNCTIONAL EXPRESSION; PROTEIN; UBIQUITIN; KINASE; PATHWAY; INTERNALIZATION; MICE; PHOSPHORYLATION; DEGRADATION	This study investigated the mechanism of agonist-induced opioid receptor down-regulation. Incubation of HEK 293 cells expressing FLAG-tagged delta and mu receptors with agonists caused a time-dependent decrease in opioid receptor levels assayed by immunoblotting. Pulse-chase experiments using [S-35]methionine metabolic labeling indicated that the turnover rate of delta receptors was accelerated 5-fold following agonist stimulation. Inactivation of functional G(i) and G(o) proteins by pertussis toxin-attenuated down-regulation of the mu opioid receptor, while down-regulation of the delta opioid receptor was unaffected. Pretreatment of cells with inhibitors of lysosomal proteases, calpain, and caspases had little effect on mu and delta opioid receptor down-regulation. In marked contrast, pretreatment with proteasome inhibitors attenuated agonist-induced mu and delta receptor down-regulation. In addition, incubation of cells with proteasome inhibitors in the absence of agonists increased steady-state mu and delta opioid receptor levels. Immunoprecipitation of mu and delta opioid receptors followed by immunoblotting with ubiquitin antibodies suggested that preincubation with proteasome inhibitors promoted accumulation of polyubiquitinated receptors. These data provide evidence that the ubiquitin/proteasome pathway plays a role in agonist-induced down-regulation and basal turnover of opioid receptors.	Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Biochem & Mol Biol, Newark, NJ 07103 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center	Howells, RD (corresponding author), Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Biochem & Mol Biol, 185 S Orange Ave, Newark, NJ 07103 USA.	howells@umdnj.edu			NATIONAL INSTITUTE ON DRUG ABUSE [R01DA009113] Funding Source: NIH RePORTER; NIDA NIH HHS [DA09113] Funding Source: Medline	NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA))		Breuer P, 1998, J BIOL CHEM, V273, P33254, DOI 10.1074/jbc.273.50.33254; Burt AR, 1996, BIOCHEM J, V320, P227, DOI 10.1042/bj3200227; CARTER BD, 1993, P NATL ACAD SCI USA, V90, P4062, DOI 10.1073/pnas.90.9.4062; Chakrabarti S, 1997, MOL PHARMACOL, V52, P105, DOI 10.1124/mol.52.1.105; Chaturvedi K, 2000, MOL BRAIN RES, V80, P166, DOI 10.1016/S0169-328X(00)00134-0; Chaturvedi K, 2000, MOL BRAIN RES, V76, P64, DOI 10.1016/S0169-328X(99)00332-0; Chaturvedi K, 2000, BIOPOLYMERS, V55, P334, DOI 10.1002/1097-0282(2000)55:4<334::AID-BIP1006>3.0.CO;2-S; CHEN Y, 1993, MOL PHARMACOL, V44, P8; Chu P, 1997, J BIOL CHEM, V272, P27124, DOI 10.1074/jbc.272.43.27124; Cvejic S, 1997, J BIOL CHEM, V272, P26959, DOI 10.1074/jbc.272.43.26959; DEVERAUX Q, 1994, J BIOL CHEM, V269, P7059; EVANS CJ, 1992, SCIENCE, V258, P1952, DOI 10.1126/science.1335167; FENTEANY G, 1995, SCIENCE, V268, P726, DOI 10.1126/science.7732382; Ferguson SSG, 1996, SCIENCE, V271, P363, DOI 10.1126/science.271.5247.363; GOLDSTEIN A, 1989, MOL PHARMACOL, V36, P265; Goodman OB, 1996, NATURE, V383, P447, DOI 10.1038/383447a0; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Hicke L, 1996, CELL, V84, P277, DOI 10.1016/S0092-8674(00)80982-4; Hicke L, 1999, TRENDS CELL BIOL, V9, P107, DOI 10.1016/S0962-8924(98)01491-3; Jeffers M, 1997, MOL CELL BIOL, V17, P799, DOI 10.1128/MCB.17.2.799; Jockers R, 1999, J BIOL CHEM, V274, P28900, DOI 10.1074/jbc.274.41.28900; Jordan BA, 1999, NATURE, V399, P697, DOI 10.1038/21441; Keith DE, 1998, MOL PHARMACOL, V53, P377, DOI 10.1124/mol.53.3.377; Keith DE, 1996, J BIOL CHEM, V271, P19021, DOI 10.1074/jbc.271.32.19021; KIEFFER BL, 1992, P NATL ACAD SCI USA, V89, P12048, DOI 10.1073/pnas.89.24.12048; Ko JL, 1999, MOL BRAIN RES, V69, P171, DOI 10.1016/S0169-328X(99)00094-7; Kornilova E, 1996, J BIOL CHEM, V271, P30340, DOI 10.1074/jbc.271.48.30340; Kramer HK, 2000, BIOCHEM PHARMACOL, V60, P781, DOI 10.1016/S0006-2952(00)00400-7; LAUGWITZ KL, 1993, NEURON, V10, P233, DOI 10.1016/0896-6273(93)90314-H; Law PY, 2000, ANNU REV PHARMACOL, V40, P389, DOI 10.1146/annurev.pharmtox.40.1.389; Law SF, 1997, J PHARMACOL EXP THER, V281, P1476; Lefkowitz RJ, 1998, J BIOL CHEM, V273, P18677, DOI 10.1074/jbc.273.30.18677; Loh HH, 1998, MOL BRAIN RES, V54, P321, DOI 10.1016/S0169-328X(97)00353-7; MANSOUR A, 1995, TRENDS NEUROSCI, V18, P22, DOI 10.1016/0166-2236(95)93946-U; Matthes HWD, 1996, NATURE, V383, P819, DOI 10.1038/383819a0; MEHDI S, 1991, TRENDS BIOCHEM SCI, V16, P150, DOI 10.1016/0968-0004(91)90058-4; Miura H, 1996, BIOCHEM BIOPH RES CO, V227, P684, DOI 10.1006/bbrc.1996.1569; MORI S, 1995, J BIOL CHEM, V270, P29447, DOI 10.1074/jbc.270.49.29447; Obin MS, 1996, J BIOL CHEM, V271, P14473, DOI 10.1074/jbc.271.24.14473; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; PAYNE DM, 1991, EMBO J, V10, P885, DOI 10.1002/j.1460-2075.1991.tb08021.x; PEI G, 1995, MOL PHARMACOL, V48, P173; Penela P, 1998, J BIOL CHEM, V273, P35238, DOI 10.1074/jbc.273.52.35238; Polakiewicz RD, 1998, J BIOL CHEM, V273, P23534, DOI 10.1074/jbc.273.36.23534; PRATHER PL, 1994, J BIOL CHEM, V269, P21293; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; Shahrestanifar MS, 1996, NEUROCHEM RES, V21, P1295, DOI 10.1007/BF02532370; Simonin F, 1998, EMBO J, V17, P886, DOI 10.1093/emboj/17.4.886; Singh VK, 1997, NEUROIMMUNOMODULAT, V4, P285, DOI 10.1159/000097349; Sora I, 1997, P NATL ACAD SCI USA, V94, P1544, DOI 10.1073/pnas.94.4.1544; Tanaka K, 1998, J BIOCHEM-TOKYO, V123, P195; Terrell J, 1998, MOL CELL, V1, P193, DOI 10.1016/S1097-2765(00)80020-9; Tian MT, 1997, J EXP MED, V185, P1517, DOI 10.1084/jem.185.8.1517; Trapaidze N, 1996, J BIOL CHEM, V271, P29279, DOI 10.1074/jbc.271.46.29279; Tsao PI, 2000, J BIOL CHEM, V275, P11130, DOI 10.1074/jbc.275.15.11130; van Kerkhof P, 2000, J BIOL CHEM, V275, P1575, DOI 10.1074/jbc.275.3.1575; VINITSKY A, 1994, J BIOL CHEM, V269, P29860; Wess J, 1998, PHARMACOL THERAPEUT, V80, P231, DOI 10.1016/S0163-7258(98)00030-8; Whistler JL, 1998, P NATL ACAD SCI USA, V95, P9914, DOI 10.1073/pnas.95.17.9914; Yabaluri N, 1997, MOL PHARMACOL, V52, P896, DOI 10.1124/mol.52.5.896; Yamin TT, 1997, J BIOL CHEM, V272, P21540, DOI 10.1074/jbc.272.34.21540; YASUDA K, 1993, P NATL ACAD SCI USA, V90, P6736, DOI 10.1073/pnas.90.14.6736; Zhang J, 1998, P NATL ACAD SCI USA, V95, P7157, DOI 10.1073/pnas.95.12.7157	63	110	113	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 13	2001	276	15					12345	12355		10.1074/jbc.M008054200	http://dx.doi.org/10.1074/jbc.M008054200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	421UK	11152677	hybrid			2022-12-25	WOS:000168081800121
J	Henry, SP; Takanosu, M; Boyd, TC; Mayne, PM; Eberspaecher, H; Zhou, W; de Crombrugghe, B; Hook, M; Mayne, R				Henry, SP; Takanosu, M; Boyd, TC; Mayne, PM; Eberspaecher, H; Zhou, W; de Crombrugghe, B; Hook, M; Mayne, R			Expression pattern and gene characterization of asporin - A newly discovered member of the leucine-rich repeat protein family	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KERATAN SULFATE PROTEOGLYCAN; STATIONARY NIGHT BLINDNESS; COMPLETE CDNA CLONING; GROWTH-FACTOR-BETA; EXTRACELLULAR-MATRIX; MOLECULAR-CLONING; DERMATAN SULFATE; COLLAGEN FIBRILLOGENESIS; CHROMOSOMAL LOCALIZATION; OSTEOINDUCTIVE FACTOR	We have discovered a new member of the class I small leucine-rich repeat proteoglycan (SLRP) family which is distinct from the other class I SLRPs since it possesses a unique stretch of aspartate residues at its N terminus. For this reason, we called the molecule asporin. The deduced amino acid sequence is about 50% identical (and 70% similar) to decorin and biglycan. However, asporin does not contain a serine/glycine dipeptide sequence required for the assembly of O-linked glycosaminoglycans and is probably not a proteoglycan. The tissue expression of asporin partially overlaps with the expression of decorin and biglycan. During mouse embryonic development, asporin mRNA expression was detected primarily in the skeleton and other specialized connective tissues; very little asporin message was detected in the major parenchymal organs. The mouse asporin gene structure is similar to that of biglycan and decorin with 8 exons. The asporin gene is localized to human chromosome 9q22-9q21.3 where asporin is part of a SLRP gene cluster that includes extracellular matrix protein 2, osteoadherin, and osteoglycin. Further analysis shows that, with the exception of biglycan, all known SLRP genes reside in three gene clusters.	Univ Alabama, Dept Cell Biol, Birmingham, AL 35294 USA; Univ Texas, Grad Sch Biomed Sci, Houston, TX 77030 USA; Texas A&M Univ Syst, Hlth Sci Ctr, Ctr Extracellular Matrix Biol, Inst Biosci & Technol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Mol Genet, Houston, TX 77030 USA	University of Alabama System; University of Alabama Birmingham; University of Texas System; Texas A&M University System; Texas A&M University College Station; Texas A&M Health Science Center; University of Texas System; University of Texas Health Science Center Houston; University of Texas System; UTMD Anderson Cancer Center	Mayne, R (corresponding author), Univ Alabama, Dept Cell Biol, Box 302,Volker Hall, Birmingham, AL 35294 USA.				NIAMS NIH HHS [P01 AR42919-05, R37 AR30481] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R37AR030481, P01AR042919] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ATSUMI T, 1990, CELL DIFFER DEV, V30, P109, DOI 10.1016/0922-3371(90)90079-C; Bech-Hansen NT, 2000, NAT GENET, V26, P319, DOI 10.1038/81619; BENGTSSON E, 1995, J BIOL CHEM, V270, P25639, DOI 10.1074/jbc.270.43.25639; BIANCO P, 1990, J HISTOCHEM CYTOCHEM, V38, P1549, DOI 10.1177/38.11.2212616; BLOCHBERGER TC, 1992, J BIOL CHEM, V267, P347; BORDER WA, 1990, CELL DIFFER DEV, V32, P425, DOI 10.1016/0922-3371(90)90059-6; BORDER WA, 1992, NATURE, V360, P361, DOI 10.1038/360361a0; Chakravarti S, 1998, J CELL BIOL, V141, P1277, DOI 10.1083/jcb.141.5.1277; Corpuz LM, 1996, J BIOL CHEM, V271, P9759, DOI 10.1074/jbc.271.16.9759; Csordas G, 2000, J BIOL CHEM, V275, P32879, DOI 10.1074/jbc.M005609200; Danielson KG, 1997, J CELL BIOL, V136, P729, DOI 10.1083/jcb.136.3.729; Danielson KG, 1999, MAMM GENOME, V10, P201, DOI 10.1007/s003359900971; Deere M, 1996, GENOMICS, V38, P399, DOI 10.1006/geno.1996.0643; Ezura Y, 2000, J CELL BIOL, V151, P779, DOI 10.1083/jcb.151.4.779; FISHER LW, 1989, J BIOL CHEM, V264, P4571; Friedman JS, 2000, INVEST OPHTH VIS SCI, V41, P2059; Funderburgh JL, 1997, J BIOL CHEM, V272, P28089, DOI 10.1074/jbc.272.44.28089; GALLAGHER JT, 1983, BIOCHEM J, V215, P107, DOI 10.1042/bj2150107; Grover J, 1996, GENOMICS, V38, P109, DOI 10.1006/geno.1996.0605; GROVER J, 1995, J BIOL CHEM, V270, P21942, DOI 10.1074/jbc.270.37.21942; Grover J, 1997, GENOMICS, V45, P379, DOI 10.1006/geno.1997.4951; HEDBOM E, 1989, J BIOL CHEM, V264, P6898; HILDEBRAND A, 1994, BIOCHEM J, V302, P527, DOI 10.1042/bj3020527; Hobby P, 2000, MOL VIS, V6, P72; Hocking AM, 1998, MATRIX BIOL, V17, P1; Iozzo RV, 1996, FASEB J, V10, P598, DOI 10.1096/fasebj.10.5.8621059; Johnson HJ, 1997, J BIOL CHEM, V272, P18709, DOI 10.1074/jbc.272.30.18709; KOBE B, 1994, TRENDS BIOCHEM SCI, V19, P415, DOI 10.1016/0968-0004(94)90090-6; KRUMDIECK R, 1992, J IMMUNOL, V149, P3695; KRUSIUS T, 1986, P NATL ACAD SCI USA, V83, P7683, DOI 10.1073/pnas.83.20.7683; Kurita K, 1996, BIOCHEM J, V318, P909, DOI 10.1042/bj3180909; MADISEN L, 1990, DNA CELL BIOL, V9, P303, DOI 10.1089/dna.1990.9.303; MARCHUK D, 1991, NUCLEIC ACIDS RES, V19, P1154, DOI 10.1093/nar/19.5.1154; NEAME PJ, 1994, J BIOL CHEM, V269, P21547; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; Nishiu J, 1998, GENOMICS, V52, P378, DOI 10.1006/geno.1998.5455; OLDBERG A, 1989, EMBO J, V8, P2601, DOI 10.1002/j.1460-2075.1989.tb08399.x; Pellegata NS, 2000, NAT GENET, V25, P91, DOI 10.1038/75664; Pusch CM, 2000, NAT GENET, V26, P324, DOI 10.1038/81627; RADA JA, 1993, EXP EYE RES, V56, P635, DOI 10.1006/exer.1993.1081; Reardon AJ, 2000, J BIOL CHEM, V275, P2123, DOI 10.1074/jbc.275.3.2123; SCHMIDT G, 1987, J CELL BIOL, V104, P1683, DOI 10.1083/jcb.104.6.1683; SCHOLZEN T, 1994, J BIOL CHEM, V269, P28270; SHINOMURA T, 1992, J BIOL CHEM, V267, P1265; Sommarin Y, 1998, J BIOL CHEM, V273, P16723, DOI 10.1074/jbc.273.27.16723; Svensson L, 2000, FEBS LETT, V470, P178, DOI 10.1016/S0014-5793(00)01314-4; Svensson L, 1999, J BIOL CHEM, V274, P9636, DOI 10.1074/jbc.274.14.9636; SZTROLOVICS R, 1994, GENOMICS, V23, P715, DOI 10.1006/geno.1994.1567; TRAUPE H, 1992, GENOMICS, V13, P481, DOI 10.1016/0888-7543(92)90279-2; VOGEL KG, 1984, BIOCHEM J, V223, P587, DOI 10.1042/bj2230587; WEGROWSKI Y, 1995, GENOMICS, V30, P8, DOI 10.1006/geno.1995.0002; Wendel M, 1998, J CELL BIOL, V141, P839, DOI 10.1083/jcb.141.3.839; WHINNA HC, 1993, J BIOL CHEM, V268, P3920; Wilda M, 2000, J BONE MINER RES, V15, P2187, DOI 10.1359/jbmr.2000.15.11.2187; WINNEMOLLER M, 1992, EUR J CELL BIOL, V59, P47; Xu TS, 1998, NAT GENET, V20, P78, DOI 10.1038/1746; YAMAGUCHI Y, 1988, NATURE, V336, P244, DOI 10.1038/336244a0; Zhao Q, 1997, DEV DYNAM, V209, P377, DOI 10.1002/(SICI)1097-0177(199708)209:4<377::AID-AJA5>3.0.CO;2-F	58	129	140	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 13	2001	276	15					12212	12221		10.1074/jbc.M011290200	http://dx.doi.org/10.1074/jbc.M011290200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	421UK	11152695	hybrid			2022-12-25	WOS:000168081800104
J	Ashizawa, S; Nishizawa, H; Yamada, M; Higashi, H; Kondo, T; Ozawa, H; Kakita, A; Hatakeyama, M				Ashizawa, S; Nishizawa, H; Yamada, M; Higashi, H; Kondo, T; Ozawa, H; Kakita, A; Hatakeyama, M			Collective inhibition of pRB family proteins by phosphorylation in cells with p16(INK4a) loss or cyclin E overexpression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETINOBLASTOMA GENE-PRODUCT; TUMOR-SUPPRESSOR PROTEIN; E2F TRANSCRIPTION FACTOR; GROWTH SUPPRESSION; S-PHASE; DISTINCT MECHANISMS; P107; P130; RB; EXPRESSION	The activity of the retinoblastoma protein pRB is regulated by phosphorylation that is mediated by G(1) cyclin-associated cyclin-dependent kinases (CDKs). Since the pRB-related pocket proteins p107 and p130 share general structures and biological functions with pRB, their activity is also considered to be regulated by phosphorylation. In this work, we generated phosphorylation-resistant p107 and p130 molecules by replacing potential cyclin CDK phosphorylation sites with non-phosphorylatable alanine residues. These phosphorylation-resistant mutants retained the ability to bind E2F and cyclin. Upon introduction into p16(INK4a)-deficient U2-OS osteosarcoma cells, in which cyclin D-CDK4/6 is dysregulated, the phosphorylation-resistant mutants, but not wild-type p107 or p130, were capable of inhibiting cell proliferation. Furthermore, when ectopically expressed in pRB-deficient SAOS-8 osteosarcoma cells, the wild-type as well as the phosphorylation-resistant pRB family proteins were capable of inducing large flat cells. The flat cell-inducing activity of the wild-type proteins, but not that of the phosphorylation-resistant mutants; was:abolished by coexpressing cyclin E. Our results indicate that the elevated cyclin D- or cyclin E-associated kinase leads to systemic inactivation of the pRB family proteins and suggest that dysregulation of the pRB kinase provokes an aberrant cell cycle in a broader range of cell types than those induced by genetic inactivation of the RB gene.	Hokkaido Univ, Inst Med Genet, Div Mol Oncol, Kita Ku, Sapporo, Hokkaido 0600815, Japan; Japanese Fdn Canc Res, Inst Canc, Dept Viral Oncol, Toshima Ku, Tokyo 1708455, Japan; Kitasato Univ, Sch Med, Dept Surg, Sagamihara, Kanagawa 228555, Japan	Hokkaido University; Japanese Foundation for Cancer Research; Kitasato University	Hatakeyama, M (corresponding author), Hokkaido Univ, Inst Med Genet, Div Mol Oncol, Kita Ku, Nishi 7, Sapporo, Hokkaido 0600815, Japan.	mhata@imm.hokudai.ac.jp	Higashi, Hideaki/F-6872-2012					BEIJERSBERGEN RL, 1995, GENE DEV, V9, P1340, DOI 10.1101/gad.9.11.1340; BEIJERSBERGEN RL, 1994, GENE DEV, V8, P2680, DOI 10.1101/gad.8.22.2680; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; Chew YP, 1998, ONCOGENE, V17, P2177, DOI 10.1038/sj.onc.1202443; Claudio PP, 1996, CANCER RES, V56, P2003; CLAUDIO PP, 1994, CANCER RES, V54, P5556; COBRINIK D, 1993, GENE DEV, V7, P2392, DOI 10.1101/gad.7.12a.2392; Cobrinik D, 1996, GENE DEV, V10, P1633, DOI 10.1101/gad.10.13.1633; DELMER A, 1995, LEUKEMIA, V9, P1240; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; EWEN ME, 1992, SCIENCE, V255, P85, DOI 10.1126/science.1532457; EWEN ME, 1991, CELL, V66, P1155, DOI 10.1016/0092-8674(91)90038-Z; FAHA B, 1992, SCIENCE, V255, P87, DOI 10.1126/science.1532458; GINSBERG D, 1994, GENE DEV, V8, P2665, DOI 10.1101/gad.8.22.2665; Grana X, 1998, ONCOGENE, V17, P3365, DOI 10.1038/sj.onc.1202575; HAMEL PA, 1992, ONCOGENE, V7, P693; HANNON GJ, 1993, GENE DEV, V7, P2378, DOI 10.1101/gad.7.12a.2378; HIJMANS EM, 1995, MOL CELL BIOL, V15, P3082; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; Hofmann F, 1996, GENE DEV, V10, P2949, DOI 10.1101/gad.10.23.2949; Hoshikawa Y, 1998, P NATL ACAD SCI USA, V95, P8574, DOI 10.1073/pnas.95.15.8574; HU QJ, 1990, EMBO J, V9, P1147, DOI 10.1002/j.1460-2075.1990.tb08221.x; HUANG HJS, 1988, SCIENCE, V242, P1563, DOI 10.1126/science.3201247; Hurford RK, 1997, GENE DEV, V11, P1447, DOI 10.1101/gad.11.11.1447; Ikeda M, 1996, P NATL ACAD SCI USA, V93, P3215, DOI 10.1073/pnas.93.8.3215; Knudsen ES, 1998, GENE DEV, V12, P2278, DOI 10.1101/gad.12.15.2278; Knudsen KE, 1999, ONCOGENE, V18, P5239, DOI 10.1038/sj.onc.1202910; Lacy S, 1997, ONCOGENE, V14, P2395, DOI 10.1038/sj.onc.1201085; Leone G, 1997, NATURE, V387, P422, DOI 10.1038/387422a0; LUKAS J, 1995, NATURE, V375, P503, DOI 10.1038/375503a0; Lukas J, 1997, GENE DEV, V11, P1479, DOI 10.1101/gad.11.11.1479; Lukas J, 1999, ONCOGENE, V18, P3930, DOI 10.1038/sj.onc.1202777; Luo RX, 1998, CELL, V92, P463, DOI 10.1016/S0092-8674(00)80940-X; MAYOL X, 1993, ONCOGENE, V8, P2561; Mayol X, 1996, ONCOGENE, V13, P237; MAYOL X, 1995, ONCOGENE, V11, P801; MEDEMA RH, 1995, P NATL ACAD SCI USA, V92, P6289, DOI 10.1073/pnas.92.14.6289; Moberg K, 1996, MOL CELL BIOL, V16, P1436; MORAN E, 1986, MOL CELL BIOL, V6, P3470, DOI 10.1128/MCB.6.10.3470; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; Mori A, 1999, ONCOGENE, V18, P6209, DOI 10.1038/sj.onc.1203044; NEVINS JR, 1992, SCIENCE, V258, P424; Ohtani K, 1995, P NATL ACAD SCI USA, V92, P12146, DOI 10.1073/pnas.92.26.12146; OTTERSON GA, 1995, ONCOGENE, V11, P1211; Parreno M, 2000, J VIROL, V74, P3166, DOI 10.1128/JVI.74.7.3166-3176.2000; QIN XQ, 1995, MOL CELL BIOL, V15, P742; QIN XQ, 1992, GENE DEV, V6, P953, DOI 10.1101/gad.6.6.953; Ruas M, 1999, ONCOGENE, V18, P5423, DOI 10.1038/sj.onc.1202918; Ruas M, 1998, BBA-REV CANCER, V1378, pF115, DOI 10.1016/S0304-419X(98)00017-1; Russo AA, 1998, NATURE, V395, P237, DOI 10.1038/26155; SARDET C, 1995, P NATL ACAD SCI USA, V92, P2403, DOI 10.1073/pnas.92.6.2403; SELLERS WR, 1995, P NATL ACAD SCI USA, V92, P11544, DOI 10.1073/pnas.92.25.11544; Sellers WR, 1998, GENE DEV, V12, P95, DOI 10.1101/gad.12.1.95; SELLERS WR, 1996, BIOCHIM BIOPHYS ACTA, V1288, P1; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; Serrano M, 1997, EXP CELL RES, V237, P7, DOI 10.1006/excr.1997.3824; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Steeg PS, 1998, BREAST CANCER RES TR, V52, P17, DOI 10.1023/A:1006102916060; SuzukiTakahashi I, 1997, BIOCHEM BIOPH RES CO, V234, P386, DOI 10.1006/bbrc.1997.6654; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; TAM SW, 1994, ONCOGENE, V9, P2663; TEMPLETON DJ, 1991, P NATL ACAD SCI USA, V88, P3033, DOI 10.1073/pnas.88.8.3033; VAIRO G, 1995, GENE DEV, V9, P869, DOI 10.1101/gad.9.7.869; WANG HGH, 1993, J VIROL, V67, P476, DOI 10.1128/JVI.67.1.476-488.1993; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WEINTRAUB SJ, 1995, NATURE, V375, P812, DOI 10.1038/375812a0; WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7; Xiao ZX, 1996, P NATL ACAD SCI USA, V93, P4633, DOI 10.1073/pnas.93.10.4633; ZHU L, 1995, GENE DEV, V9, P1740, DOI 10.1101/gad.9.14.1740; ZHU L, 1995, EMBO J, V14, P1904, DOI 10.1002/j.1460-2075.1995.tb07182.x; ZHU L, 1993, GENE DEV, V7, P1111, DOI 10.1101/gad.7.7a.1111	71	21	21	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 6	2001	276	14					11362	11370		10.1074/jbc.M007992200	http://dx.doi.org/10.1074/jbc.M007992200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	420AC	11152455	hybrid			2022-12-25	WOS:000167980900106
J	Preston, TJ; Muller, WJ; Singh, G				Preston, TJ; Muller, WJ; Singh, G			Scavenging of extracellular H2O2 by catalase inhibits the proliferation of HER-2/Neu-transformed rat-1 fibroblasts through the induction of a stress response	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; NF-KAPPA-B; HYDROGEN-PEROXIDE; C-JUN; TYROSINE PHOSPHORYLATION; SUPEROXIDE-DISMUTASE; SIGNAL-TRANSDUCTION; CELL-SURVIVAL; HUMAN BREAST; RECEPTOR	High levels of reactive oxygen species (ROS) are associated with cytotoxicity, Alternatively, nontoxic levels of ROS like hydrogen peroxide (H2O2) can mediate the transmission of many intracellular signals, including those invoked in growth and transformation. To identify pathways downstream of endogenous cellular H2O2 production, the response of Rat-1 fibroblasts exhibiting differential HER-2/Neu receptor tyrosine kinase activity to removal of physiological H2O2 concentrations was investigated. The proliferation of all cells was abolished by addition of the H2O2 scavenger catalase to the culture medium; HER-2/Neu activity was not significantly affected by catalase treatment, suggesting that the target(s) of the H2O2 signal lie downstream of the receptor in our model, ERK1/2 phosphorylation was blocked by catalase in fibroblasts expressing wild type Neu, however such a response did not occur in cells possessing activated mutant Neu, This indicates that the ERK1/2 response contributes little to the growth inhibition observed. By contrast, JNK1 activity increased following the addition of catalase or H2O2, regardless of Neu activity or level of cell transformation. Phosphorylation of p38 MAPK was induced by H2O2 but not by catalase. These observations suggest that scavenging of H2O2 from the cellular environment blocks Rat-1 proliferation primarily through the activation of stress pathways.	Hamilton Reg Canc Ctr, Hamilton, ON L8V 5C2, Canada; McMaster Univ, Fac Hlth Sci, Dept Pathol & Mol Med, Hamilton, ON L8V 5C2, Canada	McMaster University; McMaster University	Singh, G (corresponding author), Hamilton Reg Canc Ctr, 699 Concess St, Hamilton, ON L8V 5C2, Canada.		Singh, Gurmit/C-6744-2014					Bae YS, 1997, J BIOL CHEM, V272, P217, DOI 10.1074/jbc.272.1.217; BARGMANN CI, 1986, CELL, V45, P649, DOI 10.1016/0092-8674(86)90779-8; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; BURDON RH, 1995, FREE RADICAL BIO MED, V18, P775, DOI 10.1016/0891-5849(94)00198-S; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; Dankort DL, 1997, MOL CELL BIOL, V17, P5410, DOI 10.1128/MCB.17.9.5410; Del Bello B, 1999, FASEB J, V13, P69; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; GAMOU S, 1995, FEBS LETT, V357, P161, DOI 10.1016/0014-5793(94)01335-X; Guyton KZ, 1996, J BIOL CHEM, V271, P4138, DOI 10.1074/jbc.271.7.3604; Hansen LL, 1999, J BIOL CHEM, V274, P25078, DOI 10.1074/jbc.274.35.25078; Ishikawa Y, 1999, BIOCHEM BIOPH RES CO, V264, P696, DOI 10.1006/bbrc.1999.1542; Kwon T, 2000, J BIOL CHEM, V275, P423, DOI 10.1074/jbc.275.1.423; Leppa S, 1999, ONCOGENE, V18, P6158, DOI 10.1038/sj.onc.1203173; LI JJ, 1995, ONCOGENE, V10, P1989; Mercurio F, 1999, ONCOGENE, V18, P6163, DOI 10.1038/sj.onc.1203174; Nilakantan V, 1998, CARCINOGENESIS, V19, P631, DOI 10.1093/carcin/19.4.631; Oberley TD, 1997, HISTOL HISTOPATHOL, V12, P525; Patterson C, 1999, J BIOL CHEM, V274, P19814, DOI 10.1074/jbc.274.28.19814; QUIN MT, 1993, J BIOL CHEM, V268, P20988; Rao GN, 1996, ONCOGENE, V13, P713; Reese DM, 1997, STEM CELLS, V15, P1, DOI 10.1002/stem.150001; Sattler M, 1999, BLOOD, V93, P2928; Schmid E, 1999, FASEB J, V13, P1491, DOI 10.1096/fasebj.13.12.1491; Shin EA, 1999, FEBS LETT, V452, P355, DOI 10.1016/S0014-5793(99)00657-2; Siegel PM, 1996, P NATL ACAD SCI USA, V93, P8878, DOI 10.1073/pnas.93.17.8878; SPITZ DR, 1993, J CELL PHYSIOL, V156, P72, DOI 10.1002/jcp.1041560111; SUNDARESAN M, 1995, SCIENCE, V270, P296, DOI 10.1126/science.270.5234.296; SZATROWSKI TP, 1991, CANCER RES, V51, P794; Tang Y, 1999, MOL CELL BIOL, V19, P1881; Tibbles LA, 1999, CELL MOL LIFE SCI, V55, P1230, DOI 10.1007/s000180050369; Venugopal R, 1998, ONCOGENE, V17, P3145, DOI 10.1038/sj.onc.1202237; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; Wenk J, 1999, J BIOL CHEM, V274, P25869, DOI 10.1074/jbc.274.36.25869; Wisdom R, 1999, EMBO J, V18, P188, DOI 10.1093/emboj/18.1.188; Yamamoto K, 1999, MOL CELL BIOL, V19, P8469; Yoshizumi M, 2000, J BIOL CHEM, V275, P11706, DOI 10.1074/jbc.275.16.11706; Zhang JH, 1998, AM J RESP CELL MOL, V19, P324, DOI 10.1165/ajrcmb.19.2.3209	39	123	128	2	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 23	2001	276	12					9558	9564		10.1074/jbc.M004617200	http://dx.doi.org/10.1074/jbc.M004617200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	413HV	11134000	hybrid			2022-12-25	WOS:000167607700124
J	Botchkareva, NV; Khlgatian, M; Longley, BJ; Botchkarev, VA; Gilchrest, BA				Botchkareva, NV; Khlgatian, M; Longley, BJ; Botchkarev, VA; Gilchrest, BA			SCF/c-kit signaling is required for cyclic regeneration of the hair pigmentation unit	FASEB JOURNAL			English	Article						melanocyte; stem cell; hair follicle; hair cycle	STEM-CELL FACTOR; FOLLICLE REGRESSION CATAGEN; TYROSINASE-RELATED PROTEIN; C57BL/6 MOUSE SKIN; C-KIT; GROWTH-FACTOR; MELANOCYTE DEVELOPMENT; TRANSCRIPTION FACTOR; NEUROTROPHIC FACTOR; KINASE RECEPTOR	Hair graying, an age-associated process of unknown etiology, is characterized by a reduced number and activity of hair follicle (HF) melanocytes, Stem cell factor (SCF) and its receptor c-kit are important for melanocyte survival during development, and mutations in these genes result in unpigmented hairs. Here we show that during cyclic HF regeneration in C57BL/6 mice, proliferating, differentiating, and melanin-producing melanocytes express c-kit, whereas presumptive melanocyte precursors do not, SCF overexpression in HF epithelium significantly increases the number and proliferative activity of melanocytes, During the induced hair cycle in C57BL/6 mice, administration of anti-c-kit antibody dose-dependently decreases hair pigmentation and leads to partially depigmented (gray) or fully depigmented (white) hairs, associated with significant decreases in melanocyte proliferation and differentiation, as determined by immunostaining and confocal microscopy, However, in the next hair cycle, the previously treated animals grow fully pigmented hairs with the normal number and distribution of melanocytes, This suggests that melanocyte stem cells are not dependent on SCF/c-kit and when appropriately stimulated can generate melano-genically active melanocytes, Therefore, the blockade of c-kit signaling offers a fully reversible model for hair depigmentation, which might be used for the studies of hair pigmentation disorders.-Botchkareva, N. V., Khlgatian, M., Longley, B. J., Botchkarev, V. A., and Gilchrest, B. A. SCF/c-kit signaling is required for cyclic regeneration of the hair pigmentation unit.	Boston Univ, Sch Med, Dept Dermatol, Boston, MA 02118 USA; Columbia Univ, Dept Dermatol, New York, NY 10027 USA	Boston University; Columbia University	Gilchrest, BA (corresponding author), Boston Univ, Sch Med, Dept Dermatol, 609 Albany St, Boston, MA 02118 USA.			Botchkarev, Vladimir/0000-0002-5212-5353				BEERMANN F, 1990, EMBO J, V9, P2819, DOI 10.1002/j.1460-2075.1990.tb07470.x; Bertolotto C, 1998, MOL CELL BIOL, V18, P694, DOI 10.1128/MCB.18.2.694; Botchkarev VA, 1998, AM J PATHOL, V153, P785, DOI 10.1016/S0002-9440(10)65621-0; Botchkarev VA, 1997, J COMP NEUROL, V386, P379, DOI 10.1002/(SICI)1096-9861(19970929)386:3<379::AID-CNE4>3.0.CO;2-Z; Botchkarev VA, 1999, FASEB J, V13, P395, DOI 10.1096/fasebj.13.2.395; Botchkarev VA, 1999, ANN NY ACAD SCI, V885, P433; Botchkarev VA, 1999, LAB INVEST, V79, P557; CHABOT B, 1988, NATURE, V335, P88, DOI 10.1038/335088a0; CHASE HB, 1954, PHYSIOL REV, V34, P113, DOI 10.1152/physrev.1954.34.1.113; COTSARELIS G, 1990, CELL, V61, P1329, DOI 10.1016/0092-8674(90)90696-C; Ermak G, 1997, J INVEST DERMATOL, V108, P160, DOI 10.1111/1523-1747.ep12332925; GALLI SJ, 1994, ADV IMMUNOL, V55, P1; GERDES J, 1990, EUR J CELL BIOL S43, V72, P88; Gilchrest BA, 1996, PHOTOCHEM PHOTOBIOL, V63, P1, DOI 10.1111/j.1751-1097.1996.tb02988.x; Grichnik JM, 1998, J INVEST DERMATOL, V111, P233, DOI 10.1046/j.1523-1747.1998.00272.x; Halaban R, 2000, PIGM CELL RES, V13, P4, DOI 10.1034/j.1600-0749.2000.130103.x; HALL PA, 1993, ONCOGENE, V8, P203; HARA M, 1995, J INVEST DERMATOL, V105, P744, DOI 10.1111/1523-1747.ep12325522; HEARING VJ, 1991, FASEB J, V5, P2902, DOI 10.1096/fasebj.5.14.1752358; Hearing VJ, 1999, J INVEST DERM SYMP P, V4, P24, DOI 10.1038/sj.jidsp.5640176; Hemesath TJ, 1998, NATURE, V391, P298, DOI 10.1038/34681; Hibberts NA, 1996, BIOCHEM BIOPH RES CO, V222, P401, DOI 10.1006/bbrc.1996.0756; Ito M, 1999, J INVEST DERMATOL, V112, P796, DOI 10.1046/j.1523-1747.1999.00552.x; JACKSON I, 1994, ANNU REV GENET, V28, P198; JACKSON IJ, 1988, P NATL ACAD SCI USA, V85, P4392, DOI 10.1073/pnas.85.12.4392; JACKSON K, 1992, SIGHT SOUND, V2, P11; JIMBOW K, 1999, FITZPATRICKS DERMATO, V1, P192; JIMENEZ M, 1988, P NATL ACAD SCI USA, V85, P3830, DOI 10.1073/pnas.85.11.3830; JIMENEZ M, 1991, J BIOL CHEM, V266, P1147; Kos L, 1999, PIGM CELL RES, V12, P13, DOI 10.1111/j.1600-0749.1999.tb00503.x; Kunisada T, 1998, DEVELOPMENT, V125, P2915; Kunisada T, 1998, J EXP MED, V187, P1565, DOI 10.1084/jem.187.10.1565; LECOIN L, 1998, MOL BASIS EPITHELIAL, P131; Lindner G, 1997, AM J PATHOL, V151, P1601; LUO D, 1995, MELANOMA RES, V5, P303, DOI 10.1097/00008390-199510000-00002; Lyle S, 1998, J CELL SCI, V111, P3179; MacKenzie MAF, 1997, DEV BIOL, V192, P99, DOI 10.1006/dbio.1997.8738; NISHIKAWA S, 1991, EMBO J, V10, P2111, DOI 10.1002/j.1460-2075.1991.tb07744.x; OKURA M, 1995, J INVEST DERMATOL, V105, P322, DOI 10.1111/1523-1747.ep12319939; Park HY, 1999, CELL MOL BIOL, V45, P919; Paus R, 1999, J INVEST DERMATOL, V113, P523, DOI 10.1046/j.1523-1747.1999.00740.x; PAUS R, 1990, BRIT J DERMATOL, V122, P777, DOI 10.1111/j.1365-2133.1990.tb06266.x; Paus R, 1999, NEW ENGL J MED, V341, P491, DOI 10.1056/NEJM199908123410706; PAUS R, 1996, J INVEST DERMATOL, V106, P889; PAUS R, 1996, ARCH DERMATOL RES, V290, P311; Paus Ralf, 1998, Journal of Dermatology (Tokyo), V25, P793; Schallreuter K, 1998, EXP DERMATOL, V7, P143, DOI 10.1111/j.1600-0625.1998.tb00315.x; Shindler KS, 1996, J HISTOCHEM CYTOCHEM, V44, P1331, DOI 10.1177/44.11.8918908; Slominski A, 1998, BBA-MOL CELL RES, V1448, P147, DOI 10.1016/S0167-4889(98)00124-4; Slominski A, 1996, J INVEST DERMATOL, V106, P1203, DOI 10.1111/1523-1747.ep12348479; SLOMINSKI A, 1994, J INVEST DERMATOL, V102, P862, DOI 10.1111/1523-1747.ep12382606; SLOMINSKI A, 1993, J INVEST DERMATOL, V101, pS90, DOI 10.1111/1523-1747.ep12362991; SLOMINSKI A, 1991, J INVEST DERMATOL, V96, P172, DOI 10.1111/1523-1747.ep12460956; STARICCO RG, 1960, J INVEST DERMATOL, V35, P185; STEEL KP, 1992, DEVELOPMENT, V115, P1111; SUGIYAMA S, 1979, J ULTRA MOL STRUCT R, V67, P40, DOI 10.1016/S0022-5320(79)80016-7; Sugiyama Sadao, 1995, Journal of Dermatology (Tokyo), V22, P396; Suzuki T, 1997, J HISTOCHEM CYTOCHEM, V45, P49, DOI 10.1177/002215549704500107; Tobin DJ, 1996, PIGM CELL RES, V9, P304, DOI 10.1111/j.1600-0749.1996.tb00122.x; Tobin DJ, 1998, J INVEST DERMATOL, V111, P941, DOI 10.1046/j.1523-1747.1998.00417.x; Tobin DJ, 1999, J INVEST DERM SYMP P, V4, P323, DOI 10.1038/sj.jidsp.5640239; TSUKAMOTO K, 1992, EMBO J, V11, P519, DOI 10.1002/j.1460-2075.1992.tb05082.x; WINDER A, 1994, CELL MOL BIOL RES, V40, P613; Wu M, 2000, GENE DEV, V14, P301; YAAR M, 1994, J CLIN INVEST, V94, P1550, DOI 10.1172/JCI117496; Yasumoto K, 1997, J BIOL CHEM, V272, P503; Yoshida H, 1996, DEVELOPMENT, V122, P1207; ZSEBO KM, 1990, CELL, V63, P213, DOI 10.1016/0092-8674(90)90302-U	68	184	202	0	18	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAR	2001	15	3					645	658		10.1096/fj.00-0368com	http://dx.doi.org/10.1096/fj.00-0368com			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	410BE	11259383				2022-12-25	WOS:000167419500022
J	Longoni, B; Boschi, E; Demontis, GC; Ratto, GM; Mosca, F				Longoni, B; Boschi, E; Demontis, GC; Ratto, GM; Mosca, F			Apoptosis and adaptive responses to oxidative stress in human endothelial cells exposed to cyclosporin A correlate with BCL-2 expression levels	FASEB JOURNAL			English	Article						confocal microscopy; reactive oxygen species; antioxidants; dihydrorhodamine 123; melatonin; transplantation	GLIOMA-CELLS; COMPLEX; NEPHROTOXICITY; MITOCHONDRIA; ATTENUATION; CALCINEURIN; INHIBITION; RELAXATION; MECHANISMS; MELATONIN	Treatment of transplanted patients with cyclosporin A (CSA) may cause adverse effects such as nephrotoxicity and hypertension, As CSA is kn1own to induce oxidative stress in several tissues, it may cause vascular problems by triggering oxidative stress in endothelial cells (EC), However, oxidative stress has been reported for acute exposure to CSA concentrations exceeding its clinical range, whereas immunosuppression requires life-long treatment with therapeutic concentrations. We therefore compared the effects of 21 h pharmacological (200 muM) vs. 8 days clinical (0.5-2.5 muM) doses of CSA on cultured human EC. Pharmacological doses of CSA cause a decrease in cell density via apoptosis and a down-regulation of the antiapoptotic protein Bcl-2. However, these effects are independent of CSA-induced oxidative stress. In contrast, therapeutic concentrations of CSA cause Bcl-2 up-regulation and modification of EC morphology, both effects blocked by antioxidants, Therefore, a low level of oxidants may act in EC as second messengers that up-regulate Bcl-2, thus promoting survival of impaired EC, Our data suggest that the oxidative stress induced by clinical concentrations of CSA may be involved in the adverse effects of the drug on the vascular system of transplanted patients via an adaptive response involving Bcl-2 up-regulation rather than an apoptotic process.-Longoni, B., Boschi, E., Demontis, G. C., Ratto, C. M., Mosca, F. Apoptosis and adaptive responses to oxidative stress in human endothelial cells exposed to cyclosporin A correlate with BCL-2 expression levels.	Univ Pisa, Dept Oncol Transplants & Adv Technol Med, Sch Med, I-56124 Pisa, Italy; Univ Pisa, Dept Physiol & Biochem, Sch Med, I-56124 Pisa, Italy; Univ Pisa, Dept Psychiat & Neurobiol, Sch Med, I-56124 Pisa, Italy; CNR, Inst Neurophysiol, I-56100 Pisa, Italy	University of Pisa; University of Pisa; University of Pisa; Consiglio Nazionale delle Ricerche (CNR)	Longoni, B (corresponding author), Univ Pisa, Dept Oncol Transplants & Adv Technol Med, Sch Med, Via Paradisa 2, I-56124 Pisa, Italy.	biancam@dfb.unipi.it	Demontis, Gian Carlo A.G./K-6963-2016; Ratto, Gian Michele/AAX-8514-2020; Ratto, Gian Michele/AAB-8719-2021	Demontis, Gian Carlo A.G./0000-0001-7641-0426; Ratto, Gian Michele/0000-0001-9632-7769				Armitage P., 1971, STAT METHODS MED RES, V1; Baliga R, 1999, DRUG METAB REV, V31, P971, DOI 10.1081/DMR-100101947; Bergmeyer HU, 1974, METHODS ENZYMATIC AN; BUTTKE TM, 1994, IMMUNOL TODAY, V15, P7, DOI 10.1016/0167-5699(94)90018-3; CLARDY J, 1995, P NATL ACAD SCI USA, V92, P56, DOI 10.1073/pnas.92.1.56; CROMPTON M, 1988, BIOCHEM J, V255, P357; Davies KJA, 1999, IUBMB LIFE, V48, P41, DOI 10.1080/152165499307404; DIEDERICH D, 1994, HYPERTENSION, V23, P957, DOI 10.1161/01.HYP.23.6.957; Durak I, 1998, NEPHRON, V78, P207, DOI 10.1159/000044912; ESTERBAUER H, 1990, METHOD ENZYMOL, V186, P407; FURCHGOTT RF, 1984, J CARDIOVASC PHARM, V6, pS336, DOI 10.1097/00005344-198406002-00008; GERKENS JF, 1989, J PHARMACOL EXP THER, V250, P1105; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; GRIFFITH TM, 1984, NATURE, V308, P645, DOI 10.1038/308645a0; Hiroyasu S, 1999, J SURG RES, V84, P204, DOI 10.1006/jsre.1999.5644; JAFFE EA, 1973, J CLIN INVEST, V52, P2745, DOI 10.1172/JCI107470; Jansen B, 1998, NAT MED, V4, P232, DOI 10.1038/nm0298-232; KAHAN BD, 1989, NEW ENGL J MED, V321, P1725; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; Kumar KV, 1999, TRANSPLANTATION, V67, P1065, DOI 10.1097/00007890-199904150-00022; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; Longoni B, 1999, BIOCHEM BIOPH RES CO, V260, P522, DOI 10.1006/bbrc.1999.0928; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Marzo I, 1998, J EXP MED, V187, P1261, DOI 10.1084/jem.187.8.1261; Mosieniak G, 1997, J NEUROCHEM, V68, P1142; MYERS BD, 1988, TRANSPLANTATION, V46, P694, DOI 10.1097/00007890-198811000-00014; MYERS BD, 1988, KIDNEY INT, V33, P590, DOI 10.1038/ki.1988.38; PFLUGL G, 1993, NATURE, V361, P91, DOI 10.1038/361091a0; POEGGELER B, 1993, J PINEAL RES, V14, P151, DOI 10.1111/j.1600-079X.1993.tb00498.x; Pyrzynska B, 2000, J NEUROCHEM, V74, P42, DOI 10.1046/j.1471-4159.2000.0740042.x; REGO A, 1990, J PHARMACOL EXP THER, V252, P165; Reiter RJ, 1999, ADV EXP MED BIOL, V467, P379; Schechner JS, 2000, P NATL ACAD SCI USA, V97, P9191, DOI 10.1073/pnas.150242297; STELLER H, 1995, SCIENCE, V267, P1445, DOI 10.1126/science.7878463; STEPHAN D, 1995, J CARDIOVASC PHARM, V26, P859, DOI 10.1097/00005344-199512000-00003; SWANSON SKH, 1992, P NATL ACAD SCI USA, V89, P3741, DOI 10.1073/pnas.89.9.3741; THERIAULT Y, 1993, NATURE, V361, P88, DOI 10.1038/361088a0; Thom SR, 2000, P NATL ACAD SCI USA, V97, P1305, DOI 10.1073/pnas.97.3.1305; WANG CY, 1995, KIDNEY INT, V47, P927, DOI 10.1038/ki.1995.138; WANG CY, 1994, TRANSPLANTATION, V58, P940, DOI 10.1097/00007890-199410270-00014; Wolf A, 1997, J PHARMACOL EXP THER, V280, P1328; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0; ZOJA C, 1986, LAB INVEST, V55, P455	43	49	49	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2001	15	3					731	740		10.1096/fj.00-0163com	http://dx.doi.org/10.1096/fj.00-0163com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	410BE	11259391				2022-12-25	WOS:000167419500030
J	St-Amand, J; Okamura, K; Matsumoto, K; Shimizu, S; Sogawa, Y				St-Amand, J; Okamura, K; Matsumoto, K; Shimizu, S; Sogawa, Y			Characterization of control and immobilized skeletal muscle: an overview from genetic engineering	FASEB JOURNAL			English	Article						muscle atrophy; mRNA; serial analysis of gene expression (SAGE); sarcopenia; gene regulation	EXPRESSED SEQUENCE TAGS; MESSENGER-RNA; SERIAL ANALYSIS; CHROMOSOMAL LOCALIZATION; SELENOPROTEIN-W; CDNA LIBRARY; HUMAN-GENOME; CELL-CYCLE; RAT; ATROPHY	To elucidate the molecular basis of muscle atrophy, we have performed the serial analysis of gene expression (SAGE) method with control and immobilized muscles of 10 rats. The genes that expressed >0.5% in muscle are involved in the following three functions: I) contraction (troponin I, C and T; myosin light chain 1-3; actin; tropomyosin; and parvalbumin), 2) energy metabolism (cytochrome c oxidase I and III, creatine kinase, glyceraldehyde-3-phosphate-dehydrogenase, phosphoglycerate mutase, ATPase 6, and aldolase A), and 3) housekeeping (lens epithelial protein). Muscle atrophy appears to be caused by changes in mRNA levels of specific regulators of proteolysis, protein synthesis, and contractile apparatus assembling, such as polyubiquitin, elongation factor 2, and nebulin. Immobilization has produced a decrease more than threefold in gene expression of enzymes involved in energy metabolism, especially ATPase, cytochrome c oxidase, NADH dehydrogenase, and protein phosphatase 1. Differential gene expressions of selenoprotein W and uroporphyrinogen decarboxylase, which can be involved in oxidative stress, were also observed. Other genes with various functions, such as cholesterol metabolism and growth factors, were also differentially expressed. Moreover, novel genes regulated by immobilization were discovered. Thus, the current study allows a better understanding of global muscle characteristics and the molecular mechanisms of sedentarity and sarcopenia.-St-Amand, J., Okamura, IC, Matsumoto, K., Shimizu, S., Sogawa, Y. Characterization of control and immobilized skeletal muscle: an overview from genetic engineering.	Otsuka Pharmaceut Co Ltd, Saga Res Inst, Saga 8420195, Japan	Otsuka Pharmaceutical	St-Amand, J (corresponding author), Louisiana State Univ, Pennington Biomed Res Ctr, Human Genom Lab, 6400 Perkins Rd, Baton Rouge, LA 70808 USA.			St-Amand, Jonny/0000-0002-2595-6127				ADAMS GR, 1995, J CELL PHYSL, V79, P368; APPELL HJ, 1990, SPORTS MED, V10, P42, DOI 10.2165/00007256-199010010-00005; Appell HJ, 1997, INT J SPORTS MED, V18, P157; Argyropoulos G, 1998, J LIPID RES, V39, P1870; Baldwin KM, 1996, MED SCI SPORT EXER, V28, P983, DOI 10.1097/00005768-199608000-00008; Beilstein MA, 1996, J INORG BIOCHEM, V61, P117, DOI 10.1016/0162-0134(95)00045-3; Booth FW, 1996, J APPL PHYSIOL, V81, P1941, DOI 10.1152/jappl.1996.81.5.1941; BOUCHARD C, 1993, ANNU REV NUTR, V13, P337, DOI 10.1146/annurev.nu.13.070193.002005; BREITBART RE, 1986, J MOL BIOL, V188, P313, DOI 10.1016/0022-2836(86)90157-9; Chen HX, 1998, J EXP MED, V188, P1657, DOI 10.1084/jem.188.9.1657; CHEN MJG, 1993, J BIOL CHEM, V268, P20327; CHOMYN A, 1986, SCIENCE, V234, P614, DOI 10.1126/science.3764430; Collins FS, 1999, NEW ENGL J MED, V341, P28, DOI 10.1056/NEJM199907013410106; Cros N, 1999, AM J PHYSIOL-REG I, V276, pR308, DOI 10.1152/ajpregu.1999.276.2.R308; Datson NA, 1999, NUCLEIC ACIDS RES, V27, P1300, DOI 10.1093/nar/27.5.1300; EPSTEIN P, 1986, J BIOL CHEM, V261, P5886; EVANS WJ, 1995, J GERONTOL A-BIOL, V50, P5, DOI 10.1093/gerona/50A.Special_Issue.5; Gonzalez-Zulueta M, 1998, J NEUROSCI, V18, P2040; HERBISON GJ, 1978, ARCH PHYS MED REHAB, V59, P301; Holben DH, 1999, J AM DIET ASSOC, V99, P836, DOI 10.1016/S0002-8223(99)00198-4; Horne MC, 1996, J BIOL CHEM, V271, P6050, DOI 10.1074/jbc.271.11.6050; HOULGATTE R, 1995, GENOME RES, V5, P272, DOI 10.1101/gr.5.3.272; HWANG DM, 1995, GENOMICS, V30, P293, DOI 10.1006/geno.1995.9874; INOUE C, 1988, BIOCHEM BIOPH RES CO, V150, P1302, DOI 10.1016/0006-291X(88)90771-1; JABS EW, 1994, HUM GENET, V93, P600; Jankala H, 1997, J APPL PHYSIOL, V82, P977, DOI 10.1152/jappl.1997.82.3.977; Kenzelmann M, 1999, NUCLEIC ACIDS RES, V27, P917, DOI 10.1093/nar/27.3.917; Koepp DM, 1999, CELL, V97, P431, DOI 10.1016/S0092-8674(00)80753-9; KONDO H, 1993, AM J PHYSIOL, V265, pE839, DOI 10.1152/ajpendo.1993.265.6.E839; Lanfranchi G, 1996, GENOME RES, V6, P35, DOI 10.1101/gr.6.1.35; Lecker SH, 1999, J NUTR, V129, p227S, DOI 10.1093/jn/129.1.227S; Lee CK, 1999, SCIENCE, V285, P1390, DOI 10.1126/science.285.5432.1390; Lenka N, 1998, PROG NUCLEIC ACID RE, V61, P309, DOI 10.1016/S0079-6603(08)60830-2; Leung MK, 1999, GENOMICS, V61, P307, DOI 10.1006/geno.1999.5970; LOPEZFERNANDEZ LA, 1995, BBA-GENE STRUCT EXPR, V1263, P10, DOI 10.1016/0167-4781(95)00065-O; MCKNIGHT GL, 1992, J BIOL CHEM, V267, P12131; MEDINA R, 1995, BIOCHEM J, V307, P631, DOI 10.1042/bj3070631; MURPHY WI, 1975, J MOL BIOL, V99, P809, DOI 10.1016/S0022-2836(75)80187-2; MURRAY RK, 1993, HARPERS BIOCH, P647; NISHIO Y, 1994, FASEB J, V8, P103, DOI 10.1096/fasebj.8.1.8299882; OJALA D, 1981, NATURE, V290, P470, DOI 10.1038/290470a0; Pennisi E, 1999, SCIENCE, V286, P449, DOI 10.1126/science.286.5439.449; PERIASAMY M, 1984, J BIOL CHEM, V259, P3595; POEHLMAN ET, 1992, METABOLISM, V41, P1351, DOI 10.1016/0026-0495(92)90107-L; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; ROMMENS JM, 1989, SCIENCE, V245, P1059, DOI 10.1126/science.2772657; RUIZOPAZO N, 1987, J BIOL CHEM, V262, P4755; Sanchez JC, 1997, ELECTROPHORESIS, V18, P150, DOI 10.1002/elps.1150180127; Schiaffino S, 1996, PHYSIOL REV, V76, P371, DOI 10.1152/physrev.1996.76.2.371; SCHLERF A, 1988, EMBO J, V7, P2387, DOI 10.1002/j.1460-2075.1988.tb03083.x; Schwaller B, 1999, AM J PHYSIOL-CELL PH, V276, pC395, DOI 10.1152/ajpcell.1999.276.2.C395; SHIMOMURA Y, 1984, J BIOL CHEM, V259, P4059; SIMONEAU JA, 1989, AM J PHYSIOL, V257, pE567, DOI 10.1152/ajpendo.1989.257.4.E567; St-Amand J, 1999, MED SCI SPORT EXER, V31, P692, DOI 10.1097/00005768-199905000-00011; TZAGOLOFF A, 1986, ANNU REV BIOCHEM, V55, P249, DOI 10.1146/annurev.bi.55.070186.001341; VELCULESCU VE, 1995, SCIENCE, V270, P484, DOI 10.1126/science.270.5235.484; Velculescu VE, 1997, CELL, V88, P243, DOI 10.1016/S0092-8674(00)81845-0; VENDELAND SC, 1995, P NATL ACAD SCI USA, V92, P8749, DOI 10.1073/pnas.92.19.8749; Welle S, 1999, GENOME RES, V9, P506; Zhang L, 1997, SCIENCE, V276, P1268, DOI 10.1126/science.276.5316.1268; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0	61	81	83	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAR	2001	15	3					684	692		10.1096/fj.00-0150com	http://dx.doi.org/10.1096/fj.00-0150com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	410BE	11259386				2022-12-25	WOS:000167419500025
J	Fan, SJ; Ma, YX; Wang, CG; Yuan, RQ; Meng, QH; Wang, JA; Erdos, M; Goldberg, ID; Webb, P; Kushner, PJ; Pestell, RG; Rosen, EM				Fan, SJ; Ma, YX; Wang, CG; Yuan, RQ; Meng, QH; Wang, JA; Erdos, M; Goldberg, ID; Webb, P; Kushner, PJ; Pestell, RG; Rosen, EM			Role of direct interaction in BRCA1 inhibition of estrogen receptor activity	ONCOGENE			English	Article						BRCA1; estrogen receptor (ER); breast cancer; activation function-2 (AF-2)	TRANSCRIPTIONAL ACTIVATION; OVARIAN-CANCER; BREAST; MUTATIONS; BINDING	The BRCA1 gene was previously found to inhibit the transcriptional activity of the estrogen receptor [ER-alpha] in human breast and prostate cancer cell Lines. In this study, we found that breast cancer-associated mutations of BRCA1 abolish or reduce its ability to inhibit ER-alpha activity and that domains within the amino- and carboxyl-termini of the BRCA1 protein are required for the inhibition. BRCA1 inhibition of ER-alpha activity was demonstrated under conditions in which a BRCA1 transgene was transiently or stably over-expressed in cell lines with endogenous wild-type BRCA1 and in a breast cancer cell line that lacks endogenous functional BRCA1 (HCC1937), In addition, BRCA1 blocked the expression of two endogenous estrogen-regulated gene products in human breast cancer cells: pS2 and cathepsin D, The BRCA1 protein was found to associate with ER-alpha in vivo and to bind to ER-alpha in vitro, by an estrogen-independent interaction that mapped to the amino-terminal region of BRCA1 (ca, amino acid 1-300) and the conserved carboxyl-terminal activation function [AF-2] domain of ER-alpha, Furthermore, several truncated BRCA1 proteins containing the amino-terminal ER-alpha binding region blocked the ability of the full-length BRCA1 protein to inhibit ER-alpha activity. Our findings suggest that the amino-terminus of BRCA1 interacts with ER-alpha, while the carboxyl-terminus of BRCA1 may function as a transcriptional repression domain.	Albert Einstein Coll Med, Long Isl Jewish Med Ctr, Dept Radiat Oncol, New York, NY 11040 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Dev & Mol Biol, Bronx, NY 10461 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Med, Bronx, NY 10461 USA; Yeshiva Univ Albert Einstein Coll Med, Duv Human Endocrine Tumor Biol, Bronx, NY 10461 USA; NHGRI, Genet & Mol Biol Branch, NIH, Bethesda, MD 20892 USA; Univ Calif San Francisco, Sch Med, Metab Res Unit, San Francisco, CA 94143 USA	Northwell Health; Yeshiva University; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); University of California System; University of California San Francisco	Rosen, EM (corresponding author), Albert Einstein Coll Med, Long Isl Jewish Med Ctr, Dept Radiat Oncol, Long Isl Campus,270-05 76th Ave, New York, NY 11040 USA.		Meng, Q./GSI-6185-2022		NCI NIH HHS [R01-CA70897] Funding Source: Medline; NIEHS NIH HHS [R01-ES09169 , +] Funding Source: Medline; PHS HHS [R01-82599] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA070897] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES009169] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Chapman MS, 1996, NATURE, V382, P678, DOI 10.1038/382678a0; Chen YM, 1999, J CELL PHYSIOL, V181, P385, DOI 10.1002/(SICI)1097-4652(199912)181:3<385::AID-JCP2>3.0.CO;2-4; Chlebowski RT, 2000, NEW ENGL J MED, V343, P191, DOI 10.1056/NEJM200007203430307; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Fan S, 1999, SCIENCE, V284, P1354, DOI 10.1126/science.284.5418.1354; Fan SJ, 1998, ONCOGENE, V16, P3069, DOI 10.1038/sj.onc.1202116; FAUST PL, 1985, P NATL ACAD SCI USA, V82, P4910, DOI 10.1073/pnas.82.15.4910; FORD D, 1994, LANCET, V343, P692, DOI 10.1016/S0140-6736(94)91578-4; FRIEDMAN LS, 1994, NAT GENET, V8, P399, DOI 10.1038/ng1294-399; Henttu PMA, 1997, MOL CELL BIOL, V17, P1832, DOI 10.1128/MCB.17.4.1832; JELTSCH JM, 1987, NUCLEIC ACIDS RES, V15, P1401, DOI 10.1093/nar/15.4.1401; Loman N, 1998, CANCER, V83, P310, DOI 10.1002/(SICI)1097-0142(19980715)83:2<310::AID-CNCR15>3.0.CO;2-W; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; Monteiro ANA, 1996, P NATL ACAD SCI USA, V93, P13595, DOI 10.1073/pnas.93.24.13595; Struewing JP, 1997, NEW ENGL J MED, V336, P1401, DOI 10.1056/NEJM199705153362001; Tirkkonen M, 1997, CANCER RES, V57, P1222; WANG CY, 1993, SCIENCE, V260, P1330, DOI 10.1126/science.8493578; Webb P, 1998, MOL ENDOCRINOL, V12, P1605, DOI 10.1210/me.12.10.1605; Webber MM, 1997, PROSTATE, V30, P58; Yarden RI, 1999, P NATL ACAD SCI USA, V96, P4983, DOI 10.1073/pnas.96.9.4983; Yu X, 1998, J BIOL CHEM, V273, P25388, DOI 10.1074/jbc.273.39.25388	21	203	218	0	8	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 4	2001	20	1					77	87		10.1038/sj.onc.1204073	http://dx.doi.org/10.1038/sj.onc.1204073			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	391NE	11244506				2022-12-25	WOS:000166361400009
J	Kim, JB; Sharp, PA				Kim, JB; Sharp, PA			Positive transcription elongation factor b phosphorylates hSPT5 and RNA polymerase II carboxyl-terminal domain independently of cyclin-dependent kinase-activating kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIV-1 TAT-ACTIVATION; FACTOR P-TEFB; MESSENGER-RNA; IN-VITRO; HIGH-AFFINITY; HELA-CELLS; PROTEIN; COMPLEX; SPT5; TFIIH	The CDK9-cyclin T kinase complex, positive transcription elongation factor b (P-TEFb), stimulates the process of elongation of RNA polymerase (Pol) II during transcription of human immunodeficiency virus. P-TEFb associates with the human immunodeficiency virus Tat protein and with the transactivation response element to form a specific complex, thereby mediating efficient elongation. Here, we show that P-TEFb preferentially phosphorylates hSPT5 as compared with the carboxyl-terminal domain of RNA Pol II in vitro. Phosphorylation of hSPT5 by P-TEFb occurred on threonine and serine residues in its carboxyl-terminal repeat domains. In addition, we provide several lines of evidence that P-TEFb is a CDK-activating kinase (CAK)-independent kinase. For example, CDK9 was not phosphorylated by CAK, whereas CDK2-cyclin A kinase activity was dramatically enhanced by CAR. Therefore, it is likely that P-TEFb participates in regulation of elongation by RNA Pol II by phosphorylation of its substrates, hSPT5 and the CTD of RNA Pol II, in a CAK-independent manner.	MIT, Dept Biol, Ctr Canc Res, Cambridge, MA 02139 USA; Seoul Natl Univ, Sch Biol Sci, Seoul 151742, South Korea	Massachusetts Institute of Technology (MIT); Seoul National University (SNU)	Sharp, PA (corresponding author), MIT, Dept Biol, Ctr Canc Res, 77 Massachusetts Ave, Cambridge, MA 02139 USA.	sharppa@mit.edu		KIM, Jae Bum/0000-0003-2337-6935	NATIONAL CANCER INSTITUTE [P01CA042063, P30CA014051] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI032486] Funding Source: NIH RePORTER; NCI NIH HHS [P01-CA42063, P30-CA14051] Funding Source: Medline; NIAID NIH HHS [R01-AI32486] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Andrulis ED, 2000, GENE DEV, V14, P2635, DOI 10.1101/gad.844200; Bieniasz PD, 1998, EMBO J, V17, P7056, DOI 10.1093/emboj/17.23.7056; Chen D, 1999, MOL CELL BIOL, V19, P2863; Chen D, 1999, P NATL ACAD SCI USA, V96, P13468, DOI 10.1073/pnas.96.23.13468; Cho EJ, 1997, GENE DEV, V11, P3319, DOI 10.1101/gad.11.24.3319; CHODOSH LA, 1989, J BIOL CHEM, V264, P2250; Cujec TP, 1997, GENE DEV, V11, P2645, DOI 10.1101/gad.11.20.2645; Cullen BR, 1998, CELL, V93, P685, DOI 10.1016/S0092-8674(00)81431-2; Dynlacht BD, 1997, NATURE, V389, P149, DOI 10.1038/38225; EGYHAZI E, 1974, J MOL BIOL, V84, P173, DOI 10.1016/0022-2836(74)90220-4; Emerman M, 1998, SCIENCE, V280, P1880, DOI 10.1126/science.280.5371.1880; FENG S, 1988, NATURE, V334, P165, DOI 10.1038/334165a0; Fong YW, 2000, MOL CELL BIOL, V20, P5897, DOI 10.1128/MCB.20.16.5897-5907.2000; Fujinaga K, 1999, P NATL ACAD SCI USA, V96, P1285, DOI 10.1073/pnas.96.4.1285; Garber ME, 2000, MOL CELL BIOL, V20, P6958, DOI 10.1128/MCB.20.18.6958-6969.2000; Garber ME, 1998, GENE DEV, V12, P3512, DOI 10.1101/gad.12.22.3512; GarciaMartinez LF, 1997, EMBO J, V16, P2836, DOI 10.1093/emboj/16.10.2836; Hampsey M, 1998, MICROBIOL MOL BIOL R, V62, P465, DOI 10.1128/MMBR.62.2.465-503.1998; Hartzog GA, 1998, GENE DEV, V12, P357, DOI 10.1101/gad.12.3.357; Hirose Y, 2000, GENE DEV, V14, P1415; Hoeijmakers JHJ, 1996, CURR OPIN GENET DEV, V6, P26, DOI 10.1016/S0959-437X(96)90006-4; Holstege FCP, 1999, P NATL ACAD SCI USA, V96, P2, DOI 10.1073/pnas.96.1.2; Isel C, 1999, J MOL BIOL, V290, P929, DOI 10.1006/jmbi.1999.2933; Ivanov D, 2000, MOL CELL BIOL, V20, P2970, DOI 10.1128/MCB.20.9.2970-2983.2000; Jones KA, 1997, GENE DEV, V11, P2593, DOI 10.1101/gad.11.20.2593; KAMPS MP, 1989, ANAL BIOCHEM, V176, P22, DOI 10.1016/0003-2697(89)90266-2; Kaplan CD, 2000, GENE DEV, V14, P2623, DOI 10.1101/gad.831900; Kim JB, 1999, MOL CELL BIOL, V19, P5960; Kwak YT, 1999, J MOL BIOL, V288, P57, DOI 10.1006/jmbi.1999.2664; Li XY, 1998, GENE DEV, V12, P2992, DOI 10.1101/gad.12.19.2992; Mancebo HSY, 1997, GENE DEV, V11, P2633, DOI 10.1101/gad.11.20.2633; MARCINIAK RA, 1990, CELL, V63, P791, DOI 10.1016/0092-8674(90)90145-5; MARCINIAK RA, 1991, EMBO J, V10, P4189, DOI 10.1002/j.1460-2075.1991.tb04997.x; MARSHALL NF, 1995, J BIOL CHEM, V270, P12335, DOI 10.1074/jbc.270.21.12335; Marshall NF, 1996, J BIOL CHEM, V271, P27176, DOI 10.1074/jbc.271.43.27176; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; Parada CA, 1999, EMBO J, V18, P3688, DOI 10.1093/emboj/18.13.3688; Parada CA, 1996, NATURE, V384, P375, DOI 10.1038/384375a0; Peng JM, 1998, J BIOL CHEM, V273, P13855, DOI 10.1074/jbc.273.22.13855; Peng JM, 1998, GENE DEV, V12, P755, DOI 10.1101/gad.12.5.755; Ping YH, 1999, J BIOL CHEM, V274, P7399, DOI 10.1074/jbc.274.11.7399; Price DH, 2000, MOL CELL BIOL, V20, P2629, DOI 10.1128/MCB.20.8.2629-2634.2000; RATNASABAPATHY R, 1990, GENE DEV, V4, P2061, DOI 10.1101/gad.4.12a.2061; Rodriguez CR, 2000, MOL CELL BIOL, V20, P104, DOI 10.1128/MCB.20.1.104-112.2000; SEHGAL PB, 1976, CELL, V9, P473, DOI 10.1016/0092-8674(76)90092-1; Svejstrup JQ, 1996, TRENDS BIOCHEM SCI, V21, P346, DOI 10.1016/0968-0004(96)10046-3; TAMM I, 1976, J CELL BIOL, V69, P229, DOI 10.1083/jcb.69.2.229; Tirode F, 1999, MOL CELL, V3, P87, DOI 10.1016/S1097-2765(00)80177-X; VANDERGEER P, 1994, ELECTROPHORESIS, V15, P544, DOI 10.1002/elps.1150150173; Wada T, 1998, EMBO J, V17, P7395, DOI 10.1093/emboj/17.24.7395; Wada T, 1998, GENE DEV, V12, P343, DOI 10.1101/gad.12.3.343; Wei P, 1998, CELL, V92, P451, DOI 10.1016/S0092-8674(00)80939-3; Wu-Baer F, 1998, J MOL BIOL, V277, P179, DOI 10.1006/jmbi.1997.1601; Yamaguchi Y, 1999, CELL, V97, P41, DOI 10.1016/S0092-8674(00)80713-8; Yamaguchi Y, 1999, J BIOL CHEM, V274, P8085, DOI 10.1074/jbc.274.12.8085; YANKULOV K, 1995, J BIOL CHEM, V270, P23922, DOI 10.1074/jbc.270.41.23922; Zhou Q, 1998, EMBO J, V17, P3681, DOI 10.1093/emboj/17.13.3681; ZHOU QA, 1995, EMBO J, V14, P321, DOI 10.1002/j.1460-2075.1995.tb07006.x; Zhou QA, 1996, SCIENCE, V274, P605, DOI 10.1126/science.274.5287.605; Zhu YR, 1997, GENE DEV, V11, P2622, DOI 10.1101/gad.11.20.2622	60	152	157	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 13	2001	276	15					12317	12323		10.1074/jbc.M010908200	http://dx.doi.org/10.1074/jbc.M010908200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	421UK	11145967	hybrid			2022-12-25	WOS:000168081800117
J	Diana, F; Sgarra, R; Manfioletti, G; Rustighi, A; Poletto, D; Sciortino, MT; Mastino, A; Giancotti, V				Diana, F; Sgarra, R; Manfioletti, G; Rustighi, A; Poletto, D; Sciortino, MT; Mastino, A; Giancotti, V			A link between apoptosis and degree of phosphorylation of high mobility group A1a protein in leukemic cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HISTONE H1; IN-VIVO; CHROMATIN CONDENSATION; DNA FRAGMENTATION; NUCLEAR PROTEINS; CDC2 KINASE; HMG-I; BINDING; EXPRESSION; ACTIVATION	Nuclear phosphoprotein HMGA1a, high mobility group A1a, (previously HMGI) has been investigated during apoptosis. A change in the degree of phosphorylation of HMGA1a has been observed during apoptosis induced in four leukemic cell lines (HL60, K562, NB4, and U937) by drugs (etoposide, camptothecin) or herpes simplex virus type-1. Both hyper-phosphorylation and de-phosphorylation of HMGA1a have been ascertained by liquid chromatography-mass spectrometry. Hyperphosphorylation (at least five phosphate groups/ HMGA1a molecule) occurs at the early apoptotic stages and is probably related to HMGA1a displacement from DNA and chromatin release from the nuclear scaffold. De-phosphorylation (one phosphate or no phosphate groups/HMGA1a molecule) accompanies the later formation of highly condensed chromatin in the apoptotic bodies. We report for the first time a direct link between the degree of phosphorylation of HMGA1a protein and apoptosis according to a process that involves the entire amount of HMGA1a present in the cells and, consequently, whole chromatin. At the same time we report that variously phosphorylated forms of HMGA1a protein are also mono-methylated.	Univ Trieste, Dipartimento Biochim Biofis & Chim Macromol, I-34127 Trieste, Italy; Ctr Riferimento Oncol, I-33081 Aviano, Italy; Univ Messina, Dipartimento Sci Microbiol Genet & Mol, I-98100 Messina, Italy	University of Trieste; IRCCS Aviano (CRO); University of Messina	Giancotti, V (corresponding author), Univ Trieste, Dipartimento Biochim Biofis & Chim Macromol, Via Licio Giorgieri, I-34127 Trieste, Italy.	giancot@bbcm.univ.trieste.it	Sciortino, Maria Teresa/B-9425-2012; Mastino, Antonio/A-4686-2008	Sciortino, Maria Teresa/0000-0002-8519-7724; Mastino, Antonio/0000-0002-0338-6450; MANFIOLETTI, GUIDALBERTO/0000-0001-7913-2601; Sgarra, Riccardo/0000-0002-4496-2856				Ajiro K, 2000, J BIOL CHEM, V275, P439, DOI 10.1074/jbc.275.1.439; Bandiera A, 1998, CANCER RES, V58, P426; Banks GC, 2000, BIOCHEMISTRY-US, V39, P8333, DOI 10.1021/bi000378+; Bosman FT, 1999, VIRCHOWS ARCH, V435, P391, DOI 10.1007/s004280050416; Brunetti A, 2001, FASEB J, V15, P492, DOI 10.1096/fj.00-0190com; Bustin M, 1999, MOL CELL BIOL, V19, P5237; BUSTIN M, 1996, PROG NUCL ACIDS RES, V84, pS35; Chiappetta G, 1998, CANCER RES, V58, P4193; Chiappetta G, 1996, ONCOGENE, V13, P2439; Choi KS, 1999, J BIOL CHEM, V274, P31775, DOI 10.1074/jbc.274.45.31775; DELBINO G, 1991, EXP CELL RES, V193, P27, DOI 10.1016/0014-4827(91)90534-2; FERRANTI P, 1992, J BIOL CHEM, V267, P22486; FROELICHAMMON SJ, 1995, J BIOL CHEM, V270, P21429, DOI 10.1074/jbc.270.37.21429; GIANCOTTI V, 1993, EUR J BIOCHEM, V213, P825, DOI 10.1111/j.1432-1033.1993.tb17825.x; GIANCOTTI V, 1991, EUR J BIOCHEM, V198, P211, DOI 10.1111/j.1432-1033.1991.tb16003.x; GIANCOTTI V, 1985, CANCER RES, V45, P6051; GIANCOTTI V, 1989, EXP CELL RES, V184, P538, DOI 10.1016/0014-4827(89)90352-2; GIANCOTTI V, 1987, EMBO J, V6, P1981, DOI 10.1002/j.1460-2075.1987.tb02461.x; Giancotti V, 1996, BIOCHEM J, V317, P865, DOI 10.1042/bj3170865; Gohring F, 1997, BIOCHEMISTRY-US, V36, P8276, DOI 10.1021/bi970480f; Hendzel MJ, 1998, J BIOL CHEM, V273, P24470, DOI 10.1074/jbc.273.38.24470; Hill DA, 1999, NUCLEIC ACIDS RES, V27, P2135, DOI 10.1093/nar/27.10.2135; Huth JR, 1997, NAT STRUCT BIOL, V4, P657, DOI 10.1038/nsb0897-657; JANSEN E, 1999, GENE THER MOL BIOL, V3, P387; Johns EW, 1982, HMG CHROMOSOMAL PROT; JOHNSON KR, 1988, J BIOL CHEM, V263, P18338; KAS E, 1992, EMBO J, V11, P705, DOI 10.1002/j.1460-2075.1992.tb05103.x; Kratzmeier M, 2000, J BIOL CHEM, V275, P30478, DOI 10.1074/jbc.M003956200; Liu WM, 1999, CANCER RES, V59, P5695; MANFIOLETTI G, 1991, NUCLEIC ACIDS RES, V19, P6793, DOI 10.1093/nar/19.24.6793; Mantovani F, 1998, NUCLEIC ACIDS RES, V26, P1433, DOI 10.1093/nar/26.6.1433; Martelli AM, 1998, J HISTOCHEM CYTOCHEM, V46, P863, DOI 10.1177/002215549804600710; Martins LM, 1997, BLOOD, V90, P4283, DOI 10.1182/blood.V90.11.4283.4283_4283_4296; Martins LM, 1998, BLOOD, V92, P3042, DOI 10.1182/blood.V92.9.3042.421k55_3042_3049; MARUSHIGE Y, 1995, ANTICANCER RES, V15, P267; Mastino A, 1997, CELL DEATH DIFFER, V4, P629, DOI 10.1038/sj.cdd.4400289; Morana SJ, 1996, J BIOL CHEM, V271, P18263, DOI 10.1074/jbc.271.30.18263; NISSEN MS, 1991, J BIOL CHEM, V266, P19945; PALVIMO J, 1989, FEBS LETT, V257, P101, DOI 10.1016/0014-5793(89)81796-X; Pronk GJ, 1996, SCIENCE, V271, P808, DOI 10.1126/science.271.5250.808; REEVES R, 1991, P NATL ACAD SCI USA, V88, P1671, DOI 10.1073/pnas.88.5.1671; Rogakou EP, 2000, J BIOL CHEM, V275, P9390, DOI 10.1074/jbc.275.13.9390; Schwanbeck R, 1997, J BIOL CHEM, V272, P27476, DOI 10.1074/jbc.272.43.27476; Shao RG, 1997, J BIOL CHEM, V272, P31321, DOI 10.1074/jbc.272.50.31321; SHIBATA K, 1993, J BIOL CHEM, V268, P18431; SHIBATA K, 1990, EUR J BIOCHEM, V192, P87, DOI 10.1111/j.1432-1033.1990.tb19199.x; Slee EA, 1996, BIOCHEM J, V315, P21, DOI 10.1042/bj3150021; Sun XM, 1999, J BIOL CHEM, V274, P5053, DOI 10.1074/jbc.274.8.5053; WANG DZ, 1995, J BIOL CHEM, V270, P22924, DOI 10.1074/jbc.270.39.22924; Widmann C, 1998, J BIOL CHEM, V273, P7141, DOI 10.1074/jbc.273.12.7141; Wilm M, 1996, ANAL CHEM, V68, P1, DOI 10.1021/ac9509519; Wolffe A., 1998, CHROMATIN STRUCTURE; Xiao DM, 2000, J NEUROCHEM, V74, P392, DOI 10.1046/j.1471-4159.2000.0740392.x; Yoshida M, 1997, EXP CELL RES, V232, P225, DOI 10.1006/excr.1997.3538; ZHAO K, 1993, EMBO J, V12, P3237, DOI 10.1002/j.1460-2075.1993.tb05993.x; Zhou X, 1998, Keio J Med, V47, P73; Zhu N, 1997, ANAL BIOCHEM, V246, P155, DOI 10.1006/abio.1997.2018	57	47	48	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 6	2001	276	14					11354	11361		10.1074/jbc.M009521200	http://dx.doi.org/10.1074/jbc.M009521200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	420AC	11145960	hybrid			2022-12-25	WOS:000167980900105
J	Linderoth, NA; Simon, MN; Hainfeld, JF; Sastry, S				Linderoth, NA; Simon, MN; Hainfeld, JF; Sastry, S			Binding of antigenic peptide to the endoplasmic reticulum-resident protein gp96/GRP94 heat shock chaperone occurs in higher order complexes - Essential role of some aromatic amino acid residues in the peptide-binding site	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURES; SH2 DOMAIN; GP96 GRP94; HSP90; RECEPTOR; FAMILY; FORMS; DNA	Vaccination with heat shock protein gp96-antigenic peptide complexes produces a powerful specific immune response against cancers and infectious diseases in some experimental animal models, and gp96-peptide complexes are now being tested in human clinical trials. gp96 appears to serve as a natural adjuvant for chaperoning antigenic peptides into the immune surveillance pathways. A fundamental issue that needs to be addressed is the mechanism of binding of antigenic peptide to gp96, Here, we show using scanning transmission electron microscopy that recombinant gp96 binds peptide in stable multimeric complexes, which may have biological significance. To open the possibility for genetically engineering gp96 for improved immunogenicity and to understand if molecular recognition plays a role in the binding of antigenic peptide, we mutagenized some specific aromatic amino acids in the presumed peptide-binding pocket. Replacement of Tyr-667 or Tyr-678 to Ala reduced affinity for peptide whereas conversion of Trp-654 to Tyr increased peptide binding. Similarly, changing Trp-621 to Phe or Leu or Ala or lie negatively affected peptide binding whereas changing Trp-621 to Tyr or Val positively affected peptide binding, Probing the peptide microenvironment in gp86-peptide complexes, suggested that hydrophobic interactions land perhaps hydrogen bonding/stacking interactions) may play a role in peptide loading by gp96.	Rockefeller Univ, Mol Genet Lab, New York, NY 10021 USA; Brookhaven Natl Lab, Dept Biol, Upton, NY 11973 USA	Rockefeller University; United States Department of Energy (DOE); Brookhaven National Laboratory	Sastry, S (corresponding author), Rockefeller Univ, Mol Genet Lab, 1230 York Ave, New York, NY 10021 USA.	sastrys@rockvax.rockefeller.edu			NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR001777] Funding Source: NIH RePORTER; NCRR NIH HHS [P41-RR01777] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Arnold-Schild D, 1999, J IMMUNOL, V162, P3757; Binder RJ, 2000, NAT IMMUNOL, V1, P151, DOI 10.1038/77835; Blachere NE, 1997, J EXP MED, V186, P1315, DOI 10.1084/jem.186.8.1315; Csermely P, 1998, PHARMACOL THERAPEUT, V79, P129, DOI 10.1016/S0163-7258(98)00013-8; Gregori L, 1997, J BIOL CHEM, V272, P58; GUPTA RS, 1995, MOL BIOL EVOL, V12, P1063; Ishii T, 1999, J IMMUNOL, V162, P1303; KOCH G, 1986, J CELL SCI, V86, P217; KUNKEL TA, 1991, METHOD ENZYMOL, V204, P125; LAKOWICZ JR, 1983, PRINCIPLES FLUORESCE, V10, P128; LEE CH, 1994, STRUCTURE, V2, P423, DOI 10.1016/S0969-2126(00)00044-7; Linderoth NA, 2001, BIOCHEMISTRY-US, V40, P1483, DOI 10.1021/bi0016218; Linderoth NA, 2000, J BIOL CHEM, V275, P5472, DOI 10.1074/jbc.275.8.5472; MINAMI Y, 1991, J BIOL CHEM, V266, P10099; MINAMI Y, 1994, MOL CELL BIOL, V14, P1459, DOI 10.1128/MCB.14.2.1459; MINAMI Y, 1993, J BIOL CHEM, V268, P9604; Nicchitta CV, 1998, CURR OPIN IMMUNOL, V10, P103, DOI 10.1016/S0952-7915(98)80039-3; Sastry S, 1999, J BIOL CHEM, V274, P12023, DOI 10.1074/jbc.274.17.12023; Soti C, 1998, Pathol Oncol Res, V4, P316; Srivastava PK, 1998, IMMUNITY, V8, P657, DOI 10.1016/S1074-7613(00)80570-1; SRIVASTAVA PK, 1994, IMMUNOGENETICS, V39, P93; STANFIELD RL, 1995, CURR OPIN STRUC BIOL, V5, P103, DOI 10.1016/0959-440X(95)80015-S; SUTO R, 1995, SCIENCE, V269, P1585, DOI 10.1126/science.7545313; Tamura Y, 1997, SCIENCE, V278, P117, DOI 10.1126/science.278.5335.117; WACHSMAN JT, 1987, GENETICS, V115, P405; WAKSMAN G, 1993, CELL, V72, P779, DOI 10.1016/0092-8674(93)90405-F; Wall JS, 1998, METHOD CELL BIOL, V53, P139; WALL JS, 1986, ANNU REV BIOPHYS BIO, V15, P355; Wassenberg JJ, 1999, J CELL SCI, V112, P2167; Wearsch PA, 1998, BIOCHEMISTRY-US, V37, P5709, DOI 10.1021/bi9801006; Wearsch PA, 1996, BIOCHEMISTRY-US, V35, P16760, DOI 10.1021/bi962068q; WELCH WJ, 1982, J BIOL CHEM, V257, P4949; ZHANG WG, 1992, P NATL ACAD SCI USA, V89, P8403, DOI 10.1073/pnas.89.17.8403	33	20	21	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 6	2001	276	14					11049	11054		10.1074/jbc.M010059200	http://dx.doi.org/10.1074/jbc.M010059200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	420AC	11148208	hybrid			2022-12-25	WOS:000167980900065
J	Campbell, RA; Bhat-Nakshatri, P; Patel, NM; Constantinidou, D; Ali, S; Nakshatri, H				Campbell, RA; Bhat-Nakshatri, P; Patel, NM; Constantinidou, D; Ali, S; Nakshatri, H			Phosphatidylinositol 3-kinase/AKT-mediated activation of estrogen receptor alpha - A new model for anti-estrogen resistance	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BREAST-CANCER CELLS; TRANSCRIPTIONAL ACTIVATION; SIGNAL-TRANSDUCTION; BCL-2 EXPRESSION; GENE-EXPRESSION; BINDING PROTEIN; KINASE-B; PHOSPHORYLATION; TAMOXIFEN; 3-KINASE	Estrogen receptors (ERs) mediate most of the biological effects of estrogen in mammary and uterine epithelial cells by binding to estrogen response elements in the promoter region of target genes or through protein-protein interactions. Anti-estrogens such as tamoxifen inhibit the growth of ER-positive breast cancers by reducing the expression of estrogen-regulated genes. However, anti-estrogen-resistant growth of ER-positive tumors remains a significant clinical problem. Here we show that phosphatidylinositol (PI) 3-kinase and AKT activate ER alpha in the absence of estrogen. Although PI 3-kinase increased the activity of both estrogen-independent activation function 1 (AF-1) and estrogen-dependent activation function 2 (AF-2) of ER alpha, AKT increased the activity of only AF-1, PTEN and a catalytically inactive AKT decreased PI 3-kinase-induced AF-1 activity, suggesting that PI I-kinase utilizes AKT-dependent and AKT-independent pathways in activating ER alpha. The consensus AKT phosphorylation site Ser-167 of ER alpha is required for phosphorylation and activation by AKT, In addition, LY294002, a specific inhibitor of the PI 3-kinase/AKT pathway, reduced phosphorylation of ER alpha in vivo, Moreover, AKT overexpression led to up-regulation of estrogen-regulated pS2 gene, Bcl-2, and macrophage inhibitory cytokine 1. We demonstrate that AKT protects breast cancer cells from tamoxifen-induced apoptosis. Taken together, these results define a molecular link between activation of the PI3-kinase/AKT survival pathways, hormone-independent activation of ER alpha, and inhibition of tamoxifen-induced apoptotic regression.	Indiana Univ, Sch Med, Dept Surg, Indianapolis, IN 46202 USA; Indiana Univ, Sch Med, Dept Biochem & Mol Biol, Indianapolis, IN 46202 USA; Indiana Univ, Sch Med, Walther Oncol Ctr, Indianapolis, IN 46202 USA; Hammersmith Hosp, Dept Canc Med, Imperial Coll Sch Med, London W12 0NN, England	Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; Walther Cancer Institute; Imperial College London	Nakshatri, H (corresponding author), Indiana Canc Res Inst, R4-202,1044 W Walnut St, Indianapolis, IN 46202 USA.		Ali, Simak/M-6912-2018	Ali, Simak/0000-0002-1320-0816; Nakshatri, Harikrishna/0000-0001-8876-0052; Coombes, Raoul Charles/0000-0002-4811-1100				Akimoto K, 1996, EMBO J, V15, P788, DOI 10.1002/j.1460-2075.1996.tb00414.x; ARNOLD SF, 1994, MOL ENDOCRINOL, V8, P1208, DOI 10.1210/me.8.9.1208; BELLACOSA A, 1995, INT J CANCER, V64, P280, DOI 10.1002/ijc.2910640412; BERRY M, 1989, P NATL ACAD SCI USA, V86, P1218, DOI 10.1073/pnas.86.4.1218; Bunone G, 1996, EMBO J, V15, P2174, DOI 10.1002/j.1460-2075.1996.tb00571.x; Bursch W, 1996, CARCINOGENESIS, V17, P1595, DOI 10.1093/carcin/17.8.1595; Cantley LC, 1999, P NATL ACAD SCI USA, V96, P4240, DOI 10.1073/pnas.96.8.4240; Chien PY, 1999, MOL ENDOCRINOL, V13, P2122, DOI 10.1210/me.13.12.2122; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; DAUVOIS S, 1993, J CELL SCI, V106, P1377; de Haan G, 2000, J BIOL CHEM, V275, P13493, DOI 10.1074/jbc.275.18.13493; de Mora JF, 2000, MOL CELL BIOL, V20, P5041, DOI 10.1128/MCB.20.14.5041-5047.2000; Dong LA, 1999, J BIOL CHEM, V274, P32099, DOI 10.1074/jbc.274.45.32099; Dupont J, 2000, J BIOL CHEM, V275, P35893, DOI 10.1074/jbc.M006741200; Elledge RM, 1997, J CLIN ONCOL, V15, P1916, DOI 10.1200/JCO.1997.15.5.1916; Endoh H, 1999, MOL CELL BIOL, V19, P5363; Fairlie WD, 1999, J LEUKOCYTE BIOL, V65, P2, DOI 10.1002/jlb.65.1.2; Frodin M, 1999, MOL CELL ENDOCRINOL, V151, P65, DOI 10.1016/S0303-7207(99)00061-1; Glass CK, 2000, GENE DEV, V14, P121; Hyder SM, 1999, BIOCHEM PHARMACOL, V57, P597, DOI 10.1016/S0006-2952(98)00355-4; Joel PB, 1998, MOL CELL BIOL, V18, P1978, DOI 10.1128/MCB.18.4.1978; Johnston SRD, 1997, ANTI-CANCER DRUG, V8, P911, DOI 10.1097/00001813-199711000-00002; Kahlert S, 2000, J BIOL CHEM, V275, P18447, DOI 10.1074/jbc.M910345199; KATO S, 1995, SCIENCE, V270, P1491, DOI 10.1126/science.270.5241.1491; Klippel A, 1996, MOL CELL BIOL, V16, P4117; Kuiper GGJM, 1996, P NATL ACAD SCI USA, V93, P5925, DOI 10.1073/pnas.93.12.5925; Kumar R, 1996, CLIN CANCER RES, V2, P1215; Lavinsky RM, 1998, P NATL ACAD SCI USA, V95, P2920, DOI 10.1073/pnas.95.6.2920; Lee AV, 1995, BIOMED PHARMACOTHER, V49, P415, DOI 10.1016/0753-3322(96)82678-3; Liaw D, 1997, NAT GENET, V16, P64, DOI 10.1038/ng0597-64; Lupu R, 1996, BREAST CANCER RES TR, V38, P57, DOI 10.1007/BF01803784; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; METZGER D, 1995, J BIOL CHEM, V270, P9535, DOI 10.1074/jbc.270.16.9535; Nakatani K, 1999, J BIOL CHEM, V274, P21528, DOI 10.1074/jbc.274.31.21528; NAKSHATRI H, 1994, J BIOL CHEM, V269, P890; Pace P, 1997, J BIOL CHEM, V272, P25832, DOI 10.1074/jbc.272.41.25832; Perillo B, 2000, MOL CELL BIOL, V20, P2890, DOI 10.1128/MCB.20.8.2890-2901.2000; Pugazhenthi S, 2000, J BIOL CHEM, V275, P10761, DOI 10.1074/jbc.275.15.10761; Rameh LE, 1999, J BIOL CHEM, V274, P8347, DOI 10.1074/jbc.274.13.8347; Rogatsky I, 1999, J BIOL CHEM, V274, P22296, DOI 10.1074/jbc.274.32.22296; Shayesteh L, 1999, NAT GENET, V21, P99, DOI 10.1038/5042; Simoncini T, 2000, NATURE, V407, P538, DOI 10.1038/35035131; Skov S, 1998, TISSUE ANTIGENS, V51, P215; Tonks NK, 1999, SCIENCE, V286, P2096, DOI 10.1126/science.286.5447.2096; Vander Heiden MG, 1999, NAT CELL BIOL, V1, pE209, DOI 10.1038/70237; Zimmermann S, 1999, SCIENCE, V286, P1741, DOI 10.1126/science.286.5445.1741	47	743	775	1	40	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 30	2001	276	13					9817	9824		10.1074/jbc.M010840200	http://dx.doi.org/10.1074/jbc.M010840200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	420GC	11139588	hybrid, Green Published			2022-12-25	WOS:000167996400033
J	Jones, PL; Sachs, LM; Rouse, N; Wade, PA; Shi, YB				Jones, PL; Sachs, LM; Rouse, N; Wade, PA; Shi, YB			Multiple N-CoR complexes contain distinct histone deacetylases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THYROID-HORMONE RECEPTOR; TRANSCRIPTIONAL REPRESSION; COREPRESSOR COMPLEX; YEAST; GENE; SMRT; INTERACTS; COMPONENT; MSIN3	N-CoR (nuclear receptor corepressor) is a corepressor for multiple transcription factors including unliganded thyroid hormone receptors (TRs). In vitro, N-CoR can interact with the Sin3 corepressor, which in turn binds to the histone deacetylase Rpd3 (HDAC1), predicting the existence of a corepressor complex containing N-CoR, Sin3, and histone deacetylase. However, previous biochemical studies of endogenous Sin3 complexes have failed to find an N CoR association. Xenopus laevis eggs and oocytes contain all of the necessary components for transcriptional repression by unliganded TRs. In this study, we report the biochemical fractionation of three novel macromolecular complexes containing N-CoR, two of which possess histone deacetylase activity, from Xenopus egg extract. One complex contains Sin3, Rpd3, and RbAp48; the second complex contains a Sin3-independent histone deacetylase; and the third complex lacks histone deacetylase activity. This study describes the first biochemical isolation of endogenous N-CoR-containing HDAC complexes and illustrates that N-CoR associates with distinct histone deacetylases that are both dependent and independent of Sin3. Immunoprecipitation studies show that N-CoR binds to unliganded TR expressed in the frog oocyte, confirming that N-CoR complexes are involved in repression by unliganded TR. These results suggest that N-CoR targets transcriptional repression of specific promoters through at least two distinct histone deacetylase pathways.	NICHD, UMM, LME, NIH, Bethesda, MD 20892 USA; Emory Univ, Dept Pathol, Atlanta, GA 30322 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); Emory University	Shi, YB (corresponding author), NICHD, UMM, LME, NIH, Bldg 18T,Rm 106, Bethesda, MD 20892 USA.	Shi@helix.nih.gov	Sachs, Laurent/AAE-1504-2020; Wade, Paul A/D-2374-2019	Wade, Paul A/0000-0002-6042-357X; Shi, Yun-Bo/0000-0002-6330-0639	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [ZIAHD001901] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD001901] Funding Source: NIH RePORTER	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Alland L, 1997, NATURE, V387, P49, DOI 10.1038/387049a0; CHEN JD, 1995, NATURE, V377, P454, DOI 10.1038/377454a0; Collingwood TN, 1999, J MOL ENDOCRINOL, V23, P255, DOI 10.1677/jme.0.0230255; Fischle W, 1999, J BIOL CHEM, V274, P11713, DOI 10.1074/jbc.274.17.11713; Glass CK, 2000, GENE DEV, V14, P121; Grozinger CM, 1999, P NATL ACAD SCI USA, V96, P4868, DOI 10.1073/pnas.96.9.4868; Guenther MG, 2000, GENE DEV, V14, P1048; Harlow E, 1999, USING ANTIBODIES LAB, P321; Hassig CA, 1997, CELL, V89, P341, DOI 10.1016/S0092-8674(00)80214-7; Heinzel T, 1997, NATURE, V387, P43, DOI 10.1038/387043a0; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; Hu X, 2000, TRENDS ENDOCRIN MET, V11, P6, DOI 10.1016/S1043-2760(99)00215-5; Huang EY, 2000, GENE DEV, V14, P45; Imhof A, 1998, CURR BIOL, V8, pR422, DOI 10.1016/S0960-9822(98)70268-4; Jepsen K, 2000, CELL, V102, P753, DOI 10.1016/S0092-8674(00)00064-7; Jones PL, 1998, NAT GENET, V19, P187, DOI 10.1038/561; Kao HY, 2000, GENE DEV, V14, P55; Laherty CD, 1998, MOL CELL, V2, P33, DOI 10.1016/S1097-2765(00)80111-2; Lemercier C, 2000, J BIOL CHEM, V275, P15594, DOI 10.1074/jbc.M908437199; Li JW, 2000, EMBO J, V19, P4342, DOI 10.1093/emboj/19.16.4342; Nicolas E, 2000, J BIOL CHEM, V275, P9797, DOI 10.1074/jbc.275.13.9797; Parthun MR, 1996, CELL, V87, P85, DOI 10.1016/S0092-8674(00)81325-2; QIAN YW, 1993, NATURE, V364, P648, DOI 10.1038/364648a0; Rundlett SE, 1996, P NATL ACAD SCI USA, V93, P14503, DOI 10.1073/pnas.93.25.14503; Vermaak D, 1999, MOL CELL BIOL, V19, P5847; Wade PA, 1998, CURR BIOL, V8, P843, DOI 10.1016/S0960-9822(98)70328-8; WADE PA, 1998, METHODS ENZYMOL; Wen YD, 2000, P NATL ACAD SCI USA, V97, P7202, DOI 10.1073/pnas.97.13.7202; WONG JM, 1995, GENE DEV, V9, P2696, DOI 10.1101/gad.9.21.2696; Wong JM, 1998, EMBO J, V17, P520, DOI 10.1093/emboj/17.2.520; Wong JM, 1997, EMBO J, V16, P3158, DOI 10.1093/emboj/16.11.3158; Yang WM, 1997, J BIOL CHEM, V272, P28001, DOI 10.1074/jbc.272.44.28001; Zhang Y, 1998, CELL, V95, P279, DOI 10.1016/S0092-8674(00)81758-4; Zhang Y, 1997, CELL, V89, P357, DOI 10.1016/S0092-8674(00)80216-0	34	80	83	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 23	2001	276	12					8807	8811		10.1074/jbc.C000879200	http://dx.doi.org/10.1074/jbc.C000879200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	413HV	11254656	hybrid			2022-12-25	WOS:000167607700027
J	Deaglio, S; Mallone, R; Baj, G; Donati, D; Giraudo, G; Corno, F; Bruzzone, S; Guena, M; Ausiello, C; Malavasi, F				Deaglio, S; Mallone, R; Baj, G; Donati, D; Giraudo, G; Corno, F; Bruzzone, S; Guena, M; Ausiello, C; Malavasi, F			Human CD38 and its ligand CD31 define a unique lamina propria T lymphocyte signaling pathway	FASEB JOURNAL			English	Article									Univ Turin, Sch Med, Dept Genet Biol & Biochem, Immunogenet Lab, I-10126 Turin, Italy; Univ Turin, Sch Med, Surg Clin 1, I-10126 Turin, Italy; Univ Turin, Sch Med, IRCC, Clin Immunol Lab, I-10126 Turin, Italy; Univ Genoa, Dept Expt Med, Biochem Sect, Genoa, Italy; Natl Inst Hlth, ISS, Rome, Italy	University of Turin; University of Turin; University of Turin; University of Genoa; Istituto Superiore di Sanita (ISS)	Malavasi, F (corresponding author), Univ Turin, Sch Med, Dept Genet Biol & Biochem, Immunogenet Lab, Via Santena 19, I-10126 Turin, Italy.		Bruzzone, Santina/A-4264-2015; Ausiello, Clara/G-3232-2011; Mallone, Roberto/H-4430-2013	Bruzzone, Santina/0000-0003-2034-3716; Mallone, Roberto/0000-0002-9846-8861; MALAVASI, Fabio/0000-0002-1844-174X; Geuna, Massimo/0000-0002-6475-5547	Telethon [E.0662] Funding Source: Medline	Telethon(Fondazione Telethon)			0	31	32	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAR	2001	15	3					580	582						3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	410BE	11259373				2022-12-25	WOS:000167419500011
J	Johnson, CA; Padget, K; Austin, CA; Turner, BM				Johnson, CA; Padget, K; Austin, CA; Turner, BM			Deacetylase activity associates with topoisomerase II and is necessary for etoposide-induced apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HISTONE DEACETYLASE; TRANSCRIPTIONAL REPRESSION; COMPLEX; CHROMATIN; BETA; CONDENSATION; ACETYLATION; EXPRESSION; MECHANISM; INTERACTS	DNA topoisomerase II (topo II) is a ubiquitous nuclear enzyme that is involved in DNA replication, transcription, chromosome segregation, and apoptosis, Here we show by immunoprecipitation, pull down with glutathione S-transferase fusion proteins, and yeast two-hybrid analysis that both topo II alpha and -beta physically interact with the histone deacetylase HDAC1. The in vitro DNA decatenation activity of recombinant topo II alpha and -beta is inhibited by association with catalytically inactive, recombinant HDAC1. We provide evidence for the in vivo significance of the topo II-HDAC1 association, showing that inhibition of HDAC activity with trichostatin A suppresses apoptosis induced by the topo II poison etoposide, but not by the topoisomerase I inhibitor camptothecin, We suggest that chromatin remodeling by an HDAC-containing complex facilitates both topo II-catalyzed DNA rearrangement and etoposide-induced DNA damage in vivo.	Univ Birmingham, Dept Anat, Chromatin & Gene Express Grp, Birmingham B15 2TT, W Midlands, England; Univ Newcastle Upon Tyne, Sch Med, Sch Biochem & Genet, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England	University of Birmingham; Newcastle University - UK	Turner, BM (corresponding author), Univ Birmingham, Dept Anat, Chromatin & Gene Express Grp, Birmingham B15 2TT, W Midlands, England.			Johnson, Colin/0000-0002-2979-8234; Austin, Caroline/0000-0002-1921-5947				Allera C, 1997, J BIOL CHEM, V272, P10817; AUSTIN CA, 1995, J BIOL CHEM, V270, P15739, DOI 10.1074/jbc.270.26.15739; Austin CA, 1998, BIOESSAYS, V20, P215, DOI 10.1002/(SICI)1521-1878(199803)20:3<215::AID-BIES5>3.0.CO;2-Q; BARTEL PL, 1995, METHOD ENZYMOL, V254, P241; Brehm A, 1998, NATURE, V391, P597, DOI 10.1038/35404; Burden DA, 1998, BBA-GENE STRUCT EXPR, V1400, P139, DOI 10.1016/S0167-4781(98)00132-8; Cowell IG, 2000, EXP CELL RES, V255, P86, DOI 10.1006/excr.1999.4772; Cowell IG, 1998, EXP CELL RES, V243, P232, DOI 10.1006/excr.1998.4150; Durrieu F, 2000, CURR BIOL, V10, P923, DOI 10.1016/S0960-9822(00)00620-5; Earnshaw WC, 1999, ANNU REV BIOCHEM, V68, P383, DOI 10.1146/annurev.biochem.68.1.383; FROELICHAMMON SJ, 1995, J BIOL CHEM, V270, P21429, DOI 10.1074/jbc.270.37.21429; Green DR, 2000, CELL, V102, P1, DOI 10.1016/S0092-8674(00)00003-9; Ikura T, 2000, CELL, V102, P463, DOI 10.1016/S0092-8674(00)00051-9; Johnson CA, 1999, SEMIN CELL DEV BIOL, V10, P179, DOI 10.1006/scdb.1999.0299; Kaufmann SH, 2000, EXP CELL RES, V256, P42, DOI 10.1006/excr.2000.4838; Kratzmeier M, 2000, J BIOL CHEM, V275, P30478, DOI 10.1074/jbc.M003956200; Murphy M, 1999, GENE DEV, V13, P2490, DOI 10.1101/gad.13.19.2490; Nan XS, 1998, NATURE, V393, P386, DOI 10.1038/30764; Ng HH, 2000, TRENDS BIOCHEM SCI, V25, P121; Struhl K, 1998, GENE DEV, V12, P599, DOI 10.1101/gad.12.5.599; Taunton J, 1996, SCIENCE, V272, P408, DOI 10.1126/science.272.5260.408; Tsai SC, 2000, NAT GENET, V26, P349, DOI 10.1038/81671; VERMES I, 1995, J IMMUNOL METHODS, V184, P39, DOI 10.1016/0022-1759(95)00072-I; Wade PA, 1999, NAT GENET, V23, P62, DOI 10.1038/12664; Wang JC, 1996, ANNU REV BIOCHEM, V65, P635, DOI 10.1146/annurev.bi.65.070196.003223; WHITE DA, 1999, METHODS COMPANION ME, V10, P417; YOSHIDA M, 1995, BIOESSAYS, V17, P423, DOI 10.1002/bies.950170510; Zhang Y, 1998, CELL, V95, P279, DOI 10.1016/S0092-8674(00)81758-4	28	77	87	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 16	2001	276	7					4539	4542		10.1074/jbc.C000824200	http://dx.doi.org/10.1074/jbc.C000824200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	428WH	11136718	hybrid			2022-12-25	WOS:000168484300004
J	Bateman, RL; Bhanumoorthy, P; Witte, JF; McClard, RW; Grompe, M; Timm, DE				Bateman, RL; Bhanumoorthy, P; Witte, JF; McClard, RW; Grompe, M; Timm, DE			Mechanistic inferences from the crystal structure of fumarylacetoacetate hydrolase with a bound phosphorus-based inhibitors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINEMIA TYPE-I; STATE ANALOG INHIBITORS; LETHAL ALBINO MICE; HEREDITARY TYROSINEMIA; 4-HYDROXYPHENYLPYRUVATE DIOXYGENASE; HEPATIC-DYSFUNCTION; MURINE MODEL; GENE-THERAPY; ENZYME; HEPATOCYTES	Fumarylacetoacetate hydrolase (FAH) catalyzes the hydrolytic cleavage of a carbon-carbon bond in fumarylacetoacetate to yield fumarate and acetoacetate as the final step of Phe and Tyr degradation. This unusual reaction is an essential human metabolic function, with loss of FAH activity causing the fatal metabolic disease hereditary tyrosinemia type I (HT1), An enzymatic mechanism involving a catalytic metal ion, a Glu/His catalytic dyed, and a charged oxyanion hole was previously proposed based on recently determined FAH crystal structures. Here we report the development and characterization of an FAH inhibitor, 4-(hydroxymethylphosphinoyl)-3-oxo-butanoic acid (HMPOBA), that competes with the physiological substrate with a K-i of 85 muM. The crystal structure of FAH complexed with HMPOBA refined at 1.3-Angstrom resolution reveals the molecular basis for the competitive inhibition, supports the proposed formation of a tetrahedral alkoxy transition state intermediate during the FAH catalyzed reaction, and reveals a Mg2+ bound in the enzyme's active site. The analysis of FAH structures corresponding to different catalytic states reveals significant active site sidechain motions that may also be related to catalytic function. Thus, these results advance the understanding of an essential catabolic reaction associated with a fatal metabolic disease and provide insight into the structure-based development of FAH inhibitors.	Indiana Univ, Dept Biochem, Indianapolis, IN 46202 USA; Oregon Hlth Sci Univ, Dept Mol & Med Genet, Portland, OR 97201 USA; Reed Coll, Dept Chem, Portland, OR 97202 USA	Indiana University System; Indiana University-Purdue University Indianapolis; Oregon Health & Science University; Reed College - Oregon	Timm, DE (corresponding author), Indiana Univ, Dept Biochem, Indianapolis, IN 46202 USA.			Grompe, Markus/0000-0002-6616-4345				Ames B. N., 1966, METHOD ENZYMOL, P115, DOI DOI 10.1016/0076-6879(66)08014-5; BARTLETT PA, 1983, BIOCHEMISTRY-US, V22, P4618, DOI 10.1021/bi00289a002; BrUnger A. T., 1992, X PLOR VERSION 3 1 S; *CCP4, 1979, SERC UK COLL COMP PR; DIAZ E, 1995, J BIOL CHEM, V270, P6403, DOI 10.1074/jbc.270.11.6403; Endo F, 1997, J BIOL CHEM, V272, P24426, DOI 10.1074/jbc.272.39.24426; FRASER ME, 1992, BIOCHEMISTRY-US, V31, P5201, DOI 10.1021/bi00137a016; GILBERT-BARNESS E, 1990, Pediatric Pathology, V10, P243; GROMPE M, 1993, GENE DEV, V7, P2298, DOI 10.1101/gad.7.12a.2298; GROMPE M, 1995, NAT GENET, V10, P453, DOI 10.1038/ng0895-453; HANSON JE, 1989, BIOCHEMISTRY-US, V28, P6294, DOI 10.1021/bi00441a022; Harding MM, 1999, ACTA CRYSTALLOGR D, V55, P1432, DOI 10.1107/S0907444999007374; HSIANG HH, 1972, BIOCHEMISTRY-US, V11, P2098, DOI 10.1021/bi00761a016; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Jorquera R, 1999, FASEB J, V13, P2284, DOI 10.1096/fasebj.13.15.2284; Jorquera R, 1997, BIOCHEM BIOPH RES CO, V232, P42, DOI 10.1006/bbrc.1997.6220; KNOX WE, 1955, J BIOL CHEM, V216, P479; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KVITTINGEN EA, 1986, SCAND J CLIN LAB INV, V46, P27; LINDBLAD B, 1977, P NATL ACAD SCI USA, V74, P4641, DOI 10.1073/pnas.74.10.4641; LINDSTEDT S, 1992, LANCET, V340, P813, DOI 10.1016/0140-6736(92)92685-9; MAHURAN DJ, 1997, CAN J BIOCHEM, V55, P1; MANNE V, 1995, ONCOGENE, V10, P1763; MITCHELL G, 1990, NEW ENGL J MED, V322, P432, DOI 10.1056/NEJM199002153220704; Nandhagopal N, 1997, P JPN ACAD B-PHYS, V73, P154, DOI 10.2183/pjab.73.154; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Overturf K, 1997, HUM GENE THER, V8, P513, DOI 10.1089/hum.1997.8.5-513; Overturf K, 1996, NAT GENET, V12, P266, DOI 10.1038/ng0396-266; PARADIS K, 1990, AM J HUM GENET, V47, P338; PHILLIPS MA, 1992, BIOCHEMISTRY-US, V31, P959, DOI 10.1021/bi00119a003; RUPPERT S, 1992, GENE DEV, V6, P1430, DOI 10.1101/gad.6.8.1430; StLouis M, 1997, HUM MUTAT, V9, P291, DOI 10.1002/(SICI)1098-1004(1997)9:4<291::AID-HUMU1>3.0.CO;2-9; STONER E, 1984, PEDIATR RES, V18, P1332, DOI 10.1203/00006450-198412000-00023; Timm DE, 1999, STRUCTURE, V7, P1023, DOI 10.1016/S0969-2126(99)80170-1; TIMMIS KN, 1994, ANNU REV MICROBIOL, V48, P525, DOI 10.1146/annurev.mi.48.100194.002521; WEILER L, 1970, J AM CHEM SOC, V92, P6702, DOI 10.1021/ja00725a088	36	49	51	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 4	2001	276	18					15284	15291		10.1074/jbc.M007621200	http://dx.doi.org/10.1074/jbc.M007621200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	429QQ	11154690	hybrid			2022-12-25	WOS:000168528800101
J	Kumar, R; Grammatikakis, N; Chinkers, M				Kumar, R; Grammatikakis, N; Chinkers, M			Regulation of the atrial natriuretic peptide receptor by heat shock protein 90 complexes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOMINANT-NEGATIVE MUTANT; GUANYLYL CYCLASES; IMMUNOPHILIN FKBP51; SQUIRREL-MONKEY; HSP90; KINASE; DOMAIN; PHOSPHATASE-5; DEGRADATION; ACTIVATION	Heat shock protein 90 (hsp90) is a chaperone required for the proper folding and trafficking of many proteins involved in signal transduction. We tested whether hsp90 plays a role as a chaperone for GC-A, the membrane guanylate cyclase that acts as a receptor for atrial natriuretic peptide (ANP). When cultured cells expressing recombinant GC-A were treated with geldanamycin, an inhibitor of hsp90 function, the ANP-stimulated production of cyclic GMP was inhibited. This suggested that hsp90 was required for GC-A processing and/or stability. A physical association between hsp90 and GC-A was demonstrated in coimmunoprecipitation experiments. Treatment with geldanamycin disrupted this association and led to the accumulation of complexes containing GC-A and heat shock protein 70 (hsp70). Protein folding pathways involving hsp70 and hsp90 include several pathway-specific co-chaperones. Complexes between GC-A and hsp90 contained the co-chaperone p50(cdc37), typically found associated with protein. kinase hsp(90) heterocomplexes, GC-A immunoprecipitates did not contain detectable amounts of Hop, FKBP51, FKBP52, PP5, or p23, all co-chaperones found in hsp90 complexes with other signaling proteins. The association of hsp90 and p50(cdc37) with GC-A was dependent on the kinase homology domain of this receptor but not on its ANP-binding, transmembrane, or guanylate cyclase domains. The data suggest that GC-A is regulated by hsp90 complexes similar to those involved in the maturation of protein kinases.	Univ S Alabama, Dept Pharmacol, Mobile, AL 36688 USA; Lankenau Inst Med Res, Wynnewood, PA 19096 USA	University of South Alabama; Lankenau Medical Center; Lankenau Institute for Medical Research	Chinkers, M (corresponding author), Univ S Alabama, Dept Pharmacol, Mobile, AL 36688 USA.				NHLBI NIH HHS [HL 47063] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL047063] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Birnby DA, 2000, GENETICS, V155, P85; Buchner J, 1999, TRENDS BIOCHEM SCI, V24, P136, DOI 10.1016/S0968-0004(99)01373-0; Busconi L, 2000, J BIOL CHEM, V275, P1565, DOI 10.1074/jbc.275.3.1565; Chen MS, 1996, J BIOL CHEM, V271, P32315, DOI 10.1074/jbc.271.50.32315; CHINKERS M, 1994, P NATL ACAD SCI USA, V91, P11075, DOI 10.1073/pnas.91.23.11075; CHINKERS M, 1992, J BIOL CHEM, V267, P18589; CHINKERS M, 1989, SCIENCE, V245, P1392, DOI 10.1126/science.2571188; CUTFORTH T, 1994, CELL, V77, P1027, DOI 10.1016/0092-8674(94)90442-1; Denny WB, 2000, ENDOCRINOLOGY, V141, P4107, DOI 10.1210/en.141.11.4107; Garcia-Cardena G, 1998, NATURE, V392, P821, DOI 10.1038/33934; Grammatikakis N, 1999, MOL CELL BIOL, V19, P1661; Hartson SD, 2000, BIOCHEMISTRY-US, V39, P7631, DOI 10.1021/bi000315r; Hartson SD, 1998, J BIOL CHEM, V273, P8475, DOI 10.1074/jbc.273.14.8475; Holt SE, 1999, GENE DEV, V13, P817, DOI 10.1101/gad.13.7.817; Hunter T, 1997, TRENDS CELL BIOL, V7, P157, DOI 10.1016/S0962-8924(97)01027-1; KOLLER KJ, 1992, MOL CELL BIOL, V12, P2581, DOI 10.1128/MCB.12.6.2581; Laura RP, 1998, BIOCHEMISTRY-US, V37, P11264, DOI 10.1021/bi9809674; Loo MA, 1998, EMBO J, V17, P6879, DOI 10.1093/emboj/17.23.6879; Lucas KA, 2000, PHARMACOL REV, V52, P375; Neckers L, 1999, DRUG RESIST UPDATE, V2, P165, DOI 10.1054/drup.1999.0082; Pearl LH, 2000, CURR OPIN STRUC BIOL, V10, P46, DOI 10.1016/S0959-440X(99)00047-0; Pratt WB, 1997, ENDOCR REV, V18, P306, DOI 10.1210/er.18.3.306; Reynolds PD, 1999, J CLIN ENDOCR METAB, V84, P663, DOI 10.1210/jc.84.2.663; Silverstein AM, 1997, J BIOL CHEM, V272, P16224, DOI 10.1074/jbc.272.26.16224; SINGH S, 1988, NATURE, V334, P708, DOI 10.1038/334708a0	25	27	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 6	2001	276	14					11371	11375		10.1074/jbc.M010480200	http://dx.doi.org/10.1074/jbc.M010480200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	420AC	11152473	hybrid			2022-12-25	WOS:000167980900107
J	Van Baelen, K; Vanoevelen, J; Missiaen, L; Raeymaekers, L; Wuytack, F				Van Baelen, K; Vanoevelen, J; Missiaen, L; Raeymaekers, L; Wuytack, F			The Golgi PMR1 P-type ATPase of Caenorhabditis elegans - Identification of the gene and demonstration of calcium and manganese transport	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YEAST SECRETORY PATHWAY; ENDOPLASMIC-RETICULUM; SARCOPLASMIC-RETICULUM; PROPERTIES DISTINCT; MOLECULAR-CLONING; CA2+ PUMP; ION-PUMP; EF-HAND; CA2+-ATPASE; MUTATIONS	In recent years, it has been well established that the Ca2+ concentration in the lumen of intracellular organelles is a key determinant of cell function. Despite the fact that essential functions of the Golgi apparatus depend on the Ca2+ and Mn2+ concentration in its lumen, little is known on the transport system responsible for ion accumulation. The Golgis ion pump PMR1 has been functionally studied only in yeast. In humans, mutations in the orthologous gene ATP2C1 cause Hailey-Hailey disease. We report here the identification of the PMR1 homologue in the model organism Caenorhabditis elegans and after ectopic expression the direct study of its ion transport in permeabilized COS-1 cells. The C. elegans genome is predicted to contain a single PMR1 orthologue on chromosome I. We found evidence for alternative splicing in the 5'-untranslated region, but no indication for the generation of different protein isoforms. C. elegans PMR1 overexpressed in COS-1 cells transports Ca2+ and Mn2+ with high affinity into the Golgi apparatus in a thapsigargin-insensitive manner. Part of the accumulated Ca2+ can be released by inositol 1,4,5-trisphosphate, in agreement with the idea that the Golgis apparatus is an inositol 1,4,5-trisphosphate-sensitive Ca2+ store.	Katholieke Univ Leuven, Physiol Lab, B-3000 Louvain, Belgium	KU Leuven	Van Baelen, K (corresponding author), Katholieke Univ Leuven, Physiol Lab, Campus Gasthuisberg,Herestr 49, B-3000 Louvain, Belgium.	Kurt.Vanbaelen@med.kuleuven.ac.be	Vanoevelen, Jo M/F-2686-2013	Vanoevelen, Jo M/0000-0003-1830-8858				ANDERSEN JP, 1992, J BIOL CHEM, V267, P2767; ANTEBI A, 1992, MOL BIOL CELL, V3, P633, DOI 10.1091/mbc.3.6.633; Baylis HA, 1999, J MOL BIOL, V294, P467, DOI 10.1006/jmbi.1999.3229; Benito B, 2000, MOL MICROBIOL, V35, P1079, DOI 10.1046/j.1365-2958.2000.01776.x; Berridge MJ, 1998, NATURE, V395, P645, DOI 10.1038/27094; BLUMENTHAL T, 1988, TRENDS GENET, V4, P305, DOI 10.1016/0168-9525(88)90107-2; C elegans Sequencing Consortium, 1998, SCIENCE, V282, P2012, DOI 10.1126/science.282.5396.2012; Cools J, 1999, BLOOD, V94, P1820, DOI 10.1182/blood.V94.5.1820.417k09_1820_1824; Corbett EF, 2000, TRENDS BIOCHEM SCI, V25, P307, DOI 10.1016/S0968-0004(00)01588-7; Degand I, 1999, MOL MICROBIOL, V31, P545, DOI 10.1046/j.1365-2958.1999.01195.x; Durr G, 1998, MOL BIOL CELL, V9, P1149, DOI 10.1091/mbc.9.5.1149; FABIATO A, 1979, J PHYSIOL-PARIS, V75, P463; GUNTESKIHAMBLIN AM, 1992, BIOCHEMISTRY-US, V31, P7600, DOI 10.1021/bi00148a023; Honore B, 2000, FEBS LETT, V466, P11, DOI 10.1016/S0014-5793(99)01780-9; Hu ZL, 2000, NAT GENET, V24, P61, DOI 10.1038/71701; IVESSA NE, 1995, J BIOL CHEM, V270, P25960, DOI 10.1074/jbc.270.43.25960; Kraev A, 1999, J BIOL CHEM, V274, P4254, DOI 10.1074/jbc.274.7.4254; LAPINSKAS PJ, 1995, MOL CELL BIOL, V15, P1382; Lin P, 1999, J CELL BIOL, V145, P279, DOI 10.1083/jcb.145.2.279; Lin P, 1998, J CELL BIOL, V141, P1515, DOI 10.1083/jcb.141.7.1515; Locke EG, 2000, MOL CELL BIOL, V20, P6686, DOI 10.1128/MCB.20.18.6686-6694.2000; MacLennan DH, 1997, J BIOL CHEM, V272, P28815, DOI 10.1074/jbc.272.46.28815; Mandal D, 2000, J BIOL CHEM, V275, P23933, DOI 10.1074/jbc.M002619200; Martell A. E., 1974, CRITICAL STABILITY C; MISSIAEN L, 1994, J BIOL CHEM, V269, P7238; Pinton P, 1998, EMBO J, V17, P5298, DOI 10.1093/emboj/17.18.5298; Porat A, 2000, J BIOL CHEM, V275, P29233, DOI 10.1074/jbc.M005316200; Pryor PR, 2000, J CELL BIOL, V149, P1053, DOI 10.1083/jcb.149.5.1053; RUDOLPH HK, 1989, CELL, V58, P133, DOI 10.1016/0092-8674(89)90410-8; SARKADI B, 1986, J BIOL CHEM, V261, P9552; Sorin A, 1997, J BIOL CHEM, V272, P9895; Sudbrak R, 2000, HUM MOL GENET, V9, P1131, DOI 10.1093/hmg/9.7.1131; Taylor RS, 1997, MOL BIOL CELL, V8, P1911, DOI 10.1091/mbc.8.10.1911; Toyoshima C, 2000, NATURE, V405, P647, DOI 10.1038/35015017; VERBOOMEN H, 1992, BIOCHEM J, V286, P591, DOI 10.1042/bj2860591; Wei Y, 1999, BIOCHEMISTRY-US, V38, P14534, DOI 10.1021/bi9911233; Wei Y, 2000, J BIOL CHEM, V275, P23927, DOI 10.1074/jbc.M002618200; WUYTACK F, 1994, J BIOL CHEM, V269, P1410; WUYTACK F, 1982, BIOCHIM BIOPHYS ACTA, V693, P45, DOI 10.1016/0005-2736(82)90469-2; Yagodin S, 1999, CELL CALCIUM, V25, P429, DOI 10.1054/ceca.1999.0043; ZHA XH, 1995, AM J PHYSIOL-CELL PH, V268, pC1133, DOI 10.1152/ajpcell.1995.268.5.C1133	41	74	78	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 6	2001	276	14					10683	10691		10.1074/jbc.M010553200	http://dx.doi.org/10.1074/jbc.M010553200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	420AC	11134055	hybrid			2022-12-25	WOS:000167980900018
J	Zimmermann, J; Lamerant, N; Grossenbacher, R; Furst, P				Zimmermann, J; Lamerant, N; Grossenbacher, R; Furst, P			Proteasome- and p38-dependent regulation of ERK3 expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE; HUMAN HOMOLOG; CHOP GADD153; P53; APOPTOSIS; GENES; PHOSPHORYLATION; TRANSCRIPTION; DEGRADATION; INHIBITORS	Proteasome inhibition leads to accumulation of transcription factors, heat shock proteins, cyclins, and other proteasome substrate proteins by blocking their proteolytic degradation. An increase in gene transcription upon proteasome inhibition was found for a group of proteins, including p21(WAF1/CIP1), ubiquitin, and transcription factors, In this study, we have demonstrated selective up-regulation of extracellular signal-regulated kinase 3 (ERK3) mRNA and protein expression upon treatment with peptide based proteasome inhibitors or lactacystin. ERK3 is a family member of the mitogen-activated protein kinases (also called ERK) that are key mediators of signal transduction from the cell surface to the nucleus. ERK3 up-regulation is independent of the p53, Bcl2, and caspase 3 status of cells. p38 pathway kinase inhibitors prevent proteasome-dependent ERK3 induction and enhance the antiproliferative effect of proteasome inhibitors. MCF-7 cells expressing ERK3 ectopically show increased resistance toward proteasome inhibition. The results indicate that ERK3 expression is a consequence of p38 pathway activation and most probably represents an intracellular defense or rescue mechanism against cell stress and damage induced by proteasome inhibition.	Novartis Pharma AG, Oncol Res, CH-4002 Basel, Switzerland	Novartis	Furst, P (corresponding author), Novartis Pharma AG, Oncol Res, WKL-125-13-14, CH-4002 Basel, Switzerland.	peter.fuerst@pharma.novartis.com						Amundson SA, 1999, ONCOGENE, V18, P3666, DOI 10.1038/sj.onc.1202676; Blagosklonny MV, 1996, BIOCHEM BIOPH RES CO, V227, P564, DOI 10.1006/bbrc.1996.1546; Camarillo IG, 1997, P SOC EXP BIOL MED, V215, P198, DOI 10.3181/00379727-215-44129; CANO E, 1995, TRENDS BIOCHEM SCI, V20, P117, DOI 10.1016/S0968-0004(00)88978-1; Chang DD, 1998, ONCOGENE, V16, P1921, DOI 10.1038/sj.onc.1201715; Cheng M, 1996, J BIOL CHEM, V271, P8951, DOI 10.1074/jbc.271.15.8951; Cheng M, 1996, J BIOL CHEM, V271, P12057, DOI 10.1074/jbc.271.20.12057; DAVIS RJ, 1994, TRENDS BIOCHEM SCI, V19, P470, DOI 10.1016/0968-0004(94)90132-5; DAVIS RJ, 1995, MOL REPROD DEV, V42, P459, DOI 10.1002/mrd.1080420414; Dimmeler S, 1999, J EXP MED, V189, P1815, DOI 10.1084/jem.189.11.1815; Eymin B, 1997, CANCER RES, V57, P686; He HL, 1998, J BIOL CHEM, V273, P25015, DOI 10.1074/jbc.273.39.25015; ISAACS WB, 1991, CANCER RES, V51, P4716; Janicke RU, 1998, J BIOL CHEM, V273, P9357, DOI 10.1074/jbc.273.16.9357; Khokhlatchev A, 1997, J BIOL CHEM, V272, P11057; Kim D, 1999, BIOCHEM BIOPH RES CO, V254, P264, DOI 10.1006/bbrc.1998.9840; Kleines M, 2000, BBA-GENE STRUCT EXPR, V1492, P139, DOI 10.1016/S0167-4781(00)00098-1; Kummer JL, 1997, J BIOL CHEM, V272, P20490, DOI 10.1074/jbc.272.33.20490; Matsumoto M, 1996, FEBS LETT, V395, P143, DOI 10.1016/0014-5793(96)01016-2; Meloche S, 1996, ONCOGENE, V13, P1575; Meriin AB, 1998, J BIOL CHEM, V273, P6373, DOI 10.1074/jbc.273.11.6373; Nieves-Neira W, 1999, INT J CANCER, V82, P396, DOI 10.1002/(SICI)1097-0215(19990730)82:3<396::AID-IJC13>3.0.CO;2-Z; *PE APPL BIOS, 1997, US B PE APPL BIOS, V2; Qi XM, 1997, ONCOGENE, V15, P1207, DOI 10.1038/sj.onc.1201290; SCHENA M, 1995, SCIENCE, V270, P467, DOI 10.1126/science.270.5235.467; Shalon D, 1996, GENOME RES, V6, P639, DOI 10.1101/gr.6.7.639; Tchernitsa OI, 1999, ONCOGENE, V18, P5448, DOI 10.1038/sj.onc.1202987; THOMPSON AM, 1990, BRIT J CANCER, V61, P74, DOI 10.1038/bjc.1990.17; Tibbles LA, 1999, CELL MOL LIFE SCI, V55, P1230, DOI 10.1007/s000180050369; VanLint C, 1996, GENE EXPRESSION, V5, P245; WANG NP, 1993, ONCOGENE, V8, P279; Wang XZ, 1996, SCIENCE, V272, P1347, DOI 10.1126/science.272.5266.1347; WOLF D, 1985, P NATL ACAD SCI USA, V82, P790, DOI 10.1073/pnas.82.3.790; YOSHIDA H, 1992, JPN J CANCER RES, V83, P324, DOI 10.1111/j.1349-7006.1992.tb00109.x; Young PR, 1997, J BIOL CHEM, V272, P12116, DOI 10.1074/jbc.272.18.12116; ZHU AX, 1994, MOL CELL BIOL, V14, P8202, DOI 10.1128/MCB.14.12.8202; Zimmermann J, 2000, ONCOGENE, V19, P2913, DOI 10.1038/sj.onc.1203606	37	32	34	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 6	2001	276	14					10759	10766		10.1074/jbc.M008567200	http://dx.doi.org/10.1074/jbc.M008567200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	420AC	11148204	hybrid			2022-12-25	WOS:000167980900028
J	Bebenek, A; Dressman, HK; Carver, GT; Ng, SS; Petrov, V; Yang, GW; Konigsberg, WH; Karam, JD; Drake, JW				Bebenek, A; Dressman, HK; Carver, GT; Ng, SS; Petrov, V; Yang, GW; Konigsberg, WH; Karam, JD; Drake, JW			Interacting fidelity defects in the replicative DNA polymerase of bacteriophage RB69	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							T-EVEN BACTERIOPHAGES; SPONTANEOUS MUTATION; CRYSTAL-STRUCTURE; BIOCHEMICAL BASIS; ESCHERICHIA-COLI; KLENOW FRAGMENT; MISMATCH REPAIR; MUTANTS; RATES; GENE	The DNA polymerases (gp43s) of the related bacteriophages T4 and RB69 are B family (polymerase alpha class) enzymes that determine the fidelity of phage DNA replication. A T4 whose gene 43 has been mutationally inactivated can be replicated by a cognate RB69 gp43 encoded by a recombinant plasmid in T l-infected Escherichia coli. We used this phage-plasmid complementation assay to obtain rapid and sensitive measurements of the mutational specificities of mutator derivatives of the RB69 enzyme, RB69 gp43s lacking proofreading function (Exo(-) enzymes) and/or substituted with alanine, serine, or threonine at the conserved polymerase function residue Tyr(567) (Pol(Y567(A/S/T)) enzymes) were examined for their effects on the reversion of specific mutations in the T4 rII gene and on forward mutation in the T4 rI gene. The results reveal that Tyr567 is a key determinant of the fidelity of base selection and that the Pol and fro functions are strongly coupled in this B family enzyme, In vitro assays show that the Pol(Y567A) EXO- enzyme generates mispairs more frequently but extends them less efficiently than does a pol(+) Exo- enzyme. Other replicative DNA polymerases may control fidelity by strategies similar to those used by RB69 gp43.	NIEHS, Mol Genet Lab, NIH, Res Triangle Pk, NC 27709 USA; Tulane Univ, Hlth Sci Ctr, Dept Biochem, New Orleans, LA 70112 USA; Yale Univ, Dept Mol Biophys & Biochem, New Haven, CT 06510 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); Tulane University; Yale University	Drake, JW (corresponding author), NIEHS, Mol Genet Lab, NIH, E3-01,Rm E-344,111 S Alexander Dr, Res Triangle Pk, NC 27709 USA.			Bebenek, Anna/0000-0001-5374-8205	NIDDK NIH HHS [DK09070] Funding Source: Medline; NIGMS NIH HHS [GM54627, GM18842] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK009070, R01DK009070] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [Z01ES061054, ZIAES061054] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054627] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bebenek A, 1999, J BACTERIOL, V181, P3123, DOI 10.1128/JB.181.10.3123-3128.1999; Bell JB, 1997, J BIOL CHEM, V272, P7345, DOI 10.1074/jbc.272.11.7345; BENZER S, 1961, P NATL ACAD SCI USA, V47, P403, DOI 10.1073/pnas.47.3.403; BESSMAN MJ, 1977, J MOL BIOL, V116, P115, DOI 10.1016/0022-2836(77)90122-X; BRAITHWAITE DK, 1993, NUCLEIC ACIDS RES, V21, P787, DOI 10.1093/nar/21.4.787; Brautigam CA, 1998, CURR OPIN STRUC BIOL, V8, P54, DOI 10.1016/S0959-440X(98)80010-9; CARROLL SS, 1991, BIOCHEMISTRY-US, V30, P804, DOI 10.1021/bi00217a034; CONKLING MA, 1980, J MOL BIOL, V143, P303, DOI 10.1016/0022-2836(80)90192-8; CONKLING MA, 1984, GENETICS, V107, P505; Doublie S, 1998, NATURE, V391, P251, DOI 10.1038/34593; Drake JW, 1998, GENETICS, V148, P1667; DRAKE JW, 1991, P NATL ACAD SCI USA, V88, P7160, DOI 10.1073/pnas.88.16.7160; DRAKE JW, 1963, J MOL BIOL, V6, P268, DOI 10.1016/S0022-2836(63)80088-1; DRAKE JW, 1994, MOL BIOL BACTERIOP T, V4, P98; Dressman HK, 1997, P NATL ACAD SCI USA, V94, P8042, DOI 10.1073/pnas.94.15.8042; ECHOLS H, 1991, ANNU REV BIOCHEM, V60, P477, DOI 10.1146/annurev.biochem.60.1.477; FREY MW, 1993, P NATL ACAD SCI USA, V90, P2579, DOI 10.1073/pnas.90.7.2579; GOODMAN MF, 1993, CRIT REV BIOCHEM MOL, V28, P83, DOI 10.3109/10409239309086792; Goodman MF, 1997, P NATL ACAD SCI USA, V94, P10493, DOI 10.1073/pnas.94.20.10493; Hopfner KP, 1999, P NATL ACAD SCI USA, V96, P3600, DOI 10.1073/pnas.96.7.3600; JOHNSON KA, 1993, ANNU REV BIOCHEM, V62, P685, DOI 10.1146/annurev.bi.62.070193.003345; KARAM JD, 1973, J VIROL, V11, P933, DOI 10.1128/JVI.11.6.933-945.1973; Kunkel TA, 2000, ANNU REV BIOCHEM, V69, P497, DOI 10.1146/annurev.biochem.69.1.497; Morales JC, 2000, BIOCHEMISTRY-US, V39, P2626, DOI 10.1021/bi992173a; Moran S, 1997, P NATL ACAD SCI USA, V94, P10506, DOI 10.1073/pnas.94.20.10506; NELSON MA, 1982, MOL GEN GENET, V188, P60, DOI 10.1007/BF00332996; Nossal NG, 1998, GENETICS, V148, P1535; Paddison P, 1998, GENETICS, V148, P1539; PATEL SS, 1991, BIOCHEMISTRY-US, V30, P511, DOI 10.1021/bi00216a029; PRIBNOW D, 1981, J MOL BIOL, V149, P337, DOI 10.1016/0022-2836(81)90477-0; Reha-Krantz LJ, 1998, GENETICS, V148, P1551; REHAKRANTZ LJ, 1991, P NATL ACAD SCI USA, V88, P2417, DOI 10.1073/pnas.88.6.2417; REHAKRANTZ LJ, 1994, MOL BIOL BACTERIOP T, V4, P307; Rodriguez AC, 2000, J MOL BIOL, V299, P447, DOI 10.1006/jmbi.2000.3728; Rosche WA, 2000, METHODS, V20, P4, DOI 10.1006/meth.1999.0901; Russell R.L., 1967, SPECIATION T EVEN BA; RUSSELL RL, 1974, GENETICS, V78, P989; SANTOS ME, 1994, GENETICS, V138, P553; SCHAAPER RM, 1993, J BIOL CHEM, V268, P23762; SCHAAPER RM, 1989, EMBO J, V8, P3511, DOI 10.1002/j.1460-2075.1989.tb08516.x; Shamoo Y, 1999, CELL, V99, P155, DOI 10.1016/S0092-8674(00)81647-5; SINGER BS, 1984, MOL GEN GENET, V193, P104, DOI 10.1007/BF00327422; Smith LA, 1998, GENETICS, V148, P1611; SNUSTAD DP, 1968, VIROLOGY, V35, P550, DOI 10.1016/0042-6822(68)90285-7; STREISINGER G, 1966, COLD SPRING HARB SYM, V31, P77, DOI 10.1101/SQB.1966.031.01.014; SUGINO A, 1984, J MOL BIOL, V176, P239, DOI 10.1016/0022-2836(84)90422-4; Wang CC, 1997, J BIOL CHEM, V272, P17703, DOI 10.1074/jbc.272.28.17703; WANG CC, 1995, J BIOL CHEM, V270, P26558, DOI 10.1074/jbc.270.44.26558; Wang FJ, 1998, GENETICS, V148, P1655; Wang J, 1997, CELL, V89, P1087, DOI 10.1016/S0092-8674(00)80296-2; Yang GW, 1999, BIOCHEMISTRY-US, V38, P8094, DOI 10.1021/bi990653w; Yeh LS, 1998, J BACTERIOL, V180, P2005, DOI 10.1128/JB.180.8.2005-2013.1998; Zhao YX, 1999, STRUCTURE, V7, P1189, DOI 10.1016/S0969-2126(00)80053-2	53	53	54	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 30	2001	276	13					10387	10397		10.1074/jbc.M007707200	http://dx.doi.org/10.1074/jbc.M007707200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	420GC	11133987	hybrid			2022-12-25	WOS:000167996400105
J	Sato, H; Kuriyama-Matsumura, K; Hashimoto, T; Sasaki, H; Wang, HY; Ishii, T; Mann, GE; Bannai, S				Sato, H; Kuriyama-Matsumura, K; Hashimoto, T; Sasaki, H; Wang, HY; Ishii, T; Mann, GE; Bannai, S			Effect of oxygen on induction of the cystine transporter by bacterial lipopolysaccharide in mouse peritoneal macrophages	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-TRANSPORT; GAMMA-GLUTAMYLCYSTEINE SYNTHETASE; NF-KAPPA-B; TRANSCRIPTION FACTOR; ARGININE TRANSPORT; MEMBRANE-PROTEIN; NITRIC-OXIDE; HEAVY-CHAIN; GLUTATHIONE; METABOLISM	Amino acid transport in mouse peritoneal macrophages is mediated by several membrane carriers with different substrate specificity and sensitivity to environmental stimuli. We reported previously that transport activities of cystine and arginine in the macrophages were induced markedly by low concentrations of bacterial lipopolysaccharide (LPS), It is known that a variety of macrophage functions are affected by ambient oxygen tension. In this study, we have investigated the effects of oxygen on the induction of amino acid transport activity by LPS and found that the induction of cystine, but not arginine, transport activity was dependent on the ambient oxygen tension. When the macrophages were cultured with 2% O-2 in the presence of 1 ng/ml LPS, induction of cystine transport activity was reduced by similar to 70% compared with cells cultured under normoxic conditions. In macrophages, transport of cystine is mediated by a Na+-independent anionic amino acid transporter named system x(c)(-). System x(c)(-) is composed of two protein components, xCT and 4F2hc, and the expression of xCT was closely correlated with system x(c)(-) activity. A putative NF-kappaB binding site was found in the 5 ' -flanking region of the xCT gene, but the enhanced expression of xCT by LPS and oxygen was not mediated by NF-KB binding. An increase in intracellular GSH in macrophages paralleled induction of xCT, but not gamma -glutamylcysteine synthetase, These results suggest the importance of system x(c)(-) in antioxidant defense in macrophages exposed to LPS and oxidative stress.	Univ Tsukuba, Inst Basic Med Sci, Dept Biochem, Tsukuba, Ibaraki 3058575, Japan; Kings Coll London, Guys Kings & St Thomas Sch Biomed Sci, Ctr Cardiovasc Biol & Med, London SE1 1UL, England	University of Tsukuba; University of London; King's College London	Sato, H (corresponding author), Univ Tsukuba, Inst Basic Med Sci, Dept Biochem, Tsukuba, Ibaraki 3058575, Japan.	hideyo-s@md.tsukuba.ac.jp		Mann, Giovanni/0000-0001-7311-2044				BANNAI S, 1986, J MEMBRANE BIOL, V89, P1, DOI 10.1007/BF01870891; BANNAI S, 1980, J BIOL CHEM, V255, P2372; BOGLE RG, 1992, BIOCHEM J, V284, P15, DOI 10.1042/bj2840015; Chasseaud L F, 1979, Adv Cancer Res, V29, P175, DOI 10.1016/S0065-230X(08)60848-9; CHRISTENSEN HN, 1990, PHYSIOL REV, V70, P43, DOI 10.1152/physrev.1990.70.1.43; CLOSS EI, 1993, J BIOL CHEM, V268, P20796; COTGREAVE IA, 1986, J BIOCHEM BIOPH METH, V13, P231, DOI 10.1016/0165-022X(86)90102-8; Deves R, 2000, J MEMBRANE BIOL, V173, P165, DOI 10.1007/s002320001017; GOTTESDIENER KM, 1988, MOL CELL BIOL, V8, P3809, DOI 10.1128/MCB.8.9.3809; Ishii T, 2000, J BIOL CHEM, V275, P16023, DOI 10.1074/jbc.275.21.16023; Itoh K, 1997, BIOCHEM BIOPH RES CO, V236, P313, DOI 10.1006/bbrc.1997.6943; Kanai Y, 1998, J BIOL CHEM, V273, P23629, DOI 10.1074/jbc.273.37.23629; Kaul N, 1998, FREE RADICAL BIO MED, V24, P202, DOI 10.1016/S0891-5849(97)00209-8; Lewis JS, 1999, J LEUKOCYTE BIOL, V66, P889, DOI 10.1002/jlb.66.6.889; Li HF, 1999, AM J PHYSIOL-CELL PH, V276, pC803, DOI 10.1152/ajpcell.1999.276.4.C803; Mastroberardino L, 1998, NATURE, V395, P288, DOI 10.1038/26246; Monick MM, 1999, J BIOL CHEM, V274, P18075, DOI 10.1074/jbc.274.25.18075; Mulcahy RT, 1997, J BIOL CHEM, V272, P7445, DOI 10.1074/jbc.272.11.7445; SAGARA J, 1993, J NEUROCHEM, V61, P1667, DOI 10.1111/j.1471-4159.1993.tb09801.x; Sagara JI, 1996, J NEUROCHEM, V66, P1876; SATO H, 1991, BIOCHIM BIOPHYS ACTA, V1069, P46, DOI 10.1016/0005-2736(91)90102-E; SATO H, 1995, BIOCHEM J, V310, P547, DOI 10.1042/bj3100547; SATO H, 1987, J BIOL CHEM, V262, P13015; Sato H, 1999, J BIOL CHEM, V274, P11455, DOI 10.1074/jbc.274.17.11455; SATO H, 1992, J LEUKOCYTE BIOL, V52, P161, DOI 10.1002/jlb.52.2.161; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; Sekhar KR, 1997, RADIAT RES, V147, P592, DOI 10.2307/3579626; Shibazaki T, 1996, BBA-MOL CELL RES, V1311, P150, DOI 10.1016/0167-4889(95)00198-0; Takeuchi O, 1999, IMMUNITY, V11, P443, DOI 10.1016/S1074-7613(00)80119-3; TIETZE F, 1969, ANAL BIOCHEM, V27, P502, DOI 10.1016/0003-2697(69)90064-5; Torrents D, 1998, J BIOL CHEM, V273, P32437, DOI 10.1074/jbc.273.49.32437; TOWELL ME, 1976, J APPL PHYSIOL, V41, P245, DOI 10.1152/jappl.1976.41.2.245; WATANABE H, 1987, J EXP MED, V165, P628, DOI 10.1084/jem.165.3.628	33	76	77	3	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 30	2001	276	13					10407	10412		10.1074/jbc.M007216200	http://dx.doi.org/10.1074/jbc.M007216200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	420GC	11136724	hybrid			2022-12-25	WOS:000167996400107
J	Hayashi, M; Tapping, RI; Chao, TH; Lo, JF; King, CC; Yang, Y; Lee, JD				Hayashi, M; Tapping, RI; Chao, TH; Lo, JF; King, CC; Yang, Y; Lee, JD			BMK1 mediates growth factor-induced cell proliferation through direct cellular activation of serum and glucocorticoid-inducible kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THREONINE PROTEIN-KINASE; MAP KINASE; PROTEIN-KINASE-1 BMK1; SIGNALING PATHWAYS; CYCLE; SGK; BMK1/ERK5; FAMILY	Activation of the mammalian mitogen-activated protein kinase known as BMK1 is required for growth factor-induced cell proliferation. To understand the mechanism by which BMK1 mediates this cellular response, this kinase was used as bait in a yeast two-hybrid-based library screening. Here, we report the identification of serum and glucocorticoid-inducible kinase (SGK) as a cellular protein that physically interacts with BMK1. During growth factor-induced cell stimulation, BMK1 activates SGK by phosphorylation at serine 78. This BMK1-mediated phosphorylation event is necessary for the activation of SGK and, more importantly, for cell proliferation induced by growth factors.	Scripps Res Inst, Dept Immunol, La Jolla, CA 92037 USA; RW Johnson Pharmaceut Res Inst, San Diego, CA 92121 USA	Scripps Research Institute; Johnson & Johnson; Johnson & Johnson USA	Lee, JD (corresponding author), Scripps Res Inst, Dept Immunol, La Jolla, CA 92037 USA.		King, Cecile/Q-9794-2019; Lo, Jeng-Fan/AAE-9626-2020; Lo, Jeng-Fan/ABB-2820-2020	King, Cecile/0000-0003-2193-2563; Lo, Jeng-Fan/0000-0001-7188-9140; Lo, Jeng-Fan/0000-0001-7188-9140	NATIONAL CANCER INSTITUTE [R01CA079871] Funding Source: NIH RePORTER; NCI NIH HHS [CA79871] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abe J, 1996, J BIOL CHEM, V271, P16586, DOI 10.1074/jbc.271.28.16586; Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Alessi DR, 1998, CURR BIOL, V8, P69, DOI 10.1016/S0960-9822(98)70037-5; Bell LM, 2000, J BIOL CHEM, V275, P25262, DOI 10.1074/jbc.M002076200; Brushia Robert J., 1999, Frontiers in Bioscience, V4, pd618, DOI 10.2741/Brushia; Buse P, 1999, J BIOL CHEM, V274, P7253, DOI 10.1074/jbc.274.11.7253; Chao TH, 1999, J BIOL CHEM, V274, P36035, DOI 10.1074/jbc.274.51.36035; Chou MM, 1998, CURR BIOL, V8, P1069, DOI 10.1016/S0960-9822(98)70444-0; Fiddes RJ, 1998, ONCOGENE, V16, P2803, DOI 10.1038/sj.onc.1201815; Kato Y, 2000, J BIOL CHEM, V275, P18534, DOI 10.1074/jbc.M001573200; Kato Y, 1997, EMBO J, V16, P7054, DOI 10.1093/emboj/16.23.7054; Kato Y, 1998, NATURE, V395, P713, DOI 10.1038/27234; Kobayashi T, 1999, BIOCHEM J, V344, P189, DOI 10.1042/0264-6021:3440189; Kobayashi T, 1999, BIOCHEM J, V339, P319, DOI 10.1042/0264-6021:3390319; LEE JD, 1995, BIOCHEM BIOPH RES CO, V213, P715, DOI 10.1006/bbrc.1995.2189; Park J, 1999, EMBO J, V18, P3024, DOI 10.1093/emboj/18.11.3024; Pelech S L, 1995, Prog Cell Cycle Res, V1, P33; Roovers K, 2000, BIOESSAYS, V22, P818, DOI 10.1002/1521-1878(200009)22:9<818::AID-BIES7>3.3.CO;2-Y; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; SHIBUYA EK, 1992, EMBO J, V11, P3963, DOI 10.1002/j.1460-2075.1992.tb05490.x; SHIOZAKI K, 1995, NATURE, V378, P739, DOI 10.1038/378739a0; STOKOE D, 1992, EMBO J, V11, P3985, DOI 10.1002/j.1460-2075.1992.tb05492.x; Waldegger S, 1997, P NATL ACAD SCI USA, V94, P4440, DOI 10.1073/pnas.94.9.4440; WEBSTER MK, 1993, MOL CELL BIOL, V13, P2031, DOI 10.1128/MCB.13.4.2031; WEBSTER MK, 1993, J BIOL CHEM, V268, P11482; Wilkinson MG, 2000, FASEB J, V14, P2147, DOI 10.1096/fj.00-0102rev; ZHOU GC, 1995, J BIOL CHEM, V270, P12665, DOI 10.1074/jbc.270.21.12665	27	100	108	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 23	2001	276	12					8631	8634		10.1074/jbc.C000838200	http://dx.doi.org/10.1074/jbc.C000838200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	413HV	11254654	hybrid			2022-12-25	WOS:000167607700003
J	Suzuki, Y; Yoda, T; Ruhul, A; Sugiura, W				Suzuki, Y; Yoda, T; Ruhul, A; Sugiura, W			Molecular cloning and characterization of the gene coding for azoreductase from Bacillus sp OY1-2 isolated from soil	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AZO DYES; MINERALIZATION; DEHYDROGENASE; STREPTOMYCES	Azo dyes are regarded as pollutants because they are not readily reduced under aerobic conditions. Bacillus sp, OY1-2 transforms azo dyes into colorless compounds, and this reduction is mediated by a reductase activity for the azo group in the presence of NADPH, A 1.2-kbp EcoRI fragment containing the gene that encodes azoreductase was cloned by screening the genomic library of Bacillus sp, OY1-2 with digoxigenin-labeled probe designed from the N-terminal amino acid sequence of the purified enzyme. An open reading frame encoding the azoreductase, consisting of 178 amino acids, was predicted from the nucleotide sequence. In addition, because only a Bacillus subtillis hypothetical protein was discovered in the public databases (with an amino acid identity of 52.8%), the gene encoding the azoreductase cloned in this study was predicted to be a member of a novel family of reductases. Southern blot analysis revealed that the azoreductase gene exists as a single copy gene on a chromosome. Escherichia coli-expressing recombinant azoreductase gave a ten times greater reducing activity toward azo dyes than the original Bacillus sp, OY1-2, In addition, the expressed azoreductase purified from the recombinant E. coli lysate by Red-Sepharose affinity chromatography showed a similar activity and specificity as the native enzyme. This is the first report describing the sequencing and characterization of a gene encoding the azo dye-reducing enzyme, azoreductase, from aerobic bacteria and its expression in E. coli.	Osaka Prefectural Inst Publ Hlth, Dept Pathol, Higashinari Ku, Osaka 5370025, Japan; Osaka Prefectural Inst Publ Hlth, Dept Food Microbiol, Higashinari Ku, Osaka 5370025, Japan; Osaka Prefectural Inst Publ Hlth, Dept Environm Sanitat, Higashinari Ku, Osaka 5370025, Japan	Osaka Prefectural Institute of Public Health; Osaka Prefectural Institute of Public Health; Osaka Prefectural Institute of Public Health	Suzuki, Y (corresponding author), Osaka Prefectural Inst Publ Hlth, Dept Pathol, Higashinari Ku, 1-3-69 Nakamichi, Osaka 5370025, Japan.	suzuki@iph.pref.osaka.jp	Suzuki, Yasuhiko/F-6890-2012					AUSUBEL FM, 1999, SHORT PROTOCOLS MOL; Bragg PD, 1997, ARCH BIOCHEM BIOPHYS, V338, P57, DOI 10.1006/abbi.1996.9797; HAUG W, 1991, APPL ENVIRON MICROB, V57, P3144, DOI 10.1128/AEM.57.11.3144-3149.1991; HEISS GS, 1992, FEMS MICROBIOL LETT, V99, P221, DOI 10.1111/j.1574-6968.1992.tb05571.x; KIM SMF, 1991, APPL ENVIRON MICROB, V57, P2413, DOI 10.1128/AEM.57.8.2413-2417.1991; Kulla H. G., 1981, MICROBIAL DEGRADATIO, V12, P387; LEVINE WG, 1991, DRUG METAB REV, V23, P253, DOI 10.3109/03602539109029761; MCKIE JH, 1993, BIOCHIM BIOPHYS ACTA, V1202, P61, DOI 10.1016/0167-4838(93)90063-W; Meyer U., 1981, MICROBIAL DEGRADATIO, P371; PASTIGRIGSBY MB, 1992, APPL ENVIRON MICROB, V58, P3605, DOI 10.1128/AEM.58.11.3605-3613.1992; PASZCZYNSKI A, 1992, APPL ENVIRON MICROB, V58, P3598, DOI 10.1128/AEM.58.11.3598-3604.1992; Rafii F, 1999, J BASIC MICROB, V39, P29, DOI 10.1002/(SICI)1521-4028(199903)39:1<29::AID-JOBM29>3.0.CO;2-W; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHULZERETTMER R, 1996, TEXTILVEREDLUNG, V31, P13; Shimada T, 2000, PROTEIN EXPRES PURIF, V20, P73, DOI 10.1006/prep.2000.1302; SHINE J, 1974, Proceedings of the National Academy of Sciences of the United States of America, V71, P1342, DOI 10.1073/pnas.71.4.1342; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; Sugiura W, 1999, J BIOSCI BIOENG, V88, P577, DOI 10.1016/S1389-1723(00)87680-X; Suzuki Y, 1995, Kansenshogaku Zasshi, V69, P413; Tan NCG, 1999, APPL MICROBIOL BIOT, V51, P865, DOI 10.1007/s002530051475; Zolinger H., 1987, COLOR CHEM SYNTHESES, V1	21	120	142	1	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 23	2001	276	12					9059	9065		10.1074/jbc.M008083200	http://dx.doi.org/10.1074/jbc.M008083200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	413HV	11134015	hybrid			2022-12-25	WOS:000167607700060
J	Frohlich, RF; Hansen, SG; Lisby, M; Grainge, I; Westergaard, O; Jayaram, M; Knudsen, BR				Frohlich, RF; Hansen, SG; Lisby, M; Grainge, I; Westergaard, O; Jayaram, M; Knudsen, BR			Inhibition of Flp recombinase by the topoisomerase I-targeting drugs, camptothecin and NSC-314622	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-SPECIFIC RECOMBINATION; DNA CLEAVAGE; CRYSTAL-STRUCTURE; ESCHERICHIA-COLI; MUTATIONS; MECHANISM; SEQUENCE; COMPLEX; IDENTIFICATION; RESISTANCE	Recombinases of the h-Int family and type IB topoisomerases act by introducing transient single strand breaks in DNA using chemically identical reaction schemes. Recent structural data have supported the relationship between the two enzyme groups by revealing considerable similarities in the architecture of their catalytic pockets. In this study we show that the Int-type recombinase Flp is inhibited by the two structurally unrelated topoisomerase I-directed anti-cancer drugs, camptothecin (CPT) and NSC-314622. The interaction of these drugs with topoisomerase I is very specific with several single amino acid substitutions conferring drug resistance to the enzyme. Thus, the observed interaction of CPT and NSC-314622 with Flp, which is comparable to their interaction with the cleavage complex formed by topoisomerase I, strongly supports a close mechanistic and evolutionary relationship between the two enzymes. The results suggest that Flp and other Int family recombinases may provide model systems for dissecting the molecular mechanisms of topoisomerase I-directed anti-cancer therapeutic agents.	Aarhus Univ, Dept Mol & Struct Biol, DK-8000 Aarhus C, Denmark; Univ Texas, Sect Mol Genet & Microbiol, Austin, TX 78712 USA	Aarhus University; University of Texas System; University of Texas Austin	Knudsen, BR (corresponding author), Aarhus Univ, Dept Mol & Struct Biol, Bldg 130,CF Mollers ALle, DK-8000 Aarhus C, Denmark.		Grainge, Ian RF/A-9031-2010; Lisby, Michael/K-9814-2014	Grainge, Ian RF/0000-0001-8268-583X; Lisby, Michael/0000-0002-4830-5247; Knudsen, Birgitta Ruth/0000-0002-3484-3802				ABREMSKI K, 1986, J BIOL CHEM, V261, P391; BENEDETTI P, 1993, CANCER RES, V53, P4343; Caruthers M H, 1983, Gene Amplif Anal, V3, P1; CHEN JW, 1992, MOL CELL BIOL, V12, P3757, DOI 10.1128/MCB.12.9.3757; CHEN JW, 1992, CELL, V69, P647, DOI 10.1016/0092-8674(92)90228-5; Chen Y, 2000, MOL CELL, V6, P885, DOI 10.1016/S1097-2765(05)00088-2; Cheng CH, 1998, CELL, V92, P841, DOI 10.1016/S0092-8674(00)81411-7; CHRISTIANSEN K, 1993, J BIOL CHEM, V268, P9690; Christiansen K, 1996, ANN NY ACAD SCI, V803, P50, DOI 10.1111/j.1749-6632.1996.tb26376.x; Guo F, 1997, NATURE, V389, P40, DOI 10.1038/37925; GUPTA M, 1995, BBA-GENE STRUCT EXPR, V1262, P1, DOI 10.1016/0167-4781(95)00029-G; GUPTA M, 1992, J BIOL CHEM, V267, P24177; HERTZBERG RP, 1990, J BIOL CHEM, V265, P19287; HERTZBERG RP, 1989, BIOCHEMISTRY-US, V28, P4629, DOI 10.1021/bi00437a018; JAXEL C, 1991, J BIOL CHEM, V266, P20418; JAYARAM M, 1994, TRENDS BIOCHEM SCI, V19, P78, DOI 10.1016/0968-0004(94)90039-6; KIKUCHI Y, 1979, P NATL ACAD SCI USA, V76, P3760, DOI 10.1073/pnas.76.8.3760; KJELDSEN E, 1988, J MOL BIOL, V202, P333, DOI 10.1016/0022-2836(88)90462-7; Knudsen BR, 1997, J MOL BIOL, V266, P93, DOI 10.1006/jmbi.1996.0767; Kohlhagen G, 1998, MOL PHARMACOL, V54, P50, DOI 10.1124/mol.54.1.50; LEE J, 1993, J BIOL CHEM, V268, P17564; LEE J, 1995, J BIOL CHEM, V270, P23203, DOI 10.1074/jbc.270.39.23203; Lee J, 1999, EMBO J, V18, P784, DOI 10.1093/emboj/18.3.784; Li XG, 1996, ANN NY ACAD SCI, V803, P111, DOI 10.1111/j.1749-6632.1996.tb26381.x; Lisby M, 1998, BIOCHEMISTRY-US, V37, P10815, DOI 10.1021/bi980757r; POMMIER Y, 1995, P NATL ACAD SCI USA, V92, P8861, DOI 10.1073/pnas.92.19.8861; Pommier Y, 1998, BBA-GENE STRUCT EXPR, V1400, P83, DOI 10.1016/S0167-4781(98)00129-8; Pond CD, 1999, ANTI-CANCER DRUG, V10, P647, DOI 10.1097/00001813-199908000-00004; PRASAD PV, 1987, P NATL ACAD SCI USA, V84, P2189, DOI 10.1073/pnas.84.8.2189; Redinbo MR, 1998, SCIENCE, V279, P1504, DOI 10.1126/science.279.5356.1504; Redinbo MR, 2000, BIOCHEMISTRY-US, V39, P6832, DOI 10.1021/bi992690t; SADOWSKI PD, 1995, PROG NUCLEIC ACID RE, V51, P53, DOI 10.1016/S0079-6603(08)60876-4; Sekiguchi JA, 1996, P NATL ACAD SCI USA, V93, P785, DOI 10.1073/pnas.93.2.785; SHUMAN S, 1988, J BIOL CHEM, V263, P16401; SHUMAN S, 1991, P NATL ACAD SCI USA, V88, P10104, DOI 10.1073/pnas.88.22.10104; Stewart L, 1998, SCIENCE, V279, P1534, DOI 10.1126/science.279.5356.1534; Straub T, 1997, BIOCHEMISTRY-US, V36, P10777, DOI 10.1021/bi970417q; TANIZAWA A, 1993, J BIOL CHEM, V268, P25463; THOMSEN B, 1987, EMBO J, V6, P1817, DOI 10.1002/j.1460-2075.1987.tb02436.x; Wang LF, 1997, CANCER RES, V57, P1516; Xu CJ, 1998, MOL CELL, V1, P729, DOI 10.1016/S1097-2765(00)80072-6	41	1	2	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 9	2001	276	10					6993	6997		10.1074/jbc.C000901200	http://dx.doi.org/10.1074/jbc.C000901200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	410MC	11152668	hybrid			2022-12-25	WOS:000167442900019
J	Bussolino, DF; Guido, ME; Gil, GA; Borioli, GA; Renner, ML; Grabois, VR; Conde, CB; Caputto, BL				Bussolino, DF; Guido, ME; Gil, GA; Borioli, GA; Renner, ML; Grabois, VR; Conde, CB; Caputto, BL			c-Fos associates with the endoplasmic reticulum and activates phospholipid metabolism	FASEB JOURNAL			English	Article									Univ Nacl Cordoba, Fac Ciencias Quim, Dept Quim Biol, CIQUIBIC, RA-5000 Cordoba, Argentina	National University of Cordoba	Caputto, BL (corresponding author), Univ Nacl Cordoba, Fac Ciencias Quim, Dept Quim Biol, CIQUIBIC, Pabellon Argentina,Ciudad Univ, RA-5000 Cordoba, Argentina.		GIL, GERMAN A./T-3018-2019; Renner, Marianne/H-5315-2011	GIL, GERMAN A./0000-0001-6714-2693; Conde, Cecilia/0000-0002-5103-6391; Renner, Marianne/0000-0002-8727-6581					0	56	56	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAR	2001	15	3					556	558						3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	410BE	11259365				2022-12-25	WOS:000167419500003
J	Yakmovych, I; Ten Dijke, P; Heldin, CH; Souchelnytskyi, S				Yakmovych, I; Ten Dijke, P; Heldin, CH; Souchelnytskyi, S			Regulation of Smad signaling by protein kinase C	FASEB JOURNAL			English	Article									Ludwig Inst Canc Res, Biomed Ctr, S-75124 Uppsala, Sweden; Natl Acad Sci Ukraine, Inst Biochem, Lviv, Ukraine; Netherlands Canc Inst, NL-1066 CX Amsterdam, Netherlands	Ludwig Institute for Cancer Research; National Academy of Sciences Ukraine; Netherlands Cancer Institute	Souchelnytskyi, S (corresponding author), Ludwig Inst Canc Res, Biomed Ctr, Box 595,Husargatan Str 3, S-75124 Uppsala, Sweden.		Souchelnytskyi, Serhiy/J-9446-2014; Dijke, Peter ten/AAG-4660-2021; Souchelnytskyi, Serhiy/G-6491-2011	Dijke, Peter ten/0000-0002-7234-342X; Souchelnytskyi, Serhiy/0000-0001-8243-9276					0	149	157	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAR	2001	15	3					553	555						3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	410BE	11259364				2022-12-25	WOS:000167419500002
J	Salemi, M; Strimmer, K; Hall, WW; Duffy, M; Delaporte, E; Mboup, S; Peeters, M; Vandamme, AM				Salemi, M; Strimmer, K; Hall, WW; Duffy, M; Delaporte, E; Mboup, S; Peeters, M; Vandamme, AM			Dating the common ancestor of SIVcpz and HIV-1 group M and the origin of HIV-1 subtypes using a new method to uncover clock-like molecular evolution	FASEB JOURNAL			English	Article									Katholieke Univ Leuven, Rega Inst Med Res, B-3000 Louvain, Belgium; Max Planck Inst Biochem, GSF, MIPS, D-82152 Martinsried, Germany; Natl Univ Ireland Univ Coll Dublin, Conway Inst Biomol & Biomed Res, Dept Med Microbiol, Dublin 4, Ireland; IRD, Retrovirus Lab, Montpellier, France	KU Leuven; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; Max Planck Society; University College Dublin; Institut de Recherche pour le Developpement (IRD)	Vandamme, AM (corresponding author), Katholieke Univ Leuven, Rega Inst Med Res, Minderbroedersstr 10, B-3000 Louvain, Belgium.	annemie.vandamme@uz.kuleuven.ac.be	Strimmer, Korbinian/C-1522-2009; Vandamme, Anne-Mieke/I-4127-2012; Delaporte, Eric/J-5397-2018	Strimmer, Korbinian/0000-0001-7917-2056; Vandamme, Anne-Mieke/0000-0002-6594-2766; Delaporte, Eric/0000-0002-1822-9853					0	101	107	1	23	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	FEB	2001	15	2					276	278		10.1096/fj.00-0449fje	http://dx.doi.org/10.1096/fj.00-0449fje			3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	400LK	11156935				2022-12-25	WOS:000166872900001
J	Comhair, SAA; Bhathena, PR; Farver, C; Thunnissen, FBJM; Erzurum, SC				Comhair, SAA; Bhathena, PR; Farver, C; Thunnissen, FBJM; Erzurum, SC			Extracellular glutathione peroxidase induction in asthmatic lungs: evidence for redox regulation of expression in human airway epithelial cells	FASEB JOURNAL			English	Article						reactive oxygen species; asthma; lung; nitrotyrosine	NITRIC-OXIDE SYNTHASE; PLASMA GLUTATHIONE; SUPEROXIDE-DISMUTASE; LINING FLUID; EXHALED AIR; ANTIOXIDANT; GENE; OXIDATION; OXIDANTS; DEXAMETHASONE	A critical first-line antioxidant defense on the airway epithelial surface against reactive oxygen and nitrogen species (ROS and RNS) is extracellular glutathione peroxidase (eGPx). Little is known about the regulation of eGPx or its role in ROS-mediated lung diseases such as asthma. Here we show that eGPx is increased in the asthmatic airway in comparison to healthy controls. Higher levels of eGPx mRNA in asthmatic airway epithelium verified bronchial epithelial cells as the source for the increased eGPx, The eGPx mRNA in bronchial epithelial cells in vitro increased eightfold after exposure to ROS and glutathione, an essential cofactor for eGPx activity. Alterations in intracellular and extracellular oxidized and reduced glutathione were temporally associated with eGPx induction, further supporting redox mechanisms in gene expression, Overexpression of superoxide dismutase, but not catalase, inhibited induction and identified superoxide as a key intermediary. The eGPx mRNA half-life was not affected by ROS, suggesting a transcriptional mechanism for eGPx regulation. Fusion genes of deletion fragments of the eGPx gene 5' flanking region driving a reporter gene conclusively identified the ROS-responsive region, which contained the consensus DNA binding site for the redox-regulated transcription factor, activator protein 1.	Cleveland Clin Fdn, Dept Pulm & Crit Care Med, Lerner Res Inst, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Dept Canc Biol, Lerner Res Inst, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Dept Pathol, Lerner Res Inst, Cleveland, OH 44195 USA; Canisius Wilhelmina Hosp, Dept Pathol, NL-6500 GS Nijmegen, Netherlands	Cleveland Clinic Foundation; Cleveland Clinic Foundation; Cleveland Clinic Foundation; Canisius-Wilhelmina Hospital	Erzurum, SC (corresponding author), Cleveland Clin Fdn, Dept Pulm & Crit Care Med, Lerner Res Inst, 9500 Euclid Ave,A90, Cleveland, OH 44195 USA.	erzurus@ccf.org		Thunnissen, Erik/0000-0001-5355-8508	NHLBI NIH HHS [HL 60917] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL060917, R37HL060917] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADAMS JD, 1983, J PHARMACOL EXP THER, V227, P749; Arteel GE, 1999, FEBS LETT, V445, P226, DOI 10.1016/S0014-5793(99)00073-3; ASAHI M, 1995, J BIOL CHEM, V270, P21035, DOI 10.1074/jbc.270.36.21035; Asahi M, 1997, J BIOL CHEM, V272, P19152, DOI 10.1074/jbc.272.31.19152; Avissar N, 1996, AM J PHYSIOL-LUNG C, V270, pL173, DOI 10.1152/ajplung.1996.270.2.L173; AVISSAR N, 1991, J NUTR, V121, P1243, DOI 10.1093/jn/121.8.1243; AVISSAR N, 1994, AM J PHYSIOL, V266, pC367, DOI 10.1152/ajpcell.1994.266.2.C367; CALHOUN WJ, 1992, AM REV RESPIR DIS, V145, P317, DOI 10.1164/ajrccm/145.2_Pt_1.317; CANTIN AM, 1987, J APPL PHYSIOL, V63, P152, DOI 10.1152/jappl.1987.63.1.152; Cheng WH, 1999, FASEB J, V13, P1467, DOI 10.1096/fasebj.13.11.1467; CHU FF, 1992, BLOOD, V79, P3233; Comhair SAA, 1999, AM J RESP CRIT CARE, V159, P1824, DOI 10.1164/ajrccm.159.6.9810044; Comhair SAA, 2000, AM J RESP CELL MOL, V23, P350, DOI 10.1165/ajrcmb.23.3.4076; Comhair SAA, 2000, LANCET, V355, P624, DOI 10.1016/S0140-6736(99)04736-4; Danel C, 1998, HUM GENE THER, V9, P1487, DOI 10.1089/hum.1998.9.10-1487; DENEKE SM, 1989, AM J PHYSIOL, V257, pL163, DOI 10.1152/ajplung.1989.257.4.L163; DeRaeve HR, 1997, AM J PHYSIOL-LUNG C, V272, pL148, DOI 10.1152/ajplung.1997.272.1.L148; Guo FH, 1997, J CLIN INVEST, V100, P829, DOI 10.1172/JCI119598; HAMID Q, 1993, LANCET, V342, P1510, DOI 10.1016/S0140-6736(05)80083-2; Hou YC, 1996, BIOCHEM BIOPH RES CO, V228, P88, DOI 10.1006/bbrc.1996.1620; HOWIE AF, 1995, BIOCHEM J, V308, P713, DOI 10.1042/bj3080713; Jobsis Q, 1997, EUR RESPIR J, V10, P519; Kaminsky DA, 1999, J ALLERGY CLIN IMMUN, V104, P747, DOI 10.1016/S0091-6749(99)70283-6; KANAZAWA H, 1991, CHEST, V100, P1319, DOI 10.1378/chest.100.5.1319; KELLY FJ, 1999, LANCET, V354, P9177; KHARITONOV SA, 1994, LANCET, V343, P133, DOI 10.1016/S0140-6736(94)90931-8; Kingsley PD, 1998, MOL REPROD DEV, V49, P343, DOI 10.1002/(SICI)1098-2795(199804)49:4<343::AID-MRD1>3.3.CO;2-T; Klatt P, 1999, FASEB J, V13, P1481, DOI 10.1096/fasebj.13.12.1481; MALTER JS, 1991, J BIOL CHEM, V266, P3167; MARKLUND S, 1974, EUR J BIOCHEM, V47, P469; MEISTER A, 1983, ANNU REV BIOCHEM, V52, P711, DOI 10.1146/annurev.bi.52.070183.003431; Misso NLA, 2000, FREE RADICAL BIO MED, V28, P934, DOI 10.1016/S0891-5849(00)00177-5; *NAT ASTHM ED PREV, 1997, PUBL NAT ASTHM ED PR, V97, P7809; Pietarinen-Runtti P, 1998, AM J RESP CELL MOL, V19, P286, DOI 10.1165/ajrcmb.19.2.2836; Pinkus R, 1996, J BIOL CHEM, V271, P13422, DOI 10.1074/jbc.271.23.13422; Polito AJ, 1998, J ALLERGY CLIN IMMUN, V102, P714, DOI 10.1016/S0091-6749(98)70008-9; Rahman I, 1998, AM J PHYSIOL-LUNG C, V275, pL80, DOI 10.1152/ajplung.1998.275.1.L80; Rahman I, 1999, J BIOL CHEM, V274, P5088, DOI 10.1074/jbc.274.8.5088; Ren B, 1997, J MOL BIOL, V268, P869, DOI 10.1006/jmbi.1997.1005; Saleh D, 1998, FASEB J, V12, P929, DOI 10.1096/fasebj.12.11.929; Sen CK, 1996, FASEB J, V10, P709, DOI 10.1096/fasebj.10.7.8635688; SIEST J, 1997, J BIOL CHEM, V44; Smith L. J., 1996, FOLDING DESIGN, V1, pR95; SMITH LJ, 1993, AM REV RESPIR DIS, V147, P1461, DOI 10.1164/ajrccm/147.6_Pt_1.1461; Sun Y, 1996, FREE RADICAL BIO MED, V21, P335, DOI 10.1016/0891-5849(96)00109-8; Tham DM, 1998, AM J PHYSIOL-GASTR L, V275, pG1463, DOI 10.1152/ajpgi.1998.275.6.G1463; THOMAS EL, 1988, J BIOL CHEM, V263, P2178; van der Vliet A, 1999, AM J RESP CRIT CARE, V160, P1; WINTERBOURN CC, 1989, BIOCHEM PHARMACOL, V38, P271, DOI 10.1016/0006-2952(89)90037-3; WINTERBOURN CC, 1993, FREE RADICAL BIO MED, V14, P85, DOI 10.1016/0891-5849(93)90512-S; YOSHIMURA S, 1994, GENE, V145, P293	51	130	133	0	11	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2001	15	1					70	78		10.1096/fj.00-0085com	http://dx.doi.org/10.1096/fj.00-0085com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	390TH	11149894				2022-12-25	WOS:000166312400015
J	Faber-Elmann, A; Grabovsky, V; Dayan, M; Sela, M; Alon, R; Mozes, E				Faber-Elmann, A; Grabovsky, V; Dayan, M; Sela, M; Alon, R; Mozes, E			An altered peptide ligand inhibits the activities of matrix metalloproteinase-9 and phospholipase C, and inhibits T cell interactions with VCAM-1 induced in vivo by a myasthenogenic T cell epitope	FASEB JOURNAL			English	Article						autoimmune myasthenia gravis; T cell receptor; immunomodulation; T cell adhesiveness	LYMPHOCYTE ANTIGEN RECEPTORS; ACETYLCHOLINE-RECEPTOR; AUTOIMMUNE-RESPONSE; SIGNAL-TRANSDUCTION; ADHESION MOLECULES; INTEGRIN VLA-4; ALPHA-SUBUNIT; GRAVIS; ANALOGS; FLOW	Myasthenia gravis (MG) is a T cell-regulated, antibody-mediated autoimmune disease. Immunization with two myasthenogenic peptides, p195-212 and p259-271, which are sequences of the human acetylcholine receptor, resulted in MG-associated immune responses. A dual altered peptide ligand (APL) composed of the two APLs of the myasthenogenic peptides inhibited, in vitro and in vivo, those responses. This study was aimed at understanding the mechanism(s) underlying the in vivo inhibitory properties of the dual APL. To this end, we analyzed T cells of mice that were immunized with p259-271 for their adhesiveness toward vascular cell adhesion molecule 1, for the activity of their secreted matrix metalloproteinases (MMPs), and for their intracellular phospholipase C (PLC) activity. Immunization with p259-271 triggered the above three activities and in vivo administration of the dual APL inhibited the latter. Thus, treatment of mice with the dual APL interferes with functions required for T cells to migrate and interact with the self-AChR. This is the first indication that very late antigen 4, MMP-9, and PLC are targets for immunomodulation of autoreactive T cells by altered peptide ligands.	Weizmann Inst Sci, Dept Immunol, IL-76100 Rehovot, Israel	Weizmann Institute of Science	Mozes, E (corresponding author), Weizmann Inst Sci, Dept Immunol, IL-76100 Rehovot, Israel.	edna.mozes@weizmann.ac.il	ALON, RONEN/GRX-6987-2022	Alon, Ronen/0000-0001-9161-6369				AlberolaIla J, 1997, ANNU REV IMMUNOL, V15, P125, DOI 10.1146/annurev.immunol.15.1.125; ALON R, 1995, J CELL BIOL, V128, P1243, DOI 10.1083/jcb.128.6.1243; Anzai N, 1999, BLOOD, V93, P3317, DOI 10.1182/blood.V93.10.3317.410k12_3317_3326; Archelos JJ, 1997, MOL MED TODAY, V3, P310, DOI 10.1016/S1357-4310(97)01066-6; AXELROD O, 1986, IMMUNOBIOLOGY, V172, P99, DOI 10.1016/S0171-2985(86)80056-0; BIRKEDALHANSEN H, 1995, CURR OPIN CELL BIOL, V7, P728, DOI 10.1016/0955-0674(95)80116-2; BROCKE S, 1990, IMMUNOLOGY, V69, P495; BROCKE S, 1988, J CLIN INVEST, V82, P1894, DOI 10.1172/JCI113807; Butcher EC, 1996, SCIENCE, V272, P60, DOI 10.1126/science.272.5258.60; Chan AC, 1996, CURR OPIN IMMUNOL, V8, P394, DOI 10.1016/S0952-7915(96)80130-0; CHAN AC, 1994, ANNU REV IMMUNOL, V12, P555, DOI 10.1146/annurev.iy.12.040194.003011; Chen C, 1999, J IMMUNOL, V162, P1084; CONTITRONCONI BM, 1994, CRIT REV BIOCHEM MOL, V29, P69, DOI 10.3109/10409239409086798; DRACHMAN DB, 1994, NEW ENGL J MED, V330, P1797, DOI 10.1056/NEJM199406233302507; EVAVOLD BD, 1993, IMMUNOL TODAY, V14, P602, DOI 10.1016/0167-5699(93)90200-5; Faber-Elmann A, 1998, P NATL ACAD SCI USA, V95, P14320, DOI 10.1073/pnas.95.24.14320; FABERELMANN A, 2000, IN PRESS INT IMMUNOL, V12; FUCHS S, 1976, NATURE, V263, P329, DOI 10.1038/263329a0; Goetzl EJ, 1996, J IMMUNOL, V156, P1; Gross J., 1981, CELL BIOL EXTRACELLU; HEMLER ME, 1990, IMMUNOL REV, V114, P45, DOI 10.1111/j.1600-065X.1990.tb00561.x; KASSNER PD, 1995, MOL BIOL CELL, V6, P661, DOI 10.1091/mbc.6.6.661; Katz-Levy Y, 1998, J NEUROIMMUNOL, V85, P78, DOI 10.1016/S0165-5728(97)00265-8; KatzLevy Y, 1997, P NATL ACAD SCI USA, V94, P3200, DOI 10.1073/pnas.94.7.3200; Kirshner SL, 1996, SCAND J IMMUNOL, V44, P512, DOI 10.1046/j.1365-3083.1996.d01-330.x; LAWRENCE MB, 1991, CELL, V65, P859, DOI 10.1016/0092-8674(91)90393-D; LINDSTROM J, 1988, ADV IMMUNOL, V42, P233, DOI 10.1016/S0065-2776(08)60847-0; LOBB RR, 1994, J CLIN INVEST, V94, P1722, DOI 10.1172/JCI117519; Madri JA, 1996, BIOCHEM CELL BIOL, V74, P749, DOI 10.1139/o96-082; Massova I, 1998, FASEB J, V12, P1075, DOI 10.1096/fasebj.12.12.1075; McMurray RW, 1996, SEMIN ARTHRITIS RHEU, V25, P215, DOI 10.1016/S0049-0172(96)80034-5; Mobley JL, 1996, J IMMUNOL, V156, P948; Paas-Rozner M, 2000, P NATL ACAD SCI USA, V97, P2168, DOI 10.1073/pnas.040554597; PICKER LJ, 1994, CURR OPIN IMMUNOL, V6, P394, DOI 10.1016/0952-7915(94)90118-X; RIIKONEN T, 1995, J BIOL CHEM, V270, P13548, DOI 10.1074/jbc.270.22.13548; ROMANIC AM, 1994, J CELL BIOL, V125, P1165, DOI 10.1083/jcb.125.5.1165; SANCHEZMADRID F, 1998, J IMMUNOL, V161, P65; Shingleton WD, 1996, BIOCHEM CELL BIOL, V74, P759, DOI 10.1139/o96-083; SLOANLANCASTER J, 1995, CURR OPIN IMMUNOL, V7, P103, DOI 10.1016/0952-7915(95)80035-2; SloanLancaster J, 1996, ANNU REV IMMUNOL, V14, P1, DOI 10.1146/annurev.immunol.14.1.1; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4; Zisman E, 1996, P NATL ACAD SCI USA, V93, P4492, DOI 10.1073/pnas.93.9.4492	43	9	12	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2001	15	1					187	194		10.1096/fj.99-0976com	http://dx.doi.org/10.1096/fj.99-0976com			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	390TH	11149906				2022-12-25	WOS:000166312400027
J	Okamoto, T; Izumi, H; Imamura, T; Takano, H; Ise, T; Uchiumi, T; Kuwano, M; Kohno, K				Okamoto, T; Izumi, H; Imamura, T; Takano, H; Ise, T; Uchiumi, T; Kuwano, M; Kohno, K			Direct interaction of p53 with the Y-box binding protein, YB-1: a mechanism for regulation of human gene expression	ONCOGENE			English	Article						Y-box binding proteins; p53; protein binding; transcriptional regulation	COLD-SHOCK DOMAIN; C-TERMINAL DOMAIN; HUMAN MDR1 GENE; DNA-BINDING; MESSENGER-RNA; ACTIVATION; PHOSPHORYLATION; SEQUENCE; DAMAGE; PROMOTER	The Y-box binding protein, YB-1, belongs to a family of multifunctional proteins which regulate gene expression on both transcriptional and translational levels. The tumor suppressor gene p53 displays growth suppressive properties by regulating gene expression through transcriptional regulation, We now demonstrate that YB-1 directly interacts with p53 using an in vitro pull-down assay. Using immunochemical co-precipitation methods, we also found that the two proteins are bound in vivo. Deletion analysis showed that three independent domains of YB-1, one at the N-terminal and two at the C-terminal, interact with p53. Conversely, a 14 amino acid sequence at the C-terminal of p53 was required for its interaction with YB-1, Gel mobility shift assays showed that the interaction of YB-1 with p53 stimulated the sequence-specific DNA binding of p53 to its consensus sequence, By contrast, this interaction inhibited the binding of YB-1, Using a p53-responsive p21 promoter linked to a reporter gene, it can be shown that antisense expression of YB-1 inhibits the induction of this promoter by p53 in transient transfection assays, These findings delineate a straightforward mechanism for gene expression through p53-YB-1 interaction.	Univ Occupat & Environm Hlth, Dept Biol Mol, Yahatanishi Ku, Kitakyushu, Fukuoka 8078555, Japan; Kyushu Univ, Grad Sch Med Sci, Dept Biochem Med, Fukuoka 8128582, Japan	University of Occupational & Environmental Health - Japan; Kyushu University	Kohno, K (corresponding author), Univ Occupat & Environm Hlth, Dept Biol Mol, Yahatanishi Ku, 1-1 Iseigaoka, Kitakyushu, Fukuoka 8078555, Japan.							ASAKUNO K, 1994, BIOCHEM BIOPH RES CO, V199, P1428, DOI 10.1006/bbrc.1994.1390; BAKALKIN G, 1994, P NATL ACAD SCI USA, V91, P413, DOI 10.1073/pnas.91.1.413; Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; Bargou RC, 1997, NAT MED, V3, P378; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; CHIN KV, 1992, SCIENCE, V255, P459, DOI 10.1126/science.1346476; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Evdokimova VM, 1998, J BIOL CHEM, V273, P3574, DOI 10.1074/jbc.273.6.3574; Furukawa M, 1998, J BIOL CHEM, V273, P10550, DOI 10.1074/jbc.273.17.10550; GOLDSMITH ME, 1993, J BIOL CHEM, V268, P5856; Gottlieb TM, 1996, BBA-REV CANCER, V1287, P77, DOI 10.1016/0304-419X(95)00019-C; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; Gu W, 1998, BIOL REPROD, V59, P1266, DOI 10.1095/biolreprod59.5.1266; HALAZONETIS TD, 1993, EMBO J, V12, P1021, DOI 10.1002/j.1460-2075.1993.tb05743.x; HASEGAWA SL, 1991, NUCLEIC ACIDS RES, V19, P4915, DOI 10.1093/nar/19.18.4915; Herbert TP, 1999, NUCLEIC ACIDS RES, V27, P1747, DOI 10.1093/nar/27.7.1747; HUPP TR, 1995, CELL, V83, P237, DOI 10.1016/0092-8674(95)90165-5; Ise T, 1999, CANCER RES, V59, P342; Jayaraman L, 1998, GENE DEV, V12, P462, DOI 10.1101/gad.12.4.462; Kapoor M, 1998, P NATL ACAD SCI USA, V95, P2834, DOI 10.1073/pnas.95.6.2834; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; Kelm RJ, 1999, J BIOL CHEM, V274, P14238, DOI 10.1074/jbc.274.20.14238; KOHNO K, 1994, J BIOL CHEM, V269, P20503; Koike K, 1997, FEBS LETT, V417, P390, DOI 10.1016/S0014-5793(97)01296-9; LADOMERY M, 1995, BIOESSAYS, V17, P9, DOI 10.1002/bies.950170104; LEE S, 1995, CELL, V81, P1013, DOI 10.1016/S0092-8674(05)80006-6; LENZ J, 1990, P NATL ACAD SCI USA, V87, P3396, DOI 10.1073/pnas.87.9.3396; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Li WW, 1997, MOL CELL BIOL, V17, P61, DOI 10.1128/MCB.17.1.61; Matsumoto K, 1998, TRENDS CELL BIOL, V8, P318, DOI 10.1016/S0962-8924(98)01300-2; Matsumoto K, 1996, J BIOL CHEM, V271, P22706, DOI 10.1074/jbc.271.37.22706; MIYASHITA T, 1995, CELL, V80, P293; Oda Y, 1998, CLIN CANCER RES, V4, P2273; Ohga T, 1998, J BIOL CHEM, V273, P5997, DOI 10.1074/jbc.273.11.5997; Ohga T, 1996, CANCER RES, V56, P4224; OKAMOTO K, 1994, EMBO J, V13, P4816, DOI 10.1002/j.1460-2075.1994.tb06807.x; Raj GV, 1996, J VIROL, V70, P5944, DOI 10.1128/JVI.70.9.5944-5953.1996; Ruzanov PV, 1999, J CELL SCI, V112, P3487; Safak R, 1999, MOL CELL BIOL, V19, P2712; Sakaguchi K, 1998, GENE DEV, V12, P2831, DOI 10.1101/gad.12.18.2831; Sommerville J, 1999, BIOESSAYS, V21, P319, DOI 10.1002/(SICI)1521-1878(199904)21:4<319::AID-BIES8>3.3.CO;2-V; Thottassery JV, 1997, P NATL ACAD SCI USA, V94, P11037, DOI 10.1073/pnas.94.20.11037; UCHIUMI T, 1993, CELL GROWTH DIFFER, V4, P147; WANG XW, 1995, NAT GENET, V10, P188, DOI 10.1038/ng0695-188; Waterman MJF, 1998, NAT GENET, V19, P175, DOI 10.1038/542; WOLFFE AP, 1994, BIOESSAYS, V16, P245, DOI 10.1002/bies.950160407	46	134	141	0	4	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 14	2000	19	54					6194	6202		10.1038/sj.onc.1204029	http://dx.doi.org/10.1038/sj.onc.1204029			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	388YK	11175333				2022-12-25	WOS:000166210500002
J	Bogliolo, M; Taylor, RM; Caldecott, KW; Frosina, G				Bogliolo, M; Taylor, RM; Caldecott, KW; Frosina, G			Reduced ligation during DNA base excision repair supported by BRCA2 mutant cells	ONCOGENE			English	Article						DNA base excision repair; BRCA2; DNA ligation; abasic sites; uracil	BREAST-CANCER SUSCEPTIBILITY; LIGASE-III; POLYMERASE-BETA; IN-VITRO; PANCREATIC CARCINOMAS; MAMMALIAN-CELLS; RADIATION; MUTATIONS; COMPLEX; XRCC1	The brest cancer predisposing genes BRCA1 and BRCA2 appear to be involved in DNA repair. In particular, the sensitivity of BRCA2-deficient mouse embryonic fibroblasts to ionizing radiation and the demonstrated interaction of the BRCA2 protein with Rad51, a major factor in recombinational repair, indicate that BRCA2 is important for double strand break repair. The human BRCA2-deficient human cell line Capan-1, whilst being sensitive to ionizing radiation, is also sensitive to the alkylating agent methymethanesulfonate, The major lesions induced by this agent are methylated bases which are removed primarily by the base excision repair (BER) pathway. We have investigated the efficiency of BER in Capan-1 cells by an in vitro assay in which plasmid substrates containing a single lesion are repaired by mammalian cell extracts. In comparison to the control cell lines BxPC-3, T24 and MCF7, Capan-1 cells exhibited a reduced rate of DNA ligation during both the single-nucleotide insertion and PCNA-dependent pathways of BER, The reduced rate of DNA ligation exhibited by Capan-1 cell extracts was complemented by addition of bacteriophage T4 DNA ligase or human DNA ligase III, BXCA2-mutant Capan-1 cells may possess reduced DNA ligase activity during BER.	Ist Nazl Ric Canc, DNA Repair Unit, Mutagenesis Lab, I-16132 Genoa, Italy; Univ Manchester, Sch Biol Sci, AstraZeneca Lab Cell & Mol Biol, Manchester M13 9PT, Lancs, England	University of Genoa; IRCCS AOU San Martino IST; AstraZeneca; University of Manchester	Frosina, G (corresponding author), Ist Nazl Ric Canc, DNA Repair Unit, Mutagenesis Lab, Largo Rosanna Benzi 10, I-16132 Genoa, Italy.		Bogliolo, Massimo/J-1631-2019; Caldecott, Keith/S-4245-2019; Frosina, Guido/Z-2382-2019	Frosina, Guido/0000-0002-6717-5097; Bogliolo, Massimo/0000-0001-8240-7784; Caldecott, Keith/0000-0003-4255-9016	Telethon [E.0728] Funding Source: Medline	Telethon(Fondazione Telethon)		Abbott DW, 1998, J NATL CANCER I, V90, P978, DOI 10.1093/jnci/90.13.978; Biade S, 1998, J BIOL CHEM, V273, P898, DOI 10.1074/jbc.273.2.898; Caldecott KW, 1996, NUCLEIC ACIDS RES, V24, P4387, DOI 10.1093/nar/24.22.4387; CALDECOTT KW, 1994, MOL CELL BIOL, V14, P68, DOI 10.1128/MCB.14.1.68; Caldecott KW, 1995, NUCLEIC ACIDS RES, V23, P4836, DOI 10.1093/nar/23.23.4836; Cappelli E, 2000, CARCINOGENESIS, V21, P1135, DOI 10.1093/carcin/21.6.1135; Cappelli E, 1997, J BIOL CHEM, V272, P23970, DOI 10.1074/jbc.272.38.23970; Chen PL, 1998, P NATL ACAD SCI USA, V95, P5287, DOI 10.1073/pnas.95.9.5287; Connor F, 1997, NAT GENET, V17, P423, DOI 10.1038/ng1297-423; DIANOV G, 1992, MOL CELL BIOL, V12, P1605, DOI 10.1128/MCB.12.4.1605; Frosina G, 1999, METH MOL B, V113, P301; Frosina G, 1996, J BIOL CHEM, V271, P9573, DOI 10.1074/jbc.271.16.9573; Goggins M, 1996, CANCER RES, V56, P5360; Grawunder U, 1997, NATURE, V388, P492, DOI 10.1038/41358; Kubota Y, 1996, EMBO J, V15, P6662, DOI 10.1002/j.1460-2075.1996.tb01056.x; Livingston DM, 1997, JAMA-J AM MED ASSOC, V277, P1476; Ludwig T, 1997, GENE DEV, V11, P1226, DOI 10.1101/gad.11.10.1226; Morimatsu M, 1998, CANCER RES, V58, P3441; Neuhausen S, 1996, NAT GENET, V13, P126, DOI 10.1038/ng0596-126; Patel KJ, 1998, MOL CELL, V1, P347, DOI 10.1016/S1097-2765(00)80035-0; Prasad R, 1996, J BIOL CHEM, V271, P16000, DOI 10.1074/jbc.271.27.16000; Rahman N, 1998, ANNU REV GENET, V32, P95, DOI 10.1146/annurev.genet.32.1.95; REDSTON MS, 1994, CANCER RES, V54, P3025; Schutte M, 1997, CANCER RES, V57, P3126; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; Sharan SK, 1997, NATURE, V386, P804, DOI 10.1038/386804a0; Su LK, 1998, ONCOGENE, V17, P2377, DOI 10.1038/sj.onc.1202162; Suzuki A, 1997, GENE DEV, V11, P1242, DOI 10.1101/gad.11.10.1242; TANAKA M, 1992, CELL, V68, P755, DOI 10.1016/0092-8674(92)90150-B; Teo SH, 2000, CURR BIOL, V10, P165, DOI 10.1016/S0960-9822(00)00317-1; Welcsh PL, 2000, TRENDS GENET, V16, P69, DOI 10.1016/S0168-9525(99)01930-7; Yuan SSF, 1999, CANCER RES, V59, P3547	32	19	19	1	3	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 23	2000	19	50					5781	5787		10.1038/sj.onc.1203951	http://dx.doi.org/10.1038/sj.onc.1203951			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	376VP	11126365				2022-12-25	WOS:000165477700010
J	Lorenzo, P; Aspberg, A; Onnerfjord, P; Bayliss, MT; Neame, PJ; Heinegard, D				Lorenzo, P; Aspberg, A; Onnerfjord, P; Bayliss, MT; Neame, PJ; Heinegard, D			Identification and characterization of asporin - A novel member of the leucine-rich repeat protein family closely related to decorin and biglycan	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KERATAN SULFATE PROTEOGLYCAN; STATIONARY NIGHT BLINDNESS; EXTRACELLULAR-MATRIX; BONE SIALOPROTEIN; CHROMOSOMAL LOCALIZATION; MOLECULAR-CLONING; CORE PROTEIN; OSTEOINDUCTIVE FACTOR; CRYSTAL-FORMATION; COLLAGEN FIBRILS	Asporin, a novel member of the leucine-rich repeat family of proteins, was partially purified from human articular cartilage and meniscus. Cloning of human and mouse asporin cDNAs revealed that the protein is closely related to decorin and biglycan. It contains a putative propeptide, 4 amino-terminal cysteines, 10 leucine-rich repeats, and 2 C-terminal cysteines. In contrast to decorin and biglycan, asporin is not a proteoglycan. Instead, asporin contains a unique stretch of aspartic acid residues in its amino-terminal region. A polymorphism was identified in that the number of consecutive aspartate residues varied from 11 to 15. The 8 exons of the human asporin gene span 26 kilobases on chromosome 9q31.1-32, and the putative promoter region lacks TATA consensus sequences. The asporin mRNA is expressed in a variety of human tissues with higher levels in osteoarthritic articular cartilage, aorta, uterus, heart, and liver. The deduced amino acid sequence of asporin was confirmed by mass spectrometry of the isolated protein resulting in 84% sequence coverage. The protein contains an N-glycosylation site at Asn(281) with a heterogeneous oligosaccharide structure and a potential O-glycosylation site at Ser(54). The name asporin reflects the aspartate-rich amino terminus and the overall similarity to decorin.	Univ Lund, Dept Cell & Mol Biol, Sect Connect Tissue Biol, SE-22184 Lund, Sweden; Shriners Hosp Children, Tampa, FL 33612 USA; Univ London Royal Vet Coll, London NW1 0TU, England	Lund University; University of London; University of London Royal Veterinary College	Heinegard, D (corresponding author), Univ Lund, Dept Cell & Mol Biol, Sect Connect Tissue Biol, BMC Plan C12, SE-22184 Lund, Sweden.		Onnerfjord, Patrik/R-3131-2019	Onnerfjord, Patrik/0000-0002-2345-2937; Aspberg, Anders/0000-0002-6588-6944				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Bech-Hansen NT, 2000, NAT GENET, V26, P319, DOI 10.1038/81619; BENGTSSON E, 1995, J BIOL CHEM, V270, P25639, DOI 10.1074/jbc.270.43.25639; Bengtsson E, 2000, J BIOL CHEM, V275, P40695, DOI 10.1074/jbc.M007917200; BLOCHBERGER TC, 1992, J BIOL CHEM, V267, P347; CARDIN AD, 1989, ARTERIOSCLEROSIS, V9, P21, DOI 10.1161/01.ATV.9.1.21; Chakravarti S, 1998, J CELL BIOL, V141, P1277, DOI 10.1083/jcb.141.5.1277; Cooper CA, 2001, PROTEOMICS, V1, P340, DOI 10.1002/1615-9861(200102)1:2<340::AID-PROT340>3.0.CO;2-B; Corpuz LM, 1996, J BIOL CHEM, V271, P9759, DOI 10.1074/jbc.271.16.9759; DANIELSON KG, 1993, GENOMICS, V15, P146, DOI 10.1006/geno.1993.1022; Danielson KG, 1997, J CELL BIOL, V136, P729, DOI 10.1083/jcb.136.3.729; Deere M, 1996, GENOMICS, V38, P399, DOI 10.1006/geno.1996.0643; Ehring H, 1997, RAPID COMMUN MASS SP, V11, P1867; FISHER LW, 1991, J BIOL CHEM, V266, P14371; FISHER LW, 1989, J BIOL CHEM, V264, P4571; Friedman JS, 2000, INVEST OPHTH VIS SCI, V41, P2059; Funderburgh JL, 1997, J BIOL CHEM, V272, P28089, DOI 10.1074/jbc.272.44.28089; HEDBOM E, 1989, J BIOL CHEM, V264, P6898; HEDBOM E, 1993, J BIOL CHEM, V268, P27307; HEINEGARD D, 1987, METHOD ENZYMOL, V144, P319; HILDEBRAND A, 1994, BIOCHEM J, V302, P527, DOI 10.1042/bj3020527; Hobby P, 2000, MOL VIS, V6, P72; Hocking AM, 1996, J BIOL CHEM, V271, P19571, DOI 10.1074/jbc.271.32.19571; HUNTER GK, 1993, P NATL ACAD SCI USA, V90, P8562, DOI 10.1073/pnas.90.18.8562; HUNTER GK, 1994, BIOCHEM J, V300, P723, DOI 10.1042/bj3000723; HUNTER GK, 1994, BIOCHEM J, V302, P175, DOI 10.1042/bj3020175; Iozzo RV, 1997, CRIT REV BIOCHEM MOL, V32, P141, DOI 10.3109/10409239709108551; Jimenez SA, 1998, OSTEOARTHRITIS, P31; Johnson HJ, 1997, J BIOL CHEM, V272, P18709, DOI 10.1074/jbc.272.30.18709; KRUSIUS T, 1986, P NATL ACAD SCI USA, V83, P7683, DOI 10.1073/pnas.83.20.7683; Lorenzo P, 1998, J BIOL CHEM, V273, P23469, DOI 10.1074/jbc.273.36.23469; MADISEN L, 1990, DNA CELL BIOL, V9, P303, DOI 10.1089/dna.1990.9.303; NEAME PJ, 1994, J BIOL CHEM, V269, P21547; Nishiu J, 1998, GENOMICS, V52, P378, DOI 10.1006/geno.1998.5455; OLDBERG A, 1986, P NATL ACAD SCI USA, V83, P8819, DOI 10.1073/pnas.83.23.8819; OLDBERG A, 1988, J BIOL CHEM, V263, P19430; Oldberg A, 1996, FEBS LETT, V386, P29, DOI 10.1016/0014-5793(96)00407-3; OLDBERG A, 1989, EMBO J, V8, P2601, DOI 10.1002/j.1460-2075.1989.tb08399.x; PAULSSON M, 1983, BIOCHEM J, V212, P659, DOI 10.1042/bj2120659; Pusch CM, 2000, NAT GENET, V26, P324, DOI 10.1038/81627; Reardon AJ, 2000, J BIOL CHEM, V275, P2123, DOI 10.1074/jbc.275.3.2123; Sambrook J., 2002, MOL CLONING LAB MANU; Sarioglu H, 2000, ELECTROPHORESIS, V21, P2209, DOI 10.1002/1522-2683(20000601)21:11<2209::AID-ELPS2209>3.0.CO;2-T; Schuerenbeg M, 2000, ANAL CHEM, V72, P3436, DOI 10.1021/ac000092a; Scott IC, 2000, J BIOL CHEM, V275, P30504, DOI 10.1074/jbc.M004846200; SHINOMURA T, 1992, J BIOL CHEM, V267, P1265; Shintani S, 2000, J MOL EVOL, V51, P363, DOI 10.1007/s002390010098; Sommarin Y, 1998, J BIOL CHEM, V273, P16723, DOI 10.1074/jbc.273.27.16723; Svensson L, 1999, J BIOL CHEM, V274, P9636, DOI 10.1074/jbc.274.14.9636; VOGEL KG, 1987, COLLAGEN REL RES, V7, P105; VOGEL KG, 1984, BIOCHEM J, V223, P587, DOI 10.1042/bj2230587; Zhang WZ, 2000, ANAL CHEM, V72, P2482, DOI 10.1021/ac991363o	52	163	177	1	26	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 13	2001	276	15					12201	12211		10.1074/jbc.M010932200	http://dx.doi.org/10.1074/jbc.M010932200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	421UK	11152692	hybrid			2022-12-25	WOS:000168081800103
J	Fujino, T; Kondo, J; Ishikawa, M; Morikawa, K; Yamamoto, TT				Fujino, T; Kondo, J; Ishikawa, M; Morikawa, K; Yamamoto, TT			Acetyl-CoA synthetase 2, a mitochondrial matrix enzyme involved in the oxidation of acetate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHOLINERGIC NERVE-TERMINALS; MOLECULAR CHARACTERIZATION; RAT; CELLS; EXPRESSION; PROTEINS; LIVER	Using peptide sequences derived from bovine cardiac acetyl-CoA synthetase (AceCS), we isolated and characterized cDNAs for a bovine and murine cardiac enzyme designated AceCS2. We also isolated a murine cDNA encoding a hepatic type enzyme, designated AceCS1, identical one reported recently (Luong, A., Hannah, V. C., Brown, M. S., and Goldstein, J. L. (2000) J. Biol. Chem. 275, 26458-26466). Murine AceCS1 and AceCS2 were purified to:homogeneity and characterized. Among C2-C5 short and medium chain fatty acids, both enzymes preferentially utilize acetate with similar affinity. The AceCS2 transcripts are expressed in a wide range of tissues, with the highest levels in heart, and are apparently absent from the liver. The levels of AceCS2 mRNA in skeletal muscle were increased markedly under ketogenic conditions. Subcellular fractionation revealed that AceCS2 is a mitochondrial matrix enzyme. [C-14]Acetate incorporation indicated that acetyl-CoAs produced by AceCS2 are utilized mainly for oxidation.	Tohoku Univ, Gene Res Ctr, Aoba Ku, Sendai, Miyagi 9818555, Japan; Mitsubishi Tokyo Pharmaceut Inc, Yokohama Res Ctr, Yokohama, Kanagawa 2270033, Japan; Biomed Engn Res Inst, Suita, Osaka 5650874, Japan	Tohoku University	Yamamoto, TT (corresponding author), Tohoku Univ, Gene Res Ctr, Aoba Ku, 1 1 Tsutsumidori Amamiya, Sendai, Miyagi 9818555, Japan.	yama@biochem.tohoku.ac.jp						AKANJI AO, 1989, CLIN CHIM ACTA, V185, P25, DOI 10.1016/0009-8981(89)90127-7; BREMER J, 1984, FATTY ACID METABOLIS, P113; Brown MS, 1997, CELL, V89, P331, DOI 10.1016/S0092-8674(00)80213-5; BUCKLEY BM, 1977, BIOCHEM J, V166, P539, DOI 10.1042/bj1660539; Carroll PT, 1997, BRAIN RES, V753, P47, DOI 10.1016/S0006-8993(96)01485-0; CRABTREE B, 1989, BIOCHEM J, V257, P673, DOI 10.1042/bj2570673; Fujino T, 1996, J BIOL CHEM, V271, P16748, DOI 10.1074/jbc.271.28.16748; FUJINO T, 1992, J BIOCHEM-TOKYO, V111, P197, DOI 10.1093/oxfordjournals.jbchem.a123737; Harlow E., 1988, ANTIBODIES LAB MANUA; Iijima H, 1996, EUR J BIOCHEM, V242, P186, DOI 10.1111/j.1432-1033.1996.0186r.x; ISHIKAWA M, 1995, TOHOKU J EXP MED, V175, P55, DOI 10.1620/tjem.175.55; Jeanmougin F, 1998, TRENDS BIOCHEM SCI, V23, P403, DOI 10.1016/S0968-0004(98)01285-7; Kang MJ, 1997, P NATL ACAD SCI USA, V94, P2880, DOI 10.1073/pnas.94.7.2880; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Luong A, 2000, J BIOL CHEM, V275, P26458, DOI 10.1074/jbc.M004160200; MATSUNAGA T, 1985, EUR J BIOCHEM, V152, P331, DOI 10.1111/j.1432-1033.1985.tb09202.x; MIYAZAWA S, 1985, J BIOCHEM, V98, P723, DOI 10.1093/oxfordjournals.jbchem.a135330; Nakai K, 1999, TRENDS BIOCHEM SCI, V24, P34, DOI 10.1016/S0968-0004(98)01336-X; Oikawa E, 1998, J BIOCHEM, V124, P679, DOI 10.1093/oxfordjournals.jbchem.a022165; OKAYAMA H, 1982, MOL CELL BIOL, V2, P161, DOI 10.1128/MCB.2.2.161; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SEUFERT CD, 1974, BIOCHEM BIOPH RES CO, V57, P901, DOI 10.1016/0006-291X(74)90631-7; STERRI SH, 1980, J NEUROCHEM, V35, P249, DOI 10.1111/j.1471-4159.1980.tb12511.x; SUZUKI H, 1990, J BIOL CHEM, V265, P8681; TAKAI T, 1990, BIOCHIM BIOPHYS ACTA, V1048, P105, DOI 10.1016/0167-4781(90)90029-2; Tanaka T, 1981, Methods Enzymol, V71 Pt C, P334; TOH H, 1991, Protein Sequences and Data Analysis, V4, P111; TOH H, 1990, Protein Sequences and Data Analysis, V3, P517; WEBSTER LT, 1963, J BIOL CHEM, V238, P4010	29	212	219	1	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 6	2001	276	14					11420	11426		10.1074/jbc.M008782200	http://dx.doi.org/10.1074/jbc.M008782200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	420AC	11150295	hybrid			2022-12-25	WOS:000167980900115
J	Riehman, K; Crews, C; Fridovich-Keil, JL				Riehman, K; Crews, C; Fridovich-Keil, JL			Relationship between genotype, activity, and galactose sensitivity in yeast expressing patient alleles of human galactose-1-phosphate uridylyltransferase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							URIDYLTRANSFERASE GENE; MOLECULAR CHARACTERIZATION; URIDYL TRANSFERASE; SACCHAROMYCES-CEREVISIAE; CLASSICAL GALACTOSEMIA; MILD GALACTOSEMIA; BIOCHEMICAL BASIS; Q188R MUTATION; MOUSE MODEL; GALT GENE	Impairment of the human enzyme galactose-1-phosphate uridylyltransferase (GALT) results in the potentially lethal disorder galactosemia; the biochemical basis of pathophysiology in galactosemia remains unknown, We have applied a yeast expression system for human GALT to test the hypothesis that genotype will correlate with GALT activity measured in, vitro and with metabolite levels and galactose sensitivity measured in vivo. In particular, we have determined the relative degree of functional impairment associated with each of 16 patient-derived hGALT alleles; activities ranged from null to essentially normal. Next, we utilized strains expressing these alleles to demonstrate a clear inverse relationship between GALT activity and galactose sensitivity. Finally, we monitored accumulation of galactose-1-P, :UDP-gal, and UDP-glc in yeast expressing a subset of these alleles, As reported for humans, yeast deficient in GALT, but not their wild type counterparts, demonstrated elevated levels of galactose l-phosphate and diminished UDP-gal upon exposure to galactose, These results present the first clear evidence in a genetically and biochemically amenable model system of a relationship between GALT genotype, enzyme activity, sensitivity to galactose, and aberrant metabolite accumulation. As such, these data lay a foundation for future studies into the underlying mechanism(s) of galactose sensitivity in yeast and perhaps other eukaryotes, including humans.	Emory Univ, Sch Med, Dept Genet, Atlanta, GA 30322 USA; Emory Univ, Sch Med, Grad Program Genet & Mol Biol, Atlanta, GA 30322 USA	Emory University; Emory University	Fridovich-Keil, JL (corresponding author), Emory Univ, Sch Med, Dept Genet, Rm 431C Dent Bldg,1462 Clifton Rd NE, Atlanta, GA 30322 USA.				NIDDK NIH HHS [DK46403] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK046403, R29DK046403] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ai YJ, 2000, HUM MOL GENET, V9, P1821, DOI 10.1093/hmg/9.12.1821; ANDERSEN MW, 1984, HUM GENET, V65, P287, DOI 10.1007/BF00286519; ASHINO J, 1995, HUM MUTAT, V6, P36, DOI 10.1002/humu.1380060108; BERGMEYER H, 1974, METHOD ENZYMAT AN, P1291; Christacos NC, 2000, MOL GENET METAB, V70, P272, DOI 10.1006/mgme.2000.3019; Crews C, 2000, J BIOL CHEM, V275, P22847, DOI 10.1074/jbc.M001053200; DOUGLAS HC, 1964, GENETICS, V49, P837; ELSAS LJ, 1995, AM J HUM GENET, V56, P630; ELSAS LJ, 1995, EUR J PEDIATR, V154, pS21, DOI 10.1007/BF02143798; Elsevier JP, 1996, P NATL ACAD SCI USA, V93, P7166, DOI 10.1073/pnas.93.14.7166; Elsevier JP, 1996, J BIOL CHEM, V271, P32002, DOI 10.1074/jbc.271.50.32002; Frey PA, 1996, FASEB J, V10, P461, DOI 10.1096/fasebj.10.4.8647345; FRIDOVICHKEIL JL, 1995, AM J HUM GENET, V56, P640; FRIDOVICHKEIL JL, 1993, P NATL ACAD SCI USA, V90, P398, DOI 10.1073/pnas.90.2.398; FridovichKeil JL, 1995, BIOCHEM MOL MED, V56, P121, DOI 10.1006/bmme.1995.1067; Geeganage S, 1998, BIOCHEMISTRY-US, V37, P14500, DOI 10.1021/bi9815546; GUTHRIE C, 1991, METHOD ENZYMOL, V194, P281; Henderson JM, 2000, J BIOL CHEM, V275, P30088, DOI 10.1074/jbc.M005259200; Hirokawa H, 1999, EUR J HUM GENET, V7, P757, DOI 10.1038/sj.ejhg.5200368; Holton J. B., 2000, METABOLIC MOL BASES, P1553; Kabir MA, 2000, MOL GEN GENET, V262, P1113, DOI 10.1007/PL00008654; KAUFMAN FR, 1994, J PEDIATR-US, V125, P225, DOI 10.1016/S0022-3476(94)70197-0; Lai K, 1999, J BIOL CHEM, V274, P6559, DOI 10.1074/jbc.274.10.6559; Lai K, 1996, J PEDIATR-US, V128, P89, DOI 10.1016/S0022-3476(96)70432-8; Lai K, 2000, BIOCHEM BIOPH RES CO, V271, P392, DOI 10.1006/bbrc.2000.2629; LESLIE ND, 1992, GENOMICS, V14, P474, DOI 10.1016/S0888-7543(05)80244-7; Leslie ND, 1996, BIOCHEM MOL MED, V59, P7, DOI 10.1006/bmme.1996.0057; MCCLARY JA, 1989, BIOTECHNIQUES, V7, P282; Mehta DV, 1999, BBA-MOL BASIS DIS, V1454, P217, DOI 10.1016/S0925-4439(99)00037-X; NG WG, 1991, NEONATAL SCREENING 9, P181; Ninfali P, 1996, J NEUROL, V243, P102; Ning C, 2000, PEDIATR RES, V48, P211, DOI 10.1203/00006450-200008000-00015; Quimby BB, 1996, J BIOL CHEM, V271, P26835, DOI 10.1074/jbc.271.43.26835; REICHARDT JKV, 1992, BIOCHEMISTRY-US, V31, P5430, DOI 10.1021/bi00139a002; REICHARDT JKV, 1991, AM J HUM GENET, V49, P860; REICHARDT JKV, 1991, P NATL ACAD SCI USA, V88, P2633, DOI 10.1073/pnas.88.7.2633; Segal S, 1995, METABOLIC MOL BASIS, P967; Shield JPH, 2000, ARCH DIS CHILD, V83, P248, DOI 10.1136/adc.83.3.248; Shin YS, 1999, J INHERIT METAB DIS, V22, P327, DOI 10.1023/A:1005516523196; Shin YS, 1998, J INHERIT METAB DIS, V21, P232, DOI 10.1023/A:1005303818858; Shin YS, 1996, EUR J PEDIATR, V155, P393, DOI 10.1007/s004310050425; SOMMER M, 1995, J INHERIT METAB DIS, V18, P567, DOI 10.1007/BF02436001; Tyfield L, 1999, HUM MUTAT, V13, P417, DOI 10.1002/(SICI)1098-1004(1999)13:6<417::AID-HUMU1>3.0.CO;2-0; WAGGONER DD, 1990, J INHERIT METAB DIS, V13, P802, DOI 10.1007/BF01800204; Wang BBT, 1998, MOL GENET METAB, V63, P263, DOI 10.1006/mgme.1998.2678; Wedekind JE, 1996, BIOCHEMISTRY-US, V35, P11560, DOI 10.1021/bi9612677; Wells L, 1997, J INHERIT METAB DIS, V20, P633, DOI 10.1023/A:1005314207513; Wohlers TM, 2000, J INHERIT METAB DIS, V23, P713, DOI 10.1023/A:1005682913784; XU YK, 1995, CLIN CHIM ACTA, V235, P125, DOI 10.1016/0009-8981(95)06013-X; Zekanowski C, 1999, J INHERIT METAB DIS, V22, P679; ZYDOWSKY LD, 1992, PROTEIN SCI, V1, P961, DOI 10.1002/pro.5560010801	51	44	44	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 6	2001	276	14					10634	10640		10.1074/jbc.M009583200	http://dx.doi.org/10.1074/jbc.M009583200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	420AC	11152465	hybrid			2022-12-25	WOS:000167980900011
J	Shah, AM; Li, SX; Anderson, KS; Sweasy, JB				Shah, AM; Li, SX; Anderson, KS; Sweasy, JB			Y265H mutator mutant of DNA polymerase beta - Proper geometric alignment is critical for fidelity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STATE KINETIC-ANALYSIS; CRYSTAL-STRUCTURES; GAPPED DNA; MECHANISM; REPLICATION; EXCISION; REPAIR; PROCESSIVITY; SUBSTITUTE; DOMAIN	DNA polymerases have the unique ability to select a specific deoxynucleoside triphosphate from a pool of similarly structured substrates. One of these enzymes, DNA polymerase beta, offers a simple system to relate polymerase structure to the fidelity of DNA synthesis. In this study, a mutator DNA polymerase beta, Y265H, was identified using an in vivo genetic screen. Purified Y265H produced errors at a 40-fold higher frequency than the wild-type protein in a forward mutation assay. At 37 degreesC, transient kinetic analysis demonstrated that the alteration:caused a 111-fold decrease in the maximum rate of polymerization and a 117-fold loss in fidelity for G misincorporation opposite template A. Our data suggest that the maximum rate of polymerization was reduced, because Y265H was dramatically impaired in its ability to perform nucleotidyl transfer in the presence of the correct nucleotide substrate. In contrast, at 20 degreesC, the mutant protein had a fidelity similar to wildtype enzyme. Both proteins at 20 degreesC demonstrate a rapid change in protein conformation, followed by a slow chemical step. These data suggest that proper geometric alignment of template, 3'-OH of the primer, magnesium ions, dNTP substrates, and the active site residues of DNA polymerase beta are important factors in polymerase fidelity and provide the first evidence that Tyr-265 is important for this alignment to occur properly in DNA polymerase beta.	Yale Univ, Sch Med, Dept Therapeut Radiol, New Haven, CT 06520 USA; Yale Univ, Sch Med, Dept Genet, New Haven, CT 06520 USA; Yale Univ, Sch Med, Dept Pharmacol, New Haven, CT 06520 USA	Yale University; Yale University; Yale University	Sweasy, JB (corresponding author), Yale Univ, Sch Med, Dept Therapeut Radiol, 333 Cedar St,POB 208240, New Haven, CT 06520 USA.				NATIONAL CANCER INSTITUTE [T32CA009259, F32CA083250, R01CA080830, T32CA009159] Funding Source: NIH RePORTER; NCI NIH HHS [T32-CA09259, F32-CA83250, CA80830, T32-CA09159] Funding Source: Medline; NIGMS NIH HHS [GM49551] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ahn JW, 1998, BIOCHEM J, V331, P79, DOI 10.1042/bj3310079; CARSON M, 1991, J APPL CRYSTALLOGR, V24, P958, DOI 10.1107/S0021889891007240; Chagovetz AM, 1997, J BIOL CHEM, V272, P27501, DOI 10.1074/jbc.272.44.27501; Eckert KA, 1997, NUCLEIC ACIDS RES, V25, P1450, DOI 10.1093/nar/25.7.1450; Feng JA, 1998, BIOCHEMISTRY-US, V37, P9605, DOI 10.1021/bi9808619; JOHNSONKA, 1993, ANN REV BIOCH, V62, P686; JOYCE CM, 1995, J BACTERIOL, V177, P6321, DOI 10.1128/jb.177.22.6321-6329.1995; KATI WM, 1992, J BIOL CHEM, V267, P25988; Kosa JL, 1999, J BIOL CHEM, V274, P3851, DOI 10.1074/jbc.274.6.3851; Kosa JL, 1999, J BIOL CHEM, V274, P35866, DOI 10.1074/jbc.274.50.35866; Li SX, 1999, BIOCHEMISTRY-US, V38, P4800, DOI 10.1021/bi9827058; Loeb LA, 1996, MUTAT RES-FUND MOL M, V350, P279, DOI 10.1016/0027-5107(95)00117-4; Loeb LA, 1998, ADV CANCER RES, V72, P25, DOI 10.1016/S0065-230X(08)60699-5; MATSUMOTO Y, 1995, SCIENCE, V269, P699, DOI 10.1126/science.7624801; Opresko PL, 2000, BIOCHEMISTRY-US, V39, P11399, DOI 10.1021/bi000698t; Opresko PL, 1998, BIOCHEMISTRY-US, V37, P2111, DOI 10.1021/bi9722711; PATEL SS, 1991, BIOCHEMISTRY-US, V30, P511, DOI 10.1021/bi00216a029; Pelletier H, 1996, BIOCHEMISTRY-US, V35, P12742, DOI 10.1021/bi952955d; Plug AW, 1997, P NATL ACAD SCI USA, V94, P1327, DOI 10.1073/pnas.94.4.1327; Sawaya MR, 1997, BIOCHEMISTRY-US, V36, P11205, DOI 10.1021/bi9703812; Sobol RW, 2000, NATURE, V405, P807, DOI 10.1038/35015598; Sobol RW, 1996, NATURE, V379, P183, DOI 10.1038/379183a0; SOWERS LC, 1986, P NATL ACAD SCI USA, V83, P5434, DOI 10.1073/pnas.83.15.5434; Steitz TA, 1999, J BIOL CHEM, V274, P17395, DOI 10.1074/jbc.274.25.17395; SWEASY JB, 1992, J BIOL CHEM, V267, P1407; SWEASY JB, 1995, J BACTERIOL, V177, P2923, DOI 10.1128/jb.177.10.2923-2925.1995; Washington SL, 1997, P NATL ACAD SCI USA, V94, P1321, DOI 10.1073/pnas.94.4.1321; Werneburg BG, 1996, BIOCHEMISTRY-US, V35, P7041, DOI 10.1021/bi9527202; Zhong XJ, 1998, J AM CHEM SOC, V120, P235, DOI 10.1021/ja973507r; Zhong XJ, 1997, BIOCHEMISTRY-US, V36, P11891, DOI 10.1021/bi963181j	30	63	64	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 6	2001	276	14					10824	10831		10.1074/jbc.M008680200	http://dx.doi.org/10.1074/jbc.M008680200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	420AC	11154692	hybrid			2022-12-25	WOS:000167980900037
J	Shpak, E; Barbar, E; Leykam, JF; Kieliszewski, MJ				Shpak, E; Barbar, E; Leykam, JF; Kieliszewski, MJ			Contiguous hydroxyproline residues direct hydroxyproline arabinosylation in Nicotiana tabacum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-WALL GLYCOPROTEIN; SUSPENSION-CULTURED-CELLS; ARABINOGALACTAN-PROTEINS; MASS-SPECTROMETRY; RICH EXTENSIN; PROLINE; GENE; GLYCOPEPTIDES; BIOSYNTHESIS; ARABINOSIDES	Hydroxyproline (Hyp) O-glycosylation characterizes the hydroxyproline-rich glycoprotein (HRGP) superfamily of the plant extracellular matrix. Hyp glycosylation occurs in two modes: Arabinosylation adds short oligoarabinosides (Hyp-arabinosides) while galactosylation leads to the addition of larger arabinogalactan polysaccharides (Hyp-polysaccharides). We hypothesize that sequence-dependent glycosylation of small peptide motifs results in glycomodules. These small functional units in combination with other repetitive peptide modules define the properties of HRGPs. The Hyp contiguity hypothesis predicts arabinosylation of contiguous Hyp residues and galactosylation of clustered noncontiguous Hyp residues. To determine the minimum level of Hyp contiguity that directs arabinosylation, we designed a series of synthetic genes encoding repetitive (Ser-Pro(2))(n), (Ser-Pro(3))(n), and (Ser-Pro(4))(n). A signal sequence targeted these endogenous substrates to the endoplasmic reticulum/Golgi for post-translational proline hydroxylation and glycosylation in transformed Nicotiana tabacum cells. The fusion glycoproteins also contained green fluorescence protein, facilitating their detection and isolation. The (Ser-Pro(2))(n) and (Ser-Hyp(4))(n) fusion glycoproteins yielded Hyp-arabinosides but no Hyp-polysaccharide. The motif (Ser-Pro(3))(n) was incompletely hydroxylated, yielding mixed contiguous/noncontiguous Hyp and a corresponding mixture of Hyparabinosides and Hyp-polysaccharides, These results plus circular dichroic spectra of the glycosylated and deglycosylated (Ser-Pro(2))(n), (Ser-Pro(3))(n), and (Ser-Pro(4))(n) modules corroborate the Hyp contiguity hypothesis and indicate that Hyp O-glycosylation is indeed sequence-driven.	Ohio Univ, Dept Chem & Biochem, Clippinger Labs, Athens, OH 45701 USA; Michigan State Univ, Dept Biochem, E Lansing, MI 48824 USA	University System of Ohio; Ohio University; Michigan State University	Kieliszewski, MJ (corresponding author), Ohio Univ, Dept Chem & Biochem, Clippinger Labs, Athens, OH 45701 USA.	kielisze@helios.phy.ohiou.edu		Shpak, Elena/0000-0002-5702-7517; Barbar, Elisar/0000-0003-4892-5259				AKIYAMA Y, 1980, AGR BIOL CHEM TOKYO, V44, P2487, DOI 10.1080/00021369.1980.10864347; AN G, 1988, PLANT MOL BIOL MANUA, V1, P1; ASPINALL GO, 1969, CAN J BIOCHEM, V47, P1070; BACIC A, 1987, CARBOHYD RES, V162, P85, DOI 10.1016/0008-6215(87)80203-3; BALDWIN TC, 1993, PLANT PHYSIOL, V103, P115, DOI 10.1104/pp.103.1.115; BHATTI T, 1970, BIOCHIM BIOPHYS ACTA, V222, P339, DOI 10.1016/0304-4165(70)90122-4; BLUMENKR.N, 1973, ANAL BIOCHEM, V54, P484, DOI 10.1016/0003-2697(73)90377-1; BOWN DP, 1993, GENE, V134, P229, DOI 10.1016/0378-1119(93)90098-N; CHO YP, 1976, PHYTOCHEMISTRY, V15, P165, DOI 10.1016/S0031-9422(00)89077-9; Choi SB, 2000, NATURE, V407, P765, DOI 10.1038/35037633; DEFAYE J, 1986, CARBOHYD RES, V150, P221, DOI 10.1016/0008-6215(86)80018-0; FINCHER GB, 1983, ANNU REV PLANT PHYS, V34, P47, DOI 10.1146/annurev.pp.34.060183.000403; FONG C, 1992, PLANT PHYSIOL, V99, P548, DOI 10.1104/pp.99.2.548; Goodrum LJ, 2000, PHYTOCHEMISTRY, V54, P99, DOI 10.1016/S0031-9422(00)00043-1; HILLESTAD A, 1977, PHYTOCHEMISTRY, V16, P1953, DOI 10.1016/0031-9422(77)80103-9; HOMER RB, 1979, PLANTA, V146, P217, DOI 10.1007/BF00388235; Karacsonyi S, 1998, CARBOHYD RES, V307, P271, DOI 10.1016/S0008-6215(98)00052-4; KIELISZEWSKI M, 1987, PLANT PHYSIOL, V85, P823, DOI 10.1104/pp.85.3.823; KIELISZEWSKI M, 1992, PLANT PHYSIOL, V98, P919, DOI 10.1104/pp.98.3.919; KIELISZEWSKI MJ, 1990, PLANT PHYSIOL, V92, P316, DOI 10.1104/pp.92.2.316; KIELISZEWSKI MJ, 1992, PLANT PHYSIOL, V99, P538, DOI 10.1104/pp.99.2.538; KIELISZEWSKI MJ, 1995, J BIOL CHEM, V270, P2541, DOI 10.1074/jbc.270.6.2541; KIELISZEWSKI MJ, 1994, PLANT J, V5, P157, DOI 10.1046/j.1365-313X.1994.05020157.x; Kieliszewski MJ, 1997, PHYTOCHEMISTRY, V45, P9, DOI 10.1016/S0031-9422(96)00794-7; Lamport D. T. A., 1980, The biochemistry of plants. A comprehensive treatise. Volume 3. Carbohydrates: structure and function., P501; LAMPORT DTA, 1967, NATURE, V216, P1322, DOI 10.1038/2161322a0; LAMPORT DTA, 1973, BIOCHEM J, V133, P125, DOI 10.1042/bj1330125; LAMPORT DTA, 1971, PLANT PHYSIOL, V48, P454, DOI 10.1104/pp.48.4.454; Lamport DTA, 1977, RECENT ADV PHYTOCHEM, V11, P79; MARCUS A, 1991, PHYSIOL PLANTARUM, V81, P273; MAZAU D, 1988, PLANT PHYSIOL, V86, P540, DOI 10.1104/pp.86.2.540; MCCORMICK S, 1986, PLANT CELL REP, V5, P81, DOI 10.1007/BF00269239; MCGRATH KP, 1990, BIOTECHNOL PROGR, V6, P188, DOI 10.1021/bp00003a004; Merkouropoulos G, 1999, PLANTA, V208, P212, DOI 10.1007/s004250050552; MORT AJ, 1977, ANAL BIOCHEM, V82, P289, DOI 10.1016/0003-2697(77)90165-8; Myllyharju J, 1999, EMBO J, V18, P306, DOI 10.1093/emboj/18.2.306; Nothnagel EA, 1997, INT REV CYTOL, V174, P195, DOI 10.1016/S0074-7696(08)62118-X; PARMENTIER Y, 1995, PLANT MOL BIOL, V29, P279, DOI 10.1007/BF00043652; RABANAL F, 1993, BIOPOLYMERS, V33, P1019, DOI 10.1002/bip.360330704; REES DA, 1977, POLYSACCHARIDE SHAPE, P41; RUBINSTEIN AL, 1995, P NATL ACAD SCI USA, V92, P3086, DOI 10.1073/pnas.92.8.3086; Ruggiero F, 2000, FEBS LETT, V469, P132, DOI 10.1016/S0014-5793(00)01259-X; SADAVA D, 1971, BIOCHIM BIOPHYS ACTA, V227, P278, DOI 10.1016/0005-2744(71)90060-X; SAULNIER L, 1992, CARBOHYD RES, V224, P219, DOI 10.1016/0008-6215(92)84108-5; SERPE MD, 1994, PLANTA, V193, P542, DOI 10.1007/BF02411560; Shpak E, 1999, P NATL ACAD SCI USA, V96, P14736, DOI 10.1073/pnas.96.26.14736; SMITH JJ, 1986, PHYTOCHEMISTRY, V25, P1021, DOI 10.1016/S0031-9422(00)81547-2; TANAKA M, 1980, BIOCHIM BIOPHYS ACTA, V616, P188, DOI 10.1016/0005-2744(80)90137-0; VANHOLST GJ, 1984, PLANT PHYSIOL, V74, P247, DOI 10.1104/pp.74.2.247; ZHU JK, 1993, PLANTA, V190, P221	50	107	112	1	13	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 6	2001	276	14					11272	11278		10.1074/jbc.M011323200	http://dx.doi.org/10.1074/jbc.M011323200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	420AC	11154705	hybrid			2022-12-25	WOS:000167980900094
J	Usui, Y; Nakase, M; Hotta, H; Urisu, A; Aoki, N; Kitajima, K; Matsuda, T				Usui, Y; Nakase, M; Hotta, H; Urisu, A; Aoki, N; Kitajima, K; Matsuda, T			A 33-kDa allergen from rice (Oryza sativa L. Japonica) - cDNA cloning, expression, and identification as a novel glyoxalase I	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRYPSIN-INHIBITOR FAMILY; ESCHERICHIA-COLI; 14-16 KDA; PROTEINS; GENE; SEQUENCE; PURIFICATION; PLANTS; RNA	Cereal proteins are known to cause allergic reactions such as Baker's asthma and severe atopic dermatitis to certain populations. In rice allergy, proteins with molecular masses of 14-16, 26, 33, and 56 kDa have been demonstrated to be potentially allergenic. In this study, to identify and characterize the 33-kDa allergen, designated Glb33, this protein was first purified to homogeneity, and its cDNA clone was isolated. When expressed in Escherichia coli, the recombinant Glb33 was shown to be as reactive as the native Glb33 with mouse IgG and patients' IgE antibodies to Glb33. The Glb33 cDNA coded for a protein of 291 amino acids with two 120-amino acid residue repeats, and the amino acid sequence showed similarity to glyoxalase I from various organisms, including human, plant, yeast, and bacterium. As expected, both native Glb33 purified from rice seeds and the recombinant protein had glyoxalase I activity that catalyzes condensation of methylglyoxal and glutathione into S-lactoylglutathione. However, Glb33 had a higher sequence identity to the bacterial glyoxalase I rather than to known plant and yeast enzymes. Both the Glb33 transcript and the protein were detected not only in maturing seeds of rice but also in its stem and leaf. Taken all together, the rice allergen, Glb33, was identified to be a novel type of plant glyoxalase I that is expressed in various plant tissues, including maturing seeds.	Nagoya Univ, Dept Appl Mol Biosci, Grad Sch Bioagr Sci, Nagoya, Aichi 4648601, Japan; Fujita Hlth Univ, Sch Med, Dept Pediat, Toyoake, Aichi 4701101, Japan	Nagoya University; Fujita Health University	Matsuda, T (corresponding author), Nagoya Univ, Dept Appl Mol Biosci, Grad Sch Bioagr Sci, Nagoya, Aichi 4648601, Japan.	tmatsuda@agr.nagoya-u.ac.jp						ADACHI T, 1993, PLANT MOL BIOL, V21, P239, DOI 10.1007/BF00019940; Arai T, 1998, INTERNAL MED, V37, P98, DOI 10.2169/internalmedicine.37.98; Baldo B. A., 1984, Advances in Cereal Science and Technology, V6, P289; Breiteneder H, 2000, J ALLERGY CLIN IMMUN, V106, P27, DOI 10.1067/mai.2000.106929; CARBONERO P, 1993, INNOVATIONS PROTEASE, P333; Clugston SL, 1998, BIOCHEMISTRY-US, V37, P8754, DOI 10.1021/bi972791w; Clugston SL, 1998, J MOL EVOL, V47, P230, DOI 10.1007/PL00006380; De Rocher EJ, 1998, PLANT PHYSIOL, V117, P1445, DOI 10.1104/pp.117.4.1445; ENGVALL E, 1972, J IMMUNOL, V109, P129; Espartero J, 1995, PLANT MOL BIOL, V29, P1223, DOI 10.1007/BF00020464; GarciaCasado G, 1996, GLYCOBIOLOGY, V6, P471, DOI 10.1093/glycob/6.4.471; HIGGINS DG, 1988, GENE, V73, P237, DOI 10.1016/0378-1119(88)90330-7; IKEZAWA Z, 1992, ACTA DERM-VENEREOL, P103; INOUE Y, 1987, J BIOCHEM-TOKYO, V102, P583, DOI 10.1093/oxfordjournals.jbchem.a122091; Inoue Y, 1996, J BIOL CHEM, V271, P25958, DOI 10.1074/jbc.271.42.25958; IZUMI H, 1992, FEBS LETT, V302, P213, DOI 10.1016/0014-5793(92)80443-K; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIMAS GG, 1990, PLANTA, V181, P1, DOI 10.1007/BF00202318; Maruyama N, 1998, EUR J BIOCHEM, V255, P739, DOI 10.1046/j.1432-1327.1998.2550739.x; MCKENDREE W, 1997, PLANT PHYSIOL, V115, P314; Nakase M, 1996, J AGR FOOD CHEM, V44, P2624, DOI 10.1021/jf9508099; RACKER E, 1951, J BIOL CHEM, V190, P685; RANGANATHAN S, 1993, J BIOL CHEM, V268, P5661; Rensink WA, 1998, PLANT PHYSIOL, V118, P691, DOI 10.1104/pp.118.2.691; Sampson HA, 1999, J ALLERGY CLIN IMMUN, V103, P717, DOI 10.1016/S0091-6749(99)70411-2; SHIBASAKI M, 1979, J ALLERGY CLIN IMMUN, V64, P259, DOI 10.1016/0091-6749(79)90141-6; Tada Y, 1996, FEBS LETT, V391, P341, DOI 10.1016/0014-5793(96)00773-9; Tavernarakis N, 2000, NAT GENET, V24, P180, DOI 10.1038/72850; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; URISU A, 1991, INT ARCH ALLER A IMM, V96, P244, DOI 10.1159/000235502; Veena, 1999, PLANT J, V17, P385, DOI 10.1046/j.1365-313X.1999.00390.x	31	81	86	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 6	2001	276	14					11376	11381		10.1074/jbc.M010337200	http://dx.doi.org/10.1074/jbc.M010337200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	420AC	11139585	hybrid			2022-12-25	WOS:000167980900108
J	Geha, RM; Rebrin, I; Chen, K; Shih, JC				Geha, RM; Rebrin, I; Chen, K; Shih, JC			Substrate and inhibitor specificities for human monoamine oxidase A and B are influenced by a single amino acid	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; BEHAVIOR; GENES; SELECTIVITY; FORMS; RAT	Monoamine oxidase (MAO) is responsible for the oxidation of biogenic and dietary amines, It exists as two isoforms, A and B, which have a 70% amino acid identity and different substrate and inhibitor specificities. This study reports the identification of residues responsible for conferring this specificity in human MAO A and B, Using site-directed mutagenesis we reciprocally interchanged three pairs of corresponding nonconserved amino acids within the central portion of human MAO. Mutant MAO A-I335Y became like MAO B, which exhibits a higher preference for beta -phenylethylamine than for the MAO A preferred substrate serotonin (5-hydroxytryptamine), and became more sensitive to deprenyl (MAO B-specific inhibitor) than to clorgyline (MAO A-specific inhibitor). The reciprocal mutant MAO B-Y326I exhibited an increased preference for 5-hydroxytryptamine, a decreased preference for beta -phenylethylamine, and, similar to MAO A, was more sensitive to clorgyline than to deprenyl, These mutants also showed a distinct shift in sensitivity for the MAO A- and B-selective inhibitors Ro 41-1049 and Ro 16-6491. Mutant pair MAO A-T245I and MAO B-I236T and mutant pair MAO A-D328G and MAO B-G319D reduced catalytic activity but did not alter specificity. Our results indicate that Ile-335 in MAO A and Tyr-326 in MAO B play a critical role in determining substrate and inhibitor specificities in human MAO A and B.	Univ So Calif, Sch Pharm, Dept Mol Pharmacol & Toxicol, Los Angeles, CA 90089 USA; Univ So Calif, Sch Med, Dept Cell & Neurobiol, Los Angeles, CA 90089 USA	University of Southern California; University of Southern California	Shih, JC (corresponding author), 1985 Zonal Ave, Los Angeles, CA 90089 USA.				NIMH NIH HHS [K05 MH00796, R01 MH37020, R37 MH39085] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [R37MH039085, K05MH000796, R01MH037020] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		BACH AWJ, 1988, P NATL ACAD SCI USA, V85, P4934, DOI 10.1073/pnas.85.13.4934; Binda C, 1999, STRUCTURE, V7, P265, DOI 10.1016/S0969-2126(99)80037-9; BRUNNER HG, 1993, SCIENCE, V262, P578, DOI 10.1126/science.8211186; CASES O, 1995, SCIENCE, V268, P1763, DOI 10.1126/science.7792602; CESURA A M, 1988, Pharmacological Research Communications, V20, P51, DOI 10.1016/S0031-6989(88)80547-2; Cesura AM, 1996, EUR J BIOCHEM, V236, P996, DOI 10.1111/j.1432-1033.1996.00996.x; CESURA AM, 1989, MOL PHARMACOL, V37, P358; Chen K, 1996, J NEUROCHEM, V66, P797; CHEN K, 1994, MOL PHARMACOL, V46, P1226; Crossen R., 1996, BACULOVIRUS EXPRESSI; Egashira T, 1999, JPN J PHARMACOL, V81, P115, DOI 10.1254/jjp.81.115; Geha RM, 2000, J NEUROCHEM, V75, P1304, DOI 10.1046/j.1471-4159.2000.751304.x; GLOVER V, 1977, NATURE, V265, P80, DOI 10.1038/265080a0; GOTTOWIK J, 1993, FEBS LETT, V317, P152, DOI 10.1016/0014-5793(93)81512-X; GOTTOWIK J, 1995, EUR J BIOCHEM, V230, P934, DOI 10.1111/j.1432-1033.1995.tb20639.x; GREENAWALT JW, 1970, J CELL BIOL, V46, P173, DOI 10.1083/jcb.46.1.173; GRIMSBY J, 1991, P NATL ACAD SCI USA, V88, P3637, DOI 10.1073/pnas.88.9.3637; Grimsby J, 1996, LIFE SCI, V58, P777, DOI 10.1016/0024-3205(95)02356-9; GRIMSBY J, 1997, NAT GENET, V17, P1; Inoue H, 1999, J PHARMACOL EXP THER, V291, P856; Knoll J, 1972, Adv Biochem Psychopharmacol, V5, P393; KRUEGER MJ, 1995, BIOCHEM BIOPH RES CO, V206, P556, DOI 10.1006/bbrc.1995.1079; LAN NC, 1989, GENOMICS, V4, P552, DOI 10.1016/0888-7543(89)90279-6; OCARROLL A, 1983, N-S ARCH PHARMACOL, V312, P51; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Shih JC, 1999, ANNU REV NEUROSCI, V22, P197, DOI 10.1146/annurev.neuro.22.1.197; Tsugeno Y, 1997, J BIOL CHEM, V272, P14033, DOI 10.1074/jbc.272.22.14033; TSUGENO Y, 1995, J BIOCHEM-TOKYO, V118, P974, DOI 10.1093/jb/118.5.974; Veselovsky AV, 1998, BIOCHEMISTRY-MOSCOW+, V63, P1441; WU HF, 1993, MOL PHARMACOL, V43, P888	30	139	142	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 30	2001	276	13					9877	9882		10.1074/jbc.M006972200	http://dx.doi.org/10.1074/jbc.M006972200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	420GC	11134050	hybrid			2022-12-25	WOS:000167996400041
J	Geminard, C; Nault, F; Johnstone, RM; Vidal, M				Geminard, C; Nault, F; Johnstone, RM; Vidal, M			Characteristics of the interaction between Hsc70 and the transferrin receptor in exosomes released during reticulocyte maturation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR CHAPERONE HSC70; CELL-DERIVED EXOSOMES; HEAT-SHOCK-PROTEIN; IMMUNOSUPPRESSANT DEOXYSPERGUALIN; UNCOATING ATPASE; SELECTIVE EXTERNALIZATION; SHEEP RETICULOCYTES; HSP70; DOMAIN; ACCUMULATION	The transferrin receptor (TfR) of reticulocytes is released in vesicular form (exosomes) during their maturation to erythrocytes, The heat shock cognate 70-kDa protein (Hsc70) has been demonstrated to interact with the cytosolic domain of the TfR and could thus trigger the receptor toward this secretion pathway. We investigated the characteristics of the interaction between Hsc70 and the TfR in exosomes with an in vitro binding assay using TfR immobilized on Sepharose beads and purified Hsc70. The results show that Hsc70 binds to exosomal TfR with characteristics expected of a chaperone/peptide interaction. We demonstrated that heat-denatured luciferase competed for in vitro binding, dependent on the nucleotide bound to Hsc70, and that this interaction activates the ATPase activity of Hsc70. Moreover, we used immunosuppressive agents that interact with Hsc70, thus decreasing Hsc70 binding to TfR in our in vitro binding assay and enabling us to assess the role of this interaction in vivo during reticulocyte maturation.	Univ Montpellier 2, UMR 5539, CNRS, F-34095 Montpellier, France; McGill Univ, Dept Biochem, Montreal, PQ H3G 1Y6, Canada	Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier; McGill University	Vidal, M (corresponding author), Univ Montpellier 2, UMR 5539, CNRS, CC107, F-34095 Montpellier, France.		Geminard, Charles/O-8035-2018	GEMINARD, Charles/0000-0002-0018-9566				ADAM MA, 1987, BIOCHEM J, V242, P151, DOI 10.1042/bj2420151; Barouch W, 1997, BIOCHEMISTRY-US, V36, P4303, DOI 10.1021/bi962727z; BAYNES RD, 1994, J LAB CLIN MED, V123, P407; Chamberlain LH, 1997, J BIOL CHEM, V272, P31420, DOI 10.1074/jbc.272.50.31420; CHAPPELL TG, 1986, CELL, V45, P3, DOI 10.1016/0092-8674(86)90532-5; CHIANG HL, 1989, SCIENCE, V246, P282; CLEAVELAND JS, 1993, BIOCHEM BIOPH RES CO, V195, P455, DOI 10.1006/bbrc.1993.2065; DAVIS JQ, 1986, J BIOL CHEM, V261, P5368; FOURIE AM, 1994, J BIOL CHEM, V269, P30470; FRAKER PJ, 1978, BIOCHEM BIOPH RES CO, V80, P849, DOI 10.1016/0006-291X(78)91322-0; FUCHS H, 1995, BIOCHEMISTRY-US, V34, P6196, DOI 10.1021/bi00018a024; GAO BC, 1993, J BIOL CHEM, V268, P8507; HOEGER PH, 1994, J IMMUNOL, V153, P3908; Jiang CW, 1998, AM J PHYSIOL-CELL PH, V275, pC171, DOI 10.1152/ajpcell.1998.275.1.C171; Johnstone RM, 1996, J CELL PHYSIOL, V168, P333, DOI 10.1002/(SICI)1097-4652(199608)168:2<333::AID-JCP12>3.0.CO;2-4; JOHNSTONE RM, 1987, J BIOL CHEM, V262, P9412; JOHNSTONE RM, 1991, J CELL PHYSIOL, V147, P27, DOI 10.1002/jcp.1041470105; Komesli S, 1999, INT J IMMUNOPHARMACO, V21, P349, DOI 10.1016/S0192-0561(99)00017-X; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Liu QL, 1996, J BIOL CHEM, V271, P29937, DOI 10.1074/jbc.271.47.29937; Luders J, 2000, J BIOL CHEM, V275, P14817, DOI 10.1074/jbc.275.20.14817; MATHEW A, 1995, BIOCHEM J, V308, P823, DOI 10.1042/bj3080823; MCCARTY JS, 1995, J MOL BIOL, V249, P126, DOI 10.1006/jmbi.1995.0284; Minami Y, 1996, J BIOL CHEM, V271, P19617, DOI 10.1074/jbc.271.32.19617; NADEAU K, 1994, BIOCHEMISTRY-US, V33, P2561, DOI 10.1021/bi00175a027; NADLER SG, 1992, SCIENCE, V258, P484, DOI 10.1126/science.1411548; PALLEROS DR, 1994, J BIOL CHEM, V269, P13107; PAN BT, 1985, J CELL BIOL, V101, P942, DOI 10.1083/jcb.101.3.942; PAN BT, 1983, CELL, V33, P967, DOI 10.1016/0092-8674(83)90040-5; Rabesandratana H, 1998, BLOOD, V91, P2573, DOI 10.1182/blood.V91.7.2573.2573_2573_2580; Raposo G, 1997, MOL BIOL CELL, V8, P2631, DOI 10.1091/mbc.8.12.2631; RAPOSO G, 1996, J EXP MED, V183, P1; SADIS S, 1992, BIOCHEMISTRY-US, V31, P9406, DOI 10.1021/bi00154a012; Strickland E, 1997, J BIOL CHEM, V272, P25421, DOI 10.1074/jbc.272.41.25421; Thery C, 1999, J CELL BIOL, V147, P599, DOI 10.1083/jcb.147.3.599; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Vidal M, 1997, J CELL SCI, V110, P1867; Wolins N, 1997, J CELL BIOL, V139, P1735, DOI 10.1083/jcb.139.7.1735; ZIEGELHOFFER T, 1995, J BIOL CHEM, V270, P10412, DOI 10.1074/jbc.270.18.10412; ZIEMIENOWICZ A, 1995, J BIOL CHEM, V270, P15479, DOI 10.1074/jbc.270.26.15479; Zitvogel L, 1998, NAT MED, V4, P594, DOI 10.1038/nm0598-594	41	60	64	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 30	2001	276	13					9910	9916		10.1074/jbc.M009641200	http://dx.doi.org/10.1074/jbc.M009641200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	420GC	11133993	hybrid			2022-12-25	WOS:000167996400046
J	Sawamura, N; Gong, JS; Garver, WS; Heidenreich, RA; Ninomiya, H; Ohno, K; Yanagisawa, K; Michikawa, M				Sawamura, N; Gong, JS; Garver, WS; Heidenreich, RA; Ninomiya, H; Ohno, K; Yanagisawa, K; Michikawa, M			Site-specific phosphorylation of tau accompanied by activation of mitogen-activated protein kinase (MAPK) in brains of Niemann-Pick type C mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PAIRED HELICAL FILAMENTS; DISEASE TYPE-C; ALZHEIMERS-DISEASE; NEUROFIBRILLARY TANGLES; APOLIPOPROTEIN-E; INTRACELLULAR TRAFFICKING; ABNORMAL PHOSPHORYLATION; ANTIGENIC DETERMINANTS; CHOLESTEROL; ALLELE	Niemann-Pick type C (NPC) disease is characterized by an accumulation of cholesterol in most tissues and progressive neurodegeneration with the formation of neurofibrillary tangles. Neurofibrillary tangles are composed of paired helical filaments (PHF), a major component of which is the hyperphosphorylated tau. In this study we used NPC heterozygous and NPC homozygous mouse brains to investigate the molecular mechanism responsible for tauopathy in NPC, Immunoblot analysis using anti-tau antibodies (Tau-1, PHF-1, AT-180, and AT-100) revealed site-specific phosphorylation of tau at Ser-396 and Ser-404 in the brains of NPC homozygous mice. Mitogen-activated protein kinase, a potential serine kinase known to phosphorylate tau, was activated, whereas other serine kinases such as glycogen synthase kinase-3 beta and cyclin-dependent kinase 5 were inactive. Morphological examination demonstrated that a number of neurons the perikarya of which strongly immunostained with PHF-1, exhibited polymorphorous cytoplasmic inclusion bodies and multi-concentric lamellar-like bodies. Importantly, the accumulation of intracellular cholesterol in NPC mouse brains was determined to be a function of age. From these results we conclude that abnormal cholesterol metabolism due to the genetic mutation in NPC1 may be responsible for activation of the mitogen-activated protein kinase-signaling pathway and site-specific phosphorylation of tau in vivo, leading to tauopathy in NPC.	Natl Inst Longev Sci, Dept Dementia Res, Aichi 4748522, Japan; Univ Arizona, Steele Mem Childrens Res Ctr, Dept Pediat, Tucson, AZ 85724 USA; Tottori Univ, Fac Med, Dept Neurobiol, Yonago, Tottori 683, Japan	University of Arizona; Tottori University	Michikawa, M (corresponding author), Natl Inst Longev Sci, Dept Dementia Res, 36-3 Gengo, Aichi 4748522, Japan.		Sawamura, Naoya/K-1663-2018	Sawamura, Naoya/0000-0003-4753-1119	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK056732] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK56732] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARENDT T, 1995, NEUROSCIENCE, V68, P5, DOI 10.1016/0306-4522(95)00146-A; AUER IA, 1995, ACTA NEUROPATHOL, V90, P547; Billingsley ML, 1997, BIOCHEM J, V323, P577, DOI 10.1042/bj3230577; CORDER EH, 1993, SCIENCE, V261, P921, DOI 10.1126/science.8346443; Cruz JC, 2000, J BIOL CHEM, V275, P4013, DOI 10.1074/jbc.275.6.4013; ELFENBEIN IB, 1968, JOHNS HOPKINS MED J, V123, P205; Fan QW, 2001, J NEUROCHEM, V76, P391, DOI 10.1046/j.1471-4159.2001.00063.x; Furuchi T, 1998, J BIOL CHEM, V273, P21099, DOI 10.1074/jbc.273.33.21099; Garver WS, 2000, J LIPID RES, V41, P673; Garver WS, 1999, BBA-MOL BASIS DIS, V1453, P193, DOI 10.1016/S0925-4439(98)00101-X; GOEDERT M, 1992, NEURON, V8, P159, DOI 10.1016/0896-6273(92)90117-V; GOEDERT M, 1992, FEBS LETT, V312, P95, DOI 10.1016/0014-5793(92)81418-L; Goedert M., 1996, MOL GENETIC BASIS NE, P613; GRUNDKEIQBAL I, 1986, P NATL ACAD SCI USA, V83, P4913, DOI 10.1073/pnas.83.13.4913; GRUNDKEIQBAL I, 1986, J BIOL CHEM, V261, P6084; Gu YJ, 1996, J NEUROCHEM, V67, P1235; Henderson LP, 2000, J BIOL CHEM, V275, P20179, DOI 10.1074/jbc.M001793200; Higgins ME, 1999, MOL GENET METAB, V68, P1, DOI 10.1006/mgme.1999.2882; Kobayashi T, 1999, NAT CELL BIOL, V1, P113, DOI 10.1038/10084; KOSIK KS, 1988, NEURON, V1, P817, DOI 10.1016/0896-6273(88)90129-8; Lange Y, 2000, J BIOL CHEM, V275, P17468, DOI 10.1074/jbc.M000875200; LEE VMY, 1991, SCIENCE, V251, P675, DOI 10.1126/science.1899488; Liscum L, 1998, CURR OPIN LIPIDOL, V9, P131, DOI 10.1097/00041433-199804000-00009; Loftus SK, 1997, SCIENCE, V277, P232, DOI 10.1126/science.277.5323.232; LOVE S, 1995, BRAIN, V118, P119, DOI 10.1093/brain/118.1.119; MORISHIMAKAWASHIMA M, 1995, J BIOL CHEM, V270, P823, DOI 10.1074/jbc.270.2.823; MORRIS MD, 1982, AM J PATHOL, V108, P140; Neufeld EB, 1999, J BIOL CHEM, V274, P9627, DOI 10.1074/jbc.274.14.9627; NUKINA N, 1986, J BIOCHEM-TOKYO, V99, P1541, DOI 10.1093/oxfordjournals.jbchem.a135625; PENTCHEV PG, 1985, P NATL ACAD SCI USA, V82, P8247, DOI 10.1073/pnas.82.23.8247; PENTCHEV PG, 1995, METABOLIC BASIS INHE, P2624; SAUNDERS AM, 1993, NEUROLOGY, V43, P1467, DOI 10.1212/WNL.43.8.1467; Shea TB, 1999, CELL MOL NEUROBIOL, V19, P223, DOI 10.1023/A:1006977127422; STRITTMATTER WJ, 1993, P NATL ACAD SCI USA, V90, P1977, DOI 10.1073/pnas.90.5.1977; SUZUKI K, 1995, ACTA NEUROPATHOL, V89, P227; SZENDREI GI, 1993, J NEUROSCI RES, V34, P243, DOI 10.1002/jnr.490340212; WOOD JG, 1986, P NATL ACAD SCI USA, V83, P4040, DOI 10.1073/pnas.83.11.4040; Xie CL, 1999, AM J PHYSIOL-ENDOC M, V276, pE336, DOI 10.1152/ajpendo.1999.276.2.E336; Xie CL, 1999, P NATL ACAD SCI USA, V96, P11992, DOI 10.1073/pnas.96.21.11992	39	92	98	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 30	2001	276	13					10314	10319		10.1074/jbc.M009733200	http://dx.doi.org/10.1074/jbc.M009733200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	420GC	11152466	hybrid			2022-12-25	WOS:000167996400097
J	Cohen, B; Barkan, D; Levy, Y; Goldberg, I; Fridman, E; Kopolovic, J; Rubinstein, M				Cohen, B; Barkan, D; Levy, Y; Goldberg, I; Fridman, E; Kopolovic, J; Rubinstein, M			Leptin induces angiopoietin-2 expression in adipose tissues	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MICROVASCULAR ENDOTHELIAL-CELLS; ANGIOGENIC FACTOR; GENE-EXPRESSION; GROWTH-FACTOR; OBESE GENE; FAT PADS; TIE2; RECEPTOR; DIFFERENTIATION; ADIPOCYTES	Adipose tissues consisting of adipocytes, microvasculature, and stroma are completely ablated upon overexpression of leptin in rats. This tissue regression is mediated by enhanced lipid beta-oxidation, adipocyte dedifferentiation, and apoptosis. To further characterize this phenomenon, we studied the possible effect of leptin on the adipose microvasculature. Tissue microvasculature is maintained by the interplay between positive and negative signals mediated by factors including vascular endothelial growth factor (VEGF), basic fibroblast growth factor, angiopoletin-1 (Ang-1), and Ang-2. Expression of the negative signal Ang-2 was reported in fetal tissues and in the adult ovary, which undergoes vascular remodeling or regression. We demonstrate that leptin induces the expression of Ang-a in adipose tissue without a concomitant increase in VEGF. Induction of Ang-2 occurred in an autocrine manner, as demonstrated in cultured adipocytes but not in several other cell types. This tissue-specific induction of Ang-2 coincided with initiation of apoptosis in adipose endothelial cells. We propose that induction of Ang-2 by leptin in adipose cells is one of the events leading to adipose tissue regression.	Weizmann Inst Sci, Dept Mol Genet, IL-76100 Rehovot, Israel; Chaim Sheba Med Ctr, Dept Pathol, IL-52621 Ramat Gan, Israel	Weizmann Institute of Science; Chaim Sheba Medical Center	Rubinstein, M (corresponding author), Weizmann Inst Sci, Dept Mol Genet, IL-76100 Rehovot, Israel.			Rubinstein, Menachem/0000-0002-3472-6614; Barkan, Dalit/0000-0003-4714-0580				Barkan D, 1999, ENDOCRINOLOGY, V140, P1731, DOI 10.1210/en.140.4.1731; Bouloumie A, 1998, CIRC RES, V83, P1059, DOI 10.1161/01.RES.83.10.1059; Chen GX, 1996, P NATL ACAD SCI USA, V93, P14795, DOI 10.1073/pnas.93.25.14795; Cohen B, 1996, SCIENCE, V274, P1185, DOI 10.1126/science.274.5290.1185; Considine RV, 1997, INT J BIOCHEM CELL B, V29, P1255, DOI 10.1016/S1357-2725(97)00050-2; Crandall DL, 1997, MICROCIRCULATION-LON, V4, P211, DOI 10.3109/10739689709146786; Davis S, 1996, CELL, V87, P1161, DOI 10.1016/S0092-8674(00)81812-7; Flier JS, 1997, P NATL ACAD SCI USA, V94, P4242, DOI 10.1073/pnas.94.9.4242; Fruhbeck G, 1997, BIOCHEM BIOPH RES CO, V240, P590, DOI 10.1006/bbrc.1997.7716; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; Goede V, 1998, LAB INVEST, V78, P1385; GREEN H, 1979, J CELL PHYSIOL, V101, P169, DOI 10.1002/jcp.1041010119; GREEN H, 1975, CELL, V5, P19, DOI 10.1016/0092-8674(75)90087-2; Hanahan D, 1997, SCIENCE, V277, P48, DOI 10.1126/science.277.5322.48; Holash J, 1999, SCIENCE, V284, P1994, DOI 10.1126/science.284.5422.1994; Kim I, 2000, BIOCHEM BIOPH RES CO, V269, P361, DOI 10.1006/bbrc.2000.2296; Lee GH, 1996, NATURE, V379, P632, DOI 10.1038/379632a0; Maisonpierre PC, 1997, SCIENCE, V277, P55, DOI 10.1126/science.277.5322.55; Mandriota SJ, 1998, CIRC RES, V83, P852, DOI 10.1161/01.RES.83.8.852; Mandrup S, 1997, P NATL ACAD SCI USA, V94, P4300, DOI 10.1073/pnas.94.9.4300; Novick D, 1999, IMMUNITY, V10, P127, DOI 10.1016/S1074-7613(00)80013-8; Oh H, 1999, J BIOL CHEM, V274, P15732, DOI 10.1074/jbc.274.22.15732; Otani A, 1999, INVEST OPHTH VIS SCI, V40, P1912; Qian H, 1998, ENDOCRINOLOGY, V139, P791, DOI 10.1210/en.139.2.791; Sierra-Honigmann MR, 1998, SCIENCE, V281, P1683, DOI 10.1126/science.281.5383.1683; SILVERMAN KJ, 1988, BIOCHEM BIOPH RES CO, V153, P347, DOI 10.1016/S0006-291X(88)81229-4; Soukas A, 2000, GENE DEV, V14, P963; Suri C, 1998, SCIENCE, V282, P468, DOI 10.1126/science.282.5388.468; TARGAGLIA LA, 1995, CELL, V83, P1263; Wang MY, 1999, J BIOL CHEM, V274, P17541, DOI 10.1074/jbc.274.25.17541; Wang ZW, 1999, P NATL ACAD SCI USA, V96, P10373, DOI 10.1073/pnas.96.18.10373; Witzenbichler B, 1998, J BIOL CHEM, V273, P18514, DOI 10.1074/jbc.273.29.18514; Zhang QX, 1997, J SURG RES, V67, P147, DOI 10.1006/jsre.1996.4983; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0; Zhou YT, 1999, P NATL ACAD SCI USA, V96, P2391, DOI 10.1073/pnas.96.5.2391; Zhou YT, 1997, P NATL ACAD SCI USA, V94, P6386, DOI 10.1073/pnas.94.12.6386	36	75	79	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 16	2001	276	11					7697	7700		10.1074/jbc.C000634200	http://dx.doi.org/10.1074/jbc.C000634200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	411AA	11152449	hybrid			2022-12-25	WOS:000167474900003
J	Zhuo, LS; Yoneda, M; Zhao, M; Yingsung, W; Yoshida, N; Kitagawa, Y; Kawamura, K; Suzuki, T; Kimata, K				Zhuo, LS; Yoneda, M; Zhao, M; Yingsung, W; Yoshida, N; Kitagawa, Y; Kawamura, K; Suzuki, T; Kimata, K			Defect in SHAP-hyaluronan complex causes severe female infertility - A study by inactivation of the bikunin gene in mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-TRYPSIN INHIBITOR; CUMULUS EXTRACELLULAR-MATRIX; CELL-OOCYTE COMPLEXES; HUMAN PLASMA; HEAVY-CHAIN; CODING SEQUENCE; MOUSE; PROTEIN; ACID; FAMILY	Hyaluronan (HA) associates with proteins and proteoglycans to form the extracellular HA-rich matrices that significantly affect cellular behaviors. So far, only the heavy chains of the plasma inter-alpha -trypsin inhibitor (ITI) family, designated as SHAPs (serum-derived hyaluronan-associated proteins), have been shown to bind covalently to HA. The physiological significance of such a unique covalent complex has been unknown but is of great interest, because HA and the ITI family are abundant in tissues and in plasma, respectively, and the SHAP-HA complex is formed wherever HA meets plasma. We abolished the formation of the SHAP-HA complex in mice by targeting the gene of bikunin, the light chain of the ITI family members, which is essential for their biosynthesis. As a consequence, the cumulus oophorus, an investing structure unique to the oocyte of higher mammals, had a defect in forming the extracellular HA-rich matrix during expansion. The ovulated oocytes were completely devoid of matrix and were unfertilized, leading to severe female infertility. Intraperitoneal administration of ITI, accompanied by the formation of the SHAP-HA complex, fully rescued the defects. We conclude that the SHAP-HA complex Is a major component of the HA-rich matrix of the cumulus oophorus and is essential for fertilization in vivo.	Aichi Med Univ, Inst Mol Sci Med, Aichi 4801195, Japan; Nagoya Univ, Grad Sch Bioagr Sci, Grad Program Regulat Biol Signals, Chikusa Ku, Nagoya, Aichi 4648601, Japan; Japan SLC Inc, Hamamatsu, Shizuoka 4338114, Japan	Aichi Medical University; Nagoya University	Kimata, K (corresponding author), Aichi Med Univ, Inst Mol Sci Med, Aichi 4801195, Japan.	kimata@amugw.aichi-med-u.ac.jp						ATMANI F, 1993, UROL RES, V21, P61, DOI 10.1007/BF00295195; Berggard T, 1997, EUR J BIOCHEM, V245, P676, DOI 10.1111/j.1432-1033.1997.00676.x; BLOM A, 1995, J BIOL CHEM, V270, P9698, DOI 10.1074/jbc.270.17.9698; Blom AM, 1999, J BIOL CHEM, V274, P298, DOI 10.1074/jbc.274.1.298; CAMAIONI A, 1993, J BIOL CHEM, V268, P20473; Camaioni A, 1996, ARCH BIOCHEM BIOPHYS, V325, P190, DOI 10.1006/abbi.1996.0024; CASTILLO GM, 1993, FEBS LETT, V318, P292, DOI 10.1016/0014-5793(93)80531-X; CHAN P, 1995, BIOCHEM J, V306, P505, DOI 10.1042/bj3060505; CHEN L, 1993, MOL REPROD DEV, V34, P87, DOI 10.1002/mrd.1080340114; CHEN L, 1992, J BIOL CHEM, V267, P12380; Chen L, 1996, J BIOL CHEM, V271, P19409, DOI 10.1074/jbc.271.32.19409; ENGHILD JJ, 1991, J BIOL CHEM, V266, P747; Eriksen GV, 1999, BIOCHEM J, V340, P613, DOI 10.1042/0264-6021:3400613; Fulop C, 1997, ARCH BIOCHEM BIOPHYS, V337, P261, DOI 10.1006/abbi.1996.9793; Fulop C, 1997, GENE, V202, P95, DOI 10.1016/S0378-1119(97)00459-9; Hess KA, 1999, BIOL REPROD, V61, P436, DOI 10.1095/biolreprod61.2.436; HOCHSTRASSER K, 1981, H-S Z PHYSIOL CHEM, V362, P1357, DOI 10.1515/bchm2.1981.362.2.1357; HUANG L, 1993, J BIOL CHEM, V268, P26725; KAUMEYER JF, 1986, NUCLEIC ACIDS RES, V14, P7839, DOI 10.1093/nar/14.20.7839; Kida D, 1999, J RHEUMATOL, V26, P1230; KNUDSON CB, 1993, FASEB J, V7, P1233, DOI 10.1096/fasebj.7.13.7691670; Kobayashi H, 1999, ENDOCRINOLOGY, V140, P3835, DOI 10.1210/en.140.8.3835; KOBAYASHI H, 1995, INT J CANCER, V63, P455, DOI 10.1002/ijc.2910630326; LARSEN WJ, 1986, DEV BIOL, V113, P517, DOI 10.1016/0012-1606(86)90187-9; LAURENT TC, 1992, FASEB J, V6, P2397, DOI 10.1096/fasebj.6.7.1563592; Lindqvist A, 1999, GENE, V234, P329, DOI 10.1016/S0378-1119(99)00191-2; Mizon C, 1996, J IMMUNOL METHODS, V190, P61, DOI 10.1016/0022-1759(95)00257-X; Nakayashiki N, 1997, JPN J HUM GENET, V42, P363, DOI 10.1007/BF02766960; POWERS RW, 1995, AM J PHYSIOL-ENDOC M, V269, pE290, DOI 10.1152/ajpendo.1995.269.2.E290; PROKSCH GJ, 1973, CLIN BIOCHEM, V6, P200, DOI 10.1016/S0009-9120(73)80027-X; Salier JP, 1996, BIOCHEM J, V315, P1, DOI 10.1042/bj3150001; SALUSTRI A, 1989, J BIOL CHEM, V264, P13840; SUGIKI M, 1989, ENZYME, V42, P31, DOI 10.1159/000469004; TALBOT P, 1984, DEV BIOL, V103, P159, DOI 10.1016/0012-1606(84)90017-4; Thuveson M, 1999, J BIOL CHEM, V274, P6741, DOI 10.1074/jbc.274.10.6741; Toole B. P., 1991, CELL BIOL EXTRACELLU, P305; Yamamoto T, 1996, J BIOCHEM-TOKYO, V120, P145; YONEDA M, 1990, J BIOL CHEM, V265, P5247; Yoneda M, 2000, INT CONGR SER, V1196, P21; YONEDA M, 1998, CONNECT TISSUE, V30, P69; ZHAO M, 1995, J BIOL CHEM, V270, P26657, DOI 10.1074/jbc.270.44.26657	41	205	214	1	23	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 16	2001	276	11					7693	7696		10.1074/jbc.C000899200	http://dx.doi.org/10.1074/jbc.C000899200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	411AA	11145954	hybrid			2022-12-25	WOS:000167474900002
J	Schild, L; Keilhoff, G; Augustin, W; Reiser, G; Striggow, F				Schild, L; Keilhoff, G; Augustin, W; Reiser, G; Striggow, F			Distinct Ca2+ thresholds determine cytochrome c release or permeability transition pore opening in brain mitochondria	FASEB JOURNAL			English	Article									Univ Magdeburg, Inst Clin Chem & Pathol Biochem, Dept Pathol Biochem, D-39120 Magdeburg, Germany; Univ Magdeburg, Inst Med Neurobiol, D-39120 Magdeburg, Germany; Univ Magdeburg, Fac Med, Inst Neurobiochem, D-39120 Magdeburg, Germany	Otto von Guericke University; Otto von Guericke University; Otto von Guericke University	Schild, L (corresponding author), Univ Magdeburg, Inst Clin Chem & Pathol Biochem, Dept Pathol Biochem, Leipziger Str 44, D-39120 Magdeburg, Germany.								0	77	87	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAR	2001	15	3					565	567						3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	410BE	11259368				2022-12-25	WOS:000167419500006
J	Andrade, FH; Reid, MB; Westerblad, H				Andrade, FH; Reid, MB; Westerblad, H			Contractile response of skeletal muscle to low peroxide concentrations: myofibrillar calcium sensitivity as a likely target for redox-modulation	FASEB JOURNAL			English	Article									Univ Hosp Cleveland, Res Inst, Cleveland, OH 44106 USA; Karolinska Inst, Dept Physiol & Pharmacol, S-17177 Stockholm, Sweden; Case Western Reserve Univ, Dept Neurol, Cleveland, OH 44106 USA; Baylor Coll Med, Pulm & Crit Care Med Sect, Houston, TX 77030 USA	University Hospitals of Cleveland; Karolinska Institutet; Case Western Reserve University; Baylor College of Medicine	Andrade, FH (corresponding author), Univ Hosp Cleveland, Res Inst, Wearn 650,11100 Euclid Ave, Cleveland, OH 44106 USA.		Andrade, Francisco H/F-1258-2011	Andrade, Francisco H/0000-0002-2460-5798; Westerblad, Hakan/0000-0002-8180-3029					0	137	140	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	FEB	2001	15	2					309	311						3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	400LK	11156946				2022-12-25	WOS:000166872900012
J	Ruediger, R; Pham, HT; Walter, G				Ruediger, R; Pham, HT; Walter, G			Disruption of protein phosphatase 2A subunit interaction in human cancers with mutations in the A alpha subunit gene	ONCOGENE			English	Article						PP2A; A alpha subunit; mutation; human cancer; tumor suppressor	SERINE THREONINE PHOSPHATASES; REGULATORY B-SUBUNITS; PP2A CORE ENZYME; MOLECULAR-CLONING; CATALYTIC SUBUNIT; SEQUENCE-ANALYSIS; TUMOR-ANTIGENS; OKADAIC ACID; PPP2R1B GENE; T-ANTIGENS	The A subunit of protein phosphatase 2A (PP2A) consists of 15 nonidentical repeats. The catalytic C subunit binds to C-terminal repeats 11-15 and regulatory B subunits bind to N-terminal repeats 1-10, Recently, four cancer-associated mutants of the A alpha subunit have been described: Glu64-->Asp in lung carcinoma, Glu64 --> Gly in breast carcinoma, Arg418 --> Trp in melanoma, and Delta 171-589 in breast carcinoma, Based on our model of PP2A, we predicted that Glu64-->Asp and Glu64-->Gly might be defective in B subunit binding, whereas Arg418-->Trp and Delta 171 - 589 might bind neither B nor C subunits, We generated these mutants by site-directed mutagenesis and assayed their ability to associate with different forms of B subunits (B, B', B") or with the catalytic C subunit, The results demonstrate that all mutants are defective in binding either B or B and C subunits, Specifically, the N-terminal mutants, Glu64-->Asp and Glu64-->Gly, are defective in B' but normal in B, B", and C subunit binding, whereas the C-terminal mutants Arg418-->Trp and Delta 171-589 bind none of the B subunits nor the C subunit, The implications of these findings with regard to the potential role of PP2A as a tumor suppressor are discussed.	Univ Calif San Diego, Dept Pathol, La Jolla, CA 92093 USA	University of California System; University of California San Diego	Walter, G (corresponding author), Univ Calif San Diego, Dept Pathol, La Jolla, CA 92093 USA.				NATIONAL CANCER INSTITUTE [R01CA036111] Funding Source: NIH RePORTER; NCI NIH HHS [CA-36111] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BIALOJAN C, 1988, BIOCHEM J, V256, P283, DOI 10.1042/bj2560283; Bienz M, 1999, CURR OPIN GENET DEV, V9, P595, DOI 10.1016/S0959-437X(99)00016-7; Brewis N, 2000, AM J PHYSIOL-HEART C, V279, pH1307, DOI 10.1152/ajpheart.2000.279.3.H1307; Calin GA, 2000, ONCOGENE, V19, P1191, DOI 10.1038/sj.onc.1203389; Campbell IG, 1999, ONCOGENE, V18, P6367, DOI 10.1038/sj.onc.1203070; CEGIELSKA A, 1994, MOL CELL BIOL, V14, P4616, DOI 10.1128/MCB.14.7.4616; CHEN SC, 1989, J BIOL CHEM, V264, P7267; COHEN P, 1989, J BIOL CHEM, V264, P21435; Csortos C, 1996, J BIOL CHEM, V271, P2578, DOI 10.1074/jbc.271.5.2578; GREEN DD, 1987, P NATL ACAD SCI USA, V84, P4880, DOI 10.1073/pnas.84.14.4880; Groves MR, 1999, CELL, V96, P99, DOI 10.1016/S0092-8674(00)80963-0; HEALY AM, 1991, MOL CELL BIOL, V11, P5767, DOI 10.1128/MCB.11.11.5767; HEMMINGS BA, 1990, BIOCHEMISTRY-US, V29, P3166, DOI 10.1021/bi00465a002; HENDRIX P, 1993, J BIOL CHEM, V268, P15267; KAMIBAYASHI C, 1994, J BIOL CHEM, V269, P20139; KAMIBAYASHI C, 1992, J BIOL CHEM, V267, P21864; KAMIBAYASHI C, 1991, J BIOL CHEM, V266, P13251; KITAGAWA Y, 1988, BIOCHIM BIOPHYS ACTA, V951, P123, DOI 10.1016/0167-4781(88)90032-2; Kremmer E, 1997, MOL CELL BIOL, V17, P1692, DOI 10.1128/MCB.17.3.1692; MAYER RE, 1991, BIOCHEMISTRY-US, V30, P3589, DOI 10.1021/bi00229a001; McCright B, 1996, J BIOL CHEM, V271, P22081, DOI 10.1074/jbc.271.36.22081; MCCRIGHT B, 1995, J BIOL CHEM, V270, P26123, DOI 10.1074/jbc.270.44.26123; MUMBY MC, 1993, PHYSIOL REV, V73, P673, DOI 10.1152/physrev.1993.73.4.673; Nagase T, 1997, J BIOCHEM, V122, P178; PALLAS DC, 1992, J VIROL, V66, P886, DOI 10.1128/JVI.66.2.886-893.1992; Peifer M, 2000, SCIENCE, V287, P1606, DOI 10.1126/science.287.5458.1606; RUEDIGER R, 1994, J VIROL, V68, P123, DOI 10.1128/JVI.68.1.123-129.1994; RUEDIGER R, 1992, MOL CELL BIOL, V12, P4872, DOI 10.1128/MCB.12.11.4872; Ruediger R, 1997, VIROLOGY, V238, P432, DOI 10.1006/viro.1997.8873; Ruediger R, 1999, J VIROL, V73, P839, DOI 10.1128/JVI.73.1.839-842.1999; Seeling JM, 1999, SCIENCE, V283, P2089, DOI 10.1126/science.283.5410.2089; SILVA OBD, 1987, FEBS LETT, V221, P415, DOI 10.1016/0014-5793(87)80966-3; STONE SR, 1987, BIOCHEMISTRY-US, V26, P7215, DOI 10.1021/bi00397a003; SUGANUMA M, 1988, P NATL ACAD SCI USA, V85, P1768, DOI 10.1073/pnas.85.6.1768; Takagi Y, 2000, GUT, V47, P268, DOI 10.1136/gut.47.2.268; Tanabe O, 1996, FEBS LETT, V379, P107, DOI 10.1016/0014-5793(95)01500-0; Tehrani MA, 1996, J BIOL CHEM, V271, P5164; Turowski P, 1997, EUR J BIOCHEM, V248, P200, DOI 10.1111/j.1432-1033.1997.t01-1-00200.x; Virshup DM, 2000, CURR OPIN CELL BIOL, V12, P180, DOI 10.1016/S0955-0674(99)00074-5; Voorhoeve PM, 1999, ONCOGENE, V18, P515, DOI 10.1038/sj.onc.1202316; WALTER G, 1989, P NATL ACAD SCI USA, V86, P8669, DOI 10.1073/pnas.86.22.8669; WALTER G, 1993, BIOCHIM BIOPHYS ACTA, V1155, P207, DOI 10.1016/0304-419X(93)90005-W; Wang SS, 1998, SCIENCE, V282, P284, DOI 10.1126/science.282.5387.284; Yan Z, 2000, MOL CELL BIOL, V20, P1021, DOI 10.1128/MCB.20.3.1021-1029.2000; ZOLNIEROWICZ S, 1994, BIOCHEMISTRY-US, V33, P11858, DOI 10.1021/bi00205a023	45	128	134	0	6	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 4	2001	20	1					10	15		10.1038/sj.onc.1204059	http://dx.doi.org/10.1038/sj.onc.1204059			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	391NE	11244497				2022-12-25	WOS:000166361400002
J	Lu, ML; Arrick, BA				Lu, ML; Arrick, BA			Transactivation of the p21 promoter by BRCA1 splice variants in mammary epithelial cells: evidence for both common and distinct activities of wildtype and mutant forms	ONCOGENE			English	Article						BRCA1; transcriptional activation; p21; alternative splicing	SPORADIC BREAST-CANCER; TRANSCRIPTIONAL ACTIVATION; RING FINGER; MUTATIONS; PROTEIN; LOCALIZATION; EXPRESSION; INTERACT; GROWTH; CYCLE	We have evaluated the transcriptional activation of a human p21 promoter reporter construct by transfection of BRCA1 expression constructs into tumorigenic and nontumorigenic human breast cell lines. Two cell lines with wildtype p53 (MCF-7 and MCF10A) demonstrated: transcriptional activation of the p21 promoter by full-length BRCA1 (BRCA1(L)) as well as by two splice variants that lack most of exon 11 (BRCA1(S) and BRCA1(S-9,10)). In contrast, two cell lines with mutant p53 (MDA-231 and HCC1937) were inactive. Co-transfection of BRCA1L with BRCA1(S) or BRCA1(S-9,10) exhibited synergistic p21 promoter activation, due to augmented expression of the cytomegalovirus promoter-based BRCA1 expression constructs. We examined the transcriptional activity of two known sequence alterations in BRCA1, one that results in a carboxy-terminal truncation of BRCA1 and is clearly pathogenic, and the other a missense mutation that is suspected of predisposing to cancer. Although both mutations have been shown to be defective in some assays of transactivation, we observed both mutations to be fully active in activation of the p21 promoter when incorporated in the full-length BRCA1(L). In contrast, these mutations rendered BRCA1(S) inactive. These observations indicate that such transcriptional assays cannot serve as the basis for a functional appraisal of BRCA1 sequence alterations encountered in the course of genetic testing.	Dartmouth Med Sch, Dept Med, Hanover, NH 03755 USA	Dartmouth College	Arrick, BA (corresponding author), Dartmouth Med Sch, Dept Med, Kellogg Box 0128, Hanover, NH 03755 USA.				NCI NIH HHS [R01 CA-77772] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA077772] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Brzovic PS, 1998, J BIOL CHEM, V273, P7795, DOI 10.1074/jbc.273.14.7795; Chai YL, 1999, ONCOGENE, V18, P263, DOI 10.1038/sj.onc.1202323; Chapman MS, 1996, NATURE, V382, P678, DOI 10.1038/382678a0; Chen YM, 1999, J CELL PHYSIOL, V181, P385, DOI 10.1002/(SICI)1097-4652(199912)181:3<385::AID-JCP2>3.0.CO;2-4; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Frank TS, 1998, J CLIN ONCOL, V16, P2417, DOI 10.1200/JCO.1998.16.7.2417; FUTREAL PA, 1994, SCIENCE, V266, P120, DOI 10.1126/science.7939630; Hayes F, 2000, CANCER RES, V60, P2411; Jensen DE, 1998, ONCOGENE, V16, P1097, DOI 10.1038/sj.onc.1201861; Klemp J, 2000, EUR J CANCER, V36, P1209, DOI 10.1016/S0959-8049(00)00112-X; Li S, 1999, J BIOL CHEM, V274, P11334, DOI 10.1074/jbc.274.16.11334; Lu ML, 1996, CANCER RES, V56, P4578; Magdinier F, 1998, ONCOGENE, V17, P3169, DOI 10.1038/sj.onc.1202248; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; Monteiro ANA, 1996, P NATL ACAD SCI USA, V93, P13595, DOI 10.1073/pnas.93.24.13595; Ouchi T, 1998, P NATL ACAD SCI USA, V95, P2302, DOI 10.1073/pnas.95.5.2302; Pao GM, 2000, P NATL ACAD SCI USA, V97, P1020, DOI 10.1073/pnas.97.3.1020; Rio PG, 1999, INT J CANCER, V80, P823, DOI 10.1002/(SICI)1097-0215(19990315)80:6<823::AID-IJC5>3.0.CO;2-3; Scully R, 1999, MOL CELL, V4, P1093, DOI 10.1016/S1097-2765(00)80238-5; Seery LT, 1999, INT J CANCER, V84, P258, DOI 10.1002/(SICI)1097-0215(19990621)84:3<258::AID-IJC10>3.3.CO;2-8; Shao NS, 1996, ONCOGENE, V13, P1; Somasundaram K, 1997, NATURE, V389, P187, DOI 10.1038/38291; Struewing JP, 1997, NEW ENGL J MED, V336, P1401, DOI 10.1056/NEJM199705153362001; Thakur S, 1997, MOL CELL BIOL, V17, P444, DOI 10.1128/MCB.17.1.444; THOMPSON ME, 1995, NAT GENET, V9, P444, DOI 10.1038/ng0495-444; Tomlinson GE, 1998, CANCER RES, V58, P3237; Wang HC, 1997, ONCOGENE, V15, P143, DOI 10.1038/sj.onc.1201252; Welcsh PL, 2000, TRENDS GENET, V16, P69, DOI 10.1016/S0168-9525(99)01930-7; Wilson CA, 1999, NAT GENET, V21, P236, DOI 10.1038/6029; Wilson E.O., 1997, BIODIVERSITY, P1; Xu XL, 1999, MOL CELL, V3, P389, DOI 10.1016/S1097-2765(00)80466-9; Yu X, 1998, J BIOL CHEM, V273, P25388, DOI 10.1074/jbc.273.39.25388; Zhang HB, 1998, ONCOGENE, V16, P1713, DOI 10.1038/sj.onc.1201932	33	18	18	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 14	2000	19	54					6351	6360		10.1038/sj.onc.1204025	http://dx.doi.org/10.1038/sj.onc.1204025			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	388YK	11175350	Bronze			2022-12-25	WOS:000166210500019
J	Posern, G; Rapp, UR; Feller, SM				Posern, G; Rapp, UR; Feller, SM			The Crk signaling pathway contributes to the bombesin-induced activation of the small GTPase Rap1 in Swiss 3T3 cells	ONCOGENE			English	Article						Crk; CRKL; Rap1; bombesin; SH3 domains; signal transduction	NUCLEOTIDE-EXCHANGE FACTOR; TYROSINE PHOSPHORYLATION; ADAPTER PROTEINS; BINDING PROTEINS; GROWTH-FACTOR; FACTOR C3G; KINASE; RAS; FAMILY; GENE	Rap1 is a small GTPase implicated in cell proliferation and differentiation, The mechanisms how endogenous Rapt is activated by many mitogenic stimuli including the neuropeptide bombesin remained unclear. Here we analyse which signaling pathways are necessary for Rapt activation. Bombesin-mediated Rap1 activation in Swiss 3T3 and primary mouse embryo fibroblasts requires signaling components similar to those being essential for complex formation between p130Cas and Crk adapter proteins. The Crk/CRKL-binding region of the Rap1-specific exchange factor C3G (CBR) inhibits the bombesin-stimulated Rap1 activity in transfected Swiss 3T3 cells. Further characterization in COS cells showed that the CBR or a c-Crk I SH3 mutant specifically reduces both the basal as well as the stimulated Rap1 activity in a dose-dependent manner, whereas Ras is not affected. The CBR is complexed with endogenous c-Crk II and CRKL and blocks the protein association with catalytically active C3G, Such suppressors of Crk signaling do not affect Erk-phosphorylation induced by bombesin, Embryonic fibroblasts from b-raf knockout mice showed a bombesin-inducible Erk-phosphorylation, providing evidence that B-Raf does not link Rap1, to Erk-activation in bombesin-stimulated fibroblasts, We conclude that cellular Crk/CRKL complexes, recruited to upstream signaling components, contribute to basal and bombesin-induced Rapt activity, which is independent from the Ras-Raf-Erk pathway under these circumstances.	Univ Wurzburg, MSZ, Inst Med Strahlenkunde & Zellforschung, D-97078 Wurzburg, Germany	University of Wurzburg	Feller, SM (corresponding author), Univ Wurzburg, MSZ, Inst Med Strahlenkunde & Zellforschung, Versbacher Str 5, D-97078 Wurzburg, Germany.							Altschuler DL, 1998, P NATL ACAD SCI USA, V95, P7475, DOI 10.1073/pnas.95.13.7475; Asha H, 1999, EMBO J, V18, P605, DOI 10.1093/emboj/18.3.605; Blaukat A, 1999, J BIOL CHEM, V274, P14893, DOI 10.1074/jbc.274.21.14893; Bos JL, 1998, EMBO J, V17, P6776, DOI 10.1093/emboj/17.23.6776; Boussiotis VA, 1997, SCIENCE, V278, P124, DOI 10.1126/science.278.5335.124; Casamassima A, 1997, J BIOL CHEM, V272, P9363; CUTTITTA F, 1985, NATURE, V316, P823, DOI 10.1038/316823a0; de Rooij J, 1998, NATURE, V396, P474, DOI 10.1038/24884; Feller SM, 1998, J CELL PHYSIOL, V177, P535, DOI 10.1002/(SICI)1097-4652(199812)177:4<535::AID-JCP5>3.3.CO;2-5; Franke B, 1997, EMBO J, V16, P252, DOI 10.1093/emboj/16.2.252; GOTOH T, 1995, MOL CELL BIOL, V15, P6746; HARIHARAN IK, 1991, CELL, V67, P717, DOI 10.1016/0092-8674(91)90066-8; Herrmann C, 1996, J BIOL CHEM, V271, P6794, DOI 10.1074/jbc.271.12.6794; Kawasaki H, 1998, SCIENCE, V282, P2275, DOI 10.1126/science.282.5397.2275; Kawasaki H, 1998, P NATL ACAD SCI USA, V95, P13278, DOI 10.1073/pnas.95.22.13278; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; KNUDSEN BS, 1994, J BIOL CHEM, V269, P32781; MITCHELL FM, 1995, J BIOL CHEM, V270, P8623, DOI 10.1074/jbc.270.15.8623; Nakamoto T, 1996, J BIOL CHEM, V271, P8959, DOI 10.1074/jbc.271.15.8959; Olson MF, 1998, NATURE, V394, P295, DOI 10.1038/28425; PIZON V, 1988, ONCOGENE, V3, P201; Posern G, 1998, ONCOGENE, V16, P1903, DOI 10.1038/sj.onc.1201714; Posern G, 1998, J BIOL CHEM, V273, P24297, DOI 10.1074/jbc.273.38.24297; Rozengurt E, 1998, J CELL PHYSIOL, V177, P507, DOI 10.1002/(SICI)1097-4652(199812)177:4<507::AID-JCP2>3.0.CO;2-K; Ruff SJ, 1997, J BIOL CHEM, V272, P1263, DOI 10.1074/jbc.272.2.1263; SASAKI H, 1995, J BIOL CHEM, V270, P21206, DOI 10.1074/jbc.270.36.21206; Schlaepfer DD, 1998, TRENDS CELL BIOL, V8, P151, DOI 10.1016/S0962-8924(97)01172-0; Serebriiskii I, 1999, J BIOL CHEM, V274, P17080, DOI 10.1074/jbc.274.24.17080; Serebriiskii I, 1997, ONCOGENE, V15, P1043, DOI 10.1038/sj.onc.1201268; Seufferlein T, 1996, J BIOL CHEM, V271, P21471, DOI 10.1074/jbc.271.35.21471; Sparks AB, 1996, P NATL ACAD SCI USA, V93, P1540, DOI 10.1073/pnas.93.4.1540; TANAKA M, 1995, MOL CELL BIOL, V15, P6829; Taylor SJ, 1996, CURR BIOL, V6, P1621, DOI 10.1016/S0960-9822(02)70785-9; Tsukamoto N, 1999, J BIOL CHEM, V274, P18463, DOI 10.1074/jbc.274.26.18463; Wojnowski L, 1997, NAT GENET, V16, P293, DOI 10.1038/ng0797-293; York RD, 1998, NATURE, V392, P622, DOI 10.1038/33451; YOSHIDA Y, 1992, MOL CELL BIOL, V12, P3407, DOI 10.1128/MCB.12.8.3407; Zwartkruis FJT, 1998, EMBO J, V17, P5905, DOI 10.1093/emboj/17.20.5905	38	10	11	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 14	2000	19	54					6361	6368		10.1038/sj.onc.1204027	http://dx.doi.org/10.1038/sj.onc.1204027			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	388YK	11175351				2022-12-25	WOS:000166210500020
J	Wang, DY; Yamamoto, S; Hijiya, N; Benveniste, EN; Gladson, CL				Wang, DY; Yamamoto, S; Hijiya, N; Benveniste, EN; Gladson, CL			Transcriptional regulation of the human osteopontin promoter: functional analysis and DNA-protein interactions	ONCOGENE			English	Article						osteopontin; promoter; transcriptional regulation; malignant astrocytoma; astrocytes; glioma	C-MYC; GENE-EXPRESSION; IN-VIVO; NEOPLASTIC TRANSFORMATION; EXTRACELLULAR-MATRIX; MESSENGER-RNA; CELLS; VITRONECTIN; MECHANISM; CLONING	Synthesis of cell attachment proteins and cytokines, such as osteopontin (OPN), can promote tumor cell remodeling of the extracellular matrix into an environment that promotes tumor cell attachment and migration, We investigated the transcriptional regulation of OPN in the U-251MG and U-87MG human malignant astrocytoma cell lines. Deletion and mutagenesis analyses of the OPN promoter region identified a proximal promoter clement (-24 to -94 relative to the transcription initiation site) that is essential for maintaining high levels of OPN expression in the tumor cells. This clement, designated RE-1, consists of two cis-acting elements, RE-la (-55 to -86) and RE-lb (-22 to -45), which act synergistically to regulate the activity of the OPN promoter, Gel shift assays using nuclear extracts of U-251MG cells demonstrated that RE-la contains binding sites for transcription factors Spl, the glucocorticoid receptor, and the E-box-binding factors, whereas RE-lh contains a binding site for the octamer motif-binding protein (OCT-1/OCT-2), Inclusion of antibodies directed toward Myc and OCT-1 in the gel shift assays indicated that Myc and OCT-1 participate in forming DNA-protein complexes on the RE-la and RE-lb elements, respectively. Our results identify two previously unrecognized elements in the OPN promoter that act synergistically to promote upregulation of OPN synthesis by tumor cells but are regulated by different transcription factors.	Univ Alabama Birmingham, Dept Pathol, Div Neuropathol, Birmingham, AL 35294 USA; Univ Alabama Birmingham, Dept Cell Biol, Birmingham, AL 35294 USA; Univ Alabama Birmingham, Dept Cell Biol, Birmingham, AL 35294 USA; Oita Med Univ, Dept Pathol, Oita 87955, Japan	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; Oita University	Gladson, CL (corresponding author), Univ Alabama Birmingham, Dept Pathol, Div Neuropathol, LHRB 567,701 19th St S, Birmingham, AL 35294 USA.				NCI NIH HHS [CA59958, CA75682] Funding Source: Medline; NINDS NIH HHS [NS 34856] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA059958, R01CA075682] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS034856] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; BENVENISTE EN, 1991, J BIOL CHEM, V266, P18119; Broaddus WC, 1997, NEUROSURGERY, V41, P908, DOI 10.1097/00006123-199710000-00027; BROWN LF, 1994, AM J PATHOL, V145, P610; CASTAGNOLA P, 1991, J BIOL CHEM, V266, P9944; Chackalaparampil I, 1996, ONCOGENE, V12, P1457; CHAMBERS AF, 1992, ANTICANCER RES, V12, P43; CHANG PL, 1993, CANCER RES, V53, P2217; Denhardt DT, 1998, J CELL BIOCHEM, P92, DOI 10.1002/(SICI)1097-4644(1998)72:30/31+<92::AID-JCB13>3.0.CO;2-A; DENHARDT DT, 1993, FASEB J, V7, P1475, DOI 10.1096/fasebj.7.15.8262332; ENGELHARD HH, 1989, J NEUROSURG, V71, P224, DOI 10.3171/jns.1989.71.2.0224; GARDNER HAR, 1994, ONCOGENE, V9, P2321; Gladson CL, 1999, J NEUROPATH EXP NEUR, V58, P1029, DOI 10.1097/00005072-199910000-00001; GLADSON CL, 1995, J CELL SCI, V108, P947; Gladson CL, 2000, NEUROSCI LETT, V283, P157, DOI 10.1016/S0304-3940(00)00876-4; GLADSON CL, 1991, J CLIN INVEST, V88, P1924, DOI 10.1172/JCI115516; GREGOR PD, 1990, GENE DEV, V4, P1730, DOI 10.1101/gad.4.10.1730; GUO XJ, 1995, MOL CELL BIOL, V15, P476, DOI 10.1128/MCB.15.1.476; Henriksson M, 1996, ADV CANCER RES, V68, P109, DOI 10.1016/S0065-230X(08)60353-X; HIJIYA N, 1994, BIOCHEM J, V303, P255, DOI 10.1042/bj3030255; LI LH, 1994, EMBO J, V13, P4070, DOI 10.1002/j.1460-2075.1994.tb06724.x; LIAW L, 1995, J CLIN INVEST, V95, P713, DOI 10.1172/JCI117718; Manji SS, 1998, J CELL PHYSIOL, V176, P1; NODA M, 1988, J BIOL CHEM, V263, P13916; ORIAN JM, 1992, BRIT J CANCER, V66, P106, DOI 10.1038/bjc.1992.225; Pijuan-Thompson V, 1999, EXP CELL RES, V249, P86, DOI 10.1006/excr.1999.4458; RUSSELL DS, 1989, PATHOLOGY TUMOURS NE, P83; SAITOH Y, 1995, LAB INVEST, V72, P55; Sato M, 1998, ONCOGENE, V17, P1517, DOI 10.1038/sj.onc.1202064; SENGER DR, 1988, CANCER RES, V48, P5770; SINGH K, 1995, J BIOL CHEM, V270, P28471; SMITH JH, 1987, J CELL BIOCHEM, V34, P13, DOI 10.1002/jcb.240340103; Stein GS, 1999, J CELL BIOCHEM, P24; SU LC, 1995, ONCOGENE, V10, P2163; Tezuka KI, 1996, J BIOL CHEM, V271, P22713, DOI 10.1074/jbc.271.37.22713; TRENT J, 1986, P NATL ACAD SCI USA, V83, P470, DOI 10.1073/pnas.83.2.470; Vanacker JM, 1998, CELL GROWTH DIFFER, V9, P1007; Wang DY, 1997, J BIOL CHEM, V272, P14244, DOI 10.1074/jbc.272.22.14244; YAMAMOTO KR, 1985, ANNU REV GENET, V19, P209, DOI 10.1146/annurev.genet.19.1.209	39	53	58	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 23	2000	19	50					5801	5809		10.1038/sj.onc.1203917	http://dx.doi.org/10.1038/sj.onc.1203917			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	376VP	11126367				2022-12-25	WOS:000165477700012
J	Lo, KWH; Naisbitt, S; Fan, JS; Sheng, M; Zhang, MJ				Lo, KWH; Naisbitt, S; Fan, JS; Sheng, M; Zhang, MJ			The 8-kDa dynein light chain binds to its targets via a conserved (K/R)XTQT motif	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE SYNTHASE; INTERMEDIATE-CHAIN; HEAVY-CHAIN; PROTEIN INHIBITOR; MYOSIN-V; DIMERIZATION; PURIFICATION; INTERACTS; TRANSPORT; FLAGELLA	Cytoplasmic dynein is a large, multisubunit molecular motor that translocates cargoes toward the minus ends of microtubules. Proper functioning of the dynein motor requires precise assembly of its various subunits. Using purified recombinant proteins, we show that the highly conserved 8-kDa light chain (DLC8) binds to the intermediate chain of the dynein complex. The DLC8-binding region was mapped to a highly conserved 10-residue fragment (amino acid sequence SYSKETQTPL) C-terminal to the second alternative splicing site of dynein intermediate chain. Yeast two-hybrid screening using DLC8 as bait identified numerous additional DLC8-binding proteins. Biochemical and mutational analysis of selected DLC8 binding proteins revealed that DLC8 binds to a consensus sequence containing a (K/R)XTQT motif. The (K/R)XTQT motif interacts with the common target-accepting grooves of DLC8 dimer. The role of each conserved amino acid residue in this pentapeptide motif in supporting complex formation with DLC8 was systematically studied using site-directed mutagenesis.	Hong Kong Univ Sci & Technol, Dept Biochem, Kowloon, Hong Kong, Peoples R China; Massachusetts Gen Hosp, Howard Hughes Med Inst, Boston, MA 02114 USA; Massachusetts Gen Hosp, Dept Neurobiol, Boston, MA 02114 USA; Harvard Univ, Sch Med, Boston, MA 02114 USA	Hong Kong University of Science & Technology; Harvard University; Massachusetts General Hospital; Howard Hughes Medical Institute; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School	Zhang, MJ (corresponding author), Hong Kong Univ Sci & Technol, Dept Biochem, Clear Water Bay, Kowloon, Hong Kong, Peoples R China.			Zhang, Mingjie/0000-0001-9404-0190; Sheng, Morgan/0000-0002-8703-5366				Beckwith SM, 1998, J CELL BIOL, V143, P1239, DOI 10.1083/jcb.143.5.1239; Benashski SE, 1997, J BIOL CHEM, V272, P20929, DOI 10.1074/jbc.272.33.20929; Crackower MA, 1999, GENOMICS, V55, P257, DOI 10.1006/geno.1998.5665; Crepieux P, 1997, MOL CELL BIOL, V17, P7375, DOI 10.1128/MCB.17.12.7375; Fan JS, 2001, J MOL BIOL, V306, P97, DOI 10.1006/jmbi.2000.4374; Fan JS, 1998, J BIOL CHEM, V273, P33472, DOI 10.1074/jbc.273.50.33472; Farmer BT, 1996, NAT STRUCT BIOL, V3, P995, DOI 10.1038/nsb1296-995; Habura A, 1999, J BIOL CHEM, V274, P15447, DOI 10.1074/jbc.274.22.15447; Hirokawa N, 1998, SCIENCE, V279, P519, DOI 10.1126/science.279.5350.519; Jacob Y, 2000, J VIROL, V74, P10217, DOI 10.1128/JVI.74.21.10217-10222.2000; Jaffrey SR, 1996, SCIENCE, V274, P774, DOI 10.1126/science.274.5288.774; King SM, 2000, BBA-MOL CELL RES, V1496, P60, DOI 10.1016/S0167-4889(00)00009-4; King SM, 1996, J BIOL CHEM, V271, P19358, DOI 10.1074/jbc.271.32.19358; Liang J, 1999, NAT STRUCT BIOL, V6, P735; MITCHELL DR, 1986, CELL MOTIL CYTOSKEL, V6, P510, DOI 10.1002/cm.970060510; Mok YK, 2001, J BIOL CHEM, V276, P14067, DOI 10.1074/jbc.M011358200; Naisbitt S, 2000, J NEUROSCI, V20, P4524, DOI 10.1523/JNEUROSCI.20-12-04524.2000; Nurminsky DI, 1998, MOL CELL BIOL, V18, P6816, DOI 10.1128/MCB.18.11.6816; Pazour GJ, 1998, J CELL BIOL, V141, P979, DOI 10.1083/jcb.141.4.979; PFISTER KK, 1982, CELL MOTIL CYTOSKEL, V2, P525, DOI 10.1002/cm.970020604; PIPERNO G, 1979, J BIOL CHEM, V254, P3084; Puthalakath H, 1999, MOL CELL, V3, P287, DOI 10.1016/S1097-2765(00)80456-6; Raux H, 2000, J VIROL, V74, P10212, DOI 10.1128/JVI.74.21.10212-10216.2000; Schnorrer F, 2000, NAT CELL BIOL, V2, P185, DOI 10.1038/35008601; Susalka SJ, 2000, BBA-MOL CELL RES, V1496, P76, DOI 10.1016/S0167-4889(00)00010-0; Tynan SH, 2000, J BIOL CHEM, V275, P32769, DOI 10.1074/jbc.M001537200; Vallee RB, 1996, SCIENCE, V271, P1539, DOI 10.1126/science.271.5255.1539; VAUGHAN KT, 1995, J CELL BIOL, V131, P1507, DOI 10.1083/jcb.131.6.1507	28	159	162	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 27	2001	276	17					14059	14066		10.1074/jbc.M010320200	http://dx.doi.org/10.1074/jbc.M010320200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	426PB	11148209	hybrid			2022-12-25	WOS:000168356600076
J	Pare, JF; Roy, S; Galarneau, L; Belanger, L				Pare, JF; Roy, S; Galarneau, L; Belanger, L			The mouse fetoprotein transcription factor (FTF) gene promoter is regulated by three GATA elements with tandem E box and Nkx motifs, and FTF in turn activates the Hnf3 beta, Hnf4 alpha, and Hnf1 alpha gene promoters	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR RECEPTOR; BILE-ACID; ALPHA-1-FETOPROTEIN GENE; DEFINITIVE ENDODERM; MOLECULAR-CLONING; ORPHAN RECEPTORS; GUT ENDODERM; FTZ-F1 GENE; FACTOR LFB1; LIVER	Fetoprotein transcription factor (FTF) is an orphan nuclear receptor that activates the alpha (1)-fetoprotein gene during early liver developmental growth. Here we sought to define better the position of FTF in transcriptional cascades leading to hepatic differentiation. The mouse FTF gene was isolated and assigned to chromosome 1 band E4 (one mFTF pseudogene was also found). Exon/intron mapping shows an mFTF gene structure similar to that of its close homologue SF1, with two more N-terminal exons in the mFTF gene; exon mapping also delimits several FTF mRNA 5 '- and 3 ' -splice variants. The mFTF transcription initiation site was located in adult liver at 238 nucleotides from the first translation initiator codon, with six canonical GATA, E box, and Nkx motifs clustered between -50/-140 base pairs (bp) from the cap site; DNA/protein binding assays also pinpointed an HNF4-binding element at +36 bp and an FTF-binding element at -257 bp. Transfection assays and point mutations showed that the mFTF promoter is activated by GATA, HNF4 alpha, FTF, Nkx, and basic helix-loop-helix factors, with marked cooperativity between GATA and HNF4 alpha, A tandem GATA/E box activatory motif in the proximal mFTF promoter is strikingly similar to a composite motif coactivated by differentiation inducers in the hematopoietic lineage; a tandem GATA-Nkx motif in the distal mFTF promoter is also similar to a composite motif transducing differentiation signals from transforming growth factor-a-like receptors in the cardiogenic lineage. Three genes encoding transcription factors critical to early hepatic differentiation, Hnf3 beta, Hnf4 alpha, and Hnf1 alpha, each contain dual FTF-binding elements in their proximal promoters, and all three promoters are activated by FTF in transfection assays. Direct DNA binding action and cooperativity was demonstrated between FTF and HNF3 beta on the Hnf3 beta promoter and between FTF and HNF4 alpha on the Hnf1 alpha promoter. These combined results suggest that FTF is an early intermediary between endodermal specification signals and downstream genes that establish and amplify the hepatic phenotype.	Univ Laval, Hotel Dieu, Ctr Rech Cancerol, Dept Biol Med,Fac Med, Quebec City, PQ G1R 2J6, Canada	Laval University	Belanger, L (corresponding author), Hop Hotel Dieu, Canc Res Ctr, Quebec City, PQ G1R 2J6, Canada.	luc.belanger@crhdq.ulaval.ca						ANG SL, 1993, DEVELOPMENT, V119, P1301; Apergis GA, 1998, J BIOL CHEM, V273, P2917, DOI 10.1074/jbc.273.5.2917; BARTKOWSKI S, 1993, MOL CELL BIOL, V13, P421, DOI 10.1128/MCB.13.1.421; BELANGER L, 1994, J BIOL CHEM, V269, P5481; BELANGER L, 1975, NATURE, V256, P657, DOI 10.1038/256657a0; BERNIER D, 1993, MOL CELL BIOL, V13, P1619, DOI 10.1128/MCB.13.3.1619; BLUMENFELD M, 1991, DEVELOPMENT, V113, P589; Bossard P, 1998, DEVELOPMENT, V125, P4909; Chai C, 2000, MECH DEVELOP, V91, P421, DOI 10.1016/S0925-4773(99)00312-3; CHEN CY, 1995, J BIOL CHEM, V270, P15628, DOI 10.1074/jbc.270.26.15628; Cohen-Kaminsky S, 1998, EMBO J, V17, P5151, DOI 10.1093/emboj/17.17.5151; del Castillo-Olivares A, 2000, J BIOL CHEM, V275, P17793, DOI 10.1074/jbc.M000996200; del Castillo-Olivares A, 2000, NUCLEIC ACIDS RES, V28, P3587; Durocher D, 1997, EMBO J, V16, P5687, DOI 10.1093/emboj/16.18.5687; ELLINGERZIEGELBAUER H, 1995, MOL ENDOCRINOL, V9, P872, DOI 10.1210/me.9.7.872; ELLINGERZIEGELBAUER H, 1994, MOL CELL BIOL, V14, P2786, DOI 10.1128/MCB.14.4.2786; Galarneau L, 1998, CYTOGENET CELL GENET, V82, P269, DOI 10.1159/000015116; Galarneau L, 1996, MOL CELL BIOL, V16, P3853; Gilbert S, 2000, J VIROL, V74, P5032, DOI 10.1128/JVI.74.11.5032-5039.2000; Goodwin B, 2000, MOL CELL, V6, P517, DOI 10.1016/S1097-2765(00)00051-4; GUERTIN M, 1988, MOL CELL BIOL, V8, P1398, DOI 10.1128/MCB.8.4.1398; IKEDA Y, 1993, MOL ENDOCRINOL, V7, P852, DOI 10.1210/me.7.7.852; Jung JN, 1999, SCIENCE, V284, P1998, DOI 10.1126/science.284.5422.1998; Koutsourakis M, 1999, DEVELOPMENT, V126, P723; Ktistaki E, 1997, MOL CELL BIOL, V17, P2790, DOI 10.1128/MCB.17.5.2790; Kudo T, 1997, GENE, V197, P261, DOI 10.1016/S0378-1119(97)00270-9; KUO CJ, 1992, NATURE, V355, P457, DOI 10.1038/355457a0; LAVORGNA G, 1991, SCIENCE, V252, P848, DOI 10.1126/science.1709303; LEDOUARIN NM, 1975, MED BIOL, V53, P427; Lee YK, 1999, J BIOL CHEM, V274, P20869, DOI 10.1074/jbc.274.30.20869; Li JX, 2000, GENE DEV, V14, P464; Li M, 1998, J BIOL CHEM, V273, P29022, DOI 10.1074/jbc.273.44.29022; Lin WW, 2000, BIOCHEM J, V348, P439, DOI 10.1042/0264-6021:3480439; Lu TT, 2000, MOL CELL, V6, P507, DOI 10.1016/S1097-2765(00)00050-2; Monzen K, 1999, MOL CELL BIOL, V19, P7096; Nakajima T, 2000, GENE, V248, P203, DOI 10.1016/S0378-1119(00)00119-0; Nawata H, 1999, J STEROID BIOCHEM, V69, P323, DOI 10.1016/S0960-0760(99)00081-3; Nitta M, 1999, P NATL ACAD SCI USA, V96, P6660, DOI 10.1073/pnas.96.12.6660; *NUCL REC NOM COMM, 1909, CELL, V97, P161; PANI L, 1992, MOL CELL BIOL, V12, P552, DOI 10.1128/MCB.12.2.552; Rausa FM, 1999, MECH DEVELOP, V89, P185, DOI 10.1016/S0925-4773(99)00209-9; Ryffel GU, 2000, MECH DEVELOP, V90, P65, DOI 10.1016/S0925-4773(99)00230-0; Samadani U, 1996, MOL CELL BIOL, V16, P6273; Sinal CJ, 2000, CELL, V102, P731, DOI 10.1016/S0092-8674(00)00062-3; TAKETO M, 1995, GENOMICS, V25, P565, DOI 10.1016/0888-7543(95)80059-U; Tremblay JJ, 1999, MOL ENDOCRINOL, V13, P1388, DOI 10.1210/me.13.8.1388; Tremblay KD, 2000, DEVELOPMENT, V127, P3079; Wadman IA, 1997, EMBO J, V16, P3145, DOI 10.1093/emboj/16.11.3145; Weber H, 1996, DEVELOPMENT, V122, P1975; ZAPP D, 1993, MOL CELL BIOL, V13, P6416, DOI 10.1128/MCB.13.10.6416; Zaret K, 1998, CURR OPIN GENET DEV, V8, P526, DOI 10.1016/S0959-437X(98)80006-3; Zaret K, 1999, DEV BIOL, V209, P1, DOI 10.1006/dbio.1999.9228; ZHONG WM, 1994, MOL CELL BIOL, V14, P7276, DOI 10.1128/MCB.14.11.7276	53	80	90	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 20	2001	276	16					13136	13144		10.1074/jbc.M010737200	http://dx.doi.org/10.1074/jbc.M010737200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	423VN	11145965	hybrid			2022-12-25	WOS:000168198600094
J	Ruvolo, PP; Gao, FQ; Blalock, WL; Deng, XM; May, WS				Ruvolo, PP; Gao, FQ; Blalock, WL; Deng, XM; May, WS			Ceramide regulates protein synthesis by a novel mechanism involving the cellular PKR activator RAX	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KINASE PKR; INDUCED APOPTOSIS; STRESS; RNA; INITIATION; INHIBITION; PHOSPHORYLATION; DEATH; CELLS; DEPHOSPHORYLATION	The sphingolipid ceramide is an important second signal molecule and potent apoptotic agent. The production of ceramide is associated with virtually every known stress stimulus, and thus, generation of this sphingolipid has been suggested as a universal feature of apoptosis. Recent studies suggest that an important component of cell death following diverse stress stimuli (e.g. interleukin-3 withdrawal, sodium arsenite treatment, and peroxide treatment) is the activation of the double-stranded RNA-activable protein kinase, PKR, resulting in the inhibition of protein synthesis (Ito, T., Jagus, R., and May, W. S. (1994) Proc. Natl. Acad. Sci. U.S.A. 91, 7455-7459). The recently discovered cellular PKR activator, RAX, is phosphorylated in association with PKR activation (Ito, T., Yang, M., and May, W. S. (1999) J. Biol. Chem. 274, 15427-15432). Since RAX is phosphorylated by an as yet undetermined SAPK and ceramide is a potent activator of SAPKs such as JNK, a role for ceramide in the activation of RAX might be possible. Results indicate that overexpression of exogenous RAX potentiates ceramide-induced killing. Furthermore, ceramide can potently inhibit protein synthesis. Since ceramide potently promotes RAX and eukaryotic initiation factor-2 alpha phosphorylation, a possible role for ceramide in this process may involve the activation of PKR by RAX. Since 2-aminopurine, a serine/threonine kinase inhibitor that has previously been shown to inhibit PKR, blocks both the potentiation of ceramide killing by RAX and ceramide-induced inhibition of protein synthesis, ceramide appears to promote PKR activation, at least indirectly. Collectively, these findings suggest a novel role for ceramide in the regulation of protein synthesis and apoptosis.	Univ Florida, Shands Canc Ctr, Gainesville, FL 32610 USA; Univ Florida, Dept Med, Gainesville, FL 32610 USA	State University System of Florida; University of Florida; State University System of Florida; University of Florida	Ruvolo, PP (corresponding author), Univ Florida, Shands Canc Ctr, POB 100232, Gainesville, FL 32610 USA.		Blalock, William L/C-6959-2019	Blalock, William L/0000-0002-8045-4840	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL054083] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL54083] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Basu S, 1998, J BIOL CHEM, V273, P30419, DOI 10.1074/jbc.273.46.30419; Basu S, 1998, ONCOGENE, V17, P3277, DOI 10.1038/sj.onc.1202570; Bielawska AE, 1997, AM J PATHOL, V151, P1257; BOSE R, 1995, CELL, V82, P405, DOI 10.1016/0092-8674(95)90429-8; Clemens MJ, 1997, J INTERF CYTOK RES, V17, P503, DOI 10.1089/jir.1997.17.503; DEBENEDETTI A, 1983, J BIOL CHEM, V258, P4556; Der SD, 1997, P NATL ACAD SCI USA, V94, P3279, DOI 10.1073/pnas.94.7.3279; Hannun YA, 1996, SCIENCE, V274, P1855, DOI 10.1126/science.274.5294.1855; Hannun YA, 2000, TRENDS CELL BIOL, V10, P73, DOI 10.1016/S0962-8924(99)01694-3; HANNUN YA, 1994, J BIOL CHEM, V269, P3125; Harding HP, 1999, NATURE, V397, P271, DOI 10.1038/16729; HERSHEY JWB, 1993, SEMIN VIROL, V4, P201, DOI 10.1006/smvy.1993.1016; HOVANESSIAN AG, 1993, SEMIN VIROL, V4, P237, DOI 10.1006/smvy.1993.1020; HU YH, 1993, J INTERFERON RES, V13, P323, DOI 10.1089/jir.1993.13.323; Ito T, 1999, J BIOL CHEM, V274, P15427, DOI 10.1074/jbc.274.22.15427; Ito T, 1999, BIOCHEM BIOPH RES CO, V265, P589, DOI 10.1006/bbrc.1999.1727; ITO T, 1994, P NATL ACAD SCI USA, V91, P7455, DOI 10.1073/pnas.91.16.7455; Jarvis WD, 1997, MOL PHARMACOL, V52, P935, DOI 10.1124/mol.52.6.935; Jarvis WD, 1996, CLIN CANCER RES, V2, P1; Kolesnick R, 1999, TRENDS BIOCHEM SCI, V24, P224, DOI 10.1016/S0968-0004(99)01408-5; Kolesnick RN, 1998, ANNU REV PHYSIOL, V60, P643, DOI 10.1146/annurev.physiol.60.1.643; Kumar KU, 1999, MOL CELL BIOL, V19, P1116; LANGLAND JO, 1992, J BIOL CHEM, V267, P10729; Lee JY, 1996, J BIOL CHEM, V271, P13169, DOI 10.1074/jbc.271.22.13169; MATTHEWS MB, 1993, SEMIN VIROL, V4, P247; MERRICK WC, 1992, MICROBIOL REV, V56, P241; OBEID LM, 1993, SCIENCE, V259, P1769, DOI 10.1126/science.8456305; Patel CV, 2000, J BIOL CHEM, V275, P37993, DOI 10.1074/jbc.M004762200; Patel RC, 1998, EMBO J, V17, P4379, DOI 10.1093/emboj/17.15.4379; PROSTKO CR, 1992, J BIOL CHEM, V267, P16751; QUINTANS J, 1994, BIOCHEM BIOPH RES CO, V202, P710, DOI 10.1006/bbrc.1994.1988; ROWLANDS AG, 1988, J BIOL CHEM, V263, P5526; Ruvolo PP, 1999, J BIOL CHEM, V274, P20296, DOI 10.1074/jbc.274.29.20296; SAMUEL CE, 1993, J BIOL CHEM, V268, P7603; Schubert KM, 2000, J BIOL CHEM, V275, P13330, DOI 10.1074/jbc.275.18.13330; Sheikh MS, 1999, ONCOGENE, V18, P6121, DOI 10.1038/sj.onc.1203131; Smyth M J, 1997, Adv Pharmacol, V41, P133, DOI 10.1016/S1054-3589(08)61057-1; Tan SL, 1999, J INTERF CYTOK RES, V19, P543, DOI 10.1089/107999099313677; TEPPER CG, 1995, P NATL ACAD SCI USA, V92, P8443, DOI 10.1073/pnas.92.18.8443; WESTWICK JK, 1995, J BIOL CHEM, V270, P22689, DOI 10.1074/jbc.270.39.22689; Williams BRG, 1999, ONCOGENE, V18, P6112, DOI 10.1038/sj.onc.1203127; Wu SY, 1998, BIOCHEMISTRY-US, V37, P13816, DOI 10.1021/bi981472h; Yeung MC, 1996, P NATL ACAD SCI USA, V93, P12451, DOI 10.1073/pnas.93.22.12451; Zamanian-Daryoush M, 1999, ONCOGENE, V18, P315, DOI 10.1038/sj.onc.1202293; Zhu SH, 1997, J BIOL CHEM, V272, P14434, DOI 10.1074/jbc.272.22.14434; Zundel W, 1998, GENE DEV, V12, P1941, DOI 10.1101/gad.12.13.1941	46	65	68	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 13	2001	276	15					11754	11758		10.1074/jbc.M011400200	http://dx.doi.org/10.1074/jbc.M011400200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	421UK	11148216	hybrid			2022-12-25	WOS:000168081800045
J	dos Santos, CMA; van Kerkhof, P; Strous, GJ				dos Santos, CMA; van Kerkhof, P; Strous, GJ			The signal transduction of the growth hormone receptor is regulated by the ubiquitin/proteasome system and continues after endocytosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGAND-INDUCED INTERNALIZATION; CLATHRIN-MEDIATED ENDOCYTOSIS; PROTEIN-TYROSINE PHOSPHATASES; ERYTHROPOIETIN RECEPTOR; CYTOPLASMIC DOMAIN; JAK/STAT PATHWAY; UBIQUITIN SYSTEM; JAK2; KINASE; SHP-2	The growth hormone receptor (GHR) intracellular domain contains all of the information required for signal transduction as well as for endocytosis. Previously, we showed that the proteasome mediates the clathrin-mediated endocytosis of the GHR. Here, we present evidence that the proteasomal inhibitor MG132 prolongs the GH-induced activity of both GHR and JAK2, presumably through stabilization of GHR and JAK2 tyrosine phosphorylation, If proteasomal inhibitor was combined with ligand in an endocytosis-deficient GHR mutant, the same phenomenon occurred indicating that proteasomal action on tyrosine dephosphorylation is independent of endocytosis. Experiments with a GHR-truncated tail mutant (GHR-(1-369)) led to a prolonged JAK2 phosphorylation caused by the loss of a phosphatase-binding site. This raised the question of what happens to the signal transduction of the GHR after its internalization. Co-immunoprecipitation of GH . GHR complexes before and after endocytosis showed that JAK2 as well as other activated proteins are bound to the GHR not only at the cell surface but also intracellularly, suggesting that the GHR signal transduction continues in endosomes. Additionally, these results provide evidence that GHR is present in endosomes both in its full-length and truncated form, indicating that the receptor is down-regulated by the proteasome.	Univ Utrecht, Med Ctr, Dept Cell Biol, NL-3584 CX Utrecht, Netherlands; Inst Biomembranes, NL-3584 CX Utrecht, Netherlands	Utrecht University	Strous, GJ (corresponding author), Univ Utrecht, Med Ctr, Dept Cell Biol, Heidelberglaan 100,AZU-G02-525, NL-3584 CX Utrecht, Netherlands.			van Kerkhof, Peter/0000-0002-8954-2230				Adams TE, 1998, J BIOL CHEM, V273, P1285, DOI 10.1074/jbc.273.3.1285; ALLEVATO G, 1995, J BIOL CHEM, V270, P17210, DOI 10.1074/jbc.270.29.17210; Argetsinger LS, 1996, PHYSIOL REV, V76, P1089, DOI 10.1152/physrev.1996.76.4.1089; Callus BA, 1998, BLOOD, V91, P3182, DOI 10.1182/blood.V91.9.3182.3182_3182_3192; Carter-Su C, 1998, RECENT PROG HORM RES, V53, P61; Ceresa BP, 1998, MOL CELL BIOL, V18, P3862, DOI 10.1128/MCB.18.7.3862; Fauman EB, 1996, TRENDS BIOCHEM SCI, V21, P413, DOI 10.1016/S0968-0004(96)10059-1; FRANK SJ, 1994, ENDOCRINOLOGY, V135, P2228, DOI 10.1210/en.135.5.2228; Gesbert F, 1998, J BIOL CHEM, V273, P18273, DOI 10.1074/jbc.273.29.18273; Govers R, 1999, EMBO J, V18, P28, DOI 10.1093/emboj/18.1.28; Govers R, 1997, EMBO J, V16, P4851, DOI 10.1093/emboj/16.16.4851; Hackett RH, 1997, J BIOL CHEM, V272, P11128; HERSHKO A, 1992, ANNU REV BIOCHEM, V61, P761, DOI 10.1146/annurev.bi.61.070192.003553; Jiao HY, 1996, MOL CELL BIOL, V16, P6985; KELLY PA, 1993, RECENT PROG HORM RES, V48, P123; Kim SO, 1998, J BIOL CHEM, V273, P2344, DOI 10.1074/jbc.273.4.2344; KLINGMULLER U, 1995, CELL, V80, P729, DOI 10.1016/0092-8674(95)90351-8; Mellado M, 1997, J BIOL CHEM, V272, P9189; MURPHY LJ, 1984, ENDOCRINOLOGY, V115, P1625, DOI 10.1210/endo-115-4-1625; Myers MG, 1998, J BIOL CHEM, V273, P26908, DOI 10.1074/jbc.273.41.26908; Neel BG, 1997, CURR OPIN CELL BIOL, V9, P193, DOI 10.1016/S0955-0674(97)80063-4; Piao XH, 1996, P NATL ACAD SCI USA, V93, P14665, DOI 10.1073/pnas.93.25.14665; Ram PA, 1999, J BIOL CHEM, V274, P35553, DOI 10.1074/jbc.274.50.35553; ROUPAS P, 1988, MOL CELL ENDOCRINOL, V57, P93, DOI 10.1016/0303-7207(88)90037-8; Smit LS, 1996, MOL ENDOCRINOL, V10, P519, DOI 10.1210/me.10.5.519; Starr R, 1997, NATURE, V387, P917, DOI 10.1038/43206; Stofega MR, 2000, J BIOL CHEM, V275, P28222; Stofega MR, 1998, J BIOL CHEM, V273, P7112, DOI 10.1074/jbc.273.12.7112; Strous GJ, 1999, J CELL SCI, V112, P1417; Strous GJ, 1997, J BIOL CHEM, V272, P40; Strous GJ, 1996, EMBO J, V15, P3806, DOI 10.1002/j.1460-2075.1996.tb00754.x; Thirone ACP, 1999, ENDOCRINOLOGY, V140, P55, DOI 10.1210/en.140.1.55; van Kerkhof P, 2000, J BIOL CHEM, V275, P1575, DOI 10.1074/jbc.275.3.1575; Vanderkuur JA, 1997, ENDOCRINOLOGY, V138, P4301, DOI 10.1210/en.138.10.4301; VANDERKUUR JA, 1994, J BIOL CHEM, V269, P21709; Verdier F, 1998, J BIOL CHEM, V273, P28185, DOI 10.1074/jbc.273.43.28185; Vieira AV, 1996, SCIENCE, V274, P2086, DOI 10.1126/science.274.5295.2086; WANG YD, 1995, MOL ENDOCRINOL, V9, P303, DOI 10.1210/me.9.3.303; Yaron A, 1997, EMBO J, V16, P6486, DOI 10.1093/emboj/16.21.6486; Yin TG, 1997, J BIOL CHEM, V272, P1032, DOI 10.1074/jbc.272.2.1032; You M, 1999, MOL CELL BIOL, V19, P2416, DOI 10.1128/mcb.19.3.2416; Yu CL, 1997, J BIOL CHEM, V272, P14017, DOI 10.1074/jbc.272.22.14017; Zhang JG, 1999, P NATL ACAD SCI USA, V96, P2071, DOI 10.1073/pnas.96.5.2071	43	34	39	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 6	2001	276	14					10839	10846		10.1074/jbc.M003635200	http://dx.doi.org/10.1074/jbc.M003635200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	420AC	11152671	hybrid			2022-12-25	WOS:000167980900039
J	Mischel, PS; Smith, SG; Vining, ER; Valletta, JS; Mobley, WC; Reichardt, LF				Mischel, PS; Smith, SG; Vining, ER; Valletta, JS; Mobley, WC; Reichardt, LF			The extracellular domain of p75(NTR) is necessary to inhibit neurotrophin-3 signaling through TrkA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NERVE GROWTH-FACTOR; XENOPUS-LAEVIS OOCYTES; AFFINITY NGF RECEPTOR; SYMPATHETIC NEURONS; FUNCTIONAL INTERACTIONS; SENSORY NEURONS; FACTOR-BINDING; PC12 CELLS; IN-VIVO; P75	The TrkA receptor is activated primarily by nerve growth factor (NGF), but it can also be activated by high concentrations of neurotrophin 3 (NT-3). The pan-neurotrophin receptor p75(NTR) strongly inhibits activation of TrbA by NT-3 but not by NGF. To examine the role of p75(NTR) in regulating the specificity of TrkA signaling, we expressed both receptors in Xenopus oocytes. Application of NGF or NT-3 to oocytes expressing TrkA alone resulted in efflux of Ca-45(2+) by a phospholipase C-gamma -dependent pathway. Coexpression of p75(NTR) with TrkA inhibited Ca-45(2+) efflux in response to NT-3 but not NGF. The inhibitory effect on NT-3 activation of TrkA increased with increasing expression of p75(NTR). Coexpression of a truncated p75(NTR) receptor lacking all but the first 9 amino acids of the cytoplasmic domain inhibited NT-3 stimulation of Ca-45(2+) efflux, whereas coexpression of an epidermal growth factor receptor/p75(NTR) chimera (extracellular domain of epidermal growth factor receptor with transmembrane and cytoplasmic domains of p75(NTR)) did not inhibit NT-3 signaling through TrkA. These studies demonstrated that the extracellular domain of p75(NTR) was necessary to inhibit NT-3 signaling through TrkA. Remarkably, p75(NTR) binding to NT-3 was not required to prevent signaling through TrkA, since occupying p75(NTR) with brain-derived neurotrophic factor or anti-p75 antibody (REX) did not rescue the ability of NT-3 to activate Ca-45(2+) efflux. These data suggested a physical association between TrkA and p75(NTR). Documenting this physical interaction, we showed that p75(NTR) and TrkA could be coimmunoprecipitated from Xenopus oocytes. Our results suggest that the interaction of these two receptors on the cell surface mediated the inhibition of NT-3-activated signaling through TrkA.	Univ Calif Los Angeles, Med Ctr, Dept Pathol & Lab Med, Los Angeles, CA 90095 USA; Univ Calif San Francisco, Dept Physiol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Pediat, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Howard Hughes Med Inst, San Francisco, CA 94143 USA; Stanford Univ, Med Ctr, Dept Neurol & Neurol Sci, Stanford, CA 94305 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; Howard Hughes Medical Institute; University of California System; University of California San Francisco; Stanford University	Mischel, PS (corresponding author), Univ Calif Los Angeles, Med Ctr, Dept Pathol & Lab Med, 10833 Le Conte Ave, Los Angeles, CA 90095 USA.				NIMH NIH HHS [P50 MH048200-070005, MH48200] Funding Source: Medline; NINDS NIH HHS [NS10301, F32 NS010301, NS24054, R01 NS024054] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [P50MH048200] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [F32NS010301, R01NS024054] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Bamji SX, 1998, J CELL BIOL, V140, P911, DOI 10.1083/jcb.140.4.911; BARKER PA, 1994, J BIOL CHEM, V269, P30645; BARKER PA, 1994, NEURON, V13, P203, DOI 10.1016/0896-6273(94)90470-7; BATTLEMAN DS, 1993, J NEUROSCI, V13, P941; Belliveau DJ, 1997, J CELL BIOL, V136, P375, DOI 10.1083/jcb.136.2.375; BENEDETTI M, 1993, P NATL ACAD SCI USA, V90, P7859, DOI 10.1073/pnas.90.16.7859; Bibel M, 1999, EMBO J, V18, P616, DOI 10.1093/emboj/18.3.616; Bilderback TR, 1999, J BIOL CHEM, V274, P257, DOI 10.1074/jbc.274.1.257; BIRREN SJ, 1993, DEVELOPMENT, V119, P597; BOTHWELL M, 1995, ANNU REV NEUROSCI, V18, P223, DOI 10.1146/annurev.neuro.18.1.223; Brennan C, 1999, NAT NEUROSCI, V2, P699, DOI 10.1038/11158; CasacciaBonnefil P, 1996, NATURE, V383, P716, DOI 10.1038/383716a0; CHAO MV, 1995, TRENDS NEUROSCI, V18, P321, DOI 10.1016/0166-2236(95)93922-K; CLARY DO, 1994, P NATL ACAD SCI USA, V91, P11133, DOI 10.1073/pnas.91.23.11133; Davey F, 1998, CURR BIOL, V8, P915, DOI 10.1016/S0960-9822(07)00371-5; DAVIES AM, 1995, EMBO J, V14, P4482, DOI 10.1002/j.1460-2075.1995.tb00127.x; Eide FF, 1996, J NEUROSCI, V16, P3123; EMFORS P, 1994, CELL, V77, P503; FARINAS I, 1994, NATURE, V369, P658, DOI 10.1038/369658a0; Filtz TM, 1996, J BIOL CHEM, V271, P31121, DOI 10.1074/jbc.271.49.31121; Francis N, 1999, DEV BIOL, V210, P411, DOI 10.1006/dbio.1999.9269; Gargano N, 1997, J NEUROSCI RES, V50, P1; GILLO B, 1987, J PHYSIOL-LONDON, V392, P349, DOI 10.1113/jphysiol.1987.sp016784; Hamanoue M, 1999, MOL CELL NEUROSCI, V14, P28, DOI 10.1006/mcne.1999.0770; HANTZOPOULOS PA, 1994, NEURON, V13, P187, DOI 10.1016/0896-6273(94)90469-3; Hartzell HC, 1996, J GEN PHYSIOL, V108, P157, DOI 10.1085/jgp.108.3.157; HEMPSTEAD BL, 1991, NATURE, V350, P678, DOI 10.1038/350678a0; Huang C, 1999, J BIOL CHEM, V274, P36707, DOI 10.1074/jbc.274.51.36707; Huang EJ, 1999, DEVELOPMENT, V126, P2191; HUBER LJ, 1995, J NEUROSCI RES, V40, P557, DOI 10.1002/jnr.490400415; Kimpinski K, 1999, NEUROSCIENCE, V93, P253, DOI 10.1016/S0306-4522(99)00156-6; Kohn J, 1999, J NEUROSCI, V19, P5393; LEE KF, 1994, DEVELOPMENT, V120, P1027; LIMAN ER, 1992, NEURON, V9, P861, DOI 10.1016/0896-6273(92)90239-A; MacPhee IJ, 1997, J BIOL CHEM, V272, P23547, DOI 10.1074/jbc.272.38.23547; MAHADEO D, 1994, J BIOL CHEM, V269, P6884; Reichardt L. F., 1997, MOL CELLULAR APPROAC, P220; RICHTER JD, 1981, CELL, V27, P183, DOI 10.1016/0092-8674(81)90372-X; Ross AH, 1996, J CELL BIOL, V132, P945, DOI 10.1083/jcb.132.5.945; Ross GM, 1998, EUR J NEUROSCI, V10, P890, DOI 10.1046/j.1460-9568.1998.00094.x; SCHULTZ P, 1992, CELL SIGNAL, V4, P153, DOI 10.1016/0898-6568(92)90079-N; Segal RA, 1996, ANNU REV NEUROSCI, V19, P463, DOI 10.1146/annurev.ne.19.030196.002335; SOREQ H, 1992, METHOD ENZYMOL, V207, P225; UENO H, 1993, J BIOL CHEM, V268, P22814; VERDI JM, 1994, NEURON, V13, P1359, DOI 10.1016/0896-6273(94)90421-9; Vesa J, 2000, J BIOL CHEM, V275, P24414, DOI 10.1074/jbc.M001641200; WESKAMP G, 1991, NEURON, V6, P649, DOI 10.1016/0896-6273(91)90067-A; WOLF DE, 1995, J BIOL CHEM, V270, P2133, DOI 10.1074/jbc.270.5.2133; Wyatt S, 1997, EMBO J, V16, P3115, DOI 10.1093/emboj/16.11.3115; WYATT S, 1995, J CELL BIOL, V130, P1435, DOI 10.1083/jcb.130.6.1435; YAN H, 1991, SCIENCE, V252, P561, DOI 10.1126/science.1850551; Yoon SO, 1998, J NEUROSCI, V18, P3273; ZHOU J, 1995, J NEUROCHEM, V65, P1146	53	70	71	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 6	2001	276	14					11294	11301		10.1074/jbc.M005132200	http://dx.doi.org/10.1074/jbc.M005132200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	420AC	11150291	Green Accepted, hybrid			2022-12-25	WOS:000167980900097
J	Bezombes, C; Segui, B; Cuvillier, O; Bruno, AP; Uro-Coste, E; Gouaze, V; Andrieu-Abadie, N; Carpentier, S; Laurent, G; Salvayre, R; Jaffrezou, JP; Levade, T				Bezombes, C; Segui, B; Cuvillier, O; Bruno, AP; Uro-Coste, E; Gouaze, V; Andrieu-Abadie, N; Carpentier, S; Laurent, G; Salvayre, R; Jaffrezou, JP; Levade, T			Lysosomal sphingomyelinase is not solicited for apoptosis signaling	FASEB JOURNAL			English	Article									CHU Rangueil, Lab Biochim Med, INSERM, U466, F-31403 Toulouse, France; Inst Claudius Regaud, INSERM, E9910, F-31052 Toulouse, France	CHU de Toulouse; Institut National de la Sante et de la Recherche Medicale (Inserm); Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Institut Claudius Regaud	Levade, T (corresponding author), CHU Rangueil, Lab Biochim Med, INSERM, U466, 1 Ave Jean Poulhes, F-31403 Toulouse, France.		Levade, Thierry/O-8948-2014; Gouaze-Andersson, Valerie/O-9180-2014; Bezombes, Christine/AAC-1724-2020; Andrieu-Abadie, Nathalie/N-6793-2013; Ségui, Bruno/O-8957-2014; CUVILLIER, Olivier/B-2567-2009; CUVILLIER, Olivier/S-1631-2019; Bezombes, Christine/G-2743-2017; Bezombes, christine/X-8479-2019	Gouaze-Andersson, Valerie/0000-0002-1797-515X; Andrieu-Abadie, Nathalie/0000-0003-2698-1970; Ségui, Bruno/0000-0002-6119-1889; CUVILLIER, Olivier/0000-0003-3346-375X; CUVILLIER, Olivier/0000-0003-3346-375X; Bezombes, christine/0000-0003-4079-4872					0	49	51	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	FEB	2001	15	2					297	299						3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	400LK	11156942				2022-12-25	WOS:000166872900008
J	de Toledo, SM; Azzam, EI; Dahlberg, WK; Gooding, TB; Little, JB				de Toledo, SM; Azzam, EI; Dahlberg, WK; Gooding, TB; Little, JB			ATM complexes with HDM2 and promotes its rapid phosphorylation in a p53-independent manner in normal and tumor human cells exposed to ionizing radiation	ONCOGENE			English	Article						MDM2; ATM; p53; ionizing radiation; UV	WILD-TYPE P53; ATAXIA-TELANGIECTASIA; DNA-DAMAGE; GENOTOXIC STRESS; MDM-2 ONCOGENE; UV IRRADIATION; IN-VIVO; PROTEIN; FIBROBLASTS; DEGRADATION	To further understand the mechanism(s) by which DNA damage activates p53, we analysed the expression levels of p53 and HDM2 (the human homolog of murine MDM2) in various human diploid fibroblast and tumor cell strains during the period that precedes activation of known downstream effecters of p53, In X-irradiated human cells, HDM2 protein was rapidly phosphorylated in serine/threonine residues in a p53, p14(ARF) and p73-independent manner. In p53 wild-type cells, HDM2 phosphorylation precedes a detectable increase in the levels of p53 and is not observed in ataxia telangiectasia (AT) fibroblasts, The transfection of AT cells with a vector expressing ATM restored the ability to rapidly phosphorylate HDM2 following X-irradiation, confirming a role for ATM in its phosphorylation, We also show that ATM complexes with HDM2, The DNA lesions signaling the early rapid phosphorylation of HDM2 are a result of X-ray and not UV-type damage. The ATM-promoted early covalent modification of HDM2 in X-irradiated human cells may provide a mechanism to activate p53.	Harvard Univ, Sch Publ Hlth, Dept Canc Cell Biol, Radiobiol Lab, Boston, MA 02115 USA	Harvard University; Harvard T.H. Chan School of Public Health	Little, JB (corresponding author), Harvard Univ, Sch Publ Hlth, Dept Canc Cell Biol, Radiobiol Lab, Boston, MA 02115 USA.				NATIONAL CANCER INSTITUTE [R35CA047542] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES000002] Funding Source: NIH RePORTER; NCI NIH HHS [CA-47542] Funding Source: Medline; NIEHS NIH HHS [ES-00002] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Abraham J, 1999, ONCOGENE, V18, P1521, DOI 10.1038/sj.onc.1202454; Ashcroft M, 1999, MOL CELL BIOL, V19, P1751; Ashcroft M, 1999, ONCOGENE, V18, P7637, DOI 10.1038/sj.onc.1203012; Azzam EI, 1997, CELL GROWTH DIFFER, V8, P1161; Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; Blattner C, 1999, ONCOGENE, V18, P1723, DOI 10.1038/sj.onc.1202480; Bottger A, 1997, CURR BIOL, V7, P860, DOI 10.1016/S0960-9822(06)00374-5; BOULIKAS T, 1995, CRIT REV EUKAR GENE, V5, P1; Chehab NH, 1999, P NATL ACAD SCI USA, V96, P13777, DOI 10.1073/pnas.96.24.13777; Chen LH, 1999, MOL MED, V5, P21, DOI 10.1007/BF03402136; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; de Toledo SM, 1998, CELL GROWTH DIFFER, V9, P887; DETOLEDO SM, 1995, INT J RADIAT BIOL, V67, P135, DOI 10.1080/09553009514550171; FINLAY CA, 1993, MOL CELL BIOL, V13, P301, DOI 10.1128/MCB.13.1.301; Freedman DA, 1999, CELL MOL LIFE SCI, V55, P96, DOI 10.1007/s000180050273; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; Grossman SR, 1998, MOL CELL, V2, P405, DOI 10.1016/S1097-2765(00)80140-9; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Hirao A, 2000, SCIENCE, V287, P1824, DOI 10.1126/science.287.5459.1824; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KHANNA KK, 1993, ONCOGENE, V8, P3307; Khosravi R, 1999, P NATL ACAD SCI USA, V96, P14973, DOI 10.1073/pnas.96.26.14973; KUBUTTAT MHG, 1997, NATURE, V387, P299; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; Landers JE, 1997, CANCER RES, V57, P3562; Lavin LF, 1999, INT J RADIAT BIOL, V75, P1201; LITTLE JB, 1985, RADIAT RES, V101, P81, DOI 10.2307/3576305; Liu ZG, 1996, NATURE, V384, P273, DOI 10.1038/384273a0; Maki CG, 1996, CANCER RES, V56, P2649; Maki CG, 1997, MOL CELL BIOL, V17, P355, DOI 10.1128/MCB.17.1.355; MALTZMAN W, 1984, MOL CELL BIOL, V4, P1689, DOI 10.1128/MCB.4.9.1689; Meek DW, 1999, ONCOGENE, V18, P7666, DOI 10.1038/sj.onc.1202951; Midgley CA, 1997, ONCOGENE, V15, P1179, DOI 10.1038/sj.onc.1201459; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; NELSON WG, 1994, MOL CELL BIOL, V14, P1815, DOI 10.1128/MCB.14.3.1815; OLSON DC, 1993, ONCOGENE, V8, P2353; PICKSLEY SM, 1994, ONCOGENE, V9, P2523; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; Prives C, 1998, CELL, V95, P5, DOI 10.1016/S0092-8674(00)81774-2; Roth J, 1998, EMBO J, V17, P554, DOI 10.1093/emboj/17.2.554; Rotman G, 1999, ONCOGENE, V18, P6135, DOI 10.1038/sj.onc.1203124; Sionov RV, 1999, J BIOL CHEM, V274, P8371, DOI 10.1074/jbc.274.13.8371; Stommel JM, 1999, EMBO J, V18, P1660, DOI 10.1093/emboj/18.6.1660; Tao WK, 1999, P NATL ACAD SCI USA, V96, P6937, DOI 10.1073/pnas.96.12.6937; Unger T, 1999, EMBO J, V18, P1805, DOI 10.1093/emboj/18.7.1805; Wu L, 1997, MOL MED, V3, P441, DOI 10.1007/BF03401691; Zeng XY, 1999, MOL CELL BIOL, V19, P3257; Ziv Y, 1997, ONCOGENE, V15, P159, DOI 10.1038/sj.onc.1201319	49	52	52	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 14	2000	19	54					6185	6193		10.1038/sj.onc.1204020	http://dx.doi.org/10.1038/sj.onc.1204020			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	388YK	11175332				2022-12-25	WOS:000166210500001
J	Nakaya, N; Lowe, SW; Taya, Y; Chenchik, A; Enikolopov, G				Nakaya, N; Lowe, SW; Taya, Y; Chenchik, A; Enikolopov, G			Specific pattern of p53 phosphorylation during nitric oxide-induced cell cycle arrest	ONCOGENE			English	Article						nitric oxide; p53; proliferation; cell cycle arrest; phosphorylation	DNA-DAMAGE; RIBONUCLEOTIDE REDUCTASE; DROSOPHILA DEVELOPMENT; GROWTH; APOPTOSIS; DIFFERENTIATION; PROLIFERATION; ACTIVATION; INHIBITION; RADIATION	Nitric oxide (NO) is an efficient inhibitor of cell proliferation. Here we show that part of the antiproliferative activity of NO in fibroblasts is mediated through p53 signaling pathway. Cells from p53-/- knockout mice are compromised in their ability to stop dividing in the presence of NO, NO strongly induces expression of genes which are transcriptional targets of p53, and p53 is necessary for some, but not all, of the transcription activation effects of NO, Furthermore, NO strongly increases the cellular level of p53 protein. Since phosphorylation of particular residues of the p53 molecule has been correlated with its functional activity, we determined the phosphorylation pattern of p53 molecule after exposure to NO and compared it with the phosphorylation patterns that develop upon treatment with gamma-irradiation, UV light, and adriamycin. We found that NO induces a specific signature pattern of p53 phosphorylation, distinct from the patterns evoked by other inducers. This study suggests that NO activates specific signaling pathways that may partially overlap, but that do not coincide, with signaling pathways activated by other known inducers of p53 activity.	Cold Spring Harbor Lab, Cold Spring Harbor, NY 11724 USA; Natl Canc Ctr, Res Inst, Chuo Ku, Tokyo 104, Japan; Clontech Labs Inc, Palo Alto, CA 94303 USA	Cold Spring Harbor Laboratory; National Cancer Center - Japan	Enikolopov, G (corresponding author), Cold Spring Harbor Lab, POB 100,1 Bungtown Rd, Cold Spring Harbor, NY 11724 USA.		Enikolopov, Grigori/P-5731-2019; Enikolopov, Grigori N/B-7771-2009	Enikolopov, Grigori/0000-0001-8178-8917; Enikolopov, Grigori N/0000-0001-8178-8917				BREDT DS, 1994, ANNU REV BIOCHEM, V63, P175, DOI 10.1146/annurev.bi.63.070194.001135; Brune B, 1998, EUR J PHARMACOL, V351, P261, DOI 10.1016/S0014-2999(98)00274-X; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; El-Deiry WS, 1998, SEMIN CANCER BIOL, V8, P345, DOI 10.1006/scbi.1998.0097; Enikolopov G, 1999, CELL DEATH DIFFER, V6, P956, DOI 10.1038/sj.cdd.4400577; Forrester K, 1996, P NATL ACAD SCI USA, V93, P2442, DOI 10.1073/pnas.93.6.2442; GARG UC, 1990, BIOCHEM BIOPH RES CO, V171, P474, DOI 10.1016/0006-291X(90)91417-Q; GARTHWAITE J, 1995, ANNU REV PHYSIOL, V57, P683, DOI 10.1146/annurev.ph.57.030195.003343; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; Gibbs SM, 1998, NEURON, V20, P83, DOI 10.1016/S0896-6273(00)80436-5; GROSS SS, 1995, ANNU REV PHYSIOL, V57, P737, DOI 10.1146/annurev.ph.57.030195.003513; Ishida A, 1997, J BIOL CHEM, V272, P10050; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; Keefer LK, 1996, METHOD ENZYMOL, V268, P281; Keefer LK, 1996, ADV EXP MED BIOL, V387, P177; Kuzin B, 1996, CELL, V87, P639, DOI 10.1016/S0092-8674(00)81384-7; KWON NS, 1991, J EXP MED, V174, P761, DOI 10.1084/jem.174.4.761; LEPOIVRE M, 1990, J BIOL CHEM, V265, P14143; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Lipton SA, 1999, CELL DEATH DIFFER, V6, P943, DOI 10.1038/sj.cdd.4400580; Lu H, 1998, P NATL ACAD SCI USA, V95, P6399, DOI 10.1073/pnas.95.11.6399; Madden SL, 1997, ONCOGENE, V15, P1079, DOI 10.1038/sj.onc.1201091; MANNICK JB, 1994, CELL, V79, P1137, DOI 10.1016/0092-8674(94)90005-1; Messmer UK, 1996, BIOCHEM J, V319, P299, DOI 10.1042/bj3190299; NATHAN C, 1994, CELL, V78, P915, DOI 10.1016/0092-8674(94)90266-6; Nicotera P, 1999, CELL DEATH DIFFER, V6, P931, DOI 10.1038/sj.cdd.4400583; Papapetropoulos A, 1997, AM J PATHOL, V150, P1835; PEUNOVA N, 1995, NATURE, V375, P68, DOI 10.1038/375068a0; Poluha W, 1997, J BIOL CHEM, V272, P24002, DOI 10.1074/jbc.272.38.24002; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Prives C, 1998, CELL, V95, P5, DOI 10.1016/S0092-8674(00)81774-2; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Siliciano JD, 1997, GENE DEV, V11, P3471, DOI 10.1101/gad.11.24.3471; STAMLER JS, 1994, CELL, V78, P931, DOI 10.1016/0092-8674(94)90269-0; STAMLER JS, 1996, METHODS NITRIC OXIDE, P521; Tamir S, 1996, METHOD ENZYMOL, V269, P230; Waterman MJF, 1998, NAT GENET, V19, P175, DOI 10.1038/542; Wingrove JA, 1999, CELL, V98, P105, DOI 10.1016/S0092-8674(00)80610-8	38	57	58	0	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 14	2000	19	54					6369	6375		10.1038/sj.onc.1204100	http://dx.doi.org/10.1038/sj.onc.1204100			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	388YK	11175352				2022-12-25	WOS:000166210500021
J	Ababou, M; Dutertre, S; Lecluse, Y; Onclercq, R; Chatton, B; Amor-Gueret, M				Ababou, M; Dutertre, S; Lecluse, Y; Onclercq, R; Chatton, B; Amor-Gueret, M			ATM-dependent phosphorylation and accumulation of endogenous BLM protein in response to ionizing radiation	ONCOGENE			English	Article						Bloom's syndrome; ATM; phosphorylation; ionizing radiation; cell cycle checkpoints	SYNDROME GENE-PRODUCT; DNA-DAMAGE RESPONSE; ATAXIA-TELANGIECTASIA; CHROMATID EXCHANGES; BLOOM-SYNDROME; INSTABILITY; CANCER; BRCA1; P53; LYMPHOCYTES	Bloom's syndrome (BS), a rare genetic disease, arises through mutations in both alleles of the BLM gene which encodes a 3'-5' DNA helicase identified as a member of the RecQ family, BS patients exhibit a high predisposition to development of all types of cancer affecting the general population and BLM-deficient cells display a strong genetic instability. We recently showed that ELM protein expression is regulated during the cell cycle, accumulating to high levels in S phase, persisting in G2/M and sharply declining in G1, suggesting a possible implication of BLM in a replication (S phase) and/or post-replication (G2 phase) process, Here we show that, in response to ionizing radiation, BLM-deficient cells exhibit a normal p53 response as well as an intact G1/S cell cycle checkpoint, which indicates that ATM and p53 pathways are functional in BS cells. We also show that the BLM defect is associated with a partial escape of cells from the gamma -irradiation-induced G2/M cell cycle checkpoint. Finally, we present data demonstrating that, in response to ionizing radiation, BLM protein is phosphorylated and accumulates through an ATM-dependent pathway. Altogether, our data indicate that BLM participates in the cellular response to ionizing radiation by acting as an ATM kinase downstream effector.	Inst Gustave Roussy, Unite Mixte Rech 1598, CNRS, F-94805 Villejuif, France; Inst Gustave Roussy, IFR 54, Serv Cytomet Flux, F-94805 Villejuif, France; CU Strasbourg, Inst Genet & Biol Mol & Cellulaire, CNRS, ULP,INSERM, F-67404 Illkirch Graffenstaden, France	Centre National de la Recherche Scientifique (CNRS); UNICANCER; Gustave Roussy; UNICANCER; Gustave Roussy; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Amor-Gueret, M (corresponding author), Inst Gustave Roussy, Unite Mixte Rech 1598, CNRS, 39 Rue Camille Desmoulins, F-94805 Villejuif, France.		CHATTON, Bruno/R-3813-2019	CHATTON, Bruno/0000-0003-4515-7119; ababou, mouna/0000-0003-4276-3754				AURIAS A, 1985, CANCER GENET CYTOGEN, V16, P131, DOI 10.1016/0165-4608(85)90006-8; Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; Barakat A, 2000, Hum Mutat, V15, P584, DOI 10.1002/1098-1004(200006)15:6<584::AID-HUMU28>3.0.CO;2-I; BARTRAM CR, 1976, ANN HUM GENET, V40, P79, DOI 10.1111/j.1469-1809.1976.tb00166.x; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; Carney JP, 1998, CELL, V93, P477, DOI 10.1016/S0092-8674(00)81175-7; Collister M, 1998, CARCINOGENESIS, V19, P2115, DOI 10.1093/carcin/19.12.2115; Cortez D, 1999, SCIENCE, V286, P1162, DOI 10.1126/science.286.5442.1162; Dasika GK, 1999, ONCOGENE, V18, P7883, DOI 10.1038/sj.onc.1203283; Dutertre S, 2000, ONCOGENE, V19, P2731, DOI 10.1038/sj.onc.1203595; ELLIS NA, 1995, CELL, V83, P655, DOI 10.1016/0092-8674(95)90105-1; FUTREAL PA, 1994, SCIENCE, V266, P120, DOI 10.1126/science.7939630; GALLOWAY SM, 1977, MUTAT RES, V45, P343, DOI 10.1016/0027-5107(77)90144-0; Gatei M, 2000, NAT GENET, V25, P115, DOI 10.1038/75508; GERMAN J, 1993, MEDICINE, V72, P393, DOI 10.1097/00005792-199311000-00003; Gowen LC, 1998, SCIENCE, V281, P1009, DOI 10.1126/science.281.5379.1009; GURLEY LR, 1978, EUR J BIOCHEM, V84, P1, DOI 10.1111/j.1432-1033.1978.tb12135.x; HARTWELL L, 1992, CELL, V71, P543, DOI 10.1016/0092-8674(92)90586-2; Karow JK, 2000, P NATL ACAD SCI USA, V97, P6504, DOI 10.1073/pnas.100448097; Karow JK, 1997, J BIOL CHEM, V272, P30611, DOI 10.1074/jbc.272.49.30611; KIM ST, 2000, J BIOL CHEM, V274, P613; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; Lim DS, 2000, NATURE, V404, P613, DOI 10.1038/35007091; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; MEYN MS, 1995, CANCER RES, V55, P5991; Sauve DM, 1999, J CELL BIOL, V145, P225, DOI 10.1083/jcb.145.2.225; SAVITSKY K, 1995, HUM MOL GENET, V4, P2025, DOI 10.1093/hmg/4.11.2025; Wang WS, 2000, EMBO J, V19, P3428, DOI 10.1093/emboj/19.13.3428; Wang Y, 2000, GENE DEV, V14, P927; WEINERT T, 1993, SEMIN CANCER BIOL, V4, P129; Wim JM, 1997, MOL CELL BIOL, V17, P5016, DOI 10.1128/MCB.17.9.5016; Xu XL, 1999, MOL CELL, V3, P389, DOI 10.1016/S1097-2765(00)80466-9; ZHOU S, 1993, J BIOL CHEM, V268, P17754	33	74	75	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 7	2000	19	52					5955	5963		10.1038/sj.onc.1204003	http://dx.doi.org/10.1038/sj.onc.1204003			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	382MY	11146546				2022-12-25	WOS:000165827900001
J	Kuhne, C; Gardiol, D; Guarnaccia, C; Amenitsch, H; Banks, L				Kuhne, C; Gardiol, D; Guarnaccia, C; Amenitsch, H; Banks, L			Differential regulation of human papillomavirus E6 by protein kinase A: conditional degradation of human discs large protein by oncogenic E6	ONCOGENE			English	Article						papillomavirus E6 protein; protein kinase A; Dlg; PDZ-domain; ubiquitin; cervical cancer	PROTEASOME-MEDIATED DEGRADATION; CALCIUM-INDUCED DIFFERENTIATION; LARGE TUMOR-SUPPRESSOR; CELL-CYCLE REGULATION; P70 S6 KINASE; IN-VIVO; HUMAN KERATINOCYTES; EPITHELIAL-CELLS; HPV-18 E6; P53	The protein Kinase A (PKA) pathway was found to selectively regulate the function of oncogenic but not non-oncogenic E6 proteins, High risk E6 proteins are phosphorylated at their D1g/PDZ binding motif at the C-terminus by a PKA like activity. This PKA and PDZ binding module is found only for human PV, is strictly conserved in all the transforming HPVs and is absent in all the low risk HPV types. We present evidence of a conditional regulation of E6 induced degradation of Dig, HPV18E6 positive but not HPV negative keratinocytes exhibit increased Dig steady state levels under conditions of high PKA activity, with a concomitant increase in the presence of Dig at tight junctions, vitro binding experiments show that E6 phosphorylation by PKA reduces its binding to Dig and molecular modelling can explain this observation in a structural context, E6 dependent degradation of Dig in cells with high PKA levels is inhibited and this is dependent on phosphorylation of the PDZ binding site in E6, In contrast, the degradation of p53 induced by E6 is not affected by PKA, We propose a differential regulation of E6 for the ubiquitin mediated degradation of specific E6 target proteins.	Int Ctr Genet Engn & Biotechnol, I-34012 Trieste, Italy; Austrian Acad Sci, Inst Biophys & Xray Struct Res, A-8010 Graz, Austria	International Center for Genetic Engineering & Biotechnology (ICGEB); Austrian Academy of Sciences	Kuhne, C (corresponding author), Int Ctr Genet Engn & Biotechnol, Padriciano 99, I-34012 Trieste, Italy.			Amenitsch, Heinz/0000-0002-0788-1336				Balda MS, 1998, J CELL SCI, V111, P541; BANKS L, 1986, EUR J BIOCHEM, V159, P529, DOI 10.1111/j.1432-1033.1986.tb09919.x; BOYNTON AL, 1983, ADV CYCLIC NUCL PROT, V15, P193; Cabral JHM, 1996, NATURE, V382, P649, DOI 10.1038/382649a0; CHOCHUNG YS, 1990, CANCER RES, V50, P7093; Cohen NA, 1996, NEURON, V17, P759, DOI 10.1016/S0896-6273(00)80207-X; CROOK T, 1991, CELL, V67, P547, DOI 10.1016/0092-8674(91)90529-8; deVilliers EM, 1997, INT J CANCER, V73, P356, DOI 10.1002/(SICI)1097-0215(19971104)73:3<356::AID-IJC9>3.3.CO;2-S; Doyle DA, 1996, CELL, V85, P1067, DOI 10.1016/S0092-8674(00)81307-0; Edelmann HML, 1996, J BIOL CHEM, V271, P963, DOI 10.1074/jbc.271.2.963; Fernandez A, 1995, Prog Cell Cycle Res, V1, P241; FOSTER SA, 1994, J VIROL, V68, P5698, DOI 10.1128/JVI.68.9.5698-5705.1994; Gao QS, 2000, J BIOL CHEM, V275, P14824, DOI 10.1074/jbc.275.20.14824; Gardiol D, 1999, ONCOGENE, V18, P5487, DOI 10.1038/sj.onc.1202920; GLASS DB, 1989, J BIOL CHEM, V264, P8802; Gross-Mesilaty S, 1998, P NATL ACAD SCI USA, V95, P8058, DOI 10.1073/pnas.95.14.8058; HATEBOER G, 1993, P NATL ACAD SCI USA, V90, P8489, DOI 10.1073/pnas.90.18.8489; HAUSEN HZ, 1991, SCIENCE, V254, P1167, DOI 10.1126/science.1659743; KATO JY, 1994, CELL, V79, P487, DOI 10.1016/0092-8674(94)90257-7; KEMP BE, 1975, P NATL ACAD SCI USA, V72, P3448, DOI 10.1073/pnas.72.9.3448; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; Kiyono T, 1998, NATURE, V396, P84, DOI 10.1038/23962; Kiyono T, 1997, P NATL ACAD SCI USA, V94, P11612, DOI 10.1073/pnas.94.21.11612; KREBS EG, 1979, ANNU REV BIOCHEM, V48, P923, DOI 10.1146/annurev.bi.48.070179.004423; Kuhne C, 1998, J BIOL CHEM, V273, P34302, DOI 10.1074/jbc.273.51.34302; Le SS, 1997, P NATL ACAD SCI USA, V94, P6670, DOI 10.1073/pnas.94.13.6670; LEIGHTON IA, 1995, FEBS LETT, V375, P289, DOI 10.1016/0014-5793(95)01170-J; Liu Y, 1999, J VIROL, V73, P7297, DOI 10.1128/JVI.73.9.7297-7307.1999; LOS M, 1995, NATURE, V375, P81, DOI 10.1038/375081a0; Maki CG, 1996, CANCER RES, V56, P2649; PAN HC, 1994, GENE DEV, V8, P1285, DOI 10.1101/gad.8.11.1285; PAN HC, 1995, GENE DEV, V9, P2157, DOI 10.1101/gad.9.17.2157; PIM D, 1994, ONCOGENE, V9, P1869; Ponting CP, 1997, BIOESSAYS, V19, P469, DOI 10.1002/bies.950190606; Sherman L, 1997, VIROLOGY, V237, P296, DOI 10.1006/viro.1997.8778; Sherman L, 1996, J VIROL, V70, P3269, DOI 10.1128/JVI.70.5.3269-3279.1996; Song SY, 1999, J VIROL, V73, P5887, DOI 10.1128/JVI.73.7.5887-5893.1999; TAYLOR SS, 1990, ANNU REV BIOCHEM, V59, P971, DOI 10.1146/annurev.bi.59.070190.004543; Thomas M, 1998, ONCOGENE, V17, P2943, DOI 10.1038/sj.onc.1202223; UHLER MD, 1987, J BIOL CHEM, V262, P15202; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; WU J, 1993, SCIENCE, V262, P1065, DOI 10.1126/science.7694366; zurHausen H, 1996, BBA-REV CANCER, V1288, pF55	43	59	60	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 30	2000	19	51					5884	5891		10.1038/sj.onc.1203988	http://dx.doi.org/10.1038/sj.onc.1203988			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	378CA	11127819				2022-12-25	WOS:000165563100007
J	Kallberg, Y; Gustafsson, M; Persson, B; Thyberg, J; Johansson, J				Kallberg, Y; Gustafsson, M; Persson, B; Thyberg, J; Johansson, J			Prediction of amyloid fibril-forming proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYPEPTIDE SP-C; SECONDARY-STRUCTURE; THERMODYNAMIC STABILITY; 3-DIMENSIONAL STRUCTURE; NMR STRUCTURE; BETA-PEPTIDE; PRION; CONFORMATIONS; RECOGNITION; EVOLUTION	In Alzheimer's disease and spongiform encephalopathies proteins transform from their native states into fibrils, We find that several amyloid-forming proteins harbor an a-helix in a polypeptide segment that should form a beta -strand according to secondary structure predictions. In 1324 nonredundant protein structures, 37 beta -strands with greater than or equal to7 residues were predicted in segments where the experimentally determined structures show helices, These discordances include the prion protein (helix 2, positions 179-191), the Alzheimer amyloid beta -peptide (alpha beta, positions 16-23), and lung surfactant protein C (SP-C, positions 12-27), In addition, human coagulation factor XIII (positions 258-266), triacylglycerol lipase from Candida antarctica (positions 256-266), and D-alanyl-D-alanine transpeptidase from Streptomyces R61 (positions 92-106) contain a discordant helix, These proteins have not been reported to form fibrils hut in this study were found to form fibrils in buffered saline at pH 7.4. By replacing valines in the discordant helical part of SP-C with leucines, an alpha -helix is found experimentally and by secondary structure predictions. This analogue does not form fibrils under conditions where SP-C forms abundant fibrils, Likewise, when alpha beta residues 14-23 are removed or changed to a nondiscordant sequence, fibrils are no longer formed. We propose that alpha -helix/beta -strand-discordant stretches are associated with amyloid fibril formation.	Karolinska Inst, Dept Med Biochem & Biophys, S-17177 Stockholm, Sweden; Karolinska Inst, Med Nobel Inst, Dept Cell & Mol Biol, S-17177 Stockholm, Sweden	Karolinska Institutet; Karolinska Institutet	Johansson, J (corresponding author), Karolinska Inst, Dept Med Biochem & Biophys, S-17177 Stockholm, Sweden.	jan.johansson@mbb.ki.se		Johansson, Jan/0000-0002-8719-4703				ABAGYAN R, 1994, J MOL BIOL, V235, P983, DOI 10.1006/jmbi.1994.1052; Arnoux P, 1999, NAT STRUCT BIOL, V6, P516; BARROW CJ, 1992, J MOL BIOL, V225, P1075, DOI 10.1016/0022-2836(92)90106-T; BARSUKOV IL, 1992, EUR J BIOCHEM, V206, P665, DOI 10.1111/j.1432-1033.1992.tb16972.x; Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235; BODE W, 1992, NATURE, V358, P164, DOI 10.1038/358164a0; Booth DR, 1997, NATURE, V385, P787, DOI 10.1038/385787a0; Cherfils J, 1998, NATURE, V392, P101, DOI 10.1038/32210; Chiti F, 1999, P NATL ACAD SCI USA, V96, P3590, DOI 10.1073/pnas.96.7.3590; Chou P Y, 1978, Adv Enzymol Relat Areas Mol Biol, V47, P45; Dobson CM, 1999, TRENDS BIOCHEM SCI, V24, P329, DOI 10.1016/S0968-0004(99)01445-0; GAUSTAFSSON M, UNPUB; Glockshuber R, 1998, FEBS LETT, V426, P291, DOI 10.1016/S0014-5793(98)00372-X; Gomis-Ruth FX, 1998, PROTEIN SCI, V7, P283; Guijarro JI, 1998, P NATL ACAD SCI USA, V95, P4224, DOI 10.1073/pnas.95.8.4224; Gustafsson M, 1999, FEBS LETT, V464, P138, DOI 10.1016/S0014-5793(99)01692-0; HOBOHM U, 1992, PROTEIN SCI, V1, P409; HUANG ZW, 1994, P NATL ACAD SCI USA, V91, P7139, DOI 10.1073/pnas.91.15.7139; James TL, 1997, P NATL ACAD SCI USA, V94, P10086, DOI 10.1073/pnas.94.19.10086; Jimenez JL, 1999, EMBO J, V18, P815, DOI 10.1093/emboj/18.4.815; JOHANSSON J, 1995, FEBS LETT, V362, P261, DOI 10.1016/0014-5793(95)00216-V; JOHANSSON J, 1995, BIOCHEM J, V307, P535, DOI 10.1042/bj3070535; JOHANSSON J, 1994, BIOCHEMISTRY-US, V33, P6015, DOI 10.1021/bi00185a042; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; KELLY JA, 1985, J BIOL CHEM, V260, P6449; Kelly JW, 1996, CURR OPIN STRUC BIOL, V6, P11, DOI 10.1016/S0959-440X(96)80089-3; Kelly JW, 1998, P NATL ACAD SCI USA, V95, P930, DOI 10.1073/pnas.95.3.930; Kurochkin IV, 1998, FEBS LETT, V427, P153, DOI 10.1016/S0014-5793(98)00422-0; Lansbury PT, 1999, P NATL ACAD SCI USA, V96, P3342, DOI 10.1073/pnas.96.7.3342; LI SC, 1994, NAT STRUCT BIOL, V1, P368, DOI 10.1038/nsb0694-368; Liemann S, 1999, BIOCHEMISTRY-US, V38, P3258, DOI 10.1021/bi982714g; Naslund J, 2000, JAMA-J AM MED ASSOC, V283, P1571, DOI 10.1001/jama.283.12.1571; Nilsson G, 1998, EUR J BIOCHEM, V255, P116, DOI 10.1046/j.1432-1327.1998.2550116.x; PAN KM, 1993, P NATL ACAD SCI USA, V90, P10962, DOI 10.1073/pnas.90.23.10962; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; Riek R, 1996, NATURE, V382, P180, DOI 10.1038/382180a0; ROSENZWEIG AC, 1995, CHEM BIOL, V2, P409, DOI 10.1016/1074-5521(95)90222-8; ROST B, 1994, PROTEINS, V19, P55, DOI 10.1002/prot.340190108; ROST B, 1993, J MOL BIOL, V232, P584, DOI 10.1006/jmbi.1993.1413; Selkoe DJ, 1999, NATURE, V399, pA23, DOI 10.1038/399a023; SIPE JD, 1992, ANNU REV BIOCHEM, V61, P947, DOI 10.1146/annurev.bi.61.070192.004503; STAHL N, 1993, BIOCHEMISTRY-US, V32, P1991, DOI 10.1021/bi00059a016; Swietnicki W, 1998, J BIOL CHEM, V273, P31048, DOI 10.1074/jbc.273.47.31048; Szyperski T, 1998, PROTEIN SCI, V7, P2533, DOI 10.1002/pro.5560071206; Tjernberg LO, 1996, J BIOL CHEM, V271, P8545, DOI 10.1074/jbc.271.15.8545; Tjernberg LO, 1999, J BIOL CHEM, V274, P12619, DOI 10.1074/jbc.274.18.12619; West MW, 1999, P NATL ACAD SCI USA, V96, P11211, DOI 10.1073/pnas.96.20.11211; Wetzel R, 1996, CELL, V86, P699, DOI 10.1016/S0092-8674(00)80143-9; Zahn R, 2000, P NATL ACAD SCI USA, V97, P145, DOI 10.1073/pnas.97.1.145; Zhang H, 1997, BIOCHEMISTRY-US, V36, P3543, DOI 10.1021/bi961965r	50	261	274	0	25	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 20	2001	276	16					12945	12950		10.1074/jbc.M010402200	http://dx.doi.org/10.1074/jbc.M010402200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	423VN	11134035	hybrid			2022-12-25	WOS:000168198600070
J	Ionescu, AM; Schwarz, EM; Vinson, C; Puzas, JE; Rosier, R; Reynolds, PR; O'Keefe, RJ				Ionescu, AM; Schwarz, EM; Vinson, C; Puzas, JE; Rosier, R; Reynolds, PR; O'Keefe, RJ			PTHrP modulates chondrocyte differentiation through AP-1 and CREB signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HORMONE-RELATED PEPTIDE; DEPENDENT PROTEIN-KINASE; C-FOS EXPRESSION; PARATHYROID-HORMONE; GROWTH-PLATE; X COLLAGEN; TERMINAL DIFFERENTIATION; OSTEOBLASTIC CELLS; TRANSGENIC MICE; INDIAN HEDGEHOG	During the process of differentiation, chondrocytes integrate a complex array of signals from local or systemic factors like parathyroid hormone-related peptide (PTHrP), Indian hedgehog, bone morphogenetic proteins and transforming growth factor beta, While PTHrP is known to be a critical regulator of chondrocyte proliferation and differentiation, the signaling pathways through which this factor acts remain to be elucidated. Here we show that both cAMP response element-binding protein (CREB) and AP-1 activation are critical to PTHrP signaling in chondrocytes. PTHrP treatment leads to rapid CREB phosphorylation and activation, while CREB DNA binding activity is constitutive, In contrast, PTHrP induces AP-1 DNA binding activity through induction of c-Fos protein expression. PTHrP activates CRE and TRE reporter constructs primarily through PKA-mediated signaling events. Both signaling pathways were found to be important mediators of PTHrP effects on chondrocyte phenotype, Alone, PTHrP suppresses maturation and stimulates proliferation of the chondrocyte cultures, However, in the presence of dominant negative inhibitors of CREB and c-Fos, these PTHrP effects were suppressed, and chondrocyte maturation was accelerated. Moreover, in combination, the effects of dominant negative c-Fos and CREB are synergistic, suggesting interaction between these signaling pathways during chondrocyte differentiation.	Univ Rochester, Med Ctr, Sch Med & Dent, Dept Orthopaed, Rochester, NY 14642 USA; Univ Rochester, Sch Med & Dent, Dept Biochem & Biophys, Rochester, NY 14642 USA; NCI, NIH, Bethesda, MD 20892 USA	University of Rochester; University of Rochester; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	O'Keefe, RJ (corresponding author), Univ Rochester, Med Ctr, Sch Med & Dent, Dept Orthopaed, Box 665,601 Elmwood Ave, Rochester, NY 14642 USA.	regis_okeefe@urmc.rochester.edu			NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR038945] Funding Source: NIH RePORTER; NIAMS NIH HHS [R01 AR 38945] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Ahn S, 1998, MOL CELL BIOL, V18, P967, DOI 10.1128/MCB.18.2.967; AMIZUKA N, 1994, J CELL BIOL, V126, P1611, DOI 10.1083/jcb.126.6.1611; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; Anouar Y, 1999, MOL PHARMACOL, V56, P162, DOI 10.1124/mol.56.1.162; Ausubel F, 1997, SHORT PROTOCOLS MOL; Barton K, 1996, NATURE, V379, P81, DOI 10.1038/379081a0; Beier F, 1999, P NATL ACAD SCI USA, V96, P1433, DOI 10.1073/pnas.96.4.1433; Brown JR, 1998, MOL CELL BIOL, V18, P5609, DOI 10.1128/MCB.18.9.5609; BUCKWALTER JA, 1986, J BONE JOINT SURG AM, V68A, P243, DOI 10.2106/00004623-198668020-00010; Chung U, 2000, J BONE MINER RES, V15, pS175; CLOHISY JC, 1992, MOL ENDOCRINOL, V6, P1834, DOI 10.1210/me.6.11.1834; Eggers A, 2000, BIOCHEM J, V345, P201, DOI 10.1042/0264-6021:3450201; ENSLEN H, 1995, BIOCHEM BIOPH RES CO, V207, P1038, DOI 10.1006/bbrc.1995.1289; GIBSON GJ, 1995, DEV DYNAM, V203, P468, DOI 10.1002/aja.1002030409; GINTY DD, 1994, CELL, V77, P713, DOI 10.1016/0092-8674(94)90055-8; GONZALEZ GA, 1989, NATURE, V337, P749, DOI 10.1038/337749a0; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; Grimsrud CD, 1999, J BONE MINER RES, V14, P475, DOI 10.1359/jbmr.1999.14.4.475; Guo J, 2000, J BONE MINER RES, V15, pS152; HABENER JF, 1990, MOL ENDOCRINOL, V4, P1087, DOI 10.1210/mend-4-8-1087; Hata R, 1998, J CEREBR BLOOD F MET, V18, P1325, DOI 10.1097/00004647-199812000-00007; HATORI M, 1995, J BONE MINER RES, V10, P1960, DOI 10.1002/jbmr.5650101216; Ishikawa Y, 1997, J BONE MINER RES, V12, P356, DOI 10.1359/jbmr.1997.12.3.356; Kameda T, 1997, CELL GROWTH DIFFER, V8, P495; KARAPLIS AC, 1994, GENE DEV, V8, P277, DOI 10.1101/gad.8.3.277; Kirsch T, 1997, J CELL BIOL, V137, P1149, DOI 10.1083/jcb.137.5.1149; Klaus G, 1997, KIDNEY INT, V52, P45, DOI 10.1038/ki.1997.302; Lanske B, 1996, SCIENCE, V273, P663, DOI 10.1126/science.273.5275.663; LEBOY PS, 1989, J BIOL CHEM, V264, P17281; Lee K, 1996, ENDOCRINOLOGY, V137, P5109, DOI 10.1210/en.137.11.5109; LEWINSON D, 1992, ANAT REC, V233, P504, DOI 10.1002/ar.1092330403; LINSENMAYER TF, 1991, DEVELOPMENT, V111, P191; McCauley LK, 1997, ENDOCRINOLOGY, V138, P5427, DOI 10.1210/en.138.12.5427; Montminy M, 1997, ANNU REV BIOCHEM, V66, P807, DOI 10.1146/annurev.biochem.66.1.807; OKEEFE RJ, 1989, J BONE JOINT SURG AM, V71A, P607, DOI 10.2106/00004623-198971040-00017; Pateder DB, 2000, EXP CELL RES, V256, P555, DOI 10.1006/excr.2000.4860; Pearman AT, 1996, J BIOL CHEM, V271, P25715, DOI 10.1074/jbc.271.41.25715; Porte D, 1999, ONCOGENE, V18, P667, DOI 10.1038/sj.onc.1202333; Pugazhenthi S, 2000, J BIOL CHEM, V275, P10761, DOI 10.1074/jbc.275.15.10761; Reimold AM, 1996, NATURE, V379, P262, DOI 10.1038/379262a0; Rudolph D, 1998, P NATL ACAD SCI USA, V95, P4481, DOI 10.1073/pnas.95.8.4481; RUTHER U, 1987, NATURE, V325, P412, DOI 10.1038/325412a0; SAMUELS ML, 1993, MOL CELL BIOL, V13, P6241, DOI 10.1128/MCB.13.10.6241; Schipani E, 1997, P NATL ACAD SCI USA, V94, P13689, DOI 10.1073/pnas.94.25.13689; SCHWARZ EM, 1993, P NATL ACAD SCI USA, V90, P7734, DOI 10.1073/pnas.90.16.7734; Segre G V, 1992, J Endocrinol Invest, V15, P11; Selvamurugan N, 1998, J BIOL CHEM, V273, P10647, DOI 10.1074/jbc.273.17.10647; Suda N, 1999, J BONE MINER RES, V14, P1838, DOI 10.1359/jbmr.1999.14.11.1838; Tyson DR, 1999, ENDOCRINOLOGY, V140, P1255, DOI 10.1210/en.140.3.1255; Vanhoutte P, 1999, MOL CELL BIOL, V19, P136; Volk SW, 1998, J BONE MINER RES, V13, P1521, DOI 10.1359/jbmr.1998.13.10.1521; Vortkamp A, 1996, SCIENCE, V273, P613, DOI 10.1126/science.273.5275.613; WANG ZQ, 1995, CANCER RES, V55, P6244; WARMAN ML, 1993, NAT GENET, V5, P79, DOI 10.1038/ng0993-79; Weir EC, 1996, P NATL ACAD SCI USA, V93, P10240, DOI 10.1073/pnas.93.19.10240; White BR, 1999, MOL ENDOCRINOL, V13, P566, DOI 10.1210/me.13.4.566; WRIGHT E, 1995, NAT GENET, V9, P15, DOI 10.1038/ng0195-15; Zerega B, 1999, J BONE MINER RES, V14, P1281, DOI 10.1359/jbmr.1999.14.8.1281; ZUSCIK MJ, 1994, CELL CALCIUM, V16, P112, DOI 10.1016/0143-4160(94)90006-X; ZUSCIK MJ, 1994, ARCH BIOCHEM BIOPHYS, V315, P352, DOI 10.1006/abbi.1994.1511	60	93	98	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 13	2001	276	15					11639	11647		10.1074/jbc.M006564200	http://dx.doi.org/10.1074/jbc.M006564200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	421UK	11136722	hybrid			2022-12-25	WOS:000168081800031
J	Shiseki, K; Murai, N; Motojima, F; Hisabori, T; Yoshida, M; Taguchi, H				Shiseki, K; Murai, N; Motojima, F; Hisabori, T; Yoshida, M; Taguchi, H			Synchronized domain-opening motion of GroEL is essential for communication between the two rings	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACTERIAL CHAPERONIN GROEL; CRYSTAL-STRUCTURE; POLYPEPTIDE BINDING; ATPASE CYCLE; COOPERATIVITY; HYDROLYSIS; MECHANISM; RESIDUES	Escherichia coli chaperonin GroEL consists of two stacked rings of seven identical subunits each. Accompanying binding of ATP and GroES to one ring of GroEL, that ring undergoes a large en bloc domain movement, in which the apical domain twists upward and outward. A mutant GroEL(AEX) (C138S,C458S,C519S,D83C,K327C) in the oxidized form is locked in a closed conformation by an interdomain disulfide cross-link and cannot hydrolyze ATP (Murai, N., Makino, Y., and Yoshida, M. (1996) J. Biol. Chem. 271, 28229-28234). By reconstitution of GroEL complex from subunits of both wild-type GroEL and oxidized GroEL(AEX), hybrid GroEL complexes containing various numbers of oxidized GroELAEX subunits were prepared. ATPase activity of the hybrid GroEL containing one or two oxidized GroEL(AEX) subunits per ring was about 70% higher than that of wild-type GroEL. Based on the detailed analysis of the ATPase activity, we concluded that inter-ring negative cooperativity was lost in the hybrid GroEL, indicating that synchronized opening of the subunits in one ring is necessary for the negative cooperativity. Indeed, hybrid GroEL complex reconstituted from subunits of wild-type and GroEL mutant (D398A), which is ATPase-deficient but can undergo domain opening motion, retained the negative cooperativity of ATPase. In contrast, the ability of GroEL to assist protein folding was impaired by the presence of a single oxidized GroEL(AEX) subunit in a ring. Taken together, cooperative conformational transitions in GroEL rings ensure the functional communication between the two rings of GroEL.	Tokyo Inst Technol, Chem Resources Lab, Yokohama, Kanagawa 2268503, Japan	Tokyo Institute of Technology	Taguchi, H (corresponding author), Tokyo Inst Technol, Chem Resources Lab, R-1,4259 Nagatsuta, Yokohama, Kanagawa 2268503, Japan.		Motojima, Fumihiro/J-2389-2014; taguchi, hideki/AAM-2663-2021; MURAI, NORIYUKI/V-5747-2018; Taguchi, Hideki/B-6946-2009; Hisabori, Toru/E-5205-2014	Motojima, Fumihiro/0000-0003-4461-8673; taguchi, hideki/0000-0002-6612-9339; MURAI, NORIYUKI/0000-0002-1552-5104; Taguchi, Hideki/0000-0002-6612-9339; Hisabori, Toru/0000-0003-2046-0277				Aharoni A, 1996, J MOL BIOL, V258, P732, DOI 10.1006/jmbi.1996.0282; BOCHKAREVA ES, 1994, J BIOL CHEM, V269, P23869; BOCHKAREVA ES, 1992, J BIOL CHEM, V267, P6796; Boisvert DC, 1996, NAT STRUCT BIOL, V3, P170, DOI 10.1038/nsb0296-170; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRAIG K, 1994, NATURE, V371, P578, DOI 10.1038/371578a0; Bukau B, 1998, CELL, V92, P351, DOI 10.1016/S0092-8674(00)80928-9; FENTON WA, 1994, NATURE, V371, P614, DOI 10.1038/371614a0; GELADOPOULOS TP, 1991, ANAL BIOCHEM, V192, P112, DOI 10.1016/0003-2697(91)90194-X; GRAY TE, 1991, FEBS LETT, V292, P254, DOI 10.1016/0014-5793(91)80878-7; JACKSON GS, 1993, BIOCHEMISTRY-US, V32, P2554, DOI 10.1021/bi00061a013; KIRINO H, 1991, J BIOCHEM-TOKYO, V109, P852, DOI 10.1093/oxfordjournals.jbchem.a123470; Motojima F, 2000, BIOCHEM BIOPH RES CO, V267, P842, DOI 10.1006/bbrc.1999.2020; Murai N, 1996, J BIOL CHEM, V271, P28229, DOI 10.1074/jbc.271.45.28229; Roseman AM, 1996, CELL, V87, P241, DOI 10.1016/S0092-8674(00)81342-2; Rye HS, 1999, CELL, V97, P325, DOI 10.1016/S0092-8674(00)80742-4; Rye HS, 1997, NATURE, V388, P792, DOI 10.1038/42047; Sigler PB, 1998, ANNU REV BIOCHEM, V67, P581, DOI 10.1146/annurev.biochem.67.1.581; TAGUCHI H, 1991, J BIOL CHEM, V266, P22411; TODD MJ, 1994, SCIENCE, V265, P659, DOI 10.1126/science.7913555; White HE, 1997, NAT STRUCT BIOL, V4, P690, DOI 10.1038/nsb0997-690; Xu ZH, 1997, NATURE, V388, P741, DOI 10.1038/41944; YBARRA J, 1995, J BIOL CHEM, V270, P22113, DOI 10.1074/jbc.270.38.22113; YIFRACH O, 1995, BIOCHEMISTRY-US, V34, P5303, DOI 10.1021/bi00016a001	24	18	18	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 6	2001	276	14					11335	11338		10.1074/jbc.M010348200	http://dx.doi.org/10.1074/jbc.M010348200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	420AC	11139586	hybrid			2022-12-25	WOS:000167980900102
J	Cheng, XG; Hart, GW				Cheng, XG; Hart, GW			Alternative O-glycosylation/O-phosphorylation of serine-16 in murine estrogen receptor beta - Post-translational regulation of turnover and transactivation activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LINKED N-ACETYLGLUCOSAMINE; SITE-SPECIFIC INCORPORATION; UNNATURAL AMINO-ACIDS; NUCLEAR-PORE; TETRATRICOPEPTIDE REPEATS; GLCNAC TRANSFERASE; PROTEIN-PHOSPHORYLATION; CYTOPLASMIC PROTEINS; CELLULAR-REGULATION; CYTOSOLIC PROTEINS	O-Linked N-acetylglucosamine (O-GlcNAc) is a dynamic post-translational modification abundant on nuclear and cytoplasmic proteins. Recently, we demonstrated that the murine estrogen receptor-beta (mER-beta) is alternatively O-GlcNAcylated or O-phosphorylated at Ser(16). Analyses of mER-betas containing mutations in the three adjacent hydroxyl amino acids at this locus confirmed that Ser(16) is the major site of O-GlcNAc modification on mER-beta and that mutants lacking hydoxyl amino acids at this locus are glycosylation-deficient. Pulse-chase studies in transfected Cos-1 cells demonstrate that the turnover rate of the mutant containing a glutamic acid moiety at Ser(16), which mimics constitutive phosphorylation at this locus, is faster than that of the wild type receptor. Whereas, the mutant without hydroxyl amino acids at this locus is degraded at a slower rate, indicating that O-GlcNAc/O-phosphate at Ser(16) modulates mER-beta protein stability. Luciferase reporter assays also show that the Ser(16) locus mutants have abnormal transactivation activities, suggesting that the two alternative modifications at Ser(16) on mER-beta may also be involved in transcriptional regulation. DNA mobility shift assays show that the mutants do not have altered DNA binding. Green fluorescence protein constructs of both wild type and mutant forms of mER-beta show that the receptor is nearly exclusively localized within the nucleus. It appears that reciprocal occupancy of Ser(16) by either O-phosphate or O-GlcNAc modulates the degradation and activity of mER-beta.	Johns Hopkins Univ, Sch Med, Dept Biol Chem, Baltimore, MD 21205 USA; Univ Alabama, Grad Program, Dept Biochem & Mol Genet, Birmingham, AL 35294 USA	Johns Hopkins University; University of Alabama System; University of Alabama Birmingham	Hart, GW (corresponding author), Johns Hopkins Univ, Sch Med, Dept Biol Chem, 725 N Wolfe St, Baltimore, MD 21205 USA.			Hart, Gerald/0000-0001-7812-4351	NCI NIH HHS [R01 CA42486] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA042486] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Arnold CS, 1996, J BIOL CHEM, V271, P28741, DOI 10.1074/jbc.271.46.28741; Ashcroft M, 1999, MOL CELL BIOL, V19, P1751; Barkhem T, 1998, MOL PHARMACOL, V54, P105, DOI 10.1124/mol.54.1.105; Chen DS, 1999, MOL CELL BIOL, V19, P1002; Cheng XG, 2000, BIOCHEMISTRY-US, V39, P11609, DOI 10.1021/bi000755i; CHOU CF, 1994, J CELL SCI, V107, P1833; CHOU TY, 1995, P NATL ACAD SCI USA, V92, P4417, DOI 10.1073/pnas.92.10.4417; CHOU TY, 1995, J BIOL CHEM, V270, P18961, DOI 10.1074/jbc.270.32.18961; Comer FI, 2000, J BIOL CHEM, V275, P29179, DOI 10.1074/jbc.R000010200; Couse JF, 1999, SCIENCE, V286, P2328, DOI 10.1126/science.286.5448.2328; DATTA B, 1989, J BIOL CHEM, V264, P20620; DONG DLY, 1994, J BIOL CHEM, V269, P19321; Du XL, 2000, P NATL ACAD SCI USA, V97, P12222, DOI 10.1073/pnas.97.22.12222; Edwards DP, 1999, VITAM HORM, V55, P165; FISCHER EH, 1993, ANGEW CHEM INT EDIT, V32, P1130, DOI 10.1002/anie.199311301; HAGMANN J, 1992, J BIOL CHEM, V267, P14424; HALTIWANGER RS, 1990, J BIOL CHEM, V265, P2563; HALTIWANGER RS, 1992, J BIOL CHEM, V267, P9005; Han I, 1997, MOL CELL BIOL, V17, P2550, DOI 10.1128/MCB.17.5.2550; Han I, 2000, BIOCHEM J, V350, P109, DOI 10.1042/0264-6021:3500109; HANOVER JA, 1987, J BIOL CHEM, V262, P9887; HANOVER JA, 1992, FASEB J, V6, P2288, DOI 10.1096/fasebj.6.6.1312045; Hart GW, 1997, ANNU REV BIOCHEM, V66, P315, DOI 10.1146/annurev.biochem.66.1.315; HECHT SM, 1978, J BIOL CHEM, V253, P4517; HOLT GD, 1987, J CELL BIOL, V104, P1157, DOI 10.1083/jcb.104.5.1157; Htun H, 1999, MOL BIOL CELL, V10, P471, DOI 10.1091/mbc.10.2.471; JACKSON SP, 1988, CELL, V55, P125, DOI 10.1016/0092-8674(88)90015-3; Jaffe L, 1997, GENE DEV, V11, P1327, DOI 10.1101/gad.11.10.1327; Jiang MS, 1997, J BIOL CHEM, V272, P2421; KEARSE KP, 1991, P NATL ACAD SCI USA, V88, P1701, DOI 10.1073/pnas.88.5.1701; KELLY WG, 1993, J BIOL CHEM, V268, P10416; KRAMER MF, 1999, CURR PROT MOL BIOL, V3; KREBS EG, 1993, ANGEW CHEM INT EDIT, V32, P1122, DOI 10.1002/anie.199311221; Krege JH, 1998, P NATL ACAD SCI USA, V95, P15677, DOI 10.1073/pnas.95.26.15677; Kreppel LK, 1999, J BIOL CHEM, V274, P32015, DOI 10.1074/jbc.274.45.32015; Kreppel LK, 1997, J BIOL CHEM, V272, P9308; Kuiper GGJM, 1997, FEBS LETT, V410, P87, DOI 10.1016/S0014-5793(97)00413-4; Kuiper GGJM, 1996, P NATL ACAD SCI USA, V93, P5925, DOI 10.1073/pnas.93.12.5925; KUMAR V, 1988, CELL, V55, P145, DOI 10.1016/0092-8674(88)90017-7; Liu DR, 1997, P NATL ACAD SCI USA, V94, P10092, DOI 10.1073/pnas.94.19.10092; Liu ZP, 1997, GENE DEV, V11, P3413, DOI 10.1101/gad.11.24.3413; Lubas WA, 1997, J BIOL CHEM, V272, P9316; Medina L, 1998, GLYCOBIOLOGY, V8, P383, DOI 10.1093/glycob/8.4.383; Molinari E, 1999, EMBO J, V18, P6439, DOI 10.1093/emboj/18.22.6439; Mosselman S, 1996, FEBS LETT, V392, P49, DOI 10.1016/0014-5793(96)00782-X; Muramatsu M, 2000, BIOCHEM BIOPH RES CO, V270, P1, DOI 10.1006/bbrc.2000.2214; Nawaz Z, 1999, P NATL ACAD SCI USA, V96, P1858, DOI 10.1073/pnas.96.5.1858; NOREN CJ, 1989, SCIENCE, V244, P182, DOI 10.1126/science.2649980; PAKDEL F, 1993, J STEROID BIOCHEM, V46, P663, DOI 10.1016/0960-0760(93)90307-I; Parker MG, 1995, VITAM HORM, V51, P267, DOI 10.1016/S0083-6729(08)61041-9; REASON AJ, 1992, J BIOL CHEM, V267, P16911; Rechsteiner M, 1996, TRENDS BIOCHEM SCI, V21, P267, DOI 10.1016/S0968-0004(96)10031-1; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; Roos MD, 1997, MOL CELL BIOL, V17, P6472, DOI 10.1128/MCB.17.11.6472; ROQUEMORE EP, 1994, METHOD ENZYMOL, V230, P443; Roquemore EP, 1996, BIOCHEMISTRY-US, V35, P3578, DOI 10.1021/bi951918j; SCHINDLER M, 1987, J BIOL CHEM, V262, P1254; Shaw P, 1996, ONCOGENE, V12, P921; Shibata H, 1997, RECENT PROG HORM RES, V52, P141; Tremblay GB, 1997, MOL ENDOCRINOL, V11, P353, DOI 10.1210/me.11.3.353	60	149	167	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 30	2001	276	13					10570	10575		10.1074/jbc.M010411200	http://dx.doi.org/10.1074/jbc.M010411200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	420GC	11150304	hybrid			2022-12-25	WOS:000167996400127
J	Sado, K; Ayusawa, D; Enomoto, A; Suganuma, T; Oshimura, M; Sato, K; Koyama, H				Sado, K; Ayusawa, D; Enomoto, A; Suganuma, T; Oshimura, M; Sato, K; Koyama, H			Identification of a mutated DNA ligase IV gene in the X-ray-hypersensitive mutant SX10 of mouse FM3A cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; STRAND BREAK REPAIR; V(D)J RECOMBINATION; MAMMALIAN-CELLS; COMPLEMENTATION GROUP; IONIZING-RADIATION; SENSITIVE MUTANTS; MOLECULAR-CLONING; DIVERSE MUTAGENS; DEFECT	The mouse carcinoma cell line SX10 is a hypersensitive mutant to x-rays and bleomycin, An earlier complementation test suggests that SX10 would belong to x-ray-cross complementing group (XRCC) 4, However, in this study, a human XRCC4 expression vector failed to complement the SX10 phenotype, Consistent with the previous report, SX10 showed the same level of DNA-dependent protein kinase activity as the wild-type SR-l, We isolated and analyzed hybrids between SX10 and human diploid fibroblast cells and found that human chromosome 13 conferred the x-ray resistance to the hybrids, suggesting that a candidate gene would be located on this chromosome, Polymerase chain reaction analysis with these hybrids and x-ray-resistant transformants obtained by introducing human chromosomes into SX10 indicated that the mutant was likely to be defective in DNA ligase IV Sequence analysis of the DNA ligase N gene confirmed that a defect in SX10 was attributed to a transition of G to A at nucleotide position 1413 of the gene, leading to an amino acid substitution from Trp at residue 471 to a stop codon, Revertant clones (Rev1-3) derived from SX10 showed a restored x-ray resistance; Rev1 reverted to the original nucleotide G at position 1413, whereas Revs and Rev3 to C, Transfection of a mouse DNA ligase N cDNA vector into SX10 restored the resistance to both x-rays and bleomycin, SX10 showed a reduced frequency of chromosomal integration of transfected DNA, but the revertants restored the frequency found in the wild-type cells. These results suggest a possible involvement of DNA ligase IV in the integration event of foreign DNA as well as a crucial role in DNA double-strand break repair.	Yokohama City Univ, Kihara Inst Biol Res, Totsuka Ku, Yokohama, Kanagawa 2440813, Japan; Yokohama City Univ, Grad Sch Integrated Sci, Totsuka Ku, Yokohama, Kanagawa 2440813, Japan; Kinki Univ, Fac Biol Oriented Sci & Technol, Wakayama, Japan; Tottori Univ, Fac Med, Sch Life Sci, Dept Mol & Cell Genet, Yonago, Tottori 6838504, Japan; Univ Tokyo, Grad Sch Med, Dept Radiat Oncol, Tokyo 1130033, Japan	Yokohama City University; Yokohama City University; Kindai University (Kinki University); Tottori University; University of Tokyo	Koyama, H (corresponding author), Yokohama City Univ, Kihara Inst Biol Res, Totsuka Ku, Maioka Cho, Yokohama, Kanagawa 2440813, Japan.							Barnes DE, 1998, CURR BIOL, V8, P1395, DOI 10.1016/S0960-9822(98)00021-9; Blunt T, 1996, P NATL ACAD SCI USA, V93, P10285, DOI 10.1073/pnas.93.19.10285; BLUNT T, 1995, CELL, V80, P813, DOI 10.1016/0092-8674(95)90360-7; Busch DB, 1996, MUTAT RES-DNA REPAIR, V363, P209, DOI 10.1016/0921-8777(96)00014-6; Critchlow SE, 1998, TRENDS BIOCHEM SCI, V23, P394, DOI 10.1016/S0968-0004(98)01284-5; Critchlow SE, 1997, CURR BIOL, V7, P588, DOI 10.1016/S0960-9822(06)00258-2; Danska JS, 1996, MOL CELL BIOL, V16, P5507; DORIN JR, 1992, HUM MOL GENET, V1, P53, DOI 10.1093/hmg/1.1.53; Featherstone C, 1999, MUTAT RES-DNA REPAIR, V434, P3, DOI 10.1016/S0921-8777(99)00006-3; FINNIE NJ, 1995, P NATL ACAD SCI USA, V92, P320, DOI 10.1073/pnas.92.1.320; Frank KM, 1998, NATURE, V396, P173, DOI 10.1038/24172; Fujimaki K, 1996, SOMAT CELL MOLEC GEN, V22, P279, DOI 10.1007/BF02369567; Fukumura R, 1998, J BIOL CHEM, V273, P13058, DOI 10.1074/jbc.273.21.13058; Gao YJ, 1998, CELL, V95, P891, DOI 10.1016/S0092-8674(00)81714-6; Gellert M, 1997, ADV IMMUNOL, V64, P39, DOI 10.1016/S0065-2776(08)60886-X; GOTTLIEB TM, 1993, CELL, V72, P131, DOI 10.1016/0092-8674(93)90057-W; Grawunder U, 1998, MOL CELL, V2, P477, DOI 10.1016/S1097-2765(00)80147-1; Grawunder U, 1997, NATURE, V388, P492, DOI 10.1038/41358; Grawunder U, 1998, CURR BIOL, V8, P873, DOI 10.1016/S0960-9822(07)00349-1; GU Y, 1997, P NATL ACAD SCI USA, V94, P8067; JACKSON SP, 1995, TRENDS BIOCHEM SCI, V20, P412, DOI 10.1016/S0968-0004(00)89090-8; JEGGO PA, 1991, MUTAT RES, V254, P125, DOI 10.1016/0921-8777(91)90003-8; JEGGO PA, 1983, MUTAT RES, V112, P313, DOI 10.1016/0167-8817(83)90026-3; Jeggo PA, 1997, MUTAT RES-DNA REPAIR, V384, P1, DOI 10.1016/S0921-8777(97)00009-8; KANAAR P, 1988, TRENDS CELL BIOL, V8, P483; KIRCHGESSNER CU, 1995, SCIENCE, V267, P1178, DOI 10.1126/science.7855601; Kobayashi M, 1998, GENE, V215, P329, DOI 10.1016/S0378-1119(98)00283-2; KOYAMA H, 1982, CANCER RES, V42, P4210; LEESMILLER SP, 1995, SCIENCE, V267, P1183, DOI 10.1126/science.7855602; Li ZY, 1995, CELL, V83, P1079, DOI 10.1016/0092-8674(95)90135-3; Liu N, 1997, P NATL ACAD SCI USA, V94, P9232, DOI 10.1073/pnas.94.17.9232; MCBRIDE OW, 1973, P NATL ACAD SCI USA, V70, P1258, DOI 10.1073/pnas.70.4.1258; Merrihew RV, 1996, MOL CELL BIOL, V16, P10; Peterson SR, 1997, J BIOL CHEM, V272, P10227; Riballo E, 1999, CURR BIOL, V9, P699, DOI 10.1016/S0960-9822(99)80311-X; ROTH DB, 1986, MOL CELL BIOL, V6, P4295, DOI 10.1128/MCB.6.12.4295; ROTH DB, 1988, ILLEGITIMATE RECOMBI, P621; ROUET P, 1994, MOL CELL BIOL, V14, P8096, DOI 10.1128/MCB.14.12.8096; SAMEC S, 1994, GENOMICS, V21, P283, DOI 10.1006/geno.1994.1261; SATO K, 1979, RADIAT RES, V78, P167, DOI 10.2307/3575014; SATO K, 1986, JPN J CANCER RES, V77, P456; STACKHOUSE MA, 1994, MUTAT RES, V323, P47, DOI 10.1016/0165-7992(94)90044-2; TACCIOLI GE, 1994, J BIOL CHEM, V269, P7439; TACCIOLI GE, 1994, SCIENCE, V265, P1442, DOI 10.1126/science.8073286; TEBBS RS, 1995, P NATL ACAD SCI USA, V92, P6354, DOI 10.1073/pnas.92.14.6354; THACKER J, 1995, HUM MOL GENET, V4, P113, DOI 10.1093/hmg/4.1.113; THOMPSON LH, 1990, MOL CELL BIOL, V10, P6160, DOI 10.1128/MCB.10.12.6160; Tomkinson AE, 1998, MUTAT RES-DNA REPAIR, V407, P1, DOI 10.1016/S0921-8777(97)00050-5; WARD JF, 1988, PROG NUCLEIC ACID RE, V35, P95, DOI 10.1016/S0079-6603(08)60611-X; WATERS RL, 1995, MUTAT RES, P1; WEI YF, 1995, MOL CELL BIOL, V15, P3206; WOOSTER R, 1994, SCIENCE, V265, P2088, DOI 10.1126/science.8091231; YUNIS JJ, 1983, SCIENCE, V221, P227, DOI 10.1126/science.6336310	53	26	26	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 30	2001	276	13					9742	9748		10.1074/jbc.M010530200	http://dx.doi.org/10.1074/jbc.M010530200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	420GC	11133995	hybrid			2022-12-25	WOS:000167996400023
J	Heredia, J; Crooks, M; Zhu, ZW				Heredia, J; Crooks, M; Zhu, ZW			Phosphorylation and Cu+ coordination-dependent DNA binding of the transcription factor Mac1p in the regulation of copper transport	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CUP2 GENE-PRODUCT; SACCHAROMYCES-CEREVISIAE; YEAST; EXPRESSION; PROTEIN; ACTIVATION; DOMAIN; DEGRADATION; REPRESSION	Copper ions are essential at a proper level yet toxic when present in excess. To maintain a proper intracellular level, cells must be able to sense the changes in copper ion concentrations. The yeast transcription factor Mac1p plays a critical role in the transcriptional regulation of CTR1 and CTR3, both encoding high affinity copper ion transporters. Here we report that the Mac1p binding of the copper ion-responsive elements (CuREs) in the promoters of CTR1 and CTR3 is affected by copper ions. On one hand, the Mac1p DNA binding is Cu+ coordination dependent, and on the other hand, exogenous Cu+ and isoelectronic Ag+ ions disrupt the DNA binding of Mac1p, These results suggest that the Mac1p is able to sense two different levels of copper ions. These two levels are probably the physiological and toxic copper levels in yeast cells. Furthermore, we found that Mac1p undergoes posttranslational phosphorylation modification in yeast and that the phosphorylation is required for the Mac1p to become DNA-binding active. Nonphosphorylated Mac1p is unable to bind the CTR1 promoter DNA, The data support the model of intradomain interactions and indicate further that the phosphorylation probably prevents the inhibition of DNA-binding domain activity by the activation domain of Mac1p, Taken together, these findings demonstrate that Mac1p functions critically in maintaining a proper intracellular concentration of copper ions.	Univ Calif Santa Cruz, Dept Environm Toxicol, Santa Cruz, CA 95064 USA	University of California System; University of California Santa Cruz	Zhu, ZW (corresponding author), Univ Calif Santa Cruz, Dept Environm Toxicol, Santa Cruz, CA 95064 USA.	zhu@biology.ucsc.edu			NIGMS NIH HHS [GM58082-01] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R55GM058082] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AUSUBEL FM, 1999, SHORT PROTOCOLS MOL; Bhalla US, 1999, SCIENCE, V283, P381, DOI 10.1126/science.283.5400.381; BUCHMAN C, 1989, MOL CELL BIOL, V9, P4091, DOI 10.1128/MCB.9.9.4091; Casas C, 1997, YEAST, V13, P621, DOI 10.1002/(SICI)1097-0061(19970615)13:7<621::AID-YEA121>3.0.CO;2-U; DANCIS A, 1994, CELL, V76, P393, DOI 10.1016/0092-8674(94)90345-X; EVANS CF, 1990, MOL CELL BIOL, V10, P426, DOI 10.1128/MCB.10.1.426; Graden JA, 1997, P NATL ACAD SCI USA, V94, P5550, DOI 10.1073/pnas.94.11.5550; HALLIWELL B, 1990, METHOD ENZYMOL, V186, P1; Harris ZL, 1996, AM J CLIN NUTR, V63, P836; Jensen LT, 1998, J BIOL CHEM, V273, P23805, DOI 10.1074/jbc.273.37.23805; Jensen LT, 1998, EMBO J, V17, P5400, DOI 10.1093/emboj/17.18.5400; JUNGMANN J, 1993, EMBO J, V12, P5051, DOI 10.1002/j.1460-2075.1993.tb06198.x; KARIN KD, 1993, BIOINORGANIC CHEM CO; Knight SAB, 1996, GENE DEV, V10, P1917, DOI 10.1101/gad.10.15.1917; Labbe S, 1997, J BIOL CHEM, V272, P15951, DOI 10.1074/jbc.272.25.15951; Labbe S, 1999, J BIOL CHEM, V274, P36252, DOI 10.1074/jbc.274.51.36252; Linder M, 1991, BIOCH COPPER; Liu HD, 1996, GENE DEV, V10, P592; Lu PJ, 1999, SCIENCE, V283, P1325, DOI 10.1126/science.283.5406.1325; MUMBERG D, 1995, GENE, V156, P119, DOI 10.1016/0378-1119(95)00037-7; Ooi CE, 1996, EMBO J, V15, P3515, DOI 10.1002/j.1460-2075.1996.tb00720.x; Pena MMO, 2000, J BIOL CHEM, V275, P33244, DOI 10.1074/jbc.M005392200; Rae TD, 1999, SCIENCE, V284, P805, DOI 10.1126/science.284.5415.805; Serpe M, 1999, J BIOL CHEM, V274, P29211, DOI 10.1074/jbc.274.41.29211; SZCZYPKA MS, 1989, MOL CELL BIOL, V9, P421, DOI 10.1128/MCB.9.2.421; THIELE DJ, 1992, NUCLEIC ACIDS RES, V20, P1183, DOI 10.1093/nar/20.6.1183; THIELE DJ, 1988, MOL CELL BIOL, V8, P2745, DOI 10.1128/MCB.8.7.2745; THORVALDSEN JL, 1994, BIOCHEMISTRY-US, V33, P9566, DOI 10.1021/bi00198a024; VULPE CD, 1995, ANNU REV NUTR, V15, P293, DOI 10.1146/annurev.nu.15.070195.001453; WELCH J, 1989, EMBO J, V8, P255, DOI 10.1002/j.1460-2075.1989.tb03371.x; YamaguchiIwai Y, 1997, J BIOL CHEM, V272, P17711, DOI 10.1074/jbc.272.28.17711; Zhu ZW, 1996, CELL, V87, P459, DOI 10.1016/S0092-8674(00)81366-5; Zhu ZW, 1998, J BIOL CHEM, V273, P1277, DOI 10.1074/jbc.273.3.1277	33	27	31	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 23	2001	276	12					8793	8797		10.1074/jbc.M008179200	http://dx.doi.org/10.1074/jbc.M008179200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	413HV	11134042	hybrid, Green Submitted			2022-12-25	WOS:000167607700025
J	Barylko, B; Gerber, SH; Binns, DD; Grichine, N; Khvotchev, M; Sudhof, TC; Albanesi, JP				Barylko, B; Gerber, SH; Binns, DD; Grichine, N; Khvotchev, M; Sudhof, TC; Albanesi, JP			A novel family of phosphatidylinositol 4-kinases conserved from yeast to humans	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PURIFICATION; KINASE; PHOSPHOINOSITIDES; REGULATORS; PROTEINS	Phosphatidylinositolpolyphosphates (PIPs) are centrally involved in many biological processes, ranging from cell growth and organization of the actin cytoskeleton to endo- and exocytosis. Phosphorylation of phosphatidylinositol at the D-4 position, an essential step in the biosynthesis of PIPs, appears to be catalyzed by two biochemically distinct enzymes. However, only one of these two enzymes has been molecularly characterized. We now describe a novel class of phosphatidylinositol 4-kinases that probably corresponds to the missing element in phosphatidylinositol metabolism. These kinases are highly conserved evolutionarily, but unrelated to previously characterized phosphatidylinositol kinases, and thus represent the founding members of a new family. The novel phosphatidylinositol 4-kinases, which are widely expressed in cells, only phosphorylate phosphatidylinositol, are potently inhibited by adenosine, but are insensitive to wortmannin or phenylarsine oxide. Although they lack an obvious transmembrane domain, they are strongly attached to membranes by palmitoylation. Our data suggest that independent pathways for phosphatidylinositol 4-phosphate synthesis emerged during evolution, possibly to allow tight temporal and spatial control over the production of this key signaling molecule.	Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Mol Genet, Ctr Basic Neurosci, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Howard Hughes Med Inst, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Biochem, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Albanesi, JP (corresponding author), Univ Texas, SW Med Ctr, Dept Pharmacol, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	jalban@mednet.swmed.edu	Khvotchev, Mikhail/G-5411-2013	Khvotchev, Mikhail/0000-0001-9328-8549	NIGMS NIH HHS [GM55562] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Balla T, 1998, BBA-MOL CELL BIOL L, V1436, P69, DOI 10.1016/S0005-2760(98)00134-9; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; CARPENTER CL, 1990, BIOCHEMISTRY-US, V29, P11147, DOI 10.1021/bi00503a001; Carpenter CL, 1998, NAT STRUCT BIOL, V5, P843, DOI 10.1038/2283; DeCamilli P, 1996, SCIENCE, V271, P1533, DOI 10.1126/science.271.5255.1533; Downing GJ, 1996, BIOCHEMISTRY-US, V35, P3587, DOI 10.1021/bi9517493; ENDEMANN G, 1987, BIOCHEMISTRY-US, V26, P6845, DOI 10.1021/bi00395a039; ENDEMANN GC, 1991, BIOCHEM J, V273, P63, DOI 10.1042/bj2730063; Felsenstein J, 1996, METHOD ENZYMOL, V266, P418; Fruman DA, 1998, ANNU REV BIOCHEM, V67, P481, DOI 10.1146/annurev.biochem.67.1.481; Gehrmann T, 1998, EUR J BIOCHEM, V253, P357, DOI 10.1046/j.1432-1327.1998.2530357.x; HUSEBYE ES, 1990, BIOCHIM BIOPHYS ACTA, V1042, P330, DOI 10.1016/0005-2760(90)90161-P; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LINDER ME, 1995, METHOD ENZYMOL, V250, P314; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Martin TFJ, 1998, ANNU REV CELL DEV BI, V14, P231, DOI 10.1146/annurev.cellbio.14.1.231; Martin TFJ, 1997, CURR OPIN NEUROBIOL, V7, P331, DOI 10.1016/S0959-4388(97)80060-8; MICHELL RH, 1967, BIOCHIM BIOPHYS ACTA, V144, P649, DOI 10.1016/0005-2760(67)90053-7; NICKELS JT, 1992, J BIOL CHEM, V267, P16297; PETERSON GL, 1979, ANAL BIOCHEM, V100, P201, DOI 10.1016/0003-2697(79)90222-7; PIKE LJ, 1992, ENDOCR REV, V13, P692, DOI 10.1210/er.13.4.692; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Schwartz JJ, 1998, CULT SP CEL, P179; SMITH AD, 1967, BIOCHEM J, V103, P480, DOI 10.1042/bj1030480; Tolias KF, 1999, CHEM PHYS LIPIDS, V98, P69, DOI 10.1016/S0009-3084(99)00019-5; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VANCE DE, 1991, BIOCH LIPIDS LIPOPRO, P205; WAGNER MC, 1992, J CELL BIOL, V119, P163, DOI 10.1083/jcb.119.1.163; WALKER DH, 1988, BIOCHEMISTRY-US, V27, P6504, DOI 10.1021/bi00417a046; WETZKER R, 1991, EUR J BIOCHEM, V200, P179, DOI 10.1111/j.1432-1033.1991.tb21065.x; WHITMAN M, 1988, NATURE, V332, P644, DOI 10.1038/332644a0; Zeidler MP, 1999, CURR BIOL, V9, P1363, DOI 10.1016/S0960-9822(00)80081-0	33	133	138	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 16	2001	276	11					7705	7708		10.1074/jbc.C000861200	http://dx.doi.org/10.1074/jbc.C000861200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	411AA	11244087	hybrid			2022-12-25	WOS:000167474900005
J	Zhang, H; Shi, XQ; Hampong, M; Blanis, L; Pelech, S				Zhang, H; Shi, XQ; Hampong, M; Blanis, L; Pelech, S			Stress-induced inhibition of ERK1 and ERK2 by direct interaction with p38 MAP kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION PATHWAY; ACTIVATED PROTEIN-KINASE; EXPRESSION; P38(MAPK)	We have identified a direct physical interaction between the stress signaling p38 alpha MAP kinase and the mitogen-activated protein kinases ERK1 and ERK2 by affinity chromatography and coimmunoprecipitation studies. Phosphorylation and activation of p38 alpha enhanced its interaction with ERK1/2, and this correlated with inhibition of ERK1/2 phosphotransferase activity. The loss of epidermal growth factor-induced activation and phosphorylation of ERK1/2 but not of their direct activator MEK1 in HeLa cells transfected with the p38 alpha activator MKK6(E) indicated that activated p38 alpha may sequester ERK1/2 and sterically block their phosphorylation by MEK1.	Univ British Columbia, Dept Med, Vancouver, BC V6T 1Z3, Canada; Kinexus Bioinformat Corp, Vancouver, BC V6T 1Z4, Canada	University of British Columbia	Pelech, S (corresponding author), Univ British Columbia, Dept Med, Koerner Pavil,2211 Wesbrook Mall, Vancouver, BC V6T 1Z3, Canada.							BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; English J, 1999, EXP CELL RES, V253, P255, DOI 10.1006/excr.1999.4687; Ichijo H, 1999, ONCOGENE, V18, P6087, DOI 10.1038/sj.onc.1203129; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Leppa S, 1999, ONCOGENE, V18, P6158, DOI 10.1038/sj.onc.1203173; Ludwig S, 1998, J BIOL CHEM, V273, P1917, DOI 10.1074/jbc.273.4.1917; Morrison DL, 2000, J BIOL CHEM, V275, P34236, DOI 10.1074/jbc.M004656200; Ono K, 2000, CELL SIGNAL, V12, P1, DOI 10.1016/S0898-6568(99)00071-6; Raingeaud J, 1996, MOL CELL BIOL, V16, P1247; Sambrook J., 2002, MOL CLONING LAB MANU; Sayed M, 2000, J BIOL CHEM, V275, P16569, DOI 10.1074/jbc.M000312200; Singh RP, 1999, J BIOL CHEM, V274, P19593, DOI 10.1074/jbc.274.28.19593; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4	13	150	152	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 9	2001	276	10					6905	6908		10.1074/jbc.C000917200	http://dx.doi.org/10.1074/jbc.C000917200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	410MC	11238443	hybrid			2022-12-25	WOS:000167442900007
J	Peng, YH; Chen, LH; Li, CG; Lu, WG; Agrawal, S; Chen, JD				Peng, YH; Chen, LH; Li, CG; Lu, WG; Agrawal, S; Chen, JD			Stabilization of the MDM2 oncoprotein by mutant p53	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							P53-INDEPENDENT ROLE; EMBRYONIC LETHALITY; MDM2-DEFICIENT MICE; FUNCTION MUTATIONS; TERMINAL DOMAIN; TUMOR-CELLS; PROTEIN; GAIN; EXPRESSION; OVEREXPRESSION	MDM2 is a short-lived protein that regulates p53 degradation. We report here that transient coexpression of MDM2 and several p53 hotspot mutants resulted in stabilization and increased expression of MDM2. Ectopic expression of the mutant p53(175H) allele by recombinant adenovirus infection or stable transfection also stabilized endogenous MDM2 in p53-null cells. A panel of human tumor cell lines expressing different endogenous mutant p53 alleles also contained stabilized nuclear MDM2 at elevated levels when compared with p53 null cells. MDM2 was present in complexes with mutant p53 in tumor cells, and stabilization of MDM2 required direct binding to mutant p53. These results reveal a novel property of mutant p53 and a unique feature of tumors with p53 missense mutations. Accumulation of stable MDM2 may contribute to tumorigenesis through its p53-independent transforming functions.	H Lee Moffitt Canc Ctr & Res Inst, Mol Oncol Program, Tampa, FL 33612 USA; Hybridon Inc, Cambridge, MA 02139 USA	H Lee Moffitt Cancer Center & Research Institute	Chen, JD (corresponding author), H Lee Moffitt Canc Ctr & Res Inst, Mol Oncol Program, 12902 Magnolia Dr, Tampa, FL 33612 USA.	JCHEN@Moffitt.usf.edu		Agrawal, Sudhir/0000-0003-4275-2510				BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; Blandino G, 1999, ONCOGENE, V18, P477, DOI 10.1038/sj.onc.1202314; Blattner C, 1999, MOL CELL BIOL, V19, P3704; CHEN JD, 1993, MOL CELL BIOL, V13, P4107, DOI 10.1128/MCB.13.7.4107; CORDONCARDO C, 1994, CANCER RES, V54, P794; CRIPPS KJ, 1994, ONCOGENE, V9, P2739; DITTMER D, 1993, NAT GENET, V4, P42, DOI 10.1038/ng0593-42; Endo K, 2000, LIVER, V20, P209, DOI 10.1034/j.1600-0676.2000.020003209.x; Fang SY, 2000, J BIOL CHEM, V275, P8945, DOI 10.1074/jbc.275.12.8945; Frazier MW, 1998, MOL CELL BIOL, V18, P3735, DOI 10.1128/MCB.18.7.3735; Gualberto A, 1998, P NATL ACAD SCI USA, V95, P5166, DOI 10.1073/pnas.95.9.5166; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; HOLLSTEIN M, 1994, NUCLEIC ACIDS RES, V22, P3551; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; HSIAO M, 1994, AM J PATHOL, V145, P702; JONES SN, 1995, NATURE, V378, P206, DOI 10.1038/378206a0; Jones SN, 1998, P NATL ACAD SCI USA, V95, P15608, DOI 10.1073/pnas.95.26.15608; Juven-Gershon T, 1999, MOL MED, V5, P71, DOI 10.1007/BF03402141; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; LANDERS JE, 1994, ONCOGENE, V9, P2745; LIN JY, 1995, ONCOGENE, V10, P2387; Loughran O, 2000, MOL CELL BIOL, V20, P2186, DOI 10.1128/MCB.20.6.2186-2197.2000; LUNA RMD, 1995, NATURE, V378, P203; Lundgren K, 1997, GENE DEV, V11, P714, DOI 10.1101/gad.11.6.714; MARTIN K, 1995, NATURE, V375, P691, DOI 10.1038/375691a0; Midgley CA, 1997, ONCOGENE, V15, P1179, DOI 10.1038/sj.onc.1201459; Nagata Y, 1999, ONCOGENE, V18, P6037, DOI 10.1038/sj.onc.1202978; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; OLSON DC, 1993, ONCOGENE, V8, P2353; Pan Y, 1999, CANCER RES, V59, P2064; Ries S, 2000, CELL, V103, P321, DOI 10.1016/S0092-8674(00)00123-9; Shaulian E, 1997, ONCOGENE, V15, P2717, DOI 10.1038/sj.onc.1201453; Soong R, 1996, HUM PATHOL, V27, P1050, DOI 10.1016/S0046-8177(96)90282-8; Sun PQ, 1998, SCIENCE, V282, P2270, DOI 10.1126/science.282.5397.2270; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; XIAO ZX, 1995, NATURE, V375, P694, DOI 10.1038/375694a0	36	54	57	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 2	2001	276	9					6874	6878		10.1074/jbc.C000781200	http://dx.doi.org/10.1074/jbc.C000781200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	407FF	11152666	hybrid			2022-12-25	WOS:000167261000103
J	Ulens, C; Tytgat, J				Ulens, C; Tytgat, J			Functional heteromerization of HCN1 and HCN2 pacemaker channels	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HETEROMULTIMERIC K+ CHANNELS; BETA-GAMMA-SUBUNITS; MU-OPIOID RECEPTOR; ADENYLYL-CYCLASE; MOLECULAR CHARACTERIZATION; POTASSIUM CHANNELS; XENOPUS-OOCYTES; CATION CHANNELS; MESSENGER-RNA; BRAIN	An important step toward understanding the molecular basis of the functional diversity of pacemaker currents in spontaneously active cells has been the identification of a gene family encoding hyperpolarization-activated cyclic nucleotide-sensitive cation nonselective (HCN) channels. Three of the four gene products that have been expressed so far give rise to pacemaker channels with distinct activation kinetics and are differentially distributed among the brain, with considerable overlap between some isoforms. This raises the possibility that HCN channels may coassemble to form heteromeric channels in some areas, similar to other K+ channels. In this study, we have provided evidence for functional heteromerization of HCN1 and HCN2 channels using a concatenated cDNA construct encoding two connected subunits. We have observed that heteromeric channels activate several-fold faster than HCN2 and only a little slower than HCN1. Furthermore, the voltage dependence of activation is more similar to HCN2, whereas the cAMP sensitivity is intermediate between HCN1 and HCN2. This phenotype shows marked similarity to the current arising from coexpressed HCN1 and HCN2 subunits in oocytes and the native pacemaker current in CA1 pyramidal neurons. We suggest that heteromerization may increase the functional diversity beyond the levels expected from the number of HCN channel genes and their differential distribution.	Catholic Univ Louvain, Toxicol Lab, B-3000 Louvain, Belgium	Universite Catholique Louvain	Tytgat, J (corresponding author), Catholic Univ Louvain, Toxicol Lab, Van Evenstr 4, B-3000 Louvain, Belgium.		Tytgat, Jan/F-1560-2010	Tytgat, Jan/0000-0003-1778-6022				CHAN JSC, 1995, J NEUROCHEM, V65, P2682; CHRISTIE MJ, 1990, NEURON, V4, P405, DOI 10.1016/0896-6273(90)90052-H; Claeysen S, 1999, MOL PHARMACOL, V55, P910; Clapham DE, 1998, NEURON, V21, P5, DOI 10.1016/S0896-6273(00)80508-5; DIFRANCESCO D, 1993, ANNU REV PHYSIOL, V55, P455, DOI 10.1146/annurev.physiol.55.1.455; DIFRANCESCO D, 1991, NATURE, V351, P145, DOI 10.1038/351145a0; FEDERMAN AD, 1992, NATURE, V356, P159, DOI 10.1038/356159a0; Franz O, 2000, EUR J NEUROSCI, V12, P2685, DOI 10.1046/j.1460-9568.2000.00151.x; ISACOFF EY, 1990, NATURE, V345, P530, DOI 10.1038/345530a0; Ishii TM, 1999, J BIOL CHEM, V274, P12835, DOI 10.1074/jbc.274.18.12835; KRAPIVINSKY G, 1995, NATURE, V374, P135, DOI 10.1038/374135a0; LIMAN ER, 1992, NEURON, V9, P861, DOI 10.1016/0896-6273(92)90239-A; Ludwig A, 1998, NATURE, V393, P587, DOI 10.1038/31255; Ludwig A, 1999, EMBO J, V18, P2323, DOI 10.1093/emboj/18.9.2323; Moosmang S, 1999, BIOL CHEM, V380, P975, DOI 10.1515/BC.1999.121; Peckys D, 1999, NEUROSCIENCE, V88, P1093, DOI 10.1016/S0306-4522(98)00251-6; Pessia M, 1996, EMBO J, V15, P2980, DOI 10.1002/j.1460-2075.1996.tb00661.x; RUPPERSBERG JP, 1990, NATURE, V345, P535, DOI 10.1038/345535a0; Santoro B, 1999, ANN NY ACAD SCI, V868, P741, DOI 10.1111/j.1749-6632.1999.tb11353.x; Santoro B, 1998, CELL, V93, P717, DOI 10.1016/S0092-8674(00)81434-8; Santoro B, 2000, J NEUROSCI, V20, P5264, DOI 10.1523/JNEUROSCI.20-14-05264.2000; Santoro B, 1997, P NATL ACAD SCI USA, V94, P14815, DOI 10.1073/pnas.94.26.14815; Seifert R, 1999, P NATL ACAD SCI USA, V96, P9391, DOI 10.1073/pnas.96.16.9391; SHENG M, 1993, NATURE, V365, P72, DOI 10.1038/365072a0; TANG WJ, 1991, SCIENCE, V254, P1500, DOI 10.1126/science.1962211; Ulens C, 2000, J PHARMACOL EXP THER, V294, P1024; Villmann C, 1997, J NEUROSCI, V17, P7634, DOI 10.1523/jneurosci.17-20-07634.1997; WANG H, 1993, NATURE, V365, P75, DOI 10.1038/365075a0	28	167	171	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 2	2001	276	9					6069	6072		10.1074/jbc.C000738200	http://dx.doi.org/10.1074/jbc.C000738200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	407FF	11133998	hybrid			2022-12-25	WOS:000167261000004
J	Herrera, B; Alvarez, AM; Sanchez, A; Fernandez, M; Roncero, C; Benito, M; Fabregat, I				Herrera, B; Alvarez, AM; Sanchez, A; Fernandez, M; Roncero, C; Benito, M; Fabregat, I			Reactive oxygen species (ROS) mediates the mitochondrial-dependent apoptosis induced by transforming growth factor beta in fetal hepatocytes	FASEB JOURNAL			English	Article						cytochrome c; caspases; Bcl-x	CYTOCHROME-C RELEASE; FACTOR BETA(1)-INDUCED APOPTOSIS; PERMEABILITY TRANSITION PORE; RAT HEPATOCYTES; CASPASE ACTIVATION; HYDROGEN-PEROXIDE; TGF-BETA; BAX; BCL-2; EXPRESSION	Treatment of fetal rat hepatocytes with transforming growth factor beta (TGF-beta) is followed by apoptotic cell death, Analysis of radical oxygen species (ROS) content and mitochondrial transmembrane potential (Delta Psi (m)), using specific fluorescent probes in FACScan and confocal microscopy, showed that TGF-beta mediates ROS production that precedes the loss of Delta Psi (m), the release of cytochrome c, and the activation of caspase 3. TGF-beta induces a decrease in the protein and mRNA levels of bcl-x(L), an antiapoptotic member of the Bcl-2 family. In contrast, there is no change in the expression and/or translocation of Bax, a proapoptotic member of the same family. EGF maintains Bcl-x(L), preventing Delta Psi (m) collapse and release of cytochrome c, The presence of radical scavengers blocks the decrease in bcl-x(L) levels, Delta Psi (m) collapse, cytochrome c release, and activation of caspase 3; in contrast, the presence of glutathione synthesis inhibitors such as BSO accentuated the effect. The incubation of fetal hepatocytes in the presence of ter-butyl-hydroperoxide alone produces a decrease in bcl-x(L). These results indicate that during the apoptosis mediated by TGF-beta in fetal hepatocytes, ROS may be responsible for the decrease in bcl-x(L) mRNA levels that precedes the loss of Delta Psi (m), the release of cytochrome c, and the activation of caspase 3, culminating in cell death.	Univ Complutense Madrid, Dept Bioquim & Biol Mol, Fac Farm,Inst Bioquim, CSIC,Ctr Mixto, E-28040 Madrid, Spain; Univ Complutense Madrid, Ctr Citometria Flujo & Microscopia Confocal, Fac Farm, E-28040 Madrid, Spain	Complutense University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); Complutense University of Madrid	Fabregat, I (corresponding author), Univ Complutense Madrid, Dept Bioquim & Biol Mol, Fac Farm,Inst Bioquim, CSIC,Ctr Mixto, E-28040 Madrid, Spain.	isabelf@eucmax.sim.ucm.es	Roncero, Cesáreo/H-9039-2015; Sánchez, Aránzazu/H-7810-2015; Alvarez-Barrientos, Alberto/L-9299-2014; Herrera, Blanca/K-1803-2014; Fernández, Margarita/H-9077-2015; Benito, Manuel/J-5637-2014; Fabregat, Isabel/H-7038-2015	Roncero, Cesáreo/0000-0001-7608-8553; Sánchez, Aránzazu/0000-0001-9145-6633; Alvarez-Barrientos, Alberto/0000-0003-4761-0212; Herrera, Blanca/0000-0002-2415-2055; Fernández, Margarita/0000-0001-7207-2028; Benito, Manuel/0000-0002-7218-406X; Fabregat, Isabel/0000-0003-0136-8440				Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Antonsson B, 2000, BIOCHEM J, V345, P271, DOI 10.1042/0264-6021:3450271; Brenner C, 2000, ONCOGENE, V19, P329, DOI 10.1038/sj.onc.1203298; Byrne AM, 1999, HEPATOLOGY, V29, P1523, DOI 10.1002/hep.510290521; CARACENI P, 1995, BBA-MOL CELL RES, V1268, P249, DOI 10.1016/0167-4889(95)00077-6; Chen CL, 2000, MOL CELL BIOL, V20, P2687, DOI 10.1128/MCB.20.8.2687-2695.2000; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Christensen JG, 1998, CELL GROWTH DIFFER, V9, P815; Constantini P., 1996, J BIOL CHEM, V271, P6746; Crompton M, 1999, BIOCHEM J, V341, P233, DOI 10.1042/0264-6021:3410233; Fabregat I, 1996, FEBS LETT, V384, P14, DOI 10.1016/0014-5793(96)00266-9; Fadeel B, 1999, FASEB J, V13, P1647, DOI 10.1096/fasebj.13.13.1647; Fan GS, 1996, ONCOGENE, V12, P1909; Finucane DM, 1999, J BIOL CHEM, V274, P2225, DOI 10.1074/jbc.274.4.2225; Garcia-Ruiz C, 2000, FASEB J, V14, P847, DOI 10.1096/fasebj.14.7.847; Garcia-Trevijano ER, 1999, HEPATOLOGY, V29, P960, DOI 10.1002/hep.510290346; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Hildeman DA, 1999, IMMUNITY, V10, P735, DOI 10.1016/S1074-7613(00)80072-2; InayatHussain SH, 1997, HEPATOLOGY, V25, P1516, DOI 10.1002/hep.510250634; Jacobs-Helber SM, 1998, MOL CELL BIOL, V18, P3699, DOI 10.1128/MCB.18.7.3699; Karbowski M, 1999, FREE RADICAL BIO MED, V26, P396, DOI 10.1016/S0891-5849(98)00209-3; KAYANOKI Y, 1994, J BIOL CHEM, V269, P15488; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Kowaltowski AJ, 1999, FREE RADICAL BIO MED, V26, P463, DOI 10.1016/S0891-5849(98)00216-0; Kroemer G, 2000, NAT MED, V6, P513, DOI 10.1038/74994; Lafon C, 1996, CELL GROWTH DIFFER, V7, P1095; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; LOWERSON SA, 1992, ANAL BIOCHEM, V205, P372, DOI 10.1016/0003-2697(92)90453-E; Marzo I, 1998, SCIENCE, V281, P2027, DOI 10.1126/science.281.5385.2027; Massague J, 2000, GENE DEV, V14, P627; Narita M, 1998, P NATL ACAD SCI USA, V95, P14681, DOI 10.1073/pnas.95.25.14681; OBERHAMMER FA, 1992, P NATL ACAD SCI USA, V89, P5408, DOI 10.1073/pnas.89.12.5408; OHBA M, 1994, J CELL BIOL, V126, P1079, DOI 10.1083/jcb.126.4.1079; Patel T, 1998, SEMIN LIVER DIS, V18, P105, DOI 10.1055/s-2007-1007147; Pitot HC, 1998, HEPATOLOGY, V28, P1, DOI 10.1002/hep.510280101; Rodrigues CMP, 1999, CELL DEATH DIFFER, V6, P842, DOI 10.1038/sj.cdd.4400560; RONCERO C, 1989, BIOCHIM BIOPHYS ACTA, V1012, P320, DOI 10.1016/0167-4889(89)90115-8; Saltzman A, 1998, EXP CELL RES, V242, P244, DOI 10.1006/excr.1998.4096; Sanchez A, 1999, EXP CELL RES, V252, P281, DOI 10.1006/excr.1999.4624; Sanchez A, 1996, J BIOL CHEM, V271, P7416, DOI 10.1074/jbc.271.13.7416; SANCHEZ A, 1995, J CELL PHYSIOL, V165, P398, DOI 10.1002/jcp.1041650221; Sanchez A, 1997, HEPATOLOGY, V26, P935, DOI 10.1002/hep.510260420; Sen CK, 1996, FASEB J, V10, P709, DOI 10.1096/fasebj.10.7.8635688; Shima Y, 1999, HEPATOLOGY, V30, P1215, DOI 10.1002/hep.510300503; Shimizu S, 1999, NATURE, V399, P483, DOI 10.1038/20959; Silva M, 1999, J BIOL CHEM, V274, P22165, DOI 10.1074/jbc.274.32.22165; Simon AR, 1998, AM J PHYSIOL-CELL PH, V275, pC1640, DOI 10.1152/ajpcell.1998.275.6.C1640; Stoll SW, 1998, ONCOGENE, V16, P1493, DOI 10.1038/sj.onc.1201657; Teramoto T, 1998, BIOCHEM BIOPH RES CO, V251, P56, DOI 10.1006/bbrc.1998.9411; Thannickal VJ, 1995, J BIOL CHEM, V270, P30334, DOI 10.1074/jbc.270.51.30334; Thorgeirsson SS, 1998, SEMIN LIVER DIS, V18, P115, DOI 10.1055/s-2007-1007148; VanderHeiden MG, 1997, CELL, V91, P627, DOI 10.1016/S0092-8674(00)80450-X; Yamamoto M, 1998, HEPATOLOGY, V27, P959, DOI 10.1002/hep.510270410; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; ZAMZAMI N, 1995, J EXP MED, V182, P367, DOI 10.1084/jem.182.2.367	55	272	283	0	22	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2001	15	3					741	751		10.1096/fj.00-0267com	http://dx.doi.org/10.1096/fj.00-0267com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	410BE	11259392				2022-12-25	WOS:000167419500031
J	Qu, XW; Wang, H; De Plaen, IG; Rozenfeld, RA; Hsueh, W				Qu, XW; Wang, H; De Plaen, IG; Rozenfeld, RA; Hsueh, W			Neuronal nitric oxide synthase (NOS) regulates the expression of inducible NOS in rat small intestine via modulation of nuclear factor kappa B	FASEB JOURNAL			English	Article						NO; gene regulation; transcription factor	PLATELET-ACTIVATING-FACTOR; CELL-ADHESION MOLECULE-1; MESSENGER-RNA; ENDOTHELIAL-CELLS; GENE-EXPRESSION; DNA-BINDING; INHIBITION; ALPHA; INFLAMMATION; SUPEROXIDE	We previously reported that neuronal nitric oxide synthase (nNOS) is the predominant NOS in the intestine. Inducible NOS (iNOS), an enzyme involved in the inflammatory response, is regulated by cytokines via the transcriptional factor NF-kappaB. We examined a new mechanism of intestinal iNOS regulation with respect to the role of nNOS and its effect on NF-kappaB. Young Sprague-Dawley rats were treated for 4 days with 1) saline, 2) 7-nitroindazole (7-NI, specific nNOS inhibitor), 3) 7-NI + pyrrolidine dithiocarbamate (PDTC, NF-kappaB inhibitor), or 4) PDTC. Intestinal iNOS mRNA, NF-kappaB activity, and the tissue content of the regulatory I kappaB alpha were examined. We found that 7-NI-treated animals had higher intestinal NF-kappaB (p50-p65) activity, lower I kappaB alpha content, and increased intestinal iNOS mRNA, iNOS protein, and iNOS activity compared with controls. All of these changes were abolished when PDTC was given together with 7-NI. PDTC alone had no effect. 7-NI induces a delayed increase in intestinal myeloperoxidase activity (after elevation in NF-kappaB and iNOS), which could be abrogated by PDTC, We conclude that in normal rat small intestine, nNOS suppresses the gene expression of iNOS through NF-kappaB down-regulation and that nNOS suppression leads to I kappaB alpha degradation, NF-kappaB activation, and iNOS expression.	Northwestern Univ, Sch Med, Childrens Mem Med Ctr, Dept Pathol, Chicago, IL 60614 USA; Northwestern Univ, Sch Med, Childrens Mem Med Ctr, Dept Pediat, Chicago, IL 60614 USA	Northwestern University; Northwestern University	Hsueh, W (corresponding author), Childrens Mem Hosp, Dept Pathol, 2300 Childrens Plaza, Chicago, IL 60614 USA.	w-hsueh@nwu.edu		De Plaen, Isabelle G/0000-0002-1742-2926				ANGGARD E, 1994, LANCET, V343, P1199, DOI 10.1016/S0140-6736(94)92405-8; Baeuerle PA, 1998, CELL, V95, P729, DOI 10.1016/S0092-8674(00)81694-3; Beckman JS, 1996, AM J PHYSIOL-CELL PH, V271, pC1424; BOHLEN HG, 1992, AM J PHYSIOL, V262, pH813, DOI 10.1152/ajpheart.1992.262.3.H813; BROWN K, 1993, P NATL ACAD SCI USA, V90, P2532, DOI 10.1073/pnas.90.6.2532; Chandrasekar B, 1999, CIRCULATION, V99, P427, DOI 10.1161/01.CIR.99.3.427; CHARTRAIN NA, 1994, J BIOL CHEM, V269, P6765; CHEN CC, 1995, J IMMUNOL, V155, P3538; Chen K, 1996, BIOCHEM BIOPH RES CO, V224, P703, DOI 10.1006/bbrc.1996.1087; CLANCY RM, 1992, J CLIN INVEST, V90, P1116, DOI 10.1172/JCI115929; Colasanti M, 1997, J BIOL CHEM, V272, P7582, DOI 10.1074/jbc.272.12.7582; COLASANTI M, 1995, J BIOL CHEM, V270, P26731, DOI 10.1074/jbc.270.45.26731; De Plaen IG, 1998, BBA-LIPID LIPID MET, V1392, P185, DOI 10.1016/S0005-2760(98)00024-1; DECATERINA R, 1995, J CLIN INVEST, V96, P60, DOI 10.1172/JCI118074; DERYCKERE F, 1994, BIOTECHNIQUES, V16, P405; DiazGuerra MJM, 1996, J BIOL CHEM, V271, P30114, DOI 10.1074/jbc.271.47.30114; DIEDERICH D, 1990, AM J PHYSIOL, V258, pH445, DOI 10.1152/ajpheart.1990.258.2.H445; GABOURY J, 1993, AM J PHYSIOL, V265, pH862, DOI 10.1152/ajpheart.1993.265.3.H862; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Haas M, 1998, J LEUKOCYTE BIOL, V63, P395, DOI 10.1002/jlb.63.3.395; Holzer P, 1997, J PHARMACOL EXP THER, V280, P154; Khan BV, 1996, P NATL ACAD SCI USA, V93, P9114, DOI 10.1073/pnas.93.17.9114; KUBES P, 1991, P NATL ACAD SCI USA, V88, P4651, DOI 10.1073/pnas.88.11.4651; KUBES P, 1993, AM J PHYSIOL, V264, pG143, DOI 10.1152/ajpgi.1993.264.1.G143; LEVIN J, 1970, J LAB CLIN MED, V75, P903; MACNAUL KL, 1993, BIOCHEM BIOPH RES CO, V196, P1330, DOI 10.1006/bbrc.1993.2398; Matthews JR, 1996, NUCLEIC ACIDS RES, V24, P2236, DOI 10.1093/nar/24.12.2236; McCafferty DM, 1997, GASTROENTEROLOGY, V112, P1022, DOI 10.1053/gast.1997.v112.pm9041266; Michel T, 1997, J CLIN INVEST, V100, P2146, DOI 10.1172/JCI119750; MILLER MJS, 1993, SCAND J GASTROENTERO, V28, P149, DOI 10.3109/00365529309096062; MYERS PR, 1995, AM J PHYSIOL-HEART C, V268, pH955, DOI 10.1152/ajpheart.1995.268.3.H955; Nathan C, 1997, J CLIN INVEST, V100, P2417, DOI 10.1172/JCI119782; NICHOLS K, 1993, GASTROENTEROLOGY, V105, P1651, DOI 10.1016/0016-5085(93)91060-U; Park SK, 1997, BIOCHEM J, V322, P609, DOI 10.1042/bj3220609; PARK SK, 1994, BIOCHEM BIOPH RES CO, V201, P762, DOI 10.1006/bbrc.1994.1766; PENG HB, 1995, J BIOL CHEM, V270, P14214, DOI 10.1074/jbc.270.23.14214; Peng HB, 1998, J IMMUNOL, V161, P1970; Perko MJ, 1998, J PHYSIOL-LONDON, V513, P907, DOI 10.1111/j.1469-7793.1998.907ba.x; Qu XW, 1999, BBA-MOL CELL RES, V1451, P211, DOI 10.1016/S0167-4889(99)00076-2; Qu XW, 1999, CRIT CARE MED, V27, P356, DOI 10.1097/00003246-199902000-00043; Qu XW, 1999, GUT, V44, P203, DOI 10.1136/gut.44.2.203; REMICK DG, 1990, AM J PATHOL, V136, P49; SCHULZ JB, 1995, J NEUROCHEM, V64, P936, DOI 10.1046/j.1471-4159.1995.64020936.x; Spiecker M, 1998, J LEUKOCYTE BIOL, V63, P732, DOI 10.1002/jlb.63.6.732; SUZUKI N, 1994, EUR J PHARMACOL, V251, P221, DOI 10.1016/0014-2999(94)90403-0; Szabo C, 1996, SHOCK, V6, P25, DOI 10.1097/00024382-199607000-00006; THANOS D, 1995, CELL, V80, P529, DOI 10.1016/0092-8674(95)90506-5; Togashi H, 1997, P NATL ACAD SCI USA, V94, P2676, DOI 10.1073/pnas.94.6.2676; Wang Y, 1995, Curr Opin Nephrol Hypertens, V4, P12, DOI 10.1097/00041552-199501000-00003; Weisbrodt NW, 1996, AM J PHYSIOL-GASTR L, V271, pG454, DOI 10.1152/ajpgi.1996.271.3.G454; Xia Y, 1997, P NATL ACAD SCI USA, V94, P6954, DOI 10.1073/pnas.94.13.6954; YANCEY SL, 1993, J APPL PHYSIOL, V75, P1334, DOI 10.1152/jappl.1993.75.3.1334; YOSHIZUMI M, 1993, CIRC RES, V73, P205, DOI 10.1161/01.RES.73.1.205; ZHU L, 1992, ARCH BIOCHEM BIOPHYS, V298, P452, DOI 10.1016/0003-9861(92)90434-X	54	59	60	1	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2001	15	2					439	446		10.1096/fj.99-0343com	http://dx.doi.org/10.1096/fj.99-0343com			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	400LK	11156959				2022-12-25	WOS:000166872900025
J	Germani, A; Bruzzoni-Giovanelli, H; Fellous, A; Gisselbrecht, S; Varin-Blank, N; Calvo, F				Germani, A; Bruzzoni-Giovanelli, H; Fellous, A; Gisselbrecht, S; Varin-Blank, N; Calvo, F			SIAH-1 interacts with alpha-tubulin and degrades the kinesin Kid by the proteasome pathway during mitosis	ONCOGENE			English	Article						SIAH-1; kid; mitosis; ubiquitin degradation; kinesin	ELONGATION-FACTOR 1-ALPHA; TUMOR SUPPRESSION; MURINE HOMOLOGS; BINDING-PROTEIN; SINA GENE; DROSOPHILA; APOPTOSIS; ABSENTIA; CHROMOSOMES; ACTIVATION	SIAH-1, a human homologue of the Drosophila seven in absentia (Sina), has been implicated in ubiquitin-mediated proteolysis of different target proteins through its N-terminal RING finger domain, SIAH-1 is also induced during p53-mediated apoptosis, Furthermore, SIAH-1-transfected breast cancer cell line MCF-7 exhibits an altered mitotic process resulting in multi-nucleated giant cells, Now, using the two-hybrid system, we identified two new SIAH interacting proteins: Kid (kinesin like DNA binding protein) and a-tubulin. We demonstrate that SIAH is involved in the degradation of Kid via the ubiquitin-proteasome pathway. Our results suggest that SIAH-1 but not its N-terminal deletion mutant, affects the mitosis by an enhanced reduction of kinesin levels, Our results imply, for the first time, SIAH-1 in regulating the degradation of proteins directly implicated in the mitotic process.	Hop Cochin, Unite 363 INSERM, Inst Cochin Genet Mol, F-75014 Paris, France; Hop St Louis, Inst Genet Mol, Lab Pharmacol Expt & Clin, INSERM EP9932, F-75010 Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Germani, A (corresponding author), Hop Cochin, Unite 363 INSERM, Inst Cochin Genet Mol, 27 Rue Faubourg St Jacques, F-75014 Paris, France.		Varin-Blank, Nadine/G-4396-2013	VARIN-BLANK, Nadine/0000-0003-2769-018X; calvo, fabien/0000-0002-0298-7633				Amson RB, 1996, P NATL ACAD SCI USA, V93, P3953, DOI 10.1073/pnas.93.9.3953; Antonio C, 2000, CELL, V102, P425, DOI 10.1016/S0092-8674(00)00048-9; Bruzzoni-Giovanelli H, 1999, ONCOGENE, V18, P7101, DOI 10.1038/sj.onc.1203187; CARTHEW RW, 1990, CELL, V63, P561, DOI 10.1016/0092-8674(90)90452-K; CHANG HC, 1995, CELL, V80, P463, DOI 10.1016/0092-8674(95)90497-2; CONDEELIS J, 1995, TRENDS BIOCHEM SCI, V20, P169, DOI 10.1016/S0968-0004(00)88998-7; DELLA NG, 1993, DEVELOPMENT, V117, P1333; DICKSON BJ, 1995, CELL, V80, P453, DOI 10.1016/0092-8674(95)90496-4; Freemont PS, 2000, CURR BIOL, V10, pR84, DOI 10.1016/S0960-9822(00)00287-6; Funabiki H, 2000, CELL, V102, P411, DOI 10.1016/S0092-8674(00)00047-7; Germani A, 1999, MOL CELL BIOL, V19, P3798; Glover DM, 1996, J CELL BIOL, V135, P1681, DOI 10.1083/jcb.135.6.1681; Holloway AJ, 1997, GENOMICS, V41, P160, DOI 10.1006/geno.1997.4642; Hu G, 1999, MOL CELL BIOL, V19, P724; Hu G, 1997, GENOMICS, V46, P103, DOI 10.1006/geno.1997.4997; Hu G, 1997, GENE DEV, V11, P2701, DOI 10.1101/gad.11.20.2701; Jourdain L, 1997, BIOCHEMISTRY-US, V36, P10817, DOI 10.1021/bi971491b; Li FZ, 1999, NAT CELL BIOL, V1, P461, DOI 10.1038/70242; Li SH, 1997, CELL, V90, P469, DOI 10.1016/S0092-8674(00)80507-3; Linares-Cruz G, 1998, P NATL ACAD SCI USA, V95, P1131, DOI 10.1073/pnas.95.3.1131; Lorick KL, 1999, P NATL ACAD SCI USA, V96, P11364, DOI 10.1073/pnas.96.20.11364; Moore RC, 1998, CELL MOTIL CYTOSKEL, V41, P168, DOI 10.1002/(SICI)1097-0169(1998)41:2<168::AID-CM7>3.0.CO;2-A; Nemani M, 1996, P NATL ACAD SCI USA, V93, P9039, DOI 10.1073/pnas.93.17.9039; Nogales E, 1998, NATURE, V391, P199, DOI 10.1038/34465; Page AM, 1999, ANNU REV BIOCHEM, V68, P583, DOI 10.1146/annurev.biochem.68.1.583; Pfleger CM, 2000, GENE DEV, V14, P655; SHEIKH MS, 1995, ONCOGENE, V11, P1899; SHIINA N, 1994, SCIENCE, V266, P282, DOI 10.1126/science.7939665; Tang AH, 1997, CELL, V90, P459, DOI 10.1016/S0092-8674(00)80506-1; THEURKAUF WE, 1992, J CELL BIOL, V116, P1167, DOI 10.1083/jcb.116.5.1167; Tokai N, 1996, EMBO J, V15, P457, DOI 10.1002/j.1460-2075.1996.tb00378.x; Zhang JS, 1998, GENE DEV, V12, P1775, DOI 10.1101/gad.12.12.1775	32	73	78	0	8	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 7	2000	19	52					5997	6006		10.1038/sj.onc.1204002	http://dx.doi.org/10.1038/sj.onc.1204002			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	382MY	11146551				2022-12-25	WOS:000165827900006
J	Perez-Losada, J; Sanchez-Martin, M; Rodriguez-Garcia, MA; Perez-Mancera, PA; Pintado, B; Flores, T; Battaner, E; Sanchez-Garcia, I				Perez-Losada, J; Sanchez-Martin, M; Rodriguez-Garcia, MA; Perez-Mancera, PA; Pintado, B; Flores, T; Battaner, E; Sanchez-Garcia, I			Liposarcoma initiated by FUS/TLS-CHOP: the FUS/TLS domain plays a critical Pole in the pathogenesis of liposarcoma	ONCOGENE			English	Article						chromosomal abnormality; malignant solid tumors; adipose tissue; cancer development	HUMAN MYELOID-LEUKEMIA; RNA-BINDING PROTEIN; CHROMOSOMAL TRANSLOCATION; MYXOID LIPOSARCOMA; TRANSCRIPTIONAL ACTIVATION; ONCOGENIC TRANSFORMATION; CHIMERIC PROTEIN; TLS-CHOP; GENE; FUSION	The most common chromosomal translocation in liposarcomas, t(12;16)(q13;p11), creates the FUS/TLS-CHOP fusion gene. We previously developed a mouse model of liposarcoma by expressing PUS-CHOP in murine mesenchymal stem cells. In order to understand how PUS-CHOP can initiate liposarcoma, we have now generated transgenic mice expressing altered forms of the PUS-CHOP protein. Transgenic mice expressing high levels of CHOP, which lacks the FUS domain, do not develop any tumor despite its tumorigenicity in vitro and widespread activity of the EF1 alpha promoter, These animals consistently show the accumulation of a glycoprotein material within the terminally differentiated adipocytes, a characteristic figure of liposarcomas associated with PUS-CHOP. On the contrary, transgenic mice expressing the altered form of PUS-CHOP created by the in frame fusion of the PUS domain to the carboxy end of CHOP (CHOP-FUS) developed liposarcomas. No tumors of other tissues were found in these transgenic mice despite widespread activity of the EF1 alpha promoter. The characteristics of the liposarcomas arising in the CHOP-PUS mice were very similar to those previously observed in our PUS-CHOP transgenic mice indicating that the FUS domain is required not only for transformation but also influences the phenotype of the tumor cells. These results provide evidence that the FUS domain of PUS-CHOP plays a specific and critical role in the pathogenesis of liposarcoma.	Univ Salamanca, CSIC, Ctr Invest Canc, Inst Bilogia Mol & Celular Canc, E-37008 Salamanca, Spain; Ctr Invest & Tecnol, Area Reprod Anim, Madrid 28040, Spain; Univ Salamanca, Serv Anat Patol, Salamanca 37007, Spain; Univ Salamanca, Dept Bioquim & Biol Mol, Salamanca 37007, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Investigacion del Cancer (CIC); CSIC-USAL - Instituto de Biologia Molecular y Celular del Cancer de Salamanca (IBMCC); University of Salamanca; University of Salamanca; University of Salamanca	Sanchez-Garcia, I (corresponding author), Univ Salamanca, CSIC, Ctr Invest Canc, Inst Bilogia Mol & Celular Canc, E-37008 Salamanca, Spain.		Sanchez-Martin, Manuel/N-5327-2016; SANCHEZ-GARCIA, ISIDRO/A-5631-2019; Pérez-Losada, Jesús/A-5883-2019; Pintado, Belen/N-3233-2014	Sanchez-Martin, Manuel/0000-0001-8370-1336; Pérez-Losada, Jesús/0000-0003-2400-624X; Pintado, Belen/0000-0002-8485-2520; SANCHEZ-GARCIA, ISIDRO/0000-0001-6989-9905	NCI NIH HHS [1 R01 CA79955-01] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA079955] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adelmant G, 1998, J BIOL CHEM, V273, P15574, DOI 10.1074/jbc.273.25.15574; Aman P, 1996, GENOMICS, V37, P1, DOI 10.1006/geno.1996.0513; BARONE MV, 1994, GENE DEV, V8, P453, DOI 10.1101/gad.8.4.453; BATCHVAROVA N, 1995, EMBO J, V14, P4654, DOI 10.1002/j.1460-2075.1995.tb00147.x; CARLSON SG, 1993, MOL CELL BIOL, V13, P4736, DOI 10.1128/MCB.13.8.4736; Castellanos A, 1997, BLOOD, V90, P2168, DOI 10.1182/blood.V90.6.2168.2168_2168_2174; CHANG HR, 1989, CANCER, V64, P1514, DOI 10.1002/1097-0142(19891001)64:7<1514::AID-CNCR2820640726>3.0.CO;2-2; CROZAT A, 1993, NATURE, V363, P640, DOI 10.1038/363640a0; Cui KY, 2000, J BIOL CHEM, V275, P7591, DOI 10.1074/jbc.275.11.7591; FORNACE AJ, 1989, MOL CELL BIOL, V9, P4196, DOI 10.1128/MCB.9.10.4196; ICHIKAWA H, 1994, CANCER RES, V54, P2865; KNIGHT JC, 1995, CANCER RES, V55, P24; Kuroda M, 1997, AM J PATHOL, V151, P735; MACK TM, 1995, CANCER-AM CANCER SOC, V75, P211, DOI 10.1002/1097-0142(19950101)75:1+<211::AID-CNCR2820751309>3.0.CO;2-X; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; PANAGOPOULOS I, 1995, ONCOGENE, V11, P1133; PANAGOPOULOS I, 1994, GENE CHROMOSOME CANC, V11, P256, DOI 10.1002/gcc.2870110408; Perez-Losada J, 2000, ONCOGENE, V19, P2413, DOI 10.1038/sj.onc.1203572; PRASAD DDK, 1994, ONCOGENE, V9, P3717; PRICE BD, 1992, CANCER RES, V52, P3814; RABBITTS TH, 1993, NAT GENET, V4, P175, DOI 10.1038/ng0693-175; RON D, 1992, GENE DEV, V6, P439, DOI 10.1101/gad.6.3.439; Sanchez-Garcia I, 1997, ANNU REV GENET, V31, P429, DOI 10.1146/annurev.genet.31.1.429; SANCHEZGARCIA I, 1994, P NATL ACAD SCI USA, V91, P7869, DOI 10.1073/pnas.91.17.7869; SHIMIZU K, 1993, P NATL ACAD SCI USA, V90, P10280, DOI 10.1073/pnas.90.21.10280; Tontonoz P, 1997, P NATL ACAD SCI USA, V94, P237, DOI 10.1073/pnas.94.1.237; Wang XZ, 1996, MOL CELL BIOL, V16, P4273; ZINSZNER H, 1994, GENE DEV, V8, P2513, DOI 10.1101/gad.8.21.2513	28	55	59	1	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 7	2000	19	52					6015	6022		10.1038/sj.onc.1204018	http://dx.doi.org/10.1038/sj.onc.1204018			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	382MY	11146553				2022-12-25	WOS:000165827900008
J	Deguin-Chambon, V; Vacher, M; Jullien, M; May, E; Bourdon, JC				Deguin-Chambon, V; Vacher, M; Jullien, M; May, E; Bourdon, JC			Direct transactivation of c-Ha-Ras gene by p53: evidence for its involvement in p53 transactivation activity and p53-mediated apoptosis	ONCOGENE			English	Article						p53 RE; c-Ha-Ras; transactivation; Ras.GTP; p53-stability	PROTEIN-KINASE-C; CELL-CYCLE MACHINERY; TUMOR-SUPPRESSOR P53; WILD-TYPE P53; BINDING-SITE; NEUROBLASTOMA-CELLS; PHORBOL ESTER; FIRST INTRON; T-ANTIGEN; IN-VITRO	p53 protein is a sequence-specific transcriptional activator which induces the expression of a number of cellular genes involved in different metabolic pathways, We report that the computer-selected sequence in human and mouse C-Ha-Ras gene confers to a reporter gene the ability to be directly transactivated by wild-type p53 either ovrespressed or activated in response to a cellular stress. By analysing human transformed cell lines, we showed, at both mRNA and protein level, that the endogenous C-Ha-Ras gene expression is positively regulated by wt p53 protein, The stimulation of c-Ha-Ras gene expression in Saos-2Ts cells by a temperature shift down to the permissive temperature for the p53-wt conformation is associated with a significant increase in the activated form of p21(e-11a-Ras) protein. Furthermore, in human transformed cell lines, the transient expression of a dominant interfering mutant of c-Ha-Ras greatly reduced the ability of p53 to induce apoptosis and inhibited the p53-dependent transactivation. This is due, at least in part, to a decrease in the protein (but not mRNA) level of the transiently expressed p53, indicating that inactivation of p21(e-11a-Ras) signalling pathways led to a specific degradation of p53 protein, We therefore suggest that, by inducing c-Ha-Ras, p53 activates a positive feedback loop that counteracts the negative feedback loop mediated by Mdm2.	CEA, DSV, UMR217 CNRS, Lab Cancerogenese Mol, F-92265 Fontenay Aux Roses, France; Univ Dundee, Dept Biochem, CRC, Cell Transformat Res Grp, Dundee DD1 4HN, Scotland	CEA; University of Dundee	May, E (corresponding author), CEA, DSV, UMR217 CNRS, Lab Cancerogenese Mol, BP6, F-92265 Fontenay Aux Roses, France.		JC, Bourdon/A-4439-2008	JC, Bourdon/0000-0003-4623-9386				Aktas H, 1997, MOL CELL BIOL, V17, P3850, DOI 10.1128/MCB.17.7.3850; Bates S, 1998, NATURE, V395, P124, DOI 10.1038/25867; Bourdon JC, 1997, ONCOGENE, V14, P85, DOI 10.1038/sj.onc.1200804; BROWN K, 1988, MOL CARCINOGEN, V1, P161, DOI 10.1002/mc.2940010304; Cadoret A, 1997, ONCOGENE, V14, P1589, DOI 10.1038/sj.onc.1200992; Campbell SL, 1998, ONCOGENE, V17, P1395, DOI 10.1038/sj.onc.1202174; CANNON JV, 1990, EMBO J, V9, P1595; Chiloeches A, 1999, J BIOL CHEM, V274, P19762, DOI 10.1074/jbc.274.28.19762; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CRAWFORD L, 1982, J VIROL, V42, P612, DOI 10.1128/JVI.42.2.612-620.1982; Delphin C, 1997, EUR J BIOCHEM, V245, P684, DOI 10.1111/j.1432-1033.1997.t01-1-00684.x; DELPHIN C, 1994, J BIOL CHEM, V269, P29579; deRooij J, 1997, ONCOGENE, V14, P623, DOI 10.1038/sj.onc.1201005; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; HERRMANN C, 1995, J BIOL CHEM, V270, P2901, DOI 10.1074/jbc.270.7.2901; Hu MCT, 1997, ONCOGENE, V15, P2277, DOI 10.1038/sj.onc.1201401; Kamijo T, 1998, P NATL ACAD SCI USA, V95, P8292, DOI 10.1073/pnas.95.14.8292; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Lane DP, 1997, TRENDS BIOCHEM SCI, V22, P372, DOI 10.1016/S0968-0004(97)01119-5; Leone G, 1997, NATURE, V387, P422, DOI 10.1038/387422a0; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; MAY E, 1989, ONCOGENE, V4, P1037; May P, 1999, ONCOGENE, V18, P7621, DOI 10.1038/sj.onc.1203285; Mazzoni IE, 1999, J NEUROSCI, V19, P9716; MILNE DM, 1995, J BIOL CHEM, V270, P5511, DOI 10.1074/jbc.270.10.5511; MILNE DM, 1994, J BIOL CHEM, V269, P9253; MIYASHITA T, 1995, CELL, V80, P293; Olson MF, 1998, NATURE, V394, P295, DOI 10.1038/28425; OMILLI F, 1986, MOL CELL BIOL, V6, P1875, DOI 10.1128/MCB.6.6.1875; Palmero I, 1998, NATURE, V395, P125, DOI 10.1038/25870; PARADA LF, 1982, NATURE, V297, P474, DOI 10.1038/297474a0; Peeper DS, 1997, NATURE, V386, P177, DOI 10.1038/386177a0; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; ROMANO JW, 1989, ONCOGENE, V4, P1483; Ronca F, 1997, J BIOL CHEM, V272, P4252, DOI 10.1074/jbc.272.7.4252; SCHWEIGHOFFER F, 1993, MOL CELL BIOL, V13, P39, DOI 10.1128/MCB.13.1.39; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; SHAULIAN E, 1995, ONCOGENE, V10, P671; Smart P, 1999, ONCOGENE, V18, P7378, DOI 10.1038/sj.onc.1203260; SPANDIDOS DA, 1995, INT J ONCOL, V7, P1029; STEPHEN CW, 1995, J MOL BIOL, V248, P58, DOI 10.1006/jmbi.1995.0202; Stott FJ, 1998, EMBO J, V17, P5001, DOI 10.1093/emboj/17.17.5001; TAKENAKA I, 1995, J BIOL CHEM, V270, P5405, DOI 10.1074/jbc.270.10.5405; TEGTMEYER P, 1975, J VIROL, V16, P168, DOI 10.1128/JVI.16.1.168-178.1975; TELLIEZ JB, 1995, MOL CARCINOGEN, V12, P137, DOI 10.1002/mc.2940120305; TOKINO T, 1994, HUM MOL GENET, V3, P1537, DOI 10.1093/hmg/3.9.1537; YAMATO K, 1995, ONCOGENE, V11, P1; Yonish-Rouach E, 1994, Cell Death Differ, V1, P39; YonishRouach E, 1995, ONCOGENE, V11, P2197; Youmell M, 1998, BIOCHEM BIOPH RES CO, V245, P514, DOI 10.1006/bbrc.1998.8471; ZHANG W, 1995, INT J ONCOL, V7, P1021; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4	56	22	22	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 30	2000	19	51					5831	5841		10.1038/sj.onc.1203960	http://dx.doi.org/10.1038/sj.onc.1203960			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	378CA	11127813				2022-12-25	WOS:000165563100001
J	Kuraguchi, M; Edelmann, W; Yang, K; Lipkin, M; Kucherlapati, R; Brown, AMC				Kuraguchi, M; Edelmann, W; Yang, K; Lipkin, M; Kucherlapati, R; Brown, AMC			Tumor-associated Apc mutations in Mlh1(-/-) Apc(1638N) mice reveal a mutational signature of Mlh1 deficiency	ONCOGENE			English	Article						Mlh1; Apc; colorectal cancer; mouse models; mutation analysis	NONPOLYPOSIS COLORECTAL-CANCER; MISMATCH REPAIR DEFICIENCY; CARCINOMA CELL-LINES; FAMILIAL ADENOMATOUS POLYPOSIS; MULTIPLE INTESTINAL NEOPLASIA; BETA-CATENIN; SUPPRESSOR PROTEIN; DNA MISMATCH; MOUSE MODEL; SACCHAROMYCES-CEREVISIAE	Apc(1638N) mice, which are heterozygous for a germline mutation in Ape, typically de, clop three to five spontaneous intestinal tumors per animal, in most cases this is associated,vith allelic loss of wildtype Ape. We have previously reported that the multiplicity of intestinal tumors is increased dramatically by crossing Apc(1638N) with an Mlh1-deficient mouse strain that represents an animal model of hereditary non-polyposis colorectal cancer (HNPCC). The increased tumor multiplicity in these mice was associated with somatic mutations in the Ape tumor suppressor gene, Here, we have examined the nature and distribution of 91 Ape mutations implicated in the de, development of intestinal tumors in Mlh1 (-/-) Apc(1638N) animals. Protein truncation mutations were detected in a majority of tumor samples, indicating that the prevailing mechanism of Ape mutation in tumors is altered from allelic loss to intragenic mutation as a result of Mlh1 deficiency, The observed mutations were a mixture of base substitutions (27%) and frameshifts (73%). Most frameshifts wire detected within dinucleotide repeats and there were prominent mutational hotspots within sequences of this sort at codons 927-929, 1209-1211 and 1461-1464, The observed Ape mutations caused protein truncation upstream of the third 20 amino acid beta -catenin binding domain and the first Axin-binding SAMP repeat, yielding Ape proteins that are predicted to be deficient in destabilizing beta -catenin, Our results reveal a characteristic mutational signature in APC that is attributable to Mlh1 deficiency. This demonstrates a direct effect of Mlh1 deficiency in the mutation of Apc in these tumors, and provides data that clarify the role of Mlh1 in mammalian DNA mismatch repair.	Rockefeller Univ, Strang Canc Res Lab, New York, NY 10021 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Mol Genet, Bronx, NY 10461 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Cell Biol, Bronx, NY 10461 USA; Cornell Univ, Weill Med Coll, Dept Cell Biol & Anat, New York, NY 10021 USA	Rockefeller University; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Cornell University	Brown, AMC (corresponding author), Rockefeller Univ, Strang Canc Res Lab, 1230 York Ave, New York, NY 10021 USA.		Kucherlapati, Raju/ABC-8807-2021		DIVISION OF CANCER PREVENTION AND CONTROL [N01CN065031] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA047207, R01CA067944, R01CA076329] Funding Source: NIH RePORTER; NCI NIH HHS [N01-CN-65031, CA76329, CA67944, R01 CA047207] Funding Source: Medline	DIVISION OF CANCER PREVENTION AND CONTROL(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Behrens J, 1998, SCIENCE, V280, P596, DOI 10.1126/science.280.5363.596; BHATTACHARYYA NP, 1994, P NATL ACAD SCI USA, V91, P6319, DOI 10.1073/pnas.91.14.6319; BRANCH P, 1995, CANCER RES, V55, P2304; Crawford HC, 1999, ONCOGENE, V18, P2883, DOI 10.1038/sj.onc.1202627; DEWIND N, 1995, CELL, V82, P321, DOI 10.1016/0092-8674(95)90319-4; Edelmann W, 1996, CELL, V85, P1125, DOI 10.1016/S0092-8674(00)81312-4; Edelmann W, 1999, CANCER RES, V59, P1301; FISHEL R, 1995, CURR OPIN GENET DEV, V5, P382, DOI 10.1016/0959-437X(95)80055-7; FODDE R, 1994, P NATL ACAD SCI USA, V91, P8969, DOI 10.1073/pnas.91.19.8969; GRODEN J, 1991, CELL, V66, P589, DOI 10.1016/0092-8674(81)90021-0; Habraken Y, 1997, CURR BIOL, V7, P790, DOI 10.1016/S0960-9822(06)00337-X; Habraken Y, 1998, J BIOL CHEM, V273, P9837, DOI 10.1074/jbc.273.16.9837; Hart MJ, 1998, CURR BIOL, V8, P573, DOI 10.1016/S0960-9822(98)70226-X; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Huang J, 1996, P NATL ACAD SCI USA, V93, P9049, DOI 10.1073/pnas.93.17.9049; JOSLYN G, 1991, CELL, V66, P601, DOI 10.1016/0092-8674(81)90022-2; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; KINZLER KW, 1991, SCIENCE, V253, P661, DOI 10.1126/science.1651562; Kitaeva MN, 1997, CANCER RES, V57, P4478; Kolodner R, 1996, GENE DEV, V10, P1433, DOI 10.1101/gad.10.12.1433; Konishi M, 1996, GASTROENTEROLOGY, V111, P307, DOI 10.1053/gast.1996.v111.pm8690195; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; LEVY DB, 1994, CANCER RES, V54, P5953; LI GM, 1995, P NATL ACAD SCI USA, V92, P1950, DOI 10.1073/pnas.92.6.1950; MARRA G, 1995, J NATL CANCER I, V87, P1114, DOI 10.1093/jnci/87.15.1114; Marsischky GT, 1996, GENE DEV, V10, P407, DOI 10.1101/gad.10.4.407; Matsumine A, 1996, SCIENCE, V272, P1020, DOI 10.1126/science.272.5264.1020; MIYAKI M, 1994, CANCER RES, V54, P3011; Miyaki M, 1999, CANCER RES, V59, P4506; Miyoshi Yasuo, 1992, Human Molecular Genetics, V1, P229; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; MOSER AR, 1990, SCIENCE, V247, P322, DOI 10.1126/science.2296722; MUNEMITSU S, 1994, CANCER RES, V54, P3676; MUNEMITSU S, 1995, P NATL ACAD SCI USA, V92, P3046, DOI 10.1073/pnas.92.7.3046; Nusse R, 1997, CELL, V89, P321, DOI 10.1016/S0092-8674(00)80210-X; Ohzeki S, 1997, CARCINOGENESIS, V18, P1127, DOI 10.1093/carcin/18.6.1127; OSHIMA M, 1995, P NATL ACAD SCI USA, V92, P4482, DOI 10.1073/pnas.92.10.4482; PARSONS R, 1993, CELL, V75, P1227, DOI 10.1016/0092-8674(93)90331-J; PEIFER M, 1994, CELL, V76, P789, DOI 10.1016/0092-8674(94)90353-0; Peltomaki P, 1997, ADV CANCER RES, V71, P93, DOI 10.1016/S0065-230X(08)60097-4; Polakis P, 1997, BBA-REV CANCER, V1332, pF127, DOI 10.1016/S0304-419X(97)00008-5; PROLLA TA, 1994, SCIENCE, V265, P1091, DOI 10.1126/science.8066446; PROLLA TA, 1994, MOL CELL BIOL, V14, P407, DOI 10.1128/MCB.14.1.407; Rosin-Arbesfeld R, 2000, NATURE, V406, P1009, DOI 10.1038/35023016; RUBINFELD B, 1993, SCIENCE, V262, P1731, DOI 10.1126/science.8259518; Rubinfeld B, 1997, CANCER RES, V57, P4624; Saparbaev M, 1996, GENETICS, V142, P727; Shoemaker AR, 2000, ONCOGENE, V19, P2774, DOI 10.1038/sj.onc.1203574; Shoemaker AR, 1997, CANCER RES, V57, P1999; Shtutman M, 1999, P NATL ACAD SCI USA, V96, P5522, DOI 10.1073/pnas.96.10.5522; SMITH KJ, 1994, CANCER RES, V54, P3672; Smits R, 1997, CARCINOGENESIS, V18, P321, DOI 10.1093/carcin/18.2.321; Smits R, 1999, GENE DEV, V13, P1309, DOI 10.1101/gad.13.10.1309; Sparks AB, 1998, CANCER RES, V58, P1130; SU LK, 1992, SCIENCE, V256, P668, DOI 10.1126/science.1350108; SU LK, 1993, SCIENCE, V262, P1734, DOI 10.1126/science.8259519; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; Umar A, 1998, GENETICS, V148, P1637; Willert K, 1998, CURR OPIN GENET DEV, V8, P95, DOI 10.1016/S0959-437X(98)80068-3; Yang K, 1997, J EXP ZOOL, V277, P245, DOI 10.1002/(SICI)1097-010X(19970215)277:3<245::AID-JEZ5>3.3.CO;2-N	60	39	44	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 23	2000	19	50					5755	5763		10.1038/sj.onc.1203962	http://dx.doi.org/10.1038/sj.onc.1203962			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	376VP	11126362				2022-12-25	WOS:000165477700007
J	Schmidt, K; Schrader, M; Kern, HF; Kleene, R				Schmidt, K; Schrader, M; Kern, HF; Kleene, R			Regulated apical secretion of zymogens in rat pancreas - Involvement of the glycosylphosphatidylinositol-anchored glycoprotein GP-2, the lectin ZG16p, and cholesterol-glycosphingolipid-enriched microdomains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INFLUENZA-VIRUS HEMAGGLUTININ; TRANS-GOLGI NETWORK; MDCK EPITHELIAL-CELLS; ACINAR-CELLS; TRANSMEMBRANE DOMAIN; GRANULE FORMATION; ENZYME PROTEINS; PLASMA-MEMBRANE; SORTING SIGNAL; BIOGENESIS	We examined the role of glycosphingolipid- and cholesterol-enriched microdomains, or rafts, in the sorting of digestive enzymes into zymogen granules destined for apical secretion and in granule formation. Isolated membranes of zymogen granules from pancreatic acinar cells showed an enrichment in cholesterol and sphingomyelin and formed detergent-insoluble glycolipid-enriched complexes. These complexes floated to the lighter fractions of sucrose density gradients and contained the glycosylphosphatidylinositol (GPI)-anchored glycoprotein GP-2, the lectin ZG16p, and sulfated matrix proteoglycans. Morphological and pulse-chase studies with isolated pancreatic lobules revealed that after inhibition of GPI-anchor biosynthesis by mannosamine or the fungal metabolite YW 3548, granule formation was impaired leading to an accumulation of newly synthesized proteins in the Golgi apparatus and the rough endoplasmic reticulum. Furthermore, the membrane attachment of matrix proteoglycans was diminished. After cholesterol depletion or inhibition of glycosphingolipid synthesis by fumonisin B1, the formation of zymogen granules as well as the formation of detergent-insoluble complexes was reduced. In addition, cholesterol depletion led to constitutive secretion of newly synthesized proteins, e.g. amylase, indicating that zymogens were missorted. Together, these data provide first evidence that in polarized acinar cells of the exocrine pancreas GPI-anchored proteins, e.g, GP-2, and cholesterol-sphingolipid-enriched microdomains are required for granule formation as well as for regulated secretion of zymogens and may function as sorting platforms for secretory proteins destined for apical delivery.	Univ Marburg, Dept Cell Biol & Cell Pathol, D-35033 Marburg, Germany	Philipps University Marburg	Schrader, M (corresponding author), Univ Marburg, Dept Cell Biol & Cell Pathol, Robert Koch Str 5, D-35033 Marburg, Germany.							Arvan P, 1998, BIOCHEM J, V332, P593, DOI 10.1042/bj3320593; Baldoni E, 1995, EUR J HISTOCHEM, V39, P253; BROWN DA, 1989, SCIENCE, V245, P1499, DOI 10.1126/science.2571189; BROWN DA, 1992, CELL, V68, P533, DOI 10.1016/0092-8674(92)90189-J; Chuang JZ, 1998, J CELL BIOL, V142, P1245, DOI 10.1083/jcb.142.5.1245; CRONSHAGEN U, 1994, EUR J CELL BIOL, V65, P366; DANIELSEN EM, 1995, BIOCHEMISTRY-US, V34, P1596, DOI 10.1021/bi00005a016; DANIELSEN EM, 1995, J CELL BIOL, V131, P939, DOI 10.1083/jcb.131.4.939; Dartsch H, 1998, EUR J CELL BIOL, V75, P211, DOI 10.1016/S0171-9335(98)80115-5; Dhanvantari S, 2000, J BIOL CHEM, V275, P29887, DOI 10.1074/jbc.M005364200; DITTIE A, 1992, EUR J CELL BIOL, V58, P243; FIEDLER K, 1995, CELL, V81, P309, DOI 10.1016/0092-8674(95)90380-1; Freedman SD, 1998, EUR J CELL BIOL, V75, P163, DOI 10.1016/S0171-9335(98)80058-7; FREEDMAN SD, 1993, BIOCHEM BIOPH RES CO, V197, P992, DOI 10.1006/bbrc.1993.2577; GORELICK FS, 1981, PHYSL GASTROINTESTIN, V2, P773; HANSEN LJ, 1983, P NATL ACAD SCI-BIOL, V80, P4379, DOI 10.1073/pnas.80.14.4379; Harder T, 1997, CURR OPIN CELL BIOL, V9, P534, DOI 10.1016/S0955-0674(97)80030-0; HEMPELMANN E, 1986, ELECTROPHORESIS, V7, P481, DOI 10.1002/elps.1150071011; HUMMEL BCW, 1959, CAN J BIOCHEM PHYS, V37, P1393, DOI 10.1139/o59-157; Huttner WB, 1995, COLD SPRING HARB SYM, V60, P315, DOI 10.1101/SQB.1995.060.01.036; Keller P, 1998, J CELL BIOL, V140, P1357, DOI 10.1083/jcb.140.6.1357; KILSDONK EPC, 1995, J BIOL CHEM, V270, P17250, DOI 10.1074/jbc.270.29.17250; Kleene R, 1999, EUR J CELL BIOL, V78, P79, DOI 10.1016/S0171-9335(99)80009-0; Kundu A, 1996, J VIROL, V70, P6508, DOI 10.1128/JVI.70.9.6508-6515.1996; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Laine J, 1996, J HISTOCHEM CYTOCHEM, V44, P481, DOI 10.1177/44.5.8627005; LEBLOND FA, 1993, BIOCHEM J, V291, P289, DOI 10.1042/bj2910289; Lin SS, 1998, J CELL BIOL, V142, P51, DOI 10.1083/jcb.142.1.51; LISANTI MP, 1989, J CELL BIOL, V109, P2145, DOI 10.1083/jcb.109.5.2145; LISANTI MP, 1991, EMBO J, V10, P1969, DOI 10.1002/j.1460-2075.1991.tb07726.x; MAYS RW, 1995, J CELL BIOL, V130, P1105, DOI 10.1083/jcb.130.5.1105; Neufeld EB, 1996, J BIOL CHEM, V271, P21604, DOI 10.1074/jbc.271.35.21604; New R.R., 1990, LIPOSOMES PRACTICAL; OHTANI Y, 1989, EUR J BIOCHEM, V186, P17, DOI 10.1111/j.1432-1033.1989.tb15171.x; RALTON JE, 1993, J BIOL CHEM, V268, P24183; RAUSCH U, 1987, CELL TISSUE RES, V247, P187, DOI 10.1007/BF00216561; RICK W, 1974, METHOD ENZYMAT AN, V1, P149; Rodriguez-Boulan E, 1999, TRENDS CELL BIOL, V9, P291, DOI 10.1016/S0962-8924(99)01595-0; Roper K, 2000, NAT CELL BIOL, V2, P582, DOI 10.1038/35023524; SCHEELE GA, 1994, PANCREAS, V9, P139, DOI 10.1097/00006676-199403000-00001; SCHEELE GA, 1975, J BIOL CHEM, V250, P2660; Scheiffele P, 1997, EMBO J, V16, P5501, DOI 10.1093/emboj/16.18.5501; Schmidt K, 2000, J CELL SCI, V113, P2233; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; SIMONS K, 1988, BIOCHEMISTRY-US, V27, P6197, DOI 10.1021/bi00417a001; Sun AQ, 1998, AM J PHYSIOL-GASTR L, V275, pG1045, DOI 10.1152/ajpgi.1998.275.5.G1045; Sutterlin C, 1997, EMBO J, V16, P6374, DOI 10.1093/emboj/16.21.6374; Thiele C, 1998, SEMIN CELL DEV BIOL, V9, P511, DOI 10.1006/scdb.1998.0259; Tooze SA, 1998, BBA-MOL CELL RES, V1404, P231, DOI 10.1016/S0167-4889(98)00059-7; WESSEL D, 1984, ANAL BIOCHEM, V138, P141, DOI 10.1016/0003-2697(84)90782-6	50	64	64	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 27	2001	276	17					14315	14323		10.1074/jbc.M006221200	http://dx.doi.org/10.1074/jbc.M006221200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	426PB	11152672	hybrid			2022-12-25	WOS:000168356600106
J	Shaked, GM; Meiner, Z; Avraham, I; Taraboulos, A; Gabizon, R				Shaked, GM; Meiner, Z; Avraham, I; Taraboulos, A; Gabizon, R			Reconstitution of prion infectivity from solubilized protease-resistant PrP and nonprotein components of prion rods	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INCUBATION PERIOD; SCRAPIE INFECTIVITY; MASS-SPECTROMETRY; CULTURED-CELLS; PROTEINS; ISOFORM; AGENT; CONFORMATIONS; ACCUMULATION; MOLECULES	The scrapie isoform of the prion protein, PrPSc, is the only identified component of the infectious prion, an agent causing neurodegenerative diseases such as Creutzfeldt-Jakob disease and bovine spongiform encephalopathy, Following proteolysis, PrPSc is trimmed to a fragment designated PrP 27-30, Both PrPSc and PrP 27-30 molecules tend to aggregate and precipitate as amyloid rods when membranes from prion-infected brain are extracted with detergents. Although prion rods mere also shown to contain lipids and sugar polymers, no physiological role has yet been attributed, to these molecules. In this work, we show that prion infectivity can be reconstituted by combining Me2SO-solubilized PrP 27-30, which at best contained low prion infectivity, with nonprotein components of prion rods (heavy fraction after deproteination, originating from a scrapie-infected hamster brain), which did not present any infectivity. Whereas heparanase digestion of the heavy fraction after deproteination (originating from a scrapie-infected hamster brain), before its combination with solubilized PrP 27-30, considerably reduced the reconstitution of infectivity, preliminary results suggest that infectivity can be greatly increased by combining nonaggregated protease-resistant PrP with heparan sulfate, a known component of amyloid plaques in the brain. We submit that whereas PrP 27-30 is probably the obligatory template for the conversion of Pr-Pc to PrPSc, sulfated sugar polymers may play an important role in the pathogenesis of prion diseases.	Hadassah Univ Hosp, Agnes Ginges Ctr Human Neurogenet, Dept Neurol, IL-91120 Jerusalem, Israel; Hebrew Univ Jerusalem, Sch Med, Dept Mol Biol, IL-91120 Jerusalem, Israel	Hebrew University of Jerusalem; Hebrew University of Jerusalem	Gabizon, R (corresponding author), Hadassah Univ Hosp, Agnes Ginges Ctr Human Neurogenet, Dept Neurol, IL-91120 Jerusalem, Israel.							Appel TR, 1999, BIOL CHEM, V380, P1295, DOI 10.1515/BC.1999.165; BESSEN RA, 1994, J VIROL, V68, P7859, DOI 10.1128/JVI.68.12.7859-7868.1994; CAUGHEY B, 1994, J VIROL, V68, P2135, DOI 10.1128/JVI.68.4.2135-2141.1994; CAUGHEY B, 1993, J VIROL, V67, P643, DOI 10.1128/JVI.67.2.643-650.1993; Cohen FE, 1998, ANNU REV BIOCHEM, V67, P793, DOI 10.1146/annurev.biochem.67.1.793; DEARMOND SJ, 1993, P NATL ACAD SCI USA, V90, P6449, DOI 10.1073/pnas.90.14.6449; EHLERS B, 1984, J GEN VIROL, V65, P1325, DOI 10.1099/0022-1317-65-8-1325; FARQUHAR CF, 1986, J GEN VIROL, V67, P463, DOI 10.1099/0022-1317-67-3-463; GABIZON R, 1987, P NATL ACAD SCI USA, V84, P4017, DOI 10.1073/pnas.84.12.4017; GABIZON R, 1993, J CELL PHYSIOL, V157, P319, DOI 10.1002/jcp.1041570215; Hill AF, 1999, J GEN VIROL, V80, P11, DOI 10.1099/0022-1317-80-1-11; Hill AF, 1997, NATURE, V389, P448, DOI 10.1038/38925; JEFFREY M, 1992, NEUROSCI LETT, V147, P106, DOI 10.1016/0304-3940(92)90785-6; KANEKO K, 1995, P NATL ACAD SCI USA, V92, P11160, DOI 10.1073/pnas.92.24.11160; KASCSAK RJ, 1985, J GEN VIROL, V66, P1715, DOI 10.1099/0022-1317-66-8-1715; KASCSAK RJ, 1987, J VIROL, V61, P3688, DOI 10.1128/JVI.61.12.3688-3693.1987; KELLINGS K, 1992, J GEN VIROL, V73, P1025, DOI 10.1099/0022-1317-73-4-1025; KIMBERLIN RH, 1986, J GEN VIROL, V67, P255, DOI 10.1099/0022-1317-67-2-255; Klein TR, 1998, BIOL CHEM, V379, P655, DOI 10.1515/bchm.1998.379.6.655; KOCISKO DA, 1994, NATURE, V370, P471, DOI 10.1038/370471a0; LADOGANA A, 1992, J GEN VIROL, V73, P661, DOI 10.1099/0022-1317-73-3-661; Lasmezas CI, 1997, SCIENCE, V275, P402, DOI 10.1126/science.275.5298.402; MEYER RK, 1986, P NATL ACAD SCI USA, V83, P2310, DOI 10.1073/pnas.83.8.2310; MICHEL B, 1987, REV NEUROL, V143, P526; PAN KM, 1993, P NATL ACAD SCI USA, V90, P10962, DOI 10.1073/pnas.90.23.10962; PRUSINER SB, 1980, BIOCHEMISTRY-US, V19, P4883, DOI 10.1021/bi00562a028; Prusiner SB, 1998, BRAIN PATHOL, V8, P499; Riesner D, 1996, J VIROL, V70, P1714, DOI 10.1128/JVI.70.3.1714-1722.1996; Safar J, 1998, NAT MED, V4, P1157, DOI 10.1038/2654; Shaked GM, 1999, J BIOL CHEM, V274, P17981, DOI 10.1074/jbc.274.25.17981; SHYNG SL, 1995, J BIOL CHEM, V270, P30221; SNOW AD, 1988, AM J PATHOL, V133, P456; STAHL N, 1993, BIOCHEMISTRY-US, V32, P1991, DOI 10.1021/bi00059a016; Supattapone S, 1999, P NATL ACAD SCI USA, V96, P14529, DOI 10.1073/pnas.96.25.14529; Telling GC, 1996, SCIENCE, V274, P2079, DOI 10.1126/science.274.5295.2079	35	57	58	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 27	2001	276	17					14324	14328		10.1074/jbc.M007815200	http://dx.doi.org/10.1074/jbc.M007815200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	426PB	11152454	hybrid			2022-12-25	WOS:000168356600107
J	Denisov, IG; Makris, TM; Sligar, SG				Denisov, IG; Makris, TM; Sligar, SG			Cryotrapped reaction intermediates of cytochrome P450 studied by radiolytic reduction with phosphorus-32	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ONE-ELECTRON REDUCTION; SPECTROSCOPY; EPR; HEMOGLOBIN; MECHANISM; PORPHYRIN; MOSSBAUER; COMPOUND; P-450CAM; PROTEIN	Unstable reaction intermediates of the cytochrome P450 catalytic cycle have been prepared at cryogenic temperatures using radiolytic one-electron reduction of the oxy-P450 CYP101 complex. Since a rate-limiting step in the catalytic cycle of the enzyme is the reduction of the ferrous oxygenated heme protein, subsequent reaction intermediates do not normally accumulate. Using Co-60 gamma -irradiation, the primary reduced oxy-P450 species at 77 K has been identified as a superoxo- or hydroperoxo-Fe3+-heme complex (Davydov, R., Macdonald, I. D, G,, Makris, T, M., Sligar, S. G., and Hoffman, B, M. (1999) J, Am. Chem. Sec. 121, 10654-10655). The electronic absorption spectroscopy is an essential tool to characterize cytochrome P450 intermediates and complements paramagnetic methods, which are blind to important diamagnetic or antiferromagnetically coupled states. We report a method of trapping unstable states of redox enzymes using phosphorus-32 as an internal source of electrons. me determine the W-visible optical spectra of the reduced oxygenated state of CYP101 and show that the primary intermediate, a hydroperoxo-P450, is stable below 180 K and converts smoothly to the product complex at similar to 195 K, In the course of the thermal annealing, no spectral changes indicating the presence of oxoferryl species (the so-called compound I type spectrum) was observed.	Univ Illinois, Beckman Inst Adv Sci & Technol, Urbana, IL 61801 USA; Univ Illinois, Dept Biochem, Urbana, IL 61801 USA; Univ Illinois, Ctr Biophys & Computat Biol, Urbana, IL 61801 USA	University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign	Sligar, SG (corresponding author), Univ Illinois, Beckman Inst Adv Sci & Technol, 405 N Mathews Ave, Urbana, IL 61801 USA.	s-sligar@uiuc.edu	Denisov, Ilia G/J-6590-2013; Denisov, Gleb S/J-6549-2013; Makris, Thomas/W-9965-2019	Denisov, Ilia G/0000-0002-7878-2626; Denisov, Gleb S/0000-0002-1246-0552; Makris, Thomas/0000-0001-7927-620X	NIGMS NIH HHS [GM33773, GM31756] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM031756, R01GM031756] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BEREZIN IV, 1964, RUSS J PHYS CHEM, V38, P1468; BLUMENFELD LA, 1979, BIOCHIM BIOPHYS ACTA, V549, P255, DOI 10.1016/0304-4173(79)90002-8; Brugna M, 2000, P NATL ACAD SCI USA, V97, P2069, DOI 10.1073/pnas.030539897; CHAMPION PM, 1989, J AM CHEM SOC, V111, P3433, DOI 10.1021/ja00191a053; Cunningham ID, 1999, J CHEM SOC PERK T 2, P2133, DOI 10.1039/a903511g; Davydov R, 1999, J AM CHEM SOC, V121, P10654, DOI 10.1021/ja9918829; DAVYDOV R, 1994, J AM CHEM SOC, V116, P11120, DOI 10.1021/ja00103a029; Davydov R, 2001, J AM CHEM SOC, V123, P1403, DOI 10.1021/ja003583l; DAVYDOV R, 1991, FEBS LETT, V295, P113, DOI 10.1016/0014-5793(91)81398-R; Davydov RM, 1999, J AM CHEM SOC, V121, P10656, DOI 10.1021/ja992425v; DAVYDOV RM, 1978, MOL BIOL+, V12, P1037; de Montellano Ortiz, CYTOCHROME P450 STRU; DEMONTELLANO O, 1995, PR; DIPRIMO C, 1992, FEBS LETT, V312, P252, DOI 10.1016/0014-5793(92)80946-E; FESSENDEN RW, 1970, ADV RADIAT CHEM, V7, P1; GASYNA Z, 1979, BIOCHIM BIOPHYS ACTA, V577, P207, DOI 10.1016/0005-2795(79)90022-9; GASYNA Z, 1979, FEBS LETT, V106, P213, DOI 10.1016/0014-5793(79)80730-9; Green MT, 1999, J AM CHEM SOC, V121, P7939, DOI 10.1021/ja991541v; GRESCHNER S, 1979, ACTA BIOL MED GER, V38, P443; Groves John T., 1995, P3; HARDWICK TJ, 1952, CAN J CHEM, V30, P39, DOI 10.1139/v52-005; Harris D, 1998, J AM CHEM SOC, V120, P4308, DOI 10.1021/ja974110q; Karlsson A, 2000, J INORG BIOCHEM, V78, P83, DOI 10.1016/S0162-0134(99)00213-5; Khriachtchev L, 2000, NATURE, V406, P874, DOI 10.1038/35022551; KOBAYASHI K, 1987, J BIOL CHEM, V262, P5445; Kolodziejski M, 1997, J MOL STRUCT, V437, P543, DOI 10.1016/S0022-2860(97)00221-4; MAGONOV SN, 1978, MOL BIOL+, V12, P913; MAGONOV SN, 1978, MOL BIOL+, V12, P919; MAGONOV SN, 1978, MOL BIOL+, V12, P725; Newcomb M, 2000, ACCOUNTS CHEM RES, V33, P449, DOI 10.1021/ar960058b; Oshtrakh MI, 1999, RADIAT PHYS CHEM, V55, P549, DOI 10.1016/S0969-806X(99)00300-X; PEISACH M, 1960, NATURE, V187, P58, DOI 10.1038/187058a0; PRUSAKOV VE, 1985, FEBS LETT, V186, P158, DOI 10.1016/0014-5793(85)80700-6; Schlichting I, 2000, SCIENCE, V287, P1615, DOI 10.1126/science.287.5458.1615; SCHULER RH, 1956, J CHEM PHYS, V24, P56, DOI 10.1063/1.1700854; Shibata Y, 1999, BIOCHEMISTRY-US, V38, P1789, DOI 10.1021/bi9815694; Spinks J. W. T., 1990, INTRO RAD CHEM, P364; SYMONS MCR, 1978, PROC R SOC SER B-BIO, V201, P285, DOI 10.1098/rspb.1978.0046; SYMONS MCR, 1989, J CHEM SOC FARAD T 1, V85, P2427, DOI 10.1039/f19898502427; TURNER JJ, 1963, SCIENCE, V140, P974, DOI 10.1126/science.140.3570.974-a; UNGER BP, 1986, J BIOL CHEM, V261, P1158; Urano Y, 1997, J AM CHEM SOC, V119, P12008, DOI 10.1021/ja972892h; WATANABE Y, 2000, PORPHYRIN HDB, V4, P97; YAMAMOTO O, 1982, INT J RADIAT BIOL, V42, P661, DOI 10.1080/09553008214551631	44	92	93	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 13	2001	276	15					11648	11652		10.1074/jbc.M010219200	http://dx.doi.org/10.1074/jbc.M010219200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	421UK	11152470	hybrid			2022-12-25	WOS:000168081800032
J	Kim, YS; Min, JK; Kim, D; Jung, J				Kim, YS; Min, JK; Kim, D; Jung, J			A soluble auxin-binding protein, ABP(57) - Purification with anti-bovine serum albumin antibody and characterization of its mechanistic role in the auxin effect on plant plasma membrane H+-ATPase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCED CELL ELONGATION; C-TERMINAL REGION; PHOSPHORYLATION; IDENTIFICATION; RECEPTORS; KINASE; GROWTH; SIGNAL	ABP(57) is an aurin-binding protein that possesses receptor function. In this study, a protocol for ABP(57) purification was developed on the basis of cross-reactivity shown between ABP(57) and antisera raised against bovine serum albumin, which enabled us to purify ABP(57) with a high yield and to further characterize it. ABP(57) activates plant plasma membrane H+-ATPase (PM H+- ATPase) via direct interaction. The binding of indole-3-acetic acid (IAA) to the primary binding site on ABP(57) caused a marked increase in the affinity of ABP(57) for PM H+-ATPase, which was accompanied by a change in ABP(57) conformation. Meanwhile, additional IAA binding to the secondary site on ABP(57) nullified the initial effect without inducing further conformational change. When ABP(57) with IAA occupying only the primary site interacted with PM H+-ATPase, no IAA could access the secondary site. These results suggest that IAA induced biphasic alteration in the affinity of ABP(57) for PM H+-ATPase correlates with a bell-shaped dose response of the enzyme to IAA, There is also a possibility that, whereas the stimulation phase of the response is associated with a conformational change of ABP` the de-stimulation phase probably results from hindrance arising directly from the presence of IAA at the secondary site.	Seoul Natl Univ, Sch Agr Biotechnol, Suwon 441744, South Korea; Natl Inst Agr Sci & Technol, Div Biochem, Suwon 441100, South Korea	Seoul National University (SNU)	Jung, J (corresponding author), Seoul Natl Univ, Sch Agr Biotechnol, Suwon 441744, South Korea.	jinjung@snu.ac.kr		Min, Jungki/0000-0003-1860-3064				BARBIERBRYGOO H, 1995, CRIT REV PLANT SCI, V14, P1, DOI 10.1080/713608067; BARBIERBRYGOO H, 1991, PLANT J, V1, P83, DOI 10.1111/j.1365-313X.1991.00083.x; BARRIERBRYGOO H, 1989, P NATL ACAD SCI USA, V86, P891, DOI 10.1073/pnas.86.3.891; Baunsgaard L, 1998, PLANT J, V13, P661, DOI 10.1046/j.1365-313X.1998.00083.x; Bertuzzi A, 1997, CLIN CHIM ACTA, V265, P183, DOI 10.1016/S0009-8981(97)00117-4; BRAHMS S, 1977, P NATL ACAD SCI USA, V74, P3208, DOI 10.1073/pnas.74.8.3208; CLELAND R, 1972, PLANTA, V104, P1, DOI 10.1007/BF00387679; CROSS JW, 1991, NEW BIOL, V3, P813; DUFOUR JP, 1988, METHOD ENZYMOL, V157, P513; Fuglsang AT, 1999, J BIOL CHEM, V274, P36774, DOI 10.1074/jbc.274.51.36774; Fullone MR, 1998, J BIOL CHEM, V273, P7698, DOI 10.1074/jbc.273.13.7698; HARLOW E, 1988, ANTIBODIES; Jahn T, 1997, PLANT CELL, V9, P1805, DOI 10.1105/tpc.9.10.1805; JOHNSON WC, 1972, J AM CHEM SOC, V94, P4389, DOI 10.1021/ja00767a084; JONES AM, 1992, BIOESSAYS, V14, P43, DOI 10.1002/bies.950140109; KARZ W, 1990, PHYSIOL PLANTARUM, V80, P257; Kim YS, 1998, FEBS LETT, V438, P241, DOI 10.1016/S0014-5793(98)01307-6; KIM YS, 2000, IN PRESS PLANT GROWT; KLAMBT D, 1990, PLANT MOL BIOL, V14, P1045, DOI 10.1007/BF00019401; LARSSON C, 1987, METHOD ENZYMOL, V148, P558; MATTSON G, 1993, MOL BIOL REP, V17, P167, DOI 10.1007/BF00986726; Maudoux O, 2000, J BIOL CHEM, V275, P17762, DOI 10.1074/jbc.M909690199; Oecking C, 1997, PLANT J, V12, P441, DOI 10.1046/j.1365-313X.1997.12020441.x; PALMGREN MG, 1990, PLANT PHYSIOL, V92, P871, DOI 10.1104/pp.92.4.871; PALMGREN MG, 1990, PLANT PHYSIOL, V94, P882, DOI 10.1104/pp.94.3.882; PALMGREN MG, 1991, J BIOL CHEM, V266, P20470; Peters Jr T., 1996, ALL ALBUMIN BIOCH GE, P76, DOI DOI 10.1016/B978-012552110-9/50005-2; Pittz E P, 1973, Methods Enzymol, V27, P209; RADERMACHER E, 1993, J PLANT PHYSIOL, V141, P698, DOI 10.1016/S0176-1617(11)81577-4; RAYLE DL, 1992, PLANT PHYSIOL, V99, P1271, DOI 10.1104/pp.99.4.1271; SANTONI V, 1991, PLANTA, V185, P227, DOI 10.1007/BF00194065; SCHERER GFE, 1993, PLANTA, V191, P515, DOI 10.1007/BF00195753; SERRANO R, 1988, METHOD ENZYMOL, V157, P533; SHEN WH, 1988, P NATL ACAD SCI USA, V85, P3417, DOI 10.1073/pnas.85.10.3417; Svennelid F, 1999, PLANT CELL, V11, P2379, DOI 10.1105/tpc.11.12.2379; Sze H, 1999, PLANT CELL, V11, P677, DOI 10.1105/tpc.11.4.677; VENIS MA, 1995, CRIT REV PLANT SCI, V14, P27, DOI 10.1080/713608065; VERGHESE GM, 1994, J BIOL CHEM, V269, P9361; Yi HJ, 1996, PHYSIOL PLANTARUM, V96, P359, DOI 10.1111/j.1399-3054.1996.tb00445.x	39	49	57	0	0	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 6	2001	276	14					10730	10736		10.1074/jbc.M009416200	http://dx.doi.org/10.1074/jbc.M009416200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	420AC	11154693	hybrid			2022-12-25	WOS:000167980900024
J	Savinainen, A; Garcia, EP; Dorow, D; Marshall, J; Liu, YF				Savinainen, A; Garcia, EP; Dorow, D; Marshall, J; Liu, YF			Kainate receptor activation induces mixed lineage kinase-mediated cellular signaling cascades via post-synaptic density protein 95	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCED APOPTOSIS; PSD-95; HIPPOCAMPUS; HUNTINGTON; EXPRESSION; SEIZURES; FAMILY; MEMBER; MICE	Kainate receptor glutamate receptor 6 (GluR6) subunit-deficient and c-Jun N-terminal kinase 3 (JNK3)-null mice share similar phenotypes including resistance to kainite-induced epileptic seizures and neuronal toxicity (Yang, D. D., Kuan, C-Y., Whitmarsh, A. J., Rincon, M., Zheng, T. S., Davis, R. J., Rakis, P., and Flavell, R. (1997) Nature 389, 865-869; Mulle, C., Seiler, A. Perez-Otano, I., Dickinson-Anson, H., Castillo, P. E., Bureau, I., Maron, C., Gage, F. H., Mann, J. R., Bettler, B., and Heinemmann, S.F. (1998) Nature 392, 601-605). This suggests that JNK activation may be involved in GluR6-mediated excitotoxicity. We provide evidence that postsynaptic density protein (PSD-95) links GluR6 to JNK activation by anchoring mixed lineage kinase (MLK) 2 or MLK3, upstream activators of JNKs, to the receptor complex. Association of MLK2 and MLK3 with PSD-95 in HN33 cells and rat brain preparations is dependent upon the SH3 domain of PSD-95, and expression of GluR6 in HN33 cells activated JNKs and induced neuronal apoptosis. Deletion of the PSD-BB-binding site of GluR6 reduced both JNK activation and neuronal toxicity. Co-expression of dominant negative MLK2, MLK3, or mitogen-activated kinase kinase (MKK) 4 and MKK7 also significantly attenuated JNK activation and neuronal toxicity mediated by GluR6, and co-expression of PSD-95 with a deficient Src homology 3 domain also inhibited GluR6-induced JNK activation and neuronal toxicity. Our results suggest that PSD-95 plays a critical role in GluR6-mediated JNK activation and excitotoxicity by anchoring MLK to the receptor complex.	Northeastern Univ, Dept Pharmaceut Sci, Boston, MA 02115 USA; Brown Univ, Dept Mol Pharmacol Physiol & Biotechnol, Providence, RI USA; Peter MacCallum Canc Inst, Trecowthick Res Ctr, Melbourne, Vic 3000, Australia	Northeastern University; Brown University; Peter Maccallum Cancer Center	Liu, YF (corresponding author), Northeastern Univ, Dept Pharmaceut Sci, 312 Mugar Hall,360 Huntington Ave, Boston, MA 02115 USA.	yafliu@lynx.neu.edu						BEAL MF, 1986, NATURE, V321, P168, DOI 10.1038/321168a0; Brenman JE, 1996, CELL, V84, P757, DOI 10.1016/S0092-8674(00)81053-3; Cha JHJ, 1999, PHILOS T R SOC B, V354, P981, DOI 10.1098/rstb.1999.0449; Chittajallu R, 1999, TRENDS PHARMACOL SCI, V20, P26, DOI 10.1016/S0165-6147(98)01286-3; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; Frerking M, 2000, CURR OPIN NEUROBIOL, V10, P342, DOI 10.1016/S0959-4388(00)00094-5; Garcia EP, 1998, NEURON, V21, P727, DOI 10.1016/S0896-6273(00)80590-5; Hirai S, 1997, J BIOL CHEM, V272, P15167, DOI 10.1074/jbc.272.24.15167; HOLLMANN M, 1994, ANNU REV NEUROSCI, V17, P31, DOI 10.1146/annurev.ne.17.030194.000335; Kawasaki H, 1997, J BIOL CHEM, V272, P18518, DOI 10.1074/jbc.272.30.18518; Kim E, 1996, NEURON, V17, P103, DOI 10.1016/S0896-6273(00)80284-6; KORNAU HC, 1995, SCIENCE, V269, P1737, DOI 10.1126/science.7569905; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; Liu YF, 1998, J BIOL CHEM, V273, P28873, DOI 10.1074/jbc.273.44.28873; Liu YF, 1997, J BIOL CHEM, V272, P8121, DOI 10.1074/jbc.272.13.8121; Liu YF, 2000, J BIOL CHEM, V275, P19035, DOI 10.1074/jbc.C000180200; MacDonald ME, 1999, NEUROLOGY, V53, P1330, DOI 10.1212/WNL.53.6.1330; Migaud M, 1998, NATURE, V396, P433, DOI 10.1038/24790; Mulle C, 1998, NATURE, V392, P601, DOI 10.1038/33408; Nagata K, 1998, EMBO J, V17, P149, DOI 10.1093/emboj/17.1.149; NIETHAMMER M, 1997, NEURON, V16, P2157; Rubinsztein DC, 1997, P NATL ACAD SCI USA, V94, P3872, DOI 10.1073/pnas.94.8.3872; Sattler R, 1999, SCIENCE, V284, P1845, DOI 10.1126/science.284.5421.1845; Schauwecker PE, 2000, BRAIN RES, V884, P116, DOI 10.1016/S0006-8993(00)02888-2; Telfeian AE, 2000, NEUROBIOL DIS, V7, P362, DOI 10.1006/nbdi.2000.0294; Tezuka T, 1999, P NATL ACAD SCI USA, V96, P435, DOI 10.1073/pnas.96.2.435; WAGSTER MV, 1994, EXP NEUROL, V127, P70, DOI 10.1006/exnr.1994.1081; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Yang DD, 1997, NATURE, V389, P865, DOI 10.1038/39899	29	98	103	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 6	2001	276	14					11382	11386		10.1074/jbc.M100190200	http://dx.doi.org/10.1074/jbc.M100190200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	420AC	11152698	hybrid			2022-12-25	WOS:000167980900109
J	Russell, SJ; Johnston, SA				Russell, SJ; Johnston, SA			Evidence that proteolysis of Ga14 cannot explain the transcriptional effects of proteasome ATPase mutations	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; MEDIATED DEGRADATION; REGULATORY PARTICLE; ACTIVATION DOMAIN; YEAST PROTEASOME; 26-S PROTEASE; 26S PROTEASE; SUBUNIT; FAMILY; CODES	The Gal system of Saccharomyces cerevisiae is a paradigm for eukaryotic gene regulation. Expression of genes required for growth on galactose is regulated by the transcriptional activator Ga14. The activation function of Ga14 has been localized to 34 amino acids near the C terminus of the protein. The gal4D allele of GAL4 encodes a truncated protein in which only 14 amino acids of the activation domain remain. Expression of GAL genes is dramatically reduced in gal4D strains and these strains are unable to grow on galactose as the sole carbon source. Overexpression of gal4D partially relieves the defect in GAL gene expression and allows growth on galactose. A search for extragenic suppressors of gal4D identified recessive mutations in the SUG1 and SUG2 genes, which encode ATPases of the 19S regulatory complex of the proteasome. The proteasome is responsible for the ATP-dependent degradation of proteins marked for destruction by the ubiquitin system. It has been commonly assumed that effects of SUGI and SUG2 mutations on transcription are explained by alterations in the proteolysis of gal4D protein. We have investigated this assumption. Surprisingly, we find that SUGI and SUG2 alleles that are unable to suppress gal4D cause a larger increase in gal4D protein levels than do suppressing alleles. in addition, mutations in genes encoding subunits of the proteolytic 20S sub-complex of the proteasome increase the levels of gal4D protein but do not rescue its transcriptional activity, Therefore, an alteration in the proteolysis of gal4D by the proteasome cannot explain the effects of mutations in SUGI and SUG2 on expression of GAL genes. These findings suggest that the 19S regulatory complex may play a more direct role in transcription.	Univ Texas, SW Med Ctr, Dept Internal Med, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Biochem, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Biochem & Mol Biol Grad Program, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Johnston, SA (corresponding author), Univ Texas, SW Med Ctr, Dept Internal Med, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	stephen.johnston@utsouthwestern.edu						Beyer A, 1997, PROTEIN SCI, V6, P2043; Braun BC, 1999, NAT CELL BIOL, V1, P221, DOI 10.1038/12043; CONFALONIERI F, 1995, BIOESSAYS, V17, P639, DOI 10.1002/bies.950170710; DUBIEL W, 1994, BIOL CHEM H-S, V375, P237, DOI 10.1515/bchm3.1994.375.4.237; DUBIEL W, 1993, FEBS LETT, V323, P276, DOI 10.1016/0014-5793(93)81356-5; DUBIEL W, 1992, J BIOL CHEM, V267, P22699; GHISLAIN M, 1993, NATURE, V366, P358, DOI 10.1038/366358a0; Glickman MH, 1998, MOL CELL BIOL, V18, P3149, DOI 10.1128/MCB.18.6.3149; Guthrie C., 1991, GUIDE YEAST GENETICS, P194; HEINEMEYER W, 1993, J BIOL CHEM, V268, P5115; HILT W, 1993, J BIOL CHEM, V268, P3479; LEVCHENKO I, 1995, GENE DEV, V9, P2399, DOI 10.1101/gad.9.19.2399; Masuyama H, 1998, J CELL BIOCHEM, V71, P429, DOI 10.1002/(SICI)1097-4644(19981201)71:3<429::AID-JCB11>3.0.CO;2-P; MATSUMOTO K, 1980, J BACTERIOL, V141, P508, DOI 10.1128/JB.141.2.508-527.1980; MCCUSKER JH, 1988, GENETICS, V119, P303; MCCUSKER JH, 1988, GENETICS, V119, P317; MHAMMEDIALAOUI A, 1994, MOL MICROBIOL, V11, P1109, DOI 10.1111/j.1365-2958.1994.tb00387.x; Molinari E, 1999, EMBO J, V18, P6439, DOI 10.1093/emboj/18.22.6439; RUBIN DM, 1995, CURR BIOL, V5, P854, DOI 10.1016/S0960-9822(95)00172-2; Rubin DM, 1996, NATURE, V379, P655, DOI 10.1038/379655a0; Russell SJ, 1999, J BIOL CHEM, V274, P21943, DOI 10.1074/jbc.274.31.21943; Russell SJ, 1996, J BIOL CHEM, V271, P32810, DOI 10.1074/jbc.271.51.32810; Russell SJ, 1999, MOL CELL, V3, P687, DOI 10.1016/S1097-2765(01)80001-0; RUSSELL SJ, 1999, THESIS U TEXAS SW ME; St-Arnaud R, 1999, J CELL BIOCHEM, P32; Swaffield JC, 1996, NATURE, V379, P658, DOI 10.1038/379658a0; SWAFFIELD JC, 1992, NATURE, V357, P698, DOI 10.1038/357698a0; THOMAS BJ, 1989, CELL, V56, P619, DOI 10.1016/0092-8674(89)90584-9; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WEISSMAN JS, 1995, SCIENCE, V268, P523, DOI 10.1126/science.7725096; WENZEL T, 1995, NAT STRUCT BIOL, V2, P199, DOI 10.1038/nsb0395-199; XU QL, 1995, MOL CELL BIOL, V15, P6025	32	34	35	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 30	2001	276	13					9825	9831		10.1074/jbc.M010889200	http://dx.doi.org/10.1074/jbc.M010889200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	420GC	11152478	hybrid			2022-12-25	WOS:000167996400034
J	Wan, M; Shi, XM; Feng, X; Cao, X				Wan, M; Shi, XM; Feng, X; Cao, X			Transcriptional mechanisms of bone morphogenetic protein-induced osteoprotegrin gene expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OSTEOCLASTOGENESIS-INHIBITORY FACTOR; MESSENGER-RNA LEVELS; TRANSFORMING GROWTH-FACTOR-BETA-1; SMAD PROTEINS; FACTOR OCIF; CELL-LINE; DIFFERENTIATION; MARROW; ACTIVATION; C3H10T1/2	Osteoprotegerin (OPG), an osteoblast-secreted decoy receptor, specifically binds to osteoclast differentiation factor and inhibits osteoclast maturation. Members of the transforming growth factor-beta superfamily including bone morphogenetic proteins (SMPs) stimulate OPG mRNA expression. In this study, we have characterized the transcription mechanism of BMP-induced OPG gene expression. Transfection of Smadl and a constitutively active BMP type IA receptor ALK3 (Q233) stimulated the OPG promoter. Deletion analysis of the OPG promoter identified two Hoxc-8 binding sites that respond to BMP stimulation. Glutathione S-transferase-Hoxc-8 protein binds to these two Hox sites specifically. Consistent with the transfection results of the native promoter, ALK3 or Smadl linker region, which interacts with Hoxc-8, stimulated the activation of the reporter construct with the two Hox sites. Overexpression of Hoxc-8 inhibited the induced promoter activity. When the two Hox binding sites were mutated, ALK3 or Smadl linker region no longer activated the transcription. Importantly, Smadl linker region induced both OPG promoter activity and endogenous OPG protein expression in 2T3 osteoblastic cells. The medium from cells transfected with Smadl linker region expression plasmid effectively inhibited osteoclastogenesis. Collectively, our data indicate that Hox sites mediate both OPG promoter construct activity and endogenous OPG gene expression in response to BMP stimulation.	Univ Alabama Birmingham, Dept Pathol, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham	Cao, X (corresponding author), 1670 Univ Blvd,VH G002, Birmingham, AL 35294 USA.	Cao@path.uab.edu			NIDDK NIH HHS [DK 53757] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK053757] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AHRENS M, 1993, DNA CELL BIOL, V12, P871, DOI 10.1089/dna.1993.12.871; BIZZARRI C, 1994, J BIOL CHEM, V269, P13817; Brandstrom H, 1998, BIOCHEM BIOPH RES CO, V247, P338, DOI 10.1006/bbrc.1998.8783; Brandstrom H, 1998, BIOCHEM BIOPH RES CO, V248, P454, DOI 10.1006/bbrc.1998.8993; Bucay N, 1998, GENE DEV, V12, P1260, DOI 10.1101/gad.12.9.1260; CHAMBERS TJ, 1993, P NATL ACAD SCI USA, V90, P5578, DOI 10.1073/pnas.90.12.5578; FENG JQ, 1995, J BIOL CHEM, V270, P28364, DOI 10.1074/jbc.270.47.28364; Hakeda Y, 1998, BIOCHEM BIOPH RES CO, V251, P796, DOI 10.1006/bbrc.1998.9523; Hofbauer LC, 1998, BIOCHEM BIOPH RES CO, V250, P776, DOI 10.1006/bbrc.1998.9394; Hoodless PA, 1996, CELL, V85, P489, DOI 10.1016/S0092-8674(00)81250-7; HOROWITZ MC, 1993, SCIENCE, V260, P626, DOI 10.1126/science.8480174; KATAGIRI T, 1990, BIOCHEM BIOPH RES CO, V172, P295, DOI 10.1016/S0006-291X(05)80208-6; Kawabata M, 1998, EMBO J, V17, P4056, DOI 10.1093/emboj/17.14.4056; Kim J, 1997, NATURE, V388, P304, DOI 10.1038/40906; Kong YY, 1999, NATURE, V402, P304, DOI 10.1038/35005552; Kong YY, 1999, NATURE, V397, P315, DOI 10.1038/16852; Kretzschmar M, 1997, GENE DEV, V11, P984, DOI 10.1101/gad.11.8.984; Kwon BS, 1998, FASEB J, V12, P845, DOI 10.1096/fasebj.12.10.845; Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092-8674(00)81569-X; MANOLAGAS SC, 1995, NEW ENGL J MED, V332, P305, DOI 10.1056/NEJM199502023320506; Massague J, 2000, EMBO J, V19, P1745, DOI 10.1093/emboj/19.8.1745; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; McHugh KP, 2000, J CLIN INVEST, V105, P433, DOI 10.1172/JCI8905; Mizuno A, 1998, BIOCHEM BIOPH RES CO, V247, P610, DOI 10.1006/bbrc.1998.8697; Murakami T, 1998, BIOCHEM BIOPH RES CO, V252, P747, DOI 10.1006/bbrc.1998.9723; Schmitt JM, 1999, J ORTHOPAED RES, V17, P269, DOI 10.1002/jor.1100170217; Shi XM, 1999, J BIOL CHEM, V274, P13711, DOI 10.1074/jbc.274.19.13711; Simonet WS, 1997, CELL, V89, P309, DOI 10.1016/S0092-8674(00)80209-3; STERNER JM, 1995, J BIOL CHEM, V270, P9281, DOI 10.1074/jbc.270.16.9281; SUDA T, 1992, ENDOCR REV, V13, P66, DOI 10.1210/er.13.1.66; Takai H, 1998, J BIOL CHEM, V273, P27091, DOI 10.1074/jbc.273.42.27091; Tsuda E, 1997, BIOCHEM BIOPH RES CO, V234, P137, DOI 10.1006/bbrc.1997.6603; Verschueren K, 1999, J BIOL CHEM, V274, P20489, DOI 10.1074/jbc.274.29.20489; Vidal ONA, 1998, BIOCHEM BIOPH RES CO, V248, P696, DOI 10.1006/bbrc.1998.9035; WANG EA, 1990, P NATL ACAD SCI USA, V87, P2220, DOI 10.1073/pnas.87.6.2220; Wrana JL, 2000, CELL, V100, P189, DOI 10.1016/S0092-8674(00)81556-1; Yang XL, 2000, J BIOL CHEM, V275, P1065, DOI 10.1074/jbc.275.2.1065; Yasuda H, 1998, ENDOCRINOLOGY, V139, P1329, DOI 10.1210/en.139.3.1329; Yasuda H, 1998, P NATL ACAD SCI USA, V95, P3597, DOI 10.1073/pnas.95.7.3597; ZHOU H, 1993, J CELL PHYSIOL, V155, P112, DOI 10.1002/jcp.1041550115	40	80	92	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 30	2001	276	13					10119	10125		10.1074/jbc.M006918200	http://dx.doi.org/10.1074/jbc.M006918200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	420GC	11139569	hybrid			2022-12-25	WOS:000167996400072
J	Zhang, LH; Wu, SL; Rubin, CS				Zhang, LH; Wu, SL; Rubin, CS			Structural properties and mechanisms that govern association of C kinase adapter 1 with protein kinase C3 and the cell periphery	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAENORHABDITIS-ELEGANS; PTB DOMAIN; REGULATED EXPRESSION; SIGNAL-TRANSDUCTION; BINDING-PROTEIN; IN-VITRO; II-BETA; POLARITY; ZETA; GENE	Association of an atypical protein kinase C (aPKC) with an adapter protein can affect the location, activity, substrate specificity, and physiological role of the phosphotransferase, Knowledge of mechanisms that govern formation and intracellular targeting of aPKC adapter protein complexes is limited. Caenorhabditis elegans protein kinase C adapter proteins (CKA1 and CKA1S) bind and target aPKCs and provide prototypes for mechanistic analysis. CKA1 binds an aPKC (PKC3) via a phosphotyrosine binding (PTB) domain. A distinct, Arg/Lys-rich N-terminal region targets CKA1 to the cell periphery. We discovered that a short segment ((212)GGIDNGAFHEHEI(224)) of the V-2 (linker) region of PKC3 creates a binding surface that interacts with the PTB domain of CKA1/CKA1S. The docking domain of PKC3 differs from classical PTB ligands by the absence of Tyr and Pro. Substitution of Ile(214), Asn(216), or Phe(219) with Ala abrogates binding of PKC3 with CKA1; these residues cooperatively configure a docking site that complements an apolar surface of the CKA1 PTB domain. Phosphorylation site domains (PSD1, residues 11-25; PSD2, residues 61-77) in CKA1 route the adapter land tethered PKC3) to the cell periphery, Phosphorylation of Ser(17) and Ser(65) in PSDs 1 and 2 elicits translocation of CKA1 from the cell surface to cytoplasm, Activities of DAG-stimulated PKCs and opposing protein Ser/Thr phosphatases can dynamically regulate the distribution of adapter protein between the cell periphery and cytoplasm.	Albert Einstein Coll Med, Dept Mol Pharmacol, Atran Labs, Bronx, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine	Rubin, CS (corresponding author), Albert Einstein Coll Med, Dept Mol Pharmacol, Atran Labs, Forch 229,1300 Morris Pk Ave, Bronx, NY 10461 USA.				NIGMS NIH HHS [GM22792] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM022792] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADEREM A, 1992, CELL, V71, P713, DOI 10.1016/0092-8674(92)90546-O; Arbuzova A, 1998, BBA-REV BIOMEMBRANES, V1376, P369, DOI 10.1016/S0304-4157(98)00011-2; Bargmann CI, 1998, ANNU REV NEUROSCI, V21, P279, DOI 10.1146/annurev.neuro.21.1.279; Berra E, 1997, MOL CELL BIOL, V17, P4346, DOI 10.1128/MCB.17.8.4346; Berra E, 1995, EMBO J, V14, P6157, DOI 10.1002/j.1460-2075.1995.tb00306.x; BLACKSHEAR PJ, 1993, J BIOL CHEM, V268, P1501; BREGMAN DB, 1989, J BIOL CHEM, V264, P4648; Chen Q, 1997, J BIOL CHEM, V272, P15247, DOI 10.1074/jbc.272.24.15247; Diaz-Meco MT, 1999, J BIOL CHEM, V274, P19606, DOI 10.1074/jbc.274.28.19606; DIAZMECO MT, 1994, EMBO J, V13, P2842, DOI 10.1002/j.1460-2075.1994.tb06578.x; DiazMeco MT, 1996, MOL CELL BIOL, V16, P105; DiazMeco MT, 1996, CELL, V86, P777, DOI 10.1016/S0092-8674(00)80152-X; Forman-Kay JD, 1999, CURR OPIN STRUC BIOL, V9, P690, DOI 10.1016/S0959-440X(99)00031-7; GLANTZ SB, 1993, J BIOL CHEM, V268, P12796; Gong JP, 1999, SCIENCE, V285, P1565, DOI 10.1126/science.285.5433.1565; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; HIRSCH AH, 1992, J BIOL CHEM, V267, P2131; Hung TJ, 1999, DEVELOPMENT, V126, P127; IslasTrejo A, 1997, J BIOL CHEM, V272, P6629, DOI 10.1074/jbc.272.10.6629; Izumi Y, 1998, J CELL BIOL, V143, P95, DOI 10.1083/jcb.143.1.95; Joberty G, 2000, NAT CELL BIOL, V2, P531, DOI 10.1038/35019573; LAND M, 1994, J BIOL CHEM, V269, P9234; LAND M, 1994, J BIOL CHEM, V269, P14820; Li SC, 1998, NAT STRUCT BIOL, V5, P1075, DOI 10.1038/4185; Li Y, 1996, J BIOL CHEM, V271, P16862, DOI 10.1074/jbc.271.28.16862; Lin D, 2000, NAT CELL BIOL, V2, P540, DOI 10.1038/35019582; Margolis B, 1999, TRENDS ENDOCRIN MET, V10, P262, DOI 10.1016/S1043-2760(99)00168-X; MCLAUGHLIN S, 1995, TRENDS BIOCHEM SCI, V20, P272, DOI 10.1016/S0968-0004(00)89042-8; Mellor H, 1998, BIOCHEM J, V332, P281, DOI 10.1042/bj3320281; Meyer D, 1999, J BIOL CHEM, V274, P35113, DOI 10.1074/jbc.274.49.35113; Moghal N, 1999, CURR OPIN CELL BIOL, V11, P190, DOI 10.1016/S0955-0674(99)80025-8; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; Puls A, 1997, P NATL ACAD SCI USA, V94, P6191, DOI 10.1073/pnas.94.12.6191; Qiu RG, 2000, CURR BIOL, V10, P697, DOI 10.1016/S0960-9822(00)00535-2; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; Sanz L, 1999, EMBO J, V18, P3044, DOI 10.1093/emboj/18.11.3044; Standaert ML, 1999, J BIOL CHEM, V274, P25308, DOI 10.1074/jbc.274.36.25308; Tabuse Y, 1998, DEVELOPMENT, V125, P3607; UEMURA T, 1989, CELL, V58, P349, DOI 10.1016/0092-8674(89)90849-0; Wang YX, 1999, J BIOL CHEM, V274, P13859, DOI 10.1074/jbc.274.20.13859; Wu SL, 1998, J BIOL CHEM, V273, P1130, DOI 10.1074/jbc.273.2.1130; Zhang LH, 2001, J BIOL CHEM, V276, P10463, DOI 10.1074/jbc.M008990200; Zhong WM, 1996, NEURON, V17, P43, DOI 10.1016/S0896-6273(00)80279-2; Zhou GS, 1997, J BIOL CHEM, V272, P31130, DOI 10.1074/jbc.272.49.31130; Zwahlen C, 2000, EMBO J, V19, P1505, DOI 10.1093/emboj/19.7.1505	45	6	8	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 30	2001	276	13					10476	10484		10.1074/jbc.M008991200	http://dx.doi.org/10.1074/jbc.M008991200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	420GC	11134025	hybrid			2022-12-25	WOS:000167996400115
J	Tian, LJ; Duncan, RR; Hammond, MSL; Coghill, LS; Wen, H; Rusinova, R; Clark, AG; Levitan, IB; Shipston, MJ				Tian, LJ; Duncan, RR; Hammond, MSL; Coghill, LS; Wen, H; Rusinova, R; Clark, AG; Levitan, IB; Shipston, MJ			Alternative splicing switches potassium channel sensitivity to protein phosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LARGE-CONDUCTANCE; KINASE-A; MODULATION; RAT; SLOWPOKE; BRAIN; DEPHOSPHORYLATION; MYOMETRIUM; INHIBITION; SUBUNIT	Alternative exon splicing and reversible protein phosphorylation of large conductance calcium-activated potassium (BK) channels represent fundamental control mechanisms for the regulation of cellular excitability. BK channels are encoded by a single gene that undergoes extensive, hormonally regulated exon splicing. In native tissues BK channels display considerable diversity and plasticity in their regulation by cAMP-dependent protein kinase (PKA). Differential regulation of alternatively spliced BK channels by PKA may provide a molecular basis for the diversity and plasticity of BK channel sensitivities to PKA. Here we demonstrate that PKA activates BK channels lacking splice inserts (ZERO) but inhibits channels expressing a 59-amino acid exon at splice site 2 (STREX-1). Channel activation is dependent upon a conserved C-terminal PKA consensus motif (S869), whereas inhibition is mediated via a STREX-1 exon-specific PKA consensus site. Thus, alternative splicing acts as a molecular switch to determine the sensitivity of potassium channels to protein phosphorylation.	Univ Edinburgh, Membrane Biol Grp, Sch Med, Edinburgh EH8 9AG, Midlothian, Scotland; Univ Edinburgh, MRC, Sch Med, Membrane & Adapter Prot Cooperat Grp, Edinburgh EH8 9AG, Midlothian, Scotland; Univ Penn, Sch Med, Dept Neurosci, Philadelphia, PA 19104 USA	University of Edinburgh; University of Edinburgh; University of Pennsylvania	Shipston, MJ (corresponding author), Univ Edinburgh, Membrane Biol Grp, Sch Med, Reviot Pl, Edinburgh EH8 9AG, Midlothian, Scotland.		Shipston, Mike/C-7309-2013	Shipston, Mike/0000-0001-7544-582X; Duncan, Rory/0000-0003-0693-910X				ADELMAN JP, 1992, NEURON, V9, P209, DOI 10.1016/0896-6273(92)90160-F; Benkusky NA, 2000, J BIOL CHEM, V275, P27712; Brenner R, 2000, NATURE, V407, P870, DOI 10.1038/35038011; BUTLER A, 1993, SCIENCE, V261, P221, DOI 10.1126/science.7687074; CHUNG SK, 1991, SCIENCE, V253, P560, DOI 10.1126/science.1857986; Clark AG, 1999, J PHYSIOL-LONDON, V516, P45, DOI 10.1111/j.1469-7793.1999.045aa.x; Dworetzky SI, 1996, J NEUROSCI, V16, P4543; LAGRUTTA A, 1994, J BIOL CHEM, V269, P20347; LEE K, 1995, J PHYSIOL-LONDON, V488, P319, DOI 10.1113/jphysiol.1995.sp020969; LEVITAN IB, 1994, ANNU REV PHYSIOL, V56, P193, DOI 10.1146/annurev.ph.56.030194.001205; Nara M, 1998, J BIOL CHEM, V273, P14920, DOI 10.1074/jbc.273.24.14920; PALLANCK L, 1994, HUM MOL GENET, V3, P1239, DOI 10.1093/hmg/3.8.1239; PEREZ G, 1994, AM J PHYSIOL, V266, pC1459, DOI 10.1152/ajpcell.1994.266.5.C1459; REINHART PH, 1991, J NEUROSCI, V11, P1627; REINHART PH, 1995, J NEUROSCI, V15, P4572; ROBITAILLE R, 1992, J NEUROSCI, V12, P297; Saito M, 1997, J BIOL CHEM, V272, P11710, DOI 10.1074/jbc.272.18.11710; Shipston MJ, 1996, J BIOL CHEM, V271, P9197, DOI 10.1074/jbc.271.16.9197; Shipston MJ, 1999, MOL ENDOCRINOL, V13, P1728, DOI 10.1210/me.13.10.1728; TSENGCRANK J, 1994, NEURON, V13, P1315, DOI 10.1016/0896-6273(94)90418-9; Vergara C, 1998, CURR OPIN NEUROBIOL, V8, P321, DOI 10.1016/S0959-4388(98)80056-1; WANG J, 1999, J NEUROSCI, V19, P1; WHITE RE, 1991, NATURE, V351, P570, DOI 10.1038/351570a0; Xia XM, 1998, J NEUROSCI, V18, P2360; Xie JY, 1998, SCIENCE, V280, P443, DOI 10.1126/science.280.5362.443; Zhou XB, 2000, J PHYSIOL-LONDON, V524, P339, DOI 10.1111/j.1469-7793.2000.t01-1-00339.x; Zhou Y, 1999, NEURON, V22, P809, DOI 10.1016/S0896-6273(00)80739-4	27	167	172	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 16	2001	276	11					7717	7720		10.1074/jbc.C000741200	http://dx.doi.org/10.1074/jbc.C000741200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	411AA	11244090	hybrid			2022-12-25	WOS:000167474900008
J	Huber-Lang, MS; Sarma, JV; McGuire, SR; Lu, KT; Guo, RF; Padgaonkar, VA; Younkin, EM; Laudes, IJ; Riedemann, NC; Younger, JG; Ward, PA				Huber-Lang, MS; Sarma, JV; McGuire, SR; Lu, KT; Guo, RF; Padgaonkar, VA; Younkin, EM; Laudes, IJ; Riedemann, NC; Younger, JG; Ward, PA			Protective effects of anti-C5a peptide antibodies in experimental sepsis	FASEB JOURNAL			English	Article									Univ Michigan, Sch Med, Dept Pathol, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Med, Dept Emergency Med, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Ward, PA (corresponding author), Univ Michigan, Sch Med, Dept Pathol, 1301 Catherine Rd, Ann Arbor, MI 48109 USA.		Huber-Lang, Markus/AAJ-2209-2020	Younger, John/0000-0002-0820-0635					0	104	114	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAR	2001	15	3					568	570						3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	410BE	11259369				2022-12-25	WOS:000167419500007
J	Loeffler, M; Daugas, E; Susin, SA; Zamzami, N; Metivier, D; Nieminen, AL; Brothers, G; Penninger, JM; Kroemer, G				Loeffler, M; Daugas, E; Susin, SA; Zamzami, N; Metivier, D; Nieminen, AL; Brothers, G; Penninger, JM; Kroemer, G			Dominant cell death induction by extramitochondrially targeted apoptosis-inducing factor	FASEB JOURNAL			English	Article						AIF; apoptosis; Bcl-2; caspases; cytochrome c	MITOCHONDRIAL INTERMEMBRANE SPACE; CYTOCHROME-C; ADENYLATE KINASE; GD3 GANGLIOSIDE; FACTOR AIF; BCL-2; RELEASE; ACTIVATION; PROTEINS; REQUIREMENT	The complete AIF cDNA comprising the amino-terminal mitochondrial localization sequence (MLS) and the oxidoreductase domain has been fused in its carboxyl terminus to enhanced green fluorescent protein (GFP), thereby engineering an AIF-GFP fusion protein that is selectively targeted to the mitochondrial intermembrane space. Upon induction of apoptosis, the AIF-GFP protein translocates together with cytochrome c (Cyt-c) to the extramitochondrial compartment. Microinjection of recombinant AIF leads to the release of AIF-GFP and Cyt-c-GFP, indicating that ectopic AIF can favor permeabilization of the outer mitochondrial membrane. These mitochondrial effects of AIF are caspase independent, whereas the Cyt-c-microinjection induced translocation of AIF-GFP and Cyt-c-GFP is suppressed by the pan-caspase inhibitor Z-VAD.fmk. Upon prolonged culture, transfection-enforced overexpression of AIF results in spontaneous translocation of AIF-GFP from mitochondria, nuclear chromatin condensation, and cell death. These effects are caspase independent and do not rely on the oxidoreductase function of AIF. Spontaneous AIF-GFP translocation and subsequent nuclear apoptosis can be retarded by overexpression of a Bcl-2 protein selectively targeted to mitochondria, but not by a Bcl-2 protein targeted to the endoplasmic reticulum. Overexpression of a mutant AIF protein in which the MLS has been deleted (AIF Delta 1-100) results in the primary cytosolic accumulation of AIF. AIF Delta 1-100-induced cell death is suppressed by neither Z-VAD.fmk or by Bcl-2. Thus, extramitochondrially targeted AIF is a dominant cell death inducer.	Inst Gustave Roussy, CNRS, UMR 1599, F-94805 Villejuif, France; Hop Tenon, Assistance Publ Hop Paris, Serv Nephrol B, F-75020 Paris, France; Case Western Reserve Univ, Sch Med, Dept Anat, Cleveland, OH 44106 USA; Univ Toronto, Amgen Inst, Toronto, ON M5G 2C1, Canada; Univ Toronto, Ontario Canc Inst, Dept Med Biophys & Immunol, Toronto, ON M5G 2C1, Canada	Centre National de la Recherche Scientifique (CNRS); UNICANCER; Gustave Roussy; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Tenon - APHP; UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; Sorbonne Universite; Case Western Reserve University; University of Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto	Kroemer, G (corresponding author), Inst Gustave Roussy, CNRS, UMR 1599, Pavillon Rech 1,39 Rue Camille Desmoulins, F-94805 Villejuif, France.	kroemer@igr.fr	Kroemer, Guido/AAY-9859-2020; KROEMER, Guido/B-4263-2013; Penninger, Josef M/I-6860-2013; Susin, Santos A/Q-6754-2017	KROEMER, Guido/0000-0002-9334-4405; Penninger, Josef M/0000-0002-8194-3777; Susin, Santos A/0000-0002-3366-1628; DAUGAS, Eric/0000-0001-7256-7979				BEASLEY EM, 1993, EMBO J, V12, P2303, DOI 10.1002/j.1460-2075.1993.tb05884.x; Budihardjo I, 1999, ANNU REV CELL DEV BI, V15, P269, DOI 10.1146/annurev.cellbio.15.1.269; Coves J, 1999, BIOCHEM J, V342, P465, DOI 10.1042/0264-6021:3420465; Daugas E, 2000, FEBS LETT, V476, P118, DOI 10.1016/S0014-5793(00)01731-2; Daugas E, 2000, FASEB J, V14, P729, DOI 10.1096/fasebj.14.5.729; DeMaria R, 1997, SCIENCE, V277, P1652, DOI 10.1126/science.277.5332.1652; Enari M, 1998, NATURE, V391, P43, DOI 10.1038/34112; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; He HL, 1997, J CELL BIOL, V138, P1219, DOI 10.1083/jcb.138.6.1219; Heiskanen KM, 1999, J BIOL CHEM, V274, P5654, DOI 10.1074/jbc.274.9.5654; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Kluck RM, 1997, EMBO J, V16, P4639, DOI 10.1093/emboj/16.15.4639; Kohler C, 1999, FEBS LETT, V447, P10, DOI 10.1016/S0014-5793(99)00251-3; Kroemer G, 1997, NAT MED, V3, P614, DOI 10.1038/nm0697-614; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Liu XS, 1998, P NATL ACAD SCI USA, V95, P8461, DOI 10.1073/pnas.95.15.8461; Lorenzo HK, 1999, CELL DEATH DIFFER, V6, P516, DOI 10.1038/sj.cdd.4400527; MAJANDER A, 1994, J BIOL CHEM, V269, P21037; ODONNELL VB, 1993, BIOCHEM J, V290, P41, DOI 10.1042/bj2900041; Patterson SD, 2000, CELL DEATH DIFFER, V7, P137, DOI 10.1038/sj.cdd.4400640; Reed JC, 1997, NATURE, V387, P773, DOI 10.1038/42867; Samali A, 1999, EMBO J, V18, P2040, DOI 10.1093/emboj/18.8.2040; Samejima K, 1998, J CELL BIOL, V143, P225, DOI 10.1083/jcb.143.1.225; Scorrano L, 1999, J BIOL CHEM, V274, P22581, DOI 10.1074/jbc.274.32.22581; Single B, 1998, CELL DEATH DIFFER, V5, P1001, DOI 10.1038/sj.cdd.4400462; Susin SA, 2000, J EXP MED, V192, P571, DOI 10.1084/jem.192.4.571; Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135; Susin SA, 1997, J EXP MED, V186, P25, DOI 10.1084/jem.186.1.25; Susin SA, 1996, J EXP MED, V184, P1331, DOI 10.1084/jem.184.4.1331; Vander Heiden MG, 1999, NAT CELL BIOL, V1, pE209, DOI 10.1038/70237; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Zamzami N, 1996, J EXP MED, V183, P1533, DOI 10.1084/jem.183.4.1533; Zhu WJ, 1996, EMBO J, V15, P4130, DOI 10.1002/j.1460-2075.1996.tb00788.x	33	194	208	1	9	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2001	15	3					758	767		10.1096/fj.00-0388com	http://dx.doi.org/10.1096/fj.00-0388com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	410BE	11259394				2022-12-25	WOS:000167419500033
J	Gilroy, DW; Saunders, MA; Sansores-Garcia, L; Matijevic-Aleksic, N; Wu, KK				Gilroy, DW; Saunders, MA; Sansores-Garcia, L; Matijevic-Aleksic, N; Wu, KK			Cell cycle-dependent expression of cyclooxygenase-2 in human fibroblasts	FASEB JOURNAL			English	Article									Univ Texas, Sch Med, Vasc Biol Res Ctr, Houston, TX 77030 USA; Univ Texas, Sch Med, Div Hematol, Dept Med, Houston, TX 77030 USA; Acad Sinica, Inst Biomed Sci, Vasc Biol Program, Taipei, Taiwan	University of Texas System; University of Texas System; Academia Sinica - Taiwan	Wu, KK (corresponding author), Univ Texas, Sch Med, Vasc Biol Res Ctr, 6431 Fannin,MSB 5-016, Houston, TX 77030 USA.		Wu, Kenneth Kun-Yu/B-1070-2010; Gilroy, Derek W/C-2588-2009; Gilroy, Derek/AAP-7227-2020	Gilroy, Derek/0000-0003-3476-0844; Sansores-Garcia, Leticia/0000-0003-2510-225X					0	33	36	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	FEB	2001	15	2					288	290						3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	400LK	11156939				2022-12-25	WOS:000166872900005
J	Tavernier, B; Li, JM; El-Omar, AM; Lanone, S; Yang, ZK; Trayer, IP; Mebazaa, A; Shah, AM				Tavernier, B; Li, JM; El-Omar, AM; Lanone, S; Yang, ZK; Trayer, IP; Mebazaa, A; Shah, AM			Cardiac contractile impairment associated with increased phosphorylation of troponin I in endotoxemic rats	FASEB JOURNAL			English	Article									Kings Coll London, GKT Sch Med, Dept Cardiol, London SE5 9PJ, England; Hop Lariboisiere, Dept Anesthesiol, F-75475 Paris, France; Cardiff Univ, Dept Cardiol, Cardiff CF4 4XN, S Glam, Wales; Univ Birmingham, Sch Biosci, Birmingham B15 2TT, W Midlands, England	University of London; King's College London; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Lariboisiere-Fernand-Widal - APHP; UDICE-French Research Universities; Universite Paris Cite; Cardiff University; University of Birmingham	Shah, AM (corresponding author), Kings Coll London, GKT Sch Med, Dept Cardiol, Denmark Hill Campus,Bessemer Rd, London SE5 9PJ, England.	ajay.shah@kcl.ac.uk	Lanone, Sophie/I-4042-2016	Lanone, Sophie/0000-0003-2509-8799; Shah, Ajay/0000-0002-6547-0631					0	69	69	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	FEB	2001	15	2					294	296		10.1096/fj.00-0433fje	http://dx.doi.org/10.1096/fj.00-0433fje			3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	400LK	11156941				2022-12-25	WOS:000166872900007
J	Wanagat, J; Cao, ZJ; Pathare, P; Aiken, JM				Wanagat, J; Cao, ZJ; Pathare, P; Aiken, JM			Mitochondrial DNA deletion mutations colocalize with segmental electron transport system abnormalities, muscle fiber atrophy, fiber splitting, and oxidative damage in sarcopenia	FASEB JOURNAL			English	Article						aging; skeletal muscle; laser capture microdissection	AGING SKELETAL-MUSCLE; RAGGED-RED FIBERS; CONTRACTILE PROPERTIES; CALORIC RESTRICTION; SOLEUS MUSCLE; HUMAN HEARTS; WILD-TYPE; AGE; RATS; NUMBER	The in vivo cellular impact of age-associated mitochondrial DNA mutations is unknown, We hypothesized that mitochondrial DNA deletion mutations contribute to the fiber atrophy and loss that cause sarcopenia, the age-related decline of muscle mass and function. We examined 82,713 rectus femoris muscle fibers from Fischer 344 x Brown Norway F-1 hybrid rats of ages 5, 18, and 38 months through 1000 microns by serial cryosectioning and histochemical staining for cytochrome c oxidase and succinate dehydrogenase, Between 5 and 38 months of age, the rectus femoris muscle in the hybrid rat demonstrated a 33% decrease in mass concomitant with a 30% decrease in total fibers at the muscle mid-belly, We observed significant increases in the number of mitochondrial abnormalities with age from 289 +/- 8 ETS abnormal fibers in the entire 5-month-old rectus femoris to 1094 +/- 126 in the 38-month-old as calculated from the volume density of these abnormalities. Segmental mitochondrial abnormalities contained mitochondrial DNA deletion mutations as revealed by laser capture microdissection and whole mitochondrial genome amplification, Muscle fibers harboring mitochondrial deletions often displayed atrophy, splitting and increased steady-state levels of oxidative nucleic damage. These data suggest a causal role for age-associated mitochondrial DNA deletion mutations in sarcopenia.	Univ Wisconsin, Dept Anim Hlth & Biomed Sci, Madison, WI 53706 USA; Univ Wisconsin, Sch Med, Med Scientist Training Program, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Aiken, JM (corresponding author), Univ Wisconsin, Dept Anim Hlth & Biomed Sci, 1656 Linden Dr, Madison, WI 53706 USA.		Wanagat, Jonathan/B-2856-2009	Aiken, Judd/0000-0001-6119-4521; Wanagat, Jonathan/0000-0002-8460-8616	NIA NIH HHS [P01 AG11915, R01 AG11604, T32 AG00213] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [T32AG000213, R01AG011604, P01AG011915] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ALNAQEEB MA, 1987, J ANAT, V153, P31; ANSVED T, 1989, J NEUROL SCI, V93, P105, DOI 10.1016/0022-510X(89)90165-2; ANSVED T, 1995, ACTA PHYSIOL SCAND, V154, P291, DOI 10.1111/j.1748-1716.1995.tb09913.x; ASPNES LE, 1997, FASEB J, V11, P673; BENJAMIN IJ, 1989, CIRC RES, V65, P657, DOI 10.1161/01.RES.65.3.657; BENZI G, 1992, NEUROBIOL AGING, V13, P361, DOI 10.1016/0197-4580(92)90109-B; BOVERIS A, 1973, BIOCHEM J, V134, P707, DOI 10.1042/bj1340707; Brierley EJ, 1996, QJM-MON J ASSOC PHYS, V89, P251; BROWN LM, 1982, MUSCLE NERVE, V5, P645, DOI 10.1002/mus.880050810; BROWN M, 1987, AGE AGEING, V16, P244, DOI 10.1093/ageing/16.4.244; BYRNE E, 1992, MUTAT RES, V275, P125, DOI 10.1016/0921-8734(92)90017-J; Chariot P, 1996, ACTA NEUROPATHOL, V91, P530, DOI 10.1007/s004010050462; Croteau DL, 1999, MUTAT RES-DNA REPAIR, V434, P137, DOI 10.1016/S0921-8777(99)00025-7; Desai VG, 1996, ARCH BIOCHEM BIOPHYS, V333, P145, DOI 10.1006/abbi.1996.0375; Dubowitz V., 1985, MUSCLE BIOPSY PRACTI; ENRIGHT HU, 1992, NUCLEIC ACIDS RES, V20, P3341, DOI 10.1093/nar/20.13.3341; EVANS WJ, 1995, J GERONTOL A-BIOL, V50, P5, DOI 10.1093/gerona/50A.Special_Issue.5; Fernandes G, 1997, J CLIN IMMUNOL, V17, P85, DOI 10.1023/A:1027344730553; Fiori MG, 1996, CLIN NEUROPATHOL, V15, P240; FUJISAWA K, 1974, J NEUROL SCI, V22, P353, DOI 10.1016/0022-510X(74)90006-9; GONYEA W, 1977, ACTA PHYSIOL SCAND, V99, P105, DOI 10.1111/j.1748-1716.1977.tb10358.x; HARMAN D, 1956, J GERONTOL, V11, P298, DOI 10.1093/geronj/11.3.298; HAYAKAWA M, 1991, BIOCHEM BIOPH RES CO, V179, P1023, DOI 10.1016/0006-291X(91)91921-X; HAYAKAWA M, 1993, MOL CELL BIOCHEM, V119, P95, DOI 10.1007/BF00926859; HAYAKAWA M, 1992, BIOCHEM BIOPH RES CO, V189, P979, DOI 10.1016/0006-291X(92)92300-M; HAYASHI JI, 1991, P NATL ACAD SCI USA, V88, P10614, DOI 10.1073/pnas.88.23.10614; HOLLOSZY JO, 1991, MECH AGEING DEV, V60, P199, DOI 10.1016/0047-6374(91)90131-I; Howard C, 1998, UNBIASED STEREOLOGY; Khrapko K, 1999, NUCLEIC ACIDS RES, V27, P2434, DOI 10.1093/nar/27.11.2434; Kwong LK, 2000, ARCH BIOCHEM BIOPHYS, V373, P16, DOI 10.1006/abbi.1999.1495; LARSSON L, 1986, J NEUROL SCI, V76, P69, DOI 10.1016/0022-510X(86)90143-7; Lass A, 1998, FREE RADICAL BIO MED, V25, P1089, DOI 10.1016/S0891-5849(98)00144-0; Lee CM, 1998, FREE RADICAL BIO MED, V25, P964, DOI 10.1016/S0891-5849(98)00185-3; Lee HC, 1998, FEBS LETT, V441, P292, DOI 10.1016/S0014-5793(98)01564-6; LEXELL J, 1988, J NEUROL SCI, V84, P275, DOI 10.1016/0022-510X(88)90132-3; LJUNGMAN M, 1992, MOL CARCINOGEN, V5, P264, DOI 10.1002/mc.2940050406; LOPEZ ME, 1999, EXERCISE OXYGEN TOXI, P831; LOPEZ ME, 2000, IN PRESS MUTAT RES; MECOCCI P, 1993, ANN NEUROL, V34, P609, DOI 10.1002/ana.410340416; Mita S, 1998, MUSCLE NERVE, V21, P490, DOI 10.1002/(SICI)1097-4598(199804)21:4<490::AID-MUS7>3.0.CO;2-4; Moraes C T, 1996, Methods Enzymol, V264, P522, DOI 10.1016/S0076-6879(96)64046-4; Mueller-Hoecker J., 1992, Mutation Research, V275, P115; Mueller-Hoecker J., 1993, Virchows Archiv A Pathological Anatomy and Histopathology, V422, P7; Mueller-Hoecker J., 1996, Mechanisms of Ageing and Development, V86, P197; Mueller-Hoecker J., 1992, Pathology Research and Practice, V188, P701; MUELLER-HOECKER J, 1990, Journal of the Neurological Sciences, V100, P14; MUELLER-HOECKER J, 1989, American Journal of Pathology, V134, P1167; Mueller-Hoecker Josef, 1997, Hepatology, V26, P709; OH SJ, 1992, ANN NEUROL, V32, P253; Ozawa M, 1998, J NEUROL SCI, V159, P170, DOI 10.1016/S0022-510X(98)00152-X; PINZ KG, 1995, J BIOL CHEM, V270, P9202, DOI 10.1074/jbc.270.16.9202; Porteous WK, 1998, EUR J BIOCHEM, V257, P192, DOI 10.1046/j.1432-1327.1998.2570192.x; RICHTER C, 1992, MUTAT RES, V275, P249, DOI 10.1016/0921-8734(92)90029-O; RIFAI Z, 1995, ANN NEUROL, V37, P24, DOI 10.1002/ana.410370107; Rosenberg IH, 1997, J NUTR, V127, pS990, DOI 10.1093/jn/127.5.990S; SADEH M, 1988, J NEUROL SCI, V87, P67, DOI 10.1016/0022-510X(88)90055-X; SCHULTZ E, 1994, REV PHYSL BIOCH PHAR, V123, P214; SCIACCO M, 1994, HUM MOL GENET, V3, P13, DOI 10.1093/hmg/3.1.13; SELIGMAN AM, 1968, J CELL BIOL, V38, P1, DOI 10.1083/jcb.38.1.1; Sheehan D.C., 1980, THEORY PRACTICE HIST; Short K. R., 1999, Journal of Endocrinological Investigation, V22, P95; SHOUBRIDGE EA, 1990, CELL, V62, P43, DOI 10.1016/0092-8674(90)90238-A; SOHAL RS, 1994, MECH AGEING DEV, V76, P215, DOI 10.1016/0047-6374(94)91595-4; SUGIYAMA S, 1993, BIOCHEM MOL BIOL INT, V30, P937	64	284	288	0	19	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	FEB	2001	15	2					322	332		10.1096/fj.00-0320com	http://dx.doi.org/10.1096/fj.00-0320com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	400LK	11156948				2022-12-25	WOS:000166872900014
J	Kashiwagi, M; Ohba, M; Watanabe, H; Ishino, K; Kasahara, K; Sanai, Y; Taya, Y; Kuroki, T				Kashiwagi, M; Ohba, M; Watanabe, H; Ishino, K; Kasahara, K; Sanai, Y; Taya, Y; Kuroki, T			PKC eta associates with cyclin E/cdk2/p21 complex, phosphorylates p21 and inhibits cdk2 kinase in keratinocytes	ONCOGENE			English	Article						PKC eta; cell cycle; keratinocytes; p21	PLECKSTRIN HOMOLOGY DOMAIN; CAPILLARY ENDOTHELIAL-CELLS; PROTEIN-KINASE; PHORBOL ESTER; C-DELTA; MOUSE KERATINOCYTES; ACTIVATING KINASE; BINDING PROTEIN; NPKC-ETA; DIFFERENTIATION	PKC is activated on the cell membrane by phospholipids, thereby transducing signals to intracellular pathways. We provide here another function of PKC, namely, regulating cell cycle by interaction with the cyclin E/cdk2/p21 complex. Among the 10 isoforms of PKC, PKC eta is predominantly expressed in squamous cell epithelia and induces terminal differentiation of keratinocytes, PKC eta that is endogenously expressed or overexpressed was found to associate with the cyclin E/cdk2/p21 complex in keratinocytes of mice and humans. Requirement of a possible adaptor protein to the binding was suggested by the reconstitution of PKC eta and the cyclin E/cdk2/p21 complex which were prepared from human keratinocytes or Sf9 insect cells. Colocalization of PKC eta with cdk2 and cyclin E was observed in the cytoplasm, particularly in the perinuclear region. p21 was phosphorylated in the complex in a PKC-activator dependent manner. Association of PKC eta with cdk2 resulted in marked inhibition of cdk2-kinase activity when measured by phosphorylation of Rb, Dominant negative PKC eta associated with the cyclin E/cdk2/p21 complex, but caused a little inhibition of cdk2 kinase activity. Among the known regulatory mechanisms of cdk2 activity, dephosphorylation of Thr160 was demonstrated.	Showa Univ, Inst Mol Oncol, Shinagawa Ku, Tokyo 1428555, Japan; Tokyo Metropolitan Inst Med Sci, Dept Biochem Cell Res, Bunkyo Ku, Tokyo 1130021, Japan; Natl Canc Ctr, Res Inst, Div Biol, Chuo Ku, Tokyo 1040045, Japan	Showa University; Tokyo Metropolitan Institute of Medical Science; National Cancer Center - Japan	Kuroki, T (corresponding author), Showa Univ, Inst Mol Oncol, Shinagawa Ku, 1-5-8 Katanodai, Tokyo 1428555, Japan.		Kuroki, Toshio/A-9500-2011	Kuroki, Toshio/0000-0001-6369-4351; Kasahara, Kohji/0000-0001-7010-8365				Ashton AW, 1999, J BIOL CHEM, V274, P20805, DOI 10.1074/jbc.274.30.20805; Chapline C, 1998, J BIOL CHEM, V273, P19482, DOI 10.1074/jbc.273.31.19482; CHIDA K, 1994, MOL CELL BIOL, V14, P3782, DOI 10.1128/MCB.14.6.3782; Di Cunto F, 1998, SCIENCE, V280, P1069, DOI 10.1126/science.280.5366.1069; DiazMeco MT, 1996, CELL, V86, P777, DOI 10.1016/S0092-8674(00)80152-X; Doornbos RP, 1999, J BIOL CHEM, V274, P8589, DOI 10.1074/jbc.274.13.8589; Elledge SJ, 1996, SCIENCE, V274, P1664, DOI 10.1126/science.274.5293.1664; FISHER RP, 1995, CELL, V83, P47, DOI 10.1016/0092-8674(95)90233-3; FISHER RP, 1994, CELL, V78, P713, DOI 10.1016/0092-8674(94)90535-5; FUJISE A, 1994, J BIOL CHEM, V269, P31642; Harrington EO, 1997, J BIOL CHEM, V272, P7390, DOI 10.1074/jbc.272.11.7390; IKUTA T, 1994, CELL GROWTH DIFFER, V5, P943; Ishino K, 1998, JPN J CANCER RES, V89, P1126, DOI 10.1111/j.1349-7006.1998.tb00507.x; Izumi Y, 1998, J CELL BIOL, V143, P95, DOI 10.1083/jcb.143.1.95; Jain N, 1999, J BIOL CHEM, V274, P24392, DOI 10.1074/jbc.274.34.24392; Jaumot M, 1997, BIOCHEM BIOPH RES CO, V241, P434, DOI 10.1006/bbrc.1997.7787; KANEGAE Y, 1994, JPN J MED SCI BIOL, V47, P157, DOI 10.7883/yoken1952.47.157; KONISHI H, 1994, BIOCHEM BIOPH RES CO, V205, P1770, DOI 10.1006/bbrc.1994.2874; Kuroki T, 1999, J INVEST DERM SYMP P, V4, P153, DOI 10.1038/sj.jidsp.5640200; Le Good JA, 1998, SCIENCE, V281, P2042, DOI 10.1126/science.281.5385.2042; Livneh E, 1996, ONCOGENE, V12, P1545; Missero C, 1996, GENE DEV, V10, P3065, DOI 10.1101/gad.10.23.3065; Miyake S, 1996, P NATL ACAD SCI USA, V93, P1320, DOI 10.1073/pnas.93.3.1320; Mochly-Rosen D, 1998, FASEB J, V12, P35; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; Morgan DO, 1997, ANNU REV CELL DEV BI, V13, P261, DOI 10.1146/annurev.cellbio.13.1.261; Morrow TA, 1999, MOL CELL BIOL, V19, P5608; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; Ohba M, 1998, MOL CELL BIOL, V18, P5199, DOI 10.1128/MCB.18.9.5199; OSADA S, 1993, CELL GROWTH DIFFER, V4, P167; OSADA S, 1990, J BIOL CHEM, V265, P22434; Pal S, 1997, J BIOL CHEM, V272, P27509, DOI 10.1074/jbc.272.44.27509; POON RYC, 1995, SCIENCE, V270, P90, DOI 10.1126/science.270.5233.90; Puls A, 1997, P NATL ACAD SCI USA, V94, P6191, DOI 10.1073/pnas.94.12.6191; Resnick MS, 1998, J BIOL CHEM, V273, P27654, DOI 10.1074/jbc.273.42.27654; Romanelli A, 1999, MOL CELL BIOL, V19, P2921; Ron D, 1999, J BIOL CHEM, V274, P19003, DOI 10.1074/jbc.274.27.19003; Sanz L, 1999, EMBO J, V18, P3044, DOI 10.1093/emboj/18.11.3044; Scott MT, 2000, J BIOL CHEM, V275, P11529, DOI 10.1074/jbc.275.15.11529; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Slosberg ED, 1999, ONCOGENE, V18, P6658, DOI 10.1038/sj.onc.1203083; Staudinger J, 1997, J BIOL CHEM, V272, P32019, DOI 10.1074/jbc.272.51.32019; Ueffing M, 1997, ONCOGENE, V15, P2921, DOI 10.1038/sj.onc.1201477; Waldron RT, 1999, J BIOL CHEM, V274, P9224, DOI 10.1074/jbc.274.14.9224; Watanabe H, 1998, P NATL ACAD SCI USA, V95, P1392, DOI 10.1073/pnas.95.4.1392; WATANABE T, 1992, P NATL ACAD SCI USA, V89, P10159, DOI 10.1073/pnas.89.21.10159; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; YAO L, 1994, P NATL ACAD SCI USA, V91, P9175, DOI 10.1073/pnas.91.19.9175; Yaroslavskiy B, 1999, BLOOD, V93, P2907; Zhang PM, 1999, GENE DEV, V13, P213, DOI 10.1101/gad.13.2.213	51	61	62	0	3	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 14	2000	19	54					6334	6341		10.1038/sj.onc.1204028	http://dx.doi.org/10.1038/sj.onc.1204028			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	388YK	11175348				2022-12-25	WOS:000166210500017
J	Cui, XS; Donehower, LA				Cui, XS; Donehower, LA			Differential gene expression in mouse mammary adenocarcinomas in the presence and absence of wild type p53	ONCOGENE			English	Article						p53; mouse mammary tumor; Wnt-1; p21(WAF1/CIP1); c-kit; cyclin B1	TUMOR-CELL PROLIFERATION; MUSCLE ALPHA-ACTIN; CYCLIN-G; TRANSCRIPTIONAL TARGET; TRANSGENIC MICE; SUPPRESSOR P53; BREAST-CANCER; GROWTH; P21; ARREST	The tumor suppressor p53 transcriptionally regulates a large number of target genes that may affect cell growth and cell death pathways. To better understand the role of p53 loss in tumorigenesis, me have developed a mouse mammary cancer model, the Wnt-1 TG/p53 model. Wnt-1 transgenic females that are p53-/- develop mammary adenocarcinomas that arise sooner, grow faster, appear more anaplastic, and have higher levels of chromosomal instability than their Wnt-1 transgenic p53+/+ counterparts. In this study, we used several assays to determine whether the presence or absence of p53 affects gene expression patterns in the mammary adenocarcinomas. Most of the differentially expressed genes are increased in p53+/+ tumors and many of these represent known target genes of p53 (p21(WAF1/C1P1) cyclin G1, alpha smooth muscle actin, and cytokeratin 19), Some of these genes (cytokeratin 19, alpha smooth muscle actin, and kappa casein) represent mammary gland differentiation markers which may contribute to the inhibited tumor progression and are consistent with the more differentiated histopathology observed in the p53+/+ tumors. Several differentially expressed genes are growth regulatory in function (p21, c-kit, and cyclin B1) and their altered expression levels correlate well with the differing growth properties of the p53+/+ and p53-/- tumors. Thus, while tumors can arise and progress in the presence of functioning wild type p53, p53 may directly or indirectly regulate expression of an array of genes that facilitate differentiation and inhibit proliferation, contributing to a more differentiated, slow growing, and genomically stable phenotype.	Baylor Coll Med, Dept Mol Virol & Microbiol, Houston, TX 77030 USA; Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine	Donehower, LA (corresponding author), Baylor Coll Med, Dept Mol Virol & Microbiol, 1 Baylor Plaza, Houston, TX 77030 USA.							Ashman LK, 1999, INT J BIOCHEM CELL B, V31, P1037, DOI 10.1016/S1357-2725(99)00076-X; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Comer KA, 1998, ONCOGENE, V16, P1299, DOI 10.1038/sj.onc.1201645; Donehower LA, 1996, BBA-REV CANCER, V1242, P171, DOI 10.1016/0304-419X(95)00013-6; DONEHOWER LA, 1995, GENE DEV, V9, P882, DOI 10.1101/gad.9.7.882; Dulic V, 1998, MOL CELL BIOL, V18, P546, DOI 10.1128/MCB.18.1.546; El-Deiry WS, 1998, SEMIN CANCER BIOL, V8, P345, DOI 10.1006/scbi.1998.0097; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Freedman DA, 1999, CELL MOL LIFE SCI, V55, P96, DOI 10.1007/s000180050273; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; Ginger MR, 1999, COMP BIOCHEM PHYS B, V124, P133, DOI 10.1016/S0305-0491(99)00110-8; Gorospe M, 1999, GENE EXPRESSION, V7, P377; GUGLIOTTA P, 1988, J HISTOCHEM CYTOCHEM, V36, P659, DOI 10.1177/36.6.3367051; HARPER JW, 1995, MOL BIOL CELL, V6, P387, DOI 10.1091/mbc.6.4.387; HARPER JW, 1993, CELL, V75, P805; HIBI K, 1991, ONCOGENE, V6, P2291; Innocente SA, 1999, P NATL ACAD SCI USA, V96, P2147, DOI 10.1073/pnas.96.5.2147; Jones JM, 1997, CELL GROWTH DIFFER, V8, P829; Jones JM, 1999, CELL GROWTH DIFFER, V10, P213; Kirsch DG, 1998, J CLIN ONCOL, V16, P3158, DOI 10.1200/JCO.1998.16.9.3158; LEAVITT J, 1985, NATURE, V316, P840, DOI 10.1038/316840a0; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; Lozano G, 2000, NATURE, V404, P24, DOI 10.1038/35003670; MAZARS R, 1992, CANCER RES, V52, P3918; MIYASHITA T, 1995, CELL, V80, P293; Moll UM, 1998, CRIT REV ORAL BIOL M, V9, P23, DOI 10.1177/10454411980090010101; MUSUNURU K, 1997, CELL CYCLE REGULATOR; NATALI PG, 1992, INT J CANCER, V52, P713, DOI 10.1002/ijc.2910520508; NATALI PG, 1992, INT J CANCER, V52, P197, DOI 10.1002/ijc.2910520207; NATALI PG, 1995, CANCER RES, V55, P1787; Nishida K, 1996, ANTICANCER RES, V16, P3397; OKAMOTO K, 1994, EMBO J, V13, P4816, DOI 10.1002/j.1460-2075.1994.tb06807.x; Okamoto K, 1999, ONCOGENE, V18, P4606, DOI 10.1038/sj.onc.1202821; OWENS GK, 1986, J CELL BIOL, V102, P343, DOI 10.1083/jcb.102.2.343; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; RUDLAND PS, 1993, J HISTOCHEM CYTOCHEM, V41, P543, DOI 10.1177/41.4.8450194; Shimizu A, 1998, BIOCHEM BIOPH RES CO, V242, P529, DOI 10.1006/bbrc.1997.8004; Smith ML, 1997, EXP CELL RES, V230, P61, DOI 10.1006/excr.1996.3402; Taylor WR, 1999, MOL BIOL CELL, V10, P3607, DOI 10.1091/mbc.10.11.3607; THOR AD, 1992, JNCI-J NATL CANCER I, V84, P845, DOI 10.1093/jnci/84.11.845; TSUKAMOTO AS, 1988, CELL, V55, P619, DOI 10.1016/0092-8674(88)90220-6; Wallace-Brodeur RR, 1999, CELL MOL LIFE SCI, V55, P64, DOI 10.1007/s000180050270; WynfordThomas D, 1997, EUR J CANCER, V33, P716, DOI 10.1016/S0959-8049(97)00064-6; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; Yu J, 1999, P NATL ACAD SCI USA, V96, P14517, DOI 10.1073/pnas.96.25.14517; Zhao RB, 2000, GENE DEV, V14, P981	47	26	26	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 7	2000	19	52					5988	5996		10.1038/sj.onc.1203993	http://dx.doi.org/10.1038/sj.onc.1203993			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	382MY	11146550				2022-12-25	WOS:000165827900005
J	Zhang, M; Shi, Y; Magit, D; Furth, PA; Sager, R				Zhang, M; Shi, Y; Magit, D; Furth, PA; Sager, R			Reduced mammary tumor progression in WAP-TAg/WAP-maspin bitransgenic mice	ONCOGENE			English	Article						maspin; WAP-TAg transgenic mice; mammary tumor progression	BREAST-CANCER; T-ANTIGEN; SERPIN; CELLS; EXPRESSION; SUPPRESSOR; SV40; GENE; TRANSACTIVATION; INVASION	Maspin is a unique serpin involved in the suppression of tumor growth and metastasis. To investigate whether increased levels of maspin protect against tumor progression in vivo, we established a transgenic model in which maspin is targeted to mammary epithelial cells by the Whey Acidic Protein (WAP) promoter for overexpression. We crossed these WAP-maspin transgenic mice with the WAP-TAg mouse model of tumor progression. Maspin overexpression increased the rate of apoptosis of both preneoplastic and carcinomatous mammary epithelial cells. Maspin reduced tumor growth through a combination of reduced angiogenesis and increased apoptosis, The number of pulmonary metastases was reduced in the presence of maspin overexpression, These data demonstrate that targeted overexpression of maspin can inhibit tumor progression in vivo, likely through a combination of increased apoptosis, decreased angiogenesis, and inhibition of tumor cell migration.	Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA; Univ Maryland, Dept Med, Baltimore, MD 21201 USA; Univ Maryland, Inst Human Virol, Baltimore, MD 21201 USA; Dana Farber Canc Inst, Boston, MA 02115 USA	Baylor College of Medicine; University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; Harvard University; Dana-Farber Cancer Institute	Zhang, M (corresponding author), Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA.				NATIONAL CANCER INSTITUTE [R01CA079736] Funding Source: NIH RePORTER; NCI NIH HHS [CA79736] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Domann FE, 2000, INT J CANCER, V85, P805, DOI 10.1002/(SICI)1097-0215(20000315)85:6<805::AID-IJC12>3.0.CO;2-5; DYSON N, 1989, CELL, V58, P249, DOI 10.1016/0092-8674(89)90839-8; Faraldo MM, 1998, EMBO J, V17, P2139, DOI 10.1093/emboj/17.8.2139; Hendrix MJC, 2000, NAT MED, V6, P374, DOI 10.1038/74624; LEE EYHP, 1988, SCIENCE, V241, P218, DOI 10.1126/science.3388033; Li ML, 1996, CELL GROWTH DIFFER, V7, P3; Li ML, 2000, ONCOGENE, V19, P1010, DOI 10.1038/sj.onc.1203271; MIETZ JA, 1992, EMBO J, V11, P5013, DOI 10.1002/j.1460-2075.1992.tb05608.x; Obermair A, 1997, J NATL CANCER I, V89, P1212, DOI 10.1093/jnci/89.16.1212; PEMBERTON PA, 1995, J BIOL CHEM, V270, P15832, DOI 10.1074/jbc.270.26.15832; Pemberton PA, 1997, J HISTOCHEM CYTOCHEM, V45, P1697, DOI 10.1177/002215549704501213; Sager R, 1996, CURR TOP MICROBIOL, V213, P51; SAGER R, 1994, COLD SPRING HARB SYM, V59, P537, DOI 10.1101/SQB.1994.059.01.060; Seftor REB, 1998, CANCER RES, V58, P5681; Sheng S, 1996, P NATL ACAD SCI USA, V93, P11669, DOI 10.1073/pnas.93.21.11669; SHENG SJ, 1994, J BIOL CHEM, V269, P30988; Sternlicht MD, 1997, CLIN CANCER RES, V3, P1949; Tsujii M, 1998, CELL, V93, P705, DOI 10.1016/S0092-8674(00)81433-6; TZENG YJ, 1993, ONCOGENE, V8, P1965; Xia WY, 2000, ONCOGENE, V19, P2398, DOI 10.1038/sj.onc.1203535; Zhang M, 1997, MOL MED, V3, P49, DOI 10.1007/BF03401667; Zhang M, 1997, P NATL ACAD SCI USA, V94, P5673, DOI 10.1073/pnas.94.11.5673; Zhang M, 2000, NAT MED, V6, P196, DOI 10.1038/72303; Zhang M, 1999, DEV BIOL, V215, P278, DOI 10.1006/dbio.1999.9442; Zhang M, 1997, CELL GROWTH DIFFER, V8, P179; Zou ZQ, 2000, J BIOL CHEM, V275, P6051, DOI 10.1074/jbc.275.9.6051; ZOU ZQ, 1994, SCIENCE, V263, P526, DOI 10.1126/science.8290962	27	62	68	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 7	2000	19	52					6053	6058		10.1038/sj.onc.1204006	http://dx.doi.org/10.1038/sj.onc.1204006			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	382MY	11146557				2022-12-25	WOS:000165827900012
J	Suzuki, A; Kadota, N; Hara, T; Nakagami, Y; Izumi, T; Takenawa, T; Sabe, H; Endo, T				Suzuki, A; Kadota, N; Hara, T; Nakagami, Y; Izumi, T; Takenawa, T; Sabe, H; Endo, T			Meltrin alpha cytoplasmic domain interacts with SH3 domains of Src and Grb2 and is phosphorylated by v-Src	ONCOGENE			English	Article						ADAM/MDC family; meltrin alpha/ADAM12; SH3 domain; Src family; Grb2/Ash; tyrosine phosphorylation	NECROSIS-FACTOR-ALPHA; ROUS-SARCOMA VIRUS; METALLOPROTEASE-DISINTEGRIN; SIGNAL-TRANSDUCTION; TYROSINE PHOSPHORYLATION; INTRACELLULAR MATURATION; HOMOLOGY-3 DOMAINS; CELL-ADHESION; MOUSE EMBRYO; PROTEIN	Meltrin alpha /ADAM12 is a member of the ADAM/MDC family proteins characterized by the presence of metalloprotease and disintegrin domains. This protein also contains a single transmembrane domain and a relatively long cytoplasmic domain containing several proline-rich sequences. These sequences are compatible with the consensus sequences for binding the Src homology 3 (SH3) domains. To determine whether the proline-rich sequences interact with SH3 domains in several proteins, binding of recombinant SH3 domains to the meltrin alpha cytoplasmic domain was analysed by pull-down assays. The SH3 domains of Src and Yes bound strongly, but that of Abl or phosphatidylinositol 3-kinase p85 subunit did not. Full-length Grb2/Ash bound strongly, whereas its N-terminal SH3 domain alone did less strongly. Src and Grb2 in bovine brain extracts also bound to meltrin alpha cytoplasmic domain on affinity resin, Furthermore, immunoprecipitation with alpha monoclonal antibody to meltrin alpha resulted in coprecipitation of Src and Grb2 with meltrin alpha in cell extracts, suggesting that Src and Grb2 are associated in vivo with meltrin alpha cytoplasmic domain. This notion was also supported by the findings that exogenously expressed meltrin cytoplasmic domain coexisted with Src and Grb2 on the membrane ruffles. The C-terminal Tyr901 of meltrin alpha was phosphorylated both initio and in cultured cells by v-Src. These results may imply that meltrin alpha cytoplasmic domain is involved in a signal transduction for some biological function through the interaction with SH3-containing proteins.	Chiba Univ, Fac Sci, Dept Biol, Inage Ku, Chiba 2638522, Japan; Univ Tokyo, Inst Med Sci, Dept Biochem, Tokyo 1088639, Japan; Osaka Biosci Inst, Dept Mol Biol, Suita, Osaka 5650874, Japan	Chiba University; University of Tokyo	Endo, T (corresponding author), Chiba Univ, Fac Sci, Dept Biol, Inage Ku, 1-33 Yayoicho, Chiba 2638522, Japan.		Sabe, Hisataka/A-4066-2012; Sabe, Hisataka/GPF-4385-2022					ALEXANDROPOULOS K, 1995, P NATL ACAD SCI USA, V92, P3110, DOI 10.1073/pnas.92.8.3110; Alfandari D, 1997, DEV BIOL, V182, P314, DOI 10.1006/dbio.1996.8458; ALMEIDA EAC, 1995, CELL, V81, P1095, DOI 10.1016/S0092-8674(05)80014-5; BADER D, 1982, J CELL BIOL, V95, P763, DOI 10.1083/jcb.95.3.763; BARSAGI D, 1993, CELL, V74, P83, DOI 10.1016/0092-8674(93)90296-3; BenZeev A, 1997, CURR OPIN CELL BIOL, V9, P99, DOI 10.1016/S0955-0674(97)80158-5; Birge RB, 1996, GENES CELLS, V1, P595, DOI 10.1046/j.1365-2443.1996.00258.x; Black RA, 1997, NATURE, V385, P729, DOI 10.1038/385729a0; Black RA, 1998, CURR OPIN CELL BIOL, V10, P654, DOI 10.1016/S0955-0674(98)80042-2; BLOBEL CP, 1992, NATURE, V356, P248, DOI 10.1038/356248a0; Brown MT, 1996, BBA-REV CANCER, V1287, P121, DOI 10.1016/0304-419X(96)00003-0; CARTER N, 1997, CURRENT PROTOCOLS PR; Chen MS, 1999, J CELL BIOL, V144, P549, DOI 10.1083/jcb.144.3.549; Cho CH, 1998, SCIENCE, V281, P1857, DOI 10.1126/science.281.5384.1857; COHEN GB, 1995, CELL, V80, P237, DOI 10.1016/0092-8674(95)90406-9; CROSS FR, 1983, CELL, V34, P597, DOI 10.1016/0092-8674(83)90392-6; DAVIDPFEUTY T, 1990, J CELL BIOL, V111, P3097, DOI 10.1083/jcb.111.6.3097; denHertog J, 1996, EMBO J, V15, P3016, DOI 10.1002/j.1460-2075.1996.tb00665.x; ENDO T, 1992, J BIOCHEM-TOKYO, V112, P321, DOI 10.1093/oxfordjournals.jbchem.a123899; Endo T, 1996, J BIOL CHEM, V271, P27855, DOI 10.1074/jbc.271.44.27855; ENDO T, 1987, CELL, V49, P515, DOI 10.1016/0092-8674(87)90454-5; Endo T, 1998, J CELL SCI, V111, P1081; FENG SB, 1994, SCIENCE, V266, P1241, DOI 10.1126/science.7526465; GOUT I, 1993, CELL, V75, P25, DOI 10.1016/0092-8674(93)90676-H; Howard L, 1999, J BIOL CHEM, V274, P31693, DOI 10.1074/jbc.274.44.31693; Huovila APJ, 1996, CURR OPIN CELL BIOL, V8, P692, DOI 10.1016/S0955-0674(96)80111-6; Iba K, 1999, AM J PATHOL, V154, P1489, DOI 10.1016/S0002-9440(10)65403-X; Izumi Y, 1998, EMBO J, V17, P7260, DOI 10.1093/emboj/17.24.7260; Kanemitsu MY, 1997, J BIOL CHEM, V272, P22824, DOI 10.1074/jbc.272.36.22824; Kurisaki T, 1998, MECH DEVELOP, V73, P211, DOI 10.1016/S0925-4773(98)00043-4; LIM WA, 1994, NATURE, V372, P375, DOI 10.1038/372375a0; Loechel F, 1998, J BIOL CHEM, V273, P16993, DOI 10.1074/jbc.273.27.16993; Lum L, 1998, J BIOL CHEM, V273, P26236, DOI 10.1074/jbc.273.40.26236; Matsui T, 1996, EMBO J, V15, P2208, DOI 10.1002/j.1460-2075.1996.tb00574.x; Matsumoto K, 1997, ONCOGENE, V15, P2409, DOI 10.1038/sj.onc.1201416; MATUOKA K, 1993, EMBO J, V12, P3467, DOI 10.1002/j.1460-2075.1993.tb06021.x; MATUOKA K, 1992, P NATL ACAD SCI USA, V89, P9015, DOI 10.1073/pnas.89.19.9015; MIKI H, 1994, J BIOL CHEM, V269, P5489; Moss ML, 1997, NATURE, V385, P733, DOI 10.1038/385733a0; Nath D, 1999, J CELL SCI, V112, P579; NIGG EA, 1982, P NATL ACAD SCI-BIOL, V79, P5322, DOI 10.1073/pnas.79.17.5322; Okkenhaug K, 1998, J BIOL CHEM, V273, P21194, DOI 10.1074/jbc.273.33.21194; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; Qi HL, 1999, SCIENCE, V283, P91, DOI 10.1126/science.283.5398.91; REZNIKOFF CA, 1973, CANCER RES, V33, P3231; Roghani M, 1999, J BIOL CHEM, V274, P3531, DOI 10.1074/jbc.274.6.3531; SABE H, 1992, P NATL ACAD SCI USA, V89, P2190, DOI 10.1073/pnas.89.6.2190; Schlondorff J, 1999, J CELL SCI, V112, P3603; Schwartz MA, 1995, ANNU REV CELL DEV BI, V11, P549, DOI 10.1146/annurev.cellbio.11.1.549; SHIBASAKI F, 1994, BIOCHEM J, V302, P551, DOI 10.1042/bj3020551; Sparks AB, 1996, P NATL ACAD SCI USA, V93, P1540, DOI 10.1073/pnas.93.4.1540; Thomas SM, 1997, ANNU REV CELL DEV BI, V13, P513, DOI 10.1146/annurev.cellbio.13.1.513; TSUKITA S, 1991, J CELL BIOL, V113, P867, DOI 10.1083/jcb.113.4.867; Weskamp G, 1996, J CELL BIOL, V132, P717, DOI 10.1083/jcb.132.4.717; WOLFSBERG TG, 1995, J CELL BIOL, V131, P275, DOI 10.1083/jcb.131.2.275; Wolfsberg TG, 1996, DEV BIOL, V180, P389, DOI 10.1006/dbio.1996.0313; YAFFE D, 1977, NATURE, V270, P725, DOI 10.1038/270725a0; YAGAMIHIROMASA T, 1995, NATURE, V377, P652, DOI 10.1038/377652a0; Yamada KM, 1997, CURR OPIN CELL BIOL, V9, P76, DOI 10.1016/S0955-0674(97)80155-X; YANG B, 1995, J BIOL CHEM, V270, P11711, DOI 10.1074/jbc.270.20.11711; Zhang XP, 1998, J BIOL CHEM, V273, P7345, DOI 10.1074/jbc.273.13.7345	61	46	51	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 30	2000	19	51					5842	5850		10.1038/sj.onc.1203986	http://dx.doi.org/10.1038/sj.onc.1203986			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	378CA	11127814				2022-12-25	WOS:000165563100002
J	Pfeiffer, M; Koch, T; Schroder, H; Klutzny, M; Kirscht, S; Kreienkamp, HJ; Hollt, V; Schulz, S				Pfeiffer, M; Koch, T; Schroder, H; Klutzny, M; Kirscht, S; Kreienkamp, HJ; Hollt, V; Schulz, S			Homo- and heterodimerization of somatostatin receptor subtypes - Inactivation of sst(3) receptor function by heterodimerization with sst(2A)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT SPINAL-CORD; GABA(B) RECEPTOR; DIMERIZATION; IDENTIFICATION; DOPAMINE; DOMAIN; OLIGOMERIZATION; LOCALIZATION; ACTIVATION; ASSEMBLE	Several recent studies suggest that G protein-coupled receptors can assemble as heterodimers or hetero-oligomers with enhanced functional activity. However, inactivation of a fully functional receptor by heterodimerization has not been documented. Here we show that the somatostatin receptor (sst) subtypes sst(2A) and sst(3) exist as homodimers at the plasma membrane when expressed in human embryonic kidney 293 cells. Moreover, in coimmunoprecipitation studies using differentially epitope tagged receptors, we provide direct evidence for heterodimerization of sst(2A) and sst(3). The sst(2A)-sst(3) heterodimer exhibited high affinity binding to somatostatin-14 and the sst(2)-selective ligand L-779,976 but not to the sst(3)-selective ligand L-796,778, Like the sst(2A) homodimer, the sst(2A)-sst(3) heterodimer stimulated guanosine 5'-3-O-(thio)triphosphate (GTP gammaS) binding, inhibition of adenylyl cyclase, and activation of extracellular signal-regulated kinases after exposure to the sst(2)-selective ligand L-779,976, However, unlike the sst(3) homodimer, the sst(2A)-sst(3) heterodimer did not promote GTP gammaS binding, adenylyl cyclase inhibition, or extracellular signal-regulated kinase activation in the presence of the sst(3)-selective ligand L-796,778, Interestingly, during prolonged somatostatin-14 exposure, the sst(2A)-sst(3) heterodimer desensitized at a slower rate than the sst(2A) and sst(3) homodimers. Both sst(2A) and sst(3) homodimers underwent agonist-induced endocytosis in the presence of somatostatin-14, In contrast, the sst(2A)-sst(3) heterodimer separated at the plasma membrane, and only sst, but not sst, underwent agonist induced endocytosis after exposure to somatostatin-14, Together, heterodimerization of sst(2A) and sst(3) results in a new receptor with a pharmacological and functional profile resembling that of the sst(2A) receptor, however with a greater resistance to agonist-induced desensitization. Thus, inactivation of sst(3) receptor function by heterodimerization with sst(2A) or possibly other G protein-coupled receptors may explain some of the difficulties in detecting sst(3)-specific binding and signaling in mammalian tissues.	Otto von Guericke Univ, Dept Pharmacol & Toxicol, Inst Pharmakol & Toxikol, D-39120 Magdeburg, Germany; Univ Hamburg, Hosp Eppendorf, Inst Zellbiochem & Klin Neurobiol, D-20246 Hamburg, Germany	Otto von Guericke University; University of Hamburg	Schulz, S (corresponding author), Otto von Guericke Univ, Dept Pharmacol & Toxicol, Inst Pharmakol & Toxikol, Leipziger Str 44, D-39120 Magdeburg, Germany.		Schulz, Stefan/A-6928-2017	Schulz, Stefan/0000-0002-5997-8885				AbdAlla S, 2000, NATURE, V407, P94, DOI 10.1038/35024095; AGNERS S, 2000, P NATL ACAD SCI USA, V97, P3684; Bai M, 1998, J BIOL CHEM, V273, P23605, DOI 10.1074/jbc.273.36.23605; Cvejic S, 1997, J BIOL CHEM, V272, P26959, DOI 10.1074/jbc.272.43.26959; George SR, 2000, J BIOL CHEM, V275, P26128, DOI 10.1074/jbc.M000345200; George SR, 1998, J BIOL CHEM, V273, P30244, DOI 10.1074/jbc.273.46.30244; Handel M, 1999, NEUROSCIENCE, V89, P909, DOI 10.1016/S0306-4522(98)00354-6; Hebert TE, 1996, J BIOL CHEM, V271, P16384, DOI 10.1074/jbc.271.27.16384; Jones KA, 1998, NATURE, V396, P674, DOI 10.1038/25348; Jordan BA, 1999, NATURE, V399, P697, DOI 10.1038/21441; Kaupmann K, 1998, NATURE, V396, P683, DOI 10.1038/25360; KAUPMANN K, 1993, FEBS LETT, V331, P53, DOI 10.1016/0014-5793(93)80296-7; Kuner R, 1999, SCIENCE, V283, P74, DOI 10.1126/science.283.5398.74; Marshall FH, 1999, TRENDS PHARMACOL SCI, V20, P396, DOI 10.1016/S0165-6147(99)01383-8; Meyerhof W, 1998, Rev Physiol Biochem Pharmacol, V133, P55; Ng GYK, 1996, BIOCHEM BIOPH RES CO, V227, P200, DOI 10.1006/bbrc.1996.1489; Ng GYK, 1999, J BIOL CHEM, V274, P7607, DOI 10.1074/jbc.274.12.7607; Pace AJ, 1999, J BIOL CHEM, V274, P11629, DOI 10.1074/jbc.274.17.11629; Patel YC, 1999, FRONT NEUROENDOCRIN, V20, P157, DOI 10.1006/frne.1999.0183; PEREZ J, 1994, N-S ARCH PHARMACOL, V349, P145; Rocheville M, 2000, SCIENCE, V288, P154, DOI 10.1126/science.288.5463.154; Rocheville M, 2000, J BIOL CHEM, V275, P7862, DOI 10.1074/jbc.275.11.7862; Rohrer SP, 1998, SCIENCE, V282, P737, DOI 10.1126/science.282.5389.737; Romano C, 1996, J BIOL CHEM, V271, P28612, DOI 10.1074/jbc.271.45.28612; Schulz S, 1998, NEUROSCI LETT, V257, P37, DOI 10.1016/S0304-3940(98)00803-9; Schulz S, 1998, CLIN CANCER RES, V4, P2047; Schulz S, 1998, EUR J NEUROSCI, V10, P3700, DOI 10.1046/j.1460-9568.1998.00386.x; Schulz S, 2000, CLIN CANCER RES, V6, P1865; Ward DT, 1998, J BIOL CHEM, V273, P14476, DOI 10.1074/jbc.273.23.14476; White JH, 1998, NATURE, V396, P679, DOI 10.1038/25354; Zeng FY, 1999, J BIOL CHEM, V274, P19487, DOI 10.1074/jbc.274.27.19487	31	271	278	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 27	2001	276	17					14027	14036		10.1074/jbc.M006084200	http://dx.doi.org/10.1074/jbc.M006084200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	426PB	11134004	hybrid			2022-12-25	WOS:000168356600072
J	Shimojo, M; Lee, JH; Hersh, LB				Shimojo, M; Lee, JH; Hersh, LB			Role of zinc finger domains of the transcription factor neuron-restrictive silencer factor/repressor element-1 silencing transcription factor in DNA binding and nuclear localization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-ADHESION MOLECULE; SODIUM-CHANNEL GENE; HISTONE DEACETYLASE; TARGET GENES; EXPRESSION; PROTEIN; REST; IDENTIFICATION; TRANSLOCATION; REPRESSION	The transcription factor neuron-restrictive silencer factor/repressor element-1 (RE-1) silencing transcription factor (NRSF/REST) contains nine zinc finger domains and binds to the DNA element, neuron-restrictive silencer element/repressor element-1. REST4, a C-terminally truncated form of NRSF/REST, contains the five N-terminal zinc fingers and binds weakly to DNA yet is transported into the nucleus. To study the contribution of zinc fingers 6-8 to DNA binding, each was mutated. A mutation in zinc finger 6 or 8 had little effect; however, mutation of zinc finger 7 diminished DNA binding. Mutations in any two of these zinc fingers eliminated DNA binding. The contribution of zinc fingers 2-5 to nuclear targeting was studied. Deletion of zinc finger 5 prevented nuclear targeting. Mutations in zinc finger 2, 4, or 5 did not abolish nuclear targeting. However, a zinc finger 3 mutation together with a zinc finger 2 mutation localized to the nuclear envelope. A zinc finger 3 mutation alone or in combination with a zinc finger 4 or 5 mutation produced a punctate nuclear distribution. These results suggest the presence of signals for nuclear targeting, for nuclear entry, and for release from the translocation machinery within zinc fingers 2-5 of REST 4.	Univ Kentucky, Albert B Chandler Med Ctr, Dept Biochem, Lexington, KY 40536 USA	University of Kentucky	Hersh, LB (corresponding author), Univ Kentucky, Albert B Chandler Med Ctr, Dept Biochem, 800 Roe St, Lexington, KY 40536 USA.	lhersh@pop.uky.edu	Shimojo, Masahito/T-8086-2019	Shimojo, Masahito/0000-0003-1859-4444	NATIONAL INSTITUTE ON AGING [R01AG005893, R55AG005893] Funding Source: NIH RePORTER; NIA NIH HHS [AG05893] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Bai G, 1998, J BIOL CHEM, V273, P1086, DOI 10.1074/jbc.273.2.1086; Bruening W, 1996, FEBS LETT, V393, P41, DOI 10.1016/0014-5793(96)00853-8; Chen ZF, 1998, NAT GENET, V20, P136, DOI 10.1038/2431; CHONG JHA, 1995, CELL, V80, P949, DOI 10.1016/0092-8674(95)90298-8; Grimes JA, 2000, J BIOL CHEM, V275, P9461, DOI 10.1074/jbc.275.13.9461; Huang YF, 1999, NAT NEUROSCI, V2, P867, DOI 10.1038/13165; KALLUNKI P, 1995, J BIOL CHEM, V270, P21291, DOI 10.1074/jbc.270.36.21291; Kallunki P, 1997, J CELL BIOL, V138, P1343, DOI 10.1083/jcb.138.6.1343; KRANER SD, 1992, NEURON, V9, P37, DOI 10.1016/0896-6273(92)90218-3; Lee JH, 2000, MOL BRAIN RES, V80, P88, DOI 10.1016/S0169-328X(00)00129-7; LEE JH, 2000, J MOL NEUROSCI, V80, P88; LEE JS, 1993, P NATL ACAD SCI USA, V90, P6145, DOI 10.1073/pnas.90.13.6145; LI LA, 1993, P NATL ACAD SCI USA, V90, P1460, DOI 10.1073/pnas.90.4.1460; Lonnerberg P, 1996, J BIOL CHEM, V271, P33358, DOI 10.1074/jbc.271.52.33358; MATHENY C, 1994, J BIOL CHEM, V269, P8176; MILNE CA, 1993, J BIOL CHEM, V268, P11364; MORI N, 1992, NEURON, V9, P45, DOI 10.1016/0896-6273(92)90219-4; Naruse Y, 1999, P NATL ACAD SCI USA, V96, P13691, DOI 10.1073/pnas.96.24.13691; NEWMEYER DD, 1988, CELL, V52, P641, DOI 10.1016/0092-8674(88)90402-3; Palm K, 1998, J NEUROSCI, V18, P1280; RICHARDSON WD, 1988, CELL, V52, P655, DOI 10.1016/0092-8674(88)90403-5; SCHOENHERR CJ, 1995, SCIENCE, V267, P1360, DOI 10.1126/science.7871435; Shimojo M, 1999, MOL CELL BIOL, V19, P6788; TapiaRamirez J, 1997, P NATL ACAD SCI USA, V94, P1177, DOI 10.1073/pnas.94.4.1177; Wolfe SA, 2000, ANNU REV BIOPH BIOM, V29, P183, DOI 10.1146/annurev.biophys.29.1.183	25	51	55	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 20	2001	276	16					13121	13126		10.1074/jbc.M011193200	http://dx.doi.org/10.1074/jbc.M011193200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	423VN	11145971	hybrid			2022-12-25	WOS:000168198600092
J	Antonsson, B; Montessuit, S; Sanchez, B; Martinou, JC				Antonsson, B; Montessuit, S; Sanchez, B; Martinou, JC			Bax is present as a high molecular weight oligomer/complex in the mitochondrial membrane of apoptotic cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C RELEASE; ADENINE-NUCLEOTIDE TRANSLOCASE; PERMEABILITY TRANSITION PORE; CHANNEL-FORMING ACTIVITY; BCL-X-L; BH3 DOMAIN; CASPASE ACTIVATION; MONOMERIC PROTEIN; CYCLOPHILIN-D; ION-CHANNEL	Bax is a Bcl-2 family protein with proapoptotic activity, which has been shown to trigger cytochrome c release from mitochondria both in vitro and in vivo. In control HeLa cells, Bax is present in the cytosol and weakly associated with mitochondria as a monomer with an apparent molecular mass of 20,000 Da. After treatment of the HeLa cells with the apoptosis inducer staurosporine or UV irradiation, Bax associated with mitochondria is present as two large molecular weight oligomers/complexes of 96,000 and 260,000 Da, which are integrated into the mitochondrial membrane. Bcl-2 prevents Bax oligomerization and insertion into the mitochondrial membrane. The outer mitochondrial membrane protein voltage-dependent anion channel and the inner mitochondrial membrane protein adenosine nucleotide translocator do not coelute with the large molecular weight Bax oligomers/complexes on gel filtration. Bax oligomerization appears to be required for its proapoptotic activity, and the Bax oligomer/complex might constitute the structural entirety of the cytochrome c-conducting channel in the outer mitochondrial membrane.	Serono Int SA, Serono Pharmaceut Res Inst, CH-1228 Geneva, Switzerland	Merck & Company; Serono International S.A.	Antonsson, B (corresponding author), Serono Int SA, Serono Pharmaceut Res Inst, 14 Chemin Aulx, CH-1228 Geneva, Switzerland.			martinou, Jean-claude/0000-0002-9847-2051				Antonsson B, 2000, BIOCHEM J, V345, P271, DOI 10.1042/0264-6021:3450271; Antonsson B, 1997, SCIENCE, V277, P370, DOI 10.1126/science.277.5324.370; BORNER C, 1994, J CELL BIOL, V126, P1059, DOI 10.1083/jcb.126.4.1059; Bossy-Wetzel E, 1998, EMBO J, V17, P37, DOI 10.1093/emboj/17.1.37; CHITTENDEN T, 1995, EMBO J, V14, P733; Chou JJ, 1999, CELL, V96, P615, DOI 10.1016/S0092-8674(00)80572-3; Conus S, 2000, EMBO J, V19, P1534, DOI 10.1093/emboj/19.7.1534; Crompton M, 1998, EUR J BIOCHEM, V258, P729, DOI 10.1046/j.1432-1327.1998.2580729.x; Desagher S, 1999, J CELL BIOL, V144, P891, DOI 10.1083/jcb.144.5.891; Du CY, 2000, CELL, V102, P33, DOI 10.1016/S0092-8674(00)00008-8; Eskes R, 1998, J CELL BIOL, V143, P217, DOI 10.1083/jcb.143.1.217; Eskes R, 2000, MOL CELL BIOL, V20, P929, DOI 10.1128/MCB.20.3.929-935.2000; Estoppey S, 1997, CELL DEATH DIFFER, V4, P34, DOI 10.1038/sj.cdd.4400205; Finucane DM, 1999, J BIOL CHEM, V274, P2225, DOI 10.1074/jbc.274.4.2225; Goldstein JC, 2000, NAT CELL BIOL, V2, P156, DOI 10.1038/35004029; Goping IS, 1998, J CELL BIOL, V143, P207, DOI 10.1083/jcb.143.1.207; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Griffiths GJ, 1999, J CELL BIOL, V144, P903, DOI 10.1083/jcb.144.5.903; Gross A, 1998, EMBO J, V17, P3878, DOI 10.1093/emboj/17.14.3878; HELENIUS A, 1975, BIOCHIM BIOPHYS ACTA, V415, P29, DOI 10.1016/0304-4157(75)90016-7; Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710; Hsu YT, 1997, P NATL ACAD SCI USA, V94, P3668, DOI 10.1073/pnas.94.8.3668; Hsu YT, 1997, J BIOL CHEM, V272, P13829, DOI 10.1074/jbc.272.21.13829; Hsu YT, 1998, J BIOL CHEM, V273, P10777, DOI 10.1074/jbc.273.17.10777; Hunter JJ, 1996, J BIOL CHEM, V271, P8521, DOI 10.1074/jbc.271.15.8521; JACOBSON MD, 1997, CURR BIOL, V7, P277; Jurgensmeier JM, 1998, P NATL ACAD SCI USA, V95, P4997, DOI 10.1073/pnas.95.9.4997; Kelekar A, 1998, TRENDS CELL BIOL, V8, P324, DOI 10.1016/S0962-8924(98)01321-X; Knudson CM, 1997, NAT GENET, V16, P358, DOI 10.1038/ng0897-358; Kohler C, 1999, FEBS LETT, V447, P10, DOI 10.1016/S0014-5793(99)00251-3; KRAJEWSKI S, 1993, CANCER RES, V53, P4701; Kroemer G, 1997, NAT MED, V3, P614, DOI 10.1038/nm0697-614; Kroemer G, 1997, CELL DEATH DIFFER, V4, P443, DOI 10.1038/sj.cdd.4400266; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Lorenzo HK, 1999, CELL DEATH DIFFER, V6, P516, DOI 10.1038/sj.cdd.4400527; Martinou JC, 2000, NAT CELL BIOL, V2, pE41, DOI 10.1038/35004069; Marzo I, 1998, SCIENCE, V281, P2027, DOI 10.1126/science.281.5385.2027; McDonnell JM, 1999, CELL, V96, P625, DOI 10.1016/S0092-8674(00)80573-5; Minn AJ, 1997, NATURE, V385, P353, DOI 10.1038/385353a0; Montessuit S, 1999, PROTEIN EXPRES PURIF, V15, P202, DOI 10.1006/prep.1998.1010; Muchmore SW, 1996, NATURE, V381, P335, DOI 10.1038/381335a0; NEWBY AC, 1982, TECHNIQUES LIPID MEM, P1; NEWMEYER DD, 1994, CELL, V79, P353, DOI 10.1016/0092-8674(94)90203-8; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; Reed JC, 1997, NATURE, V387, P773, DOI 10.1038/42867; ROJO M, 1994, BBA-BIOENERGETICS, V1187, P360, DOI 10.1016/0005-2728(94)90010-8; Rosse T, 1998, NATURE, V391, P496, DOI 10.1038/35160; Saito M, 2000, NAT CELL BIOL, V2, P553, DOI 10.1038/35019596; Sattler M, 1997, SCIENCE, V275, P983, DOI 10.1126/science.275.5302.983; Schendel SL, 1997, P NATL ACAD SCI USA, V94, P5113, DOI 10.1073/pnas.94.10.5113; Schlesinger PH, 1997, P NATL ACAD SCI USA, V94, P11357, DOI 10.1073/pnas.94.21.11357; SEDLAK TW, 1995, P NATL ACAD SCI USA, V92, P7834, DOI 10.1073/pnas.92.17.7834; Shimizu S, 1999, NATURE, V399, P483, DOI 10.1038/20959; Single B, 1998, CELL DEATH DIFFER, V5, P1001, DOI 10.1038/sj.cdd.4400462; Suzuki M, 2000, CELL, V103, P645, DOI 10.1016/S0092-8674(00)00167-7; Vander Heiden MG, 1999, NAT CELL BIOL, V1, pE209, DOI 10.1038/70237; Verhagen AM, 2000, CELL, V102, P43, DOI 10.1016/S0092-8674(00)00009-X; Wang K, 1996, GENE DEV, V10, P2859, DOI 10.1101/gad.10.22.2859; Wolter KG, 1997, J CELL BIOL, V139, P1281, DOI 10.1083/jcb.139.5.1281; Wood DE, 1998, ONCOGENE, V17, P1069, DOI 10.1038/sj.onc.1202034; Woodfield K, 1998, BIOCHEM J, V336, P287, DOI 10.1042/bj3360287; Yang E, 1996, BLOOD, V88, P386, DOI 10.1182/blood.V88.2.386.bloodjournal882386; YIN XM, 1994, NATURE, V369, P321, DOI 10.1038/369321a0; Zha JP, 1997, J BIOL CHEM, V272, P24101, DOI 10.1074/jbc.272.39.24101	64	579	597	2	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 13	2001	276	15					11615	11623		10.1074/jbc.M010810200	http://dx.doi.org/10.1074/jbc.M010810200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	421UK	11136736	hybrid			2022-12-25	WOS:000168081800028
J	Bishop, N; Woodman, P				Bishop, N; Woodman, P			TSG101/mammalian VPS23 and mammalian VPS28 interact directly and are recruited to VPS4-induced endosomes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN SECONDARY STRUCTURE; STRUCTURE PREDICTION; TSG101 PROTEIN; PREVACUOLAR COMPARTMENT; YEAST; SEQUENCE; ATPASE; VACUOLAR; DOMAIN; IDENTIFICATION	Class E vacuolar protein sorting (vps) proteins are required for appropriate sorting of receptors within the yeast endocytic pathway, and most probably function in the biogenesis of multivesicular bodies. We have identified the mammalian orthologue of Vps28p as a 221-amino acid cytosolic protein that interacts with TSG101/ mammalian VPS23 to form part of a multiprotein complex. Co-immunoprecipitation and cross-linking experiments demonstrated that hVPS28 and TSG101 interact directly and that binding requires structural information within the conserved C-terminal portion of TSG101. TSG101 and hVPS28 are predominantly cytosolic. However, when endosomal vacuolization was induced by the expression of a dominant-negative mutant of another class E vps protein, human VPS4, a portion of both TSG101 and hVPS28 translocated to the surface of these vacuoles. We conclude that TSG101 and its interacting components are directly involved in endosomal sorting.	Univ Manchester, Sch Biol Sci, Manchester M13 9PT, Lancs, England	University of Manchester	Woodman, P (corresponding author), Univ Manchester, Sch Biol Sci, 2-205 Stopford Bldg,Oxford Rd, Manchester M13 9PT, Lancs, England.	pwoodman@fs1.scg.man.ac.uk						Babst M, 1998, EMBO J, V17, P2982, DOI 10.1093/emboj/17.11.2982; Babst M, 2000, TRAFFIC, V1, P248, DOI 10.1034/j.1600-0854.2000.010307.x; Babst M, 1997, EMBO J, V16, P1820, DOI 10.1093/emboj/16.8.1820; Bishop N, 2000, MOL BIOL CELL, V11, P227, DOI 10.1091/mbc.11.1.227; Blanchet C, 2000, BIOINFORMATICS, V16, P286, DOI 10.1093/bioinformatics/16.3.286; Brunner J, 1996, TRENDS CELL BIOL, V6, P154, DOI 10.1016/0962-8924(96)40001-0; Bryant NJ, 1998, MICROBIOL MOL BIOL R, V62, P230, DOI 10.1128/MMBR.62.1.230-247.1998; CONFALONIERI F, 1995, BIOESSAYS, V17, P639, DOI 10.1002/bies.950170710; DELEAGE G, 1987, PROTEIN ENG, V1, P289, DOI 10.1093/protein/1.4.289; Di Fiore PP, 1999, CURR OPIN CELL BIOL, V11, P483, DOI 10.1016/S0955-0674(99)80069-6; FernandezSilva P, 1997, EMBO J, V16, P1066, DOI 10.1093/emboj/16.5.1066; Ferrer M, 1999, ONCOGENE, V18, P2253, DOI 10.1038/sj.onc.1202551; Frishman D, 1996, PROTEIN ENG, V9, P133, DOI 10.1093/protein/9.2.133; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; Garnier J, 1996, METHOD ENZYMOL, V266, P540; GEOURJON C, 1994, PROTEIN ENG, V7, P157, DOI 10.1093/protein/7.2.157; Geourjon C, 1995, COMPUT APPL BIOSCI, V11, P681; GIBRAT JF, 1987, J MOL BIOL, V198, P425, DOI 10.1016/0022-2836(87)90292-0; GORLICH D, 1991, METHOD CELL BIOL, V34, P241; Guermeur Y, 1999, BIOINFORMATICS, V15, P413, DOI 10.1093/bioinformatics/15.5.413; Hampl M, 1998, BIOCHEM BIOPH RES CO, V248, P753, DOI 10.1006/bbrc.1998.9038; Higgins DG, 1996, METHOD ENZYMOL, V266, P383; Hittelman AB, 1999, EMBO J, V18, P5380, DOI 10.1093/emboj/18.19.5380; Hyman J, 2000, J CELL BIOL, V149, P537, DOI 10.1083/jcb.149.3.537; King RD, 1996, PROTEIN SCI, V5, P2298, DOI 10.1002/pro.5560051116; Koonin EV, 1997, NAT GENET, V16, P330, DOI 10.1038/ng0897-330; KRIEG UC, 1986, P NATL ACAD SCI USA, V83, P8604, DOI 10.1073/pnas.83.22.8604; Lennon G, 1996, GENOMICS, V33, P151, DOI 10.1006/geno.1996.0177; Leonhard K, 1999, NATURE, V398, P348, DOI 10.1038/18704; LEVIN JM, 1986, FEBS LETT, V205, P303, DOI 10.1016/0014-5793(86)80917-6; Levkowitz G, 1999, MOL CELL, V4, P1029, DOI 10.1016/S1097-2765(00)80231-2; Li LM, 1996, CELL, V85, P319, DOI 10.1016/S0092-8674(00)81111-3; Li Y, 1999, MOL CELL BIOL, V19, P3588; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; MAUCUER A, 1995, P NATL ACAD SCI USA, V92, P3100, DOI 10.1073/pnas.92.8.3100; Mellman I, 1996, ANNU REV CELL DEV BI, V12, P575, DOI 10.1146/annurev.cellbio.12.1.575; MUNN AL, 1994, J CELL BIOL, V127, P373, DOI 10.1083/jcb.127.2.373; Nothwehr SF, 1996, MOL CELL BIOL, V16, P2700; Odorizzi G, 1998, CELL, V95, P847, DOI 10.1016/S0092-8674(00)81707-9; Patel S, 1998, TRENDS CELL BIOL, V8, P65, DOI 10.1016/S0962-8924(97)01212-9; PERIER F, 1994, FEBS LETT, V351, P286, DOI 10.1016/0014-5793(94)00879-5; PIPER RC, 1995, J CELL BIOL, V131, P603, DOI 10.1083/jcb.131.3.603; Ponting CP, 1997, J MOL MED-JMM, V75, P467; RAYMOND CK, 1992, MOL BIOL CELL, V3, P1389, DOI 10.1091/mbc.3.12.1389; Rieder SE, 1996, MOL BIOL CELL, V7, P985, DOI 10.1091/mbc.7.6.985; ROST B, 1993, J MOL BIOL, V232, P584, DOI 10.1006/jmbi.1993.1413; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Shu W, 1999, BIOCHEMISTRY-US, V38, P5378, DOI 10.1021/bi990199w; Simmerman HKB, 1996, J BIOL CHEM, V271, P5941, DOI 10.1074/jbc.271.10.5941; SOBEL A, 1991, TRENDS BIOCHEM SCI, V16, P301, DOI 10.1016/0968-0004(91)90123-D; Steiner P, 1997, NAT GENET, V16, P332, DOI 10.1038/ng0897-332; Strous GJ, 1999, J CELL SCI, V112, P1417; Swanton E, 1998, MOL BIOL CELL, V9, P1633, DOI 10.1091/mbc.9.7.1633; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Watanabe M, 1998, BIOCHEM BIOPH RES CO, V245, P900, DOI 10.1006/bbrc.1998.8547; WESSEL D, 1984, ANAL BIOCHEM, V138, P141, DOI 10.1016/0003-2697(84)90782-6; Xie WQ, 1998, P NATL ACAD SCI USA, V95, P1595, DOI 10.1073/pnas.95.4.1595; Yoshimori T, 2000, MOL BIOL CELL, V11, P747, DOI 10.1091/mbc.11.2.747; Zhong Q, 1998, CANCER RES, V58, P2699	59	162	168	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 13	2001	276	15					11735	11742		10.1074/jbc.M009863200	http://dx.doi.org/10.1074/jbc.M009863200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	421UK	11134028	hybrid			2022-12-25	WOS:000168081800043
J	Corey, S; Clapham, DE				Corey, S; Clapham, DE			The stoichiometry of G beta gamma binding to G-protein-regulated inwardly rectifying K(+) channels (GIRKs)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECTIFIER POTASSIUM CHANNELS; HETEROTRIMERIC G-PROTEIN; CRYSTAL-STRUCTURE; I-KACH; SUBUNITS; ACTIVATION; BRAIN; IDENTIFICATION; MEMBRANE; MICE	G-protein-coupled inwardly rectifying K(+) (GIRK; Kir3.x) channels are the primary effecters of numerous G-protein-coupled receptors, GIRK channels decrease cellular excitability by hyperpolarizing the membrane potential in cardiac cells, neurons, and secretory cells. Although direct regulation of GIRKs by the heterotrimeric G-protein subunit G beta gamma has been extensively studied, little is known about the number of G beta gamma binding sites per channel. Here we demonstrate that purified GIRK (Kir 3.x) tetramers can be chemically cross-linked to exogenously purified G beta gamma subunits. The observed laddering pattern of G beta gamma attachment to GIRK4 homotetramers was consistent with the binding of one, two, three, or four G beta gamma molecules per channel tetramer. The fraction of channels chemically cross-linked to four G beta gamma molecules increased with increasing G beta gamma concentrations and approached saturation. These results suggest that GIRK tetrameric channels have four G beta gamma binding sites. Thus, GIRK (Kir 3.x) channels, like the distantly related cyclic nucleotide-gated channels, are tetramers and exhibit a 1:1 subunit/ligand binding stoichiometry.	Harvard Univ, Childrens Hosp, Sch Med, Howard Hughes Med Inst, Boston, MA 02115 USA; Mayo Clin & Mayo Fdn, Neurosci Program, Rochester, MN 55905 USA	Harvard University; Boston Children's Hospital; Harvard Medical School; Howard Hughes Medical Institute; Mayo Clinic	Clapham, DE (corresponding author), Harvard Univ, Childrens Hosp, Sch Med, Howard Hughes Med Inst, 1309 Enders,320 Longwood Ave, Boston, MA 02115 USA.	clapham@rascal.med.harvard.edu	Clapham, David/S-1123-2019; Clapham, David/R-5974-2019	Clapham, David/0000-0002-4459-9428; 				CAMPS M, 1992, EUR J BIOCHEM, V206, P821, DOI 10.1111/j.1432-1033.1992.tb16990.x; CHENJ, 1995, SCIENCE, V268, P1166; CHOU H, 1991, RES COMMUN CHEM PATH, V74, P117; Clapham DE, 1997, ANNU REV PHARMACOL, V37, P167, DOI 10.1146/annurev.pharmtox.37.1.167; CLARK KL, 1993, MOL CELL BIOL, V13, P1; Corey S, 1998, J BIOL CHEM, V273, P5271, DOI 10.1074/jbc.273.9.5271; Corey S, 1998, J BIOL CHEM, V273, P27499, DOI 10.1074/jbc.273.42.27499; Doupnik CA, 1996, NEUROPHARMACOLOGY, V35, P923, DOI 10.1016/0028-3908(96)00125-6; Gaudet R, 1996, CELL, V87, P577, DOI 10.1016/S0092-8674(00)81376-8; HASSON MS, 1994, MOL CELL BIOL, V14, P1054, DOI 10.1128/MCB.14.2.1054; He C, 1999, J BIOL CHEM, V274, P12517, DOI 10.1074/jbc.274.18.12517; Herlitze S, 1996, NATURE, V380, P258, DOI 10.1038/380258a0; Huang CL, 1997, FEBS LETT, V405, P291, DOI 10.1016/S0014-5793(97)00197-X; Huang CL, 1998, NATURE, V391, P803, DOI 10.1038/35882; HUANG CL, 1995, NEURON, V15, P1133, DOI 10.1016/0896-6273(95)90101-9; Ikeda SR, 1996, NATURE, V380, P255, DOI 10.1038/380255a0; ITO H, 1991, J GEN PHYSIOL, V98, P517, DOI 10.1085/jgp.98.3.517; IvanovaNikolova TT, 1997, J GEN PHYSIOL, V109, P245, DOI 10.1085/jgp.109.2.245; JELACIC TM, 2000, J BIOL CHEM; Kennedy ME, 1996, NEUROPHARMACOLOGY, V35, P831, DOI 10.1016/0028-3908(96)00132-3; Kennedy ME, 1999, J BIOL CHEM, V274, P2571, DOI 10.1074/jbc.274.4.2571; KRAPIVINSKY G, 1995, J BIOL CHEM, V270, P28777, DOI 10.1074/jbc.270.48.28777; Krapivinsky G, 1998, J BIOL CHEM, V273, P16946, DOI 10.1074/jbc.273.27.16946; KRAPIVINSKY G, 1995, J BIOL CHEM, V270, P29059, DOI 10.1074/jbc.270.49.29059; KUNKEL MT, 1995, CELL, V83, P443, DOI 10.1016/0092-8674(95)90122-1; KURACHI Y, 1989, PFLUG ARCH EUR J PHY, V413, P325, DOI 10.1007/BF00583550; KURACHI Y, 1992, PROG NEUROBIOL, V39, P229, DOI 10.1016/0301-0082(92)90017-9; Lambright DG, 1996, NATURE, V379, P311, DOI 10.1038/379311a0; LANGHANSRAJASEKARAN SA, 1995, P NATL ACAD SCI USA, V92, P8601, DOI 10.1073/pnas.92.19.8601; Liu MY, 1997, J BIOL CHEM, V272, P18801, DOI 10.1074/jbc.272.30.18801; LOGOTHETIS DE, 1987, NATURE, V325, P321, DOI 10.1038/325321a0; LOTERSZTAJN S, 1992, J BIOL CHEM, V267, P2375; Ma JY, 1997, NEURON, V19, P443, DOI 10.1016/S0896-6273(00)80952-6; Nakajima Y, 1996, FEBS LETT, V390, P217, DOI 10.1016/0014-5793(96)00661-8; Navarro B, 1996, SCIENCE, V272, P1950, DOI 10.1126/science.272.5270.1950; NEER EJ, 1994, NATURE, V371, P297, DOI 10.1038/371297a0; Nemec J, 1999, BIOPHYS J, V76, P246, DOI 10.1016/S0006-3495(99)77193-6; PATIL N, 1995, NAT GENET, V11, P126, DOI 10.1038/ng1095-126; PITCHER JA, 1992, SCIENCE, V257, P1264, DOI 10.1126/science.1325672; PRIVAT A, 1978, ACTA NEUROPATHOL, V42, P137, DOI 10.1007/BF00690980; RAKIC P, 1973, J COMP NEUROL, V152, P133, DOI 10.1002/cne.901520203; Ruiz M, 1997, NATURE, V389, P389, DOI 10.1038/38744; Schreibmayer W, 1996, NATURE, V380, P624, DOI 10.1038/380624a0; Signorini S, 1997, P NATL ACAD SCI USA, V94, P923, DOI 10.1073/pnas.94.3.923; Silverman SK, 1996, J BIOL CHEM, V271, P30524, DOI 10.1074/jbc.271.48.30524; SLAUGHTER RS, 1983, J BIOL CHEM, V258, P3183; SLESINGER PA, 1995, NEURON, V15, P1145, DOI 10.1016/0896-6273(95)90102-7; Sondek J, 1996, NATURE, V379, P369, DOI 10.1038/379369a0; STEPHENS L, 1994, CELL, V77, P83, DOI 10.1016/0092-8674(94)90237-2; STERNWEIS PC, 1984, J BIOL CHEM, V259, P3806; Sui JL, 1998, P NATL ACAD SCI USA, V95, P1307, DOI 10.1073/pnas.95.3.1307; TAKAO K, 1994, NEURON, V13, P747, DOI 10.1016/0896-6273(94)90041-8; TANG WJ, 1991, SCIENCE, V254, P1500, DOI 10.1126/science.1962211; Tucker SJ, 1996, AM J PHYSIOL-HEART C, V271, pH379, DOI 10.1152/ajpheart.1996.271.1.H379; Weiss JN, 1997, FASEB J, V11, P835, DOI 10.1096/fasebj.11.11.9285481; WHITEWAY M, 1989, CELL, V56, P467, DOI 10.1016/0092-8674(89)90249-3; Wickman K, 2000, J NEUROSCI, V20, P5608, DOI 10.1523/JNEUROSCI.20-15-05608.2000; Wickman K, 1998, NEURON, V20, P103, DOI 10.1016/S0896-6273(00)80438-9; WICKMAN KD, 1994, NATURE, V368, P255, DOI 10.1038/368255a0; Yan K, 1997, J BIOL CHEM, V272, P2056; Yan K, 1996, J BIOL CHEM, V271, P17597, DOI 10.1074/jbc.271.30.17597	61	36	37	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 6	2001	276	14					11409	11413		10.1074/jbc.M100058200	http://dx.doi.org/10.1074/jbc.M100058200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	420AC	11148218	hybrid			2022-12-25	WOS:000167980900113
J	Koike, M; Shiomi, T; Koike, A				Koike, M; Shiomi, T; Koike, A			Dimerization and nuclear localization of Ku proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STRAND BREAK REPAIR; V(D)J RECOMBINATION; DNA-BINDING; SUBCELLULAR-LOCALIZATION; INTERACTION REGIONS; KINASE; GROWTH; GENE; EXPRESSION; COMPONENTS	Ku, a heterodimer of Ku70 and Ku80, plays a key role in multiple nuclear processes, e.g. DNA repair, chromosome maintenance, and transcription regulation. Heterodimerization is essential for Ku-dependent DNA repair in vivo although its role is poorly understood. Some lines of evidence suggest that heterodimerization is required for the stabilization of Ku70 and Ku80. Here we show that the heterodimerization of these Ku subunits is important for their nuclear entry. When transfected into Ku-deficient xrs-6 cells, exogenous Ku70 and Ku80 tagged with green fluorescent protein accumulated into the nucleus, whereas each nuclear localization signal (NLS)-dysfunctional mutant was undetectable in the nucleus, supporting the idea that each Ku can translocate to the nucleus through its own NLS. On the other hand, the nuclear accumulation of each NLS-dysfunctional mutant was markedly enhanced by the presence of an exogenous wild-type counterpart. In Ku-expressing HeLa cells, each NLS-dysfunctional mutant, as well as wild-type Ku70 and Ku80, was still detectable in the nucleus, whereas the double mutant of each Ku subunit with decreased functions of both nuclear targeting and dimerization was undetectable in the nucleus. Our results indicate that each Ku subunit can translocate to the nucleus not only through its own NLS but also through heterodimerization with each other.	Natl Inst Radiol Sci, Genome Res Grp, Inage Ku, Chiba 2638555, Japan	National Institutes for Quantum Science & Technology	Koike, M (corresponding author), Natl Inst Radiol Sci, Genome Res Grp, Inage Ku, 4-9-1 Anagawa, Chiba 2638555, Japan.		Koike, Manabu/AAP-3107-2021					ANDERSON CW, 1993, TRENDS BIOCHEM SCI, V18, P433, DOI 10.1016/0968-0004(93)90144-C; Brown KD, 2000, J BIOL CHEM, V275, P6651, DOI 10.1074/jbc.275.9.6651; Cary RB, 1998, NUCLEIC ACIDS RES, V26, P974, DOI 10.1093/nar/26.4.974; CHALFIE M, 1994, SCIENCE, V263, P802, DOI 10.1126/science.8303295; DANZIEL RG, 1992, AUTOIMMUNITY, V13, P265; Errami A, 1996, MOL CELL BIOL, V16, P1519; Fewell JW, 1996, J CELL SCI, V109, P1937; Gao YJ, 1998, IMMUNITY, V9, P367, DOI 10.1016/S1074-7613(00)80619-6; Grawunder U, 1996, EUR J BIOCHEM, V241, P931, DOI 10.1111/j.1432-1033.1996.00931.x; Gu YS, 1997, IMMUNITY, V7, P653, DOI 10.1016/S1074-7613(00)80386-6; Jin SF, 1997, EMBO J, V16, P6874, DOI 10.1093/emboj/16.22.6874; Koike M, 1998, BIOCHEM BIOPH RES CO, V252, P679, DOI 10.1006/bbrc.1998.9368; Koike M, 1999, ONCOGENE, V18, P7495, DOI 10.1038/sj.onc.1203247; Koike M, 1999, EXP CELL RES, V250, P401, DOI 10.1006/excr.1999.4507; KOIKE M, 1995, ONCOGENE, V10, P117; Koike M, 2000, BIOCHEM BIOPH RES CO, V276, P1105, DOI 10.1006/bbrc.2000.3567; Koike M, 1999, J CELL SCI, V112, P4031; Li GC, 1998, MOL CELL, V2, P1, DOI 10.1016/S1097-2765(00)80108-2; MIMORI T, 1986, J BIOL CHEM, V261, P2274; Morio T, 1999, IMMUNITY, V11, P339, DOI 10.1016/S1074-7613(00)80109-0; Nigg EA, 1997, NATURE, V386, P779, DOI 10.1038/386779a0; Nussenzweig A, 1996, NATURE, V382, P551, DOI 10.1038/382551a0; Osipovich O, 1997, J BIOL CHEM, V272, P27259, DOI 10.1074/jbc.272.43.27259; PRABHAKAR BS, 1990, J CLIN INVEST, V86, P1301, DOI 10.1172/JCI114838; REEVES WH, 1992, RHEUM DIS CLIN N AM, V18, P391; SATOH M, 1995, EUR J CELL BIOL, V66, P127; Singleton BK, 1997, MOL CELL BIOL, V17, P1264, DOI 10.1128/MCB.17.3.1264; Singleton BK, 1999, MOL CELL BIOL, V19, P3267; TACCIOLI GE, 1994, SCIENCE, V265, P1442, DOI 10.1126/science.8073286; Teoh G, 1998, J CLIN INVEST, V101, P1379; Wang JS, 1998, J BIOL CHEM, V273, P842, DOI 10.1074/jbc.273.2.842; WEAVER DT, 1995, ADV IMMUNOL, V58, P29, DOI 10.1016/S0065-2776(08)60619-7; Wu XT, 1996, MOL CELL BIOL, V16, P5186; Zhu CM, 1996, CELL, V86, P379, DOI 10.1016/S0092-8674(00)80111-7	34	55	57	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 6	2001	276	14					11167	11173		10.1074/jbc.M010902200	http://dx.doi.org/10.1074/jbc.M010902200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	420AC	11152690	hybrid			2022-12-25	WOS:000167980900079
J	Liu, PQ; Rebar, EJ; Zhang, L; Liu, Q; Jamieson, AC; Liang, YX; Qi, H; Li, PX; Chen, BL; Mendel, MC; Zhong, XH; Lee, YL; Eisenberg, SP; Spratt, SK; Case, CC; Wolffe, AP				Liu, PQ; Rebar, EJ; Zhang, L; Liu, Q; Jamieson, AC; Liang, YX; Qi, H; Li, PX; Chen, BL; Mendel, MC; Zhong, XH; Lee, YL; Eisenberg, SP; Spratt, SK; Case, CC; Wolffe, AP			Regulation of an endogenous locus using a panel of designed zinc finger proteins targeted to accessible chromatin regions - Activation of vascular endothelial growth factor A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCED TRANSCRIPTIONAL ACTIVATION; DNA-BINDING SPECIFICITIES; CORONARY-ARTERY DISEASE; C6 GLIOMA-CELLS; FACTOR GENE; FACTOR EXPRESSION; CRYSTAL-STRUCTURE; MESSENGER-RNA; VEGF121 CDNA; HYPOXIA	We have mapped conserved regions of enhanced DNase I accessibility within the endogenous chromosomal locus of vascular endothelial growth factor A (VEGF-A). Synthetic zinc finger protein (ZFP) transcription factors were designed to target DNA sequences contained within the DNase I-hypersensitive regions. These ZFPs, when fused to either VP16 or p65 transcriptional activation domains, were able to activate expression of the VEGF-A gene as assayed by mRNA accumulation and VEGF-A protein secretion through a range exceeding that induced by hypoxic stress. Importantly, multiple splice variants of VEGF-A mRNA with defined physiological functions were induced by a single engineered ZFP transcription factor. We present evidence for an enhanced activation of VEGF-A gene transcription by ZFP transcription factors fused to VP16 and p65 targeted to two distinct chromosomal sites >500 base pairs upstream or downstream of the transcription start site. Our strategy provides a novel approach for dissecting the requirements for gene regulation at a distance without altering the DNA sequence of the endogenous target locus.	Sangamo BioSci Inc, Point Richmond Tech Ctr, Richmond, CA 94804 USA	Sangamo Therapeutics, Inc.	Wolffe, AP (corresponding author), Sangamo BioSci Inc, Point Richmond Tech Ctr, 501 Canal Blvd,Suite A100, Richmond, CA 94804 USA.							Akiri G, 1998, ONCOGENE, V17, P227, DOI 10.1038/sj.onc.1202019; ARCHER TK, 1992, SCIENCE, V255, P1573, DOI 10.1126/science.1347958; Bartsevich VV, 2000, MOL PHARMACOL, V58, P1; Beerli RR, 2000, P NATL ACAD SCI USA, V97, P1495, DOI 10.1073/pnas.040552697; Carmeliet P, 1999, NAT MED, V5, P495, DOI 10.1038/8379; Carmeliet P, 1996, NATURE, V380, P435, DOI 10.1038/380435a0; CHALFIE M, 1994, SCIENCE, V263, P802, DOI 10.1126/science.8303295; CHATTERJEE S, 1995, NATURE, V374, P820, DOI 10.1038/374820a0; CHOO Y, 1994, P NATL ACAD SCI USA, V91, P11168, DOI 10.1073/pnas.91.23.11168; CHOO Y, 1994, P NATL ACAD SCI USA, V91, P11163, DOI 10.1073/pnas.91.23.11163; Chua CC, 1998, FREE RADICAL BIO MED, V25, P891, DOI 10.1016/S0891-5849(98)00115-4; Cohen T, 1996, J BIOL CHEM, V271, P736, DOI 10.1074/jbc.271.2.736; Damert A, 1997, BIOCHEM J, V327, P419, DOI 10.1042/bj3270419; DESJARLAIS JR, 1992, PROTEINS, V12, P101, DOI 10.1002/prot.340120202; DESJARLAIS JR, 1993, P NATL ACAD SCI USA, V90, P2256, DOI 10.1073/pnas.90.6.2256; DESJARLAIS JR, 1992, P NATL ACAD SCI USA, V89, P7345, DOI 10.1073/pnas.89.16.7345; DESJARLAIS JR, 1992, PROTEINS, V13, P272; Diaz BV, 2000, J BIOL CHEM, V275, P642, DOI 10.1074/jbc.275.1.642; Elrod-Erickson M, 1998, STRUCTURE, V6, P451, DOI 10.1016/S0969-2126(98)00047-1; Esakof DD, 1999, HUM GENE THER, V10, P2307, DOI 10.1089/10430349950016951; Ferrara N, 1996, NATURE, V380, P439, DOI 10.1038/380439a0; Ferrara N, 1999, J MOL MED, V77, P527, DOI 10.1007/s001099900019; Flamme I, 1997, MECH DEVELOP, V63, P51, DOI 10.1016/S0925-4773(97)00674-6; Forsythe JA, 1996, MOL CELL BIOL, V16, P4604; Grant RA, 2000, BIOCHEMISTRY-US, V39, P8187, DOI 10.1021/bi000071a; Greisman HA, 1997, SCIENCE, V275, P657, DOI 10.1126/science.275.5300.657; GROSS DS, 1988, ANNU REV BIOCHEM, V57, P159, DOI 10.1146/annurev.bi.57.070188.001111; Grunstein J, 2000, MOL CELL BIOL, V20, P7282, DOI 10.1128/MCB.20.19.7282-7291.2000; Hendel RC, 2000, CIRCULATION, V101, P118, DOI 10.1161/01.CIR.101.2.118; IKEDA E, 1995, J BIOL CHEM, V270, P19761, DOI 10.1074/jbc.270.34.19761; Isner JM, 1996, LANCET, V348, P370, DOI 10.1016/S0140-6736(96)03361-2; Isner JM, 1998, J VASC SURG, V28, P964, DOI 10.1016/S0741-5214(98)70022-9; Jamieson AC, 1996, P NATL ACAD SCI USA, V93, P12834, DOI 10.1073/pnas.93.23.12834; JAMIESON AC, 1994, BIOCHEMISTRY-US, V33, P5689, DOI 10.1021/bi00185a004; Kim JS, 1997, P NATL ACAD SCI USA, V94, P3616, DOI 10.1073/pnas.94.8.3616; Kimura H, 2000, BLOOD, V95, P189, DOI 10.1182/blood.V95.1.189.001k05_189_197; Kimura H, 2001, J BIOL CHEM, V276, P2292, DOI 10.1074/jbc.M008398200; KLAGES N, 1995, NATURE, V374, P822, DOI 10.1038/374822a0; Kraus WL, 1999, MOL CELL BIOL, V19, P8123; LADOUX A, 1994, BIOCHEM BIOPH RES CO, V204, P794, DOI 10.1006/bbrc.1994.2529; LEVY AP, 1995, J BIOL CHEM, V270, P13333, DOI 10.1074/jbc.270.22.13333; Li JW, 2000, MOL CELL BIOL, V20, P2031, DOI 10.1128/MCB.20.6.2031-2042.2000; Liu Q, 1997, P NATL ACAD SCI USA, V94, P5525, DOI 10.1073/pnas.94.11.5525; LIU YX, 1995, CIRC RES, V77, P638, DOI 10.1161/01.RES.77.3.638; Milanini J, 1998, J BIOL CHEM, V273, P18165, DOI 10.1074/jbc.273.29.18165; Naar AM, 1999, NATURE, V398, P828, DOI 10.1038/19789; PAVLETICH NP, 1991, SCIENCE, V252, P809, DOI 10.1126/science.2028256; Rachez C, 1999, NATURE, V398, P824, DOI 10.1038/19783; Rebar EJ, 1996, METHOD ENZYMOL, V267, P129; REBAR EJ, 1994, SCIENCE, V263, P671, DOI 10.1126/science.8303274; Rosengart TK, 1999, ANN SURG, V230, P466, DOI 10.1097/00000658-199910000-00002; Rosengart TK, 1999, CIRCULATION, V100, P468, DOI 10.1161/01.CIR.100.5.468; RUBEN SM, 1991, SCIENCE, V251, P1490, DOI 10.1126/science.2006423; Ryuto M, 1996, J BIOL CHEM, V271, P28220, DOI 10.1074/jbc.271.45.28220; SADOWSKI I, 1988, NATURE, V335, P563, DOI 10.1038/335563a0; Salimath B, 2000, ONCOGENE, V19, P3470, DOI 10.1038/sj.onc.1203672; Segal DJ, 1999, P NATL ACAD SCI USA, V96, P2758, DOI 10.1073/pnas.96.6.2758; Tse C, 1998, MOL CELL BIOL, V18, P4629, DOI 10.1128/MCB.18.8.4629; Wolffe AP, 1999, NUCLEIC ACIDS RES, V27, P711, DOI 10.1093/nar/27.3.711; Yancopoulos GD, 2000, NATURE, V407, P242, DOI 10.1038/35025215; Zhang L, 2000, J BIOL CHEM, V275, P33850, DOI 10.1074/jbc.M005341200	61	200	257	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 6	2001	276	14					11323	11334		10.1074/jbc.M011172200	http://dx.doi.org/10.1074/jbc.M011172200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	420AC	11145970	hybrid			2022-12-25	WOS:000167980900101
J	Uversky, VN; Li, J; Fink, AL				Uversky, VN; Li, J; Fink, AL			Evidence for a partially folded intermediate in alpha-synuclein fibril formation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFORM INFRARED-SPECTROSCOPY; FAMILIAL PARKINSONS-DISEASE; X-RAY-SCATTERING; ALZHEIMERS-DISEASE; LEWY BODIES; SECONDARY STRUCTURE; FIBER DIFFRACTION; AMYLOID FIBRILS; MOLTEN GLOBULE; THIOFLAVINE-T	Intracellular proteinaceous aggregates (Lewy bodies and Lewy neurites) of alpha -synuclein are hallmarks of neurodegenerative diseases such as Parkinson's disease, dementia with Lewy bodies, and multiple systemic atrophy. However, the molecular mechanisms underlying alpha -synuclein aggregation into such filamentous inclusions remain unknown. An intriguing aspect of this problem is that: alpha -synuclein is a natively unfolded protein, with little or no ordered structure under physiological conditions. This raises the question of how an essentially disordered protein is transformed into highly organized fibrils. In the search for an answer to this question, we have investigated the effects of pH and temperature on the structural properties and fibrillation kinetics of human recombinant alpha -synuclein. Either a decrease in pH or an increase in temperature transformed alpha -synuclein into a partially folded conformation, The presence of this intermediate is strongly correlated with the enhanced formation of alpha -synuclein fibrils. We propose a model for the fibrillation of alpha -synuclein in which the first step is the conformational transformation of the natively unfolded protein into the aggregation-competent partially folded intermediate.	Univ Calif Santa Cruz, Dept Chem & Biochem, Santa Cruz, CA 95064 USA	University of California System; University of California Santa Cruz	Fink, AL (corresponding author), Univ Calif Santa Cruz, Dept Chem & Biochem, Santa Cruz, CA 95064 USA.	enzyme@cats.ucsc.edu	Uversky, Vladimir N./F-4515-2011	Uversky, Vladimir N./0000-0002-4037-5857				Arawaka S, 1998, NEUROLOGY, V51, P887, DOI 10.1212/WNL.51.3.887; Arima K, 1998, BRAIN RES, V808, P93, DOI 10.1016/S0006-8993(98)00734-3; BALDWIN RL, 1986, P NATL ACAD SCI USA, V83, P8069, DOI 10.1073/pnas.83.21.8069; BARTL F, 1995, BIOPHYS J, V68, P104, DOI 10.1016/S0006-3495(95)80164-5; BUCHET R, 1991, BIOCHIM BIOPHYS ACTA, V1068, P201, DOI 10.1016/0005-2736(91)90211-P; Creighton T. E., 1993, PROTEINS STRUCTURES; Crowther RA, 1998, FEBS LETT, V436, P309, DOI 10.1016/S0014-5793(98)01146-6; DAMASCHUN G, 1991, BIOCHIM BIOPHYS ACTA, V1078, P289, DOI 10.1016/0167-4838(91)90571-G; Davidson WS, 1998, J BIOL CHEM, V273, P9443, DOI 10.1074/jbc.273.16.9443; DUFFY PE, 1965, J NEUROPATH EXP NEUR, V24, P398, DOI 10.1097/00005072-196507000-00003; FAHMY K, 1993, P NATL ACAD SCI USA, V90, P10206, DOI 10.1073/pnas.90.21.10206; FINK AL, 1999, ENCY MOL BIOL, P140; Galvin J E, 1999, Adv Neurol, V80, P313; GAST K, 1995, BIOCHEMISTRY-US, V34, P13211, DOI 10.1021/bi00040a037; GEORGE JM, 1995, NEURON, V15, P361, DOI 10.1016/0896-6273(95)90040-3; Glatter O., 1982, SMALL ANGLE X RAY SC; Goedert M, 1997, NATURE, V388, P232, DOI 10.1038/40767; Irizarry MC, 1998, J NEUROPATH EXP NEUR, V57, P334, DOI 10.1097/00005072-199804000-00005; IWAI A, 1995, NEURON, V14, P467, DOI 10.1016/0896-6273(95)90302-X; JAKES R, 1994, FEBS LETT, V345, P27, DOI 10.1016/0014-5793(94)00395-5; JARRETT JT, 1993, CELL, V73, P1055, DOI 10.1016/0092-8674(93)90635-4; JARRETT JT, 1992, BIOCHEMISTRY-US, V31, P12345, DOI 10.1021/bi00164a008; Jensen PH, 1998, J BIOL CHEM, V273, P26292, DOI 10.1074/jbc.273.41.26292; Jo EJ, 2000, J BIOL CHEM, V275, P34328, DOI 10.1074/jbc.M004345200; Kay MS, 1999, P NATL ACAD SCI USA, V96, P2007, DOI 10.1073/pnas.96.5.2007; KHURANA R, 2001, IN PRESS BIOCHEMISTR, V39; Kruger R, 1998, NAT GENET, V18, P106, DOI 10.1038/ng0298-106; LEVINE H, 1995, NEUROBIOL AGING, V16, P755, DOI 10.1016/0197-4580(95)00052-G; Lomakin A, 1997, P NATL ACAD SCI USA, V94, P7942, DOI 10.1073/pnas.94.15.7942; MAROTEAUX L, 1988, J NEUROSCI, V8, P2804; Murphy DD, 2000, J NEUROSCI, V20, P3214, DOI 10.1523/JNEUROSCI.20-09-03214.2000; NAIKI H, 1989, ANAL BIOCHEM, V177, P244, DOI 10.1016/0003-2697(89)90046-8; NAIKI H, 1990, LAB INVEST, V62, P768; OBERG K, 1994, BIOCHEMISTRY-US, V33, P2628, DOI 10.1021/bi00175a035; Oberg KA, 1998, ANAL BIOCHEM, V256, P92, DOI 10.1006/abio.1997.2486; OKAZAKI H, 1961, J NEUROPATHOL EXP NE, V21, P422; Polymeropoulos MH, 1997, SCIENCE, V276, P2045, DOI 10.1126/science.276.5321.2045; RODIONOVA NA, 1989, MOL BIOL+, V23, P528; SCHMID FX, 1995, CURR BIOL, V5, P993, DOI 10.1016/S0960-9822(95)00197-7; SEMISOTNOV GV, 1991, BIOPOLYMERS, V31, P119, DOI 10.1002/bip.360310111; Serpell LC, 2000, P NATL ACAD SCI USA, V97, P4897, DOI 10.1073/pnas.97.9.4897; Spillantini MG, 1998, P NATL ACAD SCI USA, V95, P6469, DOI 10.1073/pnas.95.11.6469; Spillantini MG, 1997, NATURE, V388, P839, DOI 10.1038/42166; Trojanowski JQ, 1998, CELL DEATH DIFFER, V5, P832, DOI 10.1038/sj.cdd.4400432; Tsuruta H, 1998, J APPL CRYSTALLOGR, V31, P672, DOI 10.1107/S0021889898002702; Tu PH, 1998, ANN NEUROL, V44, P415, DOI 10.1002/ana.410440324; UVERSKY VN, 1993, BIOCHEMISTRY-US, V32, P13288, DOI 10.1021/bi00211a042; Uversky VN, 2000, PROTEINS, V41, P415, DOI 10.1002/1097-0134(20001115)41:3<415::AID-PROT130>3.3.CO;2-Z; WAKATSUKI S, 1992, REV SCI INSTRUM, V63, P1736, DOI 10.1063/1.1143332; Weinreb PH, 1996, BIOCHEMISTRY-US, V35, P13709, DOI 10.1021/bi961799n; Wood SJ, 1999, J BIOL CHEM, V274, P19509, DOI 10.1074/jbc.274.28.19509	51	874	890	1	124	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 6	2001	276	14					10737	10744		10.1074/jbc.M010907200	http://dx.doi.org/10.1074/jbc.M010907200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	420AC	11152691	hybrid			2022-12-25	WOS:000167980900025
J	Larson, ED; Drummond, JT				Larson, ED; Drummond, JT			Human mismatch repair and G center dot T mismatch binding by hMutS alpha in vitro is inhibited by adriamycin, actinomycin D, and nogalamycin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA TOPOISOMERASE-II; HUMAN CELL-LINE; TUMOR-CELLS; DEOXYRIBONUCLEIC-ACID; MICROSATELLITE INSTABILITY; REPLICATION FIDELITY; EQUILIBRIUM BINDING; GENOME INSTABILITY; ANTICANCER AGENTS; NUCLEAR EXTRACTS	Loss of the human DNA mismatch repair pathway confers cross-resistance to structurally unrelated anticancer drugs. Examples include cisplatin, doxorubicin (adriamycin), and specific alkylating agents. We focused on defining the molecular events that link adriamycin to mismatch repair-dependent drug resistance because adriamycin, unlike drugs that covalently modify DNA can interact reversibly with DNA. We found that adriamycin, nogalamycin, and actinomycin D comprise a class of drugs that reversibly inhibits human mismatch repair in vitro at low micromolar concentrations. The substrate DNA was not covalently modified by adriamycin treatment in a way that prevents repair, and the inhibition was independent of the number of intercalation sites separating the mismatch and the DNA nick used to direct repair, from 10 to 808 base pairs. Over the broad concentration range tested, there was no evidence for recognition of intercalated adriamycin by MutS alpha as if it were an insertion mismatch. Inhibition apparently results from the ability of the intercalated drug to prevent mismatch binding, shown using a defined mobility shift assay, which occurs at drug concentrations that inhibit repair. These data suggest that adriamycin interacts with the mismatch repair pathway through a mechanism distinct from the manner by which covalent DNA lesions are processed.	Indiana Univ, Dept Biol, Bloomington, IN 47405 USA	Indiana University System; Indiana University Bloomington	Drummond, JT (corresponding author), Indiana Univ, Dept Biol, Bloomington, IN 47405 USA.				NIGMS NIH HHS [GM 07757-21] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Acharya S, 1996, P NATL ACAD SCI USA, V93, P13629, DOI 10.1073/pnas.93.24.13629; Anthoney DA, 1996, CANCER RES, V56, P1374; Arcamone F., 1981, DOXORUBICIN; BACHUR NR, 1992, MOL PHARMACOL, V41, P993; Ban C, 1998, CELL, V95, P541, DOI 10.1016/S0092-8674(00)81621-9; BARCELO F, 1988, BIOCHEM PHARMACOL, V37, P2133, DOI 10.1016/0006-2952(88)90571-0; BHATTACHARYYA NP, 1994, P NATL ACAD SCI USA, V91, P6319, DOI 10.1073/pnas.91.14.6319; BRESLOFF JL, 1981, BIOCHEMISTRY-US, V20, P3547, DOI 10.1021/bi00515a038; Brown R, 1997, ONCOGENE, V15, P45, DOI 10.1038/sj.onc.1201167; Buermeyer AB, 1999, ANNU REV GENET, V33, P533, DOI 10.1146/annurev.genet.33.1.533; CHAIRES JB, 1982, BIOCHEMISTRY-US, V21, P3933, DOI 10.1021/bi00260a005; CHEN GL, 1984, J BIOL CHEM, V259, P3560; CUMMINGS J, 1992, BIOCHEM PHARMACOL, V44, P2165, DOI 10.1016/0006-2952(92)90343-H; D'Atri S, 1998, MOL PHARMACOL, V54, P334, DOI 10.1124/mol.54.2.334; DRUMMOND JT, 1995, SCIENCE, V268, P1909, DOI 10.1126/science.7604264; Duckett DR, 1996, P NATL ACAD SCI USA, V93, P6443, DOI 10.1073/pnas.93.13.6443; Duckett DR, 1999, P NATL ACAD SCI USA, V96, P12384, DOI 10.1073/pnas.96.22.12384; EASTMAN A, 1986, BIOCHEMISTRY-US, V25, P3912, DOI 10.1021/bi00361a026; EGORIN MJ, 1974, CANCER RES, V34, P2243; FANG WH, 1993, J BIOL CHEM, V268, P11838; Fink D, 1998, CLIN CANCER RES, V4, P1; Fishel R, 1998, GENE DEV, V12, P2096, DOI 10.1101/gad.12.14.2096; FORNARI FA, 1994, MOL PHARMACOL, V45, P649; FOX KR, 1992, EUR J BIOCHEM, V209, P31, DOI 10.1111/j.1432-1033.1992.tb17257.x; GAO YG, 1990, BIOCHEMISTRY-US, V29, P10307, DOI 10.1021/bi00497a004; GIGLI M, 1988, BIOCHIM BIOPHYS ACTA, V950, P13, DOI 10.1016/0167-4781(88)90068-1; GOLDMACHER VS, 1986, J BIOL CHEM, V261, P2462; Gong JG, 1999, NATURE, V399, P806; GOODMAN MF, 1974, P NATL ACAD SCI USA, V71, P1193, DOI 10.1073/pnas.71.4.1193; Gradia S, 1997, CELL, V91, P995, DOI 10.1016/S0092-8674(00)80490-0; GRAVES DE, 1983, BIOCHEMISTRY-US, V22, P3941, DOI 10.1021/bi00285a033; Hickman MJ, 1999, P NATL ACAD SCI USA, V96, P10764, DOI 10.1073/pnas.96.19.10764; HOLDEN JA, 1985, J BIOL CHEM, V260, P4491; HOLMES J, 1990, P NATL ACAD SCI USA, V87, P5837, DOI 10.1073/pnas.87.15.5837; Hu T, 1998, J BIOL CHEM, V273, P9586, DOI 10.1074/jbc.273.16.9586; Jiricny J, 1998, MUTAT RES-DNA REPAIR, V409, P107, DOI 10.1016/S0921-8777(98)00056-1; KARRAN P, 1994, BIOESSAYS, V16, P833, DOI 10.1002/bies.950161110; KAT A, 1993, P NATL ACAD SCI USA, V90, P6424, DOI 10.1073/pnas.90.14.6424; KOI M, 1994, CANCER RES, V54, P4308; Kolodner RD, 1999, CURR OPIN GENET DEV, V9, P89, DOI 10.1016/S0959-437X(99)80013-6; Lage H, 1999, J CANCER RES CLIN, V125, P156, DOI 10.1007/s004320050258; LI GM, 1995, P NATL ACAD SCI USA, V92, P1950, DOI 10.1073/pnas.92.6.1950; MACGREGOR RB, 1987, BIOCHEMISTRY-US, V26, P4008, DOI 10.1021/bi00387a040; MACGREGOR RB, 1985, BIOCHEMISTRY-US, V24, P5503, DOI 10.1021/bi00341a034; Mello JA, 1996, CHEM BIOL, V3, P579, DOI 10.1016/S1074-5521(96)90149-0; Modrich P, 1997, J BIOL CHEM, V272, P24727, DOI 10.1074/jbc.272.40.24727; Modrich P, 1996, ANNU REV BIOCHEM, V65, P101, DOI 10.1146/annurev.bi.65.070196.000533; MONACO RR, 1993, BIOCHEM BIOPH RES CO, V196, P975, DOI 10.1006/bbrc.1993.2345; MULLER W, 1968, J MOL BIOL, V35, P251, DOI 10.1016/S0022-2836(68)80024-5; O'Driscoll M, 1999, CARCINOGENESIS, V20, P799, DOI 10.1093/carcin/20.5.799; PACHTER JA, 1982, BIOCHEMISTRY-US, V21, P1541, DOI 10.1021/bi00536a012; PALOMBO F, 1995, SCIENCE, V268, P1912, DOI 10.1126/science.7604265; Palombo F, 1996, CURR BIOL, V6, P1181, DOI 10.1016/S0960-9822(02)70685-4; PIERSON V, 1989, BIOCHEM PHARMACOL, V38, P1395, DOI 10.1016/0006-2952(89)90178-0; RIZZO V, 1989, BIOCHEMISTRY-US, V28, P274, DOI 10.1021/bi00427a038; SENTENAC A, 1968, BIOCHIM BIOPHYS ACTA, V161, P299, DOI 10.1016/0005-2787(68)90108-1; SHEARMAN CW, 1983, J BIOL CHEM, V258, P4477; SHERMAN SE, 1987, CHEM REV, V87, P1153, DOI 10.1021/cr00081a013; SINGH B, 1983, ENVIRON MUTAGEN, V5, P871, DOI 10.1002/em.2860050611; SKLADANOWSKI A, 1994, BIOCHEM PHARMACOL, V47, P2279, DOI 10.1016/0006-2952(94)90266-6; SKLADANOWSKI A, 1994, BIOCHEM PHARMACOL, V47, P2269, DOI 10.1016/0006-2952(94)90265-8; SU SS, 1988, J BIOL CHEM, V263, P6829; TEWEY KM, 1984, SCIENCE, V226, P466, DOI 10.1126/science.6093249; THOMAS DC, 1991, J BIOL CHEM, V266, P3744; Umar A, 1996, EUR J BIOCHEM, V238, P297, DOI 10.1111/j.1432-1033.1996.0297z.x; VIGEVANI A, 1980, DOXORUBICIN ANAL PRO, V9; WANG JC, 1971, J MOL BIOL, V55, P523, DOI 10.1016/0022-2836(71)90334-2; WANG JC, 1974, J MOL BIOL, V89, P783, DOI 10.1016/0022-2836(74)90053-9; Yamada M, 1997, NUCLEIC ACIDS RES, V25, P491, DOI 10.1093/nar/25.3.491; YU YJ, 1994, MUTAT RES LETT, V325, P91, DOI 10.1016/0165-7992(94)90007-8; ZUNINO F, 1975, CANCER RES, V35, P754	71	24	24	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 30	2001	276	13					9775	9783		10.1074/jbc.M006390200	http://dx.doi.org/10.1074/jbc.M006390200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	420GC	11134041	hybrid			2022-12-25	WOS:000167996400028
J	Majima, E; Ishida, M; Miki, S; Shinohara, Y; Terada, H				Majima, E; Ishida, M; Miki, S; Shinohara, Y; Terada, H			Specific labeling of the bovine heart mitochondrial phosphate carrier with fluorescein 5-isothiocyanate - Roles of Lys(185) and putative adenine nucleotide recognition site in phosphate transport	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADP/ATP CARRIER; ACTIVE-SITE; UNCOUPLING PROTEIN; CYSTEINE RESIDUES; BINDING-SITE; EOSIN; LOOPS; EOSIN-5-MALEIMIDE; BACTERIORHODOPSIN; TRANSLOCATION	The amine/SH-modifying fluorescein 5-isothiocyanate (FITC) specifically labeled Lys(185) in the putative membrane-spanning region of the phosphate carrier from both the cytosolic and matrix sides of bovine heart mitochondria at 0 degreesC and pH 7.2, and the labeling inhibited the phosphate transport. Nonmodifying fluorescein derivatives having similar structural features to those of ADP and ATP (Majima, E., Yamaguchi, N., Chuman, H,, Shinohara, Y., Ishida, M., Goto, S., and Terada, H, (1998) Biochemistry 37, 424-432) inhibited the specific FITC labeling and phosphate transport, but the nonfluorescein phenylisothiocyanate did not inhibit FITC labeling, suggesting that there is a region recognizing the adenine nucleotides in the phosphate carrier and that this region is closely associated with the transport activity. The phosphate transport inhibitor pyridoxal 5 ' -phosphate inhibited the specific FITC labeling, possibly due to competitive modification of Lys(185), In addition, FITC inhibited the ADP transport and specific labeling of the ADP/ATP carrier with the fluorescein SH reagent eosin 5-maleimide, Based on these results, we discuss the structural features of the phosphate carrier in relation to its transport activity.	Univ Tokushima, Fac Pharmaceut Sci, Tokushima 7708506, Japan; APRO Life Sci Inst, Naruto 7720001, Japan	Tokushima University	Terada, H (corresponding author), Univ Tokushima, Fac Pharmaceut Sci, Shomachi 1, Tokushima 7708506, Japan.							AQUILA H, 1987, FEBS LETT, V212, P1, DOI 10.1016/0014-5793(87)81546-6; BRAND L, 1967, BIOCHEMISTRY-US, V6, P3510, DOI 10.1021/bi00863a024; Briggs C, 1999, BIOCHEMISTRY-US, V38, P5096, DOI 10.1021/bi982945n; CAPOBIANCO L, 1991, BIOCHEMISTRY-US, V30, P4963, DOI 10.1021/bi00234a018; CARILLI CT, 1982, J BIOL CHEM, V257, P5601; CREIGHTON TE, 1993, PROTEINS STRUCTURES, P10; FARLEY RA, 1984, J BIOL CHEM, V259, P9532; FLETTERICK RJ, 1975, P NATL ACAD SCI USA, V72, P38, DOI 10.1073/pnas.72.1.38; GATTO C, 1993, AM J PHYSIOL, V264, pC1577, DOI 10.1152/ajpcell.1993.264.6.C1577; GENCHI G, 1988, BIOCHIM BIOPHYS ACTA, V936, P413, DOI 10.1016/0005-2728(88)90018-7; HOUSTEK J, 1985, J BIOL CHEM, V260, P6288; KARLISH SJD, 1980, J BIOENERG BIOMEMBR, V12, P111, DOI 10.1007/BF00744678; KHORANA HG, 1993, P NATL ACAD SCI USA, V90, P1166, DOI 10.1073/pnas.90.4.1166; KLINGENBERG M, 1993, J BIOENERG BIOMEMBR, V25, P447, DOI 10.1007/BF01108402; KOLVE HVD, 1985, J BIOL CHEM, V260, P15889; Kramer R, 1996, KIDNEY INT, V49, P947, DOI 10.1038/ki.1996.133; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANYI JK, 1993, BIOCHIM BIOPHYS ACTA, V1183, P241, DOI 10.1016/0005-2728(93)90226-6; LIGETI E, 1987, EUR J BIOCHEM, V167, P167, DOI 10.1111/j.1432-1033.1987.tb13319.x; MAJIMA E, 1994, BIOCHEMISTRY-US, V33, P9530, DOI 10.1021/bi00198a019; Majima E, 1998, BIOCHEMISTRY-US, V37, P424, DOI 10.1021/bi9710683; MAJIMA E, 1993, J BIOL CHEM, V268, P22181; MAJIMA E, 1995, J BIOL CHEM, V270, P29548, DOI 10.1074/jbc.270.49.29548; MCKINLEYMCKEE JS, 1972, EUR J BIOCHEM, V28, P1, DOI 10.1111/j.1432-1033.1972.tb01877.x; MEANS GE, 1971, J BIOL CHEM, V246, P5532; Nakamura S, 1997, J BIOL CHEM, V272, P6232, DOI 10.1074/jbc.272.10.6232; PARDO JP, 1988, J BIOL CHEM, V263, P18664; Phelps A, 1996, BIOCHEMISTRY-US, V35, P10757, DOI 10.1021/bi961052x; PODHRADSKY D, 1979, EXPERIENTIA, V35, P154, DOI 10.1007/BF01920581; RUNSWICK MJ, 1987, EMBO J, V6, P1367, DOI 10.1002/j.1460-2075.1987.tb02377.x; Schroers A, 1998, J BIOL CHEM, V273, P14269, DOI 10.1074/jbc.273.23.14269; SKOU JC, 1983, BIOCHIM BIOPHYS ACTA, V727, P101, DOI 10.1016/0005-2736(83)90373-5; Smith, 1967, METHOD ENZYMOL, V10, P81, DOI DOI 10.1016/0076-6879(67)10016-5; SOMERVILLE LL, 1977, BIOCHIM BIOPHYS ACTA, V481, P493, DOI 10.1016/0005-2744(77)90282-0; STAPPEN R, 1993, BIOCHIM BIOPHYS ACTA, V1149, P40, DOI 10.1016/0005-2736(93)90022-R; STAPPEN R, 1994, J BIOL CHEM, V269, P11240; Takabatake R, 1999, PLANT MOL BIOL, V40, P479, DOI 10.1023/A:1006285009435; Terada H, 1997, PROG COLL POL SCI S, V106, P192, DOI 10.1007/BF01189519; WALKER JE, 1993, J BIOENERG BIOMEMBR, V25, P435, DOI 10.1007/BF01108401; WASSARMAN PM, 1971, J MOL BIOL, V60, P509, DOI 10.1016/0022-2836(71)90185-9	40	15	15	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 30	2001	276	13					9792	9799		10.1074/jbc.M007222200	http://dx.doi.org/10.1074/jbc.M007222200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	420GC	11133984	hybrid			2022-12-25	WOS:000167996400030
J	Zhang, JH; Barr, VA; Mo, YY; Rojkova, AM; Liu, SH; Simonds, WF				Zhang, JH; Barr, VA; Mo, YY; Rojkova, AM; Liu, SH; Simonds, WF			Nuclear localization of G protein beta(5) and regulator of G protein signaling 7 in neurons and brain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAMMA-SUBUNIT; RGS PROTEINS; P115 RHOGEF; COMPLEX; G-BETA-5; DNA; TRANSLOCATION; ACTIVATION; EXPRESSION; RECEPTORS	The role that G beta (5) regulator of G protein signaling (RGS) complexes play in signal transduction in brain remains unknown. The subcellular localization of G beta (5) and RGS7 was examined in rat PC12 pheochromocytoma cells and mouse brain. Both nuclear and cytosolic localization of G beta (5) and RGS7 was evident in PC12 cells by immunocytochemical staining. Subcellular fractionation of PC12 cells demonstrated G beta (5) immunoreactivity in the membrane, cytosolic, and nuclear fractions. Analysis by limited proteolysis confirmed the identity of G beta (5) in the nuclear fraction, Subcellular fractionation of mouse brain demonstrated G beta (5) and RGS7 but not G gamma (2/3) immunoreactivity in the nuclear fraction. RGS7 and G beta (5) were tightly complexed in the brain nuclear extract as evidenced by their coimmunoprecipitation with anti-RGS7 antibodies. Chimeric protein constructs containing green fluorescent protein fused to wild-type G beta (5) but not green fluorescent fusion proteins with G beta (1) or a mutant G beta (5) impaired in its ability to bind to RGS7 demonstrated nuclear localization in transfected PC12 cells, These findings suggest that G beta (5) undergoes nuclear translocation in neurons via an RGS-dependent mechanism. The novel intracellular distribution of G beta (5). RGS protein complexes suggests a potential role in neurons communicating between classical heterotrimeric G protein subunits and/or their effecters at the plasma membrane and the cell nucleus.	NIDDK, Metab Dis Branch, NIH, Bethesda, MD 20892 USA; NIDDK, Diabet Branch, NIH, Bethesda, MD 20892 USA; Univ Illinois, Coll Med, Dept Mol Genet, Chicago, IL 60607 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Simonds, WF (corresponding author), NIDDK, Metab Dis Branch, NIH, Bldg 10,Rm 8C-101,10 Ctr Dr,MSC 1752, Bethesda, MD 20892 USA.	wfs@helix.nih.gov	Mo, Yin-Yuan/B-6141-2011; Rozhkova, Alexandra/E-5607-2014; Mo, Yin-Yuan/R-8255-2019	Rozhkova, Alexandra/0000-0003-4901-4705; 	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [ZIADK043304, Z01DK043304] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Barr VA, 1999, J BIOL CHEM, V274, P21416, DOI 10.1074/jbc.274.30.21416; Benzing T, 2000, J BIOL CHEM, V275, P28167; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Cabrera JL, 1998, BIOCHEM BIOPH RES CO, V249, P898, DOI 10.1006/bbrc.1998.9218; Chatterjee TK, 2000, J BIOL CHEM, V275, P24013, DOI 10.1074/jbc.M002082200; Crouch MF, 1997, FASEB J, V11, P189, DOI 10.1096/fasebj.11.2.9039962; Dessauer CW, 1996, CLIN SCI, V91, P527, DOI 10.1042/cs0910527; Dulin NO, 2000, J BIOL CHEM, V275, P21317, DOI 10.1074/jbc.M910079199; Fletcher JE, 1998, J BIOL CHEM, V273, P636, DOI 10.1074/jbc.273.1.636; Fukuhara S, 1999, J BIOL CHEM, V274, P5868, DOI 10.1074/jbc.274.9.5868; Gautam N, 1998, CELL SIGNAL, V10, P447, DOI 10.1016/S0898-6568(98)00006-0; Grebenok RJ, 1997, PLANT J, V11, P573, DOI 10.1046/j.1365-313X.1997.11030573.x; Hart MJ, 1998, SCIENCE, V280, P2112, DOI 10.1126/science.280.5372.2112; He W, 1998, NEURON, V20, P95, DOI 10.1016/S0896-6273(00)80437-7; Jans DA, 1996, PHYSIOL REV, V76, P651, DOI 10.1152/physrev.1996.76.3.651; Jin T, 2000, SCIENCE, V287, P1034, DOI 10.1126/science.287.5455.1034; Kozasa T, 1998, SCIENCE, V280, P2109, DOI 10.1126/science.280.5372.2109; Levay K, 1999, P NATL ACAD SCI USA, V96, P2503, DOI 10.1073/pnas.96.5.2503; Liang JJ, 2000, J NEUROSCI RES, V60, P58, DOI 10.1002/(SICI)1097-4547(20000401)60:1<58::AID-JNR6>3.0.CO;2-L; Liang JJ, 1998, J NEUROCHEM, V71, P345; Lindorfer MA, 1998, J BIOL CHEM, V273, P34429, DOI 10.1074/jbc.273.51.34429; Lopez-Girona A, 1999, NATURE, V397, P172, DOI 10.1038/16488; Maier U, 2000, J BIOL CHEM, V275, P13746, DOI 10.1074/jbc.275.18.13746; Makino ER, 1999, P NATL ACAD SCI USA, V96, P1947, DOI 10.1073/pnas.96.5.1947; MURAKAMI T, 1992, BIOCHEMISTRY-US, V31, P2905, DOI 10.1021/bi00126a009; Obrdlik P, 2000, FEBS LETT, V476, P208, DOI 10.1016/S0014-5793(00)01706-3; Posner BA, 1999, J BIOL CHEM, V274, P31087, DOI 10.1074/jbc.274.43.31087; RYE HS, 1992, NUCLEIC ACIDS RES, V20, P2803, DOI 10.1093/nar/20.11.2803; Schilling G, 1999, NEURON, V24, P275, DOI 10.1016/S0896-6273(00)80839-9; Snow BE, 1998, P NATL ACAD SCI USA, V95, P13307, DOI 10.1073/pnas.95.22.13307; Snow BE, 1999, P NATL ACAD SCI USA, V96, P6489, DOI 10.1073/pnas.96.11.6489; Watson AJ, 1996, J BIOL CHEM, V271, P28154, DOI 10.1074/jbc.271.45.28154; WATSON AJ, 1994, J BIOL CHEM, V269, P22150; Willard FS, 2000, IMMUNOL CELL BIOL, V78, P387, DOI 10.1046/j.1440-1711.2000.00927.x; Witherow DS, 2000, J BIOL CHEM, V275, P24872, DOI 10.1074/jbc.M001535200; Zhang JH, 2000, J NEUROCHEM, V75, P393, DOI 10.1046/j.1471-4159.2000.0750393.x; Zhang JH, 2000, J NEUROSCI, V20, part. no., DOI 10.1523/JNEUROSCI.20-03-j0004.2000; Zhang SY, 1996, J BIOL CHEM, V271, P33575, DOI 10.1074/jbc.271.52.33575	39	66	67	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 30	2001	276	13					10284	10289		10.1074/jbc.M009247200	http://dx.doi.org/10.1074/jbc.M009247200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	420GC	11152459	hybrid			2022-12-25	WOS:000167996400093
J	Zhang, LH; Wu, SL; Rubin, CS				Zhang, LH; Wu, SL; Rubin, CS			A novel adapter protein employs a phosphotyrosine binding domain and exceptionally basic N-terminal domains to capture and localize an atypical protein kinase C - Characterization of Caenorhabditis elegans C kinase adapter 1, a protein that avidly binds protein kinase C3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANCHOR PROTEIN; PTB DOMAIN; SIGNAL-TRANSDUCTION; REGULATORY SUBUNIT; TIGHT JUNCTION; MESSENGER-RNA; RAT-BRAIN; CELL FATE; ZETA; EXPRESSION	Atypical protein kinase C isoforms (aPKCs) transmit regulatory signals to effector proteins located in the cytoplasm, nucleus, cytoskeleton, and membranes. Mechanisms by which aPKCs encounter and control effector proteins in various microenvironments are poorly understood. By using a protein interaction screen, we discovered two novel proteins that adapt a Caenorhabditis elegans aPKC (PKC3) for specialized (localized) functions; protein kinase C adapter 1 (CKA1, 593 amino acids) and CKA1S (549 amino acids) are derived from a unique mRNA by alternative utilization of two translation initiation codons. CKA1S and CKA1 are routed to the cell periphery by exceptionally basic N-terminal regions that include classical phosphorylation site domains (PSDs). Tethering of PKC3 is mediated by a segment of CKA1 that constitutes a phosphotyrosine binding (PTB) domain. Two aromatic amino acids (Phe(175) and Phe(221)) are indispensable for creation of a PKC3-binding surface and/or stabilization of CKA1 aPKC complexes. Patterns of CKA1 gene promoter activity and CKA1/CKA1S protein localization in vivo overlap with patterns established for PKC3 expression and distribution. Transfection experiments demonstrated that CKA1/CKA1S sequesters PKC3 in intact cells. Structural information in CKA1/CKA1S enables delivery of adapters to the lateral plasma membrane surface (near tight junctions) in polarized epithelial cells. Thus, a PTB domain and PSDs collaborate in a novel fashion in CKA1/CKA1S to enable tethering and targeting of PKC3. Avid ligation of a PKC isoform is a previously unappreciated function for a PTB module.	Albert Einstein Coll Med, Dept Mol Pharmacol, Atran Labs, Bronx, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine	Rubin, CS (corresponding author), Albert Einstein Coll Med, Dept Mol Pharmacol, Atran Labs, Forch 229,1300 Morris Pk Ave, Bronx, NY 10461 USA.	rubin@aecom.yu.edu			NIGMS NIH HHS [GM22792] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM022792] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADEREM A, 1992, CELL, V71, P713, DOI 10.1016/0092-8674(92)90546-O; AKIMOTO K, 1994, J BIOL CHEM, V269, P12677; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Balda MS, 1998, J CELL SCI, V111, P541; Bargmann CI, 1998, ANNU REV NEUROSCI, V21, P279, DOI 10.1146/annurev.neuro.21.1.279; Berra E, 1997, MOL CELL BIOL, V17, P4346, DOI 10.1128/MCB.17.8.4346; Berra E, 1995, EMBO J, V14, P6157, DOI 10.1002/j.1460-2075.1995.tb00306.x; Black JD, 2000, FRONT BIOSCI-LANDMRK, V5, pD406, DOI 10.2741/Black; BLACKSHEAR PJ, 1993, J BIOL CHEM, V268, P1501; BLUMENTHAL T, 1988, TRENDS GENET, V4, P305, DOI 10.1016/0168-9525(88)90107-2; BREGMAN DB, 1989, J BIOL CHEM, V264, P4648; C elegans Sequencing Consortium, 1998, SCIENCE, V282, P2012, DOI 10.1126/science.282.5396.2012; Cereijido M, 1998, ANNU REV PHYSIOL, V60, P161, DOI 10.1146/annurev.physiol.60.1.161; Chen Q, 1997, J BIOL CHEM, V272, P15247, DOI 10.1074/jbc.272.24.15247; Chou MM, 1998, CURR BIOL, V8, P1069, DOI 10.1016/S0960-9822(98)70444-0; Diaz-Meco MT, 1999, J BIOL CHEM, V274, P19606, DOI 10.1074/jbc.274.28.19606; DIAZMECO MT, 1994, EMBO J, V13, P2842, DOI 10.1002/j.1460-2075.1994.tb06578.x; DiazMeco MT, 1996, MOL CELL BIOL, V16, P105; DiazMeco MT, 1996, CELL, V86, P777, DOI 10.1016/S0092-8674(00)80152-X; Doornbos RP, 1999, J BIOL CHEM, V274, P8589, DOI 10.1074/jbc.274.13.8589; Fields Stanley, 1993, Methods (Orlando), V5, P116, DOI 10.1006/meth.1993.1016; Forman-Kay JD, 1999, CURR OPIN STRUC BIOL, V9, P690, DOI 10.1016/S0959-440X(99)00031-7; FREEDMAN JH, 1993, J BIOL CHEM, V268, P2554; GLANTZ SB, 1993, J BIOL CHEM, V268, P12796; Gong JP, 1999, SCIENCE, V285, P1565, DOI 10.1126/science.285.5433.1565; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; HIRSCH AH, 1992, J BIOL CHEM, V267, P2131; HU ED, 1990, J BIOL CHEM, V265, P5072; HUG H, 1993, BIOCHEM J, V291, P329, DOI 10.1042/bj2910329; Hung TJ, 1999, DEVELOPMENT, V126, P127; Izumi Y, 1998, J CELL BIOL, V143, P95, DOI 10.1083/jcb.143.1.95; Jan YN, 2000, CELL, V100, P599, DOI 10.1016/S0092-8674(00)80695-9; Jan YN, 1998, NATURE, V392, P775, DOI 10.1038/33854; KIKKAWA U, 1989, ANNU REV BIOCHEM, V58, P31, DOI 10.1146/annurev.bi.58.070189.000335; KRAUSE M, 1987, CELL, V49, P753, DOI 10.1016/0092-8674(87)90613-1; LAND M, 1994, J BIOL CHEM, V269, P14820; Li SC, 1998, NAT STRUCT BIOL, V5, P1075, DOI 10.1038/4185; Li Y, 1996, J BIOL CHEM, V271, P16862, DOI 10.1074/jbc.271.28.16862; Margolis B, 1999, TRENDS ENDOCRIN MET, V10, P262, DOI 10.1016/S1043-2760(99)00168-X; MCLAUGHLIN S, 1995, TRENDS BIOCHEM SCI, V20, P272, DOI 10.1016/S0968-0004(00)89042-8; Mellor H, 1998, BIOCHEM J, V332, P281, DOI 10.1042/bj3320281; Meyer D, 1999, J BIOL CHEM, V274, P35113, DOI 10.1074/jbc.274.49.35113; Moghal N, 1999, CURR OPIN CELL BIOL, V11, P190, DOI 10.1016/S0955-0674(99)80025-8; Newton AC, 1997, CURR OPIN CELL BIOL, V9, P161, DOI 10.1016/S0955-0674(97)80058-0; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; ONO Y, 1989, P NATL ACAD SCI USA, V86, P3099, DOI 10.1073/pnas.86.9.3099; Puls A, 1997, P NATL ACAD SCI USA, V94, P6191, DOI 10.1073/pnas.94.12.6191; RODRIGUEZBOULAN E, 1992, ANNU REV CELL BIOL, V8, P395, DOI 10.1146/annurev.cb.08.110192.002143; Romanelli A, 1999, MOL CELL BIOL, V19, P2921; Rossi EA, 1999, J BIOL CHEM, V274, P27201, DOI 10.1074/jbc.274.38.27201; Sanz L, 1999, EMBO J, V18, P3044, DOI 10.1093/emboj/18.11.3044; Schultz J, 2000, NUCLEIC ACIDS RES, V28, P231, DOI 10.1093/nar/28.1.231; Standaert ML, 1999, J BIOL CHEM, V274, P25308, DOI 10.1074/jbc.274.36.25308; Stevenson BR, 1998, ANNU REV CELL DEV BI, V14, P89, DOI 10.1146/annurev.cellbio.14.1.89; Tabuse Y, 1998, DEVELOPMENT, V125, P3607; Toker A., 1998, FRONT BIOSCI-LANDMRK, V3, P1134, DOI 10.2741/A350; UEMURA T, 1989, CELL, V58, P349, DOI 10.1016/0092-8674(89)90849-0; VINIEGRA S, 1988, J BIOL CHEM, V263, P7099; Wang YX, 1999, J BIOL CHEM, V274, P13859, DOI 10.1074/jbc.274.20.13859; WAYS DK, 1992, J BIOL CHEM, V267, P4799; White J., 1988, NEMATODE CAENORHABDI, V17, P81; Wu SL, 1998, J BIOL CHEM, V273, P1130, DOI 10.1074/jbc.273.2.1130; Yaich L, 1998, J BIOL CHEM, V273, P10381, DOI 10.1074/jbc.273.17.10381; Zhang LH, 2001, J BIOL CHEM, V276, P10476, DOI 10.1074/jbc.M008991200; Zhong WM, 1996, NEURON, V17, P43, DOI 10.1016/S0896-6273(00)80279-2; Zhou GS, 1997, J BIOL CHEM, V272, P31130, DOI 10.1074/jbc.272.49.31130; Zwahlen C, 2000, EMBO J, V19, P1505, DOI 10.1093/emboj/19.7.1505	68	9	11	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 30	2001	276	13					10463	10475		10.1074/jbc.M008990200	http://dx.doi.org/10.1074/jbc.M008990200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	420GC	11134024	hybrid			2022-12-25	WOS:000167996400114
J	Van Oosten, MV; Rensen, PCN; Van Amersfoort, ES; Van Eck, M; Van Dam, AM; Breve, JJP; Vogel, T; Panet, A; Van Berkel, TJC; Kuiper, J				Van Oosten, MV; Rensen, PCN; Van Amersfoort, ES; Van Eck, M; Van Dam, AM; Breve, JJP; Vogel, T; Panet, A; Van Berkel, TJC; Kuiper, J			Apolipoprotein E protects against-bacterial lipopolysaccharide-induced lethality - A new therapeutic approach to treat Gram-negative sepsis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; E-DEFICIENT MICE; BONE-MARROW TRANSPLANTATION; HIGH-DENSITY-LIPOPROTEINS; SEPTIC SHOCK; MONOCLONAL-ANTIBODY; CHYLOMICRONS ALTER; ENDOTOXEMIC SHOCK; CONTROLLED TRIAL; BINDING-PROTEIN	Septic shock is the most common cause of death in intensive care units and no effective treatment is available at present. Lipopolysaccharide (LPS) is the primary mediator of Gram-negative sepsis by inducing the production of macrophage-derived cytokines. Previously, we showed that apolipoprotein E (apoE), an established modulator of lipid metabolism, can bind LPS, thereby redirecting LPS from macrophages to hepatocytes in vivo. We now report that intravenously administered LPS strongly increases the serum levels of apoE. In addition, apoE can prevent the LPS-induced production of cytokines and subsequent death in rodents. Finally, apoE-deficient mice show a significantly higher sensitivity toward LPS than control wild-type mice. These findings indicate that apoE may have a physiological role in the protection against sepsis, and recombinant apoE may be used therapeutically to protect against LPS-induced endotoxemia.	Leiden Univ, Sylvius Labs, Leiden Amsterdam Ctr Drug Res, Div Biopharmaceut, NL-2300 RA Leiden, Netherlands; Free Univ Amsterdam, Fac Med, Dept Pharmacol, Neurosci Res Inst, NL-1081 BT Amsterdam, Netherlands; Biotechnol Gen Ltd, IL-76326 Rehovot, Israel	Leiden University; Leiden University - Excl LUMC; Vrije Universiteit Amsterdam	Kuiper, J (corresponding author), Leiden Univ, Sylvius Labs, Leiden Amsterdam Ctr Drug Res, Div Biopharmaceut, POB 9503, NL-2300 RA Leiden, Netherlands.	j.kuiper@lacdr.leidenuniv.nl	Rensen, Patrick C.N./D-7176-2018; van Amersfoort, Edwin S/J-9944-2018; Van Berkel, Theo/ABD-7677-2021	Rensen, Patrick C.N./0000-0002-8455-4988; 				AARDEN LA, 1987, EUR J IMMUNOL, V17, P1411, DOI 10.1002/eji.1830171004; ABRAHAM E, 1995, JAMA-J AM MED ASSOC, V273, P934, DOI 10.1001/jama.273.12.934; AUERBACH BJ, 1989, J BIOL CHEM, V264, P10264; Beutler B, 2000, CURR OPIN MICROBIOL, V3, P23, DOI 10.1016/S1369-5274(99)00046-6; BONE RC, 1995, CRIT CARE MED, V23, P994, DOI 10.1097/00003246-199506000-00003; CHENSUE SW, 1991, AM J PATHOL, V138, P395; de Bont N, 1999, J LIPID RES, V40, P680; Dinarello C A, 1994, Adv Pharmacol, V25, P21, DOI 10.1016/S1054-3589(08)60429-9; Dinarello CA, 1996, BLOOD, V87, P2095, DOI 10.1182/blood.V87.6.2095.bloodjournal8762095; FIEDLER VB, 1992, J LAB CLIN MED, V120, P574; FISHER CJ, 1994, JAMA-J AM MED ASSOC, V271, P1836, DOI 10.1001/jama.271.23.1836; FLEGEL WA, 1993, INFECT IMMUN, V61, P5140, DOI 10.1128/IAI.61.12.5140-5146.1993; Fraunberger P, 1997, ATHEROSCLEROSIS, V134, P349, DOI 10.1016/S0021-9150(97)89781-X; GALANOS C, 1979, P NATL ACAD SCI USA, V76, P5939, DOI 10.1073/pnas.76.11.5939; GALLAY P, 1993, P NATL ACAD SCI USA, V90, P9935, DOI 10.1073/pnas.90.21.9935; Giroir BP, 1997, LANCET, V350, P1439, DOI 10.1016/S0140-6736(97)06468-4; GLAUSER MP, 1991, LANCET, V338, P732, DOI 10.1016/0140-6736(91)91452-Z; HARRIS HW, 1993, J CLIN INVEST, V91, P1028, DOI 10.1172/JCI116259; HARRIS HW, 1990, J CLIN INVEST, V86, P696, DOI 10.1172/JCI114765; Harris HW, 1998, HEPATOLOGY, V27, P1341, DOI 10.1002/hep.510270521; Henderson B, 1996, MICROBIOL REV, V60, P316, DOI 10.1128/MMBR.60.2.316-341.1996; Heumann D, 1996, J ENDOTOXIN RES, V3, P87, DOI 10.1177/096805199600300201; HINSHAW LB, 1990, CIRC SHOCK, V30, P279; Laskowitz DT, 1997, J NEUROIMMUNOL, V76, P70, DOI 10.1016/S0165-5728(97)00021-0; Laskowitz DT, 1998, NEUROREPORT, V9, P615, DOI 10.1097/00001756-199803090-00010; LI P, 1995, CELL, V80, P401, DOI 10.1016/0092-8674(95)90490-5; LINTON MF, 1995, SCIENCE, V267, P1034, DOI 10.1126/science.7863332; MAHLEY RW, 1988, SCIENCE, V240, P622, DOI 10.1126/science.3283935; MATHISON JC, 1988, J CLIN INVEST, V81, P1925, DOI 10.1172/JCI113540; MISTRY MJ, 1995, CELL IMMUNOL, V160, P14, DOI 10.1016/0008-8749(95)80004-3; Netea MG, 1998, INFECT IMMUN, V66, P2365, DOI 10.1128/IAI.66.5.2365-2367.1998; PARKER TS, 1995, INFECT IMMUN, V63, P253, DOI 10.1128/IAI.63.1.253-258.1995; PARRILLO JE, 1990, ANN INTERN MED, V113, P227, DOI 10.7326/0003-4819-113-3-227; PARRILLO JE, 1993, NEW ENGL J MED, V328, P1471, DOI 10.1056/nejm199305203282008; Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085; RAETZ CRH, 1990, ANNU REV BIOCHEM, V59, P129, DOI 10.1146/annurev.bi.59.070190.001021; RAETZ CRH, 1991, FASEB J, V5, P2652, DOI 10.1096/fasebj.5.12.1916089; READ TE, 1993, INFECT IMMUN, V61, P3496, DOI 10.1128/IAI.61.8.3496-3502.1993; RENSEN PCN, 1995, NAT MED, V1, P221, DOI 10.1038/nm0395-221; Rensen PCN, 1997, J CLIN INVEST, V99, P2438, DOI 10.1172/JCI119427; RIETSCHEL ET, 1994, FASEB J, V8, P217, DOI 10.1096/fasebj.8.2.8119492; Roselaar SE, 1997, CIRCULATION, V96, P1937; TOBIAS PS, 1989, J BIOL CHEM, V264, P10867; TRACEY KJ, 1994, ANNU REV MED, V45, P491, DOI 10.1146/annurev.med.45.1.491; TRACEY KJ, 1987, NATURE, V330, P662, DOI 10.1038/330662a0; ULEVITCH RJ, 1979, J CLIN INVEST, V64, P1516, DOI 10.1172/JCI109610; VanEck M, 1997, ARTERIOSCL THROM VAS, V17, P3117, DOI 10.1161/01.ATV.17.11.3117; VANLENTEN BJ, 1986, P NATL ACAD SCI USA, V83, P2704; VANREE JH, 1994, ATHEROSCLEROSIS, V111, P25, DOI 10.1016/0021-9150(94)90188-0; VanVelzen AG, 1997, BIOCHEM J, V322, P411; WAAGE A, 1989, J EXP MED, V169, P333, DOI 10.1084/jem.169.1.333	51	140	142	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 23	2001	276	12					8820	8824		10.1074/jbc.M009915200	http://dx.doi.org/10.1074/jbc.M009915200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	413HV	11136731	hybrid			2022-12-25	WOS:000167607700029
J	Donahue, RJ; Razmara, M; Hoek, JB; Knudsen, TB				Donahue, RJ; Razmara, M; Hoek, JB; Knudsen, TB			Direct influence of the p53 tumor suppressor on mitochondrial biogenesis and function	FASEB JOURNAL			English	Article						16S rRNA; PK11195; peripheral benzodiazepine receptor	WILD-TYPE P53; BENZODIAZEPINE RECEPTOR; DNA MUTATIONS; CELL-LINE; APOPTOSIS; PROTEIN; MOUSE; IDENTIFICATION; LOCALIZATION; GENES	Mitochondrial localization of p53 has been observed in several cell systems, but an understanding of its organelle-based physiological activity remains incomplete. The purpose of the present study was to investigate the mitochondrial DNA genomic response to dominant-negative p53 mutant miniprotein (p53DD) fused to a mitochondrial import signal. Constructs were generated to express mitochondrial targeted enhanced green fluorescent protein (mEGFP) or dominant-negative mutant p53 miniprotein (m53DD) by in-frame fusion to the signal peptide sequence of murine Cox8l. Control cytosolic vectors (cEGFP, c53DD) had the signal sequence placed in antisense orientation. NIH 3T3 cells were transiently transfected with these vectors in various combinations. Mitochondrial 16S ribosomal RNA (16S rRNA) expression and fluorochrome staining with Mitotracker Red CMXRos (Delta Psim) were decreased in cells expressing m53DD, Both alterations were specific for mitochondrial import competence (e.g., m53DD vs. c53DD) as well as the passenger protein (e.g., m53DD vs. mEGFP). The normal functional state of mitochondria was restored with PK11195, a specific ligand of the mitochondrial peripheral-type benzodiazepine receptor. Negative dominance of m53DD on 16S rRNA expression and CMXRos staining, and rescue of these parameters with PK11195, imply a direct positive effect of p53 on mitochondrial biogenesis and function.-Donahue, R. J., Razmara, M., Hock, J. B., Knudsen, T. B. Direct influence of the p53 tumor suppressor on mitochondrial biogenesis and function.	Thomas Jefferson Univ, Jefferson Med Coll, Dept Pathol Anat & Cell Biol, Philadelphia, PA 19107 USA	Jefferson University	Knudsen, TB (corresponding author), Thomas Jefferson Univ, Jefferson Med Coll, Dept Pathol Anat & Cell Biol, 1020 Locust St, Philadelphia, PA 19107 USA.			Hoek, Jan/0000-0001-7127-4218	NIEHS NIH HHS [R01 ES09120, T32 ES07282] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES009120, T32ES007282] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		AUSUBELL FM, 1989, CURRENT PROTOCOLS MO; BIBB MJ, 1981, CELL, V26, P167, DOI 10.1016/0092-8674(81)90300-7; Bonsing BA, 1997, CYTOMETRY, V28, P11, DOI 10.1002/(SICI)1097-0320(19970501)28:1<11::AID-CYTO2>3.3.CO;2-H; Bourdon JC, 1997, ONCOGENE, V14, P85, DOI 10.1038/sj.onc.1200804; Bowman T, 1996, GENE DEV, V10, P826, DOI 10.1101/gad.10.7.826; CAHILL A, 1995, ANAL BIOCHEM, V232, P47, DOI 10.1006/abio.1995.9962; Castedo M, 1995, EUR J IMMUNOL, V25, P3277, DOI 10.1002/eji.1830251212; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; Choi J, 1999, CELL MOL LIFE SCI, V55, P38, DOI 10.1007/s000180050268; Crawford DR, 1997, FREE RADICAL BIO MED, V22, P551, DOI 10.1016/S0891-5849(96)00380-2; Demonacos CV, 1996, STEROIDS, V61, P226, DOI 10.1016/0039-128X(96)00019-0; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDIERY WS, 1992, NAT GENET, V1, P45; Fliss MS, 2000, SCIENCE, V287, P2017, DOI 10.1126/science.287.5460.2017; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; GOGLIA F, 1989, MOL CELL ENDOCRINOL, V62, P41, DOI 10.1016/0303-7207(89)90111-1; Goping IS, 1998, J CELL BIOL, V143, P207, DOI 10.1083/jcb.143.1.207; Graeber TG, 1996, NATURE, V379, P88, DOI 10.1038/379088a0; GRAEBER TG, 1994, MOL CELL BIOL, V14, P6264, DOI 10.1128/MCB.14.9.6264; Hirsch T, 1998, EXP CELL RES, V241, P426, DOI 10.1006/excr.1998.4084; Ibrahim MM, 1998, BBA-MOL CELL RES, V1403, P254, DOI 10.1016/S0167-4889(98)00066-4; IGLESIAS T, 1995, BIOCHEM BIOPH RES CO, V210, P995, DOI 10.1006/bbrc.1995.1755; Johnson TM, 1996, P NATL ACAD SCI USA, V93, P11848, DOI 10.1073/pnas.93.21.11848; KASTAN MB, 1991, CANCER RES, V51, P6304; Kato MV, 1999, LEUKEMIA LYMPHOMA, V33, P181, DOI 10.3109/10428199909093740; Katsumoto T, 1995, BIOL CELL, V84, P167, DOI 10.1016/0248-4900(96)89426-3; Knudsen TB, 2000, TERATOLOGY, V62, P238; Li PF, 1999, EMBO J, V18, P6027, DOI 10.1093/emboj/18.21.6027; Lill R, 1996, CURR OPIN CELL BIOL, V8, P505, DOI 10.1016/S0955-0674(96)80028-7; Linke SP, 1996, GENE DEV, V10, P934, DOI 10.1101/gad.10.8.934; Liu YA, 1998, MOL BIOL CELL, V9, P15, DOI 10.1091/mbc.9.1.15; MAKRIS GJ, 1995, BIOCHIM BIOPHYS ACTA, V1308, P197; Marchenko ND, 2000, J BIOL CHEM, V275, P16202, DOI 10.1074/jbc.275.21.16202; Marchetti P, 1996, CANCER RES, V56, P2033; McLure KG, 1996, ONCOGENE, V13, P1297; Merrick BA, 1996, BBA-PROTEIN STRUCT M, V1297, P57; MIYASHITA T, 1995, CELL, V80, P293; NELSON WG, 1994, MOL CELL BIOL, V14, P1815, DOI 10.1128/MCB.14.3.1815; Okamura S, 1999, ONCOL RES, V11, P281; Pastorino JG, 1996, J BIOL CHEM, V271, P29792, DOI 10.1074/jbc.271.47.29792; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Polyak K, 1998, NAT GENET, V20, P291, DOI 10.1038/3108; Prives C, 1999, J PATHOL, V187, P112; RIZZUTO R, 1995, CURR BIOL, V5, P635, DOI 10.1016/S0960-9822(95)00128-X; Sabapathy K, 1997, EMBO J, V16, P6217, DOI 10.1093/emboj/16.20.6217; SHAULIAN E, 1992, MOL CELL BIOL, V12, P581; SHAY JW, 1987, MUTAT RES, V186, P149, DOI 10.1016/0165-1110(87)90028-5; Smalheiser NR, 1996, MOL BIOL CELL, V7, P1003, DOI 10.1091/mbc.7.7.1003; WARBURG O, 1956, SCIENCE, V123, P309, DOI 10.1126/science.123.3191.309; Wolter KG, 1997, J CELL BIOL, V139, P1281, DOI 10.1083/jcb.139.5.1281; Wright G, 1999, EXP CELL RES, V246, P443, DOI 10.1006/excr.1998.4331	51	56	57	1	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAR	2001	15	3					635	644		10.1096/fj.00-0262com	http://dx.doi.org/10.1096/fj.00-0262com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	410BE	11259382				2022-12-25	WOS:000167419500021
J	Tohka, S; Laukkanen, ML; Jalkanen, S; Salmi, M				Tohka, S; Laukkanen, ML; Jalkanen, S; Salmi, M			Vascular adhesion protein 1 (VAP-1) functions as a molecular brake during granulocyte rolling and mediates recruitment in vivo	FASEB JOURNAL			English	Article						inflammation; rolling; extravasation; migration; monoamine oxidases	P-SELECTIN; IN-VIVO; TRANSENDOTHELIAL MIGRATION; LEUKOCYTE ACCUMULATION; LYMPHOCYTE BINDING; ENDOTHELIAL-CELLS; MICE DEFICIENT; SHEAR; PECAM-1; VENULES	Granulocyte extravasation from the blood into tissues is a prerequisite for a proper inflammatory response. It is regulated by a multistep adhesion cascade consisting of successive contacts between leukocyte surface receptors and their endothelial ligands on vessels. Vascular adhesion protein 1 (VAP-1) is an endothelial surface glycoprotein with two functions. It is an enzyme (monoamine oxidase) and an adhesion molecule for lymphocytes, Its function in binding of granulocytes or in leukocyte trafficking into sites of inflammation in vivo has remained unknown. Here we show that treatment of rabbits with anti-VAP-1 monoclonal antibodies abrogates similar to 70% of granulocyte extravasation into a site of an experimental inflammation, Using intravital microscopy, VAP-1 blockade is shown to increase the velocity of the rolling granulocytes and the frequency of their jerky skippings during the rolling. In addition, the number of firmly bound leukocytes decreased by 44% when VAP-1 was rendered nonfunctional, Our results suggest that VAP-1 functions as a molecular brake early in the adhesion cascade and consequently decreases the firm adherence; it may also directly influence the transmigration step. These data elucidate a new interplayer in the granulocyte extravasation process and provide a novel physiological function for a member of the monoamine oxidase family.	Turku Univ, MediCity Res Lab, FIN-20520 Turku, Finland; Natl Publ Hlth Inst, Turku, Finland; VTT Biotechnol & Food Res, Espoo, Finland	University of Turku; Finland National Institute for Health & Welfare; VTT Technical Research Center Finland	Salmi, M (corresponding author), Turku Univ, MediCity Res Lab, Tykistokatu 6A, FIN-20520 Turku, Finland.							Alon R, 1996, J CELL BIOL, V135, P849, DOI 10.1083/jcb.135.3.849; ARFORS KE, 1987, BLOOD, V69, P338; Armour KL, 1999, EUR J IMMUNOL, V29, P2613, DOI 10.1002/(SICI)1521-4141(199908)29:08<2613::AID-IMMU2613>3.0.CO;2-J; Baggiolini M, 1998, NATURE, V392, P565, DOI 10.1038/33340; Bianchi E, 1997, IMMUNOL TODAY, V18, P586, DOI 10.1016/S0167-5699(97)01162-6; BOSSE R, 1994, EUR J IMMUNOL, V24, P3019, DOI 10.1002/eji.1830241215; BULLARD DC, 1995, J CLIN INVEST, V95, P1782, DOI 10.1172/JCI117856; Butcher EC, 1996, SCIENCE, V272, P60, DOI 10.1126/science.272.5258.60; Chen SQ, 1999, J CELL BIOL, V144, P185, DOI 10.1083/jcb.144.1.185; DIAMOND MS, 1994, CURR BIOL, V4, P506, DOI 10.1016/S0960-9822(00)00111-1; Duncan GS, 1999, J IMMUNOL, V162, P3022; Frenette PS, 1996, CELL, V84, P563, DOI 10.1016/S0092-8674(00)81032-6; Jaakkola K, 1999, AM J PATHOL, V155, P1953, DOI 10.1016/S0002-9440(10)65514-9; JALKANEN S, 1987, J CELL BIOL, V105, P983, DOI 10.1083/jcb.105.2.983; Jung U, 1998, J CLIN INVEST, V102, P1526, DOI 10.1172/JCI119893; Kansas GS, 1996, BLOOD, V88, P3259, DOI 10.1182/blood.V88.9.3259.bloodjournal8893259; KETTLEBOROUGH CA, 1993, EUR J IMMUNOL, V23, P206, DOI 10.1002/eji.1830230132; KLINMAN JP, 1994, ANNU REV BIOCHEM, V63, P299, DOI 10.1146/annurev.bi.63.070194.001503; Kunkel EJ, 1996, CIRC RES, V79, P1196, DOI 10.1161/01.RES.79.6.1196; Kurkijarvi R, 1998, J IMMUNOL, V161, P1549; Ley K, 1998, CIRC RES, V83, P287, DOI 10.1161/01.RES.83.3.287; LEY K, 1991, CIRC RES, V69, P1034, DOI 10.1161/01.RES.69.4.1034; Lyles GA, 1996, INT J BIOCHEM CELL B, V28, P259, DOI 10.1016/1357-2725(95)00130-1; MCEVER RP, 1995, J BIOL CHEM, V270, P11025, DOI 10.1074/jbc.270.19.11025; MULLER WA, 1993, J EXP MED, V178, P449, DOI 10.1084/jem.178.2.449; Newman PJ, 1997, J CLIN INVEST, V99, P3, DOI 10.1172/JCI119129; OLOFSSON AM, 1994, BLOOD, V84, P2749, DOI 10.1182/blood.V84.8.2749.bloodjournal8482749; Salmi M, 1997, ADV IMMUNOL, V64, P139, DOI 10.1016/S0065-2776(08)60889-5; SALMI M, 1992, SCIENCE, V257, P1407, DOI 10.1126/science.1529341; Salmi M, 1996, J EXP MED, V183, P569, DOI 10.1084/jem.183.2.569; Salmi M, 1997, J EXP MED, V186, P589, DOI 10.1084/jem.186.4.589; SLIGH JE, 1993, P NATL ACAD SCI USA, V90, P8529, DOI 10.1073/pnas.90.18.8529; Smith DJ, 1998, J EXP MED, V188, P17, DOI 10.1084/jem.188.1.17; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; STEWART M, 1995, CURR OPIN CELL BIOL, V7, P690, DOI 10.1016/0955-0674(95)80111-1; VONANDRIAN UH, 1992, AM J PHYSIOL, V263, pH1034, DOI 10.1152/ajpheart.1992.263.4.H1034; Wakelin MW, 1996, J EXP MED, V184, P229, DOI 10.1084/jem.184.1.229; Walcheck B, 1996, J CLIN INVEST, V98, P1081, DOI 10.1172/JCI118888; Wilmot CM, 1999, SCIENCE, V286, P1724, DOI 10.1126/science.286.5445.1724	39	74	78	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	FEB	2001	15	2					373	382		10.1096/fj.00-0240com	http://dx.doi.org/10.1096/fj.00-0240com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	400LK	11156953				2022-12-25	WOS:000166872900019
J	Dedio, J; Konig, P; Wohlfart, P; Schroeder, C; Kummer, W; Muller-Esterl, W				Dedio, J; Konig, P; Wohlfart, P; Schroeder, C; Kummer, W; Muller-Esterl, W			NOSIP, a novel modulator of endothelial nitric oxide synthase activity	FASEB JOURNAL			English	Article						eNOS; yeast two-hybrid system; protein-protein interaction; subcellular trafficking	INDUCIBLE NO SYNTHASE; IN-VIVO; CAVEOLAE; CELLS; PROTEIN; PALMITOYLATION; TRANSLOCATION; CALMODULIN; RECEPTOR; DOMAIN	Production of nitric oxide (NO) in endothelial cells is regulated by direct interactions of endothelial nitric oxide synthase (eNOS) with effector proteins such as Ca2+-calmodulin, by posttranslational modifications such as phosphorylation via protein kinase B, and by translocation of the enzyme from the plasma membrane caveolae to intracellular compartments. Reversible acylation of eNOS is thought to contribute to the intracellular trafficking of the enzyme; however, protein factor(s) that govern the translocation of the enzyme are still unknown, Here we have used the yeast two-hybrid system and identified a novel 34 kDa protein, termed NOSIP (eNOS interacting protein), which avidly binds to the carboxyl-terminal region of the eNOS oxygenase domain. Coimmunoprecipitation studies demonstrated the specific interaction of eNOS and NOSIP in vitro and in vivo, and complex formation was inhibited by a synthetic peptide of the caveolin-1 scaffolding domain. NO production was significantly reduced in eNOS-expressing CHO cells (CHO-eNOS) that transiently overexpressed NOSIP, Stimulation with the calcium ionophore A23187 induced the reversible translocation of eNOS from the detergent-insoluble to the detergent-soluble fractions of CHO-eNOS, and this translocation was completely prevented by transient coexpression of NOSIP in CHO-eNOS, Immunofluorescence studies revealed a prominent plasma membrane staining for eNOS in CHO-eNOS that aas abolished in the presence of NOSIP. Subcellular fractionation studies identified eNOS in the caveolin-rich membrane fractions of CHO-eNOS, and coexpression of NOSIP caused a shift of eNOS to intracellular compartments, We conclude that NOSIP is a novel type of modulator that promotes translocation of eNOS from the plasma membrane to intracellular sites, thereby uncoupling eNOS from plasma membrane caveolae and inhibiting NO synthesis.	Johannes Gutenberg Univ Mainz, Inst Physiol Chem & Pathobiochem, D-55099 Mainz, Germany; Univ Hosp, Inst Biochem 2, Frankfurt, Germany; Univ Giessen, Inst Anat & Cell Biol, D-35385 Giessen, Germany; Aventis, Dis Grp Cardiovasc Agents, D-65926 Frankfurt, Germany	Johannes Gutenberg University of Mainz; Goethe University Frankfurt; Goethe University Frankfurt Hospital; Justus Liebig University Giessen; Sanofi-Aventis	Muller-Esterl, W (corresponding author), Univ Hosp, Inst Biochem 2, Theodor Stern Kai 7, D-60590 Frankfurt, Germany.	wme@biochem2.de	König, Peter/AAK-2021-2020	Kummer, Wolfgang/0000-0002-3946-0683				Beck KF, 1999, J EXP BIOL, V202, P645; BREDT DS, 1990, P NATL ACAD SCI USA, V87, P682, DOI 10.1073/pnas.87.2.682; BREDT DS, 1994, ANNU REV BIOCHEM, V63, P175, DOI 10.1146/annurev.bi.63.070194.001135; Brown GC, 1999, BBA-BIOENERGETICS, V1411, P351, DOI 10.1016/S0005-2728(99)00025-0; Couet J, 1997, J BIOL CHEM, V272, P6525, DOI 10.1074/jbc.272.10.6525; Dimmeler S, 1999, NATURE, V399, P601, DOI 10.1038/21224; Feron O, 1996, J BIOL CHEM, V271, P22810, DOI 10.1074/jbc.271.37.22810; Forstermann U, 1998, FASEB J, V12, P773; FORSTERMANN U, 1991, P NATL ACAD SCI USA, V88, P1788, DOI 10.1073/pnas.88.5.1788; Fulton D, 1999, NATURE, V399, P597, DOI 10.1038/21218; Garcia-Cardena G, 1998, NATURE, V392, P821, DOI 10.1038/33934; GarciaCardena G, 1996, P NATL ACAD SCI USA, V93, P6448, DOI 10.1073/pnas.93.13.6448; GarciaCardena G, 1997, J BIOL CHEM, V272, P25437, DOI 10.1074/jbc.272.41.25437; Gath I, 1996, FASEB J, V10, P1614, DOI 10.1096/fasebj.10.14.9002553; Ghosh S, 1998, J BIOL CHEM, V273, P22267, DOI 10.1074/jbc.273.35.22267; Goetz RM, 1999, P NATL ACAD SCI USA, V96, P2788, DOI 10.1073/pnas.96.6.2788; GOLEMIS EA, 1993, CURRENT PROTOCOLS MO, V3; GUO FH, 1995, P NATL ACAD SCI USA, V92, P7809, DOI 10.1073/pnas.92.17.7809; Ju H, 1998, J BIOL CHEM, V273, P24025, DOI 10.1074/jbc.273.37.24025; Ju H, 1997, J BIOL CHEM, V272, P18522, DOI 10.1074/jbc.272.30.18522; KUO MS, 1986, CARBOHYD RES, V156, P173, DOI 10.1016/S0008-6215(00)90109-5; Liu JW, 1997, J CELL BIOL, V137, P1525, DOI 10.1083/jcb.137.7.1525; Liu JW, 1996, BIOCHEMISTRY-US, V35, P13277, DOI 10.1021/bi961720e; LUNDSTROM K, 1995, J RECEPT SIGNAL TR R, V15, P23, DOI 10.3109/10799899509045204; Michel JB, 1997, J BIOL CHEM, V272, P25907, DOI 10.1074/jbc.272.41.25907; Michel T, 1997, J CLIN INVEST, V100, P2146, DOI 10.1172/JCI119750; MICHEL T, 1993, P NATL ACAD SCI USA, V90, P6252, DOI 10.1073/pnas.90.13.6252; NATHAN C, 1994, CELL, V78, P915, DOI 10.1016/0092-8674(94)90266-6; Prabhakar P, 1998, J BIOL CHEM, V273, P27383, DOI 10.1074/jbc.273.42.27383; ROBINSON LJ, 1995, J BIOL CHEM, V270, P995, DOI 10.1074/jbc.270.3.995; Shaul PW, 1996, J BIOL CHEM, V271, P6518, DOI 10.1074/jbc.271.11.6518; Song KS, 1996, J BIOL CHEM, V271, P9690, DOI 10.1074/jbc.271.16.9690; Sowa G, 1999, J BIOL CHEM, V274, P22524, DOI 10.1074/jbc.274.32.22524; Wohlfart P, 1997, J PHARMACOL EXP THER, V280, P1109	34	134	142	1	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2001	15	1					79	89		10.1096/fj.00-0078com	http://dx.doi.org/10.1096/fj.00-0078com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	390TH	11149895				2022-12-25	WOS:000166312400016
J	Yegutkin, GG; Henttinen, T; Jalkanen, S				Yegutkin, GG; Henttinen, T; Jalkanen, S			Extracellular ATP formation on vascular endothelial cells is mediated by ecto-nucleotide kinase activities via phosphotransfer reactions	FASEB JOURNAL			English	Article						adenine nucleotides; ecto-enzymes; hydrolysis; interconversion; vasculature	SMOOTH-MUSCLE CELLS; ADENINE-NUCLEOTIDES; DIPHOSPHOHYDROLASE; SYNTHASE; SURFACE; CD39; IDENTIFICATION; LYMPHOCYTES; EXPRESSION; HYDROLYSIS	Cell surface ecto-nucleotidases are considered the major effector system for inactivation of extracellular adenine nucleotides, whereas the alternative possibility of ATP synthesis has received little attention, Using a TLC assay, we investigated the main exchange activities of H-3-labeled adenine nucleotides on the cultured human umbilical vein endothelial cells, Stepwise nucleotide degradation to adenosine occurred when a particular nucleotide was present alone, whereas combined cell treatment with ATP and either [H-3]AMP or [H-3]ADP caused unexpected phosphorylation of H-3-nucleotides via the backward reactions AMP --> ADP --> ATP. The following two groups of nucleotide-converting ecto-enzymes were identified based on inhibition and substrate specificity studies: 1) ecto-nucleotidases, ATP-diphosphohydrolase, and 5'-nucleotidase; 2) ecto-nucleotide kinases, adenylate kinase, and nucleoside diphosphate kinase. Ecto-nucleoside diphosphate kinase possessed the highest activity, as revealed by comparative kinetic analysis, and was capable of using both adenine and nonadenine nucleotides as phosphate donors and acceptors. The transphosphorylation mechanism was confirmed by direct transfer of the gamma -phosphate from [gamma-P-32]ATP to AMP or nucleoside diphosphates and by measurement of extracellular ATP synthesis using luciferin-luciferase luminometry, The data demonstrate the coexistence of opposite, ATP-consuming and ATP-generating, pathways on the cell surface and provide a novel mechanism for regulating the duration and magnitude of purinergic signaling in the vasculature.	Univ Turku, MediCity Res Lab, FIN-20520 Turku, Finland; Natl Publ Hlth Inst, FIN-20520 Turku, Finland	University of Turku; Finland National Institute for Health & Welfare	Yegutkin, GG (corresponding author), Univ Turku, MediCity Res Lab, Tykistokatu 6A, FIN-20520 Turku, Finland.		Yegutkin, Gennady G./K-3815-2014	Yegutkin, Gennady G./0000-0001-6684-7982				AGREN G, 1974, J CELL PHYSIOL, V83, P91, DOI 10.1002/jcp.1040830113; Airas L, 1997, J CELL BIOL, V136, P421, DOI 10.1083/jcb.136.2.421; Boyer PD, 1997, ANNU REV BIOCHEM, V66, P717, DOI 10.1146/annurev.biochem.66.1.717; Burnstock G, 1997, NEUROPHARMACOLOGY, V36, P1127, DOI 10.1016/S0028-3908(97)00125-1; Clifford EE, 1997, AM J PHYSIOL-CELL PH, V273, pC973, DOI 10.1152/ajpcell.1997.273.3.C973; DAS B, 1994, J EXP MED, V180, P273, DOI 10.1084/jem.180.1.273; DUBYAK GR, 1993, AM J PHYSIOL, V265, pC577, DOI 10.1152/ajpcell.1993.265.3.C577; Dzeja PP, 1998, FASEB J, V12, P523, DOI 10.1096/fasebj.12.7.523; Enjyoji K, 1999, NAT MED, V5, P1010, DOI 10.1038/12447; Goding JW, 1998, IMMUNOL REV, V161, P11, DOI 10.1111/j.1600-065X.1998.tb01568.x; GORDON EL, 1989, J BIOL CHEM, V264, P18986; Grobben B, 1999, J NEUROCHEM, V72, P826, DOI 10.1046/j.1471-4159.1999.0720826.x; Harden TK, 1999, PROG BRAIN RES, V120, P135; HARDEN TK, 1995, ANNU REV PHARMACOL, V35, P541, DOI 10.1146/annurev.pharmtox.35.1.541; Ilangumaran S, 2000, IMMUNOL TODAY, V21, P2, DOI 10.1016/S0167-5699(99)01494-2; Kaczmarek E, 1996, J BIOL CHEM, V271, P33116, DOI 10.1074/jbc.271.51.33116; Koziak K, 1999, THROMB HAEMOSTASIS, V82, P1538; Lazarowski ER, 1997, J BIOL CHEM, V272, P20402, DOI 10.1074/jbc.272.33.20402; LAZAROWSKI ER, 2000, 2 INT WORKSH ECT REL, P283; Marcus AJ, 1997, J CLIN INVEST, V99, P1351, DOI 10.1172/JCI119294; MEGHJI P, 1995, BIOCHEM J, V308, P725, DOI 10.1042/bj3080725; Moser TL, 1999, P NATL ACAD SCI USA, V96, P2811, DOI 10.1073/pnas.96.6.2811; NORMAN GA, 1974, J CHROMATOGR, V90, P105, DOI 10.1016/S0021-9673(01)94779-X; PEARSON JD, 1980, BIOCHEM J, V190, P421, DOI 10.1042/bj1900421; Piacentini L, 1996, MOL CELL BIOCHEM, V157, P59; PLESNER L, 1995, INT REV CYTOL, V158, P141; Postel EH, 1998, INT J BIOCHEM CELL B, V30, P1291, DOI 10.1016/S1357-2725(98)00087-9; Ralevic V, 1998, PHARMACOL REV, V50, P413; Resta R, 1998, IMMUNOL REV, V161, P95, DOI 10.1111/j.1600-065X.1998.tb01574.x; ROBSON S, 2000, EMERGING THER TARGET, V4, P155; RONQUIST G, 1968, ACTA PHYSIOL SCAND, V74, P594, DOI 10.1111/j.1748-1716.1968.tb04270.x; Wang TF, 1996, J BIOL CHEM, V271, P9898, DOI 10.1074/jbc.271.17.9898; Yan HG, 1999, ADV ENZYMOL RAMB, V73, P103, DOI 10.1002/9780470123195.ch4; Yegutkin G, 2000, BRIT J PHARMACOL, V129, P921, DOI 10.1038/sj.bjp.0703136; Yegutkin GG, 1998, BBA-BIOMEMBRANES, V1373, P227, DOI 10.1016/S0005-2736(98)00108-4; ZIMMER AM, 1992, ANTIBODY IMMUNOCONJ, V5, P285; Zimmermann H, 1999, TRENDS PHARMACOL SCI, V20, P231, DOI 10.1016/S0165-6147(99)01293-6; Zimmermann H, 1996, PROG NEUROBIOL, V49, P589, DOI 10.1016/0301-0082(96)00026-3	38	104	105	2	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JAN	2001	15	1					251	260		10.1096/fj.00-0268com	http://dx.doi.org/10.1096/fj.00-0268com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	390TH	11149913				2022-12-25	WOS:000166312400034
J	Kruzelock, RP; Cuevas, BD; Wiener, JR; Xu, FJ; Yu, YH; Cabeza-Arvelaiz, Y; Pershouse, M; Lovell, MM; Killary, AM; Mills, GB; Bast, RC				Kruzelock, RP; Cuevas, BD; Wiener, JR; Xu, FJ; Yu, YH; Cabeza-Arvelaiz, Y; Pershouse, M; Lovell, MM; Killary, AM; Mills, GB; Bast, RC			Functional evidence for an ovarian cancer tumor suppressor gene on chromosome 22 by microcell-mediated chromosome transfer	ONCOGENE			English	Article						ovarian cancer; human chromosome 22; tumor suppressor genes; microcell-mediated chromosome transfer	NEUROFIBROMATOSIS TYPE-2 GENE; ADENOCARCINOMA CELL-LINES; FREQUENT LOSS; ALLELE LOSS; LONG ARM; SPORADIC MENINGIOMAS; MAMMALIAN-CELLS; LOW-GRADE; NF2 GENE; HETEROZYGOSITY	The identity of many tumor suppressor genes important in epithelial ovarian cancer tumorigenesis remains unknown. In an effort to localize a novel tumor suppressor on chromosome 22, a psv(2)neo tagged human chromosome 22 was transferred into the malignant epithelial ovarian cancer cell line, SKOV-3, by microcell-mediated chromosome transfer. Complete suppression of the transformed phenotype was observed in 16 of 18 individual microcell hybrid clones as evidenced by the complete abrogation of cell growth under anchorage-independent conditions. In vitro doubling times were also dramatically reduced, as was the ability to, form subcutaneous tumors in CD1 nu/nu mice. Only one polymorphic marker, D22S429, segregated with decreased transformation and tumorigenic potential, suggesting that an unrecognized tumor suppressor may localize to chromosome 22q11-q12, These data provide functional support for the presence of a novel tumor suppressor locus (or loci) on chromosome 22 that is important in ovarian cancer tumorigenesis.	Baylor Coll Med, Howard Hughes Med Inst, Houston, TX 77030 USA; Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Mol Oncol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Clin Invest, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Div Med, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Div Lab Med, Houston, TX 77030 USA; Grad Sch Biomed Sci, Houston, TX 77225 USA	Baylor College of Medicine; Howard Hughes Medical Institute; Baylor College of Medicine; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Kruzelock, RP (corresponding author), Baylor Coll Med, Howard Hughes Med Inst, Houston, TX 77030 USA.		Yu, Yan/GYV-4514-2022; Bast, Robert C/E-6585-2011	Bast, Robert C/0000-0003-4621-8462				AKAGI K, 1995, INT J CANCER, V60, P178, DOI 10.1002/ijc.2910600208; ALHADEFF B, 1977, CYTOGENET CELL GENET, V19, P236, DOI 10.1159/000130814; ALLAN GJ, 1994, HUM MUTAT, V3, P283, DOI 10.1002/humu.1380030317; AMFO K, 1995, ONCOGENE, V11, P351; ANDERSON MJ, 1993, FASEB J, V7, P826, DOI 10.1096/fasebj.7.10.8344482; Bandera CA, 1997, CANCER RES, V57, P513; BIEGEL JA, 1996, GENE CHROMOSOME CANC, V16, P84; Boente Matthew P., 1993, Current Opinion in Oncology, V5, P900, DOI 10.1097/00001622-199309000-00020; BOLGER GB, 1985, NEW ENGL J MED, V312, P564, DOI 10.1056/NEJM198502283120907; Bryan EJ, 1996, CANCER RES, V56, P719; BUICK RN, 1985, CANCER RES, V45, P3668; BUIJS A, 1995, ONCOGENE, V10, P1511; BURGERS PMJ, 1987, ANAL BIOCHEM, V163, P391, DOI 10.1016/0003-2697(87)90240-5; CHENEVIXTRENCH G, 1992, ONCOGENE, V7, P1059; CHENEVIXTRENCH G, 1994, AM J HUM GENET, V55, P143; Cheng PC, 1996, J NATL CANCER I, V88, P510, DOI 10.1093/jnci/88.8.510; CLIBY W, 1993, CANCER RES, V53, P2393; COGEN PH, 1991, CANCER GENET CYTOGEN, V53, P271, DOI 10.1016/0165-4608(91)90104-3; COLLINS JE, 1995, NATURE, V377, P367; DEPREZ RHL, 1995, ONCOGENE, V10, P1521; DODSON MK, 1993, CANCER RES, V53, P4456; DRACOPLOI NC, 1997, CURRENT PROTOCOLS HU; DUMANSKI JP, 1990, CANCER RES, V50, P5863; DUMANSKI JP, 1987, P NATL ACAD SCI USA, V84, P9275, DOI 10.1073/pnas.84.24.9275; ECCLES DM, 1992, ONCOGENE, V7, P2069; ECCLES DM, 1992, BRIT J CANCER, V65, P40, DOI 10.1038/bjc.1992.8; ECCLES DM, 1992, DIS MARKERS, V10, P95; Edelson MI, 1997, ONCOGENE, V14, P2979, DOI 10.1038/sj.onc.1201271; EHLEN T, 1990, ONCOGENE, V5, P219; ENGLEFIELD P, 1994, BRIT J CANCER, V70, P905, DOI 10.1038/bjc.1994.418; Gallion HH, 1996, AM J OBSTET GYNECOL, V174, P1102, DOI 10.1016/S0002-9378(96)70651-8; GALLION HH, 1992, GYNECOL ONCOL, V47, P137, DOI 10.1016/0090-8258(92)90096-2; Hatta Y, 1997, BRIT J CANCER, V75, P1256, DOI 10.1038/bjc.1997.214; IRVING RM, 1993, ARCH OTOLARYNGOL, V119, P1222; IWABUCHI H, 1995, CANCER RES, V55, P6172; Jacoby LB, 1996, GENE CHROMOSOME CANC, V17, P45, DOI 10.1002/(SICI)1098-2264(199609)17:1<45::AID-GCC7>3.0.CO;2-2; Kerr J, 1996, ONCOGENE, V13, P1815; KILLARY AM, 1995, METHOD ENZYMOL, V254, P133; KINZLER KW, 1993, NATURE, V363, P495, DOI 10.1038/363495a0; Kruzelock RP, 1997, CANCER RES, V57, P106; LEE JH, 1990, CANCER RES, V50, P2724; LEE JH, 1989, CANCER RES, V49, P1220; LI SB, 1991, J NATL CANCER I, V83, P637, DOI 10.1093/jnci/83.9.637; MARKIE D, 1993, SOMAT CELL MOLEC GEN, V19, P161, DOI 10.1007/BF01233531; MENDEZ MJ, 1991, GENOMICS, V10, P661, DOI 10.1016/0888-7543(91)90449-O; NG HK, 1995, NEUROSURGERY, V37, P764, DOI 10.1227/00006123-199510000-00022; PACHNIS V, 1990, P NATL ACAD SCI USA, V87, P5109, DOI 10.1073/pnas.87.13.5109; PAPI L, 1995, HUM GENET, V95, P347, DOI 10.1007/BF00225206; PEYRARD M, 1994, HUM MOL GENET, V3, P1393, DOI 10.1093/hmg/3.8.1393; RIMESSI P, 1994, ONCOGENE, V9, P3467; RISINGER JI, 1994, NAT GENET, V7, P98, DOI 10.1038/ng0594-98; RUTTLEDGE MH, 1994, NAT GENET, V6, P180, DOI 10.1038/ng0294-180; SAITO S, 1992, CANCER RES, V52, P5815; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SANSON M, 1993, HUM MOL GENET, V2, P1215, DOI 10.1093/hmg/2.8.1215; SATO T, 1991, CANCER RES, V51, P5118; SCHNEIDER G, 1992, HUM GENET, V88, P579, DOI 10.1007/BF00219348; Schofield DE, 1996, GENE CHROMOSOME CANC, V15, P10, DOI 10.1002/(SICI)1098-2264(199601)15:1<10::AID-GCC2>3.3.CO;2-1; SHIN E, 1993, JPN J CANCER RES, V84, P402, DOI 10.1111/j.1349-7006.1993.tb00150.x; SHISEKI M, 1994, CANCER RES, V54, P5643; SILVERMAN M, 1997, P AM ASSOC CANC RES, V38, P1018; SMIDT M, 1990, J CLIN INVEST, V86, P1151, DOI 10.1172/JCI114820; STANBRIDGE EJ, 1978, P NATL ACAD SCI USA, V75, P1466, DOI 10.1073/pnas.75.3.1466; STECK PA, 1995, GENE CHROMOSOME CANC, V12, P255; TAKAHASHI K, 1993, HEPATOLOGY, V17, P794, DOI 10.1002/hep.1840170508; TANAKA N, 1992, GENE CHROMOSOME CANC, V5, P399, DOI 10.1002/gcc.2870050416; Versteege I, 1998, NATURE, V394, P203, DOI 10.1038/28212; WELLENREUTHER R, 1995, AM J PATHOL, V146, P827; YANA I, 1995, INT J CANCER, V60, P174, DOI 10.1002/ijc.2910600207; ZENKLUSEN JC, 1995, ONCOGENE, V11, P359	70	8	8	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 14	2000	19	54					6277	6285		10.1038/sj.onc.1204013	http://dx.doi.org/10.1038/sj.onc.1204013			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	388YK	11175342				2022-12-25	WOS:000166210500011
J	Johnstone, RW; Wei, W; Greenway, A; Trapani, JA				Johnstone, RW; Wei, W; Greenway, A; Trapani, JA			Functional interaction between p53 and the interferon-inducible nucleoprotein IFI 16	ONCOGENE			English	Article						transcription; IFI 16; p53; interferon	NUCLEAR DIFFERENTIATION ANTIGEN; TUMOR-SUPPRESSOR P53; DNA-BINDING FUNCTION; TRANSCRIPTIONAL ACTIVATION; CELL-PROLIFERATION; PROTEIN P202; INHIBITION; GENE; EXPRESSION; CLUSTER	Interferons are important in regulating cell growth and differentiation, immune function and initiating anti-viral responses. While the pleotrophic actions of interferons have been well documented, the molecular mechanisms underpinning their biological effects have not been fully characterized. IFI 16 is a member of the interferon-inducible HIN-200 family of nuclear proteins, which we have recently shown can function as a potent transcriptional repressor. A murine member of the HIN-200 family, p202, can indirectly interact with p53 via the p53 binding protein (p53bp) and inhibit p53-mediated transcriptional activation. The binding activity of p202 to p53bp was shown to require the conserved MFHATVAT motif present in all 200 amino acid repeat regions of HIN-200 proteins. Given that IFI 16 contains two MFHATVAT motifs, we sought to determine whether IFI 16 may form a complex with p53 and if so to ascertain the functional significance of this interaction. We demonstrate that IFI 16 can directly bind to the C-terminal region of p53 and augment p53-mediated transcriptional activation without altering the steady state levels of p53. Thus, in addition to its ability to directly regulate gene expression, IFI 16 can also modulate the transcription function of other cellular transcription factors. These findings demonstrate a possible link between gene induction following interferon stimulation and p53-mediated cellular events.	Peter MacCallum Canc Inst, Gene Regulat Lab, Canc Immunol Div, Melbourne, Vic 3002, Australia; Macfarlane Burnet Ctr Med Res, Fairfield, Vic 3078, Australia	Peter Maccallum Cancer Center	Johnstone, RW (corresponding author), Peter MacCallum Canc Inst, Gene Regulat Lab, Canc Immunol Div, Smorgon Family Bldg,St Andrews Pl, Melbourne, Vic 3002, Australia.		Johnstone, Ricky w/H-3748-2014	Johnstone, Ricky w/0000-0001-7053-9237; Trapani, Joseph/0000-0003-0983-1532				Arany I, 1996, IN VIVO, V10, P119; BURRUS GR, 1992, J CELL BIOCHEM, V48, P190, DOI 10.1002/jcb.240480210; CHEN JD, 1993, MOL CELL BIOL, V13, P4107, DOI 10.1128/MCB.13.7.4107; Choubey D, 1996, EMBO J, V15, P5668, DOI 10.1002/j.1460-2075.1996.tb00951.x; CHOUBEY D, 1989, J BIOL CHEM, V264, P17182; Choubey D, 1997, ONCOGENE, V15, P291, DOI 10.1038/sj.onc.1201184; CHOUBEY D, 1995, J BIOL CHEM, V270, P6134, DOI 10.1074/jbc.270.11.6134; Cuddihy AR, 1999, MOL CELL BIOL, V19, P2475; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Datta B, 1996, J BIOL CHEM, V271, P27544, DOI 10.1074/jbc.271.44.27544; Datta B, 1998, MOL CELL BIOL, V18, P1074, DOI 10.1128/MCB.18.2.1074; DAWSON MJ, 1995, BIOCHEM BIOPH RES CO, V214, P152, DOI 10.1006/bbrc.1995.2269; DAWSON MJ, 1996, J LEUKOCYTE BIOL, V60, P1; DeYoung KL, 1997, ONCOGENE, V15, P453, DOI 10.1038/sj.onc.1201206; DUHL DM, 1989, J CELL PHYSIOL, V141, P148, DOI 10.1002/jcp.1041410122; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Fuchs SY, 1998, ONCOGENE, V17, P2543, DOI 10.1038/sj.onc.1202200; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; Gribaudo G, 1997, EUR J BIOCHEM, V249, P258, DOI 10.1111/j.1432-1033.1997.t01-1-00258.x; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; Gutterman JU, 1999, CELL GROWTH DIFFER, V10, P93; Hobeika AC, 1999, J INTERF CYTOK RES, V19, P1351, DOI 10.1089/107999099312812; HUPP TR, 1993, NUCLEIC ACIDS RES, V21, P3167, DOI 10.1093/nar/21.14.3167; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; Johnstone RW, 1998, J BIOL CHEM, V273, P17172, DOI 10.1074/jbc.273.27.17172; Johnstone RW, 1998, BIOCHEMISTRY-US, V37, P11924, DOI 10.1021/bi981069a; Johnstone RW, 1999, MOL CELL BIOL, V19, P5833; KAELIN WG, 1991, CELL, V64, P521, DOI 10.1016/0092-8674(91)90236-R; Koul D, 1998, BIOCHEM BIOPH RES CO, V247, P379, DOI 10.1006/bbrc.1998.8804; Lambert PF, 1998, J BIOL CHEM, V273, P33048, DOI 10.1074/jbc.273.49.33048; Landolfo S, 1998, BIOCHIMIE, V80, P721, DOI 10.1016/S0300-9084(99)80025-X; Lembo D, 1995, J BIOL REG HOMEOS AG, V9, P42; Lembo M, 1998, ONCOGENE, V16, P1543, DOI 10.1038/sj.onc.1201677; LENGYEL P, 1995, SEMIN VIROL, V6, P203, DOI 10.1006/smvy.1995.0025; Liu CJ, 1999, EMBO J, V18, P2845, DOI 10.1093/emboj/18.10.2845; Marston NJ, 1998, ONCOGENE, V16, P3123, DOI 10.1038/sj.onc.1201856; Matsuzawa S, 1998, EMBO J, V17, P2736, DOI 10.1093/emboj/17.10.2736; MCLEAN IW, 1974, J HISTOCHEM CYTOCHEM, V22, P1077, DOI 10.1177/22.12.1077; Min W, 1996, MOL CELL BIOL, V16, P359; MIYASHITA T, 1995, CELL, V80, P293; Rodriguez MS, 1999, EMBO J, V18, P6455, DOI 10.1093/emboj/18.22.6455; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; Shaw P, 1996, ONCOGENE, V12, P921; SHI Y, 1991, CELL, V67, P377, DOI 10.1016/0092-8674(91)90189-6; SHI Y, 1997, BIOCHIM BIOPHYS ACTA, V1332, P49; Stark GR, 1998, ANNU REV BIOCHEM, V67, P227, DOI 10.1146/annurev.biochem.67.1.227; STENGER JE, 1994, EMBO J, V13, P6011, DOI 10.1002/j.1460-2075.1994.tb06947.x; Subramaniam PS, 1997, J INTERF CYTOK RES, V17, P11, DOI 10.1089/jir.1997.17.11; Tanaka N, 1996, NATURE, V382, P816, DOI 10.1038/382816a0; TANNENBAUM CS, 1993, J LEUKOCYTE BIOL, V53, P563, DOI 10.1002/jlb.53.5.563; TRAPANI JA, 1992, IMMUNOGENETICS, V36, P369; TRAPANI JA, 1993, BIOCHEM BIOPH RES CO, V195, P910, DOI 10.1006/bbrc.1993.2131; WANG ZY, 1993, J BIOL CHEM, V268, P9972; Xie JP, 1998, J CELL BIOCHEM, V70, P489, DOI 10.1002/(SICI)1097-4644(19980915)70:4<489::AID-JCB6>3.0.CO;2-F; Yan DH, 1999, ONCOGENE, V18, P807, DOI 10.1038/sj.onc.1202369; YEW PR, 1992, NATURE, V357, P82, DOI 10.1038/357082a0	56	79	85	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 7	2000	19	52					6033	6042		10.1038/sj.onc.1204005	http://dx.doi.org/10.1038/sj.onc.1204005			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	382MY	11146555				2022-12-25	WOS:000165827900010
J	Schulbach, MC; Mahapatra, S; Macchia, M; Barontini, S; Papi, C; Minutolo, F; Bertini, S; Brennan, PJ; Crick, DC				Schulbach, MC; Mahapatra, S; Macchia, M; Barontini, S; Papi, C; Minutolo, F; Bertini, S; Brennan, PJ; Crick, DC			Purification, enzymatic characterization, and inhibition of the Z-farnesyl diphosphate synthase from Mycobacterium tuberculosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UNDECAPRENYL PYROPHOSPHATE SYNTHETASE; CIS-ISOPRENYLTRANSFERASE ACTIVITY; SUBSTRATE-SPECIFICITY; LACTOBACILLUS-PLANTARUM; BIOSYNTHESIS; PRENYLTRANSFERASE; IDENTIFICATION; INTERMEDIATE; TRANSFERASE; MUTAGENESIS	We have recently shown that open reading frame Rv1086 of the Mycobacterium tuberculosis H37Rv genome sequence encodes a unique isoprenyl diphosphate synthase. The product of this enzyme, omega ,E,Z-farnesyl diphosphate, is an intermediate for the synthesis of decaprenyl phosphate, which has a central role in the biosynthesis of most features of the mycobacterial cell wall, including peptidoglycan, arabinan, linker unit galactan, and lipoarabinomannan. We have now purified Z-farnesyl diphosphate synthase to near homogeneity using a novel mycobacterial expression system. Z-Farnesyl diphosphate synthase catalyzed the addition of isopentenyl diphosphate to omega ,E-geranyl diphosphate or omega ,Z-neryl diphosphate yielding omega ,E,Z-farnesyl diphosphate and omega ,Z,Z-farnesyl diphosphate, respectively. The enzyme has an absolute requirement for a divalent cation, an optimal pH range of 7-8, and K-m values of 124 muM for isopentenyl diphosphate, 38 muM for geranyl diphosphate, and 16 muM for neryl diphosphate. Inhibitors of the Z-farnesyl diphosphate synthase were designed and chemically synthesized as stable analogs of omega ,E-geranyl diphosphate in which the labile diphosphate moiety was replaced with stable moieties. Studies with these compounds revealed that the active site of Z-farnesyl diphosphate synthase differs substantially from E-farnesyl diphosphate synthase from pig brain (Sus scrofa).	Colorado State Univ, Dept Microbiol, Ft Collins, CO 80523 USA; Univ Pisa, Dipartimento Sci Farmaceut, I-56126 Pisa, Italy	Colorado State University; University of Pisa	Crick, DC (corresponding author), Colorado State Univ, Dept Microbiol, Ft Collins, CO 80523 USA.		Minutolo, Filippo/A-7480-2011; Mahapatra, Sebabrata/D-6033-2017; Crick, Dean/H-8251-2017	Minutolo, Filippo/0000-0002-3312-104X; Crick, Dean/0000-0001-9281-7058; BERTINI, SIMONE/0000-0001-8832-8075; MACCHIA, MARCO/0000-0002-5565-2044	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI018357, R37AI018357, R22AI018357] Funding Source: NIH RePORTER; NIAID NIH HHS [AI46393, AI18357] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALLEN CM, 1976, ARCH BIOCHEM BIOPHYS, V175, P236, DOI 10.1016/0003-9861(76)90504-X; ANDERSON RG, 1972, BIOCHEM J, V127, P11, DOI 10.1042/bj1270011; Apfel CM, 1999, J BACTERIOL, V181, P483, DOI 10.1128/JB.181.2.483-492.1999; BABA T, 1985, J BIOL CHEM, V260, P467; BABA T, 1978, BIOCHEMISTRY-US, V17, P5598, DOI 10.1021/bi00619a003; Baddiley J, 1972, Essays Biochem, V8, P35; Besra GS, 1997, J BIOL CHEM, V272, P18460, DOI 10.1074/jbc.272.29.18460; BESRA GS, 1994, P NATL ACAD SCI USA, V91, P12735, DOI 10.1073/pnas.91.26.12735; Cole ST, 1998, NATURE, V393, P537, DOI 10.1038/31159; COOKE MP, 1981, SYNTHESIS STUTTGART, V4, P283; CRICK DC, 1991, J NEUROCHEM, V57, P1354, DOI 10.1111/j.1471-4159.1991.tb08301.x; CRICK DC, 1994, J BIOL CHEM, V269, P10559; CRICK DC, 1994, J NEUROCHEM, V62, P247; DAVISSON VJ, 1985, METHOD ENZYMOL, V110, P130; DEWICK PM, 1995, NAT PROD REP, V12, P507, DOI 10.1039/np9951200507; DORSEY JK, 1966, J BIOL CHEM, V241, P5353; ERICSSON J, 1992, J BIOL CHEM, V267, P19730; ERICSSON J, 1991, EUR J BIOCHEM, V202, P789, DOI 10.1111/j.1432-1033.1991.tb16434.x; FUJII H, 1982, BIOCHIM BIOPHYS ACTA, V712, P716; GREEN TR, 1974, BIOCHEMISTRY-US, V13, P4720, DOI 10.1021/bi00720a007; HIGASHI Y, 1970, J BIOL CHEM, V245, P3683; HOLLOWAY PW, 1967, BIOCHEM J, V104, P57, DOI 10.1042/bj1040057; ISHII K, 1986, BIOCHEM J, V233, P773, DOI 10.1042/bj2330773; KEENAN MV, 1974, ARCH BIOCHEM BIOPHYS, V161, P375, DOI 10.1016/0003-9861(74)90318-X; Kellogg BA, 1997, CURR OPIN CHEM BIOL, V1, P570, DOI 10.1016/S1367-5931(97)80054-3; KOYAMA T, 1977, J BIOCHEM-TOKYO, V82, P1585, DOI 10.1093/oxfordjournals.jbchem.a131853; Koyama T, 2000, BIOCHEMISTRY-US, V39, P463, DOI 10.1021/bi991621b; Macchia M, 1996, J MED CHEM, V39, P1352, DOI 10.1021/jm960127s; MACCHIA M, 1997, Patent No. 9719091; Mikusova K, 1996, J BIOL CHEM, V271, P7820, DOI 10.1074/jbc.271.13.7820; Narita K, 1999, J BIOCHEM-TOKYO, V126, P566, DOI 10.1093/oxfordjournals.jbchem.a022487; OGURA K, 1969, J BIOCHEM-TOKYO, V66, P117, DOI 10.1093/oxfordjournals.jbchem.a129113; Ohnuma S, 1996, J BIOL CHEM, V271, P18831, DOI 10.1074/jbc.271.31.18831; Ohnuma S, 1997, J BIOCHEM-TOKYO, V121, P696; Ohnuma SI, 1996, J BIOL CHEM, V271, P10087, DOI 10.1074/jbc.271.17.10087; PATEL DV, 1995, J MED CHEM, V38, P2906, DOI 10.1021/jm00015a013; POPJAK G, 1969, BIOCHEM J, V111, P333, DOI 10.1042/bj1110333; PRASHAD M, 1993, EUR J MED CHEM, V28, P527, DOI 10.1016/0223-5234(93)90022-7; REED BC, 1975, BIOCHEMISTRY-US, V14, P50, DOI 10.1021/bi00672a009; RIEBER M, 1969, J GEN MICROBIOL, V55, P155, DOI 10.1099/00221287-55-1-155; Schulbach MC, 2000, J BIOL CHEM, V275, P22876, DOI 10.1074/jbc.M003194200; Shimizu N, 1998, J BIOL CHEM, V273, P19476, DOI 10.1074/jbc.273.31.19476; STORM DR, 1973, J BIOL CHEM, V248, P3940; TAKAYAMA K, 1973, BIOCHIM BIOPHYS ACTA, V316, P212, DOI 10.1016/0005-2760(73)90011-8; TAKAYAMA K, 1970, J BIOL CHEM, V245, P6251; TARSHIS LC, 1994, BIOCHEMISTRY-US, V33, P10871, DOI 10.1021/bi00202a004; VANHEIJENOORT J, 1996, ESCHERICHIA COLI SAL, P1025; Wolucka BA, 1998, GLYCOBIOLOGY, V8, P955, DOI 10.1093/glycob/8.10.955; WOLUCKA BA, 1994, J BIOL CHEM, V269, P23328	49	46	53	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 13	2001	276	15					11624	11630		10.1074/jbc.M007168200	http://dx.doi.org/10.1074/jbc.M007168200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	421UK	11152452	hybrid			2022-12-25	WOS:000168081800029
J	Shimizu, A; Tada, K; Shukunami, C; Hiraki, Y; Kurokawa, T; Magane, N; Kurokawa-Seo, M				Shimizu, A; Tada, K; Shukunami, C; Hiraki, Y; Kurokawa, T; Magane, N; Kurokawa-Seo, M			A novel alternatively spliced fibroblast growth factor receptor 3 isoform lacking the acid box domain is expressed during chondrogenic differentiation of ATDC5 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DETERMINE LIGAND-BINDING; THANATOPHORIC DYSPLASIA; FGF RECEPTOR; HEPARAN-SULFATE; KINASE DOMAIN; FACTOR FAMILY; LINE ATDC5; SPECIFICITY; ACTIVATION; GENE	To determine the role of fibroblast growth factor (FGF).FGF receptor (FGFR) signaling in chondrogenesis, we analyzed the gene expression of alternatively spliced FGFRs during chondrogenic differentiation of ATDC5 cells in vitro. Two isoforms of FGFR3 were expressed in these cells. One was the complete form of FGFR3 (FGFR3) already reported, and the other was a novel one that lacks the acid box domain (FGFR3 Delta AB). The gene of FGFR3 Delta AB was expressed in undifferentiated ATDC5 cells. In contrast, the transcripts of FGFR3 were not detectable in undifferentiated cells but increased during cellular condensation, which is an obligatory step for chondrogenic differentiation. FGFR1 and FGFR2 expression was higher than that of FGFR3 in undifferentiated cells. The gene expression of cell cycle inhibitor p21 was induced during cell condensation and correlated best with the expression of FGFR3 among the FGFR isoforms expressed. The differential expression of FGFR3 isoforms during chondrogenesis suggests that these isoforms may play different roles in the regulation of growth and differentiation in chondrocytes. To define the mitogenic response of FGFR3 Delta AB and FGFR3 to FGFs, their cDNAs were stably transfected into mouse BaF3 pro-B cells. FGFR3 preferentially mediates the mitogenic response to FGF1 and poor response to FGF2, In contrast, FGFR3 Delta AB mediated a higher mitogenic response to FGF2 as well as to FGF1, In addition, FGFR3 Delta AB responds to FGF1 at lower concentrations of heparin than FGFR3 does. These results suggest that the acid box plays an important role in the regulation of FGFR3 to mediate biological activities in response to FGFs.	Kyoto Sangyo Univ, Dept Biotechnol, Fac Engn, Kita Ku, Kyoto 6038555, Japan; Kyoto Univ, Dept Mol Interact & Tissue Engn, Inst Frontier Med Sci, Sakyo Ku, Kyoto 6068507, Japan; Takeda Chem Ind Ltd, Discovery Res Labs 3, Pharmaceut Discovery Res Div, Yodogawa Ku, Osaka 5328686, Japan	Kyoto Sangyo University; Kyoto University; Takeda Chemical Industries	Kurokawa-Seo, M (corresponding author), Kyoto Sangyo Univ, Dept Biotechnol, Fac Engn, Kita Ku, Kyoto 6038555, Japan.	mseo@cc.kyoto-su.ac.jp	Shukunami, Chisa/G-2887-2019	Shukunami, Chisa/0000-0001-5616-6761				ATSUMI T, 1990, CELL DIFFER DEV, V30, P109, DOI 10.1016/0922-3371(90)90079-C; AVIVI A, 1993, FEBS LETT, V330, P249, DOI 10.1016/0014-5793(93)80882-U; Bansal R, 1996, MOL CELL NEUROSCI, V7, P263, DOI 10.1006/mcne.1996.0020; BELLUS GA, 1995, NAT GENET, V10, P357, DOI 10.1038/ng0795-357; Burke D, 1998, TRENDS BIOCHEM SCI, V23, P59, DOI 10.1016/S0968-0004(97)01170-5; CHAMPIONARNAUD P, 1991, ONCOGENE, V6, P979; CHAUDHURI MM, 1993, J CELL PHYSIOL, V157, P209, DOI 10.1002/jcp.1041570202; Chellaiah A, 1999, J BIOL CHEM, V274, P34785, DOI 10.1074/jbc.274.49.34785; CHELLAIAH AT, 1994, J BIOL CHEM, V269, P11620; Chin YE, 1996, SCIENCE, V272, P719, DOI 10.1126/science.272.5262.719; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Colvin JS, 1996, NAT GENET, V12, P390, DOI 10.1038/ng0496-390; CROSSLEY PH, 1995, DEVELOPMENT, V121, P439; Deng CX, 1996, CELL, V84, P911, DOI 10.1016/S0092-8674(00)81069-7; EISEMANN A, 1991, ONCOGENE, V6, P1195; Hubbard SR, 1998, J BIOL CHEM, V273, P11987, DOI 10.1074/jbc.273.20.11987; JOHNSON DE, 1993, ADV CANCER RES, V60, P1; JOHNSON DE, 1990, MOL CELL BIOL, V10, P4728, DOI 10.1128/MCB.10.9.4728; Kan M, 1999, J BIOL CHEM, V274, P15947, DOI 10.1074/jbc.274.22.15947; KEEGAN K, 1991, P NATL ACAD SCI USA, V88, P1095, DOI 10.1073/pnas.88.4.1095; KEEGAN K, 1991, ONCOGENE, V6, P2229; Kemler R, 1989, CURR OPIN CELL BIOL, V1, P892, DOI 10.1016/0955-0674(89)90055-0; KLAGSBRUN M, 1985, P NATL ACAD SCI USA, V82, P805, DOI 10.1073/pnas.82.3.805; KLAGSBRUN M, 1977, EXP CELL RES, V105, P99, DOI 10.1016/0014-4827(77)90155-0; KUROKAWA T, 1987, FEBS LETT, V213, P189, DOI 10.1016/0014-5793(87)81489-8; Martin GR, 1998, GENE DEV, V12, P1571, DOI 10.1101/gad.12.11.1571; MIYAMOTO M, 1993, MOL CELL BIOL, V13, P4251, DOI 10.1128/MCB.13.7.4251; Naski MC, 1996, NAT GENET, V13, P233, DOI 10.1038/ng0696-233; NISWANDER L, 1993, CELL, V75, P579, DOI 10.1016/0092-8674(93)90391-3; Ornitz DM, 2000, BIOESSAYS, V22, P108, DOI 10.1002/(SICI)1521-1878(200002)22:2<108::AID-BIES2>3.0.CO;2-M; Ornitz DM, 1996, J BIOL CHEM, V271, P15292, DOI 10.1074/jbc.271.25.15292; ORNITZ DM, 1992, J BIOL CHEM, V267, P16305; ORRURTREGER A, 1993, DEV BIOL, V158, P475, DOI 10.1006/dbio.1993.1205; ORRURTREGER A, 1991, DEVELOPMENT, V113, P1419; PETERCASTRO AV, 1997, GENOMICS, V41, P10; PETERS K, 1993, DEV BIOL, V155, P423, DOI 10.1006/dbio.1993.1040; Plotnikov AN, 1999, CELL, V98, P641, DOI 10.1016/S0092-8674(00)80051-3; ROUSSEAU F, 1994, NATURE, V371, P252, DOI 10.1038/371252a0; Sahni M, 1999, GENE DEV, V13, P1361, DOI 10.1101/gad.13.11.1361; SAVAGE MP, 1995, DEV DYNAM, V202, P343, DOI 10.1002/aja.1002020404; SHIANG R, 1994, CELL, V78, P335, DOI 10.1016/0092-8674(94)90302-6; SHIMOMURA Y, 1975, CALC TISS RES, V19, P179, DOI 10.1007/BF02564002; Shukunami C, 1998, EXP CELL RES, V241, P1, DOI 10.1006/excr.1998.4045; Shukunami C, 1996, J CELL BIOL, V133, P457, DOI 10.1083/jcb.133.2.457; Su WCS, 1997, NATURE, V386, P288, DOI 10.1038/386288a0; Tavormina PL, 1999, AM J HUM GENET, V64, P722, DOI 10.1086/302275; TAVORMINA PL, 1995, NAT GENET, V9, P321, DOI 10.1038/ng0395-321; WANG F, 1995, J BIOL CHEM, V270, P10231, DOI 10.1074/jbc.270.17.10231; WANG JK, 1994, MOL CELL BIOL, V14, P181, DOI 10.1128/MCB.14.1.181; Wang YC, 1999, P NATL ACAD SCI USA, V96, P4455, DOI 10.1073/pnas.96.8.4455; Webster MK, 1997, MOL CELL BIOL, V17, P5739, DOI 10.1128/MCB.17.10.5739; Webster MK, 1996, EMBO J, V15, P520, DOI 10.1002/j.1460-2075.1996.tb00384.x; Webster MK, 1997, TRENDS GENET, V13, P178, DOI 10.1016/S0168-9525(97)01131-1; WERNER S, 1992, MOL CELL BIOL, V12, P82, DOI 10.1128/MCB.12.1.82; Xu XL, 1999, DEV BIOL, V208, P293, DOI 10.1006/dbio.1999.9227; Xu XL, 1999, CELL TISSUE RES, V296, P33, DOI 10.1007/s004410051264; YAMAGUCHI F, 1994, P NATL ACAD SCI USA, V91, P484, DOI 10.1073/pnas.91.2.484; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W; ZIMMER Y, 1993, J BIOL CHEM, V268, P7899	59	43	46	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 6	2001	276	14					11031	11040		10.1074/jbc.M003535200	http://dx.doi.org/10.1074/jbc.M003535200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	420AC	11134040	hybrid			2022-12-25	WOS:000167980900063
J	Blanc, V; Navaratnam, N; Henderson, JO; Anant, S; Kennedy, S; Jarmuz, A; Scott, J; Davidson, NO				Blanc, V; Navaratnam, N; Henderson, JO; Anant, S; Kennedy, S; Jarmuz, A; Scott, J; Davidson, NO			(O)over-cap vertical bar identification of GRY-RBP as an apolipoprotein B RNA-binding protein that interacts with both apobec-1 and apobec-1 complementation factor to modulate C to U editing	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA; CYTIDINE DEAMINASE; CATALYTIC SUBUNIT; MOLECULAR-CLONING; SEQUENCE REQUIREMENTS; EVOLUTIONARY ORIGINS; SECONDARY STRUCTURE; ENZYME-COMPLEX; SITE; INVITRO	C to U editing of apolipoprotein B (apoB) mRNA involves the interaction of a multicomponent editing enzyme complex with a requisite RNA sequence embedded within an AU-rich context. This enzyme complex includes apobec-1, an RNA-specific cytidine deaminase, and apobec-1 complementation factor (ACF), a novel 65-kDa RNA-binding protein, that together represent the minimal core of the editing enzyme complex. The precise composition of the hole-enzyme, however, remains unknown. We have previously isolated an enriched fraction of S100 extracts, prepared from chicken intestinal cells, that displays apoB RNA binding and which, following supplementation with apobec-1, permits efficient C to U editing. Peptide sequencing of this most active fraction reveals the presence of ACF as well as GRY-RBP, an RNA-binding protein with similar to 50% homology to ACF, GRY-RBP was independently isolated from a two-hybrid screen of chicken intestinal cDNA. GRY-RBP binds to ACF, to apobec-1, and also binds apoB RNA. Experiments using recombinant proteins demonstrate that GRY-RBP binds to ACF and inhibits both the binding of ACF to apoB RNA and C to U RNA editing. This competitive inhibition is rescued by addition of ACF, suggesting that GRY-RBP binds to and sequesters ACF, As further evidence of the role of GRY-RBP, rat hepatoma cells treated with an antisense oligonucleotide to GRY-RBP demonstrated an increase in C to U editing of endogenous apoB RNA. ACF and GRY-RBP colocalize in the nucleus of transfected cells and, in cotransfection experiments with apobec-1, each appears to colocalize in a predominantly nuclear distribution. Taken together, the results indicate that GRY-RBP is a member of the ACF gene family that may function to modulate C to U RNA editing through binding either to ACF or to apobec-1 or, alternatively, to the target RNA itself.	Washington Univ, Sch Med, Div Gastroenterol, Dept Internal Med, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Mol Biol & Pharmacol, St Louis, MO 63110 USA; Hammersmith Hosp, Imperial Coll, Sch Med, Clin Sci Ctr,MRC,Mol Med Grp, London W12 0NN, England; Hammersmith Hosp, Imperial Coll, Sch Med, Div Natl Heart & Lung Inst, London W12 0NN, England	Washington University (WUSTL); Washington University (WUSTL); Imperial College London; Imperial College London	Davidson, NO (corresponding author), Washington Univ, Sch Med, Div Gastroenterol, Dept Internal Med, Box 8124,660 S Euclid Ave, St Louis, MO 63110 USA.		Anant, Shrikant/AAF-8020-2020		NHLBI NIH HHS [HL-38180] Funding Source: Medline; NIDDK NIH HHS [DK-52574, DK-56260] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL038180, R01HL038180] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK056260, P30DK052574] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANANT S, 1995, J BIOL CHEM, V270, P14762, DOI 10.1074/jbc.270.24.14762; Anant S, 2000, MOL CELL BIOL, V20, P1982, DOI 10.1128/MCB.20.6.1982-1992.2000; Anant S, 1998, BIOL CHEM, V379, P1075, DOI 10.1515/bchm.1998.379.8-9.1075; ANANT S, 1997, NUCL ACIDS S SER, V36, P115; BACKUS JW, 1992, NUCLEIC ACIDS RES, V20, P6007, DOI 10.1093/nar/20.22.6007; BRESLOW JL, 1988, PHYSIOL REV, V68, P85, DOI 10.1152/physrev.1988.68.1.85; CHEN SH, 1990, J BIOL CHEM, V265, P6811; CHEN SH, 1987, SCIENCE, V238, P363, DOI 10.1126/science.3659919; DAVIES MS, 1989, J BIOL CHEM, V264, P13395; DRISCOLL DM, 1993, MOL CELL BIOL, V13, P7288, DOI 10.1128/MCB.13.12.7288; GREEVE J, 1993, J LIPID RES, V34, P1367; Greeve J, 1998, BIOL CHEM, V379, P1063, DOI 10.1515/bchm.1998.379.8-9.1063; HARRIS SG, 1993, J BIOL CHEM, V268, P7382; Hassfeld W, 1998, NUCLEIC ACIDS RES, V26, P439, DOI 10.1093/nar/26.2.439; Hersberger M, 1999, J BIOL CHEM, V274, P34590, DOI 10.1074/jbc.274.49.34590; Hersberger M, 1998, J BIOL CHEM, V273, P9435, DOI 10.1074/jbc.273.16.9435; Hirano K, 1996, J BIOL CHEM, V271, P9887, DOI 10.1074/jbc.271.17.9887; KOHTZ JD, 1994, NATURE, V368, P119, DOI 10.1038/368119a0; LAU PP, 1994, P NATL ACAD SCI USA, V91, P8522, DOI 10.1073/pnas.91.18.8522; Lau PP, 1997, J BIOL CHEM, V272, P1452, DOI 10.1074/jbc.272.3.1452; Lellek H, 2000, J BIOL CHEM, V275, P19848, DOI 10.1074/jbc.M001786200; MACGINNITIE AJ, 1995, J BIOL CHEM, V270, P14768, DOI 10.1074/jbc.270.24.14768; Mehta A, 2000, MOL CELL BIOL, V20, P1846, DOI 10.1128/MCB.20.5.1846-1854.2000; Mehta A, 1998, MOL CELL BIOL, V18, P4426, DOI 10.1128/MCB.18.8.4426; Morrison JR, 1996, P NATL ACAD SCI USA, V93, P7154, DOI 10.1073/pnas.93.14.7154; Nakamuta M, 1996, J BIOL CHEM, V271, P25981, DOI 10.1074/jbc.271.42.25981; NAVARATNAM N, 1993, P NATL ACAD SCI USA, V90, P222, DOI 10.1073/pnas.90.1.222; NAVARATNAM N, 1993, J BIOL CHEM, V268, P20709; Navaratnam N, 1998, J MOL BIOL, V275, P695, DOI 10.1006/jmbi.1997.1506; NAVARATNAM N, 1995, CELL, V81, P187, DOI 10.1016/0092-8674(95)90328-3; POWELL LM, 1987, CELL, V50, P831, DOI 10.1016/0092-8674(87)90510-1; Richardson N, 1998, J BIOL CHEM, V273, P31707, DOI 10.1074/jbc.273.48.31707; Schock D, 1996, P NATL ACAD SCI USA, V93, P1097, DOI 10.1073/pnas.93.3.1097; SHAH RR, 1991, J BIOL CHEM, V266, P16301; SMITH HC, 1991, P NATL ACAD SCI USA, V88, P1489, DOI 10.1073/pnas.88.4.1489; TENG BB, 1993, SCIENCE, V260, P1816, DOI 10.1126/science.8511591; TENG BB, 1992, J BIOL CHEM, V267, P21265; Yang Y, 1997, J BIOL CHEM, V272, P27700, DOI 10.1074/jbc.272.44.27700; Yang Y, 2000, J BIOL CHEM, V275, P22663, DOI 10.1074/jbc.M910406199; YOUNG SG, 1990, CIRCULATION, V82, P1574, DOI 10.1161/01.CIR.82.5.1574	40	82	91	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 30	2001	276	13					10272	10283		10.1074/jbc.M006435200	http://dx.doi.org/10.1074/jbc.M006435200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	420GC	11134005	hybrid			2022-12-25	WOS:000167996400092
J	Okamura, Y; Watari, M; Jerud, ES; Young, DW; Ishizaka, ST; Rose, J; Chow, JC; Strauss, JF				Okamura, Y; Watari, M; Jerud, ES; Young, DW; Ishizaka, ST; Rose, J; Chow, JC; Strauss, JF			The extra domain A of fibronectin activates toll-like receptor 4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-EXPRESSION; FRAGMENTS MODULATE; PROTEIN; FAMILY; INDUCTION; LIGAND; MMP-9	Cellular fibronectin, which contains an alternatively spliced exon encoding type III repeat extra domain A (EDA), is produced in response to tissue injury, Fragments of fibronectin have been implicated in physiological and pathological processes, especially tissue remodeling associated with inflammation. Because EDA-containing fibronectin fragments produce cellular responses similar to those provoked by bacterial lipopolysaccharide (LPS), we examined the ability of recombinant EDA to activate Toll-like receptor 4 (TLR4), the signaling receptor stimulated by LPS. We found that recombinant EDA, but not other recombinant fibronectin domains, activates human TLR4 expressed in a cell type (HEK 293 cells) that normally lacks this Toll-like receptor. EDA stimulation of TLR4 was dependent upon co-expression of MD-2, a TLR4 accessory protein. Unlike LPS, the activity of EDA was heat-sensitive and persisted in the presence of the LPS-binding antibiotic polymyxin B and a potent LPS antagonist, E5564, which completely suppressed LPS activation of TLR4, These observations provided a mechanism by which EDA-containing fibronectin fragments promote expression of genes involved in the inflammatory response.	Univ Penn, Med Ctr, Ctr Res Reprod & Womens Hlth, Philadelphia, PA 19104 USA; Eisai Res Inst, Dept Mol Biol & Biochem & Signal Transduct, Wilmington, MA USA	University of Pennsylvania; Pennsylvania Medicine; Eisai Co Ltd	Strauss, JF (corresponding author), Univ Penn, Med Ctr, Ctr Res Reprod & Womens Hlth, 1354 BRB 2-3,421 Curie Blvd, Philadelphia, PA 19104 USA.	jfs3@mail.med.upenn.edu			NICHD NIH HHS [HD-34612] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD034612] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		[Anonymous], 1991, CELL BIOL EXTRACELLU; Asea A, 2000, NAT MED, V6, P435, DOI 10.1038/74697; Barilla ML, 2000, SEMIN ARTHRITIS RHEU, V29, P252, DOI 10.1016/S0049-0172(00)80012-8; Chaudhary PM, 1998, BLOOD, V91, P4020, DOI 10.1182/blood.V91.11.4020.411a44_4020_4027; Chow JC, 1999, J BIOL CHEM, V274, P10689, DOI 10.1074/jbc.274.16.10689; Esparza J, 1999, BLOOD, V94, P2754, DOI 10.1182/blood.V94.8.2754.420k09_2754_2766; Fenton MJ, 1998, J LEUKOCYTE BIOL, V64, P25, DOI 10.1002/jlb.64.1.25; George J, 2000, AM J PATHOL, V156, P115, DOI 10.1016/S0002-9440(10)64711-6; Grant MB, 1998, DIABETES, V47, P1335, DOI 10.2337/diabetes.47.8.1335; HINO K, 1995, ARTHRITIS RHEUM-US, V38, P678, DOI 10.1002/art.1780380516; Janeway CA, 1999, CURR BIOL, V9, pR879, DOI 10.1016/S0960-9822(00)80073-1; JARNAGIN WR, 1994, J CELL BIOL, V127, P2037, DOI 10.1083/jcb.127.6.2037; Kapila YL, 1996, MATRIX BIOL, V15, P251, DOI 10.1016/S0945-053X(96)90116-X; Lien E, 2000, J CLIN INVEST, V105, P497, DOI 10.1172/JCI8541; Medzhitov R, 1997, NATURE, V388, P394, DOI 10.1038/41131; Medzhitov R, 1998, MOL CELL, V2, P253, DOI 10.1016/S1097-2765(00)80136-7; Mizuguchi K, 1998, TRENDS BIOCHEM SCI, V23, P239, DOI 10.1016/S0968-0004(98)01216-X; Ohashi K, 2000, J IMMUNOL, V164, P558, DOI 10.4049/jimmunol.164.2.558; Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085; Rock FL, 1998, P NATL ACAD SCI USA, V95, P588, DOI 10.1073/pnas.95.2.588; Saito S, 1999, J BIOL CHEM, V274, P30756, DOI 10.1074/jbc.274.43.30756; SATO H, 1993, ONCOGENE, V8, P395; Shimazu R, 1999, J EXP MED, V189, P1777, DOI 10.1084/jem.189.11.1777; Tremble P M, 1992, Matrix Suppl, V1, P212; VADILLOORTEGA F, 1995, AM J PATHOL, V146, P148; Wright SD, 1999, J EXP MED, V189, P605, DOI 10.1084/jem.189.4.605; Xie B, 1998, J BIOL CHEM, V273, P11576, DOI 10.1074/jbc.273.19.11576; Yang H, 2000, J BIOL CHEM, V275, P20861, DOI 10.1074/jbc.M002896200	28	900	964	1	48	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 30	2001	276	13					10229	10233		10.1074/jbc.M100099200	http://dx.doi.org/10.1074/jbc.M100099200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	420GC	11150311	hybrid			2022-12-25	WOS:000167996400087
J	Untergasser, G; Rumpold, H; Plas, E; Madersbacher, S; Berger, P				Untergasser, G; Rumpold, H; Plas, E; Madersbacher, S; Berger, P			A low-molecular-weight fraction of human seminal plasma activates adenylyl cyclase and induces caspase 3-independent apoptosis in prostatic epithelial cells by decreasing mitochondrial potential and Bcl-2/Bax ratio	FASEB JOURNAL			English	Article						SMP; aging; HPLC analysis; cAMP; mitochondria; Par-4; p53	HUMAN-SEMEN; CANCER; HYPERPLASIA; INVOLVEMENT; PROLACTIN; LINE	The majority of elderly men are affected by benign and malign diseases of the prostate that are governed by endocrine factors and local stromal/epithelial and luminal/epithelial interactions. Prostate epithelial cells secrete numerous factors into the seminal plasma (SMP) that are thought to be responsible for nutrition, accurate pH, and ionic environment of sperm. Our hypothesis assumes that prostatic factors responsible for optimal fertility might have retrograde influences on epithelial cell growth, differentiation, and function. SMP was analyzed for proteins and other biologically active substances by size exclusion highperformance liquid chromatography. Each fraction was investigated for its effect on cell growth and death. A low molecular mass fraction (2-4 kDa) was responsible for inducing apoptosis in proliferating prostate epithelial cells. Signal transduction was mediated by the production of cAMP; no significant changes in tyrosine phosphorylation of membrane receptors were observed. Mechanisms of apoptosis, i.e., caspase- and mitochondria-dependent pathways, were investigated in prostate epithelial cells by caspase activity assays, annexin/propidium iodide staining, changes in mitochondrial potential, p53, Par-4, Bax, and Bcl-2 protein levels. SMP induced p53- and Bcl-2-dependent apoptosis without activation of caspase-3. Obviously, SMP contains protective factors that help eliminate degenerated cells and control epithelial renewal. Age-related changes in the composition of SMP or the susceptibility of epithelial cells might, therefore, contribute to proliferative prostatic diseases.-untergasser, G., Rumpold, H., Plas, E., Madersbacher, S., Berger, P. A low molecular weight fraction of human seminal plasma activates adenylyl cyclase and induces caspase 3-independent apoptosis in prostatic epithelial cells by decreasing mitochondrial potential and Bcl-2/Bax ratio.	Austrian Acad Sci, Inst Biomed Aging Res, A-6020 Innsbruck, Austria; Ludwig Boltzmann Inst Androl & Urol, Vienna, Austria; Univ Vienna, Dept Urol, A-1010 Vienna, Austria	Austrian Academy of Sciences; Ludwig Boltzmann Institute; University of Vienna	Berger, P (corresponding author), Austrian Acad Sci, Inst Biomed Aging Res, Rennweg 10, A-6020 Innsbruck, Austria.			Rumpold, Holger/0000-0002-4118-0111				Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Aumuller G, 1990, Int Rev Cytol, V121, P127, DOI 10.1016/S0074-7696(08)60660-9; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CARTER BS, 1990, PROSTATE, V16, P187, DOI 10.1002/pros.2990160302; Claus S, 1997, J UROLOGY, V158, P217, DOI 10.1097/00005392-199707000-00074; COCKLE SM, 1994, BBA-MOL BASIS DIS, V1227, P60, DOI 10.1016/0925-4439(94)90107-4; COCKLE SM, 1989, J ENDOCRINOL, V120, P31, DOI 10.1677/joe.0.1200031; Colao A, 1998, J CLIN ENDOCR METAB, V83, P775, DOI 10.1210/jc.83.3.775; COSTELLO LC, 1994, PROSTATE, V24, P162, DOI 10.1002/pros.2990240311; DONDI D, 1994, CANCER RES, V54, P4091; EDWARDS JJ, 1981, CLIN CHEM, V27, P1335; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; HAYWARD SW, 1995, IN VITRO CELL DEV-AN, V31, P14; KELLY RW, 1991, CLIN EXP IMMUNOL, V86, P550; Mantzoros CS, 1997, BRIT J CANCER, V76, P1115, DOI 10.1038/bjc.1997.520; Marcelli M, 1999, J CLIN ENDOCR METAB, V84, P3463, DOI 10.1210/jc.84.10.3463; Marzo I, 1998, SCIENCE, V281, P2027, DOI 10.1126/science.281.5385.2027; Molinari M, 1996, ONCOGENE, V13, P2077; *NAT KIDN UR DIS A, 1990, LONG RANG PLAN WIND; Parker SL, 1997, CA-CANCER J CLIN, V47, P5, DOI 10.3322/canjclin.47.1.5; Perlman H, 1999, CELL DEATH DIFFER, V6, P48, DOI 10.1038/sj.cdd.4400453; Sells SF, 1997, MOL CELL BIOL, V17, P3823, DOI 10.1128/MCB.17.7.3823; SELLS SF, 1994, CELL GROWTH DIFFER, V5, P457; Shapiro E, 1996, TXB BENIGN PROSTATIC, P17; Srivastava RK, 1998, MOL CELL BIOL, V18, P3509, DOI 10.1128/MCB.18.6.3509; Untergasser G, 1999, EXP GERONTOL, V34, P275, DOI 10.1016/S0531-5565(98)00063-1; Wennbo H, 1997, ENDOCRINOLOGY, V138, P4410, DOI 10.1210/en.138.10.4410	27	22	23	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAR	2001	15	3					673	683		10.1096/fj.00-0270com	http://dx.doi.org/10.1096/fj.00-0270com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	410BE	11259385				2022-12-25	WOS:000167419500024
J	Ilan, N; Mohsenin, A; Cheung, L; Madri, JA				Ilan, N; Mohsenin, A; Cheung, L; Madri, JA			PECAM-1 shedding during apoptosis generates a membrane-anchored truncated molecule with unique signaling characteristics	FASEB JOURNAL			English	Article						platelet-endothelial cell adhesion molecule (CD31); endothelium; apoptosis; shedding; cleavage	CELL-ADHESION MOLECULE-1; RECEPTOR TYROSINE KINASE; ACTIVATED PROTEIN-KINASE; BETA-CATENIN; TRANSENDOTHELIAL MIGRATION; EXTRACELLULAR-MATRIX; ECTODOMAIN CLEAVAGE; ENDOTHELIAL-CELLS; CYCLIN D1; IN-VITRO	Shedding of cell surface molecules, including growth factor receptors, provides a mechanism by which cells regulate signal transduction events. Here we show that platelet-endothelial cell adhesion molecule (PECAM)-1 is shed from the endothelial cell surface during apoptosis and accumulates in the culture medium as a similar to 100 kDa soluble protein. The cleavage mediating the shedding is matrix metalloproteinase (MMP) dependent, as GM6001, a broad-spectrum MMP inhibitor, inhibits PECAM-1 accumulation in the culture medium in a dose-responsive manner. In addition to the 100 kDa soluble fragment, PECAM-1 cleavage generates the formation of a truncated (Tr.) similar to 28 kDa molecule, composed of the transmembrane and the cytoplasmic PECAM-1 domains. Transfections of the full-length (F1) and the Tr. PECAM-1 gene constructs into endothelial and nonendothelial cells were performed. We found 1) significantly more gamma -catenin and SHP-2 bound to the truncated than to the full-length PECAM-1; 2) stable expression of the truncated PECAM-1 in SW480 colon carcinoma cells resulted in a dramatic decrease in cell proliferation, whereas expression of comparable levels of the full-length PECAM-1 had no effect; 3) the decrease observed in cell proliferation is due, in part, to an increase in programmed cell death (apoptosis) and correlated with continuous caspase 8 cleavage and p38/JNK phosphorylation. These results support the intimate involvement of PECAM-1 in signal transduction cascades and also suggest that caspase substrates (e.g., PECAM-1) may possess distinct and unique functions on cleavage.	Yale Univ, Sch Med, Dept Pathol, New Haven, CT 06520 USA	Yale University	Madri, JA (corresponding author), Yale Univ, Sch Med, Dept Pathol, 310 Cedar St,POB 208023, New Haven, CT 06520 USA.	joseph.madri@yale.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL028373] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK038979] Funding Source: NIH RePORTER; NHLBI NIH HHS [R37-HL28373] Funding Source: Medline; NIDDK NIH HHS [P01-DK38979] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALON T, 1995, NAT MED, V1, P1024, DOI 10.1038/nm1095-1024; Arch RH, 1998, GENE DEV, V12, P2821, DOI 10.1101/gad.12.18.2821; Benjamin LE, 1999, J CLIN INVEST, V103, P159, DOI 10.1172/JCI5028; Bird IN, 1999, J CELL SCI, V112, P1989; Brancolini C, 1997, J CELL BIOL, V139, P759, DOI 10.1083/jcb.139.3.759; Bratton SB, 2000, EXP CELL RES, V256, P27, DOI 10.1006/excr.2000.4835; Cabrera N, 1996, J CELL BIOL, V132, P427, DOI 10.1083/jcb.132.3.427; Chaudhary PM, 1999, J BIOL CHEM, V274, P19211, DOI 10.1074/jbc.274.27.19211; Chen CS, 1997, SCIENCE, V276, P1425, DOI 10.1126/science.276.5317.1425; Cross TG, 2000, EXP CELL RES, V256, P34, DOI 10.1006/excr.2000.4836; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Duncan GS, 1999, J IMMUNOL, V162, P3022; Feehan C, 1996, J BIOL CHEM, V271, P7019, DOI 10.1074/jbc.271.12.7019; Ferrara N, 1997, ENDOCR REV, V18, P4, DOI 10.1210/er.18.1.4; Folkman J, 1996, CELL, V87, P1153, DOI 10.1016/S0092-8674(00)81810-3; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; Galan A, 2000, J BIOL CHEM, V275, P11418, DOI 10.1074/jbc.275.15.11418; Gerber HP, 1998, J BIOL CHEM, V273, P30336, DOI 10.1074/jbc.273.46.30336; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; HERMISTON ML, 1995, J CELL BIOL, V129, P489, DOI 10.1083/jcb.129.2.489; Herren B, 1998, MOL BIOL CELL, V9, P1589, DOI 10.1091/mbc.9.6.1589; Hooper NM, 1997, BIOCHEM J, V321, P265, DOI 10.1042/bj3210265; Ilan N, 1998, J CELL SCI, V111, P3621; Ilan N, 2000, J BIOL CHEM, V275, P21435, DOI 10.1074/jbc.M001857200; Ilan N, 1999, J CELL SCI, V112, P3005; Izumi Y, 1998, EMBO J, V17, P7260, DOI 10.1093/emboj/17.24.7260; Jackson DE, 1997, J BIOL CHEM, V272, P6986, DOI 10.1074/jbc.272.11.6986; Kim CS, 1998, LAB INVEST, V78, P583; Kito M, 1999, BIOCHEM BIOPH RES CO, V257, P771, DOI 10.1006/bbrc.1999.0497; Kothakota S, 1997, SCIENCE, V278, P294, DOI 10.1126/science.278.5336.294; Levkau B, 1998, J EXP MED, V187, P579, DOI 10.1084/jem.187.4.579; Levkau B, 1998, MOL CELL, V1, P553, DOI 10.1016/S1097-2765(00)80055-6; Liao F, 1999, J IMMUNOL, V163, P5640; Liao F, 1997, J EXP MED, V185, P1349, DOI 10.1084/jem.185.7.1349; Liu XS, 1997, CELL, V89, P175, DOI 10.1016/S0092-8674(00)80197-X; Losy J, 1999, J NEUROIMMUNOL, V99, P169, DOI 10.1016/S0165-5728(99)00092-2; Lu TT, 1997, J BIOL CHEM, V272, P14442, DOI 10.1074/jbc.272.22.14442; Lu TT, 1996, P NATL ACAD SCI USA, V93, P11808, DOI 10.1073/pnas.93.21.11808; MASSAGUE J, 1993, ANNU REV BIOCHEM, V62, P515, DOI 10.1146/annurev.bi.62.070193.002503; McCarthy MJ, 1999, LAB INVEST, V79, P889; MEREDITH JE, 1993, MOL BIOL CELL, V4, P953, DOI 10.1091/mbc.4.9.953; Meredith JE, 1997, TRENDS CELL BIOL, V7, P146, DOI 10.1016/S0962-8924(97)01002-7; MOHLER KM, 1994, NATURE, V370, P218, DOI 10.1038/370218a0; MULLER WA, 1993, J EXP MED, V178, P449, DOI 10.1084/jem.178.2.449; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; OBESO J, 1990, LAB INVEST, V63, P259; Peters JM, 1999, NATURE, V401, P345, DOI 10.1038/43830; Pinter E, 1997, AM J PATHOL, V150, P1523; Reinhard C, 1997, EMBO J, V16, P1080, DOI 10.1093/emboj/16.5.1080; ROSKELLEY CD, 1994, P NATL ACAD SCI USA, V91, P12378, DOI 10.1073/pnas.91.26.12378; Sakanaka C, 1999, P NATL ACAD SCI USA, V96, P12548, DOI 10.1073/pnas.96.22.12548; Salvesen GS, 1997, CELL, V91, P443, DOI 10.1016/S0092-8674(00)80430-4; Schwager SLU, 1999, BIOCHEMISTRY-US, V38, P10388, DOI 10.1021/bi990357j; Shtutman M, 1999, P NATL ACAD SCI USA, V96, P5522, DOI 10.1073/pnas.96.10.5522; Tan XQ, 1998, TRENDS CELL BIOL, V8, P116, DOI 10.1016/S0962-8924(97)01208-7; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; Tlsty TD, 1998, CURR OPIN CELL BIOL, V10, P647, DOI 10.1016/S0955-0674(98)80041-0; Tournier C, 2000, SCIENCE, V288, P870, DOI 10.1126/science.288.5467.870; Toyoshima F, 1997, J CELL BIOL, V139, P1005, DOI 10.1083/jcb.139.4.1005; VAPORCIYAN AA, 1993, SCIENCE, V262, P1580, DOI 10.1126/science.8248808; Vecchi M, 1997, J CELL BIOL, V139, P995, DOI 10.1083/jcb.139.4.995; Werb Z, 1997, CELL, V91, P439, DOI 10.1016/S0092-8674(00)80429-8; Wilson DJ, 1996, EUR J IMMUNOL, V26, P989, DOI 10.1002/eji.1830260505; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Yabkowitz R, 1999, BLOOD, V93, P1969, DOI 10.1182/blood.V93.6.1969.406k14_1969_1979	65	108	113	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2001	15	2					362	372		10.1096/fj.00-0372com	http://dx.doi.org/10.1096/fj.00-0372com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	400LK	11156952				2022-12-25	WOS:000166872900018
J	Neuzil, J; Weber, T; Schroder, A; Lu, M; Ostermann, G; Gellert, N; Mayne, GC; Olejnicka, B; Negre-Salvayre, A; Sticha, M; Coffey, RJ; Weber, C				Neuzil, J; Weber, T; Schroder, A; Lu, M; Ostermann, G; Gellert, N; Mayne, GC; Olejnicka, B; Negre-Salvayre, A; Sticha, M; Coffey, RJ; Weber, C			Induction of cancer cell apoptosis by alpha-tocopheryl succinate: molecular pathways and structural requirements	FASEB JOURNAL			English	Article						vitamin E succinate; protein kinase C; programmed cell death; colon cancer	PROTEIN-KINASE-C; CHOLESTERYL HEMISUCCINATE; MEDIATED APOPTOSIS; OXIDATIVE STRESS; PHOSPHATASE 2A; VITAMIN-E; INHIBITION; ACTIVATION; EXPRESSION; PHOSPHORYLATION	The vitamin E analog alpha -tocopheryl succinate (alpha -TOS) can induce apoptosis. We show that the proapoptotic activity of alpha -TOS in hematopoietic and cancer cell lines involves inhibition of protein kinase C (PKC), since phorbol myristyl acetate prevented alpha -TOS-triggered apoptosis. More selective effecters indicated that alpha -TOS reduced PKC alpha isotype activity by increasing protein phosphatase 2A (PP2A) activity. The role of PKC alpha inhibition in alpha -TOS-induced apoptosis was confirmed using antisense oligonucleotides or PKC alpha overexpression. Gain- or loss-of-function bcl-2 mutants implied modulation of bcl-2 activity by PKC/PP2A as a mitochondrial target of alpha -TOS-induced proapoptotic signals. Structural analogs revealed that alpha -tocopheryl and succinyl moieties are both required for maximizing these effects. In mice with colon cancer xenografts, alpha -TOS suppressed tumor growth by 80%. This epitomizes cancer cell killing by a pharmacologically relevant compound without known side effects.	Univ Munich, Inst Prevent Cardiovasc Dis, D-80336 Munich, Germany; Univ Munich, Med Policlin, D-80336 Munich, Germany; Vanderbilt Univ, Med Ctr N, Nashville, TN USA; Flinders Univ S Australia, Adelaide, SA 5001, Australia; Linkoping Univ Hosp, Dept Pathol 2, Linkoping, Sweden; INSERM, Dept Biochem, Toulouse, France; Charles Univ, Fac Sci, Prague, Czech Republic	University of Munich; University of Munich; Vanderbilt University; Flinders University South Australia; Linkoping University; Institut National de la Sante et de la Recherche Medicale (Inserm); Charles University Prague	Neuzil, J (corresponding author), Univ Munich, Inst Prevent Cardiovasc Dis, Pettenkoferstr 9, D-80336 Munich, Germany.		Olejnicka, Beata/AAY-6457-2021; Sticha, Martin/E-6158-2017; Neuzil, Jiri/H-7204-2014; Weber, Christian/AAW-2153-2020	Sticha, Martin/0000-0001-8008-7668; Neuzil, Jiri/0000-0002-2478-2460; Weber, Christian/0000-0003-4610-8714; Negre-Salvayre, Anne/0000-0003-2136-5706				BURTON GW, 1990, ANNU REV NUTR, V10, P357, DOI [10.1146/annurev.nu.10.070190.002041, 10.1146/annurev.nutr.10.1.357]; Cachia O, 1998, J BIOL CHEM, V273, P32801, DOI 10.1074/jbc.273.49.32801; Chandra J, 1997, BLOOD, V90, P3673, DOI 10.1182/blood.V90.9.3673; Chen CY, 1999, J BIOL CHEM, V274, P15320, DOI 10.1074/jbc.274.22.15320; Chinery R, 1997, NAT MED, V3, P1233, DOI 10.1038/nm1197-1233; Devaraj S, 1998, CURR OPIN LIPIDOL, V9, P11, DOI 10.1097/00041433-199802000-00004; DEVERAJ S, 1996, J CLIN INVEST, V98, P756; Djuric Z, 1997, CANCER LETT, V111, P133, DOI 10.1016/S0304-3835(96)04522-3; Erl W, 1999, CIRC RES, V84, P668, DOI 10.1161/01.RES.84.6.668; Erl W, 1997, AM J PHYSIOL-HEART C, V273, pH634, DOI 10.1152/ajpheart.1997.273.2.H634; FARISS MW, 1994, CANCER RES, V54, P3346; Ferraris C, 1997, EXP CELL RES, V234, P37, DOI 10.1006/excr.1997.3601; Frey MR, 1997, J BIOL CHEM, V272, P9424; Fujii T, 2000, J BIOL CHEM, V275, P7574, DOI 10.1074/jbc.275.11.7574; GENOT EM, 1995, J BIOL CHEM, V270, P9833, DOI 10.1074/jbc.270.17.9833; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; Israel K, 2000, NUTR CANCER, V36, P90, DOI 10.1207/S15327914NC3601_13; Ito T, 1997, J BIOL CHEM, V272, P11671, DOI 10.1074/jbc.272.18.11671; Jha MN, 1999, NUTR CANCER, V35, P189, DOI 10.1207/S15327914NC352_14; Kasibhatla S, 1998, MOL CELL, V1, P543, DOI 10.1016/S1097-2765(00)80054-4; Keaney JF, 1996, J CLIN INVEST, V98, P386, DOI 10.1172/JCI118804; Keranen LM, 1995, CURR BIOL, V5, P1394, DOI 10.1016/S0960-9822(95)00277-6; Krohn AJ, 1998, J NEUROSCI, V18, P8186; Lee JY, 1996, J BIOL CHEM, V271, P13169, DOI 10.1074/jbc.271.22.13169; Li Q, 1999, J BIOL CHEM, V274, P3764, DOI 10.1074/jbc.274.6.3764; Livneh E, 1997, EUR J BIOCHEM, V248, P1, DOI 10.1111/j.1432-1033.1997.t01-4-00001.x; LU Y, 1994, J IMMUNOL, V153, P1495; MARTIN SJ, 1995, J EXP MED, V182, P1545, DOI 10.1084/jem.182.5.1545; Mayne GC, 1998, J BIOL CHEM, V273, P24115, DOI 10.1074/jbc.273.37.24115; McKay RA, 1999, J BIOL CHEM, V274, P1715, DOI 10.1074/jbc.274.3.1715; Mellor H, 1998, BIOCHEM J, V332, P281, DOI 10.1042/bj3320281; Neuzil J, 1999, FEBS LETT, V445, P295, DOI 10.1016/S0014-5793(99)00141-6; Neuzil J, 1997, FREE RADICAL BIO MED, V22, P57, DOI 10.1016/S0891-5849(96)00224-9; NEWTON AC, 1995, J BIOL CHEM, V270, P28495, DOI 10.1074/jbc.270.48.28495; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; OLLINGER K, 1995, FREE RADICAL BIO MED, V19, P565, DOI 10.1016/0891-5849(95)00062-3; Parekh DB, 2000, EMBO J, V19, P496, DOI 10.1093/emboj/19.4.496; Qian M, 1997, ONCOGENE, V15, P223, DOI 10.1038/sj.onc.1201181; Ricciarelli R, 1998, ARCH BIOCHEM BIOPHYS, V355, P197, DOI 10.1006/abbi.1998.0732; Ricciarelli R, 1998, BIOCHEM J, V334, P243, DOI 10.1042/bj3340243; Roberg K, 1998, AM J PATHOL, V152, P1151; Ruvolo PP, 1999, J BIOL CHEM, V274, P20296, DOI 10.1074/jbc.274.29.20296; Santoro MF, 1998, J BIOL CHEM, V273, P13119, DOI 10.1074/jbc.273.21.13119; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Shao RG, 1997, J BIOL CHEM, V272, P31321, DOI 10.1074/jbc.272.50.31321; Singh I, 1998, J BIOL CHEM, V273, P20354, DOI 10.1074/jbc.273.32.20354; Slater SJ, 1998, J BIOL CHEM, V273, P23160, DOI 10.1074/jbc.273.36.23160; Suzuki Y, 1998, FEBS LETT, V425, P209, DOI 10.1016/S0014-5793(98)00228-2; SUZUKI YJ, 1993, BIOCHEM MOL BIOL INT, V31, P693; Tasinato A, 1995, P NATL ACAD SCI USA, V92, P12190, DOI 10.1073/pnas.92.26.12190; Vaux DL, 1996, P NATL ACAD SCI USA, V93, P2239, DOI 10.1073/pnas.93.6.2239; Wang RX, 1998, J IMMUNOL, V161, P2201; WAYS DK, 1995, J CLIN INVEST, V95, P1906, DOI 10.1172/JCI117872; Whelan RDH, 1998, ONCOGENE, V16, P1939, DOI 10.1038/sj.onc.1201725; ZAMZAMI N, 1995, J EXP MED, V182, P367, DOI 10.1084/jem.182.2.367; Zhang CH, 1996, J IMMUNOL, V157, P3980	56	247	269	1	32	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	FEB	2001	15	2					403	415		10.1096/fj.00-0251com	http://dx.doi.org/10.1096/fj.00-0251com			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	400LK	11156956				2022-12-25	WOS:000166872900022
J	Trott, RL; Kalive, M; Paroush, Z; Bidwai, AP				Trott, RL; Kalive, M; Paroush, Z; Bidwai, AP			Drosophila melanogaster casein kinase II interacts with and phosphorylates the basic helix-loop-helix proteins m5, m7, and m8 derived from the Enhancer of split complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NOTCH SIGNALING PATHWAY; SACCHAROMYCES-CEREVISIAE; CATALYTIC SUBUNIT; ESCHERICHIA-COLI; BETA-SUBUNIT; TYROSINE PHOSPHORYLATION; CAENORHABDITIS-ELEGANS; SUBSTRATE-SPECIFICITY; REGULATORY SUBUNIT; SYNTHETIC PEPTIDES	Drosophila melanogaster casein kinase II (DmCKII) is composed of catalytic (alpha) and regulatory (beta) subunits associated as an alpha (2)beta (2) heterotetramer. Using the two-hybrid system, we have screened a D. melanogaster embryo cDNA library for proteins that interact with DmCKII alpha. One of the cDNAs isolated in this screen encodes m7, a basic helix-loop-helix (bHLH)-type transcription factor encoded by the Enhancer of split complex (E(spl)C), which regulates neurogenesis. m7 interacts with DmCKII alpha but not with DmCKII beta, suggesting that this interaction is specific for the catalytic subunit of DmCKII. In addition to m7, we demonstrate that DmCKII alpha also interacts with two other E(spl)C-derived bHLH proteins, m5 and m8, but not with other members, such as m3 and mC. Consistent with the specificity observed for the interaction of DmCKII alpha with these bHLH proteins, sequence alignment suggests that only m5, m7, and m8 contain a consensus site for phosphorylation by CKII within a subdomain unique to these three proteins. Accordingly, these three proteins are phosphorylated by DmCKII alpha, as well as by the alpha (2)beta (2), holoenzyme purified from Drosophila embryos. In line with the prediction of a single consensus site for CKII, replacement of Ser(159) of m8 with either Ala or Asp abolishes phosphorylation, identifying this residue as the site of phosphorylation. We also demonstrate that m8 forms a direct physical complex with purified DmCKII, corroborating the observed two-hybrid interaction between these proteins. Finally, substitution of Ser(159) of m8 with Ala attenuates interaction with DmCKII alpha, whereas substitution with Asp abolishes the interaction. These studies constitute the first demonstration that DmCKII interacts with and phosphorylates m5, m7, and m8 and suggest a biochemical and/or structural basis for the functional equivalency of these bHLH proteins that is observed in the context of neurogenesis.	W Virginia Univ, Dept Biol, Morgantown, WV 26506 USA; Hebrew Univ Jerusalem, Hadassah Med Sch, Dept Biochem, IL-91120 Jerusalem, Israel	West Virginia University; Hebrew University of Jerusalem	Bidwai, AP (corresponding author), W Virginia Univ, Dept Biol, POB 6057,Brooks Hall, Morgantown, WV 26506 USA.			Bidwai, Ashok/0000-0002-4297-5629				Alifragis P, 1997, P NATL ACAD SCI USA, V94, P13099, DOI 10.1073/pnas.94.24.13099; ALLENDE JE, 1995, FASEB J, V9, P313, DOI 10.1096/fasebj.9.5.7896000; Ausubel F. M., 1988, CURRENT PROTOCOLS MO; BEVERLEY SM, 1984, J MOL EVOL, V21, P1, DOI 10.1007/BF02100622; Bidwai A P, 1999, Mol Cell Biol Res Commun, V1, P21, DOI 10.1006/mcbr.1999.0103; BIDWAI AP, 1994, ARCH BIOCHEM BIOPHYS, V309, P348, DOI 10.1006/abbi.1994.1123; BIDWAI AP, 1993, ARCH BIOCHEM BIOPHYS, V300, P265, DOI 10.1006/abbi.1993.1037; BIDWAI AP, 1992, J BIOL CHEM, V267, P18790; Bidwai Ashok P., 2000, Molecular Cell Biology Research Communications, V3, P283, DOI 10.1006/mcbr.2000.0223; Blaumueller CM, 1997, PERSPECT DEV NEUROBI, V4, P325; BOURBON HM, 1995, J BIOL CHEM, V270, P11130, DOI 10.1074/jbc.270.19.11130; BRAND AH, 1993, DEVELOPMENT, V118, P401; Bray S, 1998, CELL, V93, P499, DOI 10.1016/S0092-8674(00)81180-0; CamposOrtega JA, 1997, PERSPECT DEV NEUROBI, V4, P267; CAMPOSORTEGA JA, 1995, MOL NEUROBIOL, V10, P75, DOI 10.1007/BF02740668; CARDENAS ME, 1992, EMBO J, V11, P1785, DOI 10.1002/j.1460-2075.1992.tb05230.x; CHIEN CT, 1991, P NATL ACAD SCI USA, V88, P9578, DOI 10.1073/pnas.88.21.9578; COLLINGE MA, 1994, PLANT MOL BIOL, V25, P649, DOI 10.1007/BF00029603; DAHMUS GK, 1984, J BIOL CHEM, V259, P9001; delaPompa J, 1997, DEVELOPMENT, V124, P1139; DELIDAKIS C, 1992, P NATL ACAD SCI USA, V89, P8731, DOI 10.1073/pnas.89.18.8731; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; ESTOJAK J, 1995, MOL CELL BIOL, V15, P5820; FEILOTTER HE, 1994, NUCLEIC ACIDS RES, V22, P1502, DOI 10.1093/nar/22.8.1502; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; Fisher AL, 1998, GENE DEV, V12, P1931, DOI 10.1101/gad.12.13.1931; FISHER AL, 1996, MOL CELL BIOL, V16, P257; FUJITAYAMAGUCHI Y, 1989, P NATL ACAD SCI USA, V86, P7306, DOI 10.1073/pnas.86.19.7306; GEISLER R, 1992, CELL, V71, P613, DOI 10.1016/0092-8674(92)90595-4; Giebel B, 1997, P NATL ACAD SCI USA, V94, P6250, DOI 10.1073/pnas.94.12.6250; Gigliani F, 1996, MOL GEN GENET, V251, P628, DOI 10.1007/BF02174111; Glover CVC, 1998, PROG NUCLEIC ACID RE, V59, P95; GLOVER CVC, 1983, J BIOL CHEM, V258, P3258; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; HANNA DE, 1995, J BIOL CHEM, V270, P25905, DOI 10.1074/jbc.270.43.25905; HU E, 1990, J BIOL CHEM, V265, P20609; HU ED, 1990, J BIOL CHEM, V265, P5072; Hunter T, 1997, CELL, V88, P333, DOI 10.1016/S0092-8674(00)81872-3; Israel A, 1997, NATURE, V388, P519, DOI 10.1038/41433; Jaffe L, 1997, GENE DEV, V11, P1327, DOI 10.1101/gad.11.10.1327; JENNINGS B, 1994, DEVELOPMENT, V120, P3537; KLAMBT C, 1989, EMBO J, V8, P203, DOI 10.1002/j.1460-2075.1989.tb03365.x; KNUST E, 1992, GENETICS, V132, P505; KUENZEL EA, 1987, J BIOL CHEM, V262, P9136; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Ligoxygakis P, 1999, DEVELOPMENT, V126, P2205; LIN WJ, 1991, J BIOL CHEM, V266, P5664; MAIER D, 1993, P NATL ACAD SCI USA, V90, P5464, DOI 10.1073/pnas.90.12.5464; Marin O, 1999, J BIOL CHEM, V274, P29260, DOI 10.1074/jbc.274.41.29260; MEGGIO F, 1992, EUR J BIOCHEM, V205, P939, DOI 10.1111/j.1432-1033.1992.tb16860.x; MEGGIO F, 1994, BIOCHEMISTRY-US, V33, P4336, DOI 10.1021/bi00180a030; MEGGIO F, 1983, FEBS LETT, V162, P235, DOI 10.1016/0014-5793(83)80762-5; MEGGIO F, 1984, J BIOL CHEM, V259, P4576; MEGGIO F, 1994, CELL MOL BIOL RES, V40, P401; Miller JH., 1972, EXPT MOL GENETICS; MIYATA Y, 1992, J BIOL CHEM, V267, P7042; OELLERS N, 1994, MOL GEN GENET, V244, P465, DOI 10.1007/BF00583897; Packman LC, 1997, FEBS LETT, V400, P45, DOI 10.1016/S0014-5793(96)01324-5; PADMANABHA R, 1990, MOL CELL BIOL, V10, P4089, DOI 10.1128/MCB.10.8.4089; PAROUSH Z, 1994, CELL, V79, P805, DOI 10.1016/0092-8674(94)90070-1; PINNA LA, 1994, CELL MOL BIOL RES, V40, P383; Rechsteiner M, 1996, TRENDS BIOCHEM SCI, V21, P267, DOI 10.1016/S0968-0004(96)10031-1; Rethinaswamy A, 1998, J BIOL CHEM, V273, P5869, DOI 10.1074/jbc.273.10.5869; ROUSSOU I, 1994, MOL CELL BIOL, V14, P576, DOI 10.1128/MCB.14.1.576; SAXENA A, 1987, MOL CELL BIOL, V7, P3409, DOI 10.1128/MCB.7.10.3409; SELDIN DC, 1995, SCIENCE, V267, P894, DOI 10.1126/science.7846532; SNELL V, 1994, EMBO J, V13, P2066, DOI 10.1002/j.1460-2075.1994.tb06481.x; Toczyski DP, 1997, CELL, V90, P1097, DOI 10.1016/S0092-8674(00)80375-X; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Willert K, 1997, EMBO J, V16, P3089, DOI 10.1093/emboj/16.11.3089; Wilson LK, 1997, J BIOL CHEM, V272, P12961, DOI 10.1074/jbc.272.20.12961; Yamamoto Y, 2000, MOL CELL BIOL, V20, P3655, DOI 10.1128/MCB.20.10.3655-3666.2000; YANG XL, 1994, EMBO J, V13, P5878, DOI 10.1002/j.1460-2075.1994.tb06933.x; YANG XO, 1992, SCIENCE, V257, P680, DOI 10.1126/science.1496382; YASUKAWA T, 1995, J BIOL CHEM, V270, P25328, DOI 10.1074/jbc.270.43.25328; Zhao T, 1999, J BIOL CHEM, V274, P15095, DOI 10.1074/jbc.274.21.15095	76	29	29	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 19	2001	276	3					2159	2167		10.1074/jbc.M005996200	http://dx.doi.org/10.1074/jbc.M005996200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	394MN	11208814	hybrid			2022-12-25	WOS:000166528000069
J	Kamynina, E; Debonneville, C; Bens, M; Vandewalle, A; Staub, O				Kamynina, E; Debonneville, C; Bens, M; Vandewalle, A; Staub, O			A novel mouse Nedd4 protein suppresses the activity of the epithelial Na+ channel	FASEB JOURNAL			English	Article						Liddle's syndrome; hypertension; Na+ transport; ubiquitination; HECT domain; ENaC; protein-protein interaction; WW domain; isoform	SODIUM-CHANNEL; LIDDLES-SYNDROME; BETA-SUBUNIT; WW DOMAINS; PY MOTIF; PSEUDOHYPOALDOSTERONISM TYPE-1; HUMAN HYPERTENSION; MISSENSE MUTATION; MEMBRANE TOPOLOGY; GAMMA-SUBUNIT	Liddle's syndrome is a form of inherited hypertension linked to mutations in the genes encoding the epithelial Na+ channel (ENaC). These mutations alter or delete PY motifs involved in protein-protein interactions with a ubiquitin-protein ligase, Nedd4. Here we show that Na+ transporting cells, derived from mouse cortical collecting duct, express two Nedd4 proteins with different structural organization and characteristics of ENaC regulation: 1) the classical Nedd4 therein referred to as Nedd4-1) containing one amino-terminal C2, three WW, and one HECT-ubiquitin protein ligase domain and 2) a novel Nedd4 protein (Nedd4-2), homologous to Xenopus Nedd4 and comprising four WW, one HECT, yet lacking a C2 domain, Nedd4-2, but not Nedd4-1, inhibits ENaC activity when coexpressed in Xenopus oocytes and this property correlates with the ability to bind to ENaC, as only Nedd4-2 coimmunoprecipitates with ENaC. Furthermore, this interaction depends on the presence of at least one PY motif in the ENaC complex and on WW domains 3 and 4 in Nedd4-2, Thus, these results suggest that the novel suppressor protein Nedd4-2 is the regulator of ENaC and hence a potential susceptibility gene for arterial hypertension.	Univ Lausanne, Inst Pharmacol & Toxicol, CH-1005 Lausanne, Switzerland; Univ Paris 07, Inst Federatif Rech 02, U478, INSERM, F-75870 Paris 18, France	University of Lausanne; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Staub, O (corresponding author), Univ Lausanne, Inst Pharmacol & Toxicol, Rue du Bugnon 27, CH-1005 Lausanne, Switzerland.	olivier.staub@ipharm.unil.ch						Abriel H, 1999, J CLIN INVEST, V103, P667, DOI 10.1172/JCI5713; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Bens M, 1999, J AM SOC NEPHROL, V10, P923; Bonifacino JS, 1998, ANNU REV CELL DEV BI, V14, P19, DOI 10.1146/annurev.cellbio.14.1.19; CANESSA CM, 1994, NATURE, V367, P463, DOI 10.1038/367463a0; CANESSA CM, 1994, AM J PHYSIOL-CELL PH, V267, pC1682, DOI 10.1152/ajpcell.1994.267.6.C1682; CANESSA CM, 1993, NATURE, V361, P467, DOI 10.1038/361467a0; Chang SS, 1996, NAT GENET, V12, P248, DOI 10.1038/ng0396-248; CHEN HI, 1995, P NATL ACAD SCI USA, V92, P7819, DOI 10.1073/pnas.92.17.7819; Dinudom A, 1998, P NATL ACAD SCI USA, V95, P7169, DOI 10.1073/pnas.95.12.7169; Farr TJ, 2000, BIOCHEM J, V345, P503, DOI 10.1042/0264-6021:3450503; Felley-Bosco E, 1999, ELECTROPHORESIS, V20, P3508, DOI 10.1002/(SICI)1522-2683(19991201)20:18<3508::AID-ELPS3508>3.0.CO;2-7; Firsov D, 1998, EMBO J, V17, P344, DOI 10.1093/emboj/17.2.344; Firsov D, 1996, P NATL ACAD SCI USA, V93, P15370, DOI 10.1073/pnas.93.26.15370; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; Garty H, 1997, PHYSIOL REV, V77, P359, DOI 10.1152/physrev.1997.77.2.359; Goulet CC, 1998, J BIOL CHEM, V273, P30012, DOI 10.1074/jbc.273.45.30012; HANSSON JH, 1995, P NATL ACAD SCI USA, V92, P11495, DOI 10.1073/pnas.92.25.11495; HANSSON JH, 1995, NAT GENET, V11, P76, DOI 10.1038/ng0995-76; Harvey KF, 1999, J BIOL CHEM, V274, P12525, DOI 10.1074/jbc.274.18.12525; HEIN C, 1995, MOL MICROBIOL, V18, P77, DOI 10.1111/j.1365-2958.1995.mmi_18010077.x; Hicke L, 1999, TRENDS CELL BIOL, V9, P107, DOI 10.1016/S0962-8924(98)01491-3; Inoue J, 1998, J CLIN ENDOCR METAB, V83, P2210, DOI 10.1210/jc.83.6.2210; Inoue T, 1998, EUR J ENDOCRINOL, V138, P691, DOI 10.1530/eje.0.1380691; Ishikawa T, 1998, J GEN PHYSIOL, V111, P825, DOI 10.1085/jgp.111.6.825; Kanelis V, 1998, BIOCHEM CELL BIOL, V76, P341, DOI 10.1139/bcb-76-2-3-341; Koepf EK, 1999, BIOCHEMISTRY-US, V38, P14338, DOI 10.1021/bi991105l; Kozak M, 1999, GENE, V234, P187, DOI 10.1016/S0378-1119(99)00210-3; KUMAR S, 1992, BIOCHEM BIOPH RES CO, V185, P1155, DOI 10.1016/0006-291X(92)91747-E; Kumar S, 1997, GENOMICS, V40, P435, DOI 10.1006/geno.1996.4582; LIDDLE GW, 1963, T ASSOC AM PHYSICIAN, V76, P199; NELSON RM, 1989, ANAL BIOCHEM, V180, P147, DOI 10.1016/0003-2697(89)90103-6; Plant PJ, 1997, J BIOL CHEM, V272, P32329, DOI 10.1074/jbc.272.51.32329; Puoti A, 1997, P NATL ACAD SCI USA, V94, P5949, DOI 10.1073/pnas.94.11.5949; Rebhun JF, 1998, DNA SEQUENCE, V9, P295, DOI 10.3109/10425179809008468; RENARD S, 1994, J BIOL CHEM, V269, P12981; Rotin D, 2000, J MEMBRANE BIOL, V176, P1; Schild L, 1996, EMBO J, V15, P2381, DOI 10.1002/j.1460-2075.1996.tb00594.x; Schultz J, 1998, P NATL ACAD SCI USA, V95, P5857, DOI 10.1073/pnas.95.11.5857; SHIMKETS RA, 1994, CELL, V79, P407, DOI 10.1016/0092-8674(94)90250-X; SNYDER PM, 1994, J BIOL CHEM, V269, P24379; Staub O, 1996, EMBO J, V15, P2371, DOI 10.1002/j.1460-2075.1996.tb00593.x; Staub O, 1997, EMBO J, V16, P6325, DOI 10.1093/emboj/16.21.6325; Strautnieks SS, 1996, NAT GENET, V13, P248, DOI 10.1038/ng0696-248; Tamura H, 1996, J CLIN INVEST, V97, P1780, DOI 10.1172/JCI118606; Warnock DG, 1998, KIDNEY INT, V53, P18, DOI 10.1046/j.1523-1755.1998.00728.x	46	235	241	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2001	15	1					204	214		10.1096/fj.00-0191com	http://dx.doi.org/10.1096/fj.00-0191com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	390TH	11149908				2022-12-25	WOS:000166312400029
